<SEC-DOCUMENT>0001062993-22-001182.txt : 20220118
<SEC-HEADER>0001062993-22-001182.hdr.sgml : 20220118
<ACCEPTANCE-DATETIME>20220118164519
ACCESSION NUMBER:		0001062993-22-001182
CONFORMED SUBMISSION TYPE:	20-F/A
PUBLIC DOCUMENT COUNT:		63
CONFORMED PERIOD OF REPORT:	20210930
FILED AS OF DATE:		20220118
DATE AS OF CHANGE:		20220118

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			BRIGHT MINDS BIOSCIENCES INC.
		CENTRAL INDEX KEY:			0001827401
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			A1
		FISCAL YEAR END:			0930

	FILING VALUES:
		FORM TYPE:		20-F/A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-40997
		FILM NUMBER:		22535694

	BUSINESS ADDRESS:	
		STREET 1:		19 VESTRY STREET
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10013
		BUSINESS PHONE:		6474072515

	MAIL ADDRESS:	
		STREET 1:		19 VESTRY STREET
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10013
</SEC-HEADER>
<DOCUMENT>
<TYPE>20-F/A
<SEQUENCE>1
<FILENAME>form20fa.htm
<DESCRIPTION>FORM 20-F/A
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>
<!--INTEGIX by Ez-XBRL-->
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2018-01-31" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ifrs-full="http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full" xmlns:drug="http://brightmindsbio.com/20210930" xmlns:currency="http://xbrl.sec.gov/currency/2020-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2020-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2020-01-31" xmlns:country="http://xbrl.sec.gov/country/2020-01-31" xmlns:srt="http://fasb.org/srt/2020-01-31">

<head>
    <meta http-equiv="Content-Type" content="text/html; charset=UTF-8" />
    <title>Bright Minds Biosciences Inc.: Form 20-F/A - Filed by newsfilecorp.com</title>
</head>

<body>

    <div style="font-family: 'Times New Roman'; font-size: 10pt;">
        <div style="display: none;">
            <ix:header>
                <ix:hidden><ix:nonFraction name="drug:TotalAnnualMinimumRoyaltiesCurrentYears" id="Fxbrl_20211229013458419" xsi:nil="true" contextRef="C_20210401to20210423_drugAgreementAxis_drugLicenseAgreementMember" unitRef="CAD"></ix:nonFraction>
                    <ix:nonNumeric name="drug:NonCapitalLossCarryForwardsYearOfExpiry" id="Fxbrl_20211228221904526" contextRef="C_20201001to20210930_drugIncomeTaxAuthorityNameOfCountryAxis_drugTaxAuthorityOfCanadaMember_drugNonCapitalLossCarryForwardsYearOfOriginAxis_drugTaxYearOfOrigin2019Member">2039</ix:nonNumeric>
                    <ix:nonNumeric name="drug:NonCapitalLossCarryForwardsYearOfExpiry" id="Fxbrl_20211228221912500" contextRef="C_20201001to20210930_drugIncomeTaxAuthorityNameOfCountryAxis_drugTaxAuthorityOfCanadaMember_drugNonCapitalLossCarryForwardsYearOfOriginAxis_drugTaxYearOfOrigin2020Member">2040</ix:nonNumeric>
                    <ix:nonNumeric name="drug:NonCapitalLossCarryForwardsYearOfExpiry" id="Fxbrl_20211228221915311" contextRef="C_20201001to20210930_drugIncomeTaxAuthorityNameOfCountryAxis_drugTaxAuthorityOfCanadaMember_drugNonCapitalLossCarryForwardsYearOfOriginAxis_drugTaxYearOfOrigin2021Member">2041</ix:nonNumeric>
                    <ix:nonNumeric name="dei:EntityCentralIndexKey" id="Fdei_EntityCentralIndexKey20211227125953579" contextRef="C_20201001to20210930">0001827401</ix:nonNumeric>
                    <ix:nonNumeric name="dei:AmendmentFlag" id="Fdei_AmendmentFlag20211227130004095" contextRef="C_20201001to20210930">true</ix:nonNumeric>
                    <ix:nonNumeric name="dei:CurrentFiscalYearEndDate" id="Fdei_CurrentFiscalYearEndDate20211227130033503" contextRef="C_20201001to20210930">--09-30</ix:nonNumeric>
                    <ix:nonNumeric name="dei:DocumentFiscalYearFocus" id="Fdei_DocumentFiscalYearFocus20211227130053805" contextRef="C_20201001to20210930">2021</ix:nonNumeric>
                    <ix:nonNumeric name="dei:DocumentFiscalPeriodFocus" id="Fdei_DocumentFiscalPeriodFocus20211227130104855" contextRef="C_20201001to20210930">FY</ix:nonNumeric>
                    <ix:nonNumeric name="dei:EntityAddressCountry" id="Fdei_EntityAddressCountry20211228132535640" contextRef="C_20201001to20210930">US</ix:nonNumeric>
                </ix:hidden>
                <ix:references>
                    <link:schemaRef xlink:type="simple" xlink:href="drug-20210930.xsd"></link:schemaRef>
                </ix:references>
                <ix:resources>
                    <xbrli:context id="C_20201001to20210930">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001827401</xbrli:identifier>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2020-10-01</xbrli:startDate>
                            <xbrli:endDate>2021-09-30</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20201001to20210930_deiEntityAddressesAddressTypeAxis_deiBusinessContactMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001827401</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="dei:EntityAddressesAddressTypeAxis">dei:BusinessContactMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2020-10-01</xbrli:startDate>
                            <xbrli:endDate>2021-09-30</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20210930">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001827401</xbrli:identifier>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2021-09-30</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20200930">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001827401</xbrli:identifier>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2020-09-30</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20191001to20200930">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001827401</xbrli:identifier>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2019-10-01</xbrli:startDate>
                            <xbrli:endDate>2020-09-30</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20190601to20190930">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001827401</xbrli:identifier>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2019-06-01</xbrli:startDate>
                            <xbrli:endDate>2019-09-30</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20190531_ifrsfullComponentsOfEquityAxis_ifrsfullIssuedCapitalMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001827401</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2019-05-31</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20190531_ifrsfullComponentsOfEquityAxis_drugSubscriptionReceivableMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001827401</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">drug:SubscriptionReceivableMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2019-05-31</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20190531_ifrsfullComponentsOfEquityAxis_drugSubscriptionReceivedMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001827401</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">drug:SubscriptionReceivedMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2019-05-31</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20190531_ifrsfullComponentsOfEquityAxis_ifrsfullOtherReservesMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001827401</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OtherReservesMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2019-05-31</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20190531_ifrsfullComponentsOfEquityAxis_ifrsfullRetainedEarningsMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001827401</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2019-05-31</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20190531">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001827401</xbrli:identifier>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2019-05-31</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20190601to20190930_ifrsfullComponentsOfEquityAxis_ifrsfullIssuedCapitalMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001827401</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2019-06-01</xbrli:startDate>
                            <xbrli:endDate>2019-09-30</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20190601to20190930_ifrsfullComponentsOfEquityAxis_drugSubscriptionReceivableMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001827401</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">drug:SubscriptionReceivableMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2019-06-01</xbrli:startDate>
                            <xbrli:endDate>2019-09-30</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20190601to20190930_ifrsfullComponentsOfEquityAxis_drugSubscriptionReceivedMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001827401</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">drug:SubscriptionReceivedMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2019-06-01</xbrli:startDate>
                            <xbrli:endDate>2019-09-30</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20190601to20190930_ifrsfullComponentsOfEquityAxis_ifrsfullOtherReservesMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001827401</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OtherReservesMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2019-06-01</xbrli:startDate>
                            <xbrli:endDate>2019-09-30</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20190601to20190930_ifrsfullComponentsOfEquityAxis_ifrsfullRetainedEarningsMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001827401</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2019-06-01</xbrli:startDate>
                            <xbrli:endDate>2019-09-30</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20190930_ifrsfullComponentsOfEquityAxis_ifrsfullIssuedCapitalMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001827401</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2019-09-30</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20190930_ifrsfullComponentsOfEquityAxis_drugSubscriptionReceivableMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001827401</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">drug:SubscriptionReceivableMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2019-09-30</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20190930_ifrsfullComponentsOfEquityAxis_drugSubscriptionReceivedMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001827401</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">drug:SubscriptionReceivedMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2019-09-30</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20190930_ifrsfullComponentsOfEquityAxis_ifrsfullOtherReservesMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001827401</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OtherReservesMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2019-09-30</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20190930_ifrsfullComponentsOfEquityAxis_ifrsfullRetainedEarningsMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001827401</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2019-09-30</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20190930">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001827401</xbrli:identifier>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2019-09-30</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20191001to20200930_ifrsfullComponentsOfEquityAxis_ifrsfullIssuedCapitalMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001827401</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2019-10-01</xbrli:startDate>
                            <xbrli:endDate>2020-09-30</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20191001to20200930_ifrsfullComponentsOfEquityAxis_drugSubscriptionReceivableMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001827401</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">drug:SubscriptionReceivableMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2019-10-01</xbrli:startDate>
                            <xbrli:endDate>2020-09-30</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20191001to20200930_ifrsfullComponentsOfEquityAxis_drugSubscriptionReceivedMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001827401</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">drug:SubscriptionReceivedMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2019-10-01</xbrli:startDate>
                            <xbrli:endDate>2020-09-30</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20191001to20200930_ifrsfullComponentsOfEquityAxis_ifrsfullOtherReservesMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001827401</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OtherReservesMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2019-10-01</xbrli:startDate>
                            <xbrli:endDate>2020-09-30</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20191001to20200930_ifrsfullComponentsOfEquityAxis_ifrsfullRetainedEarningsMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001827401</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2019-10-01</xbrli:startDate>
                            <xbrli:endDate>2020-09-30</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20200930_ifrsfullComponentsOfEquityAxis_ifrsfullIssuedCapitalMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001827401</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2020-09-30</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20200930_ifrsfullComponentsOfEquityAxis_drugSubscriptionReceivableMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001827401</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">drug:SubscriptionReceivableMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2020-09-30</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20200930_ifrsfullComponentsOfEquityAxis_drugSubscriptionReceivedMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001827401</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">drug:SubscriptionReceivedMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2020-09-30</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20200930_ifrsfullComponentsOfEquityAxis_ifrsfullOtherReservesMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001827401</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OtherReservesMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2020-09-30</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20200930_ifrsfullComponentsOfEquityAxis_ifrsfullRetainedEarningsMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001827401</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2020-09-30</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20201001to20210930_ifrsfullComponentsOfEquityAxis_ifrsfullIssuedCapitalMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001827401</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2020-10-01</xbrli:startDate>
                            <xbrli:endDate>2021-09-30</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20201001to20210930_ifrsfullComponentsOfEquityAxis_drugSubscriptionReceivableMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001827401</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">drug:SubscriptionReceivableMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2020-10-01</xbrli:startDate>
                            <xbrli:endDate>2021-09-30</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20201001to20210930_ifrsfullComponentsOfEquityAxis_drugSubscriptionReceivedMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001827401</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">drug:SubscriptionReceivedMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2020-10-01</xbrli:startDate>
                            <xbrli:endDate>2021-09-30</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20201001to20210930_ifrsfullComponentsOfEquityAxis_ifrsfullOtherReservesMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001827401</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OtherReservesMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2020-10-01</xbrli:startDate>
                            <xbrli:endDate>2021-09-30</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20201001to20210930_ifrsfullComponentsOfEquityAxis_ifrsfullRetainedEarningsMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001827401</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2020-10-01</xbrli:startDate>
                            <xbrli:endDate>2021-09-30</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20210930_ifrsfullComponentsOfEquityAxis_ifrsfullIssuedCapitalMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001827401</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2021-09-30</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20210930_ifrsfullComponentsOfEquityAxis_drugSubscriptionReceivableMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001827401</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">drug:SubscriptionReceivableMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2021-09-30</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20210930_ifrsfullComponentsOfEquityAxis_drugSubscriptionReceivedMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001827401</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">drug:SubscriptionReceivedMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2021-09-30</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20210930_ifrsfullComponentsOfEquityAxis_ifrsfullOtherReservesMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001827401</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OtherReservesMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2021-09-30</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20210930_ifrsfullComponentsOfEquityAxis_ifrsfullRetainedEarningsMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001827401</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2021-09-30</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20180930">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001827401</xbrli:identifier>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2018-09-30</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20210930to20210930">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001827401</xbrli:identifier>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2021-09-30</xbrli:startDate>
                            <xbrli:endDate>2021-09-30</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20190425_ifrsfullCategoriesOfRelatedPartiesAxis_drugPsilocybinlabsLtdMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001827401</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">drug:PsilocybinlabsLtdMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2019-04-25</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20190807_ifrsfullCategoriesOfRelatedPartiesAxis_drugPsilocybinlabsLtdMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001827401</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">drug:PsilocybinlabsLtdMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2019-08-07</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20190930_ifrsfullClassesOfShareCapitalAxis_drugStockOptionsMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001827401</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">drug:StockOptionsMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2019-09-30</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20191001to20200930_ifrsfullClassesOfShareCapitalAxis_drugStockOptionsMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001827401</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">drug:StockOptionsMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2019-10-01</xbrli:startDate>
                            <xbrli:endDate>2020-09-30</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20200930_ifrsfullClassesOfShareCapitalAxis_drugStockOptionsMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001827401</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">drug:StockOptionsMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2020-09-30</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20201001to20210930_ifrsfullClassesOfShareCapitalAxis_drugStockOptionsMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001827401</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">drug:StockOptionsMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2020-10-01</xbrli:startDate>
                            <xbrli:endDate>2021-09-30</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20210930_ifrsfullClassesOfShareCapitalAxis_drugStockOptionsMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001827401</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">drug:StockOptionsMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2021-09-30</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20210930_drugExpiryDateAxis_drugExpiryDateTwentyOneSeptemberTwoThousandAndTwentyFourMember_ifrsfullClassesOfShareCapitalAxis_drugStockOptionsMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001827401</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="drug:ExpiryDateAxis">drug:ExpiryDateTwentyOneSeptemberTwoThousandAndTwentyFourMember</xbrldi:explicitMember>
                                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">drug:StockOptionsMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2021-09-30</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20210930_drugExpiryDateAxis_drugExpiryDateTwentyThreeJulyTwoThousandAndTwentyFiveMember_ifrsfullClassesOfShareCapitalAxis_drugStockOptionsMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001827401</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="drug:ExpiryDateAxis">drug:ExpiryDateTwentyThreeJulyTwoThousandAndTwentyFiveMember</xbrldi:explicitMember>
                                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">drug:StockOptionsMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2021-09-30</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20210930_drugExpiryDateAxis_drugExpiryDateSeventeenNovemberTwoThousandAndTwentyFiveMember_ifrsfullClassesOfShareCapitalAxis_drugStockOptionsMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001827401</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="drug:ExpiryDateAxis">drug:ExpiryDateSeventeenNovemberTwoThousandAndTwentyFiveMember</xbrldi:explicitMember>
                                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">drug:StockOptionsMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2021-09-30</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20210930_drugExpiryDateAxis_drugExpiryDateTwentyEightAprilTwoThousandAndTwentySixMember_ifrsfullClassesOfShareCapitalAxis_drugStockOptionsMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001827401</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="drug:ExpiryDateAxis">drug:ExpiryDateTwentyEightAprilTwoThousandAndTwentySixMember</xbrldi:explicitMember>
                                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">drug:StockOptionsMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2021-09-30</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20210930_drugExpiryDateAxis_drugExpiryDateFifteenJuneTwoThousandAndTwentySixMember_ifrsfullClassesOfShareCapitalAxis_drugStockOptionsMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001827401</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="drug:ExpiryDateAxis">drug:ExpiryDateFifteenJuneTwoThousandAndTwentySixMember</xbrldi:explicitMember>
                                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">drug:StockOptionsMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2021-09-30</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20201001to20210930_drugExpiryDateAxis_drugExpiryDateTwentyOneSeptemberTwoThousandAndTwentyFourMember_ifrsfullClassesOfShareCapitalAxis_drugStockOptionsMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001827401</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="drug:ExpiryDateAxis">drug:ExpiryDateTwentyOneSeptemberTwoThousandAndTwentyFourMember</xbrldi:explicitMember>
                                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">drug:StockOptionsMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2020-10-01</xbrli:startDate>
                            <xbrli:endDate>2021-09-30</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20201001to20210930_drugExpiryDateAxis_drugExpiryDateTwentyThreeJulyTwoThousandAndTwentyFiveMember_ifrsfullClassesOfShareCapitalAxis_drugStockOptionsMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001827401</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="drug:ExpiryDateAxis">drug:ExpiryDateTwentyThreeJulyTwoThousandAndTwentyFiveMember</xbrldi:explicitMember>
                                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">drug:StockOptionsMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2020-10-01</xbrli:startDate>
                            <xbrli:endDate>2021-09-30</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20201001to20210930_drugExpiryDateAxis_drugExpiryDateSeventeenNovemberTwoThousandAndTwentyFiveMember_ifrsfullClassesOfShareCapitalAxis_drugStockOptionsMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001827401</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="drug:ExpiryDateAxis">drug:ExpiryDateSeventeenNovemberTwoThousandAndTwentyFiveMember</xbrldi:explicitMember>
                                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">drug:StockOptionsMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2020-10-01</xbrli:startDate>
                            <xbrli:endDate>2021-09-30</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20201001to20210930_drugExpiryDateAxis_drugExpiryDateTwentyEightAprilTwoThousandAndTwentySixMember_ifrsfullClassesOfShareCapitalAxis_drugStockOptionsMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001827401</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="drug:ExpiryDateAxis">drug:ExpiryDateTwentyEightAprilTwoThousandAndTwentySixMember</xbrldi:explicitMember>
                                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">drug:StockOptionsMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2020-10-01</xbrli:startDate>
                            <xbrli:endDate>2021-09-30</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20201001to20210930_drugExpiryDateAxis_drugExpiryDateFifteenJuneTwoThousandAndTwentySixMember_ifrsfullClassesOfShareCapitalAxis_drugStockOptionsMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001827401</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="drug:ExpiryDateAxis">drug:ExpiryDateFifteenJuneTwoThousandAndTwentySixMember</xbrldi:explicitMember>
                                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">drug:StockOptionsMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2020-10-01</xbrli:startDate>
                            <xbrli:endDate>2021-09-30</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20190930_ifrsfullClassesOfShareCapitalAxis_drugRestrictedShareUnitMember_ifrsfullTypesOfSharebasedPaymentArrangementsAxis_drugEquitySettledShareBasedPaymentArrangementsMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001827401</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">drug:RestrictedShareUnitMember</xbrldi:explicitMember>
                                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">drug:EquitySettledShareBasedPaymentArrangementsMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2019-09-30</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20190930_ifrsfullClassesOfShareCapitalAxis_drugRestrictedShareUnitMember_ifrsfullTypesOfSharebasedPaymentArrangementsAxis_drugCashSettledShareBasedPaymentArrangementsMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001827401</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">drug:RestrictedShareUnitMember</xbrldi:explicitMember>
                                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">drug:CashSettledShareBasedPaymentArrangementsMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2019-09-30</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20190930_ifrsfullClassesOfShareCapitalAxis_drugRestrictedShareUnitMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001827401</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">drug:RestrictedShareUnitMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2019-09-30</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20191001to20200930_ifrsfullClassesOfShareCapitalAxis_drugRestrictedShareUnitMember_ifrsfullTypesOfSharebasedPaymentArrangementsAxis_drugEquitySettledShareBasedPaymentArrangementsMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001827401</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">drug:RestrictedShareUnitMember</xbrldi:explicitMember>
                                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">drug:EquitySettledShareBasedPaymentArrangementsMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2019-10-01</xbrli:startDate>
                            <xbrli:endDate>2020-09-30</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20191001to20200930_ifrsfullClassesOfShareCapitalAxis_drugRestrictedShareUnitMember_ifrsfullTypesOfSharebasedPaymentArrangementsAxis_drugCashSettledShareBasedPaymentArrangementsMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001827401</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">drug:RestrictedShareUnitMember</xbrldi:explicitMember>
                                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">drug:CashSettledShareBasedPaymentArrangementsMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2019-10-01</xbrli:startDate>
                            <xbrli:endDate>2020-09-30</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20191001to20200930_ifrsfullClassesOfShareCapitalAxis_drugRestrictedShareUnitMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001827401</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">drug:RestrictedShareUnitMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2019-10-01</xbrli:startDate>
                            <xbrli:endDate>2020-09-30</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20200930_ifrsfullClassesOfShareCapitalAxis_drugRestrictedShareUnitMember_ifrsfullTypesOfSharebasedPaymentArrangementsAxis_drugEquitySettledShareBasedPaymentArrangementsMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001827401</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">drug:RestrictedShareUnitMember</xbrldi:explicitMember>
                                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">drug:EquitySettledShareBasedPaymentArrangementsMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2020-09-30</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20200930_ifrsfullClassesOfShareCapitalAxis_drugRestrictedShareUnitMember_ifrsfullTypesOfSharebasedPaymentArrangementsAxis_drugCashSettledShareBasedPaymentArrangementsMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001827401</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">drug:RestrictedShareUnitMember</xbrldi:explicitMember>
                                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">drug:CashSettledShareBasedPaymentArrangementsMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2020-09-30</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20200930_ifrsfullClassesOfShareCapitalAxis_drugRestrictedShareUnitMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001827401</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">drug:RestrictedShareUnitMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2020-09-30</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20201001to20210930_ifrsfullClassesOfShareCapitalAxis_drugRestrictedShareUnitMember_ifrsfullTypesOfSharebasedPaymentArrangementsAxis_drugEquitySettledShareBasedPaymentArrangementsMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001827401</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">drug:RestrictedShareUnitMember</xbrldi:explicitMember>
                                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">drug:EquitySettledShareBasedPaymentArrangementsMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2020-10-01</xbrli:startDate>
                            <xbrli:endDate>2021-09-30</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20201001to20210930_ifrsfullClassesOfShareCapitalAxis_drugRestrictedShareUnitMember_ifrsfullTypesOfSharebasedPaymentArrangementsAxis_drugCashSettledShareBasedPaymentArrangementsMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001827401</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">drug:RestrictedShareUnitMember</xbrldi:explicitMember>
                                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">drug:CashSettledShareBasedPaymentArrangementsMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2020-10-01</xbrli:startDate>
                            <xbrli:endDate>2021-09-30</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20201001to20210930_ifrsfullClassesOfShareCapitalAxis_drugRestrictedShareUnitMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001827401</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">drug:RestrictedShareUnitMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2020-10-01</xbrli:startDate>
                            <xbrli:endDate>2021-09-30</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20210930_ifrsfullClassesOfShareCapitalAxis_drugRestrictedShareUnitMember_ifrsfullTypesOfSharebasedPaymentArrangementsAxis_drugEquitySettledShareBasedPaymentArrangementsMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001827401</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">drug:RestrictedShareUnitMember</xbrldi:explicitMember>
                                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">drug:EquitySettledShareBasedPaymentArrangementsMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2021-09-30</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20210930_ifrsfullClassesOfShareCapitalAxis_drugRestrictedShareUnitMember_ifrsfullTypesOfSharebasedPaymentArrangementsAxis_drugCashSettledShareBasedPaymentArrangementsMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001827401</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">drug:RestrictedShareUnitMember</xbrldi:explicitMember>
                                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">drug:CashSettledShareBasedPaymentArrangementsMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2021-09-30</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20210930_ifrsfullClassesOfShareCapitalAxis_drugRestrictedShareUnitMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001827401</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">drug:RestrictedShareUnitMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2021-09-30</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20201001to20210930_ifrsfullClassesOfShareCapitalAxis_drugStockOptionsMember_ifrsfullTypesOfSharebasedPaymentArrangementsAxis_drugEquitySettledShareBasedPaymentArrangementsMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001827401</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">drug:StockOptionsMember</xbrldi:explicitMember>
                                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">drug:EquitySettledShareBasedPaymentArrangementsMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2020-10-01</xbrli:startDate>
                            <xbrli:endDate>2021-09-30</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20191001to20200930_ifrsfullClassesOfShareCapitalAxis_drugStockOptionsMember_ifrsfullTypesOfSharebasedPaymentArrangementsAxis_drugEquitySettledShareBasedPaymentArrangementsMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001827401</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">drug:StockOptionsMember</xbrldi:explicitMember>
                                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">drug:EquitySettledShareBasedPaymentArrangementsMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2019-10-01</xbrli:startDate>
                            <xbrli:endDate>2020-09-30</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20190531to20190930_ifrsfullClassesOfShareCapitalAxis_drugStockOptionsMember_ifrsfullTypesOfSharebasedPaymentArrangementsAxis_drugEquitySettledShareBasedPaymentArrangementsMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001827401</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">drug:StockOptionsMember</xbrldi:explicitMember>
                                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">drug:EquitySettledShareBasedPaymentArrangementsMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2019-05-31</xbrli:startDate>
                            <xbrli:endDate>2019-09-30</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20190531to20190930_ifrsfullClassesOfShareCapitalAxis_drugRestrictedShareUnitMember_ifrsfullTypesOfSharebasedPaymentArrangementsAxis_drugEquitySettledShareBasedPaymentArrangementsMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001827401</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">drug:RestrictedShareUnitMember</xbrldi:explicitMember>
                                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">drug:EquitySettledShareBasedPaymentArrangementsMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2019-05-31</xbrli:startDate>
                            <xbrli:endDate>2019-09-30</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20201001to20210930_ifrsfullTypesOfSharebasedPaymentArrangementsAxis_drugEquitySettledShareBasedPaymentArrangementsMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001827401</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">drug:EquitySettledShareBasedPaymentArrangementsMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2020-10-01</xbrli:startDate>
                            <xbrli:endDate>2021-09-30</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20191001to20200930_ifrsfullTypesOfSharebasedPaymentArrangementsAxis_drugEquitySettledShareBasedPaymentArrangementsMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001827401</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">drug:EquitySettledShareBasedPaymentArrangementsMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2019-10-01</xbrli:startDate>
                            <xbrli:endDate>2020-09-30</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20190531to20190930_ifrsfullTypesOfSharebasedPaymentArrangementsAxis_drugEquitySettledShareBasedPaymentArrangementsMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001827401</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">drug:EquitySettledShareBasedPaymentArrangementsMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2019-05-31</xbrli:startDate>
                            <xbrli:endDate>2019-09-30</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20190531to20190930_ifrsfullClassesOfShareCapitalAxis_drugRestrictedShareUnitMember_ifrsfullTypesOfSharebasedPaymentArrangementsAxis_drugCashSettledShareBasedPaymentArrangementsMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001827401</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">drug:RestrictedShareUnitMember</xbrldi:explicitMember>
                                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">drug:CashSettledShareBasedPaymentArrangementsMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2019-05-31</xbrli:startDate>
                            <xbrli:endDate>2019-09-30</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20190531to20190930">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001827401</xbrli:identifier>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2019-05-31</xbrli:startDate>
                            <xbrli:endDate>2019-09-30</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20201001to20210930_drugConsolidatedStatementsOfComprehensiveIncomeLossStatementLocationAxis_drugConsultingFeesMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001827401</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="drug:ConsolidatedStatementsOfComprehensiveIncomeLossStatementLocationAxis">drug:ConsultingFeesMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2020-10-01</xbrli:startDate>
                            <xbrli:endDate>2021-09-30</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20191001to20200930_drugConsolidatedStatementsOfComprehensiveIncomeLossStatementLocationAxis_drugConsultingFeesMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001827401</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="drug:ConsolidatedStatementsOfComprehensiveIncomeLossStatementLocationAxis">drug:ConsultingFeesMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2019-10-01</xbrli:startDate>
                            <xbrli:endDate>2020-09-30</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20190531to20190930_drugConsolidatedStatementsOfComprehensiveIncomeLossStatementLocationAxis_drugConsultingFeesMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001827401</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="drug:ConsolidatedStatementsOfComprehensiveIncomeLossStatementLocationAxis">drug:ConsultingFeesMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2019-05-31</xbrli:startDate>
                            <xbrli:endDate>2019-09-30</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20201001to20210930_drugConsolidatedStatementsOfComprehensiveIncomeLossStatementLocationAxis_drugDirectorsCompensationMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001827401</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="drug:ConsolidatedStatementsOfComprehensiveIncomeLossStatementLocationAxis">drug:DirectorsCompensationMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2020-10-01</xbrli:startDate>
                            <xbrli:endDate>2021-09-30</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20191001to20200930_drugConsolidatedStatementsOfComprehensiveIncomeLossStatementLocationAxis_drugDirectorsCompensationMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001827401</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="drug:ConsolidatedStatementsOfComprehensiveIncomeLossStatementLocationAxis">drug:DirectorsCompensationMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2019-10-01</xbrli:startDate>
                            <xbrli:endDate>2020-09-30</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20190531to20190930_drugConsolidatedStatementsOfComprehensiveIncomeLossStatementLocationAxis_drugDirectorsCompensationMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001827401</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="drug:ConsolidatedStatementsOfComprehensiveIncomeLossStatementLocationAxis">drug:DirectorsCompensationMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2019-05-31</xbrli:startDate>
                            <xbrli:endDate>2019-09-30</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20201001to20210930_drugConsolidatedStatementsOfComprehensiveIncomeLossStatementLocationAxis_drugMarketingAdvertisingAndInvestorRelationsMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001827401</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="drug:ConsolidatedStatementsOfComprehensiveIncomeLossStatementLocationAxis">drug:MarketingAdvertisingAndInvestorRelationsMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2020-10-01</xbrli:startDate>
                            <xbrli:endDate>2021-09-30</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20191001to20200930_drugConsolidatedStatementsOfComprehensiveIncomeLossStatementLocationAxis_drugMarketingAdvertisingAndInvestorRelationsMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001827401</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="drug:ConsolidatedStatementsOfComprehensiveIncomeLossStatementLocationAxis">drug:MarketingAdvertisingAndInvestorRelationsMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2019-10-01</xbrli:startDate>
                            <xbrli:endDate>2020-09-30</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20190531to20190930_drugConsolidatedStatementsOfComprehensiveIncomeLossStatementLocationAxis_drugMarketingAdvertisingAndInvestorRelationsMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001827401</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="drug:ConsolidatedStatementsOfComprehensiveIncomeLossStatementLocationAxis">drug:MarketingAdvertisingAndInvestorRelationsMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2019-05-31</xbrli:startDate>
                            <xbrli:endDate>2019-09-30</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20201001to20210930_drugConsolidatedStatementsOfComprehensiveIncomeLossStatementLocationAxis_drugProfessionalFeesMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001827401</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="drug:ConsolidatedStatementsOfComprehensiveIncomeLossStatementLocationAxis">drug:ProfessionalFeesMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2020-10-01</xbrli:startDate>
                            <xbrli:endDate>2021-09-30</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20191001to20200930_drugConsolidatedStatementsOfComprehensiveIncomeLossStatementLocationAxis_drugProfessionalFeesMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001827401</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="drug:ConsolidatedStatementsOfComprehensiveIncomeLossStatementLocationAxis">drug:ProfessionalFeesMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2019-10-01</xbrli:startDate>
                            <xbrli:endDate>2020-09-30</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20190531to20190930_drugConsolidatedStatementsOfComprehensiveIncomeLossStatementLocationAxis_drugProfessionalFeesMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001827401</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="drug:ConsolidatedStatementsOfComprehensiveIncomeLossStatementLocationAxis">drug:ProfessionalFeesMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2019-05-31</xbrli:startDate>
                            <xbrli:endDate>2019-09-30</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20201001to20210930_drugConsolidatedStatementsOfComprehensiveIncomeLossStatementLocationAxis_drugResearchAndDevelopmentMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001827401</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="drug:ConsolidatedStatementsOfComprehensiveIncomeLossStatementLocationAxis">drug:ResearchAndDevelopmentMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2020-10-01</xbrli:startDate>
                            <xbrli:endDate>2021-09-30</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20191001to20200930_drugConsolidatedStatementsOfComprehensiveIncomeLossStatementLocationAxis_drugResearchAndDevelopmentMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001827401</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="drug:ConsolidatedStatementsOfComprehensiveIncomeLossStatementLocationAxis">drug:ResearchAndDevelopmentMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2019-10-01</xbrli:startDate>
                            <xbrli:endDate>2020-09-30</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20190531to20190930_drugConsolidatedStatementsOfComprehensiveIncomeLossStatementLocationAxis_drugResearchAndDevelopmentMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001827401</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="drug:ConsolidatedStatementsOfComprehensiveIncomeLossStatementLocationAxis">drug:ResearchAndDevelopmentMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2019-05-31</xbrli:startDate>
                            <xbrli:endDate>2019-09-30</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20190930_ifrsfullClassesOfShareCapitalAxis_drugWarrantsMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001827401</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">drug:WarrantsMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2019-09-30</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20191001to20200930_ifrsfullClassesOfShareCapitalAxis_drugWarrantsMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001827401</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">drug:WarrantsMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2019-10-01</xbrli:startDate>
                            <xbrli:endDate>2020-09-30</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20200930_ifrsfullClassesOfShareCapitalAxis_drugWarrantsMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001827401</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">drug:WarrantsMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2020-09-30</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20201001to20210930_ifrsfullClassesOfShareCapitalAxis_drugWarrantsMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001827401</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">drug:WarrantsMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2020-10-01</xbrli:startDate>
                            <xbrli:endDate>2021-09-30</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20210930_ifrsfullClassesOfShareCapitalAxis_drugWarrantsMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001827401</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">drug:WarrantsMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2021-09-30</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20210930_drugExpiryDateAxis_drugExpiryDateThirtyJulyTwoThousandAndTwentyFourMember_ifrsfullClassesOfShareCapitalAxis_drugWarrantsMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001827401</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="drug:ExpiryDateAxis">drug:ExpiryDateThirtyJulyTwoThousandAndTwentyFourMember</xbrldi:explicitMember>
                                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">drug:WarrantsMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2021-09-30</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20201001to20210930_drugExpiryDateAxis_drugExpiryDateThirtyJulyTwoThousandAndTwentyFourMember_ifrsfullClassesOfShareCapitalAxis_drugWarrantsMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001827401</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="drug:ExpiryDateAxis">drug:ExpiryDateThirtyJulyTwoThousandAndTwentyFourMember</xbrldi:explicitMember>
                                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">drug:WarrantsMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2020-10-01</xbrli:startDate>
                            <xbrli:endDate>2021-09-30</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20210930_drugExpiryDateAxis_drugExpiryDateSeventeenMarchTwoThousandAndTwentyFourOneMember_ifrsfullClassesOfShareCapitalAxis_drugWarrantsMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001827401</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="drug:ExpiryDateAxis">drug:ExpiryDateSeventeenMarchTwoThousandAndTwentyFourOneMember</xbrldi:explicitMember>
                                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">drug:WarrantsMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2021-09-30</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20201001to20210930_drugExpiryDateAxis_drugExpiryDateSeventeenMarchTwoThousandAndTwentyFourOneMember_ifrsfullClassesOfShareCapitalAxis_drugWarrantsMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001827401</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="drug:ExpiryDateAxis">drug:ExpiryDateSeventeenMarchTwoThousandAndTwentyFourOneMember</xbrldi:explicitMember>
                                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">drug:WarrantsMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2020-10-01</xbrli:startDate>
                            <xbrli:endDate>2021-09-30</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20210930_drugExpiryDateAxis_drugExpiryDateSeventeenMarchTwoThousandAndTwentyFourTwoMember_ifrsfullClassesOfShareCapitalAxis_drugWarrantsMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001827401</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="drug:ExpiryDateAxis">drug:ExpiryDateSeventeenMarchTwoThousandAndTwentyFourTwoMember</xbrldi:explicitMember>
                                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">drug:WarrantsMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2021-09-30</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20201001to20210930_drugExpiryDateAxis_drugExpiryDateSeventeenMarchTwoThousandAndTwentyFourTwoMember_ifrsfullClassesOfShareCapitalAxis_drugWarrantsMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001827401</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="drug:ExpiryDateAxis">drug:ExpiryDateSeventeenMarchTwoThousandAndTwentyFourTwoMember</xbrldi:explicitMember>
                                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">drug:WarrantsMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2020-10-01</xbrli:startDate>
                            <xbrli:endDate>2021-09-30</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20201101to20201102_ifrsfullClassesOfShareCapitalAxis_drugSecondTrancheOfNonBrokeredPrivatePlacementMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001827401</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">drug:SecondTrancheOfNonBrokeredPrivatePlacementMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2020-11-01</xbrli:startDate>
                            <xbrli:endDate>2020-11-02</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20201102_ifrsfullClassesOfShareCapitalAxis_drugSecondTrancheOfNonBrokeredPrivatePlacementMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001827401</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">drug:SecondTrancheOfNonBrokeredPrivatePlacementMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2020-11-02</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20210101to20210106_drugAgreementAxis_drugDebtSettlementAgreementMember_ifrsfullCategoriesOfRelatedPartiesAxis_drugConsultantMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001827401</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="drug:AgreementAxis">drug:DebtSettlementAgreementMember</xbrldi:explicitMember>
                                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">drug:ConsultantMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2021-01-01</xbrli:startDate>
                            <xbrli:endDate>2021-01-06</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20210106_drugAgreementAxis_drugDebtSettlementAgreementMember_ifrsfullCategoriesOfRelatedPartiesAxis_drugConsultantMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001827401</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="drug:AgreementAxis">drug:DebtSettlementAgreementMember</xbrldi:explicitMember>
                                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">drug:ConsultantMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2021-01-06</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20210301to20210317">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001827401</xbrli:identifier>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2021-03-01</xbrli:startDate>
                            <xbrli:endDate>2021-03-17</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20210317">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001827401</xbrli:identifier>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2021-03-17</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20210301to20210317_ifrsfullCategoriesOfRelatedPartiesAxis_drugUnderwritersMember_ifrsfullClassesOfShareCapitalAxis_drugWarrantsMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001827401</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">drug:UnderwritersMember</xbrldi:explicitMember>
                                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">drug:WarrantsMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2021-03-01</xbrli:startDate>
                            <xbrli:endDate>2021-03-17</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20210401to20210406_ifrsfullClassesOfShareCapitalAxis_drugWarrantsMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001827401</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">drug:WarrantsMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2021-04-01</xbrli:startDate>
                            <xbrli:endDate>2021-04-06</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20210401to20210406_ifrsfullCategoriesOfRelatedPartiesAxis_drugThreeInvestorsMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001827401</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">drug:ThreeInvestorsMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2021-04-01</xbrli:startDate>
                            <xbrli:endDate>2021-04-06</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20210401to20210423_ifrsfullClassesOfShareCapitalAxis_drugEscrowedSharePurchaseWarrantsMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001827401</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">drug:EscrowedSharePurchaseWarrantsMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2021-04-01</xbrli:startDate>
                            <xbrli:endDate>2021-04-23</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20210401to20210428">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001827401</xbrli:identifier>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2021-04-01</xbrli:startDate>
                            <xbrli:endDate>2021-04-28</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20210428">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001827401</xbrli:identifier>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2021-04-28</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20200901to20200930_ifrsfullClassesOfShareCapitalAxis_drugFirstTrancheOfNonBrokeredPrivatePlacementMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001827401</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">drug:FirstTrancheOfNonBrokeredPrivatePlacementMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2020-09-01</xbrli:startDate>
                            <xbrli:endDate>2020-09-30</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20200930_ifrsfullClassesOfShareCapitalAxis_drugFirstTrancheOfNonBrokeredPrivatePlacementMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001827401</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">drug:FirstTrancheOfNonBrokeredPrivatePlacementMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2020-09-30</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20190701to20190730_ifrsfullClassesOfShareCapitalAxis_drugNonBrokeredPrivatePlacementMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001827401</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">drug:NonBrokeredPrivatePlacementMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2019-07-01</xbrli:startDate>
                            <xbrli:endDate>2019-07-30</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20190730_ifrsfullClassesOfShareCapitalAxis_drugNonBrokeredPrivatePlacementMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001827401</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">drug:NonBrokeredPrivatePlacementMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2019-07-30</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20201001to20210930_ifrsfullClassesOfShareCapitalAxis_drugNonBrokeredPrivatePlacementMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001827401</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">drug:NonBrokeredPrivatePlacementMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2020-10-01</xbrli:startDate>
                            <xbrli:endDate>2021-09-30</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20201001to20201031_ifrsfullClassesOfShareCapitalAxis_drugSpecialWarrantsMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001827401</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">drug:SpecialWarrantsMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2020-10-01</xbrli:startDate>
                            <xbrli:endDate>2020-10-31</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20201101to20201102_ifrsfullClassesOfShareCapitalAxis_drugSpecialWarrantsMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001827401</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">drug:SpecialWarrantsMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2020-11-01</xbrli:startDate>
                            <xbrli:endDate>2020-11-02</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20210101to20210119_ifrsfullClassesOfShareCapitalAxis_drugSpecialWarrantsMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001827401</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">drug:SpecialWarrantsMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2021-01-01</xbrli:startDate>
                            <xbrli:endDate>2021-01-19</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20210201to20210203_ifrsfullClassesOfShareCapitalAxis_drugSpecialWarrantsMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001827401</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">drug:SpecialWarrantsMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2021-02-01</xbrli:startDate>
                            <xbrli:endDate>2021-02-03</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20190701to20190731">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001827401</xbrli:identifier>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2019-07-01</xbrli:startDate>
                            <xbrli:endDate>2019-07-31</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20191007to20200928">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001827401</xbrli:identifier>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2019-10-07</xbrli:startDate>
                            <xbrli:endDate>2020-09-28</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20210128_drugAgreementAxis_drugEscrowAgreementMember_ifrsfullClassesOfShareCapitalAxis_drugWarrantsMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001827401</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="drug:AgreementAxis">drug:EscrowAgreementMember</xbrldi:explicitMember>
                                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">drug:WarrantsMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2021-01-28</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20210201to20210208_drugAgreementAxis_drugEscrowAgreementMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001827401</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="drug:AgreementAxis">drug:EscrowAgreementMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2021-02-01</xbrli:startDate>
                            <xbrli:endDate>2021-02-08</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20201101to20201117_ifrsfullCategoriesOfRelatedPartiesAxis_drugChiefFinancialOfficerTwoDirectorsAndSevenConsultantsMember_ifrsfullClassesOfShareCapitalAxis_drugStockOptionsMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001827401</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">drug:ChiefFinancialOfficerTwoDirectorsAndSevenConsultantsMember</xbrldi:explicitMember>
                                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">drug:StockOptionsMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2020-11-01</xbrli:startDate>
                            <xbrli:endDate>2020-11-17</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20201101to20201117_drugStockOptionAxis_drugStockOptionsOneMember_ifrsfullCategoriesOfRelatedPartiesAxis_drugChiefFinancialOfficerTwoDirectorsAndSevenConsultantsMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001827401</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="drug:StockOptionAxis">drug:StockOptionsOneMember</xbrldi:explicitMember>
                                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">drug:ChiefFinancialOfficerTwoDirectorsAndSevenConsultantsMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2020-11-01</xbrli:startDate>
                            <xbrli:endDate>2020-11-17</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20201101to20201117_drugStockOptionAxis_drugStockOptionsOneMember_drugVestingsAxis_drugFirstTrancheMember_ifrsfullCategoriesOfRelatedPartiesAxis_drugChiefFinancialOfficerTwoDirectorsAndSevenConsultantsMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001827401</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="drug:StockOptionAxis">drug:StockOptionsOneMember</xbrldi:explicitMember>
                                <xbrldi:explicitMember dimension="drug:VestingsAxis">drug:FirstTrancheMember</xbrldi:explicitMember>
                                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">drug:ChiefFinancialOfficerTwoDirectorsAndSevenConsultantsMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2020-11-01</xbrli:startDate>
                            <xbrli:endDate>2020-11-17</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20201101to20201117_drugStockOptionAxis_drugStockOptionsTwoMember_ifrsfullCategoriesOfRelatedPartiesAxis_drugChiefFinancialOfficerTwoDirectorsAndSevenConsultantsMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001827401</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="drug:StockOptionAxis">drug:StockOptionsTwoMember</xbrldi:explicitMember>
                                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">drug:ChiefFinancialOfficerTwoDirectorsAndSevenConsultantsMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2020-11-01</xbrli:startDate>
                            <xbrli:endDate>2020-11-17</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20201101to20201117_drugStockOptionAxis_drugStockOptionsTwoMember_drugVestingsAxis_drugSecondTrancheMember_ifrsfullCategoriesOfRelatedPartiesAxis_drugChiefFinancialOfficerTwoDirectorsAndSevenConsultantsMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001827401</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="drug:StockOptionAxis">drug:StockOptionsTwoMember</xbrldi:explicitMember>
                                <xbrldi:explicitMember dimension="drug:VestingsAxis">drug:SecondTrancheMember</xbrldi:explicitMember>
                                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">drug:ChiefFinancialOfficerTwoDirectorsAndSevenConsultantsMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2020-11-01</xbrli:startDate>
                            <xbrli:endDate>2020-11-17</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20210401to20210428_ifrsfullCategoriesOfRelatedPartiesAxis_drugThreeConsultantsMember_ifrsfullClassesOfShareCapitalAxis_drugStockOptionsMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001827401</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">drug:ThreeConsultantsMember</xbrldi:explicitMember>
                                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">drug:StockOptionsMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2021-04-01</xbrli:startDate>
                            <xbrli:endDate>2021-04-28</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20201101to20201117_drugStockOptionAxis_drugStockOptionsThreeMember_ifrsfullCategoriesOfRelatedPartiesAxis_drugChiefFinancialOfficerTwoDirectorsAndSevenConsultantsMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001827401</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="drug:StockOptionAxis">drug:StockOptionsThreeMember</xbrldi:explicitMember>
                                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">drug:ChiefFinancialOfficerTwoDirectorsAndSevenConsultantsMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2020-11-01</xbrli:startDate>
                            <xbrli:endDate>2020-11-17</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20201101to20201117_drugStockOptionAxis_drugStockOptionsFourMember_ifrsfullCategoriesOfRelatedPartiesAxis_drugChiefFinancialOfficerTwoDirectorsAndSevenConsultantsMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001827401</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="drug:StockOptionAxis">drug:StockOptionsFourMember</xbrldi:explicitMember>
                                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">drug:ChiefFinancialOfficerTwoDirectorsAndSevenConsultantsMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2020-11-01</xbrli:startDate>
                            <xbrli:endDate>2020-11-17</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20201117_ifrsfullCategoriesOfRelatedPartiesAxis_drugChiefFinancialOfficerTwoDirectorsAndSevenConsultantsMember_ifrsfullClassesOfShareCapitalAxis_drugStockOptionsMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001827401</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">drug:ChiefFinancialOfficerTwoDirectorsAndSevenConsultantsMember</xbrldi:explicitMember>
                                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">drug:StockOptionsMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2020-11-17</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20210401to20210428_drugStockOptionAxis_drugStockOptionsOneMember_ifrsfullCategoriesOfRelatedPartiesAxis_drugThreeConsultantsMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001827401</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="drug:StockOptionAxis">drug:StockOptionsOneMember</xbrldi:explicitMember>
                                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">drug:ThreeConsultantsMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2021-04-01</xbrli:startDate>
                            <xbrli:endDate>2021-04-28</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20210401to20210428_drugStockOptionAxis_drugStockOptionsOneMember_drugVestingsAxis_drugSixthTrancheMember_ifrsfullCategoriesOfRelatedPartiesAxis_drugThreeConsultantsMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001827401</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="drug:StockOptionAxis">drug:StockOptionsOneMember</xbrldi:explicitMember>
                                <xbrldi:explicitMember dimension="drug:VestingsAxis">drug:SixthTrancheMember</xbrldi:explicitMember>
                                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">drug:ThreeConsultantsMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2021-04-01</xbrli:startDate>
                            <xbrli:endDate>2021-04-28</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20210401to20210428_drugStockOptionAxis_drugStockOptionsTwoMember_ifrsfullCategoriesOfRelatedPartiesAxis_drugThreeConsultantsMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001827401</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="drug:StockOptionAxis">drug:StockOptionsTwoMember</xbrldi:explicitMember>
                                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">drug:ThreeConsultantsMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2021-04-01</xbrli:startDate>
                            <xbrli:endDate>2021-04-28</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20210428_ifrsfullCategoriesOfRelatedPartiesAxis_drugThreeConsultantsMember_ifrsfullClassesOfShareCapitalAxis_drugStockOptionsMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001827401</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">drug:ThreeConsultantsMember</xbrldi:explicitMember>
                                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">drug:StockOptionsMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2021-04-28</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20210601to20210615_ifrsfullCategoriesOfRelatedPartiesAxis_drugDirectorAndConsultantMember_ifrsfullClassesOfShareCapitalAxis_drugStockOptionsMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001827401</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">drug:DirectorAndConsultantMember</xbrldi:explicitMember>
                                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">drug:StockOptionsMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2021-06-01</xbrli:startDate>
                            <xbrli:endDate>2021-06-15</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20210601to20210615_drugVestingsAxis_drugSixthTrancheMember_ifrsfullCategoriesOfRelatedPartiesAxis_drugDirectorAndConsultantMember_ifrsfullClassesOfShareCapitalAxis_drugStockOptionsMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001827401</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="drug:VestingsAxis">drug:SixthTrancheMember</xbrldi:explicitMember>
                                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">drug:DirectorAndConsultantMember</xbrldi:explicitMember>
                                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">drug:StockOptionsMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2021-06-01</xbrli:startDate>
                            <xbrli:endDate>2021-06-15</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20210601to20210615_drugVestingsAxis_drugSeventhTrancheMember_ifrsfullCategoriesOfRelatedPartiesAxis_drugDirectorAndConsultantMember_ifrsfullClassesOfShareCapitalAxis_drugStockOptionsMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001827401</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="drug:VestingsAxis">drug:SeventhTrancheMember</xbrldi:explicitMember>
                                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">drug:DirectorAndConsultantMember</xbrldi:explicitMember>
                                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">drug:StockOptionsMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2021-06-01</xbrli:startDate>
                            <xbrli:endDate>2021-06-15</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20210601to20210615_drugVestingsAxis_drugEighthTrancheMember_ifrsfullCategoriesOfRelatedPartiesAxis_drugDirectorAndConsultantMember_ifrsfullClassesOfShareCapitalAxis_drugStockOptionsMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001827401</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="drug:VestingsAxis">drug:EighthTrancheMember</xbrldi:explicitMember>
                                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">drug:DirectorAndConsultantMember</xbrldi:explicitMember>
                                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">drug:StockOptionsMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2021-06-01</xbrli:startDate>
                            <xbrli:endDate>2021-06-15</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20210601to20210615_drugVestingsAxis_drugNinthTrancheMember_ifrsfullCategoriesOfRelatedPartiesAxis_drugDirectorAndConsultantMember_ifrsfullClassesOfShareCapitalAxis_drugStockOptionsMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001827401</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="drug:VestingsAxis">drug:NinthTrancheMember</xbrldi:explicitMember>
                                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">drug:DirectorAndConsultantMember</xbrldi:explicitMember>
                                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">drug:StockOptionsMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2021-06-01</xbrli:startDate>
                            <xbrli:endDate>2021-06-15</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20210615_ifrsfullCategoriesOfRelatedPartiesAxis_drugDirectorAndConsultantMember_ifrsfullClassesOfShareCapitalAxis_drugStockOptionsMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001827401</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">drug:DirectorAndConsultantMember</xbrldi:explicitMember>
                                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">drug:StockOptionsMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2021-06-15</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20210901to20210921_ifrsfullCategoriesOfRelatedPartiesAxis_drugConsultantMember_ifrsfullClassesOfShareCapitalAxis_drugStockOptionsMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001827401</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">drug:ConsultantMember</xbrldi:explicitMember>
                                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">drug:StockOptionsMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2021-09-01</xbrli:startDate>
                            <xbrli:endDate>2021-09-21</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20210901to20210921_drugVestingsAxis_drugTwelfthTrancheMember_ifrsfullCategoriesOfRelatedPartiesAxis_drugConsultantMember_ifrsfullClassesOfShareCapitalAxis_drugStockOptionsMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001827401</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="drug:VestingsAxis">drug:TwelfthTrancheMember</xbrldi:explicitMember>
                                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">drug:ConsultantMember</xbrldi:explicitMember>
                                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">drug:StockOptionsMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2021-09-01</xbrli:startDate>
                            <xbrli:endDate>2021-09-21</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20210901to20210921_drugVestingsAxis_drugThirteenthTrancheMember_ifrsfullCategoriesOfRelatedPartiesAxis_drugConsultantMember_ifrsfullClassesOfShareCapitalAxis_drugStockOptionsMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001827401</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="drug:VestingsAxis">drug:ThirteenthTrancheMember</xbrldi:explicitMember>
                                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">drug:ConsultantMember</xbrldi:explicitMember>
                                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">drug:StockOptionsMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2021-09-01</xbrli:startDate>
                            <xbrli:endDate>2021-09-21</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20210901to20210921_drugVestingsAxis_drugFourteenthTrancheMember_ifrsfullCategoriesOfRelatedPartiesAxis_drugConsultantMember_ifrsfullClassesOfShareCapitalAxis_drugStockOptionsMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001827401</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="drug:VestingsAxis">drug:FourteenthTrancheMember</xbrldi:explicitMember>
                                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">drug:ConsultantMember</xbrldi:explicitMember>
                                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">drug:StockOptionsMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2021-09-01</xbrli:startDate>
                            <xbrli:endDate>2021-09-21</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20210901to20210921_drugVestingsAxis_drugFifteenthTrancheMember_ifrsfullCategoriesOfRelatedPartiesAxis_drugConsultantMember_ifrsfullClassesOfShareCapitalAxis_drugStockOptionsMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001827401</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="drug:VestingsAxis">drug:FifteenthTrancheMember</xbrldi:explicitMember>
                                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">drug:ConsultantMember</xbrldi:explicitMember>
                                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">drug:StockOptionsMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2021-09-01</xbrli:startDate>
                            <xbrli:endDate>2021-09-21</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20210921_ifrsfullCategoriesOfRelatedPartiesAxis_drugConsultantMember_ifrsfullClassesOfShareCapitalAxis_drugStockOptionsMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001827401</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">drug:ConsultantMember</xbrldi:explicitMember>
                                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">drug:StockOptionsMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2021-09-21</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20200701to20200723_ifrsfullClassesOfShareCapitalAxis_drugStockOptionsMember_srtTitleOfIndividualAxis_drugChiefMedicalOfficerMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001827401</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">drug:StockOptionsMember</xbrldi:explicitMember>
                                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">drug:ChiefMedicalOfficerMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2020-07-01</xbrli:startDate>
                            <xbrli:endDate>2020-07-23</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20200723_ifrsfullClassesOfShareCapitalAxis_drugStockOptionsMember_srtTitleOfIndividualAxis_drugChiefMedicalOfficerMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001827401</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">drug:StockOptionsMember</xbrldi:explicitMember>
                                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">drug:ChiefMedicalOfficerMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2020-07-23</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20200723_ifrsfullClassesOfShareCapitalAxis_drugRestrictedShareUnitMember_srtTitleOfIndividualAxis_drugChiefMedicalOfficerMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001827401</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">drug:RestrictedShareUnitMember</xbrldi:explicitMember>
                                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">drug:ChiefMedicalOfficerMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2020-07-23</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20200918_ifrsfullClassesOfShareCapitalAxis_drugRestrictedShareUnitMember_srtTitleOfIndividualAxis_drugChiefMedicalOfficerMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001827401</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">drug:RestrictedShareUnitMember</xbrldi:explicitMember>
                                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">drug:ChiefMedicalOfficerMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2020-09-18</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20210601to20210615_ifrsfullClassesOfShareCapitalAxis_drugWarrantsMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001827401</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">drug:WarrantsMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2021-06-01</xbrli:startDate>
                            <xbrli:endDate>2021-06-15</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20201101to20201117_drugStockOptionAxis_drugStockOptionsTwoMember_drugVestingsAxis_drugThirdTrancheMember_ifrsfullCategoriesOfRelatedPartiesAxis_drugChiefFinancialOfficerTwoDirectorsAndSevenConsultantsMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001827401</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="drug:StockOptionAxis">drug:StockOptionsTwoMember</xbrldi:explicitMember>
                                <xbrldi:explicitMember dimension="drug:VestingsAxis">drug:ThirdTrancheMember</xbrldi:explicitMember>
                                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">drug:ChiefFinancialOfficerTwoDirectorsAndSevenConsultantsMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2020-11-01</xbrli:startDate>
                            <xbrli:endDate>2020-11-17</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20201101to20201117_drugStockOptionAxis_drugStockOptionsTwoMember_drugVestingsAxis_drugFourthTrancheMember_ifrsfullCategoriesOfRelatedPartiesAxis_drugChiefFinancialOfficerTwoDirectorsAndSevenConsultantsMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001827401</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="drug:StockOptionAxis">drug:StockOptionsTwoMember</xbrldi:explicitMember>
                                <xbrldi:explicitMember dimension="drug:VestingsAxis">drug:FourthTrancheMember</xbrldi:explicitMember>
                                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">drug:ChiefFinancialOfficerTwoDirectorsAndSevenConsultantsMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2020-11-01</xbrli:startDate>
                            <xbrli:endDate>2020-11-17</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20201101to20201117_drugStockOptionAxis_drugStockOptionsThreeMember_drugVestingsAxis_drugSecondTrancheMember_ifrsfullCategoriesOfRelatedPartiesAxis_drugChiefFinancialOfficerTwoDirectorsAndSevenConsultantsMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001827401</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="drug:StockOptionAxis">drug:StockOptionsThreeMember</xbrldi:explicitMember>
                                <xbrldi:explicitMember dimension="drug:VestingsAxis">drug:SecondTrancheMember</xbrldi:explicitMember>
                                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">drug:ChiefFinancialOfficerTwoDirectorsAndSevenConsultantsMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2020-11-01</xbrli:startDate>
                            <xbrli:endDate>2020-11-17</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20201101to20201117_drugStockOptionAxis_drugStockOptionsThreeMember_drugVestingsAxis_drugFifthTrancheMember_ifrsfullCategoriesOfRelatedPartiesAxis_drugChiefFinancialOfficerTwoDirectorsAndSevenConsultantsMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001827401</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="drug:StockOptionAxis">drug:StockOptionsThreeMember</xbrldi:explicitMember>
                                <xbrldi:explicitMember dimension="drug:VestingsAxis">drug:FifthTrancheMember</xbrldi:explicitMember>
                                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">drug:ChiefFinancialOfficerTwoDirectorsAndSevenConsultantsMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2020-11-01</xbrli:startDate>
                            <xbrli:endDate>2020-11-17</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20201101to20201117_drugStockOptionAxis_drugStockOptionsFourMember_drugVestingsAxis_drugSixthTrancheMember_ifrsfullCategoriesOfRelatedPartiesAxis_drugChiefFinancialOfficerTwoDirectorsAndSevenConsultantsMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001827401</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="drug:StockOptionAxis">drug:StockOptionsFourMember</xbrldi:explicitMember>
                                <xbrldi:explicitMember dimension="drug:VestingsAxis">drug:SixthTrancheMember</xbrldi:explicitMember>
                                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">drug:ChiefFinancialOfficerTwoDirectorsAndSevenConsultantsMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2020-11-01</xbrli:startDate>
                            <xbrli:endDate>2020-11-17</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20201101to20201117_drugStockOptionAxis_drugStockOptionsFourMember_drugVestingsAxis_drugSeventhTrancheMember_ifrsfullCategoriesOfRelatedPartiesAxis_drugChiefFinancialOfficerTwoDirectorsAndSevenConsultantsMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001827401</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="drug:StockOptionAxis">drug:StockOptionsFourMember</xbrldi:explicitMember>
                                <xbrldi:explicitMember dimension="drug:VestingsAxis">drug:SeventhTrancheMember</xbrldi:explicitMember>
                                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">drug:ChiefFinancialOfficerTwoDirectorsAndSevenConsultantsMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2020-11-01</xbrli:startDate>
                            <xbrli:endDate>2020-11-17</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20201101to20201117_drugStockOptionAxis_drugStockOptionsFourMember_drugVestingsAxis_drugEighthTrancheMember_ifrsfullCategoriesOfRelatedPartiesAxis_drugChiefFinancialOfficerTwoDirectorsAndSevenConsultantsMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001827401</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="drug:StockOptionAxis">drug:StockOptionsFourMember</xbrldi:explicitMember>
                                <xbrldi:explicitMember dimension="drug:VestingsAxis">drug:EighthTrancheMember</xbrldi:explicitMember>
                                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">drug:ChiefFinancialOfficerTwoDirectorsAndSevenConsultantsMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2020-11-01</xbrli:startDate>
                            <xbrli:endDate>2020-11-17</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20210401to20210428_drugStockOptionAxis_drugStockOptionsOneMember_drugVestingsAxis_drugSeventhTrancheMember_ifrsfullCategoriesOfRelatedPartiesAxis_drugThreeConsultantsMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001827401</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="drug:StockOptionAxis">drug:StockOptionsOneMember</xbrldi:explicitMember>
                                <xbrldi:explicitMember dimension="drug:VestingsAxis">drug:SeventhTrancheMember</xbrldi:explicitMember>
                                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">drug:ThreeConsultantsMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2021-04-01</xbrli:startDate>
                            <xbrli:endDate>2021-04-28</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20210401to20210428_drugStockOptionAxis_drugStockOptionsOneMember_drugVestingsAxis_drugEighthTrancheMember_ifrsfullCategoriesOfRelatedPartiesAxis_drugThreeConsultantsMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001827401</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="drug:StockOptionAxis">drug:StockOptionsOneMember</xbrldi:explicitMember>
                                <xbrldi:explicitMember dimension="drug:VestingsAxis">drug:EighthTrancheMember</xbrldi:explicitMember>
                                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">drug:ThreeConsultantsMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2021-04-01</xbrli:startDate>
                            <xbrli:endDate>2021-04-28</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20210401to20210428_drugStockOptionAxis_drugStockOptionsOneMember_drugVestingsAxis_drugNinthTrancheMember_ifrsfullCategoriesOfRelatedPartiesAxis_drugThreeConsultantsMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001827401</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="drug:StockOptionAxis">drug:StockOptionsOneMember</xbrldi:explicitMember>
                                <xbrldi:explicitMember dimension="drug:VestingsAxis">drug:NinthTrancheMember</xbrldi:explicitMember>
                                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">drug:ThreeConsultantsMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2021-04-01</xbrli:startDate>
                            <xbrli:endDate>2021-04-28</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20210401to20210428_drugStockOptionAxis_drugStockOptionsTwoMember_drugVestingsAxis_drugTenthTrancheMember_ifrsfullCategoriesOfRelatedPartiesAxis_drugThreeConsultantsMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001827401</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="drug:StockOptionAxis">drug:StockOptionsTwoMember</xbrldi:explicitMember>
                                <xbrldi:explicitMember dimension="drug:VestingsAxis">drug:TenthTrancheMember</xbrldi:explicitMember>
                                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">drug:ThreeConsultantsMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2021-04-01</xbrli:startDate>
                            <xbrli:endDate>2021-04-28</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20210401to20210428_drugStockOptionAxis_drugStockOptionsTwoMember_drugVestingsAxis_drugSixthTrancheMember_ifrsfullCategoriesOfRelatedPartiesAxis_drugThreeConsultantsMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001827401</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="drug:StockOptionAxis">drug:StockOptionsTwoMember</xbrldi:explicitMember>
                                <xbrldi:explicitMember dimension="drug:VestingsAxis">drug:SixthTrancheMember</xbrldi:explicitMember>
                                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">drug:ThreeConsultantsMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2021-04-01</xbrli:startDate>
                            <xbrli:endDate>2021-04-28</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20210401to20210428_drugStockOptionAxis_drugStockOptionsTwoMember_drugVestingsAxis_drugEleventhTrancheMember_ifrsfullCategoriesOfRelatedPartiesAxis_drugThreeConsultantsMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001827401</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="drug:StockOptionAxis">drug:StockOptionsTwoMember</xbrldi:explicitMember>
                                <xbrldi:explicitMember dimension="drug:VestingsAxis">drug:EleventhTrancheMember</xbrldi:explicitMember>
                                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">drug:ThreeConsultantsMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2021-04-01</xbrli:startDate>
                            <xbrli:endDate>2021-04-28</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20210401to20210428_drugStockOptionAxis_drugStockOptionsTwoMember_drugVestingsAxis_drugSeventhTrancheMember_ifrsfullCategoriesOfRelatedPartiesAxis_drugThreeConsultantsMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001827401</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="drug:StockOptionAxis">drug:StockOptionsTwoMember</xbrldi:explicitMember>
                                <xbrldi:explicitMember dimension="drug:VestingsAxis">drug:SeventhTrancheMember</xbrldi:explicitMember>
                                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">drug:ThreeConsultantsMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2021-04-01</xbrli:startDate>
                            <xbrli:endDate>2021-04-28</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20201102">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001827401</xbrli:identifier>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2020-11-02</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20200711">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001827401</xbrli:identifier>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2020-07-11</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20210101to20210121_ifrsfullClassesOfShareCapitalAxis_drugStockOptionsMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001827401</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">drug:StockOptionsMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2021-01-01</xbrli:startDate>
                            <xbrli:endDate>2021-01-21</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20200501to20200526_drugAgreementAxis_drugOptionAgreementMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001827401</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="drug:AgreementAxis">drug:OptionAgreementMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2020-05-01</xbrli:startDate>
                            <xbrli:endDate>2020-05-26</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20210401to20210423_drugAgreementAxis_drugLicenseAgreementMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001827401</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="drug:AgreementAxis">drug:LicenseAgreementMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2021-04-01</xbrli:startDate>
                            <xbrli:endDate>2021-04-23</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20210401to20210423_drugAgreementAxis_drugPriorToSublicensingAgreementsMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001827401</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="drug:AgreementAxis">drug:PriorToSublicensingAgreementsMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2021-04-01</xbrli:startDate>
                            <xbrli:endDate>2021-04-23</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20210401to20210423_drugAgreementAxis_drugAfterSublicensingAgreementsMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001827401</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="drug:AgreementAxis">drug:AfterSublicensingAgreementsMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2021-04-01</xbrli:startDate>
                            <xbrli:endDate>2021-04-23</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20200601to20200605_drugAgreementAxis_drugIndependentConsultantAgreementMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001827401</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="drug:AgreementAxis">drug:IndependentConsultantAgreementMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2020-06-01</xbrli:startDate>
                            <xbrli:endDate>2020-06-05</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20210301to20210331_drugAgreementAxis_drugIndependentConsultantAgreementMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001827401</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="drug:AgreementAxis">drug:IndependentConsultantAgreementMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2021-03-01</xbrli:startDate>
                            <xbrli:endDate>2021-03-31</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20210801to20210831_drugAgreementAxis_drugIndependentConsultantAgreementMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001827401</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="drug:AgreementAxis">drug:IndependentConsultantAgreementMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2021-08-01</xbrli:startDate>
                            <xbrli:endDate>2021-08-31</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20200601to20210412_drugAgreementAxis_drugScientificAdvisoryBoardAgreementsMember_ifrsfullRangeAxis_ifrsfullBottomOfRangeMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001827401</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="drug:AgreementAxis">drug:ScientificAdvisoryBoardAgreementsMember</xbrldi:explicitMember>
                                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2020-06-01</xbrli:startDate>
                            <xbrli:endDate>2021-04-12</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20201101to20201117_drugAgreementAxis_drugScientificAdvisoryBoardAgreementsMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001827401</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="drug:AgreementAxis">drug:ScientificAdvisoryBoardAgreementsMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2020-11-01</xbrli:startDate>
                            <xbrli:endDate>2020-11-17</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20200601to20210412_drugAgreementAxis_drugScientificAdvisoryBoardAgreementsMember_ifrsfullRangeAxis_ifrsfullTopOfRangeMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001827401</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="drug:AgreementAxis">drug:ScientificAdvisoryBoardAgreementsMember</xbrldi:explicitMember>
                                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2020-06-01</xbrli:startDate>
                            <xbrli:endDate>2021-04-12</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20210101to20210131_drugAgreementAxis_drugScientificAdvisoryBoardAgreementsMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001827401</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="drug:AgreementAxis">drug:ScientificAdvisoryBoardAgreementsMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2021-01-01</xbrli:startDate>
                            <xbrli:endDate>2021-01-31</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20201118to20210428_drugAgreementAxis_drugConsultingAgreementsMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001827401</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="drug:AgreementAxis">drug:ConsultingAgreementsMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2020-11-18</xbrli:startDate>
                            <xbrli:endDate>2021-04-28</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20201001to20210930_drugAgreementAxis_drugConsultingAgreementsMember_ifrsfullRangeAxis_ifrsfullBottomOfRangeMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001827401</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="drug:AgreementAxis">drug:ConsultingAgreementsMember</xbrldi:explicitMember>
                                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2020-10-01</xbrli:startDate>
                            <xbrli:endDate>2021-09-30</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20201001to20210930_drugAgreementAxis_drugConsultingAgreementsMember_ifrsfullRangeAxis_ifrsfullTopOfRangeMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001827401</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="drug:AgreementAxis">drug:ConsultingAgreementsMember</xbrldi:explicitMember>
                                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2020-10-01</xbrli:startDate>
                            <xbrli:endDate>2021-09-30</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20201001to20201009_drugAgreementAxis_drugConsultingAgreementsMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001827401</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="drug:AgreementAxis">drug:ConsultingAgreementsMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2020-10-01</xbrli:startDate>
                            <xbrli:endDate>2020-10-09</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20201101to20201106_drugAgreementAxis_drugConsultingAgreementsMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001827401</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="drug:AgreementAxis">drug:ConsultingAgreementsMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2020-11-01</xbrli:startDate>
                            <xbrli:endDate>2020-11-06</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20201101to20201117_drugAgreementAxis_drugConsultingAgreementsMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001827401</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="drug:AgreementAxis">drug:ConsultingAgreementsMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2020-11-01</xbrli:startDate>
                            <xbrli:endDate>2020-11-17</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20210301to20210331_drugAgreementAxis_drugIndependentContractorAgreementToServeAsChiefScienceOfficerMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001827401</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="drug:AgreementAxis">drug:IndependentContractorAgreementToServeAsChiefScienceOfficerMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2021-03-01</xbrli:startDate>
                            <xbrli:endDate>2021-03-31</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20210801to20210831_drugAgreementAxis_drugIndependentContractorAgreementToServeAsChiefScienceOfficerMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001827401</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="drug:AgreementAxis">drug:IndependentContractorAgreementToServeAsChiefScienceOfficerMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2021-08-01</xbrli:startDate>
                            <xbrli:endDate>2021-08-31</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20210930_ifrsfullClassesOfFinancialInstrumentsAxis_drugFinancialInstrumentsAtFairValueThroughProfitOrLossMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001827401</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">drug:FinancialInstrumentsAtFairValueThroughProfitOrLossMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2021-09-30</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20200930_ifrsfullClassesOfFinancialInstrumentsAxis_drugFinancialInstrumentsAtFairValueThroughProfitOrLossMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001827401</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">drug:FinancialInstrumentsAtFairValueThroughProfitOrLossMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2020-09-30</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20210930_ifrsfullClassesOfFinancialInstrumentsAxis_drugFinancialInstrumentsAtAmortizedCostMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001827401</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">drug:FinancialInstrumentsAtAmortizedCostMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2021-09-30</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20200930_ifrsfullClassesOfFinancialInstrumentsAxis_drugFinancialInstrumentsAtAmortizedCostMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001827401</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">drug:FinancialInstrumentsAtAmortizedCostMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2020-09-30</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20210930_ifrsfullTypesOfRisksAxis_ifrsfullCreditRiskMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001827401</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CreditRiskMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2021-09-30</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20210930_ifrsfullTypesOfRisksAxis_ifrsfullCurrencyRiskMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001827401</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CurrencyRiskMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2021-09-30</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20210930_ifrsfullTypesOfRisksAxis_ifrsfullLiquidityRiskMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001827401</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:LiquidityRiskMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2021-09-30</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20191001to20200930_drugCategoriesOfResearchAndDevelopmentExpensesAxis_drugLaboratoryCostsMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001827401</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="drug:CategoriesOfResearchAndDevelopmentExpensesAxis">drug:LaboratoryCostsMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2019-10-01</xbrli:startDate>
                            <xbrli:endDate>2020-09-30</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20190601to20190930_drugCategoriesOfResearchAndDevelopmentExpensesAxis_drugLaboratoryCostsMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001827401</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="drug:CategoriesOfResearchAndDevelopmentExpensesAxis">drug:LaboratoryCostsMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2019-06-01</xbrli:startDate>
                            <xbrli:endDate>2019-09-30</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20191001to20200930_drugCategoriesOfResearchAndDevelopmentExpensesAxis_drugNovelDrugDevelopmentMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001827401</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="drug:CategoriesOfResearchAndDevelopmentExpensesAxis">drug:NovelDrugDevelopmentMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2019-10-01</xbrli:startDate>
                            <xbrli:endDate>2020-09-30</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20190601to20190930_drugCategoriesOfResearchAndDevelopmentExpensesAxis_drugNovelDrugDevelopmentMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001827401</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="drug:CategoriesOfResearchAndDevelopmentExpensesAxis">drug:NovelDrugDevelopmentMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2019-06-01</xbrli:startDate>
                            <xbrli:endDate>2019-09-30</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20191001to20200930_drugCategoriesOfResearchAndDevelopmentExpensesAxis_ifrsfullCopyrightsPatentsAndOtherIndustrialPropertyRightsServiceAndOperatingRightsMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001827401</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="drug:CategoriesOfResearchAndDevelopmentExpensesAxis">ifrs-full:CopyrightsPatentsAndOtherIndustrialPropertyRightsServiceAndOperatingRightsMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2019-10-01</xbrli:startDate>
                            <xbrli:endDate>2020-09-30</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20190601to20190930_drugCategoriesOfResearchAndDevelopmentExpensesAxis_ifrsfullCopyrightsPatentsAndOtherIndustrialPropertyRightsServiceAndOperatingRightsMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001827401</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="drug:CategoriesOfResearchAndDevelopmentExpensesAxis">ifrs-full:CopyrightsPatentsAndOtherIndustrialPropertyRightsServiceAndOperatingRightsMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2019-06-01</xbrli:startDate>
                            <xbrli:endDate>2019-09-30</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20191001to20200930_drugCategoriesOfResearchAndDevelopmentExpensesAxis_drugSalaryAndSubcontractorsMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001827401</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="drug:CategoriesOfResearchAndDevelopmentExpensesAxis">drug:SalaryAndSubcontractorsMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2019-10-01</xbrli:startDate>
                            <xbrli:endDate>2020-09-30</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20190601to20190930_drugCategoriesOfResearchAndDevelopmentExpensesAxis_drugSalaryAndSubcontractorsMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001827401</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="drug:CategoriesOfResearchAndDevelopmentExpensesAxis">drug:SalaryAndSubcontractorsMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2019-06-01</xbrli:startDate>
                            <xbrli:endDate>2019-09-30</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20191001to20200930_drugCategoriesOfResearchAndDevelopmentExpensesAxis_drugShareBasedCompensationMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001827401</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="drug:CategoriesOfResearchAndDevelopmentExpensesAxis">drug:ShareBasedCompensationMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2019-10-01</xbrli:startDate>
                            <xbrli:endDate>2020-09-30</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20190601to20190930_drugCategoriesOfResearchAndDevelopmentExpensesAxis_drugShareBasedCompensationMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001827401</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="drug:CategoriesOfResearchAndDevelopmentExpensesAxis">drug:ShareBasedCompensationMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2019-06-01</xbrli:startDate>
                            <xbrli:endDate>2019-09-30</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20201001to20210930_drugCategoriesOfResearchAndDevelopmentExpensesAxis_drugLaboratoryCostsMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001827401</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="drug:CategoriesOfResearchAndDevelopmentExpensesAxis">drug:LaboratoryCostsMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2020-10-01</xbrli:startDate>
                            <xbrli:endDate>2021-09-30</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20201001to20210930_drugCategoriesOfResearchAndDevelopmentExpensesAxis_drugNovelDrugDevelopmentMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001827401</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="drug:CategoriesOfResearchAndDevelopmentExpensesAxis">drug:NovelDrugDevelopmentMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2020-10-01</xbrli:startDate>
                            <xbrli:endDate>2021-09-30</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20201001to20210930_drugCategoriesOfResearchAndDevelopmentExpensesAxis_ifrsfullCopyrightsPatentsAndOtherIndustrialPropertyRightsServiceAndOperatingRightsMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001827401</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="drug:CategoriesOfResearchAndDevelopmentExpensesAxis">ifrs-full:CopyrightsPatentsAndOtherIndustrialPropertyRightsServiceAndOperatingRightsMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2020-10-01</xbrli:startDate>
                            <xbrli:endDate>2021-09-30</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20201001to20210930_drugCategoriesOfResearchAndDevelopmentExpensesAxis_drugSalaryAndSubcontractorsMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001827401</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="drug:CategoriesOfResearchAndDevelopmentExpensesAxis">drug:SalaryAndSubcontractorsMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2020-10-01</xbrli:startDate>
                            <xbrli:endDate>2021-09-30</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20201001to20210930_drugCategoriesOfResearchAndDevelopmentExpensesAxis_drugShareBasedCompensationMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001827401</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="drug:CategoriesOfResearchAndDevelopmentExpensesAxis">drug:ShareBasedCompensationMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2020-10-01</xbrli:startDate>
                            <xbrli:endDate>2021-09-30</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20210601to20210930_ifrsfullClassesOfAssetsAxis_drugCommercialLaboratoryLeaseMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001827401</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">drug:CommercialLaboratoryLeaseMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2021-06-01</xbrli:startDate>
                            <xbrli:endDate>2021-09-30</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20210901to20210930_ifrsfullClassesOfAssetsAxis_ifrsfullBuildingsMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001827401</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:BuildingsMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2021-09-01</xbrli:startDate>
                            <xbrli:endDate>2021-09-30</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20210601to20210930_ifrsfullClassesOfAssetsAxis_ifrsfullBuildingsMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001827401</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:BuildingsMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2021-06-01</xbrli:startDate>
                            <xbrli:endDate>2021-09-30</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20181001to20190930">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001827401</xbrli:identifier>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2018-10-01</xbrli:startDate>
                            <xbrli:endDate>2019-09-30</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20210930_ifrsfullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_ifrsfullUnusedTaxLossesMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001827401</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:UnusedTaxLossesMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2021-09-30</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20200930_ifrsfullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_ifrsfullUnusedTaxLossesMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001827401</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:UnusedTaxLossesMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2020-09-30</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20210930_ifrsfullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_drugTemporaryDifferencesShareIssueCostsMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001827401</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">drug:TemporaryDifferencesShareIssueCostsMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2021-09-30</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20200930_ifrsfullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_drugTemporaryDifferencesShareIssueCostsMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001827401</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">drug:TemporaryDifferencesShareIssueCostsMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2020-09-30</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20210930_ifrsfullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_drugTemporaryDifferencesIntangibleAssetsMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001827401</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">drug:TemporaryDifferencesIntangibleAssetsMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2021-09-30</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20200930_ifrsfullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_drugTemporaryDifferencesIntangibleAssetsMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001827401</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">drug:TemporaryDifferencesIntangibleAssetsMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2020-09-30</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20210930_ifrsfullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_drugTemporaryDifferencesValuationAllowanceMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001827401</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">drug:TemporaryDifferencesValuationAllowanceMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2021-09-30</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20200930_ifrsfullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_drugTemporaryDifferencesValuationAllowanceMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001827401</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">drug:TemporaryDifferencesValuationAllowanceMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2020-09-30</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20201001to20210930_drugIncomeTaxAuthorityNameOfCountryAxis_drugTaxAuthorityOfCanadaMember_drugNonCapitalLossCarryForwardsYearOfOriginAxis_drugTaxYearOfOrigin2019Member">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001827401</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="drug:IncomeTaxAuthorityNameOfCountryAxis">drug:TaxAuthorityOfCanadaMember</xbrldi:explicitMember>
                                <xbrldi:explicitMember dimension="drug:NonCapitalLossCarryForwardsYearOfOriginAxis">drug:TaxYearOfOrigin2019Member</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2020-10-01</xbrli:startDate>
                            <xbrli:endDate>2021-09-30</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20201001to20210930_drugIncomeTaxAuthorityNameOfCountryAxis_drugTaxAuthorityOfCanadaMember_drugNonCapitalLossCarryForwardsYearOfOriginAxis_drugTaxYearOfOrigin2020Member">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001827401</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="drug:IncomeTaxAuthorityNameOfCountryAxis">drug:TaxAuthorityOfCanadaMember</xbrldi:explicitMember>
                                <xbrldi:explicitMember dimension="drug:NonCapitalLossCarryForwardsYearOfOriginAxis">drug:TaxYearOfOrigin2020Member</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2020-10-01</xbrli:startDate>
                            <xbrli:endDate>2021-09-30</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20201001to20210930_drugIncomeTaxAuthorityNameOfCountryAxis_drugTaxAuthorityOfCanadaMember_drugNonCapitalLossCarryForwardsYearOfOriginAxis_drugTaxYearOfOrigin2021Member">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001827401</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="drug:IncomeTaxAuthorityNameOfCountryAxis">drug:TaxAuthorityOfCanadaMember</xbrldi:explicitMember>
                                <xbrldi:explicitMember dimension="drug:NonCapitalLossCarryForwardsYearOfOriginAxis">drug:TaxYearOfOrigin2021Member</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2020-10-01</xbrli:startDate>
                            <xbrli:endDate>2021-09-30</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20210930_drugIncomeTaxAuthorityNameOfCountryAxis_drugTaxAuthorityOfCanadaMember_drugNonCapitalLossCarryForwardsYearOfOriginAxis_drugTaxYearOfOrigin2019Member">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001827401</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="drug:IncomeTaxAuthorityNameOfCountryAxis">drug:TaxAuthorityOfCanadaMember</xbrldi:explicitMember>
                                <xbrldi:explicitMember dimension="drug:NonCapitalLossCarryForwardsYearOfOriginAxis">drug:TaxYearOfOrigin2019Member</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2021-09-30</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20210930_drugIncomeTaxAuthorityNameOfCountryAxis_drugTaxAuthorityOfCanadaMember_drugNonCapitalLossCarryForwardsYearOfOriginAxis_drugTaxYearOfOrigin2020Member">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001827401</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="drug:IncomeTaxAuthorityNameOfCountryAxis">drug:TaxAuthorityOfCanadaMember</xbrldi:explicitMember>
                                <xbrldi:explicitMember dimension="drug:NonCapitalLossCarryForwardsYearOfOriginAxis">drug:TaxYearOfOrigin2020Member</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2021-09-30</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20210930_drugIncomeTaxAuthorityNameOfCountryAxis_drugTaxAuthorityOfCanadaMember_drugNonCapitalLossCarryForwardsYearOfOriginAxis_drugTaxYearOfOrigin2021Member">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001827401</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="drug:IncomeTaxAuthorityNameOfCountryAxis">drug:TaxAuthorityOfCanadaMember</xbrldi:explicitMember>
                                <xbrldi:explicitMember dimension="drug:NonCapitalLossCarryForwardsYearOfOriginAxis">drug:TaxYearOfOrigin2021Member</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2021-09-30</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20210930_drugIncomeTaxAuthorityNameOfCountryAxis_drugTaxAuthorityOfCanadaMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001827401</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="drug:IncomeTaxAuthorityNameOfCountryAxis">drug:TaxAuthorityOfCanadaMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2021-09-30</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20190930_drugIncomeTaxAuthorityNameOfCountryAxis_drugTaxAuthorityOfCanadaMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001827401</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="drug:IncomeTaxAuthorityNameOfCountryAxis">drug:TaxAuthorityOfCanadaMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2019-09-30</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20210930_drugIncomeTaxAuthorityNameOfCountryAxis_drugTaxAuthorityOfUnitedStatesMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001827401</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="drug:IncomeTaxAuthorityNameOfCountryAxis">drug:TaxAuthorityOfUnitedStatesMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2021-09-30</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20190930_drugIncomeTaxAuthorityNameOfCountryAxis_drugTaxAuthorityOfUnitedStatesMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001827401</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="drug:IncomeTaxAuthorityNameOfCountryAxis">drug:TaxAuthorityOfUnitedStatesMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2019-09-30</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20210930_drugIncomeTaxAuthorityNameOfCountryAxis_drugTaxAuthorityOfAustraliaMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001827401</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="drug:IncomeTaxAuthorityNameOfCountryAxis">drug:TaxAuthorityOfAustraliaMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2021-09-30</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20190930_drugIncomeTaxAuthorityNameOfCountryAxis_drugTaxAuthorityOfAustraliaMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001827401</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="drug:IncomeTaxAuthorityNameOfCountryAxis">drug:TaxAuthorityOfAustraliaMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2019-09-30</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20211001to20211101_drugTypeOfArrangementsAxis_drugLetterAgreementMember_ifrsfullNonadjustingEventsAfterReportingPeriodAxis_drugSubsequentEventsMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001827401</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="drug:TypeOfArrangementsAxis">drug:LetterAgreementMember</xbrldi:explicitMember>
                                <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">drug:SubsequentEventsMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2021-10-01</xbrli:startDate>
                            <xbrli:endDate>2021-11-01</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20211101_drugTypeOfArrangementsAxis_drugLetterAgreementMember_ifrsfullNonadjustingEventsAfterReportingPeriodAxis_drugSubsequentEventsMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001827401</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="drug:TypeOfArrangementsAxis">drug:LetterAgreementMember</xbrldi:explicitMember>
                                <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">drug:SubsequentEventsMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2021-11-01</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20211101_drugTranchesAxis_drugFirstTrancheMember_drugTypeOfArrangementsAxis_drugLetterAgreementMember_ifrsfullNonadjustingEventsAfterReportingPeriodAxis_drugSubsequentEventsMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001827401</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="drug:TranchesAxis">drug:FirstTrancheMember</xbrldi:explicitMember>
                                <xbrldi:explicitMember dimension="drug:TypeOfArrangementsAxis">drug:LetterAgreementMember</xbrldi:explicitMember>
                                <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">drug:SubsequentEventsMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2021-11-01</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20211101_drugTranchesAxis_drugSecondTrancheMember_drugTypeOfArrangementsAxis_drugLetterAgreementMember_ifrsfullNonadjustingEventsAfterReportingPeriodAxis_drugSubsequentEventsMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001827401</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="drug:TranchesAxis">drug:SecondTrancheMember</xbrldi:explicitMember>
                                <xbrldi:explicitMember dimension="drug:TypeOfArrangementsAxis">drug:LetterAgreementMember</xbrldi:explicitMember>
                                <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">drug:SubsequentEventsMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2021-11-01</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20211101_drugTranchesAxis_drugThirdTrancheMember_drugTypeOfArrangementsAxis_drugLetterAgreementMember_ifrsfullNonadjustingEventsAfterReportingPeriodAxis_drugSubsequentEventsMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001827401</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="drug:TranchesAxis">drug:ThirdTrancheMember</xbrldi:explicitMember>
                                <xbrldi:explicitMember dimension="drug:TypeOfArrangementsAxis">drug:LetterAgreementMember</xbrldi:explicitMember>
                                <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">drug:SubsequentEventsMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2021-11-01</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20211001to20211109_drugTypeOfArrangementsAxis_drugLetterAgreementMember_ifrsfullNonadjustingEventsAfterReportingPeriodAxis_drugSubsequentEventsMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001827401</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="drug:TypeOfArrangementsAxis">drug:LetterAgreementMember</xbrldi:explicitMember>
                                <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">drug:SubsequentEventsMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2021-10-01</xbrli:startDate>
                            <xbrli:endDate>2021-11-09</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:unit id="CAD">
                        <xbrli:measure>iso4217:CAD</xbrli:measure>
                    </xbrli:unit>
                    <xbrli:unit id="CAD_per_share">
                        <xbrli:divide>
                            <xbrli:unitNumerator>
                                <xbrli:measure>iso4217:CAD</xbrli:measure>
                            </xbrli:unitNumerator>
                            <xbrli:unitDenominator>
                                <xbrli:measure>xbrli:shares</xbrli:measure>
                            </xbrli:unitDenominator>
                        </xbrli:divide>
                    </xbrli:unit>
                    <xbrli:unit id="Percent">
                        <xbrli:measure>xbrli:pure</xbrli:measure>
                    </xbrli:unit>
                    <xbrli:unit id="Share">
                        <xbrli:measure>xbrli:shares</xbrli:measure>
                    </xbrli:unit>
                    <xbrli:unit id="Shares">
                        <xbrli:measure>drug:Shares</xbrli:measure>
                    </xbrli:unit>
                    <xbrli:unit id="USD">
                        <xbrli:measure>iso4217:USD</xbrli:measure>
                    </xbrli:unit>
                    <xbrli:unit id="Unit_Per_Share">
                        <xbrli:divide>
                            <xbrli:unitNumerator>
                                <xbrli:measure>iso4217:CAD</xbrli:measure>
                            </xbrli:unitNumerator>
                            <xbrli:unitDenominator>
                                <xbrli:measure>drug:Shares</xbrli:measure>
                            </xbrli:unitDenominator>
                        </xbrli:divide>
                    </xbrli:unit>
                    <xbrli:unit id="Year">
                        <xbrli:measure>drug:Year</xbrli:measure>
                    </xbrli:unit>
                </ix:resources>
            </ix:header>
        </div>
        <div>
            <div>
                <hr style="height: 3px; width: 100%; background-color: black;" />
                <p style="margin-bottom: 0pt; text-align: center;"><span style="font-size: 18pt;"><span style="font-family: Times New Roman,Times,serif;"><b>UNITED STATES</b></span></span></p>
                <p style="margin-top: 0pt; margin-bottom: 0pt; text-align: center;"><span style="font-size: 18pt;"><span style="font-family: Times New Roman,Times,serif;"><b>SECURITIES AND EXCHANGE COMMISSION </b></span></span></p>
                <p style="margin-top: 0px; text-align: center; margin-bottom: 0px;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">Washington, D.C. 20549</span></span></p>
                <p style="margin-top: 0px; text-align: center; margin-bottom: 0px;">&#160;</p>
                <p style="text-align: center; margin-top: 0px; margin-bottom: 0px;"><span style="font-size: 18pt;"><span style="font-family: Times New Roman,Times,serif;"><b>FORM <ix:nonNumeric id="Fxbrl_20211227133624053" name="dei:DocumentType" contextRef="C_20201001to20210930">20-F/A</ix:nonNumeric></b></span></span></p>
                <p style="text-align: center; margin-top: 0px; margin-bottom: 0px;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>(Amendment No. 1)</b></span></span></p>
                <p style="text-align: center; margin-top: 0px; margin-bottom: 0px;">&#160;</p>
                <p style="margin-top: 0px; margin-bottom: 0px; text-align: center;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">
                            <ix:nonNumeric id="Fxbrl_20211227133655465" name="dei:DocumentRegistrationStatement" format="ixt:booleanfalse" contextRef="C_20201001to20210930">&#9744;</ix:nonNumeric> REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) or 12(g) OF THE <i>SECURITIES EXCHANGE ACT OF 1934</i>
                        </span></span></p>
                <p style="text-align: justify; margin-top: 0px; margin-bottom: 0px;">&#160;</p>
                <p style="text-align: center; margin-top: 0px; margin-bottom: 0px;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">OR</span></span></p>
                <p style="text-align: center; margin-top: 0px; margin-bottom: 0px;">&#160;</p>
                <p style="margin-top: 0px; margin-bottom: 0px; text-align: center;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">
                            <ix:nonNumeric id="Fxbrl_20211227133704248" name="dei:DocumentAnnualReport" format="ixt:booleantrue" contextRef="C_20201001to20210930">&#9746;</ix:nonNumeric> ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE <i>SECURITIES EXCHANGE ACT OF 1934</i>
                        </span></span></p>
                <p style="text-align: justify; margin-top: 0px; margin-bottom: 0px;">&#160;</p>
                <p style="text-align: center; margin-top: 0px; margin-bottom: 0px;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">For the fiscal year ended <span style="text-decoration: underline;"><b>
                                    <ix:nonNumeric id="Fxbrl_20211227133718692" name="dei:DocumentPeriodEndDate" format="ixt:datemonthdayyearen" contextRef="C_20201001to20210930">September 30, 2021</ix:nonNumeric>
                                </b></span></span></span></p>
                <p style="text-align: center; margin-top: 0px; margin-bottom: 0px;">&#160;</p>
                <p style="text-align: center; margin-top: 0px; margin-bottom: 0px;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">OR</span></span></p>
                <p style="text-align: center; margin-top: 0px; margin-bottom: 0px;">&#160;</p>
                <p style="margin-top: 0px; margin-bottom: 0px; text-align: center;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">
                            <ix:nonNumeric id="Fxbrl_20211227133708582" name="dei:DocumentTransitionReport" format="ixt:booleanfalse" contextRef="C_20201001to20210930">&#9744;</ix:nonNumeric> TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE <i>SECURITIES EXCHANGE ACT OF 1934</i>
                        </span></span></p>
                <p style="text-align: justify; margin-top: 0px; margin-bottom: 0px;">&#160;</p>
                <p style="text-align: center; margin-top: 0px; margin-bottom: 0px;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">For the transition period from _______________ to _______________</span></span></p>
                <p style="text-align: center; margin-top: 0px; margin-bottom: 0px;">&#160;</p>
                <p style="text-align: center; margin-top: 0px; margin-bottom: 0px;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">OR</span></span></p>
                <p style="text-align: center; margin-top: 0px; margin-bottom: 0px;">&#160;</p>
                <p style="margin-top: 0px; margin-bottom: 0px; text-align: center;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">
                            <ix:nonNumeric id="Fxbrl_20211227133712580" name="dei:DocumentShellCompanyReport" format="ixt:booleanfalse" contextRef="C_20201001to20210930">&#9744;</ix:nonNumeric> SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE <i>SECURITIES EXCHANGE ACT OF 1934</i>
                        </span></span></p>
                <p style="text-align: justify; margin-top: 0px; margin-bottom: 0px;">&#160;</p>
                <p style="text-align: center; margin-top: 0px; margin-bottom: 0px;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">Date of event requiring this shell company report _______________</span></span></p>
                <p style="text-align: center; margin-top: 0px; margin-bottom: 0px;">&#160;</p>
                <p style="text-align: center; margin-top: 0px; margin-bottom: 0px;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">Commission file number <span style="text-decoration: underline;"><b>
                                    <ix:nonNumeric id="Fxbrl_20211227133904872" name="dei:EntityFileNumber" contextRef="C_20201001to20210930">001-40997</ix:nonNumeric>
                                </b></span></span></span></p>
                <p style="margin: 0pt;">&#160;</p>
                <p style="margin-bottom: 0px; text-align: center; margin-top: 0px;"><span style="font-size: 18pt;"><span style="font-family: Times New Roman,Times,serif;"><b><span style="text-decoration: underline;">
                                    <ix:nonNumeric id="Fxbrl_20211227133920615" name="dei:EntityRegistrantName" contextRef="C_20201001to20210930">BRIGHT MINDS BIOSCIENCES INC.</ix:nonNumeric>
                                </span></b></span></span></p>
                <p style="margin-top: 0px; text-align: center; margin-bottom: 0px;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">(Exact name of Registrant specified in its charter)</span></span></p>
                <p style="margin-top: 0pt; text-align: center; margin-bottom: 0px;">&#160;</p>
                <p style="margin-bottom: 0px; text-align: center; margin-top: 0px;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span style="text-decoration: underline;"><b>Not Applicable</b></span></span></span></p>
                <p style="margin-top: 0px; text-align: center; margin-bottom: 0px;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">(Translation of Registrant's name into English)</span></span></p>
                <p style="margin-top: 0px; text-align: center; margin-bottom: 0px;">&#160;</p>
                <p style="margin-bottom: 0px; text-align: center; margin-top: 0px;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span style="text-decoration: underline;"><b>British Columbia, <ix:nonNumeric id="Fxbrl_20211227133951552" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:edgarprovcountryen" contextRef="C_20201001to20210930">Canada</ix:nonNumeric></b></span></span></span></p>
                <p style="margin-top: 0px; text-align: center; margin-bottom: 0px;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">(Jurisdiction of incorporation or organization)</span></span></p>
                <p style="margin-top: 0px; text-align: center; margin-bottom: 0px;">&#160;</p>
                <p style="margin-bottom: 0px; text-align: center; margin-top: 0px;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span style="text-decoration: underline;"><b>
                                    <ix:nonNumeric id="Fxbrl_20211227134011473" name="dei:EntityAddressAddressLine1" contextRef="C_20201001to20210930">19 Vestry Street</ix:nonNumeric>, <ix:nonNumeric id="Fxbrl_20211227134030405" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" contextRef="C_20201001to20210930">New York</ix:nonNumeric>, <ix:nonNumeric id="Fxbrl_20211227161511346" name="dei:EntityAddressCityOrTown" contextRef="C_20201001to20210930">NY</ix:nonNumeric>&#160;<ix:nonNumeric id="Fxbrl_20211227134055444" name="dei:EntityAddressPostalZipCode" contextRef="C_20201001to20210930">10013</ix:nonNumeric>
                                </b></span></span></span></p>
                <p style="margin-top: 0px; text-align: center; margin-bottom: 0px;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">(Address of principal executive offices)</span></span></p>
                <p style="margin-top: 0px; text-align: center; margin-bottom: 0px;">&#160;</p>
                <p style="margin-bottom: 0px; text-align: center; margin-top: 0px;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>
                                <ix:nonNumeric id="Fxbrl_20211227134141232" name="dei:ContactPersonnelName" contextRef="C_20201001to20210930_deiEntityAddressesAddressTypeAxis_deiBusinessContactMember">Ian McDonald</ix:nonNumeric>; (<ix:nonNumeric id="Fxbrl_20211227134158579" name="dei:CityAreaCode" contextRef="C_20201001to20210930_deiEntityAddressesAddressTypeAxis_deiBusinessContactMember">647</ix:nonNumeric>) <ix:nonNumeric id="Fxbrl_20211227134215898" name="dei:LocalPhoneNumber" contextRef="C_20201001to20210930_deiEntityAddressesAddressTypeAxis_deiBusinessContactMember">407-2515</ix:nonNumeric>;
                            </b><span style="color: #0000ff; text-decoration: underline;">
                                <ix:nonNumeric id="Fxbrl_20211227134230744" name="dei:ContactPersonnelEmailAddress" contextRef="C_20201001to20210930_deiEntityAddressesAddressTypeAxis_deiBusinessContactMember">ian@brightmindsbio.com</ix:nonNumeric>
                            </span><br /><span style="text-decoration: underline;"><b>
                                    <ix:nonNumeric id="Fxbrl_20211227134108266" name="dei:EntityAddressAddressLine1" contextRef="C_20201001to20210930_deiEntityAddressesAddressTypeAxis_deiBusinessContactMember">19 Vestry Street</ix:nonNumeric>, <ix:nonNumeric id="Fxbrl_20211227134115387" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" contextRef="C_20201001to20210930_deiEntityAddressesAddressTypeAxis_deiBusinessContactMember">New York</ix:nonNumeric>, <ix:nonNumeric id="Fxbrl_20211227161545234" name="dei:EntityAddressCityOrTown" contextRef="C_20201001to20210930_deiEntityAddressesAddressTypeAxis_deiBusinessContactMember">NY</ix:nonNumeric>
                                    <ix:nonNumeric id="Fxbrl_20211227134122394" name="dei:EntityAddressPostalZipCode" contextRef="C_20201001to20210930_deiEntityAddressesAddressTypeAxis_deiBusinessContactMember">10013</ix:nonNumeric>
                                </b></span></span></span></p>
                <p style="margin-top: 0px; text-align: center; margin-bottom: 0px;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">(Name, Telephone, Email and/or Facsimile number and Address of Company Contact Person)</span></span></p>
                <p style="margin: 0pt;">&#160;</p>
                <p style="text-align: justify; margin-top: 0px; margin-bottom: 0px;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">Securities registered or to be registered pursuant to Section 12(b) of the Act.</span></span></p>
                <p style="text-align: justify; margin-top: 0px; margin-bottom: 0px;">&#160;</p>
                <table style="width: 100%; border-collapse: collapse; font-size: 10pt;" cellspacing="0" cellpadding="0">
                    <tr>
                        <td style="width: 36%; vertical-align: top; border-bottom: 0.75pt solid #000000;">
                            <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><i>Title of Each Class</i></span></span></p>
                        </td>
                        <td style="margin-top: 0pt; margin-bottom: 0pt;">
                            <p>&#160;</p>
                        </td>
                        <td style="width: 24%; vertical-align: top; border-bottom: 0.75pt solid #000000;">
                            <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><i>Trading Symbol(s)</i></span></span></p>
                        </td>
                        <td style="margin-top: 0pt; margin-bottom: 0pt;">
                            <p>&#160;</p>
                        </td>
                        <td style="width: 36%; vertical-align: top; border-bottom: 0.75pt solid #000000;">
                            <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><i>Name of each exchange on which registered</i></span></span></p>
                        </td>
                    </tr>
                    <tr>
                        <td style="vertical-align: top;">
                            <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><i><b>
                                                <ix:nonNumeric id="Fxbrl_20211227134257248" name="dei:Security12bTitle" contextRef="C_20201001to20210930">Common Shares</ix:nonNumeric>
                                            </b></i></span></span></p>
                        </td>
                        <td style="margin-top: 0pt; margin-bottom: 0pt;">
                            <p>&#160;</p>
                        </td>
                        <td style="vertical-align: top;">
                            <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><i><b>
                                                <ix:nonNumeric id="Fxbrl_20211227134314472" name="dei:TradingSymbol" contextRef="C_20201001to20210930">DRUG</ix:nonNumeric>
                                            </b></i></span></span></p>
                        </td>
                        <td style="margin-top: 0pt; margin-bottom: 0pt;">
                            <p>&#160;</p>
                        </td>
                        <td style="vertical-align: top;">
                            <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><i><b>The <ix:nonNumeric id="Fxbrl_20211227134327209" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" contextRef="C_20201001to20210930">Nasdaq</ix:nonNumeric> Stock Market LLC</b></i></span></span></p>
                        </td>
                    </tr>
                </table>
                <p style="text-align: justify; margin-top: 0px; margin-bottom: 0px;">&#160;</p>
                <p style="text-align: justify; margin-top: 0px; margin-bottom: 0px;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">Securities registered or to be registered pursuant to Section 12(g) of the Act.</span></span></p>
                <p style="margin-bottom: 0pt; text-align: center;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span style="text-decoration: underline;"><b>None</b></span></span></span></p>
                <p style="margin-top: 0pt; text-align: center;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">(Title of Class)</span></span></p>
                <hr style="page-break-after: always; text-align: center; height: 5px; width: 100%; background-color: black;" />
                <p style="margin-bottom: 0pt; text-align: left;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">Securities for which there is a reporting obligation pursuant to Section 15(d) of the Act.</span></span></p>
                <p style="margin-bottom: 0pt; text-align: center;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span style="text-decoration: underline;"><b>None</b></span></span></span></p>
                <p style="margin-top: 0px; text-align: center; margin-bottom: 0px;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">(Title of Class)</span></span></p>
                <p style="margin-top: 0px; text-align: center; margin-bottom: 0px;">&#160;</p>
                <p style="text-align: justify; margin-top: 0px; margin-bottom: 0px;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">Number of outstanding shares of each of the issuer's classes of capital or common stock as of the close of business of the period covered by the annual report.</span></span></p>
                <p style="text-align: justify; margin-top: 0px; margin-bottom: 0px;">&#160;</p>
                <p style="text-align: center; margin-top: 0px; margin-bottom: 0px;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span style="text-decoration: underline;"><b><ix:nonFraction id="Fxbrl_20211227134413747" name="dei:EntityCommonStockSharesOutstanding" decimals="INF" format="ixt:numdotdecimal" contextRef="C_20210930" unitRef="Share">11,834,361</ix:nonFraction> Common Shares Without Par Value</b></span></span></span></p>
                <p style="text-align: center; margin-top: 0px; margin-bottom: 0px;">&#160;</p>
                <p style="text-align: justify; margin-top: 0px; margin-bottom: 0px;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">Indicate by check mark if the Registrant is a well-known seasoned issuer as defined in Rule 405 of the Securities Act.</span></span></p>
                <p style="text-align: justify; margin-top: 0px; margin-bottom: 0px;">&#160;</p>
                <p style="text-align: center; margin-top: 0px; margin-bottom: 0px;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">Yes &#9744;&#160; <ix:nonNumeric id="Fxbrl_20211227134432190" name="dei:EntityWellKnownSeasonedIssuer" contextRef="C_20201001to20210930">No</ix:nonNumeric> &#9746;</span></span></p>
                <p style="text-align: center; margin-top: 0px; margin-bottom: 0px;">&#160;</p>
                <p style="text-align: justify; margin-top: 0px; margin-bottom: 0px;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">If this report is an annual or transition report, indicate by check mark if the Registrant is not required to file reports pursuant to Section 13 or 15(d) of the <i>Securities Exchange Act of 1934</i></span></span></p>
                <p style="text-align: justify; margin-top: 0px; margin-bottom: 0px;">&#160;</p>
                <p style="text-align: center; margin-top: 0px; margin-bottom: 0px;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">Yes &#9744;&#160; <ix:nonNumeric id="Fxbrl_20211227134439438" name="dei:EntityVoluntaryFilers" contextRef="C_20201001to20210930">No</ix:nonNumeric> &#9746;</span></span></p>
                <p style="text-align: center; margin-top: 0px; margin-bottom: 0px;">&#160;</p>
                <p style="text-align: justify; margin-top: 0px; margin-bottom: 0px;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">Indicate by check mark whether the Registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the <i>Securities Exchange Act of 1934 </i>during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.</span></span></p>
                <p style="text-align: justify; margin-top: 0px; margin-bottom: 0px;">&#160;</p>
                <p style="text-align: center; margin-top: 0px; margin-bottom: 0px;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">
                            <ix:nonNumeric id="Fxbrl_20211227134443141" name="dei:EntityCurrentReportingStatus" contextRef="C_20201001to20210930">Yes</ix:nonNumeric> &#9746;&#160; No &#9744;
                        </span></span></p>
                <p style="text-align: center; margin-top: 0px; margin-bottom: 0px;">&#160;</p>
                <p style="text-align: justify; margin-top: 0px; margin-bottom: 0px;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">Indicate by check mark whether the Registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167; 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the Registrant was required to submit such files).</span></span></p>
                <p style="text-align: justify; margin-top: 0px; margin-bottom: 0px;">&#160;</p>
                <p style="text-align: center; margin-top: 0px; margin-bottom: 0px;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">
                            <ix:nonNumeric id="Fxbrl_20211227134448157" name="dei:EntityInteractiveDataCurrent" contextRef="C_20201001to20210930">Yes</ix:nonNumeric> &#9746;&#160; No &#9744;
                        </span></span></p>
                <p style="text-align: justify; margin-top: 0px; margin-bottom: 0px;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">Indicate by check mark whether the Registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or an emerging growth company. See definition of "accelerated filer," "large accelerated filer," and "emerging growth company" in Rule 12b-2 of the Exchange Act.</span></span></p>
                <p style="text-align: justify; margin-top: 0px; margin-bottom: 0px;">&#160;</p>
                <table style="width: 100%; border-collapse: collapse; font-size: 10pt;" cellspacing="0" cellpadding="0">
                    <tr>
                        <td style="margin-top: 0pt; margin-bottom: 0pt;">
                            <p><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">Large Accelerated Filer &#9744;</span></span></p>
                        </td>
                        <td style="margin-top: 0pt; margin-bottom: 0pt;">
                            <p><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">Accelerated Filer &#9744;</span></span></p>
                        </td>
                    </tr>
                    <tr>
                        <td style="margin-top: 0pt; margin-bottom: 0pt;">
                            <p><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">
                                        <ix:nonNumeric id="Fxbrl_20211227134628914" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" contextRef="C_20201001to20210930">Non Accelerated Filer</ix:nonNumeric> &#9746;
                                    </span></span></p>
                        </td>
                        <td style="margin-top: 0pt; margin-bottom: 0pt;">
                            <p><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">Emerging Growth Company <ix:nonNumeric id="Fxbrl_20211227134657226" name="dei:EntityEmergingGrowthCompany" format="ixt:booleantrue" contextRef="C_20201001to20210930">&#9746;</ix:nonNumeric></span></span></p>
                        </td>
                    </tr>
                </table>
                <p style="text-align: justify; margin-top: 0px; margin-bottom: 0px;">&#160;</p>
                <p style="text-align: justify; margin-top: 0px; margin-bottom: 0px;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">If an emerging growth company that prepares its financial statements in accordance with U.S. GAAP, indicate by check mark if the Registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards pursuant to Section 13(a) of the Exchange Act. <ix:nonNumeric id="Fxbrl_20211227134709450" name="dei:EntityExTransitionPeriod" format="ixt:booleanfalse" contextRef="C_20201001to20210930">&#9744;</ix:nonNumeric></span></span></p>
                <p style="text-align: justify; margin-top: 0px; margin-bottom: 0px;">&#160;</p>
                <p style="text-align: justify; margin-top: 0px; margin-bottom: 0px;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">Indicate by check mark which basis of accounting the Registrant has used to prepare the financial statements included in this filing:</span></span></p>
                <p style="text-align: justify; margin-top: 0px; margin-bottom: 0px;">&#160;</p>
                <table style="width: 100%; border-collapse: collapse; font-size: 10pt;" cellspacing="0" cellpadding="0">
                    <tr>
                        <td style="width: 20%; vertical-align: top;">
                            <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">U.S. GAAP &#9744;</span></span></p>
                        </td>
                        <td style="width: 60%; vertical-align: top;">
                            <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">
                                        <ix:nonNumeric id="Fxbrl_20211227134728240" name="dei:DocumentAccountingStandard" contextRef="C_20201001to20210930">International Financial Reporting Standards</ix:nonNumeric> as issued
                                    </span></span></p>
                        </td>
                        <td style="width: 20%; vertical-align: top;">
                            <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">Other &#9744;</span></span></p>
                        </td>
                    </tr>
                    <tr>
                        <td style="vertical-align: top;">
                            <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt;">&#160;</p>
                        </td>
                        <td style="vertical-align: top;">
                            <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">by the International Accounting Standards Board &#9746;</span></span></p>
                        </td>
                        <td style="vertical-align: top;">
                            <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt;">&#160;</p>
                        </td>
                    </tr>
                </table>
                <p style="text-align: justify; margin-bottom: 0px; margin-top: 0px;">&#160;</p>
                <p style="text-align: justify; margin-bottom: 0px; margin-top: 0px;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">If "Other" has been checked in response to the previous question, indicate by check mark which financial statement item the Registrant has elected to follow:&#160; &#160; &#160; &#160; Item 17 &#9744;&#160; Item 18 &#9744;</span></span></p>
                <p style="text-align: justify; margin-top: 0px; margin-bottom: 0px;">&#160;</p>
                <p style="text-align: justify; margin-top: 0px; margin-bottom: 0px;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">If this is an annual report, indicate by check mark whether the Registrant is a shell company (as defined in Rule 12b 2 of the Exchange Act):</span></span></p>
                <p style="text-align: justify; margin-top: 0px; margin-bottom: 0px;">&#160;</p>
                <p style="text-align: center; margin-top: 0px; margin-bottom: 0px;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">Yes &#9744;&#160; No <ix:nonNumeric id="Fxbrl_20211227134750504" name="dei:EntityShellCompany" format="ixt:booleanfalse" contextRef="C_20201001to20210930">&#9746;</ix:nonNumeric></span></span></p>
                <p style="text-align: center; margin-top: 0px; margin-bottom: 0px;">&#160;</p>
                <p style="text-align: justify; margin-top: 0px; margin-bottom: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">(APPLICABLE ONLY TO ISSUERS INVOLVED IN BANKRUPTCY PROCEEDINGS DURING THE PAST FIVE YE</span><span style="font-size: 10pt;">ARS)</span></span></p>
                <hr style="page-break-after: always; text-align: center; height: 5px; width: 100%; background-color: black; margin-top: 0pt;" />
                <p style="text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">Indicate by check mark whether the Registrant has filed all documents and reports required to be filed by Sections 12, 13 or 15(d) of the <i>Securities Exchange Act of 1934</i> subsequent to the distribution of securities under a plan confirmed by a court.</span></span></p>
                <div>
                    <p style="text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">Not applicable.</span></span></p>
                    <br />
                </div>
            </div>
            <div>
                <div style="margin-top: 6pt;"><br /></div>
                <hr style="page-break-after: always; text-align: center; height: 5px; width: 100%; background-color: black; margin-top: 10pt;" />
            </div>
            <div>
                <p style="text-align: center; margin-top: 10pt;"><span style="font-family: Times New Roman, Times, serif; font-size: 10pt;"><b>EXPLANATORY NOTE</b></span></p>
                <div>
                    <ix:nonNumeric id="Fxbrl_20220115013011986" name="dei:AmendmentDescription" contextRef="C_20201001to20210930">
                        <div>
                            <p style="font-size: 10pt; font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify;"><span style="font-family: Times New Roman, Times, serif; font-size: 10pt;">Bright Minds Biosciences Inc. (the "Company") is filing this Amendment No. 1 to Form 20-F (the "<b>Form 20-F/A</b>") for the year ended September 30, 2021 to furnish Exhibit 101 to the Form 20-F, which provides certain items from our Form 20-F formatted in eXtensible Business Reporting Language ("<b>XBRL</b>"). In accordance with the policy of the Securities and Exchange Commission (the "<b>Commission</b>") stated in Release No. 33-9002, we are filing this Form 20-F/A within the 30-day period available to first-time XBRL filers following the filing of our Form 20-F, as filed with the Commission on December 29, 2021. Accordingly, this Form 20-F/A consists only of the facing page, this explanatory note, Item 18, Item 19, the signature page and Exhibit 101.</span></p>
                            <p style="font-size: 10pt; font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify;"><br /><span style="font-family: Times New Roman, Times, serif; font-size: 10pt;">No other changes have been made to the Form 20-F other than the furnishing of the exhibit described above. This Form 20-F/A does not reflect subsequent events occurring after the original date of the Form 20-F, or modify or update in any way disclosures made in the Form 20-F.</span></p>
                        </div>
                    </ix:nonNumeric>
                </div>
                <p style="font-size: 10pt; font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;">&#160;</p>
            </div>
            <div>
                <div>&#160;</div>
            </div>
        </div>
        <hr style="page-break-after: always; width: 100%; color: #000000; height: 5px; background-color: #000000;" />
        <div>
            <div>
                <div style="text-align: justify;"><a id="ITEM18"></a><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span style="color: #010000;"><b>ITEM 18. </b></span><b>FINANCIAL STATEMENTS</b></span></span></div>
                <p style="text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">Our financial statements were prepared in accordance with IFRS, as issued by the IASB, and are presented in Canadian dollars.</span></span></p>
                <p style="text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">Financial statements are filed as part of this Annual Report:</span></span></p>
                <p style="margin-top: 0pt; margin-bottom: 0pt; text-align: center; font-size: 10pt; font-family: Times New Roman, Times, serif;">&#160;</p>
                <hr style="page-break-after: always; text-align: center; height: 5px; width: 100%; background-color: black;" />
                <p style="text-align: center; margin-top: 10pt;"><img src="form20faxz004.jpg" alt=" " style="width: 802px; height: 144px;" /></p>
                <p style="text-align: center;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</b></span></span></p>
                <p style="text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>To the Board of Directors and Shareholders of Bright Minds Biosciences Inc.</b></span></span></p>
                <p style="margin-bottom: 0pt; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>Opinion on the Consolidated Financial Statements </b></span></span></p>
                <p style="margin-top: 0pt; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">We have audited the accompanying consolidated statements of financial position of Bright Minds Biosciences Inc. ("the Company") as of September 30, 2021 and 2020, and the related consolidated statements of comprehensive loss, changes in shareholders' equity and cash flows for the years ended September 30, 2021 and 2020 and the period from May 31, 2019 (date of incorporation) to September 30, 2019, and the related notes (collectively referred to as the financial statements).&#160; In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of September 30, 2021 and 2020, and the results of its operations and its cash flows for the years ended September 30, 2021 and 2020 and the period from May 31, 2019 (date of incorporation) to September 30, 2019, in conformity with International Financial Reporting Standards as issued by the International Accounting Standards Board.</span></span></p>
                <p style="margin-bottom: 0pt; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>Critical Audit Matters</b></span></span></p>
                <p style="margin-top: 0pt; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">Critical audit matters are matters arising from the current period audit of the consolidated financial statements that were communicated or required to be communicated to the audit committee and that: (1) relate to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective, or complex judgments. We determined that there are no critical audit matters.</span></span></p>
                <p style="margin-bottom: 0pt; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>Basis for Opinion</b></span></span></p>
                <p style="margin-top: 0pt; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on the Company's financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) ("PCAOB") and are required to be independent with respect to the Company in accordance with U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></span></p>
                <p style="text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance whether the financial statements are free of material misstatement, whether due to fraud or error. The Company is not required to have, nor were we engaged to perform, an audit of internal control over financial reporting. As part of our audits, we are required to obtain an understanding of internal control over financial reporting, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control over financial reporting. Accordingly, we express no such opinion.</span></span></p>
                <p style="text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.</span></span></p>
                <p style="text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>/s/ De-Visser Gray LLP</b></span></span></p>
                <p style="text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>CHARTERED PROFESSIONAL ACCOUNTANTS</b></span></span></p>
                <p style="text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">We have served as the Company's auditor since 2020.</span></span></p>
                <p style="margin-bottom: 0pt; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">Vancouver, Canada</span></span></p>
                <p style="margin-top: 0pt; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">December 24, 2021</span></span></p>
                <hr style="page-break-after: always; text-align: center; height: 5px; width: 100%; background-color: black;" />
                <table style="width: 100%; border-collapse: collapse; font-size: 10pt;" border="0" cellspacing="0" cellpadding="0">
                    <tr>
                        <td style="width: 100%;">
                            <p style="margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>Bright Minds Biosciences Inc.</b></span></span></p>
                        </td>
                    </tr>
                </table>
            </div>
            <div>
                <div>
                    <table style="width: 100%; border-collapse: collapse; font-size: 10pt;" border="0" cellspacing="0" cellpadding="0">
                        <tr>
                            <td style="width: 100%;">
                                <p style="margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">Consolidated Statements of Financial Position</span></span></p>
                                <p style="margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">(Expressed in Canadian dollars)</span></span></p>
                            </td>
                        </tr>
                    </table>
                    &#160;
                    <table style="width: 100%; border-collapse: collapse; font-size: 10pt; border-color: #000000;" cellspacing="0" cellpadding="0">
                        <tr>
                            <td style="margin-top: 0pt; margin-bottom: 0pt; border-top: 0.75pt solid #000000; vertical-align: bottom;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span style="color: #7f7f7f;">&#160;</span></span></span></td>
                            <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: center; white-space: nowrap;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span style="color: #7f7f7f;">&#160;</span></span></span></td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; white-space: nowrap;">&#160;</td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; white-space: nowrap;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>September 30,</b></span></span></td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; white-space: nowrap;">&#160;</td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; white-space: nowrap;">&#160;</td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; white-space: nowrap;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">September 30,</span></span></td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right;">&#160;</td>
                        </tr>
                        <tr>
                            <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; padding-left: 5.4pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">As at</span></span></td>
                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; text-align: center; white-space: nowrap;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>Notes</b></span></span></td>
                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;">&#160;</td>
                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>2021</b></span></span></td>
                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;">&#160;</td>
                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;">&#160;</td>
                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">2020</span></span></td>
                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right;">&#160;</td>
                        </tr>
                        <tr>
                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 5.4pt;">&#160;</td>
                            <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: center;">&#160;</td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right;">&#160;</td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>$</b></span></span></td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right;">&#160;</td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right;">&#160;</td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">$</span></span></td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right;">&#160;</td>
                        </tr>
                        <tr>
                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff; padding-left: 5.4pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>ASSETS</b></span></span></td>
                            <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: center; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>&#160;</b></span></span></td>
                            <td style="vertical-align: bottom; text-align: right; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; background-color: #e6efff;">&#160;</td>
                        </tr>
                        <tr>
                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 5.4pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>Current Assets</b></span></span></td>
                            <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: center;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>&#160;</b></span></span></td>
                            <td style="vertical-align: bottom; text-align: right;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right;">&#160;</td>
                        </tr>
                        <tr>
                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff; padding-left: 15pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">Cash and cash equivalents</span></span></td>
                            <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: center; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">9</span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b><ix:nonFraction id="Fxbrl_20211228161301545_53" name="ifrs-full:CashAndCashEquivalents" scale="0" decimals="0" format="ixt:numdotdecimal" contextRef="C_20210930" unitRef="CAD">19,760,015</ix:nonFraction></b></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><ix:nonFraction id="Fxbrl_20211228161301545_56" name="ifrs-full:CashAndCashEquivalents" scale="0" decimals="0" format="ixt:numdotdecimal" contextRef="C_20200930" unitRef="CAD">799,929</ix:nonFraction></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                        </tr>
                        <tr>
                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 15pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">Sales tax receivable</span></span></td>
                            <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: center;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 12%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b><ix:nonFraction id="Fxbrl_20211228161301545_63" name="ifrs-full:CurrentTaxAssetsCurrent" scale="0" decimals="0" format="ixt:numdotdecimal" contextRef="C_20210930" unitRef="CAD">110,146</ix:nonFraction></b></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 12%;"><span style="font-family: Times New Roman, Times, serif;"><ix:nonFraction id="Fxbrl_20211228161301545_66" name="ifrs-full:CurrentTaxAssetsCurrent" scale="0" decimals="0" format="ixt:zerodash" contextRef="C_20200930" unitRef="CAD">-</ix:nonFraction></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                        </tr>
                        <tr>
                            <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; background-color: #e6efff; padding-left: 15pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">Prepaids</span></span></td>
                            <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: center; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b><ix:nonFraction id="Fxbrl_20211228161301545_73" name="ifrs-full:CurrentPrepaidExpenses" scale="0" decimals="0" format="ixt:numdotdecimal" contextRef="C_20210930" unitRef="CAD">168,207</ix:nonFraction></b></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><ix:nonFraction id="Fxbrl_20211228161301545_76" name="ifrs-full:CurrentPrepaidExpenses" scale="0" decimals="0" format="ixt:numdotdecimal" contextRef="C_20200930" unitRef="CAD">78,287</ix:nonFraction></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                        </tr>
                        <tr>
                            <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>&#160;</b></span></span></td>
                            <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: center;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>&#160;</b></span></span></td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b><ix:nonFraction id="Fxbrl_20211228161301545_83" name="ifrs-full:CurrentAssets" scale="0" decimals="0" format="ixt:numdotdecimal" contextRef="C_20210930" unitRef="CAD">20,038,368</ix:nonFraction></b></span></span></td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><ix:nonFraction id="Fxbrl_20211228161301545_86" name="ifrs-full:CurrentAssets" scale="0" decimals="0" format="ixt:numdotdecimal" contextRef="C_20200930" unitRef="CAD">878,216</ix:nonFraction></span></span></td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                        </tr>
                        <tr>
                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff; padding-left: 5.4pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>Non-Current Assets</b></span></span></td>
                            <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: center; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>&#160;</b></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                        </tr>
                        <tr>
                            <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; padding-left: 15pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">Intangible assets</span></span></td>
                            <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: center;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">4</span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 12%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b><ix:nonFraction id="Fxbrl_20211228161301545_103" name="ifrs-full:IntangibleAssetsAndGoodwill" scale="0" decimals="0" format="ixt:numdotdecimal" contextRef="C_20210930" unitRef="CAD">2,000</ix:nonFraction></b></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 12%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><ix:nonFraction id="Fxbrl_20211228161301545_106" name="ifrs-full:IntangibleAssetsAndGoodwill" scale="0" decimals="0" format="ixt:numdotdecimal" contextRef="C_20200930" unitRef="CAD">2,000</ix:nonFraction></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                        </tr>
                        <tr>
                            <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 2.25pt double #000000; vertical-align: bottom; background-color: #e6efff; padding-left: 5.4pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>TOTAL ASSETS</b></span></span></td>
                            <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: center; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b><ix:nonFraction id="Fxbrl_20211228161301545_113" name="ifrs-full:Assets" scale="0" decimals="0" format="ixt:numdotdecimal" contextRef="C_20210930" unitRef="CAD">20,040,368</ix:nonFraction></b></span></span></td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><ix:nonFraction id="Fxbrl_20211228161301545_116" name="ifrs-full:Assets" scale="0" decimals="0" format="ixt:numdotdecimal" contextRef="C_20200930" unitRef="CAD">880,216</ix:nonFraction></span></span></td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                        </tr>
                        <tr>
                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 5.4pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>&#160;</b></span></span></td>
                            <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: center;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 12%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>&#160;</b></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 12%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                        </tr>
                        <tr>
                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff; padding-left: 5.4pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>LIABILITIES AND SHAREHOLDERS' EQUITY</b></span></span></td>
                            <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: center; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>&#160;</b></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                        </tr>
                        <tr>
                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 5.4pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>Current Liabilities</b></span></span></td>
                            <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: center;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 12%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>&#160;</b></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 12%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                        </tr>
                        <tr>
                            <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; background-color: #e6efff; padding-left: 5.4pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">&#160; &#160; Accounts payable and accrued liabilities</span></span></td>
                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff; text-align: center;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">5</span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b><ix:nonFraction id="Fxbrl_20211228161301545_153" name="ifrs-full:TradeAndOtherCurrentPayables" scale="0" decimals="0" format="ixt:numdotdecimal" contextRef="C_20210930" unitRef="CAD">638,573</ix:nonFraction></b></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><ix:nonFraction id="Fxbrl_20211228161301545_156" name="ifrs-full:TradeAndOtherCurrentPayables" scale="0" decimals="0" format="ixt:numdotdecimal" contextRef="C_20200930" unitRef="CAD">150,923</ix:nonFraction></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                        </tr>
                        <tr>
                            <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; padding-left: 5.4pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>TOTAL LIABILITIES</b></span></span></td>
                            <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: center;">&#160;</td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b><ix:nonFraction id="Fxbrl_20211228161301545_163" name="ifrs-full:Liabilities" scale="0" decimals="0" format="ixt:numdotdecimal" contextRef="C_20210930" unitRef="CAD">638,573</ix:nonFraction></b></span></span></td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><ix:nonFraction id="Fxbrl_20211228161301545_166" name="ifrs-full:Liabilities" scale="0" decimals="0" format="ixt:numdotdecimal" contextRef="C_20200930" unitRef="CAD">150,923</ix:nonFraction></span></span></td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                        </tr>
                        <tr>
                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff; padding-left: 5.4pt;">&#160;</td>
                            <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: center; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>&#160;</b></span></span></td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                        </tr>
                        <tr>
                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 5.4pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>Shareholders' equity</b></span></span></td>
                            <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: center;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 12%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>&#160;</b></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 12%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                        </tr>
                        <tr>
                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff; padding-left: 5.4pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">&#160; &#160; Share capital</span></span></td>
                            <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: center; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">6</span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b><ix:nonFraction id="Fxbrl_20211228161301545_193" name="ifrs-full:IssuedCapital" scale="0" decimals="0" format="ixt:numdotdecimal" contextRef="C_20210930" unitRef="CAD">27,080,281</ix:nonFraction></b></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><ix:nonFraction id="Fxbrl_20211228161301545_196" name="ifrs-full:IssuedCapital" scale="0" decimals="0" format="ixt:numdotdecimal" contextRef="C_20200930" unitRef="CAD">980,661</ix:nonFraction></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                        </tr>
                        <tr>
                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 5.4pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">&#160; &#160; Subscriptions receivable</span></span></td>
                            <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: center;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">6</span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 12%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>(<ix:nonFraction id="Fxbrl_20211228161301545_203" name="drug:SubscriptionsReceivable" scale="0" decimals="0" format="ixt:numdotdecimal" contextRef="C_20210930" unitRef="CAD">33,684</ix:nonFraction></b></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>)</b></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 12%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">(<ix:nonFraction id="Fxbrl_20211228161301545_206" name="drug:SubscriptionsReceivable" scale="0" decimals="0" format="ixt:numdotdecimal" contextRef="C_20200930" unitRef="CAD">1,000</ix:nonFraction></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">)</span></span></td>
                        </tr>
                        <tr>
                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff; padding-left: 5.4pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">&#160; &#160; Subscriptions received</span></span></td>
                            <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: center; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">6</span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-family: Times New Roman, Times, serif;"><b><ix:nonFraction id="Fxbrl_20211228161301545_213" name="drug:SubscriptionsReceived" scale="0" decimals="0" format="ixt:zerodash" contextRef="C_20210930" unitRef="CAD">-</ix:nonFraction></b></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><ix:nonFraction id="Fxbrl_20211228161301545_216" name="drug:SubscriptionsReceived" scale="0" decimals="0" format="ixt:numdotdecimal" contextRef="C_20200930" unitRef="CAD">147,426</ix:nonFraction></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                        </tr>
                        <tr>
                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 5.4pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">&#160; &#160; Reserves</span></span></td>
                            <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: center;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">6</span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 12%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b><ix:nonFraction id="Fxbrl_20211228161301545_223" name="ifrs-full:OtherReserves" scale="0" decimals="0" format="ixt:numdotdecimal" contextRef="C_20210930" unitRef="CAD">1,565,055</ix:nonFraction></b></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 12%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><ix:nonFraction id="Fxbrl_20211228161301545_226" name="ifrs-full:OtherReserves" scale="0" decimals="0" format="ixt:numdotdecimal" contextRef="C_20200930" unitRef="CAD">161,300</ix:nonFraction></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                        </tr>
                        <tr>
                            <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; background-color: #e6efff; padding-left: 5.4pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">&#160; &#160; Deficit</span></span></td>
                            <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>(<ix:nonFraction id="Fxbrl_20211228161301545_233" name="ifrs-full:RetainedEarnings" scale="0" decimals="0" format="ixt:numdotdecimal" sign="-" contextRef="C_20210930" unitRef="CAD">9,209,857</ix:nonFraction></b></span></span></td>
                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>)</b></span></span></td>
                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">(<ix:nonFraction id="Fxbrl_20211228161301545_236" name="ifrs-full:RetainedEarnings" scale="0" decimals="0" format="ixt:numdotdecimal" sign="-" contextRef="C_20200930" unitRef="CAD">559,094</ix:nonFraction></span></span></td>
                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">)</span></span></td>
                        </tr>
                        <tr>
                            <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; padding-left: 5.4pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>TOTAL SHAREHOLDERS' EQUITY </b></span></span></td>
                            <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: center;">&#160;</td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b><ix:nonFraction id="Fxbrl_20211228161301545_243" name="ifrs-full:Equity" scale="0" decimals="0" format="ixt:numdotdecimal" contextRef="C_20210930" unitRef="CAD">19,401,795</ix:nonFraction></b></span></span></td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><ix:nonFraction id="Fxbrl_20211228161301545_246" name="ifrs-full:Equity" scale="0" decimals="0" format="ixt:numdotdecimal" contextRef="C_20200930" unitRef="CAD">729,293</ix:nonFraction></span></span></td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                        </tr>
                        <tr>
                            <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 2.25pt double #000000; vertical-align: bottom; background-color: #e6efff; padding-left: 5.4pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY</b></span></span></td>
                            <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: center; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b><ix:nonFraction id="Fxbrl_20211228161301545_253" name="ifrs-full:EquityAndLiabilities" scale="0" decimals="0" format="ixt:numdotdecimal" contextRef="C_20210930" unitRef="CAD">20,040,368</ix:nonFraction></b></span></span></td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><ix:nonFraction id="Fxbrl_20211228161301545_256" name="ifrs-full:EquityAndLiabilities" scale="0" decimals="0" format="ixt:numdotdecimal" contextRef="C_20200930" unitRef="CAD">880,216</ix:nonFraction></span></span></td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                        </tr>
                    </table>
                    <p style="margin-bottom: 0pt; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">Nature and continuance of operations (Note 1)</span></span></p>
                    <p style="margin-top: 0pt; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">Subsequent events (Note 14)</span></span></p>
                    <table style="width: 100%; border-collapse: collapse; font-size: 10pt;" cellspacing="0" cellpadding="0">
                        <tr>
                            <td style="margin-top: 0pt; margin-bottom: 0pt;" colspan="3">
                                <p><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>Approved on behalf of the Board of Directors:</b></span></span></p>
                            </td>
                        </tr>
                        <tr>
                            <td style="margin-top: 0pt; margin-bottom: 0pt;">
                                <p>&#160;</p>
                            </td>
                            <td style="width: 4%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom;">
                                <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt;">&#160;</p>
                            </td>
                            <td style="width: 20%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom;">
                                <p style="text-align: right; margin-top: 0pt; margin-bottom: 0pt;">&#160;</p>
                            </td>
                        </tr>
                        <tr>
                            <td style="width: 46%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-bottom: 0.75pt solid #000000;">
                                <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><i>"Ian McDonald"</i></span></span></p>
                            </td>
                            <td style="width: 4%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom;">
                                <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt;">&#160;</p>
                            </td>
                            <td style="width: 42%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-bottom: 0.75pt solid #000000;" colspan="1">
                                <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><i>"Alan Kozikowski"</i></span></span></p>
                            </td>
                        </tr>
                        <tr>
                            <td style="width: 46%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-top: 0.75pt solid #000000;">
                                <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">Director</span></span></p>
                            </td>
                            <td style="width: 4%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom;">
                                <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt;">&#160;</p>
                            </td>
                            <td style="width: 42%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-top: 0.75pt solid #000000;" colspan="1">
                                <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">Director</span></span></p>
                            </td>
                        </tr>
                    </table>
                    <p style="text-align: center;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><i>The accompanying notes are an integral part of these consolidated financial statements.</i></span></span></p>
                    <div>
                        <table style="width: 100%; border-collapse: collapse; font-size: 10pt;" border="0" cellspacing="0" cellpadding="0">
                            <tr>
                                <td style="width: 100%; border-top: 0.75pt solid #000000; text-align: right;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>2&#160;</b>| Page</span></span></td>
                            </tr>
                        </table>
                    </div>
                    <hr style="page-break-after: always; text-align: center; height: 5px; width: 100%; background-color: black;" />
                </div>
            </div>
            <div>
                <div>
                    <table style="width: 100%; border-collapse: collapse; font-size: 10pt;" border="0" cellspacing="0" cellpadding="0">
                        <tr>
                            <td style="width: 100%;">
                                <p><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>Bright Minds Biosciences Inc.</b></span></span><br /><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">Consolidated Statements of Comprehensive Loss<br />(Expressed in Canadian dollars)</span></span><br /><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">&#160;&#160;</span></span></p>
                            </td>
                        </tr>
                    </table>
                    <table style="width: 100%; margin-top: 0pt; border-collapse: collapse; font-size: 10pt; border-color: #000000;" cellspacing="0" cellpadding="0">
                        <tr>
                            <td style="margin-top: 0pt; margin-bottom: 0pt; border-top: 0.75pt solid #000000; vertical-align: bottom;">&#160;</td>
                            <td style="padding-right: 5.75pt; padding-left: 5.75pt; vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: center; white-space: nowrap;">&#160;</td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; white-space: nowrap;">&#160;</td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; white-space: nowrap;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>For the year<br />ended</b></span></span></td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; white-space: nowrap;">&#160;</td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; white-space: nowrap;">&#160;</td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; white-space: nowrap;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">For the year<br />ended</span></span></td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; white-space: nowrap;">&#160;</td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; white-space: nowrap;">&#160;</td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; white-space: nowrap;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">For the period<br />ended</span></span></td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right;">&#160;</td>
                        </tr>
                        <tr>
                            <td style="padding-right: 5.75pt; padding-left: 5.75pt; vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right;">&#160;</td>
                            <td style="margin-top: 0pt; margin-bottom: 0pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>Notes</b></span></span></td>
                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;">&#160;</td>
                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>September 30, </b><br /><b>2021</b></span></span></td>
                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;">&#160;</td>
                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;">&#160;</td>
                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">September 30,<br />2020</span></span></td>
                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;">&#160;</td>
                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;">&#160;</td>
                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">September 30,<br />2019</span></span></td>
                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right;">&#160;</td>
                        </tr>
                        <tr>
                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
                            <td style="padding-right: 5.75pt; padding-left: 5.75pt; vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: center;">&#160;</td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right;">&#160;</td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>$</b></span></span></td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right;">&#160;</td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right;">&#160;</td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">$</span></span></td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right;">&#160;</td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right;">&#160;</td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">$</span></span></td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right;">&#160;</td>
                        </tr>
                        <tr>
                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff; padding-left: 5.4pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>EXPENSES</b></span></span></td>
                            <td style="padding-right: 5.75pt; padding-left: 5.75pt; vertical-align: bottom; text-align: center; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>&#160;</b></span></span></td>
                            <td style="vertical-align: bottom; text-align: right; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; background-color: #e6efff;">&#160;</td>
                        </tr>
                        <tr>
                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">&#160; &#160; &#160; Consulting fees</span></span></td>
                            <td style="padding-right: 5.75pt; padding-left: 5.75pt; vertical-align: bottom; text-align: center;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">6</span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 12%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b><ix:nonFraction id="Fxbrl_20211228163809986_43" name="drug:ConsultingFees" scale="0" decimals="0" format="ixt:numdotdecimal" contextRef="C_20201001to20210930" unitRef="CAD">394,624</ix:nonFraction></b></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 12%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><ix:nonFraction id="Fxbrl_20211228163809986_46" name="drug:ConsultingFees" scale="0" decimals="0" format="ixt:zerodash" contextRef="C_20191001to20200930" unitRef="CAD">-</ix:nonFraction></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 12%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><ix:nonFraction id="Fxbrl_20211228163809986_49" name="drug:ConsultingFees" scale="0" decimals="0" format="ixt:zerodash" contextRef="C_20190601to20190930" unitRef="CAD">-</ix:nonFraction></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                        </tr>
                        <tr>
                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">&#160; &#160; &#160; Directors' compensation</span></span></td>
                            <td style="padding-right: 5.75pt; padding-left: 5.75pt; vertical-align: bottom; text-align: center; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">6,7</span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b><ix:nonFraction id="Fxbrl_20211228163809986_53" name="ifrs-full:DirectorsRemunerationExpense" scale="0" decimals="0" format="ixt:numdotdecimal" contextRef="C_20201001to20210930" unitRef="CAD">136,612</ix:nonFraction></b></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><ix:nonFraction id="Fxbrl_20211228163809986_56" name="ifrs-full:DirectorsRemunerationExpense" scale="0" decimals="0" format="ixt:zerodash" contextRef="C_20191001to20200930" unitRef="CAD">-</ix:nonFraction></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><ix:nonFraction id="Fxbrl_20211228163809986_59" name="ifrs-full:DirectorsRemunerationExpense" scale="0" decimals="0" format="ixt:zerodash" contextRef="C_20190601to20190930" unitRef="CAD">-</ix:nonFraction></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                        </tr>
                        <tr>
                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">&#160; &#160; &#160; Foreign exchange</span></span></td>
                            <td style="padding-right: 5.75pt; padding-left: 5.75pt; vertical-align: bottom; text-align: center;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 12%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>(<ix:nonFraction id="Fxbrl_20211228163809986_63" name="ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss" scale="0" decimals="0" format="ixt:numdotdecimal" contextRef="C_20201001to20210930" unitRef="CAD">154,099</ix:nonFraction></b></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>)</b></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 12%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><ix:nonFraction id="Fxbrl_20211228163809986_66" name="ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss" scale="0" decimals="0" format="ixt:zerodash" contextRef="C_20191001to20200930" unitRef="CAD">-</ix:nonFraction></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 12%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><ix:nonFraction id="Fxbrl_20211228163809986_69" name="ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss" scale="0" decimals="0" format="ixt:zerodash" contextRef="C_20190601to20190930" unitRef="CAD">-</ix:nonFraction></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                        </tr>
                        <tr>
                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">&#160; &#160; &#160; Funds processing fees - private placements</span></span></td>
                            <td style="padding-right: 5.75pt; padding-left: 5.75pt; vertical-align: bottom; text-align: center; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b><ix:nonFraction id="Fxbrl_20211228163809986_73" name="drug:ProcessingFees" scale="0" decimals="0" format="ixt:numdotdecimal" contextRef="C_20201001to20210930" unitRef="CAD">18,665</ix:nonFraction></b></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><ix:nonFraction id="Fxbrl_20211228163809986_76" name="drug:ProcessingFees" scale="0" decimals="0" format="ixt:numdotdecimal" contextRef="C_20191001to20200930" unitRef="CAD">5,568</ix:nonFraction></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><ix:nonFraction id="Fxbrl_20211228163809986_79" name="drug:ProcessingFees" scale="0" decimals="0" format="ixt:zerodash" contextRef="C_20190601to20190930" unitRef="CAD">-</ix:nonFraction></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                        </tr>
                        <tr>
                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">&#160; &#160; &#160; Marketing, advertising, and investor relations</span></span></td>
                            <td style="padding-right: 5.75pt; padding-left: 5.75pt; vertical-align: bottom; text-align: center;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">6</span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 12%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b><ix:nonFraction id="Fxbrl_20211228163809986_83" name="ifrs-full:SalesAndMarketingExpense" scale="0" decimals="0" format="ixt:numdotdecimal" contextRef="C_20201001to20210930" unitRef="CAD">852,151</ix:nonFraction></b></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 12%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><ix:nonFraction id="Fxbrl_20211228163809986_86" name="ifrs-full:SalesAndMarketingExpense" scale="0" decimals="0" format="ixt:numdotdecimal" contextRef="C_20191001to20200930" unitRef="CAD">9,618</ix:nonFraction></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 12%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><ix:nonFraction id="Fxbrl_20211228163809986_89" name="ifrs-full:SalesAndMarketingExpense" scale="0" decimals="0" format="ixt:zerodash" contextRef="C_20190601to20190930" unitRef="CAD">-</ix:nonFraction></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                        </tr>
                        <tr>
                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">&#160; &#160; &#160; Office and administrative</span></span></td>
                            <td style="padding-right: 5.75pt; padding-left: 5.75pt; vertical-align: bottom; text-align: center; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">11</span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b><ix:nonFraction id="Fxbrl_20211228163809986_93" name="ifrs-full:GeneralAndAdministrativeExpense" scale="0" decimals="0" format="ixt:numdotdecimal" contextRef="C_20201001to20210930" unitRef="CAD">197,125</ix:nonFraction></b></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><ix:nonFraction id="Fxbrl_20211228163809986_96" name="ifrs-full:GeneralAndAdministrativeExpense" scale="0" decimals="0" format="ixt:numdotdecimal" contextRef="C_20191001to20200930" unitRef="CAD">637</ix:nonFraction></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><ix:nonFraction id="Fxbrl_20211228163809986_99" name="ifrs-full:GeneralAndAdministrativeExpense" scale="0" decimals="0" format="ixt:zerodash" contextRef="C_20190601to20190930" unitRef="CAD">-</ix:nonFraction></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                        </tr>
                        <tr>
                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">&#160; &#160; &#160; Professional fees</span></span></td>
                            <td style="padding-right: 5.75pt; padding-left: 5.75pt; vertical-align: bottom; text-align: center;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">6,7</span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 12%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b><ix:nonFraction id="Fxbrl_20211228163809986_103" name="ifrs-full:ProfessionalFeesExpense" scale="0" decimals="0" format="ixt:numdotdecimal" contextRef="C_20201001to20210930" unitRef="CAD">709,954</ix:nonFraction></b></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 12%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><ix:nonFraction id="Fxbrl_20211228163809986_106" name="ifrs-full:ProfessionalFeesExpense" scale="0" decimals="0" format="ixt:numdotdecimal" contextRef="C_20191001to20200930" unitRef="CAD">104,251</ix:nonFraction></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 12%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><ix:nonFraction id="Fxbrl_20211228163809986_109" name="ifrs-full:ProfessionalFeesExpense" scale="0" decimals="0" format="ixt:numdotdecimal" contextRef="C_20190601to20190930" unitRef="CAD">36,708</ix:nonFraction></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                        </tr>
                        <tr>
                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">&#160; &#160; &#160; Regulatory and filing</span></span></td>
                            <td style="padding-right: 5.75pt; padding-left: 5.75pt; vertical-align: bottom; text-align: center; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b><ix:nonFraction id="Fxbrl_20211228163809986_113" name="drug:RegulatoryAndFilingExpenses" scale="0" decimals="0" format="ixt:numdotdecimal" contextRef="C_20201001to20210930" unitRef="CAD">181,743</ix:nonFraction></b></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><ix:nonFraction id="Fxbrl_20211228163809986_116" name="drug:RegulatoryAndFilingExpenses" scale="0" decimals="0" format="ixt:numdotdecimal" contextRef="C_20191001to20200930" unitRef="CAD">5,451</ix:nonFraction></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><ix:nonFraction id="Fxbrl_20211228163809986_119" name="drug:RegulatoryAndFilingExpenses" scale="0" decimals="0" format="ixt:zerodash" contextRef="C_20190601to20190930" unitRef="CAD">-</ix:nonFraction></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                        </tr>
                        <tr>
                            <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">&#160; &#160; &#160; Research and development</span></span></td>
                            <td style="padding-right: 5.75pt; padding-left: 5.75pt; vertical-align: bottom; text-align: center;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">6,7,10</span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 12%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b><ix:nonFraction id="Fxbrl_20211228163809986_123" name="ifrs-full:ResearchAndDevelopmentExpense" scale="0" decimals="0" format="ixt:numdotdecimal" contextRef="C_20201001to20210930" unitRef="CAD">6,313,988</ix:nonFraction></b></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 12%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><ix:nonFraction id="Fxbrl_20211228163809986_126" name="ifrs-full:ResearchAndDevelopmentExpense" scale="0" decimals="0" format="ixt:numdotdecimal" contextRef="C_20191001to20200930" unitRef="CAD">354,852</ix:nonFraction></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 12%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><ix:nonFraction id="Fxbrl_20211228163809986_129" name="ifrs-full:ResearchAndDevelopmentExpense" scale="0" decimals="0" format="ixt:numdotdecimal" contextRef="C_20190601to20190930" unitRef="CAD">42,009</ix:nonFraction></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                        </tr>
                        <tr>
                            <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 2.25pt double #000000; vertical-align: bottom; background-color: #e6efff; padding-left: 5.4pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>Net loss and comprehensive loss</b></span></span></td>
                            <td style="padding-right: 5.75pt; padding-left: 5.75pt; vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: center; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>&#160;</b></span></span></td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>(<ix:nonFraction id="Fxbrl_20211228163809986_133" name="ifrs-full:ProfitLoss" scale="0" decimals="0" format="ixt:numdotdecimal" sign="-" contextRef="C_20201001to20210930" unitRef="CAD">8,650,763</ix:nonFraction></b></span></span></td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>)</b></span></span></td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">(<ix:nonFraction id="Fxbrl_20211228163809986_136" name="ifrs-full:ProfitLoss" scale="0" decimals="0" format="ixt:numdotdecimal" sign="-" contextRef="C_20191001to20200930" unitRef="CAD">480,377</ix:nonFraction></span></span></td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">)</span></span></td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">(<ix:nonFraction id="Fxbrl_20211228163809986_139" name="ifrs-full:ProfitLoss" scale="0" decimals="0" format="ixt:numdotdecimal" sign="-" contextRef="C_20190601to20190930" unitRef="CAD">78,717</ix:nonFraction></span></span></td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">)</span></span></td>
                        </tr>
                        <tr>
                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 5.4pt;">&#160;</td>
                            <td style="padding-right: 5.75pt; padding-left: 5.75pt; vertical-align: bottom; border-top: 2.25pt double #000000; text-align: center;">&#160;</td>
                            <td style="vertical-align: bottom; border-top: 2.25pt double #000000; text-align: left; width: 1%;">&#160;</td>
                            <td style="vertical-align: bottom; border-top: 2.25pt double #000000; text-align: right; width: 12%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>&#160;</b></span></span></td>
                            <td style="vertical-align: bottom; border-top: 2.25pt double #000000; text-align: left; width: 2%;">&#160;</td>
                            <td style="vertical-align: bottom; border-top: 2.25pt double #000000; text-align: left; width: 1%;">&#160;</td>
                            <td style="vertical-align: bottom; border-top: 2.25pt double #000000; text-align: right; width: 12%;">&#160;</td>
                            <td style="vertical-align: bottom; border-top: 2.25pt double #000000; text-align: left; width: 2%;">&#160;</td>
                            <td style="vertical-align: bottom; border-top: 2.25pt double #000000; text-align: left; width: 1%;">&#160;</td>
                            <td style="vertical-align: bottom; border-top: 2.25pt double #000000; text-align: right; width: 12%;">&#160;</td>
                            <td style="vertical-align: bottom; border-top: 2.25pt double #000000; text-align: left; width: 2%;">&#160;</td>
                        </tr>
                        <tr>
                            <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 2.25pt double #000000; vertical-align: bottom; background-color: #e6efff; padding-left: 5.4pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>Basic and diluted loss per share </b></span></span></td>
                            <td style="padding-right: 5.75pt; padding-left: 5.75pt; vertical-align: bottom; border-bottom: 2.25pt double #000000; text-align: center; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>(<ix:nonFraction id="Fxbrl_20211228163809986_153" name="ifrs-full:BasicAndDilutedEarningsLossPerShare" scale="0" decimals="2" format="ixt:numdotdecimal" sign="-" contextRef="C_20201001to20210930" unitRef="CAD_per_share">0.96</ix:nonFraction></b></span></span></td>
                            <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>)</b></span></span></td>
                            <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">(<ix:nonFraction id="Fxbrl_20211228163809986_156" name="ifrs-full:BasicAndDilutedEarningsLossPerShare" scale="0" decimals="2" format="ixt:numdotdecimal" sign="-" contextRef="C_20191001to20200930" unitRef="CAD_per_share">0.13</ix:nonFraction></span></span></td>
                            <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">)</span></span></td>
                            <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">(<ix:nonFraction id="Fxbrl_20211228163809986_159" name="ifrs-full:BasicAndDilutedEarningsLossPerShare" scale="0" decimals="2" format="ixt:numdotdecimal" sign="-" contextRef="C_20190601to20190930" unitRef="CAD_per_share">0.04</ix:nonFraction></span></span></td>
                            <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">)</span></span></td>
                        </tr>
                        <tr>
                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 5.4pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>&#160;</b></span></span></td>
                            <td style="padding-right: 5.75pt; padding-left: 5.75pt; vertical-align: bottom; border-top: 2.25pt double #000000; text-align: center;">&#160;</td>
                            <td style="vertical-align: bottom; border-top: 2.25pt double #000000; text-align: left; width: 1%;">&#160;</td>
                            <td style="vertical-align: bottom; border-top: 2.25pt double #000000; text-align: right; width: 12%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>&#160;</b></span></span></td>
                            <td style="vertical-align: bottom; border-top: 2.25pt double #000000; text-align: left; width: 2%;">&#160;</td>
                            <td style="vertical-align: bottom; border-top: 2.25pt double #000000; text-align: left; width: 1%;">&#160;</td>
                            <td style="vertical-align: bottom; border-top: 2.25pt double #000000; text-align: right; width: 12%;">&#160;</td>
                            <td style="vertical-align: bottom; border-top: 2.25pt double #000000; text-align: left; width: 2%;">&#160;</td>
                            <td style="vertical-align: bottom; border-top: 2.25pt double #000000; text-align: left; width: 1%;">&#160;</td>
                            <td style="vertical-align: bottom; border-top: 2.25pt double #000000; text-align: right; width: 12%;">&#160;</td>
                            <td style="vertical-align: bottom; border-top: 2.25pt double #000000; text-align: left; width: 2%;">&#160;</td>
                        </tr>
                        <tr>
                            <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 2.25pt double #000000; vertical-align: bottom; background-color: #e6efff; padding-left: 5.4pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>Weighted average number of common shares outstanding</b> <b> -basic and diluted</b></span></span></td>
                            <td style="padding-right: 5.75pt; padding-left: 5.75pt; vertical-align: bottom; border-bottom: 2.25pt double #000000; text-align: center; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b><ix:nonFraction id="Fxbrl_20211228163809986_173" name="ifrs-full:WeightedAverageShares" scale="0" decimals="0" format="ixt:numdotdecimal" contextRef="C_20201001to20210930" unitRef="Share">8,974,023</ix:nonFraction></b></span></span></td>
                            <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><ix:nonFraction id="Fxbrl_20211228163809986_176" name="ifrs-full:WeightedAverageShares" scale="0" decimals="0" format="ixt:numdotdecimal" contextRef="C_20191001to20200930" unitRef="Share">3,612,436</ix:nonFraction></span></span></td>
                            <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><ix:nonFraction id="Fxbrl_20211228163809986_179" name="ifrs-full:WeightedAverageShares" scale="0" decimals="0" format="ixt:numdotdecimal" contextRef="C_20190601to20190930" unitRef="Share">2,073,240</ix:nonFraction></span></span></td>
                            <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                        </tr>
                    </table>
                    <p style="text-align: center;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><i>The accompanying notes are an integral part of these consolidated financial statements.</i></span></span></p>
                    <div>
                        <table style="width: 100%; border-collapse: collapse; font-size: 10pt;" border="0" cellspacing="0" cellpadding="0">
                            <tr>
                                <td style="width: 100%; border-top: 0.75pt solid #000000; text-align: right;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>3&#160;</b>| Page</span></span></td>
                            </tr>
                        </table>
                    </div>
                    <hr style="page-break-after: always; text-align: center; height: 5px; width: 100%; background-color: black;" />
                </div>
            </div>
            <div>
                <div>
                    <table style="width: 100%; border-collapse: collapse; font-size: 10pt;" border="0" cellspacing="0" cellpadding="0">
                        <tr>
                            <td style="width: 100%;">
                                <p><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>Bright Minds Biosciences Inc.</b></span></span><br /><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">Consolidated Statements of Changes in Shareholders&#8217; Equity<br />(Expressed in Canadian Dollars)</span></span></p>
                            </td>
                        </tr>
                    </table>
                    &#160;
                    <table style="width: 100%; border-collapse: collapse; font-size: 8pt; border-color: #000000;" cellspacing="0" cellpadding="0">
                        <tr>
                            <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: justify;"><span style="font-size: 8pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="color: #7f7f7f;"><b>&#160;</b></span></span></span></td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: center;" colspan="1">&#160;</td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;" colspan="4"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Share Capital</b></span></span></td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;" colspan="1">&#160;</td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;">&#160;</td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>&#160;</b></span></span></td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;">&#160;</td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;">&#160;</td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>&#160;</b></span></span></td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;">&#160;</td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;">&#160;</td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>&#160;</b></span></span></td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;">&#160;</td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;">&#160;</td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>&#160;</b></span></span></td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;">&#160;</td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;">&#160;</td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>&#160;</b></span></span></td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: center;">&#160;</td>
                        </tr>
                        <tr>
                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; border-bottom: 0.75pt solid #000000;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>&#160;</b></span></span></td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right;">&#160;</td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Number of<br />shares</b></span></span></td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;">&#160;</td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;">&#160;</td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Share<br />capital</b></span></span></td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;">&#160;</td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;">&#160;</td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Subscriptions<br />receivable</b></span></span></td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;">&#160;</td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;">&#160;</td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Subscriptions<br />received</b></span></span></td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;">&#160;</td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;">&#160;</td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Reserves</b></span></span></td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;">&#160;</td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;">&#160;</td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Deficit</b></span></span></td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;">&#160;</td>
                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;">&#160;</td>
                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Total</b></span></span></td>
                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right;">&#160;</td>
                        </tr>
                        <tr>
                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right;">&#160;</td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right;">&#160;</td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right;">&#160;</td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right;">&#160;</td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right;">&#160;</td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right;">&#160;</td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right;">&#160;</td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right;">&#160;</td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">&#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160;$</span></span></td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right;">&#160;</td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right;">&#160;</td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right;">&#160;</td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right;">&#160;</td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right;">&#160;</td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right;">&#160;</td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right;">&#160;</td>
                        </tr>
                        <tr>
                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff; padding-left: 5.4pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Balance at May 31, 2019 (date of incorporation)</b></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b><ix:nonFraction id="Fxbrl_20211228194258211_32" name="ifrs-full:NumberOfSharesOutstanding" decimals="INF" format="ixt:zerodash" contextRef="C_20190531_ifrsfullComponentsOfEquityAxis_ifrsfullIssuedCapitalMember" unitRef="Share">-</ix:nonFraction></b></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b><ix:nonFraction id="Fxbrl_20211228194258211_35" name="ifrs-full:Equity" scale="0" decimals="0" format="ixt:zerodash" contextRef="C_20190531_ifrsfullComponentsOfEquityAxis_ifrsfullIssuedCapitalMember" unitRef="CAD">-</ix:nonFraction></b></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b><ix:nonFraction id="Fxbrl_20211228194258211_38" name="ifrs-full:Equity" scale="0" decimals="0" format="ixt:zerodash" contextRef="C_20190531_ifrsfullComponentsOfEquityAxis_drugSubscriptionReceivableMember" unitRef="CAD">-</ix:nonFraction></b></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b><ix:nonFraction id="Fxbrl_20211228194258211_311" name="ifrs-full:Equity" scale="0" decimals="0" format="ixt:zerodash" contextRef="C_20190531_ifrsfullComponentsOfEquityAxis_drugSubscriptionReceivedMember" unitRef="CAD">-</ix:nonFraction></b></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b><ix:nonFraction id="Fxbrl_20211228194258211_314" name="ifrs-full:Equity" scale="0" decimals="0" format="ixt:zerodash" contextRef="C_20190531_ifrsfullComponentsOfEquityAxis_ifrsfullOtherReservesMember" unitRef="CAD">-</ix:nonFraction></b></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b><ix:nonFraction id="Fxbrl_20211228194258211_317" name="ifrs-full:Equity" scale="0" decimals="0" format="ixt:zerodash" contextRef="C_20190531_ifrsfullComponentsOfEquityAxis_ifrsfullRetainedEarningsMember" unitRef="CAD">-</ix:nonFraction></b></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b><ix:nonFraction id="Fxbrl_20211228194258211_320" name="ifrs-full:Equity" scale="0" decimals="0" format="ixt:zerodash" contextRef="C_20190531" unitRef="CAD">-</ix:nonFraction></b></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                        </tr>
                        <tr>
                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 5.4pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Private placement</span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 7%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="Fxbrl_20211228194258211_42" name="drug:IncreaseDecreaseThroughPrivatePlacementShares" decimals="INF" format="ixt:numdotdecimal" contextRef="C_20190601to20190930_ifrsfullComponentsOfEquityAxis_ifrsfullIssuedCapitalMember" unitRef="Share">4,079,600</ix:nonFraction></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 7%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="Fxbrl_20211228194258211_45" name="drug:IncreaseDecreaseThroughPrivatePlacement" scale="0" decimals="0" format="ixt:numdotdecimal" contextRef="C_20190601to20190930_ifrsfullComponentsOfEquityAxis_ifrsfullIssuedCapitalMember" unitRef="CAD">203,980</ix:nonFraction></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 7%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(<ix:nonFraction id="Fxbrl_20211228194258211_48" name="drug:IncreaseDecreaseThroughPrivatePlacement" scale="0" decimals="0" format="ixt:numdotdecimal" sign="-" contextRef="C_20190601to20190930_ifrsfullComponentsOfEquityAxis_drugSubscriptionReceivableMember" unitRef="CAD">81,980</ix:nonFraction></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 7%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="Fxbrl_20211228194258211_411" name="drug:IncreaseDecreaseThroughPrivatePlacement" scale="0" decimals="0" format="ixt:zerodash" contextRef="C_20190601to20190930_ifrsfullComponentsOfEquityAxis_drugSubscriptionReceivedMember" unitRef="CAD">-</ix:nonFraction></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 7%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="Fxbrl_20211228194258211_414" name="drug:IncreaseDecreaseThroughPrivatePlacement" scale="0" decimals="0" format="ixt:zerodash" contextRef="C_20190601to20190930_ifrsfullComponentsOfEquityAxis_ifrsfullOtherReservesMember" unitRef="CAD">-</ix:nonFraction></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 7%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="Fxbrl_20211228194258211_417" name="drug:IncreaseDecreaseThroughPrivatePlacement" scale="0" decimals="0" format="ixt:zerodash" contextRef="C_20190601to20190930_ifrsfullComponentsOfEquityAxis_ifrsfullRetainedEarningsMember" unitRef="CAD">-</ix:nonFraction></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 7%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="Fxbrl_20211228194258211_420" name="drug:IncreaseDecreaseThroughPrivatePlacement" scale="0" decimals="0" format="ixt:numdotdecimal" contextRef="C_20190601to20190930" unitRef="CAD">122,000</ix:nonFraction></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                        </tr>
                        <tr>
                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff; padding-left: 5.4pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Acquisition of intangible assets</span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="Fxbrl_20211228194258211_52" name="drug:IncreaseDecreaseThroughAcquisitionOfIntangibleAssetsShares" decimals="INF" format="ixt:numdotdecimal" contextRef="C_20190601to20190930_ifrsfullComponentsOfEquityAxis_ifrsfullIssuedCapitalMember" unitRef="Share">40,000</ix:nonFraction></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="Fxbrl_20211228194258211_55" name="drug:IncreaseDecreaseThroughAcquisitionOfIntangibleAssets" scale="0" decimals="0" format="ixt:numdotdecimal" contextRef="C_20190601to20190930_ifrsfullComponentsOfEquityAxis_ifrsfullIssuedCapitalMember" unitRef="CAD">2,000</ix:nonFraction></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="Fxbrl_20211228194258211_58" name="drug:IncreaseDecreaseThroughAcquisitionOfIntangibleAssets" scale="0" decimals="0" format="ixt:zerodash" contextRef="C_20190601to20190930_ifrsfullComponentsOfEquityAxis_drugSubscriptionReceivableMember" unitRef="CAD">-</ix:nonFraction></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="Fxbrl_20211228194258211_511" name="drug:IncreaseDecreaseThroughAcquisitionOfIntangibleAssets" scale="0" decimals="0" format="ixt:zerodash" contextRef="C_20190601to20190930_ifrsfullComponentsOfEquityAxis_drugSubscriptionReceivedMember" unitRef="CAD">-</ix:nonFraction></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="Fxbrl_20211228194258211_514" name="drug:IncreaseDecreaseThroughAcquisitionOfIntangibleAssets" scale="0" decimals="0" format="ixt:zerodash" contextRef="C_20190601to20190930_ifrsfullComponentsOfEquityAxis_ifrsfullOtherReservesMember" unitRef="CAD">-</ix:nonFraction></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="Fxbrl_20211228194258211_517" name="drug:IncreaseDecreaseThroughAcquisitionOfIntangibleAssets" scale="0" decimals="0" format="ixt:zerodash" contextRef="C_20190601to20190930_ifrsfullComponentsOfEquityAxis_ifrsfullRetainedEarningsMember" unitRef="CAD">-</ix:nonFraction></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="Fxbrl_20211228194258211_520" name="drug:IncreaseDecreaseThroughAcquisitionOfIntangibleAssets" scale="0" decimals="0" format="ixt:numdotdecimal" contextRef="C_20190601to20190930" unitRef="CAD">2,000</ix:nonFraction></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                        </tr>
                        <tr>
                            <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; padding-left: 5.4pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Net loss</span></span></td>
                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">-</span></span></td>
                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="Fxbrl_20211228194258211_65" name="ifrs-full:ProfitLoss" scale="0" decimals="0" format="ixt:zerodash" contextRef="C_20190601to20190930_ifrsfullComponentsOfEquityAxis_ifrsfullIssuedCapitalMember" unitRef="CAD">-</ix:nonFraction></span></span></td>
                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="Fxbrl_20211228194258211_68" name="ifrs-full:ProfitLoss" scale="0" decimals="0" format="ixt:zerodash" contextRef="C_20190601to20190930_ifrsfullComponentsOfEquityAxis_drugSubscriptionReceivableMember" unitRef="CAD">-</ix:nonFraction></span></span></td>
                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="Fxbrl_20211228194258211_611" name="ifrs-full:ProfitLoss" scale="0" decimals="0" format="ixt:zerodash" contextRef="C_20190601to20190930_ifrsfullComponentsOfEquityAxis_drugSubscriptionReceivedMember" unitRef="CAD">-</ix:nonFraction></span></span></td>
                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="Fxbrl_20211228194258211_614" name="ifrs-full:ProfitLoss" scale="0" decimals="0" format="ixt:zerodash" contextRef="C_20190601to20190930_ifrsfullComponentsOfEquityAxis_ifrsfullOtherReservesMember" unitRef="CAD">-</ix:nonFraction></span></span></td>
                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(<ix:nonFraction id="Fxbrl_20211228194258211_617" name="ifrs-full:ProfitLoss" scale="0" decimals="0" format="ixt:numdotdecimal" sign="-" contextRef="C_20190601to20190930_ifrsfullComponentsOfEquityAxis_ifrsfullRetainedEarningsMember" unitRef="CAD">78,717</ix:nonFraction></span></span></td>
                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(<ix:nonFraction id="Fxbrl_20211228194258211_620" name="ifrs-full:ProfitLoss" scale="0" decimals="0" format="ixt:numdotdecimal" sign="-" contextRef="C_20190601to20190930" unitRef="CAD">78,717</ix:nonFraction></span></span></td>
                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                        </tr>
                        <tr>
                            <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; background-color: #e6efff; padding-left: 5.4pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Balance as at September 30, 2019</b></span></span></td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b><ix:nonFraction id="Fxbrl_20211228194258211_72" name="ifrs-full:NumberOfSharesOutstanding" decimals="INF" format="ixt:numdotdecimal" contextRef="C_20190930_ifrsfullComponentsOfEquityAxis_ifrsfullIssuedCapitalMember" unitRef="Share">4,119,600</ix:nonFraction></b></span></span></td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b><ix:nonFraction id="Fxbrl_20211228194258211_75" name="ifrs-full:Equity" scale="0" decimals="0" format="ixt:numdotdecimal" contextRef="C_20190930_ifrsfullComponentsOfEquityAxis_ifrsfullIssuedCapitalMember" unitRef="CAD">205,980</ix:nonFraction></b></span></span></td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>(<ix:nonFraction id="Fxbrl_20211228194258211_78" name="ifrs-full:Equity" scale="0" decimals="0" format="ixt:numdotdecimal" sign="-" contextRef="C_20190930_ifrsfullComponentsOfEquityAxis_drugSubscriptionReceivableMember" unitRef="CAD">81,980</ix:nonFraction></b></span></span></td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>)</b></span></span></td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b><ix:nonFraction id="Fxbrl_20211228194258211_711" name="ifrs-full:Equity" scale="0" decimals="0" format="ixt:zerodash" contextRef="C_20190930_ifrsfullComponentsOfEquityAxis_drugSubscriptionReceivedMember" unitRef="CAD">-</ix:nonFraction></b></span></span></td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b><ix:nonFraction id="Fxbrl_20211228194258211_714" name="ifrs-full:Equity" scale="0" decimals="0" format="ixt:zerodash" contextRef="C_20190930_ifrsfullComponentsOfEquityAxis_ifrsfullOtherReservesMember" unitRef="CAD">-</ix:nonFraction></b></span></span></td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>(<ix:nonFraction id="Fxbrl_20211228194258211_717" name="ifrs-full:Equity" scale="0" decimals="0" format="ixt:numdotdecimal" sign="-" contextRef="C_20190930_ifrsfullComponentsOfEquityAxis_ifrsfullRetainedEarningsMember" unitRef="CAD">78,717</ix:nonFraction></b></span></span></td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>)</b></span></span></td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b><ix:nonFraction id="Fxbrl_20211228194258211_720" name="ifrs-full:Equity" scale="0" decimals="0" format="ixt:numdotdecimal" contextRef="C_20190930" unitRef="CAD">45,283</ix:nonFraction></b></span></span></td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                        </tr>
                        <tr>
                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 5.4pt;">&#160;</td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 7%;">&#160;</td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 7%;">&#160;</td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 7%;">&#160;</td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 7%;">&#160;</td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 7%;">&#160;</td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 7%;">&#160;</td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 7%;">&#160;</td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                        </tr>
                        <tr>
                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff; padding-left: 5.4pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Balance as at September 30, 2019</b></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b><ix:nonFraction id="Fxbrl_20211228194258211_92" name="ifrs-full:NumberOfSharesOutstanding" decimals="INF" format="ixt:numdotdecimal" contextRef="C_20190930_ifrsfullComponentsOfEquityAxis_ifrsfullIssuedCapitalMember" unitRef="Share">4,119,600</ix:nonFraction></b></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b><ix:nonFraction id="Fxbrl_20211228194258211_95" name="ifrs-full:Equity" scale="0" decimals="0" format="ixt:numdotdecimal" contextRef="C_20190930_ifrsfullComponentsOfEquityAxis_ifrsfullIssuedCapitalMember" unitRef="CAD">205,980</ix:nonFraction></b></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>(<ix:nonFraction id="Fxbrl_20211228194258211_98" name="ifrs-full:Equity" scale="0" decimals="0" format="ixt:numdotdecimal" sign="-" contextRef="C_20190930_ifrsfullComponentsOfEquityAxis_drugSubscriptionReceivableMember" unitRef="CAD">81,980</ix:nonFraction></b></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>)</b></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b><ix:nonFraction id="Fxbrl_20211228194258211_911" name="ifrs-full:Equity" scale="0" decimals="0" format="ixt:zerodash" contextRef="C_20190930_ifrsfullComponentsOfEquityAxis_drugSubscriptionReceivedMember" unitRef="CAD">-</ix:nonFraction></b></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b><ix:nonFraction id="Fxbrl_20211228194258211_914" name="ifrs-full:Equity" scale="0" decimals="0" format="ixt:zerodash" contextRef="C_20190930_ifrsfullComponentsOfEquityAxis_ifrsfullOtherReservesMember" unitRef="CAD">-</ix:nonFraction></b></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>(<ix:nonFraction id="Fxbrl_20211228194258211_917" name="ifrs-full:Equity" scale="0" decimals="0" format="ixt:numdotdecimal" sign="-" contextRef="C_20190930_ifrsfullComponentsOfEquityAxis_ifrsfullRetainedEarningsMember" unitRef="CAD">78,717</ix:nonFraction></b></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>)</b></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b><ix:nonFraction id="Fxbrl_20211228194258211_920" name="ifrs-full:Equity" scale="0" decimals="0" format="ixt:numdotdecimal" contextRef="C_20190930" unitRef="CAD">45,283</ix:nonFraction></b></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                        </tr>
                        <tr>
                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 5.4pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Private placement</span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 7%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="Fxbrl_20211228194258211_102" name="drug:IncreaseDecreaseThroughPrivatePlacementShares" decimals="INF" format="ixt:numdotdecimal" contextRef="C_20191001to20200930_ifrsfullComponentsOfEquityAxis_ifrsfullIssuedCapitalMember" unitRef="Share">623,941</ix:nonFraction></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 7%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="Fxbrl_20211228194258211_105" name="drug:IncreaseDecreaseThroughPrivatePlacement" scale="0" decimals="0" format="ixt:numdotdecimal" contextRef="C_20191001to20200930_ifrsfullComponentsOfEquityAxis_ifrsfullIssuedCapitalMember" unitRef="CAD">779,924</ix:nonFraction></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 7%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="Fxbrl_20211228194258211_108" name="drug:IncreaseDecreaseThroughPrivatePlacement" scale="0" decimals="0" format="ixt:numdotdecimal" contextRef="C_20191001to20200930_ifrsfullComponentsOfEquityAxis_drugSubscriptionReceivableMember" unitRef="CAD">80,980</ix:nonFraction></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 7%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="Fxbrl_20211228194258211_1011" name="drug:IncreaseDecreaseThroughPrivatePlacement" scale="0" decimals="0" format="ixt:numdotdecimal" contextRef="C_20191001to20200930_ifrsfullComponentsOfEquityAxis_drugSubscriptionReceivedMember" unitRef="CAD">147,426</ix:nonFraction></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 7%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="Fxbrl_20211228194258211_1014" name="drug:IncreaseDecreaseThroughPrivatePlacement" scale="0" decimals="0" format="ixt:zerodash" contextRef="C_20191001to20200930_ifrsfullComponentsOfEquityAxis_ifrsfullOtherReservesMember" unitRef="CAD">-</ix:nonFraction></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 7%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="Fxbrl_20211228194258211_1017" name="drug:IncreaseDecreaseThroughPrivatePlacement" scale="0" decimals="0" format="ixt:zerodash" contextRef="C_20191001to20200930_ifrsfullComponentsOfEquityAxis_ifrsfullRetainedEarningsMember" unitRef="CAD">-</ix:nonFraction></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 7%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="Fxbrl_20211228194258211_1020" name="drug:IncreaseDecreaseThroughPrivatePlacement" scale="0" decimals="0" format="ixt:numdotdecimal" contextRef="C_20191001to20200930" unitRef="CAD">1,008,330</ix:nonFraction></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                        </tr>
                        <tr>
                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff; padding-left: 5.4pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Share issue costs</span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">-</span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(<ix:nonFraction id="Fxbrl_20211228194258211_115" name="ifrs-full:ShareIssueRelatedCost" scale="0" decimals="0" format="ixt:numdotdecimal" contextRef="C_20191001to20200930_ifrsfullComponentsOfEquityAxis_ifrsfullIssuedCapitalMember" unitRef="CAD">5,243</ix:nonFraction></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="Fxbrl_20211228194258211_118" name="ifrs-full:ShareIssueRelatedCost" scale="0" decimals="0" format="ixt:zerodash" contextRef="C_20191001to20200930_ifrsfullComponentsOfEquityAxis_drugSubscriptionReceivableMember" unitRef="CAD">-</ix:nonFraction></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="Fxbrl_20211228194258211_1111" name="ifrs-full:ShareIssueRelatedCost" scale="0" decimals="0" format="ixt:zerodash" contextRef="C_20191001to20200930_ifrsfullComponentsOfEquityAxis_drugSubscriptionReceivedMember" unitRef="CAD">-</ix:nonFraction></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="Fxbrl_20211228194258211_1114" name="ifrs-full:ShareIssueRelatedCost" scale="0" decimals="0" format="ixt:zerodash" contextRef="C_20191001to20200930_ifrsfullComponentsOfEquityAxis_ifrsfullOtherReservesMember" unitRef="CAD">-</ix:nonFraction></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="Fxbrl_20211228194258211_1117" name="ifrs-full:ShareIssueRelatedCost" scale="0" decimals="0" format="ixt:zerodash" contextRef="C_20191001to20200930_ifrsfullComponentsOfEquityAxis_ifrsfullRetainedEarningsMember" unitRef="CAD">-</ix:nonFraction></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(<ix:nonFraction id="Fxbrl_20211228194258211_1120" name="ifrs-full:ShareIssueRelatedCost" scale="0" decimals="0" format="ixt:numdotdecimal" contextRef="C_20191001to20200930" unitRef="CAD">5,243</ix:nonFraction></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                        </tr>
                        <tr>
                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 5.4pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Share-based compensation</span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 7%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">-</span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 7%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="Fxbrl_20211228194258211_125" name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" scale="0" decimals="0" format="ixt:zerodash" contextRef="C_20191001to20200930_ifrsfullComponentsOfEquityAxis_ifrsfullIssuedCapitalMember" unitRef="CAD">-</ix:nonFraction></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 7%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="Fxbrl_20211228194258211_128" name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" scale="0" decimals="0" format="ixt:zerodash" contextRef="C_20191001to20200930_ifrsfullComponentsOfEquityAxis_drugSubscriptionReceivableMember" unitRef="CAD">-</ix:nonFraction></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 7%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="Fxbrl_20211228194258211_1211" name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" scale="0" decimals="0" format="ixt:zerodash" contextRef="C_20191001to20200930_ifrsfullComponentsOfEquityAxis_drugSubscriptionReceivedMember" unitRef="CAD">-</ix:nonFraction></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 7%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="Fxbrl_20211228194258211_1214" name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" scale="0" decimals="0" format="ixt:numdotdecimal" contextRef="C_20191001to20200930_ifrsfullComponentsOfEquityAxis_ifrsfullOtherReservesMember" unitRef="CAD">161,300</ix:nonFraction></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 7%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="Fxbrl_20211228194258211_1217" name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" scale="0" decimals="0" format="ixt:zerodash" contextRef="C_20191001to20200930_ifrsfullComponentsOfEquityAxis_ifrsfullRetainedEarningsMember" unitRef="CAD">-</ix:nonFraction></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 7%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="Fxbrl_20211228194258211_1220" name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" scale="0" decimals="0" format="ixt:numdotdecimal" contextRef="C_20191001to20200930" unitRef="CAD">161,300</ix:nonFraction></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                        </tr>
                        <tr>
                            <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; background-color: #e6efff; padding-left: 5.4pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Net loss</span></span></td>
                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>-</b></span></span></td>
                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b><ix:nonFraction id="Fxbrl_20211228194258211_135" name="ifrs-full:ProfitLoss" scale="0" decimals="0" format="ixt:zerodash" contextRef="C_20191001to20200930_ifrsfullComponentsOfEquityAxis_ifrsfullIssuedCapitalMember" unitRef="CAD">-</ix:nonFraction></b></span></span></td>
                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b><ix:nonFraction id="Fxbrl_20211228194258211_138" name="ifrs-full:ProfitLoss" scale="0" decimals="0" format="ixt:zerodash" contextRef="C_20191001to20200930_ifrsfullComponentsOfEquityAxis_drugSubscriptionReceivableMember" unitRef="CAD">-</ix:nonFraction></b></span></span></td>
                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b><ix:nonFraction id="Fxbrl_20211228194258211_1311" name="ifrs-full:ProfitLoss" scale="0" decimals="0" format="ixt:zerodash" contextRef="C_20191001to20200930_ifrsfullComponentsOfEquityAxis_drugSubscriptionReceivedMember" unitRef="CAD">-</ix:nonFraction></b></span></span></td>
                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b><ix:nonFraction id="Fxbrl_20211228194258211_1314" name="ifrs-full:ProfitLoss" scale="0" decimals="0" format="ixt:zerodash" contextRef="C_20191001to20200930_ifrsfullComponentsOfEquityAxis_ifrsfullOtherReservesMember" unitRef="CAD">-</ix:nonFraction></b></span></span></td>
                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(<ix:nonFraction id="Fxbrl_20211228194258211_1317" name="ifrs-full:ProfitLoss" scale="0" decimals="0" format="ixt:numdotdecimal" sign="-" contextRef="C_20191001to20200930_ifrsfullComponentsOfEquityAxis_ifrsfullRetainedEarningsMember" unitRef="CAD">480,377</ix:nonFraction></span></span></td>
                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(<ix:nonFraction id="Fxbrl_20211228194258211_1320" name="ifrs-full:ProfitLoss" scale="0" decimals="0" format="ixt:numdotdecimal" sign="-" contextRef="C_20191001to20200930" unitRef="CAD">480,377</ix:nonFraction></span></span></td>
                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                        </tr>
                        <tr>
                            <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; padding-left: 5.4pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Balance as at September 30, 2020</b></span></span></td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b><ix:nonFraction id="Fxbrl_20211228194258211_142" name="ifrs-full:NumberOfSharesOutstanding" decimals="INF" format="ixt:numdotdecimal" contextRef="C_20200930_ifrsfullComponentsOfEquityAxis_ifrsfullIssuedCapitalMember" unitRef="Share">4,743,541</ix:nonFraction></b></span></span></td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b><ix:nonFraction id="Fxbrl_20211228194258211_145" name="ifrs-full:Equity" scale="0" decimals="0" format="ixt:numdotdecimal" contextRef="C_20200930_ifrsfullComponentsOfEquityAxis_ifrsfullIssuedCapitalMember" unitRef="CAD">980,661</ix:nonFraction></b></span></span></td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>(<ix:nonFraction id="Fxbrl_20211228194258211_148" name="ifrs-full:Equity" scale="0" decimals="0" format="ixt:numdotdecimal" sign="-" contextRef="C_20200930_ifrsfullComponentsOfEquityAxis_drugSubscriptionReceivableMember" unitRef="CAD">1,000</ix:nonFraction></b></span></span></td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>)</b></span></span></td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b><ix:nonFraction id="Fxbrl_20211228194258211_1411" name="ifrs-full:Equity" scale="0" decimals="0" format="ixt:numdotdecimal" contextRef="C_20200930_ifrsfullComponentsOfEquityAxis_drugSubscriptionReceivedMember" unitRef="CAD">147,426</ix:nonFraction></b></span></span></td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b><ix:nonFraction id="Fxbrl_20211228194258211_1414" name="ifrs-full:Equity" scale="0" decimals="0" format="ixt:numdotdecimal" contextRef="C_20200930_ifrsfullComponentsOfEquityAxis_ifrsfullOtherReservesMember" unitRef="CAD">161,300</ix:nonFraction></b></span></span></td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>(<ix:nonFraction id="Fxbrl_20211228194258211_1417" name="ifrs-full:Equity" scale="0" decimals="0" format="ixt:numdotdecimal" sign="-" contextRef="C_20200930_ifrsfullComponentsOfEquityAxis_ifrsfullRetainedEarningsMember" unitRef="CAD">559,094</ix:nonFraction></b></span></span></td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>)</b></span></span></td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b><ix:nonFraction id="Fxbrl_20211228194258211_1420" name="ifrs-full:Equity" scale="0" decimals="0" format="ixt:numdotdecimal" contextRef="C_20200930" unitRef="CAD">729,293</ix:nonFraction></b></span></span></td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                        </tr>
                        <tr>
                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff; padding-left: 5.4pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>&#160;</b></span></span></td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>&#160;</b></span></span></td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>&#160;</b></span></span></td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>&#160;</b></span></span></td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>&#160;</b></span></span></td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>&#160;</b></span></span></td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>&#160;</b></span></span></td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>&#160;</b></span></span></td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                        </tr>
                        <tr>
                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 5.4pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Balance as at September 30, 2020</b></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 7%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b><ix:nonFraction id="Fxbrl_20211228194258211_162" name="ifrs-full:NumberOfSharesOutstanding" decimals="INF" format="ixt:numdotdecimal" contextRef="C_20200930_ifrsfullComponentsOfEquityAxis_ifrsfullIssuedCapitalMember" unitRef="Share">4,743,541</ix:nonFraction></b></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 7%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b><ix:nonFraction id="Fxbrl_20211228194258211_165" name="ifrs-full:Equity" scale="0" decimals="0" format="ixt:numdotdecimal" contextRef="C_20200930_ifrsfullComponentsOfEquityAxis_ifrsfullIssuedCapitalMember" unitRef="CAD">980,661</ix:nonFraction></b></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 7%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>(<ix:nonFraction id="Fxbrl_20211228194258211_168" name="ifrs-full:Equity" scale="0" decimals="0" format="ixt:numdotdecimal" sign="-" contextRef="C_20200930_ifrsfullComponentsOfEquityAxis_drugSubscriptionReceivableMember" unitRef="CAD">1,000</ix:nonFraction></b></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>)</b></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 7%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b><ix:nonFraction id="Fxbrl_20211228194258211_1611" name="ifrs-full:Equity" scale="0" decimals="0" format="ixt:numdotdecimal" contextRef="C_20200930_ifrsfullComponentsOfEquityAxis_drugSubscriptionReceivedMember" unitRef="CAD">147,426</ix:nonFraction></b></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 7%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b><ix:nonFraction id="Fxbrl_20211228194258211_1614" name="ifrs-full:Equity" scale="0" decimals="0" format="ixt:numdotdecimal" contextRef="C_20200930_ifrsfullComponentsOfEquityAxis_ifrsfullOtherReservesMember" unitRef="CAD">161,300</ix:nonFraction></b></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 7%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>(<ix:nonFraction id="Fxbrl_20211228194258211_1617" name="ifrs-full:Equity" scale="0" decimals="0" format="ixt:numdotdecimal" sign="-" contextRef="C_20200930_ifrsfullComponentsOfEquityAxis_ifrsfullRetainedEarningsMember" unitRef="CAD">559,094</ix:nonFraction></b></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>)</b></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 7%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b><ix:nonFraction id="Fxbrl_20211228194258211_1620" name="ifrs-full:Equity" scale="0" decimals="0" format="ixt:numdotdecimal" contextRef="C_20200930" unitRef="CAD">729,293</ix:nonFraction></b></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                        </tr>
                        <tr>
                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff; padding-left: 5.4pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Private placements</span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="Fxbrl_20211228194258211_172" name="drug:IncreaseDecreaseThroughPrivatePlacementShares" decimals="INF" format="ixt:numdotdecimal" contextRef="C_20201001to20210930_ifrsfullComponentsOfEquityAxis_ifrsfullIssuedCapitalMember" unitRef="Share">5,049,021</ix:nonFraction></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="Fxbrl_20211228194258211_175" name="drug:IncreaseDecreaseThroughPrivatePlacement" scale="0" decimals="0" format="ixt:numdotdecimal" contextRef="C_20201001to20210930_ifrsfullComponentsOfEquityAxis_ifrsfullIssuedCapitalMember" unitRef="CAD">27,924,936</ix:nonFraction></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(<ix:nonFraction id="Fxbrl_20211228194258211_178" name="drug:IncreaseDecreaseThroughPrivatePlacement" scale="0" decimals="0" format="ixt:numdotdecimal" sign="-" contextRef="C_20201001to20210930_ifrsfullComponentsOfEquityAxis_drugSubscriptionReceivableMember" unitRef="CAD">32,684</ix:nonFraction></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(<ix:nonFraction id="Fxbrl_20211228194258211_1711" name="drug:IncreaseDecreaseThroughPrivatePlacement" scale="0" decimals="0" format="ixt:numdotdecimal" sign="-" contextRef="C_20201001to20210930_ifrsfullComponentsOfEquityAxis_drugSubscriptionReceivedMember" unitRef="CAD">147,426</ix:nonFraction></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="Fxbrl_20211228194258211_1714" name="drug:IncreaseDecreaseThroughPrivatePlacement" scale="0" decimals="0" format="ixt:zerodash" contextRef="C_20201001to20210930_ifrsfullComponentsOfEquityAxis_ifrsfullOtherReservesMember" unitRef="CAD">-</ix:nonFraction></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="Fxbrl_20211228194258211_1717" name="drug:IncreaseDecreaseThroughPrivatePlacement" scale="0" decimals="0" format="ixt:zerodash" contextRef="C_20201001to20210930_ifrsfullComponentsOfEquityAxis_ifrsfullRetainedEarningsMember" unitRef="CAD">-</ix:nonFraction></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="Fxbrl_20211228194258211_1720" name="drug:IncreaseDecreaseThroughPrivatePlacement" scale="0" decimals="0" format="ixt:numdotdecimal" contextRef="C_20201001to20210930" unitRef="CAD">27,744,826</ix:nonFraction></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                        </tr>
                        <tr>
                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 5.4pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Finder's fees - cash</span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 7%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">-</span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 7%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(<ix:nonFraction id="Fxbrl_20211228194258211_185" name="drug:IncreaseDecreaseThroughFindersFeesCash" scale="0" decimals="0" format="ixt:numdotdecimal" sign="-" contextRef="C_20201001to20210930_ifrsfullComponentsOfEquityAxis_ifrsfullIssuedCapitalMember" unitRef="CAD">1,516,317</ix:nonFraction></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 7%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="Fxbrl_20211228194258211_188" name="drug:IncreaseDecreaseThroughFindersFeesCash" scale="0" decimals="0" format="ixt:zerodash" contextRef="C_20201001to20210930_ifrsfullComponentsOfEquityAxis_drugSubscriptionReceivableMember" unitRef="CAD">-</ix:nonFraction></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 7%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="Fxbrl_20211228194258211_1811" name="drug:IncreaseDecreaseThroughFindersFeesCash" scale="0" decimals="0" format="ixt:zerodash" contextRef="C_20201001to20210930_ifrsfullComponentsOfEquityAxis_drugSubscriptionReceivedMember" unitRef="CAD">-</ix:nonFraction></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 7%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="Fxbrl_20211228194258211_1814" name="drug:IncreaseDecreaseThroughFindersFeesCash" scale="0" decimals="0" format="ixt:zerodash" contextRef="C_20201001to20210930_ifrsfullComponentsOfEquityAxis_ifrsfullOtherReservesMember" unitRef="CAD">-</ix:nonFraction></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 7%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="Fxbrl_20211228194258211_1817" name="drug:IncreaseDecreaseThroughFindersFeesCash" scale="0" decimals="0" format="ixt:zerodash" contextRef="C_20201001to20210930_ifrsfullComponentsOfEquityAxis_ifrsfullRetainedEarningsMember" unitRef="CAD">-</ix:nonFraction></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 7%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(<ix:nonFraction id="Fxbrl_20211228194258211_1820" name="drug:IncreaseDecreaseThroughFindersFeesCash" scale="0" decimals="0" format="ixt:numdotdecimal" sign="-" contextRef="C_20201001to20210930" unitRef="CAD">1,516,317</ix:nonFraction></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                        </tr>
                        <tr>
                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff; padding-left: 5.4pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Finder's fees - broker warrants</span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">-</span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(<ix:nonFraction id="Fxbrl_20211228194258211_195" name="drug:IncreaseDecreaseThroughFindersFeesBrokerWarrants" scale="0" decimals="0" format="ixt:numdotdecimal" sign="-" contextRef="C_20201001to20210930_ifrsfullComponentsOfEquityAxis_ifrsfullIssuedCapitalMember" unitRef="CAD">521,000</ix:nonFraction></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="Fxbrl_20211228194258211_198" name="drug:IncreaseDecreaseThroughFindersFeesBrokerWarrants" scale="0" decimals="0" format="ixt:zerodash" contextRef="C_20201001to20210930_ifrsfullComponentsOfEquityAxis_drugSubscriptionReceivableMember" unitRef="CAD">-</ix:nonFraction></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="Fxbrl_20211228194258211_1911" name="drug:IncreaseDecreaseThroughFindersFeesBrokerWarrants" scale="0" decimals="0" format="ixt:zerodash" contextRef="C_20201001to20210930_ifrsfullComponentsOfEquityAxis_drugSubscriptionReceivedMember" unitRef="CAD">-</ix:nonFraction></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="Fxbrl_20211228194258211_1914" name="drug:IncreaseDecreaseThroughFindersFeesBrokerWarrants" scale="0" decimals="0" format="ixt:numdotdecimal" contextRef="C_20201001to20210930_ifrsfullComponentsOfEquityAxis_ifrsfullOtherReservesMember" unitRef="CAD">521,000</ix:nonFraction></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="Fxbrl_20211228194258211_1917" name="drug:IncreaseDecreaseThroughFindersFeesBrokerWarrants" scale="0" decimals="0" format="ixt:zerodash" contextRef="C_20201001to20210930_ifrsfullComponentsOfEquityAxis_ifrsfullRetainedEarningsMember" unitRef="CAD">-</ix:nonFraction></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="Fxbrl_20211228194258211_1920" name="drug:IncreaseDecreaseThroughFindersFeesBrokerWarrants" scale="0" decimals="0" format="ixt:zerodash" contextRef="C_20201001to20210930" unitRef="CAD">-</ix:nonFraction></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                        </tr>
                        <tr>
                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 5.4pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Finder's fees - share options</span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 7%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">-</span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 7%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(<ix:nonFraction id="Fxbrl_20211228194258211_205" name="drug:IncreaseDecreaseThroughFindersFeesShareOptions" scale="0" decimals="0" format="ixt:numdotdecimal" sign="-" contextRef="C_20201001to20210930_ifrsfullComponentsOfEquityAxis_ifrsfullIssuedCapitalMember" unitRef="CAD">2,140</ix:nonFraction></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 7%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="Fxbrl_20211228194258211_208" name="drug:IncreaseDecreaseThroughFindersFeesShareOptions" scale="0" decimals="0" format="ixt:zerodash" contextRef="C_20201001to20210930_ifrsfullComponentsOfEquityAxis_drugSubscriptionReceivableMember" unitRef="CAD">-</ix:nonFraction></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 7%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="Fxbrl_20211228194258211_2011" name="drug:IncreaseDecreaseThroughFindersFeesShareOptions" scale="0" decimals="0" format="ixt:zerodash" contextRef="C_20201001to20210930_ifrsfullComponentsOfEquityAxis_drugSubscriptionReceivedMember" unitRef="CAD">-</ix:nonFraction></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 7%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="Fxbrl_20211228194258211_2014" name="drug:IncreaseDecreaseThroughFindersFeesShareOptions" scale="0" decimals="0" format="ixt:numdotdecimal" contextRef="C_20201001to20210930_ifrsfullComponentsOfEquityAxis_ifrsfullOtherReservesMember" unitRef="CAD">2,140</ix:nonFraction></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 7%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="Fxbrl_20211228194258211_2017" name="drug:IncreaseDecreaseThroughFindersFeesShareOptions" scale="0" decimals="0" format="ixt:zerodash" contextRef="C_20201001to20210930_ifrsfullComponentsOfEquityAxis_ifrsfullRetainedEarningsMember" unitRef="CAD">-</ix:nonFraction></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 7%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="Fxbrl_20211228194258211_2020" name="drug:IncreaseDecreaseThroughFindersFeesShareOptions" scale="0" decimals="0" format="ixt:zerodash" contextRef="C_20201001to20210930" unitRef="CAD">-</ix:nonFraction></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                        </tr>
                        <tr>
                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff; padding-left: 5.4pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Share issue costs</span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">-</span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(<ix:nonFraction id="Fxbrl_20211228194258211_215" name="ifrs-full:ShareIssueRelatedCost" scale="0" decimals="0" format="ixt:numdotdecimal" contextRef="C_20201001to20210930_ifrsfullComponentsOfEquityAxis_ifrsfullIssuedCapitalMember" unitRef="CAD">290,309</ix:nonFraction></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="Fxbrl_20211228194258211_218" name="ifrs-full:ShareIssueRelatedCost" scale="0" decimals="0" format="ixt:zerodash" contextRef="C_20201001to20210930_ifrsfullComponentsOfEquityAxis_drugSubscriptionReceivableMember" unitRef="CAD">-</ix:nonFraction></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="Fxbrl_20211228194258211_2111" name="ifrs-full:ShareIssueRelatedCost" scale="0" decimals="0" format="ixt:zerodash" contextRef="C_20201001to20210930_ifrsfullComponentsOfEquityAxis_drugSubscriptionReceivedMember" unitRef="CAD">-</ix:nonFraction></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="Fxbrl_20211228194258211_2114" name="ifrs-full:ShareIssueRelatedCost" scale="0" decimals="0" format="ixt:zerodash" contextRef="C_20201001to20210930_ifrsfullComponentsOfEquityAxis_ifrsfullOtherReservesMember" unitRef="CAD">-</ix:nonFraction></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="Fxbrl_20211228194258211_2117" name="ifrs-full:ShareIssueRelatedCost" scale="0" decimals="0" format="ixt:zerodash" contextRef="C_20201001to20210930_ifrsfullComponentsOfEquityAxis_ifrsfullRetainedEarningsMember" unitRef="CAD">-</ix:nonFraction></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(<ix:nonFraction id="Fxbrl_20211228194258211_2120" name="ifrs-full:ShareIssueRelatedCost" scale="0" decimals="0" format="ixt:numdotdecimal" contextRef="C_20201001to20210930" unitRef="CAD">290,309</ix:nonFraction></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                        </tr>
                        <tr>
                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 5.4pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Debt settlement with shares</span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 7%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="Fxbrl_20211228194258211_222" name="drug:IncreaseDecreaseThroughDebtSettlementWithShareShares" decimals="INF" format="ixt:numdotdecimal" contextRef="C_20201001to20210930_ifrsfullComponentsOfEquityAxis_ifrsfullIssuedCapitalMember" unitRef="Share">14,799</ix:nonFraction></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 7%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="Fxbrl_20211228194258211_225" name="drug:IncreaseDecreaseThroughDebtSettlementWithShare" scale="0" decimals="0" format="ixt:numdotdecimal" contextRef="C_20201001to20210930_ifrsfullComponentsOfEquityAxis_ifrsfullIssuedCapitalMember" unitRef="CAD">18,500</ix:nonFraction></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 7%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="Fxbrl_20211228194258211_228" name="drug:IncreaseDecreaseThroughDebtSettlementWithShare" scale="0" decimals="0" format="ixt:zerodash" contextRef="C_20201001to20210930_ifrsfullComponentsOfEquityAxis_drugSubscriptionReceivableMember" unitRef="CAD">-</ix:nonFraction></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 7%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="Fxbrl_20211228194258211_2211" name="drug:IncreaseDecreaseThroughDebtSettlementWithShare" scale="0" decimals="0" format="ixt:zerodash" contextRef="C_20201001to20210930_ifrsfullComponentsOfEquityAxis_drugSubscriptionReceivedMember" unitRef="CAD">-</ix:nonFraction></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 7%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="Fxbrl_20211228194258211_2214" name="drug:IncreaseDecreaseThroughDebtSettlementWithShare" scale="0" decimals="0" format="ixt:zerodash" contextRef="C_20201001to20210930_ifrsfullComponentsOfEquityAxis_ifrsfullOtherReservesMember" unitRef="CAD">-</ix:nonFraction></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 7%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="Fxbrl_20211228194258211_2217" name="drug:IncreaseDecreaseThroughDebtSettlementWithShare" scale="0" decimals="0" format="ixt:zerodash" contextRef="C_20201001to20210930_ifrsfullComponentsOfEquityAxis_ifrsfullRetainedEarningsMember" unitRef="CAD">-</ix:nonFraction></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 7%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="Fxbrl_20211228194258211_2220" name="drug:IncreaseDecreaseThroughDebtSettlementWithShare" scale="0" decimals="0" format="ixt:numdotdecimal" contextRef="C_20201001to20210930" unitRef="CAD">18,500</ix:nonFraction></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                        </tr>
                        <tr>
                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff; padding-left: 5.4pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Special warrant conversion</span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="Fxbrl_20211228194258211_232" name="drug:IncreaseDecreaseThroughSpecialWarrantConversionShares" decimals="INF" format="ixt:numdotdecimal" contextRef="C_20201001to20210930_ifrsfullComponentsOfEquityAxis_ifrsfullIssuedCapitalMember" unitRef="Share">16,000</ix:nonFraction></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="Fxbrl_20211228194258211_235" name="drug:IncreaseDecreaseThroughSpecialWarrantConversion" scale="0" decimals="0" format="ixt:numdotdecimal" contextRef="C_20201001to20210930_ifrsfullComponentsOfEquityAxis_ifrsfullIssuedCapitalMember" unitRef="CAD">20,000</ix:nonFraction></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="Fxbrl_20211228194258211_238" name="drug:IncreaseDecreaseThroughSpecialWarrantConversion" scale="0" decimals="0" format="ixt:zerodash" contextRef="C_20201001to20210930_ifrsfullComponentsOfEquityAxis_drugSubscriptionReceivableMember" unitRef="CAD">-</ix:nonFraction></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="Fxbrl_20211228194258211_2311" name="drug:IncreaseDecreaseThroughSpecialWarrantConversion" scale="0" decimals="0" format="ixt:zerodash" contextRef="C_20201001to20210930_ifrsfullComponentsOfEquityAxis_drugSubscriptionReceivedMember" unitRef="CAD">-</ix:nonFraction></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="Fxbrl_20211228194258211_2314" name="drug:IncreaseDecreaseThroughSpecialWarrantConversion" scale="0" decimals="0" format="ixt:zerodash" contextRef="C_20201001to20210930_ifrsfullComponentsOfEquityAxis_ifrsfullOtherReservesMember" unitRef="CAD">-</ix:nonFraction></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="Fxbrl_20211228194258211_2317" name="drug:IncreaseDecreaseThroughSpecialWarrantConversion" scale="0" decimals="0" format="ixt:zerodash" contextRef="C_20201001to20210930_ifrsfullComponentsOfEquityAxis_ifrsfullRetainedEarningsMember" unitRef="CAD">-</ix:nonFraction></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="Fxbrl_20211228194258211_2320" name="drug:IncreaseDecreaseThroughSpecialWarrantConversion" scale="0" decimals="0" format="ixt:numdotdecimal" contextRef="C_20201001to20210930" unitRef="CAD">20,000</ix:nonFraction></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                        </tr>
                        <tr>
                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 5.4pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Warrants exercised</span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 7%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="Fxbrl_20211228194258211_242" name="drug:IncreaseDecreaseThroughExerciseOfWarrantsShares" decimals="INF" format="ixt:numdotdecimal" contextRef="C_20201001to20210930_ifrsfullComponentsOfEquityAxis_ifrsfullIssuedCapitalMember" unitRef="Share">1,948,000</ix:nonFraction></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 7%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="Fxbrl_20211228194258211_245" name="ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity" scale="0" decimals="0" format="ixt:numdotdecimal" contextRef="C_20201001to20210930_ifrsfullComponentsOfEquityAxis_ifrsfullIssuedCapitalMember" unitRef="CAD">97,400</ix:nonFraction></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 7%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="Fxbrl_20211228194258211_248" name="ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity" scale="0" decimals="0" format="ixt:zerodash" contextRef="C_20201001to20210930_ifrsfullComponentsOfEquityAxis_drugSubscriptionReceivableMember" unitRef="CAD">-</ix:nonFraction></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 7%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="Fxbrl_20211228194258211_2411" name="ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity" scale="0" decimals="0" format="ixt:zerodash" contextRef="C_20201001to20210930_ifrsfullComponentsOfEquityAxis_drugSubscriptionReceivedMember" unitRef="CAD">-</ix:nonFraction></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 7%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="Fxbrl_20211228194258211_2414" name="ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity" scale="0" decimals="0" format="ixt:zerodash" contextRef="C_20201001to20210930_ifrsfullComponentsOfEquityAxis_ifrsfullOtherReservesMember" unitRef="CAD">-</ix:nonFraction></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 7%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="Fxbrl_20211228194258211_2417" name="ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity" scale="0" decimals="0" format="ixt:zerodash" contextRef="C_20201001to20210930_ifrsfullComponentsOfEquityAxis_ifrsfullRetainedEarningsMember" unitRef="CAD">-</ix:nonFraction></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 7%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="Fxbrl_20211228194258211_2420" name="ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity" scale="0" decimals="0" format="ixt:numdotdecimal" contextRef="C_20201001to20210930" unitRef="CAD">97,400</ix:nonFraction></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                        </tr>
                        <tr>
                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff; padding-left: 5.4pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Shares issued to the University</span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="Fxbrl_20211228194258211_252" name="drug:IncreaseDecreaseThroughSharesIssuedToUniversityShares" decimals="INF" format="ixt:numdotdecimal" contextRef="C_20201001to20210930_ifrsfullComponentsOfEquityAxis_ifrsfullIssuedCapitalMember" unitRef="Share">63,000</ix:nonFraction></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="Fxbrl_20211228194258211_255" name="drug:IncreaseDecreaseThroughSharesIssuedToUniversity" scale="0" decimals="0" format="ixt:numdotdecimal" contextRef="C_20201001to20210930_ifrsfullComponentsOfEquityAxis_ifrsfullIssuedCapitalMember" unitRef="CAD">368,550</ix:nonFraction></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="Fxbrl_20211228194258211_258" name="drug:IncreaseDecreaseThroughSharesIssuedToUniversity" scale="0" decimals="0" format="ixt:zerodash" contextRef="C_20201001to20210930_ifrsfullComponentsOfEquityAxis_drugSubscriptionReceivableMember" unitRef="CAD">-</ix:nonFraction></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="Fxbrl_20211228194258211_2511" name="drug:IncreaseDecreaseThroughSharesIssuedToUniversity" scale="0" decimals="0" format="ixt:zerodash" contextRef="C_20201001to20210930_ifrsfullComponentsOfEquityAxis_drugSubscriptionReceivedMember" unitRef="CAD">-</ix:nonFraction></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="Fxbrl_20211228194258211_2514" name="drug:IncreaseDecreaseThroughSharesIssuedToUniversity" scale="0" decimals="0" format="ixt:zerodash" contextRef="C_20201001to20210930_ifrsfullComponentsOfEquityAxis_ifrsfullOtherReservesMember" unitRef="CAD">-</ix:nonFraction></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="Fxbrl_20211228194258211_2517" name="drug:IncreaseDecreaseThroughSharesIssuedToUniversity" scale="0" decimals="0" format="ixt:zerodash" contextRef="C_20201001to20210930_ifrsfullComponentsOfEquityAxis_ifrsfullRetainedEarningsMember" unitRef="CAD">-</ix:nonFraction></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="Fxbrl_20211228194258211_2520" name="drug:IncreaseDecreaseThroughSharesIssuedToUniversity" scale="0" decimals="0" format="ixt:numdotdecimal" contextRef="C_20201001to20210930" unitRef="CAD">368,550</ix:nonFraction></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                        </tr>
                        <tr>
                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 5.4pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Share-based compensation</span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 7%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">-</span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 7%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="Fxbrl_20211228194258211_265" name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" scale="0" decimals="0" format="ixt:zerodash" contextRef="C_20201001to20210930_ifrsfullComponentsOfEquityAxis_ifrsfullIssuedCapitalMember" unitRef="CAD">-</ix:nonFraction></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 7%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="Fxbrl_20211228194258211_268" name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" scale="0" decimals="0" format="ixt:zerodash" contextRef="C_20201001to20210930_ifrsfullComponentsOfEquityAxis_drugSubscriptionReceivableMember" unitRef="CAD">-</ix:nonFraction></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 7%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="Fxbrl_20211228194258211_2611" name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" scale="0" decimals="0" format="ixt:zerodash" contextRef="C_20201001to20210930_ifrsfullComponentsOfEquityAxis_drugSubscriptionReceivedMember" unitRef="CAD">-</ix:nonFraction></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 7%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="Fxbrl_20211228194258211_2614" name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" scale="0" decimals="0" format="ixt:numdotdecimal" contextRef="C_20201001to20210930_ifrsfullComponentsOfEquityAxis_ifrsfullOtherReservesMember" unitRef="CAD">880,615</ix:nonFraction></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 7%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="Fxbrl_20211228194258211_2617" name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" scale="0" decimals="0" format="ixt:zerodash" contextRef="C_20201001to20210930_ifrsfullComponentsOfEquityAxis_ifrsfullRetainedEarningsMember" unitRef="CAD">-</ix:nonFraction></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 7%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="Fxbrl_20211228194258211_2620" name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" scale="0" decimals="0" format="ixt:numdotdecimal" contextRef="C_20201001to20210930" unitRef="CAD">880,615</ix:nonFraction></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                        </tr>
                        <tr>
                            <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; background-color: #e6efff; padding-left: 5.4pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Net loss</span></span></td>
                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>-</b></span></span></td>
                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b><ix:nonFraction id="Fxbrl_20211228194258211_275" name="ifrs-full:ProfitLoss" scale="0" decimals="0" format="ixt:zerodash" contextRef="C_20201001to20210930_ifrsfullComponentsOfEquityAxis_ifrsfullIssuedCapitalMember" unitRef="CAD">-</ix:nonFraction></b></span></span></td>
                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b><ix:nonFraction id="Fxbrl_20211228194258211_278" name="ifrs-full:ProfitLoss" scale="0" decimals="0" format="ixt:zerodash" contextRef="C_20201001to20210930_ifrsfullComponentsOfEquityAxis_drugSubscriptionReceivableMember" unitRef="CAD">-</ix:nonFraction></b></span></span></td>
                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b><ix:nonFraction id="Fxbrl_20211228194258211_2711" name="ifrs-full:ProfitLoss" scale="0" decimals="0" format="ixt:zerodash" contextRef="C_20201001to20210930_ifrsfullComponentsOfEquityAxis_drugSubscriptionReceivedMember" unitRef="CAD">-</ix:nonFraction></b></span></span></td>
                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b><ix:nonFraction id="Fxbrl_20211228194258211_2714" name="ifrs-full:ProfitLoss" scale="0" decimals="0" format="ixt:zerodash" contextRef="C_20201001to20210930_ifrsfullComponentsOfEquityAxis_ifrsfullOtherReservesMember" unitRef="CAD">-</ix:nonFraction></b></span></span></td>
                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(<ix:nonFraction id="Fxbrl_20211228194258211_2717" name="ifrs-full:ProfitLoss" scale="0" decimals="0" format="ixt:numdotdecimal" sign="-" contextRef="C_20201001to20210930_ifrsfullComponentsOfEquityAxis_ifrsfullRetainedEarningsMember" unitRef="CAD">8,650,763</ix:nonFraction></span></span></td>
                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(<ix:nonFraction id="Fxbrl_20211228194258211_2720" name="ifrs-full:ProfitLoss" scale="0" decimals="0" format="ixt:numdotdecimal" sign="-" contextRef="C_20201001to20210930" unitRef="CAD">8,650,763</ix:nonFraction></span></span></td>
                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                        </tr>
                        <tr>
                            <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 2.25pt double #000000; vertical-align: bottom; padding-left: 5.4pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Balance as at September 30, 2021</b></span></span></td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%;">&#160;</td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 7%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b><ix:nonFraction id="Fxbrl_20211228194258211_282" name="ifrs-full:NumberOfSharesOutstanding" decimals="INF" format="ixt:numdotdecimal" contextRef="C_20210930_ifrsfullComponentsOfEquityAxis_ifrsfullIssuedCapitalMember" unitRef="Share">11,834,361</ix:nonFraction></b></span></span></td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%;">&#160;</td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%;">&#160;</td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 7%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b><ix:nonFraction id="Fxbrl_20211228194258211_285" name="ifrs-full:Equity" scale="0" decimals="0" format="ixt:numdotdecimal" contextRef="C_20210930_ifrsfullComponentsOfEquityAxis_ifrsfullIssuedCapitalMember" unitRef="CAD">27,080,281</ix:nonFraction></b></span></span></td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%;">&#160;</td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%;">&#160;</td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 7%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>(<ix:nonFraction id="Fxbrl_20211228194258211_288" name="ifrs-full:Equity" scale="0" decimals="0" format="ixt:numdotdecimal" sign="-" contextRef="C_20210930_ifrsfullComponentsOfEquityAxis_drugSubscriptionReceivableMember" unitRef="CAD">33,684</ix:nonFraction></b></span></span></td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>)</b></span></span></td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%;">&#160;</td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 7%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b><ix:nonFraction id="Fxbrl_20211228194258211_2811" name="ifrs-full:Equity" scale="0" decimals="0" format="ixt:zerodash" contextRef="C_20210930_ifrsfullComponentsOfEquityAxis_drugSubscriptionReceivedMember" unitRef="CAD">-</ix:nonFraction></b></span></span></td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%;">&#160;</td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%;">&#160;</td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 7%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b><ix:nonFraction id="Fxbrl_20211228194258211_2814" name="ifrs-full:Equity" scale="0" decimals="0" format="ixt:numdotdecimal" contextRef="C_20210930_ifrsfullComponentsOfEquityAxis_ifrsfullOtherReservesMember" unitRef="CAD">1,565,055</ix:nonFraction></b></span></span></td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%;">&#160;</td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%;">&#160;</td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 7%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>(<ix:nonFraction id="Fxbrl_20211228194258211_2817" name="ifrs-full:Equity" scale="0" decimals="0" format="ixt:numdotdecimal" sign="-" contextRef="C_20210930_ifrsfullComponentsOfEquityAxis_ifrsfullRetainedEarningsMember" unitRef="CAD">9,209,857</ix:nonFraction></b></span></span></td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>)</b></span></span></td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%;">&#160;</td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 7%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b><ix:nonFraction id="Fxbrl_20211228194258211_2820" name="ifrs-full:Equity" scale="0" decimals="0" format="ixt:numdotdecimal" contextRef="C_20210930" unitRef="CAD">19,401,795</ix:nonFraction></b></span></span></td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%;">&#160;</td>
                        </tr>
                    </table>
                    <p style="text-align: center;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><i>The accompanying notes are an integral part of these consolidated financial statements. </i></span></span></p>
                    <div>
                        <table style="width: 100%; border-collapse: collapse; font-size: 10pt;" border="0" cellspacing="0" cellpadding="0">
                            <tr>
                                <td style="width: 100%; border-top: 0.75pt solid #000000; text-align: right;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>4&#160;</b>| Page</span></span></td>
                            </tr>
                        </table>
                    </div>
                    <hr style="page-break-after: always; text-align: center; height: 5px; width: 100%; background-color: black;" />
                </div>
            </div>
            <div>
                <div>
                    <table style="width: 100%; border-collapse: collapse; font-size: 10pt;" border="0" cellspacing="0" cellpadding="0">
                        <tr>
                            <td style="width: 100%;">
                                <p><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>Bright Minds Biosciences Inc.</b></span></span><br /><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">Consolidated Statements of Cash Flows<br />(Expressed in Canadian Dollars)</span></span></p>
                            </td>
                        </tr>
                    </table>
                    &#160;
                    <table style="width: 100%; border-collapse: collapse; font-size: 10pt; border-color: #000000;" cellspacing="0" cellpadding="0">
                        <tr>
                            <td style="margin-top: 0pt; margin-bottom: 0pt; border-top: 0.75pt solid #000000; vertical-align: bottom;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span style="color: #7f7f7f;"><b>&#160;</b></span></span></span></td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right;">&#160;</td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; white-space: nowrap;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>For the year<br />ended</b></span></span></td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; white-space: nowrap;">&#160;</td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; white-space: nowrap;">&#160;</td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; white-space: nowrap;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">For the year<br />ended</span></span></td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; white-space: nowrap;">&#160;</td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; white-space: nowrap;">&#160;</td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; white-space: nowrap;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">For the period<br />ended</span></span></td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right;">&#160;</td>
                        </tr>
                        <tr>
                            <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>&#160;</b></span></span></td>
                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right;">&#160;</td>
                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>September 30, </b><br /><b>2021</b></span></span></td>
                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;">&#160;</td>
                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;">&#160;</td>
                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">September 30,<br />2020</span></span></td>
                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;">&#160;</td>
                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;">&#160;</td>
                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">September 30,<br />2019</span></span></td>
                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right;">&#160;</td>
                        </tr>
                        <tr>
                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right;">&#160;</td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>$</b></span></span></td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right;">&#160;</td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right;">&#160;</td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">$</span></span></td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right;">&#160;</td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right;">&#160;</td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right;">&#160;</td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right;">&#160;</td>
                        </tr>
                        <tr>
                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff; padding-left: 5.4pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>Operating activities</b></span></span></td>
                            <td style="vertical-align: bottom; text-align: right; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>&#160;</b></span></span></td>
                            <td style="vertical-align: bottom; text-align: right; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; background-color: #e6efff;">&#160;</td>
                        </tr>
                        <tr>
                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 5.4pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">Net loss for the year</span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 12%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>(<ix:nonFraction id="Fxbrl_20211228210724323" name="ifrs-full:ProfitLoss" scale="0" decimals="0" format="ixt:numdotdecimal" sign="-" contextRef="C_20201001to20210930" unitRef="CAD">8,650,763</ix:nonFraction></b></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>)</b></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 12%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">(<ix:nonFraction id="Fxbrl_20211228210737306" name="ifrs-full:ProfitLoss" scale="0" decimals="0" format="ixt:numdotdecimal" sign="-" contextRef="C_20191001to20200930" unitRef="CAD">480,377</ix:nonFraction></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">)</span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 12%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">(<ix:nonFraction id="Fxbrl_20211228210742778" name="ifrs-full:ProfitLoss" scale="0" decimals="0" format="ixt:numdotdecimal" sign="-" contextRef="C_20190601to20190930" unitRef="CAD">78,717</ix:nonFraction></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">)</span></span></td>
                        </tr>
                        <tr>
                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff; padding-left: 5.4pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">Non-cash items:</span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>&#160;</b></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                        </tr>
                        <tr>
                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 5.4pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">Foreign exchange</span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 12%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>(<ix:nonFraction id="Fxbrl_20211228210958068_62" name="ifrs-full:AdjustmentsForUnrealisedForeignExchangeLossesGains" scale="0" decimals="0" format="ixt:numdotdecimal" sign="-" contextRef="C_20201001to20210930" unitRef="CAD">223,787</ix:nonFraction></b></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>)</b></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 12%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><ix:nonFraction id="Fxbrl_20211228210958068_65" name="ifrs-full:AdjustmentsForUnrealisedForeignExchangeLossesGains" scale="0" decimals="0" format="ixt:zerodash" contextRef="C_20191001to20200930" unitRef="CAD">-</ix:nonFraction></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 12%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><ix:nonFraction id="Fxbrl_20211228210958068_68" name="ifrs-full:AdjustmentsForUnrealisedForeignExchangeLossesGains" scale="0" decimals="0" format="ixt:zerodash" contextRef="C_20190601to20190930" unitRef="CAD">-</ix:nonFraction></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                        </tr>
                        <tr>
                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff; padding-left: 5.4pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">Shares recorded as research and development</span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b><ix:nonFraction id="Fxbrl_20211228210958068_72" name="drug:AdjustmentsForSharesRecordedAsResearchAndDevelopment" scale="0" decimals="0" format="ixt:numdotdecimal" contextRef="C_20201001to20210930" unitRef="CAD">368,550</ix:nonFraction></b></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><ix:nonFraction id="Fxbrl_20211228210958068_75" name="drug:AdjustmentsForSharesRecordedAsResearchAndDevelopment" scale="0" decimals="0" format="ixt:zerodash" contextRef="C_20191001to20200930" unitRef="CAD">-</ix:nonFraction></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><ix:nonFraction id="Fxbrl_20211228210958068_78" name="drug:AdjustmentsForSharesRecordedAsResearchAndDevelopment" scale="0" decimals="0" format="ixt:zerodash" contextRef="C_20190601to20190930" unitRef="CAD">-</ix:nonFraction></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                        </tr>
                        <tr>
                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 5.4pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">Share-based compensation</span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 12%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b><ix:nonFraction id="Fxbrl_20211228210958068_82" name="ifrs-full:AdjustmentsForSharebasedPayments" scale="0" decimals="0" format="ixt:numdotdecimal" contextRef="C_20201001to20210930" unitRef="CAD">880,615</ix:nonFraction></b></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 12%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><ix:nonFraction id="Fxbrl_20211228210958068_85" name="ifrs-full:AdjustmentsForSharebasedPayments" scale="0" decimals="0" format="ixt:numdotdecimal" contextRef="C_20191001to20200930" unitRef="CAD">161,300</ix:nonFraction></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 12%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><ix:nonFraction id="Fxbrl_20211228210958068_88" name="ifrs-full:AdjustmentsForSharebasedPayments" scale="0" decimals="0" format="ixt:zerodash" contextRef="C_20190601to20190930" unitRef="CAD">-</ix:nonFraction></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                        </tr>
                        <tr>
                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff; padding-left: 5.4pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">Changes in non-cash operating working capital items:</span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>&#160;</b></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                        </tr>
                        <tr>
                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 5.4pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">Sales tax receivable</span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 12%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>(<ix:nonFraction id="Fxbrl_20211228210958068_102" name="drug:AdjustmentsForDecreaseIncreaseInSalesTaxReceivable" scale="0" decimals="0" format="ixt:numdotdecimal" sign="-" contextRef="C_20201001to20210930" unitRef="CAD">110,146</ix:nonFraction></b></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>)</b></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 12%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><ix:nonFraction id="Fxbrl_20211228210958068_105" name="drug:AdjustmentsForDecreaseIncreaseInSalesTaxReceivable" scale="0" decimals="0" format="ixt:zerodash" contextRef="C_20191001to20200930" unitRef="CAD">-</ix:nonFraction></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 12%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><ix:nonFraction id="Fxbrl_20211228210958068_108" name="drug:AdjustmentsForDecreaseIncreaseInSalesTaxReceivable" scale="0" decimals="0" format="ixt:zerodash" contextRef="C_20190601to20190930" unitRef="CAD">-</ix:nonFraction></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                        </tr>
                        <tr>
                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff; padding-left: 5.4pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">Prepaids</span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>(<ix:nonFraction id="Fxbrl_20211228210958068_112" name="drug:AdjustmentsForDecreaseIncreaseInPrepaidExpenses" scale="0" decimals="0" format="ixt:numdotdecimal" sign="-" contextRef="C_20201001to20210930" unitRef="CAD">89,920</ix:nonFraction></b></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>)</b></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">(<ix:nonFraction id="Fxbrl_20211228210958068_115" name="drug:AdjustmentsForDecreaseIncreaseInPrepaidExpenses" scale="0" decimals="0" format="ixt:numdotdecimal" sign="-" contextRef="C_20191001to20200930" unitRef="CAD">78,287</ix:nonFraction></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">)</span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><ix:nonFraction id="Fxbrl_20211228210958068_118" name="drug:AdjustmentsForDecreaseIncreaseInPrepaidExpenses" scale="0" decimals="0" format="ixt:zerodash" contextRef="C_20190601to20190930" unitRef="CAD">-</ix:nonFraction></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                        </tr>
                        <tr>
                            <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; padding-left: 5.4pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">Accounts payable and accrued liabilities</span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 12%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b><ix:nonFraction id="Fxbrl_20211228210958068_122" name="ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAccountPayable" scale="0" decimals="0" format="ixt:numdotdecimal" contextRef="C_20201001to20210930" unitRef="CAD">506,150</ix:nonFraction></b></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 12%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><ix:nonFraction id="Fxbrl_20211228210958068_125" name="ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAccountPayable" scale="0" decimals="0" format="ixt:numdotdecimal" contextRef="C_20191001to20200930" unitRef="CAD">108,972</ix:nonFraction></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 12%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><ix:nonFraction id="Fxbrl_20211228210958068_128" name="ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAccountPayable" scale="0" decimals="0" format="ixt:numdotdecimal" contextRef="C_20190601to20190930" unitRef="CAD">36,708</ix:nonFraction></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                        </tr>
                        <tr>
                            <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; background-color: #e6efff; padding-left: 5.4pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>Net cash used in operating activities</b></span></span></td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>(<ix:nonFraction id="Fxbrl_20211228210958068_132" name="ifrs-full:CashFlowsFromUsedInOperatingActivities" scale="0" decimals="0" format="ixt:numdotdecimal" sign="-" contextRef="C_20201001to20210930" unitRef="CAD">7,319,301</ix:nonFraction></b></span></span></td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>)</b></span></span></td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">(<ix:nonFraction id="Fxbrl_20211228210958068_135" name="ifrs-full:CashFlowsFromUsedInOperatingActivities" scale="0" decimals="0" format="ixt:numdotdecimal" sign="-" contextRef="C_20191001to20200930" unitRef="CAD">288,392</ix:nonFraction></span></span></td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">)</span></span></td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">(<ix:nonFraction id="Fxbrl_20211228210958068_138" name="ifrs-full:CashFlowsFromUsedInOperatingActivities" scale="0" decimals="0" format="ixt:numdotdecimal" sign="-" contextRef="C_20190601to20190930" unitRef="CAD">42,009</ix:nonFraction></span></span></td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">)</span></span></td>
                        </tr>
                        <tr>
                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 5.4pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>&#160;</b></span></span></td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>&#160;</b></span></span></td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%;">&#160;</td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%;">&#160;</td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                        </tr>
                        <tr>
                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff; padding-left: 5.4pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>Financing activities</b></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>&#160;</b></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                        </tr>
                        <tr>
                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 5.4pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">Private placement proceeds</span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 12%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b><ix:nonFraction id="Fxbrl_20211228210958068_162" name="ifrs-full:ProceedsFromIssuingShares" scale="0" decimals="0" format="ixt:numdotdecimal" contextRef="C_20201001to20210930" unitRef="CAD">27,744,826</ix:nonFraction></b></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 12%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><ix:nonFraction id="Fxbrl_20211228210958068_165" name="ifrs-full:ProceedsFromIssuingShares" scale="0" decimals="0" format="ixt:numdotdecimal" contextRef="C_20191001to20200930" unitRef="CAD">1,008,330</ix:nonFraction></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 12%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><ix:nonFraction id="Fxbrl_20211228210958068_168" name="ifrs-full:ProceedsFromIssuingShares" scale="0" decimals="0" format="ixt:numdotdecimal" contextRef="C_20190601to20190930" unitRef="CAD">122,000</ix:nonFraction></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                        </tr>
                        <tr>
                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff; padding-left: 5.4pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">Finder's fees</span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>(<ix:nonFraction id="Fxbrl_20211228210958068_172" name="drug:PaymentsForFindersFees" scale="0" decimals="0" format="ixt:numdotdecimal" contextRef="C_20201001to20210930" unitRef="CAD">1,516,317</ix:nonFraction></b></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>)</b></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><ix:nonFraction id="Fxbrl_20211228210958068_175" name="drug:PaymentsForFindersFees" scale="0" decimals="0" format="ixt:zerodash" contextRef="C_20191001to20200930" unitRef="CAD">-</ix:nonFraction></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><ix:nonFraction id="Fxbrl_20211228210958068_178" name="drug:PaymentsForFindersFees" scale="0" decimals="0" format="ixt:zerodash" contextRef="C_20190601to20190930" unitRef="CAD">-</ix:nonFraction></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                        </tr>
                        <tr>
                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 5.4pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">Share issuance costs</span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 12%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>(<ix:nonFraction id="Fxbrl_20211228210958068_182" name="ifrs-full:PaymentsForShareIssueCosts" scale="0" decimals="0" format="ixt:numdotdecimal" contextRef="C_20201001to20210930" unitRef="CAD">290,309</ix:nonFraction></b></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>)</b></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 12%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><ix:nonFraction id="Fxbrl_20211228210958068_185" name="ifrs-full:PaymentsForShareIssueCosts" scale="0" decimals="0" format="ixt:zerodash" contextRef="C_20191001to20200930" unitRef="CAD">-</ix:nonFraction></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 12%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><ix:nonFraction id="Fxbrl_20211228210958068_188" name="ifrs-full:PaymentsForShareIssueCosts" scale="0" decimals="0" format="ixt:zerodash" contextRef="C_20190601to20190930" unitRef="CAD">-</ix:nonFraction></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                        </tr>
                        <tr>
                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff; padding-left: 5.4pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">Special warrant proceeds</span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b><ix:nonFraction id="Fxbrl_20211228210958068_192" name="drug:ProceedsFromIssuingWarrants" scale="0" decimals="0" format="ixt:numdotdecimal" contextRef="C_20201001to20210930" unitRef="CAD">22,875</ix:nonFraction></b></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><ix:nonFraction id="Fxbrl_20211228210958068_195" name="drug:ProceedsFromIssuingWarrants" scale="0" decimals="0" format="ixt:zerodash" contextRef="C_20191001to20200930" unitRef="CAD">-</ix:nonFraction></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><ix:nonFraction id="Fxbrl_20211228210958068_198" name="drug:ProceedsFromIssuingWarrants" scale="0" decimals="0" format="ixt:zerodash" contextRef="C_20190601to20190930" unitRef="CAD">-</ix:nonFraction></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                        </tr>
                        <tr>
                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 5.4pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">Refund of special warrant proceeds</span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 12%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>(<ix:nonFraction id="Fxbrl_20211228210958068_202" name="drug:RefundOfSpecialWarrantsProceeds" scale="0" decimals="0" format="ixt:numdotdecimal" contextRef="C_20201001to20210930" unitRef="CAD">2,875</ix:nonFraction></b></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>)</b></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 12%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><ix:nonFraction id="Fxbrl_20211228210958068_205" name="drug:RefundOfSpecialWarrantsProceeds" scale="0" decimals="0" format="ixt:zerodash" contextRef="C_20191001to20200930" unitRef="CAD">-</ix:nonFraction></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 12%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><ix:nonFraction id="Fxbrl_20211228210958068_208" name="drug:RefundOfSpecialWarrantsProceeds" scale="0" decimals="0" format="ixt:zerodash" contextRef="C_20190601to20190930" unitRef="CAD">-</ix:nonFraction></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                        </tr>
                        <tr>
                            <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; background-color: #e6efff; padding-left: 5.4pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">Warrant exercise proceeds</span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b><ix:nonFraction id="Fxbrl_20211228210958068_212" name="drug:ProceedsFromWarrantsExercise" scale="0" decimals="0" format="ixt:numdotdecimal" contextRef="C_20201001to20210930" unitRef="CAD">97,400</ix:nonFraction></b></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><ix:nonFraction id="Fxbrl_20211228210958068_215" name="drug:ProceedsFromWarrantsExercise" scale="0" decimals="0" format="ixt:zerodash" contextRef="C_20191001to20200930" unitRef="CAD">-</ix:nonFraction></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><ix:nonFraction id="Fxbrl_20211228210958068_218" name="drug:ProceedsFromWarrantsExercise" scale="0" decimals="0" format="ixt:zerodash" contextRef="C_20190601to20190930" unitRef="CAD">-</ix:nonFraction></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                        </tr>
                        <tr>
                            <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; padding-left: 5.4pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>Net cash from financing activities</b></span></span></td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b><ix:nonFraction id="Fxbrl_20211228210958068_222" name="ifrs-full:CashFlowsFromUsedInFinancingActivities" scale="0" decimals="0" format="ixt:numdotdecimal" contextRef="C_20201001to20210930" unitRef="CAD">26,055,600</ix:nonFraction></b></span></span></td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><ix:nonFraction id="Fxbrl_20211228210958068_225" name="ifrs-full:CashFlowsFromUsedInFinancingActivities" scale="0" decimals="0" format="ixt:numdotdecimal" contextRef="C_20191001to20200930" unitRef="CAD">1,008,330</ix:nonFraction></span></span></td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><ix:nonFraction id="Fxbrl_20211228210958068_228" name="ifrs-full:CashFlowsFromUsedInFinancingActivities" scale="0" decimals="0" format="ixt:numdotdecimal" contextRef="C_20190601to20190930" unitRef="CAD">122,000</ix:nonFraction></span></span></td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                        </tr>
                        <tr>
                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff; padding-left: 5.4pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>&#160;</b></span></span></td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>&#160;</b></span></span></td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                        </tr>
                        <tr>
                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 5.4pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>Change in cash </b></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 12%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b><ix:nonFraction id="Fxbrl_20211228210958068_242" name="ifrs-full:IncreaseDecreaseInCashAndCashEquivalents" scale="0" decimals="0" format="ixt:numdotdecimal" contextRef="C_20201001to20210930" unitRef="CAD">18,736,299</ix:nonFraction></b></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 12%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><ix:nonFraction id="Fxbrl_20211228210958068_245" name="ifrs-full:IncreaseDecreaseInCashAndCashEquivalents" scale="0" decimals="0" format="ixt:numdotdecimal" contextRef="C_20191001to20200930" unitRef="CAD">719,938</ix:nonFraction></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 12%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><ix:nonFraction id="Fxbrl_20211228210958068_248" name="ifrs-full:IncreaseDecreaseInCashAndCashEquivalents" scale="0" decimals="0" format="ixt:numdotdecimal" contextRef="C_20190601to20190930" unitRef="CAD">79,991</ix:nonFraction></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                        </tr>
                        <tr>
                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff; padding-left: 5.4pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>Effect of foreign exchange on cash</b></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b><ix:nonFraction id="Fxbrl_20211228210958068_252" name="ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents" scale="0" decimals="0" format="ixt:numdotdecimal" contextRef="C_20201001to20210930" unitRef="CAD">223,787</ix:nonFraction></b></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><ix:nonFraction id="Fxbrl_20211228210958068_255" name="ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents" scale="0" decimals="0" format="ixt:zerodash" contextRef="C_20191001to20200930" unitRef="CAD">-</ix:nonFraction></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><ix:nonFraction id="Fxbrl_20211228210958068_258" name="ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents" scale="0" decimals="0" format="ixt:zerodash" contextRef="C_20190601to20190930" unitRef="CAD">-</ix:nonFraction></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                        </tr>
                        <tr>
                            <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; padding-left: 5.4pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>Cash, beginning of year</b></span></span></td>
                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b><ix:nonFraction id="Fxbrl_20211228210958068_262" name="ifrs-full:CashAndCashEquivalents" scale="0" decimals="0" format="ixt:numdotdecimal" contextRef="C_20200930" unitRef="CAD">799,929</ix:nonFraction></b></span></span></td>
                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><ix:nonFraction id="Fxbrl_20211228210958068_265" name="ifrs-full:CashAndCashEquivalents" scale="0" decimals="0" format="ixt:numdotdecimal" contextRef="C_20190930" unitRef="CAD">79,991</ix:nonFraction></span></span></td>
                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><ix:nonFraction id="Fxbrl_20211228210958068_268" name="ifrs-full:CashAndCashEquivalents" scale="0" decimals="0" format="ixt:zerodash" contextRef="C_20180930" unitRef="CAD">-</ix:nonFraction></span></span></td>
                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                        </tr>
                        <tr>
                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff; padding-left: 5.4pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>&#160;</b></span></span></td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>&#160;</b></span></span></td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                        </tr>
                        <tr>
                            <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 2.25pt double #000000; vertical-align: bottom; padding-left: 5.4pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>Cash and cash equivalents, end of year</b></span></span></td>
                            <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; text-align: left; width: 1%;">&#160;</td>
                            <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; text-align: right; width: 12%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b><ix:nonFraction id="Fxbrl_20211228210958068_282" name="ifrs-full:CashAndCashEquivalents" scale="0" decimals="0" format="ixt:numdotdecimal" contextRef="C_20210930" unitRef="CAD">19,760,015</ix:nonFraction></b></span></span></td>
                            <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; text-align: left; width: 2%;">&#160;</td>
                            <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; text-align: left; width: 1%;">&#160;</td>
                            <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; text-align: right; width: 12%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><ix:nonFraction id="Fxbrl_20211228210958068_285" name="ifrs-full:CashAndCashEquivalents" scale="0" decimals="0" format="ixt:numdotdecimal" contextRef="C_20200930" unitRef="CAD">799,929</ix:nonFraction></span></span></td>
                            <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; text-align: left; width: 2%;">&#160;</td>
                            <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; text-align: left; width: 1%;">&#160;</td>
                            <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; text-align: right; width: 12%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><ix:nonFraction id="Fxbrl_20211228210958068_288" name="ifrs-full:CashAndCashEquivalents" scale="0" decimals="0" format="ixt:numdotdecimal" contextRef="C_20190930" unitRef="CAD">79,991</ix:nonFraction></span></span></td>
                            <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; text-align: left; width: 2%;">&#160;</td>
                        </tr>
                        <tr>
                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff; padding-left: 5.4pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>&#160;</b></span></span></td>
                            <td style="vertical-align: bottom; border-top: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; border-top: 2.25pt double #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>&#160;</b></span></span></td>
                            <td style="vertical-align: bottom; border-top: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; border-top: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; border-top: 2.25pt double #000000; text-align: right; width: 12%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; border-top: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; border-top: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; border-top: 2.25pt double #000000; text-align: right; width: 12%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; border-top: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                        </tr>
                        <tr>
                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 5.4pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>SUPPLEMENTARY INFORMATION</b></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 12%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>&#160;</b></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 12%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 12%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                        </tr>
                        <tr>
                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff; padding-left: 5.4pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">Debt settled by issuing shares</span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><ix:nonFraction id="Fxbrl_20211228210958068_312" name="drug:DebtSettledByIssuingShares" scale="0" decimals="0" format="ixt:numdotdecimal" contextRef="C_20201001to20210930" unitRef="CAD">18,500</ix:nonFraction></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><ix:nonFraction id="Fxbrl_20211228210958068_315" name="drug:DebtSettledByIssuingShares" scale="0" decimals="0" format="ixt:zerodash" contextRef="C_20191001to20200930" unitRef="CAD">-</ix:nonFraction></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><ix:nonFraction id="Fxbrl_20211228210958068_318" name="drug:DebtSettledByIssuingShares" scale="0" decimals="0" format="ixt:zerodash" contextRef="C_20190601to20190930" unitRef="CAD">-</ix:nonFraction></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                        </tr>
                        <tr>
                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 5.4pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">Fair value ascribed to brokers' warrants issued</span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 12%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><ix:nonFraction id="Fxbrl_20211228210958068_322" name="drug:FairValueAscribedToBrokersWarrantsIssued" scale="0" decimals="0" format="ixt:numdotdecimal" contextRef="C_20201001to20210930" unitRef="CAD">521,000</ix:nonFraction></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 12%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><ix:nonFraction id="Fxbrl_20211228210958068_325" name="drug:FairValueAscribedToBrokersWarrantsIssued" scale="0" decimals="0" format="ixt:zerodash" contextRef="C_20191001to20200930" unitRef="CAD">-</ix:nonFraction></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 12%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><ix:nonFraction id="Fxbrl_20211228210958068_328" name="drug:FairValueAscribedToBrokersWarrantsIssued" scale="0" decimals="0" format="ixt:zerodash" contextRef="C_20190601to20190930" unitRef="CAD">-</ix:nonFraction></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                        </tr>
                        <tr>
                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff; padding-left: 5.4pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">Fair value of options issued as finder's fees</span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><ix:nonFraction id="Fxbrl_20211228210958068_332" name="drug:FairValueOfOptionsIssuedAsFindersFees" scale="0" decimals="0" format="ixt:numdotdecimal" contextRef="C_20201001to20210930" unitRef="CAD">2,140</ix:nonFraction></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><ix:nonFraction id="Fxbrl_20211228210958068_335" name="drug:FairValueOfOptionsIssuedAsFindersFees" scale="0" decimals="0" format="ixt:zerodash" contextRef="C_20191001to20200930" unitRef="CAD">-</ix:nonFraction></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><ix:nonFraction id="Fxbrl_20211228210958068_338" name="drug:FairValueOfOptionsIssuedAsFindersFees" scale="0" decimals="0" format="ixt:zerodash" contextRef="C_20190601to20190930" unitRef="CAD">-</ix:nonFraction></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                        </tr>
                        <tr>
                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 5.4pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">Share issue costs included in accounts payable</span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 12%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><ix:nonFraction id="Fxbrl_20211228210958068_342" name="drug:ShareIssueCostsIncludedInAccountsPayable" scale="0" decimals="0" format="ixt:zerodash" contextRef="C_20201001to20210930" unitRef="CAD">-</ix:nonFraction></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 12%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><ix:nonFraction id="Fxbrl_20211228210958068_345" name="drug:ShareIssueCostsIncludedInAccountsPayable" scale="0" decimals="0" format="ixt:numdotdecimal" contextRef="C_20191001to20200930" unitRef="CAD">5,243</ix:nonFraction></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 12%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><ix:nonFraction id="Fxbrl_20211228210958068_348" name="drug:ShareIssueCostsIncludedInAccountsPayable" scale="0" decimals="0" format="ixt:zerodash" contextRef="C_20190601to20190930" unitRef="CAD">-</ix:nonFraction></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                        </tr>
                        <tr>
                            <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 2.25pt double #000000; vertical-align: bottom; background-color: #e6efff; padding-left: 5.4pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">Acquisition of intangible assets by issuing common shares</span></span></td>
                            <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><ix:nonFraction id="Fxbrl_20211228210958068_352" name="drug:AcquisitionOfIntangibleAssetsByIssuingCommonShares" scale="0" decimals="0" format="ixt:zerodash" contextRef="C_20201001to20210930" unitRef="CAD">-</ix:nonFraction></span></span></td>
                            <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><ix:nonFraction id="Fxbrl_20211228210958068_355" name="drug:AcquisitionOfIntangibleAssetsByIssuingCommonShares" scale="0" decimals="0" format="ixt:zerodash" contextRef="C_20191001to20200930" unitRef="CAD">-</ix:nonFraction></span></span></td>
                            <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><ix:nonFraction id="Fxbrl_20211228210958068_358" name="drug:AcquisitionOfIntangibleAssetsByIssuingCommonShares" scale="0" decimals="0" format="ixt:numdotdecimal" contextRef="C_20190601to20190930" unitRef="CAD">2,000</ix:nonFraction></span></span></td>
                            <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                        </tr>
                    </table>
                    <p style="text-align: center;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><i>The accompanying notes are an integral part of these consolidated financial statements. </i><b> </b></span></span></p>
                    <div>
                        <table style="width: 100%; border-collapse: collapse; font-size: 10pt;" border="0" cellspacing="0" cellpadding="0">
                            <tr>
                                <td style="width: 100%; border-top: 0.75pt solid #000000; text-align: right;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>5&#160;</b>| Page</span></span></td>
                            </tr>
                        </table>
                    </div>
                    <hr style="page-break-after: always; text-align: center; height: 5px; width: 100%; background-color: black;" />
                </div>
            </div>
            <div>
                <div>
                    <div>
                        <table style="width: 100%; border-collapse: collapse; font-size: 10pt;" border="0" cellspacing="0" cellpadding="0">
                            <tr>
                                <td style="width: 100%;">
                                    <p style="margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>Bright Minds Biosciences Inc.</b></span></span></p>
                                    <p style="margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">Notes to the Consolidated Financial Statements</span></span></p>
                                    <p style="margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">For the years ended September 30, 2021 and 2020 and the period from May 31, 2019 (date of incorporation) to September 30, 2019</span></span></p>
                                    <p style="margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">(Expressed in Canadian Dollars)</span></span></p>
                                </td>
                            </tr>
                        </table>
                    </div>
                    <ix:nonNumeric id="Fxbrl_20211228152627751" name="drug:DisclosureOfNatureAndContinuanceOfOperationsExplanatory" escape="true" contextRef="C_20201001to20210930">
                        <div>
                            <p style="margin-left: 18pt; text-indent: -18pt; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>1.</b><span style="width: 9pt; text-indent: 0pt; display: inline-block;">&#160;</span><b>NATURE AND CONTINUANCE OF OPERATIONS</b></span></span></p>
                            <p style="text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">Bright Minds Biosciences Inc. (the "Company") was incorporated under the Business Corporations Act of British Columbia on May 31, 2019. The Company's objective is to generate income and achieve long term profitable growth through the development of therapeutics to improve the lives of patients with certain severe and life-altering diseases. On February 8, 2021, the Company started trading on the Canadian Stock Exchange ("CSE") under the symbol DRUG. On May 17, 2021, the Company started trading on the OTCQB under the symbol BMBIF. On November 8, 2021, the Company started trading on NASDAQ under the symbol DRUG. The head office, and principal address of the Company are located at 1500 - 1055 West Georgia Street, Vancouver, British Columbia, V6E 4N7, Canada.</span></span></p>
                            <p style="text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">These consolidated financial statements have been prepared on a going concern basis which assumes that the Company will be able to realize its assets and discharge its liabilities in the normal course of business for the foreseeable future. As at September 30, 2021, the Company is not able to finance day to day activities through operations and has incurred a loss of $<ix:nonFraction id="Fxbrl_20211228152648303" name="ifrs-full:ProfitLoss" scale="0" decimals="0" format="ixt:numdotdecimal" sign="-" contextRef="C_20210930to20210930" unitRef="CAD">8,650,763</ix:nonFraction> for the year ended September 30, 2021. The Company has a deficit of $<ix:nonFraction id="Fxbrl_20211228152715046" name="ifrs-full:RetainedEarnings" scale="0" decimals="0" format="ixt:numdotdecimal" sign="-" contextRef="C_20210930" unitRef="CAD">9,209,857</ix:nonFraction> since inception and negative operating cash flows. As at September 30, 2021, the Company has working capital of $<ix:nonFraction id="Fxbrl_20211228152733166" name="drug:WorkingCapital" scale="0" decimals="0" format="ixt:numdotdecimal" contextRef="C_20210930" unitRef="CAD">19,399,795</ix:nonFraction> (September 30, 2020 - $<ix:nonFraction id="Fxbrl_20211228152740154" name="drug:WorkingCapital" scale="0" decimals="0" format="ixt:numdotdecimal" contextRef="C_20200930" unitRef="CAD">727,293</ix:nonFraction>). The continuing operations of the Company are dependent upon its ability to attain profitable operations and generate funds therefrom. Management intends to finance operating costs with equity financings, loans from directors and companies controlled by directors and/or private placement of common shares.</span></span></p>
                            <p style="text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">The coronavirus, also known as "COVID-19", has spread across the globe and is impacting worldwide economic activity. Government authorities have implemented emergency measures to mitigate the spread of the virus. The outbreak and the related mitigation measures may have an adverse impact on global economic conditions as well as on the Company's business activities specifically related to possible disruptions in the operations of the laboratories upon whom the Company relies, including laboratories situated in various parts of the United States and Europe. The extent to which the coronavirus may impact the Company's business activities will depend on future developments, such as the duration of the outbreak, travel restrictions, business disruptions, and the effectiveness of actions taken in Canada and other countries to contain and treat the disease. These events are highly uncertain and as such, the Company cannot determine their financial impact at this time.</span></span></p>
                        </div>
                    </ix:nonNumeric>
                </div>
            </div>
            <div>
                <div>
                    <ix:nonNumeric id="Fxbrl_20211228152858359" name="ifrs-full:DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory" escape="true" contextRef="C_20201001to20210930">
                        <div>
                            <p style="text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>2.</b><span style="width: 9pt; text-indent: 0pt; display: inline-block;">&#160;</span><b>STATEMENT OF COMPLIANCE AND BASIS OF PREPARATION</b></span></span></p>
                            <p style="text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">These consolidated financial statements were authorized for issue on December 24, 2021 by the directors of the Company.</span></span></p>
                            <p style="margin-bottom: 0pt; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>Statement of compliance</b></span></span></p>
                            <p style="margin-top: 0px; text-align: justify; margin-bottom: 0px;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">These consolidated financial statements have been prepared in accordance with the International Financial Reporting Standards ("IFRS") issued by the International Accounting Standards Board ("IASB") and Interpretations of the International Financial Reporting Interpretations Committee ("IFRIC"). The principal accounting policies applied in the preparation of these financial statements are set out below.</span></span></p>
                            <p style="margin-bottom: 0px; text-align: justify; margin-top: 13px;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>Basis of preparation</b></span></span></p>
                            <p style="margin-top: 0px; text-align: justify; margin-bottom: 0px;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">Depending on the applicable IFRS requirements, the measurement basis used in the preparation of these financial statements is cost, net realizable value, fair value or recoverable amount. These financial statements, except for the statement of cash flows, are based on the accrual basis.</span></span></p>
                        </div>
                    </ix:nonNumeric>
                </div>
            </div>
            <div>
                <div>
                    <ix:nonNumeric id="Fxbrl_20211228162019468" name="ifrs-full:DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory" escape="true" contextRef="C_20201001to20210930" continuedAt="F20211228162031878">
                        <div>
                            <p style="text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>3.<span style="display: inline-block; width: 9pt;">&#160;</span>SIGNIFICANT ACCOUNTING POLICIES </b></span></span></p>
                            <ix:nonNumeric id="Fxbrl_20211228162659674" name="drug:DescriptionOfAccountingPolicyForBasisOfConsolidationExplanatory" escape="true" contextRef="C_20201001to20210930" continuedAt="F20211228162709333">
                                <div>
                                    <p style="margin-bottom: 0pt; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>Basis of consolidation </b></span></span></p>
                                    <p style="margin-top: 0pt; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">These consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries Psilocybinlabs Ltd. (see Note 4), Bright Minds Biosciences LLC, a Delaware limited liability company, and Bright Minds Bioscience Pty Ltd., a proprietary company registered under the Corporations Act of Australia on June 24, 2021.&#160; On June 10, 2021, the CEO of the Company transferred, assigned and conveyed all of his membership interests in Bright Minds Biosciences LLC to the Company.</span></span></p>
                                    <p style="text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">A subsidiary is an entity that the Company controls, either directly or indirectly, where control is defined as the power to govern the financial and operating policies of an entity so as to obtain benefits from its activities. The financial results of the Company's subsidiaries are included in the financial statements from the date that control commences until the date that control ceases. The accounting policies of the Company's subsidiaries have been aligned with the policies adopted by the Company. When the Company ceases to control a subsidiary, the financial statements of that subsidiary are de-consolidated.</span></span></p>
                                </div>
                            </ix:nonNumeric>
                        </div>
                    </ix:nonNumeric>
                    <div>
                        <table style="width: 100%; border-collapse: collapse; font-size: 10pt;" border="0" cellspacing="0" cellpadding="0">
                            <tr>
                                <td style="width: 100%; text-align: center; border-top: 1pt solid black;">
                                    <p style="font-size: 10pt; font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>6</b> | Page</span></span></p>
                                </td>
                            </tr>
                        </table>
                    </div>
                    <hr style="page-break-after: always; text-align: center; height: 5px; width: 100%; background-color: black;" />
                    <div>
                        <table style="width: 100%; border-collapse: collapse; font-size: 10pt;" border="0" cellspacing="0" cellpadding="0">
                            <tr>
                                <td style="width: 100%;">
                                    <p style="margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>Bright Minds Biosciences Inc.</b></span></span></p>
                                    <p style="margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">Notes to the Consolidated Financial Statements</span></span></p>
                                    <p style="margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">For the years ended September 30, 2021 and 2020 and the period from May 31, 2019 (date of incorporation) to September 30, 2019</span></span></p>
                                    <p style="margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">(Expressed in Canadian Dollars)</span></span></p>
                                </td>
                            </tr>
                        </table>
                    </div>
                    <ix:continuation id="F20211228162031878" continuedAt="F20211228162044716">
                        <div>
                            <ix:continuation id="F20211228162709333">
                                <p style="text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">Inter-company balances and transactions, and any income and expenses arising from inter-company transactions, have been eliminated in these financial statements.</span></span></p>
                            </ix:continuation>
                            <ix:nonNumeric id="Fxbrl_20211228162737281" name="drug:DescriptionOfAccountingPolicyForCriticalAccountingEstimatesExplanatory" escape="true" contextRef="C_20201001to20210930">
                                <div>
                                    <p style="margin-bottom: 0pt; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>Critical accounting estimates</b></span></span></p>
                                    <p style="margin-top: 0pt; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">The preparation of the financial statements in conformity with IFRS requires management to make estimates, judgments and assumptions that affect the application of accounting policies and the reported amounts of assets, liabilities, income and expenses. Actual results may differ from these estimates. Estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognized in the period in which the estimates are revised and in any future periods affected.</span></span></p>
                                    <p style="text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">Certain of the Company's accounting policies and disclosures require key assumptions concerning the future and other estimates that have a significant risk of causing a material adjustment to the carrying amounts of assets and liabilities or disclosures within the next fiscal year. Where applicable, further information about the assumptions made is disclosed in the notes specific to that asset or liability. The critical accounting estimates and judgments set out below have been applied consistently to all periods presented in these financial statements.</span></span></p>
                                    <p style="margin-bottom: 0pt; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span style="text-decoration: underline;">Ability to continue as a going concern</span></span></span></p>
                                    <p style="margin-top: 0pt; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">Evaluation of the ability of the Company to realize its strategy for funding its future needs for working capital involves making judgments.</span></span></p>
                                    <p style="margin-bottom: 0pt; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span style="text-decoration: underline;">Share-based compensation</span></span></span></p>
                                    <p style="margin-top: 0pt; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">The fair value of stock options is measured using a Black Scholes option pricing model. Measurement inputs include the common share price on the grant date, the exercise price of the instrument, the expected common share price volatility, the weighted average expected life of the instruments, the expected dividends and the risk-free interest rate. Service and non-market performance conditions are not taken into account in determining fair value. The fair value of equity settled RSUs is measured based on management's best estimate of the Company's share price on the grant date.</span></span></p>
                                    <p style="text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">The share-based compensation recognized is also determined based on management's grant date estimate of the forfeitures that are expected to occur over the life of the stock options and equity settled RSUs. Cash settled RSUs outstanding are fair valued using a mark-to-market calculation based on the Company's closing common share price at the end of the period. The number of stock options and RSUs that actually vest could differ from the estimated number of awards expected to vest and any differences between the actual and estimated forfeitures are recognized prospectively as they occur.</span></span></p>
                                </div>
                            </ix:nonNumeric>
                            <ix:nonNumeric id="Fxbrl_20211228163638218" name="ifrs-full:DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory" escape="true" contextRef="C_20201001to20210930">
                                <div>
                                    <p style="margin-bottom: 0pt; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>Foreign currency translation</b></span></span></p>
                                    <p style="margin-top: 0pt; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">The functional currency of the Company, Psilocybinlabs Ltd., Bright Minds Biosciences LLC and Bright Minds Bioscience Pty Ltd. is the Canadian dollar and the presentation currency of the Company is the Canadian dollar. Transactions in currencies other than the functional currency are recorded at the rates of exchange prevailing on the transaction date. Monetary assets and liabilities that are denominated in foreign currencies are translated at the rates prevailing at each reporting date. Non-monetary assets and liabilities denominated in foreign currencies that are measured at fair value are retranslated to the functional currency at the exchange rate at the date the fair value was determined. Non-monetary items that are measured in terms of historical cost in a foreign currency are not retranslated. Foreign currency translation differences are recognized in profit or loss.</span></span></p>
                                </div>
                            </ix:nonNumeric>
                            <ix:nonNumeric id="Fxbrl_20211228163652370" name="ifrs-full:DescriptionOfAccountingPolicyForBusinessCombinationsExplanatory" escape="true" contextRef="C_20201001to20210930" continuedAt="F20211228164145011">
                                <div>
                                    <p style="margin-bottom: 0pt; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>Business combinations</b></span></span></p>
                                    <p style="margin-top: 0pt; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">The Company uses the acquisition method to account for business combinations. The Company measures goodwill as the fair value of the consideration transferred, less the net recognized amount (generally fair value) of the identifiable assets acquired and liabilities assumed, all measured as of the acquisition date. When the excess is negative, a gain on acquisition is recognized immediately in net income or loss.</span></span></p>
                                </div>
                            </ix:nonNumeric>
                        </div>
                    </ix:continuation>
                    <div>
                        <table style="width: 100%; border-collapse: collapse; font-size: 10pt;" border="0" cellspacing="0" cellpadding="0">
                            <tr>
                                <td style="width: 100%; text-align: center; border-top: 1pt solid black;">
                                    <p style="font-size: 10pt; font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>7</b> | Page</span></span></p>
                                </td>
                            </tr>
                        </table>
                    </div>
                    <hr style="page-break-after: always; text-align: center; height: 5px; width: 100%; background-color: black;" />
                    <div>
                        <table style="width: 100%; border-collapse: collapse; font-size: 10pt;" border="0" cellspacing="0" cellpadding="0">
                            <tr>
                                <td style="width: 100%;">
                                    <p style="margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>Bright Minds Biosciences Inc.</b></span></span></p>
                                    <p style="margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">Notes to the Consolidated Financial Statements</span></span></p>
                                    <p style="margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">For the years ended September 30, 2021 and 2020 and the period from May 31, 2019 (date of incorporation) to September 30, 2019</span></span></p>
                                    <p style="margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">(Expressed in Canadian Dollars)</span></span></p>
                                </td>
                            </tr>
                        </table>
                    </div>
                    <ix:continuation id="F20211228162044716" continuedAt="F20211228162131349">
                        <div>
                            <ix:continuation id="F20211228164145011">
                                <div>
                                    <p style="margin-top: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">Goodwill is not amortized and is tested for impairment annually. Additionally, goodwill is reviewed at each reporting date to determine if events or changes in circumstances indicate that the asset might be impaired, in which case an impairment test is performed. Goodwill is measured at cost less accumulated impairment losses.</span></span></p>
                                    <p style="text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">Transaction costs, other than those associated with the issue of debt or equity securities, that the Company incurs in connection with a business combination are expensed as incurred.</span></span></p>
                                </div>
                            </ix:continuation>
                            <ix:nonNumeric id="Fxbrl_20211228164211145" name="ifrs-full:DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory" escape="true" contextRef="C_20201001to20210930">
                                <div>
                                    <p style="margin-bottom: 0pt; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>Internally generated intangible assets - Research and development expenditure</b></span></span></p>
                                    <p style="margin-top: 0pt; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">Intangible assets acquired separately are initially recognized at cost. Expenditure on research activities is recognized as an expense in the period in which it is incurred. An internally-generated intangible asset arising from development (or from the development phase of an internal project) is recognized if, and only if, all of the following have been demonstrated:</span></span></p>
                                    <p style="margin-left: 36pt; margin-bottom: 0pt; text-indent: -18pt; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">&#8226;<span style="display: inline-block; width: 16.7pt;">&#160;</span>The technical feasibility of completing the intangible asset so that it will be available for use or sale;</span></span></p>
                                    <p style="margin-top: 0pt; margin-left: 36pt; margin-bottom: 0pt; text-indent: -18pt; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">&#8226;<span style="display: inline-block; width: 16.7pt;">&#160;</span>The intention to complete the intangible asset and use or sell it;</span></span></p>
                                    <p style="margin-top: 0pt; margin-left: 36pt; margin-bottom: 0pt; text-indent: -18pt; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">&#8226;<span style="display: inline-block; width: 16.7pt;">&#160;</span>The ability to use or sell the intangible asset;</span></span></p>
                                    <p style="margin-top: 0pt; margin-left: 36pt; margin-bottom: 0pt; text-indent: -18pt; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">&#8226;<span style="display: inline-block; width: 16.7pt;">&#160;</span>How the intangible asset will generate probable future economic benefits;</span></span></p>
                                    <p style="margin-top: 0pt; margin-left: 36pt; margin-bottom: 0pt; text-indent: -18pt; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">&#8226;<span style="display: inline-block; width: 16.7pt;">&#160;</span>The availability of adequate technical, financial and other resources to complete the development and to use or sell the intangible asset; and</span></span></p>
                                    <p style="margin-top: 0pt; margin-left: 36pt; text-indent: -18pt; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">&#8226;<span style="display: inline-block; width: 16.7pt;">&#160;</span>The ability to measure reliably the expenditure attributable to the intangible asset during its development.</span></span></p>
                                    <p style="text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">The amount initially recognized for internally-generated intangible assets is the sum of the expenditure incurred from the date when the intangible asset first meets the recognition criteria listed above. Where no internally-generated intangible asset can be recognized, development expenditure is recognized in profit or loss in the period in which it is incurred.</span></span></p>
                                    <p style="text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">Subsequent to initial recognition, internally-generated intangible assets are reported at cost less accumulated amortization and accumulated impairment losses, on the same basis as intangible assets that are acquired separately.</span></span></p>
                                    <p style="text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">At September 30, 2021 and 2020, the Company has not recognized any internally-generated intangible assets.</span></span></p>
                                </div>
                            </ix:nonNumeric>
                            <ix:nonNumeric id="Fxbrl_20211228164225417" name="ifrs-full:DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory" escape="true" contextRef="C_20201001to20210930">
                                <div>
                                    <p style="margin-bottom: 0pt; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>Share-based compensation awards</b></span></span></p>
                                    <p style="margin-top: 0pt; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">Share-based compensation expense relates to stock options as well as cash and equity settled restricted share units ("RSUs"). The grant date fair values of stock options and equity settled RSUs granted are recognized as an expense, with a corresponding increase in reserves in equity, over the vesting period. The amount recognized as an expense is based on the estimate of the number of awards expected to vest, which is revised if subsequent information indicates that actual forfeitures are likely to differ from the estimate. Upon exercise of stock options, the consideration paid by the holder is included in share capital and the related reserves associated with the stock options exercised is reclassified into share capital. Upon vesting of equity settled RSUs, the related reserves associated with the RSU is reclassified into share capital.</span></span></p>
                                    <p style="text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">For cash settled RSUs, the fair value of the RSUs is recognized as share-based compensation expense, with a corresponding increase in accrued liabilities over the vesting period. The amount recognized as an expense is based on the estimate of the number of RSUs expected to vest. Cash settled RSUs are measured at their fair value at each reporting period on a mark-to-market basis. Upon vesting of the cash settled RSUs, the liability is reduced by the cash payout.</span></span></p>
                                </div>
                            </ix:nonNumeric>
                            <ix:nonNumeric id="Fxbrl_20211228164238401" name="ifrs-full:DescriptionOfAccountingPolicyForProvisionsExplanatory" escape="true" contextRef="C_20201001to20210930">
                                <div>
                                    <p style="margin-bottom: 0pt; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>Provisions</b></span></span></p>
                                    <p style="margin-top: 0pt; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">A provision is recognized if, as a result of a past event, the Company has a present legal or constructive obligation that can be estimated reliably, and it is probable that an outflow of economic benefits will be required to settle the obligation. Provisions are determined by discounting the expected future cash flows at a pre-tax rate that reflects current market assessments of the time value of money and the risks specific to the liability. The unwinding of the discount is recognized as a finance cost within net income or loss.</span></span></p>
                                </div>
                            </ix:nonNumeric>
                        </div>
                    </ix:continuation>
                    <div>
                        <table style="width: 100%; border-collapse: collapse; font-size: 10pt;" border="0" cellspacing="0" cellpadding="0">
                            <tr>
                                <td style="width: 100%; text-align: center; border-top: 1pt solid black;">
                                    <p style="font-size: 10pt; font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>8</b> | Page</span></span></p>
                                </td>
                            </tr>
                        </table>
                    </div>
                    <hr style="page-break-after: always; text-align: center; height: 5px; width: 100%; background-color: black;" />
                    <div>
                        <table style="width: 100%; border-collapse: collapse; font-size: 10pt;" border="0" cellspacing="0" cellpadding="0">
                            <tr>
                                <td style="width: 100%;">
                                    <p style="margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>Bright Minds Biosciences Inc.</b></span></span></p>
                                    <p style="margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">Notes to the Consolidated Financial Statements</span></span></p>
                                    <p style="margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">For the years ended September 30, 2021 and 2020 and the period from May 31, 2019 (date of incorporation) to September 30, 2019</span></span></p>
                                    <p style="margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">(Expressed in Canadian Dollars)</span></span></p>
                                </td>
                            </tr>
                        </table>
                    </div>
                    <ix:continuation id="F20211228162131349" continuedAt="F20211228162149132">
                        <div>
                            <ix:nonNumeric id="Fxbrl_20211228164256440" name="ifrs-full:DescriptionOfAccountingPolicyForIncomeTaxExplanatory" escape="true" contextRef="C_20201001to20210930">
                                <div>
                                    <p style="margin-bottom: 0pt; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>Income taxes</b></span></span></p>
                                    <p style="margin-top: 0pt; margin-bottom: 0pt; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span style="text-decoration: underline;">Current income tax: </span></span></span></p>
                                    <p style="margin-top: 0pt; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">Current income tax assets and liabilities for the current period are measured at the amount expected to be recovered from or paid to the taxation authorities. The tax rates and tax laws used to compute the amount are those that are enacted or substantively enacted, at the reporting date, in the countries where the Company operates and generates taxable income.</span></span></p>
                                    <p style="margin-bottom: 0pt; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span style="text-decoration: underline;">Deferred tax: </span></span></span></p>
                                    <p style="margin-top: 0pt; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">Deferred tax is provided on temporary differences at the reporting date between the tax bases of assets and liabilities and their carrying amounts for financial reporting purposes. The carrying amount of deferred tax assets is reviewed at the end of each reporting period and recognized only to the extent that it is probable that sufficient taxable profit will be available to allow all or part of the deferred tax asset to be utilized.</span></span></p>
                                    <p style="text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">Deferred tax assets and liabilities are measured at the tax rates that are expected to apply to the year when the asset is realized or the liability is settled, based on tax rates (and tax laws) that have been enacted or substantively enacted by the end of the reporting period. Deferred tax assets and deferred tax liabilities are offset if a legally enforceable right exists to set off current tax assets against current income tax liabilities and the deferred taxes relate to the same taxable entity and the same taxation authority.</span></span></p>
                                </div>
                            </ix:nonNumeric>
                            <ix:nonNumeric id="Fxbrl_20211228164308737" name="ifrs-full:DescriptionOfAccountingPolicyForEarningsPerShareExplanatory" escape="true" contextRef="C_20201001to20210930">
                                <div>
                                    <p style="margin-bottom: 0pt; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>Loss per share</b></span></span></p>
                                    <p style="margin-top: 0pt; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">Basic loss per share is calculated by dividing the loss attributable to common shareholders by the weighted average number of common shares outstanding in the period. The loss attributable to common shareholders equals the reported loss attributable to owners of the Company. Diluted loss per share is calculated using the treasury stock method. Under the treasury stock method, the weighted average number of common shares outstanding for the calculation of diluted loss per share assumes that the proceeds to be received on the exercise of dilutive share options and warrants are used to repurchase common shares at the average market price during the period. Because the Company incurred net losses, the effect of dilutive instruments would be anti-dilutive and therefore diluted loss per share equals loss per share.</span></span></p>
                                </div>
                            </ix:nonNumeric>
                            <ix:nonNumeric id="Fxbrl_20211228164323097" name="ifrs-full:DescriptionOfAccountingPolicyForIssuedCapitalExplanatory" escape="true" contextRef="C_20201001to20210930">
                                <div>
                                    <p style="margin-bottom: 0pt; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>Share capital</b></span></span></p>
                                    <p style="margin-top: 0pt; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">Financial instruments issued by the Company are classified as equity only to the extent that they do not meet the definition of a financial liability or financial asset. The Company's common shares are classified as equity instruments.</span></span></p>
                                    <p style="text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">Incremental costs directly attributable to the issue of new common shares are recognized as a deduction from equity, net of tax.</span></span></p>
                                </div>
                            </ix:nonNumeric>
                            <ix:nonNumeric id="Fxbrl_20211228164345985" name="ifrs-full:DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory" escape="true" contextRef="C_20201001to20210930" continuedAt="F20211228164404691">
                                <div>
                                    <p style="margin-bottom: 0pt; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>Financial instruments</b></span></span></p>
                                    <p style="margin-top: 0pt; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">Financial instruments are accounted for in accordance with IFRS 9, "Financial Instruments: Classification and Measurement". A financial instrument is any contract that gives rise to a financial asset of one entity and a financial liability or equity instrument of another entity.</span></span></p>
                                    <p style="margin-bottom: 0pt; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span style="text-decoration: underline;">Financial assets</span></span></span></p>
                                    <p style="margin-top: 0pt; margin-bottom: 0pt; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">(a) Recognition and measurement of financial assets</span></span></p>
                                    <p style="margin-top: 0pt; margin-left: 13.5pt; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">The Company recognizes a financial asset when it becomes a party to the contractual provisions of the instrument.</span></span></p>
                                    <p style="margin-bottom: 0pt; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">(b) Classification of financial assets</span></span></p>
                                    <p style="margin-top: 0pt; margin-left: 13.5pt; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">The Company classifies financial assets at initial recognition as financial assets: measured at amortized cost, measured at fair value through other comprehensive income ("FVTOCI") or measured at fair value through profit or loss ("FVTPL").</span></span></p>
                                    <p style="margin-bottom: 0pt; text-indent: 22.5pt; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">(i) Financial assets measured at amortized cost</span></span></p>
                                    <p style="margin-top: 0pt; margin-left: 36pt; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">A financial asset that meets both of the following conditions is classified as a financial asset measured at amortized cost:</span></span></p>
                                    <p style="margin-left: 49.5pt; margin-bottom: 0pt; text-indent: -4.5pt; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">&#8226;<span style="display: inline-block; width: 1.7pt;">&#160;</span>The Company's business model for such financial assets is to hold the assets in order to collect contractual cash flows.</span></span></p>
                                    <p style="margin-top: 0pt; margin-left: 49.5pt; text-indent: -4.5pt; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">&#8226;<span style="display: inline-block; width: 1.7pt;">&#160;</span>The contractual terms of the financial asset give rise on specified dates to cash flows that are solely payments of principal and interest on the amount outstanding.</span></span></p>
                                </div>
                            </ix:nonNumeric>
                        </div>
                    </ix:continuation>
                    <div>
                        <table style="width: 100%; border-collapse: collapse; font-size: 10pt;" border="0" cellspacing="0" cellpadding="0">
                            <tr>
                                <td style="width: 100%; text-align: center; border-top: 1pt solid black;">
                                    <p style="font-size: 10pt; font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>9</b> | Page</span></span></p>
                                </td>
                            </tr>
                        </table>
                    </div>
                    <hr style="page-break-after: always; text-align: center; height: 5px; width: 100%; background-color: black;" />
                    <div>
                        <table style="width: 100%; border-collapse: collapse; font-size: 10pt; margin-bottom: 0px;" border="0" cellspacing="0" cellpadding="0">
                            <tr>
                                <td style="width: 100%;">
                                    <p style="margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>Bright Minds Biosciences Inc.</b></span></span></p>
                                    <p style="margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">Notes to the Consolidated Financial Statements</span></span></p>
                                    <p style="margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">For the years ended September 30, 2021 and 2020 and the period from May 31, 2019 (date of incorporation) to September 30, 2019</span></span></p>
                                    <p style="margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">(Expressed in Canadian Dollars)</span></span></p>
                                </td>
                            </tr>
                        </table>
                    </div>
                    <ix:continuation id="F20211228162149132" continuedAt="F20211228162357950">
                        <div>
                            <ix:continuation id="F20211228164404691" continuedAt="F20211228164418755">
                                <div>
                                    <p style="margin-left: 36pt; text-align: justify; margin-top: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">A financial asset measured at amortized cost is initially recognized at fair value plus transaction costs directly attributable to the asset. After initial recognition, the carrying amount of the financial asset measured at amortized cost is determined using the effective interest method, net of impairment loss, if necessary.</span></span></p>
                                    <p style="margin-bottom: 0pt; text-indent: 22.5pt; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">(ii) Financial assets measured at FVTOCI</span></span></p>
                                    <p style="margin-top: 0pt; margin-left: 36pt; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">A financial asset measured at FVOCI is recognized initially at fair value plus transaction costs directly attributable to the asset. After initial recognition, the asset is measured at fair value with changes in fair value included as "financial asset at fair value through other comprehensive income" in other comprehensive income or loss.</span></span></p>
                                    <p style="margin-bottom: 0pt; text-indent: 22.5pt; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">(iii) Financial assets measured at FVTPL</span></span></p>
                                    <p style="margin-top: 0pt; margin-left: 36pt; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">A financial asset measured at FVTPL is initially recognized at fair value with any associated transaction costs being recognized in profit or loss when incurred. Subsequently, the financial asset is re-measured at fair value and a gain or loss is recognized in profit or loss in the reporting period in which it arises.</span></span></p>
                                    <p style="margin-left: 36pt; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">The Company's cash and cash equivalents are classified as subsequently measured at FVTPL.</span></span></p>
                                    <p style="margin-bottom: 0pt; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">(c) Derecognition of financial assets</span></span></p>
                                    <p style="margin-top: 0pt; margin-left: 13.6pt; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">The Company derecognizes a financial asset if the contractual rights to the cash flows from the asset expire, or the Company transfers substantially all the risks and rewards of ownership of the financial asset. Any interests in transferred financial assets that are created or retained by the Company are recognized as a separate asset or liability. Gains and losses on derecognition are generally recognized in the statement of comprehensive loss. However, gains and losses on derecognition of financial assets classified as FVTOCI remain within accumulated other comprehensive income or loss.</span></span></p>
                                    <p style="margin-bottom: 0pt; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span style="text-decoration: underline;">Financial liabilities</span></span></span></p>
                                    <p style="margin-top: 0pt; margin-bottom: 0pt; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">(a) Recognition and measurement of financial liabilities</span></span></p>
                                    <p style="margin-top: 0pt; margin-left: 13.5pt; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">The Company recognizes a financial liability when it becomes a party to the contractual provisions of the instrument.</span></span></p>
                                    <p style="margin-bottom: 0pt; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">(b) Classification of financial liabilities</span></span></p>
                                    <p style="margin-top: 0pt; margin-bottom: 0pt; text-indent: 22.5pt; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">(i) Financial liabilities measured at amortized cost</span></span></p>
                                    <p style="margin-top: 0pt; margin-left: 36pt; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">A financial liability measured at amortized cost is initially measured at fair value less transaction costs directly attributable to the issuance of the financial liability. Subsequently, the financial liability is measured at amortized cost using the effective interest method.</span></span></p>
                                    <p style="margin-left: 36pt; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">The Company's accounts payable and accrued liabilities are classified as subsequently measured at amortized cost.</span></span></p>
                                    <p style="margin-bottom: 0pt; text-indent: 22.5pt; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">(ii) Financial liabilities measured at fair value through profit or loss</span></span></p>
                                    <p style="margin-top: 0pt; margin-left: 36pt; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">A financial liability measured at fair value through profit or loss is initially measured at fair value with any associated transaction costs being recognized in profit or loss when incurred. Subsequently, the financial liability is re-measured at fair value and a gain or loss is recognized in profit or loss in the reporting period in which it arises.</span></span></p>
                                    <p style="margin-bottom: 0pt; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">(c) Derecognition of financial liabilities</span></span></p>
                                    <p style="margin-top: 0pt; margin-left: 13.6pt; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">The Company derecognizes a financial liability when the financial liability is discharged, cancelled or expired. Generally, the difference between the carrying amount of the financial liability derecognized and the consideration paid and payable, including any non-cash assets transferred or liabilities assumed, is recognized in the statement of comprehensive loss.</span></span></p>
                                    <p style="margin-bottom: 0pt; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span style="text-decoration: underline;">Offsetting financial assets and liabilities</span></span></span></p>
                                    <p style="margin-top: 0pt; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">Financial assets and liabilities are offset and the net amount is presented in the statement of financial position only when the Company has a legally enforceable right to offset the recognized amounts and intends either to settle on a net basis, or to realize the asset and settle the liability simultaneously.</span></span></p>
                                    <p style="margin-bottom: 0pt; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span style="text-decoration: underline;">Impairment of financial assets</span></span></span></p>
                                    <p style="margin-top: 0pt; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">The Company recognizes a loss allowance for expected credit losses on financial assets that are measured at amortized cost.</span></span></p>
                                </div>
                            </ix:continuation>
                        </div>
                    </ix:continuation>
                    <div>
                        <table style="width: 100%; border-collapse: collapse; font-size: 10pt;" border="0" cellspacing="0" cellpadding="0">
                            <tr>
                                <td style="width: 100%; text-align: center; border-top: 1pt solid black;">
                                    <p style="font-size: 10pt; font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>10</b> | Page</span></span></p>
                                </td>
                            </tr>
                        </table>
                    </div>
                    <hr style="page-break-after: always; text-align: center; height: 5px; width: 100%; background-color: black;" />
                    <div>
                        <table style="width: 100%; border-collapse: collapse; font-size: 10pt;" border="0" cellspacing="0" cellpadding="0">
                            <tr>
                                <td style="width: 100%;">
                                    <p style="margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>Bright Minds Biosciences Inc.</b></span></span></p>
                                    <p style="margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">Notes to the Consolidated Financial Statements</span></span></p>
                                    <p style="margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">For the years ended September 30, 2021 and 2020 and the period from May 31, 2019 (date of incorporation) to September 30, 2019</span></span></p>
                                    <p style="margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">(Expressed in Canadian Dollars)</span></span></p>
                                </td>
                            </tr>
                        </table>
                    </div>
                    <ix:continuation id="F20211228162357950">
                        <div>
                            <ix:continuation id="F20211228164418755">
                                <div>
                                    <p style="margin-bottom: 0pt; text-align: justify; margin-top: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">At each reporting date, the Company measures the loss allowance for the financial asset at an amount equal to the lifetime expected credit losses if the credit risk on the financial asset has increased significantly since initial recognition. If at the reporting date, the financial asset has not increased significantly since initial recognition, the Company measures the loss allowance for the financial asset at an amount equal to the twelve-month expected credit&#160;</span></span><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">losses. The Company recognizes in the statement of comprehensive income or loss, as an impairment loss (or gain), the amount of expected credit losses (or reversal) that is required to adjust the loss allowance at the reporting date to the amount that is required to be recognized.</span></span></p>
                                </div>
                            </ix:continuation>
                            <ix:nonNumeric id="Fxbrl_20211228164437799" name="ifrs-full:DescriptionOfAccountingPolicyForLeasesExplanatory" escape="true" contextRef="C_20201001to20210930">
                                <div>
                                    <p style="margin-bottom: 0pt; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>Leases</b></span></span></p>
                                    <p style="margin-top: 0pt; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">Leases are accounted for in accordance with IFRS 16, "Leases". At inception of a contract, the Company assesses whether a contract is, or contains, a lease.&#160; A contract is, or contains, a lease if the contract conveys the right to control the use of an identified asset over a period of time in exchange for consideration.&#160; The Company assesses whether the contract involves the use of an identified asset, whether it has the right to obtain substantially all of the economic benefits from the use of the asset during the term of the contract and if it has the right to direct the use of the asset.</span></span></p>
                                    <p style="text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">As a lessee, the Company recognizes a right-of-use asset and a lease liability at the commencement date of the lease.</span></span></p>
                                    <p style="margin-bottom: 0pt; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span style="text-decoration: underline;">Right-of-use asset</span></span></span></p>
                                    <p style="margin-top: 0pt; margin-bottom: 0pt; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">The right-of-use asset is initially measured at cost, which is comprised of the initial amount of the lease liability adjusted for any lease payments made and any initial direct costs incurred at or before the commencement date, less any lease incentives received.</span></span></p>
                                    <p style="margin-top: 0pt; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">The right-of-use asset is subsequently depreciated from the commencement date to the earlier of the end of the lease term, or the end of the useful life of the asset.&#160; In addition, the right-of-use asset may be reduced due to impairment losses, if any, and adjusted for certain re-measurements of the lease liability.</span></span></p>
                                    <p style="margin-bottom: 0pt; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span style="text-decoration: underline;">Lease liability</span></span></span></p>
                                    <p style="margin-top: 0pt; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">A lease liability is initially measured at the present value of the lease payments that are not paid at the commencement date discounted by the interest rate implicit in the lease or, if that rate cannot be readily determined, the incremental borrowing rate. The lease liability is subsequently measured at amortized cost using the effective interest method.</span></span></p>
                                </div>
                            </ix:nonNumeric>
                            <ix:nonNumeric id="Fxbrl_20211228164450736" name="drug:DescriptionOfAccountingPolicyForNewStandardsAndInterpretationsNotYetAdoptedExplanatory" escape="true" contextRef="C_20201001to20210930">
                                <div>
                                    <p style="margin-bottom: 0pt; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>New standards and interpretations not yet adopted</b></span></span></p>
                                    <p style="margin-top: 0pt; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">A number of new standards, amendments to standards and interpretations are not yet effective for the year ended September 30, 2021 and have not been applied in preparing these financial statements. The following new standards have not been adopted which may impact the Company in future:</span></span></p>
                                    <p style="margin-bottom: 0pt; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span style="text-decoration: underline;">IAS 1 - Presentation of Financial Statements </span></span></span></p>
                                    <p style="margin-top: 0pt; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">An amendment to IAS 1 clarifies the criterion for classifying a liability as non-current relating to the right to defer settlement of a liability for at least 12 months after the reporting period.</span></span></p>
                                    <p style="text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">IAS 1 has amended the definition of material to "information is material if omitting, misstating or obscuring it could reasonably be expected to influence decisions that the primary users of general-purpose financial statements make on the basis of those financial statements, which provide financial information about a specific reporting entity." The previous definition of material from IAS1 was "omissions or misstatements of items are material if they could, individually or collectively, influence the economic decisions that users make on the basis of the financial statements. Materiality depends on the size and nature of the omission or misstatement judged in the surrounding circumstances. The size or nature of the item, or a combination of both, could be the determining factor."</span></span></p>
                                    <p style="margin-bottom: 0pt; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span style="text-decoration: underline;">IAS 8 - Accounting Policies, Changes in Accounting Estimates and Errors</span></span></span></p>
                                    <p style="margin-top: 0pt; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">IAS 8 amended the definition of material reflect the changes outlined above under IAS 1.</span></span></p>
                                    <p style="margin-bottom: 0pt; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span style="text-decoration: underline;">IAS 12 and IFRIC 23 - Income Taxes</span></span></span></p>
                                    <p style="margin-top: 0pt; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">IAS 12 currently provides guidance on current and deferred tax assets and liabilities however uncertainty may exist on how tax law applies to certain transactions. IFRIC 23 provides guidance on how to address uncertainty related to tax treatments.</span></span></p>
                                </div>
                            </ix:nonNumeric>
                        </div>
                    </ix:continuation>
                    <div>
                        <table style="width: 100%; border-collapse: collapse; font-size: 10pt;" border="0" cellspacing="0" cellpadding="0">
                            <tr>
                                <td style="width: 100%; text-align: center; border-top: 1pt solid black;">
                                    <p style="font-size: 10pt; font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>11</b> | Page</span></span></p>
                                </td>
                            </tr>
                        </table>
                    </div>
                </div>
            </div>
            <hr style="break-after: page; text-align: center; height: 5px; color: #000000; background-color: #000000; width: 100%;" />
            <div>
                <div>
                    <div>
                        <table style="width: 100%; border-collapse: collapse; font-size: 10pt;" border="0" cellspacing="0" cellpadding="0">
                            <tr>
                                <td style="width: 100%;">
                                    <p style="margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>Bright Minds Biosciences Inc.</b></span></span></p>
                                    <p style="margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">Notes to the Consolidated Financial Statements</span></span></p>
                                    <p style="margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">For the years ended September 30, 2021 and 2020 and the period from May 31, 2019 (date of incorporation) to September 30, 2019</span></span></p>
                                    <p style="margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">(Expressed in Canadian Dollars)</span></span></p>
                                </td>
                            </tr>
                        </table>
                    </div>
                    <ix:nonNumeric id="Fxbrl_20211228170632122" name="drug:DisclosureOfShareExchangeAndAssignmentExplanatory" escape="true" contextRef="C_20201001to20210930">
                        <div>
                            <p style="text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>4.<span style="display: inline-block; width: 9pt;">&#160;</span>SHARE EXCHANGE AND ASSIGNMENT</b></span></span></p>
                            <p style="text-align: justify; margin-bottom: 0px;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">Psilocybinlabs Ltd. ("PL") was incorporated under the laws of the province of British Columbia on April 25, 2019, with the incorporator share being held by a company controlled by the CEO of the Company. On May 17, 2019, this share was transferred to the Company. On April 25, 2019, PL entered into a confirmatory assignment and waiver (the "CAW") with an individual, which was amended and restated on May 17, 2019. Pursuant to the amended and restated CAW, this individual assigned all of the right, title and interest, including all other intellectual property rights (the Rights, as described) to PL. As compensation for the assignment of the Rights, PL issued <ix:nonFraction id="Fxbrl_20211228180500243" name="drug:NumberOfSharesIssuedByRelatedParty" decimals="INF" format="ixt:numdotdecimal" contextRef="C_20190425_ifrsfullCategoriesOfRelatedPartiesAxis_drugPsilocybinlabsLtdMember" unitRef="Share">100,000</ix:nonFraction> common shares valued at $<ix:nonFraction id="Fxbrl_20211228180513940" name="drug:ValueOfCommonStockSharesIssuedByRelatedParty" scale="0" decimals="0" format="ixt:numdotdecimal" contextRef="C_20190425_ifrsfullCategoriesOfRelatedPartiesAxis_drugPsilocybinlabsLtdMember" unitRef="CAD">2,000</ix:nonFraction> to this individual. On August 7, 2019, the Company then purchased the <ix:nonFraction id="Fxbrl_20211228180534851" name="drug:CommonStockSharesPurchased" decimals="INF" format="ixt:numdotdecimal" contextRef="C_20190807_ifrsfullCategoriesOfRelatedPartiesAxis_drugPsilocybinlabsLtdMember" unitRef="Share">100,000</ix:nonFraction> common shares of PL by issuing <ix:nonFraction id="Fxbrl_20211228180624725" name="ifrs-full:NumberOfInstrumentsOrInterestsIssuedOrIssuable" decimals="INF" format="ixt:numdotdecimal" contextRef="C_20190807_ifrsfullCategoriesOfRelatedPartiesAxis_drugPsilocybinlabsLtdMember" unitRef="Shares">100,000</ix:nonFraction> common shares of the Company valued at $<ix:nonFraction id="Fxbrl_20211228180638636" name="ifrs-full:EquityInterestsOfAcquirer" scale="0" decimals="0" format="ixt:numdotdecimal" contextRef="C_20190807_ifrsfullCategoriesOfRelatedPartiesAxis_drugPsilocybinlabsLtdMember" unitRef="CAD">2,000</ix:nonFraction>, with the reacquisition being recorded as an asset acquisition.</span></span></p>
                        </div>
                    </ix:nonNumeric>
                </div>
            </div>
            <div>
                <ix:nonNumeric id="Fxbrl_20211228162231396" name="ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory" escape="true" contextRef="C_20201001to20210930">
                    <div>
                        <p style="text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>5.<span style="display: inline-block; width: 9pt;">&#160;</span>ACCOUNTS PAYABLE AND ACCRUED LIABILITIES</b></span></span></p>
                        <ix:nonNumeric id="Fxbrl_20211228162242620" name="drug:DisclosureOfDetailedInformationAboutTradePayableAndAccruedExpensesExplanatory" escape="true" contextRef="C_20201001to20210930">
                            <table style="width: 100%; border-collapse: collapse; font-size: 10pt; border-color: #000000;" cellspacing="0" cellpadding="0">
                                <tr>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1.5pt solid #000000; border-bottom: 0.75pt solid #000000; vertical-align: bottom;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>&#160;</b></span></span></td>
                                    <td style="vertical-align: bottom; border-top: 1.5pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right;">&#160;</td>
                                    <td style="vertical-align: bottom; border-top: 1.5pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>September 30, </b><br /><b>2021</b></span></span></td>
                                    <td style="vertical-align: bottom; border-top: 1.5pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;">&#160;</td>
                                    <td style="vertical-align: bottom; border-top: 1.5pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;">&#160;</td>
                                    <td style="vertical-align: bottom; border-top: 1.5pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>September 30, </b><br /><b>2020</b></span></span></td>
                                    <td style="vertical-align: bottom; border-top: 1.5pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right;">&#160;</td>
                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>$</b></span></span></td>
                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right;">&#160;</td>
                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right;">&#160;</td>
                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>$&#160;</b></span></span></td>
                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">Accounts payable</span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b><ix:nonFraction id="Fxbrl_20211228162400108_22" name="ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers" scale="0" decimals="0" format="ixt:numdotdecimal" contextRef="C_20210930" unitRef="CAD">596,573</ix:nonFraction></b></span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><ix:nonFraction id="Fxbrl_20211228162400108_25" name="ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers" scale="0" decimals="0" format="ixt:numdotdecimal" contextRef="C_20200930" unitRef="CAD">138,423</ix:nonFraction></span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">Accrued liabilities</span></span></td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b><ix:nonFraction id="Fxbrl_20211228162400108_32" name="ifrs-full:AccrualsClassifiedAsCurrent" scale="0" decimals="0" format="ixt:numdotdecimal" contextRef="C_20210930" unitRef="CAD">42,000</ix:nonFraction></b></span></span></td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><ix:nonFraction id="Fxbrl_20211228162400108_35" name="ifrs-full:AccrualsClassifiedAsCurrent" scale="0" decimals="0" format="ixt:numdotdecimal" contextRef="C_20200930" unitRef="CAD">12,500</ix:nonFraction></span></span></td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 2.25pt double #000000; vertical-align: bottom; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">Total accounts payable and accrued liabilities</span></span></td>
                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b><ix:nonFraction id="Fxbrl_20211228162400108_42" name="ifrs-full:TradeAndOtherCurrentPayables" scale="0" decimals="0" format="ixt:numdotdecimal" contextRef="C_20210930" unitRef="CAD">638,573</ix:nonFraction></b></span></span></td>
                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><ix:nonFraction id="Fxbrl_20211228162400108_45" name="ifrs-full:TradeAndOtherCurrentPayables" scale="0" decimals="0" format="ixt:numdotdecimal" contextRef="C_20200930" unitRef="CAD">150,923</ix:nonFraction></span></span></td>
                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                </tr>
                            </table>
                        </ix:nonNumeric>
                    </div>
                </ix:nonNumeric>
            </div>
            <div>
                <div>
                    <div>
                        <div>
                            <div>
                                <ix:nonNumeric id="Fxbrl_20211229021204284" name="ifrs-full:DisclosureOfIssuedCapitalExplanatory" escape="true" contextRef="C_20201001to20210930" continuedAt="F20211229021219934">
                                    <div>
                                        <p style="text-align: justify; margin-top: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>6.<span style="display: inline-block; width: 9pt;">&#160;</span>SHARE CAPITAL</b></span></span></p>
                                        <p style="margin-bottom: 0pt; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span style="text-decoration: underline;"><b>Authorized share capital</b></span></span></span></p>
                                        <p style="margin-top: 0pt; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">Unlimited number of common shares without par value.</span></span></p>
                                        <p style="text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">
                                                    <ix:nonNumeric id="Fxbrl_20211231151630181" name="drug:DescriptionOfIssuedAndOutstandingCommonShares" contextRef="C_20201001to20210930">On November 10, 2020, the Directors of the Company approved the consolidation of the Company's issued and outstanding common shares on a 2.5:1 basis.</ix:nonNumeric> All common shares, stock options and warrant references in these financial statements reflect the effect of the share consolidation.
                                                </span></span></p>
                                        <p style="margin-bottom: 0pt; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>Issued share capital for the year ended September 30, 2021</b></span></span></p>
                                        <p style="margin-top: 0pt; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">On November 2, 2020, the Company closed the second tranche of a non-brokered private placement financing through the issuance of <ix:nonFraction id="Fxbrl_20211229044005459" name="ifrs-full:IncreaseDecreaseInNumberOfSharesOutstanding" decimals="INF" format="ixt:numdotdecimal" contextRef="C_20201101to20201102_ifrsfullClassesOfShareCapitalAxis_drugSecondTrancheOfNonBrokeredPrivatePlacementMember" unitRef="Share">1,629,138</ix:nonFraction> common shares at a price $<ix:nonFraction id="Fxbrl_20211229044011459" name="drug:IssuePricePerShare" scale="0" decimals="2" format="ixt:numdotdecimal" contextRef="C_20201102_ifrsfullClassesOfShareCapitalAxis_drugSecondTrancheOfNonBrokeredPrivatePlacementMember" unitRef="CAD_per_share">1.25</ix:nonFraction> per common share for gross proceeds of $<ix:nonFraction id="Fxbrl_20211229044018281" name="ifrs-full:ProceedsFromIssueOfOrdinaryShares" scale="0" decimals="0" format="ixt:numdotdecimal" contextRef="C_20201101to20201102_ifrsfullClassesOfShareCapitalAxis_drugSecondTrancheOfNonBrokeredPrivatePlacementMember" unitRef="CAD">2,036,422</ix:nonFraction>.</span></span></p>
                                        <p style="text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">On January 6, 2021, the Company issued <ix:nonFraction id="Fxbrl_20211229044311046" name="ifrs-full:IncreaseDecreaseInNumberOfSharesOutstanding" decimals="INF" format="ixt:numdotdecimal" contextRef="C_20210101to20210106_drugAgreementAxis_drugDebtSettlementAgreementMember_ifrsfullCategoriesOfRelatedPartiesAxis_drugConsultantMember" unitRef="Share">14,799</ix:nonFraction> common shares at a deemed price of $<ix:nonFraction id="Fxbrl_20211229044318387" name="drug:IssuePricePerShare" scale="0" decimals="2" format="ixt:numdotdecimal" contextRef="C_20210106_drugAgreementAxis_drugDebtSettlementAgreementMember_ifrsfullCategoriesOfRelatedPartiesAxis_drugConsultantMember" unitRef="CAD_per_share">1.25</ix:nonFraction> per share to settle an $<ix:nonFraction id="Fxbrl_20211229044330754" name="drug:DebtSettledThroughIssuanceOfShares" scale="0" decimals="0" format="ixt:numdotdecimal" contextRef="C_20210101to20210106_drugAgreementAxis_drugDebtSettlementAgreementMember_ifrsfullCategoriesOfRelatedPartiesAxis_drugConsultantMember" unitRef="CAD">18,500</ix:nonFraction> debt owing to a consultant pursuant to a debt settlement agreement entered into by the Company with the consultant.</span></span></p>
                                        <p style="text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">On February 3, 2021, the <ix:nonFraction id="Fxbrl_20211229180420598" name="drug:NumberOfWarrantsDeemedToBeExercised" decimals="INF" format="ixt:numdotdecimal" contextRef="C_20210201to20210203_ifrsfullClassesOfShareCapitalAxis_drugSpecialWarrantsMember" unitRef="Share">16,000</ix:nonFraction> SWs were deemed to be exercised for SW shares and <ix:nonFraction id="Fxbrl_20211230153159642" name="drug:NumberOfWarrantsDeemedToBeExercised" decimals="INF" format="ixt:numdotdecimal" contextRef="C_20210201to20210203_ifrsfullClassesOfShareCapitalAxis_drugSpecialWarrantsMember" unitRef="Share">16,000</ix:nonFraction> common shares of the Company were issued to the SW holders (see below).</span></span></p>
                                        <p style="text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">On March 17, 2021, the Company issued <ix:nonFraction id="Fxbrl_20211229044728226" name="drug:NumberOfUnitsIssued" decimals="INF" format="ixt:numdotdecimal" contextRef="C_20210301to20210317" unitRef="Share">3,419,883</ix:nonFraction> Units at a price per Unit of $<ix:nonFraction id="Fxbrl_20211229044718715" name="drug:UnitsIssuedPricePerUnit" scale="0" decimals="2" format="ixt:numdotdecimal" contextRef="C_20210317" unitRef="Unit_Per_Share">7.57</ix:nonFraction> for aggregate gross proceeds of $<ix:nonFraction id="Fxbrl_20211229044711793" name="drug:GrossProceedsFromUnitsIssued" scale="0" decimals="0" format="ixt:numdotdecimal" contextRef="C_20210301to20210317" unitRef="CAD">25,888,514</ix:nonFraction>. Each Unit comprised one common share and one-half of one common share purchase warrant of the Company. Each warrant is exercisable to acquire one common share of the Company at an exercise price of $<ix:nonFraction id="Fxbrl_20211229045137635" name="drug:ExercisePriceWarrantsGranted" scale="0" decimals="2" format="ixt:numdotdecimal" contextRef="C_20210301to20210317" unitRef="CAD_per_share">9.46</ix:nonFraction> per warrant until March 17, 2024, subject to adjustment and acceleration in certain events. If the daily volume weighted average trading price of the common shares on the CSE is equal to or greater than $<ix:nonFraction id="Fxbrl_20211229045242648" name="drug:MinimumDailyVolumeWeightedAverageTradingSharePrice" scale="0" decimals="2" format="ixt:numdotdecimal" contextRef="C_20210317" unitRef="CAD_per_share">13.25</ix:nonFraction> per common share for any 10 consecutive trading days, the Company shall have the right to accelerate the expiry date of the warrants to a date that is at least 30 trading days following the date of the Company issuing a press release disclosing such acceleration. The underwriters were paid fees for their services in the amount of $<ix:nonFraction id="Fxbrl_20211229045340407" name="drug:UnderwritersFeesPaid" scale="0" decimals="0" format="ixt:numdotdecimal" contextRef="C_20210301to20210317" unitRef="CAD">916,317</ix:nonFraction> and received compensation warrants entitling them to purchase an aggregate of <ix:nonFraction id="Fxbrl_20211230153735590" name="drug:NumberOfWarrantsIssued" decimals="INF" format="ixt:numdotdecimal" contextRef="C_20210301to20210317_ifrsfullCategoriesOfRelatedPartiesAxis_drugUnderwritersMember_ifrsfullClassesOfShareCapitalAxis_drugWarrantsMember" unitRef="Share">132,666</ix:nonFraction> common shares at a price of $<ix:nonFraction id="Fxbrl_20211230153857735" name="drug:ExercisePriceWarrantsGranted" scale="0" decimals="2" format="ixt:numdotdecimal" contextRef="C_20210301to20210317_ifrsfullCategoriesOfRelatedPartiesAxis_drugUnderwritersMember_ifrsfullClassesOfShareCapitalAxis_drugWarrantsMember" unitRef="CAD_per_share">7.57</ix:nonFraction> per common share for a period of thirty-six months following closing. These warrants have an ascribed value of $<ix:nonFraction id="Fxbrl_20211229045403345" name="drug:WarrantAscribedValue" scale="0" decimals="0" format="ixt:numdotdecimal" contextRef="C_20210301to20210317_ifrsfullCategoriesOfRelatedPartiesAxis_drugUnderwritersMember_ifrsfullClassesOfShareCapitalAxis_drugWarrantsMember" unitRef="CAD">521,000</ix:nonFraction>.</span></span></p>
                                        <p style="text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">On April 6, 2021, the Company paid a New York-based company a contingent cash fee in the amount of $<ix:nonFraction id="Fxbrl_20211229060458652" name="drug:ContingentCashFee" scale="0" decimals="0" format="ixt:numdotdecimal" contextRef="C_20210401to20210406_ifrsfullCategoriesOfRelatedPartiesAxis_drugThreeInvestorsMember" unitRef="CAD">600,000</ix:nonFraction>, being <ix:nonFraction id="Fxbrl_20211229060508530" name="drug:PercentageOfNetEquityProceedsReceivedFromThreeInvestors" scale="-2" decimals="3" format="ixt:numdotdecimal" contextRef="C_20210401to20210406_ifrsfullCategoriesOfRelatedPartiesAxis_drugThreeInvestorsMember" unitRef="Percent">4.5</ix:nonFraction>% of $<ix:nonFraction id="Fxbrl_20211229060513657" name="ifrs-full:ProceedsFromIssueOfOrdinaryShares" scale="0" decimals="0" format="ixt:numdotdecimal" contextRef="C_20210401to20210406_ifrsfullCategoriesOfRelatedPartiesAxis_drugThreeInvestorsMember" unitRef="CAD">13,333,333</ix:nonFraction> in net equity proceeds received from three investors introduced to the Company by the company. The company was also entitled to receive compensation warrants allowing it to purchase an aggregate of <ix:nonFraction id="Fxbrl_20211230154332217" name="drug:NumberOfWarrantsIssued" decimals="INF" format="ixt:numdotdecimal" contextRef="C_20210401to20210406_ifrsfullClassesOfShareCapitalAxis_drugWarrantsMember" unitRef="Share">8,807</ix:nonFraction> common shares at a price of $<ix:nonFraction id="Fxbrl_20211230154412347" name="drug:ExercisePriceWarrantsGranted" scale="0" decimals="2" format="ixt:numdotdecimal" contextRef="C_20210401to20210406_ifrsfullClassesOfShareCapitalAxis_drugWarrantsMember" unitRef="CAD_per_share">7.57</ix:nonFraction> per common share for a period of <ix:nonNumeric id="Fxbrl_20211229061018091" name="drug:TermOfWarrant" format="ixt-sec:durwordsen" contextRef="C_20210401to20210406_ifrsfullClassesOfShareCapitalAxis_drugWarrantsMember">five years</ix:nonNumeric>. These warrants, having an ascribed value of $<ix:nonFraction id="Fxbrl_20211229060308845" name="drug:WarrantAscribedValue" scale="0" decimals="0" format="ixt:numdotdecimal" contextRef="C_20210401to20210406_ifrsfullClassesOfShareCapitalAxis_drugWarrantsMember" unitRef="CAD">33,100</ix:nonFraction>, were never issued. Instead, on September 21,2021, the Company granted compensation options (see below).</span></span></p>
                                    </div>
                                </ix:nonNumeric>
                                <div>
                                    <table style="width: 100%; border-collapse: collapse; font-size: 10pt;" border="0" cellspacing="0" cellpadding="0">
                                        <tr>
                                            <td style="width: 100%; text-align: center; border-top: 1pt solid black;">
                                                <p style="font-size: 10pt; font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>12</b> | Page</span></span></p>
                                            </td>
                                        </tr>
                                    </table>
                                </div>
                                <hr style="page-break-after: always; text-align: center; height: 5px; width: 100%; background-color: black;" />
                                <div>
                                    <table style="width: 100%; border-collapse: collapse; font-size: 10pt;" border="0" cellspacing="0" cellpadding="0">
                                        <tr>
                                            <td style="width: 100%;">
                                                <p style="margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>Bright Minds Biosciences Inc.</b></span></span></p>
                                                <p style="margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">Notes to the Consolidated Financial Statements</span></span></p>
                                                <p style="margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">For the years ended September 30, 2021 and 2020 and the period from May 31, 2019 (date of incorporation) to September 30, 2019</span></span></p>
                                                <p style="margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">(Expressed in Canadian Dollars)</span></span></p>
                                            </td>
                                        </tr>
                                    </table>
                                </div>
                                <ix:continuation id="F20211229021219934" continuedAt="F20211229021241747">
                                    <div>
                                        <p style="text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">On April 23, 2021, <ix:nonFraction id="Fxbrl_20211229061501452" name="drug:NumberOfWarrantsExercised" decimals="INF" format="ixt:numdotdecimal" contextRef="C_20210401to20210423_ifrsfullClassesOfShareCapitalAxis_drugEscrowedSharePurchaseWarrantsMember" unitRef="Share">1,948,000</ix:nonFraction> escrowed share purchase warrants were exercised for $<ix:nonFraction id="Fxbrl_20211229061540621" name="drug:WeightedAverageExercisePriceOfWarrantsExercisedInShareBasedPaymentArrangement" scale="0" decimals="2" format="ixt:numdotdecimal" contextRef="C_20210401to20210423_ifrsfullClassesOfShareCapitalAxis_drugEscrowedSharePurchaseWarrantsMember" unitRef="CAD_per_share">0.05</ix:nonFraction> per share for gross proceeds of $<ix:nonFraction id="Fxbrl_20211229061603798" name="drug:GrossProceedsFromWarrantsExercised" scale="0" decimals="0" format="ixt:numdotdecimal" contextRef="C_20210401to20210423_ifrsfullClassesOfShareCapitalAxis_drugEscrowedSharePurchaseWarrantsMember" unitRef="CAD">97,400</ix:nonFraction>.&#160;</span></span></p>
                                        <p style="text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">On April 28, 2021, the Company issued <ix:nonFraction id="Fxbrl_20211229062800233" name="drug:IncreaseDecreaseThroughSharesIssuedToUniversityShares" decimals="INF" format="ixt:numdotdecimal" contextRef="C_20210401to20210428" unitRef="Share">63,000</ix:nonFraction> common shares to the University at a deemed price of $<ix:nonFraction id="Fxbrl_20211229062814471" name="drug:IssuePricePerShare" scale="0" decimals="2" format="ixt:numdotdecimal" contextRef="C_20210428" unitRef="CAD_per_share">5.85</ix:nonFraction> per share. The $<ix:nonFraction id="Fxbrl_20211229062828331" name="drug:IncreaseDecreaseThroughSharesIssuedToUniversity" scale="0" decimals="0" format="ixt:numdotdecimal" contextRef="C_20210401to20210428" unitRef="CAD">368,550</ix:nonFraction> value attributed to these shares has been recognized as a research and development expense in the consolidated statements of comprehensive loss during the year ended September 30, 2021. See Note 8.&#160;</span></span></p>
                                        <p style="margin-bottom: 0pt; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>Issued share capital for the year ended September 30, 2020</b></span></span></p>
                                        <p style="margin-top: 0pt; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">On September 30, 2020, the Company closed the first tranche of a non-brokered private placement financing through the issuance of <ix:nonFraction id="Fxbrl_20211229063007514" name="ifrs-full:IncreaseDecreaseInNumberOfSharesOutstanding" decimals="INF" format="ixt:numdotdecimal" contextRef="C_20200901to20200930_ifrsfullClassesOfShareCapitalAxis_drugFirstTrancheOfNonBrokeredPrivatePlacementMember" unitRef="Share">623,941</ix:nonFraction> common shares at a price $<ix:nonFraction id="Fxbrl_20211229063020753" name="drug:IssuePricePerShare" scale="0" decimals="2" format="ixt:numdotdecimal" contextRef="C_20200930_ifrsfullClassesOfShareCapitalAxis_drugFirstTrancheOfNonBrokeredPrivatePlacementMember" unitRef="CAD_per_share">1.25</ix:nonFraction> per common share for gross proceeds of $<ix:nonFraction id="Fxbrl_20211229063031356" name="ifrs-full:ProceedsFromIssueOfOrdinaryShares" scale="0" decimals="0" format="ixt:numdotdecimal" contextRef="C_20200901to20200930_ifrsfullClassesOfShareCapitalAxis_drugFirstTrancheOfNonBrokeredPrivatePlacementMember" unitRef="CAD">779,924</ix:nonFraction>.</span></span></p>
                                        <p style="margin-bottom: 0pt; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>Issued share capital from May 31, 2019 (date of incorporation) to September 30, 2019</b></span></span></p>
                                        <p style="margin-top: 0pt; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">On July 30, 2019, the Company closed a non-brokered private placement financing through the issuance of <ix:nonFraction id="Fxbrl_20211229063259787" name="drug:NumberOfUnitsIssued" decimals="INF" format="ixt:numdotdecimal" contextRef="C_20190701to20190730_ifrsfullClassesOfShareCapitalAxis_drugNonBrokeredPrivatePlacementMember" unitRef="Share">4,079,600</ix:nonFraction> units at a price of $<ix:nonFraction id="Fxbrl_20211229063249970" name="drug:UnitsIssuedPricePerUnit" scale="0" decimals="2" format="ixt:numdotdecimal" contextRef="C_20190730_ifrsfullClassesOfShareCapitalAxis_drugNonBrokeredPrivatePlacementMember" unitRef="Unit_Per_Share">0.05</ix:nonFraction> per unit for gross proceeds of $<ix:nonFraction id="Fxbrl_20211229063243227" name="drug:GrossProceedsFromUnitsIssued" scale="0" decimals="0" format="ixt:numdotdecimal" contextRef="C_20190701to20190730_ifrsfullClassesOfShareCapitalAxis_drugNonBrokeredPrivatePlacementMember" unitRef="CAD">203,980</ix:nonFraction>. Of this amount, $<ix:nonFraction id="Fxbrl_20211229063616831" name="drug:GrossProceedsFromUnitsIssued" scale="0" decimals="0" format="ixt:numdotdecimal" contextRef="C_20201001to20210930_ifrsfullClassesOfShareCapitalAxis_drugNonBrokeredPrivatePlacementMember" unitRef="CAD">80,980</ix:nonFraction> was received subsequent to year end. Each unit comprises one common share, and one share purchase warrant exercisable at $<ix:nonFraction id="Fxbrl_20211231152001303" name="drug:WeightedAverageExercisePriceOfWarrantsIssuedInShareBasedPaymentArrangement" scale="0" decimals="2" format="ixt:numdotdecimal" contextRef="C_20190701to20190730_ifrsfullClassesOfShareCapitalAxis_drugNonBrokeredPrivatePlacementMember" unitRef="CAD_per_share">0.05</ix:nonFraction> per share until July 30, 2024.</span></span></p>
                                        <p style="margin-bottom: 0pt; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>Special Warrants and Resulting Share Issuance</b></span></span></p>
                                        <p style="margin-top: 0pt; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">In October 2020, the Company entered into subscription agreements for special warrants (the "SWs") whereby the subscribers subscribed for a total of <ix:nonFraction id="Fxbrl_20211229063722291" name="drug:NumberOfWarrantsIssued" decimals="INF" format="ixt:numdotdecimal" contextRef="C_20201001to20201031_ifrsfullClassesOfShareCapitalAxis_drugSpecialWarrantsMember" unitRef="Share">18,300</ix:nonFraction> SWs at $<ix:nonFraction id="Fxbrl_20211229063747893" name="drug:WarrantsIssuedPricePerWarrant" scale="0" decimals="2" format="ixt:numdotdecimal" contextRef="C_20201001to20201031_ifrsfullClassesOfShareCapitalAxis_drugSpecialWarrantsMember" unitRef="CAD_per_share">1.25</ix:nonFraction> per SW, with the SWs providing that each SW is deemed to be exercised, without payment of any additional consideration and without any further action by the SW holders, for one SW share, subject to adjustment in accordance with the provisions of the SW certificate on the SW exercise date.</span></span></p>
                                        <p style="text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">On November 2, 2020, the Company issued <ix:nonFraction id="Fxbrl_20211229184210252" name="drug:NumberOfWarrantsIssued" decimals="INF" format="ixt:numdotdecimal" contextRef="C_20201101to20201102_ifrsfullClassesOfShareCapitalAxis_drugSpecialWarrantsMember" unitRef="Share">18,300</ix:nonFraction> SWs for gross proceeds of $<ix:nonFraction id="Fxbrl_20211229063853028" name="drug:ProceedsForWarrantsIssued" scale="0" decimals="0" format="ixt:numdotdecimal" contextRef="C_20201101to20201102_ifrsfullClassesOfShareCapitalAxis_drugSpecialWarrantsMember" unitRef="CAD">22,875</ix:nonFraction>. On January 19, 2021, as a result of a compliance review of the SW offering by the British Columbia Securities Commission, the Company rescinded the issuance of <ix:nonFraction id="Fxbrl_20211229063905590" name="drug:NumberOfIssuedWarrantsRescinded" decimals="INF" format="ixt:numdotdecimal" contextRef="C_20210101to20210119_ifrsfullClassesOfShareCapitalAxis_drugSpecialWarrantsMember" unitRef="Share">2,300</ix:nonFraction> SWs and refunded the $<ix:nonFraction id="Fxbrl_20211229063918736" name="drug:RefundFromIssuedWarrantsRescinded" scale="0" decimals="0" format="ixt:numdotdecimal" contextRef="C_20210101to20210119_ifrsfullClassesOfShareCapitalAxis_drugSpecialWarrantsMember" unitRef="CAD">2,875</ix:nonFraction> in proceeds received. On February 3, 2021, the $<ix:nonFraction id="Fxbrl_20211229093908558" name="drug:AmountOfEscrowProceedsReleased" scale="0" decimals="0" format="ixt:numdotdecimal" contextRef="C_20210201to20210203_ifrsfullClassesOfShareCapitalAxis_drugSpecialWarrantsMember" unitRef="CAD">20,000</ix:nonFraction> in escrowed proceeds was released to the Company, the SWs were deemed to be exercised for SW shares and <ix:nonFraction id="Fxbrl_20211230161024172" name="drug:NumberOfWarrantsDeemedToBeExercised" decimals="INF" format="ixt:numdotdecimal" contextRef="C_20210201to20210203_ifrsfullClassesOfShareCapitalAxis_drugSpecialWarrantsMember" unitRef="Share">16,000</ix:nonFraction> common shares of the Company were issued to the SW holders.</span></span></p>
                                        <p style="margin-bottom: 0pt; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>Share subscriptions received/receivable</b></span></span></p>
                                        <p style="margin-top: 0pt; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">During the fiscal year ended September 30, 2020, the Company received $<ix:nonFraction id="Fxbrl_20211229094222980" name="drug:SubscriptionsReceived" scale="0" decimals="0" format="ixt:numdotdecimal" contextRef="C_20200930" unitRef="CAD">147,426</ix:nonFraction> in subscriptions for <ix:nonFraction id="Fxbrl_20211229094303965" name="drug:NumberOfCommonSharesSubscribed" decimals="INF" format="ixt:numdotdecimal" contextRef="C_20201001to20210930" unitRef="Share">294,852</ix:nonFraction> common shares relating to the private placement that closed on November 2, 2020.</span></span></p>
                                        <p style="text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">On July 31, 2019, <ix:nonFraction id="Fxbrl_20211229100341375" name="ifrs-full:IncreaseDecreaseInNumberOfSharesOutstanding" decimals="INF" format="ixt:numdotdecimal" contextRef="C_20190701to20190731" unitRef="Share">4,049,000</ix:nonFraction> common shares were issued for which the gross proceeds of $<ix:nonFraction id="Fxbrl_20211229100349500" name="ifrs-full:ProceedsFromIssueOfOrdinaryShares" scale="0" decimals="0" format="ixt:numdotdecimal" contextRef="C_20191007to20200928" unitRef="CAD">80,980</ix:nonFraction> were received on October 7, 2019 and September 28, 2020.</span></span></p>
                                        <p style="margin-bottom: 0pt; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>Escrowed Securities</b></span></span></p>
                                        <p style="margin-top: 0pt; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">On January 28, 2021, the Company entered into an escrow agreement under National Policy 46-201 <i>Escrow for Initial Public Offerings</i> (the "Policy") in connection with the listing of common shares of the Company on the CSE, whereby <ix:nonFraction id="Fxbrl_20211229100757388" name="drug:NumberOfCommonSharesDepositedToBeHeldInEscrow" decimals="INF" format="ixt:numdotdecimal" contextRef="C_20210128_drugAgreementAxis_drugEscrowAgreementMember_ifrsfullClassesOfShareCapitalAxis_drugWarrantsMember" unitRef="Share">2,852,800</ix:nonFraction> common shares of the Company and <ix:nonFraction id="Fxbrl_20211229100624840" name="drug:NumberOfWarrantsDepositedToBeHeldInEscrow" decimals="INF" format="ixt:numdotdecimal" contextRef="C_20210128_drugAgreementAxis_drugEscrowAgreementMember_ifrsfullClassesOfShareCapitalAxis_drugWarrantsMember" unitRef="Share">1,948,000</ix:nonFraction> share purchase warrants (exercised on April 23, 2021), being an aggregate of <ix:nonFraction id="Fxbrl_20211229101530164" name="drug:AggregateSecuritiesDepositedToBeHeldInEscrow" decimals="INF" format="ixt:numdotdecimal" contextRef="C_20210128_drugAgreementAxis_drugEscrowAgreementMember_ifrsfullClassesOfShareCapitalAxis_drugWarrantsMember" unitRef="Share">4,800,800</ix:nonFraction> securities, were deposited to be held in escrow. As the Company is defined as an emerging issuer under the Policy, the escrowed securities will be released as follows:</span></span></p>
                                        <p style="text-align: justify; padding-left: 8.25pt; margin-bottom: 0pt; margin-top: 0pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">&#160; &#160;&#8226;&#160; &#160; &#160; <ix:nonFraction id="Fxbrl_20211229101936429" name="drug:EscrowedSecuritiesToBeReleasedOnceSharesAreListedOnCanadianStockExchange" decimals="INF" format="ixt:numdotdecimal" contextRef="C_20210201to20210208_drugAgreementAxis_drugEscrowAgreementMember" unitRef="Share">480,080</ix:nonFraction> on the date that the Company's shares are listed on the CSE (February 8, 2021); and</span></span></p>
                                        <p style="text-align: justify; padding-left: 8.25pt; margin-bottom: 0pt; margin-top: 0pt;"><span style="font-family: Times New Roman, Times, serif; font-size: 10pt;">&#160; &#160;&#8226;&#160; &#160; &#160; </span><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><ix:nonFraction id="Fxbrl_20211231113144057" name="drug:EscrowedSecuritiesToBeReleasedAfterListingDate" decimals="INF" format="ixt:numdotdecimal" contextRef="C_20210201to20210208_drugAgreementAxis_drugEscrowAgreementMember" unitRef="Share">720,120</ix:nonFraction> six, 12, 18, 24, 30 and 36 months after the listing date.</span></span></p>
                                        <p style="margin-bottom: 0pt; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span style="text-decoration: underline;"><b>Stock options</b></span></span></span></p>
                                        <p style="margin-top: 0pt; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">The Company's stock option plan provides for stock options to be issued to directors, officers, employees and consultants of the Company, its subsidiaries and any personal holding company of such individuals so that they may participate in the growth and development of the Company. Subject to the specific provisions of the stock option plan, eligibility, vesting period, terms of the options and the number of options granted are to be determined by the Board of Directors at the time of grant. The stock option plan allows the Board of Directors to issue up to <ix:nonFraction id="Fxbrl_20211229061358559" name="drug:PercentageOfOutstandingSharesAuthorizedUnderStockOptionPlan" scale="-2" decimals="2" format="ixt:numdotdecimal" contextRef="C_20201001to20210930_ifrsfullClassesOfShareCapitalAxis_drugStockOptionsMember" unitRef="Percent">10</ix:nonFraction>% of the Company's outstanding common shares as stock options.</span></span></p>
                                    </div>
                                </ix:continuation>
                                <div>
                                    <table style="width: 100%; border-collapse: collapse; font-size: 10pt;" border="0" cellspacing="0" cellpadding="0">
                                        <tr>
                                            <td style="width: 100%; text-align: center; border-top: 1pt solid black;">
                                                <p style="font-size: 10pt; font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>13</b>&#160;| Page</span></span></p>
                                            </td>
                                        </tr>
                                    </table>
                                </div>
                                <hr style="page-break-after: always; text-align: center; height: 5px; width: 100%; background-color: black;" />
                                <div>
                                    <table style="width: 100%; border-collapse: collapse; font-size: 10pt;" border="0" cellspacing="0" cellpadding="0">
                                        <tr>
                                            <td style="width: 100%;">
                                                <p style="margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>Bright Minds Biosciences Inc.</b></span></span></p>
                                                <p style="margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">Notes to the Consolidated Financial Statements</span></span></p>
                                                <p style="margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">For the years ended September 30, 2021 and 2020 and the period from May 31, 2019 (date of incorporation) to September 30, 2019</span></span></p>
                                                <p style="margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">(Expressed in Canadian Dollars)</span></span></p>
                                            </td>
                                        </tr>
                                    </table>
                                </div>
                                <ix:continuation id="F20211229021241747" continuedAt="F20211229021306044">
                                    <div>
                                        <p style="margin-bottom: 0pt; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>Options granted during the year ended September 30, 2021</b></span></span></p>
                                        <p style="margin-top: 0pt; margin-bottom: 11px; text-align: justify; font-size: 10pt; font-family: Times New Roman, Times, serif;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span style="line-height: normal;">On November 17, 2020, the Company granted <ix:nonFraction id="Fxbrl_20211229103146955" name="ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" decimals="INF" format="ixt:numdotdecimal" contextRef="C_20201101to20201117_ifrsfullCategoriesOfRelatedPartiesAxis_drugChiefFinancialOfficerTwoDirectorsAndSevenConsultantsMember_ifrsfullClassesOfShareCapitalAxis_drugStockOptionsMember" unitRef="Share">467,000</ix:nonFraction> options, to the Chief Financial Officer of the Company, two directors of the Company and seven consultants. These options have an exercise price of $<ix:nonFraction id="Fxbrl_20211229103227400" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019" scale="0" decimals="2" format="ixt:numdotdecimal" contextRef="C_20201101to20201117_ifrsfullCategoriesOfRelatedPartiesAxis_drugChiefFinancialOfficerTwoDirectorsAndSevenConsultantsMember_ifrsfullClassesOfShareCapitalAxis_drugStockOptionsMember" unitRef="CAD_per_share">1.25</ix:nonFraction> per share, expire on November 17, 2025 and vest as follows:</span></span></span></p>
                                        <p style="margin-top: 0pt; margin-left: 58px; margin-bottom: 0pt; text-align: justify; text-indent: -21.25pt; font-size: 10pt; font-family: Times New Roman, Times, serif;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span style="line-height: normal;">&#8226;&#160; &#160; &#160; &#160;<ix:nonFraction id="Fxbrl_20211229103720163" name="ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" decimals="INF" format="ixt:numdotdecimal" contextRef="C_20201101to20201117_drugStockOptionAxis_drugStockOptionsOneMember_ifrsfullCategoriesOfRelatedPartiesAxis_drugChiefFinancialOfficerTwoDirectorsAndSevenConsultantsMember" unitRef="Share">25,000</ix:nonFraction> options - <ix:nonFraction id="Fxbrl_20211229103729535" name="drug:VestingPercentage" scale="-2" decimals="2" format="ixt:numdotdecimal" contextRef="C_20201101to20201117_drugStockOptionAxis_drugStockOptionsOneMember_drugVestingsAxis_drugFirstTrancheMember_ifrsfullCategoriesOfRelatedPartiesAxis_drugChiefFinancialOfficerTwoDirectorsAndSevenConsultantsMember" unitRef="Percent">100</ix:nonFraction>% on the date of grant;</span></span></span></p>
                                        <p style="margin-top: 0pt; margin-left: 58px; margin-bottom: 0pt; text-align: justify; text-indent: -21.25pt; font-size: 10pt; font-family: Times New Roman, Times, serif;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span style="line-height: normal;">&#8226;&#160; &#160;&#160; &#160; <ix:nonFraction id="Fxbrl_20211229103802654" name="ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" decimals="INF" format="ixt:numdotdecimal" contextRef="C_20201101to20201117_drugStockOptionAxis_drugStockOptionsTwoMember_ifrsfullCategoriesOfRelatedPartiesAxis_drugChiefFinancialOfficerTwoDirectorsAndSevenConsultantsMember" unitRef="Share">14,000</ix:nonFraction> options - <ix:nonFraction id="Fxbrl_20211229103817151" name="drug:VestingPercentage" scale="-2" decimals="2" format="ixt:numdotdecimal" contextRef="C_20201101to20201117_drugStockOptionAxis_drugStockOptionsTwoMember_drugVestingsAxis_drugSecondTrancheMember_ifrsfullCategoriesOfRelatedPartiesAxis_drugChiefFinancialOfficerTwoDirectorsAndSevenConsultantsMember" unitRef="Percent">25</ix:nonFraction>% on the Company's listing date, <ix:nonFraction id="Fxbrl_20211229194554073" name="drug:VestingPercentage" scale="-2" decimals="2" format="ixt:numdotdecimal" contextRef="C_20201101to20201117_drugStockOptionAxis_drugStockOptionsTwoMember_drugVestingsAxis_drugThirdTrancheMember_ifrsfullCategoriesOfRelatedPartiesAxis_drugChiefFinancialOfficerTwoDirectorsAndSevenConsultantsMember" unitRef="Percent">25</ix:nonFraction>% on the first anniversary of the listing date and <ix:nonFraction id="Fxbrl_20211229194602674" name="drug:VestingPercentage" scale="-2" decimals="2" format="ixt:numdotdecimal" contextRef="C_20201101to20201117_drugStockOptionAxis_drugStockOptionsTwoMember_drugVestingsAxis_drugFourthTrancheMember_ifrsfullCategoriesOfRelatedPartiesAxis_drugChiefFinancialOfficerTwoDirectorsAndSevenConsultantsMember" unitRef="Percent">50</ix:nonFraction>% on the second anniversary of the listing date;</span></span></span></p>
                                        <p style="margin-top: 0pt; margin-left: 58px; margin-bottom: 0pt; text-align: justify; text-indent: -21.25pt; font-size: 10pt; font-family: Times New Roman, Times, serif;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span style="line-height: normal;">&#8226;&#160; &#160; &#160;&#160; <ix:nonFraction id="Fxbrl_20211229122855966" name="ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" decimals="INF" format="ixt:numdotdecimal" contextRef="C_20201101to20201117_drugStockOptionAxis_drugStockOptionsThreeMember_ifrsfullCategoriesOfRelatedPartiesAxis_drugChiefFinancialOfficerTwoDirectorsAndSevenConsultantsMember" unitRef="Share">4,000 </ix:nonFraction>options - <ix:nonFraction id="Fxbrl_20211229194616248" name="drug:VestingPercentage" scale="-2" decimals="2" format="ixt:numdotdecimal" contextRef="C_20201101to20201117_drugStockOptionAxis_drugStockOptionsThreeMember_drugVestingsAxis_drugSecondTrancheMember_ifrsfullCategoriesOfRelatedPartiesAxis_drugChiefFinancialOfficerTwoDirectorsAndSevenConsultantsMember" unitRef="Percent">50</ix:nonFraction>% on the Company's listing date and <ix:nonFraction id="Fxbrl_20211229194622792" name="drug:VestingPercentage" scale="-2" decimals="2" format="ixt:numdotdecimal" contextRef="C_20201101to20201117_drugStockOptionAxis_drugStockOptionsThreeMember_drugVestingsAxis_drugFifthTrancheMember_ifrsfullCategoriesOfRelatedPartiesAxis_drugChiefFinancialOfficerTwoDirectorsAndSevenConsultantsMember" unitRef="Percent">50</ix:nonFraction>% on the six-month anniversary of the listing date; and</span></span></span></p>
                                        <p style="margin-top: 0pt; margin-left: 58px; margin-bottom: 0pt; text-align: justify; text-indent: -21.25pt; font-size: 10pt; font-family: Times New Roman, Times, serif;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span style="line-height: normal;">&#8226;&#160; &#160; &#160;&#160; <ix:nonFraction id="Fxbrl_20211229123350466" name="ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" decimals="INF" format="ixt:numdotdecimal" contextRef="C_20201101to20201117_drugStockOptionAxis_drugStockOptionsFourMember_ifrsfullCategoriesOfRelatedPartiesAxis_drugChiefFinancialOfficerTwoDirectorsAndSevenConsultantsMember" unitRef="Share">424,000</ix:nonFraction> options - <ix:nonFraction id="Fxbrl_20211229194631710" name="drug:VestingPercentage" scale="-2" decimals="2" format="ixt:numdotdecimal" contextRef="C_20201101to20201117_drugStockOptionAxis_drugStockOptionsFourMember_drugVestingsAxis_drugSixthTrancheMember_ifrsfullCategoriesOfRelatedPartiesAxis_drugChiefFinancialOfficerTwoDirectorsAndSevenConsultantsMember" unitRef="Percent">33</ix:nonFraction>% on the first anniversary of the grant date, <ix:nonFraction id="Fxbrl_20211229194755111" name="drug:VestingPercentage" scale="-2" decimals="2" format="ixt:numdotdecimal" contextRef="C_20201101to20201117_drugStockOptionAxis_drugStockOptionsFourMember_drugVestingsAxis_drugSeventhTrancheMember_ifrsfullCategoriesOfRelatedPartiesAxis_drugChiefFinancialOfficerTwoDirectorsAndSevenConsultantsMember" unitRef="Percent">33</ix:nonFraction>% on the second anniversary of the grant date and <ix:nonFraction id="Fxbrl_20211229194805655" name="drug:VestingPercentage" scale="-2" decimals="2" format="ixt:numdotdecimal" contextRef="C_20201101to20201117_drugStockOptionAxis_drugStockOptionsFourMember_drugVestingsAxis_drugEighthTrancheMember_ifrsfullCategoriesOfRelatedPartiesAxis_drugChiefFinancialOfficerTwoDirectorsAndSevenConsultantsMember" unitRef="Percent">33</ix:nonFraction>% on the third anniversary of the grant date.</span></span></span></p>
                                        <p style="text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">The fair value of these stock options was measured using the Black Scholes option pricing model using the following inputs: i) exercise price: $<ix:nonFraction id="Fxbrl_20211229123752113" name="ifrs-full:ExercisePriceShareOptionsGranted2019" scale="0" decimals="2" format="ixt:numdotdecimal" contextRef="C_20201101to20201117_ifrsfullCategoriesOfRelatedPartiesAxis_drugChiefFinancialOfficerTwoDirectorsAndSevenConsultantsMember_ifrsfullClassesOfShareCapitalAxis_drugStockOptionsMember" unitRef="CAD_per_share">1.25</ix:nonFraction>; ii) share price: $<ix:nonFraction id="Fxbrl_20211229123825908" name="ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019" scale="0" decimals="2" format="ixt:numdotdecimal" contextRef="C_20201101to20201117_ifrsfullCategoriesOfRelatedPartiesAxis_drugChiefFinancialOfficerTwoDirectorsAndSevenConsultantsMember_ifrsfullClassesOfShareCapitalAxis_drugStockOptionsMember" unitRef="CAD_per_share">1.25</ix:nonFraction>; iii) term: <ix:nonFraction id="Fxbrl_20211229123850395" name="ifrs-full:DescriptionOfOptionLifeShareOptionsGranted" scale="0" decimals="0" format="ixt:numdotdecimal" contextRef="C_20201101to20201117_ifrsfullCategoriesOfRelatedPartiesAxis_drugChiefFinancialOfficerTwoDirectorsAndSevenConsultantsMember_ifrsfullClassesOfShareCapitalAxis_drugStockOptionsMember" unitRef="Year">5</ix:nonFraction> years; iv) volatility: <ix:nonFraction id="Fxbrl_20211229123854660" name="ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted" scale="-2" decimals="2" format="ixt:numdotdecimal" contextRef="C_20201101to20201117_ifrsfullCategoriesOfRelatedPartiesAxis_drugChiefFinancialOfficerTwoDirectorsAndSevenConsultantsMember_ifrsfullClassesOfShareCapitalAxis_drugStockOptionsMember" unitRef="Percent">100</ix:nonFraction>%; v) discount rate: <ix:nonFraction id="Fxbrl_20211229124453622" name="drug:DiscountRateStockOptionGranted" scale="-2" decimals="4" format="ixt:numdotdecimal" contextRef="C_20201117_ifrsfullCategoriesOfRelatedPartiesAxis_drugChiefFinancialOfficerTwoDirectorsAndSevenConsultantsMember_ifrsfullClassesOfShareCapitalAxis_drugStockOptionsMember" unitRef="Percent">0.43</ix:nonFraction>%; and dividends: nil.</span></span></p>
                                        <p style="margin-top: 0pt; margin-bottom: 11px; font-size: 10pt; font-family: Times New Roman, Times, serif;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span style="line-height: 107%;">On April 28, 2021, the Company granted <ix:nonFraction id="Fxbrl_20211229104501879" name="ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" decimals="INF" format="ixt:numdotdecimal" contextRef="C_20210401to20210428_ifrsfullCategoriesOfRelatedPartiesAxis_drugThreeConsultantsMember_ifrsfullClassesOfShareCapitalAxis_drugStockOptionsMember" unitRef="Share">240,000</ix:nonFraction> options to three consultants of the Company. These options have an exercise price of $<ix:nonFraction id="Fxbrl_20211229104542222" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019" scale="0" decimals="2" format="ixt:numdotdecimal" contextRef="C_20210401to20210428_ifrsfullCategoriesOfRelatedPartiesAxis_drugThreeConsultantsMember_ifrsfullClassesOfShareCapitalAxis_drugStockOptionsMember" unitRef="CAD_per_share">7.60</ix:nonFraction> per share, expire on April 28, 2026 and vest as follows:</span></span></span></p>
                                        <p style="margin-top: 0pt; margin-left: 58px; margin-bottom: 0pt; text-align: justify; text-indent: -21.25pt; font-size: 10pt; font-family: Times New Roman, Times, serif;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span style="line-height: normal;">&#8226;&#160; &#160; &#160; <ix:nonFraction id="Fxbrl_20211229125643692" name="ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" decimals="INF" format="ixt:numdotdecimal" contextRef="C_20210401to20210428_drugStockOptionAxis_drugStockOptionsOneMember_ifrsfullCategoriesOfRelatedPartiesAxis_drugThreeConsultantsMember" unitRef="Share">160,000 </ix:nonFraction>options - <ix:nonFraction id="Fxbrl_20211229125701908" name="drug:VestingPercentage" scale="-2" decimals="2" format="ixt:numdotdecimal" contextRef="C_20210401to20210428_drugStockOptionAxis_drugStockOptionsOneMember_drugVestingsAxis_drugSixthTrancheMember_ifrsfullCategoriesOfRelatedPartiesAxis_drugThreeConsultantsMember" unitRef="Percent">25</ix:nonFraction>% on the first anniversary of the grant date, <ix:nonFraction id="Fxbrl_20211229204615710" name="drug:VestingPercentage" scale="-2" decimals="2" format="ixt:numdotdecimal" contextRef="C_20210401to20210428_drugStockOptionAxis_drugStockOptionsOneMember_drugVestingsAxis_drugSeventhTrancheMember_ifrsfullCategoriesOfRelatedPartiesAxis_drugThreeConsultantsMember" unitRef="Percent">25</ix:nonFraction>% on the second anniversary of the grant date, <ix:nonFraction id="Fxbrl_20211229204629096" name="drug:VestingPercentage" scale="-2" decimals="2" format="ixt:numdotdecimal" contextRef="C_20210401to20210428_drugStockOptionAxis_drugStockOptionsOneMember_drugVestingsAxis_drugEighthTrancheMember_ifrsfullCategoriesOfRelatedPartiesAxis_drugThreeConsultantsMember" unitRef="Percent">25</ix:nonFraction>% on the third anniversary of the grant date and <ix:nonFraction id="Fxbrl_20211229204638134" name="drug:VestingPercentage" scale="-2" decimals="2" format="ixt:numdotdecimal" contextRef="C_20210401to20210428_drugStockOptionAxis_drugStockOptionsOneMember_drugVestingsAxis_drugNinthTrancheMember_ifrsfullCategoriesOfRelatedPartiesAxis_drugThreeConsultantsMember" unitRef="Percent">25</ix:nonFraction>% on the fourth anniversary of the grant date; and</span></span></span></p>
                                        <p style="margin-top: 0pt; margin-left: 58px; margin-bottom: 0pt; text-align: justify; text-indent: -21.25pt; font-size: 10pt; font-family: Times New Roman, Times, serif;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span style="line-height: normal;">&#8226;&#160; &#160; &#160; <ix:nonFraction id="Fxbrl_20211229130137460" name="ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" decimals="INF" format="ixt:numdotdecimal" contextRef="C_20210401to20210428_drugStockOptionAxis_drugStockOptionsTwoMember_ifrsfullCategoriesOfRelatedPartiesAxis_drugThreeConsultantsMember" unitRef="Share">80,000 </ix:nonFraction>options - <ix:nonFraction id="Fxbrl_20211229204648133" name="drug:VestingPercentage" scale="-2" decimals="2" format="ixt:numdotdecimal" contextRef="C_20210401to20210428_drugStockOptionAxis_drugStockOptionsTwoMember_drugVestingsAxis_drugTenthTrancheMember_ifrsfullCategoriesOfRelatedPartiesAxis_drugThreeConsultantsMember" unitRef="Percent">25</ix:nonFraction>% on the six-month anniversary of the grant date, <ix:nonFraction id="Fxbrl_20211229204700917" name="drug:VestingPercentage" scale="-2" decimals="2" format="ixt:numdotdecimal" contextRef="C_20210401to20210428_drugStockOptionAxis_drugStockOptionsTwoMember_drugVestingsAxis_drugSixthTrancheMember_ifrsfullCategoriesOfRelatedPartiesAxis_drugThreeConsultantsMember" unitRef="Percent">25</ix:nonFraction>% on the first anniversary of the grant date, <ix:nonFraction id="Fxbrl_20211229204708773" name="drug:VestingPercentage" scale="-2" decimals="2" format="ixt:numdotdecimal" contextRef="C_20210401to20210428_drugStockOptionAxis_drugStockOptionsTwoMember_drugVestingsAxis_drugEleventhTrancheMember_ifrsfullCategoriesOfRelatedPartiesAxis_drugThreeConsultantsMember" unitRef="Percent">25</ix:nonFraction>% on the eighteen-month anniversary of the grant date and <ix:nonFraction id="Fxbrl_20211229204718669" name="drug:VestingPercentage" scale="-2" decimals="2" format="ixt:numdotdecimal" contextRef="C_20210401to20210428_drugStockOptionAxis_drugStockOptionsTwoMember_drugVestingsAxis_drugSeventhTrancheMember_ifrsfullCategoriesOfRelatedPartiesAxis_drugThreeConsultantsMember" unitRef="Percent">25</ix:nonFraction>% on the second anniversary of the grant date.</span></span></span></p>
                                        <p style="text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">The fair value of these stock options was measured using the Black Scholes option pricing model using the following inputs: i) exercise price: $<ix:nonFraction id="Fxbrl_20211229130827756" name="ifrs-full:ExercisePriceShareOptionsGranted2019" scale="0" decimals="2" format="ixt:numdotdecimal" contextRef="C_20210401to20210428_ifrsfullCategoriesOfRelatedPartiesAxis_drugThreeConsultantsMember_ifrsfullClassesOfShareCapitalAxis_drugStockOptionsMember" unitRef="CAD_per_share">7.60</ix:nonFraction>; ii) share price: $<ix:nonFraction id="Fxbrl_20211229130835242" name="ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019" scale="0" decimals="2" format="ixt:numdotdecimal" contextRef="C_20210401to20210428_ifrsfullCategoriesOfRelatedPartiesAxis_drugThreeConsultantsMember_ifrsfullClassesOfShareCapitalAxis_drugStockOptionsMember" unitRef="CAD_per_share">5.98</ix:nonFraction>; iii) term: <ix:nonFraction id="Fxbrl_20211229130841315" name="ifrs-full:DescriptionOfOptionLifeShareOptionsGranted" scale="0" decimals="0" format="ixt:numdotdecimal" contextRef="C_20210401to20210428_ifrsfullCategoriesOfRelatedPartiesAxis_drugThreeConsultantsMember_ifrsfullClassesOfShareCapitalAxis_drugStockOptionsMember" unitRef="Year">5 </ix:nonFraction>years; iv) volatility: <ix:nonFraction id="Fxbrl_20211229130848489" name="ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted" scale="-2" decimals="2" format="ixt:numdotdecimal" contextRef="C_20210401to20210428_ifrsfullCategoriesOfRelatedPartiesAxis_drugThreeConsultantsMember_ifrsfullClassesOfShareCapitalAxis_drugStockOptionsMember" unitRef="Percent">100</ix:nonFraction>%; v) discount rate: <ix:nonFraction id="Fxbrl_20211229130854019" name="drug:DiscountRateStockOptionGranted" scale="-2" decimals="4" format="ixt:numdotdecimal" contextRef="C_20210428_ifrsfullCategoriesOfRelatedPartiesAxis_drugThreeConsultantsMember_ifrsfullClassesOfShareCapitalAxis_drugStockOptionsMember" unitRef="Percent">0.92</ix:nonFraction>%; and dividends: nil.</span></span></p>
                                        <p style="text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">On June 15, 2021, the Company granted <ix:nonFraction id="Fxbrl_20211229131041170" name="ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" decimals="INF" format="ixt:numdotdecimal" contextRef="C_20210601to20210615_ifrsfullCategoriesOfRelatedPartiesAxis_drugDirectorAndConsultantMember_ifrsfullClassesOfShareCapitalAxis_drugStockOptionsMember" unitRef="Share">180,000</ix:nonFraction> options to a director and a consultant of the Company. These options have an exercise price of $<ix:nonFraction id="Fxbrl_20211229131236954" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019" scale="0" decimals="2" format="ixt:numdotdecimal" contextRef="C_20210601to20210615_ifrsfullCategoriesOfRelatedPartiesAxis_drugDirectorAndConsultantMember_ifrsfullClassesOfShareCapitalAxis_drugStockOptionsMember" unitRef="CAD_per_share">7.60</ix:nonFraction> per share, expire on June 15, 2026 and vest as follows: <ix:nonFraction id="Fxbrl_20211229131502857" name="drug:VestingPercentage" scale="-2" decimals="2" format="ixt:numdotdecimal" contextRef="C_20210601to20210615_drugVestingsAxis_drugSixthTrancheMember_ifrsfullCategoriesOfRelatedPartiesAxis_drugDirectorAndConsultantMember_ifrsfullClassesOfShareCapitalAxis_drugStockOptionsMember" unitRef="Percent">25</ix:nonFraction>% on the first anniversary of the grant date, <ix:nonFraction id="Fxbrl_20211229131505665" name="drug:VestingPercentage" scale="-2" decimals="2" format="ixt:numdotdecimal" contextRef="C_20210601to20210615_drugVestingsAxis_drugSeventhTrancheMember_ifrsfullCategoriesOfRelatedPartiesAxis_drugDirectorAndConsultantMember_ifrsfullClassesOfShareCapitalAxis_drugStockOptionsMember" unitRef="Percent">25</ix:nonFraction>% on the second anniversary of the grant date, <ix:nonFraction id="Fxbrl_20211229131700044" name="drug:VestingPercentage" scale="-2" decimals="2" format="ixt:numdotdecimal" contextRef="C_20210601to20210615_drugVestingsAxis_drugEighthTrancheMember_ifrsfullCategoriesOfRelatedPartiesAxis_drugDirectorAndConsultantMember_ifrsfullClassesOfShareCapitalAxis_drugStockOptionsMember" unitRef="Percent">25</ix:nonFraction>% on the third anniversary of the grant date and <ix:nonFraction id="Fxbrl_20211229131719794" name="drug:VestingPercentage" scale="-2" decimals="2" format="ixt:numdotdecimal" contextRef="C_20210601to20210615_drugVestingsAxis_drugNinthTrancheMember_ifrsfullCategoriesOfRelatedPartiesAxis_drugDirectorAndConsultantMember_ifrsfullClassesOfShareCapitalAxis_drugStockOptionsMember" unitRef="Percent">25</ix:nonFraction>% on the fourth anniversary of the grant date. The fair value of these stock options was measured using the Black Scholes option pricing model using the following inputs: i) exercise price: $<ix:nonFraction id="Fxbrl_20211229131744083" name="ifrs-full:ExercisePriceShareOptionsGranted2019" scale="0" decimals="2" format="ixt:numdotdecimal" contextRef="C_20210601to20210615_ifrsfullCategoriesOfRelatedPartiesAxis_drugDirectorAndConsultantMember_ifrsfullClassesOfShareCapitalAxis_drugStockOptionsMember" unitRef="CAD_per_share">7.60</ix:nonFraction>; ii) share price: $<ix:nonFraction id="Fxbrl_20211229131751066" name="ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019" scale="0" decimals="2" format="ixt:numdotdecimal" contextRef="C_20210601to20210615_ifrsfullCategoriesOfRelatedPartiesAxis_drugDirectorAndConsultantMember_ifrsfullClassesOfShareCapitalAxis_drugStockOptionsMember" unitRef="CAD_per_share">5.55</ix:nonFraction>; iii) term: <ix:nonFraction id="Fxbrl_20211229131757129" name="ifrs-full:DescriptionOfOptionLifeShareOptionsGranted" scale="0" decimals="0" format="ixt:numdotdecimal" contextRef="C_20210601to20210615_ifrsfullCategoriesOfRelatedPartiesAxis_drugDirectorAndConsultantMember_ifrsfullClassesOfShareCapitalAxis_drugStockOptionsMember" unitRef="Year">5 </ix:nonFraction>years; iv) volatility: <ix:nonFraction id="Fxbrl_20211229131804512" name="ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted" scale="-2" decimals="2" format="ixt:numdotdecimal" contextRef="C_20210601to20210615_ifrsfullCategoriesOfRelatedPartiesAxis_drugDirectorAndConsultantMember_ifrsfullClassesOfShareCapitalAxis_drugStockOptionsMember" unitRef="Percent">100</ix:nonFraction>%; v) discount rate: <ix:nonFraction id="Fxbrl_20211229131811631" name="drug:DiscountRateStockOptionGranted" scale="-2" decimals="4" format="ixt:numdotdecimal" contextRef="C_20210615_ifrsfullCategoriesOfRelatedPartiesAxis_drugDirectorAndConsultantMember_ifrsfullClassesOfShareCapitalAxis_drugStockOptionsMember" unitRef="Percent">0.84</ix:nonFraction>%; and dividends: nil.</span></span></p>
                                        <p style="text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">On September 21, 2021, the Company granted <ix:nonFraction id="Fxbrl_20211229132037072" name="ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" decimals="INF" format="ixt:numdotdecimal" contextRef="C_20210901to20210921_ifrsfullCategoriesOfRelatedPartiesAxis_drugConsultantMember_ifrsfullClassesOfShareCapitalAxis_drugStockOptionsMember" unitRef="Share">8,807 </ix:nonFraction>options to a consultant of the Company (see above). These options have an exercise price of $<ix:nonFraction id="Fxbrl_20211229132123850" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019" scale="0" decimals="2" format="ixt:numdotdecimal" contextRef="C_20210901to20210921_ifrsfullCategoriesOfRelatedPartiesAxis_drugConsultantMember_ifrsfullClassesOfShareCapitalAxis_drugStockOptionsMember" unitRef="CAD_per_share">7.64</ix:nonFraction> per share, expire on September 21, 2024 and vest as follows: <ix:nonFraction id="Fxbrl_20211229132143659" name="drug:VestingPercentage" scale="-2" decimals="2" format="ixt:numdotdecimal" contextRef="C_20210901to20210921_drugVestingsAxis_drugTwelfthTrancheMember_ifrsfullCategoriesOfRelatedPartiesAxis_drugConsultantMember_ifrsfullClassesOfShareCapitalAxis_drugStockOptionsMember" unitRef="Percent">25</ix:nonFraction>% on December 21, 2021, <ix:nonFraction id="Fxbrl_20211229132229122" name="drug:VestingPercentage" scale="-2" decimals="2" format="ixt:numdotdecimal" contextRef="C_20210901to20210921_drugVestingsAxis_drugThirteenthTrancheMember_ifrsfullCategoriesOfRelatedPartiesAxis_drugConsultantMember_ifrsfullClassesOfShareCapitalAxis_drugStockOptionsMember" unitRef="Percent">25</ix:nonFraction>% on March 21, 2022, <ix:nonFraction id="Fxbrl_20211229132232345" name="drug:VestingPercentage" scale="-2" decimals="2" format="ixt:numdotdecimal" contextRef="C_20210901to20210921_drugVestingsAxis_drugFourteenthTrancheMember_ifrsfullCategoriesOfRelatedPartiesAxis_drugConsultantMember_ifrsfullClassesOfShareCapitalAxis_drugStockOptionsMember" unitRef="Percent">25</ix:nonFraction>% on June 21, 2022 and <ix:nonFraction id="Fxbrl_20211229132234634" name="drug:VestingPercentage" scale="-2" decimals="2" format="ixt:numdotdecimal" contextRef="C_20210901to20210921_drugVestingsAxis_drugFifteenthTrancheMember_ifrsfullCategoriesOfRelatedPartiesAxis_drugConsultantMember_ifrsfullClassesOfShareCapitalAxis_drugStockOptionsMember" unitRef="Percent">25</ix:nonFraction>% on September 21, 2022. The fair value of these stock options was measured using the Black Scholes option pricing model using the following inputs: i) exercise price: $<ix:nonFraction id="Fxbrl_20211229135004512" name="ifrs-full:ExercisePriceShareOptionsGranted2019" scale="0" decimals="2" format="ixt:numdotdecimal" contextRef="C_20210901to20210921_ifrsfullCategoriesOfRelatedPartiesAxis_drugConsultantMember_ifrsfullClassesOfShareCapitalAxis_drugStockOptionsMember" unitRef="CAD_per_share">7.64</ix:nonFraction>; ii) share price: $<ix:nonFraction id="Fxbrl_20211229135030515" name="ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019" scale="0" decimals="2" format="ixt:numdotdecimal" contextRef="C_20210901to20210921_ifrsfullCategoriesOfRelatedPartiesAxis_drugConsultantMember_ifrsfullClassesOfShareCapitalAxis_drugStockOptionsMember" unitRef="CAD_per_share">7.64</ix:nonFraction>; iii) term: <ix:nonFraction id="Fxbrl_20211229135042831" name="ifrs-full:DescriptionOfOptionLifeShareOptionsGranted" scale="0" decimals="0" format="ixt:numdotdecimal" contextRef="C_20210901to20210921_ifrsfullCategoriesOfRelatedPartiesAxis_drugConsultantMember_ifrsfullClassesOfShareCapitalAxis_drugStockOptionsMember" unitRef="Year">3</ix:nonFraction> years; iv) volatility: <ix:nonFraction id="Fxbrl_20211229135052991" name="ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted" scale="-2" decimals="2" format="ixt:numdotdecimal" contextRef="C_20210901to20210921_ifrsfullCategoriesOfRelatedPartiesAxis_drugConsultantMember_ifrsfullClassesOfShareCapitalAxis_drugStockOptionsMember" unitRef="Percent">100</ix:nonFraction>%; v) discount rate: <ix:nonFraction id="Fxbrl_20211229135258239" name="drug:DiscountRateStockOptionGranted" scale="-2" decimals="4" format="ixt:numdotdecimal" contextRef="C_20210921_ifrsfullCategoriesOfRelatedPartiesAxis_drugConsultantMember_ifrsfullClassesOfShareCapitalAxis_drugStockOptionsMember" unitRef="Percent">0.55</ix:nonFraction>%; and dividends: nil.</span></span></p>
                                        <p style="margin-bottom: 0pt; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>Options granted during the year ended September 30, 2020</b></span></span></p>
                                        <p style="margin-top: 0pt; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">On July 23, 2020, the Company granted <ix:nonFraction id="Fxbrl_20211229135605852" name="ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" decimals="INF" format="ixt:numdotdecimal" contextRef="C_20200701to20200723_ifrsfullClassesOfShareCapitalAxis_drugStockOptionsMember_srtTitleOfIndividualAxis_drugChiefMedicalOfficerMember" unitRef="Share">150,000</ix:nonFraction> options to the Company's Chief Medical Officer. The fair value of these stock options was measured using the Black Scholes option pricing model using the following inputs: i) exercise price: $<ix:nonFraction id="Fxbrl_20211229135703966" name="ifrs-full:ExercisePriceShareOptionsGranted2019" scale="0" decimals="2" format="ixt:numdotdecimal" contextRef="C_20200701to20200723_ifrsfullClassesOfShareCapitalAxis_drugStockOptionsMember_srtTitleOfIndividualAxis_drugChiefMedicalOfficerMember" unitRef="CAD_per_share">1.25</ix:nonFraction>; ii) share price: $<ix:nonFraction id="Fxbrl_20211229135716197" name="ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019" scale="0" decimals="2" format="ixt:numdotdecimal" contextRef="C_20200701to20200723_ifrsfullClassesOfShareCapitalAxis_drugStockOptionsMember_srtTitleOfIndividualAxis_drugChiefMedicalOfficerMember" unitRef="CAD_per_share">1.25</ix:nonFraction>; iii) term: <ix:nonFraction id="Fxbrl_20211229135724959" name="ifrs-full:DescriptionOfOptionLifeShareOptionsGranted" scale="0" decimals="0" format="ixt:numdotdecimal" contextRef="C_20200701to20200723_ifrsfullClassesOfShareCapitalAxis_drugStockOptionsMember_srtTitleOfIndividualAxis_drugChiefMedicalOfficerMember" unitRef="Year">5 </ix:nonFraction>years; iv) volatility: <ix:nonFraction id="Fxbrl_20211229135731606" name="ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted" scale="-2" decimals="2" format="ixt:numdotdecimal" contextRef="C_20200701to20200723_ifrsfullClassesOfShareCapitalAxis_drugStockOptionsMember_srtTitleOfIndividualAxis_drugChiefMedicalOfficerMember" unitRef="Percent">100</ix:nonFraction>%; v) discount rate: <ix:nonFraction id="Fxbrl_20211229135739458" name="drug:DiscountRateStockOptionGranted" scale="-2" decimals="4" format="ixt:numdotdecimal" contextRef="C_20200723_ifrsfullClassesOfShareCapitalAxis_drugStockOptionsMember_srtTitleOfIndividualAxis_drugChiefMedicalOfficerMember" unitRef="Percent">0.35</ix:nonFraction>%; and dividends: nil.</span></span></p>
                                    </div>
                                </ix:continuation>
                                <div>
                                    <table style="width: 100%; border-collapse: collapse; font-size: 10pt;" border="0" cellspacing="0" cellpadding="0">
                                        <tr>
                                            <td style="width: 100%; text-align: center; border-top: 1pt solid black;">
                                                <p style="font-size: 10pt; font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>14</b>&#160;| Page</span></span></p>
                                            </td>
                                        </tr>
                                    </table>
                                </div>
                                <hr style="page-break-after: always; text-align: center; height: 5px; width: 100%; background-color: black;" />
                                <div>
                                    <table style="width: 100%; border-collapse: collapse; font-size: 10pt;" border="0" cellspacing="0" cellpadding="0">
                                        <tr>
                                            <td style="width: 100%;">
                                                <p style="margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>Bright Minds Biosciences Inc.</b></span></span></p>
                                                <p style="margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">Notes to the Consolidated Financial Statements</span></span></p>
                                                <p style="margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">For the years ended September 30, 2021 and 2020 and the period from May 31, 2019 (date of incorporation) to September 30, 2019</span></span></p>
                                                <p style="margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">(Expressed in Canadian Dollars)</span></span></p>
                                            </td>
                                        </tr>
                                    </table>
                                </div>
                                <ix:continuation id="F20211229021306044" continuedAt="F20211229021327458">
                                    <div>
                                        <p style="text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">The following table summarizes the movements in the Company's outstanding stock options for the years ended September 30, 2021 and 2020:</span></span></p>
                                        <ix:nonNumeric id="Fxbrl_20211228202438632" name="ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory" escape="true" contextRef="C_20201001to20210930">
                                            <div>
                                                <div style="margin-left: 5.4pt;">
                                                    <table style="width: 100%; border-collapse: collapse; font-size: 10pt; border-color: #000000;" cellspacing="0" cellpadding="0">
                                                        <tr>
                                                            <td style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1.5pt solid #000000; border-bottom: 0.75pt solid #000000; vertical-align: bottom;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>&#160;</b></span></span></td>
                                                            <td style="vertical-align: bottom; border-top: 1.5pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right;">&#160;</td>
                                                            <td style="vertical-align: bottom; border-top: 1.5pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">&#160;<br /><b>Number of options</b></span></span></td>
                                                            <td style="vertical-align: bottom; border-top: 1.5pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;">&#160;</td>
                                                            <td style="vertical-align: bottom; border-top: 1.5pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;">&#160;</td>
                                                            <td style="vertical-align: bottom; border-top: 1.5pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>&#160; Weighted average&#160; </b><br /><b>exercise price</b></span></span></td>
                                                            <td style="vertical-align: bottom; border-top: 1.5pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right;">&#160;</td>
                                                        </tr>
                                                        <tr>
                                                            <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>Balance at September 30, 2019 and May 31, 2019</b></span></span></td>
                                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                            <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b><ix:nonFraction id="Fxbrl_20211228203008645" name="ifrs-full:NumberOfOutstandingShareOptions" decimals="INF" format="ixt:zerodash" contextRef="C_20190930_ifrsfullClassesOfShareCapitalAxis_drugStockOptionsMember" unitRef="Share">-</ix:nonFraction></b></span></span></td>
                                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                            <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b><ix:nonFraction id="Fxbrl_20211228204812693" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" scale="0" decimals="0" format="ixt:zerodash" contextRef="C_20190930_ifrsfullClassesOfShareCapitalAxis_drugStockOptionsMember" unitRef="CAD_per_share">-</ix:nonFraction></b></span></span></td>
                                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                        </tr>
                                                        <tr>
                                                            <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">&#160; Granted</span></span></td>
                                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><ix:nonFraction id="Fxbrl_20211228203131501" name="ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" decimals="INF" format="ixt:numdotdecimal" contextRef="C_20191001to20200930_ifrsfullClassesOfShareCapitalAxis_drugStockOptionsMember" unitRef="Share">150,000</ix:nonFraction></span></span></td>
                                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>$</b></span></span></td>
                                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><ix:nonFraction id="Fxbrl_20211228204432005" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019" scale="0" decimals="2" format="ixt:numdotdecimal" contextRef="C_20191001to20200930_ifrsfullClassesOfShareCapitalAxis_drugStockOptionsMember" unitRef="CAD_per_share">1.25</ix:nonFraction></span></span></td>
                                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                                        </tr>
                                                        <tr>
                                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>Balance at September 30, 2020</b></span></span></td>
                                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b><ix:nonFraction id="Fxbrl_20211228203439827" name="ifrs-full:NumberOfOutstandingShareOptions" decimals="INF" format="ixt:numdotdecimal" contextRef="C_20200930_ifrsfullClassesOfShareCapitalAxis_drugStockOptionsMember" unitRef="Share">150,000</ix:nonFraction></b></span></span></td>
                                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>$</b></span></span></td>
                                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b><ix:nonFraction id="Fxbrl_20211228204846412" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" scale="0" decimals="2" format="ixt:numdotdecimal" contextRef="C_20200930_ifrsfullClassesOfShareCapitalAxis_drugStockOptionsMember" unitRef="CAD_per_share">1.25</ix:nonFraction></b></span></span></td>
                                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                        </tr>
                                                        <tr>
                                                            <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">&#160; Granted</span></span></td>
                                                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                                            <td style="vertical-align: bottom; text-align: right; width: 12%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><ix:nonFraction id="Fxbrl_20211228203513495" name="ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" decimals="INF" format="ixt:numdotdecimal" contextRef="C_20201001to20210930_ifrsfullClassesOfShareCapitalAxis_drugStockOptionsMember" unitRef="Share">895,807</ix:nonFraction></span></span></td>
                                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                                            <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>$</b></span></span></td>
                                                            <td style="vertical-align: bottom; text-align: right; width: 12%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><ix:nonFraction id="Fxbrl_20211228205026138" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019" scale="0" decimals="2" format="ixt:numdotdecimal" contextRef="C_20201001to20210930_ifrsfullClassesOfShareCapitalAxis_drugStockOptionsMember" unitRef="CAD_per_share">4.29</ix:nonFraction></span></span></td>
                                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                                        </tr>
                                                        <tr>
                                                            <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: justify; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">&#160; Cancelled*</span></span></td>
                                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                            <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">(<ix:nonFraction id="Fxbrl_20211228203711789" name="ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" decimals="INF" format="ixt:numdotdecimal" contextRef="C_20201001to20210930_ifrsfullClassesOfShareCapitalAxis_drugStockOptionsMember" unitRef="Share">20,000</ix:nonFraction></span></span></td>
                                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">)</span></span></td>
                                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>$</b></span></span></td>
                                                            <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><ix:nonFraction id="Fxbrl_20211228205114791" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019" scale="0" decimals="2" format="ixt:numdotdecimal" contextRef="C_20201001to20210930_ifrsfullClassesOfShareCapitalAxis_drugStockOptionsMember" unitRef="CAD_per_share">1.25</ix:nonFraction></span></span></td>
                                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                        </tr>
                                                        <tr>
                                                            <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 2.25pt double #000000; vertical-align: bottom;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>Balance at September 30, 2021</b></span></span></td>
                                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%;">&#160;</td>
                                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 12%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b><ix:nonFraction id="Fxbrl_20211228203529839" name="ifrs-full:NumberOfOutstandingShareOptions" decimals="INF" format="ixt:numdotdecimal" contextRef="C_20210930_ifrsfullClassesOfShareCapitalAxis_drugStockOptionsMember" unitRef="Share">1,025,807</ix:nonFraction></b></span></span></td>
                                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%;">&#160;</td>
                                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>$</b></span></span></td>
                                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 12%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b><ix:nonFraction id="Fxbrl_20211228204858020" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" scale="0" decimals="2" format="ixt:numdotdecimal" contextRef="C_20210930_ifrsfullClassesOfShareCapitalAxis_drugStockOptionsMember" unitRef="CAD_per_share">3.90</ix:nonFraction></b></span></span></td>
                                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%;">&#160;</td>
                                                        </tr>
                                                    </table>
                                                </div>
                                            </div>
                                        </ix:nonNumeric>
                                        <p style="text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><i>* On January 21, 2021, the Company cancelled <ix:nonFraction id="Fxbrl_20211230145723310" name="ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" decimals="INF" format="ixt:numdotdecimal" contextRef="C_20210101to20210121_ifrsfullClassesOfShareCapitalAxis_drugStockOptionsMember" unitRef="Shares">20,000</ix:nonFraction> options granted to a consultant in error on November 17, 2020.</i></span></span></p>
                                        <p style="text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">As at September 30, 2021, the options have a weighted average remaining life of <ix:nonNumeric id="Fxbrl_20211229135844309" name="ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" format="ixt-sec:duryear" contextRef="C_20201001to20210930_ifrsfullClassesOfShareCapitalAxis_drugStockOptionsMember">4.28</ix:nonNumeric> years (September 30, 2020 -<ix:nonNumeric id="Fxbrl_20211229135906182" name="ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" format="ixt-sec:duryear" contextRef="C_20191001to20200930_ifrsfullClassesOfShareCapitalAxis_drugStockOptionsMember"> 4.81</ix:nonNumeric>).</span></span></p>
                                        <p style="text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">The following table summarizes the stock options issued and outstanding:</span></span></p>
                                        <ix:nonNumeric id="Fxbrl_20211228202513216" name="drug:DisclosureOfNumberOfIssuedAndOutstandingStockOptionsExplanatory" escape="true" contextRef="C_20201001to20210930">
                                            <div>
                                                <table style="width: 90%; border-collapse: collapse; font-size: 10pt; border-color: #000000; margin-left: auto; margin-right: auto;" cellspacing="0" cellpadding="0">
                                                    <tr>
                                                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-top: 1.5pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>&#160;</b></span></span></td>
                                                        <td style="vertical-align: bottom; border-top: 1.5pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: center;" colspan="1">&#160;</td>
                                                        <td style="vertical-align: bottom; border-top: 1.5pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;" colspan="10"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>Options Outstanding and Exercisable</b></span></span></td>
                                                        <td style="vertical-align: bottom; border-top: 1.5pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: center;" colspan="1">&#160;</td>
                                                    </tr>
                                                    <tr>
                                                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-indent: 2.8pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>&#160;</b><br /><b>Expiry Date</b></span></span></td>
                                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right;">&#160;</td>
                                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>Number of<br />options</b></span></span></td>
                                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;">&#160;</td>
                                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;">&#160;</td>
                                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>&#160;</b><br /><b>Exercisable</b></span></span></td>
                                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;">&#160;</td>
                                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;">&#160;</td>
                                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>&#160;</b><br /><b>Exercise price</b></span></span></td>
                                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;">&#160;</td>
                                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;">&#160;</td>
                                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>Remaining life<br />(Years)</b></span></span></td>
                                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right;">&#160;</td>
                                                    </tr>
                                                    <tr>
                                                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">September 21, 2024</span></span></td>
                                                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                        <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><ix:nonFraction id="Fxbrl_20211228205652752" name="ifrs-full:NumberOfOutstandingShareOptions" decimals="INF" format="ixt:numdotdecimal" contextRef="C_20210930_drugExpiryDateAxis_drugExpiryDateTwentyOneSeptemberTwoThousandAndTwentyFourMember_ifrsfullClassesOfShareCapitalAxis_drugStockOptionsMember" unitRef="Share">8,807</ix:nonFraction></span></span></td>
                                                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                        <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><ix:nonFraction id="Fxbrl_20211228210227203" name="ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" decimals="INF" format="ixt:zerodash" contextRef="C_20210930_drugExpiryDateAxis_drugExpiryDateTwentyOneSeptemberTwoThousandAndTwentyFourMember_ifrsfullClassesOfShareCapitalAxis_drugStockOptionsMember" unitRef="Share">-</ix:nonFraction></span></span></td>
                                                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">$</span></span></td>
                                                        <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><ix:nonFraction id="Fxbrl_20211228210641762" name="ifrs-full:ExercisePriceOfOutstandingShareOptions2019" scale="0" decimals="2" format="ixt:numdotdecimal" contextRef="C_20210930_drugExpiryDateAxis_drugExpiryDateTwentyOneSeptemberTwoThousandAndTwentyFourMember_ifrsfullClassesOfShareCapitalAxis_drugStockOptionsMember" unitRef="CAD_per_share">7.64</ix:nonFraction></span></span></td>
                                                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                        <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">
                                                                    <ix:nonNumeric id="Fxbrl_20211228210855274" name="ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" format="ixt-sec:duryear" contextRef="C_20201001to20210930_drugExpiryDateAxis_drugExpiryDateTwentyOneSeptemberTwoThousandAndTwentyFourMember_ifrsfullClassesOfShareCapitalAxis_drugStockOptionsMember">2.98</ix:nonNumeric>
                                                                </span></span></td>
                                                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                    </tr>
                                                    <tr>
                                                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">July 23, 2025</span></span></td>
                                                        <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                                        <td style="vertical-align: bottom; text-align: right; width: 12%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><ix:nonFraction id="Fxbrl_20211228210116540" name="ifrs-full:NumberOfOutstandingShareOptions" decimals="INF" format="ixt:numdotdecimal" contextRef="C_20210930_drugExpiryDateAxis_drugExpiryDateTwentyThreeJulyTwoThousandAndTwentyFiveMember_ifrsfullClassesOfShareCapitalAxis_drugStockOptionsMember" unitRef="Share">150,000</ix:nonFraction></span></span></td>
                                                        <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                                        <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                                        <td style="vertical-align: bottom; text-align: right; width: 12%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><ix:nonFraction id="Fxbrl_20211228210236234" name="ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" decimals="INF" format="ixt:numdotdecimal" contextRef="C_20210930_drugExpiryDateAxis_drugExpiryDateTwentyThreeJulyTwoThousandAndTwentyFiveMember_ifrsfullClassesOfShareCapitalAxis_drugStockOptionsMember" unitRef="Share">150,000</ix:nonFraction></span></span></td>
                                                        <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                                        <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">$</span></span></td>
                                                        <td style="vertical-align: bottom; text-align: right; width: 12%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><ix:nonFraction id="Fxbrl_20211228210701378" name="ifrs-full:ExercisePriceOfOutstandingShareOptions2019" scale="0" decimals="2" format="ixt:numdotdecimal" contextRef="C_20210930_drugExpiryDateAxis_drugExpiryDateTwentyThreeJulyTwoThousandAndTwentyFiveMember_ifrsfullClassesOfShareCapitalAxis_drugStockOptionsMember" unitRef="CAD_per_share">1.25</ix:nonFraction></span></span></td>
                                                        <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                                        <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                                        <td style="vertical-align: bottom; text-align: right; width: 12%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">
                                                                    <ix:nonNumeric id="Fxbrl_20211228210936779" name="ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" format="ixt-sec:duryear" contextRef="C_20201001to20210930_drugExpiryDateAxis_drugExpiryDateTwentyThreeJulyTwoThousandAndTwentyFiveMember_ifrsfullClassesOfShareCapitalAxis_drugStockOptionsMember">3.81</ix:nonNumeric>
                                                                </span></span></td>
                                                        <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                                    </tr>
                                                    <tr>
                                                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">November 17, 2025</span></span></td>
                                                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                        <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><ix:nonFraction id="Fxbrl_20211228210120581" name="ifrs-full:NumberOfOutstandingShareOptions" decimals="INF" format="ixt:numdotdecimal" contextRef="C_20210930_drugExpiryDateAxis_drugExpiryDateSeventeenNovemberTwoThousandAndTwentyFiveMember_ifrsfullClassesOfShareCapitalAxis_drugStockOptionsMember" unitRef="Share">447,000</ix:nonFraction></span></span></td>
                                                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                        <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><ix:nonFraction id="Fxbrl_20211228210324245" name="ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" decimals="INF" format="ixt:numdotdecimal" contextRef="C_20210930_drugExpiryDateAxis_drugExpiryDateSeventeenNovemberTwoThousandAndTwentyFiveMember_ifrsfullClassesOfShareCapitalAxis_drugStockOptionsMember" unitRef="Share">30,500</ix:nonFraction></span></span></td>
                                                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">$</span></span></td>
                                                        <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><ix:nonFraction id="Fxbrl_20211228210707076" name="ifrs-full:ExercisePriceOfOutstandingShareOptions2019" scale="0" decimals="2" format="ixt:numdotdecimal" contextRef="C_20210930_drugExpiryDateAxis_drugExpiryDateSeventeenNovemberTwoThousandAndTwentyFiveMember_ifrsfullClassesOfShareCapitalAxis_drugStockOptionsMember" unitRef="CAD_per_share">1.25</ix:nonFraction></span></span></td>
                                                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                        <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">
                                                                    <ix:nonNumeric id="Fxbrl_20211228210940644" name="ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" format="ixt-sec:duryear" contextRef="C_20201001to20210930_drugExpiryDateAxis_drugExpiryDateSeventeenNovemberTwoThousandAndTwentyFiveMember_ifrsfullClassesOfShareCapitalAxis_drugStockOptionsMember">4.13</ix:nonNumeric>
                                                                </span></span></td>
                                                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                    </tr>
                                                    <tr>
                                                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">April 28, 2026</span></span></td>
                                                        <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                                        <td style="vertical-align: bottom; text-align: right; width: 12%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><ix:nonFraction id="Fxbrl_20211228210126203" name="ifrs-full:NumberOfOutstandingShareOptions" decimals="INF" format="ixt:numdotdecimal" contextRef="C_20210930_drugExpiryDateAxis_drugExpiryDateTwentyEightAprilTwoThousandAndTwentySixMember_ifrsfullClassesOfShareCapitalAxis_drugStockOptionsMember" unitRef="Share">240,000</ix:nonFraction></span></span></td>
                                                        <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                                        <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                                        <td style="vertical-align: bottom; text-align: right; width: 12%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><ix:nonFraction id="Fxbrl_20211228210553560" name="ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" decimals="INF" format="ixt:zerodash" contextRef="C_20210930_drugExpiryDateAxis_drugExpiryDateTwentyEightAprilTwoThousandAndTwentySixMember_ifrsfullClassesOfShareCapitalAxis_drugStockOptionsMember" unitRef="Share">-</ix:nonFraction></span></span></td>
                                                        <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                                        <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">$</span></span></td>
                                                        <td style="vertical-align: bottom; text-align: right; width: 12%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><ix:nonFraction id="Fxbrl_20211228210716106" name="ifrs-full:ExercisePriceOfOutstandingShareOptions2019" scale="0" decimals="2" format="ixt:numdotdecimal" contextRef="C_20210930_drugExpiryDateAxis_drugExpiryDateTwentyEightAprilTwoThousandAndTwentySixMember_ifrsfullClassesOfShareCapitalAxis_drugStockOptionsMember" unitRef="CAD_per_share">7.60</ix:nonFraction></span></span></td>
                                                        <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                                        <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                                        <td style="vertical-align: bottom; text-align: right; width: 12%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">
                                                                    <ix:nonNumeric id="Fxbrl_20211228210945411" name="ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" format="ixt-sec:duryear" contextRef="C_20201001to20210930_drugExpiryDateAxis_drugExpiryDateTwentyEightAprilTwoThousandAndTwentySixMember_ifrsfullClassesOfShareCapitalAxis_drugStockOptionsMember">4.58</ix:nonNumeric>
                                                                </span></span></td>
                                                        <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                                    </tr>
                                                    <tr>
                                                        <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 2.25pt double #000000; vertical-align: bottom; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">June 15, 2026</span></span></td>
                                                        <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                        <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><ix:nonFraction id="Fxbrl_20211228210138961" name="ifrs-full:NumberOfOutstandingShareOptions" decimals="INF" format="ixt:numdotdecimal" contextRef="C_20210930_drugExpiryDateAxis_drugExpiryDateFifteenJuneTwoThousandAndTwentySixMember_ifrsfullClassesOfShareCapitalAxis_drugStockOptionsMember" unitRef="Share">180,000</ix:nonFraction></span></span></td>
                                                        <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                        <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                        <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><ix:nonFraction id="Fxbrl_20211228210530706" name="ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" decimals="INF" format="ixt:zerodash" contextRef="C_20210930_drugExpiryDateAxis_drugExpiryDateFifteenJuneTwoThousandAndTwentySixMember_ifrsfullClassesOfShareCapitalAxis_drugStockOptionsMember" unitRef="Share">-</ix:nonFraction></span></span></td>
                                                        <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                        <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">$</span></span></td>
                                                        <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><ix:nonFraction id="Fxbrl_20211228210722410" name="ifrs-full:ExercisePriceOfOutstandingShareOptions2019" scale="0" decimals="2" format="ixt:numdotdecimal" contextRef="C_20210930_drugExpiryDateAxis_drugExpiryDateFifteenJuneTwoThousandAndTwentySixMember_ifrsfullClassesOfShareCapitalAxis_drugStockOptionsMember" unitRef="CAD_per_share">7.60</ix:nonFraction></span></span></td>
                                                        <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                        <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                        <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">
                                                                    <ix:nonNumeric id="Fxbrl_20211228210950124" name="ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" format="ixt-sec:duryear" contextRef="C_20201001to20210930_drugExpiryDateAxis_drugExpiryDateFifteenJuneTwoThousandAndTwentySixMember_ifrsfullClassesOfShareCapitalAxis_drugStockOptionsMember">4.71</ix:nonNumeric>
                                                                </span></span></td>
                                                        <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                    </tr>
                                                </table>
                                            </div>
                                        </ix:nonNumeric>
                                        <p style="margin-bottom: 0pt; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span style="text-decoration: underline;"><b>Restricted share unit plan</b></span></span></span></p>
                                        <p style="margin-top: 0pt; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">The Company's restricted share unit ("RSU") plan provides RSUs to be issued to directors, officers, employees and consultants of the Company, its subsidiaries and any personal holding company of such individuals so that they may participate in the growth and development of the Company. Subject to the specific provisions of the RSU plan, eligibility, vesting period, terms of the RSUs and the number of RSUs granted are to be determined by the Board of Directors at the time of the grant. The RSU plan allows the Board of Directors to issue common shares of the company as equity settled RSUs, provided that, when combined, the maximum number of common shares reserved for issuance under all share-based compensation arrangements of the Company does not exceed 10% of the Company's outstanding common shares.</span></span></p>
                                        <p style="text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">On July 23, 2020 and September 18, 2020, the Company issued <ix:nonFraction id="Fxbrl_20211229140025888" name="drug:IssuanceOfRestrictedStockUnits" scale="0" decimals="0" format="ixt:numdotdecimal" contextRef="C_20200723_ifrsfullClassesOfShareCapitalAxis_drugRestrictedShareUnitMember_srtTitleOfIndividualAxis_drugChiefMedicalOfficerMember" unitRef="CAD">150,000</ix:nonFraction> RSUs and <ix:nonFraction id="Fxbrl_20211229140042790" name="drug:IssuanceOfRestrictedStockUnits" scale="0" decimals="0" format="ixt:numdotdecimal" contextRef="C_20200918_ifrsfullClassesOfShareCapitalAxis_drugRestrictedShareUnitMember_srtTitleOfIndividualAxis_drugChiefMedicalOfficerMember" unitRef="CAD">230,000</ix:nonFraction> RSUs, respectively, to the Chief Medical Officer of the Company. These RSUs vest on an annual basis over a period of four years commencing on the first anniversary of the grant date.</span></span></p>
                                        <p style="text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">The following table summarizes the movements in the Company's outstanding RSUs for the years ended September 30, 2021 and 2020:</span></span></p>
                                        <div>
                                            <ix:nonNumeric id="Fxbrl_20211228202543657" name="ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory" escape="true" contextRef="C_20201001to20210930">
                                                <div>
                                                    <table style="width: 100%; border-collapse: collapse; font-size: 10pt; border-color: #000000;" cellspacing="0" cellpadding="0">
                                                        <tr>
                                                            <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; border-top: 1.5pt solid #000000; vertical-align: bottom;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>&#160;</b></span></span></td>
                                                            <td style="vertical-align: bottom; border-top: 1.5pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right;">&#160;</td>
                                                            <td style="vertical-align: bottom; border-top: 1.5pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>Equity settled</b></span></span></td>
                                                            <td style="vertical-align: bottom; border-top: 1.5pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;">&#160;</td>
                                                            <td style="vertical-align: bottom; border-top: 1.5pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;" colspan="1">&#160;</td>
                                                            <td style="vertical-align: bottom; border-top: 1.5pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;" colspan="1"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>Cash settled</b></span></span></td>
                                                            <td style="vertical-align: bottom; border-top: 1.5pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;" colspan="1">&#160;</td>
                                                            <td style="vertical-align: bottom; border-top: 1.5pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;">&#160;</td>
                                                            <td style="vertical-align: bottom; border-top: 1.5pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>Total</b></span></span></td>
                                                            <td style="vertical-align: bottom; border-top: 1.5pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;">&#160;</td>
                                                        </tr>
                                                        <tr>
                                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>Balance at September 30, 2019 and May 31, 2019</b></span></span></td>
                                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><ix:nonFraction id="Fxbrl_20211228211150289_12" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" scale="0" decimals="0" format="ixt:zerodash" contextRef="C_20190930_ifrsfullClassesOfShareCapitalAxis_drugRestrictedShareUnitMember_ifrsfullTypesOfSharebasedPaymentArrangementsAxis_drugEquitySettledShareBasedPaymentArrangementsMember" unitRef="Share">-</ix:nonFraction></span></span></td>
                                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;" colspan="1">&#160;</td>
                                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;" colspan="1"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><ix:nonFraction id="Fxbrl_20211228211150289_15" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" scale="0" decimals="0" format="ixt:zerodash" contextRef="C_20190930_ifrsfullClassesOfShareCapitalAxis_drugRestrictedShareUnitMember_ifrsfullTypesOfSharebasedPaymentArrangementsAxis_drugCashSettledShareBasedPaymentArrangementsMember" unitRef="Share">-</ix:nonFraction></span></span></td>
                                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;" colspan="1">&#160;</td>
                                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><ix:nonFraction id="Fxbrl_20211228211150289_18" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" scale="0" decimals="0" format="ixt:zerodash" contextRef="C_20190930_ifrsfullClassesOfShareCapitalAxis_drugRestrictedShareUnitMember" unitRef="Share">-</ix:nonFraction></span></span></td>
                                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                        </tr>
                                                        <tr>
                                                            <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">Granted</span></span></td>
                                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><ix:nonFraction id="Fxbrl_20211228211150289_22" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" scale="0" decimals="0" format="ixt:numdotdecimal" contextRef="C_20191001to20200930_ifrsfullClassesOfShareCapitalAxis_drugRestrictedShareUnitMember_ifrsfullTypesOfSharebasedPaymentArrangementsAxis_drugEquitySettledShareBasedPaymentArrangementsMember" unitRef="Share">380,000</ix:nonFraction></span></span></td>
                                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;" colspan="1">&#160;</td>
                                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%;" colspan="1"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><ix:nonFraction id="Fxbrl_20211228211150289_25" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" scale="0" decimals="0" format="ixt:zerodash" contextRef="C_20191001to20200930_ifrsfullClassesOfShareCapitalAxis_drugRestrictedShareUnitMember_ifrsfullTypesOfSharebasedPaymentArrangementsAxis_drugCashSettledShareBasedPaymentArrangementsMember" unitRef="Share">-</ix:nonFraction></span></span></td>
                                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;" colspan="1">&#160;</td>
                                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><ix:nonFraction id="Fxbrl_20211228211150289_28" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" scale="0" decimals="0" format="ixt:numdotdecimal" contextRef="C_20191001to20200930_ifrsfullClassesOfShareCapitalAxis_drugRestrictedShareUnitMember" unitRef="Share">380,000</ix:nonFraction></span></span></td>
                                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                                        </tr>
                                                        <tr>
                                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>Balance at September 30, 2020</b></span></span></td>
                                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b><ix:nonFraction id="Fxbrl_20211228211150289_32" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" scale="0" decimals="0" format="ixt:numdotdecimal" contextRef="C_20200930_ifrsfullClassesOfShareCapitalAxis_drugRestrictedShareUnitMember_ifrsfullTypesOfSharebasedPaymentArrangementsAxis_drugEquitySettledShareBasedPaymentArrangementsMember" unitRef="Share">380,000</ix:nonFraction></b></span></span></td>
                                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><ix:nonFraction id="Fxbrl_20211228211150289_35" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" scale="0" decimals="0" format="ixt:zerodash" contextRef="C_20200930_ifrsfullClassesOfShareCapitalAxis_drugRestrictedShareUnitMember_ifrsfullTypesOfSharebasedPaymentArrangementsAxis_drugCashSettledShareBasedPaymentArrangementsMember" unitRef="Share">-</ix:nonFraction></span></span></td>
                                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b><ix:nonFraction id="Fxbrl_20211228211150289_38" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" scale="0" decimals="0" format="ixt:numdotdecimal" contextRef="C_20200930_ifrsfullClassesOfShareCapitalAxis_drugRestrictedShareUnitMember" unitRef="Share">380,000</ix:nonFraction></b></span></span></td>
                                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                        </tr>
                                                        <tr>
                                                            <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">Vested</span></span></td>
                                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">(<ix:nonFraction id="Fxbrl_20211228211150289_42" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" scale="0" decimals="0" format="ixt:numdotdecimal" contextRef="C_20201001to20210930_ifrsfullClassesOfShareCapitalAxis_drugRestrictedShareUnitMember_ifrsfullTypesOfSharebasedPaymentArrangementsAxis_drugEquitySettledShareBasedPaymentArrangementsMember" unitRef="Share">95,000</ix:nonFraction></span></span></td>
                                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">)</span></span></td>
                                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><ix:nonFraction id="Fxbrl_20211228211150289_45" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" scale="0" decimals="0" format="ixt:zerodash" contextRef="C_20201001to20210930_ifrsfullClassesOfShareCapitalAxis_drugRestrictedShareUnitMember_ifrsfullTypesOfSharebasedPaymentArrangementsAxis_drugCashSettledShareBasedPaymentArrangementsMember" unitRef="Share">-</ix:nonFraction></span></span></td>
                                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">(<ix:nonFraction id="Fxbrl_20211228211150289_48" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" scale="0" decimals="0" format="ixt:numdotdecimal" contextRef="C_20201001to20210930_ifrsfullClassesOfShareCapitalAxis_drugRestrictedShareUnitMember" unitRef="Share">95,000</ix:nonFraction></span></span></td>
                                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">)</span></span></td>
                                                        </tr>
                                                        <tr>
                                                            <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 2.25pt double #000000; vertical-align: bottom; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>Balance at September 30, 2021</b></span></span></td>
                                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b><ix:nonFraction id="Fxbrl_20211228211150289_52" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" scale="0" decimals="0" format="ixt:numdotdecimal" contextRef="C_20210930_ifrsfullClassesOfShareCapitalAxis_drugRestrictedShareUnitMember_ifrsfullTypesOfSharebasedPaymentArrangementsAxis_drugEquitySettledShareBasedPaymentArrangementsMember" unitRef="Share">285,000</ix:nonFraction></b></span></span></td>
                                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><ix:nonFraction id="Fxbrl_20211228211150289_55" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" scale="0" decimals="0" format="ixt:zerodash" contextRef="C_20210930_ifrsfullClassesOfShareCapitalAxis_drugRestrictedShareUnitMember_ifrsfullTypesOfSharebasedPaymentArrangementsAxis_drugCashSettledShareBasedPaymentArrangementsMember" unitRef="Share">-</ix:nonFraction></span></span></td>
                                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b><ix:nonFraction id="Fxbrl_20211228211150289_58" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" scale="0" decimals="0" format="ixt:numdotdecimal" contextRef="C_20210930_ifrsfullClassesOfShareCapitalAxis_drugRestrictedShareUnitMember" unitRef="Share">285,000</ix:nonFraction></b></span></span></td>
                                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                        </tr>
                                                    </table>
                                                </div>
                                            </ix:nonNumeric>
                                        </div>
                                        <p style="text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">The estimated fair value of the equity settled RSUs granted during the year ended September 30, 2020 was $<ix:nonFraction id="Fxbrl_20211229142113090" name="drug:EstimatedFairValueOfEquitySettledRsusGranted" scale="0" decimals="0" format="ixt:numdotdecimal" contextRef="C_20191001to20200930_ifrsfullClassesOfShareCapitalAxis_drugRestrictedShareUnitMember" unitRef="CAD">475,000 </ix:nonFraction>and will be recognized as an expense over the vesting period of the RSUs.</span></span></p>
                                    </div>
                                </ix:continuation>
                                <div>
                                    <table style="width: 100%; border-collapse: collapse; font-size: 10pt;" border="0" cellspacing="0" cellpadding="0">
                                        <tr>
                                            <td style="width: 100%; text-align: center; border-top: 1pt solid black;">
                                                <p style="font-size: 10pt; font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>15</b>&#160;| Page</span></span></p>
                                            </td>
                                        </tr>
                                    </table>
                                </div>
                                <hr style="page-break-after: always; text-align: center; height: 5px; width: 100%; background-color: black;" />
                                <div>
                                    <table style="width: 100%; border-collapse: collapse; font-size: 10pt;" border="0" cellspacing="0" cellpadding="0">
                                        <tr>
                                            <td style="width: 100%;">
                                                <p style="margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>Bright Minds Biosciences Inc.</b></span></span></p>
                                                <p style="margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">Notes to the Consolidated Financial Statements</span></span></p>
                                                <p style="margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">For the years ended September 30, 2021 and 2020 and the period from May 31, 2019 (date of incorporation) to September 30, 2019</span></span></p>
                                                <p style="margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">(Expressed in Canadian Dollars)</span></span></p>
                                            </td>
                                        </tr>
                                    </table>
                                </div>
                                <ix:continuation id="F20211229021327458" continuedAt="F20211229021352093">
                                    <div>
                                        <p style="text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">The accounting fair value of the equity settled RSUs as at the grant date was estimated by management using the following inputs:&#160;</span></span></p>
                                        <ix:nonNumeric id="Fxbrl_20211228202617266" name="drug:DisclosureOfDetailedInformationAboutEquitySettledRestrictedShareUnitsFairValueInputsExplanatory" escape="true" contextRef="C_20201001to20210930">
                                            <div>
                                                <table style="width: 80%; border-collapse: collapse; font-size: 10pt; border-color: #000000; margin-left: auto; margin-right: auto;" cellspacing="0" cellpadding="0">
                                                    <tr>
                                                        <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; border-top: 1.5pt solid #000000; vertical-align: bottom;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>&#160;</b></span></span></td>
                                                        <td style="vertical-align: bottom; border-top: 1.5pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right;">&#160;</td>
                                                        <td style="vertical-align: bottom; border-top: 1.5pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>Year ended<br />September 30, 2020</b></span></span></td>
                                                        <td style="vertical-align: bottom; border-top: 1.5pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right;">&#160;</td>
                                                    </tr>
                                                    <tr>
                                                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">Share price on grant date</span></span></td>
                                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">$</span></span></td>
                                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 22%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><ix:nonFraction id="Fxbrl_20211228212157350" name="drug:SharePriceOnGrantDateOfOtherEquityInstruments" scale="0" decimals="2" format="ixt:numdotdecimal" contextRef="C_20191001to20200930_ifrsfullClassesOfShareCapitalAxis_drugRestrictedShareUnitMember_ifrsfullTypesOfSharebasedPaymentArrangementsAxis_drugEquitySettledShareBasedPaymentArrangementsMember" unitRef="CAD_per_share">1.25</ix:nonFraction></span></span></td>
                                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                    </tr>
                                                    <tr>
                                                        <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">Forfeiture rate</span></span></td>
                                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 22%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><ix:nonFraction id="Fxbrl_20211228212218505" name="drug:ForfeitureRateOfOtherEquityInstruments" scale="-2" decimals="2" format="ixt:numdotdecimal" contextRef="C_20191001to20200930_ifrsfullClassesOfShareCapitalAxis_drugRestrictedShareUnitMember_ifrsfullTypesOfSharebasedPaymentArrangementsAxis_drugEquitySettledShareBasedPaymentArrangementsMember" unitRef="Percent">0</ix:nonFraction>%</span></span></td>
                                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                                    </tr>
                                                </table>
                                            </div>
                                        </ix:nonNumeric>
                                        <p style="text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">Share-based compensation expense recognized in the consolidated statements of comprehensive loss is comprised of the following:</span></span></p>
                                        <div style="margin-left: 5.4pt;">
                                            <ix:nonNumeric id="Fxbrl_20211228202640434" name="drug:DisclosureOfDetailedInformationAboutShareBasedPaymentsRecognizedInConsolidatedStatementsOfComprehensiveLossExplanatory" escape="true" contextRef="C_20201001to20210930">
                                                <div>
                                                    <table style="width: 100%; border-collapse: collapse; font-size: 10pt; border-color: #000000;" cellspacing="0" cellpadding="0">
                                                        <tr>
                                                            <td style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1.5pt solid #000000; border-bottom: 0.75pt solid #000000; vertical-align: bottom;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>&#160;</b></span></span></td>
                                                            <td style="vertical-align: bottom; border-top: 1.5pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right;">&#160;</td>
                                                            <td style="vertical-align: bottom; border-top: 1.5pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>Year ended<br />September 30,<br />2021</b></span></span></td>
                                                            <td style="vertical-align: bottom; border-top: 1.5pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;">&#160;</td>
                                                            <td style="vertical-align: bottom; border-top: 1.5pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;">&#160;</td>
                                                            <td style="vertical-align: bottom; border-top: 1.5pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">Year ended<br />September 30,<br />2020</span></span></td>
                                                            <td style="vertical-align: bottom; border-top: 1.5pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;">&#160;</td>
                                                            <td style="vertical-align: bottom; border-top: 1.5pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;">&#160;</td>
                                                            <td style="vertical-align: bottom; border-top: 1.5pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">Period ended<br />September 30,<br />2019</span></span></td>
                                                            <td style="vertical-align: bottom; border-top: 1.5pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right;">&#160;</td>
                                                        </tr>
                                                        <tr>
                                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>&#160;</b></span></span></td>
                                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right;">&#160;</td>
                                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>$</b></span></span></td>
                                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right;">&#160;</td>
                                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right;">&#160;</td>
                                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">$</span></span></td>
                                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right;">&#160;</td>
                                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right;">&#160;</td>
                                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">$</span></span></td>
                                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right;">&#160;</td>
                                                        </tr>
                                                        <tr>
                                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">Stock options</span></span></td>
                                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                            <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b><ix:nonFraction id="Fxbrl_20211228212406390_22" name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees" scale="0" decimals="0" format="ixt:numdotdecimal" contextRef="C_20201001to20210930_ifrsfullClassesOfShareCapitalAxis_drugStockOptionsMember_ifrsfullTypesOfSharebasedPaymentArrangementsAxis_drugEquitySettledShareBasedPaymentArrangementsMember" unitRef="CAD">643,963</ix:nonFraction></b></span></span></td>
                                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                            <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><ix:nonFraction id="Fxbrl_20211228212406390_25" name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees" scale="0" decimals="0" format="ixt:numdotdecimal" contextRef="C_20191001to20200930_ifrsfullClassesOfShareCapitalAxis_drugStockOptionsMember_ifrsfullTypesOfSharebasedPaymentArrangementsAxis_drugEquitySettledShareBasedPaymentArrangementsMember" unitRef="CAD">138,000</ix:nonFraction></span></span></td>
                                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                            <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><ix:nonFraction id="Fxbrl_20211228212406390_28" name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees" scale="0" decimals="0" format="ixt:zerodash" contextRef="C_20190531to20190930_ifrsfullClassesOfShareCapitalAxis_drugStockOptionsMember_ifrsfullTypesOfSharebasedPaymentArrangementsAxis_drugEquitySettledShareBasedPaymentArrangementsMember" unitRef="CAD">-</ix:nonFraction></span></span></td>
                                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                        </tr>
                                                        <tr>
                                                            <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">Restricted share units - equity settled grants</span></span></td>
                                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b><ix:nonFraction id="Fxbrl_20211228212406390_32" name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees" scale="0" decimals="0" format="ixt:numdotdecimal" contextRef="C_20201001to20210930_ifrsfullClassesOfShareCapitalAxis_drugRestrictedShareUnitMember_ifrsfullTypesOfSharebasedPaymentArrangementsAxis_drugEquitySettledShareBasedPaymentArrangementsMember" unitRef="CAD">236,652</ix:nonFraction></b></span></span></td>
                                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><ix:nonFraction id="Fxbrl_20211228212406390_35" name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees" scale="0" decimals="0" format="ixt:numdotdecimal" contextRef="C_20191001to20200930_ifrsfullClassesOfShareCapitalAxis_drugRestrictedShareUnitMember_ifrsfullTypesOfSharebasedPaymentArrangementsAxis_drugEquitySettledShareBasedPaymentArrangementsMember" unitRef="CAD">23,300</ix:nonFraction></span></span></td>
                                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><ix:nonFraction id="Fxbrl_20211228212406390_38" name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees" scale="0" decimals="0" format="ixt:zerodash" contextRef="C_20190531to20190930_ifrsfullClassesOfShareCapitalAxis_drugRestrictedShareUnitMember_ifrsfullTypesOfSharebasedPaymentArrangementsAxis_drugEquitySettledShareBasedPaymentArrangementsMember" unitRef="CAD">-</ix:nonFraction></span></span></td>
                                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                                        </tr>
                                                        <tr>
                                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">Total equity settled share-based compensation expense</span></span></td>
                                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b><ix:nonFraction id="Fxbrl_20211228212406390_42" name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees" scale="0" decimals="0" format="ixt:numdotdecimal" contextRef="C_20201001to20210930_ifrsfullTypesOfSharebasedPaymentArrangementsAxis_drugEquitySettledShareBasedPaymentArrangementsMember" unitRef="CAD">880,615</ix:nonFraction></b></span></span></td>
                                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><ix:nonFraction id="Fxbrl_20211228212406390_45" name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees" scale="0" decimals="0" format="ixt:numdotdecimal" contextRef="C_20191001to20200930_ifrsfullTypesOfSharebasedPaymentArrangementsAxis_drugEquitySettledShareBasedPaymentArrangementsMember" unitRef="CAD">161,300</ix:nonFraction></span></span></td>
                                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><ix:nonFraction id="Fxbrl_20211228212406390_48" name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees" scale="0" decimals="0" format="ixt:zerodash" contextRef="C_20190531to20190930_ifrsfullTypesOfSharebasedPaymentArrangementsAxis_drugEquitySettledShareBasedPaymentArrangementsMember" unitRef="CAD">-</ix:nonFraction></span></span></td>
                                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                        </tr>
                                                        <tr>
                                                            <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">Restricted share units - cash settled grants</span></span></td>
                                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b><ix:nonFraction id="Fxbrl_20211228212406390_52" name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees" scale="0" decimals="0" format="ixt:zerodash" contextRef="C_20201001to20210930_ifrsfullClassesOfShareCapitalAxis_drugRestrictedShareUnitMember_ifrsfullTypesOfSharebasedPaymentArrangementsAxis_drugCashSettledShareBasedPaymentArrangementsMember" unitRef="CAD">-</ix:nonFraction></b></span></span></td>
                                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><ix:nonFraction id="Fxbrl_20211228212406390_55" name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees" scale="0" decimals="0" format="ixt:zerodash" contextRef="C_20191001to20200930_ifrsfullClassesOfShareCapitalAxis_drugRestrictedShareUnitMember_ifrsfullTypesOfSharebasedPaymentArrangementsAxis_drugCashSettledShareBasedPaymentArrangementsMember" unitRef="CAD">-</ix:nonFraction></span></span></td>
                                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><ix:nonFraction id="Fxbrl_20211228212406390_58" name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees" scale="0" decimals="0" format="ixt:zerodash" contextRef="C_20190531to20190930_ifrsfullClassesOfShareCapitalAxis_drugRestrictedShareUnitMember_ifrsfullTypesOfSharebasedPaymentArrangementsAxis_drugCashSettledShareBasedPaymentArrangementsMember" unitRef="CAD">-</ix:nonFraction></span></span></td>
                                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                                        </tr>
                                                        <tr>
                                                            <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 2.25pt double #000000; vertical-align: bottom; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">Total share-based compensation expense</span></span></td>
                                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b><ix:nonFraction id="Fxbrl_20211228212406390_62" name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees" scale="0" decimals="0" format="ixt:numdotdecimal" contextRef="C_20201001to20210930" unitRef="CAD">880,615</ix:nonFraction></b></span></span></td>
                                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><ix:nonFraction id="Fxbrl_20211228212406390_65" name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees" scale="0" decimals="0" format="ixt:numdotdecimal" contextRef="C_20191001to20200930" unitRef="CAD">161,300</ix:nonFraction></span></span></td>
                                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><ix:nonFraction id="Fxbrl_20211228212406390_68" name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees" scale="0" decimals="0" format="ixt:zerodash" contextRef="C_20190531to20190930" unitRef="CAD">-</ix:nonFraction></span></span></td>
                                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                        </tr>
                                                    </table>
                                                </div>
                                            </ix:nonNumeric>
                                        </div>
                                        <p style="text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">Share-based compensation expense is included in the consolidated statements of comprehensive loss as follows:</span></span></p>
                                        <div style="margin-left: 5.4pt;">
                                            <ix:nonNumeric id="Fxbrl_20211228202706210" name="drug:DisclosureOfDetailedInformationAboutShareBasedPaymentsIncludedInConsolidatedStatementsOfComprehensiveLossExplanatory" escape="true" contextRef="C_20201001to20210930">
                                                <div>
                                                    <table style="width: 100%; border-collapse: collapse; font-size: 10pt; border-color: #000000;" cellspacing="0" cellpadding="0">
                                                        <tr>
                                                            <td style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1.5pt solid #000000; border-bottom: 0.75pt solid #000000; vertical-align: bottom;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>&#160;</b></span></span></td>
                                                            <td style="vertical-align: bottom; border-top: 1.5pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right;">&#160;</td>
                                                            <td style="vertical-align: bottom; border-top: 1.5pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>Year ended<br />September 30,<br />2021</b></span></span></td>
                                                            <td style="vertical-align: bottom; border-top: 1.5pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;">&#160;</td>
                                                            <td style="vertical-align: bottom; border-top: 1.5pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;">&#160;</td>
                                                            <td style="vertical-align: bottom; border-top: 1.5pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">Year ended<br />September 30,<br />2020</span></span></td>
                                                            <td style="vertical-align: bottom; border-top: 1.5pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;">&#160;</td>
                                                            <td style="vertical-align: bottom; border-top: 1.5pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;">&#160;</td>
                                                            <td style="vertical-align: bottom; border-top: 1.5pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">Period ended<br />September 30,<br />2019</span></span></td>
                                                            <td style="vertical-align: bottom; border-top: 1.5pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right;">&#160;</td>
                                                        </tr>
                                                        <tr>
                                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>&#160;</b></span></span></td>
                                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right;">&#160;</td>
                                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>$</b></span></span></td>
                                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right;">&#160;</td>
                                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right;">&#160;</td>
                                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">$</span></span></td>
                                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right;">&#160;</td>
                                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right;">&#160;</td>
                                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">$</span></span></td>
                                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right;">&#160;</td>
                                                        </tr>
                                                        <tr>
                                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">Consulting fees</span></span></td>
                                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                            <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b><ix:nonFraction id="Fxbrl_20211228213355534_22" name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees" scale="0" decimals="0" format="ixt:numdotdecimal" contextRef="C_20201001to20210930_drugConsolidatedStatementsOfComprehensiveIncomeLossStatementLocationAxis_drugConsultingFeesMember" unitRef="CAD">8,045</ix:nonFraction></b></span></span></td>
                                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                            <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><ix:nonFraction id="Fxbrl_20211228213355534_25" name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees" scale="0" decimals="0" format="ixt:zerodash" contextRef="C_20191001to20200930_drugConsolidatedStatementsOfComprehensiveIncomeLossStatementLocationAxis_drugConsultingFeesMember" unitRef="CAD">-</ix:nonFraction></span></span></td>
                                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                            <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><ix:nonFraction id="Fxbrl_20211228213355534_28" name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees" scale="0" decimals="0" format="ixt:zerodash" contextRef="C_20190531to20190930_drugConsolidatedStatementsOfComprehensiveIncomeLossStatementLocationAxis_drugConsultingFeesMember" unitRef="CAD">-</ix:nonFraction></span></span></td>
                                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                        </tr>
                                                        <tr>
                                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">Directors' compensation</span></span></td>
                                                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                                            <td style="vertical-align: bottom; text-align: right; width: 12%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b><ix:nonFraction id="Fxbrl_20211228213355534_32" name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees" scale="0" decimals="0" format="ixt:numdotdecimal" contextRef="C_20201001to20210930_drugConsolidatedStatementsOfComprehensiveIncomeLossStatementLocationAxis_drugDirectorsCompensationMember" unitRef="CAD">136,612</ix:nonFraction></b></span></span></td>
                                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                                            <td style="vertical-align: bottom; text-align: right; width: 12%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><ix:nonFraction id="Fxbrl_20211228213355534_35" name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees" scale="0" decimals="0" format="ixt:zerodash" contextRef="C_20191001to20200930_drugConsolidatedStatementsOfComprehensiveIncomeLossStatementLocationAxis_drugDirectorsCompensationMember" unitRef="CAD">-</ix:nonFraction></span></span></td>
                                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                                            <td style="vertical-align: bottom; text-align: right; width: 12%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><ix:nonFraction id="Fxbrl_20211228213355534_38" name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees" scale="0" decimals="0" format="ixt:zerodash" contextRef="C_20190531to20190930_drugConsolidatedStatementsOfComprehensiveIncomeLossStatementLocationAxis_drugDirectorsCompensationMember" unitRef="CAD">-</ix:nonFraction></span></span></td>
                                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                                        </tr>
                                                        <tr>
                                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">Marketing, advertising and investor relations</span></span></td>
                                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                            <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b><ix:nonFraction id="Fxbrl_20211228213355534_42" name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees" scale="0" decimals="0" format="ixt:numdotdecimal" contextRef="C_20201001to20210930_drugConsolidatedStatementsOfComprehensiveIncomeLossStatementLocationAxis_drugMarketingAdvertisingAndInvestorRelationsMember" unitRef="CAD">3,696</ix:nonFraction></b></span></span></td>
                                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                            <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><ix:nonFraction id="Fxbrl_20211228213355534_45" name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees" scale="0" decimals="0" format="ixt:zerodash" contextRef="C_20191001to20200930_drugConsolidatedStatementsOfComprehensiveIncomeLossStatementLocationAxis_drugMarketingAdvertisingAndInvestorRelationsMember" unitRef="CAD">-</ix:nonFraction></span></span></td>
                                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                            <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><ix:nonFraction id="Fxbrl_20211228213355534_48" name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees" scale="0" decimals="0" format="ixt:zerodash" contextRef="C_20190531to20190930_drugConsolidatedStatementsOfComprehensiveIncomeLossStatementLocationAxis_drugMarketingAdvertisingAndInvestorRelationsMember" unitRef="CAD">-</ix:nonFraction></span></span></td>
                                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                        </tr>
                                                        <tr>
                                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">Professional fees</span></span></td>
                                                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                                            <td style="vertical-align: bottom; text-align: right; width: 12%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b><ix:nonFraction id="Fxbrl_20211228213355534_52" name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees" scale="0" decimals="0" format="ixt:numdotdecimal" contextRef="C_20201001to20210930_drugConsolidatedStatementsOfComprehensiveIncomeLossStatementLocationAxis_drugProfessionalFeesMember" unitRef="CAD">23,126</ix:nonFraction></b></span></span></td>
                                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                                            <td style="vertical-align: bottom; text-align: right; width: 12%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><ix:nonFraction id="Fxbrl_20211228213355534_55" name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees" scale="0" decimals="0" format="ixt:zerodash" contextRef="C_20191001to20200930_drugConsolidatedStatementsOfComprehensiveIncomeLossStatementLocationAxis_drugProfessionalFeesMember" unitRef="CAD">-</ix:nonFraction></span></span></td>
                                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                                            <td style="vertical-align: bottom; text-align: right; width: 12%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><ix:nonFraction id="Fxbrl_20211228213355534_58" name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees" scale="0" decimals="0" format="ixt:zerodash" contextRef="C_20190531to20190930_drugConsolidatedStatementsOfComprehensiveIncomeLossStatementLocationAxis_drugProfessionalFeesMember" unitRef="CAD">-</ix:nonFraction></span></span></td>
                                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                                        </tr>
                                                        <tr>
                                                            <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">Research and development</span></span></td>
                                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b><ix:nonFraction id="Fxbrl_20211228213355534_62" name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees" scale="0" decimals="0" format="ixt:numdotdecimal" contextRef="C_20201001to20210930_drugConsolidatedStatementsOfComprehensiveIncomeLossStatementLocationAxis_drugResearchAndDevelopmentMember" unitRef="CAD">709,136</ix:nonFraction></b></span></span></td>
                                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><ix:nonFraction id="Fxbrl_20211228213355534_65" name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees" scale="0" decimals="0" format="ixt:numdotdecimal" contextRef="C_20191001to20200930_drugConsolidatedStatementsOfComprehensiveIncomeLossStatementLocationAxis_drugResearchAndDevelopmentMember" unitRef="CAD">161,300</ix:nonFraction></span></span></td>
                                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><ix:nonFraction id="Fxbrl_20211228213355534_68" name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees" scale="0" decimals="0" format="ixt:zerodash" contextRef="C_20190531to20190930_drugConsolidatedStatementsOfComprehensiveIncomeLossStatementLocationAxis_drugResearchAndDevelopmentMember" unitRef="CAD">-</ix:nonFraction></span></span></td>
                                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                        </tr>
                                                        <tr>
                                                            <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 2.25pt double #000000; vertical-align: bottom;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">Total share-based compensation expense</span></span></td>
                                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%;">&#160;</td>
                                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 12%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b><ix:nonFraction id="Fxbrl_20211228213355534_72" name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees" scale="0" decimals="0" format="ixt:numdotdecimal" contextRef="C_20201001to20210930" unitRef="CAD">880,615</ix:nonFraction></b></span></span></td>
                                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%;">&#160;</td>
                                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%;">&#160;</td>
                                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 12%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><ix:nonFraction id="Fxbrl_20211228213355534_75" name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees" scale="0" decimals="0" format="ixt:numdotdecimal" contextRef="C_20191001to20200930" unitRef="CAD">161,300</ix:nonFraction></span></span></td>
                                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%;">&#160;</td>
                                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%;">&#160;</td>
                                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 12%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><ix:nonFraction id="Fxbrl_20211228213355534_78" name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees" scale="0" decimals="0" format="ixt:zerodash" contextRef="C_20190531to20190930" unitRef="CAD">-</ix:nonFraction></span></span></td>
                                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%;">&#160;</td>
                                                        </tr>
                                                    </table>
                                                </div>
                                            </ix:nonNumeric>
                                        </div>
                                        <p style="margin-bottom: 0pt; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span style="text-decoration: underline;"><b>Warrants</b></span></span></span></p>
                                        <p style="margin-top: 0pt; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">The following table summarizes the movements in the Company's outstanding warrants for the years ended September 30, 2021 and 2020:</span></span></p>
                                        <div style="margin-left: 5.4pt;">
                                            <ix:nonNumeric id="Fxbrl_20211228202726585" name="drug:DisclosureOfNumberAndWeightedAverageExercisePricesOfWarrantsExplanatory" escape="true" contextRef="C_20201001to20210930">
                                                <div>
                                                    <table style="width: 100%; border-collapse: collapse; font-size: 10pt; border-color: #000000;" cellspacing="0" cellpadding="0">
                                                        <tr>
                                                            <td style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1.5pt solid #000000; border-bottom: 0.75pt solid #000000; vertical-align: bottom;">&#160;</td>
                                                            <td style="vertical-align: bottom; border-top: 1.5pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right;">&#160;</td>
                                                            <td style="vertical-align: bottom; border-top: 1.5pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>Number of warrants</b></span></span></td>
                                                            <td style="vertical-align: bottom; border-top: 1.5pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;">&#160;</td>
                                                            <td style="vertical-align: bottom; border-top: 1.5pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;">&#160;</td>
                                                            <td style="vertical-align: bottom; border-top: 1.5pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">&#160;<b>Weighted average </b><br /><b>exercise price</b></span></span></td>
                                                            <td style="vertical-align: bottom; border-top: 1.5pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right;">&#160;</td>
                                                        </tr>
                                                        <tr>
                                                            <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>Balance at September 30, 2019 and May 31, 2019</b></span></span></td>
                                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                            <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b><ix:nonFraction id="Fxbrl_20211228213841279_12" name="drug:NumberOfWarrantsOutstanding" decimals="INF" format="ixt:zerodash" contextRef="C_20190930_ifrsfullClassesOfShareCapitalAxis_drugWarrantsMember" unitRef="Share">-</ix:nonFraction></b></span></span></td>
                                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">$</span></span></td>
                                                            <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b><ix:nonFraction id="Fxbrl_20211228213841279_15" name="drug:WeightedAverageExercisePriceOfWarrantsOutstandingInShareBasedPaymentArrangement" scale="0" decimals="0" format="ixt:zerodash" contextRef="C_20190930_ifrsfullClassesOfShareCapitalAxis_drugWarrantsMember" unitRef="CAD_per_share">-</ix:nonFraction></b></span></span></td>
                                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                        </tr>
                                                        <tr>
                                                            <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">&#160; Issued</span></span></td>
                                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 15%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><ix:nonFraction id="Fxbrl_20211228213841279_22" name="drug:NumberOfWarrantsIssued" decimals="INF" format="ixt:numdotdecimal" contextRef="C_20191001to20200930_ifrsfullClassesOfShareCapitalAxis_drugWarrantsMember" unitRef="Share">4,079,600</ix:nonFraction></span></span></td>
                                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 15%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><ix:nonFraction id="Fxbrl_20211228213841279_25" name="drug:WeightedAverageExercisePriceOfWarrantsIssuedInShareBasedPaymentArrangement" scale="0" decimals="2" format="ixt:numdotdecimal" contextRef="C_20191001to20200930_ifrsfullClassesOfShareCapitalAxis_drugWarrantsMember" unitRef="CAD_per_share">0.05</ix:nonFraction></span></span></td>
                                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                                        </tr>
                                                        <tr>
                                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>Balance at September 30, 2020</b></span></span></td>
                                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b><ix:nonFraction id="Fxbrl_20211228213841279_32" name="drug:NumberOfWarrantsOutstanding" decimals="INF" format="ixt:numdotdecimal" contextRef="C_20200930_ifrsfullClassesOfShareCapitalAxis_drugWarrantsMember" unitRef="Share">4,079,600</ix:nonFraction></b></span></span></td>
                                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><ix:nonFraction id="Fxbrl_20211228213841279_35" name="drug:WeightedAverageExercisePriceOfWarrantsOutstandingInShareBasedPaymentArrangement" scale="0" decimals="2" format="ixt:numdotdecimal" contextRef="C_20200930_ifrsfullClassesOfShareCapitalAxis_drugWarrantsMember" unitRef="CAD_per_share">0.05</ix:nonFraction></span></span></td>
                                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                        </tr>
                                                        <tr>
                                                            <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">&#160; Issued*</span></span></td>
                                                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                                            <td style="vertical-align: bottom; text-align: right; width: 15%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><ix:nonFraction id="Fxbrl_20211228213841279_42" name="drug:NumberOfWarrantsIssued" decimals="INF" format="ixt:numdotdecimal" contextRef="C_20201001to20210930_ifrsfullClassesOfShareCapitalAxis_drugWarrantsMember" unitRef="Share">1,709,938</ix:nonFraction></span></span></td>
                                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                                            <td style="vertical-align: bottom; text-align: right; width: 15%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><ix:nonFraction id="Fxbrl_20211228213841279_45" name="drug:WeightedAverageExercisePriceOfWarrantsIssuedInShareBasedPaymentArrangement" scale="0" decimals="2" format="ixt:numdotdecimal" contextRef="C_20201001to20210930_ifrsfullClassesOfShareCapitalAxis_drugWarrantsMember" unitRef="CAD_per_share">9.46</ix:nonFraction></span></span></td>
                                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                                        </tr>
                                                        <tr>
                                                            <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">&#160; Issued - broker</span></span></td>
                                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                            <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><ix:nonFraction id="Fxbrl_20211228213841279_52" name="drug:NumberOfWarrantsIssuedToBroker" decimals="INF" format="ixt:numdotdecimal" contextRef="C_20201001to20210930_ifrsfullClassesOfShareCapitalAxis_drugWarrantsMember" unitRef="Share">132,666</ix:nonFraction></span></span></td>
                                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                            <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><ix:nonFraction id="Fxbrl_20211228213841279_55" name="drug:WeightedAverageExercisePriceOfWarrantsIssuedToBrokerInShareBasedPaymentArrangement" scale="0" decimals="2" format="ixt:numdotdecimal" contextRef="C_20201001to20210930_ifrsfullClassesOfShareCapitalAxis_drugWarrantsMember" unitRef="CAD_per_share">7.57</ix:nonFraction></span></span></td>
                                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                        </tr>
                                                        <tr>
                                                            <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">&#160; Exercised</span></span></td>
                                                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                                            <td style="vertical-align: bottom; text-align: right; width: 15%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">(<ix:nonFraction id="Fxbrl_20211228213841279_62" name="drug:NumberOfWarrantsExercised" decimals="INF" format="ixt:numdotdecimal" contextRef="C_20201001to20210930_ifrsfullClassesOfShareCapitalAxis_drugWarrantsMember" unitRef="Share">1,948,000</ix:nonFraction></span></span></td>
                                                            <td style="vertical-align: bottom; text-align: left; width: 2%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">)</span></span></td>
                                                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                                            <td style="vertical-align: bottom; text-align: right; width: 15%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><ix:nonFraction id="Fxbrl_20211228213841279_65" name="drug:WeightedAverageExercisePriceOfWarrantsExercisedInShareBasedPaymentArrangement" scale="0" decimals="2" format="ixt:numdotdecimal" contextRef="C_20201001to20210930_ifrsfullClassesOfShareCapitalAxis_drugWarrantsMember" unitRef="CAD_per_share">0.05</ix:nonFraction></span></span></td>
                                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                                        </tr>
                                                        <tr>
                                                            <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 2.25pt double #000000; vertical-align: bottom; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>Balance at September 30, 2021</b></span></span></td>
                                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b><ix:nonFraction id="Fxbrl_20211228213841279_72" name="drug:NumberOfWarrantsOutstanding" decimals="INF" format="ixt:numdotdecimal" contextRef="C_20210930_ifrsfullClassesOfShareCapitalAxis_drugWarrantsMember" unitRef="Share">3,974,204</ix:nonFraction></b></span></span></td>
                                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">$</span></span></td>
                                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><ix:nonFraction id="Fxbrl_20211228213841279_75" name="drug:WeightedAverageExercisePriceOfWarrantsOutstandingInShareBasedPaymentArrangement" scale="0" decimals="2" format="ixt:numdotdecimal" contextRef="C_20210930_ifrsfullClassesOfShareCapitalAxis_drugWarrantsMember" unitRef="CAD_per_share">4.35</ix:nonFraction></span></span></td>
                                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                        </tr>
                                                    </table>
                                                </div>
                                            </ix:nonNumeric>
                                        </div>
                                        <p style="text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><i>*On November 2, 2020, the Directors of the Company reduced the exercise price of the outstanding warrants from $<ix:nonFraction id="Fxbrl_20211229223356551" name="drug:WeightedAverageExercisePriceOfWarrantsOutstandingInShareBasedPaymentArrangement" scale="0" decimals="3" format="ixt:numdotdecimal" contextRef="C_20201102" unitRef="CAD_per_share">0.125</ix:nonFraction> to $<ix:nonFraction id="Fxbrl_20211229223410282" name="drug:WeightedAverageExercisePriceOfWarrantsOutstandingInShareBasedPaymentArrangement" scale="0" decimals="2" format="ixt:numdotdecimal" contextRef="C_20200711" unitRef="CAD_per_share">0.05</ix:nonFraction> effective July 11, 2020.</i></span></span></p>
                                    </div>
                                </ix:continuation>
                                <div>
                                    <table style="width: 100%; border-collapse: collapse; font-size: 10pt;" border="0" cellspacing="0" cellpadding="0">
                                        <tr>
                                            <td style="width: 100%; text-align: center; border-top: 1pt solid black;">
                                                <p style="font-size: 10pt; font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>16</b>&#160;| Page</span></span></p>
                                            </td>
                                        </tr>
                                    </table>
                                </div>
                                <hr style="page-break-after: always; text-align: center; height: 5px; width: 100%; background-color: black;" />
                                <div>
                                    <table style="width: 100%; border-collapse: collapse; font-size: 10pt;" border="0" cellspacing="0" cellpadding="0">
                                        <tr>
                                            <td style="width: 100%;">
                                                <p style="margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>Bright Minds Biosciences Inc.</b></span></span></p>
                                                <p style="margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">Notes to the Consolidated Financial Statements</span></span></p>
                                                <p style="margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">For the years ended September 30, 2021 and 2020 and the period from May 31, 2019 (date of incorporation) to September 30, 2019</span></span></p>
                                                <p style="margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">(Expressed in Canadian Dollars)</span></span></p>
                                            </td>
                                        </tr>
                                    </table>
                                </div>
                                <ix:continuation id="F20211229021352093">
                                    <div>
                                        <p style="text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">On March 17, 2021, the Company issued <ix:nonFraction id="Fxbrl_20211229140749550" name="drug:NumberOfWarrantsIssued" decimals="INF" format="ixt:numdotdecimal" contextRef="C_20210301to20210317_ifrsfullCategoriesOfRelatedPartiesAxis_drugUnderwritersMember_ifrsfullClassesOfShareCapitalAxis_drugWarrantsMember" unitRef="Share">132,666</ix:nonFraction> compensation warrants to underwriters. The fair value of these share purchase warrants of $<ix:nonFraction id="Fxbrl_20211229141147506" name="drug:FairValueOfWarrants" decimals="INF" format="ixt:numdotdecimal" contextRef="C_20210301to20210317_ifrsfullCategoriesOfRelatedPartiesAxis_drugUnderwritersMember_ifrsfullClassesOfShareCapitalAxis_drugWarrantsMember" unitRef="Share">521,000</ix:nonFraction> was measured using the Black Scholes option pricing model using the following inputs: i) exercise price: $<ix:nonFraction id="Fxbrl_20211229141220766" name="drug:ExercisePriceWarrantsGranted" scale="0" decimals="2" format="ixt:numdotdecimal" contextRef="C_20210301to20210317_ifrsfullCategoriesOfRelatedPartiesAxis_drugUnderwritersMember_ifrsfullClassesOfShareCapitalAxis_drugWarrantsMember" unitRef="CAD_per_share">7.57</ix:nonFraction>; ii) share price: $<ix:nonFraction id="Fxbrl_20211229141235476" name="drug:WeightedAverageSharePriceWarrantsGranted" scale="0" decimals="2" format="ixt:numdotdecimal" contextRef="C_20210301to20210317_ifrsfullCategoriesOfRelatedPartiesAxis_drugUnderwritersMember_ifrsfullClassesOfShareCapitalAxis_drugWarrantsMember" unitRef="CAD_per_share">6.65</ix:nonFraction>; iii) term: <ix:nonFraction id="Fxbrl_20211229141247923" name="drug:EstimatedLifeOfWarrantsGranted" scale="0" decimals="0" format="ixt:numdotdecimal" contextRef="C_20210301to20210317_ifrsfullCategoriesOfRelatedPartiesAxis_drugUnderwritersMember_ifrsfullClassesOfShareCapitalAxis_drugWarrantsMember" unitRef="Year">3</ix:nonFraction> years; iv) volatility: <ix:nonFraction id="Fxbrl_20211229141258839" name="drug:ExpectedVolatilityWarrantsGranted" scale="-2" decimals="2" format="ixt:numdotdecimal" contextRef="C_20210301to20210317_ifrsfullCategoriesOfRelatedPartiesAxis_drugUnderwritersMember_ifrsfullClassesOfShareCapitalAxis_drugWarrantsMember" unitRef="Percent">100</ix:nonFraction>%; v) discount rate: <ix:nonFraction id="Fxbrl_20211229141308615" name="drug:DiscountRateOfWarrantsGranted" scale="-2" decimals="4" format="ixt:numdotdecimal" contextRef="C_20210301to20210317_ifrsfullCategoriesOfRelatedPartiesAxis_drugUnderwritersMember_ifrsfullClassesOfShareCapitalAxis_drugWarrantsMember" unitRef="Percent">0.35</ix:nonFraction>%; and dividends: nil. The fair value of these broker warrants was recorded as a reduction against share capital.</span></span></p>
                                        <p style="text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">As at September 30, 2021, the warrants have a weighted average remaining life of <ix:nonNumeric id="Fxbrl_20211229141448500" name="drug:WeightedAverageRemainingContractualLifeOfOtherEquityInstruments" format="ixt-sec:duryear" contextRef="C_20201001to20210930_ifrsfullClassesOfShareCapitalAxis_drugWarrantsMember">2.66</ix:nonNumeric> (September 30, 2020 - <ix:nonNumeric id="Fxbrl_20211229141506061" name="drug:WeightedAverageRemainingContractualLifeOfOtherEquityInstruments" format="ixt-sec:duryear" contextRef="C_20191001to20200930_ifrsfullClassesOfShareCapitalAxis_drugWarrantsMember">3.83</ix:nonNumeric>) years.</span></span></p>
                                        <p style="text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">The following table summarizes the warrants issued and outstanding:</span></span></p>
                                        <div style="margin-left: 9pt;">
                                            <ix:nonNumeric id="Fxbrl_20211228202748130" name="drug:DisclosureOfNumberOfIssuedAndOutstandingWarrantsExplanatory" escape="true" contextRef="C_20201001to20210930">
                                                <div>
                                                    <table style="width: 100%; border-collapse: collapse; font-size: 10pt; border-color: #000000;" cellspacing="0" cellpadding="0">
                                                        <tr>
                                                            <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-top: 1.5pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>&#160;</b></span></span></td>
                                                            <td style="vertical-align: bottom; border-top: 1.5pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: center;" colspan="1">&#160;</td>
                                                            <td style="vertical-align: bottom; border-top: 1.5pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;" colspan="7"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>Warrants Outstanding</b></span></span></td>
                                                            <td style="vertical-align: bottom; border-top: 1.5pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: center;" colspan="1">&#160;</td>
                                                        </tr>
                                                        <tr>
                                                            <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>Expiry Date</b></span></span></td>
                                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right;">&#160;</td>
                                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>Number of<br />warrants</b></span></span></td>
                                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;">&#160;</td>
                                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;">&#160;</td>
                                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>&#160;</b><br /><b>Exercise price</b></span></span></td>
                                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;">&#160;</td>
                                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;">&#160;</td>
                                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>Remaining life<br />(Years)</b></span></span></td>
                                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right;">&#160;</td>
                                                        </tr>
                                                        <tr>
                                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">July 30, 2024 (1)</span></span></td>
                                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                            <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><ix:nonFraction id="Fxbrl_20211228215910095_22" name="drug:NumberOfWarrantsOutstanding" decimals="INF" format="ixt:numdotdecimal" contextRef="C_20210930_drugExpiryDateAxis_drugExpiryDateThirtyJulyTwoThousandAndTwentyFourMember_ifrsfullClassesOfShareCapitalAxis_drugWarrantsMember" unitRef="Share">2,131,600</ix:nonFraction></span></span></td>
                                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">$</span></span></td>
                                                            <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><ix:nonFraction id="Fxbrl_20211228215910095_25" name="drug:WeightedAverageExercisePriceOfWarrantsOutstandingInShareBasedPaymentArrangement" scale="0" decimals="2" format="ixt:numdotdecimal" contextRef="C_20210930_drugExpiryDateAxis_drugExpiryDateThirtyJulyTwoThousandAndTwentyFourMember_ifrsfullClassesOfShareCapitalAxis_drugWarrantsMember" unitRef="CAD_per_share">0.05</ix:nonFraction></span></span></td>
                                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                            <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">
                                                                        <ix:nonNumeric id="Fxbrl_20211228215910095_28" name="drug:WeightedAverageRemainingContractualLifeOfWarrants" format="ixt-sec:duryear" contextRef="C_20201001to20210930_drugExpiryDateAxis_drugExpiryDateThirtyJulyTwoThousandAndTwentyFourMember_ifrsfullClassesOfShareCapitalAxis_drugWarrantsMember">2.83</ix:nonNumeric>
                                                                    </span></span></td>
                                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                        </tr>
                                                        <tr>
                                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">March 17, 2024</span></span></td>
                                                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                                            <td style="vertical-align: bottom; text-align: right; width: 12%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><ix:nonFraction id="Fxbrl_20211228215910095_32" name="drug:NumberOfWarrantsOutstanding" decimals="INF" format="ixt:numdotdecimal" contextRef="C_20210930_drugExpiryDateAxis_drugExpiryDateSeventeenMarchTwoThousandAndTwentyFourOneMember_ifrsfullClassesOfShareCapitalAxis_drugWarrantsMember" unitRef="Share">1,709,938</ix:nonFraction></span></span></td>
                                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                                            <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">$</span></span></td>
                                                            <td style="vertical-align: bottom; text-align: right; width: 12%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><ix:nonFraction id="Fxbrl_20211228215910095_35" name="drug:WeightedAverageExercisePriceOfWarrantsOutstandingInShareBasedPaymentArrangement" scale="0" decimals="2" format="ixt:numdotdecimal" contextRef="C_20210930_drugExpiryDateAxis_drugExpiryDateSeventeenMarchTwoThousandAndTwentyFourOneMember_ifrsfullClassesOfShareCapitalAxis_drugWarrantsMember" unitRef="CAD_per_share">9.46</ix:nonFraction></span></span></td>
                                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                                            <td style="vertical-align: bottom; text-align: right; width: 12%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">
                                                                        <ix:nonNumeric id="Fxbrl_20211228215910095_38" name="drug:WeightedAverageRemainingContractualLifeOfWarrants" format="ixt-sec:duryear" contextRef="C_20201001to20210930_drugExpiryDateAxis_drugExpiryDateSeventeenMarchTwoThousandAndTwentyFourOneMember_ifrsfullClassesOfShareCapitalAxis_drugWarrantsMember">2.46</ix:nonNumeric>
                                                                    </span></span></td>
                                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                                        </tr>
                                                        <tr>
                                                            <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 2.25pt double #000000; vertical-align: bottom; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">March 17, 2024</span></span></td>
                                                            <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                            <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><ix:nonFraction id="Fxbrl_20211228215910095_42" name="drug:NumberOfWarrantsOutstanding" decimals="INF" format="ixt:numdotdecimal" contextRef="C_20210930_drugExpiryDateAxis_drugExpiryDateSeventeenMarchTwoThousandAndTwentyFourTwoMember_ifrsfullClassesOfShareCapitalAxis_drugWarrantsMember" unitRef="Share">132,666</ix:nonFraction></span></span></td>
                                                            <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                            <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">$</span></span></td>
                                                            <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><ix:nonFraction id="Fxbrl_20211228215910095_45" name="drug:WeightedAverageExercisePriceOfWarrantsOutstandingInShareBasedPaymentArrangement" scale="0" decimals="2" format="ixt:numdotdecimal" contextRef="C_20210930_drugExpiryDateAxis_drugExpiryDateSeventeenMarchTwoThousandAndTwentyFourTwoMember_ifrsfullClassesOfShareCapitalAxis_drugWarrantsMember" unitRef="CAD_per_share">7.57</ix:nonFraction></span></span></td>
                                                            <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                            <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                            <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">
                                                                        <ix:nonNumeric id="Fxbrl_20211228215910095_48" name="drug:WeightedAverageRemainingContractualLifeOfWarrants" format="ixt-sec:duryear" contextRef="C_20201001to20210930_drugExpiryDateAxis_drugExpiryDateSeventeenMarchTwoThousandAndTwentyFourTwoMember_ifrsfullClassesOfShareCapitalAxis_drugWarrantsMember">2.46</ix:nonNumeric>
                                                                    </span></span></td>
                                                            <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                        </tr>
                                                    </table>
                                                </div>
                                            </ix:nonNumeric>
                                        </div>
                                        <p style="text-align: justify; margin-bottom: 0px;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">(1) On June 15, 2021, the Company entered into warrant exercise agreements with the two warrant holders, whereby the warrant holders authorized the Company to issue only such number of common shares (or other class of voting securities of the Company, if applicable) as will result in the warrant holders and any other person (as defined) holding less than the threshold number of <ix:nonFraction id="Fxbrl_20211229141952369" name="drug:ThresholdPercentageOfWarrants" scale="-2" decimals="4" format="ixt:numdotdecimal" contextRef="C_20210601to20210615_ifrsfullClassesOfShareCapitalAxis_drugWarrantsMember" unitRef="Percent">4.99</ix:nonFraction>% (as defined) of any class of&#160; voting securities of the Company as of the date of exercise or conversion of the warrants.</span></span></p>
                                    </div>
                                </ix:continuation>
                            </div>
                        </div>
                    </div>
                </div>
            </div>
            <div>
                <div>
                    <ix:nonNumeric id="Fxbrl_20211228171822090" name="ifrs-full:DisclosureOfRelatedPartyExplanatory" escape="true" contextRef="C_20201001to20210930">
                        <div>
                            <p style="margin-left: 18pt; text-indent: -18pt; text-align: justify; margin-top: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>7.</b><span style="width: 9pt; text-indent: 0pt; display: inline-block;">&#160;</span><b>RELATED PARTY TRANSACTIONS</b></span></span></p>
                            <p style="text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">Related party transactions were recorded at the exchange value, which is the consideration determined and agreed to by the related parties. The Company's related parties include directors, key management and companies controlled by directors and key management.</span></span></p>
                            <p style="margin-bottom: 0pt; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span style="text-decoration: underline;">Compensation of Key Management Personnel</span></span></span></p>
                            <p style="margin-top: 0pt; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">Key management personnel are those persons that have authority and responsibility for planning, directing and controlling the activities of the Company, directly and indirectly, and by definition include the directors of the Company.</span></span></p>
                            <p style="text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">The following table summarizes expenses related to key management personnel:</span></span></p>
                            <ix:nonNumeric id="Fxbrl_20211228171839263" name="ifrs-full:DisclosureOfInformationAboutKeyManagementPersonnelExplanatory" escape="true" contextRef="C_20201001to20210930">
                                <div>
                                    <table style="width: 100%; border-collapse: collapse; font-size: 10pt; border-color: #000000;" cellspacing="0" cellpadding="0">
                                        <tr>
                                            <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-top: 1.5pt solid #000000; text-align: justify;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 1.5pt solid #000000; text-align: right;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 1.5pt solid #000000; text-align: right; white-space: nowrap;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>Year ended</b></span></span></td>
                                            <td style="vertical-align: bottom; border-top: 1.5pt solid #000000; text-align: right; white-space: nowrap;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 1.5pt solid #000000; text-align: right; white-space: nowrap;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 1.5pt solid #000000; text-align: right; white-space: nowrap;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>Year ended</b></span></span></td>
                                            <td style="vertical-align: bottom; border-top: 1.5pt solid #000000; text-align: right; white-space: nowrap;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 1.5pt solid #000000; text-align: right; white-space: nowrap;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 1.5pt solid #000000; text-align: right; white-space: nowrap;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>Period ended </b></span></span></td>
                                            <td style="vertical-align: bottom; border-top: 1.5pt solid #000000; text-align: right;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; white-space: nowrap;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>September 30, </b><br /><b>2021</b></span></span></td>
                                            <td style="vertical-align: bottom; text-align: right; white-space: nowrap;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; white-space: nowrap;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; white-space: nowrap;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>September 30, </b><br /><b>2020</b></span></span></td>
                                            <td style="vertical-align: bottom; text-align: right; white-space: nowrap;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; white-space: nowrap;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; white-space: nowrap;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>September 30,<br />2019</b></span></span></td>
                                            <td style="vertical-align: bottom; text-align: right;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: justify;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>$</b></span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">$</span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">$</span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">Professional fees</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b><ix:nonFraction id="Fxbrl_20211228171901012_32" name="drug:KeyManagementPersonnelProfessionalFees" scale="0" decimals="0" format="ixt:numdotdecimal" contextRef="C_20201001to20210930" unitRef="CAD">87,074</ix:nonFraction></b></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><ix:nonFraction id="Fxbrl_20211228171901012_35" name="drug:KeyManagementPersonnelProfessionalFees" scale="0" decimals="0" format="ixt:numdotdecimal" contextRef="C_20191001to20200930" unitRef="CAD">22,575</ix:nonFraction></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><ix:nonFraction id="Fxbrl_20211228171901012_38" name="drug:KeyManagementPersonnelProfessionalFees" scale="0" decimals="0" format="ixt:zerodash" contextRef="C_20190601to20190930" unitRef="CAD">-</ix:nonFraction></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">Research and development</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 12%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b><ix:nonFraction id="Fxbrl_20211228171901012_42" name="drug:KeyManagementPersonnelResearchAndDevelopment" scale="0" decimals="0" format="ixt:numdotdecimal" contextRef="C_20201001to20210930" unitRef="CAD">772,596</ix:nonFraction></b></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 12%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><ix:nonFraction id="Fxbrl_20211228171901012_45" name="drug:KeyManagementPersonnelResearchAndDevelopment" scale="0" decimals="0" format="ixt:numdotdecimal" contextRef="C_20191001to20200930" unitRef="CAD">26,777</ix:nonFraction></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 12%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><ix:nonFraction id="Fxbrl_20211228171901012_48" name="drug:KeyManagementPersonnelResearchAndDevelopment" scale="0" decimals="0" format="ixt:zerodash" contextRef="C_20190601to20190930" unitRef="CAD">-</ix:nonFraction></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">Share-based compensation included in directors' compensation</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b><ix:nonFraction id="Fxbrl_20211228171901012_52" name="ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment" scale="0" decimals="0" format="ixt:numdotdecimal" contextRef="C_20201001to20210930" unitRef="CAD">136,612</ix:nonFraction></b></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><ix:nonFraction id="Fxbrl_20211228171901012_55" name="ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment" scale="0" decimals="0" format="ixt:zerodash" contextRef="C_20191001to20200930" unitRef="CAD">-</ix:nonFraction></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><ix:nonFraction id="Fxbrl_20211228171901012_58" name="ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment" scale="0" decimals="0" format="ixt:zerodash" contextRef="C_20190601to20190930" unitRef="CAD">-</ix:nonFraction></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">Share-based compensation included in professional fees</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 12%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b><ix:nonFraction id="Fxbrl_20211228171901012_62" name="drug:KeyManagementPersonnelCompensationShareBasedPaymentIncludedInProfessionalFees" scale="0" decimals="0" format="ixt:numdotdecimal" contextRef="C_20201001to20210930" unitRef="CAD">23,126</ix:nonFraction></b></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 12%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><ix:nonFraction id="Fxbrl_20211228171901012_65" name="drug:KeyManagementPersonnelCompensationShareBasedPaymentIncludedInProfessionalFees" scale="0" decimals="0" format="ixt:zerodash" contextRef="C_20191001to20200930" unitRef="CAD">-</ix:nonFraction></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 12%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><ix:nonFraction id="Fxbrl_20211228171901012_68" name="drug:KeyManagementPersonnelCompensationShareBasedPaymentIncludedInProfessionalFees" scale="0" decimals="0" format="ixt:zerodash" contextRef="C_20190601to20190930" unitRef="CAD">-</ix:nonFraction></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: justify; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">Share-based compensation included in research and development</span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b><ix:nonFraction id="Fxbrl_20211228171901012_72" name="drug:KeyManagementPersonnelCompensationShareBasedPaymentIncludedInResearchAndDevelopment" scale="0" decimals="0" format="ixt:numdotdecimal" contextRef="C_20201001to20210930" unitRef="CAD">236,652</ix:nonFraction></b></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><ix:nonFraction id="Fxbrl_20211228171901012_75" name="drug:KeyManagementPersonnelCompensationShareBasedPaymentIncludedInResearchAndDevelopment" scale="0" decimals="0" format="ixt:numdotdecimal" contextRef="C_20191001to20200930" unitRef="CAD">161,300</ix:nonFraction></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><ix:nonFraction id="Fxbrl_20211228171901012_78" name="drug:KeyManagementPersonnelCompensationShareBasedPaymentIncludedInResearchAndDevelopment" scale="0" decimals="0" format="ixt:zerodash" contextRef="C_20190601to20190930" unitRef="CAD">-</ix:nonFraction></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>&#160;</b></span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 12%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b><ix:nonFraction id="Fxbrl_20211228171901012_82" name="ifrs-full:KeyManagementPersonnelCompensation" scale="0" decimals="0" format="ixt:numdotdecimal" contextRef="C_20201001to20210930" unitRef="CAD">1,256,060</ix:nonFraction></b></span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 12%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><ix:nonFraction id="Fxbrl_20211228171901012_85" name="ifrs-full:KeyManagementPersonnelCompensation" scale="0" decimals="0" format="ixt:numdotdecimal" contextRef="C_20191001to20200930" unitRef="CAD">210,652</ix:nonFraction></span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 12%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><ix:nonFraction id="Fxbrl_20211228171901012_88" name="ifrs-full:KeyManagementPersonnelCompensation" scale="0" decimals="0" format="ixt:zerodash" contextRef="C_20190601to20190930" unitRef="CAD">-</ix:nonFraction></span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%;">&#160;</td>
                                        </tr>
                                    </table>
                                </div>
                            </ix:nonNumeric>
                            <p style="text-align: justify; margin-top: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">See Note 8 for related party contractual obligations.</span></span></p>
                        </div>
                    </ix:nonNumeric>
                </div>
            </div>
            <div>
                <div>
                    <ix:nonNumeric id="Fxbrl_20211228212847030" name="ifrs-full:DisclosureOfCommitmentsExplanatory" escape="true" contextRef="C_20201001to20210930" continuedAt="F20211228212902072">
                        <div>
                            <p style="margin-left: 18pt; text-indent: -18pt; text-align: justify; margin-top: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>8.</b><span style="display: inline-block; width: 9pt;">&#160;</span><b>CONTRACTUAL OBLIGATIONS</b></span></span></p>
                            <p style="margin-bottom: 0pt; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span style="text-decoration: underline;">Option agreement</span></span></span></p>
                            <p style="margin-top: 0pt; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">On May 26, 2020, the Company entered into an option agreement (the "OA") with the University of Illinois at Chicago (the "UIC"), whereby the Company obtained the right to evaluate certain of the UIC's technology (as defined) for the purpose of making a decision as to whether to exclusively license the rights to the technology. Pursuant to the OA, the Company was granted an exclusive option to evaluate the technology and obtain an exclusive license to the patents and patent applications (as listed) and a non-exclusive right to use the technology for non-commercial research purposes. The Company paid US$<ix:nonFraction id="Fxbrl_20211228213108475" name="drug:NonRefundableOptionFeesPaid" scale="0" decimals="0" format="ixt:numdotdecimal" contextRef="C_20200501to20200526_drugAgreementAxis_drugOptionAgreementMember" unitRef="USD">15,000</ix:nonFraction> ($<ix:nonFraction id="Fxbrl_20211228213120424" name="drug:NonRefundableOptionFeesPaid" scale="0" decimals="0" format="ixt:numdotdecimal" contextRef="C_20200501to20200526_drugAgreementAxis_drugOptionAgreementMember" unitRef="CAD">20,313</ix:nonFraction>) in non-refundable option fees prior to exercising its option.&#160;</span></span></p>
                        </div>
                    </ix:nonNumeric>
                    <div>
                        <table style="width: 100%; border-collapse: collapse; font-size: 10pt; margin-top: 10pt;" border="0" cellspacing="0" cellpadding="0">
                            <tr>
                                <td style="width: 100%; text-align: center; border-top: 1pt solid black;">
                                    <p style="font-size: 10pt; font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>17</b>&#160;| Page</span></span></p>
                                </td>
                            </tr>
                        </table>
                    </div>
                    <hr style="page-break-after: always; text-align: center; height: 5px; width: 100%; background-color: black;" />
                    <div>
                        <table style="width: 100%; border-collapse: collapse; font-size: 10pt;" border="0" cellspacing="0" cellpadding="0">
                            <tr>
                                <td style="width: 100%;">
                                    <p style="margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>Bright Minds Biosciences Inc.</b></span></span></p>
                                    <p style="margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">Notes to the Consolidated Financial Statements</span></span></p>
                                    <p style="margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">For the years ended September 30, 2021 and 2020 and the period from May 31, 2019 (date of incorporation) to September 30, 2019</span></span></p>
                                    <p style="margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">(Expressed in Canadian Dollars)</span></span></p>
                                </td>
                            </tr>
                        </table>
                    </div>
                    <ix:continuation id="F20211228212902072" continuedAt="F20211228212926852">
                        <div>
                            <p style="margin-bottom: 0pt; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span style="text-decoration: underline;">License agreement</span></span></span></p>
                            <p style="margin-top: 0pt; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">On April 23, 2021, the Company entered into an exclusive license agreement with equity (the "LA") with the Board of Trustees of the UIC (the "University") whereby the University granted to the Company, in all fields of use and worldwide, an exclusive, non-transferable license with the right to sublicense under the University's rights in and to the Patent Rights (as defined) and a non-exclusive, non-transferable license with the right to sublicense under the University's rights in and to the Technical Information (as defined) to make, have made, construct, have constructed, use, import, sell, and offer for sale royalty-bearing Product (as defined). As consideration for the grant of license, the Company will pay the following amounts (in US$) to the University:</span></span></p>
                            <table style="width: 100%; font-size: 10pt; font-family: Times New Roman, Times, serif;" border="0" cellspacing="0" cellpadding="0">
                                <tr>
                                    <td style="width: 10px;">&#160;</td>
                                    <td style="text-align: center; vertical-align: top; width: 3%;">&#8226;</td>
                                    <td>
                                        <p style="font-size: 10pt; font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;"><i>Signing Fee</i> - a signing fee of $<ix:nonFraction id="Fxbrl_20211228213348198" name="drug:SigningFee" scale="0" decimals="0" format="ixt:numdotdecimal" contextRef="C_20210401to20210423_drugAgreementAxis_drugLicenseAgreementMember" unitRef="USD">100,000</ix:nonFraction> less $<ix:nonFraction id="Fxbrl_20211228213606762" name="drug:OptionFeesPaid" scale="0" decimals="0" format="ixt:numdotdecimal" contextRef="C_20210401to20210423_drugAgreementAxis_drugLicenseAgreementMember" unitRef="USD">15,000</ix:nonFraction> in option fees was paid (CDN$<ix:nonFraction id="Fxbrl_20211228213625115" name="drug:SigningFeeNetOfOptionFeesPaid" scale="0" decimals="0" format="ixt:numdotdecimal" contextRef="C_20210401to20210423_drugAgreementAxis_drugLicenseAgreementMember" unitRef="CAD">105,502</ix:nonFraction>) and <ix:nonFraction id="Fxbrl_20211228213938887" name="drug:SigningFeeSharesIssued" decimals="INF" format="ixt:numdotdecimal" contextRef="C_20210401to20210423_drugAgreementAxis_drugLicenseAgreementMember" unitRef="Share">63,000</ix:nonFraction> common shares of the Company were issued to the University (see Note 6);</p>
                                    </td>
                                </tr>
                                <tr>
                                    <td style="width: 10px;">&#160;</td>
                                    <td style="text-align: center; vertical-align: top; width: 3%;">&#160;</td>
                                    <td>&#160;</td>
                                </tr>
                                <tr>
                                    <td style="width: 10px;">&#160;</td>
                                    <td style="text-align: center; vertical-align: top; width: 3%;">&#8226;</td>
                                    <td>
                                        <p style="font-size: 10pt; font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;"><i>Net Sales</i> - royalties on Net Sales (as defined) ranging from <ix:nonFraction id="Fxbrl_20211228214027918" name="drug:PercentageOfRoyaltiesOnNetSalesUnder1Billion" scale="-2" decimals="2" format="ixt:numdotdecimal" contextRef="C_20210401to20210423_drugAgreementAxis_drugLicenseAgreementMember" unitRef="Percent">3</ix:nonFraction>% (under $1 billion) to <ix:nonFraction id="Fxbrl_20211228221237258" name="drug:PercentageOfRoyaltiesOnNetSalesOver2Billion" scale="-2" decimals="3" format="ixt:numdotdecimal" contextRef="C_20210401to20210423_drugAgreementAxis_drugLicenseAgreementMember" unitRef="Percent">4.5</ix:nonFraction>% (over $2 billion), with such royalty payments being credited toward the annual minimum for the license year in which the royalty payment accrues;</p>
                                    </td>
                                </tr>
                                <tr>
                                    <td style="width: 10px;">&#160;</td>
                                    <td style="text-align: center; vertical-align: top; width: 3%;">&#160;</td>
                                    <td>&#160;</td>
                                </tr>
                                <tr>
                                    <td style="width: 10px;">&#160;</td>
                                    <td style="text-align: center; vertical-align: top; width: 3%;">&#8226;</td>
                                    <td>
                                        <p style="font-size: 10pt; font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;"><i>Sublicensee Revenues</i> - royalties (as for net sales above) on Sublicensee Revenue (as defined), with such <ix:nonNumeric id="Fxbrl_20211228221219591" name="drug:DescriptionOfSublicenseeRevenueOfRoyaltyPaymentAccrues" contextRef="C_20210401to20210423_drugAgreementAxis_drugLicenseAgreementMember">royalty payments being credited toward the annual minimum for the license year in which the royalty payment accrues and 12% on all non-royalty revenue until the Company has raised $7.5 million and then 10% thereafter</ix:nonNumeric>;</p>
                                    </td>
                                </tr>
                                <tr>
                                    <td style="width: 10px;">&#160;</td>
                                    <td style="text-align: center; vertical-align: top; width: 3%;">&#160;</td>
                                    <td>&#160;</td>
                                </tr>
                                <tr>
                                    <td style="width: 10px;">&#160;</td>
                                    <td style="text-align: center; vertical-align: top; width: 3%;">&#8226;</td>
                                    <td>
                                        <p style="font-size: 10pt; font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;"><i>Annual Minimums</i> - if the total royalties paid to the University for any license year are less than the following annual minimums, the Company must pay the University the amount equal to the shortfall:</p>
                                    </td>
                                </tr>
                                <tr>
                                    <td style="width: 10px;">&#160;</td>
                                    <td style="text-align: center; width: 3%;">&#160;</td>
                                    <td>&#160;</td>
                                </tr>
                            </table>
                            <table style="width: 100%; font-size: 10pt; font-family: Times New Roman, Times, serif;" border="0" cellspacing="0" cellpadding="0">
                                <tr>
                                    <td style="width: 3%;">&#160;</td>
                                    <td style="width: 3%;">&#160;</td>
                                    <td style="width: 3%;"><span style="font-size: 8pt;">o</span></td>
                                    <td>
                                        <p style="font-size: 10pt; font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;">Years 1 and 2 - $<span style="-sec-ix-hidden: Fxbrl_20211229013458419;">nil</span>;</p>
                                    </td>
                                </tr>
                                <tr>
                                    <td style="width: 3%;">&#160;</td>
                                    <td style="width: 3%;">&#160;</td>
                                    <td style="width: 3%;">
                                        <p style="font-size: 10pt; font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-size: 8pt;">o</span></p>
                                    </td>
                                    <td>
                                        <p style="font-size: 10pt; font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;">Year 3 - $<ix:nonFraction id="Fxbrl_20211229013617200" name="drug:TotalAnnualMinimumRoyaltiesYear3" scale="0" decimals="0" format="ixt:numdotdecimal" contextRef="C_20210401to20210423_drugAgreementAxis_drugLicenseAgreementMember" unitRef="CAD">5,000</ix:nonFraction>;</p>
                                    </td>
                                </tr>
                                <tr>
                                    <td style="width: 3%;">&#160;</td>
                                    <td style="width: 3%;">&#160;</td>
                                    <td style="width: 3%;"><span style="font-size: 8pt;">o</span></td>
                                    <td>
                                        <p style="font-size: 10pt; font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;">Year 4 - $<ix:nonFraction id="Fxbrl_20211229013643424" name="drug:TotalAnnualMinimumRoyaltiesYear4" scale="0" decimals="0" format="ixt:numdotdecimal" contextRef="C_20210401to20210423_drugAgreementAxis_drugLicenseAgreementMember" unitRef="CAD">15,000</ix:nonFraction>;</p>
                                    </td>
                                </tr>
                                <tr>
                                    <td style="width: 3%;">&#160;</td>
                                    <td style="width: 3%;">&#160;</td>
                                    <td style="width: 3%;">
                                        <p style="font-size: 10pt; font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-size: 8pt;">o</span></p>
                                    </td>
                                    <td>
                                        <p style="font-size: 10pt; font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;">Year 5 - $<ix:nonFraction id="Fxbrl_20211229013651135" name="drug:TotalAnnualMinimumRoyaltiesYear5" scale="0" decimals="0" format="ixt:numdotdecimal" contextRef="C_20210401to20210423_drugAgreementAxis_drugLicenseAgreementMember" unitRef="CAD">35,000</ix:nonFraction>;</p>
                                    </td>
                                </tr>
                                <tr>
                                    <td style="width: 3%;">&#160;</td>
                                    <td style="width: 3%;">&#160;</td>
                                    <td style="width: 3%;"><span style="font-size: 8pt;">o</span></td>
                                    <td>
                                        <p style="font-size: 10pt; font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;">Year 6 and thereafter - $<ix:nonFraction id="Fxbrl_20211229013657727" name="drug:TotalAnnualMinimumRoyaltiesYear6AndThereafter" scale="0" decimals="0" format="ixt:numdotdecimal" contextRef="C_20210401to20210423_drugAgreementAxis_drugLicenseAgreementMember" unitRef="CAD">50,000</ix:nonFraction>; and</p>
                                    </td>
                                </tr>
                                <tr>
                                    <td style="width: 3%;">&#160;</td>
                                    <td style="width: 3%;">&#160;</td>
                                    <td style="width: 3%;">
                                        <p style="font-size: 10pt; font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-size: 8pt;">o</span></p>
                                    </td>
                                    <td>
                                        <p style="font-size: 10pt; font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;">After first commercial sale - $<ix:nonFraction id="Fxbrl_20211229013734288" name="drug:TotalAnnualMinimumRoyaltiesAfterFirstCommercialSale" scale="0" decimals="0" format="ixt:numdotdecimal" contextRef="C_20210401to20210423_drugAgreementAxis_drugLicenseAgreementMember" unitRef="CAD">250,000</ix:nonFraction> or net sales royalty, whichever is higher.</p>
                                    </td>
                                </tr>
                                <tr>
                                    <td style="width: 3%;">&#160;</td>
                                    <td style="width: 3%;">&#160;</td>
                                    <td style="width: 3%;">&#160;</td>
                                    <td>&#160;</td>
                                </tr>
                            </table>
                            <table style="width: 100%; font-size: 10pt; font-family: Times New Roman, Times, serif;" border="0" cellspacing="0" cellpadding="0">
                                <tr>
                                    <td style="width: 10px;">&#160;</td>
                                    <td style="text-align: center; vertical-align: top; width: 3%;">&#8226;</td>
                                    <td>
                                        <p style="font-size: 10pt; font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;"><i>Milestone Payments</i> - milestone payments after the occurrence of the following milestone events:</p>
                                    </td>
                                </tr>
                                <tr>
                                    <td style="width: 10px;">&#160;</td>
                                    <td style="width: 3%;">&#160;</td>
                                    <td>&#160;</td>
                                </tr>
                                <tr>
                                    <td style="width: 10px;">&#160;</td>
                                    <td style="width: 3%;">&#160;</td>
                                    <td>
                                        <p style="font-size: 10pt; font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;">Prior to any sublicensing agreements, joint ventures or change of control:</p>
                                    </td>
                                </tr>
                            </table>
                            <table style="width: 100%; font-size: 10pt; font-family: Times New Roman, Times, serif;" border="0" cellspacing="0" cellpadding="0">
                                <tr>
                                    <td style="width: 3%;">&#160;</td>
                                    <td style="width: 3%;">&#160;</td>
                                    <td style="width: 3%;">&#160;</td>
                                    <td>&#160;</td>
                                </tr>
                                <tr>
                                    <td style="width: 3%;">&#160;</td>
                                    <td style="width: 3%;">&#160;</td>
                                    <td style="width: 3%;">
                                        <p style="font-size: 10pt; font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-size: 8pt;">o</span></p>
                                    </td>
                                    <td>
                                        <p style="font-size: 10pt; font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;">$<ix:nonFraction id="Fxbrl_20211229013833832" name="drug:MilestonePaymentsUponDosingFirstPatientInPhaseITrial" scale="0" decimals="0" format="ixt:numdotdecimal" contextRef="C_20210401to20210423_drugAgreementAxis_drugPriorToSublicensingAgreementsMember" unitRef="CAD">10,000</ix:nonFraction> upon dosing the first patient in a Phase I trial;</p>
                                    </td>
                                </tr>
                                <tr>
                                    <td style="width: 3%;">&#160;</td>
                                    <td style="width: 3%;">&#160;</td>
                                    <td style="width: 3%;">
                                        <p style="font-size: 10pt; font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-size: 8pt;">o</span></p>
                                    </td>
                                    <td>
                                        <p style="font-size: 10pt; font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;">$<ix:nonFraction id="Fxbrl_20211229013857264" name="drug:MilestonePaymentsUponDosingFirstPatientInFirstPhaseIiTrial" scale="0" decimals="0" format="ixt:numdotdecimal" contextRef="C_20210401to20210423_drugAgreementAxis_drugPriorToSublicensingAgreementsMember" unitRef="CAD">50,000</ix:nonFraction> upon dosing the first patient in the first Phase II trial;</p>
                                    </td>
                                </tr>
                                <tr>
                                    <td style="width: 3%;">&#160;</td>
                                    <td style="width: 3%;">&#160;</td>
                                    <td style="width: 3%;">
                                        <p style="font-size: 10pt; font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-size: 8pt;">o</span></p>
                                    </td>
                                    <td>
                                        <p style="font-size: 10pt; font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;">$<ix:nonFraction id="Fxbrl_20211229013904320" name="drug:MilestonePaymentsUponDosingFirstPatientInFirstPhaseIiiTrial" scale="0" decimals="0" format="ixt:numdotdecimal" contextRef="C_20210401to20210423_drugAgreementAxis_drugPriorToSublicensingAgreementsMember" unitRef="CAD">250,000</ix:nonFraction> upon dosing the first patient in a Phase III trial in the first clinical indication; and</p>
                                    </td>
                                </tr>
                                <tr>
                                    <td style="width: 3%;">&#160;</td>
                                    <td style="width: 3%;">&#160;</td>
                                    <td style="width: 3%;">
                                        <p style="font-size: 10pt; font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-size: 8pt;">o</span></p>
                                    </td>
                                    <td>
                                        <p style="font-size: 10pt; font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;">$<ix:nonFraction id="Fxbrl_20211229013907766" name="drug:MilestonePaymentsUponFirstCommercialSaleOfClinical" scale="6" decimals="-6" format="ixt:numdotdecimal" contextRef="C_20210401to20210423_drugAgreementAxis_drugPriorToSublicensingAgreementsMember" unitRef="CAD">2</ix:nonFraction> million upon the first commercial sale of each clinical indication.</p>
                                    </td>
                                </tr>
                            </table>
                            <table style="width: 100%; font-size: 10pt; font-family: Times New Roman, Times, serif; margin-top: 5px;">
                                <tr>
                                    <td style="width: 10px;">&#160;</td>
                                    <td style="width: 3%;">&#160;</td>
                                    <td>
                                        <p style="font-size: 10pt; font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;">&#160;After any sublicensing agreements, joint ventures or change of control:</p>
                                    </td>
                                </tr>
                            </table>
                            <table style="width: 100%; font-size: 10pt; font-family: Times New Roman, Times, serif;" border="0" cellspacing="0" cellpadding="0">
                                <tr>
                                    <td style="width: 3%;">&#160;</td>
                                    <td style="width: 3%;">&#160;</td>
                                    <td style="width: 3%;">&#160;</td>
                                    <td>&#160;</td>
                                </tr>
                                <tr>
                                    <td style="width: 3%;">&#160;</td>
                                    <td style="width: 3%;">&#160;</td>
                                    <td style="width: 3%;">
                                        <p style="font-size: 10pt; font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-size: 8pt;">o</span></p>
                                    </td>
                                    <td>
                                        <p style="font-size: 10pt; font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;">As above;</p>
                                    </td>
                                </tr>
                                <tr>
                                    <td style="width: 3%;">&#160;</td>
                                    <td style="width: 3%;">&#160;</td>
                                    <td style="width: 3%;">
                                        <p style="font-size: 10pt; font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-size: 8pt;">o</span></p>
                                    </td>
                                    <td>
                                        <p style="font-size: 10pt; font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;">$<ix:nonFraction id="Fxbrl_20211229014106424" name="drug:MilestonePaymentsUponDosingFirstPatientInFirstPhaseIiTrial" scale="0" decimals="0" format="ixt:numdotdecimal" contextRef="C_20210401to20210423_drugAgreementAxis_drugAfterSublicensingAgreementsMember" unitRef="CAD">250,000</ix:nonFraction> upon dosing the first patient in each Phase II trial;</p>
                                    </td>
                                </tr>
                                <tr>
                                    <td style="width: 3%;">&#160;</td>
                                    <td style="width: 3%;">&#160;</td>
                                    <td style="width: 3%;">
                                        <p style="font-size: 10pt; font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-size: 8pt;">o</span></p>
                                    </td>
                                    <td>
                                        <p style="font-size: 10pt; font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;">$<ix:nonFraction id="Fxbrl_20211229014056661" name="drug:MilestonePaymentsUponDosingFirstPatientInFirstPhaseIiiTrial" scale="0" decimals="0" format="ixt:numdotdecimal" contextRef="C_20210401to20210423_drugAgreementAxis_drugAfterSublicensingAgreementsMember" unitRef="CAD">500,000</ix:nonFraction> upon dosing the first patient in each Phase III trial; and</p>
                                    </td>
                                </tr>
                                <tr>
                                    <td style="width: 3%;">&#160;</td>
                                    <td style="width: 3%;">&#160;</td>
                                    <td style="width: 3%;">
                                        <p style="font-size: 10pt; font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-size: 8pt;">o</span></p>
                                    </td>
                                    <td>
                                        <p style="font-size: 10pt; font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;">$<ix:nonFraction id="Fxbrl_20211229014049344" name="drug:MilestonePaymentsUponFirstCommercialSaleOfClinical" scale="6" decimals="-6" format="ixt:numdotdecimal" contextRef="C_20210401to20210423_drugAgreementAxis_drugAfterSublicensingAgreementsMember" unitRef="CAD">2</ix:nonFraction> million upon the first commercial sale of each clinical indication.</p>
                                    </td>
                                </tr>
                            </table>
                            <p style="text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">Unless otherwise agreed to in writing by the University, the Company will reimburse the University for all documented costs and expenses in connection with the Patent Rights, including the preparation, filing, prosecution, maintenance and defense thereof. From time to time, the anticipated costs and expenses may be significant and, upon request, the Company will pay the estimated costs and expenses in advance of such costs and expenses being incurred by the University.</span></span></p>
                        </div>
                    </ix:continuation>
                    <div>
                        <table style="width: 100%; border-collapse: collapse; font-size: 10pt;" border="0" cellspacing="0" cellpadding="0">
                            <tr>
                                <td style="width: 100%; text-align: center; border-top: 1pt solid black;">
                                    <p style="font-size: 10pt; font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>18</b>&#160;| Page</span></span></p>
                                </td>
                            </tr>
                        </table>
                    </div>
                    <hr style="page-break-after: always; text-align: center; height: 5px; width: 100%; background-color: black;" />
                    <div>
                        <table style="width: 100%; border-collapse: collapse; font-size: 10pt;" border="0" cellspacing="0" cellpadding="0">
                            <tr>
                                <td style="width: 100%;">
                                    <p style="margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>Bright Minds Biosciences Inc.</b></span></span></p>
                                    <p style="margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">Notes to the Consolidated Financial Statements</span></span></p>
                                    <p style="margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">For the years ended September 30, 2021 and 2020 and the period from May 31, 2019 (date of incorporation) to September 30, 2019</span></span></p>
                                    <p style="margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">(Expressed in Canadian Dollars)</span></span></p>
                                </td>
                            </tr>
                        </table>
                    </div>
                    <ix:continuation id="F20211228212926852" continuedAt="F20211228212947425">
                        <div>
                            <p style="text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">The term of the LA ends on the later of the last to expire of the Patent Rights, expiration of regulatory exclusivity for Product or when the Company provides notice that use of Technical Information has ceased. The University has the right to terminate the LA if the Company fails to make any required payments or is in breach of any provision of the LA.&#160; The Company may terminate the LA at any time upon providing at least 90 days written notice to the University.</span></span></p>
                            <p style="margin-bottom: 0pt; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span style="text-decoration: underline;">Related party contracts</span></span></span></p>
                            <p style="margin-top: 0pt; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">On June 5, 2020, the Company entered into an independent consultant agreement (the "ICA") whereby the consultant, a private corporation incorporated in the State of California, USA, was engaged and the consultant's representative will serve as the Company's Chief Medical Officer, with the services being provided in California. As compensation for performing these services, the consultant or the consultant's representative will participate in the Company's equity incentive plans and will be eligible for cash payments in respect of fees at such time as the Company begins to compensate other C-level personnel in cash and in similar proportion to total compensation (the "fees"). The non-cash portion of the consultant's fees for the first year of the term was in the form of a grant of <ix:nonFraction id="Fxbrl_20211229014204254" name="ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" scale="0" decimals="0" format="ixt:numdotdecimal" contextRef="C_20200601to20200605_drugAgreementAxis_drugIndependentConsultantAgreementMember" unitRef="Shares">150,000</ix:nonFraction> vested stock options and <ix:nonFraction id="Fxbrl_20211229014505682" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" scale="0" decimals="0" format="ixt:numdotdecimal" contextRef="C_20200601to20200605_drugAgreementAxis_drugIndependentConsultantAgreementMember" unitRef="Shares">150,000</ix:nonFraction> RSUs (see Note 6). The services will continue for an initial term of one year unless sooner terminated. The ICA can be terminated by either party giving the other 30 days written notice or by mutual written agreement. At the end of the initial term, the ICA will automatically be extended for additional one-year period(s) unless either party gives the other 30 days written notice. In March 2021, the Board of Directors authorized a monthly fee of US$<ix:nonFraction id="Fxbrl_20211229014932071" name="drug:MonthlyFeeAuthorizedByBoardOfDirectors" scale="0" decimals="0" format="ixt:numdotdecimal" contextRef="C_20210301to20210331_drugAgreementAxis_drugIndependentConsultantAgreementMember" unitRef="USD">15,000</ix:nonFraction> and was further amended to US$<ix:nonFraction id="Fxbrl_20211229015041976" name="drug:MonthlyFeeAuthorizedByBoardOfDirectors" scale="0" decimals="0" format="ixt:numdotdecimal" contextRef="C_20210801to20210831_drugAgreementAxis_drugIndependentConsultantAgreementMember" unitRef="USD">25,000</ix:nonFraction> in August 2021.</span></span></p>
                            <p style="text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">On October 29, 2020, the Company entered into an independent contractor agreement (the "ICA") whereby the contractor was engaged to serve as the Company's Chief Science Officer on an as-needed basis. The contractor will be compensated for these services as determined by the Board of Directors of the Company. The services will continue for an initial term of one year unless sooner terminated. The ICA can be terminated by the Company providing five working days written notice, the contractor providing three months' written notice or by mutual written agreement. At the end of the initial term, the ICA will automatically be extended for additional one-year period(s) unless the Company provides the contractor with 30 days written notice. In March 2021, the Board of Directors authorized a monthly fee of US$<ix:nonFraction id="Fxbrl_20211229163355300" name="drug:MonthlyFeeAuthorizedByBoardOfDirectors" scale="0" decimals="0" format="ixt:numdotdecimal" contextRef="C_20210301to20210331_drugAgreementAxis_drugIndependentContractorAgreementToServeAsChiefScienceOfficerMember" unitRef="USD">15,000</ix:nonFraction> and was further amended to US$<ix:nonFraction id="Fxbrl_20211229163428205" name="drug:MonthlyFeeAuthorizedByBoardOfDirectors" scale="0" decimals="0" format="ixt:numdotdecimal" contextRef="C_20210801to20210831_drugAgreementAxis_drugIndependentContractorAgreementToServeAsChiefScienceOfficerMember" unitRef="USD">25,000</ix:nonFraction> in August 2021.</span></span></p>
                            <p style="margin-bottom: 0pt; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span style="text-decoration: underline;">Scientific advisory board agreements</span></span></span></p>
                            <p style="margin-top: 0pt; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">On June 1, 2020, July 14, 2020 and April 12, 2021, the Company entered into scientific advisory board agreements (the "SABAs") whereby the advisors were retained to serve as members of the Company's scientific advisory board and as consultants to the Company and senior management in the areas of scientific, technical and business advice. As compensation for performing these services, the Company will pay the advisors hourly rates of $<ix:nonFraction id="Fxbrl_20211229015327669" name="drug:AdvisorHourlyRate" scale="0" decimals="0" format="ixt:numdotdecimal" contextRef="C_20200601to20210412_drugAgreementAxis_drugScientificAdvisoryBoardAgreementsMember_ifrsfullRangeAxis_ifrsfullBottomOfRangeMember" unitRef="USD">150</ix:nonFraction> and $<ix:nonFraction id="Fxbrl_20211229015544000" name="drug:AdvisorHourlyRate" scale="0" decimals="0" format="ixt:numdotdecimal" contextRef="C_20200601to20210412_drugAgreementAxis_drugScientificAdvisoryBoardAgreementsMember_ifrsfullRangeAxis_ifrsfullTopOfRangeMember" unitRef="USD">160</ix:nonFraction> per hour. The Company also granted <ix:nonFraction id="Fxbrl_20211229015347160" name="ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" scale="0" decimals="0" format="ixt:numdotdecimal" contextRef="C_20201101to20201117_drugAgreementAxis_drugScientificAdvisoryBoardAgreementsMember" unitRef="Shares">130,000</ix:nonFraction> share purchase options to the advisors as part of the Company's November 17, 2020 and April 28, 2021 grant of options of which <ix:nonFraction id="Fxbrl_20211229015752960" name="ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" scale="0" decimals="0" format="ixt:numdotdecimal" contextRef="C_20210101to20210131_drugAgreementAxis_drugScientificAdvisoryBoardAgreementsMember" unitRef="Shares">20,000</ix:nonFraction> options were cancelled on January 21, 2021 (see Note 6). The advisors have the same hour requirements and restrictions as noted below. The services will continue for initial terms of one year unless sooner terminated. At the end of the initial terms, the SABAs will automatically be extended for an additional one-year period(s) unless either party gives the other 30 days written notice.&#160;</span></span></p>
                            <p style="margin-bottom: 0pt; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span style="text-decoration: underline;">Consulting agreements</span></span></span></p>
                            <p style="margin-top: 0pt; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">The Company has entered into numerous consulting agreements (the "CAs") whereby the consultants were retained to serve as advisors to the Company and senior management in the areas of public relations and content creation and scientific, technical and business advice. As compensation for performing these services, the Company will pay the advisors hourly rates between US$<ix:nonFraction id="Fxbrl_20211229015915101" name="drug:AdvisorHourlyRate" scale="0" decimals="0" format="ixt:numdotdecimal" contextRef="C_20201001to20210930_drugAgreementAxis_drugConsultingAgreementsMember_ifrsfullRangeAxis_ifrsfullBottomOfRangeMember" unitRef="USD">30</ix:nonFraction> to US$<ix:nonFraction id="Fxbrl_20211229015922917" name="drug:AdvisorHourlyRate" scale="0" decimals="0" format="ixt:numdotdecimal" contextRef="C_20201001to20210930_drugAgreementAxis_drugConsultingAgreementsMember_ifrsfullRangeAxis_ifrsfullTopOfRangeMember" unitRef="USD">600</ix:nonFraction>. The Company also granted <ix:nonFraction id="Fxbrl_20211229015907037" name="ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" scale="0" decimals="0" format="ixt:numdotdecimal" contextRef="C_20201118to20210428_drugAgreementAxis_drugConsultingAgreementsMember" unitRef="Shares">302,000</ix:nonFraction> share purchase options to six advisors as part of the Company's November 17, 2020 and April 28, 2021 grant of options (see Note 6). The advisors being paid $400 and $600 per hour will reserve at least six full days of services to the Company and such additional days as requested by the Company each annual period, but not to exceed 36 full days of service per year unless otherwise agreed and up to a maximum of 288 hours total per year, unless otherwise agreed. The services will continue for initial terms of one year unless sooner terminated. At the end of the initial terms, the CAs will automatically be extended for an additional one-year period(s) unless either party gives the other 30 days written notice.</span></span></p>
                            <p style="text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">On October 9, 2020, the Company entered into a consulting agreement whereby the consultant was retained to serve as an advisor to the Company in the areas of scientific, technical and business advice. As compensation for performing these services, the Company will pay the advisor an hourly rate of US$<ix:nonFraction id="Fxbrl_20211229020336758" name="drug:AdvisorHourlyRate" scale="0" decimals="0" format="ixt:numdotdecimal" contextRef="C_20201001to20201009_drugAgreementAxis_drugConsultingAgreementsMember" unitRef="USD">130</ix:nonFraction>. The Company granted <ix:nonFraction id="Fxbrl_20211229020428020" name="ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" scale="0" decimals="0" format="ixt:numdotdecimal" contextRef="C_20201001to20201009_drugAgreementAxis_drugConsultingAgreementsMember" unitRef="Shares">90,000</ix:nonFraction> stock options to the consultant on November 17, 2020 (see Note 6).</span></span></p>
                        </div>
                    </ix:continuation>
                    <div>
                        <table style="width: 100%; border-collapse: collapse; font-size: 10pt;" border="0" cellspacing="0" cellpadding="0">
                            <tr>
                                <td style="width: 100%; text-align: center; border-top: 1pt solid black;">
                                    <p style="font-size: 10pt; font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>19</b>&#160;| Page</span></span></p>
                                </td>
                            </tr>
                        </table>
                    </div>
                    <hr style="page-break-after: always; text-align: center; height: 5px; width: 100%; background-color: black;" />
                    <div>
                        <table style="width: 100%; border-collapse: collapse; font-size: 10pt;" border="0" cellspacing="0" cellpadding="0">
                            <tr>
                                <td style="width: 100%;">
                                    <p style="margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>Bright Minds Biosciences Inc.</b></span></span></p>
                                    <p style="margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">Notes to the Consolidated Financial Statements</span></span></p>
                                    <p style="margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">For the years ended September 30, 2021 and 2020 and the period from May 31, 2019 (date of incorporation) to September 30, 2019</span></span></p>
                                    <p style="margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">(Expressed in Canadian Dollars)</span></span></p>
                                </td>
                            </tr>
                        </table>
                    </div>
                    <ix:continuation id="F20211228212947425">
                        <div>
                            <p style="text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">On November 6, 2020, the Company entered into a sponsored research agreement (the "SRA") with the University of Texas Medical Branch (the "UTMB") whereby the UTMB conducted a research program on behalf of the Company. Pursuant to the SRA, the agreement is effective as of October 15, 2020 and the research program was carried out through to its conclusion on February 15, 2021. As consideration for UTMB's performance, the Company paid US$<ix:nonFraction id="Fxbrl_20211229020511763" name="ifrs-full:ResearchAndDevelopmentExpense" scale="0" decimals="0" format="ixt:numdotdecimal" contextRef="C_20201101to20201106_drugAgreementAxis_drugConsultingAgreementsMember" unitRef="USD">66,764</ix:nonFraction> which was recorded in research and development costs.</span></span></p>
                            <p style="text-align: justify; margin-bottom: 0px;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">On November 17, 2020, the Company entered into an ICA whereby the contractor was engaged to serve as the Company's Vice President (Discovery). The contractor will be compensated for these services as determined by the Board of Directors of the Company. The services will continue for an initial term of one year unless sooner terminated. The ICA can be terminated by the Company providing five working days written notice, the contractor providing three months' written notice or by mutual written agreement. At the end of the initial term, the ICA will automatically be extended for additional one-year period(s) unless the Company provides the contractor with 30 days written notice. In March 2021, the Board of Directors authorized a monthly fee of US$<ix:nonFraction id="Fxbrl_20211229020602092" name="drug:MonthlyFeeAuthorizedByBoardOfDirectors" scale="0" decimals="0" format="ixt:numdotdecimal" contextRef="C_20201101to20201117_drugAgreementAxis_drugConsultingAgreementsMember" unitRef="USD">15,000</ix:nonFraction>.</span></span></p>
                        </div>
                    </ix:continuation>
                </div>
            </div>
            <div>
                <div>
                    <ix:nonNumeric id="Fxbrl_20211228154218915" name="ifrs-full:DisclosureOfFinancialInstrumentsExplanatory" escape="true" contextRef="C_20201001to20210930" continuedAt="F20211228154422998">
                        <div>
                            <p style="text-align: justify; margin-top: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>9.<span style="display: inline-block; width: 9pt;">&#160;</span>FINANCIAL INSTRUMENTS AND CAPITAL MANAGEMENT</b></span></span></p>
                            <p style="text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">The following table summarizes the carrying value of financial assets and liabilities:</span></span></p>
                            <ix:nonNumeric id="Fxbrl_20211228162450382" name="ifrs-full:DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory" escape="true" contextRef="C_20201001to20210930">
                                <div>
                                    <div style="margin-left: 5.4pt;">
                                        <table style="width: 100%; border-collapse: collapse; font-size: 10pt; border-color: #000000;" cellspacing="0" cellpadding="0">
                                            <tr>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1.5pt solid #000000; border-bottom: 0.75pt solid #000000; vertical-align: bottom;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>&#160;</b></span></span></td>
                                                <td style="vertical-align: bottom; border-top: 1.5pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right;">&#160;</td>
                                                <td style="vertical-align: bottom; border-top: 1.5pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>September 30, </b><br /><b>2021</b></span></span></td>
                                                <td style="vertical-align: bottom; border-top: 1.5pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;">&#160;</td>
                                                <td style="vertical-align: bottom; border-top: 1.5pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;">&#160;</td>
                                                <td style="vertical-align: bottom; border-top: 1.5pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>September 30, </b><br /><b>2020</b></span></span></td>
                                                <td style="vertical-align: bottom; border-top: 1.5pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right;">&#160;</td>
                                            </tr>
                                            <tr>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>FVTPL</b></span></span></td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right;">&#160;</td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>$</b></span></span></td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right;">&#160;</td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right;">&#160;</td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>$</b></span></span></td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right;">&#160;</td>
                                            </tr>
                                            <tr>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">&#160; Cash</span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b><ix:nonFraction id="Fxbrl_20211228162620010_22" name="ifrs-full:Cash" scale="0" decimals="0" format="ixt:numdotdecimal" contextRef="C_20210930_ifrsfullClassesOfFinancialInstrumentsAxis_drugFinancialInstrumentsAtFairValueThroughProfitOrLossMember" unitRef="CAD">19,673,765</ix:nonFraction></b></span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><ix:nonFraction id="Fxbrl_20211228162620010_25" name="ifrs-full:Cash" scale="0" decimals="0" format="ixt:numdotdecimal" contextRef="C_20200930_ifrsfullClassesOfFinancialInstrumentsAxis_drugFinancialInstrumentsAtFairValueThroughProfitOrLossMember" unitRef="CAD">799,929</ix:nonFraction></span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            </tr>
                                            <tr>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">&#160; Guaranteed investment certificate</span></span></td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b><ix:nonFraction id="Fxbrl_20211228162620010_32" name="ifrs-full:ShorttermInvestmentsClassifiedAsCashEquivalents" scale="0" decimals="0" format="ixt:numdotdecimal" contextRef="C_20210930_ifrsfullClassesOfFinancialInstrumentsAxis_drugFinancialInstrumentsAtFairValueThroughProfitOrLossMember" unitRef="CAD">86,250</ix:nonFraction></b></span></span></td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><ix:nonFraction id="Fxbrl_20211228162620010_35" name="ifrs-full:ShorttermInvestmentsClassifiedAsCashEquivalents" scale="0" decimals="0" format="ixt:zerodash" contextRef="C_20200930_ifrsfullClassesOfFinancialInstrumentsAxis_drugFinancialInstrumentsAtFairValueThroughProfitOrLossMember" unitRef="CAD">-</ix:nonFraction></span></span></td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                            </tr>
                                            <tr>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">&#160; Cash and cash equivalents</span></span></td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b><ix:nonFraction id="Fxbrl_20211228162620010_42" name="ifrs-full:CashAndCashEquivalents" scale="0" decimals="0" format="ixt:numdotdecimal" contextRef="C_20210930_ifrsfullClassesOfFinancialInstrumentsAxis_drugFinancialInstrumentsAtFairValueThroughProfitOrLossMember" unitRef="CAD">19,760,015</ix:nonFraction></b></span></span></td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><ix:nonFraction id="Fxbrl_20211228162620010_45" name="ifrs-full:CashAndCashEquivalents" scale="0" decimals="0" format="ixt:numdotdecimal" contextRef="C_20200930_ifrsfullClassesOfFinancialInstrumentsAxis_drugFinancialInstrumentsAtFairValueThroughProfitOrLossMember" unitRef="CAD">799,929</ix:nonFraction></span></span></td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            </tr>
                                            <tr>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>Amortized cost</b></span></span></td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>&#160;</b></span></span></td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%;">&#160;</td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                            </tr>
                                            <tr>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 2.25pt double #000000; vertical-align: bottom; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">&#160; Accounts payable and accrued liabilities</span></span></td>
                                                <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b><ix:nonFraction id="Fxbrl_20211228162620010_62" name="ifrs-full:TradeAndOtherCurrentPayables" scale="0" decimals="0" format="ixt:numdotdecimal" contextRef="C_20210930_ifrsfullClassesOfFinancialInstrumentsAxis_drugFinancialInstrumentsAtAmortizedCostMember" unitRef="CAD">638,573</ix:nonFraction></b></span></span></td>
                                                <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><ix:nonFraction id="Fxbrl_20211228162620010_65" name="ifrs-full:TradeAndOtherCurrentPayables" scale="0" decimals="0" format="ixt:numdotdecimal" contextRef="C_20200930_ifrsfullClassesOfFinancialInstrumentsAxis_drugFinancialInstrumentsAtAmortizedCostMember" unitRef="CAD">150,923</ix:nonFraction></span></span></td>
                                                <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            </tr>
                                        </table>
                                    </div>
                                </div>
                            </ix:nonNumeric>
                            <p style="margin-bottom: 0pt; text-align: justify; margin-top: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>Fair value measurement</b></span></span></p>
                            <p style="margin-top: 0pt; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">Financial assets and liabilities that are recognized on the statement of financial position at fair value can be classified in a hierarchy that is based on the significance of the inputs used in making the measurements.</span></span></p>
                            <p style="margin-bottom: 0pt; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span style="text-decoration: underline;">The levels in the hierarchy are:</span></span></span></p>
                            <p style="margin-top: 0pt; margin-bottom: 0pt; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">Level 1 - quoted prices (unadjusted) in active markets for identical assets or liabilities;</span></span></p>
                            <p style="margin-top: 0pt; margin-left: 39.6pt; margin-bottom: 0pt; text-indent: -39.6pt; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">Level 2 - inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly (that is, as prices) or indirectly (that is, derived from prices); and</span></span></p>
                            <p style="margin-top: 0pt; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">Level 3 - inputs for the asset or liability that are not based on observable market data (that is, unobservable inputs).</span></span></p>
                            <p style="text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">The Company's cash and cash equivalents is classified as Level 1, whereas accounts payable and accrued liabilities are classified as Level 2. As at September 30, 2021, the Company believes that the carrying values of cash and cash equivalents and accounts payable and accrued liabilities approximate their fair values because of their nature and relatively short maturity dates or durations.</span></span></p>
                            <p style="margin-bottom: 0pt; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>Financial risk management</b></span></span></p>
                            <p style="margin-top: 0pt; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">The Company is exposed in varying degrees to a variety of financial instrument related risks. The Board of Directors approves and monitors the risk management processes. The type of risk exposure and the way in which such exposure is managed is provided as follows:</span></span></p>
                            <p style="margin-bottom: 0pt; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span style="text-decoration: underline;">Credit risk </span></span></span></p>
                            <p style="margin-top: 0pt; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">Credit risk is the risk that one party to a financial instrument will fail to discharge an obligation and cause the other party to incur a financial loss. The Company's primary exposure to credit risk is on its cash and cash equivalents balance. As at September 30, 2021, the Company had cash and cash equivalents of $<ix:nonFraction id="Fxbrl_20211228163150482" name="ifrs-full:CashAndCashEquivalents" scale="0" decimals="0" format="ixt:numdotdecimal" contextRef="C_20210930_ifrsfullTypesOfRisksAxis_ifrsfullCreditRiskMember" unitRef="CAD">19,760,015</ix:nonFraction> which was held with a major bank in Canada and a major bank in the United States. Because deposits are with two banks, there is a concentration of credit risk. This risk is managed by using major banks that are high credit quality financial institutions as determined by rating agencies. The maximum exposure to credit risk is the carrying amount of the Company's financial instruments. The credit risk is assessed as low.</span></span></p>
                        </div>
                    </ix:nonNumeric>
                    <div>
                        <table style="width: 100%; border-collapse: collapse; font-size: 10pt; margin-top: 10pt;" border="0" cellspacing="0" cellpadding="0">
                            <tr>
                                <td style="width: 100%; text-align: center; border-top: 1pt solid black;">
                                    <p style="font-size: 10pt; font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>20&#160;</b>| Page</span></span></p>
                                </td>
                            </tr>
                        </table>
                    </div>
                    <hr style="page-break-after: always; text-align: center; height: 5px; width: 100%; background-color: black;" />
                    <div>
                        <table style="width: 100%; border-collapse: collapse; font-size: 10pt;" border="0" cellspacing="0" cellpadding="0">
                            <tr>
                                <td style="width: 100%;">
                                    <p style="margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>Bright Minds Biosciences Inc.</b></span></span></p>
                                    <p style="margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">Notes to the Consolidated Financial Statements</span></span></p>
                                    <p style="margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">For the years ended September 30, 2021 and 2020 and the period from May 31, 2019 (date of incorporation) to September 30, 2019</span></span></p>
                                    <p style="margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">(Expressed in Canadian Dollars)</span></span></p>
                                </td>
                            </tr>
                        </table>
                    </div>
                    <ix:continuation id="F20211228154422998">
                        <div>
                            <p style="margin-bottom: 0pt; text-align: justify; margin-top: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span style="text-decoration: underline;">Foreign exchange risk </span></span></span></p>
                            <p style="margin-top: 0pt; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">Foreign currency risk is the risk that the fair values of future cash flows of a financial instrument will fluctuate because they are denominated in currencies that differ from the respective functional currency. As at September 30, 2021, the Company had the following foreign currency balances - cash (US$<ix:nonFraction id="Fxbrl_20211228163206276" name="ifrs-full:Cash" scale="0" decimals="0" format="ixt:numdotdecimal" contextRef="C_20210930_ifrsfullTypesOfRisksAxis_ifrsfullCurrencyRiskMember" unitRef="USD">2,789,264</ix:nonFraction>) and accounts payable and accrued liabilities (US$<ix:nonFraction id="Fxbrl_20211228163214525" name="ifrs-full:TradeAndOtherCurrentPayables" scale="0" decimals="0" format="ixt:numdotdecimal" contextRef="C_20210930_ifrsfullTypesOfRisksAxis_ifrsfullCurrencyRiskMember" unitRef="USD">420,481</ix:nonFraction>). A <ix:nonFraction id="Fxbrl_20211228163343560" name="drug:PercentageOfForeignCurrencyFluctuationInUsDollarAgainstCanadianDollar" scale="-2" decimals="2" format="ixt:numdotdecimal" contextRef="C_20210930_ifrsfullTypesOfRisksAxis_ifrsfullCurrencyRiskMember" unitRef="Percent">10</ix:nonFraction>% fluctuation in the US$ against the Canadian dollar would have an impact of approximately $<ix:nonFraction id="Fxbrl_20211228163347871" name="ifrs-full:ValueAtRisk" scale="0" decimals="0" format="ixt:numdotdecimal" contextRef="C_20210930_ifrsfullTypesOfRisksAxis_ifrsfullCurrencyRiskMember" unitRef="CAD">301,807</ix:nonFraction> on the net comprehensive loss.</span></span></p>
                            <p style="margin-bottom: 0pt; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span style="text-decoration: underline;">Liquidity risk </span></span></span></p>
                            <p style="margin-top: 0pt; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">Liquidity risk arises through the excess of financial obligations over available financial assets due at any point in time. The Company's objective in managing liquidity risk is to maintain sufficient readily available reserves in order to meet its liquidity requirements at any point in time. The Company's main source of funding has been the issuance of equity securities for cash, primarily through private placements. The Company's access to financing is always uncertain. There can be no assurance of continued access to significant equity funding. As at September 30, 2021, the Company had cash and cash equivalents of $<ix:nonFraction id="Fxbrl_20211228163654068" name="ifrs-full:CashAndCashEquivalents" scale="0" decimals="0" format="ixt:numdotdecimal" contextRef="C_20210930_ifrsfullTypesOfRisksAxis_ifrsfullLiquidityRiskMember" unitRef="CAD">19,760,015</ix:nonFraction> to cover current liabilities of $<ix:nonFraction id="Fxbrl_20211228163732773" name="ifrs-full:TradeAndOtherCurrentPayables" scale="0" decimals="0" format="ixt:numdotdecimal" contextRef="C_20210930_ifrsfullTypesOfRisksAxis_ifrsfullLiquidityRiskMember" unitRef="CAD">638,573</ix:nonFraction>.</span></span></p>
                            <p style="margin-bottom: 0pt; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span style="text-decoration: underline;">Capital management</span></span></span></p>
                            <p style="margin-top: 0pt; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">Management's objective is to manage its capital to ensure that there are adequate capital resources to safeguard the Company's ability to continue as a going concern through the optimization of its capital structure. The capital structure consists of share capital and working capital. In order to achieve this objective, management makes adjustments to it in light of changes in economic conditions and risk characteristics of the underlying assets. To maintain or adjust the capital structure, management may invest its excess cash in interest bearing accounts of Canadian chartered banks and/or raise additional funds externally as needed. The Company is not subject to externally imposed capital requirements. The Company's management of capital did not change during the year ended September 30, 2021.</span></span></p>
                        </div>
                    </ix:continuation>
                </div>
            </div>
            <div>
                <ix:nonNumeric id="Fxbrl_20211228165204922" name="ifrs-full:DisclosureOfResearchAndDevelopmentExpenseExplanatory" escape="true" contextRef="C_20201001to20210930">
                    <div>
                        <p style="text-align: justify; margin-top: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>10.<span style="display: inline-block; width: 9pt;">&#160;</span>RESEARCH AND DEVELOPMENT</b></span></span></p>
                        <p style="text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">Research and development expense recognized in the consolidated statements of comprehensive loss is comprised of the following:</span></span></p>
                        <ix:nonNumeric id="Fxbrl_20211228172608751" name="drug:DisclosureOfDetailedInformationAboutResearchAndDevelopmentExplanatory" escape="true" contextRef="C_20201001to20210930">
                            <table style="border-collapse: collapse; font-size: 10pt; width: 100%;" cellspacing="0" cellpadding="0">
                                <tr>
                                    <td style="width: 36%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top; border-top: 1.5pt solid #000000;">
                                        <p style="text-align: justify; margin-top: 0pt; margin-bottom: 0pt;">&#160;</p>
                                    </td>
                                    <td style="width: 20%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-top: 1.5pt solid #000000; white-space: nowrap;">
                                        <p style="text-align: right; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>Year ended</b></span></span></p>
                                    </td>
                                    <td style="width: 17%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-top: 1.5pt solid #000000; white-space: nowrap;">
                                        <p style="text-align: right; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>Year ended</b></span></span></p>
                                    </td>
                                    <td style="width: 16%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top; border-top: 1.5pt solid #000000; white-space: nowrap;">
                                        <p style="text-align: right; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>Period ended</b></span></span></p>
                                    </td>
                                </tr>
                                <tr>
                                    <td style="width: 36%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top;">
                                        <p style="text-align: justify; margin-top: 0pt; margin-bottom: 0pt;">&#160;</p>
                                    </td>
                                    <td style="width: 20%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; white-space: nowrap;">
                                        <p style="margin-bottom: 0pt; text-align: right; margin-top: 0pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>September 30, </b></span></span></p>
                                        <p style="margin-top: 0pt; text-align: right; margin-bottom: 0pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>2021</b></span></span></p>
                                    </td>
                                    <td style="width: 17%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; white-space: nowrap;">
                                        <p style="margin-bottom: 0pt; text-align: right; margin-top: 0pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>September 30, </b></span></span></p>
                                        <p style="margin-top: 0pt; text-align: right; margin-bottom: 0pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>2020</b></span></span></p>
                                    </td>
                                    <td style="width: 16%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top; white-space: nowrap;">
                                        <p style="text-align: right; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>September 30,<br />2019</b></span></span></p>
                                    </td>
                                </tr>
                                <tr>
                                    <td style="width: 36%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top; border-top: 0.75pt solid #000000;">
                                        <p style="text-align: justify; margin-top: 0pt; margin-bottom: 0pt;">&#160;</p>
                                    </td>
                                    <td style="width: 20%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-top: 0.75pt solid #000000;">
                                        <p style="text-align: right; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>$</b></span></span></p>
                                    </td>
                                    <td style="width: 17%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-top: 0.75pt solid #000000;">
                                        <p style="text-align: right; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">$</span></span></p>
                                    </td>
                                    <td style="width: 16%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top; border-top: 0.75pt solid #000000;">
                                        <p style="text-align: right; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">$</span></span></p>
                                    </td>
                                </tr>
                                <tr>
                                    <td style="width: 36%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top; background-color: #e6efff;">
                                        <p style="text-align: justify; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">Laboratory costs (see Note 11)</span></span></p>
                                    </td>
                                    <td style="width: 20%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top; background-color: #e6efff;">
                                        <p style="text-align: right; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b><ix:nonFraction id="Fxbrl_20211228165647777" name="ifrs-full:ResearchAndDevelopmentExpense" scale="0" decimals="0" format="ixt:numdotdecimal" contextRef="C_20201001to20210930_drugCategoriesOfResearchAndDevelopmentExpensesAxis_drugLaboratoryCostsMember" unitRef="CAD">82,871</ix:nonFraction></b></span></span></p>
                                    </td>
                                    <td style="width: 17%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top; background-color: #e6efff;">
                                        <p style="text-align: right; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><ix:nonFraction id="Fxbrl_20211228165636946_32" name="ifrs-full:ResearchAndDevelopmentExpense" scale="0" decimals="0" format="ixt:numdotdecimal" contextRef="C_20191001to20200930_drugCategoriesOfResearchAndDevelopmentExpensesAxis_drugLaboratoryCostsMember" unitRef="CAD">25,874</ix:nonFraction></span></span></p>
                                    </td>
                                    <td style="width: 16%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top; background-color: #e6efff;">
                                        <p style="text-align: right; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><ix:nonFraction id="Fxbrl_20211228165636946_33" name="ifrs-full:ResearchAndDevelopmentExpense" scale="0" decimals="0" format="ixt:numdotdecimal" contextRef="C_20190601to20190930_drugCategoriesOfResearchAndDevelopmentExpensesAxis_drugLaboratoryCostsMember" unitRef="CAD">27,164</ix:nonFraction></span></span></p>
                                    </td>
                                </tr>
                                <tr>
                                    <td style="width: 36%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top;">
                                        <p style="text-align: justify; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">Novel drug development</span></span></p>
                                    </td>
                                    <td style="width: 20%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top;">
                                        <p style="text-align: right; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b><ix:nonFraction id="Fxbrl_20211228165650860" name="ifrs-full:ResearchAndDevelopmentExpense" scale="0" decimals="0" format="ixt:numdotdecimal" contextRef="C_20201001to20210930_drugCategoriesOfResearchAndDevelopmentExpensesAxis_drugNovelDrugDevelopmentMember" unitRef="CAD">3,638,910</ix:nonFraction></b></span></span></p>
                                    </td>
                                    <td style="width: 17%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top;">
                                        <p style="text-align: right; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><ix:nonFraction id="Fxbrl_20211228165636946_42" name="ifrs-full:ResearchAndDevelopmentExpense" scale="0" decimals="0" format="ixt:numdotdecimal" contextRef="C_20191001to20200930_drugCategoriesOfResearchAndDevelopmentExpensesAxis_drugNovelDrugDevelopmentMember" unitRef="CAD">110,029</ix:nonFraction></span></span></p>
                                    </td>
                                    <td style="width: 16%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top;">
                                        <p style="text-align: right; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><ix:nonFraction id="Fxbrl_20211228165636946_43" name="ifrs-full:ResearchAndDevelopmentExpense" scale="0" decimals="0" format="ixt:zerodash" contextRef="C_20190601to20190930_drugCategoriesOfResearchAndDevelopmentExpensesAxis_drugNovelDrugDevelopmentMember" unitRef="CAD">-</ix:nonFraction></span></span></p>
                                    </td>
                                </tr>
                                <tr>
                                    <td style="width: 36%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top; background-color: #e6efff;">
                                        <p style="text-align: justify; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">Patents and related payments</span></span></p>
                                    </td>
                                    <td style="width: 20%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top; background-color: #e6efff;">
                                        <p style="text-align: right; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b><ix:nonFraction id="Fxbrl_20211228165653868" name="ifrs-full:ResearchAndDevelopmentExpense" scale="0" decimals="0" format="ixt:numdotdecimal" contextRef="C_20201001to20210930_drugCategoriesOfResearchAndDevelopmentExpensesAxis_ifrsfullCopyrightsPatentsAndOtherIndustrialPropertyRightsServiceAndOperatingRightsMember" unitRef="CAD">513,302</ix:nonFraction></b></span></span></p>
                                    </td>
                                    <td style="width: 17%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top; background-color: #e6efff;">
                                        <p style="text-align: right; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><ix:nonFraction id="Fxbrl_20211228165636946_52" name="ifrs-full:ResearchAndDevelopmentExpense" scale="0" decimals="0" format="ixt:numdotdecimal" contextRef="C_20191001to20200930_drugCategoriesOfResearchAndDevelopmentExpensesAxis_ifrsfullCopyrightsPatentsAndOtherIndustrialPropertyRightsServiceAndOperatingRightsMember" unitRef="CAD">13,895</ix:nonFraction></span></span></p>
                                    </td>
                                    <td style="width: 16%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top; background-color: #e6efff;">
                                        <p style="text-align: right; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><ix:nonFraction id="Fxbrl_20211228165636946_53" name="ifrs-full:ResearchAndDevelopmentExpense" scale="0" decimals="0" format="ixt:zerodash" contextRef="C_20190601to20190930_drugCategoriesOfResearchAndDevelopmentExpensesAxis_ifrsfullCopyrightsPatentsAndOtherIndustrialPropertyRightsServiceAndOperatingRightsMember" unitRef="CAD">-</ix:nonFraction></span></span></p>
                                    </td>
                                </tr>
                                <tr>
                                    <td style="width: 36%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top;">
                                        <p style="text-align: justify; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">Salary and subcontractors</span></span></p>
                                    </td>
                                    <td style="width: 20%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top;">
                                        <p style="text-align: right; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b><ix:nonFraction id="Fxbrl_20211228165658244" name="ifrs-full:ResearchAndDevelopmentExpense" scale="0" decimals="0" format="ixt:numdotdecimal" contextRef="C_20201001to20210930_drugCategoriesOfResearchAndDevelopmentExpensesAxis_drugSalaryAndSubcontractorsMember" unitRef="CAD">1,369,769</ix:nonFraction></b></span></span></p>
                                    </td>
                                    <td style="width: 17%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top;">
                                        <p style="text-align: right; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><ix:nonFraction id="Fxbrl_20211228165636946_62" name="ifrs-full:ResearchAndDevelopmentExpense" scale="0" decimals="0" format="ixt:numdotdecimal" contextRef="C_20191001to20200930_drugCategoriesOfResearchAndDevelopmentExpensesAxis_drugSalaryAndSubcontractorsMember" unitRef="CAD">43,754</ix:nonFraction></span></span></p>
                                    </td>
                                    <td style="width: 16%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top;">
                                        <p style="text-align: right; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><ix:nonFraction id="Fxbrl_20211228165636946_63" name="ifrs-full:ResearchAndDevelopmentExpense" scale="0" decimals="0" format="ixt:numdotdecimal" contextRef="C_20190601to20190930_drugCategoriesOfResearchAndDevelopmentExpensesAxis_drugSalaryAndSubcontractorsMember" unitRef="CAD">14,845</ix:nonFraction></span></span></p>
                                    </td>
                                </tr>
                                <tr>
                                    <td style="width: 36%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top; border-bottom: 0.75pt solid #000000; background-color: #e6efff;">
                                        <p style="text-align: justify; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">Share-based compensation (see Note 6)</span></span></p>
                                    </td>
                                    <td style="width: 20%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top; border-bottom: 0.75pt solid #000000; background-color: #e6efff;">
                                        <p style="text-align: right; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b><ix:nonFraction id="Fxbrl_20211228165701075" name="ifrs-full:ResearchAndDevelopmentExpense" scale="0" decimals="0" format="ixt:numdotdecimal" contextRef="C_20201001to20210930_drugCategoriesOfResearchAndDevelopmentExpensesAxis_drugShareBasedCompensationMember" unitRef="CAD">709,136</ix:nonFraction></b></span></span></p>
                                    </td>
                                    <td style="width: 17%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top; border-bottom: 0.75pt solid #000000; background-color: #e6efff;">
                                        <p style="text-align: right; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><ix:nonFraction id="Fxbrl_20211228165636946_72" name="ifrs-full:ResearchAndDevelopmentExpense" scale="0" decimals="0" format="ixt:numdotdecimal" contextRef="C_20191001to20200930_drugCategoriesOfResearchAndDevelopmentExpensesAxis_drugShareBasedCompensationMember" unitRef="CAD">161,300</ix:nonFraction></span></span></p>
                                    </td>
                                    <td style="width: 16%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top; border-bottom: 0.75pt solid #000000; background-color: #e6efff;">
                                        <p style="text-align: right; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><ix:nonFraction id="Fxbrl_20211228165636946_73" name="ifrs-full:ResearchAndDevelopmentExpense" scale="0" decimals="0" format="ixt:zerodash" contextRef="C_20190601to20190930_drugCategoriesOfResearchAndDevelopmentExpensesAxis_drugShareBasedCompensationMember" unitRef="CAD">-</ix:nonFraction></span></span></p>
                                    </td>
                                </tr>
                                <tr>
                                    <td style="width: 36%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000;">
                                        <p style="text-align: justify; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>&#160;</b></span></span></p>
                                    </td>
                                    <td style="width: 20%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000;">
                                        <p style="text-align: right; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b><ix:nonFraction id="Fxbrl_20211228165705419" name="ifrs-full:ResearchAndDevelopmentExpense" scale="0" decimals="0" format="ixt:numdotdecimal" contextRef="C_20201001to20210930" unitRef="CAD">6,313,988</ix:nonFraction></b></span></span></p>
                                    </td>
                                    <td style="width: 17%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000;">
                                        <p style="text-align: right; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><ix:nonFraction id="Fxbrl_20211228165636946_82" name="ifrs-full:ResearchAndDevelopmentExpense" scale="0" decimals="0" format="ixt:numdotdecimal" contextRef="C_20191001to20200930" unitRef="CAD">354,852</ix:nonFraction></span></span></p>
                                    </td>
                                    <td style="width: 16%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000;">
                                        <p style="text-align: right; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><ix:nonFraction id="Fxbrl_20211228165636946_83" name="ifrs-full:ResearchAndDevelopmentExpense" scale="0" decimals="0" format="ixt:numdotdecimal" contextRef="C_20190601to20190930" unitRef="CAD">42,009</ix:nonFraction></span></span></p>
                                    </td>
                                </tr>
                            </table>
                        </ix:nonNumeric>
                    </div>
                </ix:nonNumeric>
            </div>
            <div>
                <div>
                    <ix:nonNumeric id="Fxbrl_20211228205315972" name="ifrs-full:DisclosureOfLeasesExplanatory" escape="true" contextRef="C_20201001to20210930">
                        <div>
                            <p style="text-align: justify; margin-top: 10pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>11.<span style="display: inline-block; width: 8pt;">&#160;</span>PREMISES LEASES</b></span></span></p>
                            <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Commencing June 1, 2021, the Company entered into a commercial laboratory lease in Wauwatosa, Wisconsin USA for a term of <ix:nonNumeric id="Fxbrl_20211228210132379" name="drug:TermOfLease" format="ixt-sec:durwordsen" contextRef="C_20210601to20210930_ifrsfullClassesOfAssetsAxis_drugCommercialLaboratoryLeaseMember">one year</ix:nonNumeric> at a monthly base rent of US$<ix:nonFraction id="Fxbrl_20211228210145977" name="drug:MonthlyBaseRent" scale="0" decimals="0" format="ixt:numdotdecimal" contextRef="C_20210601to20210930_ifrsfullClassesOfAssetsAxis_drugCommercialLaboratoryLeaseMember" unitRef="USD">1,709</ix:nonFraction>. For the year ended September 30, 2021, $<ix:nonFraction id="Fxbrl_20211228210400355" name="drug:LeaseCost" scale="0" decimals="0" format="ixt:numdotdecimal" contextRef="C_20210601to20210930_ifrsfullClassesOfAssetsAxis_drugCommercialLaboratoryLeaseMember" unitRef="CAD">7,003</ix:nonFraction> is included in laboratory costs (see Note 10).</span></span></p>
                            <p style="text-align: justify; margin-bottom: 0px;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Commencing September 1, 2021, the Company entered into an apartment lease in New York, New York USA for a term of <ix:nonNumeric id="Fxbrl_20211228210438410" name="drug:TermOfLease" format="ixt-sec:durwordsen" contextRef="C_20210901to20210930_ifrsfullClassesOfAssetsAxis_ifrsfullBuildingsMember">one year</ix:nonNumeric> at a monthly base rent of US$<ix:nonFraction id="Fxbrl_20211228210520727" name="drug:MonthlyBaseRent" scale="0" decimals="0" format="ixt:numdotdecimal" contextRef="C_20210901to20210930_ifrsfullClassesOfAssetsAxis_ifrsfullBuildingsMember" unitRef="USD">5,300</ix:nonFraction>. For the year ended September 30, 2021, $<ix:nonFraction id="Fxbrl_20211228210600034" name="drug:LeaseCost" scale="0" decimals="0" format="ixt:numdotdecimal" contextRef="C_20210601to20210930_ifrsfullClassesOfAssetsAxis_ifrsfullBuildingsMember" unitRef="CAD">6,700</ix:nonFraction> is included in office and administrative expense.</span></span></p>
                        </div>
                    </ix:nonNumeric>
                </div>
            </div>
            <div>
                <ix:nonNumeric id="Fxbrl_20211228212858237" name="ifrs-full:DisclosureOfIncomeTaxExplanatory" escape="true" contextRef="C_20201001to20210930" continuedAt="F20211228212914383">
                    <div>
                        <p style="text-align: justify; margin-top: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>12.<span style="display: inline-block; width: 8pt;">&#160;</span>INCOME TAXES</b></span></span></p>
                        <p style="text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">A reconciliation of the expected income tax recovery to the actual income tax recovery is as follows:</span></span></p>
                    </div>
                </ix:nonNumeric>
                <div>
                    <table style="width: 100%; border-collapse: collapse; font-size: 10pt;" border="0" cellspacing="0" cellpadding="0">
                        <tr>
                            <td style="width: 100%; text-align: center; border-top: 1pt solid black;">
                                <p style="font-size: 10pt; font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>21</b> | Page</span></span></p>
                            </td>
                        </tr>
                    </table>
                </div>
                <hr style="page-break-after: always; text-align: center; height: 5px; width: 100%; background-color: black;" />
                <div>
                    <table style="width: 100%; border-collapse: collapse; font-size: 10pt;" border="0" cellspacing="0" cellpadding="0">
                        <tr>
                            <td style="width: 100%;">
                                <p style="margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>Bright Minds Biosciences Inc.</b></span></span></p>
                                <p style="margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">Notes to the Consolidated Financial Statements</span></span></p>
                                <p style="margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">For the years ended September 30, 2021 and 2020 and the period from May 31, 2019 (date of incorporation) to September 30, 2019</span></span></p>
                                <p style="margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">(Expressed in Canadian Dollars)</span></span></p>
                            </td>
                        </tr>
                    </table>
                </div>
                <ix:continuation id="F20211228212914383">
                    <div>&#160;<ix:nonNumeric id="Fxbrl_20211228224836084" name="drug:DisclosureOfReconciliationOfExpectedIncomeTaxRecoveryToActualIncomeTaxRecoveryExplanatory" escape="true" contextRef="C_20201001to20210930">
                            <div>
                                <div style="margin-left: 36pt;">
                                    <table style="width: 100%; border-collapse: collapse; font-size: 10pt; border-color: #000000;" cellspacing="0" cellpadding="0">
                                        <tr>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; vertical-align: bottom;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>&#160;</b></span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>September 30, </b><br /><b>2021</b></span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>September 30, </b><br /><b>2020</b></span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>September 30,<br />2019</b></span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>$</b></span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>$</b></span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>$</b></span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">Net loss</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>(<ix:nonFraction id="Fxbrl_20211228190802176_22" name="ifrs-full:AccountingProfit" scale="0" decimals="0" format="ixt:numdotdecimal" sign="-" contextRef="C_20201001to20210930" unitRef="CAD">8,650,763</ix:nonFraction></b></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>)</b></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">(<ix:nonFraction id="Fxbrl_20211228190802176_25" name="ifrs-full:AccountingProfit" scale="0" decimals="0" format="ixt:numdotdecimal" sign="-" contextRef="C_20191001to20200930" unitRef="CAD">480,377</ix:nonFraction></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">)</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">(<ix:nonFraction id="Fxbrl_20211228190802176_28" name="ifrs-full:AccountingProfit" scale="0" decimals="0" format="ixt:numdotdecimal" sign="-" contextRef="C_20181001to20190930" unitRef="CAD">78,717</ix:nonFraction></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">)</span></span></td>
                                        </tr>
                                        <tr>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">Statutory tax rate</span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b><ix:nonFraction id="Fxbrl_20211228190802176_32" name="ifrs-full:ApplicableTaxRate" scale="-2" decimals="4" format="ixt:numdotdecimal" contextRef="C_20201001to20210930" unitRef="Percent">27.75</ix:nonFraction>%</b></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><ix:nonFraction id="Fxbrl_20211228190802176_35" name="ifrs-full:ApplicableTaxRate" scale="-2" decimals="2" format="ixt:numdotdecimal" contextRef="C_20191001to20200930" unitRef="Percent">27</ix:nonFraction>%</span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><ix:nonFraction id="Fxbrl_20211228190802176_38" name="ifrs-full:ApplicableTaxRate" scale="-2" decimals="2" format="ixt:numdotdecimal" contextRef="C_20181001to20190930" unitRef="Percent">27</ix:nonFraction>%</span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">Expected income tax recovery</span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>(<ix:nonFraction id="Fxbrl_20211228190802176_42" name="ifrs-full:TaxExpenseIncomeAtApplicableTaxRate" scale="0" decimals="0" format="ixt:numdotdecimal" sign="-" contextRef="C_20201001to20210930" unitRef="CAD">2,400,311</ix:nonFraction></b></span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>)</b></span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">(<ix:nonFraction id="Fxbrl_20211228190802176_45" name="ifrs-full:TaxExpenseIncomeAtApplicableTaxRate" scale="0" decimals="0" format="ixt:numdotdecimal" sign="-" contextRef="C_20191001to20200930" unitRef="CAD">129,702</ix:nonFraction></span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">)</span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">(<ix:nonFraction id="Fxbrl_20211228190802176_48" name="ifrs-full:TaxExpenseIncomeAtApplicableTaxRate" scale="0" decimals="0" format="ixt:numdotdecimal" sign="-" contextRef="C_20181001to20190930" unitRef="CAD">21,254</ix:nonFraction></span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">)</span></span></td>
                                        </tr>
                                        <tr>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">Deductible and non-deductible items</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 12%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>(<ix:nonFraction id="Fxbrl_20211228190802176_52" name="drug:TaxEffectOfDeductibleAndNotDeductibleItems" scale="0" decimals="0" format="ixt:numdotdecimal" sign="-" contextRef="C_20201001to20210930" unitRef="CAD">256,939</ix:nonFraction></b></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>)</b></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 12%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><ix:nonFraction id="Fxbrl_20211228190802176_55" name="drug:TaxEffectOfDeductibleAndNotDeductibleItems" scale="0" decimals="0" format="ixt:numdotdecimal" contextRef="C_20191001to20200930" unitRef="CAD">42,136</ix:nonFraction></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 12%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><ix:nonFraction id="Fxbrl_20211228190802176_58" name="drug:TaxEffectOfDeductibleAndNotDeductibleItems" scale="0" decimals="0" format="ixt:zerodash" contextRef="C_20181001to20190930" unitRef="CAD">-</ix:nonFraction></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">Change in deferred tax assets not recognized</span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b><ix:nonFraction id="Fxbrl_20211228190802176_62" name="drug:TaxEffectOfChangeInDeferredTaxAssetsNotRecognized" scale="0" decimals="0" format="ixt:numdotdecimal" contextRef="C_20201001to20210930" unitRef="CAD">2,657,250</ix:nonFraction></b></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><ix:nonFraction id="Fxbrl_20211228190802176_65" name="drug:TaxEffectOfChangeInDeferredTaxAssetsNotRecognized" scale="0" decimals="0" format="ixt:numdotdecimal" contextRef="C_20191001to20200930" unitRef="CAD">87,566</ix:nonFraction></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><ix:nonFraction id="Fxbrl_20211228190802176_68" name="drug:TaxEffectOfChangeInDeferredTaxAssetsNotRecognized" scale="0" decimals="0" format="ixt:numdotdecimal" contextRef="C_20181001to20190930" unitRef="CAD">21,254</ix:nonFraction></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 2.25pt double #000000; vertical-align: bottom;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">Total income tax recovery</span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 12%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b><ix:nonFraction id="Fxbrl_20211228190802176_72" name="ifrs-full:IncomeTaxExpenseContinuingOperations" scale="0" decimals="0" format="ixt:zerodash" contextRef="C_20201001to20210930" unitRef="CAD">-</ix:nonFraction></b></span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 12%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><ix:nonFraction id="Fxbrl_20211228190802176_75" name="ifrs-full:IncomeTaxExpenseContinuingOperations" scale="0" decimals="0" format="ixt:zerodash" contextRef="C_20191001to20200930" unitRef="CAD">-</ix:nonFraction></span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 12%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><ix:nonFraction id="Fxbrl_20211228190802176_78" name="ifrs-full:IncomeTaxExpenseContinuingOperations" scale="0" decimals="0" format="ixt:zerodash" contextRef="C_20181001to20190930" unitRef="CAD">-</ix:nonFraction></span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%;">&#160;</td>
                                        </tr>
                                    </table>
                                </div>
                            </div>
                        </ix:nonNumeric>
                        <p style="text-align: justify; margin-top: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">The Company has the following deductible temporary differences for which no deferred tax has been recognized:</span></span></p>
                        <ix:nonNumeric id="Fxbrl_20211228224849623" name="ifrs-full:DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory" escape="true" contextRef="C_20201001to20210930">
                            <div>
                                <div style="margin-left: 36pt;">
                                    <table style="width: 100%; border-collapse: collapse; font-size: 10pt; border-color: #000000;" cellspacing="0" cellpadding="0">
                                        <tr>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; vertical-align: bottom;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>&#160;</b></span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>September 30, </b><br /><b>2021</b></span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>September 30, </b><br /><b>2020</b></span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>$</b></span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>$</b></span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">Non-capital losses</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b><ix:nonFraction id="Fxbrl_20211228191625472_22" name="ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised" scale="0" decimals="0" format="ixt:numdotdecimal" contextRef="C_20210930_ifrsfullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_ifrsfullUnusedTaxLossesMember" unitRef="CAD">9,976,000</ix:nonFraction></b></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><ix:nonFraction id="Fxbrl_20211228191625472_25" name="ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised" scale="0" decimals="0" format="ixt:numdotdecimal" contextRef="C_20200930_ifrsfullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_ifrsfullUnusedTaxLossesMember" unitRef="CAD">403,000</ix:nonFraction></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">Share issue costs</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 15%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b><ix:nonFraction id="Fxbrl_20211228191625472_32" name="ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised" scale="0" decimals="0" format="ixt:numdotdecimal" contextRef="C_20210930_ifrsfullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_drugTemporaryDifferencesShareIssueCostsMember" unitRef="CAD">1,448,000</ix:nonFraction></b></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 15%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><ix:nonFraction id="Fxbrl_20211228191625472_35" name="ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised" scale="0" decimals="0" format="ixt:numdotdecimal" contextRef="C_20200930_ifrsfullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_drugTemporaryDifferencesShareIssueCostsMember" unitRef="CAD">4,000</ix:nonFraction></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">Intangible assets</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>(<ix:nonFraction id="Fxbrl_20211228191625472_42" name="ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised" scale="0" decimals="0" format="ixt:numdotdecimal" sign="-" contextRef="C_20210930_ifrsfullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_drugTemporaryDifferencesIntangibleAssetsMember" unitRef="CAD">1,000</ix:nonFraction></b></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>)</b></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">(<ix:nonFraction id="Fxbrl_20211228191625472_45" name="ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised" scale="0" decimals="0" format="ixt:numdotdecimal" sign="-" contextRef="C_20200930_ifrsfullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_drugTemporaryDifferencesIntangibleAssetsMember" unitRef="CAD">2,000</ix:nonFraction></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">)</span></span></td>
                                        </tr>
                                        <tr>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; border-bottom: 0.75pt solid #000000;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">Valuation allowance</span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 15%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>(<ix:nonFraction id="Fxbrl_20211228191625472_52" name="ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised" scale="0" decimals="0" format="ixt:numdotdecimal" sign="-" contextRef="C_20210930_ifrsfullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_drugTemporaryDifferencesValuationAllowanceMember" unitRef="CAD">11,423,000</ix:nonFraction></b></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>)</b></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 15%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">(<ix:nonFraction id="Fxbrl_20211228191625472_55" name="ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised" scale="0" decimals="0" format="ixt:numdotdecimal" sign="-" contextRef="C_20200930_ifrsfullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_drugTemporaryDifferencesValuationAllowanceMember" unitRef="CAD">405,000</ix:nonFraction></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">)</span></span></td>
                                        </tr>
                                        <tr>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; border-bottom: 2.25pt double #000000; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">Net deferred income tax assets</span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b><ix:nonFraction id="Fxbrl_20211228191625472_62" name="ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised" scale="0" decimals="0" format="ixt:zerodash" contextRef="C_20210930" unitRef="CAD">-</ix:nonFraction></b></span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><ix:nonFraction id="Fxbrl_20211228191625472_65" name="ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised" scale="0" decimals="0" format="ixt:zerodash" contextRef="C_20200930" unitRef="CAD">-</ix:nonFraction></span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                        </tr>
                                    </table>
                                </div>
                            </div>
                        </ix:nonNumeric>
                        <p style="text-align: justify; margin-top: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">The Company has Canadian non-capital losses of approximately $<ix:nonFraction id="Fxbrl_20211228222104778" name="drug:NonCapitalLossCarryForwards" scale="0" decimals="0" format="ixt:numdotdecimal" contextRef="C_20210930_drugIncomeTaxAuthorityNameOfCountryAxis_drugTaxAuthorityOfCanadaMember" unitRef="CAD">9,940,000</ix:nonFraction> (2019 - $<ix:nonFraction id="Fxbrl_20211228222111085" name="drug:NonCapitalLossCarryForwards" scale="0" decimals="0" format="ixt:numdotdecimal" contextRef="C_20190930_drugIncomeTaxAuthorityNameOfCountryAxis_drugTaxAuthorityOfCanadaMember" unitRef="CAD">403,000</ix:nonFraction>), US non-capital losses of $ <ix:nonFraction id="Fxbrl_20211228222200554" name="drug:NonCapitalLossCarryForwards" scale="0" decimals="0" format="ixt:numdotdecimal" contextRef="C_20210930_drugIncomeTaxAuthorityNameOfCountryAxis_drugTaxAuthorityOfUnitedStatesMember" unitRef="CAD">30,000</ix:nonFraction> (2019 - $<ix:nonFraction id="Fxbrl_20211228222207542" name="drug:NonCapitalLossCarryForwards" scale="0" decimals="0" format="ixt-sec:numwordsen" contextRef="C_20190930_drugIncomeTaxAuthorityNameOfCountryAxis_drugTaxAuthorityOfUnitedStatesMember" unitRef="CAD">Nil</ix:nonFraction>) and Australian non-capital losses of $<ix:nonFraction id="Fxbrl_20211228222230089" name="drug:NonCapitalLossCarryForwards" scale="0" decimals="0" format="ixt:numdotdecimal" contextRef="C_20210930_drugIncomeTaxAuthorityNameOfCountryAxis_drugTaxAuthorityOfAustraliaMember" unitRef="CAD">6,000</ix:nonFraction> (2019- $<ix:nonFraction id="Fxbrl_20211228222237537" name="drug:NonCapitalLossCarryForwards" scale="0" decimals="0" format="ixt-sec:numwordsen" contextRef="C_20190930_drugIncomeTaxAuthorityNameOfCountryAxis_drugTaxAuthorityOfAustraliaMember" unitRef="CAD">Nil</ix:nonFraction>), which may be carried forward and applied against taxable income in future years. Future tax benefits which may arise as a result of these losses have not been recognized in these financial statements and have been offset by a valuation allowance.</span></span></p>
                        <p style="text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">The Company's Canadian non-capital loss carry-forwards expire as follows:</span></span></p>
                        <ix:nonNumeric id="Fxbrl_20211228224903863" name="drug:DisclosureOfNonCapitalLossCarryForwardsExpiryExplanatory" escape="true" contextRef="C_20201001to20210930">
                            <div>
                                <table style="border-collapse: collapse; font-size: 10pt; width: 70%; border-color: #000000; margin-left: auto; margin-right: auto;" cellspacing="0" cellpadding="0">
                                    <tr>
                                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>Year of Origin</b></span></span></td>
                                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>Year of Expiry</b></span></span></td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;">&#160;</td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>Non-Capital Losses</b></span></span></td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: center;">&#160;</td>
                                    </tr>
                                    <tr>
                                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: center;">&#160;</td>
                                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: center;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>$</b></span></span></td>
                                        <td style="vertical-align: bottom; text-align: right;">&#160;</td>
                                    </tr>
                                    <tr>
                                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: center; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">2019</span></span></td>
                                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: center; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span style="-sec-ix-hidden: Fxbrl_20211228221904526;">2039</span></span></span></td>
                                        <td style="vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; width: 22%; text-align: right; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><ix:nonFraction id="Fxbrl_20211228222021893" name="drug:NonCapitalLossCarryForwards" scale="0" decimals="0" format="ixt:numdotdecimal" contextRef="C_20210930_drugIncomeTaxAuthorityNameOfCountryAxis_drugTaxAuthorityOfCanadaMember_drugNonCapitalLossCarryForwardsYearOfOriginAxis_drugTaxYearOfOrigin2019Member" unitRef="CAD">79,000</ix:nonFraction></span></span></td>
                                        <td style="vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;">&#160;</td>
                                    </tr>
                                    <tr>
                                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: center;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">2020</span></span></td>
                                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: center;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span style="-sec-ix-hidden: Fxbrl_20211228221912500;">2040</span></span></span></td>
                                        <td style="vertical-align: bottom; width: 1%; text-align: left;">&#160;</td>
                                        <td style="vertical-align: bottom; width: 22%; text-align: right;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><ix:nonFraction id="Fxbrl_20211228222028848" name="drug:NonCapitalLossCarryForwards" scale="0" decimals="0" format="ixt:numdotdecimal" contextRef="C_20210930_drugIncomeTaxAuthorityNameOfCountryAxis_drugTaxAuthorityOfCanadaMember_drugNonCapitalLossCarryForwardsYearOfOriginAxis_drugTaxYearOfOrigin2020Member" unitRef="CAD">324,000</ix:nonFraction></span></span></td>
                                        <td style="vertical-align: bottom; width: 2%; text-align: left;">&#160;</td>
                                    </tr>
                                    <tr>
                                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">2021</span></span></td>
                                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span style="-sec-ix-hidden: Fxbrl_20211228221915311;">2041</span></span></span></td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 22%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><ix:nonFraction id="Fxbrl_20211228222032143" name="drug:NonCapitalLossCarryForwards" scale="0" decimals="0" format="ixt:numdotdecimal" contextRef="C_20210930_drugIncomeTaxAuthorityNameOfCountryAxis_drugTaxAuthorityOfCanadaMember_drugNonCapitalLossCarryForwardsYearOfOriginAxis_drugTaxYearOfOrigin2021Member" unitRef="CAD">9,537,000</ix:nonFraction></span></span></td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                    </tr>
                                    <tr>
                                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: center;">&#160;</td>
                                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: center;">&#160;</td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%;">&#160;</td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 22%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><ix:nonFraction id="Fxbrl_20211228222035291" name="drug:NonCapitalLossCarryForwards" scale="0" decimals="0" format="ixt:numdotdecimal" contextRef="C_20210930_drugIncomeTaxAuthorityNameOfCountryAxis_drugTaxAuthorityOfCanadaMember" unitRef="CAD">9,940,000</ix:nonFraction></span></span></td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%;">&#160;</td>
                                    </tr>
                                </table>
                            </div>
                        </ix:nonNumeric>
                    </div>
                </ix:continuation>
            </div>
            <div>
                <div>
                    <ix:nonNumeric id="Fxbrl_20211228162510889" name="drug:DisclosureOfComparativeAmountsExplanatory" escape="true" contextRef="C_20201001to20210930">
                        <div>
                            <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>13.<span style="display: inline-block; width: 8pt;">&#160;</span>COMPARATIVE AMOUNTS</b></span></span></p>
                            <p style="text-align: justify; margin-bottom: 0px;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Certain of the prior year's amounts have been reclassified to conform with the current year's presentation (see Note 10).</span></span></p>
                        </div>
                    </ix:nonNumeric>
                </div>
            </div>
            <div>
                <div>
                    <ix:nonNumeric id="Fxbrl_20211228155240606" name="ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory" escape="true" contextRef="C_20201001to20210930" continuedAt="F20211228155315085">
                        <div>
                            <p style="text-align: justify; margin-top: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>14.<span style="display: inline-block; width: 8pt;">&#160;</span>SUBSEQUENT EVENTS</b></span></span></p>
                            <p style="text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">Events not disclosed elsewhere in these consolidated financial statements are as follows:</span></span></p>
                            <p style="text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">On November 1, 2021, the Company entered into a letter agreement (the "LA") with a New York-based company, whereby the company will provide investor relations services to the Company. As compensation for performing these services, the Company will pay a non-refundable monthly retainer of US$<ix:nonFraction id="Fxbrl_20211228163430937" name="drug:AmountOfNonRefundableMonthlyRetainerAsServiceCompensation" scale="0" decimals="0" format="ixt:numdotdecimal" contextRef="C_20211001to20211101_drugTypeOfArrangementsAxis_drugLetterAgreementMember_ifrsfullNonadjustingEventsAfterReportingPeriodAxis_drugSubsequentEventsMember" unitRef="CAD">5,000</ix:nonFraction> and issue <ix:nonFraction id="Fxbrl_20211228163501137" name="drug:NumberOfRestrictedStockIssuedForCompensation" decimals="INF" format="ixt:numdotdecimal" contextRef="C_20211101_drugTypeOfArrangementsAxis_drugLetterAgreementMember_ifrsfullNonadjustingEventsAfterReportingPeriodAxis_drugSubsequentEventsMember" unitRef="Share">11,200</ix:nonFraction> shares of restricted stock in three tranches: <ix:nonFraction id="Fxbrl_20211228163517849" name="drug:NumberOfRestrictedStockIssuedForCompensation" decimals="INF" format="ixt:numdotdecimal" contextRef="C_20211101_drugTranchesAxis_drugFirstTrancheMember_drugTypeOfArrangementsAxis_drugLetterAgreementMember_ifrsfullNonadjustingEventsAfterReportingPeriodAxis_drugSubsequentEventsMember" unitRef="Share">3,800</ix:nonFraction> on January 1, 2022; <ix:nonFraction id="Fxbrl_20211228163522517" name="drug:NumberOfRestrictedStockIssuedForCompensation" decimals="INF" format="ixt:numdotdecimal" contextRef="C_20211101_drugTranchesAxis_drugSecondTrancheMember_drugTypeOfArrangementsAxis_drugLetterAgreementMember_ifrsfullNonadjustingEventsAfterReportingPeriodAxis_drugSubsequentEventsMember" unitRef="Share">3,700</ix:nonFraction> on April 1, 2022 and <ix:nonFraction id="Fxbrl_20211228163527244" name="drug:NumberOfRestrictedStockIssuedForCompensation" decimals="INF" format="ixt:numdotdecimal" contextRef="C_20211101_drugTranchesAxis_drugThirdTrancheMember_drugTypeOfArrangementsAxis_drugLetterAgreementMember_ifrsfullNonadjustingEventsAfterReportingPeriodAxis_drugSubsequentEventsMember" unitRef="Share">3,700</ix:nonFraction> on July 1, 2022. If the contract is terminated prior to the issuance date, the outstanding balance is not owed. The services will continue for an initial term of one year unless sooner terminated by either party giving the other 15 days written notice. </span></span></p>
                        </div>
                    </ix:nonNumeric>
                    <div>
                        <table style="width: 100%; border-collapse: collapse; font-size: 10pt;" border="0" cellspacing="0" cellpadding="0">
                            <tr>
                                <td style="width: 100%; text-align: center; border-top: 1pt solid black;">
                                    <p style="font-size: 10pt; font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>22</b> | Page</span></span></p>
                                </td>
                            </tr>
                        </table>
                    </div>
                    <hr style="page-break-after: always; text-align: center; height: 5px; width: 100%; background-color: black;" />
                </div>
            </div>
            <div>
                <div>
                    <div>
                        <table style="width: 100%; font-size: 10pt;" border="0" cellspacing="0" cellpadding="0">
                            <tr>
                                <td style="width: 100%;">
                                    <div style="margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman, Times, serif; font-size: 10pt;"><b>Bright Minds Biosciences Inc.</b></span></div>
                                    <div style="margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman, Times, serif; font-size: 10pt;">Notes to the Consolidated Financial Statements</span></div>
                                    <div style="margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman, Times, serif; font-size: 10pt;">For the years ended September 30, 2021 and 2020 and the period from May 31, 2019 (date of incorporation) to September 30, 2019</span></div>
                                    <div style="margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman, Times, serif; font-size: 10pt;">(Expressed in Canadian Dollars)</span></div>
                                </td>
                            </tr>
                        </table>
                    </div>
                    <ix:continuation id="F20211228155315085">
                        <div>
                            <div style="text-align: justify; margin-top: 10pt;"><span style="font-family: Times New Roman, Times, serif; font-size: 10pt;">On November 9, 2021, <ix:nonFraction id="Fxbrl_20211228163913666" name="drug:NumberOfWarrantsExercised" decimals="INF" format="ixt:numdotdecimal" contextRef="C_20211001to20211109_drugTypeOfArrangementsAxis_drugLetterAgreementMember_ifrsfullNonadjustingEventsAfterReportingPeriodAxis_drugSubsequentEventsMember" unitRef="Share">12,500</ix:nonFraction> warrants were exercised for gross proceeds of $<ix:nonFraction id="Fxbrl_20211228163928849" name="drug:GrossProceedsFromWarrantsExercised" scale="0" decimals="0" format="ixt:numdotdecimal" contextRef="C_20211001to20211109_drugTypeOfArrangementsAxis_drugLetterAgreementMember_ifrsfullNonadjustingEventsAfterReportingPeriodAxis_drugSubsequentEventsMember" unitRef="CAD">118,250</ix:nonFraction>.</span><br />&#160;</div>
                            <div style="margin-top: 0pt; margin-bottom: 11px; text-align: justify; font-size: 10pt; font-family: Times New Roman, Times, serif;"><span style="font-family: Times New Roman, Times, serif; font-size: 10pt; line-height: normal;">In November 2021, the Company entered into director indemnity agreements (the "DIAs") with five directors of the Company. Pursuant to the DIAs and subject to all applicable laws, including the applicable limitations and restrictions set forth in the Business Corporations Act (British Columbia), the Company will:&#160;</span></div>
                            <div style="margin-top: 0pt; margin-bottom: 11px; text-align: justify; font-size: 10pt; font-family: Times New Roman, Times, serif;">
                                <table style="width: 100%; border: 0px;">
                                    <tr>
                                        <td style="width: 42px; padding: 0.1px;">
                                            <p style="margin-top: 6px; margin-bottom: 0pt; font-size: 10pt; font-family: Times New Roman, Times, serif;"><span style="line-height: normal; font-size: 10pt; font-family: Times New Roman, serif;">&#160; &#160; &#160; &#160;&#8226;</span></p>
                                        </td>
                                        <td style="width: 1087px; padding: 0.1px; vertical-align: top;" colspan="2">
                                            <p style="margin-top: 6px; margin-bottom: 0pt; text-align: justify; font-size: 10pt; font-family: Times New Roman, Times, serif;"><span style="font-size: 11pt; line-height: normal; font-family: Calibri, sans-serif;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman, serif;"><span style="color: black;">Indemnify and save harmless the Directors against and from:</span></span></span></span></p>
                                        </td>
                                    </tr>
                                    <tr>
                                        <td style="width: 42px; padding: 0.1px;">&#160;</td>
                                        <td style="width: 22px; padding: 0.1px; vertical-align: top;">
                                            <p style="margin-top: 10pt; margin-bottom: 0pt; font-size: 10pt; font-family: Times New Roman, Times, serif;"><span style="font-size: 11pt; line-height: normal; font-family: Calibri, sans-serif;"><span style="font-size: 8pt;"><span style="font-family: Times New Roman, serif;">o</span></span></span></p>
                                        </td>
                                        <td style="width: 1065px; padding: 0.1px; vertical-align: top;">
                                            <p style="margin-top: 10pt; margin-bottom: 0pt; text-align: justify; font-size: 10pt; font-family: Times New Roman, Times, serif;"><span style="line-height: normal; font-size: 10pt; font-family: Times New Roman, serif;">any and all charges or claims by reason of them being or having been a director of the Company or another corporation, at a time when the other corporation is or was an affiliate of the Company, or at the request of the Company;</span></p>
                                        </td>
                                    </tr>
                                    <tr>
                                        <td style="width: 42px; padding: 0.1px;">&#160;</td>
                                        <td style="width: 22px; padding: 0.1px; vertical-align: top;">
                                            <p style="margin-top: 0px; margin-bottom: 0pt; font-size: 10pt; font-family: Times New Roman, Times, serif;"><span style="font-size: 11pt; line-height: normal; font-family: Calibri, sans-serif;"><span style="font-size: 8pt;"><span style="font-family: Times New Roman, serif;">o</span></span></span></p>
                                        </td>
                                        <td style="width: 1065px; padding: 0.1px; vertical-align: top;">
                                            <p style="margin-top: 0px; margin-bottom: 0pt; text-align: justify; font-size: 10pt; font-family: Times New Roman, Times, serif;"><span style="line-height: normal; font-size: 10pt; font-family: Times New Roman, serif;">any and all costs, damages, expenses, fines, liabilities, losses and penalties (the "Consequences") which they may sustain, incur or be liable for in consequence of their acting as a director of the Company, whether sustained or incurred by reason of their negligence, default, breach of duty or trust, failure to exercise due diligence or otherwise in relation to the Company or any of its affairs; and</span></p>
                                        </td>
                                    </tr>
                                    <tr>
                                        <td style="width: 42px; padding: 0.1px;">&#160;</td>
                                        <td style="width: 22px; padding: 0.1px; vertical-align: top;">
                                            <p style="margin-top: 0px; margin-bottom: 0pt; font-size: 10pt; font-family: Times New Roman, Times, serif;"><span style="font-size: 11pt; line-height: normal; font-family: Calibri, sans-serif;"><span style="font-size: 8pt;"><span style="font-family: Times New Roman, serif;">o</span></span></span></p>
                                        </td>
                                        <td style="width: 1065px; padding: 0.1px; vertical-align: top;">
                                            <p style="margin-top: 0px; margin-bottom: 0pt; text-align: justify; font-size: 10pt; font-family: Times New Roman, Times, serif;"><span style="line-height: normal; font-size: 10pt; font-family: Times New Roman, serif;">in particular, and without in any way limiting the generality of the foregoing, any and all Consequences which they may sustain, incur or be liable for as a result of or in connection with the release or presence in the environment of substances, contaminants, litter, waste, effluent, refuse, pollutants or deleterious materials and that arise out of or are in any way connected with the management, operation, activities or existence of the Company or by virtue of them holding any other directorship with any other entity at the Company's request.</span></p>
                                        </td>
                                    </tr>
                                    <tr>
                                        <td style="width: 42px; padding: 0.1px;">
                                            <p style="margin-top: 10pt; margin-bottom: 0pt; font-size: 10pt; font-family: Times New Roman, Times, serif;"><span style="line-height: normal; font-size: 10pt; font-family: Times New Roman, serif;">&#160; &#160; &#160; &#8226;</span></p>
                                        </td>
                                        <td style="width: 1087px; padding: 0.1px; vertical-align: top;" colspan="2">
                                            <p style="margin-top: 10pt; margin-bottom: 0pt; text-align: justify; font-size: 10pt; font-family: Times New Roman, Times, serif;"><span style="line-height: normal; font-size: 10pt; font-family: Times New Roman, serif;">gross up any indemnity payment made pursuant to the DIAs by the amount of any income tax payable by the Directors in respect of that payment; and</span></p>
                                        </td>
                                    </tr>
                                    <tr>
                                        <td style="width: 42px; padding: 0.1px;">
                                            <p style="margin-top: 10pt; margin-bottom: 0pt; font-size: 10pt; font-family: Times New Roman, Times, serif;"><span style="line-height: normal; font-size: 10pt; font-family: Times New Roman, serif;">&#160; &#160; &#160; &#8226;</span></p>
                                        </td>
                                        <td style="width: 1087px; padding: 0.1px; vertical-align: top;" colspan="2">
                                            <p style="margin-top: 10pt; margin-bottom: 0pt; text-align: justify; font-size: 10pt; font-family: Times New Roman, Times, serif;"><span style="line-height: normal; font-size: 10pt; font-family: Times New Roman, serif;">indemnify the Directors for the amount of all costs they incur in obtaining any Court approval required to enable or require the Company to make a payment to them under the DIAs, or enforce the DIAs against the Company, including without limitation legal fees and disbursements on a full indemnity basis.</span></p>
                                        </td>
                                    </tr>
                                </table>
                            </div>
                            <div style="text-align: justify; margin-top: 10pt;"><span style="font-family: Times New Roman, Times, serif; font-size: 10pt;">Notwithstanding the above-noted, the Company will have no obligation to indemnify or save harmless the Directors in respect of any liability for which they are entitled to indemnity pursuant to any valid and collectible policy of insurance obtained and maintained by the Company, to the extent of the amounts actually collected by the Directors under the insurance policy.</span></div>
                        </div>
                    </ix:continuation>
                    <div>
                        <p style="margin: 0pt;">&#160;</p>
                        <table style="width: 100%; font-size: 10pt;" border="0" cellspacing="0" cellpadding="0">
                            <tr>
                                <td style="width: 100%; text-align: center; border-top: 1pt solid black;">
                                    <p style="font-size: 10pt; font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right;"><span style="font-family: Times New Roman, Times, serif; font-size: 10pt;"><b>23</b>&#160;| Page</span></p>
                                </td>
                            </tr>
                        </table>
                    </div>
                    <hr style="page-break-after: always; text-align: center; height: 5px; width: 100%; background-color: black;" />
                </div>
            </div>
            <div>
                <div>
                    <div><span style="font-size: 10pt;"><b>ITEM 19. EXHIBITS</b></span></div>
                </div>
                <div style="text-align: justify;"><br /></div>
                <div style="text-align: justify;"><span style="font-family: Times New Roman, Times, serif; font-size: 10pt;">The following exhibits are filed as part of this Annual Report on Form 20-F:</span></div>
                <div style="text-align: justify;"><br /></div>
                <table style="width: 100%; font-size: 10pt;" cellspacing="0" cellpadding="0">
                    <tr>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; width: 10%; vertical-align: top; background-color: #eeeeee;">
                            <div><a href="http://www.sec.gov/Archives/edgar/data/1827401/000106299321005781/exhibit1-1.htm"><span style="font-family: Times New Roman, Times, serif; font-size: 10pt;">1.1</span></a></div>
                        </td>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; background-color: #eeeeee;">
                            <div><a href="http://www.sec.gov/Archives/edgar/data/1827401/000106299321005781/exhibit1-1.htm"><span style="font-family: Times New Roman, Times, serif; font-size: 10pt;">Notice of Articles<sup>(1)</sup></span></a></div>
                        </td>
                    </tr>
                    <tr>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; width: 10%; vertical-align: top;">
                            <div><br /></div>
                        </td>
                        <td style="margin-top: 0pt; margin-bottom: 0pt;">
                            <div><br /></div>
                        </td>
                    </tr>
                    <tr>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; width: 10%; vertical-align: top; background-color: #eeeeee;">
                            <div><a href="http://www.sec.gov/Archives/edgar/data/1827401/000106299321005781/exhibit1-2.htm"><span style="font-family: Times New Roman, Times, serif; font-size: 10pt;">1.2</span></a></div>
                        </td>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; background-color: #eeeeee;">
                            <div><a href="http://www.sec.gov/Archives/edgar/data/1827401/000106299321005781/exhibit1-2.htm"><span style="font-family: Times New Roman, Times, serif; font-size: 10pt;">Articles<sup>(1)</sup></span></a></div>
                        </td>
                    </tr>
                    <tr>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; width: 10%; vertical-align: top;">
                            <div><br /></div>
                        </td>
                        <td style="margin-top: 0pt; margin-bottom: 0pt;">
                            <div><br /></div>
                        </td>
                    </tr>
                    <tr>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; width: 10%; vertical-align: top; background-color: #eeeeee;">
                            <div><a href="http://www.sec.gov/Archives/edgar/data/1827401/000106299321005781/exhibit2-1.htm"><span style="font-family: Times New Roman, Times, serif; font-size: 10pt;">2.1</span></a></div>
                        </td>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; background-color: #eeeeee;">
                            <div><a href="http://www.sec.gov/Archives/edgar/data/1827401/000106299321005781/exhibit2-1.htm"><span style="font-family: Times New Roman, Times, serif; font-size: 10pt;">Form of Common Share Certificate<sup>(1)</sup></span></a></div>
                        </td>
                    </tr>
                    <tr>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; width: 10%; vertical-align: top;">
                            <div><br /></div>
                        </td>
                        <td style="margin-top: 0pt; margin-bottom: 0pt;">
                            <div><br /></div>
                        </td>
                    </tr>
                    <tr>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; width: 10%; vertical-align: top; background-color: #eeeeee;">
                            <div><a href="http://www.sec.gov/Archives/edgar/data/1827401/000106299321013611/exhibit2-2.htm"><span style="font-family: Times New Roman, Times, serif; font-size: 10pt;">2.2</span></a></div>
                        </td>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; background-color: #eeeeee;">
                            <div><a href="http://www.sec.gov/Archives/edgar/data/1827401/000106299321013611/exhibit2-2.htm"><span style="font-family: Times New Roman, Times, serif; font-size: 10pt;">Description of Registrant's Securiti</span><span style="font-family: Times New Roman, Times, serif; font-size: 10pt;">es<sup>(3)</sup></span></a></div>
                        </td>
                    </tr>
                    <tr>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; width: 10%; vertical-align: top;">
                            <div><br /></div>
                        </td>
                        <td style="margin-top: 0pt; margin-bottom: 0pt;">
                            <div><br /></div>
                        </td>
                    </tr>
                    <tr>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; width: 10%; vertical-align: top; background-color: #eeeeee;">
                            <div><a href="http://www.sec.gov/Archives/edgar/data/1827401/000106299321005781/exhibit4-1.htm"><span style="font-family: Times New Roman, Times, serif; font-size: 10pt;">4.1</span></a></div>
                        </td>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; background-color: #eeeeee;">
                            <div><a href="http://www.sec.gov/Archives/edgar/data/1827401/000106299321005781/exhibit4-1.htm"><span style="font-family: Times New Roman, Times, serif; font-size: 10pt;">Escrow Agreement dated January 28, 2021<sup>(1)</sup></span></a></div>
                        </td>
                    </tr>
                    <tr>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; width: 10%; vertical-align: top;">
                            <div><br /></div>
                        </td>
                        <td style="margin-top: 0pt; margin-bottom: 0pt;">
                            <div><br /></div>
                        </td>
                    </tr>
                    <tr>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; width: 10%; vertical-align: top; background-color: #eeeeee;">
                            <div><a href="http://www.sec.gov/Archives/edgar/data/1827401/000106299321006791/exhibit4-2.htm"><span style="font-family: Times New Roman, Times, serif; font-size: 10pt;">4.2</span></a></div>
                        </td>
                        <td style="vertical-align: top; background-color: #eeeeee;">
                            <div style="text-align: justify; margin-top: 0pt; margin-bottom: 0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1827401/000106299321006791/exhibit4-2.htm"><span style="font-family: Times New Roman, Times, serif; font-size: 10pt;">Independent Contractor Agreement with Dr. Alan Kozikowski dated October 29, 2020<sup>(2</sup><sup>)+</sup></span></a></div>
                        </td>
                    </tr>
                    <tr>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; width: 10%; vertical-align: top;">
                            <div><br /></div>
                        </td>
                        <td style="margin-top: 0pt; margin-bottom: 0pt;">
                            <div><br /></div>
                        </td>
                    </tr>
                    <tr>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; width: 10%; vertical-align: top; background-color: #eeeeee;">
                            <div><a href="http://www.sec.gov/Archives/edgar/data/1827401/000106299321006791/exhibit4-3.htm"><span style="font-family: Times New Roman, Times, serif; font-size: 10pt;">4.3</span></a></div>
                        </td>
                        <td style="vertical-align: top; background-color: #eeeeee;">
                            <div style="text-align: justify; margin-top: 0pt; margin-bottom: 0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1827401/000106299321006791/exhibit4-3.htm"><span style="font-family: Times New Roman, Times, serif; font-size: 10pt;">Independent Consultant Agreement with Revati, Inc. dated June 5, 2020<sup>(2</sup><sup>)+</sup></span></a></div>
                        </td>
                    </tr>
                    <tr>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; width: 10%; vertical-align: top;">
                            <div><br /></div>
                        </td>
                        <td style="margin-top: 0pt; margin-bottom: 0pt;">
                            <div><br /></div>
                        </td>
                    </tr>
                    <tr>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; width: 10%; vertical-align: top; background-color: #eeeeee;">
                            <div><a href="http://www.sec.gov/Archives/edgar/data/1827401/000106299321006791/exhibit4-4.htm"><span style="font-family: Times New Roman, Times, serif; font-size: 10pt;">4.4</span></a></div>
                        </td>
                        <td style="vertical-align: top; background-color: #eeeeee;">
                            <div style="text-align: justify; margin-top: 0pt; margin-bottom: 0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1827401/000106299321006791/exhibit4-4.htm"><span style="font-family: Times New Roman, Times, serif; font-size: 10pt;">Independent Contractor Agreement with Dr. Giedon Shapiro dated November 17, 2021<sup>(</sup><sup>2</sup><sup>)+</sup></span></a></div>
                        </td>
                    </tr>
                    <tr>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; width: 10%; vertical-align: top;">
                            <div><br /></div>
                        </td>
                        <td style="margin-top: 0pt; margin-bottom: 0pt;">
                            <div><br /></div>
                        </td>
                    </tr>
                    <tr>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; width: 10%; vertical-align: top; background-color: #eeeeee;">
                            <div><a href="http://www.sec.gov/Archives/edgar/data/1827401/000106299321005781/exhibit4-2.htm"><span style="font-family: Times New Roman, Times, serif; font-size: 10pt;">4.5</span></a></div>
                        </td>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; background-color: #eeeeee;">
                            <div><a href="http://www.sec.gov/Archives/edgar/data/1827401/000106299321005781/exhibit4-2.htm"><span style="font-family: Times New Roman, Times, serif; font-size: 10pt;">Consulting Agreement with Dr. Krista Lanctot dated August 15, 2020<sup>(1)+</sup></span></a></div>
                        </td>
                    </tr>
                    <tr>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; width: 10%; vertical-align: top;">
                            <div><br /></div>
                        </td>
                        <td style="margin-top: 0pt; margin-bottom: 0pt;">
                            <div><br /></div>
                        </td>
                    </tr>
                    <tr>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; width: 10%; vertical-align: top; background-color: #eeeeee;">
                            <div><a href="http://www.sec.gov/Archives/edgar/data/1827401/000106299321005781/exhibit4-3.htm"><span style="font-family: Times New Roman, Times, serif; font-size: 10pt;">4.6</span></a></div>
                        </td>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; background-color: #eeeeee;">
                            <div><a href="http://www.sec.gov/Archives/edgar/data/1827401/000106299321005781/exhibit4-3.htm"><span style="font-family: Times New Roman, Times, serif; font-size: 10pt;">Consulting Agreement with Werner Tueckmantel dated August 15, 2020<sup>(1)+</sup></span></a></div>
                        </td>
                    </tr>
                    <tr>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; width: 10%; vertical-align: top;">
                            <div><br /></div>
                        </td>
                        <td style="margin-top: 0pt; margin-bottom: 0pt;">
                            <div><br /></div>
                        </td>
                    </tr>
                    <tr>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; width: 10%; vertical-align: top; background-color: #eeeeee;">
                            <div><a href="http://www.sec.gov/Archives/edgar/data/1827401/000106299321005781/exhibit4-4.htm"><span style="font-family: Times New Roman, Times, serif; font-size: 10pt;">4.7</span></a></div>
                        </td>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; background-color: #eeeeee;">
                            <div><a href="http://www.sec.gov/Archives/edgar/data/1827401/000106299321005781/exhibit4-4.htm"><span style="font-family: Times New Roman, Times, serif; font-size: 10pt;">Consulting Agreement with John McCorvy dated August 15, 2020<sup>(1)+</sup></span></a></div>
                        </td>
                    </tr>
                    <tr>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; width: 10%; vertical-align: top;">
                            <div><br /></div>
                        </td>
                        <td style="margin-top: 0pt; margin-bottom: 0pt;">
                            <div><br /></div>
                        </td>
                    </tr>
                    <tr>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; width: 10%; vertical-align: top; background-color: #eeeeee;">
                            <div><a href="http://www.sec.gov/Archives/edgar/data/1827401/000106299321005781/exhibit4-5.htm"><span style="font-family: Times New Roman, Times, serif; font-size: 10pt;">4.8</span></a></div>
                        </td>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; background-color: #eeeeee;">
                            <div><a href="http://www.sec.gov/Archives/edgar/data/1827401/000106299321005781/exhibit4-5.htm"><span style="font-family: Times New Roman, Times, serif; font-size: 10pt;">Consulting Agreement with Peter Kowey dated August 15, 2020<sup>(1)+</sup></span></a></div>
                        </td>
                    </tr>
                    <tr>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; width: 10%; vertical-align: top;">
                            <div><br /></div>
                        </td>
                        <td style="margin-top: 0pt; margin-bottom: 0pt;">
                            <div><br /></div>
                        </td>
                    </tr>
                    <tr>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; width: 10%; vertical-align: top; background-color: #eeeeee;">
                            <div><a href="http://www.sec.gov/Archives/edgar/data/1827401/000106299321005781/exhibit4-6.htm"><span style="font-family: Times New Roman, Times, serif; font-size: 10pt;">4.9</span></a></div>
                        </td>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; background-color: #eeeeee;">
                            <div><a href="http://www.sec.gov/Archives/edgar/data/1827401/000106299321005781/exhibit4-6.htm"><span style="font-family: Times New Roman, Times, serif; font-size: 10pt;">Consulting Agreement with Arina Zhukova dated August 15, 2020<sup>(1)+</sup></span></a></div>
                        </td>
                    </tr>
                    <tr>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; width: 10%; vertical-align: top;">
                            <div><br /></div>
                        </td>
                        <td style="margin-top: 0pt; margin-bottom: 0pt;">
                            <div><br /></div>
                        </td>
                    </tr>
                    <tr>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; width: 10%; vertical-align: top; background-color: #eeeeee;">
                            <div><a href="http://www.sec.gov/Archives/edgar/data/1827401/000106299321005781/exhibit4-7.htm"><span style="font-family: Times New Roman, Times, serif; font-size: 10pt;">4.10</span></a></div>
                        </td>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; background-color: #eeeeee;">
                            <div><a href="http://www.sec.gov/Archives/edgar/data/1827401/000106299321005781/exhibit4-7.htm"><span style="font-family: Times New Roman, Times, serif; font-size: 10pt;">Consulting Agreement with Laurentiu Nicolae dated August 15, 2020<sup>(1)+</sup></span></a></div>
                        </td>
                    </tr>
                    <tr>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; width: 10%; vertical-align: top;">
                            <div><br /></div>
                        </td>
                        <td style="margin-top: 0pt; margin-bottom: 0pt;">
                            <div><br /></div>
                        </td>
                    </tr>
                    <tr>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; width: 10%; vertical-align: top; background-color: #eeeeee;">
                            <div><a href="http://www.sec.gov/Archives/edgar/data/1827401/000106299321005781/exhibit4-8.htm"><span style="font-family: Times New Roman, Times, serif; font-size: 10pt;">4.11</span></a></div>
                        </td>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; background-color: #eeeeee;">
                            <div><a href="http://www.sec.gov/Archives/edgar/data/1827401/000106299321005781/exhibit4-8.htm"><span style="font-family: Times New Roman, Times, serif; font-size: 10pt;">Consulting Agreement with Jesse Damsker dated August 15, 2020<sup>(1)+</sup></span></a></div>
                        </td>
                    </tr>
                    <tr>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; width: 10%; vertical-align: top;">
                            <div><br /></div>
                        </td>
                        <td style="margin-top: 0pt; margin-bottom: 0pt;">
                            <div><br /></div>
                        </td>
                    </tr>
                    <tr>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; width: 10%; vertical-align: top; background-color: #eeeeee;">
                            <div><a href="http://www.sec.gov/Archives/edgar/data/1827401/000106299321005781/exhibit4-10.htm"><span style="font-family: Times New Roman, Times, serif; font-size: 10pt;">4.12</span></a></div>
                        </td>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; background-color: #eeeeee;">
                            <div><a href="http://www.sec.gov/Archives/edgar/data/1827401/000106299321005781/exhibit4-10.htm"><span style="font-family: Times New Roman, Times, serif; font-size: 10pt;">Consulting Agreement with Toxicology Services Inc. dated December 22, 2020<sup>(1)+</sup></span></a></div>
                        </td>
                    </tr>
                    <tr>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; width: 10%; vertical-align: top;">
                            <div><br /></div>
                        </td>
                        <td style="margin-top: 0pt; margin-bottom: 0pt;">
                            <div><br /></div>
                        </td>
                    </tr>
                    <tr>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; width: 10%; vertical-align: top; background-color: #eeeeee;">
                            <div><a href="http://www.sec.gov/Archives/edgar/data/1827401/000106299321005781/exhibit4-11.htm"><span style="font-family: Times New Roman, Times, serif; font-size: 10pt;">4.13</span></a></div>
                        </td>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; background-color: #eeeeee;">
                            <div><a href="http://www.sec.gov/Archives/edgar/data/1827401/000106299321005781/exhibit4-11.htm"><span style="font-family: Times New Roman, Times, serif; font-size: 10pt;">Consulting Agreement with Uro&#353; Laban dated January 4, 2021<sup>(1)+</sup></span></a></div>
                        </td>
                    </tr>
                    <tr>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; width: 10%; vertical-align: top;">
                            <div><br /></div>
                        </td>
                        <td style="margin-top: 0pt; margin-bottom: 0pt;">
                            <div><br /></div>
                        </td>
                    </tr>
                    <tr>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; width: 10%; vertical-align: top; background-color: #eeeeee;">
                            <div><a href="http://www.sec.gov/Archives/edgar/data/1827401/000106299321005781/exhibit4-12.htm"><span style="font-family: Times New Roman, Times, serif; font-size: 10pt;">4.14</span></a></div>
                        </td>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; background-color: #eeeeee;">
                            <div><a href="http://www.sec.gov/Archives/edgar/data/1827401/000106299321005781/exhibit4-12.htm"><span style="font-family: Times New Roman, Times, serif; font-size: 10pt;">Consulting Agreement with John McCall dated January 25, 2021<sup>(1)+</sup></span></a></div>
                        </td>
                    </tr>
                    <tr>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; width: 10%; vertical-align: top;">
                            <div><br /></div>
                        </td>
                        <td style="margin-top: 0pt; margin-bottom: 0pt;">
                            <div><br /></div>
                        </td>
                    </tr>
                    <tr>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; width: 10%; vertical-align: top; background-color: #eeeeee;">
                            <div><a href="http://www.sec.gov/Archives/edgar/data/1827401/000106299321005781/exhibit4-13.htm"><span style="font-family: Times New Roman, Times, serif; font-size: 10pt;">4.15</span></a></div>
                        </td>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; background-color: #eeeeee;">
                            <div><a href="http://www.sec.gov/Archives/edgar/data/1827401/000106299321005781/exhibit4-13.htm"><span style="font-family: Times New Roman, Times, serif; font-size: 10pt;">Independent Contractor Agreement with Bay Area Clinical Research Consulting LLC, Katherine McDougall dated May 7, 2021<sup>(1)+</sup></span></a></div>
                        </td>
                    </tr>
                    <tr>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; width: 10%; vertical-align: top;">
                            <div><br /></div>
                        </td>
                        <td style="margin-top: 0pt; margin-bottom: 0pt;">
                            <div><br /></div>
                        </td>
                    </tr>
                    <tr>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; width: 10%; vertical-align: top; background-color: #eeeeee;">
                            <div><a href="http://www.sec.gov/Archives/edgar/data/1827401/000106299321005781/exhibit4-14.htm"><span style="font-family: Times New Roman, Times, serif; font-size: 10pt;">4.16</span></a></div>
                        </td>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; background-color: #eeeeee;">
                            <div><a href="http://www.sec.gov/Archives/edgar/data/1827401/000106299321005781/exhibit4-14.htm"><span style="font-family: Times New Roman, Times, serif; font-size: 10pt;">Scientific Advisory Board Agreement with Narayan R. Kissoon, MD dated June 1, 2020<sup>(1)+</sup></span></a></div>
                        </td>
                    </tr>
                    <tr>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; width: 10%; vertical-align: top;">
                            <div><br /></div>
                        </td>
                        <td style="margin-top: 0pt; margin-bottom: 0pt;">
                            <div><br /></div>
                        </td>
                    </tr>
                    <tr>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; width: 10%; vertical-align: top; background-color: #eeeeee;">
                            <div><a href="http://www.sec.gov/Archives/edgar/data/1827401/000106299321005781/exhibit4-15.htm"><span style="font-family: Times New Roman, Times, serif; font-size: 10pt;">4.17</span></a></div>
                        </td>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; background-color: #eeeeee;">
                            <div><a href="http://www.sec.gov/Archives/edgar/data/1827401/000106299321005781/exhibit4-15.htm"><span style="font-family: Times New Roman, Times, serif; font-size: 10pt;">Scientific Advisory Board Agreement with Peter Hendricks dated July 14, 2020<sup>(1)+</sup></span></a></div>
                        </td>
                    </tr>
                    <tr>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; width: 10%; vertical-align: top;">
                            <div><br /></div>
                        </td>
                        <td style="margin-top: 0pt; margin-bottom: 0pt;">
                            <div><br /></div>
                        </td>
                    </tr>
                    <tr>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; width: 10%; vertical-align: top; background-color: #eeeeee;">
                            <div><a href="http://www.sec.gov/Archives/edgar/data/1827401/000106299321005781/exhibit4-16.htm"><span style="font-family: Times New Roman, Times, serif; font-size: 10pt;">4.18</span></a></div>
                        </td>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; background-color: #eeeeee;">
                            <div><a href="http://www.sec.gov/Archives/edgar/data/1827401/000106299321005781/exhibit4-16.htm"><span style="font-family: Times New Roman, Times, serif; font-size: 10pt;">Scientific Advisory Board Agreement with Jianmin Duan dated April 21, 2021<sup>(1)+</sup></span></a></div>
                        </td>
                    </tr>
                    <tr>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; width: 10%; vertical-align: top;">
                            <div><br /></div>
                        </td>
                        <td style="margin-top: 0pt; margin-bottom: 0pt;">
                            <div><br /></div>
                        </td>
                    </tr>
                    <tr>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; width: 10%; vertical-align: top; background-color: #eeeeee;">
                            <div><a href="http://www.sec.gov/Archives/edgar/data/1827401/000106299321005781/exhibit4-17.htm"><span style="font-family: Times New Roman, Times, serif; font-size: 10pt;">4.19</span></a></div>
                        </td>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; background-color: #eeeeee;">
                            <div><a href="http://www.sec.gov/Archives/edgar/data/1827401/000106299321005781/exhibit4-17.htm"><span style="font-family: Times New Roman, Times, serif; font-size: 10pt;">Services Agreement dated June 22, 2020 between the Company and the Medical College of Wisconsin, Inc.<sup> (1)+</sup></span></a></div>
                        </td>
                    </tr>
                    <tr>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; width: 10%; vertical-align: top;">
                            <div><br /></div>
                        </td>
                        <td style="margin-top: 0pt; margin-bottom: 0pt;">
                            <div><br /></div>
                        </td>
                    </tr>
                    <tr>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; width: 10%; vertical-align: top; background-color: #eeeeee;">
                            <div><a href="http://www.sec.gov/Archives/edgar/data/1827401/000106299321005781/exhibit4-18.htm"><span style="font-family: Times New Roman, Times, serif; font-size: 10pt;">4.20</span></a></div>
                        </td>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; background-color: #eeeeee;">
                            <div><a href="http://www.sec.gov/Archives/edgar/data/1827401/000106299321005781/exhibit4-18.htm"><span style="font-family: Times New Roman, Times, serif; font-size: 10pt;">Sponsored Research Agreement dated October 15, 2020 between the Company and the University of Texas Medical Branch at Galveston d/b/a UTMB Health<sup>(1)+</sup></span></a></div>
                        </td>
                    </tr>
                </table>
                <div style="text-align: justify;">&#160;</div>
                <div>
                    <div style="text-align: justify;"><br /></div>
                    <div>&#160;</div>
                    <hr style="page-break-after: always; text-align: center; height: 5px; width: 100%; background-color: black;" />
                </div>
                <p>&#160;</p>
                <table style="width: 100%; font-size: 10pt;" cellspacing="0" cellpadding="0">
                    <tr>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; width: 10%; vertical-align: top; background-color: #eeeeee;"><a href="http://www.sec.gov/Archives/edgar/data/1827401/000106299321005781/exhibit4-19.htm"><span style="font-family: Times New Roman, Times, serif; font-size: 10pt;">4.21</span></a></td>
                        <td style="vertical-align: top; background-color: #eeeeee; width: 89.7674%;"><a href="http://www.sec.gov/Archives/edgar/data/1827401/000106299321005781/exhibit4-19.htm"><span style="font-family: Times New Roman, Times, serif; font-size: 10pt;">First Amendment to the Sponsored Research Agreement between the Company and the University of Texas Medical Branch at Galveston d/b/a UTMB Health dated June 11, 2021<sup>(1)+</sup></span></a></td>
                    </tr>
                    <tr>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; width: 10%; vertical-align: top;">&#160;</td>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: top; width: 89.7674%;">&#160;</td>
                    </tr>
                    <tr>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; width: 10%; vertical-align: top; background-color: #eeeeee;"><a href="http://www.sec.gov/Archives/edgar/data/1827401/000106299321005781/exhibit4-20.htm"><span style="font-family: Times New Roman, Times, serif; font-size: 10pt;">4.22</span></a></td>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: top; background-color: #eeeeee; width: 89.7674%;"><a href="http://www.sec.gov/Archives/edgar/data/1827401/000106299321005781/exhibit4-20.htm"><span style="font-family: Times New Roman, Times, serif; font-size: 10pt;">Underwriting Agreement dated February 23, 2021 among the Company, Eight Capital, Stifel Nicolaus Canada Inc., Beacon Securities Limited and Haywood Securities Inc.<sup>(1)</sup></span></a></td>
                    </tr>
                    <tr>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; width: 10%; vertical-align: top;">&#160;</td>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: top; width: 89.7674%;">&#160;</td>
                    </tr>
                    <tr>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; width: 10%; vertical-align: top; background-color: #eeeeee;"><a href="http://www.sec.gov/Archives/edgar/data/1827401/000106299321005781/exhibit4-21.htm"><span style="font-family: Times New Roman, Times, serif; font-size: 10pt;">4.23</span></a></td>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: top; background-color: #eeeeee; width: 89.7674%;"><a href="http://www.sec.gov/Archives/edgar/data/1827401/000106299321005781/exhibit4-21.htm"><span style="font-family: Times New Roman, Times, serif; font-size: 10pt;">Warrant Indenture dated March 17, 2021 between the Company and Computershare Trust Company of Canada<sup>(1)</sup></span></a></td>
                    </tr>
                    <tr>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; width: 10%; vertical-align: top;">&#160;</td>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: top; width: 89.7674%;">&#160;</td>
                    </tr>
                    <tr>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; width: 10%; vertical-align: top; background-color: #eeeeee;"><a href="http://www.sec.gov/Archives/edgar/data/1827401/000106299321006791/exhibit4-25.htm"><span style="font-family: Times New Roman, Times, serif; font-size: 10pt;">4.24</span></a></td>
                        <td style="vertical-align: top; background-color: #eeeeee; width: 89.7674%;"><a href="http://www.sec.gov/Archives/edgar/data/1827401/000106299321006791/exhibit4-25.htm"><span style="font-family: Times New Roman, Times, serif; font-size: 10pt;">Option Agreement dated May 26, 2020 between the Company and the Board of Trustees of the University of Illinois.<sup>(2</sup><sup>)+</sup></span></a></td>
                    </tr>
                    <tr>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; width: 10%; vertical-align: top;">&#160;</td>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: top; width: 89.7674%;">&#160;</td>
                    </tr>
                    <tr>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; width: 10%; vertical-align: top; background-color: #eeeeee;"><a href="http://www.sec.gov/Archives/edgar/data/1827401/000106299321005781/exhibit4-22.htm"><span style="font-family: Times New Roman, Times, serif; font-size: 10pt;">4.25</span></a></td>
                        <td style="vertical-align: top; background-color: #eeeeee; width: 89.7674%;"><a href="http://www.sec.gov/Archives/edgar/data/1827401/000106299321005781/exhibit4-22.htm"><span style="font-family: Times New Roman, Times, serif; font-size: 10pt;">Exclusive License Agreement dated April 23, 2021 between the Company and the Board of Trustees of the University of Illinois.<sup>(1)+</sup></span></a></td>
                    </tr>
                    <tr>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; width: 10%; vertical-align: top;">&#160;</td>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: top; width: 89.7674%;">&#160;</td>
                    </tr>
                    <tr>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; width: 10%; vertical-align: top; background-color: #eeeeee;"><a href="http://www.sec.gov/Archives/edgar/data/1827401/000106299321013611/exhibit8-1.htm"><span style="font-family: Times New Roman, Times, serif; font-size: 10pt;">8.1</span></a></td>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: top; background-color: #eeeeee; width: 89.7674%;"><a href="http://www.sec.gov/Archives/edgar/data/1827401/000106299321013611/exhibit8-1.htm"><span style="font-family: Times New Roman, Times, serif; font-size: 10pt;">List of Subsidiaries<sup>(3)</sup></span></a></td>
                    </tr>
                    <tr>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; width: 10%; vertical-align: top;">&#160;</td>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: top; width: 89.7674%;">&#160;</td>
                    </tr>
                    <tr>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; width: 10%; vertical-align: top; background-color: #eeeeee;"><a href="http://www.sec.gov/Archives/edgar/data/1827401/000106299321005781/exhibit11-1.htm"><span style="font-family: Times New Roman, Times, serif; font-size: 10pt;">11.1</span></a></td>
                        <td style="vertical-align: top; background-color: #eeeeee; width: 89.7674%;"><a href="http://www.sec.gov/Archives/edgar/data/1827401/000106299321005781/exhibit11-1.htm"><span style="font-family: Times New Roman, Times, serif; font-size: 10pt;">Code of Business Conduct and Ethics<sup>(1)</sup></span></a></td>
                    </tr>
                    <tr>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; width: 10%; vertical-align: top;">&#160;</td>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: top; width: 89.7674%;">&#160;</td>
                    </tr>
                    <tr>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; width: 10%; vertical-align: top; background-color: #eeeeee;"><a href="http://www.sec.gov/Archives/edgar/data/1827401/000106299321013611/exhibit12-1.htm"><span style="font-family: Times New Roman, Times, serif; font-size: 10pt;">12.1</span></a></td>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: top; background-color: #eeeeee; width: 89.7674%;"><a href="http://www.sec.gov/Archives/edgar/data/1827401/000106299321013611/exhibit12-1.htm"><span style="font-family: Times New Roman, Times, serif; font-size: 10pt;">Section 302(a) Certification of CEO</span><span style="font-size: 10pt;"><sup>(3)</sup></span></a></td>
                    </tr>
                    <tr>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; width: 10%; vertical-align: top;">&#160;</td>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: top; width: 89.7674%;">&#160;</td>
                    </tr>
                    <tr>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; width: 10%; vertical-align: top; background-color: #eeeeee;"><a href="http://www.sec.gov/Archives/edgar/data/1827401/000106299321013611/exhibit12-2.htm"><span style="font-family: Times New Roman, Times, serif; font-size: 10pt;">12.2</span></a></td>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: top; background-color: #eeeeee; width: 89.7674%;"><a href="http://www.sec.gov/Archives/edgar/data/1827401/000106299321013611/exhibit12-2.htm"><span style="font-family: Times New Roman, Times, serif; font-size: 10pt;">Section 302(a) Certification of CFO</span><span style="font-size: 10pt;"><sup>(3)</sup></span></a></td>
                    </tr>
                    <tr>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; width: 10%; vertical-align: top;">&#160;</td>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: top; width: 89.7674%;">&#160;</td>
                    </tr>
                    <tr>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; width: 10%; vertical-align: top; background-color: #eeeeee;"><a href="http://www.sec.gov/Archives/edgar/data/1827401/000106299321013611/exhibit13-1.htm"><span style="font-family: Times New Roman, Times, serif; font-size: 10pt;">13.1</span></a></td>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: top; background-color: #eeeeee; width: 89.7674%;"><a href="http://www.sec.gov/Archives/edgar/data/1827401/000106299321013611/exhibit13-1.htm"><span style="font-family: Times New Roman, Times, serif; font-size: 10pt;">Section 906 Certifications of CEO and CFO<span style="font-size: 10pt;"><sup>(3)</sup></span></span></a></td>
                    </tr>
                    <tr>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; width: 10%; vertical-align: top;">&#160;</td>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: top; width: 89.7674%;">&#160;</td>
                    </tr>
                    <tr>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; width: 10%; vertical-align: top; background-color: #eeeeee;"><a href="http://www.sec.gov/Archives/edgar/data/1827401/000106299321005781/exhibit15-3.htm"><span style="font-family: Times New Roman, Times, serif; font-size: 10pt;">15.1</span></a></td>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: top; background-color: #eeeeee; width: 89.7674%;"><a href="http://www.sec.gov/Archives/edgar/data/1827401/000106299321005781/exhibit15-3.htm"><span style="font-family: Times New Roman, Times, serif; font-size: 10pt;">Audit Committee Charter<sup>(1)</sup></span></a></td>
                    </tr>
                    <tr>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; width: 10%; vertical-align: top;">&#160;</td>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: top; width: 89.7674%;">&#160;</td>
                    </tr>
                    <tr>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; width: 10%; vertical-align: top; background-color: #eeeeee;"><a href="http://www.sec.gov/Archives/edgar/data/1827401/000106299321005781/exhibit15-4.htm"><span style="font-family: Times New Roman, Times, serif; font-size: 10pt;">15.2</span></a></td>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: top; background-color: #eeeeee; width: 89.7674%;"><a href="http://www.sec.gov/Archives/edgar/data/1827401/000106299321005781/exhibit15-4.htm"><span style="font-family: Times New Roman, Times, serif; font-size: 10pt;">Nominating and Corporate Governance Committee Charter<sup>(1)</sup></span></a></td>
                    </tr>
                    <tr>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; width: 10%; vertical-align: top;">&#160;</td>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: top; width: 89.7674%;">&#160;</td>
                    </tr>
                    <tr>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; width: 10%; vertical-align: top; background-color: #eeeeee;"><a href="http://www.sec.gov/Archives/edgar/data/1827401/000106299321005781/exhibit15-5.htm"><span style="font-family: Times New Roman, Times, serif; font-size: 10pt;">15.3</span></a></td>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: top; background-color: #eeeeee; width: 89.7674%;"><a href="http://www.sec.gov/Archives/edgar/data/1827401/000106299321005781/exhibit15-5.htm"><span style="font-family: Times New Roman, Times, serif; font-size: 10pt;">Compensation Committee Charter<sup>(1)</sup></span></a></td>
                    </tr>
                    <tr>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; width: 10%; vertical-align: top;">&#160;</td>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: top; width: 89.7674%;">&#160;</td>
                    </tr>
                    <tr>
                        <td style="width: 10%; vertical-align: top; background-color: #eeeeee;"><span style="font-family: Times New Roman,Times,serif;">101.INS</span></td>
                        <td style="width: 89.7674%; vertical-align: top; background-color: #eeeeee;"><span style="font-family: Times New Roman,Times,serif;">XBRL Instance Document&#8211;the instance document does not appear in the Interactive Data File as its XBRL tags are embedded within the Inline XBRL document*</span></td>
                    </tr>
                    <tr>
                        <td style="width: 10%; vertical-align: top;">&#160;</td>
                        <td style="width: 89.7674%; vertical-align: top;">&#160;</td>
                    </tr>
                    <tr>
                        <td style="width: 10%; vertical-align: top; background-color: #eeeeee;"><span style="font-family: Times New Roman,Times,serif;"><a href="drug-20210930.xsd">101.SCH </a></span></td>
                        <td style="width: 89.7674%; vertical-align: top; background-color: #eeeeee;"><span style="font-family: Times New Roman,Times,serif;"><a href="drug-20210930.xsd">XBRL Taxonomy Extension Schema Document*</a></span></td>
                    </tr>
                    <tr style="background-color: #ffffff;">
                        <td style="width: 10%; vertical-align: top; background-color: #ffffff;">&#160;</td>
                        <td style="width: 89.7674%; vertical-align: top; background-color: #ffffff;">&#160;</td>
                    </tr>
                    <tr>
                        <td style="width: 10%; vertical-align: top; background-color: #eeeeee;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><a href="drug-20210930_cal.xml"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">101.CAL</span></span></a></span></span></td>
                        <td style="width: 89.7674%; vertical-align: top; background-color: #eeeeee;">
                            <p style="font-size: 10pt; font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><a href="drug-20210930_cal.xml"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">XBRL Taxonomy Extension Definition Linkbase Document*</span></span></a></span></span></p>
                        </td>
                    </tr>
                    <tr>
                        <td style="width: 10%; vertical-align: top;">&#160;</td>
                        <td style="width: 89.7674%; vertical-align: top;">&#160;</td>
                    </tr>
                    <tr>
                        <td style="width: 10%; vertical-align: top; background-color: #eeeeee;"><span style="font-family: Times New Roman,Times,serif;"><a href="drug-20210930_def.xml">101.DEF </a></span></td>
                        <td style="width: 89.7674%; vertical-align: top; background-color: #eeeeee;"><span style="font-family: Times New Roman,Times,serif;"><a href="drug-20210930_def.xml">XBRL Taxonomy Extension Definition Linkbase Document*</a></span></td>
                    </tr>
                    <tr>
                        <td style="width: 10%; vertical-align: top;">&#160;</td>
                        <td style="width: 89.7674%; vertical-align: top;">&#160;</td>
                    </tr>
                    <tr>
                        <td style="width: 10%; vertical-align: top; background-color: #eeeeee;"><span style="font-family: Times New Roman,Times,serif;"><a href="drug-20210930_lab.xml">101.LAB </a></span></td>
                        <td style="width: 89.7674%; vertical-align: top; background-color: #eeeeee;"><span style="font-family: Times New Roman,Times,serif;"><a href="drug-20210930_lab.xml">XBRL Taxonomy Extension Label Linkbase Document*</a></span></td>
                    </tr>
                    <tr>
                        <td style="width: 10%; vertical-align: top;">&#160;</td>
                        <td style="width: 89.7674%; vertical-align: top;">&#160;</td>
                    </tr>
                    <tr>
                        <td style="width: 10%; vertical-align: top; background-color: #eeeeee;"><span style="font-family: Times New Roman,Times,serif;"><a href="drug-20210930_pre.xml">101.PRE </a></span></td>
                        <td style="width: 89.7674%; vertical-align: top; background-color: #eeeeee;"><span style="font-family: Times New Roman,Times,serif;"><a href="drug-20210930_pre.xml">XBRL Taxonomy Extension Presentation Linkbase Document*</a></span></td>
                    </tr>
                    <tr>
                        <td style="width: 10%; vertical-align: top;">&#160;</td>
                        <td style="width: 89.7674%; vertical-align: top;">&#160;</td>
                    </tr>
                    <tr>
                        <td style="width: 10%; vertical-align: top; background-color: #eeeeee;"><span style="font-family: Times New Roman,Times,serif;">104</span></td>
                        <td style="width: 89.7674%; vertical-align: top; background-color: #eeeeee;"><span style="font-family: Times New Roman,Times,serif;">Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).*</span></td>
                    </tr>
                </table>
                <div style="margin-top: 10pt;"><span style="font-family: Times New Roman, Times, serif; font-size: 10pt;">Notes:</span></div>
                <table style="width: 100%; font-size: 10pt; margin-top: 10pt;" cellspacing="0" cellpadding="0">
                    <tr>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; width: 5%;">
                            <div><span style="font-family: Times New Roman, Times, serif; font-size: 10pt;">*</span></div>
                        </td>
                        <td style="vertical-align: top;">
                            <div style="text-align: justify; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman, Times, serif; font-size: 10pt;">Filed herewith.</span></div>
                        </td>
                    </tr>
                </table>
                <table style="width: 100%; font-size: 10pt;" cellspacing="0" cellpadding="0">
                    <tr>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: top; width: 5%;">
                            <div><span style="font-family: Times New Roman, Times, serif; font-size: 10pt;">+</span></div>
                        </td>
                        <td style="vertical-align: top;">
                            <div style="text-align: justify; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman, Times, serif; font-size: 10pt;">Portions of this exhibit have been omitted pursuant to a request for confidential treatment. Confidential information has been omitted from the exhibit in places marked "****"and has been filed separately with the SEC.</span></div>
                        </td>
                    </tr>
                    <tr>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: top; width: 5%;">
                            <div><span style="font-family: Times New Roman, Times, serif; font-size: 10pt;">(1)</span></div>
                        </td>
                        <td style="vertical-align: top;">
                            <div style="text-align: justify; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman, Times, serif; font-size: 10pt;">Filed as an exhibit to our registration statement on Form 20-F as filed with the SEC on June 17, 2021 and incorporated herein by reference.</span></div>
                        </td>
                    </tr>
                    <tr>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: top; width: 5%;">
                            <div><span style="font-family: Times New Roman, Times, serif; font-size: 10pt;">(2)</span></div>
                        </td>
                        <td style="vertical-align: top;">
                            <div style="text-align: justify; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman, Times, serif; font-size: 10pt;">Filed as an exhibit to our registration statement on Form 20-F/A (Amendment No. 1) as filed with the SEC on July 29, 2021 and incorporated herein by reference.</span></div>
                        </td>
                    </tr>
                    <tr>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: top; width: 5%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(3)</span></span></td>
                        <td style="vertical-align: top;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Previously filed.</span></span></td>
                    </tr>
                </table>
                &#160;
                <div>&#160;</div>
                <hr style="page-break-after: always; text-align: center; height: 5px; width: 100%; background-color: black;" />
                <div style="text-align: center; margin-top: 10pt;"><span style="font-family: Times New Roman, Times, serif; font-size: 10pt;"><b>SIGNATURES</b></span></div>
                <div style="text-align: justify;"><br /></div>
                <div style="text-align: justify;"><span style="font-family: Times New Roman, Times, serif; font-size: 10pt;">The registrant certifies that it meets all of the requirements for filing on Form 20-F and that it has duly caused and authorized the undersigned to sign this annual report on its behalf.</span></div>
                <div style="text-align: justify;"><br /><span style="font-family: Times New Roman, Times, serif; font-size: 10pt;">Bright Minds Biosciences Inc.</span></div>
                <div style="text-align: justify;"><br /></div>
                <div style="text-align: justify;"><span style="font-family: Times New Roman, Times, serif; font-size: 10pt;">Date: January 18, 2022</span></div>
                <div style="text-align: justify;"><br /></div>
                <table style="width: 100%; font-size: 10pt;" cellspacing="0" cellpadding="0">
                    <tr>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; width: 5%;">
                            <div><span style="font-family: Times New Roman, Times, serif; font-size: 10pt;">By:</span></div>
                        </td>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000;">
                            <div><span style="font-family: Times New Roman, Times, serif; font-size: 10pt;"><i>/s/ Ian McDonald</i></span></div>
                        </td>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; width: 50%;">
                            <div><br /></div>
                        </td>
                    </tr>
                    <tr>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; width: 5%;">
                            <div><br /></div>
                        </td>
                        <td style="margin-top: 0pt; margin-bottom: 0pt;">
                            <div><span style="font-family: Times New Roman, Times, serif; font-size: 10pt;">Ian McDonald</span></div>
                        </td>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; width: 50%;">
                            <div><br /></div>
                        </td>
                    </tr>
                    <tr>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; width: 5%;">
                            <div><br /></div>
                        </td>
                        <td style="margin-top: 0pt; margin-bottom: 0pt;">
                            <div><span style="font-family: Times New Roman, Times, serif; font-size: 10pt;">President and Chief Executive Officer</span></div>
                        </td>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; width: 50%;">
                            <div><br /></div>
                        </td>
                    </tr>
                </table>
                <div>
                    <div style="text-align: justify;">&#160;</div>
                    <div><br /></div>
                    <hr style="page-break-after: always; text-align: center; height: 5px; width: 100%; background-color: black;" />
                </div>
            </div>
        </div>
    </div>

</body>

</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>2
<FILENAME>drug-20210930.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<schema xmlns:drug="http://brightmindsbio.com/20210930" xmlns="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:deprecated="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:currency="http://xbrl.sec.gov/currency/2020-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2020-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2020-01-31" xmlns:country="http://xbrl.sec.gov/country/2020-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2018-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31" xmlns:srt="http://fasb.org/srt/2020-01-31" xmlns:us-types="http://fasb.org/us-types/2020-01-31" xmlns:srt-types="http://fasb.org/srt-types/2020-01-31" xmlns:ifrs-full="http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full" targetNamespace="http://brightmindsbio.com/20210930" elementFormDefault="qualified">
  <!-- INTEGIX by Ez-XBRL -->
  <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd"/>
  <import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd"/>
  <import namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd"/>
  <import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd"/>
  <import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd"/>
  <import namespace="http://xbrl.sec.gov/currency/2020-01-31" schemaLocation="https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd"/>
  <import namespace="http://xbrl.sec.gov/exch/2020-01-31" schemaLocation="https://xbrl.sec.gov/exch/2020/exch-2020-01-31.xsd"/>
  <import namespace="http://xbrl.sec.gov/sic/2020-01-31" schemaLocation="https://xbrl.sec.gov/sic/2020/sic-2020-01-31.xsd"/>
  <import namespace="http://xbrl.sec.gov/country/2020-01-31" schemaLocation="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd"/>
  <import namespace="http://xbrl.sec.gov/stpr/2018-01-31" schemaLocation="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd"/>
  <import namespace="http://xbrl.sec.gov/dei/2020-01-31" schemaLocation="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd"/>
  <import namespace="http://fasb.org/srt/2020-01-31" schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd"/>
  <import namespace="http://fasb.org/us-types/2020-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd"/>
  <import namespace="http://fasb.org/srt-types/2020-01-31" schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd"/>
  <import namespace="http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full" schemaLocation="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd"/>
  <annotation>
    <appinfo>
      <link:roleType roleURI="http://brightmindsbio.com/role/DocumentAndEntityInformation" id="DocumentAndEntityInformation">
        <link:definition>0001 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://brightmindsbio.com/role/ConsolidatedStatementsOfFinancialPosition" id="ConsolidatedStatementsOfFinancialPosition">
        <link:definition>0002 - Statement - Consolidated Statements of Financial Position</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://brightmindsbio.com/role/ConsolidatedStatementsOfComprehensiveLoss" id="ConsolidatedStatementsOfComprehensiveLoss">
        <link:definition>0003 - Statement - Consolidated Statements of Comprehensive Loss</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://brightmindsbio.com/role/ConsolidatedStatementsOfChangesInShareholdersEquity" id="ConsolidatedStatementsOfChangesInShareholdersEquity">
        <link:definition>0004 - Statement - Consolidated Statements of Changes in Shareholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://brightmindsbio.com/role/ConsolidatedStatementsOfCashFlows" id="ConsolidatedStatementsOfCashFlows">
        <link:definition>0005 - Statement - Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://brightmindsbio.com/role/NATUREANDCONTINUANCEOFOPERATIONS" id="NATUREANDCONTINUANCEOFOPERATIONS">
        <link:definition>0006 - Disclosure - NATURE AND CONTINUANCE OF OPERATIONS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://brightmindsbio.com/role/STATEMENTOFCOMPLIANCEANDBASISOFPREPARATION" id="STATEMENTOFCOMPLIANCEANDBASISOFPREPARATION">
        <link:definition>0007 - Disclosure - STATEMENT OF COMPLIANCE AND BASIS OF PREPARATION</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://brightmindsbio.com/role/SIGNIFICANTACCOUNTINGPOLICIES" id="SIGNIFICANTACCOUNTINGPOLICIES">
        <link:definition>0008 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://brightmindsbio.com/role/SHAREEXCHANGEANDASSIGNMENT" id="SHAREEXCHANGEANDASSIGNMENT">
        <link:definition>0009 - Disclosure - SHARE EXCHANGE AND ASSIGNMENT</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://brightmindsbio.com/role/ACCOUNTSPAYABLEANDACCRUEDLIABILITIES" id="ACCOUNTSPAYABLEANDACCRUEDLIABILITIES">
        <link:definition>0010 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED LIABILITIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://brightmindsbio.com/role/SHARECAPITAL" id="SHARECAPITAL">
        <link:definition>0011 - Disclosure - SHARE CAPITAL</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://brightmindsbio.com/role/RELATEDPARTYTRANSACTIONS" id="RELATEDPARTYTRANSACTIONS">
        <link:definition>0012 - Disclosure - RELATED PARTY TRANSACTIONS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://brightmindsbio.com/role/CONTRACTUALOBLIGATIONS" id="CONTRACTUALOBLIGATIONS">
        <link:definition>0013 - Disclosure - CONTRACTUAL OBLIGATIONS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://brightmindsbio.com/role/FINANCIALINSTRUMENTSANDCAPITALMANAGEMENT" id="FINANCIALINSTRUMENTSANDCAPITALMANAGEMENT">
        <link:definition>0014 - Disclosure - FINANCIAL INSTRUMENTS AND CAPITAL MANAGEMENT</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://brightmindsbio.com/role/RESEARCHANDDEVELOPMENT" id="RESEARCHANDDEVELOPMENT">
        <link:definition>0015 - Disclosure - RESEARCH AND DEVELOPMENT</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://brightmindsbio.com/role/PREMISESLEASES" id="PREMISESLEASES">
        <link:definition>0016 - Disclosure - PREMISES LEASES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://brightmindsbio.com/role/INCOMETAXES" id="INCOMETAXES">
        <link:definition>0017 - Disclosure - INCOME TAXES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://brightmindsbio.com/role/ComparativeAmounts" id="ComparativeAmounts">
        <link:definition>0018 - Disclosure - COMPARATIVE AMOUNTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://brightmindsbio.com/role/SUBSEQUENTEVENTS" id="SUBSEQUENTEVENTS">
        <link:definition>0019 - Disclosure - SUBSEQUENT EVENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://brightmindsbio.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies" id="SIGNIFICANTACCOUNTINGPOLICIESPolicies">
        <link:definition>0020 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://brightmindsbio.com/role/ACCOUNTSPAYABLEANDACCRUEDLIABILITIESTables" id="ACCOUNTSPAYABLEANDACCRUEDLIABILITIESTables">
        <link:definition>0021 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED LIABILITIES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://brightmindsbio.com/role/SHARECAPITALTables" id="SHARECAPITALTables">
        <link:definition>0022 - Disclosure - SHARE CAPITAL (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://brightmindsbio.com/role/RELATEDPARTYTRANSACTIONSTables" id="RELATEDPARTYTRANSACTIONSTables">
        <link:definition>0023 - Disclosure - RELATED PARTY TRANSACTIONS (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://brightmindsbio.com/role/FINANCIALINSTRUMENTSANDCAPITALMANAGEMENTTables" id="FINANCIALINSTRUMENTSANDCAPITALMANAGEMENTTables">
        <link:definition>0024 - Disclosure - FINANCIAL INSTRUMENTS AND CAPITAL MANAGEMENT (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://brightmindsbio.com/role/RESEARCHANDDEVELOPMENTTables" id="RESEARCHANDDEVELOPMENTTables">
        <link:definition>0025 - Disclosure - RESEARCH AND DEVELOPMENT (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://brightmindsbio.com/role/INCOMETAXESTables" id="INCOMETAXESTables">
        <link:definition>0026 - Disclosure - INCOME TAXES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://brightmindsbio.com/role/NATUREANDCONTINUANCEOFOPERATIONSDetailTextuals" id="NATUREANDCONTINUANCEOFOPERATIONSDetailTextuals">
        <link:definition>0027 - Disclosure - NATURE AND CONTINUANCE OF OPERATIONS (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://brightmindsbio.com/role/SIGNIFICANTACCOUNTINGPOLICIESDetailTextuals" id="SIGNIFICANTACCOUNTINGPOLICIESDetailTextuals">
        <link:definition>0028 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://brightmindsbio.com/role/SHAREEXCHANGEANDASSIGNMENTDetailTextuals" id="SHAREEXCHANGEANDASSIGNMENTDetailTextuals">
        <link:definition>0029 - Disclosure - SHARE EXCHANGE AND ASSIGNMENT (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://brightmindsbio.com/role/ACCOUNTSPAYABLEANDACCRUEDLIABILITIESDetails" id="ACCOUNTSPAYABLEANDACCRUEDLIABILITIESDetails">
        <link:definition>0030 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED LIABILITIES - Disclosure of accounts payable and accrued liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://brightmindsbio.com/role/SHARECAPITALDetailTextuals" id="SHARECAPITALDetailTextuals">
        <link:definition>0031 - Disclosure - SHARE CAPITAL (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://brightmindsbio.com/role/SHARECAPITALDetails" id="SHARECAPITALDetails">
        <link:definition>0032 - Disclosure - SHARE CAPITAL - Disclosure of number and weighted average exercise prices of share options (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://brightmindsbio.com/role/SHARECAPITALDetails1" id="SHARECAPITALDetails1">
        <link:definition>0033 - Disclosure - SHARE CAPITAL - Disclosure of number of issued and outstanding stock options (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://brightmindsbio.com/role/SHARECAPITALDetails2" id="SHARECAPITALDetails2">
        <link:definition>0034 - Disclosure - SHARE CAPITAL - Disclosure of number and weighted average exercise prices of restricted share units (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://brightmindsbio.com/role/SHARECAPITALDetails3" id="SHARECAPITALDetails3">
        <link:definition>0035 - Disclosure - SHARE CAPITAL - Disclosure of equity-settled restricted share units fair value inputs (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://brightmindsbio.com/role/SHARECAPITALDetails4" id="SHARECAPITALDetails4">
        <link:definition>0036 - Disclosure - SHARE CAPITAL - Disclosure of share based payments recognized in the consolidated statements of comprehensive loss (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://brightmindsbio.com/role/SHARECAPITALDetails5" id="SHARECAPITALDetails5">
        <link:definition>0037 - Disclosure - SHARE CAPITAL - Disclosure of share based payments included in the consolidated statements of comprehensive loss (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://brightmindsbio.com/role/SHARECAPITALDetails6" id="SHARECAPITALDetails6">
        <link:definition>0038 - Disclosure - SHARE CAPITAL -  Disclosure of number and weighted average exercise prices of warrants (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://brightmindsbio.com/role/SHARECAPITALDetails7" id="SHARECAPITALDetails7">
        <link:definition>0039 - Disclosure - SHARE CAPITAL - Disclosure of number of outstanding warrants (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://brightmindsbio.com/role/RELATEDPARTYTRANSACTIONSDetails" id="RELATEDPARTYTRANSACTIONSDetails">
        <link:definition>0040 - Disclosure - RELATED PARTY TRANSACTIONS - Disclosure of expenses related to key management personnel (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://brightmindsbio.com/role/CONTRACTUALOBLIGATIONSDetailTextuals" id="CONTRACTUALOBLIGATIONSDetailTextuals">
        <link:definition>0041 - Disclosure - CONTRACTUAL OBLIGATIONS (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://brightmindsbio.com/role/FINANCIALINSTRUMENTSANDCAPITALMANAGEMENTDetailTextuals" id="FINANCIALINSTRUMENTSANDCAPITALMANAGEMENTDetailTextuals">
        <link:definition>0042 - Disclosure - FINANCIAL INSTRUMENTS AND CAPITAL MANAGEMENT (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://brightmindsbio.com/role/FINANCIALINSTRUMENTSANDCAPITALMANAGEMENTDetails" id="FINANCIALINSTRUMENTSANDCAPITALMANAGEMENTDetails">
        <link:definition>0043 - Disclosure - FINANCIAL INSTRUMENTS AND CAPITAL MANAGEMENT - Disclosure of carrying value of financial assets and liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://brightmindsbio.com/role/RESEARCHANDDEVELOPMENTDetails" id="RESEARCHANDDEVELOPMENTDetails">
        <link:definition>0044 - Disclosure - RESEARCH AND DEVELOPMENT - Disclosure of research and development expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://brightmindsbio.com/role/PREMISESLEASESDetailTextuals" id="PREMISESLEASESDetailTextuals">
        <link:definition>0045 - Disclosure - PREMISES LEASES (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://brightmindsbio.com/role/INCOMETAXESDetailTextuals" id="INCOMETAXESDetailTextuals">
        <link:definition>0046 - Disclosure - INCOME TAXES (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://brightmindsbio.com/role/INCOMETAXESDetails" id="INCOMETAXESDetails">
        <link:definition>0047 - Disclosure - INCOME TAXES  - Disclosure of reconciliation of the expected income tax recovery to the actual income tax recovery (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://brightmindsbio.com/role/INCOMETAXESDetails1" id="INCOMETAXESDetails1">
        <link:definition>0048 - Disclosure - INCOME TAXES - Disclosure of deductible temporary differences for which no deferred tax has been recognized (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://brightmindsbio.com/role/INCOMETAXESDetails2" id="INCOMETAXESDetails2">
        <link:definition>0049 - Disclosure - INCOME TAXES  - Disclosure of non-capital loss carry-forwards expiry (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://brightmindsbio.com/role/SUBSEQUENTEVENTSDetailTextuals" id="SUBSEQUENTEVENTSDetailTextuals">
        <link:definition>0050 - Disclosure - SUBSEQUENT EVENTS (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:type="simple" xlink:href="drug-20210930_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="drug-20210930_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="drug-20210930_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="drug-20210930_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase"/>
    </appinfo>
  </annotation>
  <element name="AcquisitionOfIntangibleAssetsByIssuingCommonShares" id="drug_AcquisitionOfIntangibleAssetsByIssuingCommonShares" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="AdjustmentsForDecreaseIncreaseInPrepaidExpenses" id="drug_AdjustmentsForDecreaseIncreaseInPrepaidExpenses" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="AdjustmentsForDecreaseIncreaseInSalesTaxReceivable" id="drug_AdjustmentsForDecreaseIncreaseInSalesTaxReceivable" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="AdjustmentsForSharesRecordedAsResearchAndDevelopment" id="drug_AdjustmentsForSharesRecordedAsResearchAndDevelopment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="AdvisorHourlyRate" id="drug_AdvisorHourlyRate" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="AdvisorsHourlyRatesOfScientificAdvisoryBoardAndConsultants" id="drug_AdvisorsHourlyRatesOfScientificAdvisoryBoardAndConsultants" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="AfterSublicensingAgreementsMember" id="drug_AfterSublicensingAgreementsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="AggregatePurchaseWarrantsDeposited" id="drug_AggregatePurchaseWarrantsDeposited" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="AggregateSecuritiesDepositedToBeHeldInEscrow" id="drug_AggregateSecuritiesDepositedToBeHeldInEscrow" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="AgreementAxis" id="drug_AgreementAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" nillable="true"/>
  <element name="AgreementDomain" id="drug_AgreementDomain" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="AmountOfEscrowProceedsReleased" id="drug_AmountOfEscrowProceedsReleased" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="AmountOfNonRefundableMonthlyRetainerAsServiceCompensation" id="drug_AmountOfNonRefundableMonthlyRetainerAsServiceCompensation" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="AreasOfScientificTechnicalBusinessAdviceAdvisorsHourlyRates" id="drug_AreasOfScientificTechnicalBusinessAdviceAdvisorsHourlyRates" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="ArrangementsAndNonarrangementTransactionDomain" id="drug_ArrangementsAndNonarrangementTransactionDomain" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="BritishColumbiaSecuritiesCommissionMember" id="drug_BritishColumbiaSecuritiesCommissionMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="CashSettledShareBasedPaymentArrangementsMember" id="drug_CashSettledShareBasedPaymentArrangementsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="CategoriesOfResearchAndDevelopmentExpensesAxis" id="drug_CategoriesOfResearchAndDevelopmentExpensesAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" nillable="true"/>
  <element name="CategoriesOfResearchAndDevelopmentExpensesDomain" id="drug_CategoriesOfResearchAndDevelopmentExpensesDomain" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ChangesInNonCashWorkingOperatingCapitalBalancesAbstract" id="drug_ChangesInNonCashWorkingOperatingCapitalBalancesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ChiefFinancialOfficerTwoDirectorsAndSevenConsultantsMember" id="drug_ChiefFinancialOfficerTwoDirectorsAndSevenConsultantsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ChiefMedicalOfficerMember" id="drug_ChiefMedicalOfficerMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="CommercialLaboratoryLeaseMember" id="drug_CommercialLaboratoryLeaseMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="CommonShareSubscriptionsReceived" id="drug_CommonShareSubscriptionsReceived" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="CommonStockSharesPurchased" id="drug_CommonStockSharesPurchased" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ComparativeAmountsAbstract" id="drug_ComparativeAmountsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ConsolidatedStatementsOfComprehensiveIncomeLossStatementLocationAxis" id="drug_ConsolidatedStatementsOfComprehensiveIncomeLossStatementLocationAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" nillable="true"/>
  <element name="ConsolidatedStatementsOfComprehensiveIncomeLossStatementLocationDomain" id="drug_ConsolidatedStatementsOfComprehensiveIncomeLossStatementLocationDomain" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ConsultantMember" id="drug_ConsultantMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ConsultingAgreement2Member" id="drug_ConsultingAgreement2Member" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ConsultingAgreementsMember" id="drug_ConsultingAgreementsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ConsultingFees" id="drug_ConsultingFees" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="ConsultingFeesMember" id="drug_ConsultingFeesMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ContingentCashFee" id="drug_ContingentCashFee" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="DebtSettledByIssuingShares" id="drug_DebtSettledByIssuingShares" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="DebtSettledThroughIssuanceOfShares" id="drug_DebtSettledThroughIssuanceOfShares" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="DebtSettlementAgreementMember" id="drug_DebtSettlementAgreementMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="DecemberTwentyOneTwoZeroTwoFourMember" id="drug_DecemberTwentyOneTwoZeroTwoFourMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="DescriptionOfAccountingPolicyForBasisOfConsolidationExplanatory" id="drug_DescriptionOfAccountingPolicyForBasisOfConsolidationExplanatory" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="DescriptionOfAccountingPolicyForCriticalAccountingEstimatesExplanatory" id="drug_DescriptionOfAccountingPolicyForCriticalAccountingEstimatesExplanatory" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="DescriptionOfAccountingPolicyForInternallyGeneratedIntangibleAssetsResearchAndDevelopmentExpenditureExplanatory" id="drug_DescriptionOfAccountingPolicyForInternallyGeneratedIntangibleAssetsResearchAndDevelopmentExpenditureExplanatory" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="DescriptionOfAccountingPolicyForNewStandardsAndInterpretationsNotYetAdoptedExplanatory" id="drug_DescriptionOfAccountingPolicyForNewStandardsAndInterpretationsNotYetAdoptedExplanatory" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="DescriptionOfIssuedAndOutstandingCommonShares" id="drug_DescriptionOfIssuedAndOutstandingCommonShares" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="DescriptionOfSublicenseeRevenueOfRoyaltyPaymentAccrues" id="drug_DescriptionOfSublicenseeRevenueOfRoyaltyPaymentAccrues" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="DirectorAndConsultantMember" id="drug_DirectorAndConsultantMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="DirectorsCompensationMember" id="drug_DirectorsCompensationMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="DisclosureOfComparativeAmountsExplanatory" id="drug_DisclosureOfComparativeAmountsExplanatory" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="DisclosureOfContractualObligationAbstract" id="drug_DisclosureOfContractualObligationAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="DisclosureOfContractualObligationLineItems" id="drug_DisclosureOfContractualObligationLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="DisclosureOfContractualObligationTable" id="drug_DisclosureOfContractualObligationTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" nillable="true"/>
  <element name="DisclosureOfDetailedInformationAboutEquitySettledRestrictedShareUnitsFairValueInputsExplanatory" id="drug_DisclosureOfDetailedInformationAboutEquitySettledRestrictedShareUnitsFairValueInputsExplanatory" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="DisclosureOfDetailedInformationAboutResearchAndDevelopmentExplanatory" id="drug_DisclosureOfDetailedInformationAboutResearchAndDevelopmentExplanatory" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="DisclosureOfDetailedInformationAboutShareBasedPaymentsIncludedInConsolidatedStatementsOfComprehensiveLossExplanatory" id="drug_DisclosureOfDetailedInformationAboutShareBasedPaymentsIncludedInConsolidatedStatementsOfComprehensiveLossExplanatory" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="DisclosureOfDetailedInformationAboutShareBasedPaymentsRecognizedInConsolidatedStatementsOfComprehensiveLossExplanatory" id="drug_DisclosureOfDetailedInformationAboutShareBasedPaymentsRecognizedInConsolidatedStatementsOfComprehensiveLossExplanatory" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="DisclosureOfDetailedInformationAboutSignificantAccountingPoliciesAbstract" id="drug_DisclosureOfDetailedInformationAboutSignificantAccountingPoliciesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="DisclosureOfDetailedInformationAboutTradePayableAndAccruedExpensesExplanatory" id="drug_DisclosureOfDetailedInformationAboutTradePayableAndAccruedExpensesExplanatory" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="DisclosureOfMovementsInOutstandingWarrantsExplanatory" id="drug_DisclosureOfMovementsInOutstandingWarrantsExplanatory" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="DisclosureOfNatureAndContinuanceOfOperationsExplanatory" id="drug_DisclosureOfNatureAndContinuanceOfOperationsExplanatory" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="DisclosureOfNonCapitalLossCarryForwardsExpiryExplanatory" id="drug_DisclosureOfNonCapitalLossCarryForwardsExpiryExplanatory" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="DisclosureOfNumberAndWeightedAverageExercisePricesOfWarrantsExplanatory" id="drug_DisclosureOfNumberAndWeightedAverageExercisePricesOfWarrantsExplanatory" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="DisclosureOfNumberOfIssuedAndOutstandingStockOptionsExplanatory" id="drug_DisclosureOfNumberOfIssuedAndOutstandingStockOptionsExplanatory" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="DisclosureOfNumberOfIssuedAndOutstandingWarrantsExplanatory" id="drug_DisclosureOfNumberOfIssuedAndOutstandingWarrantsExplanatory" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="DisclosureOfReconciliationOfExpectedIncomeTaxRecoveryToActualIncomeTaxRecoveryExplanatory" id="drug_DisclosureOfReconciliationOfExpectedIncomeTaxRecoveryToActualIncomeTaxRecoveryExplanatory" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="DisclosureOfShareExchangeAndAssignmentExplanatory" id="drug_DisclosureOfShareExchangeAndAssignmentExplanatory" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="DisclosureOfShareExchangeAndAssignmentTable" id="drug_DisclosureOfShareExchangeAndAssignmentTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" nillable="true"/>
  <element name="DiscountRateOfWarrantsGranted" id="drug_DiscountRateOfWarrantsGranted" type="num:percentItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="DiscountRateStockOptionGranted" id="drug_DiscountRateStockOptionGranted" type="num:percentItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="DocumentAndEntityAbstract" id="drug_DocumentAndEntityAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="EighteenMonthAnniversaryOfGrantDateMember" id="drug_EighteenMonthAnniversaryOfGrantDateMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="EighthTrancheMember" id="drug_EighthTrancheMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="EleventhTrancheMember" id="drug_EleventhTrancheMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="EquitySettledShareBasedPaymentArrangementsMember" id="drug_EquitySettledShareBasedPaymentArrangementsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="EscrowAgreementMember" id="drug_EscrowAgreementMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="EscrowedSecuritiesMember" id="drug_EscrowedSecuritiesMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="EscrowedSecuritiesToBeReleasedAfterListingDate" id="drug_EscrowedSecuritiesToBeReleasedAfterListingDate" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="EscrowedSecuritiesToBeReleasedOnceSharesAreListedOnCanadianStockExchange" id="drug_EscrowedSecuritiesToBeReleasedOnceSharesAreListedOnCanadianStockExchange" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="EscrowedSharePurchaseWarrantsMember" id="drug_EscrowedSharePurchaseWarrantsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="EstimatedFairValueOfEquitySettledRsusGranted" id="drug_EstimatedFairValueOfEquitySettledRsusGranted" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="EstimatedLifeOfWarrantsGranted" id="drug_EstimatedLifeOfWarrantsGranted" type="xbrli:decimalItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ExercisePriceWarrantsGranted" id="drug_ExercisePriceWarrantsGranted" type="num:perShareItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ExpectedVolatilityWarrantsGranted" id="drug_ExpectedVolatilityWarrantsGranted" type="num:percentItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ExpirationPeriodDomain" id="drug_ExpirationPeriodDomain" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ExpirePeriodAxis" id="drug_ExpirePeriodAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" nillable="true"/>
  <element name="ExpiryDate" id="drug_ExpiryDate" type="xbrli:dateItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ExpiryDateAxis" id="drug_ExpiryDateAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" nillable="true"/>
  <element name="ExpiryDateDomain" id="drug_ExpiryDateDomain" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ExpiryDateFifteenJuneTwoThousandAndTwentySixMember" id="drug_ExpiryDateFifteenJuneTwoThousandAndTwentySixMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ExpiryDateSeventeenMarchTwoThousandAndTwentyFourOneMember" id="drug_ExpiryDateSeventeenMarchTwoThousandAndTwentyFourOneMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ExpiryDateSeventeenMarchTwoThousandAndTwentyFourTwoMember" id="drug_ExpiryDateSeventeenMarchTwoThousandAndTwentyFourTwoMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ExpiryDateSeventeenNovemberTwoThousandAndTwentyFiveMember" id="drug_ExpiryDateSeventeenNovemberTwoThousandAndTwentyFiveMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ExpiryDateThirtyJulyTwoThousandAndTwentyFourMember" id="drug_ExpiryDateThirtyJulyTwoThousandAndTwentyFourMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ExpiryDateTwentyEightAprilTwoThousandAndTwentySixMember" id="drug_ExpiryDateTwentyEightAprilTwoThousandAndTwentySixMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ExpiryDateTwentyOneSeptemberTwoThousandAndTwentyFourMember" id="drug_ExpiryDateTwentyOneSeptemberTwoThousandAndTwentyFourMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ExpiryDateTwentyThreeJulyTwoThousandAndTwentyFiveMember" id="drug_ExpiryDateTwentyThreeJulyTwoThousandAndTwentyFiveMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="FairValueAscribedToBrokersWarrantsIssued" id="drug_FairValueAscribedToBrokersWarrantsIssued" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="FairValueOfOptionsIssuedAsFindersFees" id="drug_FairValueOfOptionsIssuedAsFindersFees" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="FairValueOfWarrants" id="drug_FairValueOfWarrants" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="FifteenthTrancheMember" id="drug_FifteenthTrancheMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="FifthTrancheMember" id="drug_FifthTrancheMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="FinancialInstrumentsAtAmortizedCostMember" id="drug_FinancialInstrumentsAtAmortizedCostMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="FinancialInstrumentsAtFairValueThroughProfitOrLossMember" id="drug_FinancialInstrumentsAtFairValueThroughProfitOrLossMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="FirstAnniversaryOfGrantDateMember" id="drug_FirstAnniversaryOfGrantDateMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="FirstTrancheMember" id="drug_FirstTrancheMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="FirstTrancheOfNonBrokeredPrivatePlacementMember" id="drug_FirstTrancheOfNonBrokeredPrivatePlacementMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ForfeitureRateOfOtherEquityInstruments" id="drug_ForfeitureRateOfOtherEquityInstruments" type="num:percentItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="FourteenthTrancheMember" id="drug_FourteenthTrancheMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="FourthAnniversaryOfGrantDateMember" id="drug_FourthAnniversaryOfGrantDateMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="FourthTrancheMember" id="drug_FourthTrancheMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="GrantDateAxis" id="drug_GrantDateAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" nillable="true"/>
  <element name="GrantDateDomain" id="drug_GrantDateDomain" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="GrossProceedsFromUnitsIssued" id="drug_GrossProceedsFromUnitsIssued" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="GrossProceedsFromWarrantsExercised" id="drug_GrossProceedsFromWarrantsExercised" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="GrossProceedsFromWarrantsIssued" id="drug_GrossProceedsFromWarrantsIssued" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="IncomeTaxAuthorityNameOfCountryAxis" id="drug_IncomeTaxAuthorityNameOfCountryAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" nillable="true"/>
  <element name="IncomeTaxAuthorityNameOfCountryDomain" id="drug_IncomeTaxAuthorityNameOfCountryDomain" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="IncreaseDecreaseThroughAcquisitionOfIntangibleAssets" id="drug_IncreaseDecreaseThroughAcquisitionOfIntangibleAssets" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="IncreaseDecreaseThroughAcquisitionOfIntangibleAssetsShares" id="drug_IncreaseDecreaseThroughAcquisitionOfIntangibleAssetsShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="IncreaseDecreaseThroughCashDistributionForFindersFees" id="drug_IncreaseDecreaseThroughCashDistributionForFindersFees" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="IncreaseDecreaseThroughDebtSettlementWithShare" id="drug_IncreaseDecreaseThroughDebtSettlementWithShare" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="IncreaseDecreaseThroughDebtSettlementWithShareShares" id="drug_IncreaseDecreaseThroughDebtSettlementWithShareShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="IncreaseDecreaseThroughDistributionOfBrokerWarrantsForFindersFees" id="drug_IncreaseDecreaseThroughDistributionOfBrokerWarrantsForFindersFees" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="IncreaseDecreaseThroughExerciseOfOptionsForFindersFee" id="drug_IncreaseDecreaseThroughExerciseOfOptionsForFindersFee" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="IncreaseDecreaseThroughExerciseOfWarrantsShares" id="drug_IncreaseDecreaseThroughExerciseOfWarrantsShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="IncreaseDecreaseThroughFindersFeesBrokerWarrants" id="drug_IncreaseDecreaseThroughFindersFeesBrokerWarrants" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="IncreaseDecreaseThroughFindersFeesCash" id="drug_IncreaseDecreaseThroughFindersFeesCash" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="IncreaseDecreaseThroughFindersFeesShareOptions" id="drug_IncreaseDecreaseThroughFindersFeesShareOptions" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="IncreaseDecreaseThroughPrivatePlacement" id="drug_IncreaseDecreaseThroughPrivatePlacement" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="IncreaseDecreaseThroughPrivatePlacementShares" id="drug_IncreaseDecreaseThroughPrivatePlacementShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="IncreaseDecreaseThroughSharesIssuedToUniversity" id="drug_IncreaseDecreaseThroughSharesIssuedToUniversity" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="IncreaseDecreaseThroughSharesIssuedToUniversityShares" id="drug_IncreaseDecreaseThroughSharesIssuedToUniversityShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="IncreaseDecreaseThroughSpecialWarrantConversion" id="drug_IncreaseDecreaseThroughSpecialWarrantConversion" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="IncreaseDecreaseThroughSpecialWarrantConversionShares" id="drug_IncreaseDecreaseThroughSpecialWarrantConversionShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="IndependentConsultantAgreementMember" id="drug_IndependentConsultantAgreementMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="IndependentContractorAgreementToServeAsChiefMedicalOfficerMember" id="drug_IndependentContractorAgreementToServeAsChiefMedicalOfficerMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="IndependentContractorAgreementToServeAsChiefScienceOfficerMember" id="drug_IndependentContractorAgreementToServeAsChiefScienceOfficerMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="IssuanceOfRestrictedStockUnits" id="drug_IssuanceOfRestrictedStockUnits" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="IssueOfSharesUnderPrivatePlacement" id="drug_IssueOfSharesUnderPrivatePlacement" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="IssueOfSharesUnderPrivatePlacementValue" id="drug_IssueOfSharesUnderPrivatePlacementValue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="IssuePricePerShare" id="drug_IssuePricePerShare" type="num:perShareItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="JuneTwentyOneTwoZeroTwoTwoMember" id="drug_JuneTwentyOneTwoZeroTwoTwoMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="KeyManagementPersonnelCompensationShareBasedPaymentIncludedInProfessionalFees" id="drug_KeyManagementPersonnelCompensationShareBasedPaymentIncludedInProfessionalFees" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="KeyManagementPersonnelCompensationShareBasedPaymentIncludedInResearchAndDevelopment" id="drug_KeyManagementPersonnelCompensationShareBasedPaymentIncludedInResearchAndDevelopment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="KeyManagementPersonnelProfessionalFees" id="drug_KeyManagementPersonnelProfessionalFees" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="KeyManagementPersonnelResearchAndDevelopment" id="drug_KeyManagementPersonnelResearchAndDevelopment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="LaboratoryCostsMember" id="drug_LaboratoryCostsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="LeaseCost" id="drug_LeaseCost" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="LetterAgreementMember" id="drug_LetterAgreementMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="LicenseAgreementMember" id="drug_LicenseAgreementMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="MarchTwentyOneTwoZeroTwoTwoMember" id="drug_MarchTwentyOneTwoZeroTwoTwoMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="MarketingAdvertisingAndInvestorRelationsMember" id="drug_MarketingAdvertisingAndInvestorRelationsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="MilestonePaymentsUponDosingFirstPatientInFirstPhaseIiiTrial" id="drug_MilestonePaymentsUponDosingFirstPatientInFirstPhaseIiiTrial" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="MilestonePaymentsUponDosingFirstPatientInFirstPhaseIiTrial" id="drug_MilestonePaymentsUponDosingFirstPatientInFirstPhaseIiTrial" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="MilestonePaymentsUponDosingFirstPatientInPhaseITrial" id="drug_MilestonePaymentsUponDosingFirstPatientInPhaseITrial" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="MilestonePaymentsUponFirstCommercialSaleOfClinical" id="drug_MilestonePaymentsUponFirstCommercialSaleOfClinical" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="MinimumDailyVolumeWeightedAverageTradingSharePrice" id="drug_MinimumDailyVolumeWeightedAverageTradingSharePrice" type="num:perShareItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="MonthlyBaseRent" id="drug_MonthlyBaseRent" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="MonthlyFeeAuthorizedByBoardOfDirectors" id="drug_MonthlyFeeAuthorizedByBoardOfDirectors" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="NatureAndContinuanceOfOperationsAbstract" id="drug_NatureAndContinuanceOfOperationsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="NinthTrancheMember" id="drug_NinthTrancheMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="NonBrokeredPrivatePlacementMember" id="drug_NonBrokeredPrivatePlacementMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="NonCapitalLossCarryForwards" id="drug_NonCapitalLossCarryForwards" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="NonCapitalLossCarryForwardsYearOfExpiry" id="drug_NonCapitalLossCarryForwardsYearOfExpiry" type="xbrli:gYearItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="NonCapitalLossCarryForwardsYearOfOriginAxis" id="drug_NonCapitalLossCarryForwardsYearOfOriginAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" nillable="true"/>
  <element name="NonCapitalLossCarryForwardsYearOfOriginDomain" id="drug_NonCapitalLossCarryForwardsYearOfOriginDomain" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="NonRefundableOptionFeesPaid" id="drug_NonRefundableOptionFeesPaid" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="NovelDrugDevelopmentMember" id="drug_NovelDrugDevelopmentMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="NumberOfCommonSharesCalledByWarrants" id="drug_NumberOfCommonSharesCalledByWarrants" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="NumberOfCommonSharesDepositedToBeHeldInEscrow" id="drug_NumberOfCommonSharesDepositedToBeHeldInEscrow" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="NumberOfCommonSharesSubscribed" id="drug_NumberOfCommonSharesSubscribed" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="NumberOfInstrumentsOtherEquityInstrumentsIssued" id="drug_NumberOfInstrumentsOtherEquityInstrumentsIssued" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="NumberOfIssuedWarrantsRescinded" id="drug_NumberOfIssuedWarrantsRescinded" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="NumberOfRestrictedStockIssuedForCompensation" id="drug_NumberOfRestrictedStockIssuedForCompensation" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="NumberOfShareListed" id="drug_NumberOfShareListed" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="NumberOfShareOptionsCancelledInShareBasedPaymentArrangement" id="drug_NumberOfShareOptionsCancelledInShareBasedPaymentArrangement" type="xbrli:decimalItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="NumberOfSharesIssuedByRelatedParty" id="drug_NumberOfSharesIssuedByRelatedParty" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="NumberOfUnitsIssued" id="drug_NumberOfUnitsIssued" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="NumberOfWarrantsDeemedToBeExercised" id="drug_NumberOfWarrantsDeemedToBeExercised" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="NumberOfWarrantsDepositedToBeHeldInEscrow" id="drug_NumberOfWarrantsDepositedToBeHeldInEscrow" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="NumberOfWarrantsExercised" id="drug_NumberOfWarrantsExercised" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="NumberOfWarrantsIssued" id="drug_NumberOfWarrantsIssued" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="NumberOfWarrantsIssuedToBroker" id="drug_NumberOfWarrantsIssuedToBroker" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="NumberOfWarrantsOutstanding" id="drug_NumberOfWarrantsOutstanding" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="NumberOfWarrantsOutstandingInShareBasedPaymentArrangement" id="drug_NumberOfWarrantsOutstandingInShareBasedPaymentArrangement" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="OptionAgreementMember" id="drug_OptionAgreementMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="OptionFeesPaid" id="drug_OptionFeesPaid" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="PaymentsForFindersFees" id="drug_PaymentsForFindersFees" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="PercentageOfForeignCurrencyFluctuationInUsDollarAgainstCanadianDollar" id="drug_PercentageOfForeignCurrencyFluctuationInUsDollarAgainstCanadianDollar" type="num:percentItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="PercentageOfNetEquityProceedsReceivedFromThreeInvestors" id="drug_PercentageOfNetEquityProceedsReceivedFromThreeInvestors" type="num:percentItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="PercentageOfOutstandingSharesAuthorizedUnderStockOptionPlan" id="drug_PercentageOfOutstandingSharesAuthorizedUnderStockOptionPlan" type="num:percentItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="PercentageOfRoyaltiesOnNetSales" id="drug_PercentageOfRoyaltiesOnNetSales" type="num:percentItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="PercentageOfRoyaltiesOnNetSalesOver2Billion" id="drug_PercentageOfRoyaltiesOnNetSalesOver2Billion" type="num:percentItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="PercentageOfRoyaltiesOnNetSalesUnder1Billion" id="drug_PercentageOfRoyaltiesOnNetSalesUnder1Billion" type="num:percentItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="PercentageOfStockOptionPlanAllowsBoardOfDirectorsToIssue" id="drug_PercentageOfStockOptionPlanAllowsBoardOfDirectorsToIssue" type="num:percentItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="PercentageOfStockOptionShareGranted" id="drug_PercentageOfStockOptionShareGranted" type="num:percentItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="PriorToSublicensingAgreementsMember" id="drug_PriorToSublicensingAgreementsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ProceedsForWarrantsIssued" id="drug_ProceedsForWarrantsIssued" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="ProceedsFromExerciseOfSpecialWarrants" id="drug_ProceedsFromExerciseOfSpecialWarrants" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="ProceedsFromIssuingWarrants" id="drug_ProceedsFromIssuingWarrants" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="ProceedsFromWarrantsExercise" id="drug_ProceedsFromWarrantsExercise" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="ProcessingFees" id="drug_ProcessingFees" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="ProfessionalFeesMember" id="drug_ProfessionalFeesMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="PsilocybinlabsLtdMember" id="drug_PsilocybinlabsLtdMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="RefundFromIssuedWarrantsRescinded" id="drug_RefundFromIssuedWarrantsRescinded" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="RefundOfSpecialWarrantsProceeds" id="drug_RefundOfSpecialWarrantsProceeds" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="RegulatoryAndFilingExpenses" id="drug_RegulatoryAndFilingExpenses" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="RelatedPartyContractsMember" id="drug_RelatedPartyContractsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ResearchAndDevelopmentAbstract" id="drug_ResearchAndDevelopmentAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ResearchAndDevelopmentLineItems" id="drug_ResearchAndDevelopmentLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ResearchAndDevelopmentMember" id="drug_ResearchAndDevelopmentMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ResearchDevelopmentTable" id="drug_ResearchDevelopmentTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" nillable="true"/>
  <element name="RestrictedShareUnitMember" id="drug_RestrictedShareUnitMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="RoyaltiesOnNetSales" id="drug_RoyaltiesOnNetSales" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="SalaryAndSubcontractorsMember" id="drug_SalaryAndSubcontractorsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ScientificAdvisoryBoardAgreementsMember" id="drug_ScientificAdvisoryBoardAgreementsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="SecondAnniversaryOfGrantDateMember" id="drug_SecondAnniversaryOfGrantDateMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="SecondTrancheMember" id="drug_SecondTrancheMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="SecondTrancheOfNonBrokeredPrivatePlacementMember" id="drug_SecondTrancheOfNonBrokeredPrivatePlacementMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="SeptemberTwentyOneTwoZeroTwoFourMember" id="drug_SeptemberTwentyOneTwoZeroTwoFourMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="SeptemberTwentyOneTwoZeroTwoTwoMember" id="drug_SeptemberTwentyOneTwoZeroTwoTwoMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="SeventhTrancheMember" id="drug_SeventhTrancheMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ShareBasedCompensationMember" id="drug_ShareBasedCompensationMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ShareExchangeAndAssignmentAbstract" id="drug_ShareExchangeAndAssignmentAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ShareExchangeAndAssignmentLineItems" id="drug_ShareExchangeAndAssignmentLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ShareIssueCostsIncludedInAccountsPayable" id="drug_ShareIssueCostsIncludedInAccountsPayable" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="SharePriceOnGrantDateOfOtherEquityInstruments" id="drug_SharePriceOnGrantDateOfOtherEquityInstruments" type="num:perShareItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="SigningFee" id="drug_SigningFee" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="SigningFeeNetOfOptionFeesPaid" id="drug_SigningFeeNetOfOptionFeesPaid" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="SigningFeeSharesIssued" id="drug_SigningFeeSharesIssued" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="SixMonthAnniversaryGrantDateMember" id="drug_SixMonthAnniversaryGrantDateMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="SixthTrancheMember" id="drug_SixthTrancheMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="SpecialWarrantsMember" id="drug_SpecialWarrantsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="StatementOfComplianceAndBasisOfPreparationAbstract" id="drug_StatementOfComplianceAndBasisOfPreparationAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="StockOptionAxis" id="drug_StockOptionAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" nillable="true"/>
  <element name="StockOptionDomain" id="drug_StockOptionDomain" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="StockOptionsFourMember" id="drug_StockOptionsFourMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="StockOptionsMember" id="drug_StockOptionsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="StockOptionsOneMember" id="drug_StockOptionsOneMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="StockOptionsThreeMember" id="drug_StockOptionsThreeMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="StockOptionsTwoMember" id="drug_StockOptionsTwoMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="SubscriptionAgreementsMember" id="drug_SubscriptionAgreementsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="SubscriptionReceivableMember" id="drug_SubscriptionReceivableMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="SubscriptionReceivedMember" id="drug_SubscriptionReceivedMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="SubscriptionsReceivable" id="drug_SubscriptionsReceivable" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="SubscriptionsReceived" id="drug_SubscriptionsReceived" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="SubsequentEventsMember" id="drug_SubsequentEventsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="SupplementaryInformationAbstract" id="drug_SupplementaryInformationAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="TaxAuthorityOfAustraliaMember" id="drug_TaxAuthorityOfAustraliaMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="TaxAuthorityOfCanadaMember" id="drug_TaxAuthorityOfCanadaMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="TaxAuthorityOfUnitedStatesMember" id="drug_TaxAuthorityOfUnitedStatesMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="TaxEffectOfChangeInDeferredTaxAssetsNotRecognized" id="drug_TaxEffectOfChangeInDeferredTaxAssetsNotRecognized" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="TaxEffectOfDeductibleAndNotDeductibleItems" id="drug_TaxEffectOfDeductibleAndNotDeductibleItems" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="TaxRateEffectOfDeferredTaxAssetsNotRecognized" id="drug_TaxRateEffectOfDeferredTaxAssetsNotRecognized" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="TaxYearOfOrigin2019Member" id="drug_TaxYearOfOrigin2019Member" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="TaxYearOfOrigin2020Member" id="drug_TaxYearOfOrigin2020Member" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="TaxYearOfOrigin2021Member" id="drug_TaxYearOfOrigin2021Member" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="TemporaryDifferencesIntangibleAssetsMember" id="drug_TemporaryDifferencesIntangibleAssetsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="TemporaryDifferencesNonCapitalLossesMember" id="drug_TemporaryDifferencesNonCapitalLossesMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="TemporaryDifferencesShareIssueCostsMember" id="drug_TemporaryDifferencesShareIssueCostsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="TemporaryDifferencesValuationAllowanceMember" id="drug_TemporaryDifferencesValuationAllowanceMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="TenthTrancheMember" id="drug_TenthTrancheMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="TermOfLease" id="drug_TermOfLease" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="TermOfWarrant" id="drug_TermOfWarrant" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="TermsOfContract" id="drug_TermsOfContract" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ThirdAnniversaryOfGrantDateMember" id="drug_ThirdAnniversaryOfGrantDateMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ThirdTrancheMember" id="drug_ThirdTrancheMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ThirteenthTrancheMember" id="drug_ThirteenthTrancheMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ThreeConsultantsMember" id="drug_ThreeConsultantsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ThreeInvestorsMember" id="drug_ThreeInvestorsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ThresholdPercentageOfWarrants" id="drug_ThresholdPercentageOfWarrants" type="num:percentItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="TotalAnnualMinimumRoyaltiesAfterFirstCommercialSale" id="drug_TotalAnnualMinimumRoyaltiesAfterFirstCommercialSale" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="TotalAnnualMinimumRoyaltiesCurrentYears" id="drug_TotalAnnualMinimumRoyaltiesCurrentYears" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="TotalAnnualMinimumRoyaltiesNextYears" id="drug_TotalAnnualMinimumRoyaltiesNextYears" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="TotalAnnualMinimumRoyaltiesYear3" id="drug_TotalAnnualMinimumRoyaltiesYear3" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="TotalAnnualMinimumRoyaltiesYear4" id="drug_TotalAnnualMinimumRoyaltiesYear4" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="TotalAnnualMinimumRoyaltiesYear5" id="drug_TotalAnnualMinimumRoyaltiesYear5" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="TotalAnnualMinimumRoyaltiesYear6AndThereafter" id="drug_TotalAnnualMinimumRoyaltiesYear6AndThereafter" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="Tranche1Member" id="drug_Tranche1Member" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="TranchesAxis" id="drug_TranchesAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" nillable="true"/>
  <element name="TranchesDomain" id="drug_TranchesDomain" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="TwelfthTrancheMember" id="drug_TwelfthTrancheMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="TypeOfArrangementsAxis" id="drug_TypeOfArrangementsAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" nillable="true"/>
  <element name="UnderwritersFeesPaid" id="drug_UnderwritersFeesPaid" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="UnderwritersMember" id="drug_UnderwritersMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="UnitsIssuedPricePerUnit" id="drug_UnitsIssuedPricePerUnit" type="srt-types:perUnitItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="UniversityOfIllinoisAtChicagoMember" id="drug_UniversityOfIllinoisAtChicagoMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="UniversityOfTexasMedicalBranchMember" id="drug_UniversityOfTexasMedicalBranchMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ValueOfCommonStockSharesIssued" id="drug_ValueOfCommonStockSharesIssued" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="ValueOfCommonStockSharesIssuedByRelatedParty" id="drug_ValueOfCommonStockSharesIssuedByRelatedParty" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="VestingDomain" id="drug_VestingDomain" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="VestingPercentage" id="drug_VestingPercentage" type="num:percentItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="VestingsAxis" id="drug_VestingsAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" nillable="true"/>
  <element name="WarrantAscribedValue" id="drug_WarrantAscribedValue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="WarrantsIssuedPricePerWarrant" id="drug_WarrantsIssuedPricePerWarrant" type="num:perShareItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="WarrantsMember" id="drug_WarrantsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="WeightedAverageExercisePriceOfWarrantsExercisedInShareBasedPaymentArrangement" id="drug_WeightedAverageExercisePriceOfWarrantsExercisedInShareBasedPaymentArrangement" type="num:perShareItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="WeightedAverageExercisePriceOfWarrantsIssuedInShareBasedPaymentArrangement" id="drug_WeightedAverageExercisePriceOfWarrantsIssuedInShareBasedPaymentArrangement" type="num:perShareItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="WeightedAverageExercisePriceOfWarrantsIssuedToBrokerInShareBasedPaymentArrangement" id="drug_WeightedAverageExercisePriceOfWarrantsIssuedToBrokerInShareBasedPaymentArrangement" type="num:perShareItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="WeightedAverageExercisePriceOfWarrantsOutstandingInShareBasedPaymentArrangement" id="drug_WeightedAverageExercisePriceOfWarrantsOutstandingInShareBasedPaymentArrangement" type="num:perShareItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="WeightedAverageRemainingContractualLifeOfOtherEquityInstruments" id="drug_WeightedAverageRemainingContractualLifeOfOtherEquityInstruments" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="WeightedAverageRemainingContractualLifeOfWarrants" id="drug_WeightedAverageRemainingContractualLifeOfWarrants" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="WeightedAverageSharePriceWarrantsGranted" id="drug_WeightedAverageSharePriceWarrantsGranted" type="num:perShareItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="WeightedAverageTradingPriceOfCommonSharesOnCanadianStockExchange" id="drug_WeightedAverageTradingPriceOfCommonSharesOnCanadianStockExchange" type="num:perShareItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="WorkingCapital" id="drug_WorkingCapital" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>3
<FILENAME>drug-20210930_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <!-- INTEGIX by Ez-XBRL -->
  <roleRef xlink:type="simple" xlink:href="drug-20210930.xsd#ConsolidatedStatementsOfFinancialPosition" roleURI="http://brightmindsbio.com/role/ConsolidatedStatementsOfFinancialPosition"/>
  <roleRef xlink:type="simple" xlink:href="drug-20210930.xsd#ACCOUNTSPAYABLEANDACCRUEDLIABILITIESDetails" roleURI="http://brightmindsbio.com/role/ACCOUNTSPAYABLEANDACCRUEDLIABILITIESDetails"/>
  <roleRef xlink:type="simple" xlink:href="drug-20210930.xsd#ConsolidatedStatementsOfComprehensiveLoss" roleURI="http://brightmindsbio.com/role/ConsolidatedStatementsOfComprehensiveLoss"/>
  <roleRef xlink:type="simple" xlink:href="drug-20210930.xsd#RELATEDPARTYTRANSACTIONSDetails" roleURI="http://brightmindsbio.com/role/RELATEDPARTYTRANSACTIONSDetails"/>
  <roleRef xlink:type="simple" xlink:href="drug-20210930.xsd#ConsolidatedStatementsOfCashFlows" roleURI="http://brightmindsbio.com/role/ConsolidatedStatementsOfCashFlows"/>
  <roleRef xlink:type="simple" xlink:href="drug-20210930.xsd#INCOMETAXESDetails" roleURI="http://brightmindsbio.com/role/INCOMETAXESDetails"/>
  <calculationLink xlink:type="extended" xlink:role="http://brightmindsbio.com/role/ConsolidatedStatementsOfFinancialPosition">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_Assets" xlink:label="loc_ifrs-full_Assets_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CurrentAssets" xlink:label="loc_ifrs-full_CurrentAssets_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CashAndCashEquivalents" xlink:label="loc_ifrs-full_CashAndCashEquivalents_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CurrentTaxAssetsCurrent" xlink:label="loc_ifrs-full_CurrentTaxAssetsCurrent_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CurrentPrepaidExpenses" xlink:label="loc_ifrs-full_CurrentPrepaidExpenses_3"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IntangibleAssetsAndGoodwill" xlink:label="loc_ifrs-full_IntangibleAssetsAndGoodwill_5"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_EquityAndLiabilities" xlink:label="loc_ifrs-full_EquityAndLiabilities_6"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_Liabilities" xlink:label="loc_ifrs-full_Liabilities_7"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TradeAndOtherCurrentPayables" xlink:label="loc_ifrs-full_TradeAndOtherCurrentPayables_7"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_Equity" xlink:label="loc_ifrs-full_Equity_9"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_RetainedEarnings" xlink:label="loc_ifrs-full_RetainedEarnings_9"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IssuedCapital" xlink:label="loc_ifrs-full_IssuedCapital_10"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_OtherReserves" xlink:label="loc_ifrs-full_OtherReserves_11"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_SubscriptionsReceivable" xlink:label="loc_drug_SubscriptionsReceivable_12"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_SubscriptionsReceived" xlink:label="loc_drug_SubscriptionsReceived_13"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_Assets_0" xlink:to="loc_ifrs-full_CurrentAssets_1" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentAssets_1" xlink:to="loc_ifrs-full_CashAndCashEquivalents_1" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentAssets_1" xlink:to="loc_ifrs-full_CurrentTaxAssetsCurrent_2" order="10" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentAssets_1" xlink:to="loc_ifrs-full_CurrentPrepaidExpenses_3" order="20" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_Assets_0" xlink:to="loc_ifrs-full_IntangibleAssetsAndGoodwill_5" order="10" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_EquityAndLiabilities_6" xlink:to="loc_ifrs-full_Liabilities_7" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_Liabilities_7" xlink:to="loc_ifrs-full_TradeAndOtherCurrentPayables_7" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_EquityAndLiabilities_6" xlink:to="loc_ifrs-full_Equity_9" order="10" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_Equity_9" xlink:to="loc_ifrs-full_RetainedEarnings_9" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_Equity_9" xlink:to="loc_ifrs-full_IssuedCapital_10" order="10" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_Equity_9" xlink:to="loc_ifrs-full_OtherReserves_11" order="20" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_Equity_9" xlink:to="loc_drug_SubscriptionsReceivable_12" order="30" use="optional" weight="-1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_Equity_9" xlink:to="loc_drug_SubscriptionsReceived_13" order="40" use="optional" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://brightmindsbio.com/role/ACCOUNTSPAYABLEANDACCRUEDLIABILITIESDetails">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TradeAndOtherCurrentPayables" xlink:label="loc_ifrs-full_TradeAndOtherCurrentPayables_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers" xlink:label="loc_ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AccrualsClassifiedAsCurrent" xlink:label="loc_ifrs-full_AccrualsClassifiedAsCurrent_2"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_TradeAndOtherCurrentPayables_0" xlink:to="loc_ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers_1" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_TradeAndOtherCurrentPayables_0" xlink:to="loc_ifrs-full_AccrualsClassifiedAsCurrent_2" order="10" use="optional" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://brightmindsbio.com/role/ConsolidatedStatementsOfComprehensiveLoss">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ProfitLoss" xlink:label="loc_ifrs-full_ProfitLoss_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ResearchAndDevelopmentExpense" xlink:label="loc_ifrs-full_ResearchAndDevelopmentExpense_1"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_RegulatoryAndFilingExpenses" xlink:label="loc_drug_RegulatoryAndFilingExpenses_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_GeneralAndAdministrativeExpense" xlink:label="loc_ifrs-full_GeneralAndAdministrativeExpense_3"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DirectorsRemunerationExpense" xlink:label="loc_ifrs-full_DirectorsRemunerationExpense_4"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss" xlink:label="loc_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss_5"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ProfessionalFeesExpense" xlink:label="loc_ifrs-full_ProfessionalFeesExpense_6"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_SalesAndMarketingExpense" xlink:label="loc_ifrs-full_SalesAndMarketingExpense_7"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_ProcessingFees" xlink:label="loc_drug_ProcessingFees_8"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_ConsultingFees" xlink:label="loc_drug_ConsultingFees_9"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ProfitLoss_0" xlink:to="loc_ifrs-full_ResearchAndDevelopmentExpense_1" order="0" use="optional" weight="-1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ProfitLoss_0" xlink:to="loc_drug_RegulatoryAndFilingExpenses_2" order="10" use="optional" weight="-1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ProfitLoss_0" xlink:to="loc_ifrs-full_GeneralAndAdministrativeExpense_3" order="20" use="optional" weight="-1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ProfitLoss_0" xlink:to="loc_ifrs-full_DirectorsRemunerationExpense_4" order="30" use="optional" weight="-1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ProfitLoss_0" xlink:to="loc_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss_5" order="40" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ProfitLoss_0" xlink:to="loc_ifrs-full_ProfessionalFeesExpense_6" order="50" use="optional" weight="-1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ProfitLoss_0" xlink:to="loc_ifrs-full_SalesAndMarketingExpense_7" order="60" use="optional" weight="-1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ProfitLoss_0" xlink:to="loc_drug_ProcessingFees_8" order="70" use="optional" weight="-1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ProfitLoss_0" xlink:to="loc_drug_ConsultingFees_9" order="80" use="optional" weight="-1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://brightmindsbio.com/role/RELATEDPARTYTRANSACTIONSDetails">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_KeyManagementPersonnelCompensation" xlink:label="loc_ifrs-full_KeyManagementPersonnelCompensation_0"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_KeyManagementPersonnelCompensationShareBasedPaymentIncludedInResearchAndDevelopment" xlink:label="loc_drug_KeyManagementPersonnelCompensationShareBasedPaymentIncludedInResearchAndDevelopment_1"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_KeyManagementPersonnelCompensationShareBasedPaymentIncludedInProfessionalFees" xlink:label="loc_drug_KeyManagementPersonnelCompensationShareBasedPaymentIncludedInProfessionalFees_2"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_KeyManagementPersonnelProfessionalFees" xlink:label="loc_drug_KeyManagementPersonnelProfessionalFees_3"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_KeyManagementPersonnelResearchAndDevelopment" xlink:label="loc_drug_KeyManagementPersonnelResearchAndDevelopment_4"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment" xlink:label="loc_ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment_5"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_KeyManagementPersonnelCompensation_0" xlink:to="loc_drug_KeyManagementPersonnelCompensationShareBasedPaymentIncludedInResearchAndDevelopment_1" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_KeyManagementPersonnelCompensation_0" xlink:to="loc_drug_KeyManagementPersonnelCompensationShareBasedPaymentIncludedInProfessionalFees_2" order="10" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_KeyManagementPersonnelCompensation_0" xlink:to="loc_drug_KeyManagementPersonnelProfessionalFees_3" order="20" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_KeyManagementPersonnelCompensation_0" xlink:to="loc_drug_KeyManagementPersonnelResearchAndDevelopment_4" order="30" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_KeyManagementPersonnelCompensation_0" xlink:to="loc_ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment_5" order="40" use="optional" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://brightmindsbio.com/role/ConsolidatedStatementsOfCashFlows">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IncreaseDecreaseInCashAndCashEquivalents" xlink:label="loc_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:label="loc_ifrs-full_CashFlowsFromUsedInOperatingActivities_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ProfitLoss" xlink:label="loc_ifrs-full_ProfitLoss_1"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_AdjustmentsForDecreaseIncreaseInPrepaidExpenses" xlink:label="loc_drug_AdjustmentsForDecreaseIncreaseInPrepaidExpenses_2"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_AdjustmentsForDecreaseIncreaseInSalesTaxReceivable" xlink:label="loc_drug_AdjustmentsForDecreaseIncreaseInSalesTaxReceivable_3"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable" xlink:label="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable_4"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_AdjustmentsForSharesRecordedAsResearchAndDevelopment" xlink:label="loc_drug_AdjustmentsForSharesRecordedAsResearchAndDevelopment_5"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AdjustmentsForSharebasedPayments" xlink:label="loc_ifrs-full_AdjustmentsForSharebasedPayments_6"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains" xlink:label="loc_ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains_7"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:label="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities_9"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_ProceedsFromWarrantsExercise" xlink:label="loc_drug_ProceedsFromWarrantsExercise_9"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_RefundOfSpecialWarrantsProceeds" xlink:label="loc_drug_RefundOfSpecialWarrantsProceeds_10"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_PaymentsForFindersFees" xlink:label="loc_drug_PaymentsForFindersFees_11"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_ProceedsFromIssuingWarrants" xlink:label="loc_drug_ProceedsFromIssuingWarrants_12"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_PaymentsForShareIssueCosts" xlink:label="loc_ifrs-full_PaymentsForShareIssueCosts_13"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ProceedsFromIssuingShares" xlink:label="loc_ifrs-full_ProceedsFromIssuingShares_14"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents_0" xlink:to="loc_ifrs-full_CashFlowsFromUsedInOperatingActivities_1" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivities_1" xlink:to="loc_ifrs-full_ProfitLoss_1" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivities_1" xlink:to="loc_drug_AdjustmentsForDecreaseIncreaseInPrepaidExpenses_2" order="10" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivities_1" xlink:to="loc_drug_AdjustmentsForDecreaseIncreaseInSalesTaxReceivable_3" order="20" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivities_1" xlink:to="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable_4" order="30" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivities_1" xlink:to="loc_drug_AdjustmentsForSharesRecordedAsResearchAndDevelopment_5" order="40" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivities_1" xlink:to="loc_ifrs-full_AdjustmentsForSharebasedPayments_6" order="50" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivities_1" xlink:to="loc_ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains_7" order="60" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents_0" xlink:to="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities_9" order="10" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities_9" xlink:to="loc_drug_ProceedsFromWarrantsExercise_9" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities_9" xlink:to="loc_drug_RefundOfSpecialWarrantsProceeds_10" order="10" use="optional" weight="-1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities_9" xlink:to="loc_drug_PaymentsForFindersFees_11" order="20" use="optional" weight="-1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities_9" xlink:to="loc_drug_ProceedsFromIssuingWarrants_12" order="30" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities_9" xlink:to="loc_ifrs-full_PaymentsForShareIssueCosts_13" order="40" use="optional" weight="-1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities_9" xlink:to="loc_ifrs-full_ProceedsFromIssuingShares_14" order="50" use="optional" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://brightmindsbio.com/role/INCOMETAXESDetails">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:label="loc_ifrs-full_IncomeTaxExpenseContinuingOperations_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TaxExpenseIncomeAtApplicableTaxRate" xlink:label="loc_ifrs-full_TaxExpenseIncomeAtApplicableTaxRate_1"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_TaxEffectOfDeductibleAndNotDeductibleItems" xlink:label="loc_drug_TaxEffectOfDeductibleAndNotDeductibleItems_2"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_TaxEffectOfChangeInDeferredTaxAssetsNotRecognized" xlink:label="loc_drug_TaxEffectOfChangeInDeferredTaxAssetsNotRecognized_3"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_IncomeTaxExpenseContinuingOperations_0" xlink:to="loc_ifrs-full_TaxExpenseIncomeAtApplicableTaxRate_1" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_IncomeTaxExpenseContinuingOperations_0" xlink:to="loc_drug_TaxEffectOfDeductibleAndNotDeductibleItems_2" order="10" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_IncomeTaxExpenseContinuingOperations_0" xlink:to="loc_drug_TaxEffectOfChangeInDeferredTaxAssetsNotRecognized_3" order="20" use="optional" weight="1"/>
  </calculationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>4
<FILENAME>drug-20210930_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
  <!-- INTEGIX by Ez-XBRL -->
  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll"/>
  <roleRef xlink:type="simple" xlink:href="drug-20210930.xsd#DocumentAndEntityInformation" roleURI="http://brightmindsbio.com/role/DocumentAndEntityInformation"/>
  <roleRef xlink:type="simple" xlink:href="drug-20210930.xsd#SUBSEQUENTEVENTSDetailTextuals" roleURI="http://brightmindsbio.com/role/SUBSEQUENTEVENTSDetailTextuals"/>
  <roleRef xlink:type="simple" xlink:href="drug-20210930.xsd#RESEARCHANDDEVELOPMENTDetails" roleURI="http://brightmindsbio.com/role/RESEARCHANDDEVELOPMENTDetails"/>
  <roleRef xlink:type="simple" xlink:href="drug-20210930.xsd#FINANCIALINSTRUMENTSANDCAPITALMANAGEMENTDetails" roleURI="http://brightmindsbio.com/role/FINANCIALINSTRUMENTSANDCAPITALMANAGEMENTDetails"/>
  <roleRef xlink:type="simple" xlink:href="drug-20210930.xsd#FINANCIALINSTRUMENTSANDCAPITALMANAGEMENTDetailTextuals" roleURI="http://brightmindsbio.com/role/FINANCIALINSTRUMENTSANDCAPITALMANAGEMENTDetailTextuals"/>
  <roleRef xlink:type="simple" xlink:href="drug-20210930.xsd#SHAREEXCHANGEANDASSIGNMENTDetailTextuals" roleURI="http://brightmindsbio.com/role/SHAREEXCHANGEANDASSIGNMENTDetailTextuals"/>
  <roleRef xlink:type="simple" xlink:href="drug-20210930.xsd#SHARECAPITALDetails" roleURI="http://brightmindsbio.com/role/SHARECAPITALDetails"/>
  <roleRef xlink:type="simple" xlink:href="drug-20210930.xsd#SHARECAPITALDetails1" roleURI="http://brightmindsbio.com/role/SHARECAPITALDetails1"/>
  <roleRef xlink:type="simple" xlink:href="drug-20210930.xsd#SHARECAPITALDetails3" roleURI="http://brightmindsbio.com/role/SHARECAPITALDetails3"/>
  <roleRef xlink:type="simple" xlink:href="drug-20210930.xsd#SHARECAPITALDetails2" roleURI="http://brightmindsbio.com/role/SHARECAPITALDetails2"/>
  <roleRef xlink:type="simple" xlink:href="drug-20210930.xsd#SHARECAPITALDetails4" roleURI="http://brightmindsbio.com/role/SHARECAPITALDetails4"/>
  <roleRef xlink:type="simple" xlink:href="drug-20210930.xsd#SHARECAPITALDetails7" roleURI="http://brightmindsbio.com/role/SHARECAPITALDetails7"/>
  <roleRef xlink:type="simple" xlink:href="drug-20210930.xsd#SHARECAPITALDetails6" roleURI="http://brightmindsbio.com/role/SHARECAPITALDetails6"/>
  <roleRef xlink:type="simple" xlink:href="drug-20210930.xsd#SHARECAPITALDetailTextuals" roleURI="http://brightmindsbio.com/role/SHARECAPITALDetailTextuals"/>
  <roleRef xlink:type="simple" xlink:href="drug-20210930.xsd#SHARECAPITALDetails5" roleURI="http://brightmindsbio.com/role/SHARECAPITALDetails5"/>
  <roleRef xlink:type="simple" xlink:href="drug-20210930.xsd#INCOMETAXESDetails2" roleURI="http://brightmindsbio.com/role/INCOMETAXESDetails2"/>
  <roleRef xlink:type="simple" xlink:href="drug-20210930.xsd#INCOMETAXESDetailTextuals" roleURI="http://brightmindsbio.com/role/INCOMETAXESDetailTextuals"/>
  <roleRef xlink:type="simple" xlink:href="drug-20210930.xsd#INCOMETAXESDetails1" roleURI="http://brightmindsbio.com/role/INCOMETAXESDetails1"/>
  <roleRef xlink:type="simple" xlink:href="drug-20210930.xsd#ConsolidatedStatementsOfChangesInShareholdersEquity" roleURI="http://brightmindsbio.com/role/ConsolidatedStatementsOfChangesInShareholdersEquity"/>
  <roleRef xlink:type="simple" xlink:href="drug-20210930.xsd#CONTRACTUALOBLIGATIONSDetailTextuals" roleURI="http://brightmindsbio.com/role/CONTRACTUALOBLIGATIONSDetailTextuals"/>
  <roleRef xlink:type="simple" xlink:href="drug-20210930.xsd#PREMISESLEASESDetailTextuals" roleURI="http://brightmindsbio.com/role/PREMISESLEASESDetailTextuals"/>
  <definitionLink xlink:type="extended" xlink:role="http://brightmindsbio.com/role/DocumentAndEntityInformation">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressesLineItems" xlink:label="loc_dei_EntityAddressesLineItems_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressesTable" xlink:label="loc_dei_EntityAddressesTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressesAddressTypeAxis" xlink:label="loc_dei_EntityAddressesAddressTypeAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AddressTypeDomain" xlink:label="loc_dei_AddressTypeDomain_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_BusinessContactMember" xlink:label="loc_dei_BusinessContactMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AddressTypeDomain" xlink:label="loc_dei_AddressTypeDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_dei_DocumentRegistrationStatement_9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentAnnualReport" xlink:label="loc_dei_DocumentAnnualReport_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber" xlink:label="loc_dei_EntityFileNumber_11"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_12"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_ContactPersonnelName" xlink:label="loc_dei_ContactPersonnelName_13"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_dei_EntityAddressAddressLine1_14"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_dei_EntityAddressAddressLine2_15"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_dei_EntityAddressCityOrTown_16"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_dei_EntityAddressStateOrProvince_17"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_dei_EntityIncorporationStateCountryCode_18"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCountry" xlink:label="loc_dei_EntityAddressCountry_19"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_dei_EntityAddressPostalZipCode_20"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode" xlink:label="loc_dei_CityAreaCode_21"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber" xlink:label="loc_dei_LocalPhoneNumber_22"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_ContactPersonnelFaxNumber" xlink:label="loc_dei_ContactPersonnelFaxNumber_23"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_ContactPersonnelEmailAddress" xlink:label="loc_dei_ContactPersonnelEmailAddress_24"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle" xlink:label="loc_dei_Security12bTitle_25"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol" xlink:label="loc_dei_TradingSymbol_26"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName" xlink:label="loc_dei_SecurityExchangeName_27"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AnnualInformationForm" xlink:label="loc_dei_AnnualInformationForm_28"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_29"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentDescription" xlink:label="loc_dei_AmendmentDescription_30"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_dei_AuditedAnnualFinancialStatements_31"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate_32"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_33"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_34"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentAccountingStandard" xlink:label="loc_dei_DocumentAccountingStandard_35"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_dei_EntityCurrentReportingStatus_36"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_dei_EntityVoluntaryFilers_37"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_38"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus_39"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus_40"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany" xlink:label="loc_dei_EntityShellCompany_41"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_dei_EntityEmergingGrowthCompany_42"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_dei_EntityInteractiveDataCurrent_43"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentTransitionReport" xlink:label="loc_dei_DocumentTransitionReport_44"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_dei_DocumentShellCompanyReport_45"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_dei_EntityExTransitionPeriod_46"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="loc_dei_IcfrAuditorAttestationFlag_47"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_dei_EntityAddressesLineItems_0" xlink:to="loc_dei_EntityAddressesTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_dei_EntityAddressesTable_1" xlink:to="loc_dei_EntityAddressesAddressTypeAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_EntityAddressesAddressTypeAxis_1" xlink:to="loc_dei_AddressTypeDomain_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_AddressTypeDomain_1" xlink:to="loc_dei_BusinessContactMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_EntityAddressesAddressTypeAxis_1" xlink:to="loc_dei_AddressTypeDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityAddressesLineItems_0" xlink:to="loc_dei_EntityRegistrantName_6" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityAddressesLineItems_0" xlink:to="loc_dei_EntityCentralIndexKey_7" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityAddressesLineItems_0" xlink:to="loc_dei_DocumentType_8" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityAddressesLineItems_0" xlink:to="loc_dei_DocumentRegistrationStatement_9" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityAddressesLineItems_0" xlink:to="loc_dei_DocumentAnnualReport_10" order="50" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityAddressesLineItems_0" xlink:to="loc_dei_EntityFileNumber_11" order="60" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityAddressesLineItems_0" xlink:to="loc_dei_DocumentPeriodEndDate_12" order="70" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityAddressesLineItems_0" xlink:to="loc_dei_ContactPersonnelName_13" order="80" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityAddressesLineItems_0" xlink:to="loc_dei_EntityAddressAddressLine1_14" order="90" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityAddressesLineItems_0" xlink:to="loc_dei_EntityAddressAddressLine2_15" order="100" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityAddressesLineItems_0" xlink:to="loc_dei_EntityAddressCityOrTown_16" order="110" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityAddressesLineItems_0" xlink:to="loc_dei_EntityAddressStateOrProvince_17" order="120" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityAddressesLineItems_0" xlink:to="loc_dei_EntityIncorporationStateCountryCode_18" order="130" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityAddressesLineItems_0" xlink:to="loc_dei_EntityAddressCountry_19" order="140" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityAddressesLineItems_0" xlink:to="loc_dei_EntityAddressPostalZipCode_20" order="150" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityAddressesLineItems_0" xlink:to="loc_dei_CityAreaCode_21" order="160" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityAddressesLineItems_0" xlink:to="loc_dei_LocalPhoneNumber_22" order="170" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityAddressesLineItems_0" xlink:to="loc_dei_ContactPersonnelFaxNumber_23" order="180" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityAddressesLineItems_0" xlink:to="loc_dei_ContactPersonnelEmailAddress_24" order="190" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityAddressesLineItems_0" xlink:to="loc_dei_Security12bTitle_25" order="200" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityAddressesLineItems_0" xlink:to="loc_dei_TradingSymbol_26" order="210" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityAddressesLineItems_0" xlink:to="loc_dei_SecurityExchangeName_27" order="220" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityAddressesLineItems_0" xlink:to="loc_dei_AnnualInformationForm_28" order="230" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityAddressesLineItems_0" xlink:to="loc_dei_AmendmentFlag_29" order="240" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityAddressesLineItems_0" xlink:to="loc_dei_AmendmentDescription_30" order="250" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityAddressesLineItems_0" xlink:to="loc_dei_AuditedAnnualFinancialStatements_31" order="260" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityAddressesLineItems_0" xlink:to="loc_dei_CurrentFiscalYearEndDate_32" order="270" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityAddressesLineItems_0" xlink:to="loc_dei_EntityFilerCategory_33" order="280" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityAddressesLineItems_0" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_34" order="290" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityAddressesLineItems_0" xlink:to="loc_dei_DocumentAccountingStandard_35" order="300" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityAddressesLineItems_0" xlink:to="loc_dei_EntityCurrentReportingStatus_36" order="310" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityAddressesLineItems_0" xlink:to="loc_dei_EntityVoluntaryFilers_37" order="320" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityAddressesLineItems_0" xlink:to="loc_dei_EntityWellKnownSeasonedIssuer_38" order="330" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityAddressesLineItems_0" xlink:to="loc_dei_DocumentFiscalYearFocus_39" order="340" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityAddressesLineItems_0" xlink:to="loc_dei_DocumentFiscalPeriodFocus_40" order="350" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityAddressesLineItems_0" xlink:to="loc_dei_EntityShellCompany_41" order="360" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityAddressesLineItems_0" xlink:to="loc_dei_EntityEmergingGrowthCompany_42" order="370" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityAddressesLineItems_0" xlink:to="loc_dei_EntityInteractiveDataCurrent_43" order="380" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityAddressesLineItems_0" xlink:to="loc_dei_DocumentTransitionReport_44" order="390" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityAddressesLineItems_0" xlink:to="loc_dei_DocumentShellCompanyReport_45" order="400" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityAddressesLineItems_0" xlink:to="loc_dei_EntityExTransitionPeriod_46" order="410" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityAddressesLineItems_0" xlink:to="loc_dei_IcfrAuditorAttestationFlag_47" order="420" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://brightmindsbio.com/role/SUBSEQUENTEVENTSDetailTextuals">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems" xlink:label="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable" xlink:label="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:label="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NonadjustingEventsMember" xlink:label="loc_ifrs-full_NonadjustingEventsMember_1"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_SubsequentEventsMember" xlink:label="loc_drug_SubsequentEventsMember_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NonadjustingEventsMember" xlink:label="loc_ifrs-full_NonadjustingEventsMember_Default"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_TypeOfArrangementsAxis" xlink:label="loc_drug_TypeOfArrangementsAxis_5"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_ArrangementsAndNonarrangementTransactionDomain" xlink:label="loc_drug_ArrangementsAndNonarrangementTransactionDomain_5"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_LetterAgreementMember" xlink:label="loc_drug_LetterAgreementMember_5"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_ArrangementsAndNonarrangementTransactionDomain" xlink:label="loc_drug_ArrangementsAndNonarrangementTransactionDomain_Default"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_TranchesAxis" xlink:label="loc_drug_TranchesAxis_9"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_TranchesDomain" xlink:label="loc_drug_TranchesDomain_9"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_FirstTrancheMember" xlink:label="loc_drug_FirstTrancheMember_9"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_SecondTrancheMember" xlink:label="loc_drug_SecondTrancheMember_10"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_ThirdTrancheMember" xlink:label="loc_drug_ThirdTrancheMember_11"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_TranchesDomain" xlink:label="loc_drug_TranchesDomain_Default"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_AmountOfNonRefundableMonthlyRetainerAsServiceCompensation" xlink:label="loc_drug_AmountOfNonRefundableMonthlyRetainerAsServiceCompensation_16"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_NumberOfRestrictedStockIssuedForCompensation" xlink:label="loc_drug_NumberOfRestrictedStockIssuedForCompensation_17"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_TermsOfContract" xlink:label="loc_drug_TermsOfContract_18"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_NumberOfWarrantsExercised" xlink:label="loc_drug_NumberOfWarrantsExercised_19"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_GrossProceedsFromWarrantsExercised" xlink:label="loc_drug_GrossProceedsFromWarrantsExercised_20"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_0" xlink:to="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable_1" xlink:to="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_1" xlink:to="loc_ifrs-full_NonadjustingEventsMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_NonadjustingEventsMember_1" xlink:to="loc_drug_SubsequentEventsMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_1" xlink:to="loc_ifrs-full_NonadjustingEventsMember_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable_1" xlink:to="loc_drug_TypeOfArrangementsAxis_5" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_drug_TypeOfArrangementsAxis_5" xlink:to="loc_drug_ArrangementsAndNonarrangementTransactionDomain_5" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_drug_ArrangementsAndNonarrangementTransactionDomain_5" xlink:to="loc_drug_LetterAgreementMember_5" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_drug_TypeOfArrangementsAxis_5" xlink:to="loc_drug_ArrangementsAndNonarrangementTransactionDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable_1" xlink:to="loc_drug_TranchesAxis_9" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_drug_TranchesAxis_9" xlink:to="loc_drug_TranchesDomain_9" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_drug_TranchesDomain_9" xlink:to="loc_drug_FirstTrancheMember_9" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_drug_TranchesDomain_9" xlink:to="loc_drug_SecondTrancheMember_10" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_drug_TranchesDomain_9" xlink:to="loc_drug_ThirdTrancheMember_11" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_drug_TranchesAxis_9" xlink:to="loc_drug_TranchesDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_0" xlink:to="loc_drug_AmountOfNonRefundableMonthlyRetainerAsServiceCompensation_16" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_0" xlink:to="loc_drug_NumberOfRestrictedStockIssuedForCompensation_17" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_0" xlink:to="loc_drug_TermsOfContract_18" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_0" xlink:to="loc_drug_NumberOfWarrantsExercised_19" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_0" xlink:to="loc_drug_GrossProceedsFromWarrantsExercised_20" order="50" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://brightmindsbio.com/role/RESEARCHANDDEVELOPMENTDetails">
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_ResearchAndDevelopmentLineItems" xlink:label="loc_drug_ResearchAndDevelopmentLineItems_0"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_ResearchDevelopmentTable" xlink:label="loc_drug_ResearchDevelopmentTable_1"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_CategoriesOfResearchAndDevelopmentExpensesAxis" xlink:label="loc_drug_CategoriesOfResearchAndDevelopmentExpensesAxis_1"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_CategoriesOfResearchAndDevelopmentExpensesDomain" xlink:label="loc_drug_CategoriesOfResearchAndDevelopmentExpensesDomain_1"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_LaboratoryCostsMember" xlink:label="loc_drug_LaboratoryCostsMember_1"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_NovelDrugDevelopmentMember" xlink:label="loc_drug_NovelDrugDevelopmentMember_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CopyrightsPatentsAndOtherIndustrialPropertyRightsServiceAndOperatingRightsMember" xlink:label="loc_ifrs-full_CopyrightsPatentsAndOtherIndustrialPropertyRightsServiceAndOperatingRightsMember_3"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_SalaryAndSubcontractorsMember" xlink:label="loc_drug_SalaryAndSubcontractorsMember_4"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_ShareBasedCompensationMember" xlink:label="loc_drug_ShareBasedCompensationMember_5"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_CategoriesOfResearchAndDevelopmentExpensesDomain" xlink:label="loc_drug_CategoriesOfResearchAndDevelopmentExpensesDomain_Default"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ResearchAndDevelopmentExpense" xlink:label="loc_ifrs-full_ResearchAndDevelopmentExpense_10"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_drug_ResearchAndDevelopmentLineItems_0" xlink:to="loc_drug_ResearchDevelopmentTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_drug_ResearchDevelopmentTable_1" xlink:to="loc_drug_CategoriesOfResearchAndDevelopmentExpensesAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_drug_CategoriesOfResearchAndDevelopmentExpensesAxis_1" xlink:to="loc_drug_CategoriesOfResearchAndDevelopmentExpensesDomain_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_drug_CategoriesOfResearchAndDevelopmentExpensesDomain_1" xlink:to="loc_drug_LaboratoryCostsMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_drug_CategoriesOfResearchAndDevelopmentExpensesDomain_1" xlink:to="loc_drug_NovelDrugDevelopmentMember_2" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_drug_CategoriesOfResearchAndDevelopmentExpensesDomain_1" xlink:to="loc_ifrs-full_CopyrightsPatentsAndOtherIndustrialPropertyRightsServiceAndOperatingRightsMember_3" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_drug_CategoriesOfResearchAndDevelopmentExpensesDomain_1" xlink:to="loc_drug_SalaryAndSubcontractorsMember_4" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_drug_CategoriesOfResearchAndDevelopmentExpensesDomain_1" xlink:to="loc_drug_ShareBasedCompensationMember_5" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_drug_CategoriesOfResearchAndDevelopmentExpensesAxis_1" xlink:to="loc_drug_CategoriesOfResearchAndDevelopmentExpensesDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_drug_ResearchAndDevelopmentLineItems_0" xlink:to="loc_ifrs-full_ResearchAndDevelopmentExpense_10" order="10" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://brightmindsbio.com/role/FINANCIALINSTRUMENTSANDCAPITALMANAGEMENTDetails">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:label="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfFinancialInstrumentsTable" xlink:label="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:label="loc_ifrs-full_ClassesOfFinancialInstrumentsAxis_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ClassesOfFinancialInstrumentsMember" xlink:label="loc_ifrs-full_ClassesOfFinancialInstrumentsMember_1"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_FinancialInstrumentsAtFairValueThroughProfitOrLossMember" xlink:label="loc_drug_FinancialInstrumentsAtFairValueThroughProfitOrLossMember_1"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_FinancialInstrumentsAtAmortizedCostMember" xlink:label="loc_drug_FinancialInstrumentsAtAmortizedCostMember_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ClassesOfFinancialInstrumentsMember" xlink:label="loc_ifrs-full_ClassesOfFinancialInstrumentsMember_Default"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CurrentFinancialAssetsAtFairValueThroughProfitOrLossAbstract" xlink:label="loc_ifrs-full_CurrentFinancialAssetsAtFairValueThroughProfitOrLossAbstract_7"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_Cash" xlink:label="loc_ifrs-full_Cash_7"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ShorttermInvestmentsClassifiedAsCashEquivalents" xlink:label="loc_ifrs-full_ShorttermInvestmentsClassifiedAsCashEquivalents_8"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CashAndCashEquivalents" xlink:label="loc_ifrs-full_CashAndCashEquivalents_9"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CategoriesOfFinancialLiabilitiesAbstract" xlink:label="loc_ifrs-full_CategoriesOfFinancialLiabilitiesAbstract_11"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TradeAndOtherCurrentPayables" xlink:label="loc_ifrs-full_TradeAndOtherCurrentPayables_11"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_0" xlink:to="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_1" xlink:to="loc_ifrs-full_ClassesOfFinancialInstrumentsAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfFinancialInstrumentsAxis_1" xlink:to="loc_ifrs-full_ClassesOfFinancialInstrumentsMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfFinancialInstrumentsMember_1" xlink:to="loc_drug_FinancialInstrumentsAtFairValueThroughProfitOrLossMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfFinancialInstrumentsMember_1" xlink:to="loc_drug_FinancialInstrumentsAtAmortizedCostMember_2" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfFinancialInstrumentsAxis_1" xlink:to="loc_ifrs-full_ClassesOfFinancialInstrumentsMember_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_0" xlink:to="loc_ifrs-full_CurrentFinancialAssetsAtFairValueThroughProfitOrLossAbstract_7" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CurrentFinancialAssetsAtFairValueThroughProfitOrLossAbstract_7" xlink:to="loc_ifrs-full_Cash_7" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CurrentFinancialAssetsAtFairValueThroughProfitOrLossAbstract_7" xlink:to="loc_ifrs-full_ShorttermInvestmentsClassifiedAsCashEquivalents_8" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CurrentFinancialAssetsAtFairValueThroughProfitOrLossAbstract_7" xlink:to="loc_ifrs-full_CashAndCashEquivalents_9" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_0" xlink:to="loc_ifrs-full_CategoriesOfFinancialLiabilitiesAbstract_11" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CategoriesOfFinancialLiabilitiesAbstract_11" xlink:to="loc_ifrs-full_TradeAndOtherCurrentPayables_11" order="0" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://brightmindsbio.com/role/FINANCIALINSTRUMENTSANDCAPITALMANAGEMENTDetailTextuals">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:label="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfFinancialInstrumentsTable" xlink:label="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TypesOfRisksAxis" xlink:label="loc_ifrs-full_TypesOfRisksAxis_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TypesOfRisksMember" xlink:label="loc_ifrs-full_TypesOfRisksMember_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CreditRiskMember" xlink:label="loc_ifrs-full_CreditRiskMember_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CurrencyRiskMember" xlink:label="loc_ifrs-full_CurrencyRiskMember_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_LiquidityRiskMember" xlink:label="loc_ifrs-full_LiquidityRiskMember_3"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TypesOfRisksMember" xlink:label="loc_ifrs-full_TypesOfRisksMember_Default"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CashAndCashEquivalents" xlink:label="loc_ifrs-full_CashAndCashEquivalents_8"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_Cash" xlink:label="loc_ifrs-full_Cash_9"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TradeAndOtherCurrentPayables" xlink:label="loc_ifrs-full_TradeAndOtherCurrentPayables_10"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_PercentageOfForeignCurrencyFluctuationInUsDollarAgainstCanadianDollar" xlink:label="loc_drug_PercentageOfForeignCurrencyFluctuationInUsDollarAgainstCanadianDollar_11"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ValueAtRisk" xlink:label="loc_ifrs-full_ValueAtRisk_12"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_0" xlink:to="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_1" xlink:to="loc_ifrs-full_TypesOfRisksAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_TypesOfRisksAxis_1" xlink:to="loc_ifrs-full_TypesOfRisksMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TypesOfRisksMember_1" xlink:to="loc_ifrs-full_CreditRiskMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TypesOfRisksMember_1" xlink:to="loc_ifrs-full_CurrencyRiskMember_2" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TypesOfRisksMember_1" xlink:to="loc_ifrs-full_LiquidityRiskMember_3" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_TypesOfRisksAxis_1" xlink:to="loc_ifrs-full_TypesOfRisksMember_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_0" xlink:to="loc_ifrs-full_CashAndCashEquivalents_8" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_0" xlink:to="loc_ifrs-full_Cash_9" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_0" xlink:to="loc_ifrs-full_TradeAndOtherCurrentPayables_10" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_0" xlink:to="loc_drug_PercentageOfForeignCurrencyFluctuationInUsDollarAgainstCanadianDollar_11" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_0" xlink:to="loc_ifrs-full_ValueAtRisk_12" order="50" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://brightmindsbio.com/role/SHAREEXCHANGEANDASSIGNMENTDetailTextuals">
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_ShareExchangeAndAssignmentLineItems" xlink:label="loc_drug_ShareExchangeAndAssignmentLineItems_0"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_DisclosureOfShareExchangeAndAssignmentTable" xlink:label="loc_drug_DisclosureOfShareExchangeAndAssignmentTable_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:label="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:label="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_1"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_PsilocybinlabsLtdMember" xlink:label="loc_drug_PsilocybinlabsLtdMember_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:label="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_Default"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_NumberOfSharesIssuedByRelatedParty" xlink:label="loc_drug_NumberOfSharesIssuedByRelatedParty_6"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_ValueOfCommonStockSharesIssuedByRelatedParty" xlink:label="loc_drug_ValueOfCommonStockSharesIssuedByRelatedParty_7"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_CommonStockSharesPurchased" xlink:label="loc_drug_CommonStockSharesPurchased_8"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NumberOfInstrumentsOrInterestsIssuedOrIssuable" xlink:label="loc_ifrs-full_NumberOfInstrumentsOrInterestsIssuedOrIssuable_9"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_EquityInterestsOfAcquirer" xlink:label="loc_ifrs-full_EquityInterestsOfAcquirer_10"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_drug_ShareExchangeAndAssignmentLineItems_0" xlink:to="loc_drug_DisclosureOfShareExchangeAndAssignmentTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_drug_DisclosureOfShareExchangeAndAssignmentTable_1" xlink:to="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_1" xlink:to="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_1" xlink:to="loc_drug_PsilocybinlabsLtdMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_1" xlink:to="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_drug_ShareExchangeAndAssignmentLineItems_0" xlink:to="loc_drug_NumberOfSharesIssuedByRelatedParty_6" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_drug_ShareExchangeAndAssignmentLineItems_0" xlink:to="loc_drug_ValueOfCommonStockSharesIssuedByRelatedParty_7" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_drug_ShareExchangeAndAssignmentLineItems_0" xlink:to="loc_drug_CommonStockSharesPurchased_8" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_drug_ShareExchangeAndAssignmentLineItems_0" xlink:to="loc_ifrs-full_NumberOfInstrumentsOrInterestsIssuedOrIssuable_9" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_drug_ShareExchangeAndAssignmentLineItems_0" xlink:to="loc_ifrs-full_EquityInterestsOfAcquirer_10" order="50" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://brightmindsbio.com/role/SHARECAPITALDetails">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalTable" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ClassesOfShareCapitalAxis" xlink:label="loc_ifrs-full_ClassesOfShareCapitalAxis_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ClassesOfShareCapitalMember" xlink:label="loc_ifrs-full_ClassesOfShareCapitalMember_1"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_StockOptionsMember" xlink:label="loc_drug_StockOptionsMember_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ClassesOfShareCapitalMember" xlink:label="loc_ifrs-full_ClassesOfShareCapitalMember_Default"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NumberOfOutstandingShareOptions" xlink:label="loc_ifrs-full_NumberOfOutstandingShareOptions_6"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" xlink:label="loc_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement_7"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" xlink:label="loc_ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement_8"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" xlink:label="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_9"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019" xlink:label="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019_10"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019" xlink:label="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019_11"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_0" xlink:to="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_1" xlink:to="loc_ifrs-full_ClassesOfShareCapitalAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfShareCapitalAxis_1" xlink:to="loc_ifrs-full_ClassesOfShareCapitalMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfShareCapitalMember_1" xlink:to="loc_drug_StockOptionsMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfShareCapitalAxis_1" xlink:to="loc_ifrs-full_ClassesOfShareCapitalMember_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_0" xlink:to="loc_ifrs-full_NumberOfOutstandingShareOptions_6" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_0" xlink:to="loc_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement_7" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_0" xlink:to="loc_ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement_8" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_0" xlink:to="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_9" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_0" xlink:to="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019_10" order="50" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_0" xlink:to="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019_11" order="60" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://brightmindsbio.com/role/SHARECAPITALDetails1">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalTable" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ClassesOfShareCapitalAxis" xlink:label="loc_ifrs-full_ClassesOfShareCapitalAxis_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ClassesOfShareCapitalMember" xlink:label="loc_ifrs-full_ClassesOfShareCapitalMember_1"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_StockOptionsMember" xlink:label="loc_drug_StockOptionsMember_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ClassesOfShareCapitalMember" xlink:label="loc_ifrs-full_ClassesOfShareCapitalMember_Default"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_ExpiryDateAxis" xlink:label="loc_drug_ExpiryDateAxis_5"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_ExpiryDateDomain" xlink:label="loc_drug_ExpiryDateDomain_5"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_ExpiryDateTwentyOneSeptemberTwoThousandAndTwentyFourMember" xlink:label="loc_drug_ExpiryDateTwentyOneSeptemberTwoThousandAndTwentyFourMember_5"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_ExpiryDateTwentyThreeJulyTwoThousandAndTwentyFiveMember" xlink:label="loc_drug_ExpiryDateTwentyThreeJulyTwoThousandAndTwentyFiveMember_6"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_ExpiryDateSeventeenNovemberTwoThousandAndTwentyFiveMember" xlink:label="loc_drug_ExpiryDateSeventeenNovemberTwoThousandAndTwentyFiveMember_7"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_ExpiryDateTwentyEightAprilTwoThousandAndTwentySixMember" xlink:label="loc_drug_ExpiryDateTwentyEightAprilTwoThousandAndTwentySixMember_8"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_ExpiryDateFifteenJuneTwoThousandAndTwentySixMember" xlink:label="loc_drug_ExpiryDateFifteenJuneTwoThousandAndTwentySixMember_9"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_ExpiryDateDomain" xlink:label="loc_drug_ExpiryDateDomain_Default"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NumberOfOutstandingShareOptions" xlink:label="loc_ifrs-full_NumberOfOutstandingShareOptions_14"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" xlink:label="loc_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement_15"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ExercisePriceOfOutstandingShareOptions2019" xlink:label="loc_ifrs-full_ExercisePriceOfOutstandingShareOptions2019_16"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" xlink:label="loc_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019_17"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_0" xlink:to="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_1" xlink:to="loc_ifrs-full_ClassesOfShareCapitalAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfShareCapitalAxis_1" xlink:to="loc_ifrs-full_ClassesOfShareCapitalMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfShareCapitalMember_1" xlink:to="loc_drug_StockOptionsMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfShareCapitalAxis_1" xlink:to="loc_ifrs-full_ClassesOfShareCapitalMember_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_1" xlink:to="loc_drug_ExpiryDateAxis_5" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_drug_ExpiryDateAxis_5" xlink:to="loc_drug_ExpiryDateDomain_5" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_drug_ExpiryDateDomain_5" xlink:to="loc_drug_ExpiryDateTwentyOneSeptemberTwoThousandAndTwentyFourMember_5" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_drug_ExpiryDateDomain_5" xlink:to="loc_drug_ExpiryDateTwentyThreeJulyTwoThousandAndTwentyFiveMember_6" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_drug_ExpiryDateDomain_5" xlink:to="loc_drug_ExpiryDateSeventeenNovemberTwoThousandAndTwentyFiveMember_7" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_drug_ExpiryDateDomain_5" xlink:to="loc_drug_ExpiryDateTwentyEightAprilTwoThousandAndTwentySixMember_8" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_drug_ExpiryDateDomain_5" xlink:to="loc_drug_ExpiryDateFifteenJuneTwoThousandAndTwentySixMember_9" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_drug_ExpiryDateAxis_5" xlink:to="loc_drug_ExpiryDateDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_0" xlink:to="loc_ifrs-full_NumberOfOutstandingShareOptions_14" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_0" xlink:to="loc_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement_15" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_0" xlink:to="loc_ifrs-full_ExercisePriceOfOutstandingShareOptions2019_16" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_0" xlink:to="loc_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019_17" order="40" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://brightmindsbio.com/role/SHARECAPITALDetails3">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalTable" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ClassesOfShareCapitalAxis" xlink:label="loc_ifrs-full_ClassesOfShareCapitalAxis_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ClassesOfShareCapitalMember" xlink:label="loc_ifrs-full_ClassesOfShareCapitalMember_1"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_RestrictedShareUnitMember" xlink:label="loc_drug_RestrictedShareUnitMember_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ClassesOfShareCapitalMember" xlink:label="loc_ifrs-full_ClassesOfShareCapitalMember_Default"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_5"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_SharebasedPaymentArrangementsMember" xlink:label="loc_ifrs-full_SharebasedPaymentArrangementsMember_5"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_EquitySettledShareBasedPaymentArrangementsMember" xlink:label="loc_drug_EquitySettledShareBasedPaymentArrangementsMember_5"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_SharebasedPaymentArrangementsMember" xlink:label="loc_ifrs-full_SharebasedPaymentArrangementsMember_Default"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_SharePriceOnGrantDateOfOtherEquityInstruments" xlink:label="loc_drug_SharePriceOnGrantDateOfOtherEquityInstruments_10"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_ForfeitureRateOfOtherEquityInstruments" xlink:label="loc_drug_ForfeitureRateOfOtherEquityInstruments_11"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_0" xlink:to="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_1" xlink:to="loc_ifrs-full_ClassesOfShareCapitalAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfShareCapitalAxis_1" xlink:to="loc_ifrs-full_ClassesOfShareCapitalMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfShareCapitalMember_1" xlink:to="loc_drug_RestrictedShareUnitMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfShareCapitalAxis_1" xlink:to="loc_ifrs-full_ClassesOfShareCapitalMember_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_1" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_5" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_5" xlink:to="loc_ifrs-full_SharebasedPaymentArrangementsMember_5" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_5" xlink:to="loc_drug_EquitySettledShareBasedPaymentArrangementsMember_5" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_5" xlink:to="loc_ifrs-full_SharebasedPaymentArrangementsMember_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_0" xlink:to="loc_drug_SharePriceOnGrantDateOfOtherEquityInstruments_10" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_0" xlink:to="loc_drug_ForfeitureRateOfOtherEquityInstruments_11" order="20" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://brightmindsbio.com/role/SHARECAPITALDetails2">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalTable" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ClassesOfShareCapitalAxis" xlink:label="loc_ifrs-full_ClassesOfShareCapitalAxis_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ClassesOfShareCapitalMember" xlink:label="loc_ifrs-full_ClassesOfShareCapitalMember_1"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_RestrictedShareUnitMember" xlink:label="loc_drug_RestrictedShareUnitMember_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ClassesOfShareCapitalMember" xlink:label="loc_ifrs-full_ClassesOfShareCapitalMember_Default"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_5"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_SharebasedPaymentArrangementsMember" xlink:label="loc_ifrs-full_SharebasedPaymentArrangementsMember_5"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_EquitySettledShareBasedPaymentArrangementsMember" xlink:label="loc_drug_EquitySettledShareBasedPaymentArrangementsMember_5"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_CashSettledShareBasedPaymentArrangementsMember" xlink:label="loc_drug_CashSettledShareBasedPaymentArrangementsMember_6"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_SharebasedPaymentArrangementsMember" xlink:label="loc_ifrs-full_SharebasedPaymentArrangementsMember_Default"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" xlink:label="loc_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_11"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted" xlink:label="loc_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted_12"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" xlink:label="loc_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement_13"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_0" xlink:to="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_1" xlink:to="loc_ifrs-full_ClassesOfShareCapitalAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfShareCapitalAxis_1" xlink:to="loc_ifrs-full_ClassesOfShareCapitalMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfShareCapitalMember_1" xlink:to="loc_drug_RestrictedShareUnitMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfShareCapitalAxis_1" xlink:to="loc_ifrs-full_ClassesOfShareCapitalMember_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_1" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_5" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_5" xlink:to="loc_ifrs-full_SharebasedPaymentArrangementsMember_5" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_5" xlink:to="loc_drug_EquitySettledShareBasedPaymentArrangementsMember_5" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_5" xlink:to="loc_drug_CashSettledShareBasedPaymentArrangementsMember_6" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_5" xlink:to="loc_ifrs-full_SharebasedPaymentArrangementsMember_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_0" xlink:to="loc_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_11" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_0" xlink:to="loc_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted_12" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_0" xlink:to="loc_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement_13" order="30" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://brightmindsbio.com/role/SHARECAPITALDetails4">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalTable" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_SharebasedPaymentArrangementsMember" xlink:label="loc_ifrs-full_SharebasedPaymentArrangementsMember_1"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_EquitySettledShareBasedPaymentArrangementsMember" xlink:label="loc_drug_EquitySettledShareBasedPaymentArrangementsMember_1"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_CashSettledShareBasedPaymentArrangementsMember" xlink:label="loc_drug_CashSettledShareBasedPaymentArrangementsMember_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_SharebasedPaymentArrangementsMember" xlink:label="loc_ifrs-full_SharebasedPaymentArrangementsMember_Default"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ClassesOfShareCapitalAxis" xlink:label="loc_ifrs-full_ClassesOfShareCapitalAxis_6"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ClassesOfShareCapitalMember" xlink:label="loc_ifrs-full_ClassesOfShareCapitalMember_6"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_StockOptionsMember" xlink:label="loc_drug_StockOptionsMember_6"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_RestrictedShareUnitMember" xlink:label="loc_drug_RestrictedShareUnitMember_7"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ClassesOfShareCapitalMember" xlink:label="loc_ifrs-full_ClassesOfShareCapitalMember_Default"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees" xlink:label="loc_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees_12"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_0" xlink:to="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_1" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_1" xlink:to="loc_ifrs-full_SharebasedPaymentArrangementsMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_1" xlink:to="loc_drug_EquitySettledShareBasedPaymentArrangementsMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_1" xlink:to="loc_drug_CashSettledShareBasedPaymentArrangementsMember_2" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_1" xlink:to="loc_ifrs-full_SharebasedPaymentArrangementsMember_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_1" xlink:to="loc_ifrs-full_ClassesOfShareCapitalAxis_6" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfShareCapitalAxis_6" xlink:to="loc_ifrs-full_ClassesOfShareCapitalMember_6" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfShareCapitalMember_6" xlink:to="loc_drug_StockOptionsMember_6" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfShareCapitalMember_6" xlink:to="loc_drug_RestrictedShareUnitMember_7" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfShareCapitalAxis_6" xlink:to="loc_ifrs-full_ClassesOfShareCapitalMember_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_0" xlink:to="loc_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees_12" order="10" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://brightmindsbio.com/role/SHARECAPITALDetails7">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalTable" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ClassesOfShareCapitalAxis" xlink:label="loc_ifrs-full_ClassesOfShareCapitalAxis_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ClassesOfShareCapitalMember" xlink:label="loc_ifrs-full_ClassesOfShareCapitalMember_1"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_WarrantsMember" xlink:label="loc_drug_WarrantsMember_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ClassesOfShareCapitalMember" xlink:label="loc_ifrs-full_ClassesOfShareCapitalMember_Default"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_ExpiryDateAxis" xlink:label="loc_drug_ExpiryDateAxis_5"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_ExpiryDateDomain" xlink:label="loc_drug_ExpiryDateDomain_5"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_ExpiryDateThirtyJulyTwoThousandAndTwentyFourMember" xlink:label="loc_drug_ExpiryDateThirtyJulyTwoThousandAndTwentyFourMember_5"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_ExpiryDateSeventeenMarchTwoThousandAndTwentyFourOneMember" xlink:label="loc_drug_ExpiryDateSeventeenMarchTwoThousandAndTwentyFourOneMember_6"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_ExpiryDateSeventeenMarchTwoThousandAndTwentyFourTwoMember" xlink:label="loc_drug_ExpiryDateSeventeenMarchTwoThousandAndTwentyFourTwoMember_7"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_ExpiryDateDomain" xlink:label="loc_drug_ExpiryDateDomain_Default"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_NumberOfWarrantsOutstanding" xlink:label="loc_drug_NumberOfWarrantsOutstanding_12"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_WeightedAverageExercisePriceOfWarrantsOutstandingInShareBasedPaymentArrangement" xlink:label="loc_drug_WeightedAverageExercisePriceOfWarrantsOutstandingInShareBasedPaymentArrangement_13"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_WeightedAverageRemainingContractualLifeOfWarrants" xlink:label="loc_drug_WeightedAverageRemainingContractualLifeOfWarrants_14"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_0" xlink:to="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_1" xlink:to="loc_ifrs-full_ClassesOfShareCapitalAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfShareCapitalAxis_1" xlink:to="loc_ifrs-full_ClassesOfShareCapitalMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfShareCapitalMember_1" xlink:to="loc_drug_WarrantsMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfShareCapitalAxis_1" xlink:to="loc_ifrs-full_ClassesOfShareCapitalMember_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_1" xlink:to="loc_drug_ExpiryDateAxis_5" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_drug_ExpiryDateAxis_5" xlink:to="loc_drug_ExpiryDateDomain_5" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_drug_ExpiryDateDomain_5" xlink:to="loc_drug_ExpiryDateThirtyJulyTwoThousandAndTwentyFourMember_5" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_drug_ExpiryDateDomain_5" xlink:to="loc_drug_ExpiryDateSeventeenMarchTwoThousandAndTwentyFourOneMember_6" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_drug_ExpiryDateDomain_5" xlink:to="loc_drug_ExpiryDateSeventeenMarchTwoThousandAndTwentyFourTwoMember_7" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_drug_ExpiryDateAxis_5" xlink:to="loc_drug_ExpiryDateDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_0" xlink:to="loc_drug_NumberOfWarrantsOutstanding_12" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_0" xlink:to="loc_drug_WeightedAverageExercisePriceOfWarrantsOutstandingInShareBasedPaymentArrangement_13" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_0" xlink:to="loc_drug_WeightedAverageRemainingContractualLifeOfWarrants_14" order="30" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://brightmindsbio.com/role/SHARECAPITALDetails6">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalTable" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ClassesOfShareCapitalAxis" xlink:label="loc_ifrs-full_ClassesOfShareCapitalAxis_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ClassesOfShareCapitalMember" xlink:label="loc_ifrs-full_ClassesOfShareCapitalMember_1"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_WarrantsMember" xlink:label="loc_drug_WarrantsMember_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ClassesOfShareCapitalMember" xlink:label="loc_ifrs-full_ClassesOfShareCapitalMember_Default"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_NumberOfWarrantsOutstanding" xlink:label="loc_drug_NumberOfWarrantsOutstanding_6"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_NumberOfWarrantsIssued" xlink:label="loc_drug_NumberOfWarrantsIssued_7"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_NumberOfWarrantsIssuedToBroker" xlink:label="loc_drug_NumberOfWarrantsIssuedToBroker_8"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_NumberOfWarrantsExercised" xlink:label="loc_drug_NumberOfWarrantsExercised_9"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_WeightedAverageExercisePriceOfWarrantsOutstandingInShareBasedPaymentArrangement" xlink:label="loc_drug_WeightedAverageExercisePriceOfWarrantsOutstandingInShareBasedPaymentArrangement_10"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_WeightedAverageExercisePriceOfWarrantsIssuedInShareBasedPaymentArrangement" xlink:label="loc_drug_WeightedAverageExercisePriceOfWarrantsIssuedInShareBasedPaymentArrangement_11"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_WeightedAverageExercisePriceOfWarrantsIssuedToBrokerInShareBasedPaymentArrangement" xlink:label="loc_drug_WeightedAverageExercisePriceOfWarrantsIssuedToBrokerInShareBasedPaymentArrangement_12"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_WeightedAverageExercisePriceOfWarrantsExercisedInShareBasedPaymentArrangement" xlink:label="loc_drug_WeightedAverageExercisePriceOfWarrantsExercisedInShareBasedPaymentArrangement_13"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_0" xlink:to="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_1" xlink:to="loc_ifrs-full_ClassesOfShareCapitalAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfShareCapitalAxis_1" xlink:to="loc_ifrs-full_ClassesOfShareCapitalMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfShareCapitalMember_1" xlink:to="loc_drug_WarrantsMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfShareCapitalAxis_1" xlink:to="loc_ifrs-full_ClassesOfShareCapitalMember_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_0" xlink:to="loc_drug_NumberOfWarrantsOutstanding_6" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_0" xlink:to="loc_drug_NumberOfWarrantsIssued_7" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_0" xlink:to="loc_drug_NumberOfWarrantsIssuedToBroker_8" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_0" xlink:to="loc_drug_NumberOfWarrantsExercised_9" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_0" xlink:to="loc_drug_WeightedAverageExercisePriceOfWarrantsOutstandingInShareBasedPaymentArrangement_10" order="50" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_0" xlink:to="loc_drug_WeightedAverageExercisePriceOfWarrantsIssuedInShareBasedPaymentArrangement_11" order="60" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_0" xlink:to="loc_drug_WeightedAverageExercisePriceOfWarrantsIssuedToBrokerInShareBasedPaymentArrangement_12" order="70" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_0" xlink:to="loc_drug_WeightedAverageExercisePriceOfWarrantsExercisedInShareBasedPaymentArrangement_13" order="80" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://brightmindsbio.com/role/SHARECAPITALDetailTextuals">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalTable" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_1"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_AgreementAxis" xlink:label="loc_drug_AgreementAxis_1"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_AgreementDomain" xlink:label="loc_drug_AgreementDomain_1"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_DebtSettlementAgreementMember" xlink:label="loc_drug_DebtSettlementAgreementMember_1"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_EscrowAgreementMember" xlink:label="loc_drug_EscrowAgreementMember_2"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_AgreementDomain" xlink:label="loc_drug_AgreementDomain_Default"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srt_TitleOfIndividualAxis_6"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_6"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ChiefExecutiveOfficerMember" xlink:label="loc_srt_ChiefExecutiveOfficerMember_6"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_ChiefMedicalOfficerMember" xlink:label="loc_drug_ChiefMedicalOfficerMember_7"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_Default"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:label="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_11"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:label="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_11"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_ConsultantMember" xlink:label="loc_drug_ConsultantMember_11"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_UnderwritersMember" xlink:label="loc_drug_UnderwritersMember_12"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_ThreeInvestorsMember" xlink:label="loc_drug_ThreeInvestorsMember_13"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_ChiefFinancialOfficerTwoDirectorsAndSevenConsultantsMember" xlink:label="loc_drug_ChiefFinancialOfficerTwoDirectorsAndSevenConsultantsMember_14"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_ThreeConsultantsMember" xlink:label="loc_drug_ThreeConsultantsMember_15"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_DirectorAndConsultantMember" xlink:label="loc_drug_DirectorAndConsultantMember_16"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:label="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_Default"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_StockOptionAxis" xlink:label="loc_drug_StockOptionAxis_20"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_StockOptionDomain" xlink:label="loc_drug_StockOptionDomain_20"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_StockOptionsOneMember" xlink:label="loc_drug_StockOptionsOneMember_20"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_StockOptionsTwoMember" xlink:label="loc_drug_StockOptionsTwoMember_21"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_StockOptionsThreeMember" xlink:label="loc_drug_StockOptionsThreeMember_22"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_StockOptionsFourMember" xlink:label="loc_drug_StockOptionsFourMember_23"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_StockOptionDomain" xlink:label="loc_drug_StockOptionDomain_Default"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ClassesOfShareCapitalAxis" xlink:label="loc_ifrs-full_ClassesOfShareCapitalAxis_27"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ClassesOfShareCapitalMember" xlink:label="loc_ifrs-full_ClassesOfShareCapitalMember_27"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_SecondTrancheOfNonBrokeredPrivatePlacementMember" xlink:label="loc_drug_SecondTrancheOfNonBrokeredPrivatePlacementMember_27"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_SpecialWarrantsMember" xlink:label="loc_drug_SpecialWarrantsMember_28"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_WarrantsMember" xlink:label="loc_drug_WarrantsMember_29"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_EscrowedSharePurchaseWarrantsMember" xlink:label="loc_drug_EscrowedSharePurchaseWarrantsMember_30"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_FirstTrancheOfNonBrokeredPrivatePlacementMember" xlink:label="loc_drug_FirstTrancheOfNonBrokeredPrivatePlacementMember_31"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_NonBrokeredPrivatePlacementMember" xlink:label="loc_drug_NonBrokeredPrivatePlacementMember_32"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_StockOptionsMember" xlink:label="loc_drug_StockOptionsMember_33"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_RestrictedShareUnitMember" xlink:label="loc_drug_RestrictedShareUnitMember_34"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_EscrowedSecuritiesMember" xlink:label="loc_drug_EscrowedSecuritiesMember_35"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ClassesOfShareCapitalMember" xlink:label="loc_ifrs-full_ClassesOfShareCapitalMember_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_39"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_39"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_BritishColumbiaSecuritiesCommissionMember" xlink:label="loc_drug_BritishColumbiaSecuritiesCommissionMember_39"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_Default"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_VestingsAxis" xlink:label="loc_drug_VestingsAxis_43"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_VestingDomain" xlink:label="loc_drug_VestingDomain_43"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_FirstTrancheMember" xlink:label="loc_drug_FirstTrancheMember_43"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_SecondTrancheMember" xlink:label="loc_drug_SecondTrancheMember_44"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_ThirdTrancheMember" xlink:label="loc_drug_ThirdTrancheMember_45"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_FourthTrancheMember" xlink:label="loc_drug_FourthTrancheMember_46"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_FifthTrancheMember" xlink:label="loc_drug_FifthTrancheMember_47"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_SixthTrancheMember" xlink:label="loc_drug_SixthTrancheMember_48"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_SeventhTrancheMember" xlink:label="loc_drug_SeventhTrancheMember_49"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_EighthTrancheMember" xlink:label="loc_drug_EighthTrancheMember_50"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_NinthTrancheMember" xlink:label="loc_drug_NinthTrancheMember_51"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_TenthTrancheMember" xlink:label="loc_drug_TenthTrancheMember_52"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_EleventhTrancheMember" xlink:label="loc_drug_EleventhTrancheMember_53"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_TwelfthTrancheMember" xlink:label="loc_drug_TwelfthTrancheMember_54"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_ThirteenthTrancheMember" xlink:label="loc_drug_ThirteenthTrancheMember_55"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_FourteenthTrancheMember" xlink:label="loc_drug_FourteenthTrancheMember_56"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_FifteenthTrancheMember" xlink:label="loc_drug_FifteenthTrancheMember_57"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_VestingDomain" xlink:label="loc_drug_VestingDomain_Default"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_DescriptionOfIssuedAndOutstandingCommonShares" xlink:label="loc_drug_DescriptionOfIssuedAndOutstandingCommonShares_62"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NumberOfSharesIssued" xlink:label="loc_ifrs-full_NumberOfSharesIssued_63"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IncreaseDecreaseInNumberOfSharesOutstanding" xlink:label="loc_ifrs-full_IncreaseDecreaseInNumberOfSharesOutstanding_64"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_IssuePricePerShare" xlink:label="loc_drug_IssuePricePerShare_65"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_ProceedsForWarrantsIssued" xlink:label="loc_drug_ProceedsForWarrantsIssued_66"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ProceedsFromIssueOfOrdinaryShares" xlink:label="loc_ifrs-full_ProceedsFromIssueOfOrdinaryShares_67"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_DebtSettledThroughIssuanceOfShares" xlink:label="loc_drug_DebtSettledThroughIssuanceOfShares_68"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_NumberOfWarrantsDeemedToBeExercised" xlink:label="loc_drug_NumberOfWarrantsDeemedToBeExercised_69"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_NumberOfWarrantsIssued" xlink:label="loc_drug_NumberOfWarrantsIssued_70"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_WarrantsIssuedPricePerWarrant" xlink:label="loc_drug_WarrantsIssuedPricePerWarrant_71"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_GrossProceedsFromWarrantsIssued" xlink:label="loc_drug_GrossProceedsFromWarrantsIssued_72"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_NumberOfUnitsIssued" xlink:label="loc_drug_NumberOfUnitsIssued_73"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_UnitsIssuedPricePerUnit" xlink:label="loc_drug_UnitsIssuedPricePerUnit_74"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_GrossProceedsFromUnitsIssued" xlink:label="loc_drug_GrossProceedsFromUnitsIssued_75"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_WeightedAverageExercisePriceOfWarrantsIssuedInShareBasedPaymentArrangement" xlink:label="loc_drug_WeightedAverageExercisePriceOfWarrantsIssuedInShareBasedPaymentArrangement_76"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_WeightedAverageExercisePriceOfWarrantsOutstandingInShareBasedPaymentArrangement" xlink:label="loc_drug_WeightedAverageExercisePriceOfWarrantsOutstandingInShareBasedPaymentArrangement_77"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_MinimumDailyVolumeWeightedAverageTradingSharePrice" xlink:label="loc_drug_MinimumDailyVolumeWeightedAverageTradingSharePrice_78"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_WeightedAverageTradingPriceOfCommonSharesOnCanadianStockExchange" xlink:label="loc_drug_WeightedAverageTradingPriceOfCommonSharesOnCanadianStockExchange_79"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_UnderwritersFeesPaid" xlink:label="loc_drug_UnderwritersFeesPaid_80"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_IncreaseDecreaseThroughSharesIssuedToUniversityShares" xlink:label="loc_drug_IncreaseDecreaseThroughSharesIssuedToUniversityShares_81"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_IncreaseDecreaseThroughSharesIssuedToUniversity" xlink:label="loc_drug_IncreaseDecreaseThroughSharesIssuedToUniversity_82"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_NumberOfCommonSharesCalledByWarrants" xlink:label="loc_drug_NumberOfCommonSharesCalledByWarrants_83"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_NumberOfWarrantsOutstandingInShareBasedPaymentArrangement" xlink:label="loc_drug_NumberOfWarrantsOutstandingInShareBasedPaymentArrangement_84"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_WarrantAscribedValue" xlink:label="loc_drug_WarrantAscribedValue_85"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_NumberOfRestrictedStockIssuedForCompensation" xlink:label="loc_drug_NumberOfRestrictedStockIssuedForCompensation_86"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_NumberOfWarrantsExercised" xlink:label="loc_drug_NumberOfWarrantsExercised_87"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_WeightedAverageExercisePriceOfWarrantsExercisedInShareBasedPaymentArrangement" xlink:label="loc_drug_WeightedAverageExercisePriceOfWarrantsExercisedInShareBasedPaymentArrangement_88"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_GrossProceedsFromWarrantsExercised" xlink:label="loc_drug_GrossProceedsFromWarrantsExercised_89"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_ContingentCashFee" xlink:label="loc_drug_ContingentCashFee_90"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_PercentageOfNetEquityProceedsReceivedFromThreeInvestors" xlink:label="loc_drug_PercentageOfNetEquityProceedsReceivedFromThreeInvestors_91"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_TermOfWarrant" xlink:label="loc_drug_TermOfWarrant_92"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_SubscriptionsReceived" xlink:label="loc_drug_SubscriptionsReceived_93"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_NumberOfCommonSharesSubscribed" xlink:label="loc_drug_NumberOfCommonSharesSubscribed_94"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_NumberOfIssuedWarrantsRescinded" xlink:label="loc_drug_NumberOfIssuedWarrantsRescinded_95"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_RefundFromIssuedWarrantsRescinded" xlink:label="loc_drug_RefundFromIssuedWarrantsRescinded_96"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_AmountOfEscrowProceedsReleased" xlink:label="loc_drug_AmountOfEscrowProceedsReleased_97"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_PercentageOfOutstandingSharesAuthorizedUnderStockOptionPlan" xlink:label="loc_drug_PercentageOfOutstandingSharesAuthorizedUnderStockOptionPlan_98"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_PercentageOfStockOptionPlanAllowsBoardOfDirectorsToIssue" xlink:label="loc_drug_PercentageOfStockOptionPlanAllowsBoardOfDirectorsToIssue_99"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_AggregatePurchaseWarrantsDeposited" xlink:label="loc_drug_AggregatePurchaseWarrantsDeposited_100"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_NumberOfCommonSharesDepositedToBeHeldInEscrow" xlink:label="loc_drug_NumberOfCommonSharesDepositedToBeHeldInEscrow_101"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_NumberOfWarrantsDepositedToBeHeldInEscrow" xlink:label="loc_drug_NumberOfWarrantsDepositedToBeHeldInEscrow_102"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_AggregateSecuritiesDepositedToBeHeldInEscrow" xlink:label="loc_drug_AggregateSecuritiesDepositedToBeHeldInEscrow_103"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_NumberOfShareListed" xlink:label="loc_drug_NumberOfShareListed_104"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_EscrowedSecuritiesToBeReleasedOnceSharesAreListedOnCanadianStockExchange" xlink:label="loc_drug_EscrowedSecuritiesToBeReleasedOnceSharesAreListedOnCanadianStockExchange_105"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_EscrowedSecuritiesToBeReleasedAfterListingDate" xlink:label="loc_drug_EscrowedSecuritiesToBeReleasedAfterListingDate_106"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_PercentageOfStockOptionShareGranted" xlink:label="loc_drug_PercentageOfStockOptionShareGranted_107"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" xlink:label="loc_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement_108"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_VestingPercentage" xlink:label="loc_drug_VestingPercentage_109"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ExercisePriceShareOptionsGranted2019" xlink:label="loc_ifrs-full_ExercisePriceShareOptionsGranted2019_110"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019" xlink:label="loc_ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019_111"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DescriptionOfOptionLifeShareOptionsGranted" xlink:label="loc_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted_112"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted" xlink:label="loc_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted_113"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_DiscountRateStockOptionGranted" xlink:label="loc_drug_DiscountRateStockOptionGranted_114"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_IssuanceOfRestrictedStockUnits" xlink:label="loc_drug_IssuanceOfRestrictedStockUnits_115"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_EstimatedFairValueOfEquitySettledRsusGranted" xlink:label="loc_drug_EstimatedFairValueOfEquitySettledRsusGranted_116"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_FairValueOfWarrants" xlink:label="loc_drug_FairValueOfWarrants_117"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_ExercisePriceWarrantsGranted" xlink:label="loc_drug_ExercisePriceWarrantsGranted_118"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_WeightedAverageSharePriceWarrantsGranted" xlink:label="loc_drug_WeightedAverageSharePriceWarrantsGranted_119"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_EstimatedLifeOfWarrantsGranted" xlink:label="loc_drug_EstimatedLifeOfWarrantsGranted_120"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_ExpectedVolatilityWarrantsGranted" xlink:label="loc_drug_ExpectedVolatilityWarrantsGranted_121"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_DiscountRateOfWarrantsGranted" xlink:label="loc_drug_DiscountRateOfWarrantsGranted_122"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019" xlink:label="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019_123"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ExercisePriceOfOutstandingShareOptions2019" xlink:label="loc_ifrs-full_ExercisePriceOfOutstandingShareOptions2019_124"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" xlink:label="loc_ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement_125"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" xlink:label="loc_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019_126"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_WeightedAverageRemainingContractualLifeOfOtherEquityInstruments" xlink:label="loc_drug_WeightedAverageRemainingContractualLifeOfOtherEquityInstruments_127"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_ThresholdPercentageOfWarrants" xlink:label="loc_drug_ThresholdPercentageOfWarrants_128"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_0" xlink:to="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_1" xlink:to="loc_drug_AgreementAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_drug_AgreementAxis_1" xlink:to="loc_drug_AgreementDomain_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_drug_AgreementDomain_1" xlink:to="loc_drug_DebtSettlementAgreementMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_drug_AgreementDomain_1" xlink:to="loc_drug_EscrowAgreementMember_2" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_drug_AgreementAxis_1" xlink:to="loc_drug_AgreementDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_1" xlink:to="loc_srt_TitleOfIndividualAxis_6" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_TitleOfIndividualAxis_6" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_6" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_6" xlink:to="loc_srt_ChiefExecutiveOfficerMember_6" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_6" xlink:to="loc_drug_ChiefMedicalOfficerMember_7" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_TitleOfIndividualAxis_6" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_1" xlink:to="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_11" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_11" xlink:to="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_11" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_11" xlink:to="loc_drug_ConsultantMember_11" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_11" xlink:to="loc_drug_UnderwritersMember_12" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_11" xlink:to="loc_drug_ThreeInvestorsMember_13" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_11" xlink:to="loc_drug_ChiefFinancialOfficerTwoDirectorsAndSevenConsultantsMember_14" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_11" xlink:to="loc_drug_ThreeConsultantsMember_15" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_11" xlink:to="loc_drug_DirectorAndConsultantMember_16" order="50" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_11" xlink:to="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_1" xlink:to="loc_drug_StockOptionAxis_20" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_drug_StockOptionAxis_20" xlink:to="loc_drug_StockOptionDomain_20" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_drug_StockOptionDomain_20" xlink:to="loc_drug_StockOptionsOneMember_20" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_drug_StockOptionDomain_20" xlink:to="loc_drug_StockOptionsTwoMember_21" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_drug_StockOptionDomain_20" xlink:to="loc_drug_StockOptionsThreeMember_22" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_drug_StockOptionDomain_20" xlink:to="loc_drug_StockOptionsFourMember_23" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_drug_StockOptionAxis_20" xlink:to="loc_drug_StockOptionDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_1" xlink:to="loc_ifrs-full_ClassesOfShareCapitalAxis_27" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfShareCapitalAxis_27" xlink:to="loc_ifrs-full_ClassesOfShareCapitalMember_27" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfShareCapitalMember_27" xlink:to="loc_drug_SecondTrancheOfNonBrokeredPrivatePlacementMember_27" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfShareCapitalMember_27" xlink:to="loc_drug_SpecialWarrantsMember_28" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfShareCapitalMember_27" xlink:to="loc_drug_WarrantsMember_29" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfShareCapitalMember_27" xlink:to="loc_drug_EscrowedSharePurchaseWarrantsMember_30" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfShareCapitalMember_27" xlink:to="loc_drug_FirstTrancheOfNonBrokeredPrivatePlacementMember_31" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfShareCapitalMember_27" xlink:to="loc_drug_NonBrokeredPrivatePlacementMember_32" order="50" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfShareCapitalMember_27" xlink:to="loc_drug_StockOptionsMember_33" order="60" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfShareCapitalMember_27" xlink:to="loc_drug_RestrictedShareUnitMember_34" order="70" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfShareCapitalMember_27" xlink:to="loc_drug_EscrowedSecuritiesMember_35" order="80" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfShareCapitalAxis_27" xlink:to="loc_ifrs-full_ClassesOfShareCapitalMember_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_1" xlink:to="loc_dei_LegalEntityAxis_39" order="50" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_39" xlink:to="loc_dei_EntityDomain_39" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_39" xlink:to="loc_drug_BritishColumbiaSecuritiesCommissionMember_39" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_39" xlink:to="loc_dei_EntityDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_1" xlink:to="loc_drug_VestingsAxis_43" order="60" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_drug_VestingsAxis_43" xlink:to="loc_drug_VestingDomain_43" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_drug_VestingDomain_43" xlink:to="loc_drug_FirstTrancheMember_43" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_drug_VestingDomain_43" xlink:to="loc_drug_SecondTrancheMember_44" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_drug_VestingDomain_43" xlink:to="loc_drug_ThirdTrancheMember_45" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_drug_VestingDomain_43" xlink:to="loc_drug_FourthTrancheMember_46" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_drug_VestingDomain_43" xlink:to="loc_drug_FifthTrancheMember_47" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_drug_VestingDomain_43" xlink:to="loc_drug_SixthTrancheMember_48" order="50" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_drug_VestingDomain_43" xlink:to="loc_drug_SeventhTrancheMember_49" order="60" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_drug_VestingDomain_43" xlink:to="loc_drug_EighthTrancheMember_50" order="70" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_drug_VestingDomain_43" xlink:to="loc_drug_NinthTrancheMember_51" order="80" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_drug_VestingDomain_43" xlink:to="loc_drug_TenthTrancheMember_52" order="90" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_drug_VestingDomain_43" xlink:to="loc_drug_EleventhTrancheMember_53" order="100" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_drug_VestingDomain_43" xlink:to="loc_drug_TwelfthTrancheMember_54" order="110" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_drug_VestingDomain_43" xlink:to="loc_drug_ThirteenthTrancheMember_55" order="120" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_drug_VestingDomain_43" xlink:to="loc_drug_FourteenthTrancheMember_56" order="130" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_drug_VestingDomain_43" xlink:to="loc_drug_FifteenthTrancheMember_57" order="140" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_drug_VestingsAxis_43" xlink:to="loc_drug_VestingDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_0" xlink:to="loc_drug_DescriptionOfIssuedAndOutstandingCommonShares_62" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_0" xlink:to="loc_ifrs-full_NumberOfSharesIssued_63" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_0" xlink:to="loc_ifrs-full_IncreaseDecreaseInNumberOfSharesOutstanding_64" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_0" xlink:to="loc_drug_IssuePricePerShare_65" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_0" xlink:to="loc_drug_ProceedsForWarrantsIssued_66" order="50" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_0" xlink:to="loc_ifrs-full_ProceedsFromIssueOfOrdinaryShares_67" order="60" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_0" xlink:to="loc_drug_DebtSettledThroughIssuanceOfShares_68" order="70" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_0" xlink:to="loc_drug_NumberOfWarrantsDeemedToBeExercised_69" order="80" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_0" xlink:to="loc_drug_NumberOfWarrantsIssued_70" order="90" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_0" xlink:to="loc_drug_WarrantsIssuedPricePerWarrant_71" order="100" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_0" xlink:to="loc_drug_GrossProceedsFromWarrantsIssued_72" order="110" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_0" xlink:to="loc_drug_NumberOfUnitsIssued_73" order="120" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_0" xlink:to="loc_drug_UnitsIssuedPricePerUnit_74" order="130" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_0" xlink:to="loc_drug_GrossProceedsFromUnitsIssued_75" order="140" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_0" xlink:to="loc_drug_WeightedAverageExercisePriceOfWarrantsIssuedInShareBasedPaymentArrangement_76" order="150" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_0" xlink:to="loc_drug_WeightedAverageExercisePriceOfWarrantsOutstandingInShareBasedPaymentArrangement_77" order="160" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_0" xlink:to="loc_drug_MinimumDailyVolumeWeightedAverageTradingSharePrice_78" order="170" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_0" xlink:to="loc_drug_WeightedAverageTradingPriceOfCommonSharesOnCanadianStockExchange_79" order="180" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_0" xlink:to="loc_drug_UnderwritersFeesPaid_80" order="190" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_0" xlink:to="loc_drug_IncreaseDecreaseThroughSharesIssuedToUniversityShares_81" order="200" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_0" xlink:to="loc_drug_IncreaseDecreaseThroughSharesIssuedToUniversity_82" order="210" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_0" xlink:to="loc_drug_NumberOfCommonSharesCalledByWarrants_83" order="220" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_0" xlink:to="loc_drug_NumberOfWarrantsOutstandingInShareBasedPaymentArrangement_84" order="230" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_0" xlink:to="loc_drug_WarrantAscribedValue_85" order="240" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_0" xlink:to="loc_drug_NumberOfRestrictedStockIssuedForCompensation_86" order="250" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_0" xlink:to="loc_drug_NumberOfWarrantsExercised_87" order="260" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_0" xlink:to="loc_drug_WeightedAverageExercisePriceOfWarrantsExercisedInShareBasedPaymentArrangement_88" order="270" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_0" xlink:to="loc_drug_GrossProceedsFromWarrantsExercised_89" order="280" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_0" xlink:to="loc_drug_ContingentCashFee_90" order="290" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_0" xlink:to="loc_drug_PercentageOfNetEquityProceedsReceivedFromThreeInvestors_91" order="300" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_0" xlink:to="loc_drug_TermOfWarrant_92" order="310" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_0" xlink:to="loc_drug_SubscriptionsReceived_93" order="320" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_0" xlink:to="loc_drug_NumberOfCommonSharesSubscribed_94" order="330" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_0" xlink:to="loc_drug_NumberOfIssuedWarrantsRescinded_95" order="340" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_0" xlink:to="loc_drug_RefundFromIssuedWarrantsRescinded_96" order="350" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_0" xlink:to="loc_drug_AmountOfEscrowProceedsReleased_97" order="360" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_0" xlink:to="loc_drug_PercentageOfOutstandingSharesAuthorizedUnderStockOptionPlan_98" order="370" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_0" xlink:to="loc_drug_PercentageOfStockOptionPlanAllowsBoardOfDirectorsToIssue_99" order="380" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_0" xlink:to="loc_drug_AggregatePurchaseWarrantsDeposited_100" order="390" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_0" xlink:to="loc_drug_NumberOfCommonSharesDepositedToBeHeldInEscrow_101" order="400" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_0" xlink:to="loc_drug_NumberOfWarrantsDepositedToBeHeldInEscrow_102" order="410" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_0" xlink:to="loc_drug_AggregateSecuritiesDepositedToBeHeldInEscrow_103" order="420" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_0" xlink:to="loc_drug_NumberOfShareListed_104" order="430" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_0" xlink:to="loc_drug_EscrowedSecuritiesToBeReleasedOnceSharesAreListedOnCanadianStockExchange_105" order="440" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_0" xlink:to="loc_drug_EscrowedSecuritiesToBeReleasedAfterListingDate_106" order="450" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_0" xlink:to="loc_drug_PercentageOfStockOptionShareGranted_107" order="460" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_0" xlink:to="loc_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement_108" order="470" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_0" xlink:to="loc_drug_VestingPercentage_109" order="480" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_0" xlink:to="loc_ifrs-full_ExercisePriceShareOptionsGranted2019_110" order="490" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_0" xlink:to="loc_ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019_111" order="500" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_0" xlink:to="loc_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted_112" order="510" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_0" xlink:to="loc_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted_113" order="520" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_0" xlink:to="loc_drug_DiscountRateStockOptionGranted_114" order="530" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_0" xlink:to="loc_drug_IssuanceOfRestrictedStockUnits_115" order="540" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_0" xlink:to="loc_drug_EstimatedFairValueOfEquitySettledRsusGranted_116" order="550" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_0" xlink:to="loc_drug_FairValueOfWarrants_117" order="560" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_0" xlink:to="loc_drug_ExercisePriceWarrantsGranted_118" order="570" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_0" xlink:to="loc_drug_WeightedAverageSharePriceWarrantsGranted_119" order="580" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_0" xlink:to="loc_drug_EstimatedLifeOfWarrantsGranted_120" order="590" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_0" xlink:to="loc_drug_ExpectedVolatilityWarrantsGranted_121" order="600" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_0" xlink:to="loc_drug_DiscountRateOfWarrantsGranted_122" order="610" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_0" xlink:to="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019_123" order="620" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_0" xlink:to="loc_ifrs-full_ExercisePriceOfOutstandingShareOptions2019_124" order="630" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_0" xlink:to="loc_ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement_125" order="640" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_0" xlink:to="loc_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019_126" order="650" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_0" xlink:to="loc_drug_WeightedAverageRemainingContractualLifeOfOtherEquityInstruments_127" order="660" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_0" xlink:to="loc_drug_ThresholdPercentageOfWarrants_128" order="670" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://brightmindsbio.com/role/SHARECAPITALDetails5">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalTable" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_1"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_ConsolidatedStatementsOfComprehensiveIncomeLossStatementLocationAxis" xlink:label="loc_drug_ConsolidatedStatementsOfComprehensiveIncomeLossStatementLocationAxis_1"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_ConsolidatedStatementsOfComprehensiveIncomeLossStatementLocationDomain" xlink:label="loc_drug_ConsolidatedStatementsOfComprehensiveIncomeLossStatementLocationDomain_1"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_ConsultingFeesMember" xlink:label="loc_drug_ConsultingFeesMember_1"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_DirectorsCompensationMember" xlink:label="loc_drug_DirectorsCompensationMember_2"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_MarketingAdvertisingAndInvestorRelationsMember" xlink:label="loc_drug_MarketingAdvertisingAndInvestorRelationsMember_3"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_ProfessionalFeesMember" xlink:label="loc_drug_ProfessionalFeesMember_4"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_ResearchAndDevelopmentMember" xlink:label="loc_drug_ResearchAndDevelopmentMember_5"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_ConsolidatedStatementsOfComprehensiveIncomeLossStatementLocationDomain" xlink:label="loc_drug_ConsolidatedStatementsOfComprehensiveIncomeLossStatementLocationDomain_Default"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees" xlink:label="loc_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees_10"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_0" xlink:to="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_1" xlink:to="loc_drug_ConsolidatedStatementsOfComprehensiveIncomeLossStatementLocationAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_drug_ConsolidatedStatementsOfComprehensiveIncomeLossStatementLocationAxis_1" xlink:to="loc_drug_ConsolidatedStatementsOfComprehensiveIncomeLossStatementLocationDomain_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_drug_ConsolidatedStatementsOfComprehensiveIncomeLossStatementLocationDomain_1" xlink:to="loc_drug_ConsultingFeesMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_drug_ConsolidatedStatementsOfComprehensiveIncomeLossStatementLocationDomain_1" xlink:to="loc_drug_DirectorsCompensationMember_2" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_drug_ConsolidatedStatementsOfComprehensiveIncomeLossStatementLocationDomain_1" xlink:to="loc_drug_MarketingAdvertisingAndInvestorRelationsMember_3" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_drug_ConsolidatedStatementsOfComprehensiveIncomeLossStatementLocationDomain_1" xlink:to="loc_drug_ProfessionalFeesMember_4" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_drug_ConsolidatedStatementsOfComprehensiveIncomeLossStatementLocationDomain_1" xlink:to="loc_drug_ResearchAndDevelopmentMember_5" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_drug_ConsolidatedStatementsOfComprehensiveIncomeLossStatementLocationAxis_1" xlink:to="loc_drug_ConsolidatedStatementsOfComprehensiveIncomeLossStatementLocationDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_0" xlink:to="loc_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees_10" order="10" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://brightmindsbio.com/role/INCOMETAXESDetails2">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems" xlink:label="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable" xlink:label="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable_1"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_NonCapitalLossCarryForwardsYearOfOriginAxis" xlink:label="loc_drug_NonCapitalLossCarryForwardsYearOfOriginAxis_1"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_NonCapitalLossCarryForwardsYearOfOriginDomain" xlink:label="loc_drug_NonCapitalLossCarryForwardsYearOfOriginDomain_1"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_TaxYearOfOrigin2019Member" xlink:label="loc_drug_TaxYearOfOrigin2019Member_1"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_TaxYearOfOrigin2020Member" xlink:label="loc_drug_TaxYearOfOrigin2020Member_2"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_TaxYearOfOrigin2021Member" xlink:label="loc_drug_TaxYearOfOrigin2021Member_3"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_NonCapitalLossCarryForwardsYearOfOriginDomain" xlink:label="loc_drug_NonCapitalLossCarryForwardsYearOfOriginDomain_Default"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_IncomeTaxAuthorityNameOfCountryAxis" xlink:label="loc_drug_IncomeTaxAuthorityNameOfCountryAxis_7"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_IncomeTaxAuthorityNameOfCountryDomain" xlink:label="loc_drug_IncomeTaxAuthorityNameOfCountryDomain_7"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_TaxAuthorityOfCanadaMember" xlink:label="loc_drug_TaxAuthorityOfCanadaMember_7"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_IncomeTaxAuthorityNameOfCountryDomain" xlink:label="loc_drug_IncomeTaxAuthorityNameOfCountryDomain_Default"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_NonCapitalLossCarryForwardsYearOfExpiry" xlink:label="loc_drug_NonCapitalLossCarryForwardsYearOfExpiry_12"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_NonCapitalLossCarryForwards" xlink:label="loc_drug_NonCapitalLossCarryForwards_13"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_0" xlink:to="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable_1" xlink:to="loc_drug_NonCapitalLossCarryForwardsYearOfOriginAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_drug_NonCapitalLossCarryForwardsYearOfOriginAxis_1" xlink:to="loc_drug_NonCapitalLossCarryForwardsYearOfOriginDomain_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_drug_NonCapitalLossCarryForwardsYearOfOriginDomain_1" xlink:to="loc_drug_TaxYearOfOrigin2019Member_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_drug_NonCapitalLossCarryForwardsYearOfOriginDomain_1" xlink:to="loc_drug_TaxYearOfOrigin2020Member_2" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_drug_NonCapitalLossCarryForwardsYearOfOriginDomain_1" xlink:to="loc_drug_TaxYearOfOrigin2021Member_3" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_drug_NonCapitalLossCarryForwardsYearOfOriginAxis_1" xlink:to="loc_drug_NonCapitalLossCarryForwardsYearOfOriginDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable_1" xlink:to="loc_drug_IncomeTaxAuthorityNameOfCountryAxis_7" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_drug_IncomeTaxAuthorityNameOfCountryAxis_7" xlink:to="loc_drug_IncomeTaxAuthorityNameOfCountryDomain_7" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_drug_IncomeTaxAuthorityNameOfCountryDomain_7" xlink:to="loc_drug_TaxAuthorityOfCanadaMember_7" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_drug_IncomeTaxAuthorityNameOfCountryAxis_7" xlink:to="loc_drug_IncomeTaxAuthorityNameOfCountryDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_0" xlink:to="loc_drug_NonCapitalLossCarryForwardsYearOfExpiry_12" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_0" xlink:to="loc_drug_NonCapitalLossCarryForwards_13" order="20" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://brightmindsbio.com/role/INCOMETAXESDetailTextuals">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems" xlink:label="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable" xlink:label="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable_1"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_IncomeTaxAuthorityNameOfCountryAxis" xlink:label="loc_drug_IncomeTaxAuthorityNameOfCountryAxis_1"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_IncomeTaxAuthorityNameOfCountryDomain" xlink:label="loc_drug_IncomeTaxAuthorityNameOfCountryDomain_1"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_TaxAuthorityOfCanadaMember" xlink:label="loc_drug_TaxAuthorityOfCanadaMember_1"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_TaxAuthorityOfUnitedStatesMember" xlink:label="loc_drug_TaxAuthorityOfUnitedStatesMember_2"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_TaxAuthorityOfAustraliaMember" xlink:label="loc_drug_TaxAuthorityOfAustraliaMember_3"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_IncomeTaxAuthorityNameOfCountryDomain" xlink:label="loc_drug_IncomeTaxAuthorityNameOfCountryDomain_Default"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_NonCapitalLossCarryForwards" xlink:label="loc_drug_NonCapitalLossCarryForwards_8"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_0" xlink:to="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable_1" xlink:to="loc_drug_IncomeTaxAuthorityNameOfCountryAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_drug_IncomeTaxAuthorityNameOfCountryAxis_1" xlink:to="loc_drug_IncomeTaxAuthorityNameOfCountryDomain_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_drug_IncomeTaxAuthorityNameOfCountryDomain_1" xlink:to="loc_drug_TaxAuthorityOfCanadaMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_drug_IncomeTaxAuthorityNameOfCountryDomain_1" xlink:to="loc_drug_TaxAuthorityOfUnitedStatesMember_2" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_drug_IncomeTaxAuthorityNameOfCountryDomain_1" xlink:to="loc_drug_TaxAuthorityOfAustraliaMember_3" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_drug_IncomeTaxAuthorityNameOfCountryAxis_1" xlink:to="loc_drug_IncomeTaxAuthorityNameOfCountryDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_0" xlink:to="loc_drug_NonCapitalLossCarryForwards_8" order="10" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://brightmindsbio.com/role/INCOMETAXESDetails1">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems" xlink:label="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable" xlink:label="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis" xlink:label="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember" xlink:label="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_UnusedTaxLossesMember" xlink:label="loc_ifrs-full_UnusedTaxLossesMember_1"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_TemporaryDifferencesShareIssueCostsMember" xlink:label="loc_drug_TemporaryDifferencesShareIssueCostsMember_2"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_TemporaryDifferencesIntangibleAssetsMember" xlink:label="loc_drug_TemporaryDifferencesIntangibleAssetsMember_3"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_TemporaryDifferencesValuationAllowanceMember" xlink:label="loc_drug_TemporaryDifferencesValuationAllowanceMember_4"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember" xlink:label="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_Default"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised" xlink:label="loc_ifrs-full_DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised_9"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_0" xlink:to="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable_1" xlink:to="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_1" xlink:to="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_1" xlink:to="loc_ifrs-full_UnusedTaxLossesMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_1" xlink:to="loc_drug_TemporaryDifferencesShareIssueCostsMember_2" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_1" xlink:to="loc_drug_TemporaryDifferencesIntangibleAssetsMember_3" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_1" xlink:to="loc_drug_TemporaryDifferencesValuationAllowanceMember_4" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_1" xlink:to="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_0" xlink:to="loc_ifrs-full_DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised_9" order="10" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://brightmindsbio.com/role/ConsolidatedStatementsOfChangesInShareholdersEquity">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_StatementOfChangesInEquityLineItems" xlink:label="loc_ifrs-full_StatementOfChangesInEquityLineItems_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_StatementOfChangesInEquityTable" xlink:label="loc_ifrs-full_StatementOfChangesInEquityTable_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ComponentsOfEquityAxis" xlink:label="loc_ifrs-full_ComponentsOfEquityAxis_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_EquityMember" xlink:label="loc_ifrs-full_EquityMember_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IssuedCapitalMember" xlink:label="loc_ifrs-full_IssuedCapitalMember_1"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_SubscriptionReceivableMember" xlink:label="loc_drug_SubscriptionReceivableMember_2"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_SubscriptionReceivedMember" xlink:label="loc_drug_SubscriptionReceivedMember_3"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_OtherReservesMember" xlink:label="loc_ifrs-full_OtherReservesMember_4"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_RetainedEarningsMember" xlink:label="loc_ifrs-full_RetainedEarningsMember_5"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_EquityMember" xlink:label="loc_ifrs-full_EquityMember_Default"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_Equity" xlink:label="loc_ifrs-full_Equity_10"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NumberOfSharesOutstanding" xlink:label="loc_ifrs-full_NumberOfSharesOutstanding_11"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_IncreaseDecreaseThroughPrivatePlacement" xlink:label="loc_drug_IncreaseDecreaseThroughPrivatePlacement_12"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_IncreaseDecreaseThroughPrivatePlacementShares" xlink:label="loc_drug_IncreaseDecreaseThroughPrivatePlacementShares_13"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_IncreaseDecreaseThroughAcquisitionOfIntangibleAssets" xlink:label="loc_drug_IncreaseDecreaseThroughAcquisitionOfIntangibleAssets_14"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_IncreaseDecreaseThroughAcquisitionOfIntangibleAssetsShares" xlink:label="loc_drug_IncreaseDecreaseThroughAcquisitionOfIntangibleAssetsShares_15"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_IncreaseDecreaseThroughFindersFeesCash" xlink:label="loc_drug_IncreaseDecreaseThroughFindersFeesCash_16"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_IncreaseDecreaseThroughFindersFeesBrokerWarrants" xlink:label="loc_drug_IncreaseDecreaseThroughFindersFeesBrokerWarrants_17"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_IncreaseDecreaseThroughFindersFeesShareOptions" xlink:label="loc_drug_IncreaseDecreaseThroughFindersFeesShareOptions_18"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_IncreaseDecreaseThroughDebtSettlementWithShare" xlink:label="loc_drug_IncreaseDecreaseThroughDebtSettlementWithShare_19"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ShareIssueRelatedCost" xlink:label="loc_ifrs-full_ShareIssueRelatedCost_20"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_IncreaseDecreaseThroughDebtSettlementWithShareShares" xlink:label="loc_drug_IncreaseDecreaseThroughDebtSettlementWithShareShares_21"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_IncreaseDecreaseThroughSpecialWarrantConversion" xlink:label="loc_drug_IncreaseDecreaseThroughSpecialWarrantConversion_22"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_IncreaseDecreaseThroughSpecialWarrantConversionShares" xlink:label="loc_drug_IncreaseDecreaseThroughSpecialWarrantConversionShares_23"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity_24"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_IncreaseDecreaseThroughExerciseOfWarrantsShares" xlink:label="loc_drug_IncreaseDecreaseThroughExerciseOfWarrantsShares_25"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_IncreaseDecreaseThroughSharesIssuedToUniversity" xlink:label="loc_drug_IncreaseDecreaseThroughSharesIssuedToUniversity_26"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_IncreaseDecreaseThroughSharesIssuedToUniversityShares" xlink:label="loc_drug_IncreaseDecreaseThroughSharesIssuedToUniversityShares_27"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions_28"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ProfitLoss" xlink:label="loc_ifrs-full_ProfitLoss_29"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_0" xlink:to="loc_ifrs-full_StatementOfChangesInEquityTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_StatementOfChangesInEquityTable_1" xlink:to="loc_ifrs-full_ComponentsOfEquityAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ComponentsOfEquityAxis_1" xlink:to="loc_ifrs-full_EquityMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EquityMember_1" xlink:to="loc_ifrs-full_IssuedCapitalMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EquityMember_1" xlink:to="loc_drug_SubscriptionReceivableMember_2" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EquityMember_1" xlink:to="loc_drug_SubscriptionReceivedMember_3" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EquityMember_1" xlink:to="loc_ifrs-full_OtherReservesMember_4" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EquityMember_1" xlink:to="loc_ifrs-full_RetainedEarningsMember_5" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ComponentsOfEquityAxis_1" xlink:to="loc_ifrs-full_EquityMember_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_0" xlink:to="loc_ifrs-full_Equity_10" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_0" xlink:to="loc_ifrs-full_NumberOfSharesOutstanding_11" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_0" xlink:to="loc_drug_IncreaseDecreaseThroughPrivatePlacement_12" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_0" xlink:to="loc_drug_IncreaseDecreaseThroughPrivatePlacementShares_13" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_0" xlink:to="loc_drug_IncreaseDecreaseThroughAcquisitionOfIntangibleAssets_14" order="50" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_0" xlink:to="loc_drug_IncreaseDecreaseThroughAcquisitionOfIntangibleAssetsShares_15" order="60" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_0" xlink:to="loc_drug_IncreaseDecreaseThroughFindersFeesCash_16" order="70" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_0" xlink:to="loc_drug_IncreaseDecreaseThroughFindersFeesBrokerWarrants_17" order="80" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_0" xlink:to="loc_drug_IncreaseDecreaseThroughFindersFeesShareOptions_18" order="90" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_0" xlink:to="loc_drug_IncreaseDecreaseThroughDebtSettlementWithShare_19" order="100" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_0" xlink:to="loc_ifrs-full_ShareIssueRelatedCost_20" order="110" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_0" xlink:to="loc_drug_IncreaseDecreaseThroughDebtSettlementWithShareShares_21" order="120" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_0" xlink:to="loc_drug_IncreaseDecreaseThroughSpecialWarrantConversion_22" order="130" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_0" xlink:to="loc_drug_IncreaseDecreaseThroughSpecialWarrantConversionShares_23" order="140" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_0" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity_24" order="150" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_0" xlink:to="loc_drug_IncreaseDecreaseThroughExerciseOfWarrantsShares_25" order="160" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_0" xlink:to="loc_drug_IncreaseDecreaseThroughSharesIssuedToUniversity_26" order="170" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_0" xlink:to="loc_drug_IncreaseDecreaseThroughSharesIssuedToUniversityShares_27" order="180" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_0" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions_28" order="190" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_0" xlink:to="loc_ifrs-full_ProfitLoss_29" order="200" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://brightmindsbio.com/role/CONTRACTUALOBLIGATIONSDetailTextuals">
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_DisclosureOfContractualObligationLineItems" xlink:label="loc_drug_DisclosureOfContractualObligationLineItems_0"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_DisclosureOfContractualObligationTable" xlink:label="loc_drug_DisclosureOfContractualObligationTable_1"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_AgreementAxis" xlink:label="loc_drug_AgreementAxis_1"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_AgreementDomain" xlink:label="loc_drug_AgreementDomain_1"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_OptionAgreementMember" xlink:label="loc_drug_OptionAgreementMember_1"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_LicenseAgreementMember" xlink:label="loc_drug_LicenseAgreementMember_2"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_PriorToSublicensingAgreementsMember" xlink:label="loc_drug_PriorToSublicensingAgreementsMember_3"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_AfterSublicensingAgreementsMember" xlink:label="loc_drug_AfterSublicensingAgreementsMember_4"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_IndependentConsultantAgreementMember" xlink:label="loc_drug_IndependentConsultantAgreementMember_5"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_IndependentContractorAgreementToServeAsChiefScienceOfficerMember" xlink:label="loc_drug_IndependentContractorAgreementToServeAsChiefScienceOfficerMember_6"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_ScientificAdvisoryBoardAgreementsMember" xlink:label="loc_drug_ScientificAdvisoryBoardAgreementsMember_7"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_ConsultingAgreementsMember" xlink:label="loc_drug_ConsultingAgreementsMember_8"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_AgreementDomain" xlink:label="loc_drug_AgreementDomain_Default"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_RangeAxis" xlink:label="loc_ifrs-full_RangeAxis_12"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_RangesMember" xlink:label="loc_ifrs-full_RangesMember_12"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_BottomOfRangeMember" xlink:label="loc_ifrs-full_BottomOfRangeMember_12"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TopOfRangeMember" xlink:label="loc_ifrs-full_TopOfRangeMember_13"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_RangesMember" xlink:label="loc_ifrs-full_RangesMember_Default"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_NonRefundableOptionFeesPaid" xlink:label="loc_drug_NonRefundableOptionFeesPaid_18"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_SigningFee" xlink:label="loc_drug_SigningFee_19"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_OptionFeesPaid" xlink:label="loc_drug_OptionFeesPaid_20"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_SigningFeeNetOfOptionFeesPaid" xlink:label="loc_drug_SigningFeeNetOfOptionFeesPaid_21"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_SigningFeeSharesIssued" xlink:label="loc_drug_SigningFeeSharesIssued_22"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_PercentageOfRoyaltiesOnNetSales" xlink:label="loc_drug_PercentageOfRoyaltiesOnNetSales_23"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_PercentageOfRoyaltiesOnNetSalesUnder1Billion" xlink:label="loc_drug_PercentageOfRoyaltiesOnNetSalesUnder1Billion_24"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_PercentageOfRoyaltiesOnNetSalesOver2Billion" xlink:label="loc_drug_PercentageOfRoyaltiesOnNetSalesOver2Billion_25"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_RoyaltiesOnNetSales" xlink:label="loc_drug_RoyaltiesOnNetSales_26"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_DescriptionOfSublicenseeRevenueOfRoyaltyPaymentAccrues" xlink:label="loc_drug_DescriptionOfSublicenseeRevenueOfRoyaltyPaymentAccrues_27"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_TotalAnnualMinimumRoyaltiesCurrentYears" xlink:label="loc_drug_TotalAnnualMinimumRoyaltiesCurrentYears_28"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_TotalAnnualMinimumRoyaltiesNextYears" xlink:label="loc_drug_TotalAnnualMinimumRoyaltiesNextYears_29"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_TotalAnnualMinimumRoyaltiesYear3" xlink:label="loc_drug_TotalAnnualMinimumRoyaltiesYear3_30"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_TotalAnnualMinimumRoyaltiesYear4" xlink:label="loc_drug_TotalAnnualMinimumRoyaltiesYear4_31"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_TotalAnnualMinimumRoyaltiesYear5" xlink:label="loc_drug_TotalAnnualMinimumRoyaltiesYear5_32"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_TotalAnnualMinimumRoyaltiesYear6AndThereafter" xlink:label="loc_drug_TotalAnnualMinimumRoyaltiesYear6AndThereafter_33"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_TotalAnnualMinimumRoyaltiesAfterFirstCommercialSale" xlink:label="loc_drug_TotalAnnualMinimumRoyaltiesAfterFirstCommercialSale_34"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_MilestonePaymentsUponDosingFirstPatientInPhaseITrial" xlink:label="loc_drug_MilestonePaymentsUponDosingFirstPatientInPhaseITrial_35"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_MilestonePaymentsUponDosingFirstPatientInFirstPhaseIiTrial" xlink:label="loc_drug_MilestonePaymentsUponDosingFirstPatientInFirstPhaseIiTrial_36"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_MilestonePaymentsUponDosingFirstPatientInFirstPhaseIiiTrial" xlink:label="loc_drug_MilestonePaymentsUponDosingFirstPatientInFirstPhaseIiiTrial_37"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_MilestonePaymentsUponFirstCommercialSaleOfClinical" xlink:label="loc_drug_MilestonePaymentsUponFirstCommercialSaleOfClinical_38"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" xlink:label="loc_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement_39"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted" xlink:label="loc_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted_40"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" xlink:label="loc_ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement_41"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_MonthlyFeeAuthorizedByBoardOfDirectors" xlink:label="loc_drug_MonthlyFeeAuthorizedByBoardOfDirectors_42"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_AdvisorHourlyRate" xlink:label="loc_drug_AdvisorHourlyRate_43"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ResearchAndDevelopmentExpense" xlink:label="loc_ifrs-full_ResearchAndDevelopmentExpense_44"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_drug_DisclosureOfContractualObligationLineItems_0" xlink:to="loc_drug_DisclosureOfContractualObligationTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_drug_DisclosureOfContractualObligationTable_1" xlink:to="loc_drug_AgreementAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_drug_AgreementAxis_1" xlink:to="loc_drug_AgreementDomain_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_drug_AgreementDomain_1" xlink:to="loc_drug_OptionAgreementMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_drug_AgreementDomain_1" xlink:to="loc_drug_LicenseAgreementMember_2" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_drug_AgreementDomain_1" xlink:to="loc_drug_PriorToSublicensingAgreementsMember_3" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_drug_AgreementDomain_1" xlink:to="loc_drug_AfterSublicensingAgreementsMember_4" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_drug_AgreementDomain_1" xlink:to="loc_drug_IndependentConsultantAgreementMember_5" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_drug_AgreementDomain_1" xlink:to="loc_drug_IndependentContractorAgreementToServeAsChiefScienceOfficerMember_6" order="50" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_drug_AgreementDomain_1" xlink:to="loc_drug_ScientificAdvisoryBoardAgreementsMember_7" order="60" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_drug_AgreementDomain_1" xlink:to="loc_drug_ConsultingAgreementsMember_8" order="70" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_drug_AgreementAxis_1" xlink:to="loc_drug_AgreementDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_drug_DisclosureOfContractualObligationTable_1" xlink:to="loc_ifrs-full_RangeAxis_12" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_RangeAxis_12" xlink:to="loc_ifrs-full_RangesMember_12" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_RangesMember_12" xlink:to="loc_ifrs-full_BottomOfRangeMember_12" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_RangesMember_12" xlink:to="loc_ifrs-full_TopOfRangeMember_13" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_RangeAxis_12" xlink:to="loc_ifrs-full_RangesMember_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_drug_DisclosureOfContractualObligationLineItems_0" xlink:to="loc_drug_NonRefundableOptionFeesPaid_18" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_drug_DisclosureOfContractualObligationLineItems_0" xlink:to="loc_drug_SigningFee_19" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_drug_DisclosureOfContractualObligationLineItems_0" xlink:to="loc_drug_OptionFeesPaid_20" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_drug_DisclosureOfContractualObligationLineItems_0" xlink:to="loc_drug_SigningFeeNetOfOptionFeesPaid_21" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_drug_DisclosureOfContractualObligationLineItems_0" xlink:to="loc_drug_SigningFeeSharesIssued_22" order="50" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_drug_DisclosureOfContractualObligationLineItems_0" xlink:to="loc_drug_PercentageOfRoyaltiesOnNetSales_23" order="60" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_drug_DisclosureOfContractualObligationLineItems_0" xlink:to="loc_drug_PercentageOfRoyaltiesOnNetSalesUnder1Billion_24" order="70" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_drug_DisclosureOfContractualObligationLineItems_0" xlink:to="loc_drug_PercentageOfRoyaltiesOnNetSalesOver2Billion_25" order="80" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_drug_DisclosureOfContractualObligationLineItems_0" xlink:to="loc_drug_RoyaltiesOnNetSales_26" order="90" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_drug_DisclosureOfContractualObligationLineItems_0" xlink:to="loc_drug_DescriptionOfSublicenseeRevenueOfRoyaltyPaymentAccrues_27" order="100" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_drug_DisclosureOfContractualObligationLineItems_0" xlink:to="loc_drug_TotalAnnualMinimumRoyaltiesCurrentYears_28" order="110" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_drug_DisclosureOfContractualObligationLineItems_0" xlink:to="loc_drug_TotalAnnualMinimumRoyaltiesNextYears_29" order="120" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_drug_DisclosureOfContractualObligationLineItems_0" xlink:to="loc_drug_TotalAnnualMinimumRoyaltiesYear3_30" order="130" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_drug_DisclosureOfContractualObligationLineItems_0" xlink:to="loc_drug_TotalAnnualMinimumRoyaltiesYear4_31" order="140" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_drug_DisclosureOfContractualObligationLineItems_0" xlink:to="loc_drug_TotalAnnualMinimumRoyaltiesYear5_32" order="150" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_drug_DisclosureOfContractualObligationLineItems_0" xlink:to="loc_drug_TotalAnnualMinimumRoyaltiesYear6AndThereafter_33" order="160" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_drug_DisclosureOfContractualObligationLineItems_0" xlink:to="loc_drug_TotalAnnualMinimumRoyaltiesAfterFirstCommercialSale_34" order="170" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_drug_DisclosureOfContractualObligationLineItems_0" xlink:to="loc_drug_MilestonePaymentsUponDosingFirstPatientInPhaseITrial_35" order="180" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_drug_DisclosureOfContractualObligationLineItems_0" xlink:to="loc_drug_MilestonePaymentsUponDosingFirstPatientInFirstPhaseIiTrial_36" order="190" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_drug_DisclosureOfContractualObligationLineItems_0" xlink:to="loc_drug_MilestonePaymentsUponDosingFirstPatientInFirstPhaseIiiTrial_37" order="200" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_drug_DisclosureOfContractualObligationLineItems_0" xlink:to="loc_drug_MilestonePaymentsUponFirstCommercialSaleOfClinical_38" order="210" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_drug_DisclosureOfContractualObligationLineItems_0" xlink:to="loc_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement_39" order="220" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_drug_DisclosureOfContractualObligationLineItems_0" xlink:to="loc_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted_40" order="230" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_drug_DisclosureOfContractualObligationLineItems_0" xlink:to="loc_ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement_41" order="240" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_drug_DisclosureOfContractualObligationLineItems_0" xlink:to="loc_drug_MonthlyFeeAuthorizedByBoardOfDirectors_42" order="250" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_drug_DisclosureOfContractualObligationLineItems_0" xlink:to="loc_drug_AdvisorHourlyRate_43" order="260" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_drug_DisclosureOfContractualObligationLineItems_0" xlink:to="loc_ifrs-full_ResearchAndDevelopmentExpense_44" order="270" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://brightmindsbio.com/role/PREMISESLEASESDetailTextuals">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:label="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable" xlink:label="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ClassesOfAssetsAxis" xlink:label="loc_ifrs-full_ClassesOfAssetsAxis_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ClassesOfAssetsMember" xlink:label="loc_ifrs-full_ClassesOfAssetsMember_1"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_CommercialLaboratoryLeaseMember" xlink:label="loc_drug_CommercialLaboratoryLeaseMember_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_BuildingsMember" xlink:label="loc_ifrs-full_BuildingsMember_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ClassesOfAssetsMember" xlink:label="loc_ifrs-full_ClassesOfAssetsMember_Default"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_TermOfLease" xlink:label="loc_drug_TermOfLease_7"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_MonthlyBaseRent" xlink:label="loc_drug_MonthlyBaseRent_8"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_LeaseCost" xlink:label="loc_drug_LeaseCost_9"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems_0" xlink:to="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable_1" xlink:to="loc_ifrs-full_ClassesOfAssetsAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfAssetsAxis_1" xlink:to="loc_ifrs-full_ClassesOfAssetsMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfAssetsMember_1" xlink:to="loc_drug_CommercialLaboratoryLeaseMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfAssetsMember_1" xlink:to="loc_ifrs-full_BuildingsMember_2" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfAssetsAxis_1" xlink:to="loc_ifrs-full_ClassesOfAssetsMember_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems_0" xlink:to="loc_drug_TermOfLease_7" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems_0" xlink:to="loc_drug_MonthlyBaseRent_8" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems_0" xlink:to="loc_drug_LeaseCost_9" order="30" use="optional"/>
  </definitionLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>5
<FILENAME>drug-20210930_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <!-- INTEGIX by Ez-XBRL -->
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel"/>
  <labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AddressTypeDomain" xlink:label="loc_dei_AddressTypeDomain_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentDescription" xlink:label="loc_dei_AmendmentDescription_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AnnualInformationForm" xlink:label="loc_dei_AnnualInformationForm_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_dei_AuditedAnnualFinancialStatements_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_BusinessContactMember" xlink:label="loc_dei_BusinessContactMember_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode" xlink:label="loc_dei_CityAreaCode_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_ContactPersonnelEmailAddress" xlink:label="loc_dei_ContactPersonnelEmailAddress_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_ContactPersonnelFaxNumber" xlink:label="loc_dei_ContactPersonnelFaxNumber_9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_ContactPersonnelName" xlink:label="loc_dei_ContactPersonnelName_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract" xlink:label="loc_dei_CoverAbstract_11"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate_12"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentAccountingStandard" xlink:label="loc_dei_DocumentAccountingStandard_13"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentAnnualReport" xlink:label="loc_dei_DocumentAnnualReport_14"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus_15"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus_16"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_17"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_dei_DocumentRegistrationStatement_18"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_dei_DocumentShellCompanyReport_19"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentTransitionReport" xlink:label="loc_dei_DocumentTransitionReport_20"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_21"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_dei_EntityAddressAddressLine1_22"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_dei_EntityAddressAddressLine2_23"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_dei_EntityAddressCityOrTown_24"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCountry" xlink:label="loc_dei_EntityAddressCountry_25"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressesAddressTypeAxis" xlink:label="loc_dei_EntityAddressesAddressTypeAxis_26"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressesLineItems" xlink:label="loc_dei_EntityAddressesLineItems_27"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressesTable" xlink:label="loc_dei_EntityAddressesTable_28"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_dei_EntityAddressPostalZipCode_29"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_dei_EntityAddressStateOrProvince_30"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_31"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_32"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_dei_EntityCurrentReportingStatus_33"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_34"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_dei_EntityEmergingGrowthCompany_35"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_dei_EntityExTransitionPeriod_36"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber" xlink:label="loc_dei_EntityFileNumber_37"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_38"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_dei_EntityIncorporationStateCountryCode_39"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_dei_EntityInteractiveDataCurrent_40"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_41"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany" xlink:label="loc_dei_EntityShellCompany_42"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_dei_EntityVoluntaryFilers_43"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_44"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="loc_dei_IcfrAuditorAttestationFlag_45"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_46"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber" xlink:label="loc_dei_LocalPhoneNumber_47"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle" xlink:label="loc_dei_Security12bTitle_48"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName" xlink:label="loc_dei_SecurityExchangeName_49"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol" xlink:label="loc_dei_TradingSymbol_50"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_AcquisitionOfIntangibleAssetsByIssuingCommonShares" xlink:label="loc_drug_AcquisitionOfIntangibleAssetsByIssuingCommonShares_51"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_AcquisitionOfIntangibleAssetsByIssuingCommonShares" xlink:label="loc_drug_AcquisitionOfIntangibleAssetsByIssuingCommonShares_52"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_AcquisitionOfIntangibleAssetsByIssuingCommonShares" xlink:label="loc_drug_AcquisitionOfIntangibleAssetsByIssuingCommonShares_53"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_AdjustmentsForDecreaseIncreaseInPrepaidExpenses" xlink:label="loc_drug_AdjustmentsForDecreaseIncreaseInPrepaidExpenses_54"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_AdjustmentsForDecreaseIncreaseInPrepaidExpenses" xlink:label="loc_drug_AdjustmentsForDecreaseIncreaseInPrepaidExpenses_55"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_AdjustmentsForDecreaseIncreaseInPrepaidExpenses" xlink:label="loc_drug_AdjustmentsForDecreaseIncreaseInPrepaidExpenses_56"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_AdjustmentsForDecreaseIncreaseInSalesTaxReceivable" xlink:label="loc_drug_AdjustmentsForDecreaseIncreaseInSalesTaxReceivable_57"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_AdjustmentsForDecreaseIncreaseInSalesTaxReceivable" xlink:label="loc_drug_AdjustmentsForDecreaseIncreaseInSalesTaxReceivable_58"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_AdjustmentsForDecreaseIncreaseInSalesTaxReceivable" xlink:label="loc_drug_AdjustmentsForDecreaseIncreaseInSalesTaxReceivable_59"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_AdjustmentsForSharesRecordedAsResearchAndDevelopment" xlink:label="loc_drug_AdjustmentsForSharesRecordedAsResearchAndDevelopment_60"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_AdjustmentsForSharesRecordedAsResearchAndDevelopment" xlink:label="loc_drug_AdjustmentsForSharesRecordedAsResearchAndDevelopment_61"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_AdjustmentsForSharesRecordedAsResearchAndDevelopment" xlink:label="loc_drug_AdjustmentsForSharesRecordedAsResearchAndDevelopment_62"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_AdjustmentsForSharesRecordedAsResearchAndDevelopment" xlink:label="loc_drug_AdjustmentsForSharesRecordedAsResearchAndDevelopment_63"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_AdjustmentsForSharesRecordedAsResearchAndDevelopment" xlink:label="loc_drug_AdjustmentsForSharesRecordedAsResearchAndDevelopment_64"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_AdvisorHourlyRate" xlink:label="loc_drug_AdvisorHourlyRate_65"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_AdvisorHourlyRate" xlink:label="loc_drug_AdvisorHourlyRate_66"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_AdvisorHourlyRate" xlink:label="loc_drug_AdvisorHourlyRate_67"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_AdvisorsHourlyRatesOfScientificAdvisoryBoardAndConsultants" xlink:label="loc_drug_AdvisorsHourlyRatesOfScientificAdvisoryBoardAndConsultants_68"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_AdvisorsHourlyRatesOfScientificAdvisoryBoardAndConsultants" xlink:label="loc_drug_AdvisorsHourlyRatesOfScientificAdvisoryBoardAndConsultants_69"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_AfterSublicensingAgreementsMember" xlink:label="loc_drug_AfterSublicensingAgreementsMember_70"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_AfterSublicensingAgreementsMember" xlink:label="loc_drug_AfterSublicensingAgreementsMember_71"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_AfterSublicensingAgreementsMember" xlink:label="loc_drug_AfterSublicensingAgreementsMember_72"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_AggregatePurchaseWarrantsDeposited" xlink:label="loc_drug_AggregatePurchaseWarrantsDeposited_73"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_AggregatePurchaseWarrantsDeposited" xlink:label="loc_drug_AggregatePurchaseWarrantsDeposited_74"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_AggregatePurchaseWarrantsDeposited" xlink:label="loc_drug_AggregatePurchaseWarrantsDeposited_75"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_AggregateSecuritiesDepositedToBeHeldInEscrow" xlink:label="loc_drug_AggregateSecuritiesDepositedToBeHeldInEscrow_76"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_AggregateSecuritiesDepositedToBeHeldInEscrow" xlink:label="loc_drug_AggregateSecuritiesDepositedToBeHeldInEscrow_77"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_AggregateSecuritiesDepositedToBeHeldInEscrow" xlink:label="loc_drug_AggregateSecuritiesDepositedToBeHeldInEscrow_78"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_AgreementAxis" xlink:label="loc_drug_AgreementAxis_79"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_AgreementAxis" xlink:label="loc_drug_AgreementAxis_80"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_AgreementDomain" xlink:label="loc_drug_AgreementDomain_81"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_AgreementDomain" xlink:label="loc_drug_AgreementDomain_82"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_AmountOfEscrowProceedsReleased" xlink:label="loc_drug_AmountOfEscrowProceedsReleased_83"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_AmountOfEscrowProceedsReleased" xlink:label="loc_drug_AmountOfEscrowProceedsReleased_84"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_AmountOfEscrowProceedsReleased" xlink:label="loc_drug_AmountOfEscrowProceedsReleased_85"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_AmountOfNonRefundableMonthlyRetainerAsServiceCompensation" xlink:label="loc_drug_AmountOfNonRefundableMonthlyRetainerAsServiceCompensation_86"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_AmountOfNonRefundableMonthlyRetainerAsServiceCompensation" xlink:label="loc_drug_AmountOfNonRefundableMonthlyRetainerAsServiceCompensation_87"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_AmountOfNonRefundableMonthlyRetainerAsServiceCompensation" xlink:label="loc_drug_AmountOfNonRefundableMonthlyRetainerAsServiceCompensation_88"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_AreasOfScientificTechnicalBusinessAdviceAdvisorsHourlyRates" xlink:label="loc_drug_AreasOfScientificTechnicalBusinessAdviceAdvisorsHourlyRates_89"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_AreasOfScientificTechnicalBusinessAdviceAdvisorsHourlyRates" xlink:label="loc_drug_AreasOfScientificTechnicalBusinessAdviceAdvisorsHourlyRates_90"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_ArrangementsAndNonarrangementTransactionDomain" xlink:label="loc_drug_ArrangementsAndNonarrangementTransactionDomain_91"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_ArrangementsAndNonarrangementTransactionDomain" xlink:label="loc_drug_ArrangementsAndNonarrangementTransactionDomain_92"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_BritishColumbiaSecuritiesCommissionMember" xlink:label="loc_drug_BritishColumbiaSecuritiesCommissionMember_93"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_BritishColumbiaSecuritiesCommissionMember" xlink:label="loc_drug_BritishColumbiaSecuritiesCommissionMember_94"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_CashSettledShareBasedPaymentArrangementsMember" xlink:label="loc_drug_CashSettledShareBasedPaymentArrangementsMember_95"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_CashSettledShareBasedPaymentArrangementsMember" xlink:label="loc_drug_CashSettledShareBasedPaymentArrangementsMember_96"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_CashSettledShareBasedPaymentArrangementsMember" xlink:label="loc_drug_CashSettledShareBasedPaymentArrangementsMember_97"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_CategoriesOfResearchAndDevelopmentExpensesAxis" xlink:label="loc_drug_CategoriesOfResearchAndDevelopmentExpensesAxis_98"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_CategoriesOfResearchAndDevelopmentExpensesAxis" xlink:label="loc_drug_CategoriesOfResearchAndDevelopmentExpensesAxis_99"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_CategoriesOfResearchAndDevelopmentExpensesDomain" xlink:label="loc_drug_CategoriesOfResearchAndDevelopmentExpensesDomain_100"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_CategoriesOfResearchAndDevelopmentExpensesDomain" xlink:label="loc_drug_CategoriesOfResearchAndDevelopmentExpensesDomain_101"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_ChangesInNonCashWorkingOperatingCapitalBalancesAbstract" xlink:label="loc_drug_ChangesInNonCashWorkingOperatingCapitalBalancesAbstract_102"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_ChangesInNonCashWorkingOperatingCapitalBalancesAbstract" xlink:label="loc_drug_ChangesInNonCashWorkingOperatingCapitalBalancesAbstract_103"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_ChangesInNonCashWorkingOperatingCapitalBalancesAbstract" xlink:label="loc_drug_ChangesInNonCashWorkingOperatingCapitalBalancesAbstract_104"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_ChiefFinancialOfficerTwoDirectorsAndSevenConsultantsMember" xlink:label="loc_drug_ChiefFinancialOfficerTwoDirectorsAndSevenConsultantsMember_105"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_ChiefFinancialOfficerTwoDirectorsAndSevenConsultantsMember" xlink:label="loc_drug_ChiefFinancialOfficerTwoDirectorsAndSevenConsultantsMember_106"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_ChiefFinancialOfficerTwoDirectorsAndSevenConsultantsMember" xlink:label="loc_drug_ChiefFinancialOfficerTwoDirectorsAndSevenConsultantsMember_107"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_ChiefMedicalOfficerMember" xlink:label="loc_drug_ChiefMedicalOfficerMember_108"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_ChiefMedicalOfficerMember" xlink:label="loc_drug_ChiefMedicalOfficerMember_109"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_CommercialLaboratoryLeaseMember" xlink:label="loc_drug_CommercialLaboratoryLeaseMember_110"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_CommercialLaboratoryLeaseMember" xlink:label="loc_drug_CommercialLaboratoryLeaseMember_111"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_CommercialLaboratoryLeaseMember" xlink:label="loc_drug_CommercialLaboratoryLeaseMember_112"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_CommonShareSubscriptionsReceived" xlink:label="loc_drug_CommonShareSubscriptionsReceived_113"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_CommonShareSubscriptionsReceived" xlink:label="loc_drug_CommonShareSubscriptionsReceived_114"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_CommonShareSubscriptionsReceived" xlink:label="loc_drug_CommonShareSubscriptionsReceived_115"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_CommonStockSharesPurchased" xlink:label="loc_drug_CommonStockSharesPurchased_116"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_CommonStockSharesPurchased" xlink:label="loc_drug_CommonStockSharesPurchased_117"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_CommonStockSharesPurchased" xlink:label="loc_drug_CommonStockSharesPurchased_118"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_ComparativeAmountsAbstract" xlink:label="loc_drug_ComparativeAmountsAbstract_119"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_ComparativeAmountsAbstract" xlink:label="loc_drug_ComparativeAmountsAbstract_120"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_ConsolidatedStatementsOfComprehensiveIncomeLossStatementLocationAxis" xlink:label="loc_drug_ConsolidatedStatementsOfComprehensiveIncomeLossStatementLocationAxis_121"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_ConsolidatedStatementsOfComprehensiveIncomeLossStatementLocationAxis" xlink:label="loc_drug_ConsolidatedStatementsOfComprehensiveIncomeLossStatementLocationAxis_122"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_ConsolidatedStatementsOfComprehensiveIncomeLossStatementLocationDomain" xlink:label="loc_drug_ConsolidatedStatementsOfComprehensiveIncomeLossStatementLocationDomain_123"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_ConsolidatedStatementsOfComprehensiveIncomeLossStatementLocationDomain" xlink:label="loc_drug_ConsolidatedStatementsOfComprehensiveIncomeLossStatementLocationDomain_124"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_ConsultantMember" xlink:label="loc_drug_ConsultantMember_125"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_ConsultantMember" xlink:label="loc_drug_ConsultantMember_126"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_ConsultingAgreement2Member" xlink:label="loc_drug_ConsultingAgreement2Member_127"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_ConsultingAgreementsMember" xlink:label="loc_drug_ConsultingAgreementsMember_128"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_ConsultingAgreementsMember" xlink:label="loc_drug_ConsultingAgreementsMember_129"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_ConsultingFees" xlink:label="loc_drug_ConsultingFees_130"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_ConsultingFees" xlink:label="loc_drug_ConsultingFees_131"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_ConsultingFees" xlink:label="loc_drug_ConsultingFees_132"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_ConsultingFees" xlink:label="loc_drug_ConsultingFees_133"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_ConsultingFeesMember" xlink:label="loc_drug_ConsultingFeesMember_134"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_ConsultingFeesMember" xlink:label="loc_drug_ConsultingFeesMember_135"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_ConsultingFeesMember" xlink:label="loc_drug_ConsultingFeesMember_136"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_ContingentCashFee" xlink:label="loc_drug_ContingentCashFee_137"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_ContingentCashFee" xlink:label="loc_drug_ContingentCashFee_138"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_ContingentCashFee" xlink:label="loc_drug_ContingentCashFee_139"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_DebtSettledByIssuingShares" xlink:label="loc_drug_DebtSettledByIssuingShares_140"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_DebtSettledByIssuingShares" xlink:label="loc_drug_DebtSettledByIssuingShares_141"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_DebtSettledByIssuingShares" xlink:label="loc_drug_DebtSettledByIssuingShares_142"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_DebtSettledThroughIssuanceOfShares" xlink:label="loc_drug_DebtSettledThroughIssuanceOfShares_143"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_DebtSettledThroughIssuanceOfShares" xlink:label="loc_drug_DebtSettledThroughIssuanceOfShares_144"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_DebtSettledThroughIssuanceOfShares" xlink:label="loc_drug_DebtSettledThroughIssuanceOfShares_145"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_DebtSettlementAgreementMember" xlink:label="loc_drug_DebtSettlementAgreementMember_146"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_DebtSettlementAgreementMember" xlink:label="loc_drug_DebtSettlementAgreementMember_147"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_DecemberTwentyOneTwoZeroTwoFourMember" xlink:label="loc_drug_DecemberTwentyOneTwoZeroTwoFourMember_148"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_DecemberTwentyOneTwoZeroTwoFourMember" xlink:label="loc_drug_DecemberTwentyOneTwoZeroTwoFourMember_149"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_DecemberTwentyOneTwoZeroTwoFourMember" xlink:label="loc_drug_DecemberTwentyOneTwoZeroTwoFourMember_150"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_DescriptionOfAccountingPolicyForBasisOfConsolidationExplanatory" xlink:label="loc_drug_DescriptionOfAccountingPolicyForBasisOfConsolidationExplanatory_151"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_DescriptionOfAccountingPolicyForBasisOfConsolidationExplanatory" xlink:label="loc_drug_DescriptionOfAccountingPolicyForBasisOfConsolidationExplanatory_152"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_DescriptionOfAccountingPolicyForBasisOfConsolidationExplanatory" xlink:label="loc_drug_DescriptionOfAccountingPolicyForBasisOfConsolidationExplanatory_153"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_DescriptionOfAccountingPolicyForCriticalAccountingEstimatesExplanatory" xlink:label="loc_drug_DescriptionOfAccountingPolicyForCriticalAccountingEstimatesExplanatory_154"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_DescriptionOfAccountingPolicyForCriticalAccountingEstimatesExplanatory" xlink:label="loc_drug_DescriptionOfAccountingPolicyForCriticalAccountingEstimatesExplanatory_155"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_DescriptionOfAccountingPolicyForCriticalAccountingEstimatesExplanatory" xlink:label="loc_drug_DescriptionOfAccountingPolicyForCriticalAccountingEstimatesExplanatory_156"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_DescriptionOfAccountingPolicyForInternallyGeneratedIntangibleAssetsResearchAndDevelopmentExpenditureExplanatory" xlink:label="loc_drug_DescriptionOfAccountingPolicyForInternallyGeneratedIntangibleAssetsResearchAndDevelopmentExpenditureExplanatory_157"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_DescriptionOfAccountingPolicyForInternallyGeneratedIntangibleAssetsResearchAndDevelopmentExpenditureExplanatory" xlink:label="loc_drug_DescriptionOfAccountingPolicyForInternallyGeneratedIntangibleAssetsResearchAndDevelopmentExpenditureExplanatory_158"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_DescriptionOfAccountingPolicyForInternallyGeneratedIntangibleAssetsResearchAndDevelopmentExpenditureExplanatory" xlink:label="loc_drug_DescriptionOfAccountingPolicyForInternallyGeneratedIntangibleAssetsResearchAndDevelopmentExpenditureExplanatory_159"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_DescriptionOfAccountingPolicyForNewStandardsAndInterpretationsNotYetAdoptedExplanatory" xlink:label="loc_drug_DescriptionOfAccountingPolicyForNewStandardsAndInterpretationsNotYetAdoptedExplanatory_160"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_DescriptionOfAccountingPolicyForNewStandardsAndInterpretationsNotYetAdoptedExplanatory" xlink:label="loc_drug_DescriptionOfAccountingPolicyForNewStandardsAndInterpretationsNotYetAdoptedExplanatory_161"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_DescriptionOfAccountingPolicyForNewStandardsAndInterpretationsNotYetAdoptedExplanatory" xlink:label="loc_drug_DescriptionOfAccountingPolicyForNewStandardsAndInterpretationsNotYetAdoptedExplanatory_162"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_DescriptionOfIssuedAndOutstandingCommonShares" xlink:label="loc_drug_DescriptionOfIssuedAndOutstandingCommonShares_163"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_DescriptionOfIssuedAndOutstandingCommonShares" xlink:label="loc_drug_DescriptionOfIssuedAndOutstandingCommonShares_164"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_DescriptionOfIssuedAndOutstandingCommonShares" xlink:label="loc_drug_DescriptionOfIssuedAndOutstandingCommonShares_165"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_DescriptionOfSublicenseeRevenueOfRoyaltyPaymentAccrues" xlink:label="loc_drug_DescriptionOfSublicenseeRevenueOfRoyaltyPaymentAccrues_166"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_DescriptionOfSublicenseeRevenueOfRoyaltyPaymentAccrues" xlink:label="loc_drug_DescriptionOfSublicenseeRevenueOfRoyaltyPaymentAccrues_167"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_DescriptionOfSublicenseeRevenueOfRoyaltyPaymentAccrues" xlink:label="loc_drug_DescriptionOfSublicenseeRevenueOfRoyaltyPaymentAccrues_168"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_DirectorAndConsultantMember" xlink:label="loc_drug_DirectorAndConsultantMember_169"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_DirectorAndConsultantMember" xlink:label="loc_drug_DirectorAndConsultantMember_170"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_DirectorAndConsultantMember" xlink:label="loc_drug_DirectorAndConsultantMember_171"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_DirectorsCompensationMember" xlink:label="loc_drug_DirectorsCompensationMember_172"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_DirectorsCompensationMember" xlink:label="loc_drug_DirectorsCompensationMember_173"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_DirectorsCompensationMember" xlink:label="loc_drug_DirectorsCompensationMember_174"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_DisclosureOfComparativeAmountsExplanatory" xlink:label="loc_drug_DisclosureOfComparativeAmountsExplanatory_175"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_DisclosureOfComparativeAmountsExplanatory" xlink:label="loc_drug_DisclosureOfComparativeAmountsExplanatory_176"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_DisclosureOfComparativeAmountsExplanatory" xlink:label="loc_drug_DisclosureOfComparativeAmountsExplanatory_177"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_DisclosureOfContractualObligationAbstract" xlink:label="loc_drug_DisclosureOfContractualObligationAbstract_178"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_DisclosureOfContractualObligationLineItems" xlink:label="loc_drug_DisclosureOfContractualObligationLineItems_179"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_DisclosureOfContractualObligationTable" xlink:label="loc_drug_DisclosureOfContractualObligationTable_180"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_DisclosureOfContractualObligationTable" xlink:label="loc_drug_DisclosureOfContractualObligationTable_181"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_DisclosureOfDetailedInformationAboutEquitySettledRestrictedShareUnitsFairValueInputsExplanatory" xlink:label="loc_drug_DisclosureOfDetailedInformationAboutEquitySettledRestrictedShareUnitsFairValueInputsExplanatory_182"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_DisclosureOfDetailedInformationAboutEquitySettledRestrictedShareUnitsFairValueInputsExplanatory" xlink:label="loc_drug_DisclosureOfDetailedInformationAboutEquitySettledRestrictedShareUnitsFairValueInputsExplanatory_183"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_DisclosureOfDetailedInformationAboutEquitySettledRestrictedShareUnitsFairValueInputsExplanatory" xlink:label="loc_drug_DisclosureOfDetailedInformationAboutEquitySettledRestrictedShareUnitsFairValueInputsExplanatory_184"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_DisclosureOfDetailedInformationAboutResearchAndDevelopmentExplanatory" xlink:label="loc_drug_DisclosureOfDetailedInformationAboutResearchAndDevelopmentExplanatory_185"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_DisclosureOfDetailedInformationAboutResearchAndDevelopmentExplanatory" xlink:label="loc_drug_DisclosureOfDetailedInformationAboutResearchAndDevelopmentExplanatory_186"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_DisclosureOfDetailedInformationAboutResearchAndDevelopmentExplanatory" xlink:label="loc_drug_DisclosureOfDetailedInformationAboutResearchAndDevelopmentExplanatory_187"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_DisclosureOfDetailedInformationAboutShareBasedPaymentsIncludedInConsolidatedStatementsOfComprehensiveLossExplanatory" xlink:label="loc_drug_DisclosureOfDetailedInformationAboutShareBasedPaymentsIncludedInConsolidatedStatementsOfComprehensiveLossExplanatory_188"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_DisclosureOfDetailedInformationAboutShareBasedPaymentsIncludedInConsolidatedStatementsOfComprehensiveLossExplanatory" xlink:label="loc_drug_DisclosureOfDetailedInformationAboutShareBasedPaymentsIncludedInConsolidatedStatementsOfComprehensiveLossExplanatory_189"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_DisclosureOfDetailedInformationAboutShareBasedPaymentsIncludedInConsolidatedStatementsOfComprehensiveLossExplanatory" xlink:label="loc_drug_DisclosureOfDetailedInformationAboutShareBasedPaymentsIncludedInConsolidatedStatementsOfComprehensiveLossExplanatory_190"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_DisclosureOfDetailedInformationAboutShareBasedPaymentsRecognizedInConsolidatedStatementsOfComprehensiveLossExplanatory" xlink:label="loc_drug_DisclosureOfDetailedInformationAboutShareBasedPaymentsRecognizedInConsolidatedStatementsOfComprehensiveLossExplanatory_191"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_DisclosureOfDetailedInformationAboutShareBasedPaymentsRecognizedInConsolidatedStatementsOfComprehensiveLossExplanatory" xlink:label="loc_drug_DisclosureOfDetailedInformationAboutShareBasedPaymentsRecognizedInConsolidatedStatementsOfComprehensiveLossExplanatory_192"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_DisclosureOfDetailedInformationAboutShareBasedPaymentsRecognizedInConsolidatedStatementsOfComprehensiveLossExplanatory" xlink:label="loc_drug_DisclosureOfDetailedInformationAboutShareBasedPaymentsRecognizedInConsolidatedStatementsOfComprehensiveLossExplanatory_193"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_DisclosureOfDetailedInformationAboutSignificantAccountingPoliciesAbstract" xlink:label="loc_drug_DisclosureOfDetailedInformationAboutSignificantAccountingPoliciesAbstract_194"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_DisclosureOfDetailedInformationAboutTradePayableAndAccruedExpensesExplanatory" xlink:label="loc_drug_DisclosureOfDetailedInformationAboutTradePayableAndAccruedExpensesExplanatory_195"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_DisclosureOfDetailedInformationAboutTradePayableAndAccruedExpensesExplanatory" xlink:label="loc_drug_DisclosureOfDetailedInformationAboutTradePayableAndAccruedExpensesExplanatory_196"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_DisclosureOfDetailedInformationAboutTradePayableAndAccruedExpensesExplanatory" xlink:label="loc_drug_DisclosureOfDetailedInformationAboutTradePayableAndAccruedExpensesExplanatory_197"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_DisclosureOfMovementsInOutstandingWarrantsExplanatory" xlink:label="loc_drug_DisclosureOfMovementsInOutstandingWarrantsExplanatory_198"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_DisclosureOfMovementsInOutstandingWarrantsExplanatory" xlink:label="loc_drug_DisclosureOfMovementsInOutstandingWarrantsExplanatory_199"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_DisclosureOfMovementsInOutstandingWarrantsExplanatory" xlink:label="loc_drug_DisclosureOfMovementsInOutstandingWarrantsExplanatory_200"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_DisclosureOfNatureAndContinuanceOfOperationsExplanatory" xlink:label="loc_drug_DisclosureOfNatureAndContinuanceOfOperationsExplanatory_201"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_DisclosureOfNatureAndContinuanceOfOperationsExplanatory" xlink:label="loc_drug_DisclosureOfNatureAndContinuanceOfOperationsExplanatory_202"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_DisclosureOfNatureAndContinuanceOfOperationsExplanatory" xlink:label="loc_drug_DisclosureOfNatureAndContinuanceOfOperationsExplanatory_203"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_DisclosureOfNonCapitalLossCarryForwardsExpiryExplanatory" xlink:label="loc_drug_DisclosureOfNonCapitalLossCarryForwardsExpiryExplanatory_204"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_DisclosureOfNonCapitalLossCarryForwardsExpiryExplanatory" xlink:label="loc_drug_DisclosureOfNonCapitalLossCarryForwardsExpiryExplanatory_205"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_DisclosureOfNonCapitalLossCarryForwardsExpiryExplanatory" xlink:label="loc_drug_DisclosureOfNonCapitalLossCarryForwardsExpiryExplanatory_206"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_DisclosureOfNumberAndWeightedAverageExercisePricesOfWarrantsExplanatory" xlink:label="loc_drug_DisclosureOfNumberAndWeightedAverageExercisePricesOfWarrantsExplanatory_207"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_DisclosureOfNumberAndWeightedAverageExercisePricesOfWarrantsExplanatory" xlink:label="loc_drug_DisclosureOfNumberAndWeightedAverageExercisePricesOfWarrantsExplanatory_208"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_DisclosureOfNumberAndWeightedAverageExercisePricesOfWarrantsExplanatory" xlink:label="loc_drug_DisclosureOfNumberAndWeightedAverageExercisePricesOfWarrantsExplanatory_209"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_DisclosureOfNumberOfIssuedAndOutstandingStockOptionsExplanatory" xlink:label="loc_drug_DisclosureOfNumberOfIssuedAndOutstandingStockOptionsExplanatory_210"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_DisclosureOfNumberOfIssuedAndOutstandingStockOptionsExplanatory" xlink:label="loc_drug_DisclosureOfNumberOfIssuedAndOutstandingStockOptionsExplanatory_211"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_DisclosureOfNumberOfIssuedAndOutstandingStockOptionsExplanatory" xlink:label="loc_drug_DisclosureOfNumberOfIssuedAndOutstandingStockOptionsExplanatory_212"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_DisclosureOfNumberOfIssuedAndOutstandingWarrantsExplanatory" xlink:label="loc_drug_DisclosureOfNumberOfIssuedAndOutstandingWarrantsExplanatory_213"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_DisclosureOfNumberOfIssuedAndOutstandingWarrantsExplanatory" xlink:label="loc_drug_DisclosureOfNumberOfIssuedAndOutstandingWarrantsExplanatory_214"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_DisclosureOfNumberOfIssuedAndOutstandingWarrantsExplanatory" xlink:label="loc_drug_DisclosureOfNumberOfIssuedAndOutstandingWarrantsExplanatory_215"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_DisclosureOfReconciliationOfExpectedIncomeTaxRecoveryToActualIncomeTaxRecoveryExplanatory" xlink:label="loc_drug_DisclosureOfReconciliationOfExpectedIncomeTaxRecoveryToActualIncomeTaxRecoveryExplanatory_216"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_DisclosureOfReconciliationOfExpectedIncomeTaxRecoveryToActualIncomeTaxRecoveryExplanatory" xlink:label="loc_drug_DisclosureOfReconciliationOfExpectedIncomeTaxRecoveryToActualIncomeTaxRecoveryExplanatory_217"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_DisclosureOfReconciliationOfExpectedIncomeTaxRecoveryToActualIncomeTaxRecoveryExplanatory" xlink:label="loc_drug_DisclosureOfReconciliationOfExpectedIncomeTaxRecoveryToActualIncomeTaxRecoveryExplanatory_218"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_DisclosureOfShareExchangeAndAssignmentExplanatory" xlink:label="loc_drug_DisclosureOfShareExchangeAndAssignmentExplanatory_219"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_DisclosureOfShareExchangeAndAssignmentExplanatory" xlink:label="loc_drug_DisclosureOfShareExchangeAndAssignmentExplanatory_220"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_DisclosureOfShareExchangeAndAssignmentExplanatory" xlink:label="loc_drug_DisclosureOfShareExchangeAndAssignmentExplanatory_221"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_DisclosureOfShareExchangeAndAssignmentTable" xlink:label="loc_drug_DisclosureOfShareExchangeAndAssignmentTable_222"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_DisclosureOfShareExchangeAndAssignmentTable" xlink:label="loc_drug_DisclosureOfShareExchangeAndAssignmentTable_223"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_DiscountRateOfWarrantsGranted" xlink:label="loc_drug_DiscountRateOfWarrantsGranted_224"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_DiscountRateOfWarrantsGranted" xlink:label="loc_drug_DiscountRateOfWarrantsGranted_225"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_DiscountRateOfWarrantsGranted" xlink:label="loc_drug_DiscountRateOfWarrantsGranted_226"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_DiscountRateStockOptionGranted" xlink:label="loc_drug_DiscountRateStockOptionGranted_227"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_DiscountRateStockOptionGranted" xlink:label="loc_drug_DiscountRateStockOptionGranted_228"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_DiscountRateStockOptionGranted" xlink:label="loc_drug_DiscountRateStockOptionGranted_229"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_DocumentAndEntityAbstract" xlink:label="loc_drug_DocumentAndEntityAbstract_230"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_DocumentAndEntityAbstract" xlink:label="loc_drug_DocumentAndEntityAbstract_231"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_EighteenMonthAnniversaryOfGrantDateMember" xlink:label="loc_drug_EighteenMonthAnniversaryOfGrantDateMember_232"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_EighteenMonthAnniversaryOfGrantDateMember" xlink:label="loc_drug_EighteenMonthAnniversaryOfGrantDateMember_233"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_EighthTrancheMember" xlink:label="loc_drug_EighthTrancheMember_234"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_EighthTrancheMember" xlink:label="loc_drug_EighthTrancheMember_235"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_EighthTrancheMember" xlink:label="loc_drug_EighthTrancheMember_236"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_EleventhTrancheMember" xlink:label="loc_drug_EleventhTrancheMember_237"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_EleventhTrancheMember" xlink:label="loc_drug_EleventhTrancheMember_238"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_EleventhTrancheMember" xlink:label="loc_drug_EleventhTrancheMember_239"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_EquitySettledShareBasedPaymentArrangementsMember" xlink:label="loc_drug_EquitySettledShareBasedPaymentArrangementsMember_240"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_EquitySettledShareBasedPaymentArrangementsMember" xlink:label="loc_drug_EquitySettledShareBasedPaymentArrangementsMember_241"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_EquitySettledShareBasedPaymentArrangementsMember" xlink:label="loc_drug_EquitySettledShareBasedPaymentArrangementsMember_242"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_EscrowAgreementMember" xlink:label="loc_drug_EscrowAgreementMember_243"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_EscrowAgreementMember" xlink:label="loc_drug_EscrowAgreementMember_244"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_EscrowedSecuritiesMember" xlink:label="loc_drug_EscrowedSecuritiesMember_245"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_EscrowedSecuritiesMember" xlink:label="loc_drug_EscrowedSecuritiesMember_246"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_EscrowedSecuritiesToBeReleasedAfterListingDate" xlink:label="loc_drug_EscrowedSecuritiesToBeReleasedAfterListingDate_247"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_EscrowedSecuritiesToBeReleasedAfterListingDate" xlink:label="loc_drug_EscrowedSecuritiesToBeReleasedAfterListingDate_248"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_EscrowedSecuritiesToBeReleasedAfterListingDate" xlink:label="loc_drug_EscrowedSecuritiesToBeReleasedAfterListingDate_249"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_EscrowedSecuritiesToBeReleasedOnceSharesAreListedOnCanadianStockExchange" xlink:label="loc_drug_EscrowedSecuritiesToBeReleasedOnceSharesAreListedOnCanadianStockExchange_250"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_EscrowedSecuritiesToBeReleasedOnceSharesAreListedOnCanadianStockExchange" xlink:label="loc_drug_EscrowedSecuritiesToBeReleasedOnceSharesAreListedOnCanadianStockExchange_251"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_EscrowedSecuritiesToBeReleasedOnceSharesAreListedOnCanadianStockExchange" xlink:label="loc_drug_EscrowedSecuritiesToBeReleasedOnceSharesAreListedOnCanadianStockExchange_252"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_EscrowedSharePurchaseWarrantsMember" xlink:label="loc_drug_EscrowedSharePurchaseWarrantsMember_253"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_EscrowedSharePurchaseWarrantsMember" xlink:label="loc_drug_EscrowedSharePurchaseWarrantsMember_254"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_EscrowedSharePurchaseWarrantsMember" xlink:label="loc_drug_EscrowedSharePurchaseWarrantsMember_255"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_EstimatedFairValueOfEquitySettledRsusGranted" xlink:label="loc_drug_EstimatedFairValueOfEquitySettledRsusGranted_256"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_EstimatedFairValueOfEquitySettledRsusGranted" xlink:label="loc_drug_EstimatedFairValueOfEquitySettledRsusGranted_257"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_EstimatedFairValueOfEquitySettledRsusGranted" xlink:label="loc_drug_EstimatedFairValueOfEquitySettledRsusGranted_258"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_EstimatedLifeOfWarrantsGranted" xlink:label="loc_drug_EstimatedLifeOfWarrantsGranted_259"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_EstimatedLifeOfWarrantsGranted" xlink:label="loc_drug_EstimatedLifeOfWarrantsGranted_260"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_EstimatedLifeOfWarrantsGranted" xlink:label="loc_drug_EstimatedLifeOfWarrantsGranted_261"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_ExercisePriceWarrantsGranted" xlink:label="loc_drug_ExercisePriceWarrantsGranted_262"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_ExercisePriceWarrantsGranted" xlink:label="loc_drug_ExercisePriceWarrantsGranted_263"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_ExercisePriceWarrantsGranted" xlink:label="loc_drug_ExercisePriceWarrantsGranted_264"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_ExpectedVolatilityWarrantsGranted" xlink:label="loc_drug_ExpectedVolatilityWarrantsGranted_265"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_ExpectedVolatilityWarrantsGranted" xlink:label="loc_drug_ExpectedVolatilityWarrantsGranted_266"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_ExpectedVolatilityWarrantsGranted" xlink:label="loc_drug_ExpectedVolatilityWarrantsGranted_267"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_ExpirationPeriodDomain" xlink:label="loc_drug_ExpirationPeriodDomain_268"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_ExpirationPeriodDomain" xlink:label="loc_drug_ExpirationPeriodDomain_269"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_ExpirePeriodAxis" xlink:label="loc_drug_ExpirePeriodAxis_270"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_ExpirePeriodAxis" xlink:label="loc_drug_ExpirePeriodAxis_271"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_ExpiryDate" xlink:label="loc_drug_ExpiryDate_272"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_ExpiryDate" xlink:label="loc_drug_ExpiryDate_273"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_ExpiryDate" xlink:label="loc_drug_ExpiryDate_274"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_ExpiryDateAxis" xlink:label="loc_drug_ExpiryDateAxis_275"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_ExpiryDateAxis" xlink:label="loc_drug_ExpiryDateAxis_276"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_ExpiryDateDomain" xlink:label="loc_drug_ExpiryDateDomain_277"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_ExpiryDateDomain" xlink:label="loc_drug_ExpiryDateDomain_278"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_ExpiryDateFifteenJuneTwoThousandAndTwentySixMember" xlink:label="loc_drug_ExpiryDateFifteenJuneTwoThousandAndTwentySixMember_279"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_ExpiryDateFifteenJuneTwoThousandAndTwentySixMember" xlink:label="loc_drug_ExpiryDateFifteenJuneTwoThousandAndTwentySixMember_280"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_ExpiryDateFifteenJuneTwoThousandAndTwentySixMember" xlink:label="loc_drug_ExpiryDateFifteenJuneTwoThousandAndTwentySixMember_281"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_ExpiryDateSeventeenMarchTwoThousandAndTwentyFourOneMember" xlink:label="loc_drug_ExpiryDateSeventeenMarchTwoThousandAndTwentyFourOneMember_282"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_ExpiryDateSeventeenMarchTwoThousandAndTwentyFourOneMember" xlink:label="loc_drug_ExpiryDateSeventeenMarchTwoThousandAndTwentyFourOneMember_283"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_ExpiryDateSeventeenMarchTwoThousandAndTwentyFourOneMember" xlink:label="loc_drug_ExpiryDateSeventeenMarchTwoThousandAndTwentyFourOneMember_284"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_ExpiryDateSeventeenMarchTwoThousandAndTwentyFourTwoMember" xlink:label="loc_drug_ExpiryDateSeventeenMarchTwoThousandAndTwentyFourTwoMember_285"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_ExpiryDateSeventeenMarchTwoThousandAndTwentyFourTwoMember" xlink:label="loc_drug_ExpiryDateSeventeenMarchTwoThousandAndTwentyFourTwoMember_286"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_ExpiryDateSeventeenMarchTwoThousandAndTwentyFourTwoMember" xlink:label="loc_drug_ExpiryDateSeventeenMarchTwoThousandAndTwentyFourTwoMember_287"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_ExpiryDateSeventeenNovemberTwoThousandAndTwentyFiveMember" xlink:label="loc_drug_ExpiryDateSeventeenNovemberTwoThousandAndTwentyFiveMember_288"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_ExpiryDateSeventeenNovemberTwoThousandAndTwentyFiveMember" xlink:label="loc_drug_ExpiryDateSeventeenNovemberTwoThousandAndTwentyFiveMember_289"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_ExpiryDateSeventeenNovemberTwoThousandAndTwentyFiveMember" xlink:label="loc_drug_ExpiryDateSeventeenNovemberTwoThousandAndTwentyFiveMember_290"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_ExpiryDateThirtyJulyTwoThousandAndTwentyFourMember" xlink:label="loc_drug_ExpiryDateThirtyJulyTwoThousandAndTwentyFourMember_291"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_ExpiryDateThirtyJulyTwoThousandAndTwentyFourMember" xlink:label="loc_drug_ExpiryDateThirtyJulyTwoThousandAndTwentyFourMember_292"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_ExpiryDateThirtyJulyTwoThousandAndTwentyFourMember" xlink:label="loc_drug_ExpiryDateThirtyJulyTwoThousandAndTwentyFourMember_293"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_ExpiryDateTwentyEightAprilTwoThousandAndTwentySixMember" xlink:label="loc_drug_ExpiryDateTwentyEightAprilTwoThousandAndTwentySixMember_294"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_ExpiryDateTwentyEightAprilTwoThousandAndTwentySixMember" xlink:label="loc_drug_ExpiryDateTwentyEightAprilTwoThousandAndTwentySixMember_295"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_ExpiryDateTwentyEightAprilTwoThousandAndTwentySixMember" xlink:label="loc_drug_ExpiryDateTwentyEightAprilTwoThousandAndTwentySixMember_296"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_ExpiryDateTwentyOneSeptemberTwoThousandAndTwentyFourMember" xlink:label="loc_drug_ExpiryDateTwentyOneSeptemberTwoThousandAndTwentyFourMember_297"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_ExpiryDateTwentyOneSeptemberTwoThousandAndTwentyFourMember" xlink:label="loc_drug_ExpiryDateTwentyOneSeptemberTwoThousandAndTwentyFourMember_298"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_ExpiryDateTwentyOneSeptemberTwoThousandAndTwentyFourMember" xlink:label="loc_drug_ExpiryDateTwentyOneSeptemberTwoThousandAndTwentyFourMember_299"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_ExpiryDateTwentyThreeJulyTwoThousandAndTwentyFiveMember" xlink:label="loc_drug_ExpiryDateTwentyThreeJulyTwoThousandAndTwentyFiveMember_300"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_ExpiryDateTwentyThreeJulyTwoThousandAndTwentyFiveMember" xlink:label="loc_drug_ExpiryDateTwentyThreeJulyTwoThousandAndTwentyFiveMember_301"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_ExpiryDateTwentyThreeJulyTwoThousandAndTwentyFiveMember" xlink:label="loc_drug_ExpiryDateTwentyThreeJulyTwoThousandAndTwentyFiveMember_302"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_FairValueAscribedToBrokersWarrantsIssued" xlink:label="loc_drug_FairValueAscribedToBrokersWarrantsIssued_303"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_FairValueAscribedToBrokersWarrantsIssued" xlink:label="loc_drug_FairValueAscribedToBrokersWarrantsIssued_304"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_FairValueAscribedToBrokersWarrantsIssued" xlink:label="loc_drug_FairValueAscribedToBrokersWarrantsIssued_305"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_FairValueOfOptionsIssuedAsFindersFees" xlink:label="loc_drug_FairValueOfOptionsIssuedAsFindersFees_306"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_FairValueOfOptionsIssuedAsFindersFees" xlink:label="loc_drug_FairValueOfOptionsIssuedAsFindersFees_307"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_FairValueOfOptionsIssuedAsFindersFees" xlink:label="loc_drug_FairValueOfOptionsIssuedAsFindersFees_308"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_FairValueOfWarrants" xlink:label="loc_drug_FairValueOfWarrants_309"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_FairValueOfWarrants" xlink:label="loc_drug_FairValueOfWarrants_310"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_FairValueOfWarrants" xlink:label="loc_drug_FairValueOfWarrants_311"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_FifteenthTrancheMember" xlink:label="loc_drug_FifteenthTrancheMember_312"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_FifteenthTrancheMember" xlink:label="loc_drug_FifteenthTrancheMember_313"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_FifteenthTrancheMember" xlink:label="loc_drug_FifteenthTrancheMember_314"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_FifthTrancheMember" xlink:label="loc_drug_FifthTrancheMember_315"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_FifthTrancheMember" xlink:label="loc_drug_FifthTrancheMember_316"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_FifthTrancheMember" xlink:label="loc_drug_FifthTrancheMember_317"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_FinancialInstrumentsAtAmortizedCostMember" xlink:label="loc_drug_FinancialInstrumentsAtAmortizedCostMember_318"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_FinancialInstrumentsAtAmortizedCostMember" xlink:label="loc_drug_FinancialInstrumentsAtAmortizedCostMember_319"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_FinancialInstrumentsAtAmortizedCostMember" xlink:label="loc_drug_FinancialInstrumentsAtAmortizedCostMember_320"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_FinancialInstrumentsAtFairValueThroughProfitOrLossMember" xlink:label="loc_drug_FinancialInstrumentsAtFairValueThroughProfitOrLossMember_321"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_FinancialInstrumentsAtFairValueThroughProfitOrLossMember" xlink:label="loc_drug_FinancialInstrumentsAtFairValueThroughProfitOrLossMember_322"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_FinancialInstrumentsAtFairValueThroughProfitOrLossMember" xlink:label="loc_drug_FinancialInstrumentsAtFairValueThroughProfitOrLossMember_323"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_FirstAnniversaryOfGrantDateMember" xlink:label="loc_drug_FirstAnniversaryOfGrantDateMember_324"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_FirstAnniversaryOfGrantDateMember" xlink:label="loc_drug_FirstAnniversaryOfGrantDateMember_325"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_FirstTrancheMember" xlink:label="loc_drug_FirstTrancheMember_326"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_FirstTrancheMember" xlink:label="loc_drug_FirstTrancheMember_327"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_FirstTrancheMember" xlink:label="loc_drug_FirstTrancheMember_328"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_FirstTrancheMember" xlink:label="loc_drug_FirstTrancheMember_329"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_FirstTrancheOfNonBrokeredPrivatePlacementMember" xlink:label="loc_drug_FirstTrancheOfNonBrokeredPrivatePlacementMember_330"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_FirstTrancheOfNonBrokeredPrivatePlacementMember" xlink:label="loc_drug_FirstTrancheOfNonBrokeredPrivatePlacementMember_331"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_FirstTrancheOfNonBrokeredPrivatePlacementMember" xlink:label="loc_drug_FirstTrancheOfNonBrokeredPrivatePlacementMember_332"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_ForfeitureRateOfOtherEquityInstruments" xlink:label="loc_drug_ForfeitureRateOfOtherEquityInstruments_333"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_ForfeitureRateOfOtherEquityInstruments" xlink:label="loc_drug_ForfeitureRateOfOtherEquityInstruments_334"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_ForfeitureRateOfOtherEquityInstruments" xlink:label="loc_drug_ForfeitureRateOfOtherEquityInstruments_335"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_FourteenthTrancheMember" xlink:label="loc_drug_FourteenthTrancheMember_336"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_FourteenthTrancheMember" xlink:label="loc_drug_FourteenthTrancheMember_337"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_FourteenthTrancheMember" xlink:label="loc_drug_FourteenthTrancheMember_338"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_FourthAnniversaryOfGrantDateMember" xlink:label="loc_drug_FourthAnniversaryOfGrantDateMember_339"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_FourthAnniversaryOfGrantDateMember" xlink:label="loc_drug_FourthAnniversaryOfGrantDateMember_340"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_FourthTrancheMember" xlink:label="loc_drug_FourthTrancheMember_341"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_FourthTrancheMember" xlink:label="loc_drug_FourthTrancheMember_342"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_FourthTrancheMember" xlink:label="loc_drug_FourthTrancheMember_343"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_GrantDateAxis" xlink:label="loc_drug_GrantDateAxis_344"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_GrantDateAxis" xlink:label="loc_drug_GrantDateAxis_345"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_GrantDateDomain" xlink:label="loc_drug_GrantDateDomain_346"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_GrantDateDomain" xlink:label="loc_drug_GrantDateDomain_347"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_GrossProceedsFromUnitsIssued" xlink:label="loc_drug_GrossProceedsFromUnitsIssued_348"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_GrossProceedsFromUnitsIssued" xlink:label="loc_drug_GrossProceedsFromUnitsIssued_349"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_GrossProceedsFromUnitsIssued" xlink:label="loc_drug_GrossProceedsFromUnitsIssued_350"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_GrossProceedsFromWarrantsExercised" xlink:label="loc_drug_GrossProceedsFromWarrantsExercised_351"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_GrossProceedsFromWarrantsExercised" xlink:label="loc_drug_GrossProceedsFromWarrantsExercised_352"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_GrossProceedsFromWarrantsExercised" xlink:label="loc_drug_GrossProceedsFromWarrantsExercised_353"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_GrossProceedsFromWarrantsIssued" xlink:label="loc_drug_GrossProceedsFromWarrantsIssued_354"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_GrossProceedsFromWarrantsIssued" xlink:label="loc_drug_GrossProceedsFromWarrantsIssued_355"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_GrossProceedsFromWarrantsIssued" xlink:label="loc_drug_GrossProceedsFromWarrantsIssued_356"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_IncomeTaxAuthorityNameOfCountryAxis" xlink:label="loc_drug_IncomeTaxAuthorityNameOfCountryAxis_357"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_IncomeTaxAuthorityNameOfCountryAxis" xlink:label="loc_drug_IncomeTaxAuthorityNameOfCountryAxis_358"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_IncomeTaxAuthorityNameOfCountryDomain" xlink:label="loc_drug_IncomeTaxAuthorityNameOfCountryDomain_359"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_IncomeTaxAuthorityNameOfCountryDomain" xlink:label="loc_drug_IncomeTaxAuthorityNameOfCountryDomain_360"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_IncreaseDecreaseThroughAcquisitionOfIntangibleAssets" xlink:label="loc_drug_IncreaseDecreaseThroughAcquisitionOfIntangibleAssets_361"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_IncreaseDecreaseThroughAcquisitionOfIntangibleAssets" xlink:label="loc_drug_IncreaseDecreaseThroughAcquisitionOfIntangibleAssets_362"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_IncreaseDecreaseThroughAcquisitionOfIntangibleAssets" xlink:label="loc_drug_IncreaseDecreaseThroughAcquisitionOfIntangibleAssets_363"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_IncreaseDecreaseThroughAcquisitionOfIntangibleAssetsShares" xlink:label="loc_drug_IncreaseDecreaseThroughAcquisitionOfIntangibleAssetsShares_364"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_IncreaseDecreaseThroughAcquisitionOfIntangibleAssetsShares" xlink:label="loc_drug_IncreaseDecreaseThroughAcquisitionOfIntangibleAssetsShares_365"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_IncreaseDecreaseThroughAcquisitionOfIntangibleAssetsShares" xlink:label="loc_drug_IncreaseDecreaseThroughAcquisitionOfIntangibleAssetsShares_366"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_IncreaseDecreaseThroughCashDistributionForFindersFees" xlink:label="loc_drug_IncreaseDecreaseThroughCashDistributionForFindersFees_367"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_IncreaseDecreaseThroughCashDistributionForFindersFees" xlink:label="loc_drug_IncreaseDecreaseThroughCashDistributionForFindersFees_368"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_IncreaseDecreaseThroughCashDistributionForFindersFees" xlink:label="loc_drug_IncreaseDecreaseThroughCashDistributionForFindersFees_369"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_IncreaseDecreaseThroughDebtSettlementWithShare" xlink:label="loc_drug_IncreaseDecreaseThroughDebtSettlementWithShare_370"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_IncreaseDecreaseThroughDebtSettlementWithShare" xlink:label="loc_drug_IncreaseDecreaseThroughDebtSettlementWithShare_371"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_IncreaseDecreaseThroughDebtSettlementWithShare" xlink:label="loc_drug_IncreaseDecreaseThroughDebtSettlementWithShare_372"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_IncreaseDecreaseThroughDebtSettlementWithShareShares" xlink:label="loc_drug_IncreaseDecreaseThroughDebtSettlementWithShareShares_373"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_IncreaseDecreaseThroughDebtSettlementWithShareShares" xlink:label="loc_drug_IncreaseDecreaseThroughDebtSettlementWithShareShares_374"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_IncreaseDecreaseThroughDebtSettlementWithShareShares" xlink:label="loc_drug_IncreaseDecreaseThroughDebtSettlementWithShareShares_375"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_IncreaseDecreaseThroughDistributionOfBrokerWarrantsForFindersFees" xlink:label="loc_drug_IncreaseDecreaseThroughDistributionOfBrokerWarrantsForFindersFees_376"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_IncreaseDecreaseThroughDistributionOfBrokerWarrantsForFindersFees" xlink:label="loc_drug_IncreaseDecreaseThroughDistributionOfBrokerWarrantsForFindersFees_377"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_IncreaseDecreaseThroughDistributionOfBrokerWarrantsForFindersFees" xlink:label="loc_drug_IncreaseDecreaseThroughDistributionOfBrokerWarrantsForFindersFees_378"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_IncreaseDecreaseThroughExerciseOfOptionsForFindersFee" xlink:label="loc_drug_IncreaseDecreaseThroughExerciseOfOptionsForFindersFee_379"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_IncreaseDecreaseThroughExerciseOfOptionsForFindersFee" xlink:label="loc_drug_IncreaseDecreaseThroughExerciseOfOptionsForFindersFee_380"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_IncreaseDecreaseThroughExerciseOfOptionsForFindersFee" xlink:label="loc_drug_IncreaseDecreaseThroughExerciseOfOptionsForFindersFee_381"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_IncreaseDecreaseThroughExerciseOfWarrantsShares" xlink:label="loc_drug_IncreaseDecreaseThroughExerciseOfWarrantsShares_382"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_IncreaseDecreaseThroughExerciseOfWarrantsShares" xlink:label="loc_drug_IncreaseDecreaseThroughExerciseOfWarrantsShares_383"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_IncreaseDecreaseThroughExerciseOfWarrantsShares" xlink:label="loc_drug_IncreaseDecreaseThroughExerciseOfWarrantsShares_384"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_IncreaseDecreaseThroughFindersFeesBrokerWarrants" xlink:label="loc_drug_IncreaseDecreaseThroughFindersFeesBrokerWarrants_385"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_IncreaseDecreaseThroughFindersFeesBrokerWarrants" xlink:label="loc_drug_IncreaseDecreaseThroughFindersFeesBrokerWarrants_386"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_IncreaseDecreaseThroughFindersFeesBrokerWarrants" xlink:label="loc_drug_IncreaseDecreaseThroughFindersFeesBrokerWarrants_387"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_IncreaseDecreaseThroughFindersFeesCash" xlink:label="loc_drug_IncreaseDecreaseThroughFindersFeesCash_388"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_IncreaseDecreaseThroughFindersFeesCash" xlink:label="loc_drug_IncreaseDecreaseThroughFindersFeesCash_389"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_IncreaseDecreaseThroughFindersFeesCash" xlink:label="loc_drug_IncreaseDecreaseThroughFindersFeesCash_390"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_IncreaseDecreaseThroughFindersFeesShareOptions" xlink:label="loc_drug_IncreaseDecreaseThroughFindersFeesShareOptions_391"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_IncreaseDecreaseThroughFindersFeesShareOptions" xlink:label="loc_drug_IncreaseDecreaseThroughFindersFeesShareOptions_392"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_IncreaseDecreaseThroughFindersFeesShareOptions" xlink:label="loc_drug_IncreaseDecreaseThroughFindersFeesShareOptions_393"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_IncreaseDecreaseThroughPrivatePlacement" xlink:label="loc_drug_IncreaseDecreaseThroughPrivatePlacement_394"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_IncreaseDecreaseThroughPrivatePlacement" xlink:label="loc_drug_IncreaseDecreaseThroughPrivatePlacement_395"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_IncreaseDecreaseThroughPrivatePlacement" xlink:label="loc_drug_IncreaseDecreaseThroughPrivatePlacement_396"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_IncreaseDecreaseThroughPrivatePlacementShares" xlink:label="loc_drug_IncreaseDecreaseThroughPrivatePlacementShares_397"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_IncreaseDecreaseThroughPrivatePlacementShares" xlink:label="loc_drug_IncreaseDecreaseThroughPrivatePlacementShares_398"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_IncreaseDecreaseThroughPrivatePlacementShares" xlink:label="loc_drug_IncreaseDecreaseThroughPrivatePlacementShares_399"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_IncreaseDecreaseThroughSharesIssuedToUniversity" xlink:label="loc_drug_IncreaseDecreaseThroughSharesIssuedToUniversity_400"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_IncreaseDecreaseThroughSharesIssuedToUniversity" xlink:label="loc_drug_IncreaseDecreaseThroughSharesIssuedToUniversity_401"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_IncreaseDecreaseThroughSharesIssuedToUniversity" xlink:label="loc_drug_IncreaseDecreaseThroughSharesIssuedToUniversity_402"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_IncreaseDecreaseThroughSharesIssuedToUniversityShares" xlink:label="loc_drug_IncreaseDecreaseThroughSharesIssuedToUniversityShares_403"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_IncreaseDecreaseThroughSharesIssuedToUniversityShares" xlink:label="loc_drug_IncreaseDecreaseThroughSharesIssuedToUniversityShares_404"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_IncreaseDecreaseThroughSharesIssuedToUniversityShares" xlink:label="loc_drug_IncreaseDecreaseThroughSharesIssuedToUniversityShares_405"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_IncreaseDecreaseThroughSpecialWarrantConversion" xlink:label="loc_drug_IncreaseDecreaseThroughSpecialWarrantConversion_406"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_IncreaseDecreaseThroughSpecialWarrantConversion" xlink:label="loc_drug_IncreaseDecreaseThroughSpecialWarrantConversion_407"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_IncreaseDecreaseThroughSpecialWarrantConversion" xlink:label="loc_drug_IncreaseDecreaseThroughSpecialWarrantConversion_408"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_IncreaseDecreaseThroughSpecialWarrantConversionShares" xlink:label="loc_drug_IncreaseDecreaseThroughSpecialWarrantConversionShares_409"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_IncreaseDecreaseThroughSpecialWarrantConversionShares" xlink:label="loc_drug_IncreaseDecreaseThroughSpecialWarrantConversionShares_410"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_IncreaseDecreaseThroughSpecialWarrantConversionShares" xlink:label="loc_drug_IncreaseDecreaseThroughSpecialWarrantConversionShares_411"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_IndependentConsultantAgreementMember" xlink:label="loc_drug_IndependentConsultantAgreementMember_412"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_IndependentConsultantAgreementMember" xlink:label="loc_drug_IndependentConsultantAgreementMember_413"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_IndependentContractorAgreementToServeAsChiefMedicalOfficerMember" xlink:label="loc_drug_IndependentContractorAgreementToServeAsChiefMedicalOfficerMember_414"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_IndependentContractorAgreementToServeAsChiefMedicalOfficerMember" xlink:label="loc_drug_IndependentContractorAgreementToServeAsChiefMedicalOfficerMember_415"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_IndependentContractorAgreementToServeAsChiefScienceOfficerMember" xlink:label="loc_drug_IndependentContractorAgreementToServeAsChiefScienceOfficerMember_416"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_IndependentContractorAgreementToServeAsChiefScienceOfficerMember" xlink:label="loc_drug_IndependentContractorAgreementToServeAsChiefScienceOfficerMember_417"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_IndependentContractorAgreementToServeAsChiefScienceOfficerMember" xlink:label="loc_drug_IndependentContractorAgreementToServeAsChiefScienceOfficerMember_418"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_IssuanceOfRestrictedStockUnits" xlink:label="loc_drug_IssuanceOfRestrictedStockUnits_419"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_IssuanceOfRestrictedStockUnits" xlink:label="loc_drug_IssuanceOfRestrictedStockUnits_420"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_IssuanceOfRestrictedStockUnits" xlink:label="loc_drug_IssuanceOfRestrictedStockUnits_421"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_IssueOfSharesUnderPrivatePlacement" xlink:label="loc_drug_IssueOfSharesUnderPrivatePlacement_422"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_IssueOfSharesUnderPrivatePlacement" xlink:label="loc_drug_IssueOfSharesUnderPrivatePlacement_423"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_IssueOfSharesUnderPrivatePlacement" xlink:label="loc_drug_IssueOfSharesUnderPrivatePlacement_424"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_IssueOfSharesUnderPrivatePlacementValue" xlink:label="loc_drug_IssueOfSharesUnderPrivatePlacementValue_425"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_IssueOfSharesUnderPrivatePlacementValue" xlink:label="loc_drug_IssueOfSharesUnderPrivatePlacementValue_426"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_IssueOfSharesUnderPrivatePlacementValue" xlink:label="loc_drug_IssueOfSharesUnderPrivatePlacementValue_427"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_IssuePricePerShare" xlink:label="loc_drug_IssuePricePerShare_428"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_IssuePricePerShare" xlink:label="loc_drug_IssuePricePerShare_429"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_IssuePricePerShare" xlink:label="loc_drug_IssuePricePerShare_430"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_JuneTwentyOneTwoZeroTwoTwoMember" xlink:label="loc_drug_JuneTwentyOneTwoZeroTwoTwoMember_431"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_JuneTwentyOneTwoZeroTwoTwoMember" xlink:label="loc_drug_JuneTwentyOneTwoZeroTwoTwoMember_432"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_KeyManagementPersonnelCompensationShareBasedPaymentIncludedInProfessionalFees" xlink:label="loc_drug_KeyManagementPersonnelCompensationShareBasedPaymentIncludedInProfessionalFees_433"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_KeyManagementPersonnelCompensationShareBasedPaymentIncludedInProfessionalFees" xlink:label="loc_drug_KeyManagementPersonnelCompensationShareBasedPaymentIncludedInProfessionalFees_434"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_KeyManagementPersonnelCompensationShareBasedPaymentIncludedInProfessionalFees" xlink:label="loc_drug_KeyManagementPersonnelCompensationShareBasedPaymentIncludedInProfessionalFees_435"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_KeyManagementPersonnelCompensationShareBasedPaymentIncludedInResearchAndDevelopment" xlink:label="loc_drug_KeyManagementPersonnelCompensationShareBasedPaymentIncludedInResearchAndDevelopment_436"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_KeyManagementPersonnelCompensationShareBasedPaymentIncludedInResearchAndDevelopment" xlink:label="loc_drug_KeyManagementPersonnelCompensationShareBasedPaymentIncludedInResearchAndDevelopment_437"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_KeyManagementPersonnelCompensationShareBasedPaymentIncludedInResearchAndDevelopment" xlink:label="loc_drug_KeyManagementPersonnelCompensationShareBasedPaymentIncludedInResearchAndDevelopment_438"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_KeyManagementPersonnelProfessionalFees" xlink:label="loc_drug_KeyManagementPersonnelProfessionalFees_439"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_KeyManagementPersonnelProfessionalFees" xlink:label="loc_drug_KeyManagementPersonnelProfessionalFees_440"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_KeyManagementPersonnelProfessionalFees" xlink:label="loc_drug_KeyManagementPersonnelProfessionalFees_441"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_KeyManagementPersonnelResearchAndDevelopment" xlink:label="loc_drug_KeyManagementPersonnelResearchAndDevelopment_442"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_KeyManagementPersonnelResearchAndDevelopment" xlink:label="loc_drug_KeyManagementPersonnelResearchAndDevelopment_443"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_KeyManagementPersonnelResearchAndDevelopment" xlink:label="loc_drug_KeyManagementPersonnelResearchAndDevelopment_444"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_LaboratoryCostsMember" xlink:label="loc_drug_LaboratoryCostsMember_445"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_LaboratoryCostsMember" xlink:label="loc_drug_LaboratoryCostsMember_446"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_LaboratoryCostsMember" xlink:label="loc_drug_LaboratoryCostsMember_447"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_LeaseCost" xlink:label="loc_drug_LeaseCost_448"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_LeaseCost" xlink:label="loc_drug_LeaseCost_449"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_LeaseCost" xlink:label="loc_drug_LeaseCost_450"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_LetterAgreementMember" xlink:label="loc_drug_LetterAgreementMember_451"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_LetterAgreementMember" xlink:label="loc_drug_LetterAgreementMember_452"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_LicenseAgreementMember" xlink:label="loc_drug_LicenseAgreementMember_453"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_LicenseAgreementMember" xlink:label="loc_drug_LicenseAgreementMember_454"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_MarchTwentyOneTwoZeroTwoTwoMember" xlink:label="loc_drug_MarchTwentyOneTwoZeroTwoTwoMember_455"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_MarchTwentyOneTwoZeroTwoTwoMember" xlink:label="loc_drug_MarchTwentyOneTwoZeroTwoTwoMember_456"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_MarketingAdvertisingAndInvestorRelationsMember" xlink:label="loc_drug_MarketingAdvertisingAndInvestorRelationsMember_457"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_MarketingAdvertisingAndInvestorRelationsMember" xlink:label="loc_drug_MarketingAdvertisingAndInvestorRelationsMember_458"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_MarketingAdvertisingAndInvestorRelationsMember" xlink:label="loc_drug_MarketingAdvertisingAndInvestorRelationsMember_459"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_MilestonePaymentsUponDosingFirstPatientInFirstPhaseIiiTrial" xlink:label="loc_drug_MilestonePaymentsUponDosingFirstPatientInFirstPhaseIiiTrial_460"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_MilestonePaymentsUponDosingFirstPatientInFirstPhaseIiiTrial" xlink:label="loc_drug_MilestonePaymentsUponDosingFirstPatientInFirstPhaseIiiTrial_461"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_MilestonePaymentsUponDosingFirstPatientInFirstPhaseIiiTrial" xlink:label="loc_drug_MilestonePaymentsUponDosingFirstPatientInFirstPhaseIiiTrial_462"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_MilestonePaymentsUponDosingFirstPatientInFirstPhaseIiTrial" xlink:label="loc_drug_MilestonePaymentsUponDosingFirstPatientInFirstPhaseIiTrial_463"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_MilestonePaymentsUponDosingFirstPatientInFirstPhaseIiTrial" xlink:label="loc_drug_MilestonePaymentsUponDosingFirstPatientInFirstPhaseIiTrial_464"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_MilestonePaymentsUponDosingFirstPatientInFirstPhaseIiTrial" xlink:label="loc_drug_MilestonePaymentsUponDosingFirstPatientInFirstPhaseIiTrial_465"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_MilestonePaymentsUponDosingFirstPatientInPhaseITrial" xlink:label="loc_drug_MilestonePaymentsUponDosingFirstPatientInPhaseITrial_466"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_MilestonePaymentsUponDosingFirstPatientInPhaseITrial" xlink:label="loc_drug_MilestonePaymentsUponDosingFirstPatientInPhaseITrial_467"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_MilestonePaymentsUponDosingFirstPatientInPhaseITrial" xlink:label="loc_drug_MilestonePaymentsUponDosingFirstPatientInPhaseITrial_468"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_MilestonePaymentsUponFirstCommercialSaleOfClinical" xlink:label="loc_drug_MilestonePaymentsUponFirstCommercialSaleOfClinical_469"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_MilestonePaymentsUponFirstCommercialSaleOfClinical" xlink:label="loc_drug_MilestonePaymentsUponFirstCommercialSaleOfClinical_470"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_MilestonePaymentsUponFirstCommercialSaleOfClinical" xlink:label="loc_drug_MilestonePaymentsUponFirstCommercialSaleOfClinical_471"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_MinimumDailyVolumeWeightedAverageTradingSharePrice" xlink:label="loc_drug_MinimumDailyVolumeWeightedAverageTradingSharePrice_472"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_MinimumDailyVolumeWeightedAverageTradingSharePrice" xlink:label="loc_drug_MinimumDailyVolumeWeightedAverageTradingSharePrice_473"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_MinimumDailyVolumeWeightedAverageTradingSharePrice" xlink:label="loc_drug_MinimumDailyVolumeWeightedAverageTradingSharePrice_474"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_MonthlyBaseRent" xlink:label="loc_drug_MonthlyBaseRent_475"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_MonthlyBaseRent" xlink:label="loc_drug_MonthlyBaseRent_476"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_MonthlyBaseRent" xlink:label="loc_drug_MonthlyBaseRent_477"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_MonthlyFeeAuthorizedByBoardOfDirectors" xlink:label="loc_drug_MonthlyFeeAuthorizedByBoardOfDirectors_478"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_MonthlyFeeAuthorizedByBoardOfDirectors" xlink:label="loc_drug_MonthlyFeeAuthorizedByBoardOfDirectors_479"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_MonthlyFeeAuthorizedByBoardOfDirectors" xlink:label="loc_drug_MonthlyFeeAuthorizedByBoardOfDirectors_480"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_NatureAndContinuanceOfOperationsAbstract" xlink:label="loc_drug_NatureAndContinuanceOfOperationsAbstract_481"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_NinthTrancheMember" xlink:label="loc_drug_NinthTrancheMember_482"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_NinthTrancheMember" xlink:label="loc_drug_NinthTrancheMember_483"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_NinthTrancheMember" xlink:label="loc_drug_NinthTrancheMember_484"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_NonBrokeredPrivatePlacementMember" xlink:label="loc_drug_NonBrokeredPrivatePlacementMember_485"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_NonBrokeredPrivatePlacementMember" xlink:label="loc_drug_NonBrokeredPrivatePlacementMember_486"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_NonBrokeredPrivatePlacementMember" xlink:label="loc_drug_NonBrokeredPrivatePlacementMember_487"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_NonCapitalLossCarryForwards" xlink:label="loc_drug_NonCapitalLossCarryForwards_488"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_NonCapitalLossCarryForwards" xlink:label="loc_drug_NonCapitalLossCarryForwards_489"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_NonCapitalLossCarryForwards" xlink:label="loc_drug_NonCapitalLossCarryForwards_490"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_NonCapitalLossCarryForwards" xlink:label="loc_drug_NonCapitalLossCarryForwards_491"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_NonCapitalLossCarryForwardsYearOfExpiry" xlink:label="loc_drug_NonCapitalLossCarryForwardsYearOfExpiry_492"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_NonCapitalLossCarryForwardsYearOfExpiry" xlink:label="loc_drug_NonCapitalLossCarryForwardsYearOfExpiry_493"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_NonCapitalLossCarryForwardsYearOfExpiry" xlink:label="loc_drug_NonCapitalLossCarryForwardsYearOfExpiry_494"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_NonCapitalLossCarryForwardsYearOfOriginAxis" xlink:label="loc_drug_NonCapitalLossCarryForwardsYearOfOriginAxis_495"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_NonCapitalLossCarryForwardsYearOfOriginAxis" xlink:label="loc_drug_NonCapitalLossCarryForwardsYearOfOriginAxis_496"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_NonCapitalLossCarryForwardsYearOfOriginDomain" xlink:label="loc_drug_NonCapitalLossCarryForwardsYearOfOriginDomain_497"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_NonCapitalLossCarryForwardsYearOfOriginDomain" xlink:label="loc_drug_NonCapitalLossCarryForwardsYearOfOriginDomain_498"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_NonRefundableOptionFeesPaid" xlink:label="loc_drug_NonRefundableOptionFeesPaid_499"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_NonRefundableOptionFeesPaid" xlink:label="loc_drug_NonRefundableOptionFeesPaid_500"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_NonRefundableOptionFeesPaid" xlink:label="loc_drug_NonRefundableOptionFeesPaid_501"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_NovelDrugDevelopmentMember" xlink:label="loc_drug_NovelDrugDevelopmentMember_502"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_NovelDrugDevelopmentMember" xlink:label="loc_drug_NovelDrugDevelopmentMember_503"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_NovelDrugDevelopmentMember" xlink:label="loc_drug_NovelDrugDevelopmentMember_504"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_NumberOfCommonSharesCalledByWarrants" xlink:label="loc_drug_NumberOfCommonSharesCalledByWarrants_505"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_NumberOfCommonSharesCalledByWarrants" xlink:label="loc_drug_NumberOfCommonSharesCalledByWarrants_506"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_NumberOfCommonSharesCalledByWarrants" xlink:label="loc_drug_NumberOfCommonSharesCalledByWarrants_507"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_NumberOfCommonSharesDepositedToBeHeldInEscrow" xlink:label="loc_drug_NumberOfCommonSharesDepositedToBeHeldInEscrow_508"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_NumberOfCommonSharesDepositedToBeHeldInEscrow" xlink:label="loc_drug_NumberOfCommonSharesDepositedToBeHeldInEscrow_509"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_NumberOfCommonSharesDepositedToBeHeldInEscrow" xlink:label="loc_drug_NumberOfCommonSharesDepositedToBeHeldInEscrow_510"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_NumberOfCommonSharesSubscribed" xlink:label="loc_drug_NumberOfCommonSharesSubscribed_511"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_NumberOfCommonSharesSubscribed" xlink:label="loc_drug_NumberOfCommonSharesSubscribed_512"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_NumberOfCommonSharesSubscribed" xlink:label="loc_drug_NumberOfCommonSharesSubscribed_513"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_NumberOfInstrumentsOtherEquityInstrumentsIssued" xlink:label="loc_drug_NumberOfInstrumentsOtherEquityInstrumentsIssued_514"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_NumberOfInstrumentsOtherEquityInstrumentsIssued" xlink:label="loc_drug_NumberOfInstrumentsOtherEquityInstrumentsIssued_515"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_NumberOfIssuedWarrantsRescinded" xlink:label="loc_drug_NumberOfIssuedWarrantsRescinded_516"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_NumberOfIssuedWarrantsRescinded" xlink:label="loc_drug_NumberOfIssuedWarrantsRescinded_517"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_NumberOfIssuedWarrantsRescinded" xlink:label="loc_drug_NumberOfIssuedWarrantsRescinded_518"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_NumberOfRestrictedStockIssuedForCompensation" xlink:label="loc_drug_NumberOfRestrictedStockIssuedForCompensation_519"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_NumberOfRestrictedStockIssuedForCompensation" xlink:label="loc_drug_NumberOfRestrictedStockIssuedForCompensation_520"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_NumberOfRestrictedStockIssuedForCompensation" xlink:label="loc_drug_NumberOfRestrictedStockIssuedForCompensation_521"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_NumberOfShareListed" xlink:label="loc_drug_NumberOfShareListed_522"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_NumberOfShareListed" xlink:label="loc_drug_NumberOfShareListed_523"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_NumberOfShareListed" xlink:label="loc_drug_NumberOfShareListed_524"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_NumberOfShareOptionsCancelledInShareBasedPaymentArrangement" xlink:label="loc_drug_NumberOfShareOptionsCancelledInShareBasedPaymentArrangement_525"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_NumberOfShareOptionsCancelledInShareBasedPaymentArrangement" xlink:label="loc_drug_NumberOfShareOptionsCancelledInShareBasedPaymentArrangement_526"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_NumberOfSharesIssuedByRelatedParty" xlink:label="loc_drug_NumberOfSharesIssuedByRelatedParty_527"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_NumberOfSharesIssuedByRelatedParty" xlink:label="loc_drug_NumberOfSharesIssuedByRelatedParty_528"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_NumberOfSharesIssuedByRelatedParty" xlink:label="loc_drug_NumberOfSharesIssuedByRelatedParty_529"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_NumberOfUnitsIssued" xlink:label="loc_drug_NumberOfUnitsIssued_530"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_NumberOfUnitsIssued" xlink:label="loc_drug_NumberOfUnitsIssued_531"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_NumberOfUnitsIssued" xlink:label="loc_drug_NumberOfUnitsIssued_532"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_NumberOfWarrantsDeemedToBeExercised" xlink:label="loc_drug_NumberOfWarrantsDeemedToBeExercised_533"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_NumberOfWarrantsDeemedToBeExercised" xlink:label="loc_drug_NumberOfWarrantsDeemedToBeExercised_534"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_NumberOfWarrantsDeemedToBeExercised" xlink:label="loc_drug_NumberOfWarrantsDeemedToBeExercised_535"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_NumberOfWarrantsDepositedToBeHeldInEscrow" xlink:label="loc_drug_NumberOfWarrantsDepositedToBeHeldInEscrow_536"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_NumberOfWarrantsDepositedToBeHeldInEscrow" xlink:label="loc_drug_NumberOfWarrantsDepositedToBeHeldInEscrow_537"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_NumberOfWarrantsDepositedToBeHeldInEscrow" xlink:label="loc_drug_NumberOfWarrantsDepositedToBeHeldInEscrow_538"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_NumberOfWarrantsExercised" xlink:label="loc_drug_NumberOfWarrantsExercised_539"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_NumberOfWarrantsExercised" xlink:label="loc_drug_NumberOfWarrantsExercised_540"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_NumberOfWarrantsExercised" xlink:label="loc_drug_NumberOfWarrantsExercised_541"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_NumberOfWarrantsExercised" xlink:label="loc_drug_NumberOfWarrantsExercised_542"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_NumberOfWarrantsExercised" xlink:label="loc_drug_NumberOfWarrantsExercised_543"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_NumberOfWarrantsIssued" xlink:label="loc_drug_NumberOfWarrantsIssued_544"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_NumberOfWarrantsIssued" xlink:label="loc_drug_NumberOfWarrantsIssued_545"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_NumberOfWarrantsIssued" xlink:label="loc_drug_NumberOfWarrantsIssued_546"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_NumberOfWarrantsIssuedToBroker" xlink:label="loc_drug_NumberOfWarrantsIssuedToBroker_547"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_NumberOfWarrantsIssuedToBroker" xlink:label="loc_drug_NumberOfWarrantsIssuedToBroker_548"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_NumberOfWarrantsIssuedToBroker" xlink:label="loc_drug_NumberOfWarrantsIssuedToBroker_549"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_NumberOfWarrantsOutstanding" xlink:label="loc_drug_NumberOfWarrantsOutstanding_550"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_NumberOfWarrantsOutstanding" xlink:label="loc_drug_NumberOfWarrantsOutstanding_551"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_NumberOfWarrantsOutstanding" xlink:label="loc_drug_NumberOfWarrantsOutstanding_552"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_NumberOfWarrantsOutstanding" xlink:label="loc_drug_NumberOfWarrantsOutstanding_553"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_NumberOfWarrantsOutstanding" xlink:label="loc_drug_NumberOfWarrantsOutstanding_554"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_NumberOfWarrantsOutstanding" xlink:label="loc_drug_NumberOfWarrantsOutstanding_555"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_NumberOfWarrantsOutstandingInShareBasedPaymentArrangement" xlink:label="loc_drug_NumberOfWarrantsOutstandingInShareBasedPaymentArrangement_556"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_NumberOfWarrantsOutstandingInShareBasedPaymentArrangement" xlink:label="loc_drug_NumberOfWarrantsOutstandingInShareBasedPaymentArrangement_557"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_NumberOfWarrantsOutstandingInShareBasedPaymentArrangement" xlink:label="loc_drug_NumberOfWarrantsOutstandingInShareBasedPaymentArrangement_558"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_NumberOfWarrantsOutstandingInShareBasedPaymentArrangement" xlink:label="loc_drug_NumberOfWarrantsOutstandingInShareBasedPaymentArrangement_559"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_NumberOfWarrantsOutstandingInShareBasedPaymentArrangement" xlink:label="loc_drug_NumberOfWarrantsOutstandingInShareBasedPaymentArrangement_560"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_NumberOfWarrantsOutstandingInShareBasedPaymentArrangement" xlink:label="loc_drug_NumberOfWarrantsOutstandingInShareBasedPaymentArrangement_561"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_OptionAgreementMember" xlink:label="loc_drug_OptionAgreementMember_562"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_OptionAgreementMember" xlink:label="loc_drug_OptionAgreementMember_563"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_OptionFeesPaid" xlink:label="loc_drug_OptionFeesPaid_564"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_OptionFeesPaid" xlink:label="loc_drug_OptionFeesPaid_565"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_OptionFeesPaid" xlink:label="loc_drug_OptionFeesPaid_566"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_PaymentsForFindersFees" xlink:label="loc_drug_PaymentsForFindersFees_567"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_PaymentsForFindersFees" xlink:label="loc_drug_PaymentsForFindersFees_568"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_PaymentsForFindersFees" xlink:label="loc_drug_PaymentsForFindersFees_569"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_PercentageOfForeignCurrencyFluctuationInUsDollarAgainstCanadianDollar" xlink:label="loc_drug_PercentageOfForeignCurrencyFluctuationInUsDollarAgainstCanadianDollar_570"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_PercentageOfForeignCurrencyFluctuationInUsDollarAgainstCanadianDollar" xlink:label="loc_drug_PercentageOfForeignCurrencyFluctuationInUsDollarAgainstCanadianDollar_571"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_PercentageOfForeignCurrencyFluctuationInUsDollarAgainstCanadianDollar" xlink:label="loc_drug_PercentageOfForeignCurrencyFluctuationInUsDollarAgainstCanadianDollar_572"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_PercentageOfNetEquityProceedsReceivedFromThreeInvestors" xlink:label="loc_drug_PercentageOfNetEquityProceedsReceivedFromThreeInvestors_573"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_PercentageOfNetEquityProceedsReceivedFromThreeInvestors" xlink:label="loc_drug_PercentageOfNetEquityProceedsReceivedFromThreeInvestors_574"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_PercentageOfNetEquityProceedsReceivedFromThreeInvestors" xlink:label="loc_drug_PercentageOfNetEquityProceedsReceivedFromThreeInvestors_575"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_PercentageOfOutstandingSharesAuthorizedUnderStockOptionPlan" xlink:label="loc_drug_PercentageOfOutstandingSharesAuthorizedUnderStockOptionPlan_576"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_PercentageOfOutstandingSharesAuthorizedUnderStockOptionPlan" xlink:label="loc_drug_PercentageOfOutstandingSharesAuthorizedUnderStockOptionPlan_577"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_PercentageOfOutstandingSharesAuthorizedUnderStockOptionPlan" xlink:label="loc_drug_PercentageOfOutstandingSharesAuthorizedUnderStockOptionPlan_578"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_PercentageOfRoyaltiesOnNetSales" xlink:label="loc_drug_PercentageOfRoyaltiesOnNetSales_579"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_PercentageOfRoyaltiesOnNetSales" xlink:label="loc_drug_PercentageOfRoyaltiesOnNetSales_580"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_PercentageOfRoyaltiesOnNetSales" xlink:label="loc_drug_PercentageOfRoyaltiesOnNetSales_581"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_PercentageOfRoyaltiesOnNetSalesOver2Billion" xlink:label="loc_drug_PercentageOfRoyaltiesOnNetSalesOver2Billion_582"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_PercentageOfRoyaltiesOnNetSalesOver2Billion" xlink:label="loc_drug_PercentageOfRoyaltiesOnNetSalesOver2Billion_583"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_PercentageOfRoyaltiesOnNetSalesOver2Billion" xlink:label="loc_drug_PercentageOfRoyaltiesOnNetSalesOver2Billion_584"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_PercentageOfRoyaltiesOnNetSalesUnder1Billion" xlink:label="loc_drug_PercentageOfRoyaltiesOnNetSalesUnder1Billion_585"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_PercentageOfRoyaltiesOnNetSalesUnder1Billion" xlink:label="loc_drug_PercentageOfRoyaltiesOnNetSalesUnder1Billion_586"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_PercentageOfRoyaltiesOnNetSalesUnder1Billion" xlink:label="loc_drug_PercentageOfRoyaltiesOnNetSalesUnder1Billion_587"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_PercentageOfStockOptionPlanAllowsBoardOfDirectorsToIssue" xlink:label="loc_drug_PercentageOfStockOptionPlanAllowsBoardOfDirectorsToIssue_588"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_PercentageOfStockOptionPlanAllowsBoardOfDirectorsToIssue" xlink:label="loc_drug_PercentageOfStockOptionPlanAllowsBoardOfDirectorsToIssue_589"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_PercentageOfStockOptionPlanAllowsBoardOfDirectorsToIssue" xlink:label="loc_drug_PercentageOfStockOptionPlanAllowsBoardOfDirectorsToIssue_590"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_PercentageOfStockOptionShareGranted" xlink:label="loc_drug_PercentageOfStockOptionShareGranted_591"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_PercentageOfStockOptionShareGranted" xlink:label="loc_drug_PercentageOfStockOptionShareGranted_592"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_PercentageOfStockOptionShareGranted" xlink:label="loc_drug_PercentageOfStockOptionShareGranted_593"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_PriorToSublicensingAgreementsMember" xlink:label="loc_drug_PriorToSublicensingAgreementsMember_594"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_PriorToSublicensingAgreementsMember" xlink:label="loc_drug_PriorToSublicensingAgreementsMember_595"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_PriorToSublicensingAgreementsMember" xlink:label="loc_drug_PriorToSublicensingAgreementsMember_596"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_ProceedsForWarrantsIssued" xlink:label="loc_drug_ProceedsForWarrantsIssued_597"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_ProceedsForWarrantsIssued" xlink:label="loc_drug_ProceedsForWarrantsIssued_598"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_ProceedsForWarrantsIssued" xlink:label="loc_drug_ProceedsForWarrantsIssued_599"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_ProceedsFromExerciseOfSpecialWarrants" xlink:label="loc_drug_ProceedsFromExerciseOfSpecialWarrants_600"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_ProceedsFromExerciseOfSpecialWarrants" xlink:label="loc_drug_ProceedsFromExerciseOfSpecialWarrants_601"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_ProceedsFromExerciseOfSpecialWarrants" xlink:label="loc_drug_ProceedsFromExerciseOfSpecialWarrants_602"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_ProceedsFromIssuingWarrants" xlink:label="loc_drug_ProceedsFromIssuingWarrants_603"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_ProceedsFromIssuingWarrants" xlink:label="loc_drug_ProceedsFromIssuingWarrants_604"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_ProceedsFromIssuingWarrants" xlink:label="loc_drug_ProceedsFromIssuingWarrants_605"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_ProceedsFromWarrantsExercise" xlink:label="loc_drug_ProceedsFromWarrantsExercise_606"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_ProceedsFromWarrantsExercise" xlink:label="loc_drug_ProceedsFromWarrantsExercise_607"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_ProceedsFromWarrantsExercise" xlink:label="loc_drug_ProceedsFromWarrantsExercise_608"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_ProcessingFees" xlink:label="loc_drug_ProcessingFees_609"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_ProcessingFees" xlink:label="loc_drug_ProcessingFees_610"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_ProcessingFees" xlink:label="loc_drug_ProcessingFees_611"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_ProfessionalFeesMember" xlink:label="loc_drug_ProfessionalFeesMember_612"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_ProfessionalFeesMember" xlink:label="loc_drug_ProfessionalFeesMember_613"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_ProfessionalFeesMember" xlink:label="loc_drug_ProfessionalFeesMember_614"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_PsilocybinlabsLtdMember" xlink:label="loc_drug_PsilocybinlabsLtdMember_615"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_PsilocybinlabsLtdMember" xlink:label="loc_drug_PsilocybinlabsLtdMember_616"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_RefundFromIssuedWarrantsRescinded" xlink:label="loc_drug_RefundFromIssuedWarrantsRescinded_617"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_RefundFromIssuedWarrantsRescinded" xlink:label="loc_drug_RefundFromIssuedWarrantsRescinded_618"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_RefundFromIssuedWarrantsRescinded" xlink:label="loc_drug_RefundFromIssuedWarrantsRescinded_619"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_RefundOfSpecialWarrantsProceeds" xlink:label="loc_drug_RefundOfSpecialWarrantsProceeds_620"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_RefundOfSpecialWarrantsProceeds" xlink:label="loc_drug_RefundOfSpecialWarrantsProceeds_621"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_RefundOfSpecialWarrantsProceeds" xlink:label="loc_drug_RefundOfSpecialWarrantsProceeds_622"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_RefundOfSpecialWarrantsProceeds" xlink:label="loc_drug_RefundOfSpecialWarrantsProceeds_623"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_RegulatoryAndFilingExpenses" xlink:label="loc_drug_RegulatoryAndFilingExpenses_624"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_RegulatoryAndFilingExpenses" xlink:label="loc_drug_RegulatoryAndFilingExpenses_625"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_RegulatoryAndFilingExpenses" xlink:label="loc_drug_RegulatoryAndFilingExpenses_626"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_RelatedPartyContractsMember" xlink:label="loc_drug_RelatedPartyContractsMember_627"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_RelatedPartyContractsMember" xlink:label="loc_drug_RelatedPartyContractsMember_628"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_ResearchAndDevelopmentAbstract" xlink:label="loc_drug_ResearchAndDevelopmentAbstract_629"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_ResearchAndDevelopmentLineItems" xlink:label="loc_drug_ResearchAndDevelopmentLineItems_630"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_ResearchAndDevelopmentMember" xlink:label="loc_drug_ResearchAndDevelopmentMember_631"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_ResearchAndDevelopmentMember" xlink:label="loc_drug_ResearchAndDevelopmentMember_632"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_ResearchAndDevelopmentMember" xlink:label="loc_drug_ResearchAndDevelopmentMember_633"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_ResearchDevelopmentTable" xlink:label="loc_drug_ResearchDevelopmentTable_634"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_RestrictedShareUnitMember" xlink:label="loc_drug_RestrictedShareUnitMember_635"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_RestrictedShareUnitMember" xlink:label="loc_drug_RestrictedShareUnitMember_636"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_RestrictedShareUnitMember" xlink:label="loc_drug_RestrictedShareUnitMember_637"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_RoyaltiesOnNetSales" xlink:label="loc_drug_RoyaltiesOnNetSales_638"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_RoyaltiesOnNetSales" xlink:label="loc_drug_RoyaltiesOnNetSales_639"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_RoyaltiesOnNetSales" xlink:label="loc_drug_RoyaltiesOnNetSales_640"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_SalaryAndSubcontractorsMember" xlink:label="loc_drug_SalaryAndSubcontractorsMember_641"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_SalaryAndSubcontractorsMember" xlink:label="loc_drug_SalaryAndSubcontractorsMember_642"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_SalaryAndSubcontractorsMember" xlink:label="loc_drug_SalaryAndSubcontractorsMember_643"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_ScientificAdvisoryBoardAgreementsMember" xlink:label="loc_drug_ScientificAdvisoryBoardAgreementsMember_644"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_ScientificAdvisoryBoardAgreementsMember" xlink:label="loc_drug_ScientificAdvisoryBoardAgreementsMember_645"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_SecondAnniversaryOfGrantDateMember" xlink:label="loc_drug_SecondAnniversaryOfGrantDateMember_646"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_SecondAnniversaryOfGrantDateMember" xlink:label="loc_drug_SecondAnniversaryOfGrantDateMember_647"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_SecondTrancheMember" xlink:label="loc_drug_SecondTrancheMember_648"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_SecondTrancheMember" xlink:label="loc_drug_SecondTrancheMember_649"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_SecondTrancheMember" xlink:label="loc_drug_SecondTrancheMember_650"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_SecondTrancheMember" xlink:label="loc_drug_SecondTrancheMember_651"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_SecondTrancheOfNonBrokeredPrivatePlacementMember" xlink:label="loc_drug_SecondTrancheOfNonBrokeredPrivatePlacementMember_652"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_SecondTrancheOfNonBrokeredPrivatePlacementMember" xlink:label="loc_drug_SecondTrancheOfNonBrokeredPrivatePlacementMember_653"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_SecondTrancheOfNonBrokeredPrivatePlacementMember" xlink:label="loc_drug_SecondTrancheOfNonBrokeredPrivatePlacementMember_654"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_SeptemberTwentyOneTwoZeroTwoFourMember" xlink:label="loc_drug_SeptemberTwentyOneTwoZeroTwoFourMember_655"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_SeptemberTwentyOneTwoZeroTwoFourMember" xlink:label="loc_drug_SeptemberTwentyOneTwoZeroTwoFourMember_656"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_SeptemberTwentyOneTwoZeroTwoFourMember" xlink:label="loc_drug_SeptemberTwentyOneTwoZeroTwoFourMember_657"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_SeptemberTwentyOneTwoZeroTwoTwoMember" xlink:label="loc_drug_SeptemberTwentyOneTwoZeroTwoTwoMember_658"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_SeptemberTwentyOneTwoZeroTwoTwoMember" xlink:label="loc_drug_SeptemberTwentyOneTwoZeroTwoTwoMember_659"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_SeventhTrancheMember" xlink:label="loc_drug_SeventhTrancheMember_660"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_SeventhTrancheMember" xlink:label="loc_drug_SeventhTrancheMember_661"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_SeventhTrancheMember" xlink:label="loc_drug_SeventhTrancheMember_662"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_ShareBasedCompensationMember" xlink:label="loc_drug_ShareBasedCompensationMember_663"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_ShareBasedCompensationMember" xlink:label="loc_drug_ShareBasedCompensationMember_664"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_ShareBasedCompensationMember" xlink:label="loc_drug_ShareBasedCompensationMember_665"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_ShareExchangeAndAssignmentAbstract" xlink:label="loc_drug_ShareExchangeAndAssignmentAbstract_666"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_ShareExchangeAndAssignmentLineItems" xlink:label="loc_drug_ShareExchangeAndAssignmentLineItems_667"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_ShareExchangeAndAssignmentLineItems" xlink:label="loc_drug_ShareExchangeAndAssignmentLineItems_668"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_ShareIssueCostsIncludedInAccountsPayable" xlink:label="loc_drug_ShareIssueCostsIncludedInAccountsPayable_669"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_ShareIssueCostsIncludedInAccountsPayable" xlink:label="loc_drug_ShareIssueCostsIncludedInAccountsPayable_670"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_ShareIssueCostsIncludedInAccountsPayable" xlink:label="loc_drug_ShareIssueCostsIncludedInAccountsPayable_671"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_SharePriceOnGrantDateOfOtherEquityInstruments" xlink:label="loc_drug_SharePriceOnGrantDateOfOtherEquityInstruments_672"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_SharePriceOnGrantDateOfOtherEquityInstruments" xlink:label="loc_drug_SharePriceOnGrantDateOfOtherEquityInstruments_673"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_SharePriceOnGrantDateOfOtherEquityInstruments" xlink:label="loc_drug_SharePriceOnGrantDateOfOtherEquityInstruments_674"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_SigningFee" xlink:label="loc_drug_SigningFee_675"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_SigningFee" xlink:label="loc_drug_SigningFee_676"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_SigningFee" xlink:label="loc_drug_SigningFee_677"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_SigningFeeNetOfOptionFeesPaid" xlink:label="loc_drug_SigningFeeNetOfOptionFeesPaid_678"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_SigningFeeNetOfOptionFeesPaid" xlink:label="loc_drug_SigningFeeNetOfOptionFeesPaid_679"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_SigningFeeNetOfOptionFeesPaid" xlink:label="loc_drug_SigningFeeNetOfOptionFeesPaid_680"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_SigningFeeSharesIssued" xlink:label="loc_drug_SigningFeeSharesIssued_681"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_SigningFeeSharesIssued" xlink:label="loc_drug_SigningFeeSharesIssued_682"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_SigningFeeSharesIssued" xlink:label="loc_drug_SigningFeeSharesIssued_683"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_SixMonthAnniversaryGrantDateMember" xlink:label="loc_drug_SixMonthAnniversaryGrantDateMember_684"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_SixMonthAnniversaryGrantDateMember" xlink:label="loc_drug_SixMonthAnniversaryGrantDateMember_685"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_SixthTrancheMember" xlink:label="loc_drug_SixthTrancheMember_686"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_SixthTrancheMember" xlink:label="loc_drug_SixthTrancheMember_687"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_SixthTrancheMember" xlink:label="loc_drug_SixthTrancheMember_688"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_SpecialWarrantsMember" xlink:label="loc_drug_SpecialWarrantsMember_689"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_SpecialWarrantsMember" xlink:label="loc_drug_SpecialWarrantsMember_690"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_StatementOfComplianceAndBasisOfPreparationAbstract" xlink:label="loc_drug_StatementOfComplianceAndBasisOfPreparationAbstract_691"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_StockOptionAxis" xlink:label="loc_drug_StockOptionAxis_692"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_StockOptionAxis" xlink:label="loc_drug_StockOptionAxis_693"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_StockOptionDomain" xlink:label="loc_drug_StockOptionDomain_694"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_StockOptionDomain" xlink:label="loc_drug_StockOptionDomain_695"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_StockOptionsFourMember" xlink:label="loc_drug_StockOptionsFourMember_696"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_StockOptionsFourMember" xlink:label="loc_drug_StockOptionsFourMember_697"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_StockOptionsMember" xlink:label="loc_drug_StockOptionsMember_698"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_StockOptionsMember" xlink:label="loc_drug_StockOptionsMember_699"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_StockOptionsMember" xlink:label="loc_drug_StockOptionsMember_700"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_StockOptionsOneMember" xlink:label="loc_drug_StockOptionsOneMember_701"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_StockOptionsOneMember" xlink:label="loc_drug_StockOptionsOneMember_702"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_StockOptionsThreeMember" xlink:label="loc_drug_StockOptionsThreeMember_703"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_StockOptionsThreeMember" xlink:label="loc_drug_StockOptionsThreeMember_704"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_StockOptionsTwoMember" xlink:label="loc_drug_StockOptionsTwoMember_705"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_StockOptionsTwoMember" xlink:label="loc_drug_StockOptionsTwoMember_706"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_SubscriptionAgreementsMember" xlink:label="loc_drug_SubscriptionAgreementsMember_707"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_SubscriptionAgreementsMember" xlink:label="loc_drug_SubscriptionAgreementsMember_708"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_SubscriptionReceivableMember" xlink:label="loc_drug_SubscriptionReceivableMember_709"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_SubscriptionReceivableMember" xlink:label="loc_drug_SubscriptionReceivableMember_710"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_SubscriptionReceivableMember" xlink:label="loc_drug_SubscriptionReceivableMember_711"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_SubscriptionReceivedMember" xlink:label="loc_drug_SubscriptionReceivedMember_712"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_SubscriptionReceivedMember" xlink:label="loc_drug_SubscriptionReceivedMember_713"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_SubscriptionReceivedMember" xlink:label="loc_drug_SubscriptionReceivedMember_714"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_SubscriptionsReceivable" xlink:label="loc_drug_SubscriptionsReceivable_715"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_SubscriptionsReceivable" xlink:label="loc_drug_SubscriptionsReceivable_716"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_SubscriptionsReceivable" xlink:label="loc_drug_SubscriptionsReceivable_717"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_SubscriptionsReceivable" xlink:label="loc_drug_SubscriptionsReceivable_718"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_SubscriptionsReceived" xlink:label="loc_drug_SubscriptionsReceived_719"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_SubscriptionsReceived" xlink:label="loc_drug_SubscriptionsReceived_720"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_SubscriptionsReceived" xlink:label="loc_drug_SubscriptionsReceived_721"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_SubsequentEventsMember" xlink:label="loc_drug_SubsequentEventsMember_722"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_SubsequentEventsMember" xlink:label="loc_drug_SubsequentEventsMember_723"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_SupplementaryInformationAbstract" xlink:label="loc_drug_SupplementaryInformationAbstract_724"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_SupplementaryInformationAbstract" xlink:label="loc_drug_SupplementaryInformationAbstract_725"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_SupplementaryInformationAbstract" xlink:label="loc_drug_SupplementaryInformationAbstract_726"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_TaxAuthorityOfAustraliaMember" xlink:label="loc_drug_TaxAuthorityOfAustraliaMember_727"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_TaxAuthorityOfAustraliaMember" xlink:label="loc_drug_TaxAuthorityOfAustraliaMember_728"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_TaxAuthorityOfAustraliaMember" xlink:label="loc_drug_TaxAuthorityOfAustraliaMember_729"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_TaxAuthorityOfCanadaMember" xlink:label="loc_drug_TaxAuthorityOfCanadaMember_730"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_TaxAuthorityOfCanadaMember" xlink:label="loc_drug_TaxAuthorityOfCanadaMember_731"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_TaxAuthorityOfUnitedStatesMember" xlink:label="loc_drug_TaxAuthorityOfUnitedStatesMember_732"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_TaxAuthorityOfUnitedStatesMember" xlink:label="loc_drug_TaxAuthorityOfUnitedStatesMember_733"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_TaxAuthorityOfUnitedStatesMember" xlink:label="loc_drug_TaxAuthorityOfUnitedStatesMember_734"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_TaxEffectOfChangeInDeferredTaxAssetsNotRecognized" xlink:label="loc_drug_TaxEffectOfChangeInDeferredTaxAssetsNotRecognized_735"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_TaxEffectOfChangeInDeferredTaxAssetsNotRecognized" xlink:label="loc_drug_TaxEffectOfChangeInDeferredTaxAssetsNotRecognized_736"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_TaxEffectOfChangeInDeferredTaxAssetsNotRecognized" xlink:label="loc_drug_TaxEffectOfChangeInDeferredTaxAssetsNotRecognized_737"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_TaxEffectOfDeductibleAndNotDeductibleItems" xlink:label="loc_drug_TaxEffectOfDeductibleAndNotDeductibleItems_738"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_TaxEffectOfDeductibleAndNotDeductibleItems" xlink:label="loc_drug_TaxEffectOfDeductibleAndNotDeductibleItems_739"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_TaxEffectOfDeductibleAndNotDeductibleItems" xlink:label="loc_drug_TaxEffectOfDeductibleAndNotDeductibleItems_740"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_TaxEffectOfDeductibleAndNotDeductibleItems" xlink:label="loc_drug_TaxEffectOfDeductibleAndNotDeductibleItems_741"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_TaxRateEffectOfDeferredTaxAssetsNotRecognized" xlink:label="loc_drug_TaxRateEffectOfDeferredTaxAssetsNotRecognized_742"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_TaxRateEffectOfDeferredTaxAssetsNotRecognized" xlink:label="loc_drug_TaxRateEffectOfDeferredTaxAssetsNotRecognized_743"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_TaxRateEffectOfDeferredTaxAssetsNotRecognized" xlink:label="loc_drug_TaxRateEffectOfDeferredTaxAssetsNotRecognized_744"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_TaxYearOfOrigin2019Member" xlink:label="loc_drug_TaxYearOfOrigin2019Member_745"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_TaxYearOfOrigin2019Member" xlink:label="loc_drug_TaxYearOfOrigin2019Member_746"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_TaxYearOfOrigin2019Member" xlink:label="loc_drug_TaxYearOfOrigin2019Member_747"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_TaxYearOfOrigin2020Member" xlink:label="loc_drug_TaxYearOfOrigin2020Member_748"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_TaxYearOfOrigin2020Member" xlink:label="loc_drug_TaxYearOfOrigin2020Member_749"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_TaxYearOfOrigin2020Member" xlink:label="loc_drug_TaxYearOfOrigin2020Member_750"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_TaxYearOfOrigin2021Member" xlink:label="loc_drug_TaxYearOfOrigin2021Member_751"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_TaxYearOfOrigin2021Member" xlink:label="loc_drug_TaxYearOfOrigin2021Member_752"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_TaxYearOfOrigin2021Member" xlink:label="loc_drug_TaxYearOfOrigin2021Member_753"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_TemporaryDifferencesIntangibleAssetsMember" xlink:label="loc_drug_TemporaryDifferencesIntangibleAssetsMember_754"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_TemporaryDifferencesIntangibleAssetsMember" xlink:label="loc_drug_TemporaryDifferencesIntangibleAssetsMember_755"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_TemporaryDifferencesIntangibleAssetsMember" xlink:label="loc_drug_TemporaryDifferencesIntangibleAssetsMember_756"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_TemporaryDifferencesNonCapitalLossesMember" xlink:label="loc_drug_TemporaryDifferencesNonCapitalLossesMember_757"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_TemporaryDifferencesNonCapitalLossesMember" xlink:label="loc_drug_TemporaryDifferencesNonCapitalLossesMember_758"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_TemporaryDifferencesNonCapitalLossesMember" xlink:label="loc_drug_TemporaryDifferencesNonCapitalLossesMember_759"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_TemporaryDifferencesShareIssueCostsMember" xlink:label="loc_drug_TemporaryDifferencesShareIssueCostsMember_760"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_TemporaryDifferencesShareIssueCostsMember" xlink:label="loc_drug_TemporaryDifferencesShareIssueCostsMember_761"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_TemporaryDifferencesShareIssueCostsMember" xlink:label="loc_drug_TemporaryDifferencesShareIssueCostsMember_762"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_TemporaryDifferencesValuationAllowanceMember" xlink:label="loc_drug_TemporaryDifferencesValuationAllowanceMember_763"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_TemporaryDifferencesValuationAllowanceMember" xlink:label="loc_drug_TemporaryDifferencesValuationAllowanceMember_764"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_TemporaryDifferencesValuationAllowanceMember" xlink:label="loc_drug_TemporaryDifferencesValuationAllowanceMember_765"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_TenthTrancheMember" xlink:label="loc_drug_TenthTrancheMember_766"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_TenthTrancheMember" xlink:label="loc_drug_TenthTrancheMember_767"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_TenthTrancheMember" xlink:label="loc_drug_TenthTrancheMember_768"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_TermOfLease" xlink:label="loc_drug_TermOfLease_769"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_TermOfLease" xlink:label="loc_drug_TermOfLease_770"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_TermOfLease" xlink:label="loc_drug_TermOfLease_771"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_TermOfWarrant" xlink:label="loc_drug_TermOfWarrant_772"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_TermOfWarrant" xlink:label="loc_drug_TermOfWarrant_773"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_TermOfWarrant" xlink:label="loc_drug_TermOfWarrant_774"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_TermsOfContract" xlink:label="loc_drug_TermsOfContract_775"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_TermsOfContract" xlink:label="loc_drug_TermsOfContract_776"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_TermsOfContract" xlink:label="loc_drug_TermsOfContract_777"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_ThirdAnniversaryOfGrantDateMember" xlink:label="loc_drug_ThirdAnniversaryOfGrantDateMember_778"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_ThirdAnniversaryOfGrantDateMember" xlink:label="loc_drug_ThirdAnniversaryOfGrantDateMember_779"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_ThirdTrancheMember" xlink:label="loc_drug_ThirdTrancheMember_780"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_ThirdTrancheMember" xlink:label="loc_drug_ThirdTrancheMember_781"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_ThirdTrancheMember" xlink:label="loc_drug_ThirdTrancheMember_782"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_ThirdTrancheMember" xlink:label="loc_drug_ThirdTrancheMember_783"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_ThirteenthTrancheMember" xlink:label="loc_drug_ThirteenthTrancheMember_784"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_ThirteenthTrancheMember" xlink:label="loc_drug_ThirteenthTrancheMember_785"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_ThirteenthTrancheMember" xlink:label="loc_drug_ThirteenthTrancheMember_786"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_ThreeConsultantsMember" xlink:label="loc_drug_ThreeConsultantsMember_787"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_ThreeConsultantsMember" xlink:label="loc_drug_ThreeConsultantsMember_788"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_ThreeInvestorsMember" xlink:label="loc_drug_ThreeInvestorsMember_789"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_ThreeInvestorsMember" xlink:label="loc_drug_ThreeInvestorsMember_790"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_ThresholdPercentageOfWarrants" xlink:label="loc_drug_ThresholdPercentageOfWarrants_791"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_ThresholdPercentageOfWarrants" xlink:label="loc_drug_ThresholdPercentageOfWarrants_792"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_ThresholdPercentageOfWarrants" xlink:label="loc_drug_ThresholdPercentageOfWarrants_793"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_TotalAnnualMinimumRoyaltiesAfterFirstCommercialSale" xlink:label="loc_drug_TotalAnnualMinimumRoyaltiesAfterFirstCommercialSale_794"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_TotalAnnualMinimumRoyaltiesAfterFirstCommercialSale" xlink:label="loc_drug_TotalAnnualMinimumRoyaltiesAfterFirstCommercialSale_795"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_TotalAnnualMinimumRoyaltiesAfterFirstCommercialSale" xlink:label="loc_drug_TotalAnnualMinimumRoyaltiesAfterFirstCommercialSale_796"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_TotalAnnualMinimumRoyaltiesCurrentYears" xlink:label="loc_drug_TotalAnnualMinimumRoyaltiesCurrentYears_797"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_TotalAnnualMinimumRoyaltiesCurrentYears" xlink:label="loc_drug_TotalAnnualMinimumRoyaltiesCurrentYears_798"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_TotalAnnualMinimumRoyaltiesCurrentYears" xlink:label="loc_drug_TotalAnnualMinimumRoyaltiesCurrentYears_799"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_TotalAnnualMinimumRoyaltiesNextYears" xlink:label="loc_drug_TotalAnnualMinimumRoyaltiesNextYears_800"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_TotalAnnualMinimumRoyaltiesNextYears" xlink:label="loc_drug_TotalAnnualMinimumRoyaltiesNextYears_801"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_TotalAnnualMinimumRoyaltiesNextYears" xlink:label="loc_drug_TotalAnnualMinimumRoyaltiesNextYears_802"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_TotalAnnualMinimumRoyaltiesYear3" xlink:label="loc_drug_TotalAnnualMinimumRoyaltiesYear3_803"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_TotalAnnualMinimumRoyaltiesYear3" xlink:label="loc_drug_TotalAnnualMinimumRoyaltiesYear3_804"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_TotalAnnualMinimumRoyaltiesYear3" xlink:label="loc_drug_TotalAnnualMinimumRoyaltiesYear3_805"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_TotalAnnualMinimumRoyaltiesYear4" xlink:label="loc_drug_TotalAnnualMinimumRoyaltiesYear4_806"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_TotalAnnualMinimumRoyaltiesYear4" xlink:label="loc_drug_TotalAnnualMinimumRoyaltiesYear4_807"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_TotalAnnualMinimumRoyaltiesYear4" xlink:label="loc_drug_TotalAnnualMinimumRoyaltiesYear4_808"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_TotalAnnualMinimumRoyaltiesYear5" xlink:label="loc_drug_TotalAnnualMinimumRoyaltiesYear5_809"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_TotalAnnualMinimumRoyaltiesYear5" xlink:label="loc_drug_TotalAnnualMinimumRoyaltiesYear5_810"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_TotalAnnualMinimumRoyaltiesYear5" xlink:label="loc_drug_TotalAnnualMinimumRoyaltiesYear5_811"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_TotalAnnualMinimumRoyaltiesYear6AndThereafter" xlink:label="loc_drug_TotalAnnualMinimumRoyaltiesYear6AndThereafter_812"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_TotalAnnualMinimumRoyaltiesYear6AndThereafter" xlink:label="loc_drug_TotalAnnualMinimumRoyaltiesYear6AndThereafter_813"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_TotalAnnualMinimumRoyaltiesYear6AndThereafter" xlink:label="loc_drug_TotalAnnualMinimumRoyaltiesYear6AndThereafter_814"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_Tranche1Member" xlink:label="loc_drug_Tranche1Member_815"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_TranchesAxis" xlink:label="loc_drug_TranchesAxis_816"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_TranchesDomain" xlink:label="loc_drug_TranchesDomain_817"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_TwelfthTrancheMember" xlink:label="loc_drug_TwelfthTrancheMember_818"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_TwelfthTrancheMember" xlink:label="loc_drug_TwelfthTrancheMember_819"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_TwelfthTrancheMember" xlink:label="loc_drug_TwelfthTrancheMember_820"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_TypeOfArrangementsAxis" xlink:label="loc_drug_TypeOfArrangementsAxis_821"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_TypeOfArrangementsAxis" xlink:label="loc_drug_TypeOfArrangementsAxis_822"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_UnderwritersFeesPaid" xlink:label="loc_drug_UnderwritersFeesPaid_823"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_UnderwritersFeesPaid" xlink:label="loc_drug_UnderwritersFeesPaid_824"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_UnderwritersMember" xlink:label="loc_drug_UnderwritersMember_825"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_UnderwritersMember" xlink:label="loc_drug_UnderwritersMember_826"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_UnitsIssuedPricePerUnit" xlink:label="loc_drug_UnitsIssuedPricePerUnit_827"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_UnitsIssuedPricePerUnit" xlink:label="loc_drug_UnitsIssuedPricePerUnit_828"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_UnitsIssuedPricePerUnit" xlink:label="loc_drug_UnitsIssuedPricePerUnit_829"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_UniversityOfIllinoisAtChicagoMember" xlink:label="loc_drug_UniversityOfIllinoisAtChicagoMember_830"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_UniversityOfIllinoisAtChicagoMember" xlink:label="loc_drug_UniversityOfIllinoisAtChicagoMember_831"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_UniversityOfTexasMedicalBranchMember" xlink:label="loc_drug_UniversityOfTexasMedicalBranchMember_832"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_UniversityOfTexasMedicalBranchMember" xlink:label="loc_drug_UniversityOfTexasMedicalBranchMember_833"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_ValueOfCommonStockSharesIssued" xlink:label="loc_drug_ValueOfCommonStockSharesIssued_834"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_ValueOfCommonStockSharesIssued" xlink:label="loc_drug_ValueOfCommonStockSharesIssued_835"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_ValueOfCommonStockSharesIssued" xlink:label="loc_drug_ValueOfCommonStockSharesIssued_836"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_ValueOfCommonStockSharesIssuedByRelatedParty" xlink:label="loc_drug_ValueOfCommonStockSharesIssuedByRelatedParty_837"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_ValueOfCommonStockSharesIssuedByRelatedParty" xlink:label="loc_drug_ValueOfCommonStockSharesIssuedByRelatedParty_838"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_ValueOfCommonStockSharesIssuedByRelatedParty" xlink:label="loc_drug_ValueOfCommonStockSharesIssuedByRelatedParty_839"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_VestingDomain" xlink:label="loc_drug_VestingDomain_840"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_VestingPercentage" xlink:label="loc_drug_VestingPercentage_841"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_VestingPercentage" xlink:label="loc_drug_VestingPercentage_842"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_VestingPercentage" xlink:label="loc_drug_VestingPercentage_843"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_VestingsAxis" xlink:label="loc_drug_VestingsAxis_844"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_VestingsAxis" xlink:label="loc_drug_VestingsAxis_845"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_WarrantAscribedValue" xlink:label="loc_drug_WarrantAscribedValue_846"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_WarrantAscribedValue" xlink:label="loc_drug_WarrantAscribedValue_847"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_WarrantAscribedValue" xlink:label="loc_drug_WarrantAscribedValue_848"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_WarrantsIssuedPricePerWarrant" xlink:label="loc_drug_WarrantsIssuedPricePerWarrant_849"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_WarrantsIssuedPricePerWarrant" xlink:label="loc_drug_WarrantsIssuedPricePerWarrant_850"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_WarrantsIssuedPricePerWarrant" xlink:label="loc_drug_WarrantsIssuedPricePerWarrant_851"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_WarrantsMember" xlink:label="loc_drug_WarrantsMember_852"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_WarrantsMember" xlink:label="loc_drug_WarrantsMember_853"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_WarrantsMember" xlink:label="loc_drug_WarrantsMember_854"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_WeightedAverageExercisePriceOfWarrantsExercisedInShareBasedPaymentArrangement" xlink:label="loc_drug_WeightedAverageExercisePriceOfWarrantsExercisedInShareBasedPaymentArrangement_855"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_WeightedAverageExercisePriceOfWarrantsExercisedInShareBasedPaymentArrangement" xlink:label="loc_drug_WeightedAverageExercisePriceOfWarrantsExercisedInShareBasedPaymentArrangement_856"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_WeightedAverageExercisePriceOfWarrantsExercisedInShareBasedPaymentArrangement" xlink:label="loc_drug_WeightedAverageExercisePriceOfWarrantsExercisedInShareBasedPaymentArrangement_857"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_WeightedAverageExercisePriceOfWarrantsExercisedInShareBasedPaymentArrangement" xlink:label="loc_drug_WeightedAverageExercisePriceOfWarrantsExercisedInShareBasedPaymentArrangement_858"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_WeightedAverageExercisePriceOfWarrantsIssuedInShareBasedPaymentArrangement" xlink:label="loc_drug_WeightedAverageExercisePriceOfWarrantsIssuedInShareBasedPaymentArrangement_859"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_WeightedAverageExercisePriceOfWarrantsIssuedInShareBasedPaymentArrangement" xlink:label="loc_drug_WeightedAverageExercisePriceOfWarrantsIssuedInShareBasedPaymentArrangement_860"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_WeightedAverageExercisePriceOfWarrantsIssuedInShareBasedPaymentArrangement" xlink:label="loc_drug_WeightedAverageExercisePriceOfWarrantsIssuedInShareBasedPaymentArrangement_861"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_WeightedAverageExercisePriceOfWarrantsIssuedInShareBasedPaymentArrangement" xlink:label="loc_drug_WeightedAverageExercisePriceOfWarrantsIssuedInShareBasedPaymentArrangement_862"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_WeightedAverageExercisePriceOfWarrantsIssuedToBrokerInShareBasedPaymentArrangement" xlink:label="loc_drug_WeightedAverageExercisePriceOfWarrantsIssuedToBrokerInShareBasedPaymentArrangement_863"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_WeightedAverageExercisePriceOfWarrantsIssuedToBrokerInShareBasedPaymentArrangement" xlink:label="loc_drug_WeightedAverageExercisePriceOfWarrantsIssuedToBrokerInShareBasedPaymentArrangement_864"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_WeightedAverageExercisePriceOfWarrantsIssuedToBrokerInShareBasedPaymentArrangement" xlink:label="loc_drug_WeightedAverageExercisePriceOfWarrantsIssuedToBrokerInShareBasedPaymentArrangement_865"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_WeightedAverageExercisePriceOfWarrantsOutstandingInShareBasedPaymentArrangement" xlink:label="loc_drug_WeightedAverageExercisePriceOfWarrantsOutstandingInShareBasedPaymentArrangement_866"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_WeightedAverageExercisePriceOfWarrantsOutstandingInShareBasedPaymentArrangement" xlink:label="loc_drug_WeightedAverageExercisePriceOfWarrantsOutstandingInShareBasedPaymentArrangement_867"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_WeightedAverageExercisePriceOfWarrantsOutstandingInShareBasedPaymentArrangement" xlink:label="loc_drug_WeightedAverageExercisePriceOfWarrantsOutstandingInShareBasedPaymentArrangement_868"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_WeightedAverageExercisePriceOfWarrantsOutstandingInShareBasedPaymentArrangement" xlink:label="loc_drug_WeightedAverageExercisePriceOfWarrantsOutstandingInShareBasedPaymentArrangement_869"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_WeightedAverageExercisePriceOfWarrantsOutstandingInShareBasedPaymentArrangement" xlink:label="loc_drug_WeightedAverageExercisePriceOfWarrantsOutstandingInShareBasedPaymentArrangement_870"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_WeightedAverageExercisePriceOfWarrantsOutstandingInShareBasedPaymentArrangement" xlink:label="loc_drug_WeightedAverageExercisePriceOfWarrantsOutstandingInShareBasedPaymentArrangement_871"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_WeightedAverageRemainingContractualLifeOfOtherEquityInstruments" xlink:label="loc_drug_WeightedAverageRemainingContractualLifeOfOtherEquityInstruments_872"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_WeightedAverageRemainingContractualLifeOfOtherEquityInstruments" xlink:label="loc_drug_WeightedAverageRemainingContractualLifeOfOtherEquityInstruments_873"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_WeightedAverageRemainingContractualLifeOfOtherEquityInstruments" xlink:label="loc_drug_WeightedAverageRemainingContractualLifeOfOtherEquityInstruments_874"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_WeightedAverageRemainingContractualLifeOfOtherEquityInstruments" xlink:label="loc_drug_WeightedAverageRemainingContractualLifeOfOtherEquityInstruments_875"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_WeightedAverageRemainingContractualLifeOfWarrants" xlink:label="loc_drug_WeightedAverageRemainingContractualLifeOfWarrants_876"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_WeightedAverageRemainingContractualLifeOfWarrants" xlink:label="loc_drug_WeightedAverageRemainingContractualLifeOfWarrants_877"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_WeightedAverageRemainingContractualLifeOfWarrants" xlink:label="loc_drug_WeightedAverageRemainingContractualLifeOfWarrants_878"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_WeightedAverageRemainingContractualLifeOfWarrants" xlink:label="loc_drug_WeightedAverageRemainingContractualLifeOfWarrants_879"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_WeightedAverageSharePriceWarrantsGranted" xlink:label="loc_drug_WeightedAverageSharePriceWarrantsGranted_880"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_WeightedAverageSharePriceWarrantsGranted" xlink:label="loc_drug_WeightedAverageSharePriceWarrantsGranted_881"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_WeightedAverageSharePriceWarrantsGranted" xlink:label="loc_drug_WeightedAverageSharePriceWarrantsGranted_882"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_WeightedAverageTradingPriceOfCommonSharesOnCanadianStockExchange" xlink:label="loc_drug_WeightedAverageTradingPriceOfCommonSharesOnCanadianStockExchange_883"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_WeightedAverageTradingPriceOfCommonSharesOnCanadianStockExchange" xlink:label="loc_drug_WeightedAverageTradingPriceOfCommonSharesOnCanadianStockExchange_884"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_WeightedAverageTradingPriceOfCommonSharesOnCanadianStockExchange" xlink:label="loc_drug_WeightedAverageTradingPriceOfCommonSharesOnCanadianStockExchange_885"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_WorkingCapital" xlink:label="loc_drug_WorkingCapital_886"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_WorkingCapital" xlink:label="loc_drug_WorkingCapital_887"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AccountingProfit" xlink:label="loc_ifrs-full_AccountingProfit_888"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AccountingProfit" xlink:label="loc_ifrs-full_AccountingProfit_889"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AccrualsClassifiedAsCurrent" xlink:label="loc_ifrs-full_AccrualsClassifiedAsCurrent_890"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AccrualsClassifiedAsCurrent" xlink:label="loc_ifrs-full_AccrualsClassifiedAsCurrent_891"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable" xlink:label="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable_892"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable" xlink:label="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable_893"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AdjustmentsForReconcileProfitLossAbstract" xlink:label="loc_ifrs-full_AdjustmentsForReconcileProfitLossAbstract_894"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AdjustmentsForReconcileProfitLossAbstract" xlink:label="loc_ifrs-full_AdjustmentsForReconcileProfitLossAbstract_895"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AdjustmentsForSharebasedPayments" xlink:label="loc_ifrs-full_AdjustmentsForSharebasedPayments_896"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AdjustmentsForSharebasedPayments" xlink:label="loc_ifrs-full_AdjustmentsForSharebasedPayments_897"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains" xlink:label="loc_ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains_898"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains" xlink:label="loc_ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains_899"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AdministrativeExpense" xlink:label="loc_ifrs-full_AdministrativeExpense_900"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AdministrativeExpense" xlink:label="loc_ifrs-full_AdministrativeExpense_901"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ApplicableTaxRate" xlink:label="loc_ifrs-full_ApplicableTaxRate_902"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ApplicableTaxRate" xlink:label="loc_ifrs-full_ApplicableTaxRate_903"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_Assets" xlink:label="loc_ifrs-full_Assets_904"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_Assets" xlink:label="loc_ifrs-full_Assets_905"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AssetsAbstract" xlink:label="loc_ifrs-full_AssetsAbstract_906"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AssetsAbstract" xlink:label="loc_ifrs-full_AssetsAbstract_907"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_BankAndSimilarCharges" xlink:label="loc_ifrs-full_BankAndSimilarCharges_908"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_BankAndSimilarCharges" xlink:label="loc_ifrs-full_BankAndSimilarCharges_909"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_BasicAndDilutedEarningsLossPerShare" xlink:label="loc_ifrs-full_BasicAndDilutedEarningsLossPerShare_910"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_BasicAndDilutedEarningsLossPerShare" xlink:label="loc_ifrs-full_BasicAndDilutedEarningsLossPerShare_911"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_BottomOfRangeMember" xlink:label="loc_ifrs-full_BottomOfRangeMember_912"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_BuildingsMember" xlink:label="loc_ifrs-full_BuildingsMember_913"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_BuildingsMember" xlink:label="loc_ifrs-full_BuildingsMember_914"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_Cash" xlink:label="loc_ifrs-full_Cash_915"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CashAndCashEquivalents" xlink:label="loc_ifrs-full_CashAndCashEquivalents_916"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CashAndCashEquivalents" xlink:label="loc_ifrs-full_CashAndCashEquivalents_917"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CashAndCashEquivalents" xlink:label="loc_ifrs-full_CashAndCashEquivalents_918"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CashAndCashEquivalents" xlink:label="loc_ifrs-full_CashAndCashEquivalents_919"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:label="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities_920"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:label="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities_921"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:label="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_922"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:label="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_923"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:label="loc_ifrs-full_CashFlowsFromUsedInOperatingActivities_924"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:label="loc_ifrs-full_CashFlowsFromUsedInOperatingActivities_925"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" xlink:label="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_926"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" xlink:label="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_927"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CategoriesOfFinancialLiabilitiesAbstract" xlink:label="loc_ifrs-full_CategoriesOfFinancialLiabilitiesAbstract_928"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CategoriesOfFinancialLiabilitiesAbstract" xlink:label="loc_ifrs-full_CategoriesOfFinancialLiabilitiesAbstract_929"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:label="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_930"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ClassesOfAssetsAxis" xlink:label="loc_ifrs-full_ClassesOfAssetsAxis_931"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ClassesOfAssetsMember" xlink:label="loc_ifrs-full_ClassesOfAssetsMember_932"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:label="loc_ifrs-full_ClassesOfFinancialInstrumentsAxis_933"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ClassesOfFinancialInstrumentsMember" xlink:label="loc_ifrs-full_ClassesOfFinancialInstrumentsMember_934"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ClassesOfShareCapitalAxis" xlink:label="loc_ifrs-full_ClassesOfShareCapitalAxis_935"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ClassesOfShareCapitalMember" xlink:label="loc_ifrs-full_ClassesOfShareCapitalMember_936"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ComponentsOfEquityAxis" xlink:label="loc_ifrs-full_ComponentsOfEquityAxis_937"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CopyrightsPatentsAndOtherIndustrialPropertyRightsServiceAndOperatingRightsMember" xlink:label="loc_ifrs-full_CopyrightsPatentsAndOtherIndustrialPropertyRightsServiceAndOperatingRightsMember_938"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CopyrightsPatentsAndOtherIndustrialPropertyRightsServiceAndOperatingRightsMember" xlink:label="loc_ifrs-full_CopyrightsPatentsAndOtherIndustrialPropertyRightsServiceAndOperatingRightsMember_939"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CreditRiskMember" xlink:label="loc_ifrs-full_CreditRiskMember_940"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CreditRiskMember" xlink:label="loc_ifrs-full_CreditRiskMember_941"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CurrencyRiskMember" xlink:label="loc_ifrs-full_CurrencyRiskMember_942"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CurrencyRiskMember" xlink:label="loc_ifrs-full_CurrencyRiskMember_943"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities" xlink:label="loc_ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities_944"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities" xlink:label="loc_ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities_945"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CurrentAssets" xlink:label="loc_ifrs-full_CurrentAssets_946"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CurrentAssets" xlink:label="loc_ifrs-full_CurrentAssets_947"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CurrentAssetsAbstract" xlink:label="loc_ifrs-full_CurrentAssetsAbstract_948"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CurrentAssetsAbstract" xlink:label="loc_ifrs-full_CurrentAssetsAbstract_949"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CurrentFinancialAssetsAtFairValueThroughProfitOrLossAbstract" xlink:label="loc_ifrs-full_CurrentFinancialAssetsAtFairValueThroughProfitOrLossAbstract_950"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CurrentFinancialAssetsAtFairValueThroughProfitOrLossAbstract" xlink:label="loc_ifrs-full_CurrentFinancialAssetsAtFairValueThroughProfitOrLossAbstract_951"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CurrentLiabilitiesAbstract" xlink:label="loc_ifrs-full_CurrentLiabilitiesAbstract_952"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CurrentLiabilitiesAbstract" xlink:label="loc_ifrs-full_CurrentLiabilitiesAbstract_953"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CurrentPrepaidExpenses" xlink:label="loc_ifrs-full_CurrentPrepaidExpenses_954"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CurrentPrepaidExpenses" xlink:label="loc_ifrs-full_CurrentPrepaidExpenses_955"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CurrentTaxAssetsCurrent" xlink:label="loc_ifrs-full_CurrentTaxAssetsCurrent_956"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CurrentTaxAssetsCurrent" xlink:label="loc_ifrs-full_CurrentTaxAssetsCurrent_957"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised" xlink:label="loc_ifrs-full_DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised_958"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised" xlink:label="loc_ifrs-full_DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised_959"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DescriptionOfAccountingPolicyForBusinessCombinationsExplanatory" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForBusinessCombinationsExplanatory_960"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DescriptionOfAccountingPolicyForBusinessCombinationsExplanatory" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForBusinessCombinationsExplanatory_961"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory_962"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory_963"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory_964"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory_965"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory_966"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory_967"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory_968"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory_969"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DescriptionOfAccountingPolicyForIssuedCapitalExplanatory" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForIssuedCapitalExplanatory_970"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DescriptionOfAccountingPolicyForIssuedCapitalExplanatory" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForIssuedCapitalExplanatory_971"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory_972"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory_973"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory_974"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory_975"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory_976"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory_977"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory_978"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory_979"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted" xlink:label="loc_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted_980"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted" xlink:label="loc_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted_981"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DescriptionOfOptionLifeShareOptionsGranted" xlink:label="loc_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted_982"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DescriptionOfOptionLifeShareOptionsGranted" xlink:label="loc_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted_983"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DirectorsRemunerationExpense" xlink:label="loc_ifrs-full_DirectorsRemunerationExpense_984"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DirectorsRemunerationExpense" xlink:label="loc_ifrs-full_DirectorsRemunerationExpense_985"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory" xlink:label="loc_ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory_986"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory" xlink:label="loc_ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory_987"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalAbstract" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalAbstract_988"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_989"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalTable" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_990"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfCommitmentsExplanatory" xlink:label="loc_ifrs-full_DisclosureOfCommitmentsExplanatory_991"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfCommitmentsExplanatory" xlink:label="loc_ifrs-full_DisclosureOfCommitmentsExplanatory_992"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory_993"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory_994"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory" xlink:label="loc_ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory_995"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory" xlink:label="loc_ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory_996"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfFinancialInstrumentsAbstract" xlink:label="loc_ifrs-full_DisclosureOfFinancialInstrumentsAbstract_997"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfFinancialInstrumentsExplanatory" xlink:label="loc_ifrs-full_DisclosureOfFinancialInstrumentsExplanatory_998"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfFinancialInstrumentsExplanatory" xlink:label="loc_ifrs-full_DisclosureOfFinancialInstrumentsExplanatory_999"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:label="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_1000"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfFinancialInstrumentsTable" xlink:label="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_1001"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfIncomeTaxExplanatory" xlink:label="loc_ifrs-full_DisclosureOfIncomeTaxExplanatory_1002"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfIncomeTaxExplanatory" xlink:label="loc_ifrs-full_DisclosureOfIncomeTaxExplanatory_1003"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfInformationAboutKeyManagementPersonnelExplanatory" xlink:label="loc_ifrs-full_DisclosureOfInformationAboutKeyManagementPersonnelExplanatory_1004"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfInformationAboutKeyManagementPersonnelExplanatory" xlink:label="loc_ifrs-full_DisclosureOfInformationAboutKeyManagementPersonnelExplanatory_1005"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfIssuedCapitalExplanatory" xlink:label="loc_ifrs-full_DisclosureOfIssuedCapitalExplanatory_1006"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfIssuedCapitalExplanatory" xlink:label="loc_ifrs-full_DisclosureOfIssuedCapitalExplanatory_1007"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfLeasesExplanatory" xlink:label="loc_ifrs-full_DisclosureOfLeasesExplanatory_1008"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfLeasesExplanatory" xlink:label="loc_ifrs-full_DisclosureOfLeasesExplanatory_1009"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract" xlink:label="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract_1010"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems" xlink:label="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_1011"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable" xlink:label="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable_1012"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory" xlink:label="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory_1013"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory" xlink:label="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory_1014"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory" xlink:label="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory_1015"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory" xlink:label="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory_1016"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:label="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems_1017"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable" xlink:label="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable_1018"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfRelatedPartyExplanatory" xlink:label="loc_ifrs-full_DisclosureOfRelatedPartyExplanatory_1019"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfRelatedPartyExplanatory" xlink:label="loc_ifrs-full_DisclosureOfRelatedPartyExplanatory_1020"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfResearchAndDevelopmentExpenseExplanatory" xlink:label="loc_ifrs-full_DisclosureOfResearchAndDevelopmentExpenseExplanatory_1021"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfResearchAndDevelopmentExpenseExplanatory" xlink:label="loc_ifrs-full_DisclosureOfResearchAndDevelopmentExpenseExplanatory_1022"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory" xlink:label="loc_ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory_1023"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory" xlink:label="loc_ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory_1024"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory" xlink:label="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory_1025"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory" xlink:label="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory_1026"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems" xlink:label="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_1027"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable" xlink:label="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable_1028"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory" xlink:label="loc_ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory_1029"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory" xlink:label="loc_ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory_1030"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract" xlink:label="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract_1031"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory" xlink:label="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory_1032"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory" xlink:label="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory_1033"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents" xlink:label="loc_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents_1034"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents" xlink:label="loc_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents_1035"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:label="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_1036"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_Equity" xlink:label="loc_ifrs-full_Equity_1037"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_Equity" xlink:label="loc_ifrs-full_Equity_1038"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_Equity" xlink:label="loc_ifrs-full_Equity_1039"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_Equity" xlink:label="loc_ifrs-full_Equity_1040"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_EquityAbstract" xlink:label="loc_ifrs-full_EquityAbstract_1041"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_EquityAbstract" xlink:label="loc_ifrs-full_EquityAbstract_1042"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_EquityAndLiabilities" xlink:label="loc_ifrs-full_EquityAndLiabilities_1043"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_EquityAndLiabilities" xlink:label="loc_ifrs-full_EquityAndLiabilities_1044"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_EquityAndLiabilitiesAbstract" xlink:label="loc_ifrs-full_EquityAndLiabilitiesAbstract_1045"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_EquityAndLiabilitiesAbstract" xlink:label="loc_ifrs-full_EquityAndLiabilitiesAbstract_1046"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_EquityInterestsOfAcquirer" xlink:label="loc_ifrs-full_EquityInterestsOfAcquirer_1047"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_EquityInterestsOfAcquirer" xlink:label="loc_ifrs-full_EquityInterestsOfAcquirer_1048"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_EquityMember" xlink:label="loc_ifrs-full_EquityMember_1049"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_EquityMember" xlink:label="loc_ifrs-full_EquityMember_1050"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ExercisePriceOfOutstandingShareOptions2019" xlink:label="loc_ifrs-full_ExercisePriceOfOutstandingShareOptions2019_1051"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ExercisePriceOfOutstandingShareOptions2019" xlink:label="loc_ifrs-full_ExercisePriceOfOutstandingShareOptions2019_1052"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ExercisePriceShareOptionsGranted2019" xlink:label="loc_ifrs-full_ExercisePriceShareOptionsGranted2019_1053"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ExercisePriceShareOptionsGranted2019" xlink:label="loc_ifrs-full_ExercisePriceShareOptionsGranted2019_1054"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ExpenseByNatureAbstract" xlink:label="loc_ifrs-full_ExpenseByNatureAbstract_1055"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ExpenseByNatureAbstract" xlink:label="loc_ifrs-full_ExpenseByNatureAbstract_1056"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees" xlink:label="loc_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees_1057"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees" xlink:label="loc_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees_1058"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_FeeAndCommissionExpense" xlink:label="loc_ifrs-full_FeeAndCommissionExpense_1059"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_FeeAndCommissionExpense" xlink:label="loc_ifrs-full_FeeAndCommissionExpense_1060"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss" xlink:label="loc_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss_1061"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss" xlink:label="loc_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss_1062"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss" xlink:label="loc_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss_1063"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_GeneralAndAdministrativeExpense" xlink:label="loc_ifrs-full_GeneralAndAdministrativeExpense_1064"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_GeneralAndAdministrativeExpense" xlink:label="loc_ifrs-full_GeneralAndAdministrativeExpense_1065"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IncomeStatementAbstract" xlink:label="loc_ifrs-full_IncomeStatementAbstract_1066"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IncomeStatementAbstract" xlink:label="loc_ifrs-full_IncomeStatementAbstract_1067"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:label="loc_ifrs-full_IncomeTaxExpenseContinuingOperations_1068"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:label="loc_ifrs-full_IncomeTaxExpenseContinuingOperations_1069"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:label="loc_ifrs-full_IncomeTaxExpenseContinuingOperations_1070"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IncreaseDecreaseInCashAndCashEquivalents" xlink:label="loc_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents_1071"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IncreaseDecreaseInCashAndCashEquivalents" xlink:label="loc_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents_1072"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IncreaseDecreaseInCashAndCashEquivalents" xlink:label="loc_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents_1073"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IncreaseDecreaseInNumberOfSharesOutstanding" xlink:label="loc_ifrs-full_IncreaseDecreaseInNumberOfSharesOutstanding_1074"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IncreaseDecreaseInNumberOfSharesOutstanding" xlink:label="loc_ifrs-full_IncreaseDecreaseInNumberOfSharesOutstanding_1075"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity_1076"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity_1077"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions_1078"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions_1079"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IntangibleAssetsAndGoodwill" xlink:label="loc_ifrs-full_IntangibleAssetsAndGoodwill_1080"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IntangibleAssetsAndGoodwill" xlink:label="loc_ifrs-full_IntangibleAssetsAndGoodwill_1081"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IssuedCapital" xlink:label="loc_ifrs-full_IssuedCapital_1082"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IssuedCapital" xlink:label="loc_ifrs-full_IssuedCapital_1083"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IssuedCapitalMember" xlink:label="loc_ifrs-full_IssuedCapitalMember_1084"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IssuedCapitalMember" xlink:label="loc_ifrs-full_IssuedCapitalMember_1085"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_KeyManagementPersonnelCompensation" xlink:label="loc_ifrs-full_KeyManagementPersonnelCompensation_1086"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_KeyManagementPersonnelCompensation" xlink:label="loc_ifrs-full_KeyManagementPersonnelCompensation_1087"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment" xlink:label="loc_ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment_1088"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment" xlink:label="loc_ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment_1089"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_Liabilities" xlink:label="loc_ifrs-full_Liabilities_1090"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_Liabilities" xlink:label="loc_ifrs-full_Liabilities_1091"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_LiquidityRiskMember" xlink:label="loc_ifrs-full_LiquidityRiskMember_1092"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_LiquidityRiskMember" xlink:label="loc_ifrs-full_LiquidityRiskMember_1093"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract" xlink:label="loc_ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract_1094"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:label="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_1095"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NonadjustingEventsMember" xlink:label="loc_ifrs-full_NonadjustingEventsMember_1096"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NoncurrentAssetsAbstract" xlink:label="loc_ifrs-full_NoncurrentAssetsAbstract_1097"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NoncurrentAssetsAbstract" xlink:label="loc_ifrs-full_NoncurrentAssetsAbstract_1098"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NumberOfInstrumentsOrInterestsIssuedOrIssuable" xlink:label="loc_ifrs-full_NumberOfInstrumentsOrInterestsIssuedOrIssuable_1099"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NumberOfInstrumentsOrInterestsIssuedOrIssuable" xlink:label="loc_ifrs-full_NumberOfInstrumentsOrInterestsIssuedOrIssuable_1100"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted" xlink:label="loc_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted_1101"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted" xlink:label="loc_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted_1102"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted" xlink:label="loc_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted_1103"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" xlink:label="loc_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement_1104"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" xlink:label="loc_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement_1105"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" xlink:label="loc_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement_1106"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" xlink:label="loc_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_1107"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" xlink:label="loc_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_1108"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" xlink:label="loc_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_1109"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" xlink:label="loc_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_1110"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NumberOfOutstandingShareOptions" xlink:label="loc_ifrs-full_NumberOfOutstandingShareOptions_1111"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NumberOfOutstandingShareOptions" xlink:label="loc_ifrs-full_NumberOfOutstandingShareOptions_1112"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NumberOfOutstandingShareOptions" xlink:label="loc_ifrs-full_NumberOfOutstandingShareOptions_1113"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NumberOfOutstandingShareOptions" xlink:label="loc_ifrs-full_NumberOfOutstandingShareOptions_1114"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" xlink:label="loc_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement_1115"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" xlink:label="loc_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement_1116"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" xlink:label="loc_ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement_1117"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" xlink:label="loc_ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement_1118"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" xlink:label="loc_ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement_1119"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" xlink:label="loc_ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement_1120"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" xlink:label="loc_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement_1121"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" xlink:label="loc_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement_1122"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" xlink:label="loc_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement_1123"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NumberOfSharesIssued" xlink:label="loc_ifrs-full_NumberOfSharesIssued_1124"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NumberOfSharesOutstanding" xlink:label="loc_ifrs-full_NumberOfSharesOutstanding_1125"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NumberOfSharesOutstanding" xlink:label="loc_ifrs-full_NumberOfSharesOutstanding_1126"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NumberOfSharesOutstanding" xlink:label="loc_ifrs-full_NumberOfSharesOutstanding_1127"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_OtherReserves" xlink:label="loc_ifrs-full_OtherReserves_1128"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_OtherReserves" xlink:label="loc_ifrs-full_OtherReserves_1129"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_OtherReservesMember" xlink:label="loc_ifrs-full_OtherReservesMember_1130"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_OtherReservesMember" xlink:label="loc_ifrs-full_OtherReservesMember_1131"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_PaymentsForShareIssueCosts" xlink:label="loc_ifrs-full_PaymentsForShareIssueCosts_1132"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_PaymentsForShareIssueCosts" xlink:label="loc_ifrs-full_PaymentsForShareIssueCosts_1133"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_PresentationOfLeasesForLesseeAbstract" xlink:label="loc_ifrs-full_PresentationOfLeasesForLesseeAbstract_1134"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ProceedsFromIssueOfOrdinaryShares" xlink:label="loc_ifrs-full_ProceedsFromIssueOfOrdinaryShares_1135"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ProceedsFromIssuingShares" xlink:label="loc_ifrs-full_ProceedsFromIssuingShares_1136"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ProceedsFromIssuingShares" xlink:label="loc_ifrs-full_ProceedsFromIssuingShares_1137"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ProfessionalFeesExpense" xlink:label="loc_ifrs-full_ProfessionalFeesExpense_1138"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ProfessionalFeesExpense" xlink:label="loc_ifrs-full_ProfessionalFeesExpense_1139"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ProfitLoss" xlink:label="loc_ifrs-full_ProfitLoss_1140"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ProfitLoss" xlink:label="loc_ifrs-full_ProfitLoss_1141"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ProfitLoss" xlink:label="loc_ifrs-full_ProfitLoss_1142"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ProfitLoss" xlink:label="loc_ifrs-full_ProfitLoss_1143"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_RangeAxis" xlink:label="loc_ifrs-full_RangeAxis_1144"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_RangesMember" xlink:label="loc_ifrs-full_RangesMember_1145"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ReconciliationOfNumberOfSharesOutstandingAbstract" xlink:label="loc_ifrs-full_ReconciliationOfNumberOfSharesOutstandingAbstract_1146"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ResearchAndDevelopmentExpense" xlink:label="loc_ifrs-full_ResearchAndDevelopmentExpense_1147"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ResearchAndDevelopmentExpense" xlink:label="loc_ifrs-full_ResearchAndDevelopmentExpense_1148"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ResearchAndDevelopmentExpense" xlink:label="loc_ifrs-full_ResearchAndDevelopmentExpense_1149"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_RetainedEarnings" xlink:label="loc_ifrs-full_RetainedEarnings_1150"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_RetainedEarnings" xlink:label="loc_ifrs-full_RetainedEarnings_1151"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_RetainedEarningsMember" xlink:label="loc_ifrs-full_RetainedEarningsMember_1152"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_RetainedEarningsMember" xlink:label="loc_ifrs-full_RetainedEarningsMember_1153"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_SalesAndMarketingExpense" xlink:label="loc_ifrs-full_SalesAndMarketingExpense_1154"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_SalesAndMarketingExpense" xlink:label="loc_ifrs-full_SalesAndMarketingExpense_1155"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_SharebasedPaymentArrangementsMember" xlink:label="loc_ifrs-full_SharebasedPaymentArrangementsMember_1156"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ShareIssueRelatedCost" xlink:label="loc_ifrs-full_ShareIssueRelatedCost_1157"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ShareIssueRelatedCost" xlink:label="loc_ifrs-full_ShareIssueRelatedCost_1158"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ShareIssueRelatedCost" xlink:label="loc_ifrs-full_ShareIssueRelatedCost_1159"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ShorttermInvestmentsClassifiedAsCashEquivalents" xlink:label="loc_ifrs-full_ShorttermInvestmentsClassifiedAsCashEquivalents_1160"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ShorttermInvestmentsClassifiedAsCashEquivalents" xlink:label="loc_ifrs-full_ShorttermInvestmentsClassifiedAsCashEquivalents_1161"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_StatementOfCashFlowsAbstract" xlink:label="loc_ifrs-full_StatementOfCashFlowsAbstract_1162"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_StatementOfChangesInEquityAbstract" xlink:label="loc_ifrs-full_StatementOfChangesInEquityAbstract_1163"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_StatementOfChangesInEquityLineItems" xlink:label="loc_ifrs-full_StatementOfChangesInEquityLineItems_1164"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_StatementOfChangesInEquityTable" xlink:label="loc_ifrs-full_StatementOfChangesInEquityTable_1165"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_StatementOfFinancialPositionAbstract" xlink:label="loc_ifrs-full_StatementOfFinancialPositionAbstract_1166"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss" xlink:label="loc_ifrs-full_TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss_1167"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss" xlink:label="loc_ifrs-full_TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss_1168"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TaxExpenseIncomeAtApplicableTaxRate" xlink:label="loc_ifrs-full_TaxExpenseIncomeAtApplicableTaxRate_1169"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TaxExpenseIncomeAtApplicableTaxRate" xlink:label="loc_ifrs-full_TaxExpenseIncomeAtApplicableTaxRate_1170"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TemporaryDifferenceMember" xlink:label="loc_ifrs-full_TemporaryDifferenceMember_1171"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis" xlink:label="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_1172"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember" xlink:label="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_1173"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TopOfRangeMember" xlink:label="loc_ifrs-full_TopOfRangeMember_1174"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TradeAndOtherCurrentPayables" xlink:label="loc_ifrs-full_TradeAndOtherCurrentPayables_1175"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TradeAndOtherCurrentPayables" xlink:label="loc_ifrs-full_TradeAndOtherCurrentPayables_1176"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TradeAndOtherCurrentPayables" xlink:label="loc_ifrs-full_TradeAndOtherCurrentPayables_1177"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TradeAndOtherCurrentPayablesAbstract" xlink:label="loc_ifrs-full_TradeAndOtherCurrentPayablesAbstract_1178"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers" xlink:label="loc_ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers_1179"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers" xlink:label="loc_ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers_1180"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TypesOfRisksAxis" xlink:label="loc_ifrs-full_TypesOfRisksAxis_1181"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TypesOfRisksMember" xlink:label="loc_ifrs-full_TypesOfRisksMember_1182"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_1183"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_UnusedTaxLossesMember" xlink:label="loc_ifrs-full_UnusedTaxLossesMember_1184"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_UnusedTaxLossesMember" xlink:label="loc_ifrs-full_UnusedTaxLossesMember_1185"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ValueAtRisk" xlink:label="loc_ifrs-full_ValueAtRisk_1186"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ValueAtRisk" xlink:label="loc_ifrs-full_ValueAtRisk_1187"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019" xlink:label="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019_1188"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019" xlink:label="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019_1189"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019" xlink:label="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019_1190"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019" xlink:label="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019_1191"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019" xlink:label="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019_1192"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" xlink:label="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_1193"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" xlink:label="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_1194"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" xlink:label="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_1195"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" xlink:label="loc_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019_1196"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" xlink:label="loc_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019_1197"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019" xlink:label="loc_ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019_1198"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019" xlink:label="loc_ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019_1199"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_WeightedAverageShares" xlink:label="loc_ifrs-full_WeightedAverageShares_1200"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_WeightedAverageShares" xlink:label="loc_ifrs-full_WeightedAverageShares_1201"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ChiefExecutiveOfficerMember" xlink:label="loc_srt_ChiefExecutiveOfficerMember_1202"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srt_TitleOfIndividualAxis_1203"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_1204"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_AddressTypeDomain_0" xml:lang="en-US">Address Type [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_AmendmentDescription_0" xml:lang="en-US">Amendment Description</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_AmendmentFlag_0" xml:lang="en-US">Amendment Flag</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_AnnualInformationForm_0" xml:lang="en-US">Annual Information Form</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_AuditedAnnualFinancialStatements_0" xml:lang="en-US">Audited Annual Financial Statements</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_BusinessContactMember_0" xml:lang="en-US">Business Contact [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_CityAreaCode_0" xml:lang="en-US">City Area Code</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_ContactPersonnelEmailAddress_0" xml:lang="en-US">Contact Personnel Email Address</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_ContactPersonnelFaxNumber_0" xml:lang="en-US">Contact Personnel Fax Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_ContactPersonnelName_0" xml:lang="en-US">Contact Personnel Name</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_CoverAbstract_0" xml:lang="en-US">Cover [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_CurrentFiscalYearEndDate_0" xml:lang="en-US">Current Fiscal Year End Date</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentAccountingStandard_0" xml:lang="en-US">Document Accounting Standard</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentAnnualReport_0" xml:lang="en-US">Document Annual Report</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentFiscalPeriodFocus_0" xml:lang="en-US">Document Fiscal Period Focus</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentFiscalYearFocus_0" xml:lang="en-US">Document Fiscal Year Focus</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentPeriodEndDate_0" xml:lang="en-US">Document Period End Date</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentRegistrationStatement_0" xml:lang="en-US">Document Registration Statement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentShellCompanyReport_0" xml:lang="en-US">Document Shell Company Report</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentTransitionReport_0" xml:lang="en-US">Document Transition Report</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentType_0" xml:lang="en-US">Document Type</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityAddressAddressLine1_0" xml:lang="en-US">Entity Address, Address Line One</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityAddressAddressLine2_0" xml:lang="en-US">Entity Address, Address Line Two</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityAddressCityOrTown_0" xml:lang="en-US">Entity Address, City or Town</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityAddressCountry_0" xml:lang="en-US">Entity Address, Country</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityAddressesAddressTypeAxis_0" xml:lang="en-US">Entity Addresses, Address Type [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityAddressesLineItems_0" xml:lang="en-US">Entity Addresses [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityAddressesTable_0" xml:lang="en-US">Entity Addresses [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityAddressPostalZipCode_0" xml:lang="en-US">Entity Address, Postal Zip Code</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityAddressStateOrProvince_0" xml:lang="en-US">Entity Address, State or Province</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityCentralIndexKey_0" xml:lang="en-US">Entity Central Index Key</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityCommonStockSharesOutstanding_0" xml:lang="en-US">Entity Common Stock, Shares Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityCurrentReportingStatus_0" xml:lang="en-US">Entity Current Reporting Status</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityDomain_0" xml:lang="en-US">Entity [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityEmergingGrowthCompany_0" xml:lang="en-US">Entity Emerging Growth Company</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityExTransitionPeriod_0" xml:lang="en-US">Entity Ex Transition Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityFileNumber_0" xml:lang="en-US">Entity File Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityFilerCategory_0" xml:lang="en-US">Entity Filer Category</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityIncorporationStateCountryCode_0" xml:lang="en-US">Entity Incorporation, State or Country Code</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityInteractiveDataCurrent_0" xml:lang="en-US">Entity Interactive Data Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityRegistrantName_0" xml:lang="en-US">Entity Registrant Name</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityShellCompany_0" xml:lang="en-US">Entity Shell Company</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityVoluntaryFilers_0" xml:lang="en-US">Entity Voluntary Filers</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer_0" xml:lang="en-US">Entity Well-known Seasoned Issuer</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_IcfrAuditorAttestationFlag_0" xml:lang="en-US">ICFR Auditor Attestation Flag</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_LegalEntityAxis_0" xml:lang="en-US">Legal Entity [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_LocalPhoneNumber_0" xml:lang="en-US">Local Phone Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_Security12bTitle_0" xml:lang="en-US">Title of 12(b) Security</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_SecurityExchangeName_0" xml:lang="en-US">Security Exchange Name</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_TradingSymbol_0" xml:lang="en-US">Trading Symbol</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_drug_AcquisitionOfIntangibleAssetsByIssuingCommonShares_0" xml:lang="en-US">Represents amount of acquisition of intangible assets by issuing common shares.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_drug_AcquisitionOfIntangibleAssetsByIssuingCommonShares_1" xml:lang="en-US">Acquisition Of Intangible Assets By Issuing Common Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_drug_AcquisitionOfIntangibleAssetsByIssuingCommonShares_2" xml:lang="en-US">Acquisition of intangible assets by issuing common shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_drug_AdjustmentsForDecreaseIncreaseInPrepaidExpenses_0" xml:lang="en-US">Represents adjustments for decrease increase in prepaid expenses.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_drug_AdjustmentsForDecreaseIncreaseInPrepaidExpenses_1" xml:lang="en-US">Adjustments For Decrease Increase In Prepaid Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_drug_AdjustmentsForDecreaseIncreaseInPrepaidExpenses_2" xml:lang="en-US">Prepaids</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_drug_AdjustmentsForDecreaseIncreaseInSalesTaxReceivable_0" xml:lang="en-US">Represents adjustments for decrease increase in sales tax receivable.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_drug_AdjustmentsForDecreaseIncreaseInSalesTaxReceivable_1" xml:lang="en-US">Adjustments For Decrease Increase In Sales Tax Receivable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_drug_AdjustmentsForDecreaseIncreaseInSalesTaxReceivable_2" xml:lang="en-US">Sales tax receivable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_drug_AdjustmentsForSharesRecordedAsResearchAndDevelopment_0" xml:lang="en-US">The Adjustments For Shares recorded as research and development</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_drug_AdjustmentsForSharesRecordedAsResearchAndDevelopment_1" xml:lang="en-US">Shares recorded as research and development</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_drug_AdjustmentsForSharesRecordedAsResearchAndDevelopment_2" xml:lang="en-US">Adjustments For Shares Recorded As Research And Development</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_drug_AdjustmentsForSharesRecordedAsResearchAndDevelopment_3" xml:lang="en-US">Research and development</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_drug_AdjustmentsForSharesRecordedAsResearchAndDevelopment_4" xml:lang="en-US">Shares recorded as research and development</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_drug_AdvisorHourlyRate_0" xml:lang="en-US">Advisor hourly rate.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_drug_AdvisorHourlyRate_1" xml:lang="en-US">Advisor Hourly Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_drug_AdvisorHourlyRate_2" xml:lang="en-US">Advisor hourly rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_drug_AdvisorsHourlyRatesOfScientificAdvisoryBoardAndConsultants_0" xml:lang="en-US">Advisors hourly rates of scientific advisory board and consultants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_drug_AdvisorsHourlyRatesOfScientificAdvisoryBoardAndConsultants_1" xml:lang="en-US">Advisors hourly rates of Scientific advisory board and consultants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_drug_AfterSublicensingAgreementsMember_0" xml:lang="en-US">Information about after any sublicensing agreements.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_drug_AfterSublicensingAgreementsMember_1" xml:lang="en-US">After Sublicensing agreements [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_drug_AfterSublicensingAgreementsMember_2" xml:lang="en-US">Licensing agreement - after any sublicensing agreements, joint ventures or change of control [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_drug_AggregatePurchaseWarrantsDeposited_0" xml:lang="en-US">Represents the amount of aggregate purchase warrants deposited.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_drug_AggregatePurchaseWarrantsDeposited_1" xml:lang="en-US">Aggregate Purchase Warrants Deposited</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_drug_AggregatePurchaseWarrantsDeposited_2" xml:lang="en-US">Aggregate purchase warrants deposited</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_drug_AggregateSecuritiesDepositedToBeHeldInEscrow_0" xml:lang="en-US">Aggregate securities deposited to be held in escrow.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_drug_AggregateSecuritiesDepositedToBeHeldInEscrow_1" xml:lang="en-US">Aggregate Securities Deposited To Be Held In Escrow</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_drug_AggregateSecuritiesDepositedToBeHeldInEscrow_2" xml:lang="en-US">Aggregate securities deposited to be held in escrow</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_drug_AgreementAxis_0" xml:lang="en-US">Represents the types of agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_drug_AgreementAxis_1" xml:lang="en-US">Agreement [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_drug_AgreementDomain_0" xml:lang="en-US">Represents the types of agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_drug_AgreementDomain_1" xml:lang="en-US">Agreement [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_drug_AmountOfEscrowProceedsReleased_0" xml:lang="en-US">Amount of escrow proceeds released.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_drug_AmountOfEscrowProceedsReleased_1" xml:lang="en-US">Amount Of Escrow Proceeds Released</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_drug_AmountOfEscrowProceedsReleased_2" xml:lang="en-US">Amount of escrow proceeds released</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_drug_AmountOfNonRefundableMonthlyRetainerAsServiceCompensation_0" xml:lang="en-US">Amount of non-refundable monthly retainer as service compensation.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_drug_AmountOfNonRefundableMonthlyRetainerAsServiceCompensation_1" xml:lang="en-US">Amount Of Non Refundable Monthly Retainer As Service Compensation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_drug_AmountOfNonRefundableMonthlyRetainerAsServiceCompensation_2" xml:lang="en-US">Amount of non-refundable monthly retainer as service compensation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_drug_AreasOfScientificTechnicalBusinessAdviceAdvisorsHourlyRates_0" xml:lang="en-US">areas of scientific technical business advice advisors hourly rates.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_drug_AreasOfScientificTechnicalBusinessAdviceAdvisorsHourlyRates_1" xml:lang="en-US">Areas Of Scientific Technical Business Advice Advisors Hourly Rates</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_drug_ArrangementsAndNonarrangementTransactionDomain_0" xml:lang="en-US">This member stands for arrangements and nonarrangement transaction.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_drug_ArrangementsAndNonarrangementTransactionDomain_1" xml:lang="en-US">Arrangements And Nonarrangement Transaction [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_drug_BritishColumbiaSecuritiesCommissionMember_0" xml:lang="en-US">British Columbia Securities Commission [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_drug_BritishColumbiaSecuritiesCommissionMember_1" xml:lang="en-US">British Columbia Securities Commission [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_drug_CashSettledShareBasedPaymentArrangementsMember_0" xml:lang="en-US">This member stands for an agreement for cash settled transactions.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_drug_CashSettledShareBasedPaymentArrangementsMember_1" xml:lang="en-US">Cash Settled Share Based Payment Arrangements [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_drug_CashSettledShareBasedPaymentArrangementsMember_2" xml:lang="en-US">Cash settled [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_drug_CategoriesOfResearchAndDevelopmentExpensesAxis_0" xml:lang="en-US">Represents categories of Research and Development expenses.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_drug_CategoriesOfResearchAndDevelopmentExpensesAxis_1" xml:lang="en-US">Categories Of Research And Development Expenses [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_drug_CategoriesOfResearchAndDevelopmentExpensesDomain_0" xml:lang="en-US">Represents categories of Research and Development expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_drug_CategoriesOfResearchAndDevelopmentExpensesDomain_1" xml:lang="en-US">Categories Of Research And Development Expenses [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_drug_ChangesInNonCashWorkingOperatingCapitalBalancesAbstract_0" xml:lang="en-US">Changes In Non Cash Working Operating Capital Balances [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_drug_ChangesInNonCashWorkingOperatingCapitalBalancesAbstract_1" xml:lang="en-US">Changes In Non Cash Working Operating Capital Balances [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_drug_ChangesInNonCashWorkingOperatingCapitalBalancesAbstract_2" xml:lang="en-US">Changes in non-cash operating working capital items:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_drug_ChiefFinancialOfficerTwoDirectorsAndSevenConsultantsMember_0" xml:lang="en-US">Chief Financial Officer, two directors and seven consultants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_drug_ChiefFinancialOfficerTwoDirectorsAndSevenConsultantsMember_1" xml:lang="en-US">Chief Financial Officer, Two Directors And Seven Consultants [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_drug_ChiefFinancialOfficerTwoDirectorsAndSevenConsultantsMember_2" xml:lang="en-US">Chief Financial Officer, two directors and seven consultants [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_drug_ChiefMedicalOfficerMember_0" xml:lang="en-US">Chief Medical Officer.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_drug_ChiefMedicalOfficerMember_1" xml:lang="en-US">Chief Medical Officer [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_drug_CommercialLaboratoryLeaseMember_0" xml:lang="en-US">Commercial laboratory lease.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_drug_CommercialLaboratoryLeaseMember_1" xml:lang="en-US">Commercial Laboratory Lease [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_drug_CommercialLaboratoryLeaseMember_2" xml:lang="en-US">Commercial laboratory [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_drug_CommonShareSubscriptionsReceived_0" xml:lang="en-US">Represents number of common share subscriptions received.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_drug_CommonShareSubscriptionsReceived_1" xml:lang="en-US">Common Share Subscriptions Received</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_drug_CommonShareSubscriptionsReceived_2" xml:lang="en-US">Common share subscriptions received</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_drug_CommonStockSharesPurchased_0" xml:lang="en-US">Represents the number of common stock shares purchased.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_drug_CommonStockSharesPurchased_1" xml:lang="en-US">Common Stock Shares Purchased</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_drug_CommonStockSharesPurchased_2" xml:lang="en-US">Common shares purchased</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_drug_ComparativeAmountsAbstract_0" xml:lang="en-US">Comparative Amounts [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_drug_ComparativeAmountsAbstract_1" xml:lang="en-US">Comparative Amounts [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_drug_ConsolidatedStatementsOfComprehensiveIncomeLossStatementLocationAxis_0" xml:lang="en-US">Information by location in the consolidated statements of comprehensive Income (loss) statement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_drug_ConsolidatedStatementsOfComprehensiveIncomeLossStatementLocationAxis_1" xml:lang="en-US">Consolidated Statements Of Comprehensive Income (Loss) Statement Location [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_drug_ConsolidatedStatementsOfComprehensiveIncomeLossStatementLocationDomain_0" xml:lang="en-US">Location in the consolidated statements of comprehensive Income (loss) statement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_drug_ConsolidatedStatementsOfComprehensiveIncomeLossStatementLocationDomain_1" xml:lang="en-US">Consolidated Statements Of Comprehensive Income (Loss) Statement Location [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_drug_ConsultantMember_0" xml:lang="en-US">consultant [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_drug_ConsultantMember_1" xml:lang="en-US">Consultant [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_drug_ConsultingAgreement2Member_0" xml:lang="en-US">Consulting agreement 2 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_drug_ConsultingAgreementsMember_0" xml:lang="en-US">Information about consulting agreements.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_drug_ConsultingAgreementsMember_1" xml:lang="en-US">Consulting agreements [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_drug_ConsultingFees_0" xml:lang="en-US">The amount of consulting fees.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="lab_drug_ConsultingFees_1" xml:lang="en-US">Total fee and commission expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_drug_ConsultingFees_2" xml:lang="en-US">Consulting Fees</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_drug_ConsultingFees_3" xml:lang="en-US">Consulting fees</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_drug_ConsultingFeesMember_0" xml:lang="en-US">Represents the primary financial statement caption encompassing consulting fees.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_drug_ConsultingFeesMember_1" xml:lang="en-US">Consulting Fees [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_drug_ConsultingFeesMember_2" xml:lang="en-US">Consulting fees [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_drug_ContingentCashFee_0" xml:lang="en-US">Information about contingent cash fee.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_drug_ContingentCashFee_1" xml:lang="en-US">Contingent Cash Fee</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_drug_ContingentCashFee_2" xml:lang="en-US">Contingent cash fee</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_drug_DebtSettledByIssuingShares_0" xml:lang="en-US">Represents debt settled by issuing shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_drug_DebtSettledByIssuingShares_1" xml:lang="en-US">Debt Settled By Issuing Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_drug_DebtSettledByIssuingShares_2" xml:lang="en-US">Debt settled by issuing shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_drug_DebtSettledThroughIssuanceOfShares_0" xml:lang="en-US">Debt Settled Through Issuance Of Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_drug_DebtSettledThroughIssuanceOfShares_1" xml:lang="en-US">Represents amount of debt settled through issuance of shares.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_drug_DebtSettledThroughIssuanceOfShares_2" xml:lang="en-US">Debt settled through issuance of shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_drug_DebtSettlementAgreementMember_0" xml:lang="en-US">Debt Settlement Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_drug_DebtSettlementAgreementMember_1" xml:lang="en-US">Debt Settlement Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_drug_DecemberTwentyOneTwoZeroTwoFourMember_0" xml:lang="en-US">December 21, 2021.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_drug_DecemberTwentyOneTwoZeroTwoFourMember_1" xml:lang="en-US">December Twenty One Two Zero Two Four [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_drug_DecemberTwentyOneTwoZeroTwoFourMember_2" xml:lang="en-US">December 21, 2021</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_drug_DescriptionOfAccountingPolicyForBasisOfConsolidationExplanatory_0" xml:lang="en-US">The description of the entity's accounting policy for basis of consolidation.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_drug_DescriptionOfAccountingPolicyForBasisOfConsolidationExplanatory_1" xml:lang="en-US">Description Of Accounting Policy For Basis Of Consolidation Explanatory</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_drug_DescriptionOfAccountingPolicyForBasisOfConsolidationExplanatory_2" xml:lang="en-US">Basis of consolidation [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_drug_DescriptionOfAccountingPolicyForCriticalAccountingEstimatesExplanatory_0" xml:lang="en-US">The description of the entity's accounting policy for critical accounting estimates.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_drug_DescriptionOfAccountingPolicyForCriticalAccountingEstimatesExplanatory_1" xml:lang="en-US">Description Of Accounting Policy For Critical Accounting Estimates Explanatory</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_drug_DescriptionOfAccountingPolicyForCriticalAccountingEstimatesExplanatory_2" xml:lang="en-US">Critical accounting estimates [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_drug_DescriptionOfAccountingPolicyForInternallyGeneratedIntangibleAssetsResearchAndDevelopmentExpenditureExplanatory_0" xml:lang="en-US">The description of the entity's accounting policy for Internally generated intangible assets Research and development expenditure.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_drug_DescriptionOfAccountingPolicyForInternallyGeneratedIntangibleAssetsResearchAndDevelopmentExpenditureExplanatory_1" xml:lang="en-US">Description Of Accounting Policy For Internally Generated Intangible Assets Research And Development Expenditure Explanatory</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_drug_DescriptionOfAccountingPolicyForInternallyGeneratedIntangibleAssetsResearchAndDevelopmentExpenditureExplanatory_2" xml:lang="en-US">Internally generated intangible assets - Research and development expenditure [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_drug_DescriptionOfAccountingPolicyForNewStandardsAndInterpretationsNotYetAdoptedExplanatory_0" xml:lang="en-US">The description of the entity's accounting policy for New standards and interpretations not yet adopted.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_drug_DescriptionOfAccountingPolicyForNewStandardsAndInterpretationsNotYetAdoptedExplanatory_1" xml:lang="en-US">Description Of Accounting Policy For New Standards And Interpretations Not Yet Adopted Explanatory</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_drug_DescriptionOfAccountingPolicyForNewStandardsAndInterpretationsNotYetAdoptedExplanatory_2" xml:lang="en-US">New standards and interpretations not yet adopted [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_drug_DescriptionOfIssuedAndOutstandingCommonShares_0" xml:lang="en-US">Description of issued and outstanding common shares.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_drug_DescriptionOfIssuedAndOutstandingCommonShares_1" xml:lang="en-US">Description Of Issued And Outstanding Common Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_drug_DescriptionOfIssuedAndOutstandingCommonShares_2" xml:lang="en-US">Description of issued and outstanding common shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_drug_DescriptionOfSublicenseeRevenueOfRoyaltyPaymentAccrues_0" xml:lang="en-US">Information about description of sublicensee revenue of royalty payment accrues.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_drug_DescriptionOfSublicenseeRevenueOfRoyaltyPaymentAccrues_1" xml:lang="en-US">Description Of Sublicensee Revenue Of Royalty Payment Accrues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_drug_DescriptionOfSublicenseeRevenueOfRoyaltyPaymentAccrues_2" xml:lang="en-US">Description of sublicensee revenue of royalty payment accrues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_drug_DirectorAndConsultantMember_0" xml:lang="en-US">Director and consultant</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_drug_DirectorAndConsultantMember_1" xml:lang="en-US">Director And Consultant [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_drug_DirectorAndConsultantMember_2" xml:lang="en-US">Director and Consultant [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_drug_DirectorsCompensationMember_0" xml:lang="en-US">Represents the primary financial statement caption encompassing directors compensation.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_drug_DirectorsCompensationMember_1" xml:lang="en-US">Directors Compensation [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_drug_DirectorsCompensationMember_2" xml:lang="en-US">Directors' compensation [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_drug_DisclosureOfComparativeAmountsExplanatory_0" xml:lang="en-US">Disclosure of comparative amounts.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_drug_DisclosureOfComparativeAmountsExplanatory_1" xml:lang="en-US">Disclosure Of Comparative Amounts Explanatory</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_drug_DisclosureOfComparativeAmountsExplanatory_2" xml:lang="en-US">COMPARATIVE AMOUNTS [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_drug_DisclosureOfContractualObligationAbstract_0" xml:lang="en-US">Disclosure Of Contractual Obligation [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_drug_DisclosureOfContractualObligationLineItems_0" xml:lang="en-US">Disclosure Of Contractual Obligation [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_drug_DisclosureOfContractualObligationTable_0" xml:lang="en-US">Disclosure of contractual obligation.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_drug_DisclosureOfContractualObligationTable_1" xml:lang="en-US">Disclosure Of Contractual Obligation [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_drug_DisclosureOfDetailedInformationAboutEquitySettledRestrictedShareUnitsFairValueInputsExplanatory_0" xml:lang="en-US">Disclosure about equity settled restricted share units fair value inputs.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_drug_DisclosureOfDetailedInformationAboutEquitySettledRestrictedShareUnitsFairValueInputsExplanatory_1" xml:lang="en-US">Disclosure Of Detailed Information About Equity Settled Restricted Share Units Fair Value Inputs Explanatory</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_drug_DisclosureOfDetailedInformationAboutEquitySettledRestrictedShareUnitsFairValueInputsExplanatory_2" xml:lang="en-US">Disclosure of equity-settled restricted share units fair value inputs [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_drug_DisclosureOfDetailedInformationAboutResearchAndDevelopmentExplanatory_0" xml:lang="en-US">Disclosure of detailed information about research and development.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_drug_DisclosureOfDetailedInformationAboutResearchAndDevelopmentExplanatory_1" xml:lang="en-US">Disclosure Of Detailed Information About Research And Development Explanatory</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_drug_DisclosureOfDetailedInformationAboutResearchAndDevelopmentExplanatory_2" xml:lang="en-US">Disclosure of research and development expenses [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_drug_DisclosureOfDetailedInformationAboutShareBasedPaymentsIncludedInConsolidatedStatementsOfComprehensiveLossExplanatory_0" xml:lang="en-US">Disclosure of detailed information about share based payments included in consolidated statements of comprehensive loss statement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_drug_DisclosureOfDetailedInformationAboutShareBasedPaymentsIncludedInConsolidatedStatementsOfComprehensiveLossExplanatory_1" xml:lang="en-US">Disclosure Of Detailed Information About Share Based Payments Included In Consolidated Statements Of Comprehensive Loss Explanatory</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_drug_DisclosureOfDetailedInformationAboutShareBasedPaymentsIncludedInConsolidatedStatementsOfComprehensiveLossExplanatory_2" xml:lang="en-US">Disclosure of share based payments included in the consolidated statements of comprehensive loss [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_drug_DisclosureOfDetailedInformationAboutShareBasedPaymentsRecognizedInConsolidatedStatementsOfComprehensiveLossExplanatory_0" xml:lang="en-US">Disclosure of detailed information about share based payments recognized in the consolidated statements of comprehensive loss statement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_drug_DisclosureOfDetailedInformationAboutShareBasedPaymentsRecognizedInConsolidatedStatementsOfComprehensiveLossExplanatory_1" xml:lang="en-US">Disclosure Of Detailed Information About Share Based Payments Recognized In Consolidated Statements Of Comprehensive Loss Explanatory</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_drug_DisclosureOfDetailedInformationAboutShareBasedPaymentsRecognizedInConsolidatedStatementsOfComprehensiveLossExplanatory_2" xml:lang="en-US">Disclosure of share based payments recognized in the consolidated statements of comprehensive loss [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_drug_DisclosureOfDetailedInformationAboutSignificantAccountingPoliciesAbstract_0" xml:lang="en-US">Disclosure Of Detailed Information About Significant Accounting Policies [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_drug_DisclosureOfDetailedInformationAboutTradePayableAndAccruedExpensesExplanatory_0" xml:lang="en-US">The disclosure of detailed information about trade payables and accrued expenses.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_drug_DisclosureOfDetailedInformationAboutTradePayableAndAccruedExpensesExplanatory_1" xml:lang="en-US">Disclosure Of Detailed Information About Trade Payable And Accrued Expenses Explanatory</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_drug_DisclosureOfDetailedInformationAboutTradePayableAndAccruedExpensesExplanatory_2" xml:lang="en-US">Disclosure of accounts payable and accrued liabilities [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_drug_DisclosureOfMovementsInOutstandingWarrantsExplanatory_0" xml:lang="en-US">Disclosure of movements in outstanding warrants explanatory.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_drug_DisclosureOfMovementsInOutstandingWarrantsExplanatory_1" xml:lang="en-US">Disclosure Of Movements In Outstanding Warrants Explanatory</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_drug_DisclosureOfMovementsInOutstandingWarrantsExplanatory_2" xml:lang="en-US">Disclosure of number and weighted average exercise prices of warrants [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_drug_DisclosureOfNatureAndContinuanceOfOperationsExplanatory_0" xml:lang="en-US">The disclosure of nature and continuation of operation.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_drug_DisclosureOfNatureAndContinuanceOfOperationsExplanatory_1" xml:lang="en-US">Disclosure Of Nature And Continuance Of Operations Explanatory</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_drug_DisclosureOfNatureAndContinuanceOfOperationsExplanatory_2" xml:lang="en-US">NATURE AND CONTINUANCE OF OPERATIONS [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_drug_DisclosureOfNonCapitalLossCarryForwardsExpiryExplanatory_0" xml:lang="en-US">The disclosure of non-capital loss carry-forwards expiry.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_drug_DisclosureOfNonCapitalLossCarryForwardsExpiryExplanatory_1" xml:lang="en-US">Disclosure Of Non Capital Loss Carry Forwards Expiry Explanatory</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_drug_DisclosureOfNonCapitalLossCarryForwardsExpiryExplanatory_2" xml:lang="en-US">Disclosure of non-capital loss carry-forwards expiry [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_drug_DisclosureOfNumberAndWeightedAverageExercisePricesOfWarrantsExplanatory_0" xml:lang="en-US">Disclosure Of Number And Weighted Average Exercise Prices Of Warrants Explanatory</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_drug_DisclosureOfNumberAndWeightedAverageExercisePricesOfWarrantsExplanatory_1" xml:lang="en-US">Disclosure of number and weighted average exercise prices of warrants explanatory.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_drug_DisclosureOfNumberAndWeightedAverageExercisePricesOfWarrantsExplanatory_2" xml:lang="en-US">Disclosure of number and weighted average exercise prices of warrants [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_drug_DisclosureOfNumberOfIssuedAndOutstandingStockOptionsExplanatory_0" xml:lang="en-US">Disclosure of number of issued and outstanding stock options explanatory.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_drug_DisclosureOfNumberOfIssuedAndOutstandingStockOptionsExplanatory_1" xml:lang="en-US">Disclosure Of Number Of Issued And Outstanding Stock Options Explanatory</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_drug_DisclosureOfNumberOfIssuedAndOutstandingStockOptionsExplanatory_2" xml:lang="en-US">Disclosure of number of issued and outstanding stock options [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_drug_DisclosureOfNumberOfIssuedAndOutstandingWarrantsExplanatory_0" xml:lang="en-US">Disclosure of number of issued and outstanding warrants explanatory.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_drug_DisclosureOfNumberOfIssuedAndOutstandingWarrantsExplanatory_1" xml:lang="en-US">Disclosure Of Number Of Issued And Outstanding Warrants Explanatory</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_drug_DisclosureOfNumberOfIssuedAndOutstandingWarrantsExplanatory_2" xml:lang="en-US">Disclosure of number of outstanding warrants [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_drug_DisclosureOfReconciliationOfExpectedIncomeTaxRecoveryToActualIncomeTaxRecoveryExplanatory_0" xml:lang="en-US">The disclosure of reconciliation of the expected income tax recovery to the actual income tax recovery.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_drug_DisclosureOfReconciliationOfExpectedIncomeTaxRecoveryToActualIncomeTaxRecoveryExplanatory_1" xml:lang="en-US">Disclosure Of Reconciliation Of Expected Income Tax Recovery To Actual Income Tax Recovery Explanatory</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_drug_DisclosureOfReconciliationOfExpectedIncomeTaxRecoveryToActualIncomeTaxRecoveryExplanatory_2" xml:lang="en-US">Disclosure of reconciliation of the expected income tax recovery to the actual income tax recovery [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_drug_DisclosureOfShareExchangeAndAssignmentExplanatory_0" xml:lang="en-US">The disclosure of share exchange and assignment.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_drug_DisclosureOfShareExchangeAndAssignmentExplanatory_1" xml:lang="en-US">Disclosure Of Share Exchange And Assignment Explanatory</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_drug_DisclosureOfShareExchangeAndAssignmentExplanatory_2" xml:lang="en-US">SHARE EXCHANGE AND ASSIGNMENT [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_drug_DisclosureOfShareExchangeAndAssignmentTable_0" xml:lang="en-US">Schedule disclosing information related to share exchange and assignment.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_drug_DisclosureOfShareExchangeAndAssignmentTable_1" xml:lang="en-US">Disclosure Of Share Exchange And Assignment [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_drug_DiscountRateOfWarrantsGranted_0" xml:lang="en-US">Discount rate of warrants granted.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_drug_DiscountRateOfWarrantsGranted_1" xml:lang="en-US">Discount Rate Of Warrants Granted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_drug_DiscountRateOfWarrantsGranted_2" xml:lang="en-US">Discount rate, warrants granted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_drug_DiscountRateStockOptionGranted_0" xml:lang="en-US">Percentage of discount rate of stock option granted.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_drug_DiscountRateStockOptionGranted_1" xml:lang="en-US">Discount Rate, Stock Option Granted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_drug_DiscountRateStockOptionGranted_2" xml:lang="en-US">Discount rate, stock options granted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_drug_DocumentAndEntityAbstract_0" xml:lang="en-US">Document and entity.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_drug_DocumentAndEntityAbstract_1" xml:lang="en-US">Document And Entity [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_drug_EighteenMonthAnniversaryOfGrantDateMember_0" xml:lang="en-US">eighteen month anniversary of grant date.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_drug_EighteenMonthAnniversaryOfGrantDateMember_1" xml:lang="en-US">Eighteen Month Anniversary Of Grant Date [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_drug_EighthTrancheMember_0" xml:lang="en-US">Eighth tranche</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_drug_EighthTrancheMember_1" xml:lang="en-US">Eighth Tranche [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_drug_EighthTrancheMember_2" xml:lang="en-US">On the third anniversary of the grant date [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_drug_EleventhTrancheMember_0" xml:lang="en-US">Eleventh tranche.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_drug_EleventhTrancheMember_1" xml:lang="en-US">Eleventh Tranche [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_drug_EleventhTrancheMember_2" xml:lang="en-US">On the eighteen-month anniversary of the grant date [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_drug_EquitySettledShareBasedPaymentArrangementsMember_0" xml:lang="en-US">This member stands for an agreement for equity settled transactions.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_drug_EquitySettledShareBasedPaymentArrangementsMember_1" xml:lang="en-US">Equity Settled Share Based Payment Arrangements [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_drug_EquitySettledShareBasedPaymentArrangementsMember_2" xml:lang="en-US">Equity settled [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_drug_EscrowAgreementMember_0" xml:lang="en-US">escrow agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_drug_EscrowAgreementMember_1" xml:lang="en-US">Escrow Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_drug_EscrowedSecuritiesMember_0" xml:lang="en-US">Escrowed Securities [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_drug_EscrowedSecuritiesMember_1" xml:lang="en-US">Escrowed securities [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_drug_EscrowedSecuritiesToBeReleasedAfterListingDate_0" xml:lang="en-US">Escrowed Securities To Be Released After Listing Date</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_drug_EscrowedSecuritiesToBeReleasedAfterListingDate_1" xml:lang="en-US">Represents number of escrowed securities to be released after listing date.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_drug_EscrowedSecuritiesToBeReleasedAfterListingDate_2" xml:lang="en-US">Escrowed securities to be released after listing date</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_drug_EscrowedSecuritiesToBeReleasedOnceSharesAreListedOnCanadianStockExchange_0" xml:lang="en-US">Escrowed Securities To Be Released Once Shares Are Listed On Canadian Stock Exchange</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_drug_EscrowedSecuritiesToBeReleasedOnceSharesAreListedOnCanadianStockExchange_1" xml:lang="en-US">Represents escrowed securities to be released once shares are listed on Canadian Stock Exchange.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_drug_EscrowedSecuritiesToBeReleasedOnceSharesAreListedOnCanadianStockExchange_2" xml:lang="en-US">Escrowed securities to be released once shares are listed on Canadian Stock Exchange</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_drug_EscrowedSharePurchaseWarrantsMember_0" xml:lang="en-US">Escrowed share purchase warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_drug_EscrowedSharePurchaseWarrantsMember_1" xml:lang="en-US">Escrowed Share Purchase Warrants [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_drug_EscrowedSharePurchaseWarrantsMember_2" xml:lang="en-US">Escrowed share purchase warrants [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_drug_EstimatedFairValueOfEquitySettledRsusGranted_0" xml:lang="en-US">Estimated fair value of equity settled RSUs granted.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_drug_EstimatedFairValueOfEquitySettledRsusGranted_1" xml:lang="en-US">Estimated Fair Value Of Equity Settled Rsus Granted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_drug_EstimatedFairValueOfEquitySettledRsusGranted_2" xml:lang="en-US">Estimated fair value of equity settled RSUs granted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_drug_EstimatedLifeOfWarrantsGranted_0" xml:lang="en-US">Estimated life of warrants granted.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_drug_EstimatedLifeOfWarrantsGranted_1" xml:lang="en-US">Estimated Life Of Warrants Granted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_drug_EstimatedLifeOfWarrantsGranted_2" xml:lang="en-US">Estimated life, warrants granted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_drug_ExercisePriceWarrantsGranted_0" xml:lang="en-US">Exercise price, warrants granted.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_drug_ExercisePriceWarrantsGranted_1" xml:lang="en-US">Exercise Price, Warrants Granted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_drug_ExercisePriceWarrantsGranted_2" xml:lang="en-US">Exercise price, warrants granted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_drug_ExpectedVolatilityWarrantsGranted_0" xml:lang="en-US">Expected volatility of warrants granted.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_drug_ExpectedVolatilityWarrantsGranted_1" xml:lang="en-US">Expected Volatility, Warrants Granted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_drug_ExpectedVolatilityWarrantsGranted_2" xml:lang="en-US">Expected volatility, warrants granted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_drug_ExpirationPeriodDomain_0" xml:lang="en-US">Expiration period domain.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_drug_ExpirationPeriodDomain_1" xml:lang="en-US">Expiration Period [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_drug_ExpirePeriodAxis_0" xml:lang="en-US">The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_drug_ExpirePeriodAxis_1" xml:lang="en-US">Expire Period [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_drug_ExpiryDate_0" xml:lang="en-US">Represents the expiry date</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_drug_ExpiryDate_1" xml:lang="en-US">Expiry Date</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_drug_ExpiryDate_2" xml:lang="en-US">Expiry Date</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_drug_ExpiryDateAxis_0" xml:lang="en-US">The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_drug_ExpiryDateAxis_1" xml:lang="en-US">Expiry Date [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_drug_ExpiryDateDomain_0" xml:lang="en-US">This member stands for the expiry date.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_drug_ExpiryDateDomain_1" xml:lang="en-US">Expiry Date [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_drug_ExpiryDateFifteenJuneTwoThousandAndTwentySixMember_0" xml:lang="en-US">Expiry Date Fifteen June Two Thousand And Twenty Six</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_drug_ExpiryDateFifteenJuneTwoThousandAndTwentySixMember_1" xml:lang="en-US">Expiry Date Fifteen June Two Thousand And Twenty Six [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_drug_ExpiryDateFifteenJuneTwoThousandAndTwentySixMember_2" xml:lang="en-US">June 15, 2026 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_drug_ExpiryDateSeventeenMarchTwoThousandAndTwentyFourOneMember_0" xml:lang="en-US">This member stands for the expiry date of March 17, 2024.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_drug_ExpiryDateSeventeenMarchTwoThousandAndTwentyFourOneMember_1" xml:lang="en-US">Expiry Date Seventeen March Two Thousand And Twenty Four One [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_drug_ExpiryDateSeventeenMarchTwoThousandAndTwentyFourOneMember_2" xml:lang="en-US">March 17, 2024 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_drug_ExpiryDateSeventeenMarchTwoThousandAndTwentyFourTwoMember_0" xml:lang="en-US">This member stands for the expiry date of March 17, 2024.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_drug_ExpiryDateSeventeenMarchTwoThousandAndTwentyFourTwoMember_1" xml:lang="en-US">Expiry Date Seventeen March Two Thousand And Twenty Four Two [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_drug_ExpiryDateSeventeenMarchTwoThousandAndTwentyFourTwoMember_2" xml:lang="en-US">March 17, 2024 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_drug_ExpiryDateSeventeenNovemberTwoThousandAndTwentyFiveMember_0" xml:lang="en-US">This member stands for the expiry date of November 17, 2025.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_drug_ExpiryDateSeventeenNovemberTwoThousandAndTwentyFiveMember_1" xml:lang="en-US">Expiry Date Seventeen November Two Thousand And Twenty Five [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_drug_ExpiryDateSeventeenNovemberTwoThousandAndTwentyFiveMember_2" xml:lang="en-US">November 17, 2025 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_drug_ExpiryDateThirtyJulyTwoThousandAndTwentyFourMember_0" xml:lang="en-US">This member stands for the expiry date of July 30, 2024.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_drug_ExpiryDateThirtyJulyTwoThousandAndTwentyFourMember_1" xml:lang="en-US">Expiry Date Thirty July Two Thousand And Twenty Four [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_drug_ExpiryDateThirtyJulyTwoThousandAndTwentyFourMember_2" xml:lang="en-US">July 30, 2024 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_drug_ExpiryDateTwentyEightAprilTwoThousandAndTwentySixMember_0" xml:lang="en-US">This member stands for the expiry date of April 28, 2026.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_drug_ExpiryDateTwentyEightAprilTwoThousandAndTwentySixMember_1" xml:lang="en-US">Expiry Date Twenty Eight April Two Thousand And Twenty Six [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_drug_ExpiryDateTwentyEightAprilTwoThousandAndTwentySixMember_2" xml:lang="en-US">April 28, 2026 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_drug_ExpiryDateTwentyOneSeptemberTwoThousandAndTwentyFourMember_0" xml:lang="en-US">This member stands for the expiry date of September 21, 2024.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_drug_ExpiryDateTwentyOneSeptemberTwoThousandAndTwentyFourMember_1" xml:lang="en-US">Expiry Date Twenty One September Two Thousand And Twenty Four [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_drug_ExpiryDateTwentyOneSeptemberTwoThousandAndTwentyFourMember_2" xml:lang="en-US">September 21, 2024 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_drug_ExpiryDateTwentyThreeJulyTwoThousandAndTwentyFiveMember_0" xml:lang="en-US">This member stands for the expiry date of July 23, 2025.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_drug_ExpiryDateTwentyThreeJulyTwoThousandAndTwentyFiveMember_1" xml:lang="en-US">Expiry Date Twenty Three July Two Thousand And Twenty Five [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_drug_ExpiryDateTwentyThreeJulyTwoThousandAndTwentyFiveMember_2" xml:lang="en-US">July 23, 2025 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_drug_FairValueAscribedToBrokersWarrantsIssued_0" xml:lang="en-US">Fair value ascribed to brokers' warrants issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_drug_FairValueAscribedToBrokersWarrantsIssued_1" xml:lang="en-US">Fair Value Ascribed To Brokers Warrants Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_drug_FairValueAscribedToBrokersWarrantsIssued_2" xml:lang="en-US">Fair value ascribed to brokers' warrants issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_drug_FairValueOfOptionsIssuedAsFindersFees_0" xml:lang="en-US">Fair value of options issued as finder's fees</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_drug_FairValueOfOptionsIssuedAsFindersFees_1" xml:lang="en-US">Fair Value Of Options Issued As Finders Fees</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_drug_FairValueOfOptionsIssuedAsFindersFees_2" xml:lang="en-US">Fair value of options issued as finder's fees</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_drug_FairValueOfWarrants_0" xml:lang="en-US">Represents fair value of warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_drug_FairValueOfWarrants_1" xml:lang="en-US">Fair Value Of Warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_drug_FairValueOfWarrants_2" xml:lang="en-US">Fair value of share purchase warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_drug_FifteenthTrancheMember_0" xml:lang="en-US">Fifteenth tranche</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_drug_FifteenthTrancheMember_1" xml:lang="en-US">Fifteenth Tranche [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_drug_FifteenthTrancheMember_2" xml:lang="en-US">On September 21, 2022 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_drug_FifthTrancheMember_0" xml:lang="en-US">Fifth tranche</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_drug_FifthTrancheMember_1" xml:lang="en-US">Fifth Tranche [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_drug_FifthTrancheMember_2" xml:lang="en-US">On the six-month anniversary of the listing date [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_drug_FinancialInstrumentsAtAmortizedCostMember_0" xml:lang="en-US">Financial Instruments At Amortized Cost.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_drug_FinancialInstrumentsAtAmortizedCostMember_1" xml:lang="en-US">Financial Instruments At Amortized Cost [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_drug_FinancialInstrumentsAtAmortizedCostMember_2" xml:lang="en-US">Amortized cost [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_drug_FinancialInstrumentsAtFairValueThroughProfitOrLossMember_0" xml:lang="en-US">Financial Instruments At Fair Value Through Profit Or Loss.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_drug_FinancialInstrumentsAtFairValueThroughProfitOrLossMember_1" xml:lang="en-US">Financial Instruments At Fair Value Through Profit Or Loss [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_drug_FinancialInstrumentsAtFairValueThroughProfitOrLossMember_2" xml:lang="en-US">FVTPL [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_drug_FirstAnniversaryOfGrantDateMember_0" xml:lang="en-US">Represents member information related to first anniversary of grant date.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_drug_FirstAnniversaryOfGrantDateMember_1" xml:lang="en-US">First Anniversary Of Grant Date [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_drug_FirstTrancheMember_0" xml:lang="en-US">First tranche [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_drug_FirstTrancheMember_1" xml:lang="en-US">First Tranche [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_drug_FirstTrancheMember_2" xml:lang="en-US">January 1, 2022</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_drug_FirstTrancheMember_3" xml:lang="en-US">On the date of grant [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_drug_FirstTrancheOfNonBrokeredPrivatePlacementMember_0" xml:lang="en-US">First tranche of non brokered private placement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_drug_FirstTrancheOfNonBrokeredPrivatePlacementMember_1" xml:lang="en-US">First Tranche Of Non Brokered Private Placement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_drug_FirstTrancheOfNonBrokeredPrivatePlacementMember_2" xml:lang="en-US">First tranche of a non-brokered private placement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_drug_ForfeitureRateOfOtherEquityInstruments_0" xml:lang="en-US">Represents the percentage of forfeiture of other equity instruments.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_drug_ForfeitureRateOfOtherEquityInstruments_1" xml:lang="en-US">Forfeiture Rate Of Other Equity Instruments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_drug_ForfeitureRateOfOtherEquityInstruments_2" xml:lang="en-US">Forfeiture rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_drug_FourteenthTrancheMember_0" xml:lang="en-US">Fourteenth tranche</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_drug_FourteenthTrancheMember_1" xml:lang="en-US">Fourteenth Tranche [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_drug_FourteenthTrancheMember_2" xml:lang="en-US">On June 21, 2022 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_drug_FourthAnniversaryOfGrantDateMember_0" xml:lang="en-US">Represents member information related to fourth anniversary of grant date.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_drug_FourthAnniversaryOfGrantDateMember_1" xml:lang="en-US">Fourth Anniversary Of Grant Date [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_drug_FourthTrancheMember_0" xml:lang="en-US">Fourth tranche</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_drug_FourthTrancheMember_1" xml:lang="en-US">Fourth Tranche [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_drug_FourthTrancheMember_2" xml:lang="en-US">On the second anniversary of the listing date [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_drug_GrantDateAxis_0" xml:lang="en-US">The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_drug_GrantDateAxis_1" xml:lang="en-US">Grant Date [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_drug_GrantDateDomain_0" xml:lang="en-US">Grant Date [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_drug_GrantDateDomain_1" xml:lang="en-US">Grant Date [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_drug_GrossProceedsFromUnitsIssued_0" xml:lang="en-US">The amount of gross proceeds from units issued.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_drug_GrossProceedsFromUnitsIssued_1" xml:lang="en-US">Gross Proceeds From Units Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_drug_GrossProceedsFromUnitsIssued_2" xml:lang="en-US">Gross proceeds from units issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_drug_GrossProceedsFromWarrantsExercised_0" xml:lang="en-US">Represent the gross proceeds from warrants exercised.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_drug_GrossProceedsFromWarrantsExercised_1" xml:lang="en-US">Gross Proceeds From Warrants Exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_drug_GrossProceedsFromWarrantsExercised_2" xml:lang="en-US">Gross proceeds from warrants exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_drug_GrossProceedsFromWarrantsIssued_0" xml:lang="en-US">The amount of gross proceeds from warrants issued.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_drug_GrossProceedsFromWarrantsIssued_1" xml:lang="en-US">Gross Proceeds From Warrants Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_drug_GrossProceedsFromWarrantsIssued_2" xml:lang="en-US">Gross proceeds from warrants issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_drug_IncomeTaxAuthorityNameOfCountryAxis_0" xml:lang="en-US">Income tax authority name of country.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_drug_IncomeTaxAuthorityNameOfCountryAxis_1" xml:lang="en-US">Income Tax Authority Name Of Country [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_drug_IncomeTaxAuthorityNameOfCountryDomain_0" xml:lang="en-US">Income tax authority name of country.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_drug_IncomeTaxAuthorityNameOfCountryDomain_1" xml:lang="en-US">Income Tax Authority Name Of Country [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_drug_IncreaseDecreaseThroughAcquisitionOfIntangibleAssets_0" xml:lang="en-US">The increase (decrease) in equity resulting from the acquisition of of intangible assets.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_drug_IncreaseDecreaseThroughAcquisitionOfIntangibleAssets_1" xml:lang="en-US">Increase Decrease Through Acquisition Of Intangible Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_drug_IncreaseDecreaseThroughAcquisitionOfIntangibleAssets_2" xml:lang="en-US">Acquisition of intangible assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_drug_IncreaseDecreaseThroughAcquisitionOfIntangibleAssetsShares_0" xml:lang="en-US">The increase and decrease in equity resulting from acquisition of intangible assets shares.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_drug_IncreaseDecreaseThroughAcquisitionOfIntangibleAssetsShares_1" xml:lang="en-US">Increase Decrease Through Acquisition Of Intangible Assets Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_drug_IncreaseDecreaseThroughAcquisitionOfIntangibleAssetsShares_2" xml:lang="en-US">Acquisition of intangible asset (shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_drug_IncreaseDecreaseThroughCashDistributionForFindersFees_0" xml:lang="en-US">Represents the increase (decrease) through cash distribution for finder's fee.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_drug_IncreaseDecreaseThroughCashDistributionForFindersFees_1" xml:lang="en-US">Increase Decrease Through Cash Distribution For Finders Fees</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_drug_IncreaseDecreaseThroughCashDistributionForFindersFees_2" xml:lang="en-US">Finder's fees - cash</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_drug_IncreaseDecreaseThroughDebtSettlementWithShare_0" xml:lang="en-US">The increase decrease in equity through settlement of debt with shares.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_drug_IncreaseDecreaseThroughDebtSettlementWithShare_1" xml:lang="en-US">Increase Decrease Through Debt Settlement With Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_drug_IncreaseDecreaseThroughDebtSettlementWithShare_2" xml:lang="en-US">Debt settlement with shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_drug_IncreaseDecreaseThroughDebtSettlementWithShareShares_0" xml:lang="en-US">The increase (decrease) through debt settlement with share shares.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_drug_IncreaseDecreaseThroughDebtSettlementWithShareShares_1" xml:lang="en-US">Increase Decrease Through Debt Settlement With Share Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_drug_IncreaseDecreaseThroughDebtSettlementWithShareShares_2" xml:lang="en-US">Debt settlement with shares (shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_drug_IncreaseDecreaseThroughDistributionOfBrokerWarrantsForFindersFees_0" xml:lang="en-US">The Increase decrease through distribution of broker warrants for finders fees</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_drug_IncreaseDecreaseThroughDistributionOfBrokerWarrantsForFindersFees_1" xml:lang="en-US">Increase Decrease Through Distribution Of Broker Warrants For Finders Fees</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_drug_IncreaseDecreaseThroughDistributionOfBrokerWarrantsForFindersFees_2" xml:lang="en-US">Finder's fees - broker warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_drug_IncreaseDecreaseThroughExerciseOfOptionsForFindersFee_0" xml:lang="en-US">Represents increase (decrease) through exercise of options for finders fee.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_drug_IncreaseDecreaseThroughExerciseOfOptionsForFindersFee_1" xml:lang="en-US">Increase Decrease Through Exercise Of Options For Finders Fee</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_drug_IncreaseDecreaseThroughExerciseOfOptionsForFindersFee_2" xml:lang="en-US">Finder's fees - share options</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_drug_IncreaseDecreaseThroughExerciseOfWarrantsShares_0" xml:lang="en-US">The increase (decrease) through exercise of warrants shares.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_drug_IncreaseDecreaseThroughExerciseOfWarrantsShares_1" xml:lang="en-US">Increase Decrease Through Exercise Of Warrants Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_drug_IncreaseDecreaseThroughExerciseOfWarrantsShares_2" xml:lang="en-US">Warrants exercised (shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_drug_IncreaseDecreaseThroughFindersFeesBrokerWarrants_0" xml:lang="en-US">Increase Decrease Through Finders Fees Broker Warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_drug_IncreaseDecreaseThroughFindersFeesBrokerWarrants_1" xml:lang="en-US">The Increase decrease through distribution of broker warrants for finders fees.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_drug_IncreaseDecreaseThroughFindersFeesBrokerWarrants_2" xml:lang="en-US">Finder's fees - broker warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_drug_IncreaseDecreaseThroughFindersFeesCash_0" xml:lang="en-US">Increase Decrease Through Finders Fees Cash</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_drug_IncreaseDecreaseThroughFindersFeesCash_1" xml:lang="en-US">Represents the increase (decrease) through cash distribution for finder's fee.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_drug_IncreaseDecreaseThroughFindersFeesCash_2" xml:lang="en-US">Finder's fees - cash</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_drug_IncreaseDecreaseThroughFindersFeesShareOptions_0" xml:lang="en-US">Increase Decrease Through Finders Fees Share Options</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_drug_IncreaseDecreaseThroughFindersFeesShareOptions_1" xml:lang="en-US">Represents increase (decrease) through exercise of options for finders fee.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_drug_IncreaseDecreaseThroughFindersFeesShareOptions_2" xml:lang="en-US">Finder's fees - share options</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_drug_IncreaseDecreaseThroughPrivatePlacement_0" xml:lang="en-US">Increase Decrease Through Private Placement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_drug_IncreaseDecreaseThroughPrivatePlacement_1" xml:lang="en-US">Represents the amount of shares issued under private placement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_drug_IncreaseDecreaseThroughPrivatePlacement_2" xml:lang="en-US">Private placement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_drug_IncreaseDecreaseThroughPrivatePlacementShares_0" xml:lang="en-US">Increase Decrease Through Private Placement Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_drug_IncreaseDecreaseThroughPrivatePlacementShares_1" xml:lang="en-US">Represents the number of shares issued under private placement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_drug_IncreaseDecreaseThroughPrivatePlacementShares_2" xml:lang="en-US">Private placement (shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_drug_IncreaseDecreaseThroughSharesIssuedToUniversity_0" xml:lang="en-US">The increase (decrease) through shares issued to university.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_drug_IncreaseDecreaseThroughSharesIssuedToUniversity_1" xml:lang="en-US">Increase Decrease Through Shares Issued To University</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_drug_IncreaseDecreaseThroughSharesIssuedToUniversity_2" xml:lang="en-US">Shares issued to the University</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_drug_IncreaseDecreaseThroughSharesIssuedToUniversityShares_0" xml:lang="en-US">The increase (decrease) through shares issued to university shares.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_drug_IncreaseDecreaseThroughSharesIssuedToUniversityShares_1" xml:lang="en-US">Increase Decrease Through Shares Issued To University Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_drug_IncreaseDecreaseThroughSharesIssuedToUniversityShares_2" xml:lang="en-US">Shares issued to the University (shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_drug_IncreaseDecreaseThroughSpecialWarrantConversion_0" xml:lang="en-US">The increase (decrease) through special warrant conversion.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_drug_IncreaseDecreaseThroughSpecialWarrantConversion_1" xml:lang="en-US">Increase Decrease Through Special Warrant Conversion</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_drug_IncreaseDecreaseThroughSpecialWarrantConversion_2" xml:lang="en-US">Special warrant conversion</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_drug_IncreaseDecreaseThroughSpecialWarrantConversionShares_0" xml:lang="en-US">The increase (decrease) through special warrant conversion shares.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_drug_IncreaseDecreaseThroughSpecialWarrantConversionShares_1" xml:lang="en-US">Increase Decrease Through Special Warrant Conversion Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_drug_IncreaseDecreaseThroughSpecialWarrantConversionShares_2" xml:lang="en-US">Special warrant conversion (shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_drug_IndependentConsultantAgreementMember_0" xml:lang="en-US">Independent Consultant Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_drug_IndependentConsultantAgreementMember_1" xml:lang="en-US">Information about independent consultant agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_drug_IndependentContractorAgreementToServeAsChiefMedicalOfficerMember_0" xml:lang="en-US">Independent Contractor Agreement To Serve as Chief Medical Officer [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_drug_IndependentContractorAgreementToServeAsChiefMedicalOfficerMember_1" xml:lang="en-US">Independent contractor agreement to serve as Chief Medical Officer [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_drug_IndependentContractorAgreementToServeAsChiefScienceOfficerMember_0" xml:lang="en-US">Independent Contractor Agreement To Serve as Chief Science Officer.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_drug_IndependentContractorAgreementToServeAsChiefScienceOfficerMember_1" xml:lang="en-US">Independent contractor agreement to serve as Chief Science Officer [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_drug_IndependentContractorAgreementToServeAsChiefScienceOfficerMember_2" xml:lang="en-US">Independent Contractor Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_drug_IssuanceOfRestrictedStockUnits_0" xml:lang="en-US">Represents the amount of issuance of restricted stock units.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_drug_IssuanceOfRestrictedStockUnits_1" xml:lang="en-US">Issuance Of Restricted Stock Units</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_drug_IssuanceOfRestrictedStockUnits_2" xml:lang="en-US">Issuance of RSU</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_drug_IssueOfSharesUnderPrivatePlacement_0" xml:lang="en-US">Represents the number of shares issued under private placement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_drug_IssueOfSharesUnderPrivatePlacement_1" xml:lang="en-US">Issue Of Shares Under Private Placement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_drug_IssueOfSharesUnderPrivatePlacement_2" xml:lang="en-US">Private placement (shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_drug_IssueOfSharesUnderPrivatePlacementValue_0" xml:lang="en-US">Represents the amount of shares issued under private placement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_drug_IssueOfSharesUnderPrivatePlacementValue_1" xml:lang="en-US">Issue Of Shares Under Private Placement Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_drug_IssueOfSharesUnderPrivatePlacementValue_2" xml:lang="en-US">Private placement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_drug_IssuePricePerShare_0" xml:lang="en-US">Issue price per share.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_drug_IssuePricePerShare_1" xml:lang="en-US">Issue Price Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_drug_IssuePricePerShare_2" xml:lang="en-US">Shares issued price per share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_drug_JuneTwentyOneTwoZeroTwoTwoMember_0" xml:lang="en-US">June 21, 2022.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_drug_JuneTwentyOneTwoZeroTwoTwoMember_1" xml:lang="en-US">June Twenty One Two Zero Two Two [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_drug_KeyManagementPersonnelCompensationShareBasedPaymentIncludedInProfessionalFees_0" xml:lang="en-US">The amount of compensation to key management personnel in the form of share-based payments included in Professional Fees.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_drug_KeyManagementPersonnelCompensationShareBasedPaymentIncludedInProfessionalFees_1" xml:lang="en-US">Key Management Personnel Compensation Share Based Payment Included In Professional Fees</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_drug_KeyManagementPersonnelCompensationShareBasedPaymentIncludedInProfessionalFees_2" xml:lang="en-US">Share-based compensation included in professional fees</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_drug_KeyManagementPersonnelCompensationShareBasedPaymentIncludedInResearchAndDevelopment_0" xml:lang="en-US">The amount of compensation to key management personnel in the form of share-based payments included in Research And Development.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_drug_KeyManagementPersonnelCompensationShareBasedPaymentIncludedInResearchAndDevelopment_1" xml:lang="en-US">Key Management Personnel Compensation Share Based Payment Included In Research And Development</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_drug_KeyManagementPersonnelCompensationShareBasedPaymentIncludedInResearchAndDevelopment_2" xml:lang="en-US">Share-based compensation included in research and development</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_drug_KeyManagementPersonnelProfessionalFees_0" xml:lang="en-US">The amount of compensation to key management personnel in the form of professional fees.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_drug_KeyManagementPersonnelProfessionalFees_1" xml:lang="en-US">Key Management Personnel Professional Fees</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_drug_KeyManagementPersonnelProfessionalFees_2" xml:lang="en-US">Professional fees</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_drug_KeyManagementPersonnelResearchAndDevelopment_0" xml:lang="en-US">The amount of compensation to key management personnel in the form of Research And Development.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_drug_KeyManagementPersonnelResearchAndDevelopment_1" xml:lang="en-US">Key Management Personnel Research And Development</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_drug_KeyManagementPersonnelResearchAndDevelopment_2" xml:lang="en-US">Research and development</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_drug_LaboratoryCostsMember_0" xml:lang="en-US">Represents laboratory costs.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_drug_LaboratoryCostsMember_1" xml:lang="en-US">Laboratory Costs [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_drug_LaboratoryCostsMember_2" xml:lang="en-US">Laboratory costs [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_drug_LeaseCost_0" xml:lang="en-US">Amount of lease cost.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_drug_LeaseCost_1" xml:lang="en-US">Lease Cost</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_drug_LeaseCost_2" xml:lang="en-US">Lease cost</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_drug_LetterAgreementMember_0" xml:lang="en-US">This member stands for letter agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_drug_LetterAgreementMember_1" xml:lang="en-US">Letter agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_drug_LicenseAgreementMember_0" xml:lang="en-US">License agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_drug_LicenseAgreementMember_1" xml:lang="en-US">License agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_drug_MarchTwentyOneTwoZeroTwoTwoMember_0" xml:lang="en-US">March 21, 2022.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_drug_MarchTwentyOneTwoZeroTwoTwoMember_1" xml:lang="en-US">March Twenty One Two Zero Two Two [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_drug_MarketingAdvertisingAndInvestorRelationsMember_0" xml:lang="en-US">Represents the primary financial statement caption encompassing marketing, advertising and investor relations.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_drug_MarketingAdvertisingAndInvestorRelationsMember_1" xml:lang="en-US">Marketing, Advertising And Investor Relations [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_drug_MarketingAdvertisingAndInvestorRelationsMember_2" xml:lang="en-US">Marketing, advertising and investor relations [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_drug_MilestonePaymentsUponDosingFirstPatientInFirstPhaseIiiTrial_0" xml:lang="en-US">milestone payments upon dosing first patient in the first Phase III trial.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_drug_MilestonePaymentsUponDosingFirstPatientInFirstPhaseIiiTrial_1" xml:lang="en-US">Milestone Payments Upon Dosing First Patient In First Phase Iii Trial</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_drug_MilestonePaymentsUponDosingFirstPatientInFirstPhaseIiiTrial_2" xml:lang="en-US">Milestone payments upon dosing first patient in the first Phase III trial</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_drug_MilestonePaymentsUponDosingFirstPatientInFirstPhaseIiTrial_0" xml:lang="en-US">milestone payments upon dosing first patient in the first Phase II trial.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_drug_MilestonePaymentsUponDosingFirstPatientInFirstPhaseIiTrial_1" xml:lang="en-US">Milestone Payments Upon Dosing First Patient In First Phase Ii Trial</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_drug_MilestonePaymentsUponDosingFirstPatientInFirstPhaseIiTrial_2" xml:lang="en-US">Milestone payments upon dosing first patient in the first Phase II trial</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_drug_MilestonePaymentsUponDosingFirstPatientInPhaseITrial_0" xml:lang="en-US">Information about milestone payments upon dosing first patient in Phase I trial.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_drug_MilestonePaymentsUponDosingFirstPatientInPhaseITrial_1" xml:lang="en-US">Milestone Payments Upon Dosing First Patient In Phase I Trial</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_drug_MilestonePaymentsUponDosingFirstPatientInPhaseITrial_2" xml:lang="en-US">Milestone payments upon dosing first patient in Phase I trial</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_drug_MilestonePaymentsUponFirstCommercialSaleOfClinical_0" xml:lang="en-US">milestone payments upon first commercial sale of clinical.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_drug_MilestonePaymentsUponFirstCommercialSaleOfClinical_1" xml:lang="en-US">Milestone Payments Upon First Commercial Sale Of Clinical</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_drug_MilestonePaymentsUponFirstCommercialSaleOfClinical_2" xml:lang="en-US">Milestone payments upon first commercial sale of each clinical indication</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_drug_MinimumDailyVolumeWeightedAverageTradingSharePrice_0" xml:lang="en-US">The minimum daily volume weighted average trading share price.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_drug_MinimumDailyVolumeWeightedAverageTradingSharePrice_1" xml:lang="en-US">Minimum Daily Volume Weighted Average Trading Share Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_drug_MinimumDailyVolumeWeightedAverageTradingSharePrice_2" xml:lang="en-US">Minimum daily volume weighted average trading share price on the CSE</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_drug_MonthlyBaseRent_0" xml:lang="en-US">Amount of monthly base rent.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_drug_MonthlyBaseRent_1" xml:lang="en-US">Monthly Base Rent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_drug_MonthlyBaseRent_2" xml:lang="en-US">Monthly base rent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_drug_MonthlyFeeAuthorizedByBoardOfDirectors_0" xml:lang="en-US">Monthly Fee Authorized By Board of Directors.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_drug_MonthlyFeeAuthorizedByBoardOfDirectors_1" xml:lang="en-US">Monthly Fee Authorized By Board Of Directors</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_drug_MonthlyFeeAuthorizedByBoardOfDirectors_2" xml:lang="en-US">Monthly fee authorized by board of directors</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_drug_NatureAndContinuanceOfOperationsAbstract_0" xml:lang="en-US">Nature And Continuance Of Operations [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_drug_NinthTrancheMember_0" xml:lang="en-US">Ninth tranche</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_drug_NinthTrancheMember_1" xml:lang="en-US">Ninth Tranche [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_drug_NinthTrancheMember_2" xml:lang="en-US">On the fourth anniversary of the grant date [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_drug_NonBrokeredPrivatePlacementMember_0" xml:lang="en-US">Non brokered private placement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_drug_NonBrokeredPrivatePlacementMember_1" xml:lang="en-US">Non Brokered Private Placement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_drug_NonBrokeredPrivatePlacementMember_2" xml:lang="en-US">Non-brokered private placement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_drug_NonCapitalLossCarryForwards_0" xml:lang="en-US">The amont of non-capital loss carry forwards.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_drug_NonCapitalLossCarryForwards_1" xml:lang="en-US">Non Capital Loss Carry Forwards</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_drug_NonCapitalLossCarryForwards_2" xml:lang="en-US">Non-capital loss carry-forwards</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_drug_NonCapitalLossCarryForwards_3" xml:lang="en-US">Non-Capital Losses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_drug_NonCapitalLossCarryForwardsYearOfExpiry_0" xml:lang="en-US">Year of expiry for Non-capital loss carry forwards.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_drug_NonCapitalLossCarryForwardsYearOfExpiry_1" xml:lang="en-US">Non Capital Loss Carry Forwards Year Of Expiry</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_drug_NonCapitalLossCarryForwardsYearOfExpiry_2" xml:lang="en-US">Year of Expiry</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_drug_NonCapitalLossCarryForwardsYearOfOriginAxis_0" xml:lang="en-US">Information of non-capital loss carry forwards year of origin.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_drug_NonCapitalLossCarryForwardsYearOfOriginAxis_1" xml:lang="en-US">Non Capital Loss Carry Forwards Year Of Origin [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_drug_NonCapitalLossCarryForwardsYearOfOriginDomain_0" xml:lang="en-US">Information of non-capital loss carry forwards year of origin.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_drug_NonCapitalLossCarryForwardsYearOfOriginDomain_1" xml:lang="en-US">Non Capital Loss Carry Forwards Year Of Origin [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_drug_NonRefundableOptionFeesPaid_0" xml:lang="en-US">Represents the amount of non-refundable option fees paid.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_drug_NonRefundableOptionFeesPaid_1" xml:lang="en-US">Non Refundable Option Fees Paid</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_drug_NonRefundableOptionFeesPaid_2" xml:lang="en-US">Non-refundable option fees paid</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_drug_NovelDrugDevelopmentMember_0" xml:lang="en-US">Represents development for novel drug.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_drug_NovelDrugDevelopmentMember_1" xml:lang="en-US">Novel Drug Development [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_drug_NovelDrugDevelopmentMember_2" xml:lang="en-US">Novel drug development [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_drug_NumberOfCommonSharesCalledByWarrants_0" xml:lang="en-US">The number of common shares called by warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_drug_NumberOfCommonSharesCalledByWarrants_1" xml:lang="en-US">Number Of Common Shares Called By Warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_drug_NumberOfCommonSharesCalledByWarrants_2" xml:lang="en-US">Number of common shares called by warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_drug_NumberOfCommonSharesDepositedToBeHeldInEscrow_0" xml:lang="en-US">Number of common shares deposited to be held in escrow.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_drug_NumberOfCommonSharesDepositedToBeHeldInEscrow_1" xml:lang="en-US">Number Of Common Shares Deposited To Be Held In Escrow</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_drug_NumberOfCommonSharesDepositedToBeHeldInEscrow_2" xml:lang="en-US">Number of common shares deposited to be held in escrow</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_drug_NumberOfCommonSharesSubscribed_0" xml:lang="en-US">Number of common shares subscribed.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_drug_NumberOfCommonSharesSubscribed_1" xml:lang="en-US">Number Of Common Shares Subscribed</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_drug_NumberOfCommonSharesSubscribed_2" xml:lang="en-US">Number of common shares subscribed</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_drug_NumberOfInstrumentsOtherEquityInstrumentsIssued_0" xml:lang="en-US">Represents the number of instruments other equity instruments issued.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_drug_NumberOfInstrumentsOtherEquityInstrumentsIssued_1" xml:lang="en-US">Number Of Instruments Other Equity Instruments Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_drug_NumberOfIssuedWarrantsRescinded_0" xml:lang="en-US">The number of issued warrants rescinded.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_drug_NumberOfIssuedWarrantsRescinded_1" xml:lang="en-US">Number Of Issued Warrants Rescinded</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_drug_NumberOfIssuedWarrantsRescinded_2" xml:lang="en-US">Number of issued warrants rescinded</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_drug_NumberOfRestrictedStockIssuedForCompensation_0" xml:lang="en-US">Number of restricted stock issued for compensation.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_drug_NumberOfRestrictedStockIssuedForCompensation_1" xml:lang="en-US">Number Of Restricted Stock Issued For Compensation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_drug_NumberOfRestrictedStockIssuedForCompensation_2" xml:lang="en-US">Number of restricted stock issued for compensation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_drug_NumberOfShareListed_0" xml:lang="en-US">Represents the number of share listed.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_drug_NumberOfShareListed_1" xml:lang="en-US">Number Of Share Listed</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_drug_NumberOfShareListed_2" xml:lang="en-US">Number of shares listed</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_drug_NumberOfShareOptionsCancelledInShareBasedPaymentArrangement_0" xml:lang="en-US">Number Of Share Options Cancelled In Share Based Payment Arrangement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_drug_NumberOfShareOptionsCancelledInShareBasedPaymentArrangement_1" xml:lang="en-US">Number of options cancelled</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_drug_NumberOfSharesIssuedByRelatedParty_0" xml:lang="en-US">Represents the number of shares issued by related party.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_drug_NumberOfSharesIssuedByRelatedParty_1" xml:lang="en-US">Number Of Shares Issued By Related Party</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_drug_NumberOfSharesIssuedByRelatedParty_2" xml:lang="en-US">Number of shares issued by PL to individual</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_drug_NumberOfUnitsIssued_0" xml:lang="en-US">Number of units issued.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_drug_NumberOfUnitsIssued_1" xml:lang="en-US">Number Of Units Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_drug_NumberOfUnitsIssued_2" xml:lang="en-US">Number of units issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_drug_NumberOfWarrantsDeemedToBeExercised_0" xml:lang="en-US">Number of warrants deemed to be exercised.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_drug_NumberOfWarrantsDeemedToBeExercised_1" xml:lang="en-US">Number Of Warrants Deemed To Be Exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_drug_NumberOfWarrantsDeemedToBeExercised_2" xml:lang="en-US">Number of warrants deemed to be exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_drug_NumberOfWarrantsDepositedToBeHeldInEscrow_0" xml:lang="en-US">Number of warrants deposited to be held in escrow.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_drug_NumberOfWarrantsDepositedToBeHeldInEscrow_1" xml:lang="en-US">Number Of Warrants Deposited To Be Held In Escrow</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_drug_NumberOfWarrantsDepositedToBeHeldInEscrow_2" xml:lang="en-US">Number of warrants deposited to be held in escrow</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_drug_NumberOfWarrantsExercised_0" xml:lang="en-US">Represent the number of warrants exercised.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_drug_NumberOfWarrantsExercised_1" xml:lang="en-US">Number of warrants, Exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_drug_NumberOfWarrantsExercised_2" xml:lang="en-US">Number Of Warrants Exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_drug_NumberOfWarrantsExercised_3" xml:lang="en-US">Number of warrants exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_drug_NumberOfWarrantsExercised_4" xml:lang="en-US">Number of warrants, Exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_drug_NumberOfWarrantsIssued_0" xml:lang="en-US">Represents the number of warrants Issued.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_drug_NumberOfWarrantsIssued_1" xml:lang="en-US">Number Of Warrants Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_drug_NumberOfWarrantsIssued_2" xml:lang="en-US">Number of warrants, Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_drug_NumberOfWarrantsIssuedToBroker_0" xml:lang="en-US">Represents the number of warrants issued to broker.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_drug_NumberOfWarrantsIssuedToBroker_1" xml:lang="en-US">Number Of Warrants Issued To Broker</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_drug_NumberOfWarrantsIssuedToBroker_2" xml:lang="en-US">Number of warrants, Issued - broker</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_drug_NumberOfWarrantsOutstanding_0" xml:lang="en-US">Number Of Warrants Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_drug_NumberOfWarrantsOutstanding_1" xml:lang="en-US">The number of warrants outstanding.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_drug_NumberOfWarrantsOutstanding_2" xml:lang="en-US">Number of warrants, Ending Balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_drug_NumberOfWarrantsOutstanding_3" xml:lang="en-US">Number of warrants, Beginning Balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_drug_NumberOfWarrantsOutstanding_4" xml:lang="en-US">Number of outstanding warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_drug_NumberOfWarrantsOutstanding_5" xml:lang="en-US">Warrants Outstanding, Number of warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_drug_NumberOfWarrantsOutstandingInShareBasedPaymentArrangement_0" xml:lang="en-US">The number of warrants outstanding in a share-based payment arrangement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_drug_NumberOfWarrantsOutstandingInShareBasedPaymentArrangement_1" xml:lang="en-US">Number of warrants, Ending Balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_drug_NumberOfWarrantsOutstandingInShareBasedPaymentArrangement_2" xml:lang="en-US">Number of warrants, Beginning Balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_drug_NumberOfWarrantsOutstandingInShareBasedPaymentArrangement_3" xml:lang="en-US">Number Of Warrants Outstanding In Share Based Payment Arrangement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_drug_NumberOfWarrantsOutstandingInShareBasedPaymentArrangement_4" xml:lang="en-US">Number of outstanding warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_drug_NumberOfWarrantsOutstandingInShareBasedPaymentArrangement_5" xml:lang="en-US">Warrants Outstanding, Number of warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_drug_OptionAgreementMember_0" xml:lang="en-US">Option agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_drug_OptionAgreementMember_1" xml:lang="en-US">Option agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_drug_OptionFeesPaid_0" xml:lang="en-US">The amount of option fees paid.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_drug_OptionFeesPaid_1" xml:lang="en-US">Option Fees Paid</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_drug_OptionFeesPaid_2" xml:lang="en-US">Option fees paid</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_drug_PaymentsForFindersFees_0" xml:lang="en-US">Represents the payments for finders fees</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_drug_PaymentsForFindersFees_1" xml:lang="en-US">Finder's fees</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_drug_PaymentsForFindersFees_2" xml:lang="en-US">Payments For Finders Fees</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_drug_PercentageOfForeignCurrencyFluctuationInUsDollarAgainstCanadianDollar_0" xml:lang="en-US">Percentage of foreign currency fluctuation.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_drug_PercentageOfForeignCurrencyFluctuationInUsDollarAgainstCanadianDollar_1" xml:lang="en-US">Percentage Of Foreign Currency Fluctuation In Us Dollar Against Canadian Dollar</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_drug_PercentageOfForeignCurrencyFluctuationInUsDollarAgainstCanadianDollar_2" xml:lang="en-US">Percentage of foreign currency fluctuation in US dollar against Canadian dollar</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_drug_PercentageOfNetEquityProceedsReceivedFromThreeInvestors_0" xml:lang="en-US">Percentage of equity proceeds received from three investors.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_drug_PercentageOfNetEquityProceedsReceivedFromThreeInvestors_1" xml:lang="en-US">Percentage Of Net Equity Proceeds Received From Three Investors</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_drug_PercentageOfNetEquityProceedsReceivedFromThreeInvestors_2" xml:lang="en-US">Percentage of equity proceeds received from three investors</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_drug_PercentageOfOutstandingSharesAuthorizedUnderStockOptionPlan_0" xml:lang="en-US">Percentage Of Outstanding Shares Authorized Under Stock Option Plan</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_drug_PercentageOfOutstandingSharesAuthorizedUnderStockOptionPlan_1" xml:lang="en-US">Represents percentage of outstanding shares authorized under stock option plan.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_drug_PercentageOfOutstandingSharesAuthorizedUnderStockOptionPlan_2" xml:lang="en-US">Percentage of outstanding shares authorized under stock option plan</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_drug_PercentageOfRoyaltiesOnNetSales_0" xml:lang="en-US">The percentage of royalties on net sales.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_drug_PercentageOfRoyaltiesOnNetSales_1" xml:lang="en-US">Percentage Of Royalties On Net Sales</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_drug_PercentageOfRoyaltiesOnNetSales_2" xml:lang="en-US">Percentage of royalties on net sales</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_drug_PercentageOfRoyaltiesOnNetSalesOver2Billion_0" xml:lang="en-US">Information about percentage of royalties on net sales over 2 billion.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_drug_PercentageOfRoyaltiesOnNetSalesOver2Billion_1" xml:lang="en-US">Percentage Of Royalties On Net Sales Over 2 Billion</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_drug_PercentageOfRoyaltiesOnNetSalesOver2Billion_2" xml:lang="en-US">Percentage of royalties on net sales over $2 billion</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_drug_PercentageOfRoyaltiesOnNetSalesUnder1Billion_0" xml:lang="en-US">Information about percentage of royalties on net sales under $1 billion.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_drug_PercentageOfRoyaltiesOnNetSalesUnder1Billion_1" xml:lang="en-US">Percentage Of Royalties On Net Sales Under 1 Billion</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_drug_PercentageOfRoyaltiesOnNetSalesUnder1Billion_2" xml:lang="en-US">Percentage of royalties on net sales under $1 billion</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_drug_PercentageOfStockOptionPlanAllowsBoardOfDirectorsToIssue_0" xml:lang="en-US">Percentage of stock option plan allows Board of Directors to issue.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_drug_PercentageOfStockOptionPlanAllowsBoardOfDirectorsToIssue_1" xml:lang="en-US">Percentage Of Stock Option Plan Allows Board Of Directors To Issue</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_drug_PercentageOfStockOptionPlanAllowsBoardOfDirectorsToIssue_2" xml:lang="en-US">Percentage of stock option plan allows Board of Directors to issue</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_drug_PercentageOfStockOptionShareGranted_0" xml:lang="en-US">Represents the percentage of stock option share granted.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_drug_PercentageOfStockOptionShareGranted_1" xml:lang="en-US">Percentage Of Stock Option Share Granted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_drug_PercentageOfStockOptionShareGranted_2" xml:lang="en-US">Percentage of stock option share granted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_drug_PriorToSublicensingAgreementsMember_0" xml:lang="en-US">Information about prior to any sublicensing agreements.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_drug_PriorToSublicensingAgreementsMember_1" xml:lang="en-US">Prior to Sublicensing agreements [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_drug_PriorToSublicensingAgreementsMember_2" xml:lang="en-US">Licensing agreement - prior to any sublicensing agreements, joint ventures or change of control [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_drug_ProceedsForWarrantsIssued_0" xml:lang="en-US">Proceeds For Warrants Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_drug_ProceedsForWarrantsIssued_1" xml:lang="en-US">Represents amount of proceeds for warrants issued.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_drug_ProceedsForWarrantsIssued_2" xml:lang="en-US">Proceeds for warrants issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_drug_ProceedsFromExerciseOfSpecialWarrants_0" xml:lang="en-US">Represents Proceeds from exercise of Special warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_drug_ProceedsFromExerciseOfSpecialWarrants_1" xml:lang="en-US">Proceeds From Exercise Of Special Warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_drug_ProceedsFromExerciseOfSpecialWarrants_2" xml:lang="en-US">Special warrant proceeds</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_drug_ProceedsFromIssuingWarrants_0" xml:lang="en-US">Represents amount of proceeds from issuing warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_drug_ProceedsFromIssuingWarrants_1" xml:lang="en-US">Proceeds From Issuing Warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_drug_ProceedsFromIssuingWarrants_2" xml:lang="en-US">Special warrant proceeds</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_drug_ProceedsFromWarrantsExercise_0" xml:lang="en-US">Represents Proceeds From Warrants Exercise</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_drug_ProceedsFromWarrantsExercise_1" xml:lang="en-US">Proceeds From Warrants Exercise</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_drug_ProceedsFromWarrantsExercise_2" xml:lang="en-US">Warrant exercise proceeds</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_drug_ProcessingFees_0" xml:lang="en-US">The amount of expenses related to initial listing of the company.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_drug_ProcessingFees_1" xml:lang="en-US">Processing Fees</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_drug_ProcessingFees_2" xml:lang="en-US">Funds processing fees - private placements</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_drug_ProfessionalFeesMember_0" xml:lang="en-US">Represents the primary financial statement caption encompassing professional fees.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_drug_ProfessionalFeesMember_1" xml:lang="en-US">Professional Fees [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_drug_ProfessionalFeesMember_2" xml:lang="en-US">Professional fees [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_drug_PsilocybinlabsLtdMember_0" xml:lang="en-US">Psilocybinlabs Ltd.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_drug_PsilocybinlabsLtdMember_1" xml:lang="en-US">PsilocybinLabs Ltd [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_drug_RefundFromIssuedWarrantsRescinded_0" xml:lang="en-US">Refund from issued warrants rescinded.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_drug_RefundFromIssuedWarrantsRescinded_1" xml:lang="en-US">Refund From Issued Warrants Rescinded</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_drug_RefundFromIssuedWarrantsRescinded_2" xml:lang="en-US">Refund from issued warrants rescinded</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_drug_RefundOfSpecialWarrantsProceeds_0" xml:lang="en-US">Represents refund of special warrants proceeds.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_drug_RefundOfSpecialWarrantsProceeds_1" xml:lang="en-US">Refund of special warrant proceeds</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_drug_RefundOfSpecialWarrantsProceeds_2" xml:lang="en-US">Refund Of Special Warrants Proceeds</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_drug_RefundOfSpecialWarrantsProceeds_3" xml:lang="en-US">Refund of special warrant proceeds</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_drug_RegulatoryAndFilingExpenses_0" xml:lang="en-US">The amount of expenses related to regulatory and filing.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_drug_RegulatoryAndFilingExpenses_1" xml:lang="en-US">Regulatory And Filing Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_drug_RegulatoryAndFilingExpenses_2" xml:lang="en-US">Regulatory and filing</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_drug_RelatedPartyContractsMember_0" xml:lang="en-US">Information about related party contracts.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_drug_RelatedPartyContractsMember_1" xml:lang="en-US">Related Party Contracts [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_drug_ResearchAndDevelopmentAbstract_0" xml:lang="en-US">Research And Development [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_drug_ResearchAndDevelopmentLineItems_0" xml:lang="en-US">Research And Development [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_drug_ResearchAndDevelopmentMember_0" xml:lang="en-US">Represents the primary financial statement caption encompassing research and development.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_drug_ResearchAndDevelopmentMember_1" xml:lang="en-US">Research And Development [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_drug_ResearchAndDevelopmentMember_2" xml:lang="en-US">Research and development [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_drug_ResearchDevelopmentTable_0" xml:lang="en-US">Research Development [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_drug_RestrictedShareUnitMember_0" xml:lang="en-US">This member stands for restricted share unit.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_drug_RestrictedShareUnitMember_1" xml:lang="en-US">Restricted Share Unit [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_drug_RestrictedShareUnitMember_2" xml:lang="en-US">Restricted Share Units [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_drug_RoyaltiesOnNetSales_0" xml:lang="en-US">The amount of royalties on net sales.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_drug_RoyaltiesOnNetSales_1" xml:lang="en-US">Royalties On Net Sales</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_drug_RoyaltiesOnNetSales_2" xml:lang="en-US">Royalties on net sales</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_drug_SalaryAndSubcontractorsMember_0" xml:lang="en-US">Represents salary and subcontractors.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_drug_SalaryAndSubcontractorsMember_1" xml:lang="en-US">Salary And Subcontractors [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_drug_SalaryAndSubcontractorsMember_2" xml:lang="en-US">Salary and subcontractors [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_drug_ScientificAdvisoryBoardAgreementsMember_0" xml:lang="en-US">Information about scientific advisory board agreements.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_drug_ScientificAdvisoryBoardAgreementsMember_1" xml:lang="en-US">Scientific advisory board agreements [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_drug_SecondAnniversaryOfGrantDateMember_0" xml:lang="en-US">Represents the member information related to second anniversary of grant date.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_drug_SecondAnniversaryOfGrantDateMember_1" xml:lang="en-US">Second Anniversary Of Grant Date [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_drug_SecondTrancheMember_0" xml:lang="en-US">Second Tranche [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_drug_SecondTrancheMember_1" xml:lang="en-US">Second Tranche [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_drug_SecondTrancheMember_2" xml:lang="en-US">April 1, 2022</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_drug_SecondTrancheMember_3" xml:lang="en-US">On the Company's listing date [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_drug_SecondTrancheOfNonBrokeredPrivatePlacementMember_0" xml:lang="en-US">Second tranche of non brokered private placement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_drug_SecondTrancheOfNonBrokeredPrivatePlacementMember_1" xml:lang="en-US">Second Tranche Of Non Brokered Private Placement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_drug_SecondTrancheOfNonBrokeredPrivatePlacementMember_2" xml:lang="en-US">Second tranche of a non-brokered private placement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_drug_SeptemberTwentyOneTwoZeroTwoFourMember_0" xml:lang="en-US">September 21, 2024 .</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_drug_SeptemberTwentyOneTwoZeroTwoFourMember_1" xml:lang="en-US">September Twenty One Two Zero Two Four [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_drug_SeptemberTwentyOneTwoZeroTwoFourMember_2" xml:lang="en-US">September 21, 2024</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_drug_SeptemberTwentyOneTwoZeroTwoTwoMember_0" xml:lang="en-US">September 21, 2022.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_drug_SeptemberTwentyOneTwoZeroTwoTwoMember_1" xml:lang="en-US">September Twenty One Two Zero Two Two [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_drug_SeventhTrancheMember_0" xml:lang="en-US">Seventh tranche</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_drug_SeventhTrancheMember_1" xml:lang="en-US">Seventh Tranche [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_drug_SeventhTrancheMember_2" xml:lang="en-US">On the second anniversary of the grant date [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_drug_ShareBasedCompensationMember_0" xml:lang="en-US">Represents share based compensation.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_drug_ShareBasedCompensationMember_1" xml:lang="en-US">Share Based Compensation [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_drug_ShareBasedCompensationMember_2" xml:lang="en-US">Share-based compensation [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_drug_ShareExchangeAndAssignmentAbstract_0" xml:lang="en-US">Share Exchange And Assignment [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_drug_ShareExchangeAndAssignmentLineItems_0" xml:lang="en-US">Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_drug_ShareExchangeAndAssignmentLineItems_1" xml:lang="en-US">Share Exchange And Assignment [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_drug_ShareIssueCostsIncludedInAccountsPayable_0" xml:lang="en-US">Share issue costs included in accounts payable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_drug_ShareIssueCostsIncludedInAccountsPayable_1" xml:lang="en-US">Share Issue Costs Included In Accounts Payable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_drug_ShareIssueCostsIncludedInAccountsPayable_2" xml:lang="en-US">Share issue costs included in accounts payable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_drug_SharePriceOnGrantDateOfOtherEquityInstruments_0" xml:lang="en-US">Share price on grant date of Other Equity Instruments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_drug_SharePriceOnGrantDateOfOtherEquityInstruments_1" xml:lang="en-US">Share Price On Grant Date Of Other Equity Instruments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_drug_SharePriceOnGrantDateOfOtherEquityInstruments_2" xml:lang="en-US">Share price on grant date</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_drug_SigningFee_0" xml:lang="en-US">The amount of signing fee.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_drug_SigningFee_1" xml:lang="en-US">Signing Fee</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_drug_SigningFee_2" xml:lang="en-US">Signing fee</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_drug_SigningFeeNetOfOptionFeesPaid_0" xml:lang="en-US">Represents amount paid towards signing fee net of option fees.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_drug_SigningFeeNetOfOptionFeesPaid_1" xml:lang="en-US">Signing Fee Net Of Option Fees Paid</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_drug_SigningFeeNetOfOptionFeesPaid_2" xml:lang="en-US">Signing fee, net of option fees paid</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_drug_SigningFeeSharesIssued_0" xml:lang="en-US">Signing Fee, Shares Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_drug_SigningFeeSharesIssued_1" xml:lang="en-US">Represents signing fee, shares issued.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_drug_SigningFeeSharesIssued_2" xml:lang="en-US">Signing fee, shares issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_drug_SixMonthAnniversaryGrantDateMember_0" xml:lang="en-US">Represents the amount of six month anniversary grant date.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_drug_SixMonthAnniversaryGrantDateMember_1" xml:lang="en-US">Six Month Anniversary Grant Date [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_drug_SixthTrancheMember_0" xml:lang="en-US">Sixth tranche</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_drug_SixthTrancheMember_1" xml:lang="en-US">Sixth Tranche [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_drug_SixthTrancheMember_2" xml:lang="en-US">On the first anniversary of the grant date [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_drug_SpecialWarrantsMember_0" xml:lang="en-US">Special Warrants [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_drug_SpecialWarrantsMember_1" xml:lang="en-US">Special Warrants [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_drug_StatementOfComplianceAndBasisOfPreparationAbstract_0" xml:lang="en-US">Statement Of Compliance And Basis Of Preparation [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_drug_StockOptionAxis_0" xml:lang="en-US">The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_drug_StockOptionAxis_1" xml:lang="en-US">Stock Option [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_drug_StockOptionDomain_0" xml:lang="en-US">Stock Option [Domain].</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_drug_StockOptionDomain_1" xml:lang="en-US">Stock Option [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_drug_StockOptionsFourMember_0" xml:lang="en-US">Stock options four</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_drug_StockOptionsFourMember_1" xml:lang="en-US">Stock Options Four [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_drug_StockOptionsMember_0" xml:lang="en-US">This member stands for stock options.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_drug_StockOptionsMember_1" xml:lang="en-US">Stock Options [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_drug_StockOptionsMember_2" xml:lang="en-US">Stock Options [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_drug_StockOptionsOneMember_0" xml:lang="en-US">Represents member information related to stock options one.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_drug_StockOptionsOneMember_1" xml:lang="en-US">Stock Options One [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_drug_StockOptionsThreeMember_0" xml:lang="en-US">Represents member information related to stock options three.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_drug_StockOptionsThreeMember_1" xml:lang="en-US">Stock Options Three [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_drug_StockOptionsTwoMember_0" xml:lang="en-US">Represents member information related to stock options two.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_drug_StockOptionsTwoMember_1" xml:lang="en-US">Stock Options Two [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_drug_SubscriptionAgreementsMember_0" xml:lang="en-US">subscription agreements [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_drug_SubscriptionAgreementsMember_1" xml:lang="en-US">Subscription Agreements [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_drug_SubscriptionReceivableMember_0" xml:lang="en-US">Subscription Receivable [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_drug_SubscriptionReceivableMember_1" xml:lang="en-US">Subscription Receivable [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_drug_SubscriptionReceivableMember_2" xml:lang="en-US">Subscriptions receivable [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_drug_SubscriptionReceivedMember_0" xml:lang="en-US">Subscription Received [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_drug_SubscriptionReceivedMember_1" xml:lang="en-US">Subscription Received [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_drug_SubscriptionReceivedMember_2" xml:lang="en-US">Subscriptions received [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_drug_SubscriptionsReceivable_0" xml:lang="en-US">Represents the amount of subscriptions receivable.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_drug_SubscriptionsReceivable_1" xml:lang="en-US">Subscription receivable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_drug_SubscriptionsReceivable_2" xml:lang="en-US">Subscriptions Receivable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_drug_SubscriptionsReceivable_3" xml:lang="en-US">Subscription receivable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_drug_SubscriptionsReceived_0" xml:lang="en-US">Represents the amount of subscriptions received.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_drug_SubscriptionsReceived_1" xml:lang="en-US">Subscriptions Received</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_drug_SubscriptionsReceived_2" xml:lang="en-US">Subscription received</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_drug_SubsequentEventsMember_0" xml:lang="en-US">Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_drug_SubsequentEventsMember_1" xml:lang="en-US">Subsequent events [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_drug_SupplementaryInformationAbstract_0" xml:lang="en-US">Supplementary Information Abstract</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_drug_SupplementaryInformationAbstract_1" xml:lang="en-US">Supplementary Information [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_drug_SupplementaryInformationAbstract_2" xml:lang="en-US">SUPPLEMENTARY INFORMATION</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_drug_TaxAuthorityOfAustraliaMember_0" xml:lang="en-US">Tax authority of Australia.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_drug_TaxAuthorityOfAustraliaMember_1" xml:lang="en-US">Tax Authority Of Australia [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_drug_TaxAuthorityOfAustraliaMember_2" xml:lang="en-US">Tax authority of Australia [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_drug_TaxAuthorityOfCanadaMember_0" xml:lang="en-US">Tax authority of Canada [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_drug_TaxAuthorityOfCanadaMember_1" xml:lang="en-US">Tax authority of canada.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_drug_TaxAuthorityOfUnitedStatesMember_0" xml:lang="en-US">Tax authority of United States.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_drug_TaxAuthorityOfUnitedStatesMember_1" xml:lang="en-US">Tax Authority Of United States [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_drug_TaxAuthorityOfUnitedStatesMember_2" xml:lang="en-US">Tax authority of United States [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_drug_TaxEffectOfChangeInDeferredTaxAssetsNotRecognized_0" xml:lang="en-US">Tax Effect Of Change In Deferred Tax Assets Not Recognized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_drug_TaxEffectOfChangeInDeferredTaxAssetsNotRecognized_1" xml:lang="en-US">The amount that represents the difference between the tax expense (income) and the product of the accounting profit multiplied by the applicable tax rate(s) that relates to deferred tax assets not recognized.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_drug_TaxEffectOfChangeInDeferredTaxAssetsNotRecognized_2" xml:lang="en-US">Change in deferred tax assets not recognized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_drug_TaxEffectOfDeductibleAndNotDeductibleItems_0" xml:lang="en-US">The amount that represents the difference between the tax expense (income) and the product of the accounting profit multiplied by the applicable tax rate(s) that relates to expenses deductible and not deductible items in determining taxable profit (tax loss).</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_drug_TaxEffectOfDeductibleAndNotDeductibleItems_1" xml:lang="en-US">Deductible and non-deductible items</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_drug_TaxEffectOfDeductibleAndNotDeductibleItems_2" xml:lang="en-US">Tax Effect Of Deductible And Not Deductible Items</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_drug_TaxEffectOfDeductibleAndNotDeductibleItems_3" xml:lang="en-US">Deductible and non-deductible items</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_drug_TaxRateEffectOfDeferredTaxAssetsNotRecognized_0" xml:lang="en-US">The amount that represents the difference between the tax expense (income) and the product of the accounting profit multiplied by the applicable tax rate(s) that relates to deferred tax assets not recognized.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_drug_TaxRateEffectOfDeferredTaxAssetsNotRecognized_1" xml:lang="en-US">Tax Rate Effect Of Deferred Tax Assets Not Recognized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_drug_TaxRateEffectOfDeferredTaxAssetsNotRecognized_2" xml:lang="en-US">Change in deferred tax assets not recognized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_drug_TaxYearOfOrigin2019Member_0" xml:lang="en-US">Tax Year of origin 2019.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_drug_TaxYearOfOrigin2019Member_1" xml:lang="en-US">Tax Year Of Origin 2019 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_drug_TaxYearOfOrigin2019Member_2" xml:lang="en-US">2019 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_drug_TaxYearOfOrigin2020Member_0" xml:lang="en-US">Tax Year Of Origin 2020.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_drug_TaxYearOfOrigin2020Member_1" xml:lang="en-US">Tax Year Of Origin 2020 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_drug_TaxYearOfOrigin2020Member_2" xml:lang="en-US">2020 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_drug_TaxYearOfOrigin2021Member_0" xml:lang="en-US">Tax Year Of Origin 2021.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_drug_TaxYearOfOrigin2021Member_1" xml:lang="en-US">Tax Year Of Origin 2021 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_drug_TaxYearOfOrigin2021Member_2" xml:lang="en-US">2021 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_drug_TemporaryDifferencesIntangibleAssetsMember_0" xml:lang="en-US">This member stands for temporary differences intangible assets member.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_drug_TemporaryDifferencesIntangibleAssetsMember_1" xml:lang="en-US">Temporary Differences Intangible Assets [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_drug_TemporaryDifferencesIntangibleAssetsMember_2" xml:lang="en-US">Intangible assets [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_drug_TemporaryDifferencesNonCapitalLossesMember_0" xml:lang="en-US">Represents temporary differences non capital losses member.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_drug_TemporaryDifferencesNonCapitalLossesMember_1" xml:lang="en-US">Temporary Differences Non Capital Losses [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_drug_TemporaryDifferencesNonCapitalLossesMember_2" xml:lang="en-US">Non-capital losses [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_drug_TemporaryDifferencesShareIssueCostsMember_0" xml:lang="en-US">Represents temporary differences share issue costs member.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_drug_TemporaryDifferencesShareIssueCostsMember_1" xml:lang="en-US">Temporary Differences Share Issue Costs [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_drug_TemporaryDifferencesShareIssueCostsMember_2" xml:lang="en-US">Share issue costs [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_drug_TemporaryDifferencesValuationAllowanceMember_0" xml:lang="en-US">This member stands for an temporary differences valuation allowance member.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_drug_TemporaryDifferencesValuationAllowanceMember_1" xml:lang="en-US">Temporary Differences Valuation Allowance [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_drug_TemporaryDifferencesValuationAllowanceMember_2" xml:lang="en-US">Valuation allowance [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_drug_TenthTrancheMember_0" xml:lang="en-US">Tenth tranche</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_drug_TenthTrancheMember_1" xml:lang="en-US">Tenth Tranche [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_drug_TenthTrancheMember_2" xml:lang="en-US">On the six-month anniversary of the grant date [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_drug_TermOfLease_0" xml:lang="en-US">Term of lease.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_drug_TermOfLease_1" xml:lang="en-US">Term Of Lease</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_drug_TermOfLease_2" xml:lang="en-US">Term of lease</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_drug_TermOfWarrant_0" xml:lang="en-US">Information about term of warrant.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_drug_TermOfWarrant_1" xml:lang="en-US">Term Of Warrant</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_drug_TermOfWarrant_2" xml:lang="en-US">Term of warrant</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_drug_TermsOfContract_0" xml:lang="en-US">Represent the term of contract.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_drug_TermsOfContract_1" xml:lang="en-US">Terms Of Contract</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_drug_TermsOfContract_2" xml:lang="en-US">Terms of contract</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_drug_ThirdAnniversaryOfGrantDateMember_0" xml:lang="en-US">Represents the member information related to third anniversary of grant date.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_drug_ThirdAnniversaryOfGrantDateMember_1" xml:lang="en-US">Third Anniversary Of Grant Date [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_drug_ThirdTrancheMember_0" xml:lang="en-US">Third tranche</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_drug_ThirdTrancheMember_1" xml:lang="en-US">Third Tranche [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_drug_ThirdTrancheMember_2" xml:lang="en-US">July 1, 2022</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_drug_ThirdTrancheMember_3" xml:lang="en-US">On the first anniversary of the listing date [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_drug_ThirteenthTrancheMember_0" xml:lang="en-US">Thirteenth tranche</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_drug_ThirteenthTrancheMember_1" xml:lang="en-US">Thirteenth Tranche [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_drug_ThirteenthTrancheMember_2" xml:lang="en-US">On March 21, 2022 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_drug_ThreeConsultantsMember_0" xml:lang="en-US">Three consultants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_drug_ThreeConsultantsMember_1" xml:lang="en-US">Three Consultants [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_drug_ThreeInvestorsMember_0" xml:lang="en-US">Three investors [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_drug_ThreeInvestorsMember_1" xml:lang="en-US">Three Investors [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_drug_ThresholdPercentageOfWarrants_0" xml:lang="en-US">Threshold percentage of warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_drug_ThresholdPercentageOfWarrants_1" xml:lang="en-US">Threshold Percentage Of Warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_drug_ThresholdPercentageOfWarrants_2" xml:lang="en-US">Threshold percentage of warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_drug_TotalAnnualMinimumRoyaltiesAfterFirstCommercialSale_0" xml:lang="en-US">Information about total annual minimum royalties after first commercial sale.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_drug_TotalAnnualMinimumRoyaltiesAfterFirstCommercialSale_1" xml:lang="en-US">Total Annual Minimum Royalties After First Commercial Sale</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_drug_TotalAnnualMinimumRoyaltiesAfterFirstCommercialSale_2" xml:lang="en-US">Annual minimum royalties after first commercial sale</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_drug_TotalAnnualMinimumRoyaltiesCurrentYears_0" xml:lang="en-US">Information about total annual minimum royalties current years.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_drug_TotalAnnualMinimumRoyaltiesCurrentYears_1" xml:lang="en-US">Total Annual Minimum Royalties Current Years</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_drug_TotalAnnualMinimumRoyaltiesCurrentYears_2" xml:lang="en-US">Annual minimum royalties - Years 1 and 2</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_drug_TotalAnnualMinimumRoyaltiesNextYears_0" xml:lang="en-US">Information about total annual minimum royalties next years.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_drug_TotalAnnualMinimumRoyaltiesNextYears_1" xml:lang="en-US">Total Annual Minimum Royalties Next Years</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_drug_TotalAnnualMinimumRoyaltiesNextYears_2" xml:lang="en-US">Total annual minimum royalties next years</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_drug_TotalAnnualMinimumRoyaltiesYear3_0" xml:lang="en-US">Information about total annual minimum royalties current years 3.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_drug_TotalAnnualMinimumRoyaltiesYear3_1" xml:lang="en-US">Total Annual Minimum Royalties Year 3</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_drug_TotalAnnualMinimumRoyaltiesYear3_2" xml:lang="en-US">Annual minimum royalties - Year 3</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_drug_TotalAnnualMinimumRoyaltiesYear4_0" xml:lang="en-US">Information about total annual minimum royalties years 4.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_drug_TotalAnnualMinimumRoyaltiesYear4_1" xml:lang="en-US">Total Annual Minimum Royalties Year 4</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_drug_TotalAnnualMinimumRoyaltiesYear4_2" xml:lang="en-US">Annual minimum royalties - Year 4</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_drug_TotalAnnualMinimumRoyaltiesYear5_0" xml:lang="en-US">Information about total annual minimum royalties years 5.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_drug_TotalAnnualMinimumRoyaltiesYear5_1" xml:lang="en-US">Total Annual Minimum Royalties Year 5</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_drug_TotalAnnualMinimumRoyaltiesYear5_2" xml:lang="en-US">Annual minimum royalties - Year 5</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_drug_TotalAnnualMinimumRoyaltiesYear6AndThereafter_0" xml:lang="en-US">Information about total annual minimum royalties year 6 and thereafter</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_drug_TotalAnnualMinimumRoyaltiesYear6AndThereafter_1" xml:lang="en-US">Total Annual Minimum Royalties Year 6 And Thereafter</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_drug_TotalAnnualMinimumRoyaltiesYear6AndThereafter_2" xml:lang="en-US">Annual minimum royalties - Year 6 and thereafter</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_drug_Tranche1Member_0" xml:lang="en-US">Tranche 1 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_drug_TranchesAxis_0" xml:lang="en-US">Tranches [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_drug_TranchesDomain_0" xml:lang="en-US">Tranches [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_drug_TwelfthTrancheMember_0" xml:lang="en-US">Twelfth tranche</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_drug_TwelfthTrancheMember_1" xml:lang="en-US">Twelfth Tranche [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_drug_TwelfthTrancheMember_2" xml:lang="en-US">On December 21, 2021 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_drug_TypeOfArrangementsAxis_0" xml:lang="en-US">The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_drug_TypeOfArrangementsAxis_1" xml:lang="en-US">Type Of Arrangements [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_drug_UnderwritersFeesPaid_0" xml:lang="en-US">Underwriters fees paid.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_drug_UnderwritersFeesPaid_1" xml:lang="en-US">Underwriters fees paid</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_drug_UnderwritersMember_0" xml:lang="en-US">Underwriters.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_drug_UnderwritersMember_1" xml:lang="en-US">Underwriters [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_drug_UnitsIssuedPricePerUnit_0" xml:lang="en-US">Represents unit issued price per unit.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_drug_UnitsIssuedPricePerUnit_1" xml:lang="en-US">Units Issued, Price Per Unit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_drug_UnitsIssuedPricePerUnit_2" xml:lang="en-US">Units issued, price per unit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_drug_UniversityOfIllinoisAtChicagoMember_0" xml:lang="en-US">University of Illinois at Chicago</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_drug_UniversityOfIllinoisAtChicagoMember_1" xml:lang="en-US">University of Illinois At Chicago [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_drug_UniversityOfTexasMedicalBranchMember_0" xml:lang="en-US">University of Texas Medical Branch [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_drug_UniversityOfTexasMedicalBranchMember_1" xml:lang="en-US">University of Texas Medical Branch [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_drug_ValueOfCommonStockSharesIssued_0" xml:lang="en-US">Represents the amount of value of common stock shares issued.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_drug_ValueOfCommonStockSharesIssued_1" xml:lang="en-US">Value Of Common Stock Shares Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_drug_ValueOfCommonStockSharesIssued_2" xml:lang="en-US">Value of common stock shares issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_drug_ValueOfCommonStockSharesIssuedByRelatedParty_0" xml:lang="en-US">Represents the value of common stock shares issued by related party.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_drug_ValueOfCommonStockSharesIssuedByRelatedParty_1" xml:lang="en-US">Value Of Common Stock Shares Issued By Related Party</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_drug_ValueOfCommonStockSharesIssuedByRelatedParty_2" xml:lang="en-US">Value of common stock issued by PL to individual</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_drug_VestingDomain_0" xml:lang="en-US">Vesting [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_drug_VestingPercentage_0" xml:lang="en-US">Vesting percentage of share-based payment award.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_drug_VestingPercentage_1" xml:lang="en-US">Vesting Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_drug_VestingPercentage_2" xml:lang="en-US">Vesting percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_drug_VestingsAxis_0" xml:lang="en-US">The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_drug_VestingsAxis_1" xml:lang="en-US">Vestings [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_drug_WarrantAscribedValue_0" xml:lang="en-US">Warrant ascribed value.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_drug_WarrantAscribedValue_1" xml:lang="en-US">Warrant Ascribed Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_drug_WarrantAscribedValue_2" xml:lang="en-US">Warrant ascribed value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_drug_WarrantsIssuedPricePerWarrant_0" xml:lang="en-US">Warrants Issued, Price Per Warrant</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_drug_WarrantsIssuedPricePerWarrant_1" xml:lang="en-US">Represents per share price of warrants issued.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_drug_WarrantsIssuedPricePerWarrant_2" xml:lang="en-US">Warrants issued, price per warrant</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_drug_WarrantsMember_0" xml:lang="en-US">This member stands for warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_drug_WarrantsMember_1" xml:lang="en-US">Warrants [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_drug_WarrantsMember_2" xml:lang="en-US">Warrants [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_drug_WeightedAverageExercisePriceOfWarrantsExercisedInShareBasedPaymentArrangement_0" xml:lang="en-US">Represents the weighted average exercise price of warrants exercised In share based payment arrangement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_drug_WeightedAverageExercisePriceOfWarrantsExercisedInShareBasedPaymentArrangement_1" xml:lang="en-US">Weighted average exercise price, Exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_drug_WeightedAverageExercisePriceOfWarrantsExercisedInShareBasedPaymentArrangement_2" xml:lang="en-US">Weighted Average Exercise Price Of Warrants Exercised In Share Based Payment Arrangement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_drug_WeightedAverageExercisePriceOfWarrantsExercisedInShareBasedPaymentArrangement_3" xml:lang="en-US">Weighted average exercise price, Exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_drug_WeightedAverageExercisePriceOfWarrantsIssuedInShareBasedPaymentArrangement_0" xml:lang="en-US">Represents the weighted average exercise price of warrants issued In share based payment arrangement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_drug_WeightedAverageExercisePriceOfWarrantsIssuedInShareBasedPaymentArrangement_1" xml:lang="en-US">Weighted Average Exercise Price Of Warrants Issued In Share Based Payment Arrangement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_drug_WeightedAverageExercisePriceOfWarrantsIssuedInShareBasedPaymentArrangement_2" xml:lang="en-US">Weighted average exercise price, Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_drug_WeightedAverageExercisePriceOfWarrantsIssuedInShareBasedPaymentArrangement_3" xml:lang="en-US">Weighted average exercise price of warrants issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_drug_WeightedAverageExercisePriceOfWarrantsIssuedToBrokerInShareBasedPaymentArrangement_0" xml:lang="en-US">Represents the weighted average exercise price of warrants issued to broker in share based payment arrangement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_drug_WeightedAverageExercisePriceOfWarrantsIssuedToBrokerInShareBasedPaymentArrangement_1" xml:lang="en-US">Weighted Average Exercise Price Of Warrants Issued To Broker In Share Based Payment Arrangement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_drug_WeightedAverageExercisePriceOfWarrantsIssuedToBrokerInShareBasedPaymentArrangement_2" xml:lang="en-US">Weighted average exercise price, Issued - broker</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_drug_WeightedAverageExercisePriceOfWarrantsOutstandingInShareBasedPaymentArrangement_0" xml:lang="en-US">Represents the weighted average exercise price of warrants outstanding in share based payment arrangement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_drug_WeightedAverageExercisePriceOfWarrantsOutstandingInShareBasedPaymentArrangement_1" xml:lang="en-US">Weighted average exercise price, Ending Balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_drug_WeightedAverageExercisePriceOfWarrantsOutstandingInShareBasedPaymentArrangement_2" xml:lang="en-US">Weighted average exercise price, Beginning Balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_drug_WeightedAverageExercisePriceOfWarrantsOutstandingInShareBasedPaymentArrangement_3" xml:lang="en-US">Weighted Average Exercise Price Of Warrants Outstanding In Share Based Payment Arrangement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_drug_WeightedAverageExercisePriceOfWarrantsOutstandingInShareBasedPaymentArrangement_4" xml:lang="en-US">Warrants exercise price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_drug_WeightedAverageExercisePriceOfWarrantsOutstandingInShareBasedPaymentArrangement_5" xml:lang="en-US">Warrants Outstanding, Exercise price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_drug_WeightedAverageRemainingContractualLifeOfOtherEquityInstruments_0" xml:lang="en-US">The weighted average remaining contractual life of other equity instruments.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_drug_WeightedAverageRemainingContractualLifeOfOtherEquityInstruments_1" xml:lang="en-US">Weighted Average Remaining Contractual Life Of Other Equity Instruments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_drug_WeightedAverageRemainingContractualLifeOfOtherEquityInstruments_2" xml:lang="en-US">Weighted average remaining contractual life of outstanding warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_drug_WeightedAverageRemainingContractualLifeOfOtherEquityInstruments_3" xml:lang="en-US">Warrants Outstanding, Remaining life (Years)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_drug_WeightedAverageRemainingContractualLifeOfWarrants_0" xml:lang="en-US">Weighted Average Remaining Contractual Life Of Warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_drug_WeightedAverageRemainingContractualLifeOfWarrants_1" xml:lang="en-US">The weighted average remaining contractual life of warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_drug_WeightedAverageRemainingContractualLifeOfWarrants_2" xml:lang="en-US">Weighted average remaining contractual life of outstanding warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_drug_WeightedAverageRemainingContractualLifeOfWarrants_3" xml:lang="en-US">Warrants Outstanding, Remaining life (Years)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_drug_WeightedAverageSharePriceWarrantsGranted_0" xml:lang="en-US">Weighted average share price, warrants granted.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_drug_WeightedAverageSharePriceWarrantsGranted_1" xml:lang="en-US">Weighted Average Share Price, Warrants Granted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_drug_WeightedAverageSharePriceWarrantsGranted_2" xml:lang="en-US">Share price, warrants granted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_drug_WeightedAverageTradingPriceOfCommonSharesOnCanadianStockExchange_0" xml:lang="en-US">Weighted average trading price of common shares on canadian stock exchange.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_drug_WeightedAverageTradingPriceOfCommonSharesOnCanadianStockExchange_1" xml:lang="en-US">Weighted Average Trading Price Of Common Shares On Canadian Stock Exchange</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_drug_WeightedAverageTradingPriceOfCommonSharesOnCanadianStockExchange_2" xml:lang="en-US">Weighted average trading price of common shares on canadian stock exchange</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_drug_WorkingCapital_0" xml:lang="en-US">Represents the amount working capital</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_drug_WorkingCapital_1" xml:lang="en-US">Working capital</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_AccountingProfit_0" xml:lang="en-US">Accounting profit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_AccountingProfit_1" xml:lang="en-US">Net loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_AccrualsClassifiedAsCurrent_0" xml:lang="en-US">Accruals classified as current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_AccrualsClassifiedAsCurrent_1" xml:lang="en-US">Accrued liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable_0" xml:lang="en-US">Adjustments for increase (decrease) in trade accounts payable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable_1" xml:lang="en-US">Accounts payable and accrued liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_AdjustmentsForReconcileProfitLossAbstract_0" xml:lang="en-US">Adjustments to reconcile profit (loss) [abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_AdjustmentsForReconcileProfitLossAbstract_1" xml:lang="en-US">Non-cash items:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_AdjustmentsForSharebasedPayments_0" xml:lang="en-US">Adjustments for share-based payments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_AdjustmentsForSharebasedPayments_1" xml:lang="en-US">Share-based compensation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains_0" xml:lang="en-US">Adjustments for unrealised foreign exchange losses (gains)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains_1" xml:lang="en-US">Foreign exchange</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_AdministrativeExpense_0" xml:lang="en-US">Administrative expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_AdministrativeExpense_1" xml:lang="en-US">Regulatory and filing</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_ApplicableTaxRate_0" xml:lang="en-US">Applicable tax rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_ApplicableTaxRate_1" xml:lang="en-US">Statutory tax rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_Assets_0" xml:lang="en-US">Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_ifrs-full_Assets_1" xml:lang="en-US">Total assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_AssetsAbstract_0" xml:lang="en-US">Assets [abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_AssetsAbstract_1" xml:lang="en-US">Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_BankAndSimilarCharges_0" xml:lang="en-US">Bank and similar charges</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_BankAndSimilarCharges_1" xml:lang="en-US">Funds processing fees - private placements</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_BasicAndDilutedEarningsLossPerShare_0" xml:lang="en-US">Basic and diluted earnings (loss) per share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_BasicAndDilutedEarningsLossPerShare_1" xml:lang="en-US">Basic and diluted loss per share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_BottomOfRangeMember_0" xml:lang="en-US">Bottom of range [member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_BuildingsMember_0" xml:lang="en-US">Buildings [member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_BuildingsMember_1" xml:lang="en-US">Apartment [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_Cash_0" xml:lang="en-US">Cash</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_ifrs-full_CashAndCashEquivalents_0" xml:lang="en-US">Cash and cash equivalents, end of year</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_ifrs-full_CashAndCashEquivalents_1" xml:lang="en-US">Cash, beginning of year</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_CashAndCashEquivalents_2" xml:lang="en-US">Cash and cash equivalents</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_CashAndCashEquivalents_3" xml:lang="en-US">Cash and cash equivalents</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_CashFlowsFromUsedInFinancingActivities_0" xml:lang="en-US">Cash flows from (used in) financing activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_ifrs-full_CashFlowsFromUsedInFinancingActivities_1" xml:lang="en-US">Net cash from financing activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_0" xml:lang="en-US">Cash flows from (used in) financing activities [abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_1" xml:lang="en-US">Financing activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_CashFlowsFromUsedInOperatingActivities_0" xml:lang="en-US">Cash flows from (used in) operating activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_ifrs-full_CashFlowsFromUsedInOperatingActivities_1" xml:lang="en-US">Net cash used in operating activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_0" xml:lang="en-US">Cash flows from (used in) operating activities [abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_1" xml:lang="en-US">Operating activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_CategoriesOfFinancialLiabilitiesAbstract_0" xml:lang="en-US">Categories of financial liabilities [abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_CategoriesOfFinancialLiabilitiesAbstract_1" xml:lang="en-US">Amortized cost</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_CategoriesOfRelatedPartiesAxis_0" xml:lang="en-US">Categories of related parties [axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_ClassesOfAssetsAxis_0" xml:lang="en-US">Classes of assets [axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_ClassesOfAssetsMember_0" xml:lang="en-US">Assets [member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_ClassesOfFinancialInstrumentsAxis_0" xml:lang="en-US">Classes of financial instruments [axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_ClassesOfFinancialInstrumentsMember_0" xml:lang="en-US">Financial instruments, class [member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_ClassesOfShareCapitalAxis_0" xml:lang="en-US">Classes of share capital [axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_ClassesOfShareCapitalMember_0" xml:lang="en-US">Share capital [member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_ComponentsOfEquityAxis_0" xml:lang="en-US">Components of equity [axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_CopyrightsPatentsAndOtherIndustrialPropertyRightsServiceAndOperatingRightsMember_0" xml:lang="en-US">Copyrights, patents and other industrial property rights, service and operating rights [member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_CopyrightsPatentsAndOtherIndustrialPropertyRightsServiceAndOperatingRightsMember_1" xml:lang="en-US">Patents and related payments [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_CreditRiskMember_0" xml:lang="en-US">Credit risk [member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_CreditRiskMember_1" xml:lang="en-US">Credit risk [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_CurrencyRiskMember_0" xml:lang="en-US">Currency risk [member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_CurrencyRiskMember_1" xml:lang="en-US">Foreign exchange risk [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities_0" xml:lang="en-US">Current accrued expenses and other current liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities_1" xml:lang="en-US">Accrued liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_CurrentAssets_0" xml:lang="en-US">Current assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_ifrs-full_CurrentAssets_1" xml:lang="en-US">Total current assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_CurrentAssetsAbstract_0" xml:lang="en-US">Current assets [abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_CurrentAssetsAbstract_1" xml:lang="en-US">Current assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_CurrentFinancialAssetsAtFairValueThroughProfitOrLossAbstract_0" xml:lang="en-US">Current financial assets at fair value through profit or loss [abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_CurrentFinancialAssetsAtFairValueThroughProfitOrLossAbstract_1" xml:lang="en-US">FVTPL</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_CurrentLiabilitiesAbstract_0" xml:lang="en-US">Current liabilities [abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_CurrentLiabilitiesAbstract_1" xml:lang="en-US">Current liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_CurrentPrepaidExpenses_0" xml:lang="en-US">Current prepaid expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_CurrentPrepaidExpenses_1" xml:lang="en-US">Prepaids</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_CurrentTaxAssetsCurrent_0" xml:lang="en-US">Current tax assets, current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_CurrentTaxAssetsCurrent_1" xml:lang="en-US">Sales tax receivable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised_0" xml:lang="en-US">Deductible temporary differences for which no deferred tax asset is recognised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised_1" xml:lang="en-US">Temporary differences not recognized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForBusinessCombinationsExplanatory_0" xml:lang="en-US">Description of accounting policy for business combinations [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForBusinessCombinationsExplanatory_1" xml:lang="en-US">Business combinations [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory_0" xml:lang="en-US">Description of accounting policy for earnings per share [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory_1" xml:lang="en-US">Loss per share [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory_0" xml:lang="en-US">Description of accounting policy for financial instruments [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory_1" xml:lang="en-US">Financial instruments [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory_0" xml:lang="en-US">Description of accounting policy for foreign currency translation [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory_1" xml:lang="en-US">Foreign currency translation [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory_0" xml:lang="en-US">Description of accounting policy for income tax [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory_1" xml:lang="en-US">Income taxes [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForIssuedCapitalExplanatory_0" xml:lang="en-US">Description of accounting policy for issued capital [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForIssuedCapitalExplanatory_1" xml:lang="en-US">Share capital [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory_0" xml:lang="en-US">Description of accounting policy for leases [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory_1" xml:lang="en-US">Leases [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory_0" xml:lang="en-US">Description of accounting policy for provisions [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory_1" xml:lang="en-US">Provisions [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory_0" xml:lang="en-US">Description of accounting policy for research and development expense [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory_1" xml:lang="en-US">Internally generated intangible assets - Research and development expenditure [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory_0" xml:lang="en-US">Description of accounting policy for share-based payment transactions [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory_1" xml:lang="en-US">Share-based compensation awards [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted_0" xml:lang="en-US">Expected volatility, share options granted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted_1" xml:lang="en-US">Volatility rate, stock options granted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted_0" xml:lang="en-US">Option life, share options granted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted_1" xml:lang="en-US">Option life, stock options granted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DirectorsRemunerationExpense_0" xml:lang="en-US">Directors' remuneration expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DirectorsRemunerationExpense_1" xml:lang="en-US">Directors' compensation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory_0" xml:lang="en-US">Disclosure of basis of preparation of financial statements [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory_1" xml:lang="en-US">STATEMENT OF COMPLIANCE AND BASIS OF PREPARATION [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfClassesOfShareCapitalAbstract_0" xml:lang="en-US">Disclosure of classes of share capital [abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_0" xml:lang="en-US">Disclosure of classes of share capital [line items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfClassesOfShareCapitalTable_0" xml:lang="en-US">Disclosure of classes of share capital [table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfCommitmentsExplanatory_0" xml:lang="en-US">Disclosure of commitments [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_DisclosureOfCommitmentsExplanatory_1" xml:lang="en-US">CONTRACTUAL OBLIGATIONS [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory_0" xml:lang="en-US">Disclosure of detailed information about financial instruments [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory_1" xml:lang="en-US">Disclosure of carrying value of financial assets and liabilities [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory_0" xml:lang="en-US">Disclosure of events after reporting period [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory_1" xml:lang="en-US">SUBSEQUENT EVENTS [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfFinancialInstrumentsAbstract_0" xml:lang="en-US">Disclosure of detailed information about financial instruments [abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfFinancialInstrumentsExplanatory_0" xml:lang="en-US">Disclosure of financial instruments [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DisclosureOfFinancialInstrumentsExplanatory_1" xml:lang="en-US">FINANCIAL INSTRUMENTS AND CAPITAL MANAGEMENT [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_0" xml:lang="en-US">Disclosure of detailed information about financial instruments [line items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfFinancialInstrumentsTable_0" xml:lang="en-US">Disclosure of detailed information about financial instruments [table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfIncomeTaxExplanatory_0" xml:lang="en-US">Disclosure of income tax [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DisclosureOfIncomeTaxExplanatory_1" xml:lang="en-US">INCOME TAXES [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfInformationAboutKeyManagementPersonnelExplanatory_0" xml:lang="en-US">Disclosure of information about key management personnel [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DisclosureOfInformationAboutKeyManagementPersonnelExplanatory_1" xml:lang="en-US">Disclosure of expenses related to key management personnel [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfIssuedCapitalExplanatory_0" xml:lang="en-US">Disclosure of issued capital [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_DisclosureOfIssuedCapitalExplanatory_1" xml:lang="en-US">SHARE CAPITAL [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfLeasesExplanatory_0" xml:lang="en-US">Disclosure of leases [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DisclosureOfLeasesExplanatory_1" xml:lang="en-US">PREMISES LEASES [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract_0" xml:lang="en-US">Disclosure of non-adjusting events after reporting period [abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_0" xml:lang="en-US">Disclosure of non-adjusting events after reporting period [line items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable_0" xml:lang="en-US">Disclosure of non-adjusting events after reporting period [table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory_0" xml:lang="en-US">Disclosure of number and weighted average exercise prices of other equity instruments [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory_1" xml:lang="en-US">Disclosure of number and weighted average exercise prices of restricted share units [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory_0" xml:lang="en-US">Disclosure of number and weighted average exercise prices of share options [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory_1" xml:lang="en-US">Disclosure of number and weighted average exercise prices of share options [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems_0" xml:lang="en-US">Disclosure of quantitative information about right-of-use assets [line items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable_0" xml:lang="en-US">Disclosure of quantitative information about right-of-use assets [table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfRelatedPartyExplanatory_0" xml:lang="en-US">Disclosure of related party [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DisclosureOfRelatedPartyExplanatory_1" xml:lang="en-US">RELATED PARTY TRANSACTIONS [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfResearchAndDevelopmentExpenseExplanatory_0" xml:lang="en-US">Disclosure of research and development expense [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DisclosureOfResearchAndDevelopmentExpenseExplanatory_1" xml:lang="en-US">RESEARCH AND DEVELOPMENT [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory_0" xml:lang="en-US">Disclosure of significant accounting policies [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory_1" xml:lang="en-US">SIGNIFICANT ACCOUNTING POLICIES [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory_0" xml:lang="en-US">Disclosure of temporary difference, unused tax losses and unused tax credits [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory_1" xml:lang="en-US">Disclosure of deductible temporary differences for which no deferred tax has been recognized [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_0" xml:lang="en-US">Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable_0" xml:lang="en-US">Disclosure of temporary difference, unused tax losses and unused tax credits [table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory_0" xml:lang="en-US">Disclosure of trade and other payables [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory_1" xml:lang="en-US">ACCOUNTS PAYABLE AND ACCRUED LIABILITIES [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract_0" xml:lang="en-US">Disclosure of transactions between related parties [abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory_0" xml:lang="en-US">Disclosure of transactions between related parties [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory_1" xml:lang="en-US">RELATED PARTY TRANSACTIONS [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents_0" xml:lang="en-US">Effect of exchange rate changes on cash and cash equivalents</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents_1" xml:lang="en-US">Effect of foreign exchange on cash</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_EntitysTotalForRelatedPartiesMember_0" xml:lang="en-US">Entity's total for related parties [member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_ifrs-full_Equity_0" xml:lang="en-US">Balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_ifrs-full_Equity_1" xml:lang="en-US">Balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_Equity_2" xml:lang="en-US">Equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_ifrs-full_Equity_3" xml:lang="en-US">TOTAL SHAREHOLDERS' EQUITY</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_EquityAbstract_0" xml:lang="en-US">Equity [abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_EquityAbstract_1" xml:lang="en-US">Shareholders' equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_EquityAndLiabilities_0" xml:lang="en-US">Equity and liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_ifrs-full_EquityAndLiabilities_1" xml:lang="en-US">TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_EquityAndLiabilitiesAbstract_0" xml:lang="en-US">Equity and liabilities [abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_EquityAndLiabilitiesAbstract_1" xml:lang="en-US">LIABILITIES AND SHAREHOLDERS' EQUITY</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_EquityInterestsOfAcquirer_0" xml:lang="en-US">Equity interests of acquirer</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_EquityInterestsOfAcquirer_1" xml:lang="en-US">Value of common stock shares issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_EquityMember_0" xml:lang="en-US">Equity [member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_EquityMember_1" xml:lang="en-US">Equity [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_ExercisePriceOfOutstandingShareOptions2019_0" xml:lang="en-US">Exercise price of outstanding share options</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_ExercisePriceOfOutstandingShareOptions2019_1" xml:lang="en-US">Options Outstanding and Exercisable, Exercise price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_ExercisePriceShareOptionsGranted2019_0" xml:lang="en-US">Exercise price, share options granted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_ExercisePriceShareOptionsGranted2019_1" xml:lang="en-US">Exercise price, stock options granted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_ExpenseByNatureAbstract_0" xml:lang="en-US">Expenses by nature [abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_ExpenseByNatureAbstract_1" xml:lang="en-US">EXPENSES</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees_0" xml:lang="en-US">Expense from share-based payment transactions with employees</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees_1" xml:lang="en-US">Share-based compensation expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_FeeAndCommissionExpense_0" xml:lang="en-US">Fee and commission expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_FeeAndCommissionExpense_1" xml:lang="en-US">Consulting fees</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss_0" xml:lang="en-US">Foreign exchange</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss_1" xml:lang="en-US">Foreign exchange gain (loss)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss_2" xml:lang="en-US">Foreign exchange</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_GeneralAndAdministrativeExpense_0" xml:lang="en-US">General and administrative expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_GeneralAndAdministrativeExpense_1" xml:lang="en-US">Office and administrative</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_IncomeStatementAbstract_0" xml:lang="en-US">Profit or loss [abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_IncomeStatementAbstract_1" xml:lang="en-US">Income Statement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_IncomeTaxExpenseContinuingOperations_0" xml:lang="en-US">Tax expense (income)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_ifrs-full_IncomeTaxExpenseContinuingOperations_1" xml:lang="en-US">Total income tax recovery</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_IncomeTaxExpenseContinuingOperations_2" xml:lang="en-US">Total income tax recovery</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents_0" xml:lang="en-US">Increase (decrease) in cash and cash equivalents</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents_1" xml:lang="en-US">Change in cash</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents_2" xml:lang="en-US">Change in cash</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_IncreaseDecreaseInNumberOfSharesOutstanding_0" xml:lang="en-US">Increase (decrease) in number of shares outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_IncreaseDecreaseInNumberOfSharesOutstanding_1" xml:lang="en-US">Number of shares issued during period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity_0" xml:lang="en-US">Increase (decrease) through exercise of warrants, equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity_1" xml:lang="en-US">Warrants exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions_0" xml:lang="en-US">Increase (decrease) through share-based payment transactions, equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions_1" xml:lang="en-US">Share-based compensation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_IntangibleAssetsAndGoodwill_0" xml:lang="en-US">Intangible assets and goodwill</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_IntangibleAssetsAndGoodwill_1" xml:lang="en-US">Intangible assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_IssuedCapital_0" xml:lang="en-US">Issued capital</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_IssuedCapital_1" xml:lang="en-US">Share capital</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_IssuedCapitalMember_0" xml:lang="en-US">Issued capital [member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_IssuedCapitalMember_1" xml:lang="en-US">Share capital [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_KeyManagementPersonnelCompensation_0" xml:lang="en-US">Key management personnel compensation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_ifrs-full_KeyManagementPersonnelCompensation_1" xml:lang="en-US">Total expenses related to key management personnel</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment_0" xml:lang="en-US">Key management personnel compensation, share-based payment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment_1" xml:lang="en-US">Share-based compensation included in directors' compensation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_Liabilities_0" xml:lang="en-US">Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_ifrs-full_Liabilities_1" xml:lang="en-US">TOTAL LIABILITIES</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_LiquidityRiskMember_0" xml:lang="en-US">Liquidity risk [member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_LiquidityRiskMember_1" xml:lang="en-US">Liquidity risk [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract_0" xml:lang="en-US">Major components of tax expense (income) [abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_0" xml:lang="en-US">Non-adjusting events after reporting period [axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_NonadjustingEventsMember_0" xml:lang="en-US">Non-adjusting events after reporting period [member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_NoncurrentAssetsAbstract_0" xml:lang="en-US">Non-current assets [abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_NoncurrentAssetsAbstract_1" xml:lang="en-US">Non-current assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_NumberOfInstrumentsOrInterestsIssuedOrIssuable_0" xml:lang="en-US">Number of instruments or interests issued or issuable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_NumberOfInstrumentsOrInterestsIssuedOrIssuable_1" xml:lang="en-US">Number of shares issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted_0" xml:lang="en-US">Number of other equity instruments granted in share-based payment arrangement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted_1" xml:lang="en-US">Number of RSUs granted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted_2" xml:lang="en-US">Granted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement_0" xml:lang="en-US">Vested</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement_1" xml:lang="en-US">Number of other equity instruments exercised or vested in share-based payment arrangement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement_2" xml:lang="en-US">Vested</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_0" xml:lang="en-US">Ending Balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_1" xml:lang="en-US">Beginning Balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_2" xml:lang="en-US">Number of other equity instruments outstanding in share-based payment arrangement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_3" xml:lang="en-US">Number of warrants, Beginning Balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_ifrs-full_NumberOfOutstandingShareOptions_0" xml:lang="en-US">Number of options, Ending Balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_ifrs-full_NumberOfOutstandingShareOptions_1" xml:lang="en-US">Number of options, Beginning Balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_NumberOfOutstandingShareOptions_2" xml:lang="en-US">Number of share options outstanding in share-based payment arrangement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_NumberOfOutstandingShareOptions_3" xml:lang="en-US">Options Outstanding and Exercisable, Number of options</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement_0" xml:lang="en-US">Number of share options exercisable in share-based payment arrangement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement_1" xml:lang="en-US">Options Outstanding and Exercisable, Exercisable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement_0" xml:lang="en-US">Number of options, Cancelled</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement_1" xml:lang="en-US">Number of share options forfeited in share-based payment arrangement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement_2" xml:lang="en-US">Number of options cancelled</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement_3" xml:lang="en-US">Number of options, Cancelled</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement_0" xml:lang="en-US">Number of share options granted in share-based payment arrangement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement_1" xml:lang="en-US">Number of options granted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement_2" xml:lang="en-US">Number of options, Granted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_NumberOfSharesIssued_0" xml:lang="en-US">Number of shares issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_ifrs-full_NumberOfSharesOutstanding_0" xml:lang="en-US">Balance (shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_ifrs-full_NumberOfSharesOutstanding_1" xml:lang="en-US">Balance (shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_NumberOfSharesOutstanding_2" xml:lang="en-US">Number of shares outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_OtherReserves_0" xml:lang="en-US">Other reserves</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_OtherReserves_1" xml:lang="en-US">Reserves</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_OtherReservesMember_0" xml:lang="en-US">Other reserves [member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_OtherReservesMember_1" xml:lang="en-US">Reserves [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_PaymentsForShareIssueCosts_0" xml:lang="en-US">Payments for share issue costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_PaymentsForShareIssueCosts_1" xml:lang="en-US">Share issuance costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_PresentationOfLeasesForLesseeAbstract_0" xml:lang="en-US">Presentation of leases for lessee [abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_ProceedsFromIssueOfOrdinaryShares_0" xml:lang="en-US">Proceeds from issue of ordinary shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_ProceedsFromIssuingShares_0" xml:lang="en-US">Proceeds from issuing shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_ProceedsFromIssuingShares_1" xml:lang="en-US">Private placement proceeds</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_ProfessionalFeesExpense_0" xml:lang="en-US">Professional fees expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_ProfessionalFeesExpense_1" xml:lang="en-US">Professional fees</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_ProfitLoss_0" xml:lang="en-US">Profit (loss)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_ProfitLoss_1" xml:lang="en-US">Net loss for the year</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_ifrs-full_ProfitLoss_2" xml:lang="en-US">Net loss and comprehensive loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_ProfitLoss_3" xml:lang="en-US">Net loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_RangeAxis_0" xml:lang="en-US">Range [axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_RangesMember_0" xml:lang="en-US">Ranges [member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_ReconciliationOfNumberOfSharesOutstandingAbstract_0" xml:lang="en-US">Reconciliation of number of shares outstanding [abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_ResearchAndDevelopmentExpense_0" xml:lang="en-US">Research and development expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_ResearchAndDevelopmentExpense_1" xml:lang="en-US">Research and development</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_ResearchAndDevelopmentExpense_2" xml:lang="en-US">Research and development expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_RetainedEarnings_0" xml:lang="en-US">Retained earnings</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_RetainedEarnings_1" xml:lang="en-US">Deficit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_RetainedEarningsMember_0" xml:lang="en-US">Retained earnings [member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_RetainedEarningsMember_1" xml:lang="en-US">Deficit [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_SalesAndMarketingExpense_0" xml:lang="en-US">Sales and marketing expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_SalesAndMarketingExpense_1" xml:lang="en-US">Marketing, advertising, and investor relations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_SharebasedPaymentArrangementsMember_0" xml:lang="en-US">Share-based payment arrangements [member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_ifrs-full_ShareIssueRelatedCost_0" xml:lang="en-US">Share issue costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_ShareIssueRelatedCost_1" xml:lang="en-US">Share issue related cost</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_ShareIssueRelatedCost_2" xml:lang="en-US">Share issue costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_ShorttermInvestmentsClassifiedAsCashEquivalents_0" xml:lang="en-US">Short-term investments, classified as cash equivalents</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_ShorttermInvestmentsClassifiedAsCashEquivalents_1" xml:lang="en-US">Guaranteed investment certificate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_StatementOfCashFlowsAbstract_0" xml:lang="en-US">Statement of cash flows [abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_StatementOfChangesInEquityAbstract_0" xml:lang="en-US">Statement of changes in equity [abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_StatementOfChangesInEquityLineItems_0" xml:lang="en-US">Statement of changes in equity [line items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_StatementOfChangesInEquityTable_0" xml:lang="en-US">Statement of changes in equity [table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_StatementOfFinancialPositionAbstract_0" xml:lang="en-US">Statement of financial position [abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss_0" xml:lang="en-US">Tax effect of expense not deductible in determining taxable profit (tax loss)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss_1" xml:lang="en-US">Deductible and non-deductible items</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_TaxExpenseIncomeAtApplicableTaxRate_0" xml:lang="en-US">Tax expense (income) at applicable tax rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_TaxExpenseIncomeAtApplicableTaxRate_1" xml:lang="en-US">Expected income tax recovery</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_TemporaryDifferenceMember_0" xml:lang="en-US">Temporary differences [member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_0" xml:lang="en-US">Temporary difference, unused tax losses and unused tax credits [axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_0" xml:lang="en-US">Temporary difference, unused tax losses and unused tax credits [member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_TopOfRangeMember_0" xml:lang="en-US">Top of range [member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_TradeAndOtherCurrentPayables_0" xml:lang="en-US">Trade and other current payables</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_TradeAndOtherCurrentPayables_1" xml:lang="en-US">Accounts payable and accrued liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_ifrs-full_TradeAndOtherCurrentPayables_2" xml:lang="en-US">Total accounts payable and accrued liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_TradeAndOtherCurrentPayablesAbstract_0" xml:lang="en-US">Trade and other current payables [abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers_0" xml:lang="en-US">Current trade payables</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers_1" xml:lang="en-US">Accounts payable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_TypesOfRisksAxis_0" xml:lang="en-US">Types of risks [axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_TypesOfRisksMember_0" xml:lang="en-US">Risks [member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_0" xml:lang="en-US">Types of share-based payment arrangements [axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_UnusedTaxLossesMember_0" xml:lang="en-US">Unused tax losses [member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_UnusedTaxLossesMember_1" xml:lang="en-US">Non-capital losses [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_ValueAtRisk_0" xml:lang="en-US">Value at risk</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_ValueAtRisk_1" xml:lang="en-US">Foreign currency fluctuation impact on net comprehensive loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019_0" xml:lang="en-US">Weighted average exercise price of share options forfeited in share-based payment arrangement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019_1" xml:lang="en-US">Weighted average exercise price, Cancelled</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019_0" xml:lang="en-US">Weighted average exercise price of share options granted in share-based payment arrangement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019_1" xml:lang="en-US">Weighted average exercise price of options granted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019_2" xml:lang="en-US">Weighted average exercise price, Granted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_0" xml:lang="en-US">Weighted average exercise price, Ending Balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_1" xml:lang="en-US">Weighted average exercise price, Beginning Balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_2" xml:lang="en-US">Weighted average exercise price of share options outstanding in share-based payment arrangement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019_0" xml:lang="en-US">Weighted average remaining contractual life of outstanding share options</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019_1" xml:lang="en-US">Options Outstanding and Exercisable, Remaining life (Years)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019_0" xml:lang="en-US">Weighted average share price, share options granted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019_1" xml:lang="en-US">Share price, stock options granted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_WeightedAverageShares_0" xml:lang="en-US">Weighted average number of ordinary shares outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_WeightedAverageShares_1" xml:lang="en-US">Weighted average number of common shares outstanding&#160;-basic and diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_ChiefExecutiveOfficerMember_0" xml:lang="en-US">Chief Executive Officer [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_TitleOfIndividualAxis_0" xml:lang="en-US">Title of Individual [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_0" xml:lang="en-US">Title of Individual [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AddressTypeDomain_1" xlink:to="lab_dei_AddressTypeDomain_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentDescription_2" xlink:to="lab_dei_AmendmentDescription_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag_3" xlink:to="lab_dei_AmendmentFlag_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AnnualInformationForm_4" xlink:to="lab_dei_AnnualInformationForm_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditedAnnualFinancialStatements_5" xlink:to="lab_dei_AuditedAnnualFinancialStatements_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_BusinessContactMember_6" xlink:to="lab_dei_BusinessContactMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode_7" xlink:to="lab_dei_CityAreaCode_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_ContactPersonnelEmailAddress_8" xlink:to="lab_dei_ContactPersonnelEmailAddress_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_ContactPersonnelFaxNumber_9" xlink:to="lab_dei_ContactPersonnelFaxNumber_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_ContactPersonnelName_10" xlink:to="lab_dei_ContactPersonnelName_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract_11" xlink:to="lab_dei_CoverAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate_12" xlink:to="lab_dei_CurrentFiscalYearEndDate_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentAccountingStandard_13" xlink:to="lab_dei_DocumentAccountingStandard_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentAnnualReport_14" xlink:to="lab_dei_DocumentAnnualReport_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus_15" xlink:to="lab_dei_DocumentFiscalPeriodFocus_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus_16" xlink:to="lab_dei_DocumentFiscalYearFocus_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate_17" xlink:to="lab_dei_DocumentPeriodEndDate_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentRegistrationStatement_18" xlink:to="lab_dei_DocumentRegistrationStatement_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentShellCompanyReport_19" xlink:to="lab_dei_DocumentShellCompanyReport_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport_20" xlink:to="lab_dei_DocumentTransitionReport_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType_21" xlink:to="lab_dei_DocumentType_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1_22" xlink:to="lab_dei_EntityAddressAddressLine1_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine2_23" xlink:to="lab_dei_EntityAddressAddressLine2_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown_24" xlink:to="lab_dei_EntityAddressCityOrTown_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCountry_25" xlink:to="lab_dei_EntityAddressCountry_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressesAddressTypeAxis_26" xlink:to="lab_dei_EntityAddressesAddressTypeAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressesLineItems_27" xlink:to="lab_dei_EntityAddressesLineItems_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressesTable_28" xlink:to="lab_dei_EntityAddressesTable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode_29" xlink:to="lab_dei_EntityAddressPostalZipCode_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince_30" xlink:to="lab_dei_EntityAddressStateOrProvince_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey_31" xlink:to="lab_dei_EntityCentralIndexKey_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding_32" xlink:to="lab_dei_EntityCommonStockSharesOutstanding_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus_33" xlink:to="lab_dei_EntityCurrentReportingStatus_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityDomain_34" xlink:to="lab_dei_EntityDomain_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany_35" xlink:to="lab_dei_EntityEmergingGrowthCompany_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityExTransitionPeriod_36" xlink:to="lab_dei_EntityExTransitionPeriod_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber_37" xlink:to="lab_dei_EntityFileNumber_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory_38" xlink:to="lab_dei_EntityFilerCategory_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode_39" xlink:to="lab_dei_EntityIncorporationStateCountryCode_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent_40" xlink:to="lab_dei_EntityInteractiveDataCurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName_41" xlink:to="lab_dei_EntityRegistrantName_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany_42" xlink:to="lab_dei_EntityShellCompany_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityVoluntaryFilers_43" xlink:to="lab_dei_EntityVoluntaryFilers_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityWellKnownSeasonedIssuer_44" xlink:to="lab_dei_EntityWellKnownSeasonedIssuer_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_IcfrAuditorAttestationFlag_45" xlink:to="lab_dei_IcfrAuditorAttestationFlag_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LegalEntityAxis_46" xlink:to="lab_dei_LegalEntityAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber_47" xlink:to="lab_dei_LocalPhoneNumber_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle_48" xlink:to="lab_dei_Security12bTitle_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName_49" xlink:to="lab_dei_SecurityExchangeName_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol_50" xlink:to="lab_dei_TradingSymbol_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_AcquisitionOfIntangibleAssetsByIssuingCommonShares_51" xlink:to="lab_drug_AcquisitionOfIntangibleAssetsByIssuingCommonShares_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_AcquisitionOfIntangibleAssetsByIssuingCommonShares_52" xlink:to="lab_drug_AcquisitionOfIntangibleAssetsByIssuingCommonShares_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_AcquisitionOfIntangibleAssetsByIssuingCommonShares_53" xlink:to="lab_drug_AcquisitionOfIntangibleAssetsByIssuingCommonShares_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_AdjustmentsForDecreaseIncreaseInPrepaidExpenses_54" xlink:to="lab_drug_AdjustmentsForDecreaseIncreaseInPrepaidExpenses_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_AdjustmentsForDecreaseIncreaseInPrepaidExpenses_55" xlink:to="lab_drug_AdjustmentsForDecreaseIncreaseInPrepaidExpenses_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_AdjustmentsForDecreaseIncreaseInPrepaidExpenses_56" xlink:to="lab_drug_AdjustmentsForDecreaseIncreaseInPrepaidExpenses_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_AdjustmentsForDecreaseIncreaseInSalesTaxReceivable_57" xlink:to="lab_drug_AdjustmentsForDecreaseIncreaseInSalesTaxReceivable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_AdjustmentsForDecreaseIncreaseInSalesTaxReceivable_58" xlink:to="lab_drug_AdjustmentsForDecreaseIncreaseInSalesTaxReceivable_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_AdjustmentsForDecreaseIncreaseInSalesTaxReceivable_59" xlink:to="lab_drug_AdjustmentsForDecreaseIncreaseInSalesTaxReceivable_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_AdjustmentsForSharesRecordedAsResearchAndDevelopment_60" xlink:to="lab_drug_AdjustmentsForSharesRecordedAsResearchAndDevelopment_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_AdjustmentsForSharesRecordedAsResearchAndDevelopment_61" xlink:to="lab_drug_AdjustmentsForSharesRecordedAsResearchAndDevelopment_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_AdjustmentsForSharesRecordedAsResearchAndDevelopment_62" xlink:to="lab_drug_AdjustmentsForSharesRecordedAsResearchAndDevelopment_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_AdjustmentsForSharesRecordedAsResearchAndDevelopment_63" xlink:to="lab_drug_AdjustmentsForSharesRecordedAsResearchAndDevelopment_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_AdjustmentsForSharesRecordedAsResearchAndDevelopment_64" xlink:to="lab_drug_AdjustmentsForSharesRecordedAsResearchAndDevelopment_4"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_AdvisorHourlyRate_65" xlink:to="lab_drug_AdvisorHourlyRate_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_AdvisorHourlyRate_66" xlink:to="lab_drug_AdvisorHourlyRate_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_AdvisorHourlyRate_67" xlink:to="lab_drug_AdvisorHourlyRate_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_AdvisorsHourlyRatesOfScientificAdvisoryBoardAndConsultants_68" xlink:to="lab_drug_AdvisorsHourlyRatesOfScientificAdvisoryBoardAndConsultants_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_AdvisorsHourlyRatesOfScientificAdvisoryBoardAndConsultants_69" xlink:to="lab_drug_AdvisorsHourlyRatesOfScientificAdvisoryBoardAndConsultants_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_AfterSublicensingAgreementsMember_70" xlink:to="lab_drug_AfterSublicensingAgreementsMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_AfterSublicensingAgreementsMember_71" xlink:to="lab_drug_AfterSublicensingAgreementsMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_AfterSublicensingAgreementsMember_72" xlink:to="lab_drug_AfterSublicensingAgreementsMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_AggregatePurchaseWarrantsDeposited_73" xlink:to="lab_drug_AggregatePurchaseWarrantsDeposited_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_AggregatePurchaseWarrantsDeposited_74" xlink:to="lab_drug_AggregatePurchaseWarrantsDeposited_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_AggregatePurchaseWarrantsDeposited_75" xlink:to="lab_drug_AggregatePurchaseWarrantsDeposited_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_AggregateSecuritiesDepositedToBeHeldInEscrow_76" xlink:to="lab_drug_AggregateSecuritiesDepositedToBeHeldInEscrow_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_AggregateSecuritiesDepositedToBeHeldInEscrow_77" xlink:to="lab_drug_AggregateSecuritiesDepositedToBeHeldInEscrow_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_AggregateSecuritiesDepositedToBeHeldInEscrow_78" xlink:to="lab_drug_AggregateSecuritiesDepositedToBeHeldInEscrow_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_AgreementAxis_79" xlink:to="lab_drug_AgreementAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_AgreementAxis_80" xlink:to="lab_drug_AgreementAxis_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_AgreementDomain_81" xlink:to="lab_drug_AgreementDomain_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_AgreementDomain_82" xlink:to="lab_drug_AgreementDomain_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_AmountOfEscrowProceedsReleased_83" xlink:to="lab_drug_AmountOfEscrowProceedsReleased_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_AmountOfEscrowProceedsReleased_84" xlink:to="lab_drug_AmountOfEscrowProceedsReleased_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_AmountOfEscrowProceedsReleased_85" xlink:to="lab_drug_AmountOfEscrowProceedsReleased_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_AmountOfNonRefundableMonthlyRetainerAsServiceCompensation_86" xlink:to="lab_drug_AmountOfNonRefundableMonthlyRetainerAsServiceCompensation_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_AmountOfNonRefundableMonthlyRetainerAsServiceCompensation_87" xlink:to="lab_drug_AmountOfNonRefundableMonthlyRetainerAsServiceCompensation_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_AmountOfNonRefundableMonthlyRetainerAsServiceCompensation_88" xlink:to="lab_drug_AmountOfNonRefundableMonthlyRetainerAsServiceCompensation_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_AreasOfScientificTechnicalBusinessAdviceAdvisorsHourlyRates_89" xlink:to="lab_drug_AreasOfScientificTechnicalBusinessAdviceAdvisorsHourlyRates_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_AreasOfScientificTechnicalBusinessAdviceAdvisorsHourlyRates_90" xlink:to="lab_drug_AreasOfScientificTechnicalBusinessAdviceAdvisorsHourlyRates_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_ArrangementsAndNonarrangementTransactionDomain_91" xlink:to="lab_drug_ArrangementsAndNonarrangementTransactionDomain_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_ArrangementsAndNonarrangementTransactionDomain_92" xlink:to="lab_drug_ArrangementsAndNonarrangementTransactionDomain_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_BritishColumbiaSecuritiesCommissionMember_93" xlink:to="lab_drug_BritishColumbiaSecuritiesCommissionMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_BritishColumbiaSecuritiesCommissionMember_94" xlink:to="lab_drug_BritishColumbiaSecuritiesCommissionMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_CashSettledShareBasedPaymentArrangementsMember_95" xlink:to="lab_drug_CashSettledShareBasedPaymentArrangementsMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_CashSettledShareBasedPaymentArrangementsMember_96" xlink:to="lab_drug_CashSettledShareBasedPaymentArrangementsMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_CashSettledShareBasedPaymentArrangementsMember_97" xlink:to="lab_drug_CashSettledShareBasedPaymentArrangementsMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_CategoriesOfResearchAndDevelopmentExpensesAxis_98" xlink:to="lab_drug_CategoriesOfResearchAndDevelopmentExpensesAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_CategoriesOfResearchAndDevelopmentExpensesAxis_99" xlink:to="lab_drug_CategoriesOfResearchAndDevelopmentExpensesAxis_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_CategoriesOfResearchAndDevelopmentExpensesDomain_100" xlink:to="lab_drug_CategoriesOfResearchAndDevelopmentExpensesDomain_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_CategoriesOfResearchAndDevelopmentExpensesDomain_101" xlink:to="lab_drug_CategoriesOfResearchAndDevelopmentExpensesDomain_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_ChangesInNonCashWorkingOperatingCapitalBalancesAbstract_102" xlink:to="lab_drug_ChangesInNonCashWorkingOperatingCapitalBalancesAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_ChangesInNonCashWorkingOperatingCapitalBalancesAbstract_103" xlink:to="lab_drug_ChangesInNonCashWorkingOperatingCapitalBalancesAbstract_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_ChangesInNonCashWorkingOperatingCapitalBalancesAbstract_104" xlink:to="lab_drug_ChangesInNonCashWorkingOperatingCapitalBalancesAbstract_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_ChiefFinancialOfficerTwoDirectorsAndSevenConsultantsMember_105" xlink:to="lab_drug_ChiefFinancialOfficerTwoDirectorsAndSevenConsultantsMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_ChiefFinancialOfficerTwoDirectorsAndSevenConsultantsMember_106" xlink:to="lab_drug_ChiefFinancialOfficerTwoDirectorsAndSevenConsultantsMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_ChiefFinancialOfficerTwoDirectorsAndSevenConsultantsMember_107" xlink:to="lab_drug_ChiefFinancialOfficerTwoDirectorsAndSevenConsultantsMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_ChiefMedicalOfficerMember_108" xlink:to="lab_drug_ChiefMedicalOfficerMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_ChiefMedicalOfficerMember_109" xlink:to="lab_drug_ChiefMedicalOfficerMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_CommercialLaboratoryLeaseMember_110" xlink:to="lab_drug_CommercialLaboratoryLeaseMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_CommercialLaboratoryLeaseMember_111" xlink:to="lab_drug_CommercialLaboratoryLeaseMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_CommercialLaboratoryLeaseMember_112" xlink:to="lab_drug_CommercialLaboratoryLeaseMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_CommonShareSubscriptionsReceived_113" xlink:to="lab_drug_CommonShareSubscriptionsReceived_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_CommonShareSubscriptionsReceived_114" xlink:to="lab_drug_CommonShareSubscriptionsReceived_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_CommonShareSubscriptionsReceived_115" xlink:to="lab_drug_CommonShareSubscriptionsReceived_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_CommonStockSharesPurchased_116" xlink:to="lab_drug_CommonStockSharesPurchased_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_CommonStockSharesPurchased_117" xlink:to="lab_drug_CommonStockSharesPurchased_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_CommonStockSharesPurchased_118" xlink:to="lab_drug_CommonStockSharesPurchased_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_ComparativeAmountsAbstract_119" xlink:to="lab_drug_ComparativeAmountsAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_ComparativeAmountsAbstract_120" xlink:to="lab_drug_ComparativeAmountsAbstract_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_ConsolidatedStatementsOfComprehensiveIncomeLossStatementLocationAxis_121" xlink:to="lab_drug_ConsolidatedStatementsOfComprehensiveIncomeLossStatementLocationAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_ConsolidatedStatementsOfComprehensiveIncomeLossStatementLocationAxis_122" xlink:to="lab_drug_ConsolidatedStatementsOfComprehensiveIncomeLossStatementLocationAxis_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_ConsolidatedStatementsOfComprehensiveIncomeLossStatementLocationDomain_123" xlink:to="lab_drug_ConsolidatedStatementsOfComprehensiveIncomeLossStatementLocationDomain_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_ConsolidatedStatementsOfComprehensiveIncomeLossStatementLocationDomain_124" xlink:to="lab_drug_ConsolidatedStatementsOfComprehensiveIncomeLossStatementLocationDomain_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_ConsultantMember_125" xlink:to="lab_drug_ConsultantMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_ConsultantMember_126" xlink:to="lab_drug_ConsultantMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_ConsultingAgreement2Member_127" xlink:to="lab_drug_ConsultingAgreement2Member_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_ConsultingAgreementsMember_128" xlink:to="lab_drug_ConsultingAgreementsMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_ConsultingAgreementsMember_129" xlink:to="lab_drug_ConsultingAgreementsMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_ConsultingFees_130" xlink:to="lab_drug_ConsultingFees_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_ConsultingFees_131" xlink:to="lab_drug_ConsultingFees_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_ConsultingFees_132" xlink:to="lab_drug_ConsultingFees_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_ConsultingFees_133" xlink:to="lab_drug_ConsultingFees_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_ConsultingFeesMember_134" xlink:to="lab_drug_ConsultingFeesMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_ConsultingFeesMember_135" xlink:to="lab_drug_ConsultingFeesMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_ConsultingFeesMember_136" xlink:to="lab_drug_ConsultingFeesMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_ContingentCashFee_137" xlink:to="lab_drug_ContingentCashFee_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_ContingentCashFee_138" xlink:to="lab_drug_ContingentCashFee_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_ContingentCashFee_139" xlink:to="lab_drug_ContingentCashFee_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_DebtSettledByIssuingShares_140" xlink:to="lab_drug_DebtSettledByIssuingShares_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_DebtSettledByIssuingShares_141" xlink:to="lab_drug_DebtSettledByIssuingShares_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_DebtSettledByIssuingShares_142" xlink:to="lab_drug_DebtSettledByIssuingShares_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_DebtSettledThroughIssuanceOfShares_143" xlink:to="lab_drug_DebtSettledThroughIssuanceOfShares_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_DebtSettledThroughIssuanceOfShares_144" xlink:to="lab_drug_DebtSettledThroughIssuanceOfShares_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_DebtSettledThroughIssuanceOfShares_145" xlink:to="lab_drug_DebtSettledThroughIssuanceOfShares_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_DebtSettlementAgreementMember_146" xlink:to="lab_drug_DebtSettlementAgreementMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_DebtSettlementAgreementMember_147" xlink:to="lab_drug_DebtSettlementAgreementMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_DecemberTwentyOneTwoZeroTwoFourMember_148" xlink:to="lab_drug_DecemberTwentyOneTwoZeroTwoFourMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_DecemberTwentyOneTwoZeroTwoFourMember_149" xlink:to="lab_drug_DecemberTwentyOneTwoZeroTwoFourMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_DecemberTwentyOneTwoZeroTwoFourMember_150" xlink:to="lab_drug_DecemberTwentyOneTwoZeroTwoFourMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_DescriptionOfAccountingPolicyForBasisOfConsolidationExplanatory_151" xlink:to="lab_drug_DescriptionOfAccountingPolicyForBasisOfConsolidationExplanatory_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_DescriptionOfAccountingPolicyForBasisOfConsolidationExplanatory_152" xlink:to="lab_drug_DescriptionOfAccountingPolicyForBasisOfConsolidationExplanatory_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_DescriptionOfAccountingPolicyForBasisOfConsolidationExplanatory_153" xlink:to="lab_drug_DescriptionOfAccountingPolicyForBasisOfConsolidationExplanatory_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_DescriptionOfAccountingPolicyForCriticalAccountingEstimatesExplanatory_154" xlink:to="lab_drug_DescriptionOfAccountingPolicyForCriticalAccountingEstimatesExplanatory_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_DescriptionOfAccountingPolicyForCriticalAccountingEstimatesExplanatory_155" xlink:to="lab_drug_DescriptionOfAccountingPolicyForCriticalAccountingEstimatesExplanatory_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_DescriptionOfAccountingPolicyForCriticalAccountingEstimatesExplanatory_156" xlink:to="lab_drug_DescriptionOfAccountingPolicyForCriticalAccountingEstimatesExplanatory_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_DescriptionOfAccountingPolicyForInternallyGeneratedIntangibleAssetsResearchAndDevelopmentExpenditureExplanatory_157" xlink:to="lab_drug_DescriptionOfAccountingPolicyForInternallyGeneratedIntangibleAssetsResearchAndDevelopmentExpenditureExplanatory_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_DescriptionOfAccountingPolicyForInternallyGeneratedIntangibleAssetsResearchAndDevelopmentExpenditureExplanatory_158" xlink:to="lab_drug_DescriptionOfAccountingPolicyForInternallyGeneratedIntangibleAssetsResearchAndDevelopmentExpenditureExplanatory_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_DescriptionOfAccountingPolicyForInternallyGeneratedIntangibleAssetsResearchAndDevelopmentExpenditureExplanatory_159" xlink:to="lab_drug_DescriptionOfAccountingPolicyForInternallyGeneratedIntangibleAssetsResearchAndDevelopmentExpenditureExplanatory_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_DescriptionOfAccountingPolicyForNewStandardsAndInterpretationsNotYetAdoptedExplanatory_160" xlink:to="lab_drug_DescriptionOfAccountingPolicyForNewStandardsAndInterpretationsNotYetAdoptedExplanatory_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_DescriptionOfAccountingPolicyForNewStandardsAndInterpretationsNotYetAdoptedExplanatory_161" xlink:to="lab_drug_DescriptionOfAccountingPolicyForNewStandardsAndInterpretationsNotYetAdoptedExplanatory_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_DescriptionOfAccountingPolicyForNewStandardsAndInterpretationsNotYetAdoptedExplanatory_162" xlink:to="lab_drug_DescriptionOfAccountingPolicyForNewStandardsAndInterpretationsNotYetAdoptedExplanatory_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_DescriptionOfIssuedAndOutstandingCommonShares_163" xlink:to="lab_drug_DescriptionOfIssuedAndOutstandingCommonShares_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_DescriptionOfIssuedAndOutstandingCommonShares_164" xlink:to="lab_drug_DescriptionOfIssuedAndOutstandingCommonShares_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_DescriptionOfIssuedAndOutstandingCommonShares_165" xlink:to="lab_drug_DescriptionOfIssuedAndOutstandingCommonShares_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_DescriptionOfSublicenseeRevenueOfRoyaltyPaymentAccrues_166" xlink:to="lab_drug_DescriptionOfSublicenseeRevenueOfRoyaltyPaymentAccrues_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_DescriptionOfSublicenseeRevenueOfRoyaltyPaymentAccrues_167" xlink:to="lab_drug_DescriptionOfSublicenseeRevenueOfRoyaltyPaymentAccrues_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_DescriptionOfSublicenseeRevenueOfRoyaltyPaymentAccrues_168" xlink:to="lab_drug_DescriptionOfSublicenseeRevenueOfRoyaltyPaymentAccrues_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_DirectorAndConsultantMember_169" xlink:to="lab_drug_DirectorAndConsultantMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_DirectorAndConsultantMember_170" xlink:to="lab_drug_DirectorAndConsultantMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_DirectorAndConsultantMember_171" xlink:to="lab_drug_DirectorAndConsultantMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_DirectorsCompensationMember_172" xlink:to="lab_drug_DirectorsCompensationMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_DirectorsCompensationMember_173" xlink:to="lab_drug_DirectorsCompensationMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_DirectorsCompensationMember_174" xlink:to="lab_drug_DirectorsCompensationMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_DisclosureOfComparativeAmountsExplanatory_175" xlink:to="lab_drug_DisclosureOfComparativeAmountsExplanatory_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_DisclosureOfComparativeAmountsExplanatory_176" xlink:to="lab_drug_DisclosureOfComparativeAmountsExplanatory_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_DisclosureOfComparativeAmountsExplanatory_177" xlink:to="lab_drug_DisclosureOfComparativeAmountsExplanatory_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_DisclosureOfContractualObligationAbstract_178" xlink:to="lab_drug_DisclosureOfContractualObligationAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_DisclosureOfContractualObligationLineItems_179" xlink:to="lab_drug_DisclosureOfContractualObligationLineItems_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_DisclosureOfContractualObligationTable_180" xlink:to="lab_drug_DisclosureOfContractualObligationTable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_DisclosureOfContractualObligationTable_181" xlink:to="lab_drug_DisclosureOfContractualObligationTable_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_DisclosureOfDetailedInformationAboutEquitySettledRestrictedShareUnitsFairValueInputsExplanatory_182" xlink:to="lab_drug_DisclosureOfDetailedInformationAboutEquitySettledRestrictedShareUnitsFairValueInputsExplanatory_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_DisclosureOfDetailedInformationAboutEquitySettledRestrictedShareUnitsFairValueInputsExplanatory_183" xlink:to="lab_drug_DisclosureOfDetailedInformationAboutEquitySettledRestrictedShareUnitsFairValueInputsExplanatory_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_DisclosureOfDetailedInformationAboutEquitySettledRestrictedShareUnitsFairValueInputsExplanatory_184" xlink:to="lab_drug_DisclosureOfDetailedInformationAboutEquitySettledRestrictedShareUnitsFairValueInputsExplanatory_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_DisclosureOfDetailedInformationAboutResearchAndDevelopmentExplanatory_185" xlink:to="lab_drug_DisclosureOfDetailedInformationAboutResearchAndDevelopmentExplanatory_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_DisclosureOfDetailedInformationAboutResearchAndDevelopmentExplanatory_186" xlink:to="lab_drug_DisclosureOfDetailedInformationAboutResearchAndDevelopmentExplanatory_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_DisclosureOfDetailedInformationAboutResearchAndDevelopmentExplanatory_187" xlink:to="lab_drug_DisclosureOfDetailedInformationAboutResearchAndDevelopmentExplanatory_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_DisclosureOfDetailedInformationAboutShareBasedPaymentsIncludedInConsolidatedStatementsOfComprehensiveLossExplanatory_188" xlink:to="lab_drug_DisclosureOfDetailedInformationAboutShareBasedPaymentsIncludedInConsolidatedStatementsOfComprehensiveLossExplanatory_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_DisclosureOfDetailedInformationAboutShareBasedPaymentsIncludedInConsolidatedStatementsOfComprehensiveLossExplanatory_189" xlink:to="lab_drug_DisclosureOfDetailedInformationAboutShareBasedPaymentsIncludedInConsolidatedStatementsOfComprehensiveLossExplanatory_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_DisclosureOfDetailedInformationAboutShareBasedPaymentsIncludedInConsolidatedStatementsOfComprehensiveLossExplanatory_190" xlink:to="lab_drug_DisclosureOfDetailedInformationAboutShareBasedPaymentsIncludedInConsolidatedStatementsOfComprehensiveLossExplanatory_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_DisclosureOfDetailedInformationAboutShareBasedPaymentsRecognizedInConsolidatedStatementsOfComprehensiveLossExplanatory_191" xlink:to="lab_drug_DisclosureOfDetailedInformationAboutShareBasedPaymentsRecognizedInConsolidatedStatementsOfComprehensiveLossExplanatory_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_DisclosureOfDetailedInformationAboutShareBasedPaymentsRecognizedInConsolidatedStatementsOfComprehensiveLossExplanatory_192" xlink:to="lab_drug_DisclosureOfDetailedInformationAboutShareBasedPaymentsRecognizedInConsolidatedStatementsOfComprehensiveLossExplanatory_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_DisclosureOfDetailedInformationAboutShareBasedPaymentsRecognizedInConsolidatedStatementsOfComprehensiveLossExplanatory_193" xlink:to="lab_drug_DisclosureOfDetailedInformationAboutShareBasedPaymentsRecognizedInConsolidatedStatementsOfComprehensiveLossExplanatory_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_DisclosureOfDetailedInformationAboutSignificantAccountingPoliciesAbstract_194" xlink:to="lab_drug_DisclosureOfDetailedInformationAboutSignificantAccountingPoliciesAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_DisclosureOfDetailedInformationAboutTradePayableAndAccruedExpensesExplanatory_195" xlink:to="lab_drug_DisclosureOfDetailedInformationAboutTradePayableAndAccruedExpensesExplanatory_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_DisclosureOfDetailedInformationAboutTradePayableAndAccruedExpensesExplanatory_196" xlink:to="lab_drug_DisclosureOfDetailedInformationAboutTradePayableAndAccruedExpensesExplanatory_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_DisclosureOfDetailedInformationAboutTradePayableAndAccruedExpensesExplanatory_197" xlink:to="lab_drug_DisclosureOfDetailedInformationAboutTradePayableAndAccruedExpensesExplanatory_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_DisclosureOfMovementsInOutstandingWarrantsExplanatory_198" xlink:to="lab_drug_DisclosureOfMovementsInOutstandingWarrantsExplanatory_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_DisclosureOfMovementsInOutstandingWarrantsExplanatory_199" xlink:to="lab_drug_DisclosureOfMovementsInOutstandingWarrantsExplanatory_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_DisclosureOfMovementsInOutstandingWarrantsExplanatory_200" xlink:to="lab_drug_DisclosureOfMovementsInOutstandingWarrantsExplanatory_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_DisclosureOfNatureAndContinuanceOfOperationsExplanatory_201" xlink:to="lab_drug_DisclosureOfNatureAndContinuanceOfOperationsExplanatory_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_DisclosureOfNatureAndContinuanceOfOperationsExplanatory_202" xlink:to="lab_drug_DisclosureOfNatureAndContinuanceOfOperationsExplanatory_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_DisclosureOfNatureAndContinuanceOfOperationsExplanatory_203" xlink:to="lab_drug_DisclosureOfNatureAndContinuanceOfOperationsExplanatory_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_DisclosureOfNonCapitalLossCarryForwardsExpiryExplanatory_204" xlink:to="lab_drug_DisclosureOfNonCapitalLossCarryForwardsExpiryExplanatory_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_DisclosureOfNonCapitalLossCarryForwardsExpiryExplanatory_205" xlink:to="lab_drug_DisclosureOfNonCapitalLossCarryForwardsExpiryExplanatory_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_DisclosureOfNonCapitalLossCarryForwardsExpiryExplanatory_206" xlink:to="lab_drug_DisclosureOfNonCapitalLossCarryForwardsExpiryExplanatory_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_DisclosureOfNumberAndWeightedAverageExercisePricesOfWarrantsExplanatory_207" xlink:to="lab_drug_DisclosureOfNumberAndWeightedAverageExercisePricesOfWarrantsExplanatory_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_DisclosureOfNumberAndWeightedAverageExercisePricesOfWarrantsExplanatory_208" xlink:to="lab_drug_DisclosureOfNumberAndWeightedAverageExercisePricesOfWarrantsExplanatory_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_DisclosureOfNumberAndWeightedAverageExercisePricesOfWarrantsExplanatory_209" xlink:to="lab_drug_DisclosureOfNumberAndWeightedAverageExercisePricesOfWarrantsExplanatory_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_DisclosureOfNumberOfIssuedAndOutstandingStockOptionsExplanatory_210" xlink:to="lab_drug_DisclosureOfNumberOfIssuedAndOutstandingStockOptionsExplanatory_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_DisclosureOfNumberOfIssuedAndOutstandingStockOptionsExplanatory_211" xlink:to="lab_drug_DisclosureOfNumberOfIssuedAndOutstandingStockOptionsExplanatory_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_DisclosureOfNumberOfIssuedAndOutstandingStockOptionsExplanatory_212" xlink:to="lab_drug_DisclosureOfNumberOfIssuedAndOutstandingStockOptionsExplanatory_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_DisclosureOfNumberOfIssuedAndOutstandingWarrantsExplanatory_213" xlink:to="lab_drug_DisclosureOfNumberOfIssuedAndOutstandingWarrantsExplanatory_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_DisclosureOfNumberOfIssuedAndOutstandingWarrantsExplanatory_214" xlink:to="lab_drug_DisclosureOfNumberOfIssuedAndOutstandingWarrantsExplanatory_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_DisclosureOfNumberOfIssuedAndOutstandingWarrantsExplanatory_215" xlink:to="lab_drug_DisclosureOfNumberOfIssuedAndOutstandingWarrantsExplanatory_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_DisclosureOfReconciliationOfExpectedIncomeTaxRecoveryToActualIncomeTaxRecoveryExplanatory_216" xlink:to="lab_drug_DisclosureOfReconciliationOfExpectedIncomeTaxRecoveryToActualIncomeTaxRecoveryExplanatory_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_DisclosureOfReconciliationOfExpectedIncomeTaxRecoveryToActualIncomeTaxRecoveryExplanatory_217" xlink:to="lab_drug_DisclosureOfReconciliationOfExpectedIncomeTaxRecoveryToActualIncomeTaxRecoveryExplanatory_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_DisclosureOfReconciliationOfExpectedIncomeTaxRecoveryToActualIncomeTaxRecoveryExplanatory_218" xlink:to="lab_drug_DisclosureOfReconciliationOfExpectedIncomeTaxRecoveryToActualIncomeTaxRecoveryExplanatory_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_DisclosureOfShareExchangeAndAssignmentExplanatory_219" xlink:to="lab_drug_DisclosureOfShareExchangeAndAssignmentExplanatory_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_DisclosureOfShareExchangeAndAssignmentExplanatory_220" xlink:to="lab_drug_DisclosureOfShareExchangeAndAssignmentExplanatory_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_DisclosureOfShareExchangeAndAssignmentExplanatory_221" xlink:to="lab_drug_DisclosureOfShareExchangeAndAssignmentExplanatory_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_DisclosureOfShareExchangeAndAssignmentTable_222" xlink:to="lab_drug_DisclosureOfShareExchangeAndAssignmentTable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_DisclosureOfShareExchangeAndAssignmentTable_223" xlink:to="lab_drug_DisclosureOfShareExchangeAndAssignmentTable_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_DiscountRateOfWarrantsGranted_224" xlink:to="lab_drug_DiscountRateOfWarrantsGranted_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_DiscountRateOfWarrantsGranted_225" xlink:to="lab_drug_DiscountRateOfWarrantsGranted_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_DiscountRateOfWarrantsGranted_226" xlink:to="lab_drug_DiscountRateOfWarrantsGranted_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_DiscountRateStockOptionGranted_227" xlink:to="lab_drug_DiscountRateStockOptionGranted_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_DiscountRateStockOptionGranted_228" xlink:to="lab_drug_DiscountRateStockOptionGranted_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_DiscountRateStockOptionGranted_229" xlink:to="lab_drug_DiscountRateStockOptionGranted_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_DocumentAndEntityAbstract_230" xlink:to="lab_drug_DocumentAndEntityAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_DocumentAndEntityAbstract_231" xlink:to="lab_drug_DocumentAndEntityAbstract_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_EighteenMonthAnniversaryOfGrantDateMember_232" xlink:to="lab_drug_EighteenMonthAnniversaryOfGrantDateMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_EighteenMonthAnniversaryOfGrantDateMember_233" xlink:to="lab_drug_EighteenMonthAnniversaryOfGrantDateMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_EighthTrancheMember_234" xlink:to="lab_drug_EighthTrancheMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_EighthTrancheMember_235" xlink:to="lab_drug_EighthTrancheMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_EighthTrancheMember_236" xlink:to="lab_drug_EighthTrancheMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_EleventhTrancheMember_237" xlink:to="lab_drug_EleventhTrancheMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_EleventhTrancheMember_238" xlink:to="lab_drug_EleventhTrancheMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_EleventhTrancheMember_239" xlink:to="lab_drug_EleventhTrancheMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_EquitySettledShareBasedPaymentArrangementsMember_240" xlink:to="lab_drug_EquitySettledShareBasedPaymentArrangementsMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_EquitySettledShareBasedPaymentArrangementsMember_241" xlink:to="lab_drug_EquitySettledShareBasedPaymentArrangementsMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_EquitySettledShareBasedPaymentArrangementsMember_242" xlink:to="lab_drug_EquitySettledShareBasedPaymentArrangementsMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_EscrowAgreementMember_243" xlink:to="lab_drug_EscrowAgreementMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_EscrowAgreementMember_244" xlink:to="lab_drug_EscrowAgreementMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_EscrowedSecuritiesMember_245" xlink:to="lab_drug_EscrowedSecuritiesMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_EscrowedSecuritiesMember_246" xlink:to="lab_drug_EscrowedSecuritiesMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_EscrowedSecuritiesToBeReleasedAfterListingDate_247" xlink:to="lab_drug_EscrowedSecuritiesToBeReleasedAfterListingDate_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_EscrowedSecuritiesToBeReleasedAfterListingDate_248" xlink:to="lab_drug_EscrowedSecuritiesToBeReleasedAfterListingDate_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_EscrowedSecuritiesToBeReleasedAfterListingDate_249" xlink:to="lab_drug_EscrowedSecuritiesToBeReleasedAfterListingDate_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_EscrowedSecuritiesToBeReleasedOnceSharesAreListedOnCanadianStockExchange_250" xlink:to="lab_drug_EscrowedSecuritiesToBeReleasedOnceSharesAreListedOnCanadianStockExchange_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_EscrowedSecuritiesToBeReleasedOnceSharesAreListedOnCanadianStockExchange_251" xlink:to="lab_drug_EscrowedSecuritiesToBeReleasedOnceSharesAreListedOnCanadianStockExchange_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_EscrowedSecuritiesToBeReleasedOnceSharesAreListedOnCanadianStockExchange_252" xlink:to="lab_drug_EscrowedSecuritiesToBeReleasedOnceSharesAreListedOnCanadianStockExchange_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_EscrowedSharePurchaseWarrantsMember_253" xlink:to="lab_drug_EscrowedSharePurchaseWarrantsMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_EscrowedSharePurchaseWarrantsMember_254" xlink:to="lab_drug_EscrowedSharePurchaseWarrantsMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_EscrowedSharePurchaseWarrantsMember_255" xlink:to="lab_drug_EscrowedSharePurchaseWarrantsMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_EstimatedFairValueOfEquitySettledRsusGranted_256" xlink:to="lab_drug_EstimatedFairValueOfEquitySettledRsusGranted_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_EstimatedFairValueOfEquitySettledRsusGranted_257" xlink:to="lab_drug_EstimatedFairValueOfEquitySettledRsusGranted_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_EstimatedFairValueOfEquitySettledRsusGranted_258" xlink:to="lab_drug_EstimatedFairValueOfEquitySettledRsusGranted_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_EstimatedLifeOfWarrantsGranted_259" xlink:to="lab_drug_EstimatedLifeOfWarrantsGranted_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_EstimatedLifeOfWarrantsGranted_260" xlink:to="lab_drug_EstimatedLifeOfWarrantsGranted_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_EstimatedLifeOfWarrantsGranted_261" xlink:to="lab_drug_EstimatedLifeOfWarrantsGranted_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_ExercisePriceWarrantsGranted_262" xlink:to="lab_drug_ExercisePriceWarrantsGranted_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_ExercisePriceWarrantsGranted_263" xlink:to="lab_drug_ExercisePriceWarrantsGranted_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_ExercisePriceWarrantsGranted_264" xlink:to="lab_drug_ExercisePriceWarrantsGranted_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_ExpectedVolatilityWarrantsGranted_265" xlink:to="lab_drug_ExpectedVolatilityWarrantsGranted_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_ExpectedVolatilityWarrantsGranted_266" xlink:to="lab_drug_ExpectedVolatilityWarrantsGranted_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_ExpectedVolatilityWarrantsGranted_267" xlink:to="lab_drug_ExpectedVolatilityWarrantsGranted_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_ExpirationPeriodDomain_268" xlink:to="lab_drug_ExpirationPeriodDomain_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_ExpirationPeriodDomain_269" xlink:to="lab_drug_ExpirationPeriodDomain_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_ExpirePeriodAxis_270" xlink:to="lab_drug_ExpirePeriodAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_ExpirePeriodAxis_271" xlink:to="lab_drug_ExpirePeriodAxis_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_ExpiryDate_272" xlink:to="lab_drug_ExpiryDate_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_ExpiryDate_273" xlink:to="lab_drug_ExpiryDate_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_ExpiryDate_274" xlink:to="lab_drug_ExpiryDate_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_ExpiryDateAxis_275" xlink:to="lab_drug_ExpiryDateAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_ExpiryDateAxis_276" xlink:to="lab_drug_ExpiryDateAxis_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_ExpiryDateDomain_277" xlink:to="lab_drug_ExpiryDateDomain_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_ExpiryDateDomain_278" xlink:to="lab_drug_ExpiryDateDomain_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_ExpiryDateFifteenJuneTwoThousandAndTwentySixMember_279" xlink:to="lab_drug_ExpiryDateFifteenJuneTwoThousandAndTwentySixMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_ExpiryDateFifteenJuneTwoThousandAndTwentySixMember_280" xlink:to="lab_drug_ExpiryDateFifteenJuneTwoThousandAndTwentySixMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_ExpiryDateFifteenJuneTwoThousandAndTwentySixMember_281" xlink:to="lab_drug_ExpiryDateFifteenJuneTwoThousandAndTwentySixMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_ExpiryDateSeventeenMarchTwoThousandAndTwentyFourOneMember_282" xlink:to="lab_drug_ExpiryDateSeventeenMarchTwoThousandAndTwentyFourOneMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_ExpiryDateSeventeenMarchTwoThousandAndTwentyFourOneMember_283" xlink:to="lab_drug_ExpiryDateSeventeenMarchTwoThousandAndTwentyFourOneMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_ExpiryDateSeventeenMarchTwoThousandAndTwentyFourOneMember_284" xlink:to="lab_drug_ExpiryDateSeventeenMarchTwoThousandAndTwentyFourOneMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_ExpiryDateSeventeenMarchTwoThousandAndTwentyFourTwoMember_285" xlink:to="lab_drug_ExpiryDateSeventeenMarchTwoThousandAndTwentyFourTwoMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_ExpiryDateSeventeenMarchTwoThousandAndTwentyFourTwoMember_286" xlink:to="lab_drug_ExpiryDateSeventeenMarchTwoThousandAndTwentyFourTwoMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_ExpiryDateSeventeenMarchTwoThousandAndTwentyFourTwoMember_287" xlink:to="lab_drug_ExpiryDateSeventeenMarchTwoThousandAndTwentyFourTwoMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_ExpiryDateSeventeenNovemberTwoThousandAndTwentyFiveMember_288" xlink:to="lab_drug_ExpiryDateSeventeenNovemberTwoThousandAndTwentyFiveMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_ExpiryDateSeventeenNovemberTwoThousandAndTwentyFiveMember_289" xlink:to="lab_drug_ExpiryDateSeventeenNovemberTwoThousandAndTwentyFiveMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_ExpiryDateSeventeenNovemberTwoThousandAndTwentyFiveMember_290" xlink:to="lab_drug_ExpiryDateSeventeenNovemberTwoThousandAndTwentyFiveMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_ExpiryDateThirtyJulyTwoThousandAndTwentyFourMember_291" xlink:to="lab_drug_ExpiryDateThirtyJulyTwoThousandAndTwentyFourMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_ExpiryDateThirtyJulyTwoThousandAndTwentyFourMember_292" xlink:to="lab_drug_ExpiryDateThirtyJulyTwoThousandAndTwentyFourMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_ExpiryDateThirtyJulyTwoThousandAndTwentyFourMember_293" xlink:to="lab_drug_ExpiryDateThirtyJulyTwoThousandAndTwentyFourMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_ExpiryDateTwentyEightAprilTwoThousandAndTwentySixMember_294" xlink:to="lab_drug_ExpiryDateTwentyEightAprilTwoThousandAndTwentySixMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_ExpiryDateTwentyEightAprilTwoThousandAndTwentySixMember_295" xlink:to="lab_drug_ExpiryDateTwentyEightAprilTwoThousandAndTwentySixMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_ExpiryDateTwentyEightAprilTwoThousandAndTwentySixMember_296" xlink:to="lab_drug_ExpiryDateTwentyEightAprilTwoThousandAndTwentySixMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_ExpiryDateTwentyOneSeptemberTwoThousandAndTwentyFourMember_297" xlink:to="lab_drug_ExpiryDateTwentyOneSeptemberTwoThousandAndTwentyFourMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_ExpiryDateTwentyOneSeptemberTwoThousandAndTwentyFourMember_298" xlink:to="lab_drug_ExpiryDateTwentyOneSeptemberTwoThousandAndTwentyFourMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_ExpiryDateTwentyOneSeptemberTwoThousandAndTwentyFourMember_299" xlink:to="lab_drug_ExpiryDateTwentyOneSeptemberTwoThousandAndTwentyFourMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_ExpiryDateTwentyThreeJulyTwoThousandAndTwentyFiveMember_300" xlink:to="lab_drug_ExpiryDateTwentyThreeJulyTwoThousandAndTwentyFiveMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_ExpiryDateTwentyThreeJulyTwoThousandAndTwentyFiveMember_301" xlink:to="lab_drug_ExpiryDateTwentyThreeJulyTwoThousandAndTwentyFiveMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_ExpiryDateTwentyThreeJulyTwoThousandAndTwentyFiveMember_302" xlink:to="lab_drug_ExpiryDateTwentyThreeJulyTwoThousandAndTwentyFiveMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_FairValueAscribedToBrokersWarrantsIssued_303" xlink:to="lab_drug_FairValueAscribedToBrokersWarrantsIssued_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_FairValueAscribedToBrokersWarrantsIssued_304" xlink:to="lab_drug_FairValueAscribedToBrokersWarrantsIssued_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_FairValueAscribedToBrokersWarrantsIssued_305" xlink:to="lab_drug_FairValueAscribedToBrokersWarrantsIssued_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_FairValueOfOptionsIssuedAsFindersFees_306" xlink:to="lab_drug_FairValueOfOptionsIssuedAsFindersFees_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_FairValueOfOptionsIssuedAsFindersFees_307" xlink:to="lab_drug_FairValueOfOptionsIssuedAsFindersFees_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_FairValueOfOptionsIssuedAsFindersFees_308" xlink:to="lab_drug_FairValueOfOptionsIssuedAsFindersFees_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_FairValueOfWarrants_309" xlink:to="lab_drug_FairValueOfWarrants_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_FairValueOfWarrants_310" xlink:to="lab_drug_FairValueOfWarrants_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_FairValueOfWarrants_311" xlink:to="lab_drug_FairValueOfWarrants_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_FifteenthTrancheMember_312" xlink:to="lab_drug_FifteenthTrancheMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_FifteenthTrancheMember_313" xlink:to="lab_drug_FifteenthTrancheMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_FifteenthTrancheMember_314" xlink:to="lab_drug_FifteenthTrancheMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_FifthTrancheMember_315" xlink:to="lab_drug_FifthTrancheMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_FifthTrancheMember_316" xlink:to="lab_drug_FifthTrancheMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_FifthTrancheMember_317" xlink:to="lab_drug_FifthTrancheMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_FinancialInstrumentsAtAmortizedCostMember_318" xlink:to="lab_drug_FinancialInstrumentsAtAmortizedCostMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_FinancialInstrumentsAtAmortizedCostMember_319" xlink:to="lab_drug_FinancialInstrumentsAtAmortizedCostMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_FinancialInstrumentsAtAmortizedCostMember_320" xlink:to="lab_drug_FinancialInstrumentsAtAmortizedCostMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_FinancialInstrumentsAtFairValueThroughProfitOrLossMember_321" xlink:to="lab_drug_FinancialInstrumentsAtFairValueThroughProfitOrLossMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_FinancialInstrumentsAtFairValueThroughProfitOrLossMember_322" xlink:to="lab_drug_FinancialInstrumentsAtFairValueThroughProfitOrLossMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_FinancialInstrumentsAtFairValueThroughProfitOrLossMember_323" xlink:to="lab_drug_FinancialInstrumentsAtFairValueThroughProfitOrLossMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_FirstAnniversaryOfGrantDateMember_324" xlink:to="lab_drug_FirstAnniversaryOfGrantDateMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_FirstAnniversaryOfGrantDateMember_325" xlink:to="lab_drug_FirstAnniversaryOfGrantDateMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_FirstTrancheMember_326" xlink:to="lab_drug_FirstTrancheMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_FirstTrancheMember_327" xlink:to="lab_drug_FirstTrancheMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_FirstTrancheMember_328" xlink:to="lab_drug_FirstTrancheMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_FirstTrancheMember_329" xlink:to="lab_drug_FirstTrancheMember_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_FirstTrancheOfNonBrokeredPrivatePlacementMember_330" xlink:to="lab_drug_FirstTrancheOfNonBrokeredPrivatePlacementMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_FirstTrancheOfNonBrokeredPrivatePlacementMember_331" xlink:to="lab_drug_FirstTrancheOfNonBrokeredPrivatePlacementMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_FirstTrancheOfNonBrokeredPrivatePlacementMember_332" xlink:to="lab_drug_FirstTrancheOfNonBrokeredPrivatePlacementMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_ForfeitureRateOfOtherEquityInstruments_333" xlink:to="lab_drug_ForfeitureRateOfOtherEquityInstruments_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_ForfeitureRateOfOtherEquityInstruments_334" xlink:to="lab_drug_ForfeitureRateOfOtherEquityInstruments_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_ForfeitureRateOfOtherEquityInstruments_335" xlink:to="lab_drug_ForfeitureRateOfOtherEquityInstruments_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_FourteenthTrancheMember_336" xlink:to="lab_drug_FourteenthTrancheMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_FourteenthTrancheMember_337" xlink:to="lab_drug_FourteenthTrancheMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_FourteenthTrancheMember_338" xlink:to="lab_drug_FourteenthTrancheMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_FourthAnniversaryOfGrantDateMember_339" xlink:to="lab_drug_FourthAnniversaryOfGrantDateMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_FourthAnniversaryOfGrantDateMember_340" xlink:to="lab_drug_FourthAnniversaryOfGrantDateMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_FourthTrancheMember_341" xlink:to="lab_drug_FourthTrancheMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_FourthTrancheMember_342" xlink:to="lab_drug_FourthTrancheMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_FourthTrancheMember_343" xlink:to="lab_drug_FourthTrancheMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_GrantDateAxis_344" xlink:to="lab_drug_GrantDateAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_GrantDateAxis_345" xlink:to="lab_drug_GrantDateAxis_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_GrantDateDomain_346" xlink:to="lab_drug_GrantDateDomain_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_GrantDateDomain_347" xlink:to="lab_drug_GrantDateDomain_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_GrossProceedsFromUnitsIssued_348" xlink:to="lab_drug_GrossProceedsFromUnitsIssued_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_GrossProceedsFromUnitsIssued_349" xlink:to="lab_drug_GrossProceedsFromUnitsIssued_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_GrossProceedsFromUnitsIssued_350" xlink:to="lab_drug_GrossProceedsFromUnitsIssued_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_GrossProceedsFromWarrantsExercised_351" xlink:to="lab_drug_GrossProceedsFromWarrantsExercised_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_GrossProceedsFromWarrantsExercised_352" xlink:to="lab_drug_GrossProceedsFromWarrantsExercised_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_GrossProceedsFromWarrantsExercised_353" xlink:to="lab_drug_GrossProceedsFromWarrantsExercised_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_GrossProceedsFromWarrantsIssued_354" xlink:to="lab_drug_GrossProceedsFromWarrantsIssued_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_GrossProceedsFromWarrantsIssued_355" xlink:to="lab_drug_GrossProceedsFromWarrantsIssued_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_GrossProceedsFromWarrantsIssued_356" xlink:to="lab_drug_GrossProceedsFromWarrantsIssued_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_IncomeTaxAuthorityNameOfCountryAxis_357" xlink:to="lab_drug_IncomeTaxAuthorityNameOfCountryAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_IncomeTaxAuthorityNameOfCountryAxis_358" xlink:to="lab_drug_IncomeTaxAuthorityNameOfCountryAxis_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_IncomeTaxAuthorityNameOfCountryDomain_359" xlink:to="lab_drug_IncomeTaxAuthorityNameOfCountryDomain_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_IncomeTaxAuthorityNameOfCountryDomain_360" xlink:to="lab_drug_IncomeTaxAuthorityNameOfCountryDomain_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_IncreaseDecreaseThroughAcquisitionOfIntangibleAssets_361" xlink:to="lab_drug_IncreaseDecreaseThroughAcquisitionOfIntangibleAssets_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_IncreaseDecreaseThroughAcquisitionOfIntangibleAssets_362" xlink:to="lab_drug_IncreaseDecreaseThroughAcquisitionOfIntangibleAssets_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_IncreaseDecreaseThroughAcquisitionOfIntangibleAssets_363" xlink:to="lab_drug_IncreaseDecreaseThroughAcquisitionOfIntangibleAssets_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_IncreaseDecreaseThroughAcquisitionOfIntangibleAssetsShares_364" xlink:to="lab_drug_IncreaseDecreaseThroughAcquisitionOfIntangibleAssetsShares_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_IncreaseDecreaseThroughAcquisitionOfIntangibleAssetsShares_365" xlink:to="lab_drug_IncreaseDecreaseThroughAcquisitionOfIntangibleAssetsShares_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_IncreaseDecreaseThroughAcquisitionOfIntangibleAssetsShares_366" xlink:to="lab_drug_IncreaseDecreaseThroughAcquisitionOfIntangibleAssetsShares_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_IncreaseDecreaseThroughCashDistributionForFindersFees_367" xlink:to="lab_drug_IncreaseDecreaseThroughCashDistributionForFindersFees_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_IncreaseDecreaseThroughCashDistributionForFindersFees_368" xlink:to="lab_drug_IncreaseDecreaseThroughCashDistributionForFindersFees_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_IncreaseDecreaseThroughCashDistributionForFindersFees_369" xlink:to="lab_drug_IncreaseDecreaseThroughCashDistributionForFindersFees_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_IncreaseDecreaseThroughDebtSettlementWithShare_370" xlink:to="lab_drug_IncreaseDecreaseThroughDebtSettlementWithShare_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_IncreaseDecreaseThroughDebtSettlementWithShare_371" xlink:to="lab_drug_IncreaseDecreaseThroughDebtSettlementWithShare_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_IncreaseDecreaseThroughDebtSettlementWithShare_372" xlink:to="lab_drug_IncreaseDecreaseThroughDebtSettlementWithShare_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_IncreaseDecreaseThroughDebtSettlementWithShareShares_373" xlink:to="lab_drug_IncreaseDecreaseThroughDebtSettlementWithShareShares_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_IncreaseDecreaseThroughDebtSettlementWithShareShares_374" xlink:to="lab_drug_IncreaseDecreaseThroughDebtSettlementWithShareShares_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_IncreaseDecreaseThroughDebtSettlementWithShareShares_375" xlink:to="lab_drug_IncreaseDecreaseThroughDebtSettlementWithShareShares_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_IncreaseDecreaseThroughDistributionOfBrokerWarrantsForFindersFees_376" xlink:to="lab_drug_IncreaseDecreaseThroughDistributionOfBrokerWarrantsForFindersFees_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_IncreaseDecreaseThroughDistributionOfBrokerWarrantsForFindersFees_377" xlink:to="lab_drug_IncreaseDecreaseThroughDistributionOfBrokerWarrantsForFindersFees_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_IncreaseDecreaseThroughDistributionOfBrokerWarrantsForFindersFees_378" xlink:to="lab_drug_IncreaseDecreaseThroughDistributionOfBrokerWarrantsForFindersFees_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_IncreaseDecreaseThroughExerciseOfOptionsForFindersFee_379" xlink:to="lab_drug_IncreaseDecreaseThroughExerciseOfOptionsForFindersFee_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_IncreaseDecreaseThroughExerciseOfOptionsForFindersFee_380" xlink:to="lab_drug_IncreaseDecreaseThroughExerciseOfOptionsForFindersFee_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_IncreaseDecreaseThroughExerciseOfOptionsForFindersFee_381" xlink:to="lab_drug_IncreaseDecreaseThroughExerciseOfOptionsForFindersFee_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_IncreaseDecreaseThroughExerciseOfWarrantsShares_382" xlink:to="lab_drug_IncreaseDecreaseThroughExerciseOfWarrantsShares_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_IncreaseDecreaseThroughExerciseOfWarrantsShares_383" xlink:to="lab_drug_IncreaseDecreaseThroughExerciseOfWarrantsShares_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_IncreaseDecreaseThroughExerciseOfWarrantsShares_384" xlink:to="lab_drug_IncreaseDecreaseThroughExerciseOfWarrantsShares_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_IncreaseDecreaseThroughFindersFeesBrokerWarrants_385" xlink:to="lab_drug_IncreaseDecreaseThroughFindersFeesBrokerWarrants_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_IncreaseDecreaseThroughFindersFeesBrokerWarrants_386" xlink:to="lab_drug_IncreaseDecreaseThroughFindersFeesBrokerWarrants_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_IncreaseDecreaseThroughFindersFeesBrokerWarrants_387" xlink:to="lab_drug_IncreaseDecreaseThroughFindersFeesBrokerWarrants_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_IncreaseDecreaseThroughFindersFeesCash_388" xlink:to="lab_drug_IncreaseDecreaseThroughFindersFeesCash_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_IncreaseDecreaseThroughFindersFeesCash_389" xlink:to="lab_drug_IncreaseDecreaseThroughFindersFeesCash_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_IncreaseDecreaseThroughFindersFeesCash_390" xlink:to="lab_drug_IncreaseDecreaseThroughFindersFeesCash_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_IncreaseDecreaseThroughFindersFeesShareOptions_391" xlink:to="lab_drug_IncreaseDecreaseThroughFindersFeesShareOptions_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_IncreaseDecreaseThroughFindersFeesShareOptions_392" xlink:to="lab_drug_IncreaseDecreaseThroughFindersFeesShareOptions_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_IncreaseDecreaseThroughFindersFeesShareOptions_393" xlink:to="lab_drug_IncreaseDecreaseThroughFindersFeesShareOptions_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_IncreaseDecreaseThroughPrivatePlacement_394" xlink:to="lab_drug_IncreaseDecreaseThroughPrivatePlacement_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_IncreaseDecreaseThroughPrivatePlacement_395" xlink:to="lab_drug_IncreaseDecreaseThroughPrivatePlacement_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_IncreaseDecreaseThroughPrivatePlacement_396" xlink:to="lab_drug_IncreaseDecreaseThroughPrivatePlacement_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_IncreaseDecreaseThroughPrivatePlacementShares_397" xlink:to="lab_drug_IncreaseDecreaseThroughPrivatePlacementShares_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_IncreaseDecreaseThroughPrivatePlacementShares_398" xlink:to="lab_drug_IncreaseDecreaseThroughPrivatePlacementShares_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_IncreaseDecreaseThroughPrivatePlacementShares_399" xlink:to="lab_drug_IncreaseDecreaseThroughPrivatePlacementShares_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_IncreaseDecreaseThroughSharesIssuedToUniversity_400" xlink:to="lab_drug_IncreaseDecreaseThroughSharesIssuedToUniversity_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_IncreaseDecreaseThroughSharesIssuedToUniversity_401" xlink:to="lab_drug_IncreaseDecreaseThroughSharesIssuedToUniversity_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_IncreaseDecreaseThroughSharesIssuedToUniversity_402" xlink:to="lab_drug_IncreaseDecreaseThroughSharesIssuedToUniversity_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_IncreaseDecreaseThroughSharesIssuedToUniversityShares_403" xlink:to="lab_drug_IncreaseDecreaseThroughSharesIssuedToUniversityShares_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_IncreaseDecreaseThroughSharesIssuedToUniversityShares_404" xlink:to="lab_drug_IncreaseDecreaseThroughSharesIssuedToUniversityShares_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_IncreaseDecreaseThroughSharesIssuedToUniversityShares_405" xlink:to="lab_drug_IncreaseDecreaseThroughSharesIssuedToUniversityShares_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_IncreaseDecreaseThroughSpecialWarrantConversion_406" xlink:to="lab_drug_IncreaseDecreaseThroughSpecialWarrantConversion_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_IncreaseDecreaseThroughSpecialWarrantConversion_407" xlink:to="lab_drug_IncreaseDecreaseThroughSpecialWarrantConversion_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_IncreaseDecreaseThroughSpecialWarrantConversion_408" xlink:to="lab_drug_IncreaseDecreaseThroughSpecialWarrantConversion_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_IncreaseDecreaseThroughSpecialWarrantConversionShares_409" xlink:to="lab_drug_IncreaseDecreaseThroughSpecialWarrantConversionShares_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_IncreaseDecreaseThroughSpecialWarrantConversionShares_410" xlink:to="lab_drug_IncreaseDecreaseThroughSpecialWarrantConversionShares_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_IncreaseDecreaseThroughSpecialWarrantConversionShares_411" xlink:to="lab_drug_IncreaseDecreaseThroughSpecialWarrantConversionShares_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_IndependentConsultantAgreementMember_412" xlink:to="lab_drug_IndependentConsultantAgreementMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_IndependentConsultantAgreementMember_413" xlink:to="lab_drug_IndependentConsultantAgreementMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_IndependentContractorAgreementToServeAsChiefMedicalOfficerMember_414" xlink:to="lab_drug_IndependentContractorAgreementToServeAsChiefMedicalOfficerMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_IndependentContractorAgreementToServeAsChiefMedicalOfficerMember_415" xlink:to="lab_drug_IndependentContractorAgreementToServeAsChiefMedicalOfficerMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_IndependentContractorAgreementToServeAsChiefScienceOfficerMember_416" xlink:to="lab_drug_IndependentContractorAgreementToServeAsChiefScienceOfficerMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_IndependentContractorAgreementToServeAsChiefScienceOfficerMember_417" xlink:to="lab_drug_IndependentContractorAgreementToServeAsChiefScienceOfficerMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_IndependentContractorAgreementToServeAsChiefScienceOfficerMember_418" xlink:to="lab_drug_IndependentContractorAgreementToServeAsChiefScienceOfficerMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_IssuanceOfRestrictedStockUnits_419" xlink:to="lab_drug_IssuanceOfRestrictedStockUnits_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_IssuanceOfRestrictedStockUnits_420" xlink:to="lab_drug_IssuanceOfRestrictedStockUnits_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_IssuanceOfRestrictedStockUnits_421" xlink:to="lab_drug_IssuanceOfRestrictedStockUnits_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_IssueOfSharesUnderPrivatePlacement_422" xlink:to="lab_drug_IssueOfSharesUnderPrivatePlacement_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_IssueOfSharesUnderPrivatePlacement_423" xlink:to="lab_drug_IssueOfSharesUnderPrivatePlacement_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_IssueOfSharesUnderPrivatePlacement_424" xlink:to="lab_drug_IssueOfSharesUnderPrivatePlacement_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_IssueOfSharesUnderPrivatePlacementValue_425" xlink:to="lab_drug_IssueOfSharesUnderPrivatePlacementValue_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_IssueOfSharesUnderPrivatePlacementValue_426" xlink:to="lab_drug_IssueOfSharesUnderPrivatePlacementValue_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_IssueOfSharesUnderPrivatePlacementValue_427" xlink:to="lab_drug_IssueOfSharesUnderPrivatePlacementValue_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_IssuePricePerShare_428" xlink:to="lab_drug_IssuePricePerShare_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_IssuePricePerShare_429" xlink:to="lab_drug_IssuePricePerShare_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_IssuePricePerShare_430" xlink:to="lab_drug_IssuePricePerShare_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_JuneTwentyOneTwoZeroTwoTwoMember_431" xlink:to="lab_drug_JuneTwentyOneTwoZeroTwoTwoMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_JuneTwentyOneTwoZeroTwoTwoMember_432" xlink:to="lab_drug_JuneTwentyOneTwoZeroTwoTwoMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_KeyManagementPersonnelCompensationShareBasedPaymentIncludedInProfessionalFees_433" xlink:to="lab_drug_KeyManagementPersonnelCompensationShareBasedPaymentIncludedInProfessionalFees_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_KeyManagementPersonnelCompensationShareBasedPaymentIncludedInProfessionalFees_434" xlink:to="lab_drug_KeyManagementPersonnelCompensationShareBasedPaymentIncludedInProfessionalFees_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_KeyManagementPersonnelCompensationShareBasedPaymentIncludedInProfessionalFees_435" xlink:to="lab_drug_KeyManagementPersonnelCompensationShareBasedPaymentIncludedInProfessionalFees_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_KeyManagementPersonnelCompensationShareBasedPaymentIncludedInResearchAndDevelopment_436" xlink:to="lab_drug_KeyManagementPersonnelCompensationShareBasedPaymentIncludedInResearchAndDevelopment_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_KeyManagementPersonnelCompensationShareBasedPaymentIncludedInResearchAndDevelopment_437" xlink:to="lab_drug_KeyManagementPersonnelCompensationShareBasedPaymentIncludedInResearchAndDevelopment_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_KeyManagementPersonnelCompensationShareBasedPaymentIncludedInResearchAndDevelopment_438" xlink:to="lab_drug_KeyManagementPersonnelCompensationShareBasedPaymentIncludedInResearchAndDevelopment_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_KeyManagementPersonnelProfessionalFees_439" xlink:to="lab_drug_KeyManagementPersonnelProfessionalFees_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_KeyManagementPersonnelProfessionalFees_440" xlink:to="lab_drug_KeyManagementPersonnelProfessionalFees_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_KeyManagementPersonnelProfessionalFees_441" xlink:to="lab_drug_KeyManagementPersonnelProfessionalFees_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_KeyManagementPersonnelResearchAndDevelopment_442" xlink:to="lab_drug_KeyManagementPersonnelResearchAndDevelopment_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_KeyManagementPersonnelResearchAndDevelopment_443" xlink:to="lab_drug_KeyManagementPersonnelResearchAndDevelopment_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_KeyManagementPersonnelResearchAndDevelopment_444" xlink:to="lab_drug_KeyManagementPersonnelResearchAndDevelopment_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_LaboratoryCostsMember_445" xlink:to="lab_drug_LaboratoryCostsMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_LaboratoryCostsMember_446" xlink:to="lab_drug_LaboratoryCostsMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_LaboratoryCostsMember_447" xlink:to="lab_drug_LaboratoryCostsMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_LeaseCost_448" xlink:to="lab_drug_LeaseCost_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_LeaseCost_449" xlink:to="lab_drug_LeaseCost_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_LeaseCost_450" xlink:to="lab_drug_LeaseCost_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_LetterAgreementMember_451" xlink:to="lab_drug_LetterAgreementMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_LetterAgreementMember_452" xlink:to="lab_drug_LetterAgreementMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_LicenseAgreementMember_453" xlink:to="lab_drug_LicenseAgreementMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_LicenseAgreementMember_454" xlink:to="lab_drug_LicenseAgreementMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_MarchTwentyOneTwoZeroTwoTwoMember_455" xlink:to="lab_drug_MarchTwentyOneTwoZeroTwoTwoMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_MarchTwentyOneTwoZeroTwoTwoMember_456" xlink:to="lab_drug_MarchTwentyOneTwoZeroTwoTwoMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_MarketingAdvertisingAndInvestorRelationsMember_457" xlink:to="lab_drug_MarketingAdvertisingAndInvestorRelationsMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_MarketingAdvertisingAndInvestorRelationsMember_458" xlink:to="lab_drug_MarketingAdvertisingAndInvestorRelationsMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_MarketingAdvertisingAndInvestorRelationsMember_459" xlink:to="lab_drug_MarketingAdvertisingAndInvestorRelationsMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_MilestonePaymentsUponDosingFirstPatientInFirstPhaseIiiTrial_460" xlink:to="lab_drug_MilestonePaymentsUponDosingFirstPatientInFirstPhaseIiiTrial_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_MilestonePaymentsUponDosingFirstPatientInFirstPhaseIiiTrial_461" xlink:to="lab_drug_MilestonePaymentsUponDosingFirstPatientInFirstPhaseIiiTrial_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_MilestonePaymentsUponDosingFirstPatientInFirstPhaseIiiTrial_462" xlink:to="lab_drug_MilestonePaymentsUponDosingFirstPatientInFirstPhaseIiiTrial_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_MilestonePaymentsUponDosingFirstPatientInFirstPhaseIiTrial_463" xlink:to="lab_drug_MilestonePaymentsUponDosingFirstPatientInFirstPhaseIiTrial_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_MilestonePaymentsUponDosingFirstPatientInFirstPhaseIiTrial_464" xlink:to="lab_drug_MilestonePaymentsUponDosingFirstPatientInFirstPhaseIiTrial_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_MilestonePaymentsUponDosingFirstPatientInFirstPhaseIiTrial_465" xlink:to="lab_drug_MilestonePaymentsUponDosingFirstPatientInFirstPhaseIiTrial_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_MilestonePaymentsUponDosingFirstPatientInPhaseITrial_466" xlink:to="lab_drug_MilestonePaymentsUponDosingFirstPatientInPhaseITrial_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_MilestonePaymentsUponDosingFirstPatientInPhaseITrial_467" xlink:to="lab_drug_MilestonePaymentsUponDosingFirstPatientInPhaseITrial_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_MilestonePaymentsUponDosingFirstPatientInPhaseITrial_468" xlink:to="lab_drug_MilestonePaymentsUponDosingFirstPatientInPhaseITrial_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_MilestonePaymentsUponFirstCommercialSaleOfClinical_469" xlink:to="lab_drug_MilestonePaymentsUponFirstCommercialSaleOfClinical_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_MilestonePaymentsUponFirstCommercialSaleOfClinical_470" xlink:to="lab_drug_MilestonePaymentsUponFirstCommercialSaleOfClinical_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_MilestonePaymentsUponFirstCommercialSaleOfClinical_471" xlink:to="lab_drug_MilestonePaymentsUponFirstCommercialSaleOfClinical_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_MinimumDailyVolumeWeightedAverageTradingSharePrice_472" xlink:to="lab_drug_MinimumDailyVolumeWeightedAverageTradingSharePrice_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_MinimumDailyVolumeWeightedAverageTradingSharePrice_473" xlink:to="lab_drug_MinimumDailyVolumeWeightedAverageTradingSharePrice_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_MinimumDailyVolumeWeightedAverageTradingSharePrice_474" xlink:to="lab_drug_MinimumDailyVolumeWeightedAverageTradingSharePrice_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_MonthlyBaseRent_475" xlink:to="lab_drug_MonthlyBaseRent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_MonthlyBaseRent_476" xlink:to="lab_drug_MonthlyBaseRent_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_MonthlyBaseRent_477" xlink:to="lab_drug_MonthlyBaseRent_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_MonthlyFeeAuthorizedByBoardOfDirectors_478" xlink:to="lab_drug_MonthlyFeeAuthorizedByBoardOfDirectors_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_MonthlyFeeAuthorizedByBoardOfDirectors_479" xlink:to="lab_drug_MonthlyFeeAuthorizedByBoardOfDirectors_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_MonthlyFeeAuthorizedByBoardOfDirectors_480" xlink:to="lab_drug_MonthlyFeeAuthorizedByBoardOfDirectors_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_NatureAndContinuanceOfOperationsAbstract_481" xlink:to="lab_drug_NatureAndContinuanceOfOperationsAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_NinthTrancheMember_482" xlink:to="lab_drug_NinthTrancheMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_NinthTrancheMember_483" xlink:to="lab_drug_NinthTrancheMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_NinthTrancheMember_484" xlink:to="lab_drug_NinthTrancheMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_NonBrokeredPrivatePlacementMember_485" xlink:to="lab_drug_NonBrokeredPrivatePlacementMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_NonBrokeredPrivatePlacementMember_486" xlink:to="lab_drug_NonBrokeredPrivatePlacementMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_NonBrokeredPrivatePlacementMember_487" xlink:to="lab_drug_NonBrokeredPrivatePlacementMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_NonCapitalLossCarryForwards_488" xlink:to="lab_drug_NonCapitalLossCarryForwards_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_NonCapitalLossCarryForwards_489" xlink:to="lab_drug_NonCapitalLossCarryForwards_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_NonCapitalLossCarryForwards_490" xlink:to="lab_drug_NonCapitalLossCarryForwards_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_NonCapitalLossCarryForwards_491" xlink:to="lab_drug_NonCapitalLossCarryForwards_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_NonCapitalLossCarryForwardsYearOfExpiry_492" xlink:to="lab_drug_NonCapitalLossCarryForwardsYearOfExpiry_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_NonCapitalLossCarryForwardsYearOfExpiry_493" xlink:to="lab_drug_NonCapitalLossCarryForwardsYearOfExpiry_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_NonCapitalLossCarryForwardsYearOfExpiry_494" xlink:to="lab_drug_NonCapitalLossCarryForwardsYearOfExpiry_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_NonCapitalLossCarryForwardsYearOfOriginAxis_495" xlink:to="lab_drug_NonCapitalLossCarryForwardsYearOfOriginAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_NonCapitalLossCarryForwardsYearOfOriginAxis_496" xlink:to="lab_drug_NonCapitalLossCarryForwardsYearOfOriginAxis_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_NonCapitalLossCarryForwardsYearOfOriginDomain_497" xlink:to="lab_drug_NonCapitalLossCarryForwardsYearOfOriginDomain_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_NonCapitalLossCarryForwardsYearOfOriginDomain_498" xlink:to="lab_drug_NonCapitalLossCarryForwardsYearOfOriginDomain_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_NonRefundableOptionFeesPaid_499" xlink:to="lab_drug_NonRefundableOptionFeesPaid_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_NonRefundableOptionFeesPaid_500" xlink:to="lab_drug_NonRefundableOptionFeesPaid_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_NonRefundableOptionFeesPaid_501" xlink:to="lab_drug_NonRefundableOptionFeesPaid_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_NovelDrugDevelopmentMember_502" xlink:to="lab_drug_NovelDrugDevelopmentMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_NovelDrugDevelopmentMember_503" xlink:to="lab_drug_NovelDrugDevelopmentMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_NovelDrugDevelopmentMember_504" xlink:to="lab_drug_NovelDrugDevelopmentMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_NumberOfCommonSharesCalledByWarrants_505" xlink:to="lab_drug_NumberOfCommonSharesCalledByWarrants_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_NumberOfCommonSharesCalledByWarrants_506" xlink:to="lab_drug_NumberOfCommonSharesCalledByWarrants_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_NumberOfCommonSharesCalledByWarrants_507" xlink:to="lab_drug_NumberOfCommonSharesCalledByWarrants_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_NumberOfCommonSharesDepositedToBeHeldInEscrow_508" xlink:to="lab_drug_NumberOfCommonSharesDepositedToBeHeldInEscrow_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_NumberOfCommonSharesDepositedToBeHeldInEscrow_509" xlink:to="lab_drug_NumberOfCommonSharesDepositedToBeHeldInEscrow_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_NumberOfCommonSharesDepositedToBeHeldInEscrow_510" xlink:to="lab_drug_NumberOfCommonSharesDepositedToBeHeldInEscrow_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_NumberOfCommonSharesSubscribed_511" xlink:to="lab_drug_NumberOfCommonSharesSubscribed_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_NumberOfCommonSharesSubscribed_512" xlink:to="lab_drug_NumberOfCommonSharesSubscribed_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_NumberOfCommonSharesSubscribed_513" xlink:to="lab_drug_NumberOfCommonSharesSubscribed_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_NumberOfInstrumentsOtherEquityInstrumentsIssued_514" xlink:to="lab_drug_NumberOfInstrumentsOtherEquityInstrumentsIssued_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_NumberOfInstrumentsOtherEquityInstrumentsIssued_515" xlink:to="lab_drug_NumberOfInstrumentsOtherEquityInstrumentsIssued_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_NumberOfIssuedWarrantsRescinded_516" xlink:to="lab_drug_NumberOfIssuedWarrantsRescinded_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_NumberOfIssuedWarrantsRescinded_517" xlink:to="lab_drug_NumberOfIssuedWarrantsRescinded_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_NumberOfIssuedWarrantsRescinded_518" xlink:to="lab_drug_NumberOfIssuedWarrantsRescinded_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_NumberOfRestrictedStockIssuedForCompensation_519" xlink:to="lab_drug_NumberOfRestrictedStockIssuedForCompensation_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_NumberOfRestrictedStockIssuedForCompensation_520" xlink:to="lab_drug_NumberOfRestrictedStockIssuedForCompensation_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_NumberOfRestrictedStockIssuedForCompensation_521" xlink:to="lab_drug_NumberOfRestrictedStockIssuedForCompensation_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_NumberOfShareListed_522" xlink:to="lab_drug_NumberOfShareListed_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_NumberOfShareListed_523" xlink:to="lab_drug_NumberOfShareListed_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_NumberOfShareListed_524" xlink:to="lab_drug_NumberOfShareListed_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_NumberOfShareOptionsCancelledInShareBasedPaymentArrangement_525" xlink:to="lab_drug_NumberOfShareOptionsCancelledInShareBasedPaymentArrangement_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_NumberOfShareOptionsCancelledInShareBasedPaymentArrangement_526" xlink:to="lab_drug_NumberOfShareOptionsCancelledInShareBasedPaymentArrangement_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_NumberOfSharesIssuedByRelatedParty_527" xlink:to="lab_drug_NumberOfSharesIssuedByRelatedParty_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_NumberOfSharesIssuedByRelatedParty_528" xlink:to="lab_drug_NumberOfSharesIssuedByRelatedParty_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_NumberOfSharesIssuedByRelatedParty_529" xlink:to="lab_drug_NumberOfSharesIssuedByRelatedParty_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_NumberOfUnitsIssued_530" xlink:to="lab_drug_NumberOfUnitsIssued_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_NumberOfUnitsIssued_531" xlink:to="lab_drug_NumberOfUnitsIssued_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_NumberOfUnitsIssued_532" xlink:to="lab_drug_NumberOfUnitsIssued_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_NumberOfWarrantsDeemedToBeExercised_533" xlink:to="lab_drug_NumberOfWarrantsDeemedToBeExercised_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_NumberOfWarrantsDeemedToBeExercised_534" xlink:to="lab_drug_NumberOfWarrantsDeemedToBeExercised_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_NumberOfWarrantsDeemedToBeExercised_535" xlink:to="lab_drug_NumberOfWarrantsDeemedToBeExercised_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_NumberOfWarrantsDepositedToBeHeldInEscrow_536" xlink:to="lab_drug_NumberOfWarrantsDepositedToBeHeldInEscrow_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_NumberOfWarrantsDepositedToBeHeldInEscrow_537" xlink:to="lab_drug_NumberOfWarrantsDepositedToBeHeldInEscrow_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_NumberOfWarrantsDepositedToBeHeldInEscrow_538" xlink:to="lab_drug_NumberOfWarrantsDepositedToBeHeldInEscrow_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_NumberOfWarrantsExercised_539" xlink:to="lab_drug_NumberOfWarrantsExercised_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_NumberOfWarrantsExercised_540" xlink:to="lab_drug_NumberOfWarrantsExercised_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_NumberOfWarrantsExercised_541" xlink:to="lab_drug_NumberOfWarrantsExercised_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_NumberOfWarrantsExercised_542" xlink:to="lab_drug_NumberOfWarrantsExercised_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_NumberOfWarrantsExercised_543" xlink:to="lab_drug_NumberOfWarrantsExercised_4"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_NumberOfWarrantsIssued_544" xlink:to="lab_drug_NumberOfWarrantsIssued_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_NumberOfWarrantsIssued_545" xlink:to="lab_drug_NumberOfWarrantsIssued_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_NumberOfWarrantsIssued_546" xlink:to="lab_drug_NumberOfWarrantsIssued_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_NumberOfWarrantsIssuedToBroker_547" xlink:to="lab_drug_NumberOfWarrantsIssuedToBroker_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_NumberOfWarrantsIssuedToBroker_548" xlink:to="lab_drug_NumberOfWarrantsIssuedToBroker_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_NumberOfWarrantsIssuedToBroker_549" xlink:to="lab_drug_NumberOfWarrantsIssuedToBroker_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_NumberOfWarrantsOutstanding_550" xlink:to="lab_drug_NumberOfWarrantsOutstanding_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_NumberOfWarrantsOutstanding_551" xlink:to="lab_drug_NumberOfWarrantsOutstanding_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_NumberOfWarrantsOutstanding_552" xlink:to="lab_drug_NumberOfWarrantsOutstanding_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_NumberOfWarrantsOutstanding_553" xlink:to="lab_drug_NumberOfWarrantsOutstanding_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_NumberOfWarrantsOutstanding_554" xlink:to="lab_drug_NumberOfWarrantsOutstanding_4"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_NumberOfWarrantsOutstanding_555" xlink:to="lab_drug_NumberOfWarrantsOutstanding_5"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_NumberOfWarrantsOutstandingInShareBasedPaymentArrangement_556" xlink:to="lab_drug_NumberOfWarrantsOutstandingInShareBasedPaymentArrangement_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_NumberOfWarrantsOutstandingInShareBasedPaymentArrangement_557" xlink:to="lab_drug_NumberOfWarrantsOutstandingInShareBasedPaymentArrangement_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_NumberOfWarrantsOutstandingInShareBasedPaymentArrangement_558" xlink:to="lab_drug_NumberOfWarrantsOutstandingInShareBasedPaymentArrangement_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_NumberOfWarrantsOutstandingInShareBasedPaymentArrangement_559" xlink:to="lab_drug_NumberOfWarrantsOutstandingInShareBasedPaymentArrangement_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_NumberOfWarrantsOutstandingInShareBasedPaymentArrangement_560" xlink:to="lab_drug_NumberOfWarrantsOutstandingInShareBasedPaymentArrangement_4"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_NumberOfWarrantsOutstandingInShareBasedPaymentArrangement_561" xlink:to="lab_drug_NumberOfWarrantsOutstandingInShareBasedPaymentArrangement_5"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_OptionAgreementMember_562" xlink:to="lab_drug_OptionAgreementMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_OptionAgreementMember_563" xlink:to="lab_drug_OptionAgreementMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_OptionFeesPaid_564" xlink:to="lab_drug_OptionFeesPaid_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_OptionFeesPaid_565" xlink:to="lab_drug_OptionFeesPaid_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_OptionFeesPaid_566" xlink:to="lab_drug_OptionFeesPaid_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_PaymentsForFindersFees_567" xlink:to="lab_drug_PaymentsForFindersFees_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_PaymentsForFindersFees_568" xlink:to="lab_drug_PaymentsForFindersFees_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_PaymentsForFindersFees_569" xlink:to="lab_drug_PaymentsForFindersFees_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_PercentageOfForeignCurrencyFluctuationInUsDollarAgainstCanadianDollar_570" xlink:to="lab_drug_PercentageOfForeignCurrencyFluctuationInUsDollarAgainstCanadianDollar_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_PercentageOfForeignCurrencyFluctuationInUsDollarAgainstCanadianDollar_571" xlink:to="lab_drug_PercentageOfForeignCurrencyFluctuationInUsDollarAgainstCanadianDollar_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_PercentageOfForeignCurrencyFluctuationInUsDollarAgainstCanadianDollar_572" xlink:to="lab_drug_PercentageOfForeignCurrencyFluctuationInUsDollarAgainstCanadianDollar_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_PercentageOfNetEquityProceedsReceivedFromThreeInvestors_573" xlink:to="lab_drug_PercentageOfNetEquityProceedsReceivedFromThreeInvestors_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_PercentageOfNetEquityProceedsReceivedFromThreeInvestors_574" xlink:to="lab_drug_PercentageOfNetEquityProceedsReceivedFromThreeInvestors_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_PercentageOfNetEquityProceedsReceivedFromThreeInvestors_575" xlink:to="lab_drug_PercentageOfNetEquityProceedsReceivedFromThreeInvestors_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_PercentageOfOutstandingSharesAuthorizedUnderStockOptionPlan_576" xlink:to="lab_drug_PercentageOfOutstandingSharesAuthorizedUnderStockOptionPlan_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_PercentageOfOutstandingSharesAuthorizedUnderStockOptionPlan_577" xlink:to="lab_drug_PercentageOfOutstandingSharesAuthorizedUnderStockOptionPlan_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_PercentageOfOutstandingSharesAuthorizedUnderStockOptionPlan_578" xlink:to="lab_drug_PercentageOfOutstandingSharesAuthorizedUnderStockOptionPlan_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_PercentageOfRoyaltiesOnNetSales_579" xlink:to="lab_drug_PercentageOfRoyaltiesOnNetSales_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_PercentageOfRoyaltiesOnNetSales_580" xlink:to="lab_drug_PercentageOfRoyaltiesOnNetSales_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_PercentageOfRoyaltiesOnNetSales_581" xlink:to="lab_drug_PercentageOfRoyaltiesOnNetSales_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_PercentageOfRoyaltiesOnNetSalesOver2Billion_582" xlink:to="lab_drug_PercentageOfRoyaltiesOnNetSalesOver2Billion_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_PercentageOfRoyaltiesOnNetSalesOver2Billion_583" xlink:to="lab_drug_PercentageOfRoyaltiesOnNetSalesOver2Billion_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_PercentageOfRoyaltiesOnNetSalesOver2Billion_584" xlink:to="lab_drug_PercentageOfRoyaltiesOnNetSalesOver2Billion_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_PercentageOfRoyaltiesOnNetSalesUnder1Billion_585" xlink:to="lab_drug_PercentageOfRoyaltiesOnNetSalesUnder1Billion_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_PercentageOfRoyaltiesOnNetSalesUnder1Billion_586" xlink:to="lab_drug_PercentageOfRoyaltiesOnNetSalesUnder1Billion_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_PercentageOfRoyaltiesOnNetSalesUnder1Billion_587" xlink:to="lab_drug_PercentageOfRoyaltiesOnNetSalesUnder1Billion_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_PercentageOfStockOptionPlanAllowsBoardOfDirectorsToIssue_588" xlink:to="lab_drug_PercentageOfStockOptionPlanAllowsBoardOfDirectorsToIssue_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_PercentageOfStockOptionPlanAllowsBoardOfDirectorsToIssue_589" xlink:to="lab_drug_PercentageOfStockOptionPlanAllowsBoardOfDirectorsToIssue_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_PercentageOfStockOptionPlanAllowsBoardOfDirectorsToIssue_590" xlink:to="lab_drug_PercentageOfStockOptionPlanAllowsBoardOfDirectorsToIssue_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_PercentageOfStockOptionShareGranted_591" xlink:to="lab_drug_PercentageOfStockOptionShareGranted_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_PercentageOfStockOptionShareGranted_592" xlink:to="lab_drug_PercentageOfStockOptionShareGranted_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_PercentageOfStockOptionShareGranted_593" xlink:to="lab_drug_PercentageOfStockOptionShareGranted_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_PriorToSublicensingAgreementsMember_594" xlink:to="lab_drug_PriorToSublicensingAgreementsMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_PriorToSublicensingAgreementsMember_595" xlink:to="lab_drug_PriorToSublicensingAgreementsMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_PriorToSublicensingAgreementsMember_596" xlink:to="lab_drug_PriorToSublicensingAgreementsMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_ProceedsForWarrantsIssued_597" xlink:to="lab_drug_ProceedsForWarrantsIssued_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_ProceedsForWarrantsIssued_598" xlink:to="lab_drug_ProceedsForWarrantsIssued_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_ProceedsForWarrantsIssued_599" xlink:to="lab_drug_ProceedsForWarrantsIssued_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_ProceedsFromExerciseOfSpecialWarrants_600" xlink:to="lab_drug_ProceedsFromExerciseOfSpecialWarrants_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_ProceedsFromExerciseOfSpecialWarrants_601" xlink:to="lab_drug_ProceedsFromExerciseOfSpecialWarrants_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_ProceedsFromExerciseOfSpecialWarrants_602" xlink:to="lab_drug_ProceedsFromExerciseOfSpecialWarrants_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_ProceedsFromIssuingWarrants_603" xlink:to="lab_drug_ProceedsFromIssuingWarrants_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_ProceedsFromIssuingWarrants_604" xlink:to="lab_drug_ProceedsFromIssuingWarrants_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_ProceedsFromIssuingWarrants_605" xlink:to="lab_drug_ProceedsFromIssuingWarrants_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_ProceedsFromWarrantsExercise_606" xlink:to="lab_drug_ProceedsFromWarrantsExercise_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_ProceedsFromWarrantsExercise_607" xlink:to="lab_drug_ProceedsFromWarrantsExercise_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_ProceedsFromWarrantsExercise_608" xlink:to="lab_drug_ProceedsFromWarrantsExercise_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_ProcessingFees_609" xlink:to="lab_drug_ProcessingFees_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_ProcessingFees_610" xlink:to="lab_drug_ProcessingFees_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_ProcessingFees_611" xlink:to="lab_drug_ProcessingFees_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_ProfessionalFeesMember_612" xlink:to="lab_drug_ProfessionalFeesMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_ProfessionalFeesMember_613" xlink:to="lab_drug_ProfessionalFeesMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_ProfessionalFeesMember_614" xlink:to="lab_drug_ProfessionalFeesMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_PsilocybinlabsLtdMember_615" xlink:to="lab_drug_PsilocybinlabsLtdMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_PsilocybinlabsLtdMember_616" xlink:to="lab_drug_PsilocybinlabsLtdMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_RefundFromIssuedWarrantsRescinded_617" xlink:to="lab_drug_RefundFromIssuedWarrantsRescinded_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_RefundFromIssuedWarrantsRescinded_618" xlink:to="lab_drug_RefundFromIssuedWarrantsRescinded_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_RefundFromIssuedWarrantsRescinded_619" xlink:to="lab_drug_RefundFromIssuedWarrantsRescinded_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_RefundOfSpecialWarrantsProceeds_620" xlink:to="lab_drug_RefundOfSpecialWarrantsProceeds_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_RefundOfSpecialWarrantsProceeds_621" xlink:to="lab_drug_RefundOfSpecialWarrantsProceeds_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_RefundOfSpecialWarrantsProceeds_622" xlink:to="lab_drug_RefundOfSpecialWarrantsProceeds_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_RefundOfSpecialWarrantsProceeds_623" xlink:to="lab_drug_RefundOfSpecialWarrantsProceeds_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_RegulatoryAndFilingExpenses_624" xlink:to="lab_drug_RegulatoryAndFilingExpenses_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_RegulatoryAndFilingExpenses_625" xlink:to="lab_drug_RegulatoryAndFilingExpenses_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_RegulatoryAndFilingExpenses_626" xlink:to="lab_drug_RegulatoryAndFilingExpenses_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_RelatedPartyContractsMember_627" xlink:to="lab_drug_RelatedPartyContractsMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_RelatedPartyContractsMember_628" xlink:to="lab_drug_RelatedPartyContractsMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_ResearchAndDevelopmentAbstract_629" xlink:to="lab_drug_ResearchAndDevelopmentAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_ResearchAndDevelopmentLineItems_630" xlink:to="lab_drug_ResearchAndDevelopmentLineItems_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_ResearchAndDevelopmentMember_631" xlink:to="lab_drug_ResearchAndDevelopmentMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_ResearchAndDevelopmentMember_632" xlink:to="lab_drug_ResearchAndDevelopmentMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_ResearchAndDevelopmentMember_633" xlink:to="lab_drug_ResearchAndDevelopmentMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_ResearchDevelopmentTable_634" xlink:to="lab_drug_ResearchDevelopmentTable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_RestrictedShareUnitMember_635" xlink:to="lab_drug_RestrictedShareUnitMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_RestrictedShareUnitMember_636" xlink:to="lab_drug_RestrictedShareUnitMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_RestrictedShareUnitMember_637" xlink:to="lab_drug_RestrictedShareUnitMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_RoyaltiesOnNetSales_638" xlink:to="lab_drug_RoyaltiesOnNetSales_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_RoyaltiesOnNetSales_639" xlink:to="lab_drug_RoyaltiesOnNetSales_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_RoyaltiesOnNetSales_640" xlink:to="lab_drug_RoyaltiesOnNetSales_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_SalaryAndSubcontractorsMember_641" xlink:to="lab_drug_SalaryAndSubcontractorsMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_SalaryAndSubcontractorsMember_642" xlink:to="lab_drug_SalaryAndSubcontractorsMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_SalaryAndSubcontractorsMember_643" xlink:to="lab_drug_SalaryAndSubcontractorsMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_ScientificAdvisoryBoardAgreementsMember_644" xlink:to="lab_drug_ScientificAdvisoryBoardAgreementsMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_ScientificAdvisoryBoardAgreementsMember_645" xlink:to="lab_drug_ScientificAdvisoryBoardAgreementsMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_SecondAnniversaryOfGrantDateMember_646" xlink:to="lab_drug_SecondAnniversaryOfGrantDateMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_SecondAnniversaryOfGrantDateMember_647" xlink:to="lab_drug_SecondAnniversaryOfGrantDateMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_SecondTrancheMember_648" xlink:to="lab_drug_SecondTrancheMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_SecondTrancheMember_649" xlink:to="lab_drug_SecondTrancheMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_SecondTrancheMember_650" xlink:to="lab_drug_SecondTrancheMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_SecondTrancheMember_651" xlink:to="lab_drug_SecondTrancheMember_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_SecondTrancheOfNonBrokeredPrivatePlacementMember_652" xlink:to="lab_drug_SecondTrancheOfNonBrokeredPrivatePlacementMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_SecondTrancheOfNonBrokeredPrivatePlacementMember_653" xlink:to="lab_drug_SecondTrancheOfNonBrokeredPrivatePlacementMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_SecondTrancheOfNonBrokeredPrivatePlacementMember_654" xlink:to="lab_drug_SecondTrancheOfNonBrokeredPrivatePlacementMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_SeptemberTwentyOneTwoZeroTwoFourMember_655" xlink:to="lab_drug_SeptemberTwentyOneTwoZeroTwoFourMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_SeptemberTwentyOneTwoZeroTwoFourMember_656" xlink:to="lab_drug_SeptemberTwentyOneTwoZeroTwoFourMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_SeptemberTwentyOneTwoZeroTwoFourMember_657" xlink:to="lab_drug_SeptemberTwentyOneTwoZeroTwoFourMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_SeptemberTwentyOneTwoZeroTwoTwoMember_658" xlink:to="lab_drug_SeptemberTwentyOneTwoZeroTwoTwoMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_SeptemberTwentyOneTwoZeroTwoTwoMember_659" xlink:to="lab_drug_SeptemberTwentyOneTwoZeroTwoTwoMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_SeventhTrancheMember_660" xlink:to="lab_drug_SeventhTrancheMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_SeventhTrancheMember_661" xlink:to="lab_drug_SeventhTrancheMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_SeventhTrancheMember_662" xlink:to="lab_drug_SeventhTrancheMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_ShareBasedCompensationMember_663" xlink:to="lab_drug_ShareBasedCompensationMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_ShareBasedCompensationMember_664" xlink:to="lab_drug_ShareBasedCompensationMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_ShareBasedCompensationMember_665" xlink:to="lab_drug_ShareBasedCompensationMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_ShareExchangeAndAssignmentAbstract_666" xlink:to="lab_drug_ShareExchangeAndAssignmentAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_ShareExchangeAndAssignmentLineItems_667" xlink:to="lab_drug_ShareExchangeAndAssignmentLineItems_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_ShareExchangeAndAssignmentLineItems_668" xlink:to="lab_drug_ShareExchangeAndAssignmentLineItems_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_ShareIssueCostsIncludedInAccountsPayable_669" xlink:to="lab_drug_ShareIssueCostsIncludedInAccountsPayable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_ShareIssueCostsIncludedInAccountsPayable_670" xlink:to="lab_drug_ShareIssueCostsIncludedInAccountsPayable_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_ShareIssueCostsIncludedInAccountsPayable_671" xlink:to="lab_drug_ShareIssueCostsIncludedInAccountsPayable_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_SharePriceOnGrantDateOfOtherEquityInstruments_672" xlink:to="lab_drug_SharePriceOnGrantDateOfOtherEquityInstruments_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_SharePriceOnGrantDateOfOtherEquityInstruments_673" xlink:to="lab_drug_SharePriceOnGrantDateOfOtherEquityInstruments_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_SharePriceOnGrantDateOfOtherEquityInstruments_674" xlink:to="lab_drug_SharePriceOnGrantDateOfOtherEquityInstruments_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_SigningFee_675" xlink:to="lab_drug_SigningFee_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_SigningFee_676" xlink:to="lab_drug_SigningFee_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_SigningFee_677" xlink:to="lab_drug_SigningFee_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_SigningFeeNetOfOptionFeesPaid_678" xlink:to="lab_drug_SigningFeeNetOfOptionFeesPaid_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_SigningFeeNetOfOptionFeesPaid_679" xlink:to="lab_drug_SigningFeeNetOfOptionFeesPaid_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_SigningFeeNetOfOptionFeesPaid_680" xlink:to="lab_drug_SigningFeeNetOfOptionFeesPaid_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_SigningFeeSharesIssued_681" xlink:to="lab_drug_SigningFeeSharesIssued_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_SigningFeeSharesIssued_682" xlink:to="lab_drug_SigningFeeSharesIssued_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_SigningFeeSharesIssued_683" xlink:to="lab_drug_SigningFeeSharesIssued_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_SixMonthAnniversaryGrantDateMember_684" xlink:to="lab_drug_SixMonthAnniversaryGrantDateMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_SixMonthAnniversaryGrantDateMember_685" xlink:to="lab_drug_SixMonthAnniversaryGrantDateMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_SixthTrancheMember_686" xlink:to="lab_drug_SixthTrancheMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_SixthTrancheMember_687" xlink:to="lab_drug_SixthTrancheMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_SixthTrancheMember_688" xlink:to="lab_drug_SixthTrancheMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_SpecialWarrantsMember_689" xlink:to="lab_drug_SpecialWarrantsMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_SpecialWarrantsMember_690" xlink:to="lab_drug_SpecialWarrantsMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_StatementOfComplianceAndBasisOfPreparationAbstract_691" xlink:to="lab_drug_StatementOfComplianceAndBasisOfPreparationAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_StockOptionAxis_692" xlink:to="lab_drug_StockOptionAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_StockOptionAxis_693" xlink:to="lab_drug_StockOptionAxis_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_StockOptionDomain_694" xlink:to="lab_drug_StockOptionDomain_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_StockOptionDomain_695" xlink:to="lab_drug_StockOptionDomain_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_StockOptionsFourMember_696" xlink:to="lab_drug_StockOptionsFourMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_StockOptionsFourMember_697" xlink:to="lab_drug_StockOptionsFourMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_StockOptionsMember_698" xlink:to="lab_drug_StockOptionsMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_StockOptionsMember_699" xlink:to="lab_drug_StockOptionsMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_StockOptionsMember_700" xlink:to="lab_drug_StockOptionsMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_StockOptionsOneMember_701" xlink:to="lab_drug_StockOptionsOneMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_StockOptionsOneMember_702" xlink:to="lab_drug_StockOptionsOneMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_StockOptionsThreeMember_703" xlink:to="lab_drug_StockOptionsThreeMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_StockOptionsThreeMember_704" xlink:to="lab_drug_StockOptionsThreeMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_StockOptionsTwoMember_705" xlink:to="lab_drug_StockOptionsTwoMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_StockOptionsTwoMember_706" xlink:to="lab_drug_StockOptionsTwoMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_SubscriptionAgreementsMember_707" xlink:to="lab_drug_SubscriptionAgreementsMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_SubscriptionAgreementsMember_708" xlink:to="lab_drug_SubscriptionAgreementsMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_SubscriptionReceivableMember_709" xlink:to="lab_drug_SubscriptionReceivableMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_SubscriptionReceivableMember_710" xlink:to="lab_drug_SubscriptionReceivableMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_SubscriptionReceivableMember_711" xlink:to="lab_drug_SubscriptionReceivableMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_SubscriptionReceivedMember_712" xlink:to="lab_drug_SubscriptionReceivedMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_SubscriptionReceivedMember_713" xlink:to="lab_drug_SubscriptionReceivedMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_SubscriptionReceivedMember_714" xlink:to="lab_drug_SubscriptionReceivedMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_SubscriptionsReceivable_715" xlink:to="lab_drug_SubscriptionsReceivable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_SubscriptionsReceivable_716" xlink:to="lab_drug_SubscriptionsReceivable_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_SubscriptionsReceivable_717" xlink:to="lab_drug_SubscriptionsReceivable_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_SubscriptionsReceivable_718" xlink:to="lab_drug_SubscriptionsReceivable_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_SubscriptionsReceived_719" xlink:to="lab_drug_SubscriptionsReceived_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_SubscriptionsReceived_720" xlink:to="lab_drug_SubscriptionsReceived_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_SubscriptionsReceived_721" xlink:to="lab_drug_SubscriptionsReceived_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_SubsequentEventsMember_722" xlink:to="lab_drug_SubsequentEventsMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_SubsequentEventsMember_723" xlink:to="lab_drug_SubsequentEventsMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_SupplementaryInformationAbstract_724" xlink:to="lab_drug_SupplementaryInformationAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_SupplementaryInformationAbstract_725" xlink:to="lab_drug_SupplementaryInformationAbstract_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_SupplementaryInformationAbstract_726" xlink:to="lab_drug_SupplementaryInformationAbstract_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_TaxAuthorityOfAustraliaMember_727" xlink:to="lab_drug_TaxAuthorityOfAustraliaMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_TaxAuthorityOfAustraliaMember_728" xlink:to="lab_drug_TaxAuthorityOfAustraliaMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_TaxAuthorityOfAustraliaMember_729" xlink:to="lab_drug_TaxAuthorityOfAustraliaMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_TaxAuthorityOfCanadaMember_730" xlink:to="lab_drug_TaxAuthorityOfCanadaMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_TaxAuthorityOfCanadaMember_731" xlink:to="lab_drug_TaxAuthorityOfCanadaMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_TaxAuthorityOfUnitedStatesMember_732" xlink:to="lab_drug_TaxAuthorityOfUnitedStatesMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_TaxAuthorityOfUnitedStatesMember_733" xlink:to="lab_drug_TaxAuthorityOfUnitedStatesMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_TaxAuthorityOfUnitedStatesMember_734" xlink:to="lab_drug_TaxAuthorityOfUnitedStatesMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_TaxEffectOfChangeInDeferredTaxAssetsNotRecognized_735" xlink:to="lab_drug_TaxEffectOfChangeInDeferredTaxAssetsNotRecognized_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_TaxEffectOfChangeInDeferredTaxAssetsNotRecognized_736" xlink:to="lab_drug_TaxEffectOfChangeInDeferredTaxAssetsNotRecognized_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_TaxEffectOfChangeInDeferredTaxAssetsNotRecognized_737" xlink:to="lab_drug_TaxEffectOfChangeInDeferredTaxAssetsNotRecognized_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_TaxEffectOfDeductibleAndNotDeductibleItems_738" xlink:to="lab_drug_TaxEffectOfDeductibleAndNotDeductibleItems_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_TaxEffectOfDeductibleAndNotDeductibleItems_739" xlink:to="lab_drug_TaxEffectOfDeductibleAndNotDeductibleItems_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_TaxEffectOfDeductibleAndNotDeductibleItems_740" xlink:to="lab_drug_TaxEffectOfDeductibleAndNotDeductibleItems_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_TaxEffectOfDeductibleAndNotDeductibleItems_741" xlink:to="lab_drug_TaxEffectOfDeductibleAndNotDeductibleItems_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_TaxRateEffectOfDeferredTaxAssetsNotRecognized_742" xlink:to="lab_drug_TaxRateEffectOfDeferredTaxAssetsNotRecognized_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_TaxRateEffectOfDeferredTaxAssetsNotRecognized_743" xlink:to="lab_drug_TaxRateEffectOfDeferredTaxAssetsNotRecognized_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_TaxRateEffectOfDeferredTaxAssetsNotRecognized_744" xlink:to="lab_drug_TaxRateEffectOfDeferredTaxAssetsNotRecognized_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_TaxYearOfOrigin2019Member_745" xlink:to="lab_drug_TaxYearOfOrigin2019Member_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_TaxYearOfOrigin2019Member_746" xlink:to="lab_drug_TaxYearOfOrigin2019Member_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_TaxYearOfOrigin2019Member_747" xlink:to="lab_drug_TaxYearOfOrigin2019Member_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_TaxYearOfOrigin2020Member_748" xlink:to="lab_drug_TaxYearOfOrigin2020Member_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_TaxYearOfOrigin2020Member_749" xlink:to="lab_drug_TaxYearOfOrigin2020Member_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_TaxYearOfOrigin2020Member_750" xlink:to="lab_drug_TaxYearOfOrigin2020Member_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_TaxYearOfOrigin2021Member_751" xlink:to="lab_drug_TaxYearOfOrigin2021Member_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_TaxYearOfOrigin2021Member_752" xlink:to="lab_drug_TaxYearOfOrigin2021Member_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_TaxYearOfOrigin2021Member_753" xlink:to="lab_drug_TaxYearOfOrigin2021Member_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_TemporaryDifferencesIntangibleAssetsMember_754" xlink:to="lab_drug_TemporaryDifferencesIntangibleAssetsMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_TemporaryDifferencesIntangibleAssetsMember_755" xlink:to="lab_drug_TemporaryDifferencesIntangibleAssetsMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_TemporaryDifferencesIntangibleAssetsMember_756" xlink:to="lab_drug_TemporaryDifferencesIntangibleAssetsMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_TemporaryDifferencesNonCapitalLossesMember_757" xlink:to="lab_drug_TemporaryDifferencesNonCapitalLossesMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_TemporaryDifferencesNonCapitalLossesMember_758" xlink:to="lab_drug_TemporaryDifferencesNonCapitalLossesMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_TemporaryDifferencesNonCapitalLossesMember_759" xlink:to="lab_drug_TemporaryDifferencesNonCapitalLossesMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_TemporaryDifferencesShareIssueCostsMember_760" xlink:to="lab_drug_TemporaryDifferencesShareIssueCostsMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_TemporaryDifferencesShareIssueCostsMember_761" xlink:to="lab_drug_TemporaryDifferencesShareIssueCostsMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_TemporaryDifferencesShareIssueCostsMember_762" xlink:to="lab_drug_TemporaryDifferencesShareIssueCostsMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_TemporaryDifferencesValuationAllowanceMember_763" xlink:to="lab_drug_TemporaryDifferencesValuationAllowanceMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_TemporaryDifferencesValuationAllowanceMember_764" xlink:to="lab_drug_TemporaryDifferencesValuationAllowanceMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_TemporaryDifferencesValuationAllowanceMember_765" xlink:to="lab_drug_TemporaryDifferencesValuationAllowanceMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_TenthTrancheMember_766" xlink:to="lab_drug_TenthTrancheMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_TenthTrancheMember_767" xlink:to="lab_drug_TenthTrancheMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_TenthTrancheMember_768" xlink:to="lab_drug_TenthTrancheMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_TermOfLease_769" xlink:to="lab_drug_TermOfLease_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_TermOfLease_770" xlink:to="lab_drug_TermOfLease_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_TermOfLease_771" xlink:to="lab_drug_TermOfLease_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_TermOfWarrant_772" xlink:to="lab_drug_TermOfWarrant_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_TermOfWarrant_773" xlink:to="lab_drug_TermOfWarrant_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_TermOfWarrant_774" xlink:to="lab_drug_TermOfWarrant_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_TermsOfContract_775" xlink:to="lab_drug_TermsOfContract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_TermsOfContract_776" xlink:to="lab_drug_TermsOfContract_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_TermsOfContract_777" xlink:to="lab_drug_TermsOfContract_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_ThirdAnniversaryOfGrantDateMember_778" xlink:to="lab_drug_ThirdAnniversaryOfGrantDateMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_ThirdAnniversaryOfGrantDateMember_779" xlink:to="lab_drug_ThirdAnniversaryOfGrantDateMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_ThirdTrancheMember_780" xlink:to="lab_drug_ThirdTrancheMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_ThirdTrancheMember_781" xlink:to="lab_drug_ThirdTrancheMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_ThirdTrancheMember_782" xlink:to="lab_drug_ThirdTrancheMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_ThirdTrancheMember_783" xlink:to="lab_drug_ThirdTrancheMember_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_ThirteenthTrancheMember_784" xlink:to="lab_drug_ThirteenthTrancheMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_ThirteenthTrancheMember_785" xlink:to="lab_drug_ThirteenthTrancheMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_ThirteenthTrancheMember_786" xlink:to="lab_drug_ThirteenthTrancheMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_ThreeConsultantsMember_787" xlink:to="lab_drug_ThreeConsultantsMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_ThreeConsultantsMember_788" xlink:to="lab_drug_ThreeConsultantsMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_ThreeInvestorsMember_789" xlink:to="lab_drug_ThreeInvestorsMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_ThreeInvestorsMember_790" xlink:to="lab_drug_ThreeInvestorsMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_ThresholdPercentageOfWarrants_791" xlink:to="lab_drug_ThresholdPercentageOfWarrants_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_ThresholdPercentageOfWarrants_792" xlink:to="lab_drug_ThresholdPercentageOfWarrants_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_ThresholdPercentageOfWarrants_793" xlink:to="lab_drug_ThresholdPercentageOfWarrants_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_TotalAnnualMinimumRoyaltiesAfterFirstCommercialSale_794" xlink:to="lab_drug_TotalAnnualMinimumRoyaltiesAfterFirstCommercialSale_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_TotalAnnualMinimumRoyaltiesAfterFirstCommercialSale_795" xlink:to="lab_drug_TotalAnnualMinimumRoyaltiesAfterFirstCommercialSale_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_TotalAnnualMinimumRoyaltiesAfterFirstCommercialSale_796" xlink:to="lab_drug_TotalAnnualMinimumRoyaltiesAfterFirstCommercialSale_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_TotalAnnualMinimumRoyaltiesCurrentYears_797" xlink:to="lab_drug_TotalAnnualMinimumRoyaltiesCurrentYears_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_TotalAnnualMinimumRoyaltiesCurrentYears_798" xlink:to="lab_drug_TotalAnnualMinimumRoyaltiesCurrentYears_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_TotalAnnualMinimumRoyaltiesCurrentYears_799" xlink:to="lab_drug_TotalAnnualMinimumRoyaltiesCurrentYears_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_TotalAnnualMinimumRoyaltiesNextYears_800" xlink:to="lab_drug_TotalAnnualMinimumRoyaltiesNextYears_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_TotalAnnualMinimumRoyaltiesNextYears_801" xlink:to="lab_drug_TotalAnnualMinimumRoyaltiesNextYears_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_TotalAnnualMinimumRoyaltiesNextYears_802" xlink:to="lab_drug_TotalAnnualMinimumRoyaltiesNextYears_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_TotalAnnualMinimumRoyaltiesYear3_803" xlink:to="lab_drug_TotalAnnualMinimumRoyaltiesYear3_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_TotalAnnualMinimumRoyaltiesYear3_804" xlink:to="lab_drug_TotalAnnualMinimumRoyaltiesYear3_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_TotalAnnualMinimumRoyaltiesYear3_805" xlink:to="lab_drug_TotalAnnualMinimumRoyaltiesYear3_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_TotalAnnualMinimumRoyaltiesYear4_806" xlink:to="lab_drug_TotalAnnualMinimumRoyaltiesYear4_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_TotalAnnualMinimumRoyaltiesYear4_807" xlink:to="lab_drug_TotalAnnualMinimumRoyaltiesYear4_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_TotalAnnualMinimumRoyaltiesYear4_808" xlink:to="lab_drug_TotalAnnualMinimumRoyaltiesYear4_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_TotalAnnualMinimumRoyaltiesYear5_809" xlink:to="lab_drug_TotalAnnualMinimumRoyaltiesYear5_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_TotalAnnualMinimumRoyaltiesYear5_810" xlink:to="lab_drug_TotalAnnualMinimumRoyaltiesYear5_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_TotalAnnualMinimumRoyaltiesYear5_811" xlink:to="lab_drug_TotalAnnualMinimumRoyaltiesYear5_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_TotalAnnualMinimumRoyaltiesYear6AndThereafter_812" xlink:to="lab_drug_TotalAnnualMinimumRoyaltiesYear6AndThereafter_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_TotalAnnualMinimumRoyaltiesYear6AndThereafter_813" xlink:to="lab_drug_TotalAnnualMinimumRoyaltiesYear6AndThereafter_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_TotalAnnualMinimumRoyaltiesYear6AndThereafter_814" xlink:to="lab_drug_TotalAnnualMinimumRoyaltiesYear6AndThereafter_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_Tranche1Member_815" xlink:to="lab_drug_Tranche1Member_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_TranchesAxis_816" xlink:to="lab_drug_TranchesAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_TranchesDomain_817" xlink:to="lab_drug_TranchesDomain_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_TwelfthTrancheMember_818" xlink:to="lab_drug_TwelfthTrancheMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_TwelfthTrancheMember_819" xlink:to="lab_drug_TwelfthTrancheMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_TwelfthTrancheMember_820" xlink:to="lab_drug_TwelfthTrancheMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_TypeOfArrangementsAxis_821" xlink:to="lab_drug_TypeOfArrangementsAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_TypeOfArrangementsAxis_822" xlink:to="lab_drug_TypeOfArrangementsAxis_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_UnderwritersFeesPaid_823" xlink:to="lab_drug_UnderwritersFeesPaid_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_UnderwritersFeesPaid_824" xlink:to="lab_drug_UnderwritersFeesPaid_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_UnderwritersMember_825" xlink:to="lab_drug_UnderwritersMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_UnderwritersMember_826" xlink:to="lab_drug_UnderwritersMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_UnitsIssuedPricePerUnit_827" xlink:to="lab_drug_UnitsIssuedPricePerUnit_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_UnitsIssuedPricePerUnit_828" xlink:to="lab_drug_UnitsIssuedPricePerUnit_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_UnitsIssuedPricePerUnit_829" xlink:to="lab_drug_UnitsIssuedPricePerUnit_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_UniversityOfIllinoisAtChicagoMember_830" xlink:to="lab_drug_UniversityOfIllinoisAtChicagoMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_UniversityOfIllinoisAtChicagoMember_831" xlink:to="lab_drug_UniversityOfIllinoisAtChicagoMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_UniversityOfTexasMedicalBranchMember_832" xlink:to="lab_drug_UniversityOfTexasMedicalBranchMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_UniversityOfTexasMedicalBranchMember_833" xlink:to="lab_drug_UniversityOfTexasMedicalBranchMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_ValueOfCommonStockSharesIssued_834" xlink:to="lab_drug_ValueOfCommonStockSharesIssued_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_ValueOfCommonStockSharesIssued_835" xlink:to="lab_drug_ValueOfCommonStockSharesIssued_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_ValueOfCommonStockSharesIssued_836" xlink:to="lab_drug_ValueOfCommonStockSharesIssued_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_ValueOfCommonStockSharesIssuedByRelatedParty_837" xlink:to="lab_drug_ValueOfCommonStockSharesIssuedByRelatedParty_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_ValueOfCommonStockSharesIssuedByRelatedParty_838" xlink:to="lab_drug_ValueOfCommonStockSharesIssuedByRelatedParty_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_ValueOfCommonStockSharesIssuedByRelatedParty_839" xlink:to="lab_drug_ValueOfCommonStockSharesIssuedByRelatedParty_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_VestingDomain_840" xlink:to="lab_drug_VestingDomain_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_VestingPercentage_841" xlink:to="lab_drug_VestingPercentage_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_VestingPercentage_842" xlink:to="lab_drug_VestingPercentage_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_VestingPercentage_843" xlink:to="lab_drug_VestingPercentage_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_VestingsAxis_844" xlink:to="lab_drug_VestingsAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_VestingsAxis_845" xlink:to="lab_drug_VestingsAxis_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_WarrantAscribedValue_846" xlink:to="lab_drug_WarrantAscribedValue_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_WarrantAscribedValue_847" xlink:to="lab_drug_WarrantAscribedValue_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_WarrantAscribedValue_848" xlink:to="lab_drug_WarrantAscribedValue_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_WarrantsIssuedPricePerWarrant_849" xlink:to="lab_drug_WarrantsIssuedPricePerWarrant_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_WarrantsIssuedPricePerWarrant_850" xlink:to="lab_drug_WarrantsIssuedPricePerWarrant_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_WarrantsIssuedPricePerWarrant_851" xlink:to="lab_drug_WarrantsIssuedPricePerWarrant_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_WarrantsMember_852" xlink:to="lab_drug_WarrantsMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_WarrantsMember_853" xlink:to="lab_drug_WarrantsMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_WarrantsMember_854" xlink:to="lab_drug_WarrantsMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_WeightedAverageExercisePriceOfWarrantsExercisedInShareBasedPaymentArrangement_855" xlink:to="lab_drug_WeightedAverageExercisePriceOfWarrantsExercisedInShareBasedPaymentArrangement_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_WeightedAverageExercisePriceOfWarrantsExercisedInShareBasedPaymentArrangement_856" xlink:to="lab_drug_WeightedAverageExercisePriceOfWarrantsExercisedInShareBasedPaymentArrangement_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_WeightedAverageExercisePriceOfWarrantsExercisedInShareBasedPaymentArrangement_857" xlink:to="lab_drug_WeightedAverageExercisePriceOfWarrantsExercisedInShareBasedPaymentArrangement_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_WeightedAverageExercisePriceOfWarrantsExercisedInShareBasedPaymentArrangement_858" xlink:to="lab_drug_WeightedAverageExercisePriceOfWarrantsExercisedInShareBasedPaymentArrangement_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_WeightedAverageExercisePriceOfWarrantsIssuedInShareBasedPaymentArrangement_859" xlink:to="lab_drug_WeightedAverageExercisePriceOfWarrantsIssuedInShareBasedPaymentArrangement_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_WeightedAverageExercisePriceOfWarrantsIssuedInShareBasedPaymentArrangement_860" xlink:to="lab_drug_WeightedAverageExercisePriceOfWarrantsIssuedInShareBasedPaymentArrangement_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_WeightedAverageExercisePriceOfWarrantsIssuedInShareBasedPaymentArrangement_861" xlink:to="lab_drug_WeightedAverageExercisePriceOfWarrantsIssuedInShareBasedPaymentArrangement_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_WeightedAverageExercisePriceOfWarrantsIssuedInShareBasedPaymentArrangement_862" xlink:to="lab_drug_WeightedAverageExercisePriceOfWarrantsIssuedInShareBasedPaymentArrangement_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_WeightedAverageExercisePriceOfWarrantsIssuedToBrokerInShareBasedPaymentArrangement_863" xlink:to="lab_drug_WeightedAverageExercisePriceOfWarrantsIssuedToBrokerInShareBasedPaymentArrangement_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_WeightedAverageExercisePriceOfWarrantsIssuedToBrokerInShareBasedPaymentArrangement_864" xlink:to="lab_drug_WeightedAverageExercisePriceOfWarrantsIssuedToBrokerInShareBasedPaymentArrangement_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_WeightedAverageExercisePriceOfWarrantsIssuedToBrokerInShareBasedPaymentArrangement_865" xlink:to="lab_drug_WeightedAverageExercisePriceOfWarrantsIssuedToBrokerInShareBasedPaymentArrangement_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_WeightedAverageExercisePriceOfWarrantsOutstandingInShareBasedPaymentArrangement_866" xlink:to="lab_drug_WeightedAverageExercisePriceOfWarrantsOutstandingInShareBasedPaymentArrangement_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_WeightedAverageExercisePriceOfWarrantsOutstandingInShareBasedPaymentArrangement_867" xlink:to="lab_drug_WeightedAverageExercisePriceOfWarrantsOutstandingInShareBasedPaymentArrangement_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_WeightedAverageExercisePriceOfWarrantsOutstandingInShareBasedPaymentArrangement_868" xlink:to="lab_drug_WeightedAverageExercisePriceOfWarrantsOutstandingInShareBasedPaymentArrangement_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_WeightedAverageExercisePriceOfWarrantsOutstandingInShareBasedPaymentArrangement_869" xlink:to="lab_drug_WeightedAverageExercisePriceOfWarrantsOutstandingInShareBasedPaymentArrangement_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_WeightedAverageExercisePriceOfWarrantsOutstandingInShareBasedPaymentArrangement_870" xlink:to="lab_drug_WeightedAverageExercisePriceOfWarrantsOutstandingInShareBasedPaymentArrangement_4"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_WeightedAverageExercisePriceOfWarrantsOutstandingInShareBasedPaymentArrangement_871" xlink:to="lab_drug_WeightedAverageExercisePriceOfWarrantsOutstandingInShareBasedPaymentArrangement_5"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_WeightedAverageRemainingContractualLifeOfOtherEquityInstruments_872" xlink:to="lab_drug_WeightedAverageRemainingContractualLifeOfOtherEquityInstruments_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_WeightedAverageRemainingContractualLifeOfOtherEquityInstruments_873" xlink:to="lab_drug_WeightedAverageRemainingContractualLifeOfOtherEquityInstruments_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_WeightedAverageRemainingContractualLifeOfOtherEquityInstruments_874" xlink:to="lab_drug_WeightedAverageRemainingContractualLifeOfOtherEquityInstruments_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_WeightedAverageRemainingContractualLifeOfOtherEquityInstruments_875" xlink:to="lab_drug_WeightedAverageRemainingContractualLifeOfOtherEquityInstruments_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_WeightedAverageRemainingContractualLifeOfWarrants_876" xlink:to="lab_drug_WeightedAverageRemainingContractualLifeOfWarrants_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_WeightedAverageRemainingContractualLifeOfWarrants_877" xlink:to="lab_drug_WeightedAverageRemainingContractualLifeOfWarrants_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_WeightedAverageRemainingContractualLifeOfWarrants_878" xlink:to="lab_drug_WeightedAverageRemainingContractualLifeOfWarrants_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_WeightedAverageRemainingContractualLifeOfWarrants_879" xlink:to="lab_drug_WeightedAverageRemainingContractualLifeOfWarrants_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_WeightedAverageSharePriceWarrantsGranted_880" xlink:to="lab_drug_WeightedAverageSharePriceWarrantsGranted_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_WeightedAverageSharePriceWarrantsGranted_881" xlink:to="lab_drug_WeightedAverageSharePriceWarrantsGranted_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_WeightedAverageSharePriceWarrantsGranted_882" xlink:to="lab_drug_WeightedAverageSharePriceWarrantsGranted_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_WeightedAverageTradingPriceOfCommonSharesOnCanadianStockExchange_883" xlink:to="lab_drug_WeightedAverageTradingPriceOfCommonSharesOnCanadianStockExchange_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_WeightedAverageTradingPriceOfCommonSharesOnCanadianStockExchange_884" xlink:to="lab_drug_WeightedAverageTradingPriceOfCommonSharesOnCanadianStockExchange_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_WeightedAverageTradingPriceOfCommonSharesOnCanadianStockExchange_885" xlink:to="lab_drug_WeightedAverageTradingPriceOfCommonSharesOnCanadianStockExchange_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_WorkingCapital_886" xlink:to="lab_drug_WorkingCapital_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_drug_WorkingCapital_887" xlink:to="lab_drug_WorkingCapital_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AccountingProfit_888" xlink:to="lab_ifrs-full_AccountingProfit_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AccountingProfit_889" xlink:to="lab_ifrs-full_AccountingProfit_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AccrualsClassifiedAsCurrent_890" xlink:to="lab_ifrs-full_AccrualsClassifiedAsCurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AccrualsClassifiedAsCurrent_891" xlink:to="lab_ifrs-full_AccrualsClassifiedAsCurrent_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable_892" xlink:to="lab_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable_893" xlink:to="lab_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdjustmentsForReconcileProfitLossAbstract_894" xlink:to="lab_ifrs-full_AdjustmentsForReconcileProfitLossAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdjustmentsForReconcileProfitLossAbstract_895" xlink:to="lab_ifrs-full_AdjustmentsForReconcileProfitLossAbstract_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdjustmentsForSharebasedPayments_896" xlink:to="lab_ifrs-full_AdjustmentsForSharebasedPayments_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdjustmentsForSharebasedPayments_897" xlink:to="lab_ifrs-full_AdjustmentsForSharebasedPayments_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains_898" xlink:to="lab_ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains_899" xlink:to="lab_ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdministrativeExpense_900" xlink:to="lab_ifrs-full_AdministrativeExpense_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdministrativeExpense_901" xlink:to="lab_ifrs-full_AdministrativeExpense_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ApplicableTaxRate_902" xlink:to="lab_ifrs-full_ApplicableTaxRate_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ApplicableTaxRate_903" xlink:to="lab_ifrs-full_ApplicableTaxRate_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_Assets_904" xlink:to="lab_ifrs-full_Assets_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_Assets_905" xlink:to="lab_ifrs-full_Assets_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AssetsAbstract_906" xlink:to="lab_ifrs-full_AssetsAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AssetsAbstract_907" xlink:to="lab_ifrs-full_AssetsAbstract_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_BankAndSimilarCharges_908" xlink:to="lab_ifrs-full_BankAndSimilarCharges_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_BankAndSimilarCharges_909" xlink:to="lab_ifrs-full_BankAndSimilarCharges_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_BasicAndDilutedEarningsLossPerShare_910" xlink:to="lab_ifrs-full_BasicAndDilutedEarningsLossPerShare_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_BasicAndDilutedEarningsLossPerShare_911" xlink:to="lab_ifrs-full_BasicAndDilutedEarningsLossPerShare_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_BottomOfRangeMember_912" xlink:to="lab_ifrs-full_BottomOfRangeMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_BuildingsMember_913" xlink:to="lab_ifrs-full_BuildingsMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_BuildingsMember_914" xlink:to="lab_ifrs-full_BuildingsMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_Cash_915" xlink:to="lab_ifrs-full_Cash_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CashAndCashEquivalents_916" xlink:to="lab_ifrs-full_CashAndCashEquivalents_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CashAndCashEquivalents_917" xlink:to="lab_ifrs-full_CashAndCashEquivalents_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CashAndCashEquivalents_918" xlink:to="lab_ifrs-full_CashAndCashEquivalents_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CashAndCashEquivalents_919" xlink:to="lab_ifrs-full_CashAndCashEquivalents_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities_920" xlink:to="lab_ifrs-full_CashFlowsFromUsedInFinancingActivities_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities_921" xlink:to="lab_ifrs-full_CashFlowsFromUsedInFinancingActivities_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_922" xlink:to="lab_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_923" xlink:to="lab_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivities_924" xlink:to="lab_ifrs-full_CashFlowsFromUsedInOperatingActivities_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivities_925" xlink:to="lab_ifrs-full_CashFlowsFromUsedInOperatingActivities_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_926" xlink:to="lab_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_927" xlink:to="lab_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CategoriesOfFinancialLiabilitiesAbstract_928" xlink:to="lab_ifrs-full_CategoriesOfFinancialLiabilitiesAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CategoriesOfFinancialLiabilitiesAbstract_929" xlink:to="lab_ifrs-full_CategoriesOfFinancialLiabilitiesAbstract_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_930" xlink:to="lab_ifrs-full_CategoriesOfRelatedPartiesAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ClassesOfAssetsAxis_931" xlink:to="lab_ifrs-full_ClassesOfAssetsAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ClassesOfAssetsMember_932" xlink:to="lab_ifrs-full_ClassesOfAssetsMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ClassesOfFinancialInstrumentsAxis_933" xlink:to="lab_ifrs-full_ClassesOfFinancialInstrumentsAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ClassesOfFinancialInstrumentsMember_934" xlink:to="lab_ifrs-full_ClassesOfFinancialInstrumentsMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ClassesOfShareCapitalAxis_935" xlink:to="lab_ifrs-full_ClassesOfShareCapitalAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ClassesOfShareCapitalMember_936" xlink:to="lab_ifrs-full_ClassesOfShareCapitalMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ComponentsOfEquityAxis_937" xlink:to="lab_ifrs-full_ComponentsOfEquityAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CopyrightsPatentsAndOtherIndustrialPropertyRightsServiceAndOperatingRightsMember_938" xlink:to="lab_ifrs-full_CopyrightsPatentsAndOtherIndustrialPropertyRightsServiceAndOperatingRightsMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CopyrightsPatentsAndOtherIndustrialPropertyRightsServiceAndOperatingRightsMember_939" xlink:to="lab_ifrs-full_CopyrightsPatentsAndOtherIndustrialPropertyRightsServiceAndOperatingRightsMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CreditRiskMember_940" xlink:to="lab_ifrs-full_CreditRiskMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CreditRiskMember_941" xlink:to="lab_ifrs-full_CreditRiskMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrencyRiskMember_942" xlink:to="lab_ifrs-full_CurrencyRiskMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrencyRiskMember_943" xlink:to="lab_ifrs-full_CurrencyRiskMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities_944" xlink:to="lab_ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities_945" xlink:to="lab_ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentAssets_946" xlink:to="lab_ifrs-full_CurrentAssets_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentAssets_947" xlink:to="lab_ifrs-full_CurrentAssets_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentAssetsAbstract_948" xlink:to="lab_ifrs-full_CurrentAssetsAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentAssetsAbstract_949" xlink:to="lab_ifrs-full_CurrentAssetsAbstract_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentFinancialAssetsAtFairValueThroughProfitOrLossAbstract_950" xlink:to="lab_ifrs-full_CurrentFinancialAssetsAtFairValueThroughProfitOrLossAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentFinancialAssetsAtFairValueThroughProfitOrLossAbstract_951" xlink:to="lab_ifrs-full_CurrentFinancialAssetsAtFairValueThroughProfitOrLossAbstract_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentLiabilitiesAbstract_952" xlink:to="lab_ifrs-full_CurrentLiabilitiesAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentLiabilitiesAbstract_953" xlink:to="lab_ifrs-full_CurrentLiabilitiesAbstract_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentPrepaidExpenses_954" xlink:to="lab_ifrs-full_CurrentPrepaidExpenses_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentPrepaidExpenses_955" xlink:to="lab_ifrs-full_CurrentPrepaidExpenses_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentTaxAssetsCurrent_956" xlink:to="lab_ifrs-full_CurrentTaxAssetsCurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentTaxAssetsCurrent_957" xlink:to="lab_ifrs-full_CurrentTaxAssetsCurrent_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised_958" xlink:to="lab_ifrs-full_DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised_959" xlink:to="lab_ifrs-full_DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfAccountingPolicyForBusinessCombinationsExplanatory_960" xlink:to="lab_ifrs-full_DescriptionOfAccountingPolicyForBusinessCombinationsExplanatory_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfAccountingPolicyForBusinessCombinationsExplanatory_961" xlink:to="lab_ifrs-full_DescriptionOfAccountingPolicyForBusinessCombinationsExplanatory_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory_962" xlink:to="lab_ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory_963" xlink:to="lab_ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory_964" xlink:to="lab_ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory_965" xlink:to="lab_ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory_966" xlink:to="lab_ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory_967" xlink:to="lab_ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory_968" xlink:to="lab_ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory_969" xlink:to="lab_ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfAccountingPolicyForIssuedCapitalExplanatory_970" xlink:to="lab_ifrs-full_DescriptionOfAccountingPolicyForIssuedCapitalExplanatory_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfAccountingPolicyForIssuedCapitalExplanatory_971" xlink:to="lab_ifrs-full_DescriptionOfAccountingPolicyForIssuedCapitalExplanatory_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory_972" xlink:to="lab_ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory_973" xlink:to="lab_ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory_974" xlink:to="lab_ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory_975" xlink:to="lab_ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory_976" xlink:to="lab_ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory_977" xlink:to="lab_ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory_978" xlink:to="lab_ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory_979" xlink:to="lab_ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted_980" xlink:to="lab_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted_981" xlink:to="lab_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted_982" xlink:to="lab_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted_983" xlink:to="lab_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DirectorsRemunerationExpense_984" xlink:to="lab_ifrs-full_DirectorsRemunerationExpense_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DirectorsRemunerationExpense_985" xlink:to="lab_ifrs-full_DirectorsRemunerationExpense_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory_986" xlink:to="lab_ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory_987" xlink:to="lab_ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalAbstract_988" xlink:to="lab_ifrs-full_DisclosureOfClassesOfShareCapitalAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_989" xlink:to="lab_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_990" xlink:to="lab_ifrs-full_DisclosureOfClassesOfShareCapitalTable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfCommitmentsExplanatory_991" xlink:to="lab_ifrs-full_DisclosureOfCommitmentsExplanatory_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfCommitmentsExplanatory_992" xlink:to="lab_ifrs-full_DisclosureOfCommitmentsExplanatory_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory_993" xlink:to="lab_ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory_994" xlink:to="lab_ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory_995" xlink:to="lab_ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory_996" xlink:to="lab_ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsAbstract_997" xlink:to="lab_ifrs-full_DisclosureOfFinancialInstrumentsAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsExplanatory_998" xlink:to="lab_ifrs-full_DisclosureOfFinancialInstrumentsExplanatory_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsExplanatory_999" xlink:to="lab_ifrs-full_DisclosureOfFinancialInstrumentsExplanatory_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_1000" xlink:to="lab_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_1001" xlink:to="lab_ifrs-full_DisclosureOfFinancialInstrumentsTable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfIncomeTaxExplanatory_1002" xlink:to="lab_ifrs-full_DisclosureOfIncomeTaxExplanatory_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfIncomeTaxExplanatory_1003" xlink:to="lab_ifrs-full_DisclosureOfIncomeTaxExplanatory_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfInformationAboutKeyManagementPersonnelExplanatory_1004" xlink:to="lab_ifrs-full_DisclosureOfInformationAboutKeyManagementPersonnelExplanatory_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfInformationAboutKeyManagementPersonnelExplanatory_1005" xlink:to="lab_ifrs-full_DisclosureOfInformationAboutKeyManagementPersonnelExplanatory_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfIssuedCapitalExplanatory_1006" xlink:to="lab_ifrs-full_DisclosureOfIssuedCapitalExplanatory_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfIssuedCapitalExplanatory_1007" xlink:to="lab_ifrs-full_DisclosureOfIssuedCapitalExplanatory_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfLeasesExplanatory_1008" xlink:to="lab_ifrs-full_DisclosureOfLeasesExplanatory_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfLeasesExplanatory_1009" xlink:to="lab_ifrs-full_DisclosureOfLeasesExplanatory_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract_1010" xlink:to="lab_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_1011" xlink:to="lab_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable_1012" xlink:to="lab_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory_1013" xlink:to="lab_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory_1014" xlink:to="lab_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory_1015" xlink:to="lab_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory_1016" xlink:to="lab_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems_1017" xlink:to="lab_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable_1018" xlink:to="lab_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfRelatedPartyExplanatory_1019" xlink:to="lab_ifrs-full_DisclosureOfRelatedPartyExplanatory_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfRelatedPartyExplanatory_1020" xlink:to="lab_ifrs-full_DisclosureOfRelatedPartyExplanatory_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfResearchAndDevelopmentExpenseExplanatory_1021" xlink:to="lab_ifrs-full_DisclosureOfResearchAndDevelopmentExpenseExplanatory_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfResearchAndDevelopmentExpenseExplanatory_1022" xlink:to="lab_ifrs-full_DisclosureOfResearchAndDevelopmentExpenseExplanatory_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory_1023" xlink:to="lab_ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory_1024" xlink:to="lab_ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory_1025" xlink:to="lab_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory_1026" xlink:to="lab_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_1027" xlink:to="lab_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable_1028" xlink:to="lab_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory_1029" xlink:to="lab_ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory_1030" xlink:to="lab_ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract_1031" xlink:to="lab_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory_1032" xlink:to="lab_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory_1033" xlink:to="lab_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents_1034" xlink:to="lab_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents_1035" xlink:to="lab_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_1036" xlink:to="lab_ifrs-full_EntitysTotalForRelatedPartiesMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_Equity_1037" xlink:to="lab_ifrs-full_Equity_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_Equity_1038" xlink:to="lab_ifrs-full_Equity_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_Equity_1039" xlink:to="lab_ifrs-full_Equity_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_Equity_1040" xlink:to="lab_ifrs-full_Equity_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_EquityAbstract_1041" xlink:to="lab_ifrs-full_EquityAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_EquityAbstract_1042" xlink:to="lab_ifrs-full_EquityAbstract_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_EquityAndLiabilities_1043" xlink:to="lab_ifrs-full_EquityAndLiabilities_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_EquityAndLiabilities_1044" xlink:to="lab_ifrs-full_EquityAndLiabilities_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_EquityAndLiabilitiesAbstract_1045" xlink:to="lab_ifrs-full_EquityAndLiabilitiesAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_EquityAndLiabilitiesAbstract_1046" xlink:to="lab_ifrs-full_EquityAndLiabilitiesAbstract_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_EquityInterestsOfAcquirer_1047" xlink:to="lab_ifrs-full_EquityInterestsOfAcquirer_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_EquityInterestsOfAcquirer_1048" xlink:to="lab_ifrs-full_EquityInterestsOfAcquirer_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_EquityMember_1049" xlink:to="lab_ifrs-full_EquityMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_EquityMember_1050" xlink:to="lab_ifrs-full_EquityMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ExercisePriceOfOutstandingShareOptions2019_1051" xlink:to="lab_ifrs-full_ExercisePriceOfOutstandingShareOptions2019_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ExercisePriceOfOutstandingShareOptions2019_1052" xlink:to="lab_ifrs-full_ExercisePriceOfOutstandingShareOptions2019_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ExercisePriceShareOptionsGranted2019_1053" xlink:to="lab_ifrs-full_ExercisePriceShareOptionsGranted2019_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ExercisePriceShareOptionsGranted2019_1054" xlink:to="lab_ifrs-full_ExercisePriceShareOptionsGranted2019_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ExpenseByNatureAbstract_1055" xlink:to="lab_ifrs-full_ExpenseByNatureAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ExpenseByNatureAbstract_1056" xlink:to="lab_ifrs-full_ExpenseByNatureAbstract_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees_1057" xlink:to="lab_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees_1058" xlink:to="lab_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_FeeAndCommissionExpense_1059" xlink:to="lab_ifrs-full_FeeAndCommissionExpense_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_FeeAndCommissionExpense_1060" xlink:to="lab_ifrs-full_FeeAndCommissionExpense_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss_1061" xlink:to="lab_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss_1062" xlink:to="lab_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss_1063" xlink:to="lab_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_GeneralAndAdministrativeExpense_1064" xlink:to="lab_ifrs-full_GeneralAndAdministrativeExpense_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_GeneralAndAdministrativeExpense_1065" xlink:to="lab_ifrs-full_GeneralAndAdministrativeExpense_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncomeStatementAbstract_1066" xlink:to="lab_ifrs-full_IncomeStatementAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncomeStatementAbstract_1067" xlink:to="lab_ifrs-full_IncomeStatementAbstract_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncomeTaxExpenseContinuingOperations_1068" xlink:to="lab_ifrs-full_IncomeTaxExpenseContinuingOperations_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncomeTaxExpenseContinuingOperations_1069" xlink:to="lab_ifrs-full_IncomeTaxExpenseContinuingOperations_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncomeTaxExpenseContinuingOperations_1070" xlink:to="lab_ifrs-full_IncomeTaxExpenseContinuingOperations_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents_1071" xlink:to="lab_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents_1072" xlink:to="lab_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents_1073" xlink:to="lab_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncreaseDecreaseInNumberOfSharesOutstanding_1074" xlink:to="lab_ifrs-full_IncreaseDecreaseInNumberOfSharesOutstanding_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncreaseDecreaseInNumberOfSharesOutstanding_1075" xlink:to="lab_ifrs-full_IncreaseDecreaseInNumberOfSharesOutstanding_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity_1076" xlink:to="lab_ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity_1077" xlink:to="lab_ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions_1078" xlink:to="lab_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions_1079" xlink:to="lab_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IntangibleAssetsAndGoodwill_1080" xlink:to="lab_ifrs-full_IntangibleAssetsAndGoodwill_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IntangibleAssetsAndGoodwill_1081" xlink:to="lab_ifrs-full_IntangibleAssetsAndGoodwill_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IssuedCapital_1082" xlink:to="lab_ifrs-full_IssuedCapital_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IssuedCapital_1083" xlink:to="lab_ifrs-full_IssuedCapital_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IssuedCapitalMember_1084" xlink:to="lab_ifrs-full_IssuedCapitalMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IssuedCapitalMember_1085" xlink:to="lab_ifrs-full_IssuedCapitalMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_KeyManagementPersonnelCompensation_1086" xlink:to="lab_ifrs-full_KeyManagementPersonnelCompensation_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_KeyManagementPersonnelCompensation_1087" xlink:to="lab_ifrs-full_KeyManagementPersonnelCompensation_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment_1088" xlink:to="lab_ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment_1089" xlink:to="lab_ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_Liabilities_1090" xlink:to="lab_ifrs-full_Liabilities_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_Liabilities_1091" xlink:to="lab_ifrs-full_Liabilities_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_LiquidityRiskMember_1092" xlink:to="lab_ifrs-full_LiquidityRiskMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_LiquidityRiskMember_1093" xlink:to="lab_ifrs-full_LiquidityRiskMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract_1094" xlink:to="lab_ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_1095" xlink:to="lab_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NonadjustingEventsMember_1096" xlink:to="lab_ifrs-full_NonadjustingEventsMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NoncurrentAssetsAbstract_1097" xlink:to="lab_ifrs-full_NoncurrentAssetsAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NoncurrentAssetsAbstract_1098" xlink:to="lab_ifrs-full_NoncurrentAssetsAbstract_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NumberOfInstrumentsOrInterestsIssuedOrIssuable_1099" xlink:to="lab_ifrs-full_NumberOfInstrumentsOrInterestsIssuedOrIssuable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NumberOfInstrumentsOrInterestsIssuedOrIssuable_1100" xlink:to="lab_ifrs-full_NumberOfInstrumentsOrInterestsIssuedOrIssuable_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted_1101" xlink:to="lab_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted_1102" xlink:to="lab_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted_1103" xlink:to="lab_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement_1104" xlink:to="lab_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement_1105" xlink:to="lab_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement_1106" xlink:to="lab_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_1107" xlink:to="lab_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_1108" xlink:to="lab_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_1109" xlink:to="lab_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_1110" xlink:to="lab_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NumberOfOutstandingShareOptions_1111" xlink:to="lab_ifrs-full_NumberOfOutstandingShareOptions_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NumberOfOutstandingShareOptions_1112" xlink:to="lab_ifrs-full_NumberOfOutstandingShareOptions_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NumberOfOutstandingShareOptions_1113" xlink:to="lab_ifrs-full_NumberOfOutstandingShareOptions_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NumberOfOutstandingShareOptions_1114" xlink:to="lab_ifrs-full_NumberOfOutstandingShareOptions_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement_1115" xlink:to="lab_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement_1116" xlink:to="lab_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement_1117" xlink:to="lab_ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement_1118" xlink:to="lab_ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement_1119" xlink:to="lab_ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement_1120" xlink:to="lab_ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement_1121" xlink:to="lab_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement_1122" xlink:to="lab_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement_1123" xlink:to="lab_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NumberOfSharesIssued_1124" xlink:to="lab_ifrs-full_NumberOfSharesIssued_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NumberOfSharesOutstanding_1125" xlink:to="lab_ifrs-full_NumberOfSharesOutstanding_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NumberOfSharesOutstanding_1126" xlink:to="lab_ifrs-full_NumberOfSharesOutstanding_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NumberOfSharesOutstanding_1127" xlink:to="lab_ifrs-full_NumberOfSharesOutstanding_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherReserves_1128" xlink:to="lab_ifrs-full_OtherReserves_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherReserves_1129" xlink:to="lab_ifrs-full_OtherReserves_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherReservesMember_1130" xlink:to="lab_ifrs-full_OtherReservesMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherReservesMember_1131" xlink:to="lab_ifrs-full_OtherReservesMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_PaymentsForShareIssueCosts_1132" xlink:to="lab_ifrs-full_PaymentsForShareIssueCosts_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_PaymentsForShareIssueCosts_1133" xlink:to="lab_ifrs-full_PaymentsForShareIssueCosts_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_PresentationOfLeasesForLesseeAbstract_1134" xlink:to="lab_ifrs-full_PresentationOfLeasesForLesseeAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ProceedsFromIssueOfOrdinaryShares_1135" xlink:to="lab_ifrs-full_ProceedsFromIssueOfOrdinaryShares_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ProceedsFromIssuingShares_1136" xlink:to="lab_ifrs-full_ProceedsFromIssuingShares_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ProceedsFromIssuingShares_1137" xlink:to="lab_ifrs-full_ProceedsFromIssuingShares_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ProfessionalFeesExpense_1138" xlink:to="lab_ifrs-full_ProfessionalFeesExpense_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ProfessionalFeesExpense_1139" xlink:to="lab_ifrs-full_ProfessionalFeesExpense_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ProfitLoss_1140" xlink:to="lab_ifrs-full_ProfitLoss_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ProfitLoss_1141" xlink:to="lab_ifrs-full_ProfitLoss_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ProfitLoss_1142" xlink:to="lab_ifrs-full_ProfitLoss_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ProfitLoss_1143" xlink:to="lab_ifrs-full_ProfitLoss_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_RangeAxis_1144" xlink:to="lab_ifrs-full_RangeAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_RangesMember_1145" xlink:to="lab_ifrs-full_RangesMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ReconciliationOfNumberOfSharesOutstandingAbstract_1146" xlink:to="lab_ifrs-full_ReconciliationOfNumberOfSharesOutstandingAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ResearchAndDevelopmentExpense_1147" xlink:to="lab_ifrs-full_ResearchAndDevelopmentExpense_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ResearchAndDevelopmentExpense_1148" xlink:to="lab_ifrs-full_ResearchAndDevelopmentExpense_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ResearchAndDevelopmentExpense_1149" xlink:to="lab_ifrs-full_ResearchAndDevelopmentExpense_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_RetainedEarnings_1150" xlink:to="lab_ifrs-full_RetainedEarnings_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_RetainedEarnings_1151" xlink:to="lab_ifrs-full_RetainedEarnings_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_RetainedEarningsMember_1152" xlink:to="lab_ifrs-full_RetainedEarningsMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_RetainedEarningsMember_1153" xlink:to="lab_ifrs-full_RetainedEarningsMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_SalesAndMarketingExpense_1154" xlink:to="lab_ifrs-full_SalesAndMarketingExpense_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_SalesAndMarketingExpense_1155" xlink:to="lab_ifrs-full_SalesAndMarketingExpense_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_1156" xlink:to="lab_ifrs-full_SharebasedPaymentArrangementsMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ShareIssueRelatedCost_1157" xlink:to="lab_ifrs-full_ShareIssueRelatedCost_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ShareIssueRelatedCost_1158" xlink:to="lab_ifrs-full_ShareIssueRelatedCost_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ShareIssueRelatedCost_1159" xlink:to="lab_ifrs-full_ShareIssueRelatedCost_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ShorttermInvestmentsClassifiedAsCashEquivalents_1160" xlink:to="lab_ifrs-full_ShorttermInvestmentsClassifiedAsCashEquivalents_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ShorttermInvestmentsClassifiedAsCashEquivalents_1161" xlink:to="lab_ifrs-full_ShorttermInvestmentsClassifiedAsCashEquivalents_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_StatementOfCashFlowsAbstract_1162" xlink:to="lab_ifrs-full_StatementOfCashFlowsAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_StatementOfChangesInEquityAbstract_1163" xlink:to="lab_ifrs-full_StatementOfChangesInEquityAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_1164" xlink:to="lab_ifrs-full_StatementOfChangesInEquityLineItems_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_StatementOfChangesInEquityTable_1165" xlink:to="lab_ifrs-full_StatementOfChangesInEquityTable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_StatementOfFinancialPositionAbstract_1166" xlink:to="lab_ifrs-full_StatementOfFinancialPositionAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss_1167" xlink:to="lab_ifrs-full_TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss_1168" xlink:to="lab_ifrs-full_TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TaxExpenseIncomeAtApplicableTaxRate_1169" xlink:to="lab_ifrs-full_TaxExpenseIncomeAtApplicableTaxRate_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TaxExpenseIncomeAtApplicableTaxRate_1170" xlink:to="lab_ifrs-full_TaxExpenseIncomeAtApplicableTaxRate_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TemporaryDifferenceMember_1171" xlink:to="lab_ifrs-full_TemporaryDifferenceMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_1172" xlink:to="lab_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_1173" xlink:to="lab_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TopOfRangeMember_1174" xlink:to="lab_ifrs-full_TopOfRangeMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TradeAndOtherCurrentPayables_1175" xlink:to="lab_ifrs-full_TradeAndOtherCurrentPayables_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TradeAndOtherCurrentPayables_1176" xlink:to="lab_ifrs-full_TradeAndOtherCurrentPayables_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TradeAndOtherCurrentPayables_1177" xlink:to="lab_ifrs-full_TradeAndOtherCurrentPayables_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TradeAndOtherCurrentPayablesAbstract_1178" xlink:to="lab_ifrs-full_TradeAndOtherCurrentPayablesAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers_1179" xlink:to="lab_ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers_1180" xlink:to="lab_ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TypesOfRisksAxis_1181" xlink:to="lab_ifrs-full_TypesOfRisksAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TypesOfRisksMember_1182" xlink:to="lab_ifrs-full_TypesOfRisksMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_1183" xlink:to="lab_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_UnusedTaxLossesMember_1184" xlink:to="lab_ifrs-full_UnusedTaxLossesMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_UnusedTaxLossesMember_1185" xlink:to="lab_ifrs-full_UnusedTaxLossesMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ValueAtRisk_1186" xlink:to="lab_ifrs-full_ValueAtRisk_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ValueAtRisk_1187" xlink:to="lab_ifrs-full_ValueAtRisk_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019_1188" xlink:to="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019_1189" xlink:to="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019_1190" xlink:to="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019_1191" xlink:to="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019_1192" xlink:to="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_1193" xlink:to="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_1194" xlink:to="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_1195" xlink:to="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019_1196" xlink:to="lab_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019_1197" xlink:to="lab_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019_1198" xlink:to="lab_ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019_1199" xlink:to="lab_ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_WeightedAverageShares_1200" xlink:to="lab_ifrs-full_WeightedAverageShares_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_WeightedAverageShares_1201" xlink:to="lab_ifrs-full_WeightedAverageShares_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ChiefExecutiveOfficerMember_1202" xlink:to="lab_srt_ChiefExecutiveOfficerMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualAxis_1203" xlink:to="lab_srt_TitleOfIndividualAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_1204" xlink:to="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_0"/>
  </labelLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>6
<FILENAME>drug-20210930_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <!-- INTEGIX by Ez-XBRL -->
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel"/>
  <roleRef xlink:type="simple" xlink:href="drug-20210930.xsd#DocumentAndEntityInformation" roleURI="http://brightmindsbio.com/role/DocumentAndEntityInformation"/>
  <roleRef xlink:type="simple" xlink:href="drug-20210930.xsd#ConsolidatedStatementsOfFinancialPosition" roleURI="http://brightmindsbio.com/role/ConsolidatedStatementsOfFinancialPosition"/>
  <roleRef xlink:type="simple" xlink:href="drug-20210930.xsd#ComparativeAmounts" roleURI="http://brightmindsbio.com/role/ComparativeAmounts"/>
  <roleRef xlink:type="simple" xlink:href="drug-20210930.xsd#ACCOUNTSPAYABLEANDACCRUEDLIABILITIES" roleURI="http://brightmindsbio.com/role/ACCOUNTSPAYABLEANDACCRUEDLIABILITIES"/>
  <roleRef xlink:type="simple" xlink:href="drug-20210930.xsd#ACCOUNTSPAYABLEANDACCRUEDLIABILITIESTables" roleURI="http://brightmindsbio.com/role/ACCOUNTSPAYABLEANDACCRUEDLIABILITIESTables"/>
  <roleRef xlink:type="simple" xlink:href="drug-20210930.xsd#ACCOUNTSPAYABLEANDACCRUEDLIABILITIESDetails" roleURI="http://brightmindsbio.com/role/ACCOUNTSPAYABLEANDACCRUEDLIABILITIESDetails"/>
  <roleRef xlink:type="simple" xlink:href="drug-20210930.xsd#NATUREANDCONTINUANCEOFOPERATIONS" roleURI="http://brightmindsbio.com/role/NATUREANDCONTINUANCEOFOPERATIONS"/>
  <roleRef xlink:type="simple" xlink:href="drug-20210930.xsd#NATUREANDCONTINUANCEOFOPERATIONSDetailTextuals" roleURI="http://brightmindsbio.com/role/NATUREANDCONTINUANCEOFOPERATIONSDetailTextuals"/>
  <roleRef xlink:type="simple" xlink:href="drug-20210930.xsd#STATEMENTOFCOMPLIANCEANDBASISOFPREPARATION" roleURI="http://brightmindsbio.com/role/STATEMENTOFCOMPLIANCEANDBASISOFPREPARATION"/>
  <roleRef xlink:type="simple" xlink:href="drug-20210930.xsd#SUBSEQUENTEVENTS" roleURI="http://brightmindsbio.com/role/SUBSEQUENTEVENTS"/>
  <roleRef xlink:type="simple" xlink:href="drug-20210930.xsd#SUBSEQUENTEVENTSDetailTextuals" roleURI="http://brightmindsbio.com/role/SUBSEQUENTEVENTSDetailTextuals"/>
  <roleRef xlink:type="simple" xlink:href="drug-20210930.xsd#RESEARCHANDDEVELOPMENTTables" roleURI="http://brightmindsbio.com/role/RESEARCHANDDEVELOPMENTTables"/>
  <roleRef xlink:type="simple" xlink:href="drug-20210930.xsd#RESEARCHANDDEVELOPMENT" roleURI="http://brightmindsbio.com/role/RESEARCHANDDEVELOPMENT"/>
  <roleRef xlink:type="simple" xlink:href="drug-20210930.xsd#RESEARCHANDDEVELOPMENTDetails" roleURI="http://brightmindsbio.com/role/RESEARCHANDDEVELOPMENTDetails"/>
  <roleRef xlink:type="simple" xlink:href="drug-20210930.xsd#SIGNIFICANTACCOUNTINGPOLICIESDetailTextuals" roleURI="http://brightmindsbio.com/role/SIGNIFICANTACCOUNTINGPOLICIESDetailTextuals"/>
  <roleRef xlink:type="simple" xlink:href="drug-20210930.xsd#SIGNIFICANTACCOUNTINGPOLICIESPolicies" roleURI="http://brightmindsbio.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies"/>
  <roleRef xlink:type="simple" xlink:href="drug-20210930.xsd#SIGNIFICANTACCOUNTINGPOLICIES" roleURI="http://brightmindsbio.com/role/SIGNIFICANTACCOUNTINGPOLICIES"/>
  <roleRef xlink:type="simple" xlink:href="drug-20210930.xsd#FINANCIALINSTRUMENTSANDCAPITALMANAGEMENT" roleURI="http://brightmindsbio.com/role/FINANCIALINSTRUMENTSANDCAPITALMANAGEMENT"/>
  <roleRef xlink:type="simple" xlink:href="drug-20210930.xsd#FINANCIALINSTRUMENTSANDCAPITALMANAGEMENTTables" roleURI="http://brightmindsbio.com/role/FINANCIALINSTRUMENTSANDCAPITALMANAGEMENTTables"/>
  <roleRef xlink:type="simple" xlink:href="drug-20210930.xsd#FINANCIALINSTRUMENTSANDCAPITALMANAGEMENTDetails" roleURI="http://brightmindsbio.com/role/FINANCIALINSTRUMENTSANDCAPITALMANAGEMENTDetails"/>
  <roleRef xlink:type="simple" xlink:href="drug-20210930.xsd#FINANCIALINSTRUMENTSANDCAPITALMANAGEMENTDetailTextuals" roleURI="http://brightmindsbio.com/role/FINANCIALINSTRUMENTSANDCAPITALMANAGEMENTDetailTextuals"/>
  <roleRef xlink:type="simple" xlink:href="drug-20210930.xsd#ConsolidatedStatementsOfComprehensiveLoss" roleURI="http://brightmindsbio.com/role/ConsolidatedStatementsOfComprehensiveLoss"/>
  <roleRef xlink:type="simple" xlink:href="drug-20210930.xsd#RELATEDPARTYTRANSACTIONS" roleURI="http://brightmindsbio.com/role/RELATEDPARTYTRANSACTIONS"/>
  <roleRef xlink:type="simple" xlink:href="drug-20210930.xsd#RELATEDPARTYTRANSACTIONSTables" roleURI="http://brightmindsbio.com/role/RELATEDPARTYTRANSACTIONSTables"/>
  <roleRef xlink:type="simple" xlink:href="drug-20210930.xsd#RELATEDPARTYTRANSACTIONSDetails" roleURI="http://brightmindsbio.com/role/RELATEDPARTYTRANSACTIONSDetails"/>
  <roleRef xlink:type="simple" xlink:href="drug-20210930.xsd#SHAREEXCHANGEANDASSIGNMENT" roleURI="http://brightmindsbio.com/role/SHAREEXCHANGEANDASSIGNMENT"/>
  <roleRef xlink:type="simple" xlink:href="drug-20210930.xsd#SHAREEXCHANGEANDASSIGNMENTDetailTextuals" roleURI="http://brightmindsbio.com/role/SHAREEXCHANGEANDASSIGNMENTDetailTextuals"/>
  <roleRef xlink:type="simple" xlink:href="drug-20210930.xsd#SHARECAPITALTables" roleURI="http://brightmindsbio.com/role/SHARECAPITALTables"/>
  <roleRef xlink:type="simple" xlink:href="drug-20210930.xsd#SHARECAPITAL" roleURI="http://brightmindsbio.com/role/SHARECAPITAL"/>
  <roleRef xlink:type="simple" xlink:href="drug-20210930.xsd#SHARECAPITALDetails" roleURI="http://brightmindsbio.com/role/SHARECAPITALDetails"/>
  <roleRef xlink:type="simple" xlink:href="drug-20210930.xsd#SHARECAPITALDetails1" roleURI="http://brightmindsbio.com/role/SHARECAPITALDetails1"/>
  <roleRef xlink:type="simple" xlink:href="drug-20210930.xsd#SHARECAPITALDetails3" roleURI="http://brightmindsbio.com/role/SHARECAPITALDetails3"/>
  <roleRef xlink:type="simple" xlink:href="drug-20210930.xsd#SHARECAPITALDetails2" roleURI="http://brightmindsbio.com/role/SHARECAPITALDetails2"/>
  <roleRef xlink:type="simple" xlink:href="drug-20210930.xsd#SHARECAPITALDetails4" roleURI="http://brightmindsbio.com/role/SHARECAPITALDetails4"/>
  <roleRef xlink:type="simple" xlink:href="drug-20210930.xsd#SHARECAPITALDetails7" roleURI="http://brightmindsbio.com/role/SHARECAPITALDetails7"/>
  <roleRef xlink:type="simple" xlink:href="drug-20210930.xsd#SHARECAPITALDetails6" roleURI="http://brightmindsbio.com/role/SHARECAPITALDetails6"/>
  <roleRef xlink:type="simple" xlink:href="drug-20210930.xsd#SHARECAPITALDetailTextuals" roleURI="http://brightmindsbio.com/role/SHARECAPITALDetailTextuals"/>
  <roleRef xlink:type="simple" xlink:href="drug-20210930.xsd#SHARECAPITALDetails5" roleURI="http://brightmindsbio.com/role/SHARECAPITALDetails5"/>
  <roleRef xlink:type="simple" xlink:href="drug-20210930.xsd#ConsolidatedStatementsOfCashFlows" roleURI="http://brightmindsbio.com/role/ConsolidatedStatementsOfCashFlows"/>
  <roleRef xlink:type="simple" xlink:href="drug-20210930.xsd#INCOMETAXES" roleURI="http://brightmindsbio.com/role/INCOMETAXES"/>
  <roleRef xlink:type="simple" xlink:href="drug-20210930.xsd#INCOMETAXESTables" roleURI="http://brightmindsbio.com/role/INCOMETAXESTables"/>
  <roleRef xlink:type="simple" xlink:href="drug-20210930.xsd#INCOMETAXESDetails" roleURI="http://brightmindsbio.com/role/INCOMETAXESDetails"/>
  <roleRef xlink:type="simple" xlink:href="drug-20210930.xsd#INCOMETAXESDetails2" roleURI="http://brightmindsbio.com/role/INCOMETAXESDetails2"/>
  <roleRef xlink:type="simple" xlink:href="drug-20210930.xsd#INCOMETAXESDetailTextuals" roleURI="http://brightmindsbio.com/role/INCOMETAXESDetailTextuals"/>
  <roleRef xlink:type="simple" xlink:href="drug-20210930.xsd#INCOMETAXESDetails1" roleURI="http://brightmindsbio.com/role/INCOMETAXESDetails1"/>
  <roleRef xlink:type="simple" xlink:href="drug-20210930.xsd#ConsolidatedStatementsOfChangesInShareholdersEquity" roleURI="http://brightmindsbio.com/role/ConsolidatedStatementsOfChangesInShareholdersEquity"/>
  <roleRef xlink:type="simple" xlink:href="drug-20210930.xsd#CONTRACTUALOBLIGATIONS" roleURI="http://brightmindsbio.com/role/CONTRACTUALOBLIGATIONS"/>
  <roleRef xlink:type="simple" xlink:href="drug-20210930.xsd#CONTRACTUALOBLIGATIONSDetailTextuals" roleURI="http://brightmindsbio.com/role/CONTRACTUALOBLIGATIONSDetailTextuals"/>
  <roleRef xlink:type="simple" xlink:href="drug-20210930.xsd#PREMISESLEASES" roleURI="http://brightmindsbio.com/role/PREMISESLEASES"/>
  <roleRef xlink:type="simple" xlink:href="drug-20210930.xsd#PREMISESLEASESDetailTextuals" roleURI="http://brightmindsbio.com/role/PREMISESLEASESDetailTextuals"/>
  <presentationLink xlink:type="extended" xlink:role="http://brightmindsbio.com/role/DocumentAndEntityInformation">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract" xlink:label="loc_dei_CoverAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressesTable" xlink:label="loc_dei_EntityAddressesTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressesAddressTypeAxis" xlink:label="loc_dei_EntityAddressesAddressTypeAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AddressTypeDomain" xlink:label="loc_dei_AddressTypeDomain_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_BusinessContactMember" xlink:label="loc_dei_BusinessContactMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressesLineItems" xlink:label="loc_dei_EntityAddressesLineItems_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_dei_DocumentRegistrationStatement_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentAnnualReport" xlink:label="loc_dei_DocumentAnnualReport_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber" xlink:label="loc_dei_EntityFileNumber_9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_ContactPersonnelName" xlink:label="loc_dei_ContactPersonnelName_11"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_dei_EntityAddressAddressLine1_12"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_dei_EntityAddressAddressLine2_13"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_dei_EntityAddressCityOrTown_14"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_dei_EntityAddressStateOrProvince_15"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_dei_EntityIncorporationStateCountryCode_16"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCountry" xlink:label="loc_dei_EntityAddressCountry_17"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_dei_EntityAddressPostalZipCode_18"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode" xlink:label="loc_dei_CityAreaCode_19"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber" xlink:label="loc_dei_LocalPhoneNumber_20"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_ContactPersonnelFaxNumber" xlink:label="loc_dei_ContactPersonnelFaxNumber_21"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_ContactPersonnelEmailAddress" xlink:label="loc_dei_ContactPersonnelEmailAddress_22"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle" xlink:label="loc_dei_Security12bTitle_23"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol" xlink:label="loc_dei_TradingSymbol_24"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName" xlink:label="loc_dei_SecurityExchangeName_25"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AnnualInformationForm" xlink:label="loc_dei_AnnualInformationForm_26"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_27"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentDescription" xlink:label="loc_dei_AmendmentDescription_28"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_dei_AuditedAnnualFinancialStatements_29"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate_30"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_31"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_32"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentAccountingStandard" xlink:label="loc_dei_DocumentAccountingStandard_33"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_dei_EntityCurrentReportingStatus_34"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_dei_EntityVoluntaryFilers_35"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_36"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus_37"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus_38"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany" xlink:label="loc_dei_EntityShellCompany_39"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_dei_EntityEmergingGrowthCompany_40"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_dei_EntityInteractiveDataCurrent_41"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentTransitionReport" xlink:label="loc_dei_DocumentTransitionReport_42"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_dei_DocumentShellCompanyReport_43"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_dei_EntityExTransitionPeriod_44"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="loc_dei_IcfrAuditorAttestationFlag_45"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0" xlink:to="loc_dei_EntityAddressesTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityAddressesTable_1" xlink:to="loc_dei_EntityAddressesAddressTypeAxis_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityAddressesAddressTypeAxis_1" xlink:to="loc_dei_AddressTypeDomain_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_AddressTypeDomain_1" xlink:to="loc_dei_BusinessContactMember_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityAddressesTable_1" xlink:to="loc_dei_EntityAddressesLineItems_4" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityAddressesLineItems_4" xlink:to="loc_dei_EntityRegistrantName_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityAddressesLineItems_4" xlink:to="loc_dei_EntityCentralIndexKey_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityAddressesLineItems_4" xlink:to="loc_dei_DocumentType_6" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityAddressesLineItems_4" xlink:to="loc_dei_DocumentRegistrationStatement_7" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityAddressesLineItems_4" xlink:to="loc_dei_DocumentAnnualReport_8" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityAddressesLineItems_4" xlink:to="loc_dei_EntityFileNumber_9" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityAddressesLineItems_4" xlink:to="loc_dei_DocumentPeriodEndDate_10" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityAddressesLineItems_4" xlink:to="loc_dei_ContactPersonnelName_11" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityAddressesLineItems_4" xlink:to="loc_dei_EntityAddressAddressLine1_12" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityAddressesLineItems_4" xlink:to="loc_dei_EntityAddressAddressLine2_13" order="90" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityAddressesLineItems_4" xlink:to="loc_dei_EntityAddressCityOrTown_14" order="100" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityAddressesLineItems_4" xlink:to="loc_dei_EntityAddressStateOrProvince_15" order="110" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityAddressesLineItems_4" xlink:to="loc_dei_EntityIncorporationStateCountryCode_16" order="120" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityAddressesLineItems_4" xlink:to="loc_dei_EntityAddressCountry_17" order="130" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityAddressesLineItems_4" xlink:to="loc_dei_EntityAddressPostalZipCode_18" order="140" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityAddressesLineItems_4" xlink:to="loc_dei_CityAreaCode_19" order="150" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityAddressesLineItems_4" xlink:to="loc_dei_LocalPhoneNumber_20" order="160" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityAddressesLineItems_4" xlink:to="loc_dei_ContactPersonnelFaxNumber_21" order="170" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityAddressesLineItems_4" xlink:to="loc_dei_ContactPersonnelEmailAddress_22" order="180" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityAddressesLineItems_4" xlink:to="loc_dei_Security12bTitle_23" order="190" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityAddressesLineItems_4" xlink:to="loc_dei_TradingSymbol_24" order="200" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityAddressesLineItems_4" xlink:to="loc_dei_SecurityExchangeName_25" order="210" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityAddressesLineItems_4" xlink:to="loc_dei_AnnualInformationForm_26" order="220" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityAddressesLineItems_4" xlink:to="loc_dei_AmendmentFlag_27" order="230" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityAddressesLineItems_4" xlink:to="loc_dei_AmendmentDescription_28" order="240" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityAddressesLineItems_4" xlink:to="loc_dei_AuditedAnnualFinancialStatements_29" order="250" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityAddressesLineItems_4" xlink:to="loc_dei_CurrentFiscalYearEndDate_30" order="260" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityAddressesLineItems_4" xlink:to="loc_dei_EntityFilerCategory_31" order="270" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityAddressesLineItems_4" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_32" order="280" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityAddressesLineItems_4" xlink:to="loc_dei_DocumentAccountingStandard_33" order="290" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityAddressesLineItems_4" xlink:to="loc_dei_EntityCurrentReportingStatus_34" order="300" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityAddressesLineItems_4" xlink:to="loc_dei_EntityVoluntaryFilers_35" order="310" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityAddressesLineItems_4" xlink:to="loc_dei_EntityWellKnownSeasonedIssuer_36" order="320" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityAddressesLineItems_4" xlink:to="loc_dei_DocumentFiscalYearFocus_37" order="330" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityAddressesLineItems_4" xlink:to="loc_dei_DocumentFiscalPeriodFocus_38" order="340" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityAddressesLineItems_4" xlink:to="loc_dei_EntityShellCompany_39" order="350" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityAddressesLineItems_4" xlink:to="loc_dei_EntityEmergingGrowthCompany_40" order="360" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityAddressesLineItems_4" xlink:to="loc_dei_EntityInteractiveDataCurrent_41" order="370" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityAddressesLineItems_4" xlink:to="loc_dei_DocumentTransitionReport_42" order="380" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityAddressesLineItems_4" xlink:to="loc_dei_DocumentShellCompanyReport_43" order="390" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityAddressesLineItems_4" xlink:to="loc_dei_EntityExTransitionPeriod_44" order="400" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityAddressesLineItems_4" xlink:to="loc_dei_IcfrAuditorAttestationFlag_45" order="410" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://brightmindsbio.com/role/ConsolidatedStatementsOfFinancialPosition">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_StatementOfFinancialPositionAbstract" xlink:label="loc_ifrs-full_StatementOfFinancialPositionAbstract_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AssetsAbstract" xlink:label="loc_ifrs-full_AssetsAbstract_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CurrentAssetsAbstract" xlink:label="loc_ifrs-full_CurrentAssetsAbstract_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CashAndCashEquivalents" xlink:label="loc_ifrs-full_CashAndCashEquivalents_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CurrentTaxAssetsCurrent" xlink:label="loc_ifrs-full_CurrentTaxAssetsCurrent_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CurrentPrepaidExpenses" xlink:label="loc_ifrs-full_CurrentPrepaidExpenses_3"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CurrentAssets" xlink:label="loc_ifrs-full_CurrentAssets_4"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NoncurrentAssetsAbstract" xlink:label="loc_ifrs-full_NoncurrentAssetsAbstract_6"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IntangibleAssetsAndGoodwill" xlink:label="loc_ifrs-full_IntangibleAssetsAndGoodwill_6"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_Assets" xlink:label="loc_ifrs-full_Assets_8"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_EquityAndLiabilitiesAbstract" xlink:label="loc_ifrs-full_EquityAndLiabilitiesAbstract_10"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CurrentLiabilitiesAbstract" xlink:label="loc_ifrs-full_CurrentLiabilitiesAbstract_10"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TradeAndOtherCurrentPayables" xlink:label="loc_ifrs-full_TradeAndOtherCurrentPayables_10"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_Liabilities" xlink:label="loc_ifrs-full_Liabilities_12"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_EquityAbstract" xlink:label="loc_ifrs-full_EquityAbstract_13"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IssuedCapital" xlink:label="loc_ifrs-full_IssuedCapital_13"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_SubscriptionsReceivable" xlink:label="loc_drug_SubscriptionsReceivable_14"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_SubscriptionsReceived" xlink:label="loc_drug_SubscriptionsReceived_15"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_OtherReserves" xlink:label="loc_ifrs-full_OtherReserves_16"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_RetainedEarnings" xlink:label="loc_ifrs-full_RetainedEarnings_17"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_Equity" xlink:label="loc_ifrs-full_Equity_18"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_EquityAndLiabilities" xlink:label="loc_ifrs-full_EquityAndLiabilities_20"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfFinancialPositionAbstract_0" xlink:to="loc_ifrs-full_AssetsAbstract_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AssetsAbstract_1" xlink:to="loc_ifrs-full_CurrentAssetsAbstract_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CurrentAssetsAbstract_1" xlink:to="loc_ifrs-full_CashAndCashEquivalents_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CurrentAssetsAbstract_1" xlink:to="loc_ifrs-full_CurrentTaxAssetsCurrent_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CurrentAssetsAbstract_1" xlink:to="loc_ifrs-full_CurrentPrepaidExpenses_3" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CurrentAssetsAbstract_1" xlink:to="loc_ifrs-full_CurrentAssets_4" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AssetsAbstract_1" xlink:to="loc_ifrs-full_NoncurrentAssetsAbstract_6" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_NoncurrentAssetsAbstract_6" xlink:to="loc_ifrs-full_IntangibleAssetsAndGoodwill_6" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AssetsAbstract_1" xlink:to="loc_ifrs-full_Assets_8" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfFinancialPositionAbstract_0" xlink:to="loc_ifrs-full_EquityAndLiabilitiesAbstract_10" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAndLiabilitiesAbstract_10" xlink:to="loc_ifrs-full_CurrentLiabilitiesAbstract_10" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CurrentLiabilitiesAbstract_10" xlink:to="loc_ifrs-full_TradeAndOtherCurrentPayables_10" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAndLiabilitiesAbstract_10" xlink:to="loc_ifrs-full_Liabilities_12" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAndLiabilitiesAbstract_10" xlink:to="loc_ifrs-full_EquityAbstract_13" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAbstract_13" xlink:to="loc_ifrs-full_IssuedCapital_13" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAbstract_13" xlink:to="loc_drug_SubscriptionsReceivable_14" order="10" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAbstract_13" xlink:to="loc_drug_SubscriptionsReceived_15" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAbstract_13" xlink:to="loc_ifrs-full_OtherReserves_16" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAbstract_13" xlink:to="loc_ifrs-full_RetainedEarnings_17" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAbstract_13" xlink:to="loc_ifrs-full_Equity_18" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAndLiabilitiesAbstract_10" xlink:to="loc_ifrs-full_EquityAndLiabilities_20" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://brightmindsbio.com/role/ComparativeAmounts">
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_ComparativeAmountsAbstract" xlink:label="loc_drug_ComparativeAmountsAbstract_0"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_DisclosureOfComparativeAmountsExplanatory" xlink:label="loc_drug_DisclosureOfComparativeAmountsExplanatory_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_drug_ComparativeAmountsAbstract_0" xlink:to="loc_drug_DisclosureOfComparativeAmountsExplanatory_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://brightmindsbio.com/role/ACCOUNTSPAYABLEANDACCRUEDLIABILITIES">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TradeAndOtherCurrentPayablesAbstract" xlink:label="loc_ifrs-full_TradeAndOtherCurrentPayablesAbstract_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory" xlink:label="loc_ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TradeAndOtherCurrentPayablesAbstract_0" xlink:to="loc_ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://brightmindsbio.com/role/ACCOUNTSPAYABLEANDACCRUEDLIABILITIESTables">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TradeAndOtherCurrentPayablesAbstract" xlink:label="loc_ifrs-full_TradeAndOtherCurrentPayablesAbstract_0"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_DisclosureOfDetailedInformationAboutTradePayableAndAccruedExpensesExplanatory" xlink:label="loc_drug_DisclosureOfDetailedInformationAboutTradePayableAndAccruedExpensesExplanatory_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TradeAndOtherCurrentPayablesAbstract_0" xlink:to="loc_drug_DisclosureOfDetailedInformationAboutTradePayableAndAccruedExpensesExplanatory_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://brightmindsbio.com/role/ACCOUNTSPAYABLEANDACCRUEDLIABILITIESDetails">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TradeAndOtherCurrentPayablesAbstract" xlink:label="loc_ifrs-full_TradeAndOtherCurrentPayablesAbstract_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers" xlink:label="loc_ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AccrualsClassifiedAsCurrent" xlink:label="loc_ifrs-full_AccrualsClassifiedAsCurrent_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TradeAndOtherCurrentPayables" xlink:label="loc_ifrs-full_TradeAndOtherCurrentPayables_3"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TradeAndOtherCurrentPayablesAbstract_0" xlink:to="loc_ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TradeAndOtherCurrentPayablesAbstract_0" xlink:to="loc_ifrs-full_AccrualsClassifiedAsCurrent_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TradeAndOtherCurrentPayablesAbstract_0" xlink:to="loc_ifrs-full_TradeAndOtherCurrentPayables_3" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://brightmindsbio.com/role/NATUREANDCONTINUANCEOFOPERATIONS">
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_NatureAndContinuanceOfOperationsAbstract" xlink:label="loc_drug_NatureAndContinuanceOfOperationsAbstract_0"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_DisclosureOfNatureAndContinuanceOfOperationsExplanatory" xlink:label="loc_drug_DisclosureOfNatureAndContinuanceOfOperationsExplanatory_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_drug_NatureAndContinuanceOfOperationsAbstract_0" xlink:to="loc_drug_DisclosureOfNatureAndContinuanceOfOperationsExplanatory_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://brightmindsbio.com/role/NATUREANDCONTINUANCEOFOPERATIONSDetailTextuals">
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_NatureAndContinuanceOfOperationsAbstract" xlink:label="loc_drug_NatureAndContinuanceOfOperationsAbstract_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ProfitLoss" xlink:label="loc_ifrs-full_ProfitLoss_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_RetainedEarnings" xlink:label="loc_ifrs-full_RetainedEarnings_2"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_WorkingCapital" xlink:label="loc_drug_WorkingCapital_3"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_drug_NatureAndContinuanceOfOperationsAbstract_0" xlink:to="loc_ifrs-full_ProfitLoss_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_drug_NatureAndContinuanceOfOperationsAbstract_0" xlink:to="loc_ifrs-full_RetainedEarnings_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_drug_NatureAndContinuanceOfOperationsAbstract_0" xlink:to="loc_drug_WorkingCapital_3" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://brightmindsbio.com/role/STATEMENTOFCOMPLIANCEANDBASISOFPREPARATION">
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_StatementOfComplianceAndBasisOfPreparationAbstract" xlink:label="loc_drug_StatementOfComplianceAndBasisOfPreparationAbstract_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory" xlink:label="loc_ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_drug_StatementOfComplianceAndBasisOfPreparationAbstract_0" xlink:to="loc_ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://brightmindsbio.com/role/SUBSEQUENTEVENTS">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract" xlink:label="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory" xlink:label="loc_ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract_0" xlink:to="loc_ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://brightmindsbio.com/role/SUBSEQUENTEVENTSDetailTextuals">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract" xlink:label="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable" xlink:label="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:label="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NonadjustingEventsMember" xlink:label="loc_ifrs-full_NonadjustingEventsMember_1"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_SubsequentEventsMember" xlink:label="loc_drug_SubsequentEventsMember_1"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_TypeOfArrangementsAxis" xlink:label="loc_drug_TypeOfArrangementsAxis_4"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_ArrangementsAndNonarrangementTransactionDomain" xlink:label="loc_drug_ArrangementsAndNonarrangementTransactionDomain_4"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_LetterAgreementMember" xlink:label="loc_drug_LetterAgreementMember_4"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_TranchesAxis" xlink:label="loc_drug_TranchesAxis_7"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_TranchesDomain" xlink:label="loc_drug_TranchesDomain_7"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_FirstTrancheMember" xlink:label="loc_drug_FirstTrancheMember_7"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_SecondTrancheMember" xlink:label="loc_drug_SecondTrancheMember_8"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_ThirdTrancheMember" xlink:label="loc_drug_ThirdTrancheMember_9"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems" xlink:label="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_12"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_AmountOfNonRefundableMonthlyRetainerAsServiceCompensation" xlink:label="loc_drug_AmountOfNonRefundableMonthlyRetainerAsServiceCompensation_12"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_NumberOfRestrictedStockIssuedForCompensation" xlink:label="loc_drug_NumberOfRestrictedStockIssuedForCompensation_13"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_TermsOfContract" xlink:label="loc_drug_TermsOfContract_14"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_NumberOfWarrantsExercised" xlink:label="loc_drug_NumberOfWarrantsExercised_15"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_GrossProceedsFromWarrantsExercised" xlink:label="loc_drug_GrossProceedsFromWarrantsExercised_16"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract_0" xlink:to="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable_1" xlink:to="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_1" xlink:to="loc_ifrs-full_NonadjustingEventsMember_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_NonadjustingEventsMember_1" xlink:to="loc_drug_SubsequentEventsMember_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable_1" xlink:to="loc_drug_TypeOfArrangementsAxis_4" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_drug_TypeOfArrangementsAxis_4" xlink:to="loc_drug_ArrangementsAndNonarrangementTransactionDomain_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_drug_ArrangementsAndNonarrangementTransactionDomain_4" xlink:to="loc_drug_LetterAgreementMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable_1" xlink:to="loc_drug_TranchesAxis_7" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_drug_TranchesAxis_7" xlink:to="loc_drug_TranchesDomain_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_drug_TranchesDomain_7" xlink:to="loc_drug_FirstTrancheMember_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_drug_TranchesDomain_7" xlink:to="loc_drug_SecondTrancheMember_8" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_drug_TranchesDomain_7" xlink:to="loc_drug_ThirdTrancheMember_9" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable_1" xlink:to="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_12" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_12" xlink:to="loc_drug_AmountOfNonRefundableMonthlyRetainerAsServiceCompensation_12" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_12" xlink:to="loc_drug_NumberOfRestrictedStockIssuedForCompensation_13" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_12" xlink:to="loc_drug_TermsOfContract_14" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_12" xlink:to="loc_drug_NumberOfWarrantsExercised_15" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_12" xlink:to="loc_drug_GrossProceedsFromWarrantsExercised_16" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://brightmindsbio.com/role/RESEARCHANDDEVELOPMENTTables">
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_ResearchAndDevelopmentAbstract" xlink:label="loc_drug_ResearchAndDevelopmentAbstract_0"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_DisclosureOfDetailedInformationAboutResearchAndDevelopmentExplanatory" xlink:label="loc_drug_DisclosureOfDetailedInformationAboutResearchAndDevelopmentExplanatory_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_drug_ResearchAndDevelopmentAbstract_0" xlink:to="loc_drug_DisclosureOfDetailedInformationAboutResearchAndDevelopmentExplanatory_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://brightmindsbio.com/role/RESEARCHANDDEVELOPMENT">
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_ResearchAndDevelopmentAbstract" xlink:label="loc_drug_ResearchAndDevelopmentAbstract_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfResearchAndDevelopmentExpenseExplanatory" xlink:label="loc_ifrs-full_DisclosureOfResearchAndDevelopmentExpenseExplanatory_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_drug_ResearchAndDevelopmentAbstract_0" xlink:to="loc_ifrs-full_DisclosureOfResearchAndDevelopmentExpenseExplanatory_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://brightmindsbio.com/role/RESEARCHANDDEVELOPMENTDetails">
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_ResearchAndDevelopmentAbstract" xlink:label="loc_drug_ResearchAndDevelopmentAbstract_0"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_ResearchDevelopmentTable" xlink:label="loc_drug_ResearchDevelopmentTable_1"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_CategoriesOfResearchAndDevelopmentExpensesAxis" xlink:label="loc_drug_CategoriesOfResearchAndDevelopmentExpensesAxis_1"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_CategoriesOfResearchAndDevelopmentExpensesDomain" xlink:label="loc_drug_CategoriesOfResearchAndDevelopmentExpensesDomain_1"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_LaboratoryCostsMember" xlink:label="loc_drug_LaboratoryCostsMember_1"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_NovelDrugDevelopmentMember" xlink:label="loc_drug_NovelDrugDevelopmentMember_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CopyrightsPatentsAndOtherIndustrialPropertyRightsServiceAndOperatingRightsMember" xlink:label="loc_ifrs-full_CopyrightsPatentsAndOtherIndustrialPropertyRightsServiceAndOperatingRightsMember_3"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_SalaryAndSubcontractorsMember" xlink:label="loc_drug_SalaryAndSubcontractorsMember_4"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_ShareBasedCompensationMember" xlink:label="loc_drug_ShareBasedCompensationMember_5"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_ResearchAndDevelopmentLineItems" xlink:label="loc_drug_ResearchAndDevelopmentLineItems_8"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ResearchAndDevelopmentExpense" xlink:label="loc_ifrs-full_ResearchAndDevelopmentExpense_8"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_drug_ResearchAndDevelopmentAbstract_0" xlink:to="loc_drug_ResearchDevelopmentTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_drug_ResearchDevelopmentTable_1" xlink:to="loc_drug_CategoriesOfResearchAndDevelopmentExpensesAxis_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_drug_CategoriesOfResearchAndDevelopmentExpensesAxis_1" xlink:to="loc_drug_CategoriesOfResearchAndDevelopmentExpensesDomain_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_drug_CategoriesOfResearchAndDevelopmentExpensesDomain_1" xlink:to="loc_drug_LaboratoryCostsMember_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_drug_CategoriesOfResearchAndDevelopmentExpensesDomain_1" xlink:to="loc_drug_NovelDrugDevelopmentMember_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_drug_CategoriesOfResearchAndDevelopmentExpensesDomain_1" xlink:to="loc_ifrs-full_CopyrightsPatentsAndOtherIndustrialPropertyRightsServiceAndOperatingRightsMember_3" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_drug_CategoriesOfResearchAndDevelopmentExpensesDomain_1" xlink:to="loc_drug_SalaryAndSubcontractorsMember_4" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_drug_CategoriesOfResearchAndDevelopmentExpensesDomain_1" xlink:to="loc_drug_ShareBasedCompensationMember_5" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_drug_ResearchDevelopmentTable_1" xlink:to="loc_drug_ResearchAndDevelopmentLineItems_8" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_drug_ResearchAndDevelopmentLineItems_8" xlink:to="loc_ifrs-full_ResearchAndDevelopmentExpense_8" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://brightmindsbio.com/role/SIGNIFICANTACCOUNTINGPOLICIESDetailTextuals">
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_DisclosureOfDetailedInformationAboutSignificantAccountingPoliciesAbstract" xlink:label="loc_drug_DisclosureOfDetailedInformationAboutSignificantAccountingPoliciesAbstract_0"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://brightmindsbio.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies">
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_DisclosureOfDetailedInformationAboutSignificantAccountingPoliciesAbstract" xlink:label="loc_drug_DisclosureOfDetailedInformationAboutSignificantAccountingPoliciesAbstract_0"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_DescriptionOfAccountingPolicyForBasisOfConsolidationExplanatory" xlink:label="loc_drug_DescriptionOfAccountingPolicyForBasisOfConsolidationExplanatory_1"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_DescriptionOfAccountingPolicyForCriticalAccountingEstimatesExplanatory" xlink:label="loc_drug_DescriptionOfAccountingPolicyForCriticalAccountingEstimatesExplanatory_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory_3"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DescriptionOfAccountingPolicyForBusinessCombinationsExplanatory" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForBusinessCombinationsExplanatory_4"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory_5"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory_6"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory_7"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory_8"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory_9"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DescriptionOfAccountingPolicyForIssuedCapitalExplanatory" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForIssuedCapitalExplanatory_10"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory_11"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory_12"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_DescriptionOfAccountingPolicyForNewStandardsAndInterpretationsNotYetAdoptedExplanatory" xlink:label="loc_drug_DescriptionOfAccountingPolicyForNewStandardsAndInterpretationsNotYetAdoptedExplanatory_13"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_drug_DisclosureOfDetailedInformationAboutSignificantAccountingPoliciesAbstract_0" xlink:to="loc_drug_DescriptionOfAccountingPolicyForBasisOfConsolidationExplanatory_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_drug_DisclosureOfDetailedInformationAboutSignificantAccountingPoliciesAbstract_0" xlink:to="loc_drug_DescriptionOfAccountingPolicyForCriticalAccountingEstimatesExplanatory_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_drug_DisclosureOfDetailedInformationAboutSignificantAccountingPoliciesAbstract_0" xlink:to="loc_ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory_3" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_drug_DisclosureOfDetailedInformationAboutSignificantAccountingPoliciesAbstract_0" xlink:to="loc_ifrs-full_DescriptionOfAccountingPolicyForBusinessCombinationsExplanatory_4" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_drug_DisclosureOfDetailedInformationAboutSignificantAccountingPoliciesAbstract_0" xlink:to="loc_ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory_5" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_drug_DisclosureOfDetailedInformationAboutSignificantAccountingPoliciesAbstract_0" xlink:to="loc_ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory_6" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_drug_DisclosureOfDetailedInformationAboutSignificantAccountingPoliciesAbstract_0" xlink:to="loc_ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory_7" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_drug_DisclosureOfDetailedInformationAboutSignificantAccountingPoliciesAbstract_0" xlink:to="loc_ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory_8" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_drug_DisclosureOfDetailedInformationAboutSignificantAccountingPoliciesAbstract_0" xlink:to="loc_ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory_9" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_drug_DisclosureOfDetailedInformationAboutSignificantAccountingPoliciesAbstract_0" xlink:to="loc_ifrs-full_DescriptionOfAccountingPolicyForIssuedCapitalExplanatory_10" order="90" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_drug_DisclosureOfDetailedInformationAboutSignificantAccountingPoliciesAbstract_0" xlink:to="loc_ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory_11" order="100" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_drug_DisclosureOfDetailedInformationAboutSignificantAccountingPoliciesAbstract_0" xlink:to="loc_ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory_12" order="110" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_drug_DisclosureOfDetailedInformationAboutSignificantAccountingPoliciesAbstract_0" xlink:to="loc_drug_DescriptionOfAccountingPolicyForNewStandardsAndInterpretationsNotYetAdoptedExplanatory_13" order="120" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://brightmindsbio.com/role/SIGNIFICANTACCOUNTINGPOLICIES">
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_DisclosureOfDetailedInformationAboutSignificantAccountingPoliciesAbstract" xlink:label="loc_drug_DisclosureOfDetailedInformationAboutSignificantAccountingPoliciesAbstract_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory" xlink:label="loc_ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_drug_DisclosureOfDetailedInformationAboutSignificantAccountingPoliciesAbstract_0" xlink:to="loc_ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://brightmindsbio.com/role/FINANCIALINSTRUMENTSANDCAPITALMANAGEMENT">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfFinancialInstrumentsAbstract" xlink:label="loc_ifrs-full_DisclosureOfFinancialInstrumentsAbstract_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfFinancialInstrumentsExplanatory" xlink:label="loc_ifrs-full_DisclosureOfFinancialInstrumentsExplanatory_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsAbstract_0" xlink:to="loc_ifrs-full_DisclosureOfFinancialInstrumentsExplanatory_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://brightmindsbio.com/role/FINANCIALINSTRUMENTSANDCAPITALMANAGEMENTTables">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfFinancialInstrumentsAbstract" xlink:label="loc_ifrs-full_DisclosureOfFinancialInstrumentsAbstract_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsAbstract_0" xlink:to="loc_ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://brightmindsbio.com/role/FINANCIALINSTRUMENTSANDCAPITALMANAGEMENTDetails">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfFinancialInstrumentsAbstract" xlink:label="loc_ifrs-full_DisclosureOfFinancialInstrumentsAbstract_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfFinancialInstrumentsTable" xlink:label="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:label="loc_ifrs-full_ClassesOfFinancialInstrumentsAxis_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ClassesOfFinancialInstrumentsMember" xlink:label="loc_ifrs-full_ClassesOfFinancialInstrumentsMember_1"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_FinancialInstrumentsAtFairValueThroughProfitOrLossMember" xlink:label="loc_drug_FinancialInstrumentsAtFairValueThroughProfitOrLossMember_1"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_FinancialInstrumentsAtAmortizedCostMember" xlink:label="loc_drug_FinancialInstrumentsAtAmortizedCostMember_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:label="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_5"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CurrentFinancialAssetsAtFairValueThroughProfitOrLossAbstract" xlink:label="loc_ifrs-full_CurrentFinancialAssetsAtFairValueThroughProfitOrLossAbstract_5"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_Cash" xlink:label="loc_ifrs-full_Cash_5"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ShorttermInvestmentsClassifiedAsCashEquivalents" xlink:label="loc_ifrs-full_ShorttermInvestmentsClassifiedAsCashEquivalents_6"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CashAndCashEquivalents" xlink:label="loc_ifrs-full_CashAndCashEquivalents_7"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CategoriesOfFinancialLiabilitiesAbstract" xlink:label="loc_ifrs-full_CategoriesOfFinancialLiabilitiesAbstract_9"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TradeAndOtherCurrentPayables" xlink:label="loc_ifrs-full_TradeAndOtherCurrentPayables_9"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsAbstract_0" xlink:to="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_1" xlink:to="loc_ifrs-full_ClassesOfFinancialInstrumentsAxis_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfFinancialInstrumentsAxis_1" xlink:to="loc_ifrs-full_ClassesOfFinancialInstrumentsMember_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfFinancialInstrumentsMember_1" xlink:to="loc_drug_FinancialInstrumentsAtFairValueThroughProfitOrLossMember_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfFinancialInstrumentsMember_1" xlink:to="loc_drug_FinancialInstrumentsAtAmortizedCostMember_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_1" xlink:to="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_5" xlink:to="loc_ifrs-full_CurrentFinancialAssetsAtFairValueThroughProfitOrLossAbstract_5" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CurrentFinancialAssetsAtFairValueThroughProfitOrLossAbstract_5" xlink:to="loc_ifrs-full_Cash_5" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CurrentFinancialAssetsAtFairValueThroughProfitOrLossAbstract_5" xlink:to="loc_ifrs-full_ShorttermInvestmentsClassifiedAsCashEquivalents_6" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CurrentFinancialAssetsAtFairValueThroughProfitOrLossAbstract_5" xlink:to="loc_ifrs-full_CashAndCashEquivalents_7" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_5" xlink:to="loc_ifrs-full_CategoriesOfFinancialLiabilitiesAbstract_9" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CategoriesOfFinancialLiabilitiesAbstract_9" xlink:to="loc_ifrs-full_TradeAndOtherCurrentPayables_9" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://brightmindsbio.com/role/FINANCIALINSTRUMENTSANDCAPITALMANAGEMENTDetailTextuals">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfFinancialInstrumentsAbstract" xlink:label="loc_ifrs-full_DisclosureOfFinancialInstrumentsAbstract_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfFinancialInstrumentsTable" xlink:label="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TypesOfRisksAxis" xlink:label="loc_ifrs-full_TypesOfRisksAxis_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TypesOfRisksMember" xlink:label="loc_ifrs-full_TypesOfRisksMember_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CreditRiskMember" xlink:label="loc_ifrs-full_CreditRiskMember_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CurrencyRiskMember" xlink:label="loc_ifrs-full_CurrencyRiskMember_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_LiquidityRiskMember" xlink:label="loc_ifrs-full_LiquidityRiskMember_3"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:label="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_6"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CashAndCashEquivalents" xlink:label="loc_ifrs-full_CashAndCashEquivalents_6"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_Cash" xlink:label="loc_ifrs-full_Cash_7"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TradeAndOtherCurrentPayables" xlink:label="loc_ifrs-full_TradeAndOtherCurrentPayables_8"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_PercentageOfForeignCurrencyFluctuationInUsDollarAgainstCanadianDollar" xlink:label="loc_drug_PercentageOfForeignCurrencyFluctuationInUsDollarAgainstCanadianDollar_9"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ValueAtRisk" xlink:label="loc_ifrs-full_ValueAtRisk_10"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsAbstract_0" xlink:to="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_1" xlink:to="loc_ifrs-full_TypesOfRisksAxis_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfRisksAxis_1" xlink:to="loc_ifrs-full_TypesOfRisksMember_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfRisksMember_1" xlink:to="loc_ifrs-full_CreditRiskMember_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfRisksMember_1" xlink:to="loc_ifrs-full_CurrencyRiskMember_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfRisksMember_1" xlink:to="loc_ifrs-full_LiquidityRiskMember_3" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_1" xlink:to="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_6" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_6" xlink:to="loc_ifrs-full_CashAndCashEquivalents_6" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_6" xlink:to="loc_ifrs-full_Cash_7" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_6" xlink:to="loc_ifrs-full_TradeAndOtherCurrentPayables_8" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_6" xlink:to="loc_drug_PercentageOfForeignCurrencyFluctuationInUsDollarAgainstCanadianDollar_9" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_6" xlink:to="loc_ifrs-full_ValueAtRisk_10" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://brightmindsbio.com/role/ConsolidatedStatementsOfComprehensiveLoss">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IncomeStatementAbstract" xlink:label="loc_ifrs-full_IncomeStatementAbstract_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ExpenseByNatureAbstract" xlink:label="loc_ifrs-full_ExpenseByNatureAbstract_1"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_ConsultingFees" xlink:label="loc_drug_ConsultingFees_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DirectorsRemunerationExpense" xlink:label="loc_ifrs-full_DirectorsRemunerationExpense_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss" xlink:label="loc_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss_3"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_ProcessingFees" xlink:label="loc_drug_ProcessingFees_4"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_SalesAndMarketingExpense" xlink:label="loc_ifrs-full_SalesAndMarketingExpense_5"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_GeneralAndAdministrativeExpense" xlink:label="loc_ifrs-full_GeneralAndAdministrativeExpense_6"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ProfessionalFeesExpense" xlink:label="loc_ifrs-full_ProfessionalFeesExpense_7"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_RegulatoryAndFilingExpenses" xlink:label="loc_drug_RegulatoryAndFilingExpenses_8"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ResearchAndDevelopmentExpense" xlink:label="loc_ifrs-full_ResearchAndDevelopmentExpense_9"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ProfitLoss" xlink:label="loc_ifrs-full_ProfitLoss_11"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_BasicAndDilutedEarningsLossPerShare" xlink:label="loc_ifrs-full_BasicAndDilutedEarningsLossPerShare_12"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_WeightedAverageShares" xlink:label="loc_ifrs-full_WeightedAverageShares_13"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeStatementAbstract_0" xlink:to="loc_ifrs-full_ExpenseByNatureAbstract_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ExpenseByNatureAbstract_1" xlink:to="loc_drug_ConsultingFees_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ExpenseByNatureAbstract_1" xlink:to="loc_ifrs-full_DirectorsRemunerationExpense_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ExpenseByNatureAbstract_1" xlink:to="loc_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss_3" order="20" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ExpenseByNatureAbstract_1" xlink:to="loc_drug_ProcessingFees_4" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ExpenseByNatureAbstract_1" xlink:to="loc_ifrs-full_SalesAndMarketingExpense_5" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ExpenseByNatureAbstract_1" xlink:to="loc_ifrs-full_GeneralAndAdministrativeExpense_6" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ExpenseByNatureAbstract_1" xlink:to="loc_ifrs-full_ProfessionalFeesExpense_7" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ExpenseByNatureAbstract_1" xlink:to="loc_drug_RegulatoryAndFilingExpenses_8" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ExpenseByNatureAbstract_1" xlink:to="loc_ifrs-full_ResearchAndDevelopmentExpense_9" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeStatementAbstract_0" xlink:to="loc_ifrs-full_ProfitLoss_11" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeStatementAbstract_0" xlink:to="loc_ifrs-full_BasicAndDilutedEarningsLossPerShare_12" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeStatementAbstract_0" xlink:to="loc_ifrs-full_WeightedAverageShares_13" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://brightmindsbio.com/role/RELATEDPARTYTRANSACTIONS">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract" xlink:label="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfRelatedPartyExplanatory" xlink:label="loc_ifrs-full_DisclosureOfRelatedPartyExplanatory_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract_0" xlink:to="loc_ifrs-full_DisclosureOfRelatedPartyExplanatory_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://brightmindsbio.com/role/RELATEDPARTYTRANSACTIONSTables">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract" xlink:label="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfInformationAboutKeyManagementPersonnelExplanatory" xlink:label="loc_ifrs-full_DisclosureOfInformationAboutKeyManagementPersonnelExplanatory_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract_0" xlink:to="loc_ifrs-full_DisclosureOfInformationAboutKeyManagementPersonnelExplanatory_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://brightmindsbio.com/role/RELATEDPARTYTRANSACTIONSDetails">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract" xlink:label="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract_0"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_KeyManagementPersonnelProfessionalFees" xlink:label="loc_drug_KeyManagementPersonnelProfessionalFees_1"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_KeyManagementPersonnelResearchAndDevelopment" xlink:label="loc_drug_KeyManagementPersonnelResearchAndDevelopment_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment" xlink:label="loc_ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment_3"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_KeyManagementPersonnelCompensationShareBasedPaymentIncludedInProfessionalFees" xlink:label="loc_drug_KeyManagementPersonnelCompensationShareBasedPaymentIncludedInProfessionalFees_4"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_KeyManagementPersonnelCompensationShareBasedPaymentIncludedInResearchAndDevelopment" xlink:label="loc_drug_KeyManagementPersonnelCompensationShareBasedPaymentIncludedInResearchAndDevelopment_5"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_KeyManagementPersonnelCompensation" xlink:label="loc_ifrs-full_KeyManagementPersonnelCompensation_6"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract_0" xlink:to="loc_drug_KeyManagementPersonnelProfessionalFees_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract_0" xlink:to="loc_drug_KeyManagementPersonnelResearchAndDevelopment_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract_0" xlink:to="loc_ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment_3" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract_0" xlink:to="loc_drug_KeyManagementPersonnelCompensationShareBasedPaymentIncludedInProfessionalFees_4" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract_0" xlink:to="loc_drug_KeyManagementPersonnelCompensationShareBasedPaymentIncludedInResearchAndDevelopment_5" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract_0" xlink:to="loc_ifrs-full_KeyManagementPersonnelCompensation_6" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://brightmindsbio.com/role/SHAREEXCHANGEANDASSIGNMENT">
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_ShareExchangeAndAssignmentAbstract" xlink:label="loc_drug_ShareExchangeAndAssignmentAbstract_0"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_DisclosureOfShareExchangeAndAssignmentExplanatory" xlink:label="loc_drug_DisclosureOfShareExchangeAndAssignmentExplanatory_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_drug_ShareExchangeAndAssignmentAbstract_0" xlink:to="loc_drug_DisclosureOfShareExchangeAndAssignmentExplanatory_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://brightmindsbio.com/role/SHAREEXCHANGEANDASSIGNMENTDetailTextuals">
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_ShareExchangeAndAssignmentAbstract" xlink:label="loc_drug_ShareExchangeAndAssignmentAbstract_0"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_DisclosureOfShareExchangeAndAssignmentTable" xlink:label="loc_drug_DisclosureOfShareExchangeAndAssignmentTable_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:label="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:label="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_1"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_PsilocybinlabsLtdMember" xlink:label="loc_drug_PsilocybinlabsLtdMember_1"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_ShareExchangeAndAssignmentLineItems" xlink:label="loc_drug_ShareExchangeAndAssignmentLineItems_4"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_NumberOfSharesIssuedByRelatedParty" xlink:label="loc_drug_NumberOfSharesIssuedByRelatedParty_4"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_ValueOfCommonStockSharesIssuedByRelatedParty" xlink:label="loc_drug_ValueOfCommonStockSharesIssuedByRelatedParty_5"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_CommonStockSharesPurchased" xlink:label="loc_drug_CommonStockSharesPurchased_6"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NumberOfInstrumentsOrInterestsIssuedOrIssuable" xlink:label="loc_ifrs-full_NumberOfInstrumentsOrInterestsIssuedOrIssuable_7"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_EquityInterestsOfAcquirer" xlink:label="loc_ifrs-full_EquityInterestsOfAcquirer_8"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_drug_ShareExchangeAndAssignmentAbstract_0" xlink:to="loc_drug_DisclosureOfShareExchangeAndAssignmentTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_drug_DisclosureOfShareExchangeAndAssignmentTable_1" xlink:to="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_1" xlink:to="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_1" xlink:to="loc_drug_PsilocybinlabsLtdMember_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_drug_DisclosureOfShareExchangeAndAssignmentTable_1" xlink:to="loc_drug_ShareExchangeAndAssignmentLineItems_4" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_drug_ShareExchangeAndAssignmentLineItems_4" xlink:to="loc_drug_NumberOfSharesIssuedByRelatedParty_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_drug_ShareExchangeAndAssignmentLineItems_4" xlink:to="loc_drug_ValueOfCommonStockSharesIssuedByRelatedParty_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_drug_ShareExchangeAndAssignmentLineItems_4" xlink:to="loc_drug_CommonStockSharesPurchased_6" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_drug_ShareExchangeAndAssignmentLineItems_4" xlink:to="loc_ifrs-full_NumberOfInstrumentsOrInterestsIssuedOrIssuable_7" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_drug_ShareExchangeAndAssignmentLineItems_4" xlink:to="loc_ifrs-full_EquityInterestsOfAcquirer_8" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://brightmindsbio.com/role/SHARECAPITALTables">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalAbstract" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalAbstract_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory" xlink:label="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory_1"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_DisclosureOfNumberOfIssuedAndOutstandingStockOptionsExplanatory" xlink:label="loc_drug_DisclosureOfNumberOfIssuedAndOutstandingStockOptionsExplanatory_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory" xlink:label="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory_3"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_DisclosureOfDetailedInformationAboutEquitySettledRestrictedShareUnitsFairValueInputsExplanatory" xlink:label="loc_drug_DisclosureOfDetailedInformationAboutEquitySettledRestrictedShareUnitsFairValueInputsExplanatory_4"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_DisclosureOfDetailedInformationAboutShareBasedPaymentsRecognizedInConsolidatedStatementsOfComprehensiveLossExplanatory" xlink:label="loc_drug_DisclosureOfDetailedInformationAboutShareBasedPaymentsRecognizedInConsolidatedStatementsOfComprehensiveLossExplanatory_5"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_DisclosureOfDetailedInformationAboutShareBasedPaymentsIncludedInConsolidatedStatementsOfComprehensiveLossExplanatory" xlink:label="loc_drug_DisclosureOfDetailedInformationAboutShareBasedPaymentsIncludedInConsolidatedStatementsOfComprehensiveLossExplanatory_6"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_DisclosureOfNumberAndWeightedAverageExercisePricesOfWarrantsExplanatory" xlink:label="loc_drug_DisclosureOfNumberAndWeightedAverageExercisePricesOfWarrantsExplanatory_7"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_DisclosureOfNumberOfIssuedAndOutstandingWarrantsExplanatory" xlink:label="loc_drug_DisclosureOfNumberOfIssuedAndOutstandingWarrantsExplanatory_8"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalAbstract_0" xlink:to="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalAbstract_0" xlink:to="loc_drug_DisclosureOfNumberOfIssuedAndOutstandingStockOptionsExplanatory_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalAbstract_0" xlink:to="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory_3" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalAbstract_0" xlink:to="loc_drug_DisclosureOfDetailedInformationAboutEquitySettledRestrictedShareUnitsFairValueInputsExplanatory_4" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalAbstract_0" xlink:to="loc_drug_DisclosureOfDetailedInformationAboutShareBasedPaymentsRecognizedInConsolidatedStatementsOfComprehensiveLossExplanatory_5" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalAbstract_0" xlink:to="loc_drug_DisclosureOfDetailedInformationAboutShareBasedPaymentsIncludedInConsolidatedStatementsOfComprehensiveLossExplanatory_6" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalAbstract_0" xlink:to="loc_drug_DisclosureOfNumberAndWeightedAverageExercisePricesOfWarrantsExplanatory_7" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalAbstract_0" xlink:to="loc_drug_DisclosureOfNumberOfIssuedAndOutstandingWarrantsExplanatory_8" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://brightmindsbio.com/role/SHARECAPITAL">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalAbstract" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalAbstract_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfIssuedCapitalExplanatory" xlink:label="loc_ifrs-full_DisclosureOfIssuedCapitalExplanatory_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalAbstract_0" xlink:to="loc_ifrs-full_DisclosureOfIssuedCapitalExplanatory_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://brightmindsbio.com/role/SHARECAPITALDetails">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalAbstract" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalAbstract_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalTable" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ClassesOfShareCapitalAxis" xlink:label="loc_ifrs-full_ClassesOfShareCapitalAxis_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ClassesOfShareCapitalMember" xlink:label="loc_ifrs-full_ClassesOfShareCapitalMember_1"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_StockOptionsMember" xlink:label="loc_drug_StockOptionsMember_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_4"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NumberOfOutstandingShareOptions" xlink:label="loc_ifrs-full_NumberOfOutstandingShareOptions_4"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" xlink:label="loc_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement_5"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" xlink:label="loc_ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement_6"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NumberOfOutstandingShareOptions" xlink:label="loc_ifrs-full_NumberOfOutstandingShareOptions_7"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" xlink:label="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_8"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019" xlink:label="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019_9"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019" xlink:label="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019_10"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" xlink:label="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_11"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalAbstract_0" xlink:to="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_1" xlink:to="loc_ifrs-full_ClassesOfShareCapitalAxis_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfShareCapitalAxis_1" xlink:to="loc_ifrs-full_ClassesOfShareCapitalMember_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfShareCapitalMember_1" xlink:to="loc_drug_StockOptionsMember_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_1" xlink:to="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_4" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_4" xlink:to="loc_ifrs-full_NumberOfOutstandingShareOptions_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_4" xlink:to="loc_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_4" xlink:to="loc_ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement_6" order="20" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_4" xlink:to="loc_ifrs-full_NumberOfOutstandingShareOptions_7" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_4" xlink:to="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_8" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_4" xlink:to="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019_9" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_4" xlink:to="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019_10" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_4" xlink:to="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_11" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://brightmindsbio.com/role/SHARECAPITALDetails1">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalAbstract" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalAbstract_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalTable" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ClassesOfShareCapitalAxis" xlink:label="loc_ifrs-full_ClassesOfShareCapitalAxis_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ClassesOfShareCapitalMember" xlink:label="loc_ifrs-full_ClassesOfShareCapitalMember_1"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_StockOptionsMember" xlink:label="loc_drug_StockOptionsMember_1"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_ExpiryDateAxis" xlink:label="loc_drug_ExpiryDateAxis_4"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_ExpiryDateDomain" xlink:label="loc_drug_ExpiryDateDomain_4"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_ExpiryDateTwentyOneSeptemberTwoThousandAndTwentyFourMember" xlink:label="loc_drug_ExpiryDateTwentyOneSeptemberTwoThousandAndTwentyFourMember_4"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_ExpiryDateTwentyThreeJulyTwoThousandAndTwentyFiveMember" xlink:label="loc_drug_ExpiryDateTwentyThreeJulyTwoThousandAndTwentyFiveMember_5"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_ExpiryDateSeventeenNovemberTwoThousandAndTwentyFiveMember" xlink:label="loc_drug_ExpiryDateSeventeenNovemberTwoThousandAndTwentyFiveMember_6"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_ExpiryDateTwentyEightAprilTwoThousandAndTwentySixMember" xlink:label="loc_drug_ExpiryDateTwentyEightAprilTwoThousandAndTwentySixMember_7"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_ExpiryDateFifteenJuneTwoThousandAndTwentySixMember" xlink:label="loc_drug_ExpiryDateFifteenJuneTwoThousandAndTwentySixMember_8"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_11"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NumberOfOutstandingShareOptions" xlink:label="loc_ifrs-full_NumberOfOutstandingShareOptions_11"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" xlink:label="loc_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement_12"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ExercisePriceOfOutstandingShareOptions2019" xlink:label="loc_ifrs-full_ExercisePriceOfOutstandingShareOptions2019_13"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" xlink:label="loc_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019_14"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalAbstract_0" xlink:to="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_1" xlink:to="loc_ifrs-full_ClassesOfShareCapitalAxis_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfShareCapitalAxis_1" xlink:to="loc_ifrs-full_ClassesOfShareCapitalMember_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfShareCapitalMember_1" xlink:to="loc_drug_StockOptionsMember_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_1" xlink:to="loc_drug_ExpiryDateAxis_4" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_drug_ExpiryDateAxis_4" xlink:to="loc_drug_ExpiryDateDomain_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_drug_ExpiryDateDomain_4" xlink:to="loc_drug_ExpiryDateTwentyOneSeptemberTwoThousandAndTwentyFourMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_drug_ExpiryDateDomain_4" xlink:to="loc_drug_ExpiryDateTwentyThreeJulyTwoThousandAndTwentyFiveMember_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_drug_ExpiryDateDomain_4" xlink:to="loc_drug_ExpiryDateSeventeenNovemberTwoThousandAndTwentyFiveMember_6" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_drug_ExpiryDateDomain_4" xlink:to="loc_drug_ExpiryDateTwentyEightAprilTwoThousandAndTwentySixMember_7" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_drug_ExpiryDateDomain_4" xlink:to="loc_drug_ExpiryDateFifteenJuneTwoThousandAndTwentySixMember_8" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_1" xlink:to="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_11" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_11" xlink:to="loc_ifrs-full_NumberOfOutstandingShareOptions_11" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_11" xlink:to="loc_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement_12" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_11" xlink:to="loc_ifrs-full_ExercisePriceOfOutstandingShareOptions2019_13" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_11" xlink:to="loc_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019_14" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://brightmindsbio.com/role/SHARECAPITALDetails3">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalAbstract" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalAbstract_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalTable" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ClassesOfShareCapitalAxis" xlink:label="loc_ifrs-full_ClassesOfShareCapitalAxis_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ClassesOfShareCapitalMember" xlink:label="loc_ifrs-full_ClassesOfShareCapitalMember_1"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_RestrictedShareUnitMember" xlink:label="loc_drug_RestrictedShareUnitMember_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_4"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_SharebasedPaymentArrangementsMember" xlink:label="loc_ifrs-full_SharebasedPaymentArrangementsMember_4"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_EquitySettledShareBasedPaymentArrangementsMember" xlink:label="loc_drug_EquitySettledShareBasedPaymentArrangementsMember_4"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_7"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_SharePriceOnGrantDateOfOtherEquityInstruments" xlink:label="loc_drug_SharePriceOnGrantDateOfOtherEquityInstruments_7"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_ForfeitureRateOfOtherEquityInstruments" xlink:label="loc_drug_ForfeitureRateOfOtherEquityInstruments_8"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalAbstract_0" xlink:to="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_1" xlink:to="loc_ifrs-full_ClassesOfShareCapitalAxis_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfShareCapitalAxis_1" xlink:to="loc_ifrs-full_ClassesOfShareCapitalMember_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfShareCapitalMember_1" xlink:to="loc_drug_RestrictedShareUnitMember_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_1" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_4" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_4" xlink:to="loc_ifrs-full_SharebasedPaymentArrangementsMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_4" xlink:to="loc_drug_EquitySettledShareBasedPaymentArrangementsMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_1" xlink:to="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_7" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_7" xlink:to="loc_drug_SharePriceOnGrantDateOfOtherEquityInstruments_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_7" xlink:to="loc_drug_ForfeitureRateOfOtherEquityInstruments_8" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://brightmindsbio.com/role/SHARECAPITALDetails2">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalAbstract" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalAbstract_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalTable" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ClassesOfShareCapitalAxis" xlink:label="loc_ifrs-full_ClassesOfShareCapitalAxis_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ClassesOfShareCapitalMember" xlink:label="loc_ifrs-full_ClassesOfShareCapitalMember_1"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_RestrictedShareUnitMember" xlink:label="loc_drug_RestrictedShareUnitMember_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_4"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_SharebasedPaymentArrangementsMember" xlink:label="loc_ifrs-full_SharebasedPaymentArrangementsMember_4"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_EquitySettledShareBasedPaymentArrangementsMember" xlink:label="loc_drug_EquitySettledShareBasedPaymentArrangementsMember_4"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_CashSettledShareBasedPaymentArrangementsMember" xlink:label="loc_drug_CashSettledShareBasedPaymentArrangementsMember_5"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_8"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" xlink:label="loc_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_8"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted" xlink:label="loc_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted_9"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" xlink:label="loc_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement_10"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" xlink:label="loc_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_11"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalAbstract_0" xlink:to="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_1" xlink:to="loc_ifrs-full_ClassesOfShareCapitalAxis_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfShareCapitalAxis_1" xlink:to="loc_ifrs-full_ClassesOfShareCapitalMember_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfShareCapitalMember_1" xlink:to="loc_drug_RestrictedShareUnitMember_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_1" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_4" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_4" xlink:to="loc_ifrs-full_SharebasedPaymentArrangementsMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_4" xlink:to="loc_drug_EquitySettledShareBasedPaymentArrangementsMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_4" xlink:to="loc_drug_CashSettledShareBasedPaymentArrangementsMember_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_1" xlink:to="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_8" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_8" xlink:to="loc_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_8" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_8" xlink:to="loc_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted_9" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_8" xlink:to="loc_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement_10" order="20" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_8" xlink:to="loc_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_11" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://brightmindsbio.com/role/SHARECAPITALDetails4">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalAbstract" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalAbstract_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalTable" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_SharebasedPaymentArrangementsMember" xlink:label="loc_ifrs-full_SharebasedPaymentArrangementsMember_1"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_EquitySettledShareBasedPaymentArrangementsMember" xlink:label="loc_drug_EquitySettledShareBasedPaymentArrangementsMember_1"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_CashSettledShareBasedPaymentArrangementsMember" xlink:label="loc_drug_CashSettledShareBasedPaymentArrangementsMember_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ClassesOfShareCapitalAxis" xlink:label="loc_ifrs-full_ClassesOfShareCapitalAxis_5"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ClassesOfShareCapitalMember" xlink:label="loc_ifrs-full_ClassesOfShareCapitalMember_5"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_StockOptionsMember" xlink:label="loc_drug_StockOptionsMember_5"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_RestrictedShareUnitMember" xlink:label="loc_drug_RestrictedShareUnitMember_6"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_9"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees" xlink:label="loc_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees_9"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalAbstract_0" xlink:to="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_1" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_1" xlink:to="loc_ifrs-full_SharebasedPaymentArrangementsMember_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_1" xlink:to="loc_drug_EquitySettledShareBasedPaymentArrangementsMember_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_1" xlink:to="loc_drug_CashSettledShareBasedPaymentArrangementsMember_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_1" xlink:to="loc_ifrs-full_ClassesOfShareCapitalAxis_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfShareCapitalAxis_5" xlink:to="loc_ifrs-full_ClassesOfShareCapitalMember_5" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfShareCapitalMember_5" xlink:to="loc_drug_StockOptionsMember_5" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfShareCapitalMember_5" xlink:to="loc_drug_RestrictedShareUnitMember_6" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_1" xlink:to="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_9" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_9" xlink:to="loc_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees_9" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://brightmindsbio.com/role/SHARECAPITALDetails7">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalAbstract" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalAbstract_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalTable" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ClassesOfShareCapitalAxis" xlink:label="loc_ifrs-full_ClassesOfShareCapitalAxis_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ClassesOfShareCapitalMember" xlink:label="loc_ifrs-full_ClassesOfShareCapitalMember_1"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_WarrantsMember" xlink:label="loc_drug_WarrantsMember_1"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_ExpiryDateAxis" xlink:label="loc_drug_ExpiryDateAxis_4"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_ExpiryDateDomain" xlink:label="loc_drug_ExpiryDateDomain_4"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_ExpiryDateThirtyJulyTwoThousandAndTwentyFourMember" xlink:label="loc_drug_ExpiryDateThirtyJulyTwoThousandAndTwentyFourMember_4"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_ExpiryDateSeventeenMarchTwoThousandAndTwentyFourOneMember" xlink:label="loc_drug_ExpiryDateSeventeenMarchTwoThousandAndTwentyFourOneMember_5"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_ExpiryDateSeventeenMarchTwoThousandAndTwentyFourTwoMember" xlink:label="loc_drug_ExpiryDateSeventeenMarchTwoThousandAndTwentyFourTwoMember_6"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_9"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_NumberOfWarrantsOutstanding" xlink:label="loc_drug_NumberOfWarrantsOutstanding_9"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_WeightedAverageExercisePriceOfWarrantsOutstandingInShareBasedPaymentArrangement" xlink:label="loc_drug_WeightedAverageExercisePriceOfWarrantsOutstandingInShareBasedPaymentArrangement_10"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_WeightedAverageRemainingContractualLifeOfWarrants" xlink:label="loc_drug_WeightedAverageRemainingContractualLifeOfWarrants_11"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalAbstract_0" xlink:to="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_1" xlink:to="loc_ifrs-full_ClassesOfShareCapitalAxis_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfShareCapitalAxis_1" xlink:to="loc_ifrs-full_ClassesOfShareCapitalMember_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfShareCapitalMember_1" xlink:to="loc_drug_WarrantsMember_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_1" xlink:to="loc_drug_ExpiryDateAxis_4" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_drug_ExpiryDateAxis_4" xlink:to="loc_drug_ExpiryDateDomain_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_drug_ExpiryDateDomain_4" xlink:to="loc_drug_ExpiryDateThirtyJulyTwoThousandAndTwentyFourMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_drug_ExpiryDateDomain_4" xlink:to="loc_drug_ExpiryDateSeventeenMarchTwoThousandAndTwentyFourOneMember_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_drug_ExpiryDateDomain_4" xlink:to="loc_drug_ExpiryDateSeventeenMarchTwoThousandAndTwentyFourTwoMember_6" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_1" xlink:to="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_9" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_9" xlink:to="loc_drug_NumberOfWarrantsOutstanding_9" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_9" xlink:to="loc_drug_WeightedAverageExercisePriceOfWarrantsOutstandingInShareBasedPaymentArrangement_10" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_9" xlink:to="loc_drug_WeightedAverageRemainingContractualLifeOfWarrants_11" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://brightmindsbio.com/role/SHARECAPITALDetails6">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalAbstract" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalAbstract_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalTable" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ClassesOfShareCapitalAxis" xlink:label="loc_ifrs-full_ClassesOfShareCapitalAxis_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ClassesOfShareCapitalMember" xlink:label="loc_ifrs-full_ClassesOfShareCapitalMember_1"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_WarrantsMember" xlink:label="loc_drug_WarrantsMember_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_4"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_NumberOfWarrantsOutstanding" xlink:label="loc_drug_NumberOfWarrantsOutstanding_4"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_NumberOfWarrantsIssued" xlink:label="loc_drug_NumberOfWarrantsIssued_5"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_NumberOfWarrantsIssuedToBroker" xlink:label="loc_drug_NumberOfWarrantsIssuedToBroker_6"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_NumberOfWarrantsExercised" xlink:label="loc_drug_NumberOfWarrantsExercised_7"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_NumberOfWarrantsOutstanding" xlink:label="loc_drug_NumberOfWarrantsOutstanding_8"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_WeightedAverageExercisePriceOfWarrantsOutstandingInShareBasedPaymentArrangement" xlink:label="loc_drug_WeightedAverageExercisePriceOfWarrantsOutstandingInShareBasedPaymentArrangement_9"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_WeightedAverageExercisePriceOfWarrantsIssuedInShareBasedPaymentArrangement" xlink:label="loc_drug_WeightedAverageExercisePriceOfWarrantsIssuedInShareBasedPaymentArrangement_10"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_WeightedAverageExercisePriceOfWarrantsIssuedToBrokerInShareBasedPaymentArrangement" xlink:label="loc_drug_WeightedAverageExercisePriceOfWarrantsIssuedToBrokerInShareBasedPaymentArrangement_11"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_WeightedAverageExercisePriceOfWarrantsExercisedInShareBasedPaymentArrangement" xlink:label="loc_drug_WeightedAverageExercisePriceOfWarrantsExercisedInShareBasedPaymentArrangement_12"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_WeightedAverageExercisePriceOfWarrantsOutstandingInShareBasedPaymentArrangement" xlink:label="loc_drug_WeightedAverageExercisePriceOfWarrantsOutstandingInShareBasedPaymentArrangement_13"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalAbstract_0" xlink:to="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_1" xlink:to="loc_ifrs-full_ClassesOfShareCapitalAxis_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfShareCapitalAxis_1" xlink:to="loc_ifrs-full_ClassesOfShareCapitalMember_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfShareCapitalMember_1" xlink:to="loc_drug_WarrantsMember_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_1" xlink:to="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_4" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_4" xlink:to="loc_drug_NumberOfWarrantsOutstanding_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_4" xlink:to="loc_drug_NumberOfWarrantsIssued_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_4" xlink:to="loc_drug_NumberOfWarrantsIssuedToBroker_6" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_4" xlink:to="loc_drug_NumberOfWarrantsExercised_7" order="30" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_4" xlink:to="loc_drug_NumberOfWarrantsOutstanding_8" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_4" xlink:to="loc_drug_WeightedAverageExercisePriceOfWarrantsOutstandingInShareBasedPaymentArrangement_9" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_4" xlink:to="loc_drug_WeightedAverageExercisePriceOfWarrantsIssuedInShareBasedPaymentArrangement_10" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_4" xlink:to="loc_drug_WeightedAverageExercisePriceOfWarrantsIssuedToBrokerInShareBasedPaymentArrangement_11" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_4" xlink:to="loc_drug_WeightedAverageExercisePriceOfWarrantsExercisedInShareBasedPaymentArrangement_12" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_4" xlink:to="loc_drug_WeightedAverageExercisePriceOfWarrantsOutstandingInShareBasedPaymentArrangement_13" order="90" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://brightmindsbio.com/role/SHARECAPITALDetailTextuals">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalAbstract" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalAbstract_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalTable" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_1"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_AgreementAxis" xlink:label="loc_drug_AgreementAxis_1"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_AgreementDomain" xlink:label="loc_drug_AgreementDomain_1"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_DebtSettlementAgreementMember" xlink:label="loc_drug_DebtSettlementAgreementMember_1"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_EscrowAgreementMember" xlink:label="loc_drug_EscrowAgreementMember_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srt_TitleOfIndividualAxis_5"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_5"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ChiefExecutiveOfficerMember" xlink:label="loc_srt_ChiefExecutiveOfficerMember_5"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_ChiefMedicalOfficerMember" xlink:label="loc_drug_ChiefMedicalOfficerMember_6"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:label="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_9"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:label="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_9"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_ConsultantMember" xlink:label="loc_drug_ConsultantMember_9"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_UnderwritersMember" xlink:label="loc_drug_UnderwritersMember_10"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_ThreeInvestorsMember" xlink:label="loc_drug_ThreeInvestorsMember_11"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_ChiefFinancialOfficerTwoDirectorsAndSevenConsultantsMember" xlink:label="loc_drug_ChiefFinancialOfficerTwoDirectorsAndSevenConsultantsMember_12"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_ThreeConsultantsMember" xlink:label="loc_drug_ThreeConsultantsMember_13"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_DirectorAndConsultantMember" xlink:label="loc_drug_DirectorAndConsultantMember_14"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_StockOptionAxis" xlink:label="loc_drug_StockOptionAxis_17"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_StockOptionDomain" xlink:label="loc_drug_StockOptionDomain_17"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_StockOptionsOneMember" xlink:label="loc_drug_StockOptionsOneMember_17"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_StockOptionsTwoMember" xlink:label="loc_drug_StockOptionsTwoMember_18"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_StockOptionsThreeMember" xlink:label="loc_drug_StockOptionsThreeMember_19"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_StockOptionsFourMember" xlink:label="loc_drug_StockOptionsFourMember_20"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ClassesOfShareCapitalAxis" xlink:label="loc_ifrs-full_ClassesOfShareCapitalAxis_23"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ClassesOfShareCapitalMember" xlink:label="loc_ifrs-full_ClassesOfShareCapitalMember_23"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_SecondTrancheOfNonBrokeredPrivatePlacementMember" xlink:label="loc_drug_SecondTrancheOfNonBrokeredPrivatePlacementMember_23"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_SpecialWarrantsMember" xlink:label="loc_drug_SpecialWarrantsMember_24"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_WarrantsMember" xlink:label="loc_drug_WarrantsMember_25"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_EscrowedSharePurchaseWarrantsMember" xlink:label="loc_drug_EscrowedSharePurchaseWarrantsMember_26"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_FirstTrancheOfNonBrokeredPrivatePlacementMember" xlink:label="loc_drug_FirstTrancheOfNonBrokeredPrivatePlacementMember_27"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_NonBrokeredPrivatePlacementMember" xlink:label="loc_drug_NonBrokeredPrivatePlacementMember_28"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_StockOptionsMember" xlink:label="loc_drug_StockOptionsMember_29"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_RestrictedShareUnitMember" xlink:label="loc_drug_RestrictedShareUnitMember_30"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_EscrowedSecuritiesMember" xlink:label="loc_drug_EscrowedSecuritiesMember_31"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_34"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_34"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_BritishColumbiaSecuritiesCommissionMember" xlink:label="loc_drug_BritishColumbiaSecuritiesCommissionMember_34"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_VestingsAxis" xlink:label="loc_drug_VestingsAxis_37"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_VestingDomain" xlink:label="loc_drug_VestingDomain_37"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_FirstTrancheMember" xlink:label="loc_drug_FirstTrancheMember_37"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_SecondTrancheMember" xlink:label="loc_drug_SecondTrancheMember_38"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_ThirdTrancheMember" xlink:label="loc_drug_ThirdTrancheMember_39"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_FourthTrancheMember" xlink:label="loc_drug_FourthTrancheMember_40"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_FifthTrancheMember" xlink:label="loc_drug_FifthTrancheMember_41"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_SixthTrancheMember" xlink:label="loc_drug_SixthTrancheMember_42"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_SeventhTrancheMember" xlink:label="loc_drug_SeventhTrancheMember_43"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_EighthTrancheMember" xlink:label="loc_drug_EighthTrancheMember_44"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_NinthTrancheMember" xlink:label="loc_drug_NinthTrancheMember_45"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_TenthTrancheMember" xlink:label="loc_drug_TenthTrancheMember_46"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_EleventhTrancheMember" xlink:label="loc_drug_EleventhTrancheMember_47"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_TwelfthTrancheMember" xlink:label="loc_drug_TwelfthTrancheMember_48"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_ThirteenthTrancheMember" xlink:label="loc_drug_ThirteenthTrancheMember_49"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_FourteenthTrancheMember" xlink:label="loc_drug_FourteenthTrancheMember_50"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_FifteenthTrancheMember" xlink:label="loc_drug_FifteenthTrancheMember_51"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_54"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_DescriptionOfIssuedAndOutstandingCommonShares" xlink:label="loc_drug_DescriptionOfIssuedAndOutstandingCommonShares_54"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NumberOfSharesIssued" xlink:label="loc_ifrs-full_NumberOfSharesIssued_55"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IncreaseDecreaseInNumberOfSharesOutstanding" xlink:label="loc_ifrs-full_IncreaseDecreaseInNumberOfSharesOutstanding_56"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_IssuePricePerShare" xlink:label="loc_drug_IssuePricePerShare_57"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_ProceedsForWarrantsIssued" xlink:label="loc_drug_ProceedsForWarrantsIssued_58"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ProceedsFromIssueOfOrdinaryShares" xlink:label="loc_ifrs-full_ProceedsFromIssueOfOrdinaryShares_59"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_DebtSettledThroughIssuanceOfShares" xlink:label="loc_drug_DebtSettledThroughIssuanceOfShares_60"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_NumberOfWarrantsDeemedToBeExercised" xlink:label="loc_drug_NumberOfWarrantsDeemedToBeExercised_61"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_NumberOfWarrantsIssued" xlink:label="loc_drug_NumberOfWarrantsIssued_62"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_WarrantsIssuedPricePerWarrant" xlink:label="loc_drug_WarrantsIssuedPricePerWarrant_63"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_GrossProceedsFromWarrantsIssued" xlink:label="loc_drug_GrossProceedsFromWarrantsIssued_64"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_NumberOfUnitsIssued" xlink:label="loc_drug_NumberOfUnitsIssued_65"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_UnitsIssuedPricePerUnit" xlink:label="loc_drug_UnitsIssuedPricePerUnit_66"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_GrossProceedsFromUnitsIssued" xlink:label="loc_drug_GrossProceedsFromUnitsIssued_67"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_WeightedAverageExercisePriceOfWarrantsIssuedInShareBasedPaymentArrangement" xlink:label="loc_drug_WeightedAverageExercisePriceOfWarrantsIssuedInShareBasedPaymentArrangement_68"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_WeightedAverageExercisePriceOfWarrantsOutstandingInShareBasedPaymentArrangement" xlink:label="loc_drug_WeightedAverageExercisePriceOfWarrantsOutstandingInShareBasedPaymentArrangement_69"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_MinimumDailyVolumeWeightedAverageTradingSharePrice" xlink:label="loc_drug_MinimumDailyVolumeWeightedAverageTradingSharePrice_70"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_WeightedAverageTradingPriceOfCommonSharesOnCanadianStockExchange" xlink:label="loc_drug_WeightedAverageTradingPriceOfCommonSharesOnCanadianStockExchange_71"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_UnderwritersFeesPaid" xlink:label="loc_drug_UnderwritersFeesPaid_72"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_IncreaseDecreaseThroughSharesIssuedToUniversityShares" xlink:label="loc_drug_IncreaseDecreaseThroughSharesIssuedToUniversityShares_73"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_IncreaseDecreaseThroughSharesIssuedToUniversity" xlink:label="loc_drug_IncreaseDecreaseThroughSharesIssuedToUniversity_74"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_NumberOfCommonSharesCalledByWarrants" xlink:label="loc_drug_NumberOfCommonSharesCalledByWarrants_75"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_NumberOfWarrantsOutstandingInShareBasedPaymentArrangement" xlink:label="loc_drug_NumberOfWarrantsOutstandingInShareBasedPaymentArrangement_76"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_WarrantAscribedValue" xlink:label="loc_drug_WarrantAscribedValue_77"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_NumberOfRestrictedStockIssuedForCompensation" xlink:label="loc_drug_NumberOfRestrictedStockIssuedForCompensation_78"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_NumberOfWarrantsExercised" xlink:label="loc_drug_NumberOfWarrantsExercised_79"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_WeightedAverageExercisePriceOfWarrantsExercisedInShareBasedPaymentArrangement" xlink:label="loc_drug_WeightedAverageExercisePriceOfWarrantsExercisedInShareBasedPaymentArrangement_80"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_GrossProceedsFromWarrantsExercised" xlink:label="loc_drug_GrossProceedsFromWarrantsExercised_81"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_ContingentCashFee" xlink:label="loc_drug_ContingentCashFee_82"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_PercentageOfNetEquityProceedsReceivedFromThreeInvestors" xlink:label="loc_drug_PercentageOfNetEquityProceedsReceivedFromThreeInvestors_83"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_TermOfWarrant" xlink:label="loc_drug_TermOfWarrant_84"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_SubscriptionsReceived" xlink:label="loc_drug_SubscriptionsReceived_85"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_NumberOfCommonSharesSubscribed" xlink:label="loc_drug_NumberOfCommonSharesSubscribed_86"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_NumberOfIssuedWarrantsRescinded" xlink:label="loc_drug_NumberOfIssuedWarrantsRescinded_87"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_RefundFromIssuedWarrantsRescinded" xlink:label="loc_drug_RefundFromIssuedWarrantsRescinded_88"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_AmountOfEscrowProceedsReleased" xlink:label="loc_drug_AmountOfEscrowProceedsReleased_89"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_PercentageOfOutstandingSharesAuthorizedUnderStockOptionPlan" xlink:label="loc_drug_PercentageOfOutstandingSharesAuthorizedUnderStockOptionPlan_90"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_PercentageOfStockOptionPlanAllowsBoardOfDirectorsToIssue" xlink:label="loc_drug_PercentageOfStockOptionPlanAllowsBoardOfDirectorsToIssue_91"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_AggregatePurchaseWarrantsDeposited" xlink:label="loc_drug_AggregatePurchaseWarrantsDeposited_92"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_NumberOfCommonSharesDepositedToBeHeldInEscrow" xlink:label="loc_drug_NumberOfCommonSharesDepositedToBeHeldInEscrow_93"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_NumberOfWarrantsDepositedToBeHeldInEscrow" xlink:label="loc_drug_NumberOfWarrantsDepositedToBeHeldInEscrow_94"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_AggregateSecuritiesDepositedToBeHeldInEscrow" xlink:label="loc_drug_AggregateSecuritiesDepositedToBeHeldInEscrow_95"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_NumberOfShareListed" xlink:label="loc_drug_NumberOfShareListed_96"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_EscrowedSecuritiesToBeReleasedOnceSharesAreListedOnCanadianStockExchange" xlink:label="loc_drug_EscrowedSecuritiesToBeReleasedOnceSharesAreListedOnCanadianStockExchange_97"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_EscrowedSecuritiesToBeReleasedAfterListingDate" xlink:label="loc_drug_EscrowedSecuritiesToBeReleasedAfterListingDate_98"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_PercentageOfStockOptionShareGranted" xlink:label="loc_drug_PercentageOfStockOptionShareGranted_99"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" xlink:label="loc_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement_100"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_VestingPercentage" xlink:label="loc_drug_VestingPercentage_101"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ExercisePriceShareOptionsGranted2019" xlink:label="loc_ifrs-full_ExercisePriceShareOptionsGranted2019_102"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019" xlink:label="loc_ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019_103"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DescriptionOfOptionLifeShareOptionsGranted" xlink:label="loc_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted_104"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted" xlink:label="loc_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted_105"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_DiscountRateStockOptionGranted" xlink:label="loc_drug_DiscountRateStockOptionGranted_106"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_IssuanceOfRestrictedStockUnits" xlink:label="loc_drug_IssuanceOfRestrictedStockUnits_107"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_EstimatedFairValueOfEquitySettledRsusGranted" xlink:label="loc_drug_EstimatedFairValueOfEquitySettledRsusGranted_108"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_FairValueOfWarrants" xlink:label="loc_drug_FairValueOfWarrants_109"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_ExercisePriceWarrantsGranted" xlink:label="loc_drug_ExercisePriceWarrantsGranted_110"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_WeightedAverageSharePriceWarrantsGranted" xlink:label="loc_drug_WeightedAverageSharePriceWarrantsGranted_111"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_EstimatedLifeOfWarrantsGranted" xlink:label="loc_drug_EstimatedLifeOfWarrantsGranted_112"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_ExpectedVolatilityWarrantsGranted" xlink:label="loc_drug_ExpectedVolatilityWarrantsGranted_113"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_DiscountRateOfWarrantsGranted" xlink:label="loc_drug_DiscountRateOfWarrantsGranted_114"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019" xlink:label="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019_115"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ExercisePriceOfOutstandingShareOptions2019" xlink:label="loc_ifrs-full_ExercisePriceOfOutstandingShareOptions2019_116"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" xlink:label="loc_ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement_117"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" xlink:label="loc_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019_118"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_WeightedAverageRemainingContractualLifeOfOtherEquityInstruments" xlink:label="loc_drug_WeightedAverageRemainingContractualLifeOfOtherEquityInstruments_119"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_ThresholdPercentageOfWarrants" xlink:label="loc_drug_ThresholdPercentageOfWarrants_120"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalAbstract_0" xlink:to="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_1" xlink:to="loc_drug_AgreementAxis_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_drug_AgreementAxis_1" xlink:to="loc_drug_AgreementDomain_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_drug_AgreementDomain_1" xlink:to="loc_drug_DebtSettlementAgreementMember_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_drug_AgreementDomain_1" xlink:to="loc_drug_EscrowAgreementMember_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_1" xlink:to="loc_srt_TitleOfIndividualAxis_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualAxis_5" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_5" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_5" xlink:to="loc_srt_ChiefExecutiveOfficerMember_5" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_5" xlink:to="loc_drug_ChiefMedicalOfficerMember_6" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_1" xlink:to="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_9" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_9" xlink:to="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_9" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_9" xlink:to="loc_drug_ConsultantMember_9" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_9" xlink:to="loc_drug_UnderwritersMember_10" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_9" xlink:to="loc_drug_ThreeInvestorsMember_11" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_9" xlink:to="loc_drug_ChiefFinancialOfficerTwoDirectorsAndSevenConsultantsMember_12" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_9" xlink:to="loc_drug_ThreeConsultantsMember_13" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_9" xlink:to="loc_drug_DirectorAndConsultantMember_14" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_1" xlink:to="loc_drug_StockOptionAxis_17" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_drug_StockOptionAxis_17" xlink:to="loc_drug_StockOptionDomain_17" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_drug_StockOptionDomain_17" xlink:to="loc_drug_StockOptionsOneMember_17" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_drug_StockOptionDomain_17" xlink:to="loc_drug_StockOptionsTwoMember_18" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_drug_StockOptionDomain_17" xlink:to="loc_drug_StockOptionsThreeMember_19" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_drug_StockOptionDomain_17" xlink:to="loc_drug_StockOptionsFourMember_20" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_1" xlink:to="loc_ifrs-full_ClassesOfShareCapitalAxis_23" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfShareCapitalAxis_23" xlink:to="loc_ifrs-full_ClassesOfShareCapitalMember_23" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfShareCapitalMember_23" xlink:to="loc_drug_SecondTrancheOfNonBrokeredPrivatePlacementMember_23" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfShareCapitalMember_23" xlink:to="loc_drug_SpecialWarrantsMember_24" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfShareCapitalMember_23" xlink:to="loc_drug_WarrantsMember_25" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfShareCapitalMember_23" xlink:to="loc_drug_EscrowedSharePurchaseWarrantsMember_26" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfShareCapitalMember_23" xlink:to="loc_drug_FirstTrancheOfNonBrokeredPrivatePlacementMember_27" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfShareCapitalMember_23" xlink:to="loc_drug_NonBrokeredPrivatePlacementMember_28" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfShareCapitalMember_23" xlink:to="loc_drug_StockOptionsMember_29" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfShareCapitalMember_23" xlink:to="loc_drug_RestrictedShareUnitMember_30" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfShareCapitalMember_23" xlink:to="loc_drug_EscrowedSecuritiesMember_31" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_1" xlink:to="loc_dei_LegalEntityAxis_34" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_34" xlink:to="loc_dei_EntityDomain_34" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_34" xlink:to="loc_drug_BritishColumbiaSecuritiesCommissionMember_34" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_1" xlink:to="loc_drug_VestingsAxis_37" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_drug_VestingsAxis_37" xlink:to="loc_drug_VestingDomain_37" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_drug_VestingDomain_37" xlink:to="loc_drug_FirstTrancheMember_37" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_drug_VestingDomain_37" xlink:to="loc_drug_SecondTrancheMember_38" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_drug_VestingDomain_37" xlink:to="loc_drug_ThirdTrancheMember_39" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_drug_VestingDomain_37" xlink:to="loc_drug_FourthTrancheMember_40" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_drug_VestingDomain_37" xlink:to="loc_drug_FifthTrancheMember_41" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_drug_VestingDomain_37" xlink:to="loc_drug_SixthTrancheMember_42" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_drug_VestingDomain_37" xlink:to="loc_drug_SeventhTrancheMember_43" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_drug_VestingDomain_37" xlink:to="loc_drug_EighthTrancheMember_44" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_drug_VestingDomain_37" xlink:to="loc_drug_NinthTrancheMember_45" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_drug_VestingDomain_37" xlink:to="loc_drug_TenthTrancheMember_46" order="90" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_drug_VestingDomain_37" xlink:to="loc_drug_EleventhTrancheMember_47" order="100" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_drug_VestingDomain_37" xlink:to="loc_drug_TwelfthTrancheMember_48" order="110" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_drug_VestingDomain_37" xlink:to="loc_drug_ThirteenthTrancheMember_49" order="120" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_drug_VestingDomain_37" xlink:to="loc_drug_FourteenthTrancheMember_50" order="130" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_drug_VestingDomain_37" xlink:to="loc_drug_FifteenthTrancheMember_51" order="140" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_1" xlink:to="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_54" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_54" xlink:to="loc_drug_DescriptionOfIssuedAndOutstandingCommonShares_54" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_54" xlink:to="loc_ifrs-full_NumberOfSharesIssued_55" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_54" xlink:to="loc_ifrs-full_IncreaseDecreaseInNumberOfSharesOutstanding_56" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_54" xlink:to="loc_drug_IssuePricePerShare_57" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_54" xlink:to="loc_drug_ProceedsForWarrantsIssued_58" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_54" xlink:to="loc_ifrs-full_ProceedsFromIssueOfOrdinaryShares_59" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_54" xlink:to="loc_drug_DebtSettledThroughIssuanceOfShares_60" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_54" xlink:to="loc_drug_NumberOfWarrantsDeemedToBeExercised_61" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_54" xlink:to="loc_drug_NumberOfWarrantsIssued_62" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_54" xlink:to="loc_drug_WarrantsIssuedPricePerWarrant_63" order="90" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_54" xlink:to="loc_drug_GrossProceedsFromWarrantsIssued_64" order="100" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_54" xlink:to="loc_drug_NumberOfUnitsIssued_65" order="110" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_54" xlink:to="loc_drug_UnitsIssuedPricePerUnit_66" order="120" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_54" xlink:to="loc_drug_GrossProceedsFromUnitsIssued_67" order="130" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_54" xlink:to="loc_drug_WeightedAverageExercisePriceOfWarrantsIssuedInShareBasedPaymentArrangement_68" order="140" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_54" xlink:to="loc_drug_WeightedAverageExercisePriceOfWarrantsOutstandingInShareBasedPaymentArrangement_69" order="150" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_54" xlink:to="loc_drug_MinimumDailyVolumeWeightedAverageTradingSharePrice_70" order="160" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_54" xlink:to="loc_drug_WeightedAverageTradingPriceOfCommonSharesOnCanadianStockExchange_71" order="170" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_54" xlink:to="loc_drug_UnderwritersFeesPaid_72" order="180" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_54" xlink:to="loc_drug_IncreaseDecreaseThroughSharesIssuedToUniversityShares_73" order="190" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_54" xlink:to="loc_drug_IncreaseDecreaseThroughSharesIssuedToUniversity_74" order="200" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_54" xlink:to="loc_drug_NumberOfCommonSharesCalledByWarrants_75" order="210" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_54" xlink:to="loc_drug_NumberOfWarrantsOutstandingInShareBasedPaymentArrangement_76" order="220" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_54" xlink:to="loc_drug_WarrantAscribedValue_77" order="230" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_54" xlink:to="loc_drug_NumberOfRestrictedStockIssuedForCompensation_78" order="240" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_54" xlink:to="loc_drug_NumberOfWarrantsExercised_79" order="250" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_54" xlink:to="loc_drug_WeightedAverageExercisePriceOfWarrantsExercisedInShareBasedPaymentArrangement_80" order="260" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_54" xlink:to="loc_drug_GrossProceedsFromWarrantsExercised_81" order="270" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_54" xlink:to="loc_drug_ContingentCashFee_82" order="280" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_54" xlink:to="loc_drug_PercentageOfNetEquityProceedsReceivedFromThreeInvestors_83" order="290" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_54" xlink:to="loc_drug_TermOfWarrant_84" order="300" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_54" xlink:to="loc_drug_SubscriptionsReceived_85" order="310" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_54" xlink:to="loc_drug_NumberOfCommonSharesSubscribed_86" order="320" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_54" xlink:to="loc_drug_NumberOfIssuedWarrantsRescinded_87" order="330" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_54" xlink:to="loc_drug_RefundFromIssuedWarrantsRescinded_88" order="340" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_54" xlink:to="loc_drug_AmountOfEscrowProceedsReleased_89" order="350" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_54" xlink:to="loc_drug_PercentageOfOutstandingSharesAuthorizedUnderStockOptionPlan_90" order="360" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_54" xlink:to="loc_drug_PercentageOfStockOptionPlanAllowsBoardOfDirectorsToIssue_91" order="370" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_54" xlink:to="loc_drug_AggregatePurchaseWarrantsDeposited_92" order="380" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_54" xlink:to="loc_drug_NumberOfCommonSharesDepositedToBeHeldInEscrow_93" order="390" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_54" xlink:to="loc_drug_NumberOfWarrantsDepositedToBeHeldInEscrow_94" order="400" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_54" xlink:to="loc_drug_AggregateSecuritiesDepositedToBeHeldInEscrow_95" order="410" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_54" xlink:to="loc_drug_NumberOfShareListed_96" order="420" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_54" xlink:to="loc_drug_EscrowedSecuritiesToBeReleasedOnceSharesAreListedOnCanadianStockExchange_97" order="430" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_54" xlink:to="loc_drug_EscrowedSecuritiesToBeReleasedAfterListingDate_98" order="440" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_54" xlink:to="loc_drug_PercentageOfStockOptionShareGranted_99" order="450" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_54" xlink:to="loc_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement_100" order="460" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_54" xlink:to="loc_drug_VestingPercentage_101" order="470" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_54" xlink:to="loc_ifrs-full_ExercisePriceShareOptionsGranted2019_102" order="480" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_54" xlink:to="loc_ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019_103" order="490" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_54" xlink:to="loc_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted_104" order="500" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_54" xlink:to="loc_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted_105" order="510" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_54" xlink:to="loc_drug_DiscountRateStockOptionGranted_106" order="520" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_54" xlink:to="loc_drug_IssuanceOfRestrictedStockUnits_107" order="530" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_54" xlink:to="loc_drug_EstimatedFairValueOfEquitySettledRsusGranted_108" order="540" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_54" xlink:to="loc_drug_FairValueOfWarrants_109" order="550" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_54" xlink:to="loc_drug_ExercisePriceWarrantsGranted_110" order="560" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_54" xlink:to="loc_drug_WeightedAverageSharePriceWarrantsGranted_111" order="570" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_54" xlink:to="loc_drug_EstimatedLifeOfWarrantsGranted_112" order="580" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_54" xlink:to="loc_drug_ExpectedVolatilityWarrantsGranted_113" order="590" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_54" xlink:to="loc_drug_DiscountRateOfWarrantsGranted_114" order="600" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_54" xlink:to="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019_115" order="610" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_54" xlink:to="loc_ifrs-full_ExercisePriceOfOutstandingShareOptions2019_116" order="620" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_54" xlink:to="loc_ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement_117" order="630" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_54" xlink:to="loc_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019_118" order="640" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_54" xlink:to="loc_drug_WeightedAverageRemainingContractualLifeOfOtherEquityInstruments_119" order="650" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_54" xlink:to="loc_drug_ThresholdPercentageOfWarrants_120" order="660" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://brightmindsbio.com/role/SHARECAPITALDetails5">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalAbstract" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalAbstract_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalTable" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_1"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_ConsolidatedStatementsOfComprehensiveIncomeLossStatementLocationAxis" xlink:label="loc_drug_ConsolidatedStatementsOfComprehensiveIncomeLossStatementLocationAxis_1"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_ConsolidatedStatementsOfComprehensiveIncomeLossStatementLocationDomain" xlink:label="loc_drug_ConsolidatedStatementsOfComprehensiveIncomeLossStatementLocationDomain_1"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_ConsultingFeesMember" xlink:label="loc_drug_ConsultingFeesMember_1"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_DirectorsCompensationMember" xlink:label="loc_drug_DirectorsCompensationMember_2"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_MarketingAdvertisingAndInvestorRelationsMember" xlink:label="loc_drug_MarketingAdvertisingAndInvestorRelationsMember_3"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_ProfessionalFeesMember" xlink:label="loc_drug_ProfessionalFeesMember_4"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_ResearchAndDevelopmentMember" xlink:label="loc_drug_ResearchAndDevelopmentMember_5"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_8"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees" xlink:label="loc_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees_8"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalAbstract_0" xlink:to="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_1" xlink:to="loc_drug_ConsolidatedStatementsOfComprehensiveIncomeLossStatementLocationAxis_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_drug_ConsolidatedStatementsOfComprehensiveIncomeLossStatementLocationAxis_1" xlink:to="loc_drug_ConsolidatedStatementsOfComprehensiveIncomeLossStatementLocationDomain_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_drug_ConsolidatedStatementsOfComprehensiveIncomeLossStatementLocationDomain_1" xlink:to="loc_drug_ConsultingFeesMember_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_drug_ConsolidatedStatementsOfComprehensiveIncomeLossStatementLocationDomain_1" xlink:to="loc_drug_DirectorsCompensationMember_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_drug_ConsolidatedStatementsOfComprehensiveIncomeLossStatementLocationDomain_1" xlink:to="loc_drug_MarketingAdvertisingAndInvestorRelationsMember_3" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_drug_ConsolidatedStatementsOfComprehensiveIncomeLossStatementLocationDomain_1" xlink:to="loc_drug_ProfessionalFeesMember_4" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_drug_ConsolidatedStatementsOfComprehensiveIncomeLossStatementLocationDomain_1" xlink:to="loc_drug_ResearchAndDevelopmentMember_5" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_1" xlink:to="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_8" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_8" xlink:to="loc_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees_8" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://brightmindsbio.com/role/ConsolidatedStatementsOfCashFlows">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_StatementOfCashFlowsAbstract" xlink:label="loc_ifrs-full_StatementOfCashFlowsAbstract_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" xlink:label="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ProfitLoss" xlink:label="loc_ifrs-full_ProfitLoss_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AdjustmentsForReconcileProfitLossAbstract" xlink:label="loc_ifrs-full_AdjustmentsForReconcileProfitLossAbstract_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains" xlink:label="loc_ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains_2"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_AdjustmentsForSharesRecordedAsResearchAndDevelopment" xlink:label="loc_drug_AdjustmentsForSharesRecordedAsResearchAndDevelopment_3"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AdjustmentsForSharebasedPayments" xlink:label="loc_ifrs-full_AdjustmentsForSharebasedPayments_4"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_ChangesInNonCashWorkingOperatingCapitalBalancesAbstract" xlink:label="loc_drug_ChangesInNonCashWorkingOperatingCapitalBalancesAbstract_6"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_AdjustmentsForDecreaseIncreaseInSalesTaxReceivable" xlink:label="loc_drug_AdjustmentsForDecreaseIncreaseInSalesTaxReceivable_6"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_AdjustmentsForDecreaseIncreaseInPrepaidExpenses" xlink:label="loc_drug_AdjustmentsForDecreaseIncreaseInPrepaidExpenses_7"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable" xlink:label="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable_8"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:label="loc_ifrs-full_CashFlowsFromUsedInOperatingActivities_10"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:label="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_12"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ProceedsFromIssuingShares" xlink:label="loc_ifrs-full_ProceedsFromIssuingShares_12"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_PaymentsForFindersFees" xlink:label="loc_drug_PaymentsForFindersFees_13"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_PaymentsForShareIssueCosts" xlink:label="loc_ifrs-full_PaymentsForShareIssueCosts_14"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_ProceedsFromIssuingWarrants" xlink:label="loc_drug_ProceedsFromIssuingWarrants_15"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_RefundOfSpecialWarrantsProceeds" xlink:label="loc_drug_RefundOfSpecialWarrantsProceeds_16"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_ProceedsFromWarrantsExercise" xlink:label="loc_drug_ProceedsFromWarrantsExercise_17"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:label="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities_18"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IncreaseDecreaseInCashAndCashEquivalents" xlink:label="loc_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents_20"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents" xlink:label="loc_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents_21"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CashAndCashEquivalents" xlink:label="loc_ifrs-full_CashAndCashEquivalents_22"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CashAndCashEquivalents" xlink:label="loc_ifrs-full_CashAndCashEquivalents_23"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_SupplementaryInformationAbstract" xlink:label="loc_drug_SupplementaryInformationAbstract_24"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_DebtSettledByIssuingShares" xlink:label="loc_drug_DebtSettledByIssuingShares_24"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_FairValueAscribedToBrokersWarrantsIssued" xlink:label="loc_drug_FairValueAscribedToBrokersWarrantsIssued_25"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_FairValueOfOptionsIssuedAsFindersFees" xlink:label="loc_drug_FairValueOfOptionsIssuedAsFindersFees_26"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_ShareIssueCostsIncludedInAccountsPayable" xlink:label="loc_drug_ShareIssueCostsIncludedInAccountsPayable_27"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_AcquisitionOfIntangibleAssetsByIssuingCommonShares" xlink:label="loc_drug_AcquisitionOfIntangibleAssetsByIssuingCommonShares_28"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfCashFlowsAbstract_0" xlink:to="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_1" xlink:to="loc_ifrs-full_ProfitLoss_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_1" xlink:to="loc_ifrs-full_AdjustmentsForReconcileProfitLossAbstract_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AdjustmentsForReconcileProfitLossAbstract_2" xlink:to="loc_ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AdjustmentsForReconcileProfitLossAbstract_2" xlink:to="loc_drug_AdjustmentsForSharesRecordedAsResearchAndDevelopment_3" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AdjustmentsForReconcileProfitLossAbstract_2" xlink:to="loc_ifrs-full_AdjustmentsForSharebasedPayments_4" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_1" xlink:to="loc_drug_ChangesInNonCashWorkingOperatingCapitalBalancesAbstract_6" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_drug_ChangesInNonCashWorkingOperatingCapitalBalancesAbstract_6" xlink:to="loc_drug_AdjustmentsForDecreaseIncreaseInSalesTaxReceivable_6" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_drug_ChangesInNonCashWorkingOperatingCapitalBalancesAbstract_6" xlink:to="loc_drug_AdjustmentsForDecreaseIncreaseInPrepaidExpenses_7" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_drug_ChangesInNonCashWorkingOperatingCapitalBalancesAbstract_6" xlink:to="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable_8" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_1" xlink:to="loc_ifrs-full_CashFlowsFromUsedInOperatingActivities_10" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfCashFlowsAbstract_0" xlink:to="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_12" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_12" xlink:to="loc_ifrs-full_ProceedsFromIssuingShares_12" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_12" xlink:to="loc_drug_PaymentsForFindersFees_13" order="10" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_12" xlink:to="loc_ifrs-full_PaymentsForShareIssueCosts_14" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_12" xlink:to="loc_drug_ProceedsFromIssuingWarrants_15" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_12" xlink:to="loc_drug_RefundOfSpecialWarrantsProceeds_16" order="40" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_12" xlink:to="loc_drug_ProceedsFromWarrantsExercise_17" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_12" xlink:to="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities_18" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfCashFlowsAbstract_0" xlink:to="loc_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents_20" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfCashFlowsAbstract_0" xlink:to="loc_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents_21" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfCashFlowsAbstract_0" xlink:to="loc_ifrs-full_CashAndCashEquivalents_22" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfCashFlowsAbstract_0" xlink:to="loc_ifrs-full_CashAndCashEquivalents_23" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfCashFlowsAbstract_0" xlink:to="loc_drug_SupplementaryInformationAbstract_24" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_drug_SupplementaryInformationAbstract_24" xlink:to="loc_drug_DebtSettledByIssuingShares_24" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_drug_SupplementaryInformationAbstract_24" xlink:to="loc_drug_FairValueAscribedToBrokersWarrantsIssued_25" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_drug_SupplementaryInformationAbstract_24" xlink:to="loc_drug_FairValueOfOptionsIssuedAsFindersFees_26" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_drug_SupplementaryInformationAbstract_24" xlink:to="loc_drug_ShareIssueCostsIncludedInAccountsPayable_27" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_drug_SupplementaryInformationAbstract_24" xlink:to="loc_drug_AcquisitionOfIntangibleAssetsByIssuingCommonShares_28" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://brightmindsbio.com/role/INCOMETAXES">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract" xlink:label="loc_ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfIncomeTaxExplanatory" xlink:label="loc_ifrs-full_DisclosureOfIncomeTaxExplanatory_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract_0" xlink:to="loc_ifrs-full_DisclosureOfIncomeTaxExplanatory_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://brightmindsbio.com/role/INCOMETAXESTables">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract" xlink:label="loc_ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract_0"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_DisclosureOfReconciliationOfExpectedIncomeTaxRecoveryToActualIncomeTaxRecoveryExplanatory" xlink:label="loc_drug_DisclosureOfReconciliationOfExpectedIncomeTaxRecoveryToActualIncomeTaxRecoveryExplanatory_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory" xlink:label="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory_2"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_DisclosureOfNonCapitalLossCarryForwardsExpiryExplanatory" xlink:label="loc_drug_DisclosureOfNonCapitalLossCarryForwardsExpiryExplanatory_3"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract_0" xlink:to="loc_drug_DisclosureOfReconciliationOfExpectedIncomeTaxRecoveryToActualIncomeTaxRecoveryExplanatory_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract_0" xlink:to="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract_0" xlink:to="loc_drug_DisclosureOfNonCapitalLossCarryForwardsExpiryExplanatory_3" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://brightmindsbio.com/role/INCOMETAXESDetails">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract" xlink:label="loc_ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AccountingProfit" xlink:label="loc_ifrs-full_AccountingProfit_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ApplicableTaxRate" xlink:label="loc_ifrs-full_ApplicableTaxRate_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TaxExpenseIncomeAtApplicableTaxRate" xlink:label="loc_ifrs-full_TaxExpenseIncomeAtApplicableTaxRate_3"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_TaxEffectOfDeductibleAndNotDeductibleItems" xlink:label="loc_drug_TaxEffectOfDeductibleAndNotDeductibleItems_4"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_TaxEffectOfChangeInDeferredTaxAssetsNotRecognized" xlink:label="loc_drug_TaxEffectOfChangeInDeferredTaxAssetsNotRecognized_5"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:label="loc_ifrs-full_IncomeTaxExpenseContinuingOperations_6"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract_0" xlink:to="loc_ifrs-full_AccountingProfit_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract_0" xlink:to="loc_ifrs-full_ApplicableTaxRate_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract_0" xlink:to="loc_ifrs-full_TaxExpenseIncomeAtApplicableTaxRate_3" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract_0" xlink:to="loc_drug_TaxEffectOfDeductibleAndNotDeductibleItems_4" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract_0" xlink:to="loc_drug_TaxEffectOfChangeInDeferredTaxAssetsNotRecognized_5" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract_0" xlink:to="loc_ifrs-full_IncomeTaxExpenseContinuingOperations_6" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://brightmindsbio.com/role/INCOMETAXESDetails2">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract" xlink:label="loc_ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable" xlink:label="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable_1"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_NonCapitalLossCarryForwardsYearOfOriginAxis" xlink:label="loc_drug_NonCapitalLossCarryForwardsYearOfOriginAxis_1"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_NonCapitalLossCarryForwardsYearOfOriginDomain" xlink:label="loc_drug_NonCapitalLossCarryForwardsYearOfOriginDomain_1"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_TaxYearOfOrigin2019Member" xlink:label="loc_drug_TaxYearOfOrigin2019Member_1"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_TaxYearOfOrigin2020Member" xlink:label="loc_drug_TaxYearOfOrigin2020Member_2"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_TaxYearOfOrigin2021Member" xlink:label="loc_drug_TaxYearOfOrigin2021Member_3"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_IncomeTaxAuthorityNameOfCountryAxis" xlink:label="loc_drug_IncomeTaxAuthorityNameOfCountryAxis_6"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_IncomeTaxAuthorityNameOfCountryDomain" xlink:label="loc_drug_IncomeTaxAuthorityNameOfCountryDomain_6"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_TaxAuthorityOfCanadaMember" xlink:label="loc_drug_TaxAuthorityOfCanadaMember_6"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems" xlink:label="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_9"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_NonCapitalLossCarryForwardsYearOfExpiry" xlink:label="loc_drug_NonCapitalLossCarryForwardsYearOfExpiry_9"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_NonCapitalLossCarryForwards" xlink:label="loc_drug_NonCapitalLossCarryForwards_10"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract_0" xlink:to="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable_1" xlink:to="loc_drug_NonCapitalLossCarryForwardsYearOfOriginAxis_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_drug_NonCapitalLossCarryForwardsYearOfOriginAxis_1" xlink:to="loc_drug_NonCapitalLossCarryForwardsYearOfOriginDomain_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_drug_NonCapitalLossCarryForwardsYearOfOriginDomain_1" xlink:to="loc_drug_TaxYearOfOrigin2019Member_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_drug_NonCapitalLossCarryForwardsYearOfOriginDomain_1" xlink:to="loc_drug_TaxYearOfOrigin2020Member_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_drug_NonCapitalLossCarryForwardsYearOfOriginDomain_1" xlink:to="loc_drug_TaxYearOfOrigin2021Member_3" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable_1" xlink:to="loc_drug_IncomeTaxAuthorityNameOfCountryAxis_6" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_drug_IncomeTaxAuthorityNameOfCountryAxis_6" xlink:to="loc_drug_IncomeTaxAuthorityNameOfCountryDomain_6" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_drug_IncomeTaxAuthorityNameOfCountryDomain_6" xlink:to="loc_drug_TaxAuthorityOfCanadaMember_6" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable_1" xlink:to="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_9" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_9" xlink:to="loc_drug_NonCapitalLossCarryForwardsYearOfExpiry_9" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_9" xlink:to="loc_drug_NonCapitalLossCarryForwards_10" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://brightmindsbio.com/role/INCOMETAXESDetailTextuals">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract" xlink:label="loc_ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable" xlink:label="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable_1"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_IncomeTaxAuthorityNameOfCountryAxis" xlink:label="loc_drug_IncomeTaxAuthorityNameOfCountryAxis_1"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_IncomeTaxAuthorityNameOfCountryDomain" xlink:label="loc_drug_IncomeTaxAuthorityNameOfCountryDomain_1"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_TaxAuthorityOfCanadaMember" xlink:label="loc_drug_TaxAuthorityOfCanadaMember_1"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_TaxAuthorityOfUnitedStatesMember" xlink:label="loc_drug_TaxAuthorityOfUnitedStatesMember_2"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_TaxAuthorityOfAustraliaMember" xlink:label="loc_drug_TaxAuthorityOfAustraliaMember_3"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems" xlink:label="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_6"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_NonCapitalLossCarryForwards" xlink:label="loc_drug_NonCapitalLossCarryForwards_6"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract_0" xlink:to="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable_1" xlink:to="loc_drug_IncomeTaxAuthorityNameOfCountryAxis_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_drug_IncomeTaxAuthorityNameOfCountryAxis_1" xlink:to="loc_drug_IncomeTaxAuthorityNameOfCountryDomain_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_drug_IncomeTaxAuthorityNameOfCountryDomain_1" xlink:to="loc_drug_TaxAuthorityOfCanadaMember_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_drug_IncomeTaxAuthorityNameOfCountryDomain_1" xlink:to="loc_drug_TaxAuthorityOfUnitedStatesMember_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_drug_IncomeTaxAuthorityNameOfCountryDomain_1" xlink:to="loc_drug_TaxAuthorityOfAustraliaMember_3" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable_1" xlink:to="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_6" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_6" xlink:to="loc_drug_NonCapitalLossCarryForwards_6" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://brightmindsbio.com/role/INCOMETAXESDetails1">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract" xlink:label="loc_ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable" xlink:label="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis" xlink:label="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember" xlink:label="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_UnusedTaxLossesMember" xlink:label="loc_ifrs-full_UnusedTaxLossesMember_1"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_TemporaryDifferencesShareIssueCostsMember" xlink:label="loc_drug_TemporaryDifferencesShareIssueCostsMember_2"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_TemporaryDifferencesIntangibleAssetsMember" xlink:label="loc_drug_TemporaryDifferencesIntangibleAssetsMember_3"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_TemporaryDifferencesValuationAllowanceMember" xlink:label="loc_drug_TemporaryDifferencesValuationAllowanceMember_4"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems" xlink:label="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_7"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised" xlink:label="loc_ifrs-full_DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised_7"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract_0" xlink:to="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable_1" xlink:to="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_1" xlink:to="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_1" xlink:to="loc_ifrs-full_UnusedTaxLossesMember_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_1" xlink:to="loc_drug_TemporaryDifferencesShareIssueCostsMember_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_1" xlink:to="loc_drug_TemporaryDifferencesIntangibleAssetsMember_3" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_1" xlink:to="loc_drug_TemporaryDifferencesValuationAllowanceMember_4" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable_1" xlink:to="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_7" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_7" xlink:to="loc_ifrs-full_DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://brightmindsbio.com/role/ConsolidatedStatementsOfChangesInShareholdersEquity">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_StatementOfChangesInEquityAbstract" xlink:label="loc_ifrs-full_StatementOfChangesInEquityAbstract_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_StatementOfChangesInEquityTable" xlink:label="loc_ifrs-full_StatementOfChangesInEquityTable_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ComponentsOfEquityAxis" xlink:label="loc_ifrs-full_ComponentsOfEquityAxis_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IssuedCapitalMember" xlink:label="loc_ifrs-full_IssuedCapitalMember_1"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_SubscriptionReceivableMember" xlink:label="loc_drug_SubscriptionReceivableMember_2"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_SubscriptionReceivedMember" xlink:label="loc_drug_SubscriptionReceivedMember_3"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_OtherReservesMember" xlink:label="loc_ifrs-full_OtherReservesMember_4"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_RetainedEarningsMember" xlink:label="loc_ifrs-full_RetainedEarningsMember_5"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_EquityMember" xlink:label="loc_ifrs-full_EquityMember_6"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_StatementOfChangesInEquityLineItems" xlink:label="loc_ifrs-full_StatementOfChangesInEquityLineItems_8"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_Equity" xlink:label="loc_ifrs-full_Equity_8"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NumberOfSharesOutstanding" xlink:label="loc_ifrs-full_NumberOfSharesOutstanding_9"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_IncreaseDecreaseThroughPrivatePlacement" xlink:label="loc_drug_IncreaseDecreaseThroughPrivatePlacement_10"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_IncreaseDecreaseThroughPrivatePlacementShares" xlink:label="loc_drug_IncreaseDecreaseThroughPrivatePlacementShares_11"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_IncreaseDecreaseThroughAcquisitionOfIntangibleAssets" xlink:label="loc_drug_IncreaseDecreaseThroughAcquisitionOfIntangibleAssets_12"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_IncreaseDecreaseThroughAcquisitionOfIntangibleAssetsShares" xlink:label="loc_drug_IncreaseDecreaseThroughAcquisitionOfIntangibleAssetsShares_13"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_IncreaseDecreaseThroughFindersFeesCash" xlink:label="loc_drug_IncreaseDecreaseThroughFindersFeesCash_14"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_IncreaseDecreaseThroughFindersFeesBrokerWarrants" xlink:label="loc_drug_IncreaseDecreaseThroughFindersFeesBrokerWarrants_15"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_IncreaseDecreaseThroughFindersFeesShareOptions" xlink:label="loc_drug_IncreaseDecreaseThroughFindersFeesShareOptions_16"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_IncreaseDecreaseThroughDebtSettlementWithShare" xlink:label="loc_drug_IncreaseDecreaseThroughDebtSettlementWithShare_17"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ShareIssueRelatedCost" xlink:label="loc_ifrs-full_ShareIssueRelatedCost_18"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_IncreaseDecreaseThroughDebtSettlementWithShareShares" xlink:label="loc_drug_IncreaseDecreaseThroughDebtSettlementWithShareShares_19"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_IncreaseDecreaseThroughSpecialWarrantConversion" xlink:label="loc_drug_IncreaseDecreaseThroughSpecialWarrantConversion_20"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_IncreaseDecreaseThroughSpecialWarrantConversionShares" xlink:label="loc_drug_IncreaseDecreaseThroughSpecialWarrantConversionShares_21"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity_22"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_IncreaseDecreaseThroughExerciseOfWarrantsShares" xlink:label="loc_drug_IncreaseDecreaseThroughExerciseOfWarrantsShares_23"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_IncreaseDecreaseThroughSharesIssuedToUniversity" xlink:label="loc_drug_IncreaseDecreaseThroughSharesIssuedToUniversity_24"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_IncreaseDecreaseThroughSharesIssuedToUniversityShares" xlink:label="loc_drug_IncreaseDecreaseThroughSharesIssuedToUniversityShares_25"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions_26"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ProfitLoss" xlink:label="loc_ifrs-full_ProfitLoss_27"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_Equity" xlink:label="loc_ifrs-full_Equity_28"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NumberOfSharesOutstanding" xlink:label="loc_ifrs-full_NumberOfSharesOutstanding_29"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityAbstract_0" xlink:to="loc_ifrs-full_StatementOfChangesInEquityTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityTable_1" xlink:to="loc_ifrs-full_ComponentsOfEquityAxis_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ComponentsOfEquityAxis_1" xlink:to="loc_ifrs-full_IssuedCapitalMember_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ComponentsOfEquityAxis_1" xlink:to="loc_drug_SubscriptionReceivableMember_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ComponentsOfEquityAxis_1" xlink:to="loc_drug_SubscriptionReceivedMember_3" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ComponentsOfEquityAxis_1" xlink:to="loc_ifrs-full_OtherReservesMember_4" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ComponentsOfEquityAxis_1" xlink:to="loc_ifrs-full_RetainedEarningsMember_5" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ComponentsOfEquityAxis_1" xlink:to="loc_ifrs-full_EquityMember_6" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityTable_1" xlink:to="loc_ifrs-full_StatementOfChangesInEquityLineItems_8" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_8" xlink:to="loc_ifrs-full_Equity_8" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_8" xlink:to="loc_ifrs-full_NumberOfSharesOutstanding_9" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_8" xlink:to="loc_drug_IncreaseDecreaseThroughPrivatePlacement_10" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_8" xlink:to="loc_drug_IncreaseDecreaseThroughPrivatePlacementShares_11" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_8" xlink:to="loc_drug_IncreaseDecreaseThroughAcquisitionOfIntangibleAssets_12" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_8" xlink:to="loc_drug_IncreaseDecreaseThroughAcquisitionOfIntangibleAssetsShares_13" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_8" xlink:to="loc_drug_IncreaseDecreaseThroughFindersFeesCash_14" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_8" xlink:to="loc_drug_IncreaseDecreaseThroughFindersFeesBrokerWarrants_15" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_8" xlink:to="loc_drug_IncreaseDecreaseThroughFindersFeesShareOptions_16" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_8" xlink:to="loc_drug_IncreaseDecreaseThroughDebtSettlementWithShare_17" order="90" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_8" xlink:to="loc_ifrs-full_ShareIssueRelatedCost_18" order="100" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_8" xlink:to="loc_drug_IncreaseDecreaseThroughDebtSettlementWithShareShares_19" order="110" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_8" xlink:to="loc_drug_IncreaseDecreaseThroughSpecialWarrantConversion_20" order="120" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_8" xlink:to="loc_drug_IncreaseDecreaseThroughSpecialWarrantConversionShares_21" order="130" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_8" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity_22" order="140" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_8" xlink:to="loc_drug_IncreaseDecreaseThroughExerciseOfWarrantsShares_23" order="150" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_8" xlink:to="loc_drug_IncreaseDecreaseThroughSharesIssuedToUniversity_24" order="160" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_8" xlink:to="loc_drug_IncreaseDecreaseThroughSharesIssuedToUniversityShares_25" order="170" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_8" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions_26" order="180" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_8" xlink:to="loc_ifrs-full_ProfitLoss_27" order="190" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_8" xlink:to="loc_ifrs-full_Equity_28" order="200" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_8" xlink:to="loc_ifrs-full_NumberOfSharesOutstanding_29" order="210" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://brightmindsbio.com/role/CONTRACTUALOBLIGATIONS">
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_DisclosureOfContractualObligationAbstract" xlink:label="loc_drug_DisclosureOfContractualObligationAbstract_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfCommitmentsExplanatory" xlink:label="loc_ifrs-full_DisclosureOfCommitmentsExplanatory_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_drug_DisclosureOfContractualObligationAbstract_0" xlink:to="loc_ifrs-full_DisclosureOfCommitmentsExplanatory_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://brightmindsbio.com/role/CONTRACTUALOBLIGATIONSDetailTextuals">
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_DisclosureOfContractualObligationAbstract" xlink:label="loc_drug_DisclosureOfContractualObligationAbstract_0"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_DisclosureOfContractualObligationTable" xlink:label="loc_drug_DisclosureOfContractualObligationTable_1"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_AgreementAxis" xlink:label="loc_drug_AgreementAxis_1"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_AgreementDomain" xlink:label="loc_drug_AgreementDomain_1"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_OptionAgreementMember" xlink:label="loc_drug_OptionAgreementMember_1"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_LicenseAgreementMember" xlink:label="loc_drug_LicenseAgreementMember_2"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_PriorToSublicensingAgreementsMember" xlink:label="loc_drug_PriorToSublicensingAgreementsMember_3"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_AfterSublicensingAgreementsMember" xlink:label="loc_drug_AfterSublicensingAgreementsMember_4"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_IndependentConsultantAgreementMember" xlink:label="loc_drug_IndependentConsultantAgreementMember_5"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_IndependentContractorAgreementToServeAsChiefScienceOfficerMember" xlink:label="loc_drug_IndependentContractorAgreementToServeAsChiefScienceOfficerMember_6"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_ScientificAdvisoryBoardAgreementsMember" xlink:label="loc_drug_ScientificAdvisoryBoardAgreementsMember_7"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_ConsultingAgreementsMember" xlink:label="loc_drug_ConsultingAgreementsMember_8"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_RangeAxis" xlink:label="loc_ifrs-full_RangeAxis_11"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_RangesMember" xlink:label="loc_ifrs-full_RangesMember_11"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_BottomOfRangeMember" xlink:label="loc_ifrs-full_BottomOfRangeMember_11"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TopOfRangeMember" xlink:label="loc_ifrs-full_TopOfRangeMember_12"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_DisclosureOfContractualObligationLineItems" xlink:label="loc_drug_DisclosureOfContractualObligationLineItems_15"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_NonRefundableOptionFeesPaid" xlink:label="loc_drug_NonRefundableOptionFeesPaid_15"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_SigningFee" xlink:label="loc_drug_SigningFee_16"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_OptionFeesPaid" xlink:label="loc_drug_OptionFeesPaid_17"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_SigningFeeNetOfOptionFeesPaid" xlink:label="loc_drug_SigningFeeNetOfOptionFeesPaid_18"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_SigningFeeSharesIssued" xlink:label="loc_drug_SigningFeeSharesIssued_19"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_PercentageOfRoyaltiesOnNetSales" xlink:label="loc_drug_PercentageOfRoyaltiesOnNetSales_20"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_PercentageOfRoyaltiesOnNetSalesUnder1Billion" xlink:label="loc_drug_PercentageOfRoyaltiesOnNetSalesUnder1Billion_21"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_PercentageOfRoyaltiesOnNetSalesOver2Billion" xlink:label="loc_drug_PercentageOfRoyaltiesOnNetSalesOver2Billion_22"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_RoyaltiesOnNetSales" xlink:label="loc_drug_RoyaltiesOnNetSales_23"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_DescriptionOfSublicenseeRevenueOfRoyaltyPaymentAccrues" xlink:label="loc_drug_DescriptionOfSublicenseeRevenueOfRoyaltyPaymentAccrues_24"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_TotalAnnualMinimumRoyaltiesCurrentYears" xlink:label="loc_drug_TotalAnnualMinimumRoyaltiesCurrentYears_25"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_TotalAnnualMinimumRoyaltiesNextYears" xlink:label="loc_drug_TotalAnnualMinimumRoyaltiesNextYears_26"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_TotalAnnualMinimumRoyaltiesYear3" xlink:label="loc_drug_TotalAnnualMinimumRoyaltiesYear3_27"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_TotalAnnualMinimumRoyaltiesYear4" xlink:label="loc_drug_TotalAnnualMinimumRoyaltiesYear4_28"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_TotalAnnualMinimumRoyaltiesYear5" xlink:label="loc_drug_TotalAnnualMinimumRoyaltiesYear5_29"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_TotalAnnualMinimumRoyaltiesYear6AndThereafter" xlink:label="loc_drug_TotalAnnualMinimumRoyaltiesYear6AndThereafter_30"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_TotalAnnualMinimumRoyaltiesAfterFirstCommercialSale" xlink:label="loc_drug_TotalAnnualMinimumRoyaltiesAfterFirstCommercialSale_31"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_MilestonePaymentsUponDosingFirstPatientInPhaseITrial" xlink:label="loc_drug_MilestonePaymentsUponDosingFirstPatientInPhaseITrial_32"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_MilestonePaymentsUponDosingFirstPatientInFirstPhaseIiTrial" xlink:label="loc_drug_MilestonePaymentsUponDosingFirstPatientInFirstPhaseIiTrial_33"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_MilestonePaymentsUponDosingFirstPatientInFirstPhaseIiiTrial" xlink:label="loc_drug_MilestonePaymentsUponDosingFirstPatientInFirstPhaseIiiTrial_34"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_MilestonePaymentsUponFirstCommercialSaleOfClinical" xlink:label="loc_drug_MilestonePaymentsUponFirstCommercialSaleOfClinical_35"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" xlink:label="loc_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement_36"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted" xlink:label="loc_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted_37"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" xlink:label="loc_ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement_38"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_MonthlyFeeAuthorizedByBoardOfDirectors" xlink:label="loc_drug_MonthlyFeeAuthorizedByBoardOfDirectors_39"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_AdvisorHourlyRate" xlink:label="loc_drug_AdvisorHourlyRate_40"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ResearchAndDevelopmentExpense" xlink:label="loc_ifrs-full_ResearchAndDevelopmentExpense_41"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_drug_DisclosureOfContractualObligationAbstract_0" xlink:to="loc_drug_DisclosureOfContractualObligationTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_drug_DisclosureOfContractualObligationTable_1" xlink:to="loc_drug_AgreementAxis_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_drug_AgreementAxis_1" xlink:to="loc_drug_AgreementDomain_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_drug_AgreementDomain_1" xlink:to="loc_drug_OptionAgreementMember_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_drug_AgreementDomain_1" xlink:to="loc_drug_LicenseAgreementMember_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_drug_AgreementDomain_1" xlink:to="loc_drug_PriorToSublicensingAgreementsMember_3" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_drug_AgreementDomain_1" xlink:to="loc_drug_AfterSublicensingAgreementsMember_4" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_drug_AgreementDomain_1" xlink:to="loc_drug_IndependentConsultantAgreementMember_5" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_drug_AgreementDomain_1" xlink:to="loc_drug_IndependentContractorAgreementToServeAsChiefScienceOfficerMember_6" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_drug_AgreementDomain_1" xlink:to="loc_drug_ScientificAdvisoryBoardAgreementsMember_7" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_drug_AgreementDomain_1" xlink:to="loc_drug_ConsultingAgreementsMember_8" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_drug_DisclosureOfContractualObligationTable_1" xlink:to="loc_ifrs-full_RangeAxis_11" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangeAxis_11" xlink:to="loc_ifrs-full_RangesMember_11" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangesMember_11" xlink:to="loc_ifrs-full_BottomOfRangeMember_11" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangesMember_11" xlink:to="loc_ifrs-full_TopOfRangeMember_12" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_drug_DisclosureOfContractualObligationTable_1" xlink:to="loc_drug_DisclosureOfContractualObligationLineItems_15" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_drug_DisclosureOfContractualObligationLineItems_15" xlink:to="loc_drug_NonRefundableOptionFeesPaid_15" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_drug_DisclosureOfContractualObligationLineItems_15" xlink:to="loc_drug_SigningFee_16" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_drug_DisclosureOfContractualObligationLineItems_15" xlink:to="loc_drug_OptionFeesPaid_17" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_drug_DisclosureOfContractualObligationLineItems_15" xlink:to="loc_drug_SigningFeeNetOfOptionFeesPaid_18" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_drug_DisclosureOfContractualObligationLineItems_15" xlink:to="loc_drug_SigningFeeSharesIssued_19" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_drug_DisclosureOfContractualObligationLineItems_15" xlink:to="loc_drug_PercentageOfRoyaltiesOnNetSales_20" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_drug_DisclosureOfContractualObligationLineItems_15" xlink:to="loc_drug_PercentageOfRoyaltiesOnNetSalesUnder1Billion_21" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_drug_DisclosureOfContractualObligationLineItems_15" xlink:to="loc_drug_PercentageOfRoyaltiesOnNetSalesOver2Billion_22" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_drug_DisclosureOfContractualObligationLineItems_15" xlink:to="loc_drug_RoyaltiesOnNetSales_23" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_drug_DisclosureOfContractualObligationLineItems_15" xlink:to="loc_drug_DescriptionOfSublicenseeRevenueOfRoyaltyPaymentAccrues_24" order="90" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_drug_DisclosureOfContractualObligationLineItems_15" xlink:to="loc_drug_TotalAnnualMinimumRoyaltiesCurrentYears_25" order="100" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_drug_DisclosureOfContractualObligationLineItems_15" xlink:to="loc_drug_TotalAnnualMinimumRoyaltiesNextYears_26" order="110" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_drug_DisclosureOfContractualObligationLineItems_15" xlink:to="loc_drug_TotalAnnualMinimumRoyaltiesYear3_27" order="120" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_drug_DisclosureOfContractualObligationLineItems_15" xlink:to="loc_drug_TotalAnnualMinimumRoyaltiesYear4_28" order="130" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_drug_DisclosureOfContractualObligationLineItems_15" xlink:to="loc_drug_TotalAnnualMinimumRoyaltiesYear5_29" order="140" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_drug_DisclosureOfContractualObligationLineItems_15" xlink:to="loc_drug_TotalAnnualMinimumRoyaltiesYear6AndThereafter_30" order="150" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_drug_DisclosureOfContractualObligationLineItems_15" xlink:to="loc_drug_TotalAnnualMinimumRoyaltiesAfterFirstCommercialSale_31" order="160" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_drug_DisclosureOfContractualObligationLineItems_15" xlink:to="loc_drug_MilestonePaymentsUponDosingFirstPatientInPhaseITrial_32" order="170" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_drug_DisclosureOfContractualObligationLineItems_15" xlink:to="loc_drug_MilestonePaymentsUponDosingFirstPatientInFirstPhaseIiTrial_33" order="180" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_drug_DisclosureOfContractualObligationLineItems_15" xlink:to="loc_drug_MilestonePaymentsUponDosingFirstPatientInFirstPhaseIiiTrial_34" order="190" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_drug_DisclosureOfContractualObligationLineItems_15" xlink:to="loc_drug_MilestonePaymentsUponFirstCommercialSaleOfClinical_35" order="200" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_drug_DisclosureOfContractualObligationLineItems_15" xlink:to="loc_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement_36" order="210" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_drug_DisclosureOfContractualObligationLineItems_15" xlink:to="loc_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted_37" order="220" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_drug_DisclosureOfContractualObligationLineItems_15" xlink:to="loc_ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement_38" order="230" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_drug_DisclosureOfContractualObligationLineItems_15" xlink:to="loc_drug_MonthlyFeeAuthorizedByBoardOfDirectors_39" order="240" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_drug_DisclosureOfContractualObligationLineItems_15" xlink:to="loc_drug_AdvisorHourlyRate_40" order="250" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_drug_DisclosureOfContractualObligationLineItems_15" xlink:to="loc_ifrs-full_ResearchAndDevelopmentExpense_41" order="260" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://brightmindsbio.com/role/PREMISESLEASES">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_PresentationOfLeasesForLesseeAbstract" xlink:label="loc_ifrs-full_PresentationOfLeasesForLesseeAbstract_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfLeasesExplanatory" xlink:label="loc_ifrs-full_DisclosureOfLeasesExplanatory_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_PresentationOfLeasesForLesseeAbstract_0" xlink:to="loc_ifrs-full_DisclosureOfLeasesExplanatory_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://brightmindsbio.com/role/PREMISESLEASESDetailTextuals">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_PresentationOfLeasesForLesseeAbstract" xlink:label="loc_ifrs-full_PresentationOfLeasesForLesseeAbstract_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable" xlink:label="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ClassesOfAssetsAxis" xlink:label="loc_ifrs-full_ClassesOfAssetsAxis_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ClassesOfAssetsMember" xlink:label="loc_ifrs-full_ClassesOfAssetsMember_1"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_CommercialLaboratoryLeaseMember" xlink:label="loc_drug_CommercialLaboratoryLeaseMember_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_BuildingsMember" xlink:label="loc_ifrs-full_BuildingsMember_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:label="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems_5"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_TermOfLease" xlink:label="loc_drug_TermOfLease_5"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_MonthlyBaseRent" xlink:label="loc_drug_MonthlyBaseRent_6"/>
    <loc xlink:type="locator" xlink:href="drug-20210930.xsd#drug_LeaseCost" xlink:label="loc_drug_LeaseCost_7"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_PresentationOfLeasesForLesseeAbstract_0" xlink:to="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable_1" xlink:to="loc_ifrs-full_ClassesOfAssetsAxis_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfAssetsAxis_1" xlink:to="loc_ifrs-full_ClassesOfAssetsMember_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfAssetsMember_1" xlink:to="loc_drug_CommercialLaboratoryLeaseMember_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfAssetsMember_1" xlink:to="loc_ifrs-full_BuildingsMember_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable_1" xlink:to="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems_5" xlink:to="loc_drug_TermOfLease_5" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems_5" xlink:to="loc_drug_MonthlyBaseRent_6" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems_5" xlink:to="loc_drug_LeaseCost_7" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>form20faxz004.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 form20faxz004.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #__@ [0U)%051/4CH@9V0M:G!E9R!V,2XP
M("AU<VEN9R!)2D<@2E!%1R!V.3 I+"!Q=6%L:71Y(#T@.3 *_]L 0P # @(#
M @(# P,#! ,#! 4(!04$! 4*!P<&" P*# P+"@L+#0X2$ T.$0X+"Q 6$!$3
M%!45%0P/%Q@6%!@2%!44_]L 0P$#! 0%! 4)!04)% T+#104%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!04%!04%!04%!04%!04%!04_\  $0@
MD ,B P$B  (1 0,1 ?_$ !\   $% 0$! 0$!           ! @,$!08'" D*
M"__$ +40  (! P,"! ,%!00$   !?0$" P $$042(3%!!A-180<B<10R@9&A
M""-"L<$54M'P)#-B<H()"A87&!D:)28G*"DJ-#4V-S@Y.D-$149'2$E*4U15
M5E=865IC9&5F9VAI:G-T=79W>'EZ@X2%AH>(B8J2DY25EI>8F9JBHZ2EIJ>H
MJ:JRL[2UMK>XN;K"P\3%QL?(R<K2T]35UM?8V=KAXN/DY>;GZ.GJ\?+S]/7V
M]_CY^O_$ !\!  ,! 0$! 0$! 0$        ! @,$!08'" D*"__$ +41  (!
M @0$ P0'!00$  $"=P ! @,1! 4A,08205$'87$3(C*!"!1"D:&QP0DC,U+P
M%6)RT0H6)#3A)?$7&!D:)B<H*2HU-C<X.3I#1$5&1TA)2E-455976%E:8V1E
M9F=H:6IS='5V=WAY>H*#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6V
MM[BYNL+#Q,7&Q\C)RM+3U-76U]C9VN+CY.7FY^CIZO+S]/7V]_CY^O_:  P#
M 0 "$0,1 #\ _5"BBBH+"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M66K:/9,P7[3>6#B,$]-Q7.W_ (%BNCL/$6GZMH_]J:=<KJ-D59EDM?WA?'4
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MT"2VW'EH"?NX_P!DG\BOI7?_ !7^&]O\2/"LMB1'%J$'[RQN"/\ 5R ?=/\
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MD<$R+MR<#WQ2^(/C'X-\)6EQ<ZAJ,L-M;WKV-Q+;Z?<3K%<KLW(YBC8*3YB
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MX4_O:W_X3NH__&*/^%W>%/[VM_\ A.ZC_P#&*+,+G>8HQ7!_\+N\*?WM;_\
M"=U'_P",4?\ "[O"G][6_P#PG=1_^,4687.\Q1BN#_X7=X4_O:W_ .$[J/\
M\8H_X7=X4_O:W_X3NH__ !BBS"YWF*,5P?\ PN[PI_>UO_PG=1_^,4?\+N\*
M?WM;_P#"=U'_ .,4687.\Q1BN#_X7=X4_O:W_P"$[J/_ ,8H_P"%W>%/[VM_
M^$[J/_QBBS"YWF*,5P?_  N[PI_>UO\ \)W4?_C%'_"[O"G][6__  G=1_\
MC%%F%SO,48K@_P#A=WA3^]K?_A.ZC_\ &*/^%W>%/[VM_P#A.ZC_ /&*+,+G
M>8HQ7!_\+N\*?WM;_P#"=U'_ .,4?\+N\*?WM;_\)W4?_C%%F%SO,48K@_\
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M%W^%/[VM?^$[J/\ \8HLP.\Q1BN#_P"%W>%?[VM_^$[J/_QBC_A=WA7UUO\
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M!1^ HHH"P?@*/P%%% 6#\!1^ HHH"P?@*/P%%% 6#\!1^ HHH"P?@*/P%%%
M6#\!1^ HHH"P?@*/P%%% 6#\!1^ HHH"P?@*/P%%% 6#\!1^ HHH"P?@****
M L)BDR/6G'I7+?$N]\2Z;X%UBY\(Z5'K'B58-MC9RRI&KR$@ L695(4$MM)
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M&,NZ, ,[F*\ U4^-G@F?X@_#/6])L)!'K"HEYI<IZQ7L#B:W<'M^]C3/MFO
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M<M@O&XDAPY:'&,$&HM4_9[\3W7Q%N=1?1+2^UZ3Q#9ZK9_$!]0V26EG"(U:
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M()/+L8OW5G%D<<1J9"/[TS]S7HE9RMT&@HHHI#"BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
..HHHH **** "BBB@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.4</span><table class="report" border="0" cellspacing="2" id="idm140170914651624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2021 </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressesLineItems', window );"><strong>Entity Addresses [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">BRIGHT MINDS BIOSCIENCES INC.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001827401<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">20-F/A<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentRegistrationStatement', window );">Document Registration Statement</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-40997<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Sep. 30,  2021<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">19 Vestry Street<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">NY<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">NY<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">Z4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCountry', window );">Entity Address, Country</a></td>
<td class="text">US<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">10013<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Shares<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">DRUG<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentDescription', window );">Amendment Description</a></td>
<td class="text">

                            Bright Minds Biosciences Inc. (the "Company") is filing this Amendment No. 1 to Form 20-F (the "Form 20-F/A") for the year ended September 30, 2021 to furnish Exhibit 101 to the Form 20-F, which provides certain items from our Form 20-F formatted in eXtensible Business Reporting Language ("XBRL"). In accordance with the policy of the Securities and Exchange Commission (the "Commission") stated in Release No. 33-9002, we are filing this Form 20-F/A within the 30-day period available to first-time XBRL filers following the filing of our Form 20-F, as filed with the Commission on December 29, 2021. Accordingly, this Form 20-F/A consists only of the facing page, this explanatory note, Item 18, Item 19, the signature page and Exhibit 101.
                            No other changes have been made to the Form 20-F other than the furnishing of the exhibit described above. This Form 20-F/A does not reflect subsequent events occurring after the original date of the Form 20-F, or modify or update in any way disclosures made in the Form 20-F.

                    <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--09-30<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="nump">11,834,361<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentAccountingStandard', window );">Document Accounting Standard</a></td>
<td class="text">International Financial Reporting Standards<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2021<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentShellCompanyReport', window );">Document Shell Company Report</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressesAddressTypeAxis=dei_BusinessContactMember', window );">Business Contact [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressesLineItems', window );"><strong>Entity Addresses [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_ContactPersonnelName', window );">Contact Personnel Name</a></td>
<td class="text">Ian McDonald<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">19 Vestry Street<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">NY<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">NY<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">10013<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">647<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">407-2515<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_ContactPersonnelEmailAddress', window );">Contact Personnel Email Address</a></td>
<td class="text">ian@brightmindsbio.com<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of changes contained within amended document.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_ContactPersonnelEmailAddress">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Email address of contact personnel.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_ContactPersonnelEmailAddress</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_ContactPersonnelName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of contact personnel</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_ContactPersonnelName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAccountingStandard">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAccountingStandard</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:accountingStandardItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentRegistrationStatement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a registration statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number Section<br> -Section 12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentRegistrationStatement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentShellCompanyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentShellCompanyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCountry">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>ISO 3166-1 alpha-2 country code.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCountry</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:countryCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressesAddressTypeAxis=dei_BusinessContactMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressesAddressTypeAxis=dei_BusinessContactMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.4</span><table class="report" border="0" cellspacing="2" id="idm140170912124696">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Financial Position - CAD ($)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CurrentAssetsAbstract', window );"><strong>Current assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 19,760,015<span></span>
</td>
<td class="nump">$ 799,929<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CurrentTaxAssetsCurrent', window );">Sales tax receivable</a></td>
<td class="nump">110,146<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CurrentPrepaidExpenses', window );">Prepaids</a></td>
<td class="nump">168,207<span></span>
</td>
<td class="nump">78,287<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CurrentAssets', window );">Total current assets</a></td>
<td class="nump">20,038,368<span></span>
</td>
<td class="nump">878,216<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NoncurrentAssetsAbstract', window );"><strong>Non-current assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsAndGoodwill', window );">Intangible assets</a></td>
<td class="nump">2,000<span></span>
</td>
<td class="nump">2,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Assets', window );">Total assets</a></td>
<td class="nump">20,040,368<span></span>
</td>
<td class="nump">880,216<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CurrentLiabilitiesAbstract', window );"><strong>Current liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TradeAndOtherCurrentPayables', window );">Accounts payable and accrued liabilities</a></td>
<td class="nump">638,573<span></span>
</td>
<td class="nump">150,923<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Liabilities', window );">TOTAL LIABILITIES</a></td>
<td class="nump">638,573<span></span>
</td>
<td class="nump">150,923<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_EquityAbstract', window );"><strong>Shareholders' equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IssuedCapital', window );">Share capital</a></td>
<td class="nump">27,080,281<span></span>
</td>
<td class="nump">980,661<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drug_SubscriptionsReceivable', window );">Subscription receivable</a></td>
<td class="num">(33,684)<span></span>
</td>
<td class="num">(1,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drug_SubscriptionsReceived', window );">Subscription received</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">147,426<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherReserves', window );">Reserves</a></td>
<td class="nump">1,565,055<span></span>
</td>
<td class="nump">161,300<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RetainedEarnings', window );">Deficit</a></td>
<td class="num">(9,209,857)<span></span>
</td>
<td class="num">(559,094)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Equity', window );">TOTAL SHAREHOLDERS' EQUITY</a></td>
<td class="nump">19,401,795<span></span>
</td>
<td class="nump">729,293<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_EquityAndLiabilities', window );">TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY</a></td>
<td class="nump">$ 20,040,368<span></span>
</td>
<td class="nump">$ 880,216<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_drug_SubscriptionsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of subscriptions receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">drug_SubscriptionsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>drug_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_drug_SubscriptionsReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of subscriptions received.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">drug_SubscriptionsReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>drug_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of a present economic resource controlled by the entity as a result of past events. Economic resource is a right that has the potential to produce economic benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2020-01-01<br> -Paragraph 93<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_93_a&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2020-01-01<br> -Paragraph 28<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_28_c&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2020-01-01<br> -Paragraph 93<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_93_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2020-01-01<br> -Paragraph 93<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_93_e&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 55<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2020-01-01<br> -Paragraph 23<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2020-01-01<br> -Paragraph 45<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2020-01-01<br> -Paragraph B13<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_B13_a&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2020-01-01<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 54<br> -Subparagraph i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_54_i&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of assets that the entity (a) expects to realise or intends to sell or consume in its normal operating cycle; (b) holds primarily for the purpose of trading; (c) expects to realise within twelve months after the reporting period; or (d) classifies as cash or cash equivalents (as defined in IAS 7) unless the asset is restricted from being exchanged or used to settle a liability for at least twelve months after the reporting period. [Refer: Assets]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2020-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_B12_b_i&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 66<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2020-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentPrepaidExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount recognised as a current asset for expenditures made prior to the period when the economic benefit will be realised.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentPrepaidExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentTaxAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The current amount of current tax assets. [Refer: Current tax assets]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 54<br> -Subparagraph n<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_54_n&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentTaxAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Equity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of residual interest in the assets of the entity after deducting all its liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 24<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_24_a&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_32_a_i&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2020-01-01<br> -Paragraph 93<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_93_a&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2020-01-01<br> -Paragraph 93<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_93_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2020-01-01<br> -Paragraph 93<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_93_e&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 55<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Equity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EquityAndLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of the entity's equity and liabilities. [Refer: Equity; Liabilities]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 55<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EquityAndLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IntangibleAssetsAndGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of intangible assets and goodwill held by the entity. [Refer: Goodwill; Intangible assets other than goodwill]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 55<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IntangibleAssetsAndGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IssuedCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The nominal value of capital issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IssuedCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of a present obligation of the entity to transfer an economic resource as a result of past events. Economic resource is a right that has the potential to produce economic benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2020-01-01<br> -Paragraph 93<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_93_a&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2020-01-01<br> -Paragraph 93<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_93_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2020-01-01<br> -Paragraph 93<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_93_e&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2020-01-01<br> -Paragraph 28<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_28_d&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2020-01-01<br> -Paragraph 23<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 55<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A component of equity representing reserves within equity, not including retained earnings. [Refer: Retained earnings]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RetainedEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A component of equity representing the entity's cumulative undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph IG6<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_IG6&amp;doctype=Implementation%20Guidance<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RetainedEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeAndOtherCurrentPayables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of current trade payables and current other payables. [Refer: Current trade payables; Other current payables]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 54<br> -Subparagraph k<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_54_k&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeAndOtherCurrentPayables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.4</span><table class="report" border="0" cellspacing="2" id="idm140170915074648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Comprehensive Loss - CAD ($)<br></strong></div></th>
<th class="th" colspan="1">4 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExpenseByNatureAbstract', window );"><strong>EXPENSES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drug_ConsultingFees', window );">Consulting fees</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 394,624<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DirectorsRemunerationExpense', window );">Directors' compensation</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">136,612<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss', window );">Foreign exchange</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(154,099)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drug_ProcessingFees', window );">Funds processing fees - private placements</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">18,665<span></span>
</td>
<td class="nump">5,568<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SalesAndMarketingExpense', window );">Marketing, advertising, and investor relations</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">852,151<span></span>
</td>
<td class="nump">9,618<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_GeneralAndAdministrativeExpense', window );">Office and administrative</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">197,125<span></span>
</td>
<td class="nump">637<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProfessionalFeesExpense', window );">Professional fees</a></td>
<td class="nump">36,708<span></span>
</td>
<td class="nump">709,954<span></span>
</td>
<td class="nump">104,251<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drug_RegulatoryAndFilingExpenses', window );">Regulatory and filing</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">181,743<span></span>
</td>
<td class="nump">5,451<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">42,009<span></span>
</td>
<td class="nump">6,313,988<span></span>
</td>
<td class="nump">354,852<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Net loss and comprehensive loss</a></td>
<td class="num">$ (78,717)<span></span>
</td>
<td class="num">$ (8,650,763)<span></span>
</td>
<td class="num">$ (480,377)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_BasicAndDilutedEarningsLossPerShare', window );">Basic and diluted loss per share</a></td>
<td class="num">$ (0.04)<span></span>
</td>
<td class="num">$ (0.96)<span></span>
</td>
<td class="num">$ (0.13)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageShares', window );">Weighted average number of common shares outstanding&#160;-basic and diluted</a></td>
<td class="nump">2,073,240<span></span>
</td>
<td class="nump">8,974,023<span></span>
</td>
<td class="nump">3,612,436<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_drug_ConsultingFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of consulting fees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">drug_ConsultingFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>drug_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_drug_ProcessingFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expenses related to initial listing of the company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">drug_ProcessingFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>drug_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_drug_RegulatoryAndFilingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expenses related to regulatory and filing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">drug_RegulatoryAndFilingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>drug_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BasicAndDilutedEarningsLossPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of earnings per share when the basic and diluted measurements are equal. [Refer: Basic earnings (loss) per share; Diluted earnings (loss) per share]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 85<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BasicAndDilutedEarningsLossPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DirectorsRemunerationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of remuneration paid or payable to the entity's directors.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DirectorsRemunerationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExpenseByNatureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExpenseByNatureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of exchange differences recognised in profit or loss that arise from foreign currency transactions, excluding those arising on financial instruments measured at fair value through profit or loss in accordance with IFRS 9. [Refer: At fair value [member]; Financial instruments, class [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2020-01-01<br> -Section A Statement of cash flows for an entity other than a financial institution<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2020-en-r&amp;doctype=Illustrative%20Examples&amp;dita_xref=IAS07_IE_A_TI<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 21<br> -IssueDate 2020-01-01<br> -Paragraph 52<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=21&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_52_a&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense relating to general and administrative activities of the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfessionalFeesExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of fees paid or payable for professional services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfessionalFeesExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2020-01-01<br> -Paragraph 18<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_18_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause ii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_32_a_ii&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2020-01-01<br> -Paragraph 28<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_28_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Note Effective on first application of IFRS 9<br> -Name IFRS<br> -Number 4<br> -IssueDate 2020-01-01<br> -Paragraph 39L<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=4&amp;code=ifrs-tx-2020-en-b&amp;anchor=para_39L_e&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2020-01-01<br> -Paragraph 23<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2020-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2020-01-01<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_106_d_i&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Note Effective 2021-01-01<br> -Name IFRS<br> -Number 17<br> -IssueDate 2020-01-01<br> -Paragraph 113<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=17&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_113_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 81A<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_81A_a&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expenditure directly attributable to research or development activities, recognised in profit or loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2020-01-01<br> -Paragraph 126<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_126&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SalesAndMarketingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense relating to the marketing and selling of goods or services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 85<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SalesAndMarketingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of ordinary shares outstanding at the beginning of the period, adjusted by the number of ordinary shares bought back or issued during the period multiplied by a time-weighting factor.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2020-01-01<br> -Paragraph 70<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_70_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.4</span><table class="report" border="0" cellspacing="2" id="idm140170911682936">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Changes in Shareholders' Equity - CAD ($)<br></strong></div></th>
<th class="th"><div>Share capital [Member]</div></th>
<th class="th"><div>Subscriptions receivable [Member]</div></th>
<th class="th"><div>Subscriptions received [Member]</div></th>
<th class="th"><div>Reserves [Member]</div></th>
<th class="th"><div>Deficit [Member]</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Equity', window );">Balance at May. 31, 2019</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfSharesOutstanding', window );">Balance (shares) at May. 31, 2019</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drug_IncreaseDecreaseThroughPrivatePlacement', window );">Private placement</a></td>
<td class="nump">$ 203,980<span></span>
</td>
<td class="num">(81,980)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">122,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drug_IncreaseDecreaseThroughPrivatePlacementShares', window );">Private placement (shares)</a></td>
<td class="nump">4,079,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drug_IncreaseDecreaseThroughAcquisitionOfIntangibleAssets', window );">Acquisition of intangible assets</a></td>
<td class="nump">$ 2,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drug_IncreaseDecreaseThroughAcquisitionOfIntangibleAssetsShares', window );">Acquisition of intangible asset (shares)</a></td>
<td class="nump">40,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Net loss</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(78,717)<span></span>
</td>
<td class="num">(78,717)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Equity', window );">Balance at Sep. 30, 2019</a></td>
<td class="nump">$ 205,980<span></span>
</td>
<td class="num">(81,980)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(78,717)<span></span>
</td>
<td class="nump">45,283<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfSharesOutstanding', window );">Balance (shares) at Sep. 30, 2019</a></td>
<td class="nump">4,119,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drug_IncreaseDecreaseThroughPrivatePlacement', window );">Private placement</a></td>
<td class="nump">$ 779,924<span></span>
</td>
<td class="nump">80,980<span></span>
</td>
<td class="nump">147,426<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,008,330<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drug_IncreaseDecreaseThroughPrivatePlacementShares', window );">Private placement (shares)</a></td>
<td class="nump">623,941<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ShareIssueRelatedCost', window );">Share issue costs</a></td>
<td class="num">$ (5,243)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(5,243)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions', window );">Share-based compensation</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">161,300<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">161,300<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Net loss</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(480,377)<span></span>
</td>
<td class="num">(480,377)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Equity', window );">Balance at Sep. 30, 2020</a></td>
<td class="nump">$ 980,661<span></span>
</td>
<td class="num">(1,000)<span></span>
</td>
<td class="nump">147,426<span></span>
</td>
<td class="nump">161,300<span></span>
</td>
<td class="num">(559,094)<span></span>
</td>
<td class="nump">729,293<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfSharesOutstanding', window );">Balance (shares) at Sep. 30, 2020</a></td>
<td class="nump">4,743,541<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drug_IncreaseDecreaseThroughPrivatePlacement', window );">Private placement</a></td>
<td class="nump">$ 27,924,936<span></span>
</td>
<td class="num">(32,684)<span></span>
</td>
<td class="num">(147,426)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">27,744,826<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drug_IncreaseDecreaseThroughPrivatePlacementShares', window );">Private placement (shares)</a></td>
<td class="nump">5,049,021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drug_IncreaseDecreaseThroughFindersFeesCash', window );">Finder's fees - cash</a></td>
<td class="num">$ (1,516,317)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(1,516,317)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drug_IncreaseDecreaseThroughFindersFeesBrokerWarrants', window );">Finder's fees - broker warrants</a></td>
<td class="num">(521,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">521,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drug_IncreaseDecreaseThroughFindersFeesShareOptions', window );">Finder's fees - share options</a></td>
<td class="num">(2,140)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,140<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drug_IncreaseDecreaseThroughDebtSettlementWithShare', window );">Debt settlement with shares</a></td>
<td class="nump">18,500<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">18,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ShareIssueRelatedCost', window );">Share issue costs</a></td>
<td class="num">$ (290,309)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(290,309)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drug_IncreaseDecreaseThroughDebtSettlementWithShareShares', window );">Debt settlement with shares (shares)</a></td>
<td class="nump">14,799<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drug_IncreaseDecreaseThroughSpecialWarrantConversion', window );">Special warrant conversion</a></td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">20,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drug_IncreaseDecreaseThroughSpecialWarrantConversionShares', window );">Special warrant conversion (shares)</a></td>
<td class="nump">16,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity', window );">Warrants exercised</a></td>
<td class="nump">$ 97,400<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">97,400<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drug_IncreaseDecreaseThroughExerciseOfWarrantsShares', window );">Warrants exercised (shares)</a></td>
<td class="nump">1,948,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drug_IncreaseDecreaseThroughSharesIssuedToUniversity', window );">Shares issued to the University</a></td>
<td class="nump">$ 368,550<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">368,550<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drug_IncreaseDecreaseThroughSharesIssuedToUniversityShares', window );">Shares issued to the University (shares)</a></td>
<td class="nump">63,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions', window );">Share-based compensation</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">880,615<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">880,615<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Net loss</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(8,650,763)<span></span>
</td>
<td class="num">(8,650,763)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Equity', window );">Balance at Sep. 30, 2021</a></td>
<td class="nump">$ 27,080,281<span></span>
</td>
<td class="num">$ (33,684)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 1,565,055<span></span>
</td>
<td class="num">$ (9,209,857)<span></span>
</td>
<td class="nump">$ 19,401,795<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfSharesOutstanding', window );">Balance (shares) at Sep. 30, 2021</a></td>
<td class="nump">11,834,361<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_drug_IncreaseDecreaseThroughAcquisitionOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in equity resulting from the acquisition of of intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">drug_IncreaseDecreaseThroughAcquisitionOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>drug_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_drug_IncreaseDecreaseThroughAcquisitionOfIntangibleAssetsShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase and decrease in equity resulting from acquisition of intangible assets shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">drug_IncreaseDecreaseThroughAcquisitionOfIntangibleAssetsShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>drug_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_drug_IncreaseDecreaseThroughDebtSettlementWithShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase decrease in equity through settlement of debt with shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">drug_IncreaseDecreaseThroughDebtSettlementWithShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>drug_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_drug_IncreaseDecreaseThroughDebtSettlementWithShareShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) through debt settlement with share shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">drug_IncreaseDecreaseThroughDebtSettlementWithShareShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>drug_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_drug_IncreaseDecreaseThroughExerciseOfWarrantsShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) through exercise of warrants shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">drug_IncreaseDecreaseThroughExerciseOfWarrantsShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>drug_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_drug_IncreaseDecreaseThroughFindersFeesBrokerWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Increase decrease through distribution of broker warrants for finders fees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">drug_IncreaseDecreaseThroughFindersFeesBrokerWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>drug_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_drug_IncreaseDecreaseThroughFindersFeesCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the increase (decrease) through cash distribution for finder's fee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">drug_IncreaseDecreaseThroughFindersFeesCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>drug_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_drug_IncreaseDecreaseThroughFindersFeesShareOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents increase (decrease) through exercise of options for finders fee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">drug_IncreaseDecreaseThroughFindersFeesShareOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>drug_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_drug_IncreaseDecreaseThroughPrivatePlacement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of shares issued under private placement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">drug_IncreaseDecreaseThroughPrivatePlacement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>drug_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_drug_IncreaseDecreaseThroughPrivatePlacementShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the number of shares issued under private placement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">drug_IncreaseDecreaseThroughPrivatePlacementShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>drug_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_drug_IncreaseDecreaseThroughSharesIssuedToUniversity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) through shares issued to university.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">drug_IncreaseDecreaseThroughSharesIssuedToUniversity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>drug_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_drug_IncreaseDecreaseThroughSharesIssuedToUniversityShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) through shares issued to university shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">drug_IncreaseDecreaseThroughSharesIssuedToUniversityShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>drug_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_drug_IncreaseDecreaseThroughSpecialWarrantConversion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) through special warrant conversion.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">drug_IncreaseDecreaseThroughSpecialWarrantConversion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>drug_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_drug_IncreaseDecreaseThroughSpecialWarrantConversionShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) through special warrant conversion shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">drug_IncreaseDecreaseThroughSpecialWarrantConversionShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>drug_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Equity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of residual interest in the assets of the entity after deducting all its liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 24<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_24_a&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_32_a_i&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2020-01-01<br> -Paragraph 93<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_93_a&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2020-01-01<br> -Paragraph 93<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_93_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2020-01-01<br> -Paragraph 93<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_93_e&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 55<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Equity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in equity resulting from the exercise of warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_106_d&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in equity resulting from share-based payment transactions. [Refer: Equity]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -Clause iii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_106_d_iii&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares that have been authorised and issued, reduced by treasury shares held. [Refer: Treasury shares]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 79<br> -Subparagraph a<br> -Clause iv<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_79_a_iv&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2020-01-01<br> -Paragraph 18<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_18_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause ii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_32_a_ii&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2020-01-01<br> -Paragraph 28<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_28_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Note Effective on first application of IFRS 9<br> -Name IFRS<br> -Number 4<br> -IssueDate 2020-01-01<br> -Paragraph 39L<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=4&amp;code=ifrs-tx-2020-en-b&amp;anchor=para_39L_e&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2020-01-01<br> -Paragraph 23<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2020-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2020-01-01<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_106_d_i&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Note Effective 2021-01-01<br> -Name IFRS<br> -Number 17<br> -IssueDate 2020-01-01<br> -Paragraph 113<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=17&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_113_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 81A<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_81A_a&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ShareIssueRelatedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cost related to the issuance of shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_106_d&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ShareIssueRelatedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.4</span><table class="report" border="0" cellspacing="2" id="idm140170911470984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - CAD ($)<br></strong></div></th>
<th class="th" colspan="1">4 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract', window );"><strong>Operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Net loss for the year</a></td>
<td class="num">$ (78,717)<span></span>
</td>
<td class="num">$ (8,650,763)<span></span>
</td>
<td class="num">$ (480,377)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdjustmentsForReconcileProfitLossAbstract', window );"><strong>Non-cash items:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains', window );">Foreign exchange</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(223,787)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drug_AdjustmentsForSharesRecordedAsResearchAndDevelopment', window );">Shares recorded as research and development</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">368,550<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdjustmentsForSharebasedPayments', window );">Share-based compensation</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">880,615<span></span>
</td>
<td class="nump">161,300<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drug_ChangesInNonCashWorkingOperatingCapitalBalancesAbstract', window );"><strong>Changes in non-cash operating working capital items:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drug_AdjustmentsForDecreaseIncreaseInSalesTaxReceivable', window );">Sales tax receivable</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(110,146)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drug_AdjustmentsForDecreaseIncreaseInPrepaidExpenses', window );">Prepaids</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(89,920)<span></span>
</td>
<td class="num">(78,287)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable', window );">Accounts payable and accrued liabilities</a></td>
<td class="nump">36,708<span></span>
</td>
<td class="nump">506,150<span></span>
</td>
<td class="nump">108,972<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(42,009)<span></span>
</td>
<td class="num">(7,319,301)<span></span>
</td>
<td class="num">(288,392)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract', window );"><strong>Financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProceedsFromIssuingShares', window );">Private placement proceeds</a></td>
<td class="nump">122,000<span></span>
</td>
<td class="nump">27,744,826<span></span>
</td>
<td class="nump">1,008,330<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drug_PaymentsForFindersFees', window );">Finder's fees</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(1,516,317)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PaymentsForShareIssueCosts', window );">Share issuance costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">290,309<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drug_ProceedsFromIssuingWarrants', window );">Special warrant proceeds</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">22,875<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drug_RefundOfSpecialWarrantsProceeds', window );">Refund of special warrant proceeds</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(2,875)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drug_ProceedsFromWarrantsExercise', window );">Warrant exercise proceeds</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">97,400<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInFinancingActivities', window );">Net cash from financing activities</a></td>
<td class="nump">122,000<span></span>
</td>
<td class="nump">26,055,600<span></span>
</td>
<td class="nump">1,008,330<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents', window );">Change in cash</a></td>
<td class="nump">79,991<span></span>
</td>
<td class="nump">18,736,299<span></span>
</td>
<td class="nump">719,938<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents', window );">Effect of foreign exchange on cash</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">223,787<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash, beginning of year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">799,929<span></span>
</td>
<td class="nump">79,991<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents, end of year</a></td>
<td class="nump">79,991<span></span>
</td>
<td class="nump">19,760,015<span></span>
</td>
<td class="nump">799,929<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drug_SupplementaryInformationAbstract', window );"><strong>SUPPLEMENTARY INFORMATION</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drug_DebtSettledByIssuingShares', window );">Debt settled by issuing shares</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">18,500<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drug_FairValueAscribedToBrokersWarrantsIssued', window );">Fair value ascribed to brokers' warrants issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">521,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drug_FairValueOfOptionsIssuedAsFindersFees', window );">Fair value of options issued as finder's fees</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,140<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drug_ShareIssueCostsIncludedInAccountsPayable', window );">Share issue costs included in accounts payable</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">5,243<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drug_AcquisitionOfIntangibleAssetsByIssuingCommonShares', window );">Acquisition of intangible assets by issuing common shares</a></td>
<td class="nump">$ 2,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_drug_AcquisitionOfIntangibleAssetsByIssuingCommonShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents amount of acquisition of intangible assets by issuing common shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">drug_AcquisitionOfIntangibleAssetsByIssuingCommonShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>drug_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_drug_AdjustmentsForDecreaseIncreaseInPrepaidExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents adjustments for decrease increase in prepaid expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">drug_AdjustmentsForDecreaseIncreaseInPrepaidExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>drug_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_drug_AdjustmentsForDecreaseIncreaseInSalesTaxReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents adjustments for decrease increase in sales tax receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">drug_AdjustmentsForDecreaseIncreaseInSalesTaxReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>drug_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_drug_AdjustmentsForSharesRecordedAsResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Adjustments For Shares recorded as research and development</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">drug_AdjustmentsForSharesRecordedAsResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>drug_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_drug_ChangesInNonCashWorkingOperatingCapitalBalancesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Changes In Non Cash Working Operating Capital Balances [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">drug_ChangesInNonCashWorkingOperatingCapitalBalancesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>drug_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_drug_DebtSettledByIssuingShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents debt settled by issuing shares</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">drug_DebtSettledByIssuingShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>drug_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_drug_FairValueAscribedToBrokersWarrantsIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value ascribed to brokers' warrants issued</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">drug_FairValueAscribedToBrokersWarrantsIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>drug_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_drug_FairValueOfOptionsIssuedAsFindersFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of options issued as finder's fees</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">drug_FairValueOfOptionsIssuedAsFindersFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>drug_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_drug_PaymentsForFindersFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the payments for finders fees</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">drug_PaymentsForFindersFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>drug_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_drug_ProceedsFromIssuingWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents amount of proceeds from issuing warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">drug_ProceedsFromIssuingWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>drug_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_drug_ProceedsFromWarrantsExercise">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents Proceeds From Warrants Exercise</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">drug_ProceedsFromWarrantsExercise</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>drug_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_drug_RefundOfSpecialWarrantsProceeds">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents refund of special warrants proceeds.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">drug_RefundOfSpecialWarrantsProceeds</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>drug_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_drug_ShareIssueCostsIncludedInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share issue costs included in accounts payable</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">drug_ShareIssueCostsIncludedInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>drug_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_drug_SupplementaryInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Supplementary Information Abstract</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">drug_SupplementaryInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>drug_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments for increase (decrease) in trade accounts payable to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2020-01-01<br> -Paragraph 20<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_20_a&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForReconcileProfitLossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForReconcileProfitLossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForSharebasedPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments for share-based payments to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2020-01-01<br> -Paragraph 20<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_20_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForSharebasedPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments for unrealised foreign exchange losses (gains) to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2020-01-01<br> -Paragraph 20<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_20_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2020-01-01<br> -Paragraph 45<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2020-01-01<br> -Paragraph B13<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_B13_a&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2020-01-01<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 54<br> -Subparagraph i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_54_i&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash flows from (used in) financing activities, which are activities that result in changes in the size and composition of the contributed equity and borrowings of the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2020-01-01<br> -Paragraph 10<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_10&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2020-01-01<br> -Paragraph 50<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_50_d&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash flows from (used in) operating activities, which are the principal revenue-producing activities of the entity and other activities that are not investing or financing activities. [Refer: Revenue]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2020-01-01<br> -Paragraph 10<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_10&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2020-01-01<br> -Paragraph 50<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_50_d&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The effect of exchange rate changes on cash and cash equivalents held or due in a foreign currency. [Refer: Cash and cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2020-01-01<br> -Paragraph 25<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_25&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2020-01-01<br> -Paragraph 28<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_28&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in cash and cash equivalents. [Refer: Cash and cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2020-01-01<br> -Paragraph 45<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseInCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PaymentsForShareIssueCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for share issue costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2020-01-01<br> -Paragraph 17<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_17&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PaymentsForShareIssueCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProceedsFromIssuingShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuing shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2020-01-01<br> -Paragraph 17<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_17_a&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProceedsFromIssuingShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2020-01-01<br> -Paragraph 18<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_18_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause ii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_32_a_ii&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2020-01-01<br> -Paragraph 28<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_28_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Note Effective on first application of IFRS 9<br> -Name IFRS<br> -Number 4<br> -IssueDate 2020-01-01<br> -Paragraph 39L<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=4&amp;code=ifrs-tx-2020-en-b&amp;anchor=para_39L_e&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2020-01-01<br> -Paragraph 23<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2020-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2020-01-01<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_106_d_i&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Note Effective 2021-01-01<br> -Name IFRS<br> -Number 17<br> -IssueDate 2020-01-01<br> -Paragraph 113<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=17&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_113_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 81A<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_81A_a&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.4</span><table class="report" border="0" cellspacing="2" id="idm140170923861736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NATURE AND CONTINUANCE OF OPERATIONS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drug_NatureAndContinuanceOfOperationsAbstract', window );"><strong>Nature And Continuance Of Operations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drug_DisclosureOfNatureAndContinuanceOfOperationsExplanatory', window );">NATURE AND CONTINUANCE OF OPERATIONS [Text Block]</a></td>
<td class="text">
                        <div>
                            <p style="margin-left: 18pt; text-indent: -18pt; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>1.</b><span style="width: 9pt; text-indent: 0pt; display: inline-block;">&#160;</span><b>NATURE AND CONTINUANCE OF OPERATIONS</b></span></span></p>
                            <p style="text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">Bright Minds Biosciences Inc. (the "Company") was incorporated under the Business Corporations Act of British Columbia on May 31, 2019. The Company's objective is to generate income and achieve long term profitable growth through the development of therapeutics to improve the lives of patients with certain severe and life-altering diseases. On February 8, 2021, the Company started trading on the Canadian Stock Exchange ("CSE") under the symbol DRUG. On May 17, 2021, the Company started trading on the OTCQB under the symbol BMBIF. On November 8, 2021, the Company started trading on NASDAQ under the symbol DRUG. The head office, and principal address of the Company are located at 1500 - 1055 West Georgia Street, Vancouver, British Columbia, V6E 4N7, Canada.</span></span></p>
                            <p style="text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">These consolidated financial statements have been prepared on a going concern basis which assumes that the Company will be able to realize its assets and discharge its liabilities in the normal course of business for the foreseeable future. As at September 30, 2021, the Company is not able to finance day to day activities through operations and has incurred a loss of $8,650,763 for the year ended September 30, 2021. The Company has a deficit of $9,209,857 since inception and negative operating cash flows. As at September 30, 2021, the Company has working capital of $19,399,795 (September 30, 2020 - $727,293). The continuing operations of the Company are dependent upon its ability to attain profitable operations and generate funds therefrom. Management intends to finance operating costs with equity financings, loans from directors and companies controlled by directors and/or private placement of common shares.</span></span></p>
                            <p style="text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">The coronavirus, also known as "COVID-19", has spread across the globe and is impacting worldwide economic activity. Government authorities have implemented emergency measures to mitigate the spread of the virus. The outbreak and the related mitigation measures may have an adverse impact on global economic conditions as well as on the Company's business activities specifically related to possible disruptions in the operations of the laboratories upon whom the Company relies, including laboratories situated in various parts of the United States and Europe. The extent to which the coronavirus may impact the Company's business activities will depend on future developments, such as the duration of the outbreak, travel restrictions, business disruptions, and the effectiveness of actions taken in Canada and other countries to contain and treat the disease. These events are highly uncertain and as such, the Company cannot determine their financial impact at this time.</span></span></p>
                        </div>
                    <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_drug_DisclosureOfNatureAndContinuanceOfOperationsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of nature and continuation of operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">drug_DisclosureOfNatureAndContinuanceOfOperationsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>drug_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_drug_NatureAndContinuanceOfOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">drug_NatureAndContinuanceOfOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>drug_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.4</span><table class="report" border="0" cellspacing="2" id="idm140170914463288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STATEMENT OF COMPLIANCE AND BASIS OF PREPARATION<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drug_StatementOfComplianceAndBasisOfPreparationAbstract', window );"><strong>Statement Of Compliance And Basis Of Preparation [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory', window );">STATEMENT OF COMPLIANCE AND BASIS OF PREPARATION [Text Block]</a></td>
<td class="text">
                        <div>
                            <p style="text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>2.</b><span style="width: 9pt; text-indent: 0pt; display: inline-block;">&#160;</span><b>STATEMENT OF COMPLIANCE AND BASIS OF PREPARATION</b></span></span></p>
                            <p style="text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">These consolidated financial statements were authorized for issue on December 24, 2021 by the directors of the Company.</span></span></p>
                            <p style="margin-bottom: 0pt; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>Statement of compliance</b></span></span></p>
                            <p style="margin-top: 0px; text-align: justify; margin-bottom: 0px;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">These consolidated financial statements have been prepared in accordance with the International Financial Reporting Standards ("IFRS") issued by the International Accounting Standards Board ("IASB") and Interpretations of the International Financial Reporting Interpretations Committee ("IFRIC"). The principal accounting policies applied in the preparation of these financial statements are set out below.</span></span></p>
                            <p style="margin-bottom: 0px; text-align: justify; margin-top: 13px;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>Basis of preparation</b></span></span></p>
                            <p style="margin-top: 0px; text-align: justify; margin-bottom: 0px;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">Depending on the applicable IFRS requirements, the measurement basis used in the preparation of these financial statements is cost, net realizable value, fair value or recoverable amount. These financial statements, except for the statement of cash flows, are based on the accrual basis.</span></span></p>
                        </div>
                    <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_drug_StatementOfComplianceAndBasisOfPreparationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">drug_StatementOfComplianceAndBasisOfPreparationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>drug_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of the basis used for the preparation of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.4</span><table class="report" border="0" cellspacing="2" id="idm140170923786776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drug_DisclosureOfDetailedInformationAboutSignificantAccountingPoliciesAbstract', window );"><strong>Disclosure Of Detailed Information About Significant Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory', window );">SIGNIFICANT ACCOUNTING POLICIES [Text Block]</a></td>
<td class="text">
                        <div>
                            <p style="text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>3.<span style="display: inline-block; width: 9pt;">&#160;</span>SIGNIFICANT ACCOUNTING POLICIES </b></span></span></p>

                                <div>
                                    <p style="margin-bottom: 0pt; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>Basis of consolidation </b></span></span></p>
                                    <p style="margin-top: 0pt; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">These consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries Psilocybinlabs Ltd. (see Note 4), Bright Minds Biosciences LLC, a Delaware limited liability company, and Bright Minds Bioscience Pty Ltd., a proprietary company registered under the Corporations Act of Australia on June 24, 2021.&#160; On June 10, 2021, the CEO of the Company transferred, assigned and conveyed all of his membership interests in Bright Minds Biosciences LLC to the Company.</span></span></p>
                                    <p style="text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">A subsidiary is an entity that the Company controls, either directly or indirectly, where control is defined as the power to govern the financial and operating policies of an entity so as to obtain benefits from its activities. The financial results of the Company's subsidiaries are included in the financial statements from the date that control commences until the date that control ceases. The accounting policies of the Company's subsidiaries have been aligned with the policies adopted by the Company. When the Company ceases to control a subsidiary, the financial statements of that subsidiary are de-consolidated.</span></span></p>
                                </div>

                        </div>

                        <div>

                                <p style="text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">Inter-company balances and transactions, and any income and expenses arising from inter-company transactions, have been eliminated in these financial statements.</span></span></p>


                                <div>
                                    <p style="margin-bottom: 0pt; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>Critical accounting estimates</b></span></span></p>
                                    <p style="margin-top: 0pt; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">The preparation of the financial statements in conformity with IFRS requires management to make estimates, judgments and assumptions that affect the application of accounting policies and the reported amounts of assets, liabilities, income and expenses. Actual results may differ from these estimates. Estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognized in the period in which the estimates are revised and in any future periods affected.</span></span></p>
                                    <p style="text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">Certain of the Company's accounting policies and disclosures require key assumptions concerning the future and other estimates that have a significant risk of causing a material adjustment to the carrying amounts of assets and liabilities or disclosures within the next fiscal year. Where applicable, further information about the assumptions made is disclosed in the notes specific to that asset or liability. The critical accounting estimates and judgments set out below have been applied consistently to all periods presented in these financial statements.</span></span></p>
                                    <p style="margin-bottom: 0pt; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span style="text-decoration: underline;">Ability to continue as a going concern</span></span></span></p>
                                    <p style="margin-top: 0pt; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">Evaluation of the ability of the Company to realize its strategy for funding its future needs for working capital involves making judgments.</span></span></p>
                                    <p style="margin-bottom: 0pt; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span style="text-decoration: underline;">Share-based compensation</span></span></span></p>
                                    <p style="margin-top: 0pt; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">The fair value of stock options is measured using a Black Scholes option pricing model. Measurement inputs include the common share price on the grant date, the exercise price of the instrument, the expected common share price volatility, the weighted average expected life of the instruments, the expected dividends and the risk-free interest rate. Service and non-market performance conditions are not taken into account in determining fair value. The fair value of equity settled RSUs is measured based on management's best estimate of the Company's share price on the grant date.</span></span></p>
                                    <p style="text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">The share-based compensation recognized is also determined based on management's grant date estimate of the forfeitures that are expected to occur over the life of the stock options and equity settled RSUs. Cash settled RSUs outstanding are fair valued using a mark-to-market calculation based on the Company's closing common share price at the end of the period. The number of stock options and RSUs that actually vest could differ from the estimated number of awards expected to vest and any differences between the actual and estimated forfeitures are recognized prospectively as they occur.</span></span></p>
                                </div>


                                <div>
                                    <p style="margin-bottom: 0pt; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>Foreign currency translation</b></span></span></p>
                                    <p style="margin-top: 0pt; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">The functional currency of the Company, Psilocybinlabs Ltd., Bright Minds Biosciences LLC and Bright Minds Bioscience Pty Ltd. is the Canadian dollar and the presentation currency of the Company is the Canadian dollar. Transactions in currencies other than the functional currency are recorded at the rates of exchange prevailing on the transaction date. Monetary assets and liabilities that are denominated in foreign currencies are translated at the rates prevailing at each reporting date. Non-monetary assets and liabilities denominated in foreign currencies that are measured at fair value are retranslated to the functional currency at the exchange rate at the date the fair value was determined. Non-monetary items that are measured in terms of historical cost in a foreign currency are not retranslated. Foreign currency translation differences are recognized in profit or loss.</span></span></p>
                                </div>


                                <div>
                                    <p style="margin-bottom: 0pt; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>Business combinations</b></span></span></p>
                                    <p style="margin-top: 0pt; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">The Company uses the acquisition method to account for business combinations. The Company measures goodwill as the fair value of the consideration transferred, less the net recognized amount (generally fair value) of the identifiable assets acquired and liabilities assumed, all measured as of the acquisition date. When the excess is negative, a gain on acquisition is recognized immediately in net income or loss.</span></span></p>
                                </div>

                        </div>

                        <div>

                                <div>
                                    <p style="margin-top: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">Goodwill is not amortized and is tested for impairment annually. Additionally, goodwill is reviewed at each reporting date to determine if events or changes in circumstances indicate that the asset might be impaired, in which case an impairment test is performed. Goodwill is measured at cost less accumulated impairment losses.</span></span></p>
                                    <p style="text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">Transaction costs, other than those associated with the issue of debt or equity securities, that the Company incurs in connection with a business combination are expensed as incurred.</span></span></p>
                                </div>


                                <div>
                                    <p style="margin-bottom: 0pt; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>Internally generated intangible assets - Research and development expenditure</b></span></span></p>
                                    <p style="margin-top: 0pt; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">Intangible assets acquired separately are initially recognized at cost. Expenditure on research activities is recognized as an expense in the period in which it is incurred. An internally-generated intangible asset arising from development (or from the development phase of an internal project) is recognized if, and only if, all of the following have been demonstrated:</span></span></p>
                                    <p style="margin-left: 36pt; margin-bottom: 0pt; text-indent: -18pt; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">&#8226;<span style="display: inline-block; width: 16.7pt;">&#160;</span>The technical feasibility of completing the intangible asset so that it will be available for use or sale;</span></span></p>
                                    <p style="margin-top: 0pt; margin-left: 36pt; margin-bottom: 0pt; text-indent: -18pt; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">&#8226;<span style="display: inline-block; width: 16.7pt;">&#160;</span>The intention to complete the intangible asset and use or sell it;</span></span></p>
                                    <p style="margin-top: 0pt; margin-left: 36pt; margin-bottom: 0pt; text-indent: -18pt; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">&#8226;<span style="display: inline-block; width: 16.7pt;">&#160;</span>The ability to use or sell the intangible asset;</span></span></p>
                                    <p style="margin-top: 0pt; margin-left: 36pt; margin-bottom: 0pt; text-indent: -18pt; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">&#8226;<span style="display: inline-block; width: 16.7pt;">&#160;</span>How the intangible asset will generate probable future economic benefits;</span></span></p>
                                    <p style="margin-top: 0pt; margin-left: 36pt; margin-bottom: 0pt; text-indent: -18pt; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">&#8226;<span style="display: inline-block; width: 16.7pt;">&#160;</span>The availability of adequate technical, financial and other resources to complete the development and to use or sell the intangible asset; and</span></span></p>
                                    <p style="margin-top: 0pt; margin-left: 36pt; text-indent: -18pt; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">&#8226;<span style="display: inline-block; width: 16.7pt;">&#160;</span>The ability to measure reliably the expenditure attributable to the intangible asset during its development.</span></span></p>
                                    <p style="text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">The amount initially recognized for internally-generated intangible assets is the sum of the expenditure incurred from the date when the intangible asset first meets the recognition criteria listed above. Where no internally-generated intangible asset can be recognized, development expenditure is recognized in profit or loss in the period in which it is incurred.</span></span></p>
                                    <p style="text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">Subsequent to initial recognition, internally-generated intangible assets are reported at cost less accumulated amortization and accumulated impairment losses, on the same basis as intangible assets that are acquired separately.</span></span></p>
                                    <p style="text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">At September 30, 2021 and 2020, the Company has not recognized any internally-generated intangible assets.</span></span></p>
                                </div>


                                <div>
                                    <p style="margin-bottom: 0pt; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>Share-based compensation awards</b></span></span></p>
                                    <p style="margin-top: 0pt; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">Share-based compensation expense relates to stock options as well as cash and equity settled restricted share units ("RSUs"). The grant date fair values of stock options and equity settled RSUs granted are recognized as an expense, with a corresponding increase in reserves in equity, over the vesting period. The amount recognized as an expense is based on the estimate of the number of awards expected to vest, which is revised if subsequent information indicates that actual forfeitures are likely to differ from the estimate. Upon exercise of stock options, the consideration paid by the holder is included in share capital and the related reserves associated with the stock options exercised is reclassified into share capital. Upon vesting of equity settled RSUs, the related reserves associated with the RSU is reclassified into share capital.</span></span></p>
                                    <p style="text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">For cash settled RSUs, the fair value of the RSUs is recognized as share-based compensation expense, with a corresponding increase in accrued liabilities over the vesting period. The amount recognized as an expense is based on the estimate of the number of RSUs expected to vest. Cash settled RSUs are measured at their fair value at each reporting period on a mark-to-market basis. Upon vesting of the cash settled RSUs, the liability is reduced by the cash payout.</span></span></p>
                                </div>


                                <div>
                                    <p style="margin-bottom: 0pt; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>Provisions</b></span></span></p>
                                    <p style="margin-top: 0pt; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">A provision is recognized if, as a result of a past event, the Company has a present legal or constructive obligation that can be estimated reliably, and it is probable that an outflow of economic benefits will be required to settle the obligation. Provisions are determined by discounting the expected future cash flows at a pre-tax rate that reflects current market assessments of the time value of money and the risks specific to the liability. The unwinding of the discount is recognized as a finance cost within net income or loss.</span></span></p>
                                </div>

                        </div>

                        <div>

                                <div>
                                    <p style="margin-bottom: 0pt; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>Income taxes</b></span></span></p>
                                    <p style="margin-top: 0pt; margin-bottom: 0pt; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span style="text-decoration: underline;">Current income tax: </span></span></span></p>
                                    <p style="margin-top: 0pt; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">Current income tax assets and liabilities for the current period are measured at the amount expected to be recovered from or paid to the taxation authorities. The tax rates and tax laws used to compute the amount are those that are enacted or substantively enacted, at the reporting date, in the countries where the Company operates and generates taxable income.</span></span></p>
                                    <p style="margin-bottom: 0pt; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span style="text-decoration: underline;">Deferred tax: </span></span></span></p>
                                    <p style="margin-top: 0pt; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">Deferred tax is provided on temporary differences at the reporting date between the tax bases of assets and liabilities and their carrying amounts for financial reporting purposes. The carrying amount of deferred tax assets is reviewed at the end of each reporting period and recognized only to the extent that it is probable that sufficient taxable profit will be available to allow all or part of the deferred tax asset to be utilized.</span></span></p>
                                    <p style="text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">Deferred tax assets and liabilities are measured at the tax rates that are expected to apply to the year when the asset is realized or the liability is settled, based on tax rates (and tax laws) that have been enacted or substantively enacted by the end of the reporting period. Deferred tax assets and deferred tax liabilities are offset if a legally enforceable right exists to set off current tax assets against current income tax liabilities and the deferred taxes relate to the same taxable entity and the same taxation authority.</span></span></p>
                                </div>


                                <div>
                                    <p style="margin-bottom: 0pt; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>Loss per share</b></span></span></p>
                                    <p style="margin-top: 0pt; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">Basic loss per share is calculated by dividing the loss attributable to common shareholders by the weighted average number of common shares outstanding in the period. The loss attributable to common shareholders equals the reported loss attributable to owners of the Company. Diluted loss per share is calculated using the treasury stock method. Under the treasury stock method, the weighted average number of common shares outstanding for the calculation of diluted loss per share assumes that the proceeds to be received on the exercise of dilutive share options and warrants are used to repurchase common shares at the average market price during the period. Because the Company incurred net losses, the effect of dilutive instruments would be anti-dilutive and therefore diluted loss per share equals loss per share.</span></span></p>
                                </div>


                                <div>
                                    <p style="margin-bottom: 0pt; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>Share capital</b></span></span></p>
                                    <p style="margin-top: 0pt; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">Financial instruments issued by the Company are classified as equity only to the extent that they do not meet the definition of a financial liability or financial asset. The Company's common shares are classified as equity instruments.</span></span></p>
                                    <p style="text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">Incremental costs directly attributable to the issue of new common shares are recognized as a deduction from equity, net of tax.</span></span></p>
                                </div>


                                <div>
                                    <p style="margin-bottom: 0pt; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>Financial instruments</b></span></span></p>
                                    <p style="margin-top: 0pt; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">Financial instruments are accounted for in accordance with IFRS 9, "Financial Instruments: Classification and Measurement". A financial instrument is any contract that gives rise to a financial asset of one entity and a financial liability or equity instrument of another entity.</span></span></p>
                                    <p style="margin-bottom: 0pt; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span style="text-decoration: underline;">Financial assets</span></span></span></p>
                                    <p style="margin-top: 0pt; margin-bottom: 0pt; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">(a) Recognition and measurement of financial assets</span></span></p>
                                    <p style="margin-top: 0pt; margin-left: 13.5pt; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">The Company recognizes a financial asset when it becomes a party to the contractual provisions of the instrument.</span></span></p>
                                    <p style="margin-bottom: 0pt; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">(b) Classification of financial assets</span></span></p>
                                    <p style="margin-top: 0pt; margin-left: 13.5pt; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">The Company classifies financial assets at initial recognition as financial assets: measured at amortized cost, measured at fair value through other comprehensive income ("FVTOCI") or measured at fair value through profit or loss ("FVTPL").</span></span></p>
                                    <p style="margin-bottom: 0pt; text-indent: 22.5pt; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">(i) Financial assets measured at amortized cost</span></span></p>
                                    <p style="margin-top: 0pt; margin-left: 36pt; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">A financial asset that meets both of the following conditions is classified as a financial asset measured at amortized cost:</span></span></p>
                                    <p style="margin-left: 49.5pt; margin-bottom: 0pt; text-indent: -4.5pt; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">&#8226;<span style="display: inline-block; width: 1.7pt;">&#160;</span>The Company's business model for such financial assets is to hold the assets in order to collect contractual cash flows.</span></span></p>
                                    <p style="margin-top: 0pt; margin-left: 49.5pt; text-indent: -4.5pt; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">&#8226;<span style="display: inline-block; width: 1.7pt;">&#160;</span>The contractual terms of the financial asset give rise on specified dates to cash flows that are solely payments of principal and interest on the amount outstanding.</span></span></p>
                                </div>

                        </div>

                        <div>

                                <div>
                                    <p style="margin-left: 36pt; text-align: justify; margin-top: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">A financial asset measured at amortized cost is initially recognized at fair value plus transaction costs directly attributable to the asset. After initial recognition, the carrying amount of the financial asset measured at amortized cost is determined using the effective interest method, net of impairment loss, if necessary.</span></span></p>
                                    <p style="margin-bottom: 0pt; text-indent: 22.5pt; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">(ii) Financial assets measured at FVTOCI</span></span></p>
                                    <p style="margin-top: 0pt; margin-left: 36pt; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">A financial asset measured at FVOCI is recognized initially at fair value plus transaction costs directly attributable to the asset. After initial recognition, the asset is measured at fair value with changes in fair value included as "financial asset at fair value through other comprehensive income" in other comprehensive income or loss.</span></span></p>
                                    <p style="margin-bottom: 0pt; text-indent: 22.5pt; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">(iii) Financial assets measured at FVTPL</span></span></p>
                                    <p style="margin-top: 0pt; margin-left: 36pt; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">A financial asset measured at FVTPL is initially recognized at fair value with any associated transaction costs being recognized in profit or loss when incurred. Subsequently, the financial asset is re-measured at fair value and a gain or loss is recognized in profit or loss in the reporting period in which it arises.</span></span></p>
                                    <p style="margin-left: 36pt; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">The Company's cash and cash equivalents are classified as subsequently measured at FVTPL.</span></span></p>
                                    <p style="margin-bottom: 0pt; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">(c) Derecognition of financial assets</span></span></p>
                                    <p style="margin-top: 0pt; margin-left: 13.6pt; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">The Company derecognizes a financial asset if the contractual rights to the cash flows from the asset expire, or the Company transfers substantially all the risks and rewards of ownership of the financial asset. Any interests in transferred financial assets that are created or retained by the Company are recognized as a separate asset or liability. Gains and losses on derecognition are generally recognized in the statement of comprehensive loss. However, gains and losses on derecognition of financial assets classified as FVTOCI remain within accumulated other comprehensive income or loss.</span></span></p>
                                    <p style="margin-bottom: 0pt; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span style="text-decoration: underline;">Financial liabilities</span></span></span></p>
                                    <p style="margin-top: 0pt; margin-bottom: 0pt; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">(a) Recognition and measurement of financial liabilities</span></span></p>
                                    <p style="margin-top: 0pt; margin-left: 13.5pt; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">The Company recognizes a financial liability when it becomes a party to the contractual provisions of the instrument.</span></span></p>
                                    <p style="margin-bottom: 0pt; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">(b) Classification of financial liabilities</span></span></p>
                                    <p style="margin-top: 0pt; margin-bottom: 0pt; text-indent: 22.5pt; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">(i) Financial liabilities measured at amortized cost</span></span></p>
                                    <p style="margin-top: 0pt; margin-left: 36pt; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">A financial liability measured at amortized cost is initially measured at fair value less transaction costs directly attributable to the issuance of the financial liability. Subsequently, the financial liability is measured at amortized cost using the effective interest method.</span></span></p>
                                    <p style="margin-left: 36pt; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">The Company's accounts payable and accrued liabilities are classified as subsequently measured at amortized cost.</span></span></p>
                                    <p style="margin-bottom: 0pt; text-indent: 22.5pt; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">(ii) Financial liabilities measured at fair value through profit or loss</span></span></p>
                                    <p style="margin-top: 0pt; margin-left: 36pt; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">A financial liability measured at fair value through profit or loss is initially measured at fair value with any associated transaction costs being recognized in profit or loss when incurred. Subsequently, the financial liability is re-measured at fair value and a gain or loss is recognized in profit or loss in the reporting period in which it arises.</span></span></p>
                                    <p style="margin-bottom: 0pt; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">(c) Derecognition of financial liabilities</span></span></p>
                                    <p style="margin-top: 0pt; margin-left: 13.6pt; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">The Company derecognizes a financial liability when the financial liability is discharged, cancelled or expired. Generally, the difference between the carrying amount of the financial liability derecognized and the consideration paid and payable, including any non-cash assets transferred or liabilities assumed, is recognized in the statement of comprehensive loss.</span></span></p>
                                    <p style="margin-bottom: 0pt; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span style="text-decoration: underline;">Offsetting financial assets and liabilities</span></span></span></p>
                                    <p style="margin-top: 0pt; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">Financial assets and liabilities are offset and the net amount is presented in the statement of financial position only when the Company has a legally enforceable right to offset the recognized amounts and intends either to settle on a net basis, or to realize the asset and settle the liability simultaneously.</span></span></p>
                                    <p style="margin-bottom: 0pt; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span style="text-decoration: underline;">Impairment of financial assets</span></span></span></p>
                                    <p style="margin-top: 0pt; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">The Company recognizes a loss allowance for expected credit losses on financial assets that are measured at amortized cost.</span></span></p>
                                </div>

                        </div>

                        <div>

                                <div>
                                    <p style="margin-bottom: 0pt; text-align: justify; margin-top: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">At each reporting date, the Company measures the loss allowance for the financial asset at an amount equal to the lifetime expected credit losses if the credit risk on the financial asset has increased significantly since initial recognition. If at the reporting date, the financial asset has not increased significantly since initial recognition, the Company measures the loss allowance for the financial asset at an amount equal to the twelve-month expected credit&#160;</span></span><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">losses. The Company recognizes in the statement of comprehensive income or loss, as an impairment loss (or gain), the amount of expected credit losses (or reversal) that is required to adjust the loss allowance at the reporting date to the amount that is required to be recognized.</span></span></p>
                                </div>


                                <div>
                                    <p style="margin-bottom: 0pt; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>Leases</b></span></span></p>
                                    <p style="margin-top: 0pt; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">Leases are accounted for in accordance with IFRS 16, "Leases". At inception of a contract, the Company assesses whether a contract is, or contains, a lease.&#160; A contract is, or contains, a lease if the contract conveys the right to control the use of an identified asset over a period of time in exchange for consideration.&#160; The Company assesses whether the contract involves the use of an identified asset, whether it has the right to obtain substantially all of the economic benefits from the use of the asset during the term of the contract and if it has the right to direct the use of the asset.</span></span></p>
                                    <p style="text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">As a lessee, the Company recognizes a right-of-use asset and a lease liability at the commencement date of the lease.</span></span></p>
                                    <p style="margin-bottom: 0pt; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span style="text-decoration: underline;">Right-of-use asset</span></span></span></p>
                                    <p style="margin-top: 0pt; margin-bottom: 0pt; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">The right-of-use asset is initially measured at cost, which is comprised of the initial amount of the lease liability adjusted for any lease payments made and any initial direct costs incurred at or before the commencement date, less any lease incentives received.</span></span></p>
                                    <p style="margin-top: 0pt; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">The right-of-use asset is subsequently depreciated from the commencement date to the earlier of the end of the lease term, or the end of the useful life of the asset.&#160; In addition, the right-of-use asset may be reduced due to impairment losses, if any, and adjusted for certain re-measurements of the lease liability.</span></span></p>
                                    <p style="margin-bottom: 0pt; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span style="text-decoration: underline;">Lease liability</span></span></span></p>
                                    <p style="margin-top: 0pt; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">A lease liability is initially measured at the present value of the lease payments that are not paid at the commencement date discounted by the interest rate implicit in the lease or, if that rate cannot be readily determined, the incremental borrowing rate. The lease liability is subsequently measured at amortized cost using the effective interest method.</span></span></p>
                                </div>


                                <div>
                                    <p style="margin-bottom: 0pt; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>New standards and interpretations not yet adopted</b></span></span></p>
                                    <p style="margin-top: 0pt; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">A number of new standards, amendments to standards and interpretations are not yet effective for the year ended September 30, 2021 and have not been applied in preparing these financial statements. The following new standards have not been adopted which may impact the Company in future:</span></span></p>
                                    <p style="margin-bottom: 0pt; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span style="text-decoration: underline;">IAS 1 - Presentation of Financial Statements </span></span></span></p>
                                    <p style="margin-top: 0pt; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">An amendment to IAS 1 clarifies the criterion for classifying a liability as non-current relating to the right to defer settlement of a liability for at least 12 months after the reporting period.</span></span></p>
                                    <p style="text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">IAS 1 has amended the definition of material to "information is material if omitting, misstating or obscuring it could reasonably be expected to influence decisions that the primary users of general-purpose financial statements make on the basis of those financial statements, which provide financial information about a specific reporting entity." The previous definition of material from IAS1 was "omissions or misstatements of items are material if they could, individually or collectively, influence the economic decisions that users make on the basis of the financial statements. Materiality depends on the size and nature of the omission or misstatement judged in the surrounding circumstances. The size or nature of the item, or a combination of both, could be the determining factor."</span></span></p>
                                    <p style="margin-bottom: 0pt; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span style="text-decoration: underline;">IAS 8 - Accounting Policies, Changes in Accounting Estimates and Errors</span></span></span></p>
                                    <p style="margin-top: 0pt; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">IAS 8 amended the definition of material reflect the changes outlined above under IAS 1.</span></span></p>
                                    <p style="margin-bottom: 0pt; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span style="text-decoration: underline;">IAS 12 and IFRIC 23 - Income Taxes</span></span></span></p>
                                    <p style="margin-top: 0pt; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">IAS 12 currently provides guidance on current and deferred tax assets and liabilities however uncertainty may exist on how tax law applies to certain transactions. IFRIC 23 provides guidance on how to address uncertainty related to tax treatments.</span></span></p>
                                </div>

                        </div>
                    <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_drug_DisclosureOfDetailedInformationAboutSignificantAccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">drug_DisclosureOfDetailedInformationAboutSignificantAccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>drug_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant accounting policies applied by the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 117<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.4</span><table class="report" border="0" cellspacing="2" id="idm140170915383192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHARE EXCHANGE AND ASSIGNMENT<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drug_ShareExchangeAndAssignmentAbstract', window );"><strong>Share Exchange And Assignment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drug_DisclosureOfShareExchangeAndAssignmentExplanatory', window );">SHARE EXCHANGE AND ASSIGNMENT [Text Block]</a></td>
<td class="text">
                        <div>
                            <p style="text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>4.<span style="display: inline-block; width: 9pt;">&#160;</span>SHARE EXCHANGE AND ASSIGNMENT</b></span></span></p>
                            <p style="text-align: justify; margin-bottom: 0px;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">Psilocybinlabs Ltd. ("PL") was incorporated under the laws of the province of British Columbia on April 25, 2019, with the incorporator share being held by a company controlled by the CEO of the Company. On May 17, 2019, this share was transferred to the Company. On April 25, 2019, PL entered into a confirmatory assignment and waiver (the "CAW") with an individual, which was amended and restated on May 17, 2019. Pursuant to the amended and restated CAW, this individual assigned all of the right, title and interest, including all other intellectual property rights (the Rights, as described) to PL. As compensation for the assignment of the Rights, PL issued 100,000 common shares valued at $2,000 to this individual. On August 7, 2019, the Company then purchased the 100,000 common shares of PL by issuing 100,000 common shares of the Company valued at $2,000, with the reacquisition being recorded as an asset acquisition.</span></span></p>
                        </div>
                    <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_drug_DisclosureOfShareExchangeAndAssignmentExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of share exchange and assignment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">drug_DisclosureOfShareExchangeAndAssignmentExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>drug_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_drug_ShareExchangeAndAssignmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">drug_ShareExchangeAndAssignmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>drug_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.4</span><table class="report" border="0" cellspacing="2" id="idm140170915445016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACCOUNTS PAYABLE AND ACCRUED LIABILITIES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TradeAndOtherCurrentPayablesAbstract', window );"><strong>Trade and other current payables [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory', window );">ACCOUNTS PAYABLE AND ACCRUED LIABILITIES [Text Block]</a></td>
<td class="text">
                    <div>
                        <p style="text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>5.<span style="display: inline-block; width: 9pt;">&#160;</span>ACCOUNTS PAYABLE AND ACCRUED LIABILITIES</b></span></span></p>

                            <table cellpadding="0" cellspacing="0" style="width: 100%; border-collapse: collapse; font-size: 10pt; border-color: #000000;">
                                <tr>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1.5pt solid #000000; border-bottom: 0.75pt solid #000000; vertical-align: bottom;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>&#160;</b></span></span></td>
                                    <td style="vertical-align: bottom; border-top: 1.5pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right;">&#160;</td>
                                    <td style="vertical-align: bottom; border-top: 1.5pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>September 30, </b><br/><b>2021</b></span></span></td>
                                    <td style="vertical-align: bottom; border-top: 1.5pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;">&#160;</td>
                                    <td style="vertical-align: bottom; border-top: 1.5pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;">&#160;</td>
                                    <td style="vertical-align: bottom; border-top: 1.5pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>September 30, </b><br/><b>2020</b></span></span></td>
                                    <td style="vertical-align: bottom; border-top: 1.5pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right;">&#160;</td>
                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>$</b></span></span></td>
                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right;">&#160;</td>
                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right;">&#160;</td>
                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>$&#160;</b></span></span></td>
                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">Accounts payable</span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>596,573</b></span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">138,423</span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">Accrued liabilities</span></span></td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>42,000</b></span></span></td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">12,500</span></span></td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 2.25pt double #000000; vertical-align: bottom; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">Total accounts payable and accrued liabilities</span></span></td>
                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>638,573</b></span></span></td>
                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">150,923</span></span></td>
                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                </tr>
                            </table>

                    </div>
                <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of trade and other payables. [Refer: Trade and other payables]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeAndOtherCurrentPayablesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeAndOtherCurrentPayablesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.4</span><table class="report" border="0" cellspacing="2" id="idm140170912257176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHARE CAPITAL<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalAbstract', window );"><strong>Disclosure of classes of share capital [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfIssuedCapitalExplanatory', window );">SHARE CAPITAL [Text Block]</a></td>
<td class="text">
                                    <div>
                                        <p style="text-align: justify; margin-top: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>6.<span style="display: inline-block; width: 9pt;">&#160;</span>SHARE CAPITAL</b></span></span></p>
                                        <p style="margin-bottom: 0pt; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span style="text-decoration: underline;"><b>Authorized share capital</b></span></span></span></p>
                                        <p style="margin-top: 0pt; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">Unlimited number of common shares without par value.</span></span></p>
                                        <p style="text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">
                                                    On November 10, 2020, the Directors of the Company approved the consolidation of the Company's issued and outstanding common shares on a 2.5:1 basis. All common shares, stock options and warrant references in these financial statements reflect the effect of the share consolidation.
                                                </span></span></p>
                                        <p style="margin-bottom: 0pt; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>Issued share capital for the year ended September 30, 2021</b></span></span></p>
                                        <p style="margin-top: 0pt; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">On November 2, 2020, the Company closed the second tranche of a non-brokered private placement financing through the issuance of 1,629,138 common shares at a price $1.25 per common share for gross proceeds of $2,036,422.</span></span></p>
                                        <p style="text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">On January 6, 2021, the Company issued 14,799 common shares at a deemed price of $1.25 per share to settle an $18,500 debt owing to a consultant pursuant to a debt settlement agreement entered into by the Company with the consultant.</span></span></p>
                                        <p style="text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">On February 3, 2021, the 16,000 SWs were deemed to be exercised for SW shares and 16,000 common shares of the Company were issued to the SW holders (see below).</span></span></p>
                                        <p style="text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">On March 17, 2021, the Company issued 3,419,883 Units at a price per Unit of $7.57 for aggregate gross proceeds of $25,888,514. Each Unit comprised one common share and one-half of one common share purchase warrant of the Company. Each warrant is exercisable to acquire one common share of the Company at an exercise price of $9.46 per warrant until March 17, 2024, subject to adjustment and acceleration in certain events. If the daily volume weighted average trading price of the common shares on the CSE is equal to or greater than $13.25 per common share for any 10 consecutive trading days, the Company shall have the right to accelerate the expiry date of the warrants to a date that is at least 30 trading days following the date of the Company issuing a press release disclosing such acceleration. The underwriters were paid fees for their services in the amount of $916,317 and received compensation warrants entitling them to purchase an aggregate of 132,666 common shares at a price of $7.57 per common share for a period of thirty-six months following closing. These warrants have an ascribed value of $521,000.</span></span></p>
                                        <p style="text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">On April 6, 2021, the Company paid a New York-based company a contingent cash fee in the amount of $600,000, being 4.5% of $13,333,333 in net equity proceeds received from three investors introduced to the Company by the company. The company was also entitled to receive compensation warrants allowing it to purchase an aggregate of 8,807 common shares at a price of $7.57 per common share for a period of five years. These warrants, having an ascribed value of $33,100, were never issued. Instead, on September 21,2021, the Company granted compensation options (see below).</span></span></p>
                                    </div>

                                    <div>
                                        <p style="text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">On April 23, 2021, 1,948,000 escrowed share purchase warrants were exercised for $0.05 per share for gross proceeds of $97,400.&#160;</span></span></p>
                                        <p style="text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">On April 28, 2021, the Company issued 63,000 common shares to the University at a deemed price of $5.85 per share. The $368,550 value attributed to these shares has been recognized as a research and development expense in the consolidated statements of comprehensive loss during the year ended September 30, 2021. See Note 8.&#160;</span></span></p>
                                        <p style="margin-bottom: 0pt; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>Issued share capital for the year ended September 30, 2020</b></span></span></p>
                                        <p style="margin-top: 0pt; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">On September 30, 2020, the Company closed the first tranche of a non-brokered private placement financing through the issuance of 623,941 common shares at a price $1.25 per common share for gross proceeds of $779,924.</span></span></p>
                                        <p style="margin-bottom: 0pt; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>Issued share capital from May 31, 2019 (date of incorporation) to September 30, 2019</b></span></span></p>
                                        <p style="margin-top: 0pt; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">On July 30, 2019, the Company closed a non-brokered private placement financing through the issuance of 4,079,600 units at a price of $0.05 per unit for gross proceeds of $203,980. Of this amount, $80,980 was received subsequent to year end. Each unit comprises one common share, and one share purchase warrant exercisable at $0.05 per share until July 30, 2024.</span></span></p>
                                        <p style="margin-bottom: 0pt; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>Special Warrants and Resulting Share Issuance</b></span></span></p>
                                        <p style="margin-top: 0pt; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">In October 2020, the Company entered into subscription agreements for special warrants (the "SWs") whereby the subscribers subscribed for a total of 18,300 SWs at $1.25 per SW, with the SWs providing that each SW is deemed to be exercised, without payment of any additional consideration and without any further action by the SW holders, for one SW share, subject to adjustment in accordance with the provisions of the SW certificate on the SW exercise date.</span></span></p>
                                        <p style="text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">On November 2, 2020, the Company issued 18,300 SWs for gross proceeds of $22,875. On January 19, 2021, as a result of a compliance review of the SW offering by the British Columbia Securities Commission, the Company rescinded the issuance of 2,300 SWs and refunded the $2,875 in proceeds received. On February 3, 2021, the $20,000 in escrowed proceeds was released to the Company, the SWs were deemed to be exercised for SW shares and 16,000 common shares of the Company were issued to the SW holders.</span></span></p>
                                        <p style="margin-bottom: 0pt; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>Share subscriptions received/receivable</b></span></span></p>
                                        <p style="margin-top: 0pt; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">During the fiscal year ended September 30, 2020, the Company received $147,426 in subscriptions for 294,852 common shares relating to the private placement that closed on November 2, 2020.</span></span></p>
                                        <p style="text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">On July 31, 2019, 4,049,000 common shares were issued for which the gross proceeds of $80,980 were received on October 7, 2019 and September 28, 2020.</span></span></p>
                                        <p style="margin-bottom: 0pt; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>Escrowed Securities</b></span></span></p>
                                        <p style="margin-top: 0pt; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">On January 28, 2021, the Company entered into an escrow agreement under National Policy 46-201 <i>Escrow for Initial Public Offerings</i> (the "Policy") in connection with the listing of common shares of the Company on the CSE, whereby 2,852,800 common shares of the Company and 1,948,000 share purchase warrants (exercised on April 23, 2021), being an aggregate of 4,800,800 securities, were deposited to be held in escrow. As the Company is defined as an emerging issuer under the Policy, the escrowed securities will be released as follows:</span></span></p>
                                        <p style="text-align: justify; padding-left: 8.25pt; margin-bottom: 0pt; margin-top: 0pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">&#160; &#160;&#8226;&#160; &#160; &#160; 480,080 on the date that the Company's shares are listed on the CSE (February 8, 2021); and</span></span></p>
                                        <p style="text-align: justify; padding-left: 8.25pt; margin-bottom: 0pt; margin-top: 0pt;"><span style="font-family: Times New Roman, Times, serif; font-size: 10pt;">&#160; &#160;&#8226;&#160; &#160; &#160; </span><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">720,120 six, 12, 18, 24, 30 and 36 months after the listing date.</span></span></p>
                                        <p style="margin-bottom: 0pt; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span style="text-decoration: underline;"><b>Stock options</b></span></span></span></p>
                                        <p style="margin-top: 0pt; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">The Company's stock option plan provides for stock options to be issued to directors, officers, employees and consultants of the Company, its subsidiaries and any personal holding company of such individuals so that they may participate in the growth and development of the Company. Subject to the specific provisions of the stock option plan, eligibility, vesting period, terms of the options and the number of options granted are to be determined by the Board of Directors at the time of grant. The stock option plan allows the Board of Directors to issue up to 10% of the Company's outstanding common shares as stock options.</span></span></p>
                                    </div>

                                    <div>
                                        <p style="margin-bottom: 0pt; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>Options granted during the year ended September 30, 2021</b></span></span></p>
                                        <p style="margin-top: 0pt; margin-bottom: 11px; text-align: justify; font-size: 10pt; font-family: Times New Roman, Times, serif;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span style="line-height: normal;">On November 17, 2020, the Company granted 467,000 options, to the Chief Financial Officer of the Company, two directors of the Company and seven consultants. These options have an exercise price of $1.25 per share, expire on November 17, 2025 and vest as follows:</span></span></span></p>
                                        <p style="margin-top: 0pt; margin-left: 58px; margin-bottom: 0pt; text-align: justify; text-indent: -21.25pt; font-size: 10pt; font-family: Times New Roman, Times, serif;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span style="line-height: normal;">&#8226;&#160; &#160; &#160; &#160;25,000 options - 100% on the date of grant;</span></span></span></p>
                                        <p style="margin-top: 0pt; margin-left: 58px; margin-bottom: 0pt; text-align: justify; text-indent: -21.25pt; font-size: 10pt; font-family: Times New Roman, Times, serif;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span style="line-height: normal;">&#8226;&#160; &#160;&#160; &#160; 14,000 options - 25% on the Company's listing date, 25% on the first anniversary of the listing date and 50% on the second anniversary of the listing date;</span></span></span></p>
                                        <p style="margin-top: 0pt; margin-left: 58px; margin-bottom: 0pt; text-align: justify; text-indent: -21.25pt; font-size: 10pt; font-family: Times New Roman, Times, serif;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span style="line-height: normal;">&#8226;&#160; &#160; &#160;&#160; 4,000 options - 50% on the Company's listing date and 50% on the six-month anniversary of the listing date; and</span></span></span></p>
                                        <p style="margin-top: 0pt; margin-left: 58px; margin-bottom: 0pt; text-align: justify; text-indent: -21.25pt; font-size: 10pt; font-family: Times New Roman, Times, serif;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span style="line-height: normal;">&#8226;&#160; &#160; &#160;&#160; 424,000 options - 33% on the first anniversary of the grant date, 33% on the second anniversary of the grant date and 33% on the third anniversary of the grant date.</span></span></span></p>
                                        <p style="text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">The fair value of these stock options was measured using the Black Scholes option pricing model using the following inputs: i) exercise price: $1.25; ii) share price: $1.25; iii) term: 5 years; iv) volatility: 100%; v) discount rate: 0.43%; and dividends: nil.</span></span></p>
                                        <p style="margin-top: 0pt; margin-bottom: 11px; font-size: 10pt; font-family: Times New Roman, Times, serif;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span style="line-height: 107%;">On April 28, 2021, the Company granted 240,000 options to three consultants of the Company. These options have an exercise price of $7.60 per share, expire on April 28, 2026 and vest as follows:</span></span></span></p>
                                        <p style="margin-top: 0pt; margin-left: 58px; margin-bottom: 0pt; text-align: justify; text-indent: -21.25pt; font-size: 10pt; font-family: Times New Roman, Times, serif;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span style="line-height: normal;">&#8226;&#160; &#160; &#160; 160,000 options - 25% on the first anniversary of the grant date, 25% on the second anniversary of the grant date, 25% on the third anniversary of the grant date and 25% on the fourth anniversary of the grant date; and</span></span></span></p>
                                        <p style="margin-top: 0pt; margin-left: 58px; margin-bottom: 0pt; text-align: justify; text-indent: -21.25pt; font-size: 10pt; font-family: Times New Roman, Times, serif;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span style="line-height: normal;">&#8226;&#160; &#160; &#160; 80,000 options - 25% on the six-month anniversary of the grant date, 25% on the first anniversary of the grant date, 25% on the eighteen-month anniversary of the grant date and 25% on the second anniversary of the grant date.</span></span></span></p>
                                        <p style="text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">The fair value of these stock options was measured using the Black Scholes option pricing model using the following inputs: i) exercise price: $7.60; ii) share price: $5.98; iii) term: 5 years; iv) volatility: 100%; v) discount rate: 0.92%; and dividends: nil.</span></span></p>
                                        <p style="text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">On June 15, 2021, the Company granted 180,000 options to a director and a consultant of the Company. These options have an exercise price of $7.60 per share, expire on June 15, 2026 and vest as follows: 25% on the first anniversary of the grant date, 25% on the second anniversary of the grant date, 25% on the third anniversary of the grant date and 25% on the fourth anniversary of the grant date. The fair value of these stock options was measured using the Black Scholes option pricing model using the following inputs: i) exercise price: $7.60; ii) share price: $5.55; iii) term: 5 years; iv) volatility: 100%; v) discount rate: 0.84%; and dividends: nil.</span></span></p>
                                        <p style="text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">On September 21, 2021, the Company granted 8,807 options to a consultant of the Company (see above). These options have an exercise price of $7.64 per share, expire on September 21, 2024 and vest as follows: 25% on December 21, 2021, 25% on March 21, 2022, 25% on June 21, 2022 and 25% on September 21, 2022. The fair value of these stock options was measured using the Black Scholes option pricing model using the following inputs: i) exercise price: $7.64; ii) share price: $7.64; iii) term: 3 years; iv) volatility: 100%; v) discount rate: 0.55%; and dividends: nil.</span></span></p>
                                        <p style="margin-bottom: 0pt; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>Options granted during the year ended September 30, 2020</b></span></span></p>
                                        <p style="margin-top: 0pt; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">On July 23, 2020, the Company granted 150,000 options to the Company's Chief Medical Officer. The fair value of these stock options was measured using the Black Scholes option pricing model using the following inputs: i) exercise price: $1.25; ii) share price: $1.25; iii) term: 5 years; iv) volatility: 100%; v) discount rate: 0.35%; and dividends: nil.</span></span></p>
                                    </div>

                                    <div>
                                        <p style="text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">The following table summarizes the movements in the Company's outstanding stock options for the years ended September 30, 2021 and 2020:</span></span></p>

                                            <div>
                                                <div style="margin-left: 5.4pt;">
                                                    <table cellpadding="0" cellspacing="0" style="width: 100%; border-collapse: collapse; font-size: 10pt; border-color: #000000;">
                                                        <tr>
                                                            <td style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1.5pt solid #000000; border-bottom: 0.75pt solid #000000; vertical-align: bottom;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>&#160;</b></span></span></td>
                                                            <td style="vertical-align: bottom; border-top: 1.5pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right;">&#160;</td>
                                                            <td style="vertical-align: bottom; border-top: 1.5pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">&#160;<br/><b>Number of options</b></span></span></td>
                                                            <td style="vertical-align: bottom; border-top: 1.5pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;">&#160;</td>
                                                            <td style="vertical-align: bottom; border-top: 1.5pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;">&#160;</td>
                                                            <td style="vertical-align: bottom; border-top: 1.5pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>&#160; Weighted average&#160; </b><br/><b>exercise price</b></span></span></td>
                                                            <td style="vertical-align: bottom; border-top: 1.5pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right;">&#160;</td>
                                                        </tr>
                                                        <tr>
                                                            <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>Balance at September 30, 2019 and May 31, 2019</b></span></span></td>
                                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                            <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>-</b></span></span></td>
                                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                            <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>-</b></span></span></td>
                                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                        </tr>
                                                        <tr>
                                                            <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">&#160; Granted</span></span></td>
                                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">150,000</span></span></td>
                                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>$</b></span></span></td>
                                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">1.25</span></span></td>
                                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                                        </tr>
                                                        <tr>
                                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>Balance at September 30, 2020</b></span></span></td>
                                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>150,000</b></span></span></td>
                                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>$</b></span></span></td>
                                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>1.25</b></span></span></td>
                                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                        </tr>
                                                        <tr>
                                                            <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">&#160; Granted</span></span></td>
                                                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                                            <td style="vertical-align: bottom; text-align: right; width: 12%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">895,807</span></span></td>
                                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                                            <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>$</b></span></span></td>
                                                            <td style="vertical-align: bottom; text-align: right; width: 12%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">4.29</span></span></td>
                                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                                        </tr>
                                                        <tr>
                                                            <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: justify; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">&#160; Cancelled*</span></span></td>
                                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                            <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">(20,000</span></span></td>
                                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">)</span></span></td>
                                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>$</b></span></span></td>
                                                            <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">1.25</span></span></td>
                                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                        </tr>
                                                        <tr>
                                                            <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 2.25pt double #000000; vertical-align: bottom;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>Balance at September 30, 2021</b></span></span></td>
                                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%;">&#160;</td>
                                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 12%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>1,025,807</b></span></span></td>
                                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%;">&#160;</td>
                                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>$</b></span></span></td>
                                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 12%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>3.90</b></span></span></td>
                                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%;">&#160;</td>
                                                        </tr>
                                                    </table>
                                                </div>
                                            </div>

                                        <p style="text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><i>* On January 21, 2021, the Company cancelled 20,000 options granted to a consultant in error on November 17, 2020.</i></span></span></p>
                                        <p style="text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">As at September 30, 2021, the options have a weighted average remaining life of 4.28 years (September 30, 2020 - 4.81).</span></span></p>
                                        <p style="text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">The following table summarizes the stock options issued and outstanding:</span></span></p>

                                            <div>
                                                <table cellpadding="0" cellspacing="0" style="width: 90%; border-collapse: collapse; font-size: 10pt; border-color: #000000; margin-left: auto; margin-right: auto;">
                                                    <tr>
                                                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-top: 1.5pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>&#160;</b></span></span></td>
                                                        <td colspan="1" style="vertical-align: bottom; border-top: 1.5pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: center;">&#160;</td>
                                                        <td colspan="10" style="vertical-align: bottom; border-top: 1.5pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>Options Outstanding and Exercisable</b></span></span></td>
                                                        <td colspan="1" style="vertical-align: bottom; border-top: 1.5pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: center;">&#160;</td>
                                                    </tr>
                                                    <tr>
                                                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-indent: 2.8pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>&#160;</b><br/><b>Expiry Date</b></span></span></td>
                                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right;">&#160;</td>
                                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>Number of<br/>options</b></span></span></td>
                                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;">&#160;</td>
                                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;">&#160;</td>
                                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>&#160;</b><br/><b>Exercisable</b></span></span></td>
                                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;">&#160;</td>
                                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;">&#160;</td>
                                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>&#160;</b><br/><b>Exercise price</b></span></span></td>
                                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;">&#160;</td>
                                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;">&#160;</td>
                                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>Remaining life<br/>(Years)</b></span></span></td>
                                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right;">&#160;</td>
                                                    </tr>
                                                    <tr>
                                                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">September 21, 2024</span></span></td>
                                                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                        <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">8,807</span></span></td>
                                                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                        <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">-</span></span></td>
                                                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">$</span></span></td>
                                                        <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">7.64</span></span></td>
                                                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                        <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">
                                                                    2.98
                                                                </span></span></td>
                                                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                    </tr>
                                                    <tr>
                                                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">July 23, 2025</span></span></td>
                                                        <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                                        <td style="vertical-align: bottom; text-align: right; width: 12%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">150,000</span></span></td>
                                                        <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                                        <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                                        <td style="vertical-align: bottom; text-align: right; width: 12%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">150,000</span></span></td>
                                                        <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                                        <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">$</span></span></td>
                                                        <td style="vertical-align: bottom; text-align: right; width: 12%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">1.25</span></span></td>
                                                        <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                                        <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                                        <td style="vertical-align: bottom; text-align: right; width: 12%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">
                                                                    3.81
                                                                </span></span></td>
                                                        <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                                    </tr>
                                                    <tr>
                                                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">November 17, 2025</span></span></td>
                                                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                        <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">447,000</span></span></td>
                                                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                        <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">30,500</span></span></td>
                                                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">$</span></span></td>
                                                        <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">1.25</span></span></td>
                                                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                        <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">
                                                                    4.13
                                                                </span></span></td>
                                                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                    </tr>
                                                    <tr>
                                                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">April 28, 2026</span></span></td>
                                                        <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                                        <td style="vertical-align: bottom; text-align: right; width: 12%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">240,000</span></span></td>
                                                        <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                                        <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                                        <td style="vertical-align: bottom; text-align: right; width: 12%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">-</span></span></td>
                                                        <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                                        <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">$</span></span></td>
                                                        <td style="vertical-align: bottom; text-align: right; width: 12%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">7.60</span></span></td>
                                                        <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                                        <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                                        <td style="vertical-align: bottom; text-align: right; width: 12%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">
                                                                    4.58
                                                                </span></span></td>
                                                        <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                                    </tr>
                                                    <tr>
                                                        <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 2.25pt double #000000; vertical-align: bottom; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">June 15, 2026</span></span></td>
                                                        <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                        <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">180,000</span></span></td>
                                                        <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                        <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                        <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">-</span></span></td>
                                                        <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                        <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">$</span></span></td>
                                                        <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">7.60</span></span></td>
                                                        <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                        <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                        <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">
                                                                    4.71
                                                                </span></span></td>
                                                        <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                    </tr>
                                                </table>
                                            </div>

                                        <p style="margin-bottom: 0pt; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span style="text-decoration: underline;"><b>Restricted share unit plan</b></span></span></span></p>
                                        <p style="margin-top: 0pt; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">The Company's restricted share unit ("RSU") plan provides RSUs to be issued to directors, officers, employees and consultants of the Company, its subsidiaries and any personal holding company of such individuals so that they may participate in the growth and development of the Company. Subject to the specific provisions of the RSU plan, eligibility, vesting period, terms of the RSUs and the number of RSUs granted are to be determined by the Board of Directors at the time of the grant. The RSU plan allows the Board of Directors to issue common shares of the company as equity settled RSUs, provided that, when combined, the maximum number of common shares reserved for issuance under all share-based compensation arrangements of the Company does not exceed 10% of the Company's outstanding common shares.</span></span></p>
                                        <p style="text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">On July 23, 2020 and September 18, 2020, the Company issued 150,000 RSUs and 230,000 RSUs, respectively, to the Chief Medical Officer of the Company. These RSUs vest on an annual basis over a period of four years commencing on the first anniversary of the grant date.</span></span></p>
                                        <p style="text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">The following table summarizes the movements in the Company's outstanding RSUs for the years ended September 30, 2021 and 2020:</span></span></p>
                                        <div>

                                                <div>
                                                    <table cellpadding="0" cellspacing="0" style="width: 100%; border-collapse: collapse; font-size: 10pt; border-color: #000000;">
                                                        <tr>
                                                            <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; border-top: 1.5pt solid #000000; vertical-align: bottom;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>&#160;</b></span></span></td>
                                                            <td style="vertical-align: bottom; border-top: 1.5pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right;">&#160;</td>
                                                            <td style="vertical-align: bottom; border-top: 1.5pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>Equity settled</b></span></span></td>
                                                            <td style="vertical-align: bottom; border-top: 1.5pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;">&#160;</td>
                                                            <td colspan="1" style="vertical-align: bottom; border-top: 1.5pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;">&#160;</td>
                                                            <td colspan="1" style="vertical-align: bottom; border-top: 1.5pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>Cash settled</b></span></span></td>
                                                            <td colspan="1" style="vertical-align: bottom; border-top: 1.5pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;">&#160;</td>
                                                            <td style="vertical-align: bottom; border-top: 1.5pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;">&#160;</td>
                                                            <td style="vertical-align: bottom; border-top: 1.5pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>Total</b></span></span></td>
                                                            <td style="vertical-align: bottom; border-top: 1.5pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;">&#160;</td>
                                                        </tr>
                                                        <tr>
                                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>Balance at September 30, 2019 and May 31, 2019</b></span></span></td>
                                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">-</span></span></td>
                                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                            <td colspan="1" style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                            <td colspan="1" style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">-</span></span></td>
                                                            <td colspan="1" style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">-</span></span></td>
                                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                        </tr>
                                                        <tr>
                                                            <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">Granted</span></span></td>
                                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">380,000</span></span></td>
                                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                                            <td colspan="1" style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                                            <td colspan="1" style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">-</span></span></td>
                                                            <td colspan="1" style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">380,000</span></span></td>
                                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                                        </tr>
                                                        <tr>
                                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>Balance at September 30, 2020</b></span></span></td>
                                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>380,000</b></span></span></td>
                                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">-</span></span></td>
                                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>380,000</b></span></span></td>
                                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                        </tr>
                                                        <tr>
                                                            <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">Vested</span></span></td>
                                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">(95,000</span></span></td>
                                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">)</span></span></td>
                                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">-</span></span></td>
                                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">(95,000</span></span></td>
                                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">)</span></span></td>
                                                        </tr>
                                                        <tr>
                                                            <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 2.25pt double #000000; vertical-align: bottom; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>Balance at September 30, 2021</b></span></span></td>
                                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>285,000</b></span></span></td>
                                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">-</span></span></td>
                                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>285,000</b></span></span></td>
                                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                        </tr>
                                                    </table>
                                                </div>

                                        </div>
                                        <p style="text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">The estimated fair value of the equity settled RSUs granted during the year ended September 30, 2020 was $475,000 and will be recognized as an expense over the vesting period of the RSUs.</span></span></p>
                                    </div>

                                    <div>
                                        <p style="text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">The accounting fair value of the equity settled RSUs as at the grant date was estimated by management using the following inputs:&#160;</span></span></p>

                                            <div>
                                                <table cellpadding="0" cellspacing="0" style="width: 80%; border-collapse: collapse; font-size: 10pt; border-color: #000000; margin-left: auto; margin-right: auto;">
                                                    <tr>
                                                        <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; border-top: 1.5pt solid #000000; vertical-align: bottom;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>&#160;</b></span></span></td>
                                                        <td style="vertical-align: bottom; border-top: 1.5pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right;">&#160;</td>
                                                        <td style="vertical-align: bottom; border-top: 1.5pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>Year ended<br/>September 30, 2020</b></span></span></td>
                                                        <td style="vertical-align: bottom; border-top: 1.5pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right;">&#160;</td>
                                                    </tr>
                                                    <tr>
                                                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">Share price on grant date</span></span></td>
                                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">$</span></span></td>
                                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 22%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">1.25</span></span></td>
                                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                    </tr>
                                                    <tr>
                                                        <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">Forfeiture rate</span></span></td>
                                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 22%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">0%</span></span></td>
                                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                                    </tr>
                                                </table>
                                            </div>

                                        <p style="text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">Share-based compensation expense recognized in the consolidated statements of comprehensive loss is comprised of the following:</span></span></p>
                                        <div style="margin-left: 5.4pt;">

                                                <div>
                                                    <table cellpadding="0" cellspacing="0" style="width: 100%; border-collapse: collapse; font-size: 10pt; border-color: #000000;">
                                                        <tr>
                                                            <td style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1.5pt solid #000000; border-bottom: 0.75pt solid #000000; vertical-align: bottom;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>&#160;</b></span></span></td>
                                                            <td style="vertical-align: bottom; border-top: 1.5pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right;">&#160;</td>
                                                            <td style="vertical-align: bottom; border-top: 1.5pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>Year ended<br/>September 30,<br/>2021</b></span></span></td>
                                                            <td style="vertical-align: bottom; border-top: 1.5pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;">&#160;</td>
                                                            <td style="vertical-align: bottom; border-top: 1.5pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;">&#160;</td>
                                                            <td style="vertical-align: bottom; border-top: 1.5pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">Year ended<br/>September 30,<br/>2020</span></span></td>
                                                            <td style="vertical-align: bottom; border-top: 1.5pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;">&#160;</td>
                                                            <td style="vertical-align: bottom; border-top: 1.5pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;">&#160;</td>
                                                            <td style="vertical-align: bottom; border-top: 1.5pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">Period ended<br/>September 30,<br/>2019</span></span></td>
                                                            <td style="vertical-align: bottom; border-top: 1.5pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right;">&#160;</td>
                                                        </tr>
                                                        <tr>
                                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>&#160;</b></span></span></td>
                                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right;">&#160;</td>
                                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>$</b></span></span></td>
                                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right;">&#160;</td>
                                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right;">&#160;</td>
                                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">$</span></span></td>
                                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right;">&#160;</td>
                                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right;">&#160;</td>
                                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">$</span></span></td>
                                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right;">&#160;</td>
                                                        </tr>
                                                        <tr>
                                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">Stock options</span></span></td>
                                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                            <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>643,963</b></span></span></td>
                                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                            <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">138,000</span></span></td>
                                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                            <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">-</span></span></td>
                                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                        </tr>
                                                        <tr>
                                                            <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">Restricted share units - equity settled grants</span></span></td>
                                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>236,652</b></span></span></td>
                                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">23,300</span></span></td>
                                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">-</span></span></td>
                                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                                        </tr>
                                                        <tr>
                                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">Total equity settled share-based compensation expense</span></span></td>
                                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>880,615</b></span></span></td>
                                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">161,300</span></span></td>
                                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">-</span></span></td>
                                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                        </tr>
                                                        <tr>
                                                            <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">Restricted share units - cash settled grants</span></span></td>
                                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>-</b></span></span></td>
                                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">-</span></span></td>
                                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">-</span></span></td>
                                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                                        </tr>
                                                        <tr>
                                                            <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 2.25pt double #000000; vertical-align: bottom; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">Total share-based compensation expense</span></span></td>
                                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>880,615</b></span></span></td>
                                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">161,300</span></span></td>
                                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">-</span></span></td>
                                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                        </tr>
                                                    </table>
                                                </div>

                                        </div>
                                        <p style="text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">Share-based compensation expense is included in the consolidated statements of comprehensive loss as follows:</span></span></p>
                                        <div style="margin-left: 5.4pt;">

                                                <div>
                                                    <table cellpadding="0" cellspacing="0" style="width: 100%; border-collapse: collapse; font-size: 10pt; border-color: #000000;">
                                                        <tr>
                                                            <td style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1.5pt solid #000000; border-bottom: 0.75pt solid #000000; vertical-align: bottom;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>&#160;</b></span></span></td>
                                                            <td style="vertical-align: bottom; border-top: 1.5pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right;">&#160;</td>
                                                            <td style="vertical-align: bottom; border-top: 1.5pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>Year ended<br/>September 30,<br/>2021</b></span></span></td>
                                                            <td style="vertical-align: bottom; border-top: 1.5pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;">&#160;</td>
                                                            <td style="vertical-align: bottom; border-top: 1.5pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;">&#160;</td>
                                                            <td style="vertical-align: bottom; border-top: 1.5pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">Year ended<br/>September 30,<br/>2020</span></span></td>
                                                            <td style="vertical-align: bottom; border-top: 1.5pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;">&#160;</td>
                                                            <td style="vertical-align: bottom; border-top: 1.5pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;">&#160;</td>
                                                            <td style="vertical-align: bottom; border-top: 1.5pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">Period ended<br/>September 30,<br/>2019</span></span></td>
                                                            <td style="vertical-align: bottom; border-top: 1.5pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right;">&#160;</td>
                                                        </tr>
                                                        <tr>
                                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>&#160;</b></span></span></td>
                                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right;">&#160;</td>
                                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>$</b></span></span></td>
                                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right;">&#160;</td>
                                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right;">&#160;</td>
                                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">$</span></span></td>
                                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right;">&#160;</td>
                                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right;">&#160;</td>
                                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">$</span></span></td>
                                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right;">&#160;</td>
                                                        </tr>
                                                        <tr>
                                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">Consulting fees</span></span></td>
                                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                            <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>8,045</b></span></span></td>
                                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                            <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">-</span></span></td>
                                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                            <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">-</span></span></td>
                                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                        </tr>
                                                        <tr>
                                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">Directors' compensation</span></span></td>
                                                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                                            <td style="vertical-align: bottom; text-align: right; width: 12%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>136,612</b></span></span></td>
                                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                                            <td style="vertical-align: bottom; text-align: right; width: 12%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">-</span></span></td>
                                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                                            <td style="vertical-align: bottom; text-align: right; width: 12%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">-</span></span></td>
                                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                                        </tr>
                                                        <tr>
                                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">Marketing, advertising and investor relations</span></span></td>
                                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                            <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>3,696</b></span></span></td>
                                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                            <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">-</span></span></td>
                                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                            <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">-</span></span></td>
                                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                        </tr>
                                                        <tr>
                                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">Professional fees</span></span></td>
                                                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                                            <td style="vertical-align: bottom; text-align: right; width: 12%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>23,126</b></span></span></td>
                                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                                            <td style="vertical-align: bottom; text-align: right; width: 12%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">-</span></span></td>
                                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                                            <td style="vertical-align: bottom; text-align: right; width: 12%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">-</span></span></td>
                                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                                        </tr>
                                                        <tr>
                                                            <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">Research and development</span></span></td>
                                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>709,136</b></span></span></td>
                                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">161,300</span></span></td>
                                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">-</span></span></td>
                                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                        </tr>
                                                        <tr>
                                                            <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 2.25pt double #000000; vertical-align: bottom;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">Total share-based compensation expense</span></span></td>
                                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%;">&#160;</td>
                                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 12%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>880,615</b></span></span></td>
                                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%;">&#160;</td>
                                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%;">&#160;</td>
                                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 12%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">161,300</span></span></td>
                                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%;">&#160;</td>
                                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%;">&#160;</td>
                                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 12%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">-</span></span></td>
                                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%;">&#160;</td>
                                                        </tr>
                                                    </table>
                                                </div>

                                        </div>
                                        <p style="margin-bottom: 0pt; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span style="text-decoration: underline;"><b>Warrants</b></span></span></span></p>
                                        <p style="margin-top: 0pt; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">The following table summarizes the movements in the Company's outstanding warrants for the years ended September 30, 2021 and 2020:</span></span></p>
                                        <div style="margin-left: 5.4pt;">

                                                <div>
                                                    <table cellpadding="0" cellspacing="0" style="width: 100%; border-collapse: collapse; font-size: 10pt; border-color: #000000;">
                                                        <tr>
                                                            <td style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1.5pt solid #000000; border-bottom: 0.75pt solid #000000; vertical-align: bottom;">&#160;</td>
                                                            <td style="vertical-align: bottom; border-top: 1.5pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right;">&#160;</td>
                                                            <td style="vertical-align: bottom; border-top: 1.5pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>Number of warrants</b></span></span></td>
                                                            <td style="vertical-align: bottom; border-top: 1.5pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;">&#160;</td>
                                                            <td style="vertical-align: bottom; border-top: 1.5pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;">&#160;</td>
                                                            <td style="vertical-align: bottom; border-top: 1.5pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">&#160;<b>Weighted average </b><br/><b>exercise price</b></span></span></td>
                                                            <td style="vertical-align: bottom; border-top: 1.5pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right;">&#160;</td>
                                                        </tr>
                                                        <tr>
                                                            <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>Balance at September 30, 2019 and May 31, 2019</b></span></span></td>
                                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                            <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>-</b></span></span></td>
                                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">$</span></span></td>
                                                            <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>-</b></span></span></td>
                                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                        </tr>
                                                        <tr>
                                                            <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">&#160; Issued</span></span></td>
                                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 15%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">4,079,600</span></span></td>
                                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 15%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">0.05</span></span></td>
                                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                                        </tr>
                                                        <tr>
                                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>Balance at September 30, 2020</b></span></span></td>
                                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>4,079,600</b></span></span></td>
                                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">0.05</span></span></td>
                                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                        </tr>
                                                        <tr>
                                                            <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">&#160; Issued*</span></span></td>
                                                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                                            <td style="vertical-align: bottom; text-align: right; width: 15%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">1,709,938</span></span></td>
                                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                                            <td style="vertical-align: bottom; text-align: right; width: 15%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">9.46</span></span></td>
                                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                                        </tr>
                                                        <tr>
                                                            <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">&#160; Issued - broker</span></span></td>
                                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                            <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">132,666</span></span></td>
                                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                            <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">7.57</span></span></td>
                                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                        </tr>
                                                        <tr>
                                                            <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">&#160; Exercised</span></span></td>
                                                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                                            <td style="vertical-align: bottom; text-align: right; width: 15%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">(1,948,000</span></span></td>
                                                            <td style="vertical-align: bottom; text-align: left; width: 2%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">)</span></span></td>
                                                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                                            <td style="vertical-align: bottom; text-align: right; width: 15%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">0.05</span></span></td>
                                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                                        </tr>
                                                        <tr>
                                                            <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 2.25pt double #000000; vertical-align: bottom; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>Balance at September 30, 2021</b></span></span></td>
                                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>3,974,204</b></span></span></td>
                                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">$</span></span></td>
                                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">4.35</span></span></td>
                                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                        </tr>
                                                    </table>
                                                </div>

                                        </div>
                                        <p style="text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><i>*On November 2, 2020, the Directors of the Company reduced the exercise price of the outstanding warrants from $0.125 to $0.05 effective July 11, 2020.</i></span></span></p>
                                    </div>

                                    <div>
                                        <p style="text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">On March 17, 2021, the Company issued 132,666 compensation warrants to underwriters. The fair value of these share purchase warrants of $521,000 was measured using the Black Scholes option pricing model using the following inputs: i) exercise price: $7.57; ii) share price: $6.65; iii) term: 3 years; iv) volatility: 100%; v) discount rate: 0.35%; and dividends: nil. The fair value of these broker warrants was recorded as a reduction against share capital.</span></span></p>
                                        <p style="text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">As at September 30, 2021, the warrants have a weighted average remaining life of 2.66 (September 30, 2020 - 3.83) years.</span></span></p>
                                        <p style="text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">The following table summarizes the warrants issued and outstanding:</span></span></p>
                                        <div style="margin-left: 9pt;">

                                                <div>
                                                    <table cellpadding="0" cellspacing="0" style="width: 100%; border-collapse: collapse; font-size: 10pt; border-color: #000000;">
                                                        <tr>
                                                            <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-top: 1.5pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>&#160;</b></span></span></td>
                                                            <td colspan="1" style="vertical-align: bottom; border-top: 1.5pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: center;">&#160;</td>
                                                            <td colspan="7" style="vertical-align: bottom; border-top: 1.5pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>Warrants Outstanding</b></span></span></td>
                                                            <td colspan="1" style="vertical-align: bottom; border-top: 1.5pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: center;">&#160;</td>
                                                        </tr>
                                                        <tr>
                                                            <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>Expiry Date</b></span></span></td>
                                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right;">&#160;</td>
                                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>Number of<br/>warrants</b></span></span></td>
                                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;">&#160;</td>
                                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;">&#160;</td>
                                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>&#160;</b><br/><b>Exercise price</b></span></span></td>
                                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;">&#160;</td>
                                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;">&#160;</td>
                                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>Remaining life<br/>(Years)</b></span></span></td>
                                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right;">&#160;</td>
                                                        </tr>
                                                        <tr>
                                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">July 30, 2024 (1)</span></span></td>
                                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                            <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">2,131,600</span></span></td>
                                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">$</span></span></td>
                                                            <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">0.05</span></span></td>
                                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                            <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">
                                                                        2.83
                                                                    </span></span></td>
                                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                        </tr>
                                                        <tr>
                                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">March 17, 2024</span></span></td>
                                                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                                            <td style="vertical-align: bottom; text-align: right; width: 12%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">1,709,938</span></span></td>
                                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                                            <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">$</span></span></td>
                                                            <td style="vertical-align: bottom; text-align: right; width: 12%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">9.46</span></span></td>
                                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                                            <td style="vertical-align: bottom; text-align: right; width: 12%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">
                                                                        2.46
                                                                    </span></span></td>
                                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                                        </tr>
                                                        <tr>
                                                            <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 2.25pt double #000000; vertical-align: bottom; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">March 17, 2024</span></span></td>
                                                            <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                            <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">132,666</span></span></td>
                                                            <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                            <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">$</span></span></td>
                                                            <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">7.57</span></span></td>
                                                            <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                            <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                            <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">
                                                                        2.46
                                                                    </span></span></td>
                                                            <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                        </tr>
                                                    </table>
                                                </div>

                                        </div>
                                        <p style="text-align: justify; margin-bottom: 0px;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">(1) On June 15, 2021, the Company entered into warrant exercise agreements with the two warrant holders, whereby the warrant holders authorized the Company to issue only such number of common shares (or other class of voting securities of the Company, if applicable) as will result in the warrant holders and any other person (as defined) holding less than the threshold number of 4.99% (as defined) of any class of&#160; voting securities of the Company as of the date of exercise or conversion of the warrants.</span></span></p>
                                    </div>
                                <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfClassesOfShareCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfClassesOfShareCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfIssuedCapitalExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of issued capital. [Refer: Issued capital]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfIssuedCapitalExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.4</span><table class="report" border="0" cellspacing="2" id="idm140170911454888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RELATED PARTY TRANSACTIONS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract', window );"><strong>Disclosure of transactions between related parties [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfRelatedPartyExplanatory', window );">RELATED PARTY TRANSACTIONS [Text Block]</a></td>
<td class="text">
                        <div>
                            <p style="margin-left: 18pt; text-indent: -18pt; text-align: justify; margin-top: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>7.</b><span style="width: 9pt; text-indent: 0pt; display: inline-block;">&#160;</span><b>RELATED PARTY TRANSACTIONS</b></span></span></p>
                            <p style="text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">Related party transactions were recorded at the exchange value, which is the consideration determined and agreed to by the related parties. The Company's related parties include directors, key management and companies controlled by directors and key management.</span></span></p>
                            <p style="margin-bottom: 0pt; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span style="text-decoration: underline;">Compensation of Key Management Personnel</span></span></span></p>
                            <p style="margin-top: 0pt; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">Key management personnel are those persons that have authority and responsibility for planning, directing and controlling the activities of the Company, directly and indirectly, and by definition include the directors of the Company.</span></span></p>
                            <p style="text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">The following table summarizes expenses related to key management personnel:</span></span></p>

                                <div>
                                    <table cellpadding="0" cellspacing="0" style="width: 100%; border-collapse: collapse; font-size: 10pt; border-color: #000000;">
                                        <tr>
                                            <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-top: 1.5pt solid #000000; text-align: justify;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 1.5pt solid #000000; text-align: right;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 1.5pt solid #000000; text-align: right; white-space: nowrap;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>Year ended</b></span></span></td>
                                            <td style="vertical-align: bottom; border-top: 1.5pt solid #000000; text-align: right; white-space: nowrap;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 1.5pt solid #000000; text-align: right; white-space: nowrap;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 1.5pt solid #000000; text-align: right; white-space: nowrap;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>Year ended</b></span></span></td>
                                            <td style="vertical-align: bottom; border-top: 1.5pt solid #000000; text-align: right; white-space: nowrap;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 1.5pt solid #000000; text-align: right; white-space: nowrap;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 1.5pt solid #000000; text-align: right; white-space: nowrap;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>Period ended </b></span></span></td>
                                            <td style="vertical-align: bottom; border-top: 1.5pt solid #000000; text-align: right;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; white-space: nowrap;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>September 30, </b><br/><b>2021</b></span></span></td>
                                            <td style="vertical-align: bottom; text-align: right; white-space: nowrap;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; white-space: nowrap;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; white-space: nowrap;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>September 30, </b><br/><b>2020</b></span></span></td>
                                            <td style="vertical-align: bottom; text-align: right; white-space: nowrap;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; white-space: nowrap;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; white-space: nowrap;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>September 30,<br/>2019</b></span></span></td>
                                            <td style="vertical-align: bottom; text-align: right;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: justify;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>$</b></span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">$</span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">$</span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">Professional fees</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>87,074</b></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">22,575</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">-</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">Research and development</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 12%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>772,596</b></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 12%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">26,777</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 12%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">-</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">Share-based compensation included in directors' compensation</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>136,612</b></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">-</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">-</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">Share-based compensation included in professional fees</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 12%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>23,126</b></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 12%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">-</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 12%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">-</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: justify; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">Share-based compensation included in research and development</span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>236,652</b></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">161,300</span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">-</span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>&#160;</b></span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 12%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>1,256,060</b></span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 12%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">210,652</span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 12%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">-</span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%;">&#160;</td>
                                        </tr>
                                    </table>
                                </div>

                            <p style="text-align: justify; margin-top: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">See Note 8 for related party contractual obligations.</span></span></p>
                        </div>
                    <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfRelatedPartyExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related parties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 24<br> -IssueDate 2020-01-01<br> -Section Disclosures<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=24&amp;code=ifrs-tx-2020-en-r&amp;doctype=Standard&amp;dita_xref=IAS24_g13-24_TI<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfRelatedPartyExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.4</span><table class="report" border="0" cellspacing="2" id="idm140170911458568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONTRACTUAL OBLIGATIONS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drug_DisclosureOfContractualObligationAbstract', window );"><strong>Disclosure Of Contractual Obligation [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfCommitmentsExplanatory', window );">CONTRACTUAL OBLIGATIONS [Text Block]</a></td>
<td class="text">
                        <div>
                            <p style="margin-left: 18pt; text-indent: -18pt; text-align: justify; margin-top: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>8.</b><span style="display: inline-block; width: 9pt;">&#160;</span><b>CONTRACTUAL OBLIGATIONS</b></span></span></p>
                            <p style="margin-bottom: 0pt; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span style="text-decoration: underline;">Option agreement</span></span></span></p>
                            <p style="margin-top: 0pt; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">On May 26, 2020, the Company entered into an option agreement (the "OA") with the University of Illinois at Chicago (the "UIC"), whereby the Company obtained the right to evaluate certain of the UIC's technology (as defined) for the purpose of making a decision as to whether to exclusively license the rights to the technology. Pursuant to the OA, the Company was granted an exclusive option to evaluate the technology and obtain an exclusive license to the patents and patent applications (as listed) and a non-exclusive right to use the technology for non-commercial research purposes. The Company paid US$15,000 ($20,313) in non-refundable option fees prior to exercising its option.&#160;</span></span></p>
                        </div>

                        <div>
                            <p style="margin-bottom: 0pt; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span style="text-decoration: underline;">License agreement</span></span></span></p>
                            <p style="margin-top: 0pt; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">On April 23, 2021, the Company entered into an exclusive license agreement with equity (the "LA") with the Board of Trustees of the UIC (the "University") whereby the University granted to the Company, in all fields of use and worldwide, an exclusive, non-transferable license with the right to sublicense under the University's rights in and to the Patent Rights (as defined) and a non-exclusive, non-transferable license with the right to sublicense under the University's rights in and to the Technical Information (as defined) to make, have made, construct, have constructed, use, import, sell, and offer for sale royalty-bearing Product (as defined). As consideration for the grant of license, the Company will pay the following amounts (in US$) to the University:</span></span></p>
                            <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; font-family: Times New Roman, Times, serif;">
                                <tr>
                                    <td style="width: 10px;">&#160;</td>
                                    <td style="text-align: center; vertical-align: top; width: 3%;">&#8226;</td>
                                    <td>
                                        <p style="font-size: 10pt; font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;"><i>Signing Fee</i> - a signing fee of $100,000 less $15,000 in option fees was paid (CDN$105,502) and 63,000 common shares of the Company were issued to the University (see Note 6);</p>
                                    </td>
                                </tr>
                                <tr>
                                    <td style="width: 10px;">&#160;</td>
                                    <td style="text-align: center; vertical-align: top; width: 3%;">&#160;</td>
                                    <td>&#160;</td>
                                </tr>
                                <tr>
                                    <td style="width: 10px;">&#160;</td>
                                    <td style="text-align: center; vertical-align: top; width: 3%;">&#8226;</td>
                                    <td>
                                        <p style="font-size: 10pt; font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;"><i>Net Sales</i> - royalties on Net Sales (as defined) ranging from 3% (under $1 billion) to 4.5% (over $2 billion), with such royalty payments being credited toward the annual minimum for the license year in which the royalty payment accrues;</p>
                                    </td>
                                </tr>
                                <tr>
                                    <td style="width: 10px;">&#160;</td>
                                    <td style="text-align: center; vertical-align: top; width: 3%;">&#160;</td>
                                    <td>&#160;</td>
                                </tr>
                                <tr>
                                    <td style="width: 10px;">&#160;</td>
                                    <td style="text-align: center; vertical-align: top; width: 3%;">&#8226;</td>
                                    <td>
                                        <p style="font-size: 10pt; font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;"><i>Sublicensee Revenues</i> - royalties (as for net sales above) on Sublicensee Revenue (as defined), with such royalty payments being credited toward the annual minimum for the license year in which the royalty payment accrues and 12% on all non-royalty revenue until the Company has raised $7.5 million and then 10% thereafter;</p>
                                    </td>
                                </tr>
                                <tr>
                                    <td style="width: 10px;">&#160;</td>
                                    <td style="text-align: center; vertical-align: top; width: 3%;">&#160;</td>
                                    <td>&#160;</td>
                                </tr>
                                <tr>
                                    <td style="width: 10px;">&#160;</td>
                                    <td style="text-align: center; vertical-align: top; width: 3%;">&#8226;</td>
                                    <td>
                                        <p style="font-size: 10pt; font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;"><i>Annual Minimums</i> - if the total royalties paid to the University for any license year are less than the following annual minimums, the Company must pay the University the amount equal to the shortfall:</p>
                                    </td>
                                </tr>
                                <tr>
                                    <td style="width: 10px;">&#160;</td>
                                    <td style="text-align: center; width: 3%;">&#160;</td>
                                    <td>&#160;</td>
                                </tr>
                            </table>
                            <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; font-family: Times New Roman, Times, serif;">
                                <tr>
                                    <td style="width: 3%;">&#160;</td>
                                    <td style="width: 3%;">&#160;</td>
                                    <td style="width: 3%;"><span style="font-size: 8pt;">o</span></td>
                                    <td>
                                        <p style="font-size: 10pt; font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;">Years 1 and 2 - $<span style="-sec-ix-hidden: Fxbrl_20211229013458419;">nil</span>;</p>
                                    </td>
                                </tr>
                                <tr>
                                    <td style="width: 3%;">&#160;</td>
                                    <td style="width: 3%;">&#160;</td>
                                    <td style="width: 3%;">
                                        <p style="font-size: 10pt; font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-size: 8pt;">o</span></p>
                                    </td>
                                    <td>
                                        <p style="font-size: 10pt; font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;">Year 3 - $5,000;</p>
                                    </td>
                                </tr>
                                <tr>
                                    <td style="width: 3%;">&#160;</td>
                                    <td style="width: 3%;">&#160;</td>
                                    <td style="width: 3%;"><span style="font-size: 8pt;">o</span></td>
                                    <td>
                                        <p style="font-size: 10pt; font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;">Year 4 - $15,000;</p>
                                    </td>
                                </tr>
                                <tr>
                                    <td style="width: 3%;">&#160;</td>
                                    <td style="width: 3%;">&#160;</td>
                                    <td style="width: 3%;">
                                        <p style="font-size: 10pt; font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-size: 8pt;">o</span></p>
                                    </td>
                                    <td>
                                        <p style="font-size: 10pt; font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;">Year 5 - $35,000;</p>
                                    </td>
                                </tr>
                                <tr>
                                    <td style="width: 3%;">&#160;</td>
                                    <td style="width: 3%;">&#160;</td>
                                    <td style="width: 3%;"><span style="font-size: 8pt;">o</span></td>
                                    <td>
                                        <p style="font-size: 10pt; font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;">Year 6 and thereafter - $50,000; and</p>
                                    </td>
                                </tr>
                                <tr>
                                    <td style="width: 3%;">&#160;</td>
                                    <td style="width: 3%;">&#160;</td>
                                    <td style="width: 3%;">
                                        <p style="font-size: 10pt; font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-size: 8pt;">o</span></p>
                                    </td>
                                    <td>
                                        <p style="font-size: 10pt; font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;">After first commercial sale - $250,000 or net sales royalty, whichever is higher.</p>
                                    </td>
                                </tr>
                                <tr>
                                    <td style="width: 3%;">&#160;</td>
                                    <td style="width: 3%;">&#160;</td>
                                    <td style="width: 3%;">&#160;</td>
                                    <td>&#160;</td>
                                </tr>
                            </table>
                            <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; font-family: Times New Roman, Times, serif;">
                                <tr>
                                    <td style="width: 10px;">&#160;</td>
                                    <td style="text-align: center; vertical-align: top; width: 3%;">&#8226;</td>
                                    <td>
                                        <p style="font-size: 10pt; font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;"><i>Milestone Payments</i> - milestone payments after the occurrence of the following milestone events:</p>
                                    </td>
                                </tr>
                                <tr>
                                    <td style="width: 10px;">&#160;</td>
                                    <td style="width: 3%;">&#160;</td>
                                    <td>&#160;</td>
                                </tr>
                                <tr>
                                    <td style="width: 10px;">&#160;</td>
                                    <td style="width: 3%;">&#160;</td>
                                    <td>
                                        <p style="font-size: 10pt; font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;">Prior to any sublicensing agreements, joint ventures or change of control:</p>
                                    </td>
                                </tr>
                            </table>
                            <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; font-family: Times New Roman, Times, serif;">
                                <tr>
                                    <td style="width: 3%;">&#160;</td>
                                    <td style="width: 3%;">&#160;</td>
                                    <td style="width: 3%;">&#160;</td>
                                    <td>&#160;</td>
                                </tr>
                                <tr>
                                    <td style="width: 3%;">&#160;</td>
                                    <td style="width: 3%;">&#160;</td>
                                    <td style="width: 3%;">
                                        <p style="font-size: 10pt; font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-size: 8pt;">o</span></p>
                                    </td>
                                    <td>
                                        <p style="font-size: 10pt; font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;">$10,000 upon dosing the first patient in a Phase I trial;</p>
                                    </td>
                                </tr>
                                <tr>
                                    <td style="width: 3%;">&#160;</td>
                                    <td style="width: 3%;">&#160;</td>
                                    <td style="width: 3%;">
                                        <p style="font-size: 10pt; font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-size: 8pt;">o</span></p>
                                    </td>
                                    <td>
                                        <p style="font-size: 10pt; font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;">$50,000 upon dosing the first patient in the first Phase II trial;</p>
                                    </td>
                                </tr>
                                <tr>
                                    <td style="width: 3%;">&#160;</td>
                                    <td style="width: 3%;">&#160;</td>
                                    <td style="width: 3%;">
                                        <p style="font-size: 10pt; font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-size: 8pt;">o</span></p>
                                    </td>
                                    <td>
                                        <p style="font-size: 10pt; font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;">$250,000 upon dosing the first patient in a Phase III trial in the first clinical indication; and</p>
                                    </td>
                                </tr>
                                <tr>
                                    <td style="width: 3%;">&#160;</td>
                                    <td style="width: 3%;">&#160;</td>
                                    <td style="width: 3%;">
                                        <p style="font-size: 10pt; font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-size: 8pt;">o</span></p>
                                    </td>
                                    <td>
                                        <p style="font-size: 10pt; font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;">$2 million upon the first commercial sale of each clinical indication.</p>
                                    </td>
                                </tr>
                            </table>
                            <table style="width: 100%; font-size: 10pt; font-family: Times New Roman, Times, serif; margin-top: 5px;">
                                <tr>
                                    <td style="width: 10px;">&#160;</td>
                                    <td style="width: 3%;">&#160;</td>
                                    <td>
                                        <p style="font-size: 10pt; font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;">&#160;After any sublicensing agreements, joint ventures or change of control:</p>
                                    </td>
                                </tr>
                            </table>
                            <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; font-family: Times New Roman, Times, serif;">
                                <tr>
                                    <td style="width: 3%;">&#160;</td>
                                    <td style="width: 3%;">&#160;</td>
                                    <td style="width: 3%;">&#160;</td>
                                    <td>&#160;</td>
                                </tr>
                                <tr>
                                    <td style="width: 3%;">&#160;</td>
                                    <td style="width: 3%;">&#160;</td>
                                    <td style="width: 3%;">
                                        <p style="font-size: 10pt; font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-size: 8pt;">o</span></p>
                                    </td>
                                    <td>
                                        <p style="font-size: 10pt; font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;">As above;</p>
                                    </td>
                                </tr>
                                <tr>
                                    <td style="width: 3%;">&#160;</td>
                                    <td style="width: 3%;">&#160;</td>
                                    <td style="width: 3%;">
                                        <p style="font-size: 10pt; font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-size: 8pt;">o</span></p>
                                    </td>
                                    <td>
                                        <p style="font-size: 10pt; font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;">$250,000 upon dosing the first patient in each Phase II trial;</p>
                                    </td>
                                </tr>
                                <tr>
                                    <td style="width: 3%;">&#160;</td>
                                    <td style="width: 3%;">&#160;</td>
                                    <td style="width: 3%;">
                                        <p style="font-size: 10pt; font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-size: 8pt;">o</span></p>
                                    </td>
                                    <td>
                                        <p style="font-size: 10pt; font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;">$500,000 upon dosing the first patient in each Phase III trial; and</p>
                                    </td>
                                </tr>
                                <tr>
                                    <td style="width: 3%;">&#160;</td>
                                    <td style="width: 3%;">&#160;</td>
                                    <td style="width: 3%;">
                                        <p style="font-size: 10pt; font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-size: 8pt;">o</span></p>
                                    </td>
                                    <td>
                                        <p style="font-size: 10pt; font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;">$2 million upon the first commercial sale of each clinical indication.</p>
                                    </td>
                                </tr>
                            </table>
                            <p style="text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">Unless otherwise agreed to in writing by the University, the Company will reimburse the University for all documented costs and expenses in connection with the Patent Rights, including the preparation, filing, prosecution, maintenance and defense thereof. From time to time, the anticipated costs and expenses may be significant and, upon request, the Company will pay the estimated costs and expenses in advance of such costs and expenses being incurred by the University.</span></span></p>
                        </div>

                        <div>
                            <p style="text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">The term of the LA ends on the later of the last to expire of the Patent Rights, expiration of regulatory exclusivity for Product or when the Company provides notice that use of Technical Information has ceased. The University has the right to terminate the LA if the Company fails to make any required payments or is in breach of any provision of the LA.&#160; The Company may terminate the LA at any time upon providing at least 90 days written notice to the University.</span></span></p>
                            <p style="margin-bottom: 0pt; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span style="text-decoration: underline;">Related party contracts</span></span></span></p>
                            <p style="margin-top: 0pt; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">On June 5, 2020, the Company entered into an independent consultant agreement (the "ICA") whereby the consultant, a private corporation incorporated in the State of California, USA, was engaged and the consultant's representative will serve as the Company's Chief Medical Officer, with the services being provided in California. As compensation for performing these services, the consultant or the consultant's representative will participate in the Company's equity incentive plans and will be eligible for cash payments in respect of fees at such time as the Company begins to compensate other C-level personnel in cash and in similar proportion to total compensation (the "fees"). The non-cash portion of the consultant's fees for the first year of the term was in the form of a grant of 150,000 vested stock options and 150,000 RSUs (see Note 6). The services will continue for an initial term of one year unless sooner terminated. The ICA can be terminated by either party giving the other 30 days written notice or by mutual written agreement. At the end of the initial term, the ICA will automatically be extended for additional one-year period(s) unless either party gives the other 30 days written notice. In March 2021, the Board of Directors authorized a monthly fee of US$15,000 and was further amended to US$25,000 in August 2021.</span></span></p>
                            <p style="text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">On October 29, 2020, the Company entered into an independent contractor agreement (the "ICA") whereby the contractor was engaged to serve as the Company's Chief Science Officer on an as-needed basis. The contractor will be compensated for these services as determined by the Board of Directors of the Company. The services will continue for an initial term of one year unless sooner terminated. The ICA can be terminated by the Company providing five working days written notice, the contractor providing three months' written notice or by mutual written agreement. At the end of the initial term, the ICA will automatically be extended for additional one-year period(s) unless the Company provides the contractor with 30 days written notice. In March 2021, the Board of Directors authorized a monthly fee of US$15,000 and was further amended to US$25,000 in August 2021.</span></span></p>
                            <p style="margin-bottom: 0pt; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span style="text-decoration: underline;">Scientific advisory board agreements</span></span></span></p>
                            <p style="margin-top: 0pt; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">On June 1, 2020, July 14, 2020 and April 12, 2021, the Company entered into scientific advisory board agreements (the "SABAs") whereby the advisors were retained to serve as members of the Company's scientific advisory board and as consultants to the Company and senior management in the areas of scientific, technical and business advice. As compensation for performing these services, the Company will pay the advisors hourly rates of $150 and $160 per hour. The Company also granted 130,000 share purchase options to the advisors as part of the Company's November 17, 2020 and April 28, 2021 grant of options of which 20,000 options were cancelled on January 21, 2021 (see Note 6). The advisors have the same hour requirements and restrictions as noted below. The services will continue for initial terms of one year unless sooner terminated. At the end of the initial terms, the SABAs will automatically be extended for an additional one-year period(s) unless either party gives the other 30 days written notice.&#160;</span></span></p>
                            <p style="margin-bottom: 0pt; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span style="text-decoration: underline;">Consulting agreements</span></span></span></p>
                            <p style="margin-top: 0pt; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">The Company has entered into numerous consulting agreements (the "CAs") whereby the consultants were retained to serve as advisors to the Company and senior management in the areas of public relations and content creation and scientific, technical and business advice. As compensation for performing these services, the Company will pay the advisors hourly rates between US$30 to US$600. The Company also granted 302,000 share purchase options to six advisors as part of the Company's November 17, 2020 and April 28, 2021 grant of options (see Note 6). The advisors being paid $400 and $600 per hour will reserve at least six full days of services to the Company and such additional days as requested by the Company each annual period, but not to exceed 36 full days of service per year unless otherwise agreed and up to a maximum of 288 hours total per year, unless otherwise agreed. The services will continue for initial terms of one year unless sooner terminated. At the end of the initial terms, the CAs will automatically be extended for an additional one-year period(s) unless either party gives the other 30 days written notice.</span></span></p>
                            <p style="text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">On October 9, 2020, the Company entered into a consulting agreement whereby the consultant was retained to serve as an advisor to the Company in the areas of scientific, technical and business advice. As compensation for performing these services, the Company will pay the advisor an hourly rate of US$130. The Company granted 90,000 stock options to the consultant on November 17, 2020 (see Note 6).</span></span></p>
                        </div>

                        <div>
                            <p style="text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">On November 6, 2020, the Company entered into a sponsored research agreement (the "SRA") with the University of Texas Medical Branch (the "UTMB") whereby the UTMB conducted a research program on behalf of the Company. Pursuant to the SRA, the agreement is effective as of October 15, 2020 and the research program was carried out through to its conclusion on February 15, 2021. As consideration for UTMB's performance, the Company paid US$66,764 which was recorded in research and development costs.</span></span></p>
                            <p style="text-align: justify; margin-bottom: 0px;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">On November 17, 2020, the Company entered into an ICA whereby the contractor was engaged to serve as the Company's Vice President (Discovery). The contractor will be compensated for these services as determined by the Board of Directors of the Company. The services will continue for an initial term of one year unless sooner terminated. The ICA can be terminated by the Company providing five working days written notice, the contractor providing three months' written notice or by mutual written agreement. At the end of the initial term, the ICA will automatically be extended for additional one-year period(s) unless the Company provides the contractor with 30 days written notice. In March 2021, the Board of Directors authorized a monthly fee of US$15,000.</span></span></p>
                        </div>
                    <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_drug_DisclosureOfContractualObligationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">drug_DisclosureOfContractualObligationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>drug_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfCommitmentsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of commitments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfCommitmentsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.4</span><table class="report" border="0" cellspacing="2" id="idm140170911664648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FINANCIAL INSTRUMENTS AND CAPITAL MANAGEMENT<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsAbstract', window );"><strong>Disclosure of detailed information about financial instruments [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsExplanatory', window );">FINANCIAL INSTRUMENTS AND CAPITAL MANAGEMENT [Text Block]</a></td>
<td class="text">
                        <div>
                            <p style="text-align: justify; margin-top: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>9.<span style="display: inline-block; width: 9pt;">&#160;</span>FINANCIAL INSTRUMENTS AND CAPITAL MANAGEMENT</b></span></span></p>
                            <p style="text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">The following table summarizes the carrying value of financial assets and liabilities:</span></span></p>

                                <div>
                                    <div style="margin-left: 5.4pt;">
                                        <table cellpadding="0" cellspacing="0" style="width: 100%; border-collapse: collapse; font-size: 10pt; border-color: #000000;">
                                            <tr>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1.5pt solid #000000; border-bottom: 0.75pt solid #000000; vertical-align: bottom;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>&#160;</b></span></span></td>
                                                <td style="vertical-align: bottom; border-top: 1.5pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right;">&#160;</td>
                                                <td style="vertical-align: bottom; border-top: 1.5pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>September 30, </b><br/><b>2021</b></span></span></td>
                                                <td style="vertical-align: bottom; border-top: 1.5pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;">&#160;</td>
                                                <td style="vertical-align: bottom; border-top: 1.5pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;">&#160;</td>
                                                <td style="vertical-align: bottom; border-top: 1.5pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>September 30, </b><br/><b>2020</b></span></span></td>
                                                <td style="vertical-align: bottom; border-top: 1.5pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right;">&#160;</td>
                                            </tr>
                                            <tr>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>FVTPL</b></span></span></td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right;">&#160;</td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>$</b></span></span></td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right;">&#160;</td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right;">&#160;</td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>$</b></span></span></td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right;">&#160;</td>
                                            </tr>
                                            <tr>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">&#160; Cash</span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>19,673,765</b></span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">799,929</span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            </tr>
                                            <tr>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">&#160; Guaranteed investment certificate</span></span></td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>86,250</b></span></span></td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">-</span></span></td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                            </tr>
                                            <tr>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">&#160; Cash and cash equivalents</span></span></td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>19,760,015</b></span></span></td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">799,929</span></span></td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            </tr>
                                            <tr>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>Amortized cost</b></span></span></td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>&#160;</b></span></span></td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%;">&#160;</td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                            </tr>
                                            <tr>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 2.25pt double #000000; vertical-align: bottom; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">&#160; Accounts payable and accrued liabilities</span></span></td>
                                                <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>638,573</b></span></span></td>
                                                <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">150,923</span></span></td>
                                                <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            </tr>
                                        </table>
                                    </div>
                                </div>

                            <p style="margin-bottom: 0pt; text-align: justify; margin-top: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>Fair value measurement</b></span></span></p>
                            <p style="margin-top: 0pt; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">Financial assets and liabilities that are recognized on the statement of financial position at fair value can be classified in a hierarchy that is based on the significance of the inputs used in making the measurements.</span></span></p>
                            <p style="margin-bottom: 0pt; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span style="text-decoration: underline;">The levels in the hierarchy are:</span></span></span></p>
                            <p style="margin-top: 0pt; margin-bottom: 0pt; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">Level 1 - quoted prices (unadjusted) in active markets for identical assets or liabilities;</span></span></p>
                            <p style="margin-top: 0pt; margin-left: 39.6pt; margin-bottom: 0pt; text-indent: -39.6pt; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">Level 2 - inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly (that is, as prices) or indirectly (that is, derived from prices); and</span></span></p>
                            <p style="margin-top: 0pt; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">Level 3 - inputs for the asset or liability that are not based on observable market data (that is, unobservable inputs).</span></span></p>
                            <p style="text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">The Company's cash and cash equivalents is classified as Level 1, whereas accounts payable and accrued liabilities are classified as Level 2. As at September 30, 2021, the Company believes that the carrying values of cash and cash equivalents and accounts payable and accrued liabilities approximate their fair values because of their nature and relatively short maturity dates or durations.</span></span></p>
                            <p style="margin-bottom: 0pt; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>Financial risk management</b></span></span></p>
                            <p style="margin-top: 0pt; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">The Company is exposed in varying degrees to a variety of financial instrument related risks. The Board of Directors approves and monitors the risk management processes. The type of risk exposure and the way in which such exposure is managed is provided as follows:</span></span></p>
                            <p style="margin-bottom: 0pt; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span style="text-decoration: underline;">Credit risk </span></span></span></p>
                            <p style="margin-top: 0pt; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">Credit risk is the risk that one party to a financial instrument will fail to discharge an obligation and cause the other party to incur a financial loss. The Company's primary exposure to credit risk is on its cash and cash equivalents balance. As at September 30, 2021, the Company had cash and cash equivalents of $19,760,015 which was held with a major bank in Canada and a major bank in the United States. Because deposits are with two banks, there is a concentration of credit risk. This risk is managed by using major banks that are high credit quality financial institutions as determined by rating agencies. The maximum exposure to credit risk is the carrying amount of the Company's financial instruments. The credit risk is assessed as low.</span></span></p>
                        </div>

                        <div>
                            <p style="margin-bottom: 0pt; text-align: justify; margin-top: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span style="text-decoration: underline;">Foreign exchange risk </span></span></span></p>
                            <p style="margin-top: 0pt; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">Foreign currency risk is the risk that the fair values of future cash flows of a financial instrument will fluctuate because they are denominated in currencies that differ from the respective functional currency. As at September 30, 2021, the Company had the following foreign currency balances - cash (US$2,789,264) and accounts payable and accrued liabilities (US$420,481). A 10% fluctuation in the US$ against the Canadian dollar would have an impact of approximately $301,807 on the net comprehensive loss.</span></span></p>
                            <p style="margin-bottom: 0pt; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span style="text-decoration: underline;">Liquidity risk </span></span></span></p>
                            <p style="margin-top: 0pt; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">Liquidity risk arises through the excess of financial obligations over available financial assets due at any point in time. The Company's objective in managing liquidity risk is to maintain sufficient readily available reserves in order to meet its liquidity requirements at any point in time. The Company's main source of funding has been the issuance of equity securities for cash, primarily through private placements. The Company's access to financing is always uncertain. There can be no assurance of continued access to significant equity funding. As at September 30, 2021, the Company had cash and cash equivalents of $19,760,015 to cover current liabilities of $638,573.</span></span></p>
                            <p style="margin-bottom: 0pt; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span style="text-decoration: underline;">Capital management</span></span></span></p>
                            <p style="margin-top: 0pt; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">Management's objective is to manage its capital to ensure that there are adequate capital resources to safeguard the Company's ability to continue as a going concern through the optimization of its capital structure. The capital structure consists of share capital and working capital. In order to achieve this objective, management makes adjustments to it in light of changes in economic conditions and risk characteristics of the underlying assets. To maintain or adjust the capital structure, management may invest its excess cash in interest bearing accounts of Canadian chartered banks and/or raise additional funds externally as needed. The Company is not subject to externally imposed capital requirements. The Company's management of capital did not change during the year ended September 30, 2021.</span></span></p>
                        </div>
                    <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFinancialInstrumentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFinancialInstrumentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFinancialInstrumentsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for financial instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2020-01-01<br> -Section Scope<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2020-en-r&amp;doctype=Standard&amp;dita_xref=IFRS07_g3-5A_TI<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFinancialInstrumentsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.4</span><table class="report" border="0" cellspacing="2" id="idm140170911667496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RESEARCH AND DEVELOPMENT<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drug_ResearchAndDevelopmentAbstract', window );"><strong>Research And Development [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfResearchAndDevelopmentExpenseExplanatory', window );">RESEARCH AND DEVELOPMENT [Text Block]</a></td>
<td class="text">
                    <div>
                        <p style="text-align: justify; margin-top: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>10.<span style="display: inline-block; width: 9pt;">&#160;</span>RESEARCH AND DEVELOPMENT</b></span></span></p>
                        <p style="text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">Research and development expense recognized in the consolidated statements of comprehensive loss is comprised of the following:</span></span></p>

                            <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-size: 10pt; width: 100%;">
                                <tr>
                                    <td style="width: 36%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top; border-top: 1.5pt solid #000000;">
                                        <p style="text-align: justify; margin-top: 0pt; margin-bottom: 0pt;">&#160;</p>
                                    </td>
                                    <td style="width: 20%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-top: 1.5pt solid #000000; white-space: nowrap;">
                                        <p style="text-align: right; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>Year ended</b></span></span></p>
                                    </td>
                                    <td style="width: 17%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-top: 1.5pt solid #000000; white-space: nowrap;">
                                        <p style="text-align: right; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>Year ended</b></span></span></p>
                                    </td>
                                    <td style="width: 16%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top; border-top: 1.5pt solid #000000; white-space: nowrap;">
                                        <p style="text-align: right; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>Period ended</b></span></span></p>
                                    </td>
                                </tr>
                                <tr>
                                    <td style="width: 36%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top;">
                                        <p style="text-align: justify; margin-top: 0pt; margin-bottom: 0pt;">&#160;</p>
                                    </td>
                                    <td style="width: 20%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; white-space: nowrap;">
                                        <p style="margin-bottom: 0pt; text-align: right; margin-top: 0pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>September 30, </b></span></span></p>
                                        <p style="margin-top: 0pt; text-align: right; margin-bottom: 0pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>2021</b></span></span></p>
                                    </td>
                                    <td style="width: 17%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; white-space: nowrap;">
                                        <p style="margin-bottom: 0pt; text-align: right; margin-top: 0pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>September 30, </b></span></span></p>
                                        <p style="margin-top: 0pt; text-align: right; margin-bottom: 0pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>2020</b></span></span></p>
                                    </td>
                                    <td style="width: 16%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top; white-space: nowrap;">
                                        <p style="text-align: right; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>September 30,<br/>2019</b></span></span></p>
                                    </td>
                                </tr>
                                <tr>
                                    <td style="width: 36%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top; border-top: 0.75pt solid #000000;">
                                        <p style="text-align: justify; margin-top: 0pt; margin-bottom: 0pt;">&#160;</p>
                                    </td>
                                    <td style="width: 20%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-top: 0.75pt solid #000000;">
                                        <p style="text-align: right; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>$</b></span></span></p>
                                    </td>
                                    <td style="width: 17%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-top: 0.75pt solid #000000;">
                                        <p style="text-align: right; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">$</span></span></p>
                                    </td>
                                    <td style="width: 16%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top; border-top: 0.75pt solid #000000;">
                                        <p style="text-align: right; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">$</span></span></p>
                                    </td>
                                </tr>
                                <tr>
                                    <td style="width: 36%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top; background-color: #e6efff;">
                                        <p style="text-align: justify; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">Laboratory costs (see Note 11)</span></span></p>
                                    </td>
                                    <td style="width: 20%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top; background-color: #e6efff;">
                                        <p style="text-align: right; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>82,871</b></span></span></p>
                                    </td>
                                    <td style="width: 17%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top; background-color: #e6efff;">
                                        <p style="text-align: right; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">25,874</span></span></p>
                                    </td>
                                    <td style="width: 16%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top; background-color: #e6efff;">
                                        <p style="text-align: right; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">27,164</span></span></p>
                                    </td>
                                </tr>
                                <tr>
                                    <td style="width: 36%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top;">
                                        <p style="text-align: justify; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">Novel drug development</span></span></p>
                                    </td>
                                    <td style="width: 20%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top;">
                                        <p style="text-align: right; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>3,638,910</b></span></span></p>
                                    </td>
                                    <td style="width: 17%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top;">
                                        <p style="text-align: right; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">110,029</span></span></p>
                                    </td>
                                    <td style="width: 16%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top;">
                                        <p style="text-align: right; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">-</span></span></p>
                                    </td>
                                </tr>
                                <tr>
                                    <td style="width: 36%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top; background-color: #e6efff;">
                                        <p style="text-align: justify; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">Patents and related payments</span></span></p>
                                    </td>
                                    <td style="width: 20%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top; background-color: #e6efff;">
                                        <p style="text-align: right; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>513,302</b></span></span></p>
                                    </td>
                                    <td style="width: 17%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top; background-color: #e6efff;">
                                        <p style="text-align: right; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">13,895</span></span></p>
                                    </td>
                                    <td style="width: 16%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top; background-color: #e6efff;">
                                        <p style="text-align: right; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">-</span></span></p>
                                    </td>
                                </tr>
                                <tr>
                                    <td style="width: 36%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top;">
                                        <p style="text-align: justify; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">Salary and subcontractors</span></span></p>
                                    </td>
                                    <td style="width: 20%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top;">
                                        <p style="text-align: right; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>1,369,769</b></span></span></p>
                                    </td>
                                    <td style="width: 17%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top;">
                                        <p style="text-align: right; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">43,754</span></span></p>
                                    </td>
                                    <td style="width: 16%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top;">
                                        <p style="text-align: right; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">14,845</span></span></p>
                                    </td>
                                </tr>
                                <tr>
                                    <td style="width: 36%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top; border-bottom: 0.75pt solid #000000; background-color: #e6efff;">
                                        <p style="text-align: justify; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">Share-based compensation (see Note 6)</span></span></p>
                                    </td>
                                    <td style="width: 20%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top; border-bottom: 0.75pt solid #000000; background-color: #e6efff;">
                                        <p style="text-align: right; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>709,136</b></span></span></p>
                                    </td>
                                    <td style="width: 17%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top; border-bottom: 0.75pt solid #000000; background-color: #e6efff;">
                                        <p style="text-align: right; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">161,300</span></span></p>
                                    </td>
                                    <td style="width: 16%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top; border-bottom: 0.75pt solid #000000; background-color: #e6efff;">
                                        <p style="text-align: right; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">-</span></span></p>
                                    </td>
                                </tr>
                                <tr>
                                    <td style="width: 36%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000;">
                                        <p style="text-align: justify; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>&#160;</b></span></span></p>
                                    </td>
                                    <td style="width: 20%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000;">
                                        <p style="text-align: right; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>6,313,988</b></span></span></p>
                                    </td>
                                    <td style="width: 17%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000;">
                                        <p style="text-align: right; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">354,852</span></span></p>
                                    </td>
                                    <td style="width: 16%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000;">
                                        <p style="text-align: right; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">42,009</span></span></p>
                                    </td>
                                </tr>
                            </table>

                    </div>
                <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_drug_ResearchAndDevelopmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">drug_ResearchAndDevelopmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>drug_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfResearchAndDevelopmentExpenseExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of research and development expense. [Refer: Research and development expense]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfResearchAndDevelopmentExpenseExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.4</span><table class="report" border="0" cellspacing="2" id="idm140170915078168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PREMISES LEASES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PresentationOfLeasesForLesseeAbstract', window );"><strong>Presentation of leases for lessee [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfLeasesExplanatory', window );">PREMISES LEASES [Text Block]</a></td>
<td class="text">
                        <div>
                            <p style="text-align: justify; margin-top: 10pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>11.<span style="display: inline-block; width: 8pt;">&#160;</span>PREMISES LEASES</b></span></span></p>
                            <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Commencing June 1, 2021, the Company entered into a commercial laboratory lease in Wauwatosa, Wisconsin USA for a term of one year at a monthly base rent of US$1,709. For the year ended September 30, 2021, $7,003 is included in laboratory costs (see Note 10).</span></span></p>
                            <p style="text-align: justify; margin-bottom: 0px;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Commencing September 1, 2021, the Company entered into an apartment lease in New York, New York USA for a term of one year at a monthly base rent of US$5,300. For the year ended September 30, 2021, $6,700 is included in office and administrative expense.</span></span></p>
                        </div>
                    <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfLeasesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for leases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2020-01-01<br> -Section Presentation<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2020-en-r&amp;doctype=Standard&amp;dita_xref=IFRS16_g47-50_TI<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2020-01-01<br> -Section Disclosure<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2020-en-r&amp;doctype=Standard&amp;dita_xref=IFRS16_g51-60_TI<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfLeasesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PresentationOfLeasesForLesseeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PresentationOfLeasesForLesseeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.4</span><table class="report" border="0" cellspacing="2" id="idm140170915472840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract', window );"><strong>Major components of tax expense (income) [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfIncomeTaxExplanatory', window );">INCOME TAXES [Text Block]</a></td>
<td class="text">
                    <div>
                        <p style="text-align: justify; margin-top: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>12.<span style="display: inline-block; width: 8pt;">&#160;</span>INCOME TAXES</b></span></span></p>
                        <p style="text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">A reconciliation of the expected income tax recovery to the actual income tax recovery is as follows:</span></span></p>
                    </div>

                    <div>&#160;
                            <div>
                                <div style="margin-left: 36pt;">
                                    <table cellpadding="0" cellspacing="0" style="width: 100%; border-collapse: collapse; font-size: 10pt; border-color: #000000;">
                                        <tr>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; vertical-align: bottom;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>&#160;</b></span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>September 30, </b><br/><b>2021</b></span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>September 30, </b><br/><b>2020</b></span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>September 30,<br/>2019</b></span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>$</b></span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>$</b></span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>$</b></span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">Net loss</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>(8,650,763</b></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>)</b></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">(480,377</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">)</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">(78,717</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">)</span></span></td>
                                        </tr>
                                        <tr>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">Statutory tax rate</span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>27.75%</b></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">27%</span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">27%</span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">Expected income tax recovery</span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>(2,400,311</b></span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>)</b></span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">(129,702</span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">)</span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">(21,254</span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">)</span></span></td>
                                        </tr>
                                        <tr>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">Deductible and non-deductible items</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 12%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>(256,939</b></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>)</b></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 12%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">42,136</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 12%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">-</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">Change in deferred tax assets not recognized</span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>2,657,250</b></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">87,566</span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">21,254</span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 2.25pt double #000000; vertical-align: bottom;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">Total income tax recovery</span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 12%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>-</b></span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 12%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">-</span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 12%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">-</span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%;">&#160;</td>
                                        </tr>
                                    </table>
                                </div>
                            </div>

                        <p style="text-align: justify; margin-top: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">The Company has the following deductible temporary differences for which no deferred tax has been recognized:</span></span></p>

                            <div>
                                <div style="margin-left: 36pt;">
                                    <table cellpadding="0" cellspacing="0" style="width: 100%; border-collapse: collapse; font-size: 10pt; border-color: #000000;">
                                        <tr>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; vertical-align: bottom;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>&#160;</b></span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>September 30, </b><br/><b>2021</b></span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>September 30, </b><br/><b>2020</b></span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>$</b></span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>$</b></span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">Non-capital losses</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>9,976,000</b></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">403,000</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">Share issue costs</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 15%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>1,448,000</b></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 15%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">4,000</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">Intangible assets</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>(1,000</b></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>)</b></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">(2,000</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">)</span></span></td>
                                        </tr>
                                        <tr>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; border-bottom: 0.75pt solid #000000;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">Valuation allowance</span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 15%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>(11,423,000</b></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>)</b></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 15%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">(405,000</span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">)</span></span></td>
                                        </tr>
                                        <tr>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; border-bottom: 2.25pt double #000000; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">Net deferred income tax assets</span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>-</b></span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">-</span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                        </tr>
                                    </table>
                                </div>
                            </div>

                        <p style="text-align: justify; margin-top: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">The Company has Canadian non-capital losses of approximately $9,940,000 (2019 - $403,000), US non-capital losses of $ 30,000 (2019 - $Nil) and Australian non-capital losses of $6,000 (2019- $Nil), which may be carried forward and applied against taxable income in future years. Future tax benefits which may arise as a result of these losses have not been recognized in these financial statements and have been offset by a valuation allowance.</span></span></p>
                        <p style="text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">The Company's Canadian non-capital loss carry-forwards expire as follows:</span></span></p>

                            <div>
                                <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-size: 10pt; width: 70%; border-color: #000000; margin-left: auto; margin-right: auto;">
                                    <tr>
                                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>Year of Origin</b></span></span></td>
                                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>Year of Expiry</b></span></span></td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;">&#160;</td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>Non-Capital Losses</b></span></span></td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: center;">&#160;</td>
                                    </tr>
                                    <tr>
                                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: center;">&#160;</td>
                                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: center;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>$</b></span></span></td>
                                        <td style="vertical-align: bottom; text-align: right;">&#160;</td>
                                    </tr>
                                    <tr>
                                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: center; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">2019</span></span></td>
                                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: center; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span style="-sec-ix-hidden: Fxbrl_20211228221904526;">2039</span></span></span></td>
                                        <td style="vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; width: 22%; text-align: right; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">79,000</span></span></td>
                                        <td style="vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;">&#160;</td>
                                    </tr>
                                    <tr>
                                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: center;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">2020</span></span></td>
                                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: center;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span style="-sec-ix-hidden: Fxbrl_20211228221912500;">2040</span></span></span></td>
                                        <td style="vertical-align: bottom; width: 1%; text-align: left;">&#160;</td>
                                        <td style="vertical-align: bottom; width: 22%; text-align: right;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">324,000</span></span></td>
                                        <td style="vertical-align: bottom; width: 2%; text-align: left;">&#160;</td>
                                    </tr>
                                    <tr>
                                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">2021</span></span></td>
                                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span style="-sec-ix-hidden: Fxbrl_20211228221915311;">2041</span></span></span></td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 22%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">9,537,000</span></span></td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                    </tr>
                                    <tr>
                                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: center;">&#160;</td>
                                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: center;">&#160;</td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%;">&#160;</td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 22%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">9,940,000</span></span></td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%;">&#160;</td>
                                    </tr>
                                </table>
                            </div>

                    </div>
                <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfIncomeTaxExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2020-01-01<br> -Section Disclosure<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2020-en-r&amp;doctype=Standard&amp;dita_xref=IAS12_g79-88_TI<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfIncomeTaxExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.4</span><table class="report" border="0" cellspacing="2" id="idm140170915473000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMPARATIVE AMOUNTS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drug_ComparativeAmountsAbstract', window );"><strong>Comparative Amounts [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drug_DisclosureOfComparativeAmountsExplanatory', window );">COMPARATIVE AMOUNTS [Text Block]</a></td>
<td class="text">
                        <div>
                            <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>13.<span style="display: inline-block; width: 8pt;">&#160;</span>COMPARATIVE AMOUNTS</b></span></span></p>
                            <p style="text-align: justify; margin-bottom: 0px;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Certain of the prior year's amounts have been reclassified to conform with the current year's presentation (see Note 10).</span></span></p>
                        </div>
                    <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_drug_ComparativeAmountsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Comparative Amounts [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">drug_ComparativeAmountsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>drug_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_drug_DisclosureOfComparativeAmountsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of comparative amounts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">drug_DisclosureOfComparativeAmountsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>drug_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.4</span><table class="report" border="0" cellspacing="2" id="idm140170915452472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUBSEQUENT EVENTS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract', window );"><strong>Disclosure of non-adjusting events after reporting period [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory', window );">SUBSEQUENT EVENTS [Text Block]</a></td>
<td class="text">
                        <div>
                            <p style="text-align: justify; margin-top: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>14.<span style="display: inline-block; width: 8pt;">&#160;</span>SUBSEQUENT EVENTS</b></span></span></p>
                            <p style="text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">Events not disclosed elsewhere in these consolidated financial statements are as follows:</span></span></p>
                            <p style="text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">On November 1, 2021, the Company entered into a letter agreement (the "LA") with a New York-based company, whereby the company will provide investor relations services to the Company. As compensation for performing these services, the Company will pay a non-refundable monthly retainer of US$5,000 and issue 11,200 shares of restricted stock in three tranches: 3,800 on January 1, 2022; 3,700 on April 1, 2022 and 3,700 on July 1, 2022. If the contract is terminated prior to the issuance date, the outstanding balance is not owed. The services will continue for an initial term of one year unless sooner terminated by either party giving the other 15 days written notice. </span></span></p>
                        </div>

                        <div>
                            <div style="text-align: justify; margin-top: 10pt;"><span style="font-family: Times New Roman, Times, serif; font-size: 10pt;">On November 9, 2021, 12,500 warrants were exercised for gross proceeds of $118,250.</span><br/>&#160;</div>
                            <div style="margin-top: 0pt; margin-bottom: 11px; text-align: justify; font-size: 10pt; font-family: Times New Roman, Times, serif;"><span style="font-family: Times New Roman, Times, serif; font-size: 10pt; line-height: normal;">In November 2021, the Company entered into director indemnity agreements (the "DIAs") with five directors of the Company. Pursuant to the DIAs and subject to all applicable laws, including the applicable limitations and restrictions set forth in the Business Corporations Act (British Columbia), the Company will:&#160;</span></div>
                            <div style="margin-top: 0pt; margin-bottom: 11px; text-align: justify; font-size: 10pt; font-family: Times New Roman, Times, serif;">
                                <table style="width: 100%; border: 0px;">
                                    <tr>
                                        <td style="width: 42px; padding: 0.1px;">
                                            <p style="margin-top: 6px; margin-bottom: 0pt; font-size: 10pt; font-family: Times New Roman, Times, serif;"><span style="line-height: normal; font-size: 10pt; font-family: Times New Roman, serif;">&#160; &#160; &#160; &#160;&#8226;</span></p>
                                        </td>
                                        <td colspan="2" style="width: 1087px; padding: 0.1px; vertical-align: top;">
                                            <p style="margin-top: 6px; margin-bottom: 0pt; text-align: justify; font-size: 10pt; font-family: Times New Roman, Times, serif;"><span style="font-size: 11pt; line-height: normal; font-family: Calibri, sans-serif;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman, serif;"><span style="color: black;">Indemnify and save harmless the Directors against and from:</span></span></span></span></p>
                                        </td>
                                    </tr>
                                    <tr>
                                        <td style="width: 42px; padding: 0.1px;">&#160;</td>
                                        <td style="width: 22px; padding: 0.1px; vertical-align: top;">
                                            <p style="margin-top: 10pt; margin-bottom: 0pt; font-size: 10pt; font-family: Times New Roman, Times, serif;"><span style="font-size: 11pt; line-height: normal; font-family: Calibri, sans-serif;"><span style="font-size: 8pt;"><span style="font-family: Times New Roman, serif;">o</span></span></span></p>
                                        </td>
                                        <td style="width: 1065px; padding: 0.1px; vertical-align: top;">
                                            <p style="margin-top: 10pt; margin-bottom: 0pt; text-align: justify; font-size: 10pt; font-family: Times New Roman, Times, serif;"><span style="line-height: normal; font-size: 10pt; font-family: Times New Roman, serif;">any and all charges or claims by reason of them being or having been a director of the Company or another corporation, at a time when the other corporation is or was an affiliate of the Company, or at the request of the Company;</span></p>
                                        </td>
                                    </tr>
                                    <tr>
                                        <td style="width: 42px; padding: 0.1px;">&#160;</td>
                                        <td style="width: 22px; padding: 0.1px; vertical-align: top;">
                                            <p style="margin-top: 0px; margin-bottom: 0pt; font-size: 10pt; font-family: Times New Roman, Times, serif;"><span style="font-size: 11pt; line-height: normal; font-family: Calibri, sans-serif;"><span style="font-size: 8pt;"><span style="font-family: Times New Roman, serif;">o</span></span></span></p>
                                        </td>
                                        <td style="width: 1065px; padding: 0.1px; vertical-align: top;">
                                            <p style="margin-top: 0px; margin-bottom: 0pt; text-align: justify; font-size: 10pt; font-family: Times New Roman, Times, serif;"><span style="line-height: normal; font-size: 10pt; font-family: Times New Roman, serif;">any and all costs, damages, expenses, fines, liabilities, losses and penalties (the "Consequences") which they may sustain, incur or be liable for in consequence of their acting as a director of the Company, whether sustained or incurred by reason of their negligence, default, breach of duty or trust, failure to exercise due diligence or otherwise in relation to the Company or any of its affairs; and</span></p>
                                        </td>
                                    </tr>
                                    <tr>
                                        <td style="width: 42px; padding: 0.1px;">&#160;</td>
                                        <td style="width: 22px; padding: 0.1px; vertical-align: top;">
                                            <p style="margin-top: 0px; margin-bottom: 0pt; font-size: 10pt; font-family: Times New Roman, Times, serif;"><span style="font-size: 11pt; line-height: normal; font-family: Calibri, sans-serif;"><span style="font-size: 8pt;"><span style="font-family: Times New Roman, serif;">o</span></span></span></p>
                                        </td>
                                        <td style="width: 1065px; padding: 0.1px; vertical-align: top;">
                                            <p style="margin-top: 0px; margin-bottom: 0pt; text-align: justify; font-size: 10pt; font-family: Times New Roman, Times, serif;"><span style="line-height: normal; font-size: 10pt; font-family: Times New Roman, serif;">in particular, and without in any way limiting the generality of the foregoing, any and all Consequences which they may sustain, incur or be liable for as a result of or in connection with the release or presence in the environment of substances, contaminants, litter, waste, effluent, refuse, pollutants or deleterious materials and that arise out of or are in any way connected with the management, operation, activities or existence of the Company or by virtue of them holding any other directorship with any other entity at the Company's request.</span></p>
                                        </td>
                                    </tr>
                                    <tr>
                                        <td style="width: 42px; padding: 0.1px;">
                                            <p style="margin-top: 10pt; margin-bottom: 0pt; font-size: 10pt; font-family: Times New Roman, Times, serif;"><span style="line-height: normal; font-size: 10pt; font-family: Times New Roman, serif;">&#160; &#160; &#160; &#8226;</span></p>
                                        </td>
                                        <td colspan="2" style="width: 1087px; padding: 0.1px; vertical-align: top;">
                                            <p style="margin-top: 10pt; margin-bottom: 0pt; text-align: justify; font-size: 10pt; font-family: Times New Roman, Times, serif;"><span style="line-height: normal; font-size: 10pt; font-family: Times New Roman, serif;">gross up any indemnity payment made pursuant to the DIAs by the amount of any income tax payable by the Directors in respect of that payment; and</span></p>
                                        </td>
                                    </tr>
                                    <tr>
                                        <td style="width: 42px; padding: 0.1px;">
                                            <p style="margin-top: 10pt; margin-bottom: 0pt; font-size: 10pt; font-family: Times New Roman, Times, serif;"><span style="line-height: normal; font-size: 10pt; font-family: Times New Roman, serif;">&#160; &#160; &#160; &#8226;</span></p>
                                        </td>
                                        <td colspan="2" style="width: 1087px; padding: 0.1px; vertical-align: top;">
                                            <p style="margin-top: 10pt; margin-bottom: 0pt; text-align: justify; font-size: 10pt; font-family: Times New Roman, Times, serif;"><span style="line-height: normal; font-size: 10pt; font-family: Times New Roman, serif;">indemnify the Directors for the amount of all costs they incur in obtaining any Court approval required to enable or require the Company to make a payment to them under the DIAs, or enforce the DIAs against the Company, including without limitation legal fees and disbursements on a full indemnity basis.</span></p>
                                        </td>
                                    </tr>
                                </table>
                            </div>
                            <div style="text-align: justify; margin-top: 10pt;"><span style="font-family: Times New Roman, Times, serif; font-size: 10pt;">Notwithstanding the above-noted, the Company will have no obligation to indemnify or save harmless the Directors in respect of any liability for which they are entitled to indemnity pursuant to any valid and collectible policy of insurance obtained and maintained by the Company, to the extent of the amounts actually collected by the Directors under the insurance policy.</span></div>
                        </div>
                    <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for events after the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 10<br> -IssueDate 2020-01-01<br> -Section Disclosure<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=10&amp;code=ifrs-tx-2020-en-r&amp;doctype=Standard&amp;dita_xref=IAS10_g17-22_TI<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.4</span><table class="report" border="0" cellspacing="2" id="idm140170968605784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drug_DisclosureOfDetailedInformationAboutSignificantAccountingPoliciesAbstract', window );"><strong>Disclosure Of Detailed Information About Significant Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drug_DescriptionOfAccountingPolicyForBasisOfConsolidationExplanatory', window );">Basis of consolidation [Policy Text Block]</a></td>
<td class="text">
                                <div>
                                    <p style="margin-bottom: 0pt; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>Basis of consolidation </b></span></span></p>
                                    <p style="margin-top: 0pt; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">These consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries Psilocybinlabs Ltd. (see Note 4), Bright Minds Biosciences LLC, a Delaware limited liability company, and Bright Minds Bioscience Pty Ltd., a proprietary company registered under the Corporations Act of Australia on June 24, 2021.&#160; On June 10, 2021, the CEO of the Company transferred, assigned and conveyed all of his membership interests in Bright Minds Biosciences LLC to the Company.</span></span></p>
                                    <p style="text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">A subsidiary is an entity that the Company controls, either directly or indirectly, where control is defined as the power to govern the financial and operating policies of an entity so as to obtain benefits from its activities. The financial results of the Company's subsidiaries are included in the financial statements from the date that control commences until the date that control ceases. The accounting policies of the Company's subsidiaries have been aligned with the policies adopted by the Company. When the Company ceases to control a subsidiary, the financial statements of that subsidiary are de-consolidated.</span></span></p>
                                </div>

                                <p style="text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">Inter-company balances and transactions, and any income and expenses arising from inter-company transactions, have been eliminated in these financial statements.</span></span></p>
                            <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drug_DescriptionOfAccountingPolicyForCriticalAccountingEstimatesExplanatory', window );">Critical accounting estimates [Policy Text Block]</a></td>
<td class="text">
                                <div>
                                    <p style="margin-bottom: 0pt; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>Critical accounting estimates</b></span></span></p>
                                    <p style="margin-top: 0pt; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">The preparation of the financial statements in conformity with IFRS requires management to make estimates, judgments and assumptions that affect the application of accounting policies and the reported amounts of assets, liabilities, income and expenses. Actual results may differ from these estimates. Estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognized in the period in which the estimates are revised and in any future periods affected.</span></span></p>
                                    <p style="text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">Certain of the Company's accounting policies and disclosures require key assumptions concerning the future and other estimates that have a significant risk of causing a material adjustment to the carrying amounts of assets and liabilities or disclosures within the next fiscal year. Where applicable, further information about the assumptions made is disclosed in the notes specific to that asset or liability. The critical accounting estimates and judgments set out below have been applied consistently to all periods presented in these financial statements.</span></span></p>
                                    <p style="margin-bottom: 0pt; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span style="text-decoration: underline;">Ability to continue as a going concern</span></span></span></p>
                                    <p style="margin-top: 0pt; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">Evaluation of the ability of the Company to realize its strategy for funding its future needs for working capital involves making judgments.</span></span></p>
                                    <p style="margin-bottom: 0pt; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span style="text-decoration: underline;">Share-based compensation</span></span></span></p>
                                    <p style="margin-top: 0pt; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">The fair value of stock options is measured using a Black Scholes option pricing model. Measurement inputs include the common share price on the grant date, the exercise price of the instrument, the expected common share price volatility, the weighted average expected life of the instruments, the expected dividends and the risk-free interest rate. Service and non-market performance conditions are not taken into account in determining fair value. The fair value of equity settled RSUs is measured based on management's best estimate of the Company's share price on the grant date.</span></span></p>
                                    <p style="text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">The share-based compensation recognized is also determined based on management's grant date estimate of the forfeitures that are expected to occur over the life of the stock options and equity settled RSUs. Cash settled RSUs outstanding are fair valued using a mark-to-market calculation based on the Company's closing common share price at the end of the period. The number of stock options and RSUs that actually vest could differ from the estimated number of awards expected to vest and any differences between the actual and estimated forfeitures are recognized prospectively as they occur.</span></span></p>
                                </div>
                            <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory', window );">Foreign currency translation [Policy Text Block]</a></td>
<td class="text">
                                <div>
                                    <p style="margin-bottom: 0pt; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>Foreign currency translation</b></span></span></p>
                                    <p style="margin-top: 0pt; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">The functional currency of the Company, Psilocybinlabs Ltd., Bright Minds Biosciences LLC and Bright Minds Bioscience Pty Ltd. is the Canadian dollar and the presentation currency of the Company is the Canadian dollar. Transactions in currencies other than the functional currency are recorded at the rates of exchange prevailing on the transaction date. Monetary assets and liabilities that are denominated in foreign currencies are translated at the rates prevailing at each reporting date. Non-monetary assets and liabilities denominated in foreign currencies that are measured at fair value are retranslated to the functional currency at the exchange rate at the date the fair value was determined. Non-monetary items that are measured in terms of historical cost in a foreign currency are not retranslated. Foreign currency translation differences are recognized in profit or loss.</span></span></p>
                                </div>
                            <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForBusinessCombinationsExplanatory', window );">Business combinations [Policy Text Block]</a></td>
<td class="text">
                                <div>
                                    <p style="margin-bottom: 0pt; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>Business combinations</b></span></span></p>
                                    <p style="margin-top: 0pt; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">The Company uses the acquisition method to account for business combinations. The Company measures goodwill as the fair value of the consideration transferred, less the net recognized amount (generally fair value) of the identifiable assets acquired and liabilities assumed, all measured as of the acquisition date. When the excess is negative, a gain on acquisition is recognized immediately in net income or loss.</span></span></p>
                                </div>

                                <div>
                                    <p style="margin-top: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">Goodwill is not amortized and is tested for impairment annually. Additionally, goodwill is reviewed at each reporting date to determine if events or changes in circumstances indicate that the asset might be impaired, in which case an impairment test is performed. Goodwill is measured at cost less accumulated impairment losses.</span></span></p>
                                    <p style="text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">Transaction costs, other than those associated with the issue of debt or equity securities, that the Company incurs in connection with a business combination are expensed as incurred.</span></span></p>
                                </div>
                            <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory', window );">Internally generated intangible assets - Research and development expenditure [Policy Text Block]</a></td>
<td class="text">
                                <div>
                                    <p style="margin-bottom: 0pt; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>Internally generated intangible assets - Research and development expenditure</b></span></span></p>
                                    <p style="margin-top: 0pt; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">Intangible assets acquired separately are initially recognized at cost. Expenditure on research activities is recognized as an expense in the period in which it is incurred. An internally-generated intangible asset arising from development (or from the development phase of an internal project) is recognized if, and only if, all of the following have been demonstrated:</span></span></p>
                                    <p style="margin-left: 36pt; margin-bottom: 0pt; text-indent: -18pt; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">&#8226;<span style="display: inline-block; width: 16.7pt;">&#160;</span>The technical feasibility of completing the intangible asset so that it will be available for use or sale;</span></span></p>
                                    <p style="margin-top: 0pt; margin-left: 36pt; margin-bottom: 0pt; text-indent: -18pt; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">&#8226;<span style="display: inline-block; width: 16.7pt;">&#160;</span>The intention to complete the intangible asset and use or sell it;</span></span></p>
                                    <p style="margin-top: 0pt; margin-left: 36pt; margin-bottom: 0pt; text-indent: -18pt; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">&#8226;<span style="display: inline-block; width: 16.7pt;">&#160;</span>The ability to use or sell the intangible asset;</span></span></p>
                                    <p style="margin-top: 0pt; margin-left: 36pt; margin-bottom: 0pt; text-indent: -18pt; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">&#8226;<span style="display: inline-block; width: 16.7pt;">&#160;</span>How the intangible asset will generate probable future economic benefits;</span></span></p>
                                    <p style="margin-top: 0pt; margin-left: 36pt; margin-bottom: 0pt; text-indent: -18pt; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">&#8226;<span style="display: inline-block; width: 16.7pt;">&#160;</span>The availability of adequate technical, financial and other resources to complete the development and to use or sell the intangible asset; and</span></span></p>
                                    <p style="margin-top: 0pt; margin-left: 36pt; text-indent: -18pt; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">&#8226;<span style="display: inline-block; width: 16.7pt;">&#160;</span>The ability to measure reliably the expenditure attributable to the intangible asset during its development.</span></span></p>
                                    <p style="text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">The amount initially recognized for internally-generated intangible assets is the sum of the expenditure incurred from the date when the intangible asset first meets the recognition criteria listed above. Where no internally-generated intangible asset can be recognized, development expenditure is recognized in profit or loss in the period in which it is incurred.</span></span></p>
                                    <p style="text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">Subsequent to initial recognition, internally-generated intangible assets are reported at cost less accumulated amortization and accumulated impairment losses, on the same basis as intangible assets that are acquired separately.</span></span></p>
                                    <p style="text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">At September 30, 2021 and 2020, the Company has not recognized any internally-generated intangible assets.</span></span></p>
                                </div>
                            <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory', window );">Share-based compensation awards [Policy Text Block]</a></td>
<td class="text">
                                <div>
                                    <p style="margin-bottom: 0pt; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>Share-based compensation awards</b></span></span></p>
                                    <p style="margin-top: 0pt; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">Share-based compensation expense relates to stock options as well as cash and equity settled restricted share units ("RSUs"). The grant date fair values of stock options and equity settled RSUs granted are recognized as an expense, with a corresponding increase in reserves in equity, over the vesting period. The amount recognized as an expense is based on the estimate of the number of awards expected to vest, which is revised if subsequent information indicates that actual forfeitures are likely to differ from the estimate. Upon exercise of stock options, the consideration paid by the holder is included in share capital and the related reserves associated with the stock options exercised is reclassified into share capital. Upon vesting of equity settled RSUs, the related reserves associated with the RSU is reclassified into share capital.</span></span></p>
                                    <p style="text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">For cash settled RSUs, the fair value of the RSUs is recognized as share-based compensation expense, with a corresponding increase in accrued liabilities over the vesting period. The amount recognized as an expense is based on the estimate of the number of RSUs expected to vest. Cash settled RSUs are measured at their fair value at each reporting period on a mark-to-market basis. Upon vesting of the cash settled RSUs, the liability is reduced by the cash payout.</span></span></p>
                                </div>
                            <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory', window );">Provisions [Policy Text Block]</a></td>
<td class="text">
                                <div>
                                    <p style="margin-bottom: 0pt; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>Provisions</b></span></span></p>
                                    <p style="margin-top: 0pt; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">A provision is recognized if, as a result of a past event, the Company has a present legal or constructive obligation that can be estimated reliably, and it is probable that an outflow of economic benefits will be required to settle the obligation. Provisions are determined by discounting the expected future cash flows at a pre-tax rate that reflects current market assessments of the time value of money and the risks specific to the liability. The unwinding of the discount is recognized as a finance cost within net income or loss.</span></span></p>
                                </div>
                            <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory', window );">Income taxes [Policy Text Block]</a></td>
<td class="text">
                                <div>
                                    <p style="margin-bottom: 0pt; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>Income taxes</b></span></span></p>
                                    <p style="margin-top: 0pt; margin-bottom: 0pt; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span style="text-decoration: underline;">Current income tax: </span></span></span></p>
                                    <p style="margin-top: 0pt; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">Current income tax assets and liabilities for the current period are measured at the amount expected to be recovered from or paid to the taxation authorities. The tax rates and tax laws used to compute the amount are those that are enacted or substantively enacted, at the reporting date, in the countries where the Company operates and generates taxable income.</span></span></p>
                                    <p style="margin-bottom: 0pt; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span style="text-decoration: underline;">Deferred tax: </span></span></span></p>
                                    <p style="margin-top: 0pt; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">Deferred tax is provided on temporary differences at the reporting date between the tax bases of assets and liabilities and their carrying amounts for financial reporting purposes. The carrying amount of deferred tax assets is reviewed at the end of each reporting period and recognized only to the extent that it is probable that sufficient taxable profit will be available to allow all or part of the deferred tax asset to be utilized.</span></span></p>
                                    <p style="text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">Deferred tax assets and liabilities are measured at the tax rates that are expected to apply to the year when the asset is realized or the liability is settled, based on tax rates (and tax laws) that have been enacted or substantively enacted by the end of the reporting period. Deferred tax assets and deferred tax liabilities are offset if a legally enforceable right exists to set off current tax assets against current income tax liabilities and the deferred taxes relate to the same taxable entity and the same taxation authority.</span></span></p>
                                </div>
                            <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory', window );">Loss per share [Policy Text Block]</a></td>
<td class="text">
                                <div>
                                    <p style="margin-bottom: 0pt; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>Loss per share</b></span></span></p>
                                    <p style="margin-top: 0pt; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">Basic loss per share is calculated by dividing the loss attributable to common shareholders by the weighted average number of common shares outstanding in the period. The loss attributable to common shareholders equals the reported loss attributable to owners of the Company. Diluted loss per share is calculated using the treasury stock method. Under the treasury stock method, the weighted average number of common shares outstanding for the calculation of diluted loss per share assumes that the proceeds to be received on the exercise of dilutive share options and warrants are used to repurchase common shares at the average market price during the period. Because the Company incurred net losses, the effect of dilutive instruments would be anti-dilutive and therefore diluted loss per share equals loss per share.</span></span></p>
                                </div>
                            <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForIssuedCapitalExplanatory', window );">Share capital [Policy Text Block]</a></td>
<td class="text">
                                <div>
                                    <p style="margin-bottom: 0pt; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>Share capital</b></span></span></p>
                                    <p style="margin-top: 0pt; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">Financial instruments issued by the Company are classified as equity only to the extent that they do not meet the definition of a financial liability or financial asset. The Company's common shares are classified as equity instruments.</span></span></p>
                                    <p style="text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">Incremental costs directly attributable to the issue of new common shares are recognized as a deduction from equity, net of tax.</span></span></p>
                                </div>
                            <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory', window );">Financial instruments [Policy Text Block]</a></td>
<td class="text">
                                <div>
                                    <p style="margin-bottom: 0pt; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>Financial instruments</b></span></span></p>
                                    <p style="margin-top: 0pt; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">Financial instruments are accounted for in accordance with IFRS 9, "Financial Instruments: Classification and Measurement". A financial instrument is any contract that gives rise to a financial asset of one entity and a financial liability or equity instrument of another entity.</span></span></p>
                                    <p style="margin-bottom: 0pt; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span style="text-decoration: underline;">Financial assets</span></span></span></p>
                                    <p style="margin-top: 0pt; margin-bottom: 0pt; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">(a) Recognition and measurement of financial assets</span></span></p>
                                    <p style="margin-top: 0pt; margin-left: 13.5pt; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">The Company recognizes a financial asset when it becomes a party to the contractual provisions of the instrument.</span></span></p>
                                    <p style="margin-bottom: 0pt; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">(b) Classification of financial assets</span></span></p>
                                    <p style="margin-top: 0pt; margin-left: 13.5pt; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">The Company classifies financial assets at initial recognition as financial assets: measured at amortized cost, measured at fair value through other comprehensive income ("FVTOCI") or measured at fair value through profit or loss ("FVTPL").</span></span></p>
                                    <p style="margin-bottom: 0pt; text-indent: 22.5pt; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">(i) Financial assets measured at amortized cost</span></span></p>
                                    <p style="margin-top: 0pt; margin-left: 36pt; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">A financial asset that meets both of the following conditions is classified as a financial asset measured at amortized cost:</span></span></p>
                                    <p style="margin-left: 49.5pt; margin-bottom: 0pt; text-indent: -4.5pt; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">&#8226;<span style="display: inline-block; width: 1.7pt;">&#160;</span>The Company's business model for such financial assets is to hold the assets in order to collect contractual cash flows.</span></span></p>
                                    <p style="margin-top: 0pt; margin-left: 49.5pt; text-indent: -4.5pt; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">&#8226;<span style="display: inline-block; width: 1.7pt;">&#160;</span>The contractual terms of the financial asset give rise on specified dates to cash flows that are solely payments of principal and interest on the amount outstanding.</span></span></p>
                                </div>

                                <div>
                                    <p style="margin-left: 36pt; text-align: justify; margin-top: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">A financial asset measured at amortized cost is initially recognized at fair value plus transaction costs directly attributable to the asset. After initial recognition, the carrying amount of the financial asset measured at amortized cost is determined using the effective interest method, net of impairment loss, if necessary.</span></span></p>
                                    <p style="margin-bottom: 0pt; text-indent: 22.5pt; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">(ii) Financial assets measured at FVTOCI</span></span></p>
                                    <p style="margin-top: 0pt; margin-left: 36pt; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">A financial asset measured at FVOCI is recognized initially at fair value plus transaction costs directly attributable to the asset. After initial recognition, the asset is measured at fair value with changes in fair value included as "financial asset at fair value through other comprehensive income" in other comprehensive income or loss.</span></span></p>
                                    <p style="margin-bottom: 0pt; text-indent: 22.5pt; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">(iii) Financial assets measured at FVTPL</span></span></p>
                                    <p style="margin-top: 0pt; margin-left: 36pt; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">A financial asset measured at FVTPL is initially recognized at fair value with any associated transaction costs being recognized in profit or loss when incurred. Subsequently, the financial asset is re-measured at fair value and a gain or loss is recognized in profit or loss in the reporting period in which it arises.</span></span></p>
                                    <p style="margin-left: 36pt; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">The Company's cash and cash equivalents are classified as subsequently measured at FVTPL.</span></span></p>
                                    <p style="margin-bottom: 0pt; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">(c) Derecognition of financial assets</span></span></p>
                                    <p style="margin-top: 0pt; margin-left: 13.6pt; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">The Company derecognizes a financial asset if the contractual rights to the cash flows from the asset expire, or the Company transfers substantially all the risks and rewards of ownership of the financial asset. Any interests in transferred financial assets that are created or retained by the Company are recognized as a separate asset or liability. Gains and losses on derecognition are generally recognized in the statement of comprehensive loss. However, gains and losses on derecognition of financial assets classified as FVTOCI remain within accumulated other comprehensive income or loss.</span></span></p>
                                    <p style="margin-bottom: 0pt; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span style="text-decoration: underline;">Financial liabilities</span></span></span></p>
                                    <p style="margin-top: 0pt; margin-bottom: 0pt; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">(a) Recognition and measurement of financial liabilities</span></span></p>
                                    <p style="margin-top: 0pt; margin-left: 13.5pt; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">The Company recognizes a financial liability when it becomes a party to the contractual provisions of the instrument.</span></span></p>
                                    <p style="margin-bottom: 0pt; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">(b) Classification of financial liabilities</span></span></p>
                                    <p style="margin-top: 0pt; margin-bottom: 0pt; text-indent: 22.5pt; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">(i) Financial liabilities measured at amortized cost</span></span></p>
                                    <p style="margin-top: 0pt; margin-left: 36pt; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">A financial liability measured at amortized cost is initially measured at fair value less transaction costs directly attributable to the issuance of the financial liability. Subsequently, the financial liability is measured at amortized cost using the effective interest method.</span></span></p>
                                    <p style="margin-left: 36pt; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">The Company's accounts payable and accrued liabilities are classified as subsequently measured at amortized cost.</span></span></p>
                                    <p style="margin-bottom: 0pt; text-indent: 22.5pt; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">(ii) Financial liabilities measured at fair value through profit or loss</span></span></p>
                                    <p style="margin-top: 0pt; margin-left: 36pt; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">A financial liability measured at fair value through profit or loss is initially measured at fair value with any associated transaction costs being recognized in profit or loss when incurred. Subsequently, the financial liability is re-measured at fair value and a gain or loss is recognized in profit or loss in the reporting period in which it arises.</span></span></p>
                                    <p style="margin-bottom: 0pt; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">(c) Derecognition of financial liabilities</span></span></p>
                                    <p style="margin-top: 0pt; margin-left: 13.6pt; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">The Company derecognizes a financial liability when the financial liability is discharged, cancelled or expired. Generally, the difference between the carrying amount of the financial liability derecognized and the consideration paid and payable, including any non-cash assets transferred or liabilities assumed, is recognized in the statement of comprehensive loss.</span></span></p>
                                    <p style="margin-bottom: 0pt; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span style="text-decoration: underline;">Offsetting financial assets and liabilities</span></span></span></p>
                                    <p style="margin-top: 0pt; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">Financial assets and liabilities are offset and the net amount is presented in the statement of financial position only when the Company has a legally enforceable right to offset the recognized amounts and intends either to settle on a net basis, or to realize the asset and settle the liability simultaneously.</span></span></p>
                                    <p style="margin-bottom: 0pt; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span style="text-decoration: underline;">Impairment of financial assets</span></span></span></p>
                                    <p style="margin-top: 0pt; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">The Company recognizes a loss allowance for expected credit losses on financial assets that are measured at amortized cost.</span></span></p>
                                </div>

                                <div>
                                    <p style="margin-bottom: 0pt; text-align: justify; margin-top: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">At each reporting date, the Company measures the loss allowance for the financial asset at an amount equal to the lifetime expected credit losses if the credit risk on the financial asset has increased significantly since initial recognition. If at the reporting date, the financial asset has not increased significantly since initial recognition, the Company measures the loss allowance for the financial asset at an amount equal to the twelve-month expected credit&#160;</span></span><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">losses. The Company recognizes in the statement of comprehensive income or loss, as an impairment loss (or gain), the amount of expected credit losses (or reversal) that is required to adjust the loss allowance at the reporting date to the amount that is required to be recognized.</span></span></p>
                                </div>
                            <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory', window );">Leases [Policy Text Block]</a></td>
<td class="text">
                                <div>
                                    <p style="margin-bottom: 0pt; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>Leases</b></span></span></p>
                                    <p style="margin-top: 0pt; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">Leases are accounted for in accordance with IFRS 16, "Leases". At inception of a contract, the Company assesses whether a contract is, or contains, a lease.&#160; A contract is, or contains, a lease if the contract conveys the right to control the use of an identified asset over a period of time in exchange for consideration.&#160; The Company assesses whether the contract involves the use of an identified asset, whether it has the right to obtain substantially all of the economic benefits from the use of the asset during the term of the contract and if it has the right to direct the use of the asset.</span></span></p>
                                    <p style="text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">As a lessee, the Company recognizes a right-of-use asset and a lease liability at the commencement date of the lease.</span></span></p>
                                    <p style="margin-bottom: 0pt; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span style="text-decoration: underline;">Right-of-use asset</span></span></span></p>
                                    <p style="margin-top: 0pt; margin-bottom: 0pt; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">The right-of-use asset is initially measured at cost, which is comprised of the initial amount of the lease liability adjusted for any lease payments made and any initial direct costs incurred at or before the commencement date, less any lease incentives received.</span></span></p>
                                    <p style="margin-top: 0pt; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">The right-of-use asset is subsequently depreciated from the commencement date to the earlier of the end of the lease term, or the end of the useful life of the asset.&#160; In addition, the right-of-use asset may be reduced due to impairment losses, if any, and adjusted for certain re-measurements of the lease liability.</span></span></p>
                                    <p style="margin-bottom: 0pt; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span style="text-decoration: underline;">Lease liability</span></span></span></p>
                                    <p style="margin-top: 0pt; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">A lease liability is initially measured at the present value of the lease payments that are not paid at the commencement date discounted by the interest rate implicit in the lease or, if that rate cannot be readily determined, the incremental borrowing rate. The lease liability is subsequently measured at amortized cost using the effective interest method.</span></span></p>
                                </div>
                            <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drug_DescriptionOfAccountingPolicyForNewStandardsAndInterpretationsNotYetAdoptedExplanatory', window );">New standards and interpretations not yet adopted [Policy Text Block]</a></td>
<td class="text">
                                <div>
                                    <p style="margin-bottom: 0pt; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>New standards and interpretations not yet adopted</b></span></span></p>
                                    <p style="margin-top: 0pt; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">A number of new standards, amendments to standards and interpretations are not yet effective for the year ended September 30, 2021 and have not been applied in preparing these financial statements. The following new standards have not been adopted which may impact the Company in future:</span></span></p>
                                    <p style="margin-bottom: 0pt; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span style="text-decoration: underline;">IAS 1 - Presentation of Financial Statements </span></span></span></p>
                                    <p style="margin-top: 0pt; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">An amendment to IAS 1 clarifies the criterion for classifying a liability as non-current relating to the right to defer settlement of a liability for at least 12 months after the reporting period.</span></span></p>
                                    <p style="text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">IAS 1 has amended the definition of material to "information is material if omitting, misstating or obscuring it could reasonably be expected to influence decisions that the primary users of general-purpose financial statements make on the basis of those financial statements, which provide financial information about a specific reporting entity." The previous definition of material from IAS1 was "omissions or misstatements of items are material if they could, individually or collectively, influence the economic decisions that users make on the basis of the financial statements. Materiality depends on the size and nature of the omission or misstatement judged in the surrounding circumstances. The size or nature of the item, or a combination of both, could be the determining factor."</span></span></p>
                                    <p style="margin-bottom: 0pt; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span style="text-decoration: underline;">IAS 8 - Accounting Policies, Changes in Accounting Estimates and Errors</span></span></span></p>
                                    <p style="margin-top: 0pt; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">IAS 8 amended the definition of material reflect the changes outlined above under IAS 1.</span></span></p>
                                    <p style="margin-bottom: 0pt; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span style="text-decoration: underline;">IAS 12 and IFRIC 23 - Income Taxes</span></span></span></p>
                                    <p style="margin-top: 0pt; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">IAS 12 currently provides guidance on current and deferred tax assets and liabilities however uncertainty may exist on how tax law applies to certain transactions. IFRIC 23 provides guidance on how to address uncertainty related to tax treatments.</span></span></p>
                                </div>
                            <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_drug_DescriptionOfAccountingPolicyForBasisOfConsolidationExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's accounting policy for basis of consolidation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">drug_DescriptionOfAccountingPolicyForBasisOfConsolidationExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>drug_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_drug_DescriptionOfAccountingPolicyForCriticalAccountingEstimatesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's accounting policy for critical accounting estimates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">drug_DescriptionOfAccountingPolicyForCriticalAccountingEstimatesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>drug_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_drug_DescriptionOfAccountingPolicyForNewStandardsAndInterpretationsNotYetAdoptedExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's accounting policy for New standards and interpretations not yet adopted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">drug_DescriptionOfAccountingPolicyForNewStandardsAndInterpretationsNotYetAdoptedExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>drug_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_drug_DisclosureOfDetailedInformationAboutSignificantAccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">drug_DisclosureOfDetailedInformationAboutSignificantAccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>drug_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForBusinessCombinationsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's accounting policy for business combinations. [Refer: Business combinations [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 117<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_117_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForBusinessCombinationsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's accounting policy for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 117<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_117_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's accounting policy for financial instruments. [Refer: Financial instruments, class [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 117<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_117_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's accounting policy for foreign currency translation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 117<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_117_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's accounting policy for income tax.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 117<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_117_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForIssuedCapitalExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's accounting policy for issued capital. [Refer: Issued capital]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 117<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_117_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForIssuedCapitalExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's accounting policy for leases. A lease is an agreement whereby the lessor conveys to the lessee in return for a payment or series of payments the right to use an asset for an agreed period of time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 117<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_117_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's accounting policy for provisions. [Refer: Provisions]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 117<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_117_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's accounting policy for research and development expense. [Refer: Research and development expense]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 117<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_117_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's accounting policy for transactions in which the entity: (a) receives goods or services from the supplier of those goods or services (including an employee) in a share-based payment arrangement; or (b) incurs an obligation to settle the transaction with the supplier in a share-based payment arrangement when another group entity receives those goods or services. [Refer: Share-based payment arrangements [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 117<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_117_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.4</span><table class="report" border="0" cellspacing="2" id="idm140170915089032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACCOUNTS PAYABLE AND ACCRUED LIABILITIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TradeAndOtherCurrentPayablesAbstract', window );"><strong>Trade and other current payables [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drug_DisclosureOfDetailedInformationAboutTradePayableAndAccruedExpensesExplanatory', window );">Disclosure of accounts payable and accrued liabilities [Table Text Block]</a></td>
<td class="text">
                            <table cellpadding="0" cellspacing="0" style="width: 100%; border-collapse: collapse; font-size: 10pt; border-color: #000000;">
                                <tr>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1.5pt solid #000000; border-bottom: 0.75pt solid #000000; vertical-align: bottom;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>&#160;</b></span></span></td>
                                    <td style="vertical-align: bottom; border-top: 1.5pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right;">&#160;</td>
                                    <td style="vertical-align: bottom; border-top: 1.5pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>September 30, </b><br/><b>2021</b></span></span></td>
                                    <td style="vertical-align: bottom; border-top: 1.5pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;">&#160;</td>
                                    <td style="vertical-align: bottom; border-top: 1.5pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;">&#160;</td>
                                    <td style="vertical-align: bottom; border-top: 1.5pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>September 30, </b><br/><b>2020</b></span></span></td>
                                    <td style="vertical-align: bottom; border-top: 1.5pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right;">&#160;</td>
                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>$</b></span></span></td>
                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right;">&#160;</td>
                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right;">&#160;</td>
                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>$&#160;</b></span></span></td>
                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">Accounts payable</span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>596,573</b></span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">138,423</span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">Accrued liabilities</span></span></td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>42,000</b></span></span></td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">12,500</span></span></td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 2.25pt double #000000; vertical-align: bottom; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">Total accounts payable and accrued liabilities</span></span></td>
                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>638,573</b></span></span></td>
                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">150,923</span></span></td>
                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                </tr>
                            </table>
                        <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_drug_DisclosureOfDetailedInformationAboutTradePayableAndAccruedExpensesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of detailed information about trade payables and accrued expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">drug_DisclosureOfDetailedInformationAboutTradePayableAndAccruedExpensesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>drug_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeAndOtherCurrentPayablesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeAndOtherCurrentPayablesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.4</span><table class="report" border="0" cellspacing="2" id="idm140170915257736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHARE CAPITAL (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalAbstract', window );"><strong>Disclosure of classes of share capital [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory', window );">Disclosure of number and weighted average exercise prices of share options [Table Text Block]</a></td>
<td class="text">
                                            <div>
                                                <div style="margin-left: 5.4pt;">
                                                    <table cellpadding="0" cellspacing="0" style="width: 100%; border-collapse: collapse; font-size: 10pt; border-color: #000000;">
                                                        <tr>
                                                            <td style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1.5pt solid #000000; border-bottom: 0.75pt solid #000000; vertical-align: bottom;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>&#160;</b></span></span></td>
                                                            <td style="vertical-align: bottom; border-top: 1.5pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right;">&#160;</td>
                                                            <td style="vertical-align: bottom; border-top: 1.5pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">&#160;<br/><b>Number of options</b></span></span></td>
                                                            <td style="vertical-align: bottom; border-top: 1.5pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;">&#160;</td>
                                                            <td style="vertical-align: bottom; border-top: 1.5pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;">&#160;</td>
                                                            <td style="vertical-align: bottom; border-top: 1.5pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>&#160; Weighted average&#160; </b><br/><b>exercise price</b></span></span></td>
                                                            <td style="vertical-align: bottom; border-top: 1.5pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right;">&#160;</td>
                                                        </tr>
                                                        <tr>
                                                            <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>Balance at September 30, 2019 and May 31, 2019</b></span></span></td>
                                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                            <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>-</b></span></span></td>
                                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                            <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>-</b></span></span></td>
                                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                        </tr>
                                                        <tr>
                                                            <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">&#160; Granted</span></span></td>
                                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">150,000</span></span></td>
                                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>$</b></span></span></td>
                                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">1.25</span></span></td>
                                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                                        </tr>
                                                        <tr>
                                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>Balance at September 30, 2020</b></span></span></td>
                                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>150,000</b></span></span></td>
                                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>$</b></span></span></td>
                                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>1.25</b></span></span></td>
                                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                        </tr>
                                                        <tr>
                                                            <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">&#160; Granted</span></span></td>
                                                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                                            <td style="vertical-align: bottom; text-align: right; width: 12%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">895,807</span></span></td>
                                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                                            <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>$</b></span></span></td>
                                                            <td style="vertical-align: bottom; text-align: right; width: 12%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">4.29</span></span></td>
                                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                                        </tr>
                                                        <tr>
                                                            <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: justify; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">&#160; Cancelled*</span></span></td>
                                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                            <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">(20,000</span></span></td>
                                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">)</span></span></td>
                                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>$</b></span></span></td>
                                                            <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">1.25</span></span></td>
                                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                        </tr>
                                                        <tr>
                                                            <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 2.25pt double #000000; vertical-align: bottom;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>Balance at September 30, 2021</b></span></span></td>
                                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%;">&#160;</td>
                                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 12%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>1,025,807</b></span></span></td>
                                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%;">&#160;</td>
                                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>$</b></span></span></td>
                                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 12%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>3.90</b></span></span></td>
                                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%;">&#160;</td>
                                                        </tr>
                                                    </table>
                                                </div>
                                            </div>
                                        <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drug_DisclosureOfNumberOfIssuedAndOutstandingStockOptionsExplanatory', window );">Disclosure of number of issued and outstanding stock options [Table Text Block]</a></td>
<td class="text">
                                            <div>
                                                <table cellpadding="0" cellspacing="0" style="width: 90%; border-collapse: collapse; font-size: 10pt; border-color: #000000; margin-left: auto; margin-right: auto;">
                                                    <tr>
                                                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-top: 1.5pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>&#160;</b></span></span></td>
                                                        <td colspan="1" style="vertical-align: bottom; border-top: 1.5pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: center;">&#160;</td>
                                                        <td colspan="10" style="vertical-align: bottom; border-top: 1.5pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>Options Outstanding and Exercisable</b></span></span></td>
                                                        <td colspan="1" style="vertical-align: bottom; border-top: 1.5pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: center;">&#160;</td>
                                                    </tr>
                                                    <tr>
                                                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-indent: 2.8pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>&#160;</b><br/><b>Expiry Date</b></span></span></td>
                                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right;">&#160;</td>
                                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>Number of<br/>options</b></span></span></td>
                                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;">&#160;</td>
                                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;">&#160;</td>
                                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>&#160;</b><br/><b>Exercisable</b></span></span></td>
                                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;">&#160;</td>
                                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;">&#160;</td>
                                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>&#160;</b><br/><b>Exercise price</b></span></span></td>
                                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;">&#160;</td>
                                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;">&#160;</td>
                                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>Remaining life<br/>(Years)</b></span></span></td>
                                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right;">&#160;</td>
                                                    </tr>
                                                    <tr>
                                                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">September 21, 2024</span></span></td>
                                                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                        <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">8,807</span></span></td>
                                                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                        <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">-</span></span></td>
                                                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">$</span></span></td>
                                                        <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">7.64</span></span></td>
                                                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                        <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">
                                                                    2.98
                                                                </span></span></td>
                                                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                    </tr>
                                                    <tr>
                                                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">July 23, 2025</span></span></td>
                                                        <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                                        <td style="vertical-align: bottom; text-align: right; width: 12%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">150,000</span></span></td>
                                                        <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                                        <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                                        <td style="vertical-align: bottom; text-align: right; width: 12%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">150,000</span></span></td>
                                                        <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                                        <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">$</span></span></td>
                                                        <td style="vertical-align: bottom; text-align: right; width: 12%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">1.25</span></span></td>
                                                        <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                                        <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                                        <td style="vertical-align: bottom; text-align: right; width: 12%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">
                                                                    3.81
                                                                </span></span></td>
                                                        <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                                    </tr>
                                                    <tr>
                                                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">November 17, 2025</span></span></td>
                                                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                        <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">447,000</span></span></td>
                                                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                        <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">30,500</span></span></td>
                                                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">$</span></span></td>
                                                        <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">1.25</span></span></td>
                                                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                        <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">
                                                                    4.13
                                                                </span></span></td>
                                                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                    </tr>
                                                    <tr>
                                                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">April 28, 2026</span></span></td>
                                                        <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                                        <td style="vertical-align: bottom; text-align: right; width: 12%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">240,000</span></span></td>
                                                        <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                                        <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                                        <td style="vertical-align: bottom; text-align: right; width: 12%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">-</span></span></td>
                                                        <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                                        <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">$</span></span></td>
                                                        <td style="vertical-align: bottom; text-align: right; width: 12%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">7.60</span></span></td>
                                                        <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                                        <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                                        <td style="vertical-align: bottom; text-align: right; width: 12%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">
                                                                    4.58
                                                                </span></span></td>
                                                        <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                                    </tr>
                                                    <tr>
                                                        <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 2.25pt double #000000; vertical-align: bottom; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">June 15, 2026</span></span></td>
                                                        <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                        <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">180,000</span></span></td>
                                                        <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                        <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                        <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">-</span></span></td>
                                                        <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                        <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">$</span></span></td>
                                                        <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">7.60</span></span></td>
                                                        <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                        <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                        <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">
                                                                    4.71
                                                                </span></span></td>
                                                        <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                    </tr>
                                                </table>
                                            </div>
                                        <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory', window );">Disclosure of number and weighted average exercise prices of restricted share units [Table Text Block]</a></td>
<td class="text">
                                                <div>
                                                    <table cellpadding="0" cellspacing="0" style="width: 100%; border-collapse: collapse; font-size: 10pt; border-color: #000000;">
                                                        <tr>
                                                            <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; border-top: 1.5pt solid #000000; vertical-align: bottom;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>&#160;</b></span></span></td>
                                                            <td style="vertical-align: bottom; border-top: 1.5pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right;">&#160;</td>
                                                            <td style="vertical-align: bottom; border-top: 1.5pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>Equity settled</b></span></span></td>
                                                            <td style="vertical-align: bottom; border-top: 1.5pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;">&#160;</td>
                                                            <td colspan="1" style="vertical-align: bottom; border-top: 1.5pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;">&#160;</td>
                                                            <td colspan="1" style="vertical-align: bottom; border-top: 1.5pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>Cash settled</b></span></span></td>
                                                            <td colspan="1" style="vertical-align: bottom; border-top: 1.5pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;">&#160;</td>
                                                            <td style="vertical-align: bottom; border-top: 1.5pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;">&#160;</td>
                                                            <td style="vertical-align: bottom; border-top: 1.5pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>Total</b></span></span></td>
                                                            <td style="vertical-align: bottom; border-top: 1.5pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;">&#160;</td>
                                                        </tr>
                                                        <tr>
                                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>Balance at September 30, 2019 and May 31, 2019</b></span></span></td>
                                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">-</span></span></td>
                                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                            <td colspan="1" style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                            <td colspan="1" style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">-</span></span></td>
                                                            <td colspan="1" style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">-</span></span></td>
                                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                        </tr>
                                                        <tr>
                                                            <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">Granted</span></span></td>
                                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">380,000</span></span></td>
                                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                                            <td colspan="1" style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                                            <td colspan="1" style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">-</span></span></td>
                                                            <td colspan="1" style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">380,000</span></span></td>
                                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                                        </tr>
                                                        <tr>
                                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>Balance at September 30, 2020</b></span></span></td>
                                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>380,000</b></span></span></td>
                                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">-</span></span></td>
                                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>380,000</b></span></span></td>
                                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                        </tr>
                                                        <tr>
                                                            <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">Vested</span></span></td>
                                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">(95,000</span></span></td>
                                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">)</span></span></td>
                                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">-</span></span></td>
                                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">(95,000</span></span></td>
                                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">)</span></span></td>
                                                        </tr>
                                                        <tr>
                                                            <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 2.25pt double #000000; vertical-align: bottom; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>Balance at September 30, 2021</b></span></span></td>
                                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>285,000</b></span></span></td>
                                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">-</span></span></td>
                                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>285,000</b></span></span></td>
                                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                        </tr>
                                                    </table>
                                                </div>
                                            <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drug_DisclosureOfDetailedInformationAboutEquitySettledRestrictedShareUnitsFairValueInputsExplanatory', window );">Disclosure of equity-settled restricted share units fair value inputs [Table Text Block]</a></td>
<td class="text">
                                            <div>
                                                <table cellpadding="0" cellspacing="0" style="width: 80%; border-collapse: collapse; font-size: 10pt; border-color: #000000; margin-left: auto; margin-right: auto;">
                                                    <tr>
                                                        <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; border-top: 1.5pt solid #000000; vertical-align: bottom;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>&#160;</b></span></span></td>
                                                        <td style="vertical-align: bottom; border-top: 1.5pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right;">&#160;</td>
                                                        <td style="vertical-align: bottom; border-top: 1.5pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>Year ended<br/>September 30, 2020</b></span></span></td>
                                                        <td style="vertical-align: bottom; border-top: 1.5pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right;">&#160;</td>
                                                    </tr>
                                                    <tr>
                                                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">Share price on grant date</span></span></td>
                                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">$</span></span></td>
                                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 22%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">1.25</span></span></td>
                                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                    </tr>
                                                    <tr>
                                                        <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">Forfeiture rate</span></span></td>
                                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 22%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">0%</span></span></td>
                                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                                    </tr>
                                                </table>
                                            </div>
                                        <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drug_DisclosureOfDetailedInformationAboutShareBasedPaymentsRecognizedInConsolidatedStatementsOfComprehensiveLossExplanatory', window );">Disclosure of share based payments recognized in the consolidated statements of comprehensive loss [Table Text Block]</a></td>
<td class="text">
                                                <div>
                                                    <table cellpadding="0" cellspacing="0" style="width: 100%; border-collapse: collapse; font-size: 10pt; border-color: #000000;">
                                                        <tr>
                                                            <td style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1.5pt solid #000000; border-bottom: 0.75pt solid #000000; vertical-align: bottom;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>&#160;</b></span></span></td>
                                                            <td style="vertical-align: bottom; border-top: 1.5pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right;">&#160;</td>
                                                            <td style="vertical-align: bottom; border-top: 1.5pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>Year ended<br/>September 30,<br/>2021</b></span></span></td>
                                                            <td style="vertical-align: bottom; border-top: 1.5pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;">&#160;</td>
                                                            <td style="vertical-align: bottom; border-top: 1.5pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;">&#160;</td>
                                                            <td style="vertical-align: bottom; border-top: 1.5pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">Year ended<br/>September 30,<br/>2020</span></span></td>
                                                            <td style="vertical-align: bottom; border-top: 1.5pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;">&#160;</td>
                                                            <td style="vertical-align: bottom; border-top: 1.5pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;">&#160;</td>
                                                            <td style="vertical-align: bottom; border-top: 1.5pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">Period ended<br/>September 30,<br/>2019</span></span></td>
                                                            <td style="vertical-align: bottom; border-top: 1.5pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right;">&#160;</td>
                                                        </tr>
                                                        <tr>
                                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>&#160;</b></span></span></td>
                                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right;">&#160;</td>
                                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>$</b></span></span></td>
                                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right;">&#160;</td>
                                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right;">&#160;</td>
                                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">$</span></span></td>
                                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right;">&#160;</td>
                                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right;">&#160;</td>
                                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">$</span></span></td>
                                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right;">&#160;</td>
                                                        </tr>
                                                        <tr>
                                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">Stock options</span></span></td>
                                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                            <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>643,963</b></span></span></td>
                                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                            <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">138,000</span></span></td>
                                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                            <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">-</span></span></td>
                                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                        </tr>
                                                        <tr>
                                                            <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">Restricted share units - equity settled grants</span></span></td>
                                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>236,652</b></span></span></td>
                                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">23,300</span></span></td>
                                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">-</span></span></td>
                                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                                        </tr>
                                                        <tr>
                                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">Total equity settled share-based compensation expense</span></span></td>
                                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>880,615</b></span></span></td>
                                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">161,300</span></span></td>
                                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">-</span></span></td>
                                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                        </tr>
                                                        <tr>
                                                            <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">Restricted share units - cash settled grants</span></span></td>
                                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>-</b></span></span></td>
                                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">-</span></span></td>
                                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">-</span></span></td>
                                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                                        </tr>
                                                        <tr>
                                                            <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 2.25pt double #000000; vertical-align: bottom; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">Total share-based compensation expense</span></span></td>
                                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>880,615</b></span></span></td>
                                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">161,300</span></span></td>
                                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">-</span></span></td>
                                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                        </tr>
                                                    </table>
                                                </div>
                                            <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drug_DisclosureOfDetailedInformationAboutShareBasedPaymentsIncludedInConsolidatedStatementsOfComprehensiveLossExplanatory', window );">Disclosure of share based payments included in the consolidated statements of comprehensive loss [Table Text Block]</a></td>
<td class="text">
                                                <div>
                                                    <table cellpadding="0" cellspacing="0" style="width: 100%; border-collapse: collapse; font-size: 10pt; border-color: #000000;">
                                                        <tr>
                                                            <td style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1.5pt solid #000000; border-bottom: 0.75pt solid #000000; vertical-align: bottom;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>&#160;</b></span></span></td>
                                                            <td style="vertical-align: bottom; border-top: 1.5pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right;">&#160;</td>
                                                            <td style="vertical-align: bottom; border-top: 1.5pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>Year ended<br/>September 30,<br/>2021</b></span></span></td>
                                                            <td style="vertical-align: bottom; border-top: 1.5pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;">&#160;</td>
                                                            <td style="vertical-align: bottom; border-top: 1.5pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;">&#160;</td>
                                                            <td style="vertical-align: bottom; border-top: 1.5pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">Year ended<br/>September 30,<br/>2020</span></span></td>
                                                            <td style="vertical-align: bottom; border-top: 1.5pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;">&#160;</td>
                                                            <td style="vertical-align: bottom; border-top: 1.5pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;">&#160;</td>
                                                            <td style="vertical-align: bottom; border-top: 1.5pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">Period ended<br/>September 30,<br/>2019</span></span></td>
                                                            <td style="vertical-align: bottom; border-top: 1.5pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right;">&#160;</td>
                                                        </tr>
                                                        <tr>
                                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>&#160;</b></span></span></td>
                                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right;">&#160;</td>
                                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>$</b></span></span></td>
                                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right;">&#160;</td>
                                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right;">&#160;</td>
                                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">$</span></span></td>
                                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right;">&#160;</td>
                                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right;">&#160;</td>
                                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">$</span></span></td>
                                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right;">&#160;</td>
                                                        </tr>
                                                        <tr>
                                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">Consulting fees</span></span></td>
                                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                            <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>8,045</b></span></span></td>
                                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                            <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">-</span></span></td>
                                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                            <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">-</span></span></td>
                                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                        </tr>
                                                        <tr>
                                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">Directors' compensation</span></span></td>
                                                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                                            <td style="vertical-align: bottom; text-align: right; width: 12%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>136,612</b></span></span></td>
                                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                                            <td style="vertical-align: bottom; text-align: right; width: 12%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">-</span></span></td>
                                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                                            <td style="vertical-align: bottom; text-align: right; width: 12%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">-</span></span></td>
                                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                                        </tr>
                                                        <tr>
                                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">Marketing, advertising and investor relations</span></span></td>
                                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                            <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>3,696</b></span></span></td>
                                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                            <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">-</span></span></td>
                                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                            <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">-</span></span></td>
                                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                        </tr>
                                                        <tr>
                                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">Professional fees</span></span></td>
                                                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                                            <td style="vertical-align: bottom; text-align: right; width: 12%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>23,126</b></span></span></td>
                                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                                            <td style="vertical-align: bottom; text-align: right; width: 12%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">-</span></span></td>
                                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                                            <td style="vertical-align: bottom; text-align: right; width: 12%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">-</span></span></td>
                                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                                        </tr>
                                                        <tr>
                                                            <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">Research and development</span></span></td>
                                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>709,136</b></span></span></td>
                                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">161,300</span></span></td>
                                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">-</span></span></td>
                                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                        </tr>
                                                        <tr>
                                                            <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 2.25pt double #000000; vertical-align: bottom;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">Total share-based compensation expense</span></span></td>
                                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%;">&#160;</td>
                                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 12%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>880,615</b></span></span></td>
                                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%;">&#160;</td>
                                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%;">&#160;</td>
                                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 12%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">161,300</span></span></td>
                                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%;">&#160;</td>
                                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%;">&#160;</td>
                                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 12%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">-</span></span></td>
                                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%;">&#160;</td>
                                                        </tr>
                                                    </table>
                                                </div>
                                            <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drug_DisclosureOfNumberAndWeightedAverageExercisePricesOfWarrantsExplanatory', window );">Disclosure of number and weighted average exercise prices of warrants [Table Text Block]</a></td>
<td class="text">
                                                <div>
                                                    <table cellpadding="0" cellspacing="0" style="width: 100%; border-collapse: collapse; font-size: 10pt; border-color: #000000;">
                                                        <tr>
                                                            <td style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1.5pt solid #000000; border-bottom: 0.75pt solid #000000; vertical-align: bottom;">&#160;</td>
                                                            <td style="vertical-align: bottom; border-top: 1.5pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right;">&#160;</td>
                                                            <td style="vertical-align: bottom; border-top: 1.5pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>Number of warrants</b></span></span></td>
                                                            <td style="vertical-align: bottom; border-top: 1.5pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;">&#160;</td>
                                                            <td style="vertical-align: bottom; border-top: 1.5pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;">&#160;</td>
                                                            <td style="vertical-align: bottom; border-top: 1.5pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">&#160;<b>Weighted average </b><br/><b>exercise price</b></span></span></td>
                                                            <td style="vertical-align: bottom; border-top: 1.5pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right;">&#160;</td>
                                                        </tr>
                                                        <tr>
                                                            <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>Balance at September 30, 2019 and May 31, 2019</b></span></span></td>
                                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                            <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>-</b></span></span></td>
                                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">$</span></span></td>
                                                            <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>-</b></span></span></td>
                                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                        </tr>
                                                        <tr>
                                                            <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">&#160; Issued</span></span></td>
                                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 15%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">4,079,600</span></span></td>
                                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 15%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">0.05</span></span></td>
                                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                                        </tr>
                                                        <tr>
                                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>Balance at September 30, 2020</b></span></span></td>
                                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>4,079,600</b></span></span></td>
                                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">0.05</span></span></td>
                                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                        </tr>
                                                        <tr>
                                                            <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">&#160; Issued*</span></span></td>
                                                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                                            <td style="vertical-align: bottom; text-align: right; width: 15%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">1,709,938</span></span></td>
                                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                                            <td style="vertical-align: bottom; text-align: right; width: 15%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">9.46</span></span></td>
                                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                                        </tr>
                                                        <tr>
                                                            <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">&#160; Issued - broker</span></span></td>
                                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                            <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">132,666</span></span></td>
                                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                            <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">7.57</span></span></td>
                                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                        </tr>
                                                        <tr>
                                                            <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">&#160; Exercised</span></span></td>
                                                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                                            <td style="vertical-align: bottom; text-align: right; width: 15%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">(1,948,000</span></span></td>
                                                            <td style="vertical-align: bottom; text-align: left; width: 2%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">)</span></span></td>
                                                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                                            <td style="vertical-align: bottom; text-align: right; width: 15%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">0.05</span></span></td>
                                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                                        </tr>
                                                        <tr>
                                                            <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 2.25pt double #000000; vertical-align: bottom; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>Balance at September 30, 2021</b></span></span></td>
                                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>3,974,204</b></span></span></td>
                                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">$</span></span></td>
                                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">4.35</span></span></td>
                                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                        </tr>
                                                    </table>
                                                </div>
                                            <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drug_DisclosureOfNumberOfIssuedAndOutstandingWarrantsExplanatory', window );">Disclosure of number of outstanding warrants [Table Text Block]</a></td>
<td class="text">
                                                <div>
                                                    <table cellpadding="0" cellspacing="0" style="width: 100%; border-collapse: collapse; font-size: 10pt; border-color: #000000;">
                                                        <tr>
                                                            <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-top: 1.5pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>&#160;</b></span></span></td>
                                                            <td colspan="1" style="vertical-align: bottom; border-top: 1.5pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: center;">&#160;</td>
                                                            <td colspan="7" style="vertical-align: bottom; border-top: 1.5pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>Warrants Outstanding</b></span></span></td>
                                                            <td colspan="1" style="vertical-align: bottom; border-top: 1.5pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: center;">&#160;</td>
                                                        </tr>
                                                        <tr>
                                                            <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>Expiry Date</b></span></span></td>
                                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right;">&#160;</td>
                                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>Number of<br/>warrants</b></span></span></td>
                                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;">&#160;</td>
                                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;">&#160;</td>
                                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>&#160;</b><br/><b>Exercise price</b></span></span></td>
                                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;">&#160;</td>
                                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;">&#160;</td>
                                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>Remaining life<br/>(Years)</b></span></span></td>
                                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right;">&#160;</td>
                                                        </tr>
                                                        <tr>
                                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">July 30, 2024 (1)</span></span></td>
                                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                            <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">2,131,600</span></span></td>
                                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">$</span></span></td>
                                                            <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">0.05</span></span></td>
                                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                            <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">
                                                                        2.83
                                                                    </span></span></td>
                                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                        </tr>
                                                        <tr>
                                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">March 17, 2024</span></span></td>
                                                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                                            <td style="vertical-align: bottom; text-align: right; width: 12%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">1,709,938</span></span></td>
                                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                                            <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">$</span></span></td>
                                                            <td style="vertical-align: bottom; text-align: right; width: 12%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">9.46</span></span></td>
                                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                                            <td style="vertical-align: bottom; text-align: right; width: 12%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">
                                                                        2.46
                                                                    </span></span></td>
                                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                                        </tr>
                                                        <tr>
                                                            <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 2.25pt double #000000; vertical-align: bottom; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">March 17, 2024</span></span></td>
                                                            <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                            <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">132,666</span></span></td>
                                                            <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                            <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">$</span></span></td>
                                                            <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">7.57</span></span></td>
                                                            <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                            <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                            <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">
                                                                        2.46
                                                                    </span></span></td>
                                                            <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                        </tr>
                                                    </table>
                                                </div>
                                            <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_drug_DisclosureOfDetailedInformationAboutEquitySettledRestrictedShareUnitsFairValueInputsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure about equity settled restricted share units fair value inputs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">drug_DisclosureOfDetailedInformationAboutEquitySettledRestrictedShareUnitsFairValueInputsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>drug_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_drug_DisclosureOfDetailedInformationAboutShareBasedPaymentsIncludedInConsolidatedStatementsOfComprehensiveLossExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of detailed information about share based payments included in consolidated statements of comprehensive loss statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">drug_DisclosureOfDetailedInformationAboutShareBasedPaymentsIncludedInConsolidatedStatementsOfComprehensiveLossExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>drug_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_drug_DisclosureOfDetailedInformationAboutShareBasedPaymentsRecognizedInConsolidatedStatementsOfComprehensiveLossExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of detailed information about share based payments recognized in the consolidated statements of comprehensive loss statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">drug_DisclosureOfDetailedInformationAboutShareBasedPaymentsRecognizedInConsolidatedStatementsOfComprehensiveLossExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>drug_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_drug_DisclosureOfNumberAndWeightedAverageExercisePricesOfWarrantsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of number and weighted average exercise prices of warrants explanatory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">drug_DisclosureOfNumberAndWeightedAverageExercisePricesOfWarrantsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>drug_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_drug_DisclosureOfNumberOfIssuedAndOutstandingStockOptionsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of number of issued and outstanding stock options explanatory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">drug_DisclosureOfNumberOfIssuedAndOutstandingStockOptionsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>drug_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_drug_DisclosureOfNumberOfIssuedAndOutstandingWarrantsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of number of issued and outstanding warrants explanatory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">drug_DisclosureOfNumberOfIssuedAndOutstandingWarrantsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>drug_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfClassesOfShareCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfClassesOfShareCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of the number and weighted average exercise prices of other equity instruments (ie other than share options).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2020-01-01<br> -Paragraph 45<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of the number and weighted average exercise prices of share options. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2020-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_45_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.4</span><table class="report" border="0" cellspacing="2" id="idm140170923783784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RELATED PARTY TRANSACTIONS (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract', window );"><strong>Disclosure of transactions between related parties [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutKeyManagementPersonnelExplanatory', window );">Disclosure of expenses related to key management personnel [Table Text Block]</a></td>
<td class="text">
                                <div>
                                    <table cellpadding="0" cellspacing="0" style="width: 100%; border-collapse: collapse; font-size: 10pt; border-color: #000000;">
                                        <tr>
                                            <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-top: 1.5pt solid #000000; text-align: justify;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 1.5pt solid #000000; text-align: right;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 1.5pt solid #000000; text-align: right; white-space: nowrap;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>Year ended</b></span></span></td>
                                            <td style="vertical-align: bottom; border-top: 1.5pt solid #000000; text-align: right; white-space: nowrap;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 1.5pt solid #000000; text-align: right; white-space: nowrap;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 1.5pt solid #000000; text-align: right; white-space: nowrap;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>Year ended</b></span></span></td>
                                            <td style="vertical-align: bottom; border-top: 1.5pt solid #000000; text-align: right; white-space: nowrap;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 1.5pt solid #000000; text-align: right; white-space: nowrap;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 1.5pt solid #000000; text-align: right; white-space: nowrap;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>Period ended </b></span></span></td>
                                            <td style="vertical-align: bottom; border-top: 1.5pt solid #000000; text-align: right;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; white-space: nowrap;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>September 30, </b><br/><b>2021</b></span></span></td>
                                            <td style="vertical-align: bottom; text-align: right; white-space: nowrap;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; white-space: nowrap;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; white-space: nowrap;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>September 30, </b><br/><b>2020</b></span></span></td>
                                            <td style="vertical-align: bottom; text-align: right; white-space: nowrap;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; white-space: nowrap;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; white-space: nowrap;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>September 30,<br/>2019</b></span></span></td>
                                            <td style="vertical-align: bottom; text-align: right;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: justify;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>$</b></span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">$</span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">$</span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">Professional fees</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>87,074</b></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">22,575</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">-</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">Research and development</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 12%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>772,596</b></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 12%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">26,777</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 12%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">-</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">Share-based compensation included in directors' compensation</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>136,612</b></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">-</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">-</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">Share-based compensation included in professional fees</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 12%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>23,126</b></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 12%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">-</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 12%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">-</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: justify; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">Share-based compensation included in research and development</span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>236,652</b></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">161,300</span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">-</span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>&#160;</b></span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 12%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>1,256,060</b></span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 12%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">210,652</span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 12%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">-</span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%;">&#160;</td>
                                        </tr>
                                    </table>
                                </div>
                            <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfInformationAboutKeyManagementPersonnelExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of information about key management personnel. [Refer: Key management personnel of entity or parent [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfInformationAboutKeyManagementPersonnelExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.4</span><table class="report" border="0" cellspacing="2" id="idm140170923777672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FINANCIAL INSTRUMENTS AND CAPITAL MANAGEMENT (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsAbstract', window );"><strong>Disclosure of detailed information about financial instruments [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory', window );">Disclosure of carrying value of financial assets and liabilities [Table Text Block]</a></td>
<td class="text">
                                <div>
                                    <div style="margin-left: 5.4pt;">
                                        <table cellpadding="0" cellspacing="0" style="width: 100%; border-collapse: collapse; font-size: 10pt; border-color: #000000;">
                                            <tr>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1.5pt solid #000000; border-bottom: 0.75pt solid #000000; vertical-align: bottom;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>&#160;</b></span></span></td>
                                                <td style="vertical-align: bottom; border-top: 1.5pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right;">&#160;</td>
                                                <td style="vertical-align: bottom; border-top: 1.5pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>September 30, </b><br/><b>2021</b></span></span></td>
                                                <td style="vertical-align: bottom; border-top: 1.5pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;">&#160;</td>
                                                <td style="vertical-align: bottom; border-top: 1.5pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;">&#160;</td>
                                                <td style="vertical-align: bottom; border-top: 1.5pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>September 30, </b><br/><b>2020</b></span></span></td>
                                                <td style="vertical-align: bottom; border-top: 1.5pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right;">&#160;</td>
                                            </tr>
                                            <tr>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>FVTPL</b></span></span></td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right;">&#160;</td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>$</b></span></span></td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right;">&#160;</td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right;">&#160;</td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>$</b></span></span></td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right;">&#160;</td>
                                            </tr>
                                            <tr>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">&#160; Cash</span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>19,673,765</b></span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">799,929</span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            </tr>
                                            <tr>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">&#160; Guaranteed investment certificate</span></span></td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>86,250</b></span></span></td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">-</span></span></td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                            </tr>
                                            <tr>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">&#160; Cash and cash equivalents</span></span></td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>19,760,015</b></span></span></td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">799,929</span></span></td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            </tr>
                                            <tr>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>Amortized cost</b></span></span></td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>&#160;</b></span></span></td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%;">&#160;</td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                            </tr>
                                            <tr>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 2.25pt double #000000; vertical-align: bottom; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">&#160; Accounts payable and accrued liabilities</span></span></td>
                                                <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>638,573</b></span></span></td>
                                                <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">150,923</span></span></td>
                                                <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            </tr>
                                        </table>
                                    </div>
                                </div>
                            <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of detailed information about financial instruments. [Refer: Financial instruments, class [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2020-01-01<br> -Paragraph 31<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_31&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2020-01-01<br> -Paragraph 7<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_7&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2020-01-01<br> -Paragraph 35K<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_35K&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFinancialInstrumentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFinancialInstrumentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.4</span><table class="report" border="0" cellspacing="2" id="idm140170915498584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RESEARCH AND DEVELOPMENT (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drug_ResearchAndDevelopmentAbstract', window );"><strong>Research And Development [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drug_DisclosureOfDetailedInformationAboutResearchAndDevelopmentExplanatory', window );">Disclosure of research and development expenses [Table Text Block]</a></td>
<td class="text">
                            <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-size: 10pt; width: 100%;">
                                <tr>
                                    <td style="width: 36%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top; border-top: 1.5pt solid #000000;">
                                        <p style="text-align: justify; margin-top: 0pt; margin-bottom: 0pt;">&#160;</p>
                                    </td>
                                    <td style="width: 20%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-top: 1.5pt solid #000000; white-space: nowrap;">
                                        <p style="text-align: right; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>Year ended</b></span></span></p>
                                    </td>
                                    <td style="width: 17%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-top: 1.5pt solid #000000; white-space: nowrap;">
                                        <p style="text-align: right; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>Year ended</b></span></span></p>
                                    </td>
                                    <td style="width: 16%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top; border-top: 1.5pt solid #000000; white-space: nowrap;">
                                        <p style="text-align: right; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>Period ended</b></span></span></p>
                                    </td>
                                </tr>
                                <tr>
                                    <td style="width: 36%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top;">
                                        <p style="text-align: justify; margin-top: 0pt; margin-bottom: 0pt;">&#160;</p>
                                    </td>
                                    <td style="width: 20%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; white-space: nowrap;">
                                        <p style="margin-bottom: 0pt; text-align: right; margin-top: 0pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>September 30, </b></span></span></p>
                                        <p style="margin-top: 0pt; text-align: right; margin-bottom: 0pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>2021</b></span></span></p>
                                    </td>
                                    <td style="width: 17%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; white-space: nowrap;">
                                        <p style="margin-bottom: 0pt; text-align: right; margin-top: 0pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>September 30, </b></span></span></p>
                                        <p style="margin-top: 0pt; text-align: right; margin-bottom: 0pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>2020</b></span></span></p>
                                    </td>
                                    <td style="width: 16%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top; white-space: nowrap;">
                                        <p style="text-align: right; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>September 30,<br/>2019</b></span></span></p>
                                    </td>
                                </tr>
                                <tr>
                                    <td style="width: 36%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top; border-top: 0.75pt solid #000000;">
                                        <p style="text-align: justify; margin-top: 0pt; margin-bottom: 0pt;">&#160;</p>
                                    </td>
                                    <td style="width: 20%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-top: 0.75pt solid #000000;">
                                        <p style="text-align: right; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>$</b></span></span></p>
                                    </td>
                                    <td style="width: 17%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-top: 0.75pt solid #000000;">
                                        <p style="text-align: right; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">$</span></span></p>
                                    </td>
                                    <td style="width: 16%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top; border-top: 0.75pt solid #000000;">
                                        <p style="text-align: right; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">$</span></span></p>
                                    </td>
                                </tr>
                                <tr>
                                    <td style="width: 36%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top; background-color: #e6efff;">
                                        <p style="text-align: justify; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">Laboratory costs (see Note 11)</span></span></p>
                                    </td>
                                    <td style="width: 20%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top; background-color: #e6efff;">
                                        <p style="text-align: right; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>82,871</b></span></span></p>
                                    </td>
                                    <td style="width: 17%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top; background-color: #e6efff;">
                                        <p style="text-align: right; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">25,874</span></span></p>
                                    </td>
                                    <td style="width: 16%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top; background-color: #e6efff;">
                                        <p style="text-align: right; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">27,164</span></span></p>
                                    </td>
                                </tr>
                                <tr>
                                    <td style="width: 36%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top;">
                                        <p style="text-align: justify; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">Novel drug development</span></span></p>
                                    </td>
                                    <td style="width: 20%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top;">
                                        <p style="text-align: right; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>3,638,910</b></span></span></p>
                                    </td>
                                    <td style="width: 17%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top;">
                                        <p style="text-align: right; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">110,029</span></span></p>
                                    </td>
                                    <td style="width: 16%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top;">
                                        <p style="text-align: right; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">-</span></span></p>
                                    </td>
                                </tr>
                                <tr>
                                    <td style="width: 36%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top; background-color: #e6efff;">
                                        <p style="text-align: justify; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">Patents and related payments</span></span></p>
                                    </td>
                                    <td style="width: 20%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top; background-color: #e6efff;">
                                        <p style="text-align: right; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>513,302</b></span></span></p>
                                    </td>
                                    <td style="width: 17%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top; background-color: #e6efff;">
                                        <p style="text-align: right; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">13,895</span></span></p>
                                    </td>
                                    <td style="width: 16%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top; background-color: #e6efff;">
                                        <p style="text-align: right; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">-</span></span></p>
                                    </td>
                                </tr>
                                <tr>
                                    <td style="width: 36%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top;">
                                        <p style="text-align: justify; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">Salary and subcontractors</span></span></p>
                                    </td>
                                    <td style="width: 20%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top;">
                                        <p style="text-align: right; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>1,369,769</b></span></span></p>
                                    </td>
                                    <td style="width: 17%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top;">
                                        <p style="text-align: right; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">43,754</span></span></p>
                                    </td>
                                    <td style="width: 16%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top;">
                                        <p style="text-align: right; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">14,845</span></span></p>
                                    </td>
                                </tr>
                                <tr>
                                    <td style="width: 36%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top; border-bottom: 0.75pt solid #000000; background-color: #e6efff;">
                                        <p style="text-align: justify; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">Share-based compensation (see Note 6)</span></span></p>
                                    </td>
                                    <td style="width: 20%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top; border-bottom: 0.75pt solid #000000; background-color: #e6efff;">
                                        <p style="text-align: right; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>709,136</b></span></span></p>
                                    </td>
                                    <td style="width: 17%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top; border-bottom: 0.75pt solid #000000; background-color: #e6efff;">
                                        <p style="text-align: right; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">161,300</span></span></p>
                                    </td>
                                    <td style="width: 16%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top; border-bottom: 0.75pt solid #000000; background-color: #e6efff;">
                                        <p style="text-align: right; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">-</span></span></p>
                                    </td>
                                </tr>
                                <tr>
                                    <td style="width: 36%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000;">
                                        <p style="text-align: justify; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>&#160;</b></span></span></p>
                                    </td>
                                    <td style="width: 20%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000;">
                                        <p style="text-align: right; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>6,313,988</b></span></span></p>
                                    </td>
                                    <td style="width: 17%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000;">
                                        <p style="text-align: right; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">354,852</span></span></p>
                                    </td>
                                    <td style="width: 16%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000;">
                                        <p style="text-align: right; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">42,009</span></span></p>
                                    </td>
                                </tr>
                            </table>
                        <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_drug_DisclosureOfDetailedInformationAboutResearchAndDevelopmentExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of detailed information about research and development.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">drug_DisclosureOfDetailedInformationAboutResearchAndDevelopmentExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>drug_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_drug_ResearchAndDevelopmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">drug_ResearchAndDevelopmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>drug_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.4</span><table class="report" border="0" cellspacing="2" id="idm140170914512280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract', window );"><strong>Major components of tax expense (income) [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drug_DisclosureOfReconciliationOfExpectedIncomeTaxRecoveryToActualIncomeTaxRecoveryExplanatory', window );">Disclosure of reconciliation of the expected income tax recovery to the actual income tax recovery [Table Text Block]</a></td>
<td class="text">
                            <div>
                                <div style="margin-left: 36pt;">
                                    <table cellpadding="0" cellspacing="0" style="width: 100%; border-collapse: collapse; font-size: 10pt; border-color: #000000;">
                                        <tr>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; vertical-align: bottom;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>&#160;</b></span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>September 30, </b><br/><b>2021</b></span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>September 30, </b><br/><b>2020</b></span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>September 30,<br/>2019</b></span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>$</b></span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>$</b></span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>$</b></span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">Net loss</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>(8,650,763</b></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>)</b></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">(480,377</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">)</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">(78,717</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">)</span></span></td>
                                        </tr>
                                        <tr>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">Statutory tax rate</span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>27.75%</b></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">27%</span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">27%</span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">Expected income tax recovery</span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>(2,400,311</b></span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>)</b></span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">(129,702</span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">)</span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">(21,254</span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">)</span></span></td>
                                        </tr>
                                        <tr>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">Deductible and non-deductible items</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 12%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>(256,939</b></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>)</b></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 12%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">42,136</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 12%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">-</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">Change in deferred tax assets not recognized</span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>2,657,250</b></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">87,566</span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">21,254</span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 2.25pt double #000000; vertical-align: bottom;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">Total income tax recovery</span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 12%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>-</b></span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 12%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">-</span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 12%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">-</span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%;">&#160;</td>
                                        </tr>
                                    </table>
                                </div>
                            </div>
                        <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory', window );">Disclosure of deductible temporary differences for which no deferred tax has been recognized [Table Text Block]</a></td>
<td class="text">
                            <div>
                                <div style="margin-left: 36pt;">
                                    <table cellpadding="0" cellspacing="0" style="width: 100%; border-collapse: collapse; font-size: 10pt; border-color: #000000;">
                                        <tr>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; vertical-align: bottom;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>&#160;</b></span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>September 30, </b><br/><b>2021</b></span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>September 30, </b><br/><b>2020</b></span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>$</b></span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>$</b></span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">Non-capital losses</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>9,976,000</b></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">403,000</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">Share issue costs</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 15%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>1,448,000</b></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 15%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">4,000</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">Intangible assets</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>(1,000</b></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>)</b></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">(2,000</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">)</span></span></td>
                                        </tr>
                                        <tr>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; border-bottom: 0.75pt solid #000000;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">Valuation allowance</span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 15%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>(11,423,000</b></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>)</b></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 15%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">(405,000</span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">)</span></span></td>
                                        </tr>
                                        <tr>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; border-bottom: 2.25pt double #000000; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">Net deferred income tax assets</span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>-</b></span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">-</span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                        </tr>
                                    </table>
                                </div>
                            </div>
                        <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drug_DisclosureOfNonCapitalLossCarryForwardsExpiryExplanatory', window );">Disclosure of non-capital loss carry-forwards expiry [Table Text Block]</a></td>
<td class="text">
                            <div>
                                <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-size: 10pt; width: 70%; border-color: #000000; margin-left: auto; margin-right: auto;">
                                    <tr>
                                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>Year of Origin</b></span></span></td>
                                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>Year of Expiry</b></span></span></td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;">&#160;</td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>Non-Capital Losses</b></span></span></td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: center;">&#160;</td>
                                    </tr>
                                    <tr>
                                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: center;">&#160;</td>
                                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: center;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>$</b></span></span></td>
                                        <td style="vertical-align: bottom; text-align: right;">&#160;</td>
                                    </tr>
                                    <tr>
                                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: center; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">2019</span></span></td>
                                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: center; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span style="-sec-ix-hidden: Fxbrl_20211228221904526;">2039</span></span></span></td>
                                        <td style="vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; width: 22%; text-align: right; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">79,000</span></span></td>
                                        <td style="vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;">&#160;</td>
                                    </tr>
                                    <tr>
                                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: center;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">2020</span></span></td>
                                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: center;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span style="-sec-ix-hidden: Fxbrl_20211228221912500;">2040</span></span></span></td>
                                        <td style="vertical-align: bottom; width: 1%; text-align: left;">&#160;</td>
                                        <td style="vertical-align: bottom; width: 22%; text-align: right;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">324,000</span></span></td>
                                        <td style="vertical-align: bottom; width: 2%; text-align: left;">&#160;</td>
                                    </tr>
                                    <tr>
                                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">2021</span></span></td>
                                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span style="-sec-ix-hidden: Fxbrl_20211228221915311;">2041</span></span></span></td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 22%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">9,537,000</span></span></td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                    </tr>
                                    <tr>
                                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: center;">&#160;</td>
                                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: center;">&#160;</td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%;">&#160;</td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 22%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">9,940,000</span></span></td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%;">&#160;</td>
                                    </tr>
                                </table>
                            </div>
                        <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_drug_DisclosureOfNonCapitalLossCarryForwardsExpiryExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of non-capital loss carry-forwards expiry.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">drug_DisclosureOfNonCapitalLossCarryForwardsExpiryExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>drug_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_drug_DisclosureOfReconciliationOfExpectedIncomeTaxRecoveryToActualIncomeTaxRecoveryExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of reconciliation of the expected income tax recovery to the actual income tax recovery.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">drug_DisclosureOfReconciliationOfExpectedIncomeTaxRecoveryToActualIncomeTaxRecoveryExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>drug_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of types of temporary differences, unused tax losses and unused tax credits. [Refer: Unused tax credits [member]; Unused tax losses [member]; Temporary differences [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2020-01-01<br> -Paragraph 81<br> -Subparagraph g<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_81_g&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.4</span><table class="report" border="0" cellspacing="2" id="idm140170914605528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NATURE AND CONTINUANCE OF OPERATIONS (Narrative) (Details) - CAD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">4 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drug_NatureAndContinuanceOfOperationsAbstract', window );"><strong>Nature And Continuance Of Operations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (8,650,763)<span></span>
</td>
<td class="num">$ (78,717)<span></span>
</td>
<td class="num">$ (8,650,763)<span></span>
</td>
<td class="num">$ (480,377)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RetainedEarnings', window );">Deficit</a></td>
<td class="num">(9,209,857)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(9,209,857)<span></span>
</td>
<td class="num">(559,094)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drug_WorkingCapital', window );">Working capital</a></td>
<td class="nump">$ 19,399,795<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19,399,795<span></span>
</td>
<td class="nump">$ 727,293<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_drug_NatureAndContinuanceOfOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">drug_NatureAndContinuanceOfOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>drug_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_drug_WorkingCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the amount working capital</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">drug_WorkingCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>drug_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2020-01-01<br> -Paragraph 18<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_18_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause ii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_32_a_ii&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2020-01-01<br> -Paragraph 28<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_28_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Note Effective on first application of IFRS 9<br> -Name IFRS<br> -Number 4<br> -IssueDate 2020-01-01<br> -Paragraph 39L<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=4&amp;code=ifrs-tx-2020-en-b&amp;anchor=para_39L_e&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2020-01-01<br> -Paragraph 23<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2020-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2020-01-01<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_106_d_i&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Note Effective 2021-01-01<br> -Name IFRS<br> -Number 17<br> -IssueDate 2020-01-01<br> -Paragraph 113<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=17&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_113_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 81A<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_81A_a&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RetainedEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A component of equity representing the entity's cumulative undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph IG6<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_IG6&amp;doctype=Implementation%20Guidance<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RetainedEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.4</span><table class="report" border="0" cellspacing="2" id="idm140170912130488">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SHARE EXCHANGE AND ASSIGNMENT (Narrative) (Details) - PsilocybinLabs Ltd [Member]<br></strong></div></th>
<th class="th">
<div>Aug. 07, 2019 </div>
<div>CAD ($) </div>
<div>Shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Apr. 25, 2019 </div>
<div>CAD ($) </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drug_ShareExchangeAndAssignmentLineItems', window );"><strong>Share Exchange And Assignment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drug_NumberOfSharesIssuedByRelatedParty', window );">Number of shares issued by PL to individual | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drug_ValueOfCommonStockSharesIssuedByRelatedParty', window );">Value of common stock issued by PL to individual | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drug_CommonStockSharesPurchased', window );">Common shares purchased | shares</a></td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOrInterestsIssuedOrIssuable', window );">Number of shares issued | Shares</a></td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_EquityInterestsOfAcquirer', window );">Value of common stock shares issued | $</a></td>
<td class="nump">$ 2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_drug_CommonStockSharesPurchased">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the number of common stock shares purchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">drug_CommonStockSharesPurchased</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>drug_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_drug_NumberOfSharesIssuedByRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the number of shares issued by related party.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">drug_NumberOfSharesIssuedByRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>drug_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_drug_ShareExchangeAndAssignmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">drug_ShareExchangeAndAssignmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>drug_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_drug_ValueOfCommonStockSharesIssuedByRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the value of common stock shares issued by related party.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">drug_ValueOfCommonStockSharesIssuedByRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>drug_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EquityInterestsOfAcquirer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The fair value, at the acquisition date, of equity interests of the acquirer transferred as consideration in a business combination. [Refer: Business combinations [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2020-01-01<br> -Paragraph B64<br> -Subparagraph f<br> -Clause iv<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_B64_f_iv&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EquityInterestsOfAcquirer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfInstrumentsOrInterestsIssuedOrIssuable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of instruments or interests issued or issuable at acquisition date for equity interests of the acquirer transferred as consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2020-01-01<br> -Paragraph B64<br> -Subparagraph f<br> -Clause iv<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_B64_f_iv&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfInstrumentsOrInterestsIssuedOrIssuable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=drug_PsilocybinlabsLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=drug_PsilocybinlabsLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.4</span><table class="report" border="0" cellspacing="2" id="idm140170912050744">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>ACCOUNTS PAYABLE AND ACCRUED LIABILITIES - Disclosure of accounts payable and accrued liabilities (Details) - CAD ($)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TradeAndOtherCurrentPayablesAbstract', window );"><strong>Trade and other current payables [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers', window );">Accounts payable</a></td>
<td class="nump">$ 596,573<span></span>
</td>
<td class="nump">$ 138,423<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AccrualsClassifiedAsCurrent', window );">Accrued liabilities</a></td>
<td class="nump">42,000<span></span>
</td>
<td class="nump">12,500<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TradeAndOtherCurrentPayables', window );">Total accounts payable and accrued liabilities</a></td>
<td class="nump">$ 638,573<span></span>
</td>
<td class="nump">$ 150,923<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AccrualsClassifiedAsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of accruals classified as current. [Refer: Accruals]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 78<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_78&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AccrualsClassifiedAsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeAndOtherCurrentPayables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of current trade payables and current other payables. [Refer: Current trade payables; Other current payables]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 54<br> -Subparagraph k<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_54_k&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeAndOtherCurrentPayables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeAndOtherCurrentPayablesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeAndOtherCurrentPayablesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The current amount of payment due to suppliers for goods and services used in entity's business. [Refer: Current liabilities; Trade payables]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 78<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_78&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 70<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_70&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.4</span><table class="report" border="0" cellspacing="2" id="idm140170885443016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHARE CAPITAL (Narrative) (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="13">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Apr. 06, 2021 </div>
<div>CAD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Feb. 08, 2021 </div>
<div>shares</div>
</th>
<th class="th">
<div>Feb. 03, 2021 </div>
<div>CAD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Jan. 06, 2021 </div>
<div>CAD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Nov. 02, 2020 </div>
<div>CAD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 21, 2021 </div>
<div>shares </div>
<div>Year </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Jun. 15, 2021 </div>
<div>shares </div>
<div>Year </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Apr. 28, 2021 </div>
<div>CAD ($) </div>
<div>shares </div>
<div>Year </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Apr. 23, 2021 </div>
<div>CAD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 17, 2021 </div>
<div>CAD ($) </div>
<div>Year </div>
<div>$ / shares </div>
<div>$ / Shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jan. 21, 2021 </div>
<div>Shares</div>
</th>
<th class="th">
<div>Jan. 19, 2021 </div>
<div>CAD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Nov. 17, 2020 </div>
<div>shares </div>
<div>Year </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Oct. 31, 2020 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>CAD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jul. 23, 2020 </div>
<div>CAD ($) </div>
<div>shares </div>
<div>Year </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Jul. 31, 2019 </div>
<div>shares</div>
</th>
<th class="th">
<div>Jul. 30, 2019 </div>
<div>CAD ($) </div>
<div>$ / shares </div>
<div>$ / Shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>CAD ($) </div>
<div>shares </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>CAD ($) </div>
<div>shares </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Sep. 28, 2020 </div>
<div>CAD ($)</div>
</th>
<th class="th">
<div>Jan. 28, 2021 </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 18, 2020 </div>
<div>CAD ($)</div>
</th>
<th class="th">
<div>Jul. 11, 2020 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Sep. 30, 2019 </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drug_DescriptionOfIssuedAndOutstandingCommonShares', window );">Description of issued and outstanding common shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">On November 10, 2020, the Directors of the Company approved the consolidation of the Company's issued and outstanding common shares on a 2.5:1 basis.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInNumberOfSharesOutstanding', window );">Number of shares issued during period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,049,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drug_IssuePricePerShare', window );">Shares issued price per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.85<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProceedsFromIssueOfOrdinaryShares', window );">Proceeds from issue of ordinary shares | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 80,980<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drug_NumberOfUnitsIssued', window );">Number of units issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,419,883<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drug_UnitsIssuedPricePerUnit', window );">Units issued, price per unit | $ / Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.57<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drug_GrossProceedsFromUnitsIssued', window );">Gross proceeds from units issued | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,888,514<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drug_WeightedAverageExercisePriceOfWarrantsOutstandingInShareBasedPaymentArrangement', window );">Warrants exercise price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.125<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.05<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drug_MinimumDailyVolumeWeightedAverageTradingSharePrice', window );">Minimum daily volume weighted average trading share price on the CSE | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drug_UnderwritersFeesPaid', window );">Underwriters fees paid | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 916,317<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drug_IncreaseDecreaseThroughSharesIssuedToUniversityShares', window );">Shares issued to the University (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">63,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drug_IncreaseDecreaseThroughSharesIssuedToUniversity', window );">Shares issued to the University | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 368,550<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 368,550<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drug_SubscriptionsReceived', window );">Subscription received | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 147,426<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 147,426<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drug_NumberOfCommonSharesSubscribed', window );">Number of common shares subscribed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">294,852<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drug_ExercisePriceWarrantsGranted', window );">Exercise price, warrants granted | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9.46<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfShareCapitalAxis=drug_SecondTrancheOfNonBrokeredPrivatePlacementMember', window );">Second tranche of a non-brokered private placement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInNumberOfSharesOutstanding', window );">Number of shares issued during period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,629,138<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drug_IssuePricePerShare', window );">Shares issued price per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProceedsFromIssueOfOrdinaryShares', window );">Proceeds from issue of ordinary shares | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,036,422<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfShareCapitalAxis=drug_SpecialWarrantsMember', window );">Special Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drug_ProceedsForWarrantsIssued', window );">Proceeds for warrants issued | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22,875<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drug_NumberOfWarrantsDeemedToBeExercised', window );">Number of warrants deemed to be exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drug_NumberOfWarrantsIssued', window );">Number of warrants, Issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drug_WarrantsIssuedPricePerWarrant', window );">Warrants issued, price per warrant | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drug_NumberOfIssuedWarrantsRescinded', window );">Number of issued warrants rescinded</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drug_RefundFromIssuedWarrantsRescinded', window );">Refund from issued warrants rescinded | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,875<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drug_AmountOfEscrowProceedsReleased', window );">Amount of escrow proceeds released | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfShareCapitalAxis=drug_WarrantsMember', window );">Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drug_NumberOfWarrantsIssued', window );">Number of warrants, Issued</a></td>
<td class="nump">8,807<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,709,938<span></span>
</td>
<td class="nump">4,079,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drug_WeightedAverageExercisePriceOfWarrantsIssuedInShareBasedPaymentArrangement', window );">Weighted average exercise price of warrants issued | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9.46<span></span>
</td>
<td class="nump">$ 0.05<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drug_WeightedAverageExercisePriceOfWarrantsOutstandingInShareBasedPaymentArrangement', window );">Warrants exercise price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.05<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.35<span></span>
</td>
<td class="nump">$ 0.05<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drug_WarrantAscribedValue', window );">Warrant ascribed value | $</a></td>
<td class="nump">$ 33,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drug_NumberOfWarrantsExercised', window );">Number of warrants exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,948,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drug_WeightedAverageExercisePriceOfWarrantsExercisedInShareBasedPaymentArrangement', window );">Weighted average exercise price, Exercised | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.05<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drug_TermOfWarrant', window );">Term of warrant</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drug_ExercisePriceWarrantsGranted', window );">Exercise price, warrants granted | $ / shares</a></td>
<td class="nump">$ 7.57<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drug_WeightedAverageRemainingContractualLifeOfOtherEquityInstruments', window );">Weighted average remaining contractual life of outstanding warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 7 months 28 days<span></span>
</td>
<td class="text">3 years 9 months 29 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drug_ThresholdPercentageOfWarrants', window );">Threshold percentage of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfShareCapitalAxis=drug_EscrowedSharePurchaseWarrantsMember', window );">Escrowed share purchase warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drug_NumberOfWarrantsExercised', window );">Number of warrants exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,948,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drug_WeightedAverageExercisePriceOfWarrantsExercisedInShareBasedPaymentArrangement', window );">Weighted average exercise price, Exercised | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.05<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drug_GrossProceedsFromWarrantsExercised', window );">Gross proceeds from warrants exercised | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 97,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfShareCapitalAxis=drug_FirstTrancheOfNonBrokeredPrivatePlacementMember', window );">First tranche of a non-brokered private placement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInNumberOfSharesOutstanding', window );">Number of shares issued during period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">623,941<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drug_IssuePricePerShare', window );">Shares issued price per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProceedsFromIssueOfOrdinaryShares', window );">Proceeds from issue of ordinary shares | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 779,924<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfShareCapitalAxis=drug_NonBrokeredPrivatePlacementMember', window );">Non-brokered private placement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drug_NumberOfUnitsIssued', window );">Number of units issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,079,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drug_UnitsIssuedPricePerUnit', window );">Units issued, price per unit | $ / Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.05<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drug_GrossProceedsFromUnitsIssued', window );">Gross proceeds from units issued | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 203,980<span></span>
</td>
<td class="nump">$ 80,980<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drug_WeightedAverageExercisePriceOfWarrantsIssuedInShareBasedPaymentArrangement', window );">Weighted average exercise price of warrants issued | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.05<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfShareCapitalAxis=drug_StockOptionsMember', window );">Stock Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drug_PercentageOfOutstandingSharesAuthorizedUnderStockOptionPlan', window );">Percentage of outstanding shares authorized under stock option plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement', window );">Number of options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">895,807<span></span>
</td>
<td class="nump">150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019', window );">Weighted average exercise price of options granted | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.29<span></span>
</td>
<td class="nump">$ 1.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement', window );">Number of options cancelled</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019', window );">Weighted average remaining contractual life of outstanding share options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years 3 months 10 days<span></span>
</td>
<td class="text">4 years 9 months 21 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfShareCapitalAxis=drug_RestrictedShareUnitMember', window );">Restricted Share Units [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drug_EstimatedFairValueOfEquitySettledRsusGranted', window );">Estimated fair value of equity settled RSUs granted | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 475,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=drug_ConsultantMember', window );">Consultant [Member] | Stock Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement', window );">Number of options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,807<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExercisePriceShareOptionsGranted2019', window );">Exercise price, stock options granted | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.64<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019', window );">Share price, stock options granted | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.64<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted', window );">Option life, stock options granted | Year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted', window );">Volatility rate, stock options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drug_DiscountRateStockOptionGranted', window );">Discount rate, stock options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.55%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019', window );">Weighted average exercise price of options granted | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.64<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=drug_ConsultantMember', window );">Consultant [Member] | Stock Options [Member] | On December 21, 2021 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drug_VestingPercentage', window );">Vesting percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=drug_ConsultantMember', window );">Consultant [Member] | Stock Options [Member] | On March 21, 2022 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drug_VestingPercentage', window );">Vesting percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=drug_ConsultantMember', window );">Consultant [Member] | Stock Options [Member] | On June 21, 2022 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drug_VestingPercentage', window );">Vesting percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=drug_ConsultantMember', window );">Consultant [Member] | Stock Options [Member] | On September 21, 2022 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drug_VestingPercentage', window );">Vesting percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=drug_UnderwritersMember', window );">Underwriters [Member] | Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drug_NumberOfWarrantsIssued', window );">Number of warrants, Issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">132,666<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drug_WarrantAscribedValue', window );">Warrant ascribed value | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 521,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drug_FairValueOfWarrants', window );">Fair value of share purchase warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">521,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drug_ExercisePriceWarrantsGranted', window );">Exercise price, warrants granted | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.57<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drug_WeightedAverageSharePriceWarrantsGranted', window );">Share price, warrants granted | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.65<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drug_EstimatedLifeOfWarrantsGranted', window );">Estimated life, warrants granted | Year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drug_ExpectedVolatilityWarrantsGranted', window );">Expected volatility, warrants granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drug_DiscountRateOfWarrantsGranted', window );">Discount rate, warrants granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.35%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=drug_ThreeInvestorsMember', window );">Three Investors [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProceedsFromIssueOfOrdinaryShares', window );">Proceeds from issue of ordinary shares | $</a></td>
<td class="nump">$ 13,333,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drug_ContingentCashFee', window );">Contingent cash fee | $</a></td>
<td class="nump">$ 600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drug_PercentageOfNetEquityProceedsReceivedFromThreeInvestors', window );">Percentage of equity proceeds received from three investors</a></td>
<td class="nump">4.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=drug_ChiefFinancialOfficerTwoDirectorsAndSevenConsultantsMember', window );">Chief Financial Officer, two directors and seven consultants [Member] | Stock Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement', window );">Number of options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">467,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExercisePriceShareOptionsGranted2019', window );">Exercise price, stock options granted | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019', window );">Share price, stock options granted | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted', window );">Option life, stock options granted | Year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted', window );">Volatility rate, stock options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drug_DiscountRateStockOptionGranted', window );">Discount rate, stock options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.43%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019', window );">Weighted average exercise price of options granted | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=drug_ChiefFinancialOfficerTwoDirectorsAndSevenConsultantsMember', window );">Chief Financial Officer, two directors and seven consultants [Member] | Stock Options One [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement', window );">Number of options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=drug_ChiefFinancialOfficerTwoDirectorsAndSevenConsultantsMember', window );">Chief Financial Officer, two directors and seven consultants [Member] | Stock Options One [Member] | On the date of grant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drug_VestingPercentage', window );">Vesting percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=drug_ChiefFinancialOfficerTwoDirectorsAndSevenConsultantsMember', window );">Chief Financial Officer, two directors and seven consultants [Member] | Stock Options Two [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement', window );">Number of options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=drug_ChiefFinancialOfficerTwoDirectorsAndSevenConsultantsMember', window );">Chief Financial Officer, two directors and seven consultants [Member] | Stock Options Two [Member] | On the Company's listing date [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drug_VestingPercentage', window );">Vesting percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=drug_ChiefFinancialOfficerTwoDirectorsAndSevenConsultantsMember', window );">Chief Financial Officer, two directors and seven consultants [Member] | Stock Options Two [Member] | On the first anniversary of the listing date [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drug_VestingPercentage', window );">Vesting percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=drug_ChiefFinancialOfficerTwoDirectorsAndSevenConsultantsMember', window );">Chief Financial Officer, two directors and seven consultants [Member] | Stock Options Two [Member] | On the second anniversary of the listing date [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drug_VestingPercentage', window );">Vesting percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=drug_ChiefFinancialOfficerTwoDirectorsAndSevenConsultantsMember', window );">Chief Financial Officer, two directors and seven consultants [Member] | Stock Options Three [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement', window );">Number of options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=drug_ChiefFinancialOfficerTwoDirectorsAndSevenConsultantsMember', window );">Chief Financial Officer, two directors and seven consultants [Member] | Stock Options Three [Member] | On the Company's listing date [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drug_VestingPercentage', window );">Vesting percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=drug_ChiefFinancialOfficerTwoDirectorsAndSevenConsultantsMember', window );">Chief Financial Officer, two directors and seven consultants [Member] | Stock Options Three [Member] | On the six-month anniversary of the listing date [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drug_VestingPercentage', window );">Vesting percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=drug_ChiefFinancialOfficerTwoDirectorsAndSevenConsultantsMember', window );">Chief Financial Officer, two directors and seven consultants [Member] | Stock Options Four [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement', window );">Number of options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">424,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=drug_ChiefFinancialOfficerTwoDirectorsAndSevenConsultantsMember', window );">Chief Financial Officer, two directors and seven consultants [Member] | Stock Options Four [Member] | On the first anniversary of the grant date [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drug_VestingPercentage', window );">Vesting percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=drug_ChiefFinancialOfficerTwoDirectorsAndSevenConsultantsMember', window );">Chief Financial Officer, two directors and seven consultants [Member] | Stock Options Four [Member] | On the second anniversary of the grant date [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drug_VestingPercentage', window );">Vesting percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=drug_ChiefFinancialOfficerTwoDirectorsAndSevenConsultantsMember', window );">Chief Financial Officer, two directors and seven consultants [Member] | Stock Options Four [Member] | On the third anniversary of the grant date [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drug_VestingPercentage', window );">Vesting percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=drug_ThreeConsultantsMember', window );">Three Consultants [Member] | Stock Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement', window );">Number of options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">240,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExercisePriceShareOptionsGranted2019', window );">Exercise price, stock options granted | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019', window );">Share price, stock options granted | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.98<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted', window );">Option life, stock options granted | Year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted', window );">Volatility rate, stock options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drug_DiscountRateStockOptionGranted', window );">Discount rate, stock options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.92%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019', window );">Weighted average exercise price of options granted | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=drug_ThreeConsultantsMember', window );">Three Consultants [Member] | Stock Options One [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement', window );">Number of options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">160,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=drug_ThreeConsultantsMember', window );">Three Consultants [Member] | Stock Options One [Member] | On the first anniversary of the grant date [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drug_VestingPercentage', window );">Vesting percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=drug_ThreeConsultantsMember', window );">Three Consultants [Member] | Stock Options One [Member] | On the second anniversary of the grant date [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drug_VestingPercentage', window );">Vesting percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=drug_ThreeConsultantsMember', window );">Three Consultants [Member] | Stock Options One [Member] | On the third anniversary of the grant date [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drug_VestingPercentage', window );">Vesting percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=drug_ThreeConsultantsMember', window );">Three Consultants [Member] | Stock Options One [Member] | On the fourth anniversary of the grant date [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drug_VestingPercentage', window );">Vesting percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=drug_ThreeConsultantsMember', window );">Three Consultants [Member] | Stock Options Two [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement', window );">Number of options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=drug_ThreeConsultantsMember', window );">Three Consultants [Member] | Stock Options Two [Member] | On the first anniversary of the grant date [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drug_VestingPercentage', window );">Vesting percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=drug_ThreeConsultantsMember', window );">Three Consultants [Member] | Stock Options Two [Member] | On the second anniversary of the grant date [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drug_VestingPercentage', window );">Vesting percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=drug_ThreeConsultantsMember', window );">Three Consultants [Member] | Stock Options Two [Member] | On the six-month anniversary of the grant date [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drug_VestingPercentage', window );">Vesting percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=drug_ThreeConsultantsMember', window );">Three Consultants [Member] | Stock Options Two [Member] | On the eighteen-month anniversary of the grant date [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drug_VestingPercentage', window );">Vesting percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=drug_DirectorAndConsultantMember', window );">Director and Consultant [Member] | Stock Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement', window );">Number of options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">180,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExercisePriceShareOptionsGranted2019', window );">Exercise price, stock options granted | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019', window );">Share price, stock options granted | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.55<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted', window );">Option life, stock options granted | Year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted', window );">Volatility rate, stock options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drug_DiscountRateStockOptionGranted', window );">Discount rate, stock options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.84%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019', window );">Weighted average exercise price of options granted | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=drug_DirectorAndConsultantMember', window );">Director and Consultant [Member] | Stock Options [Member] | On the first anniversary of the grant date [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drug_VestingPercentage', window );">Vesting percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=drug_DirectorAndConsultantMember', window );">Director and Consultant [Member] | Stock Options [Member] | On the second anniversary of the grant date [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drug_VestingPercentage', window );">Vesting percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=drug_DirectorAndConsultantMember', window );">Director and Consultant [Member] | Stock Options [Member] | On the third anniversary of the grant date [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drug_VestingPercentage', window );">Vesting percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=drug_DirectorAndConsultantMember', window );">Director and Consultant [Member] | Stock Options [Member] | On the fourth anniversary of the grant date [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drug_VestingPercentage', window );">Vesting percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=drug_ChiefMedicalOfficerMember', window );">Chief Medical Officer [Member] | Stock Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement', window );">Number of options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExercisePriceShareOptionsGranted2019', window );">Exercise price, stock options granted | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019', window );">Share price, stock options granted | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted', window );">Option life, stock options granted | Year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted', window );">Volatility rate, stock options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drug_DiscountRateStockOptionGranted', window );">Discount rate, stock options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.35%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=drug_ChiefMedicalOfficerMember', window );">Chief Medical Officer [Member] | Restricted Share Units [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drug_IssuanceOfRestrictedStockUnits', window );">Issuance of RSU | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 230,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drug_AgreementAxis=drug_DebtSettlementAgreementMember', window );">Debt Settlement Agreement [Member] | Consultant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInNumberOfSharesOutstanding', window );">Number of shares issued during period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,799<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drug_IssuePricePerShare', window );">Shares issued price per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drug_DebtSettledThroughIssuanceOfShares', window );">Debt settled through issuance of shares | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drug_AgreementAxis=drug_EscrowAgreementMember', window );">Escrow Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drug_EscrowedSecuritiesToBeReleasedOnceSharesAreListedOnCanadianStockExchange', window );">Escrowed securities to be released once shares are listed on Canadian Stock Exchange</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">480,080<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drug_EscrowedSecuritiesToBeReleasedAfterListingDate', window );">Escrowed securities to be released after listing date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">720,120<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drug_AgreementAxis=drug_EscrowAgreementMember', window );">Escrow Agreement [Member] | Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drug_NumberOfCommonSharesDepositedToBeHeldInEscrow', window );">Number of common shares deposited to be held in escrow</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,852,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drug_NumberOfWarrantsDepositedToBeHeldInEscrow', window );">Number of warrants deposited to be held in escrow</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,948,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drug_AggregateSecuritiesDepositedToBeHeldInEscrow', window );">Aggregate securities deposited to be held in escrow</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,800,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_drug_AggregateSecuritiesDepositedToBeHeldInEscrow">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate securities deposited to be held in escrow.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">drug_AggregateSecuritiesDepositedToBeHeldInEscrow</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>drug_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_drug_AmountOfEscrowProceedsReleased">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of escrow proceeds released.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">drug_AmountOfEscrowProceedsReleased</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>drug_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_drug_ContingentCashFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Information about contingent cash fee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">drug_ContingentCashFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>drug_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_drug_DebtSettledThroughIssuanceOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents amount of debt settled through issuance of shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">drug_DebtSettledThroughIssuanceOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>drug_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_drug_DescriptionOfIssuedAndOutstandingCommonShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of issued and outstanding common shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">drug_DescriptionOfIssuedAndOutstandingCommonShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>drug_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_drug_DiscountRateOfWarrantsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Discount rate of warrants granted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">drug_DiscountRateOfWarrantsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>drug_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_drug_DiscountRateStockOptionGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of discount rate of stock option granted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">drug_DiscountRateStockOptionGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>drug_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_drug_EscrowedSecuritiesToBeReleasedAfterListingDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents number of escrowed securities to be released after listing date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">drug_EscrowedSecuritiesToBeReleasedAfterListingDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>drug_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_drug_EscrowedSecuritiesToBeReleasedOnceSharesAreListedOnCanadianStockExchange">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents escrowed securities to be released once shares are listed on Canadian Stock Exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">drug_EscrowedSecuritiesToBeReleasedOnceSharesAreListedOnCanadianStockExchange</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>drug_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_drug_EstimatedFairValueOfEquitySettledRsusGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Estimated fair value of equity settled RSUs granted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">drug_EstimatedFairValueOfEquitySettledRsusGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>drug_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_drug_EstimatedLifeOfWarrantsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Estimated life of warrants granted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">drug_EstimatedLifeOfWarrantsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>drug_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_drug_ExercisePriceWarrantsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price, warrants granted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">drug_ExercisePriceWarrantsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>drug_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_drug_ExpectedVolatilityWarrantsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected volatility of warrants granted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">drug_ExpectedVolatilityWarrantsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>drug_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_drug_FairValueOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents fair value of warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">drug_FairValueOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>drug_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_drug_GrossProceedsFromUnitsIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of gross proceeds from units issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">drug_GrossProceedsFromUnitsIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>drug_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_drug_GrossProceedsFromWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represent the gross proceeds from warrants exercised.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">drug_GrossProceedsFromWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>drug_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_drug_IncreaseDecreaseThroughSharesIssuedToUniversity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) through shares issued to university.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">drug_IncreaseDecreaseThroughSharesIssuedToUniversity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>drug_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_drug_IncreaseDecreaseThroughSharesIssuedToUniversityShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) through shares issued to university shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">drug_IncreaseDecreaseThroughSharesIssuedToUniversityShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>drug_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_drug_IssuanceOfRestrictedStockUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of issuance of restricted stock units.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">drug_IssuanceOfRestrictedStockUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>drug_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_drug_IssuePricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Issue price per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">drug_IssuePricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>drug_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_drug_MinimumDailyVolumeWeightedAverageTradingSharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The minimum daily volume weighted average trading share price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">drug_MinimumDailyVolumeWeightedAverageTradingSharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>drug_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_drug_NumberOfCommonSharesDepositedToBeHeldInEscrow">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of common shares deposited to be held in escrow.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">drug_NumberOfCommonSharesDepositedToBeHeldInEscrow</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>drug_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_drug_NumberOfCommonSharesSubscribed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of common shares subscribed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">drug_NumberOfCommonSharesSubscribed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>drug_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_drug_NumberOfIssuedWarrantsRescinded">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of issued warrants rescinded.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">drug_NumberOfIssuedWarrantsRescinded</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>drug_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_drug_NumberOfUnitsIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of units issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">drug_NumberOfUnitsIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>drug_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_drug_NumberOfWarrantsDeemedToBeExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants deemed to be exercised.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">drug_NumberOfWarrantsDeemedToBeExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>drug_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_drug_NumberOfWarrantsDepositedToBeHeldInEscrow">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants deposited to be held in escrow.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">drug_NumberOfWarrantsDepositedToBeHeldInEscrow</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>drug_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_drug_NumberOfWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represent the number of warrants exercised.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">drug_NumberOfWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>drug_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_drug_NumberOfWarrantsIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the number of warrants Issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">drug_NumberOfWarrantsIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>drug_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_drug_PercentageOfNetEquityProceedsReceivedFromThreeInvestors">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of equity proceeds received from three investors.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">drug_PercentageOfNetEquityProceedsReceivedFromThreeInvestors</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>drug_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_drug_PercentageOfOutstandingSharesAuthorizedUnderStockOptionPlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents percentage of outstanding shares authorized under stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">drug_PercentageOfOutstandingSharesAuthorizedUnderStockOptionPlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>drug_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_drug_ProceedsForWarrantsIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents amount of proceeds for warrants issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">drug_ProceedsForWarrantsIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>drug_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_drug_RefundFromIssuedWarrantsRescinded">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Refund from issued warrants rescinded.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">drug_RefundFromIssuedWarrantsRescinded</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>drug_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_drug_SubscriptionsReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of subscriptions received.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">drug_SubscriptionsReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>drug_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_drug_TermOfWarrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Information about term of warrant.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">drug_TermOfWarrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>drug_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_drug_ThresholdPercentageOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Threshold percentage of warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">drug_ThresholdPercentageOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>drug_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_drug_UnderwritersFeesPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Underwriters fees paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">drug_UnderwritersFeesPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>drug_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_drug_UnitsIssuedPricePerUnit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents unit issued price per unit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">drug_UnitsIssuedPricePerUnit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>drug_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>srt-types:perUnitItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_drug_VestingPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Vesting percentage of share-based payment award.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">drug_VestingPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>drug_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_drug_WarrantAscribedValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Warrant ascribed value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">drug_WarrantAscribedValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>drug_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_drug_WarrantsIssuedPricePerWarrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents per share price of warrants issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">drug_WarrantsIssuedPricePerWarrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>drug_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_drug_WeightedAverageExercisePriceOfWarrantsExercisedInShareBasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the weighted average exercise price of warrants exercised In share based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">drug_WeightedAverageExercisePriceOfWarrantsExercisedInShareBasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>drug_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_drug_WeightedAverageExercisePriceOfWarrantsIssuedInShareBasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the weighted average exercise price of warrants issued In share based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">drug_WeightedAverageExercisePriceOfWarrantsIssuedInShareBasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>drug_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_drug_WeightedAverageExercisePriceOfWarrantsOutstandingInShareBasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the weighted average exercise price of warrants outstanding in share based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">drug_WeightedAverageExercisePriceOfWarrantsOutstandingInShareBasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>drug_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_drug_WeightedAverageRemainingContractualLifeOfOtherEquityInstruments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average remaining contractual life of other equity instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">drug_WeightedAverageRemainingContractualLifeOfOtherEquityInstruments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>drug_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_drug_WeightedAverageSharePriceWarrantsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average share price, warrants granted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">drug_WeightedAverageSharePriceWarrantsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>drug_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The expected volatility of the share price used to calculate the fair value of the share options granted. Expected volatility is a measure of the amount by which a price is expected to fluctuate during a period. The measure of volatility used in option pricing models is the annualised standard deviation of the continuously compounded rates of return on the share over a period of time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2020-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_47_a_i&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The option life of share options granted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2020-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_47_a_i&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfOptionLifeShareOptionsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfClassesOfShareCapitalLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExercisePriceShareOptionsGranted2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exercise price of share options granted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2020-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_47_a_i&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExercisePriceShareOptionsGranted2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseInNumberOfSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in the number of shares outstanding. [Refer: Number of shares outstanding]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 79<br> -Subparagraph a<br> -Clause iv<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_79_a_iv&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseInNumberOfSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of share options forfeited in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2020-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause iii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_45_b_iii&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of share options granted in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2020-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause ii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_45_b_ii&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProceedsFromIssueOfOrdinaryShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuing of ordinary shares. [Refer: Ordinary shares [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2020-01-01<br> -Paragraph 17<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_17&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProceedsFromIssueOfOrdinaryShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average exercise price of share options granted in a share-based payment arrangement. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2020-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause ii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_45_b_ii&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average remaining contractual life of outstanding share options. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2020-01-01<br> -Paragraph 45<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_45_d&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average share price used as input to the option pricing model to calculate the fair value of share options granted. [Refer: Option pricing model [member]; Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2020-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_47_a_i&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfShareCapitalAxis=drug_SecondTrancheOfNonBrokeredPrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfShareCapitalAxis=drug_SecondTrancheOfNonBrokeredPrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfShareCapitalAxis=drug_SpecialWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfShareCapitalAxis=drug_SpecialWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfShareCapitalAxis=drug_WarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfShareCapitalAxis=drug_WarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfShareCapitalAxis=drug_EscrowedSharePurchaseWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfShareCapitalAxis=drug_EscrowedSharePurchaseWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfShareCapitalAxis=drug_FirstTrancheOfNonBrokeredPrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfShareCapitalAxis=drug_FirstTrancheOfNonBrokeredPrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfShareCapitalAxis=drug_NonBrokeredPrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfShareCapitalAxis=drug_NonBrokeredPrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfShareCapitalAxis=drug_StockOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfShareCapitalAxis=drug_StockOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfShareCapitalAxis=drug_RestrictedShareUnitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfShareCapitalAxis=drug_RestrictedShareUnitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=drug_ConsultantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=drug_ConsultantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_drug_VestingsAxis=drug_TwelfthTrancheMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">drug_VestingsAxis=drug_TwelfthTrancheMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_drug_VestingsAxis=drug_ThirteenthTrancheMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">drug_VestingsAxis=drug_ThirteenthTrancheMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_drug_VestingsAxis=drug_FourteenthTrancheMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">drug_VestingsAxis=drug_FourteenthTrancheMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_drug_VestingsAxis=drug_FifteenthTrancheMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">drug_VestingsAxis=drug_FifteenthTrancheMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=drug_UnderwritersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=drug_UnderwritersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=drug_ThreeInvestorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=drug_ThreeInvestorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=drug_ChiefFinancialOfficerTwoDirectorsAndSevenConsultantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=drug_ChiefFinancialOfficerTwoDirectorsAndSevenConsultantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_drug_StockOptionAxis=drug_StockOptionsOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">drug_StockOptionAxis=drug_StockOptionsOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_drug_VestingsAxis=drug_FirstTrancheMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">drug_VestingsAxis=drug_FirstTrancheMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_drug_StockOptionAxis=drug_StockOptionsTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">drug_StockOptionAxis=drug_StockOptionsTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_drug_VestingsAxis=drug_SecondTrancheMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">drug_VestingsAxis=drug_SecondTrancheMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_drug_VestingsAxis=drug_ThirdTrancheMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">drug_VestingsAxis=drug_ThirdTrancheMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_drug_VestingsAxis=drug_FourthTrancheMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">drug_VestingsAxis=drug_FourthTrancheMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_drug_StockOptionAxis=drug_StockOptionsThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">drug_StockOptionAxis=drug_StockOptionsThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_drug_VestingsAxis=drug_FifthTrancheMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">drug_VestingsAxis=drug_FifthTrancheMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_drug_StockOptionAxis=drug_StockOptionsFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">drug_StockOptionAxis=drug_StockOptionsFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_drug_VestingsAxis=drug_SixthTrancheMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">drug_VestingsAxis=drug_SixthTrancheMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_drug_VestingsAxis=drug_SeventhTrancheMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">drug_VestingsAxis=drug_SeventhTrancheMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_drug_VestingsAxis=drug_EighthTrancheMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">drug_VestingsAxis=drug_EighthTrancheMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=drug_ThreeConsultantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=drug_ThreeConsultantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_drug_VestingsAxis=drug_NinthTrancheMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">drug_VestingsAxis=drug_NinthTrancheMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_drug_VestingsAxis=drug_TenthTrancheMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">drug_VestingsAxis=drug_TenthTrancheMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_drug_VestingsAxis=drug_EleventhTrancheMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">drug_VestingsAxis=drug_EleventhTrancheMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=drug_DirectorAndConsultantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=drug_DirectorAndConsultantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=drug_ChiefMedicalOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=drug_ChiefMedicalOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_drug_AgreementAxis=drug_DebtSettlementAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">drug_AgreementAxis=drug_DebtSettlementAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_drug_AgreementAxis=drug_EscrowAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">drug_AgreementAxis=drug_EscrowAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.4</span><table class="report" border="0" cellspacing="2" id="idm140170912045336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHARE CAPITAL - Disclosure of number and weighted average exercise prices of share options (Details) - Stock Options [Member]<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Jan. 21, 2021 </div>
<div>Shares</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>shares </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>shares </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Number of options, Beginning Balance | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement', window );">Number of options, Granted | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">895,807<span></span>
</td>
<td class="nump">150,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement', window );">Number of options, Cancelled</a></td>
<td class="num">(20,000)<span></span>
</td>
<td class="num">(20,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Number of options, Ending Balance | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,025,807<span></span>
</td>
<td class="nump">150,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019', window );">Weighted average exercise price, Beginning Balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.25<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019', window );">Weighted average exercise price, Granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.29<span></span>
</td>
<td class="nump">1.25<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019', window );">Weighted average exercise price, Cancelled</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019', window );">Weighted average exercise price, Ending Balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.90<span></span>
</td>
<td class="nump">$ 1.25<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfClassesOfShareCapitalLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfOutstandingShareOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of share options outstanding in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2020-01-01<br> -Paragraph 45<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_45_d&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2020-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_45_b_i&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2020-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause vi<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_45_b_vi&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfOutstandingShareOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of share options forfeited in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2020-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause iii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_45_b_iii&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of share options granted in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2020-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause ii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_45_b_ii&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average exercise price of share options forfeited in a share-based payment arrangement. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2020-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause iii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_45_b_iii&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average exercise price of share options granted in a share-based payment arrangement. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2020-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause ii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_45_b_ii&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average exercise price of share options outstanding in a share-based payment arrangement. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2020-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_45_b_i&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2020-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause vi<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_45_b_vi&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfShareCapitalAxis=drug_StockOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfShareCapitalAxis=drug_StockOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.4</span><table class="report" border="0" cellspacing="2" id="idm140170885215032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHARE CAPITAL - Disclosure of number of issued and outstanding stock options (Details) - Stock Options [Member]<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>shares </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2019 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Options Outstanding and Exercisable, Number of options</a></td>
<td class="nump">1,025,807<span></span>
</td>
<td class="nump">150,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019', window );">Options Outstanding and Exercisable, Remaining life (Years)</a></td>
<td class="text">4 years 3 months 10 days<span></span>
</td>
<td class="text">4 years 9 months 21 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfShareCapitalAxis=drug_StockOptionsMember', window );">September 21, 2024 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Options Outstanding and Exercisable, Number of options</a></td>
<td class="nump">8,807<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement', window );">Options Outstanding and Exercisable, Exercisable</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExercisePriceOfOutstandingShareOptions2019', window );">Options Outstanding and Exercisable, Exercise price | $ / shares</a></td>
<td class="nump">$ 7.64<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019', window );">Options Outstanding and Exercisable, Remaining life (Years)</a></td>
<td class="text">2 years 11 months 23 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfShareCapitalAxis=drug_StockOptionsMember', window );">July 23, 2025 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Options Outstanding and Exercisable, Number of options</a></td>
<td class="nump">150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement', window );">Options Outstanding and Exercisable, Exercisable</a></td>
<td class="nump">150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExercisePriceOfOutstandingShareOptions2019', window );">Options Outstanding and Exercisable, Exercise price | $ / shares</a></td>
<td class="nump">$ 1.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019', window );">Options Outstanding and Exercisable, Remaining life (Years)</a></td>
<td class="text">3 years 9 months 21 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfShareCapitalAxis=drug_StockOptionsMember', window );">November 17, 2025 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Options Outstanding and Exercisable, Number of options</a></td>
<td class="nump">447,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement', window );">Options Outstanding and Exercisable, Exercisable</a></td>
<td class="nump">30,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExercisePriceOfOutstandingShareOptions2019', window );">Options Outstanding and Exercisable, Exercise price | $ / shares</a></td>
<td class="nump">$ 1.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019', window );">Options Outstanding and Exercisable, Remaining life (Years)</a></td>
<td class="text">4 years 1 month 17 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfShareCapitalAxis=drug_StockOptionsMember', window );">April 28, 2026 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Options Outstanding and Exercisable, Number of options</a></td>
<td class="nump">240,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement', window );">Options Outstanding and Exercisable, Exercisable</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExercisePriceOfOutstandingShareOptions2019', window );">Options Outstanding and Exercisable, Exercise price | $ / shares</a></td>
<td class="nump">$ 7.60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019', window );">Options Outstanding and Exercisable, Remaining life (Years)</a></td>
<td class="text">4 years 6 months 29 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfShareCapitalAxis=drug_StockOptionsMember', window );">June 15, 2026 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Options Outstanding and Exercisable, Number of options</a></td>
<td class="nump">180,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement', window );">Options Outstanding and Exercisable, Exercisable</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExercisePriceOfOutstandingShareOptions2019', window );">Options Outstanding and Exercisable, Exercise price | $ / shares</a></td>
<td class="nump">$ 7.60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019', window );">Options Outstanding and Exercisable, Remaining life (Years)</a></td>
<td class="text">4 years 8 months 15 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfClassesOfShareCapitalLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExercisePriceOfOutstandingShareOptions2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exercise price of outstanding share options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2020-01-01<br> -Paragraph 45<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_45_d&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExercisePriceOfOutstandingShareOptions2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfOutstandingShareOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of share options outstanding in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2020-01-01<br> -Paragraph 45<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_45_d&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2020-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_45_b_i&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2020-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause vi<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_45_b_vi&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfOutstandingShareOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of share options exercisable in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2020-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause vii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_45_b_vii&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average remaining contractual life of outstanding share options. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2020-01-01<br> -Paragraph 45<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_45_d&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfShareCapitalAxis=drug_StockOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfShareCapitalAxis=drug_StockOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_drug_ExpiryDateAxis=drug_ExpiryDateTwentyOneSeptemberTwoThousandAndTwentyFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">drug_ExpiryDateAxis=drug_ExpiryDateTwentyOneSeptemberTwoThousandAndTwentyFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_drug_ExpiryDateAxis=drug_ExpiryDateTwentyThreeJulyTwoThousandAndTwentyFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">drug_ExpiryDateAxis=drug_ExpiryDateTwentyThreeJulyTwoThousandAndTwentyFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_drug_ExpiryDateAxis=drug_ExpiryDateSeventeenNovemberTwoThousandAndTwentyFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">drug_ExpiryDateAxis=drug_ExpiryDateSeventeenNovemberTwoThousandAndTwentyFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_drug_ExpiryDateAxis=drug_ExpiryDateTwentyEightAprilTwoThousandAndTwentySixMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">drug_ExpiryDateAxis=drug_ExpiryDateTwentyEightAprilTwoThousandAndTwentySixMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_drug_ExpiryDateAxis=drug_ExpiryDateFifteenJuneTwoThousandAndTwentySixMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">drug_ExpiryDateAxis=drug_ExpiryDateFifteenJuneTwoThousandAndTwentySixMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.4</span><table class="report" border="0" cellspacing="2" id="idm140170911529240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHARE CAPITAL - Disclosure of number and weighted average exercise prices of restricted share units (Details) - Restricted Share Units [Member] - shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Beginning Balance</a></td>
<td class="nump">380,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">380,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement', window );">Vested</a></td>
<td class="num">(95,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Ending Balance</a></td>
<td class="nump">285,000<span></span>
</td>
<td class="nump">380,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfShareCapitalAxis=drug_RestrictedShareUnitMember', window );">Equity settled [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Beginning Balance</a></td>
<td class="nump">380,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">380,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement', window );">Vested</a></td>
<td class="num">(95,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Ending Balance</a></td>
<td class="nump">285,000<span></span>
</td>
<td class="nump">380,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfShareCapitalAxis=drug_RestrictedShareUnitMember', window );">Cash settled [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Beginning Balance</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement', window );">Vested</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Ending Balance</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfClassesOfShareCapitalLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of other equity instruments (ie other than share options) granted in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2020-01-01<br> -Paragraph 47<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_47_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2020-01-01<br> -Paragraph 45<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of other equity instruments (ie other than share options) exercised or vested in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2020-01-01<br> -Paragraph 45<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of other equity instruments (ie other than share options) outstanding in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2020-01-01<br> -Paragraph 45<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfShareCapitalAxis=drug_RestrictedShareUnitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfShareCapitalAxis=drug_RestrictedShareUnitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=drug_EquitySettledShareBasedPaymentArrangementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=drug_EquitySettledShareBasedPaymentArrangementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=drug_CashSettledShareBasedPaymentArrangementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=drug_CashSettledShareBasedPaymentArrangementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.4</span><table class="report" border="0" cellspacing="2" id="idm140170915349672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHARE CAPITAL - Disclosure of equity-settled restricted share units fair value inputs (Details) - Restricted Share Units [Member] - Equity settled [Member]<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2020 </div>
<div>$ / shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drug_SharePriceOnGrantDateOfOtherEquityInstruments', window );">Share price on grant date</a></td>
<td class="nump">$ 1.25<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drug_ForfeitureRateOfOtherEquityInstruments', window );">Forfeiture rate</a></td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_drug_ForfeitureRateOfOtherEquityInstruments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the percentage of forfeiture of other equity instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">drug_ForfeitureRateOfOtherEquityInstruments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>drug_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_drug_SharePriceOnGrantDateOfOtherEquityInstruments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share price on grant date of Other Equity Instruments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">drug_SharePriceOnGrantDateOfOtherEquityInstruments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>drug_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfClassesOfShareCapitalLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfShareCapitalAxis=drug_RestrictedShareUnitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfShareCapitalAxis=drug_RestrictedShareUnitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=drug_EquitySettledShareBasedPaymentArrangementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=drug_EquitySettledShareBasedPaymentArrangementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.4</span><table class="report" border="0" cellspacing="2" id="idm140170914977080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHARE CAPITAL - Disclosure of share based payments recognized in the consolidated statements of comprehensive loss (Details) - CAD ($)<br></strong></div></th>
<th class="th" colspan="1">4 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees', window );">Share-based compensation expense</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 880,615<span></span>
</td>
<td class="nump">$ 161,300<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=drug_EquitySettledShareBasedPaymentArrangementsMember', window );">Equity settled [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees', window );">Share-based compensation expense</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">880,615<span></span>
</td>
<td class="nump">161,300<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=drug_EquitySettledShareBasedPaymentArrangementsMember', window );">Equity settled [Member] | Stock Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees', window );">Share-based compensation expense</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">643,963<span></span>
</td>
<td class="nump">138,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=drug_EquitySettledShareBasedPaymentArrangementsMember', window );">Equity settled [Member] | Restricted Share Units [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees', window );">Share-based compensation expense</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">236,652<span></span>
</td>
<td class="nump">23,300<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=drug_CashSettledShareBasedPaymentArrangementsMember', window );">Cash settled [Member] | Restricted Share Units [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees', window );">Share-based compensation expense</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfClassesOfShareCapitalLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense from share-based payment transactions with employees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=drug_EquitySettledShareBasedPaymentArrangementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=drug_EquitySettledShareBasedPaymentArrangementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfShareCapitalAxis=drug_StockOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfShareCapitalAxis=drug_StockOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfShareCapitalAxis=drug_RestrictedShareUnitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfShareCapitalAxis=drug_RestrictedShareUnitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=drug_CashSettledShareBasedPaymentArrangementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=drug_CashSettledShareBasedPaymentArrangementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.4</span><table class="report" border="0" cellspacing="2" id="idm140170915285592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHARE CAPITAL - Disclosure of share based payments included in the consolidated statements of comprehensive loss (Details) - CAD ($)<br></strong></div></th>
<th class="th" colspan="1">4 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees', window );">Share-based compensation expense</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 880,615<span></span>
</td>
<td class="nump">$ 161,300<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drug_ConsolidatedStatementsOfComprehensiveIncomeLossStatementLocationAxis=drug_ConsultingFeesMember', window );">Consulting fees [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees', window );">Share-based compensation expense</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">8,045<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drug_ConsolidatedStatementsOfComprehensiveIncomeLossStatementLocationAxis=drug_DirectorsCompensationMember', window );">Directors' compensation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees', window );">Share-based compensation expense</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">136,612<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drug_ConsolidatedStatementsOfComprehensiveIncomeLossStatementLocationAxis=drug_MarketingAdvertisingAndInvestorRelationsMember', window );">Marketing, advertising and investor relations [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees', window );">Share-based compensation expense</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">3,696<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drug_ConsolidatedStatementsOfComprehensiveIncomeLossStatementLocationAxis=drug_ProfessionalFeesMember', window );">Professional fees [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees', window );">Share-based compensation expense</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">23,126<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drug_ConsolidatedStatementsOfComprehensiveIncomeLossStatementLocationAxis=drug_ResearchAndDevelopmentMember', window );">Research and development [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees', window );">Share-based compensation expense</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 709,136<span></span>
</td>
<td class="nump">$ 161,300<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfClassesOfShareCapitalLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense from share-based payment transactions with employees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_drug_ConsolidatedStatementsOfComprehensiveIncomeLossStatementLocationAxis=drug_ConsultingFeesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">drug_ConsolidatedStatementsOfComprehensiveIncomeLossStatementLocationAxis=drug_ConsultingFeesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_drug_ConsolidatedStatementsOfComprehensiveIncomeLossStatementLocationAxis=drug_DirectorsCompensationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">drug_ConsolidatedStatementsOfComprehensiveIncomeLossStatementLocationAxis=drug_DirectorsCompensationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_drug_ConsolidatedStatementsOfComprehensiveIncomeLossStatementLocationAxis=drug_MarketingAdvertisingAndInvestorRelationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">drug_ConsolidatedStatementsOfComprehensiveIncomeLossStatementLocationAxis=drug_MarketingAdvertisingAndInvestorRelationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_drug_ConsolidatedStatementsOfComprehensiveIncomeLossStatementLocationAxis=drug_ProfessionalFeesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">drug_ConsolidatedStatementsOfComprehensiveIncomeLossStatementLocationAxis=drug_ProfessionalFeesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_drug_ConsolidatedStatementsOfComprehensiveIncomeLossStatementLocationAxis=drug_ResearchAndDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">drug_ConsolidatedStatementsOfComprehensiveIncomeLossStatementLocationAxis=drug_ResearchAndDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.4</span><table class="report" border="0" cellspacing="2" id="idm140170914532024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHARE CAPITAL -  Disclosure of number and weighted average exercise prices of warrants (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 06, 2021</div></th>
<th class="th"><div>Nov. 02, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drug_WeightedAverageExercisePriceOfWarrantsOutstandingInShareBasedPaymentArrangement', window );">Weighted average exercise price, Ending Balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.125<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfShareCapitalAxis=drug_WarrantsMember', window );">Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drug_NumberOfWarrantsOutstanding', window );">Number of warrants, Beginning Balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,079,600<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drug_NumberOfWarrantsIssued', window );">Number of warrants, Issued</a></td>
<td class="nump">8,807<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,709,938<span></span>
</td>
<td class="nump">4,079,600<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drug_NumberOfWarrantsIssuedToBroker', window );">Number of warrants, Issued - broker</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">132,666<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drug_NumberOfWarrantsExercised', window );">Number of warrants, Exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,948,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drug_NumberOfWarrantsOutstanding', window );">Number of warrants, Ending Balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,974,204<span></span>
</td>
<td class="nump">4,079,600<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drug_WeightedAverageExercisePriceOfWarrantsOutstandingInShareBasedPaymentArrangement', window );">Weighted average exercise price, Beginning Balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.05<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drug_WeightedAverageExercisePriceOfWarrantsIssuedInShareBasedPaymentArrangement', window );">Weighted average exercise price, Issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.46<span></span>
</td>
<td class="nump">0.05<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drug_WeightedAverageExercisePriceOfWarrantsIssuedToBrokerInShareBasedPaymentArrangement', window );">Weighted average exercise price, Issued - broker</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.57<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drug_WeightedAverageExercisePriceOfWarrantsExercisedInShareBasedPaymentArrangement', window );">Weighted average exercise price, Exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.05<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drug_WeightedAverageExercisePriceOfWarrantsOutstandingInShareBasedPaymentArrangement', window );">Weighted average exercise price, Ending Balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.35<span></span>
</td>
<td class="nump">$ 0.05<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_drug_NumberOfWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represent the number of warrants exercised.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">drug_NumberOfWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>drug_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_drug_NumberOfWarrantsIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the number of warrants Issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">drug_NumberOfWarrantsIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>drug_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_drug_NumberOfWarrantsIssuedToBroker">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the number of warrants issued to broker.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">drug_NumberOfWarrantsIssuedToBroker</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>drug_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_drug_NumberOfWarrantsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of warrants outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">drug_NumberOfWarrantsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>drug_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_drug_WeightedAverageExercisePriceOfWarrantsExercisedInShareBasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the weighted average exercise price of warrants exercised In share based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">drug_WeightedAverageExercisePriceOfWarrantsExercisedInShareBasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>drug_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_drug_WeightedAverageExercisePriceOfWarrantsIssuedInShareBasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the weighted average exercise price of warrants issued In share based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">drug_WeightedAverageExercisePriceOfWarrantsIssuedInShareBasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>drug_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_drug_WeightedAverageExercisePriceOfWarrantsIssuedToBrokerInShareBasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the weighted average exercise price of warrants issued to broker in share based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">drug_WeightedAverageExercisePriceOfWarrantsIssuedToBrokerInShareBasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>drug_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_drug_WeightedAverageExercisePriceOfWarrantsOutstandingInShareBasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the weighted average exercise price of warrants outstanding in share based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">drug_WeightedAverageExercisePriceOfWarrantsOutstandingInShareBasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>drug_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfClassesOfShareCapitalLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfShareCapitalAxis=drug_WarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfShareCapitalAxis=drug_WarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.4</span><table class="report" border="0" cellspacing="2" id="idm140170914926936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHARE CAPITAL - Disclosure of number of outstanding warrants (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Nov. 02, 2020</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Jul. 11, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drug_WeightedAverageExercisePriceOfWarrantsOutstandingInShareBasedPaymentArrangement', window );">Warrants Outstanding, Exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.125<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.05<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfShareCapitalAxis=drug_WarrantsMember', window );">Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drug_NumberOfWarrantsOutstanding', window );">Warrants Outstanding, Number of warrants</a></td>
<td class="nump">3,974,204<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,079,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drug_WeightedAverageExercisePriceOfWarrantsOutstandingInShareBasedPaymentArrangement', window );">Warrants Outstanding, Exercise price</a></td>
<td class="nump">$ 4.35<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.05<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfShareCapitalAxis=drug_WarrantsMember', window );">Warrants [Member] | July 30, 2024 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drug_NumberOfWarrantsOutstanding', window );">Warrants Outstanding, Number of warrants</a></td>
<td class="nump">2,131,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drug_WeightedAverageExercisePriceOfWarrantsOutstandingInShareBasedPaymentArrangement', window );">Warrants Outstanding, Exercise price</a></td>
<td class="nump">$ 0.05<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drug_WeightedAverageRemainingContractualLifeOfWarrants', window );">Warrants Outstanding, Remaining life (Years)</a></td>
<td class="text">2 years 9 months 29 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfShareCapitalAxis=drug_WarrantsMember', window );">Warrants [Member] | March 17, 2024 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drug_NumberOfWarrantsOutstanding', window );">Warrants Outstanding, Number of warrants</a></td>
<td class="nump">1,709,938<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drug_WeightedAverageExercisePriceOfWarrantsOutstandingInShareBasedPaymentArrangement', window );">Warrants Outstanding, Exercise price</a></td>
<td class="nump">$ 9.46<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drug_WeightedAverageRemainingContractualLifeOfWarrants', window );">Warrants Outstanding, Remaining life (Years)</a></td>
<td class="text">2 years 5 months 15 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfShareCapitalAxis=drug_WarrantsMember', window );">Warrants [Member] | March 17, 2024 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drug_NumberOfWarrantsOutstanding', window );">Warrants Outstanding, Number of warrants</a></td>
<td class="nump">132,666<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drug_WeightedAverageExercisePriceOfWarrantsOutstandingInShareBasedPaymentArrangement', window );">Warrants Outstanding, Exercise price</a></td>
<td class="nump">$ 7.57<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drug_WeightedAverageRemainingContractualLifeOfWarrants', window );">Warrants Outstanding, Remaining life (Years)</a></td>
<td class="text">2 years 5 months 15 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_drug_NumberOfWarrantsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of warrants outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">drug_NumberOfWarrantsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>drug_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_drug_WeightedAverageExercisePriceOfWarrantsOutstandingInShareBasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the weighted average exercise price of warrants outstanding in share based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">drug_WeightedAverageExercisePriceOfWarrantsOutstandingInShareBasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>drug_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_drug_WeightedAverageRemainingContractualLifeOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average remaining contractual life of warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">drug_WeightedAverageRemainingContractualLifeOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>drug_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfClassesOfShareCapitalLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfShareCapitalAxis=drug_WarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfShareCapitalAxis=drug_WarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_drug_ExpiryDateAxis=drug_ExpiryDateThirtyJulyTwoThousandAndTwentyFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">drug_ExpiryDateAxis=drug_ExpiryDateThirtyJulyTwoThousandAndTwentyFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_drug_ExpiryDateAxis=drug_ExpiryDateSeventeenMarchTwoThousandAndTwentyFourOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">drug_ExpiryDateAxis=drug_ExpiryDateSeventeenMarchTwoThousandAndTwentyFourOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_drug_ExpiryDateAxis=drug_ExpiryDateSeventeenMarchTwoThousandAndTwentyFourTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">drug_ExpiryDateAxis=drug_ExpiryDateSeventeenMarchTwoThousandAndTwentyFourTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.4</span><table class="report" border="0" cellspacing="2" id="idm140170915237576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RELATED PARTY TRANSACTIONS - Disclosure of expenses related to key management personnel (Details) - CAD ($)<br></strong></div></th>
<th class="th" colspan="1">4 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract', window );"><strong>Disclosure of transactions between related parties [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drug_KeyManagementPersonnelProfessionalFees', window );">Professional fees</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 87,074<span></span>
</td>
<td class="nump">$ 22,575<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drug_KeyManagementPersonnelResearchAndDevelopment', window );">Research and development</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">772,596<span></span>
</td>
<td class="nump">26,777<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment', window );">Share-based compensation included in directors' compensation</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">136,612<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drug_KeyManagementPersonnelCompensationShareBasedPaymentIncludedInProfessionalFees', window );">Share-based compensation included in professional fees</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">23,126<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drug_KeyManagementPersonnelCompensationShareBasedPaymentIncludedInResearchAndDevelopment', window );">Share-based compensation included in research and development</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">236,652<span></span>
</td>
<td class="nump">161,300<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_KeyManagementPersonnelCompensation', window );">Total expenses related to key management personnel</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 1,256,060<span></span>
</td>
<td class="nump">$ 210,652<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_drug_KeyManagementPersonnelCompensationShareBasedPaymentIncludedInProfessionalFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of compensation to key management personnel in the form of share-based payments included in Professional Fees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">drug_KeyManagementPersonnelCompensationShareBasedPaymentIncludedInProfessionalFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>drug_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_drug_KeyManagementPersonnelCompensationShareBasedPaymentIncludedInResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of compensation to key management personnel in the form of share-based payments included in Research And Development.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">drug_KeyManagementPersonnelCompensationShareBasedPaymentIncludedInResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>drug_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_drug_KeyManagementPersonnelProfessionalFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of compensation to key management personnel in the form of professional fees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">drug_KeyManagementPersonnelProfessionalFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>drug_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_drug_KeyManagementPersonnelResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of compensation to key management personnel in the form of Research And Development.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">drug_KeyManagementPersonnelResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>drug_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_KeyManagementPersonnelCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of compensation to key management personnel. [Refer: Key management personnel of entity or parent [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 24<br> -IssueDate 2020-01-01<br> -Paragraph 17<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=24&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_17&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_KeyManagementPersonnelCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of compensation to key management personnel in the form of share-based payments. [Refer: Key management personnel of entity or parent [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 24<br> -IssueDate 2020-01-01<br> -Paragraph 17<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=24&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_17_e&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.4</span><table class="report" border="0" cellspacing="2" id="idm140170907990840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONTRACTUAL OBLIGATIONS (Narrative) (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="8">1 Months Ended</th>
<th class="th" colspan="1">4 Months Ended</th>
<th class="th" colspan="1">5 Months Ended</th>
<th class="th" colspan="1">10 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Nov. 06, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Oct. 09, 2020 </div>
<div>USD ($) </div>
<div>Shares</div>
</th>
<th class="th">
<div>Jun. 05, 2020 </div>
<div>Shares</div>
</th>
<th class="th">
<div>Aug. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Apr. 23, 2021 </div>
<div>CAD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Apr. 23, 2021 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 31, 2021 </div>
<div>Shares</div>
</th>
<th class="th">
<div>Nov. 17, 2020 </div>
<div>USD ($) </div>
<div>Shares</div>
</th>
<th class="th">
<div>May 26, 2020 </div>
<div>CAD ($)</div>
</th>
<th class="th">
<div>May 26, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2019 </div>
<div>CAD ($)</div>
</th>
<th class="th">
<div>Apr. 28, 2021 </div>
<div>Shares</div>
</th>
<th class="th">
<div>Apr. 12, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>CAD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>CAD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drug_DisclosureOfContractualObligationLineItems', window );"><strong>Disclosure Of Contractual Obligation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 42,009<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,313,988<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 354,852<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drug_AgreementAxis=drug_OptionAgreementMember', window );">Option agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drug_DisclosureOfContractualObligationLineItems', window );"><strong>Disclosure Of Contractual Obligation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drug_NonRefundableOptionFeesPaid', window );">Non-refundable option fees paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,313<span></span>
</td>
<td class="nump">$ 15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drug_AgreementAxis=drug_LicenseAgreementMember', window );">License agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drug_DisclosureOfContractualObligationLineItems', window );"><strong>Disclosure Of Contractual Obligation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drug_SigningFee', window );">Signing fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drug_OptionFeesPaid', window );">Option fees paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drug_SigningFeeNetOfOptionFeesPaid', window );">Signing fee, net of option fees paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 105,502<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drug_SigningFeeSharesIssued', window );">Signing fee, shares issued | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">63,000<span></span>
</td>
<td class="nump">63,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drug_PercentageOfRoyaltiesOnNetSalesUnder1Billion', window );">Percentage of royalties on net sales under $1 billion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drug_PercentageOfRoyaltiesOnNetSalesOver2Billion', window );">Percentage of royalties on net sales over $2 billion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.50%<span></span>
</td>
<td class="nump">4.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drug_DescriptionOfSublicenseeRevenueOfRoyaltyPaymentAccrues', window );">Description of sublicensee revenue of royalty payment accrues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">royalty payments being credited toward the annual minimum for the license year in which the royalty payment accrues and 12% on all non-royalty revenue until the Company has raised $7.5 million and then 10% thereafter<span></span>
</td>
<td class="text">royalty payments being credited toward the annual minimum for the license year in which the royalty payment accrues and 12% on all non-royalty revenue until the Company has raised $7.5 million and then 10% thereafter<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drug_TotalAnnualMinimumRoyaltiesCurrentYears', window );">Annual minimum royalties - Years 1 and 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drug_TotalAnnualMinimumRoyaltiesYear3', window );">Annual minimum royalties - Year 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drug_TotalAnnualMinimumRoyaltiesYear4', window );">Annual minimum royalties - Year 4</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drug_TotalAnnualMinimumRoyaltiesYear5', window );">Annual minimum royalties - Year 5</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drug_TotalAnnualMinimumRoyaltiesYear6AndThereafter', window );">Annual minimum royalties - Year 6 and thereafter</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drug_TotalAnnualMinimumRoyaltiesAfterFirstCommercialSale', window );">Annual minimum royalties after first commercial sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drug_AgreementAxis=drug_PriorToSublicensingAgreementsMember', window );">Licensing agreement - prior to any sublicensing agreements, joint ventures or change of control [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drug_DisclosureOfContractualObligationLineItems', window );"><strong>Disclosure Of Contractual Obligation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drug_MilestonePaymentsUponDosingFirstPatientInPhaseITrial', window );">Milestone payments upon dosing first patient in Phase I trial</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drug_MilestonePaymentsUponDosingFirstPatientInFirstPhaseIiTrial', window );">Milestone payments upon dosing first patient in the first Phase II trial</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drug_MilestonePaymentsUponDosingFirstPatientInFirstPhaseIiiTrial', window );">Milestone payments upon dosing first patient in the first Phase III trial</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drug_MilestonePaymentsUponFirstCommercialSaleOfClinical', window );">Milestone payments upon first commercial sale of each clinical indication</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drug_AgreementAxis=drug_AfterSublicensingAgreementsMember', window );">Licensing agreement - after any sublicensing agreements, joint ventures or change of control [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drug_DisclosureOfContractualObligationLineItems', window );"><strong>Disclosure Of Contractual Obligation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drug_MilestonePaymentsUponDosingFirstPatientInFirstPhaseIiTrial', window );">Milestone payments upon dosing first patient in the first Phase II trial</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drug_MilestonePaymentsUponDosingFirstPatientInFirstPhaseIiiTrial', window );">Milestone payments upon dosing first patient in the first Phase III trial</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drug_MilestonePaymentsUponFirstCommercialSaleOfClinical', window );">Milestone payments upon first commercial sale of each clinical indication</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drug_AgreementAxis=drug_IndependentConsultantAgreementMember', window );">Independent Consultant Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drug_DisclosureOfContractualObligationLineItems', window );"><strong>Disclosure Of Contractual Obligation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement', window );">Number of options granted | Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Number of RSUs granted | Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drug_MonthlyFeeAuthorizedByBoardOfDirectors', window );">Monthly fee authorized by board of directors</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drug_AgreementAxis=drug_IndependentContractorAgreementToServeAsChiefScienceOfficerMember', window );">Independent Contractor Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drug_DisclosureOfContractualObligationLineItems', window );"><strong>Disclosure Of Contractual Obligation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drug_MonthlyFeeAuthorizedByBoardOfDirectors', window );">Monthly fee authorized by board of directors</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drug_AgreementAxis=drug_ScientificAdvisoryBoardAgreementsMember', window );">Scientific advisory board agreements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drug_DisclosureOfContractualObligationLineItems', window );"><strong>Disclosure Of Contractual Obligation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement', window );">Number of options granted | Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">130,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement', window );">Number of options cancelled | Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drug_AgreementAxis=drug_ScientificAdvisoryBoardAgreementsMember', window );">Scientific advisory board agreements [Member] | Bottom of range [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drug_DisclosureOfContractualObligationLineItems', window );"><strong>Disclosure Of Contractual Obligation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drug_AdvisorHourlyRate', window );">Advisor hourly rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drug_AgreementAxis=drug_ScientificAdvisoryBoardAgreementsMember', window );">Scientific advisory board agreements [Member] | Top of range [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drug_DisclosureOfContractualObligationLineItems', window );"><strong>Disclosure Of Contractual Obligation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drug_AdvisorHourlyRate', window );">Advisor hourly rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 160<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drug_AgreementAxis=drug_ConsultingAgreementsMember', window );">Consulting agreements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drug_DisclosureOfContractualObligationLineItems', window );"><strong>Disclosure Of Contractual Obligation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement', window );">Number of options granted | Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">90,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">302,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drug_MonthlyFeeAuthorizedByBoardOfDirectors', window );">Monthly fee authorized by board of directors</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drug_AdvisorHourlyRate', window );">Advisor hourly rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 130<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="nump">$ 66,764<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drug_AgreementAxis=drug_ConsultingAgreementsMember', window );">Consulting agreements [Member] | Bottom of range [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drug_DisclosureOfContractualObligationLineItems', window );"><strong>Disclosure Of Contractual Obligation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drug_AdvisorHourlyRate', window );">Advisor hourly rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drug_AgreementAxis=drug_ConsultingAgreementsMember', window );">Consulting agreements [Member] | Top of range [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drug_DisclosureOfContractualObligationLineItems', window );"><strong>Disclosure Of Contractual Obligation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drug_AdvisorHourlyRate', window );">Advisor hourly rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_drug_AdvisorHourlyRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Advisor hourly rate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">drug_AdvisorHourlyRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>drug_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_drug_DescriptionOfSublicenseeRevenueOfRoyaltyPaymentAccrues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Information about description of sublicensee revenue of royalty payment accrues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">drug_DescriptionOfSublicenseeRevenueOfRoyaltyPaymentAccrues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>drug_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_drug_DisclosureOfContractualObligationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">drug_DisclosureOfContractualObligationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>drug_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_drug_MilestonePaymentsUponDosingFirstPatientInFirstPhaseIiTrial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>milestone payments upon dosing first patient in the first Phase II trial.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">drug_MilestonePaymentsUponDosingFirstPatientInFirstPhaseIiTrial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>drug_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_drug_MilestonePaymentsUponDosingFirstPatientInFirstPhaseIiiTrial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>milestone payments upon dosing first patient in the first Phase III trial.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">drug_MilestonePaymentsUponDosingFirstPatientInFirstPhaseIiiTrial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>drug_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_drug_MilestonePaymentsUponDosingFirstPatientInPhaseITrial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Information about milestone payments upon dosing first patient in Phase I trial.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">drug_MilestonePaymentsUponDosingFirstPatientInPhaseITrial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>drug_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_drug_MilestonePaymentsUponFirstCommercialSaleOfClinical">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>milestone payments upon first commercial sale of clinical.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">drug_MilestonePaymentsUponFirstCommercialSaleOfClinical</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>drug_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_drug_MonthlyFeeAuthorizedByBoardOfDirectors">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Monthly Fee Authorized By Board of Directors.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">drug_MonthlyFeeAuthorizedByBoardOfDirectors</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>drug_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_drug_NonRefundableOptionFeesPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of non-refundable option fees paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">drug_NonRefundableOptionFeesPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>drug_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_drug_OptionFeesPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of option fees paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">drug_OptionFeesPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>drug_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_drug_PercentageOfRoyaltiesOnNetSalesOver2Billion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Information about percentage of royalties on net sales over 2 billion.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">drug_PercentageOfRoyaltiesOnNetSalesOver2Billion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>drug_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_drug_PercentageOfRoyaltiesOnNetSalesUnder1Billion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Information about percentage of royalties on net sales under $1 billion.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">drug_PercentageOfRoyaltiesOnNetSalesUnder1Billion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>drug_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_drug_SigningFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of signing fee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">drug_SigningFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>drug_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_drug_SigningFeeNetOfOptionFeesPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents amount paid towards signing fee net of option fees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">drug_SigningFeeNetOfOptionFeesPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>drug_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_drug_SigningFeeSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents signing fee, shares issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">drug_SigningFeeSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>drug_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_drug_TotalAnnualMinimumRoyaltiesAfterFirstCommercialSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Information about total annual minimum royalties after first commercial sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">drug_TotalAnnualMinimumRoyaltiesAfterFirstCommercialSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>drug_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_drug_TotalAnnualMinimumRoyaltiesCurrentYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Information about total annual minimum royalties current years.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">drug_TotalAnnualMinimumRoyaltiesCurrentYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>drug_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_drug_TotalAnnualMinimumRoyaltiesYear3">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Information about total annual minimum royalties current years 3.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">drug_TotalAnnualMinimumRoyaltiesYear3</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>drug_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_drug_TotalAnnualMinimumRoyaltiesYear4">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Information about total annual minimum royalties years 4.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">drug_TotalAnnualMinimumRoyaltiesYear4</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>drug_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_drug_TotalAnnualMinimumRoyaltiesYear5">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Information about total annual minimum royalties years 5.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">drug_TotalAnnualMinimumRoyaltiesYear5</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>drug_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_drug_TotalAnnualMinimumRoyaltiesYear6AndThereafter">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Information about total annual minimum royalties year 6 and thereafter</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">drug_TotalAnnualMinimumRoyaltiesYear6AndThereafter</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>drug_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of other equity instruments (ie other than share options) granted in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2020-01-01<br> -Paragraph 47<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_47_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2020-01-01<br> -Paragraph 45<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of share options forfeited in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2020-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause iii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_45_b_iii&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of share options granted in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2020-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause ii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_45_b_ii&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expenditure directly attributable to research or development activities, recognised in profit or loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2020-01-01<br> -Paragraph 126<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_126&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_drug_AgreementAxis=drug_OptionAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">drug_AgreementAxis=drug_OptionAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_drug_AgreementAxis=drug_LicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">drug_AgreementAxis=drug_LicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_drug_AgreementAxis=drug_PriorToSublicensingAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">drug_AgreementAxis=drug_PriorToSublicensingAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_drug_AgreementAxis=drug_AfterSublicensingAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">drug_AgreementAxis=drug_AfterSublicensingAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_drug_AgreementAxis=drug_IndependentConsultantAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">drug_AgreementAxis=drug_IndependentConsultantAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_drug_AgreementAxis=drug_IndependentContractorAgreementToServeAsChiefScienceOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">drug_AgreementAxis=drug_IndependentContractorAgreementToServeAsChiefScienceOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_drug_AgreementAxis=drug_ScientificAdvisoryBoardAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">drug_AgreementAxis=drug_ScientificAdvisoryBoardAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_drug_AgreementAxis=drug_ConsultingAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">drug_AgreementAxis=drug_ConsultingAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.4</span><table class="report" border="0" cellspacing="2" id="idm140170907942472">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>FINANCIAL INSTRUMENTS AND CAPITAL MANAGEMENT (Narrative) (Details)<br></strong></div></th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>CAD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>CAD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2019 </div>
<div>CAD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2018 </div>
<div>CAD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 19,760,015<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 799,929<span></span>
</td>
<td class="nump">$ 79,991<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TradeAndOtherCurrentPayables', window );">Accounts payable and accrued liabilities</a></td>
<td class="nump">638,573<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150,923<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfRisksAxis=ifrs-full_CreditRiskMember', window );">Credit risk [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 19,760,015<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfRisksAxis=ifrs-full_CurrencyRiskMember', window );">Foreign exchange risk [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Cash', window );">Cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,789,264<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TradeAndOtherCurrentPayables', window );">Accounts payable and accrued liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 420,481<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drug_PercentageOfForeignCurrencyFluctuationInUsDollarAgainstCanadianDollar', window );">Percentage of foreign currency fluctuation in US dollar against Canadian dollar</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ValueAtRisk', window );">Foreign currency fluctuation impact on net comprehensive loss</a></td>
<td class="nump">$ 301,807<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfRisksAxis=ifrs-full_LiquidityRiskMember', window );">Liquidity risk [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="nump">19,760,015<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TradeAndOtherCurrentPayables', window );">Accounts payable and accrued liabilities</a></td>
<td class="nump">$ 638,573<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_drug_PercentageOfForeignCurrencyFluctuationInUsDollarAgainstCanadianDollar">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of foreign currency fluctuation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">drug_PercentageOfForeignCurrencyFluctuationInUsDollarAgainstCanadianDollar</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>drug_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Cash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash on hand and demand deposits. [Refer: Cash on hand]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2020-01-01<br> -Paragraph 45<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Cash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2020-01-01<br> -Paragraph 45<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2020-01-01<br> -Paragraph B13<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_B13_a&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2020-01-01<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 54<br> -Subparagraph i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_54_i&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFinancialInstrumentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeAndOtherCurrentPayables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of current trade payables and current other payables. [Refer: Current trade payables; Other current payables]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 54<br> -Subparagraph k<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_54_k&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeAndOtherCurrentPayables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ValueAtRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The measure of a potential loss exposure as a result of future market movements, based on a specified confidence interval and measurement horizon.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2020-01-01<br> -Paragraph 41<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_41&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ValueAtRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfRisksAxis=ifrs-full_CreditRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfRisksAxis=ifrs-full_CreditRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfRisksAxis=ifrs-full_CurrencyRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfRisksAxis=ifrs-full_CurrencyRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfRisksAxis=ifrs-full_LiquidityRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfRisksAxis=ifrs-full_LiquidityRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.4</span><table class="report" border="0" cellspacing="2" id="idm140170911530840">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>FINANCIAL INSTRUMENTS AND CAPITAL MANAGEMENT - Disclosure of carrying value of financial assets and liabilities (Details) - CAD ($)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CurrentFinancialAssetsAtFairValueThroughProfitOrLossAbstract', window );"><strong>FVTPL</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 19,760,015<span></span>
</td>
<td class="nump">$ 799,929<span></span>
</td>
<td class="nump">$ 79,991<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CategoriesOfFinancialLiabilitiesAbstract', window );"><strong>Amortized cost</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TradeAndOtherCurrentPayables', window );">Accounts payable and accrued liabilities</a></td>
<td class="nump">638,573<span></span>
</td>
<td class="nump">150,923<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=drug_FinancialInstrumentsAtFairValueThroughProfitOrLossMember', window );">FVTPL [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CurrentFinancialAssetsAtFairValueThroughProfitOrLossAbstract', window );"><strong>FVTPL</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Cash', window );">Cash</a></td>
<td class="nump">19,673,765<span></span>
</td>
<td class="nump">799,929<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ShorttermInvestmentsClassifiedAsCashEquivalents', window );">Guaranteed investment certificate</a></td>
<td class="nump">86,250<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="nump">19,760,015<span></span>
</td>
<td class="nump">799,929<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=drug_FinancialInstrumentsAtAmortizedCostMember', window );">Amortized cost [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CategoriesOfFinancialLiabilitiesAbstract', window );"><strong>Amortized cost</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TradeAndOtherCurrentPayables', window );">Accounts payable and accrued liabilities</a></td>
<td class="nump">$ 638,573<span></span>
</td>
<td class="nump">$ 150,923<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Cash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash on hand and demand deposits. [Refer: Cash on hand]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2020-01-01<br> -Paragraph 45<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Cash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2020-01-01<br> -Paragraph 45<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2020-01-01<br> -Paragraph B13<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_B13_a&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2020-01-01<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 54<br> -Subparagraph i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_54_i&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfFinancialLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfFinancialLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentFinancialAssetsAtFairValueThroughProfitOrLossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentFinancialAssetsAtFairValueThroughProfitOrLossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ShorttermInvestmentsClassifiedAsCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A classification of cash equivalents representing short-term investments. [Refer: Cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2020-01-01<br> -Paragraph 45<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ShorttermInvestmentsClassifiedAsCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeAndOtherCurrentPayables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of current trade payables and current other payables. [Refer: Current trade payables; Other current payables]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 54<br> -Subparagraph k<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_54_k&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeAndOtherCurrentPayables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=drug_FinancialInstrumentsAtFairValueThroughProfitOrLossMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialInstrumentsAxis=drug_FinancialInstrumentsAtFairValueThroughProfitOrLossMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=drug_FinancialInstrumentsAtAmortizedCostMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialInstrumentsAxis=drug_FinancialInstrumentsAtAmortizedCostMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.4</span><table class="report" border="0" cellspacing="2" id="idm140170911646744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RESEARCH AND DEVELOPMENT - Disclosure of research and development expense (Details) - CAD ($)<br></strong></div></th>
<th class="th" colspan="1">4 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drug_ResearchAndDevelopmentLineItems', window );"><strong>Research And Development [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="nump">$ 42,009<span></span>
</td>
<td class="nump">$ 6,313,988<span></span>
</td>
<td class="nump">$ 354,852<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drug_CategoriesOfResearchAndDevelopmentExpensesAxis=drug_LaboratoryCostsMember', window );">Laboratory costs [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drug_ResearchAndDevelopmentLineItems', window );"><strong>Research And Development [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="nump">27,164<span></span>
</td>
<td class="nump">82,871<span></span>
</td>
<td class="nump">25,874<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drug_CategoriesOfResearchAndDevelopmentExpensesAxis=drug_NovelDrugDevelopmentMember', window );">Novel drug development [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drug_ResearchAndDevelopmentLineItems', window );"><strong>Research And Development [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">3,638,910<span></span>
</td>
<td class="nump">110,029<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drug_CategoriesOfResearchAndDevelopmentExpensesAxis=ifrs-full_CopyrightsPatentsAndOtherIndustrialPropertyRightsServiceAndOperatingRightsMember', window );">Patents and related payments [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drug_ResearchAndDevelopmentLineItems', window );"><strong>Research And Development [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">513,302<span></span>
</td>
<td class="nump">13,895<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drug_CategoriesOfResearchAndDevelopmentExpensesAxis=drug_SalaryAndSubcontractorsMember', window );">Salary and subcontractors [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drug_ResearchAndDevelopmentLineItems', window );"><strong>Research And Development [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="nump">14,845<span></span>
</td>
<td class="nump">1,369,769<span></span>
</td>
<td class="nump">43,754<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drug_CategoriesOfResearchAndDevelopmentExpensesAxis=drug_ShareBasedCompensationMember', window );">Share-based compensation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drug_ResearchAndDevelopmentLineItems', window );"><strong>Research And Development [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 709,136<span></span>
</td>
<td class="nump">$ 161,300<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_drug_ResearchAndDevelopmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">drug_ResearchAndDevelopmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>drug_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expenditure directly attributable to research or development activities, recognised in profit or loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2020-01-01<br> -Paragraph 126<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_126&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_drug_CategoriesOfResearchAndDevelopmentExpensesAxis=drug_LaboratoryCostsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">drug_CategoriesOfResearchAndDevelopmentExpensesAxis=drug_LaboratoryCostsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_drug_CategoriesOfResearchAndDevelopmentExpensesAxis=drug_NovelDrugDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">drug_CategoriesOfResearchAndDevelopmentExpensesAxis=drug_NovelDrugDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_drug_CategoriesOfResearchAndDevelopmentExpensesAxis=ifrs-full_CopyrightsPatentsAndOtherIndustrialPropertyRightsServiceAndOperatingRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">drug_CategoriesOfResearchAndDevelopmentExpensesAxis=ifrs-full_CopyrightsPatentsAndOtherIndustrialPropertyRightsServiceAndOperatingRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_drug_CategoriesOfResearchAndDevelopmentExpensesAxis=drug_SalaryAndSubcontractorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">drug_CategoriesOfResearchAndDevelopmentExpensesAxis=drug_SalaryAndSubcontractorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_drug_CategoriesOfResearchAndDevelopmentExpensesAxis=drug_ShareBasedCompensationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">drug_CategoriesOfResearchAndDevelopmentExpensesAxis=drug_ShareBasedCompensationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.4</span><table class="report" border="0" cellspacing="2" id="idm140170915287832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PREMISES LEASES (Narrative) (Details)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">4 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>CAD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfAssetsAxis=drug_CommercialLaboratoryLeaseMember', window );">Commercial laboratory [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems', window );"><strong>Disclosure of quantitative information about right-of-use assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drug_TermOfLease', window );">Term of lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">1 year<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drug_MonthlyBaseRent', window );">Monthly base rent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,709<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drug_LeaseCost', window );">Lease cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,003<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfAssetsAxis=ifrs-full_BuildingsMember', window );">Apartment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems', window );"><strong>Disclosure of quantitative information about right-of-use assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drug_TermOfLease', window );">Term of lease</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drug_MonthlyBaseRent', window );">Monthly base rent</a></td>
<td class="nump">$ 5,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drug_LeaseCost', window );">Lease cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_drug_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">drug_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>drug_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_drug_MonthlyBaseRent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of monthly base rent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">drug_MonthlyBaseRent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>drug_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_drug_TermOfLease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">drug_TermOfLease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>drug_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfAssetsAxis=drug_CommercialLaboratoryLeaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfAssetsAxis=drug_CommercialLaboratoryLeaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfAssetsAxis=ifrs-full_BuildingsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfAssetsAxis=ifrs-full_BuildingsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.4</span><table class="report" border="0" cellspacing="2" id="idm140170913231608">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>INCOME TAXES (Narrative) (Details) - CAD ($)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drug_IncomeTaxAuthorityNameOfCountryAxis=drug_TaxAuthorityOfCanadaMember', window );">Tax authority of Canada [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drug_NonCapitalLossCarryForwards', window );">Non-capital loss carry-forwards</a></td>
<td class="nump">$ 9,940,000<span></span>
</td>
<td class="nump">$ 403,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drug_IncomeTaxAuthorityNameOfCountryAxis=drug_TaxAuthorityOfUnitedStatesMember', window );">Tax authority of United States [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drug_NonCapitalLossCarryForwards', window );">Non-capital loss carry-forwards</a></td>
<td class="nump">30,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drug_IncomeTaxAuthorityNameOfCountryAxis=drug_TaxAuthorityOfAustraliaMember', window );">Tax authority of Australia [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drug_NonCapitalLossCarryForwards', window );">Non-capital loss carry-forwards</a></td>
<td class="nump">$ 6,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_drug_NonCapitalLossCarryForwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amont of non-capital loss carry forwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">drug_NonCapitalLossCarryForwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>drug_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_drug_IncomeTaxAuthorityNameOfCountryAxis=drug_TaxAuthorityOfCanadaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">drug_IncomeTaxAuthorityNameOfCountryAxis=drug_TaxAuthorityOfCanadaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_drug_IncomeTaxAuthorityNameOfCountryAxis=drug_TaxAuthorityOfUnitedStatesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">drug_IncomeTaxAuthorityNameOfCountryAxis=drug_TaxAuthorityOfUnitedStatesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_drug_IncomeTaxAuthorityNameOfCountryAxis=drug_TaxAuthorityOfAustraliaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">drug_IncomeTaxAuthorityNameOfCountryAxis=drug_TaxAuthorityOfAustraliaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.4</span><table class="report" border="0" cellspacing="2" id="idm140170924043928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES  - Disclosure of reconciliation of the expected income tax recovery to the actual income tax recovery (Details) - CAD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract', window );"><strong>Major components of tax expense (income) [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AccountingProfit', window );">Net loss</a></td>
<td class="num">$ (8,650,763)<span></span>
</td>
<td class="num">$ (480,377)<span></span>
</td>
<td class="num">$ (78,717)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ApplicableTaxRate', window );">Statutory tax rate</a></td>
<td class="nump">27.75%<span></span>
</td>
<td class="nump">27.00%<span></span>
</td>
<td class="nump">27.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TaxExpenseIncomeAtApplicableTaxRate', window );">Expected income tax recovery</a></td>
<td class="num">$ (2,400,311)<span></span>
</td>
<td class="num">$ (129,702)<span></span>
</td>
<td class="num">$ (21,254)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drug_TaxEffectOfDeductibleAndNotDeductibleItems', window );">Deductible and non-deductible items</a></td>
<td class="num">(256,939)<span></span>
</td>
<td class="nump">42,136<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drug_TaxEffectOfChangeInDeferredTaxAssetsNotRecognized', window );">Change in deferred tax assets not recognized</a></td>
<td class="nump">2,657,250<span></span>
</td>
<td class="nump">87,566<span></span>
</td>
<td class="nump">21,254<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncomeTaxExpenseContinuingOperations', window );">Total income tax recovery</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_drug_TaxEffectOfChangeInDeferredTaxAssetsNotRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount that represents the difference between the tax expense (income) and the product of the accounting profit multiplied by the applicable tax rate(s) that relates to deferred tax assets not recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">drug_TaxEffectOfChangeInDeferredTaxAssetsNotRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>drug_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_drug_TaxEffectOfDeductibleAndNotDeductibleItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount that represents the difference between the tax expense (income) and the product of the accounting profit multiplied by the applicable tax rate(s) that relates to expenses deductible and not deductible items in determining taxable profit (tax loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">drug_TaxEffectOfDeductibleAndNotDeductibleItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>drug_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AccountingProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of profit (loss) for a period before deducting tax expense. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2020-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause ii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_81_c_ii&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2020-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_81_c_i&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AccountingProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ApplicableTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The applicable income tax rate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2020-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause ii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_81_c_ii&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ApplicableTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncomeTaxExpenseContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount included in the determination of profit (loss) for the period in respect of current tax and deferred tax. [Refer: Current tax expense (income); Deferred tax expense (income)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 26<br> -IssueDate 2020-01-01<br> -Paragraph 35<br> -Subparagraph b<br> -Clause viii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=26&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_35_b_viii&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2020-01-01<br> -Paragraph 23<br> -Subparagraph h<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_23_h&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2020-01-01<br> -Paragraph 79<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_79&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2020-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_81_c_i&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 82<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_82_d&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2020-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause ii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_81_c_ii&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2020-01-01<br> -Paragraph B13<br> -Subparagraph g<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_B13_g&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncomeTaxExpenseContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TaxExpenseIncomeAtApplicableTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The product of the accounting profit multiplied by the applicable tax rate(s). [Refer: Accounting profit; Applicable tax rate]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2020-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_81_c_i&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TaxExpenseIncomeAtApplicableTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.4</span><table class="report" border="0" cellspacing="2" id="idm140170915025256">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>INCOME TAXES - Disclosure of deductible temporary differences for which no deferred tax has been recognized (Details) - CAD ($)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised', window );">Temporary differences not recognized</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=ifrs-full_UnusedTaxLossesMember', window );">Non-capital losses [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised', window );">Temporary differences not recognized</a></td>
<td class="nump">9,976,000<span></span>
</td>
<td class="nump">403,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=drug_TemporaryDifferencesShareIssueCostsMember', window );">Share issue costs [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised', window );">Temporary differences not recognized</a></td>
<td class="nump">1,448,000<span></span>
</td>
<td class="nump">4,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=drug_TemporaryDifferencesIntangibleAssetsMember', window );">Intangible assets [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised', window );">Temporary differences not recognized</a></td>
<td class="num">(1,000)<span></span>
</td>
<td class="num">(2,000)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=drug_TemporaryDifferencesValuationAllowanceMember', window );">Valuation allowance [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised', window );">Temporary differences not recognized</a></td>
<td class="num">$ (11,423,000)<span></span>
</td>
<td class="num">$ (405,000)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of deductible temporary differences for which no deferred tax asset is recognised in the statement of financial position. [Refer: Temporary differences [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2020-01-01<br> -Paragraph 81<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_81_e&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=ifrs-full_UnusedTaxLossesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=ifrs-full_UnusedTaxLossesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=drug_TemporaryDifferencesShareIssueCostsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=drug_TemporaryDifferencesShareIssueCostsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=drug_TemporaryDifferencesIntangibleAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=drug_TemporaryDifferencesIntangibleAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=drug_TemporaryDifferencesValuationAllowanceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=drug_TemporaryDifferencesValuationAllowanceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.4</span><table class="report" border="0" cellspacing="2" id="idm140170924337240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES  - Disclosure of non-capital loss carry-forwards expiry (Details) - Tax authority of Canada [Member] - CAD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drug_NonCapitalLossCarryForwards', window );">Non-Capital Losses</a></td>
<td class="nump">$ 9,940,000<span></span>
</td>
<td class="nump">$ 403,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drug_NonCapitalLossCarryForwardsYearOfOriginAxis=drug_TaxYearOfOrigin2019Member', window );">2019 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drug_NonCapitalLossCarryForwardsYearOfExpiry', window );">Year of Expiry</a></td>
<td class="text">2039<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drug_NonCapitalLossCarryForwards', window );">Non-Capital Losses</a></td>
<td class="nump">$ 79,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drug_NonCapitalLossCarryForwardsYearOfOriginAxis=drug_TaxYearOfOrigin2020Member', window );">2020 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drug_NonCapitalLossCarryForwardsYearOfExpiry', window );">Year of Expiry</a></td>
<td class="text">2040<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drug_NonCapitalLossCarryForwards', window );">Non-Capital Losses</a></td>
<td class="nump">$ 324,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drug_NonCapitalLossCarryForwardsYearOfOriginAxis=drug_TaxYearOfOrigin2021Member', window );">2021 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drug_NonCapitalLossCarryForwardsYearOfExpiry', window );">Year of Expiry</a></td>
<td class="text">2041<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drug_NonCapitalLossCarryForwards', window );">Non-Capital Losses</a></td>
<td class="nump">$ 9,537,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_drug_NonCapitalLossCarryForwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amont of non-capital loss carry forwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">drug_NonCapitalLossCarryForwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>drug_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_drug_NonCapitalLossCarryForwardsYearOfExpiry">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Year of expiry for Non-capital loss carry forwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">drug_NonCapitalLossCarryForwardsYearOfExpiry</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>drug_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_drug_IncomeTaxAuthorityNameOfCountryAxis=drug_TaxAuthorityOfCanadaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">drug_IncomeTaxAuthorityNameOfCountryAxis=drug_TaxAuthorityOfCanadaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_drug_NonCapitalLossCarryForwardsYearOfOriginAxis=drug_TaxYearOfOrigin2019Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">drug_NonCapitalLossCarryForwardsYearOfOriginAxis=drug_TaxYearOfOrigin2019Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_drug_NonCapitalLossCarryForwardsYearOfOriginAxis=drug_TaxYearOfOrigin2020Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">drug_NonCapitalLossCarryForwardsYearOfOriginAxis=drug_TaxYearOfOrigin2020Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_drug_NonCapitalLossCarryForwardsYearOfOriginAxis=drug_TaxYearOfOrigin2021Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">drug_NonCapitalLossCarryForwardsYearOfOriginAxis=drug_TaxYearOfOrigin2021Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.4</span><table class="report" border="0" cellspacing="2" id="idm140170924336152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUBSEQUENT EVENTS (Narrative) (Details) - Subsequent events [Member] - Letter agreement [Member] - CAD ($)<br></strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Nov. 09, 2021</div></th>
<th class="th"><div>Nov. 01, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems', window );"><strong>Disclosure of non-adjusting events after reporting period [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drug_AmountOfNonRefundableMonthlyRetainerAsServiceCompensation', window );">Amount of non-refundable monthly retainer as service compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drug_NumberOfRestrictedStockIssuedForCompensation', window );">Number of restricted stock issued for compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,200<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drug_NumberOfWarrantsExercised', window );">Number of warrants exercised</a></td>
<td class="nump">12,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drug_GrossProceedsFromWarrantsExercised', window );">Gross proceeds from warrants exercised</a></td>
<td class="nump">$ 118,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis=drug_SubsequentEventsMember', window );">January 1, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems', window );"><strong>Disclosure of non-adjusting events after reporting period [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drug_NumberOfRestrictedStockIssuedForCompensation', window );">Number of restricted stock issued for compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,800<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis=drug_SubsequentEventsMember', window );">April 1, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems', window );"><strong>Disclosure of non-adjusting events after reporting period [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drug_NumberOfRestrictedStockIssuedForCompensation', window );">Number of restricted stock issued for compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,700<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis=drug_SubsequentEventsMember', window );">July 1, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems', window );"><strong>Disclosure of non-adjusting events after reporting period [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drug_NumberOfRestrictedStockIssuedForCompensation', window );">Number of restricted stock issued for compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,700<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_drug_AmountOfNonRefundableMonthlyRetainerAsServiceCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of non-refundable monthly retainer as service compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">drug_AmountOfNonRefundableMonthlyRetainerAsServiceCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>drug_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_drug_GrossProceedsFromWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represent the gross proceeds from warrants exercised.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">drug_GrossProceedsFromWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>drug_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_drug_NumberOfRestrictedStockIssuedForCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of restricted stock issued for compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">drug_NumberOfRestrictedStockIssuedForCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>drug_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_drug_NumberOfWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represent the number of warrants exercised.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">drug_NumberOfWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>drug_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis=drug_SubsequentEventsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NonadjustingEventsAfterReportingPeriodAxis=drug_SubsequentEventsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_drug_TypeOfArrangementsAxis=drug_LetterAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">drug_TypeOfArrangementsAxis=drug_LetterAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_drug_TranchesAxis=drug_FirstTrancheMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">drug_TranchesAxis=drug_FirstTrancheMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_drug_TranchesAxis=drug_SecondTrancheMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">drug_TranchesAxis=drug_SecondTrancheMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_drug_TranchesAxis=drug_ThirdTrancheMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">drug_TranchesAxis=drug_ThirdTrancheMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>form20fa_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31"
  xmlns:drug="http://brightmindsbio.com/20210930"
  xmlns:ifrs-full="http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2020-01-31"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="drug-20210930.xsd" xlink:type="simple"/>
    <context id="C_20201001to20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001827401</identifier>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="C_20201001to20210930_deiEntityAddressesAddressTypeAxis_deiBusinessContactMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001827401</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:EntityAddressesAddressTypeAxis">dei:BusinessContactMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="C_20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001827401</identifier>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="C_20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001827401</identifier>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="C_20191001to20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001827401</identifier>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="C_20190601to20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001827401</identifier>
        </entity>
        <period>
            <startDate>2019-06-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="C_20190531_ifrsfullComponentsOfEquityAxis_ifrsfullIssuedCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001827401</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-05-31</instant>
        </period>
    </context>
    <context id="C_20190531_ifrsfullComponentsOfEquityAxis_drugSubscriptionReceivableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001827401</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">drug:SubscriptionReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-05-31</instant>
        </period>
    </context>
    <context id="C_20190531_ifrsfullComponentsOfEquityAxis_drugSubscriptionReceivedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001827401</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">drug:SubscriptionReceivedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-05-31</instant>
        </period>
    </context>
    <context id="C_20190531_ifrsfullComponentsOfEquityAxis_ifrsfullOtherReservesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001827401</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OtherReservesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-05-31</instant>
        </period>
    </context>
    <context id="C_20190531_ifrsfullComponentsOfEquityAxis_ifrsfullRetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001827401</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-05-31</instant>
        </period>
    </context>
    <context id="C_20190531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001827401</identifier>
        </entity>
        <period>
            <instant>2019-05-31</instant>
        </period>
    </context>
    <context id="C_20190601to20190930_ifrsfullComponentsOfEquityAxis_ifrsfullIssuedCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001827401</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-06-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="C_20190601to20190930_ifrsfullComponentsOfEquityAxis_drugSubscriptionReceivableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001827401</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">drug:SubscriptionReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-06-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="C_20190601to20190930_ifrsfullComponentsOfEquityAxis_drugSubscriptionReceivedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001827401</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">drug:SubscriptionReceivedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-06-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="C_20190601to20190930_ifrsfullComponentsOfEquityAxis_ifrsfullOtherReservesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001827401</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OtherReservesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-06-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="C_20190601to20190930_ifrsfullComponentsOfEquityAxis_ifrsfullRetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001827401</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-06-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="C_20190930_ifrsfullComponentsOfEquityAxis_ifrsfullIssuedCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001827401</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="C_20190930_ifrsfullComponentsOfEquityAxis_drugSubscriptionReceivableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001827401</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">drug:SubscriptionReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="C_20190930_ifrsfullComponentsOfEquityAxis_drugSubscriptionReceivedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001827401</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">drug:SubscriptionReceivedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="C_20190930_ifrsfullComponentsOfEquityAxis_ifrsfullOtherReservesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001827401</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OtherReservesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="C_20190930_ifrsfullComponentsOfEquityAxis_ifrsfullRetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001827401</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="C_20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001827401</identifier>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="C_20191001to20200930_ifrsfullComponentsOfEquityAxis_ifrsfullIssuedCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001827401</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="C_20191001to20200930_ifrsfullComponentsOfEquityAxis_drugSubscriptionReceivableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001827401</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">drug:SubscriptionReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="C_20191001to20200930_ifrsfullComponentsOfEquityAxis_drugSubscriptionReceivedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001827401</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">drug:SubscriptionReceivedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="C_20191001to20200930_ifrsfullComponentsOfEquityAxis_ifrsfullOtherReservesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001827401</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OtherReservesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="C_20191001to20200930_ifrsfullComponentsOfEquityAxis_ifrsfullRetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001827401</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="C_20200930_ifrsfullComponentsOfEquityAxis_ifrsfullIssuedCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001827401</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="C_20200930_ifrsfullComponentsOfEquityAxis_drugSubscriptionReceivableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001827401</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">drug:SubscriptionReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="C_20200930_ifrsfullComponentsOfEquityAxis_drugSubscriptionReceivedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001827401</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">drug:SubscriptionReceivedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="C_20200930_ifrsfullComponentsOfEquityAxis_ifrsfullOtherReservesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001827401</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OtherReservesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="C_20200930_ifrsfullComponentsOfEquityAxis_ifrsfullRetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001827401</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="C_20201001to20210930_ifrsfullComponentsOfEquityAxis_ifrsfullIssuedCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001827401</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="C_20201001to20210930_ifrsfullComponentsOfEquityAxis_drugSubscriptionReceivableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001827401</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">drug:SubscriptionReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="C_20201001to20210930_ifrsfullComponentsOfEquityAxis_drugSubscriptionReceivedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001827401</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">drug:SubscriptionReceivedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="C_20201001to20210930_ifrsfullComponentsOfEquityAxis_ifrsfullOtherReservesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001827401</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OtherReservesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="C_20201001to20210930_ifrsfullComponentsOfEquityAxis_ifrsfullRetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001827401</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="C_20210930_ifrsfullComponentsOfEquityAxis_ifrsfullIssuedCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001827401</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="C_20210930_ifrsfullComponentsOfEquityAxis_drugSubscriptionReceivableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001827401</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">drug:SubscriptionReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="C_20210930_ifrsfullComponentsOfEquityAxis_drugSubscriptionReceivedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001827401</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">drug:SubscriptionReceivedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="C_20210930_ifrsfullComponentsOfEquityAxis_ifrsfullOtherReservesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001827401</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OtherReservesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="C_20210930_ifrsfullComponentsOfEquityAxis_ifrsfullRetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001827401</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="C_20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001827401</identifier>
        </entity>
        <period>
            <instant>2018-09-30</instant>
        </period>
    </context>
    <context id="C_20210930to20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001827401</identifier>
        </entity>
        <period>
            <startDate>2021-09-30</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="C_20190425_ifrsfullCategoriesOfRelatedPartiesAxis_drugPsilocybinlabsLtdMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001827401</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">drug:PsilocybinlabsLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-04-25</instant>
        </period>
    </context>
    <context id="C_20190807_ifrsfullCategoriesOfRelatedPartiesAxis_drugPsilocybinlabsLtdMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001827401</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">drug:PsilocybinlabsLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-08-07</instant>
        </period>
    </context>
    <context id="C_20190930_ifrsfullClassesOfShareCapitalAxis_drugStockOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001827401</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">drug:StockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="C_20191001to20200930_ifrsfullClassesOfShareCapitalAxis_drugStockOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001827401</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">drug:StockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="C_20200930_ifrsfullClassesOfShareCapitalAxis_drugStockOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001827401</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">drug:StockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="C_20201001to20210930_ifrsfullClassesOfShareCapitalAxis_drugStockOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001827401</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">drug:StockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="C_20210930_ifrsfullClassesOfShareCapitalAxis_drugStockOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001827401</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">drug:StockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="C_20210930_drugExpiryDateAxis_drugExpiryDateTwentyOneSeptemberTwoThousandAndTwentyFourMember_ifrsfullClassesOfShareCapitalAxis_drugStockOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001827401</identifier>
            <segment>
                <xbrldi:explicitMember dimension="drug:ExpiryDateAxis">drug:ExpiryDateTwentyOneSeptemberTwoThousandAndTwentyFourMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">drug:StockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="C_20210930_drugExpiryDateAxis_drugExpiryDateTwentyThreeJulyTwoThousandAndTwentyFiveMember_ifrsfullClassesOfShareCapitalAxis_drugStockOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001827401</identifier>
            <segment>
                <xbrldi:explicitMember dimension="drug:ExpiryDateAxis">drug:ExpiryDateTwentyThreeJulyTwoThousandAndTwentyFiveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">drug:StockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="C_20210930_drugExpiryDateAxis_drugExpiryDateSeventeenNovemberTwoThousandAndTwentyFiveMember_ifrsfullClassesOfShareCapitalAxis_drugStockOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001827401</identifier>
            <segment>
                <xbrldi:explicitMember dimension="drug:ExpiryDateAxis">drug:ExpiryDateSeventeenNovemberTwoThousandAndTwentyFiveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">drug:StockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="C_20210930_drugExpiryDateAxis_drugExpiryDateTwentyEightAprilTwoThousandAndTwentySixMember_ifrsfullClassesOfShareCapitalAxis_drugStockOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001827401</identifier>
            <segment>
                <xbrldi:explicitMember dimension="drug:ExpiryDateAxis">drug:ExpiryDateTwentyEightAprilTwoThousandAndTwentySixMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">drug:StockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="C_20210930_drugExpiryDateAxis_drugExpiryDateFifteenJuneTwoThousandAndTwentySixMember_ifrsfullClassesOfShareCapitalAxis_drugStockOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001827401</identifier>
            <segment>
                <xbrldi:explicitMember dimension="drug:ExpiryDateAxis">drug:ExpiryDateFifteenJuneTwoThousandAndTwentySixMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">drug:StockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="C_20201001to20210930_drugExpiryDateAxis_drugExpiryDateTwentyOneSeptemberTwoThousandAndTwentyFourMember_ifrsfullClassesOfShareCapitalAxis_drugStockOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001827401</identifier>
            <segment>
                <xbrldi:explicitMember dimension="drug:ExpiryDateAxis">drug:ExpiryDateTwentyOneSeptemberTwoThousandAndTwentyFourMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">drug:StockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="C_20201001to20210930_drugExpiryDateAxis_drugExpiryDateTwentyThreeJulyTwoThousandAndTwentyFiveMember_ifrsfullClassesOfShareCapitalAxis_drugStockOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001827401</identifier>
            <segment>
                <xbrldi:explicitMember dimension="drug:ExpiryDateAxis">drug:ExpiryDateTwentyThreeJulyTwoThousandAndTwentyFiveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">drug:StockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="C_20201001to20210930_drugExpiryDateAxis_drugExpiryDateSeventeenNovemberTwoThousandAndTwentyFiveMember_ifrsfullClassesOfShareCapitalAxis_drugStockOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001827401</identifier>
            <segment>
                <xbrldi:explicitMember dimension="drug:ExpiryDateAxis">drug:ExpiryDateSeventeenNovemberTwoThousandAndTwentyFiveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">drug:StockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="C_20201001to20210930_drugExpiryDateAxis_drugExpiryDateTwentyEightAprilTwoThousandAndTwentySixMember_ifrsfullClassesOfShareCapitalAxis_drugStockOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001827401</identifier>
            <segment>
                <xbrldi:explicitMember dimension="drug:ExpiryDateAxis">drug:ExpiryDateTwentyEightAprilTwoThousandAndTwentySixMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">drug:StockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="C_20201001to20210930_drugExpiryDateAxis_drugExpiryDateFifteenJuneTwoThousandAndTwentySixMember_ifrsfullClassesOfShareCapitalAxis_drugStockOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001827401</identifier>
            <segment>
                <xbrldi:explicitMember dimension="drug:ExpiryDateAxis">drug:ExpiryDateFifteenJuneTwoThousandAndTwentySixMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">drug:StockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="C_20190930_ifrsfullClassesOfShareCapitalAxis_drugRestrictedShareUnitMember_ifrsfullTypesOfSharebasedPaymentArrangementsAxis_drugEquitySettledShareBasedPaymentArrangementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001827401</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">drug:RestrictedShareUnitMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">drug:EquitySettledShareBasedPaymentArrangementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="C_20190930_ifrsfullClassesOfShareCapitalAxis_drugRestrictedShareUnitMember_ifrsfullTypesOfSharebasedPaymentArrangementsAxis_drugCashSettledShareBasedPaymentArrangementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001827401</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">drug:RestrictedShareUnitMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">drug:CashSettledShareBasedPaymentArrangementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="C_20190930_ifrsfullClassesOfShareCapitalAxis_drugRestrictedShareUnitMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001827401</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">drug:RestrictedShareUnitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="C_20191001to20200930_ifrsfullClassesOfShareCapitalAxis_drugRestrictedShareUnitMember_ifrsfullTypesOfSharebasedPaymentArrangementsAxis_drugEquitySettledShareBasedPaymentArrangementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001827401</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">drug:RestrictedShareUnitMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">drug:EquitySettledShareBasedPaymentArrangementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="C_20191001to20200930_ifrsfullClassesOfShareCapitalAxis_drugRestrictedShareUnitMember_ifrsfullTypesOfSharebasedPaymentArrangementsAxis_drugCashSettledShareBasedPaymentArrangementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001827401</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">drug:RestrictedShareUnitMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">drug:CashSettledShareBasedPaymentArrangementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="C_20191001to20200930_ifrsfullClassesOfShareCapitalAxis_drugRestrictedShareUnitMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001827401</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">drug:RestrictedShareUnitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="C_20200930_ifrsfullClassesOfShareCapitalAxis_drugRestrictedShareUnitMember_ifrsfullTypesOfSharebasedPaymentArrangementsAxis_drugEquitySettledShareBasedPaymentArrangementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001827401</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">drug:RestrictedShareUnitMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">drug:EquitySettledShareBasedPaymentArrangementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="C_20200930_ifrsfullClassesOfShareCapitalAxis_drugRestrictedShareUnitMember_ifrsfullTypesOfSharebasedPaymentArrangementsAxis_drugCashSettledShareBasedPaymentArrangementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001827401</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">drug:RestrictedShareUnitMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">drug:CashSettledShareBasedPaymentArrangementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="C_20200930_ifrsfullClassesOfShareCapitalAxis_drugRestrictedShareUnitMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001827401</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">drug:RestrictedShareUnitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="C_20201001to20210930_ifrsfullClassesOfShareCapitalAxis_drugRestrictedShareUnitMember_ifrsfullTypesOfSharebasedPaymentArrangementsAxis_drugEquitySettledShareBasedPaymentArrangementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001827401</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">drug:RestrictedShareUnitMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">drug:EquitySettledShareBasedPaymentArrangementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="C_20201001to20210930_ifrsfullClassesOfShareCapitalAxis_drugRestrictedShareUnitMember_ifrsfullTypesOfSharebasedPaymentArrangementsAxis_drugCashSettledShareBasedPaymentArrangementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001827401</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">drug:RestrictedShareUnitMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">drug:CashSettledShareBasedPaymentArrangementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="C_20201001to20210930_ifrsfullClassesOfShareCapitalAxis_drugRestrictedShareUnitMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001827401</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">drug:RestrictedShareUnitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="C_20210930_ifrsfullClassesOfShareCapitalAxis_drugRestrictedShareUnitMember_ifrsfullTypesOfSharebasedPaymentArrangementsAxis_drugEquitySettledShareBasedPaymentArrangementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001827401</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">drug:RestrictedShareUnitMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">drug:EquitySettledShareBasedPaymentArrangementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="C_20210930_ifrsfullClassesOfShareCapitalAxis_drugRestrictedShareUnitMember_ifrsfullTypesOfSharebasedPaymentArrangementsAxis_drugCashSettledShareBasedPaymentArrangementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001827401</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">drug:RestrictedShareUnitMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">drug:CashSettledShareBasedPaymentArrangementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="C_20210930_ifrsfullClassesOfShareCapitalAxis_drugRestrictedShareUnitMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001827401</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">drug:RestrictedShareUnitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="C_20201001to20210930_ifrsfullClassesOfShareCapitalAxis_drugStockOptionsMember_ifrsfullTypesOfSharebasedPaymentArrangementsAxis_drugEquitySettledShareBasedPaymentArrangementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001827401</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">drug:StockOptionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">drug:EquitySettledShareBasedPaymentArrangementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="C_20191001to20200930_ifrsfullClassesOfShareCapitalAxis_drugStockOptionsMember_ifrsfullTypesOfSharebasedPaymentArrangementsAxis_drugEquitySettledShareBasedPaymentArrangementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001827401</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">drug:StockOptionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">drug:EquitySettledShareBasedPaymentArrangementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="C_20190531to20190930_ifrsfullClassesOfShareCapitalAxis_drugStockOptionsMember_ifrsfullTypesOfSharebasedPaymentArrangementsAxis_drugEquitySettledShareBasedPaymentArrangementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001827401</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">drug:StockOptionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">drug:EquitySettledShareBasedPaymentArrangementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-05-31</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="C_20190531to20190930_ifrsfullClassesOfShareCapitalAxis_drugRestrictedShareUnitMember_ifrsfullTypesOfSharebasedPaymentArrangementsAxis_drugEquitySettledShareBasedPaymentArrangementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001827401</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">drug:RestrictedShareUnitMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">drug:EquitySettledShareBasedPaymentArrangementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-05-31</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="C_20201001to20210930_ifrsfullTypesOfSharebasedPaymentArrangementsAxis_drugEquitySettledShareBasedPaymentArrangementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001827401</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">drug:EquitySettledShareBasedPaymentArrangementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="C_20191001to20200930_ifrsfullTypesOfSharebasedPaymentArrangementsAxis_drugEquitySettledShareBasedPaymentArrangementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001827401</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">drug:EquitySettledShareBasedPaymentArrangementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="C_20190531to20190930_ifrsfullTypesOfSharebasedPaymentArrangementsAxis_drugEquitySettledShareBasedPaymentArrangementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001827401</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">drug:EquitySettledShareBasedPaymentArrangementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-05-31</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="C_20190531to20190930_ifrsfullClassesOfShareCapitalAxis_drugRestrictedShareUnitMember_ifrsfullTypesOfSharebasedPaymentArrangementsAxis_drugCashSettledShareBasedPaymentArrangementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001827401</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">drug:RestrictedShareUnitMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">drug:CashSettledShareBasedPaymentArrangementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-05-31</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="C_20190531to20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001827401</identifier>
        </entity>
        <period>
            <startDate>2019-05-31</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="C_20201001to20210930_drugConsolidatedStatementsOfComprehensiveIncomeLossStatementLocationAxis_drugConsultingFeesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001827401</identifier>
            <segment>
                <xbrldi:explicitMember dimension="drug:ConsolidatedStatementsOfComprehensiveIncomeLossStatementLocationAxis">drug:ConsultingFeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="C_20191001to20200930_drugConsolidatedStatementsOfComprehensiveIncomeLossStatementLocationAxis_drugConsultingFeesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001827401</identifier>
            <segment>
                <xbrldi:explicitMember dimension="drug:ConsolidatedStatementsOfComprehensiveIncomeLossStatementLocationAxis">drug:ConsultingFeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="C_20190531to20190930_drugConsolidatedStatementsOfComprehensiveIncomeLossStatementLocationAxis_drugConsultingFeesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001827401</identifier>
            <segment>
                <xbrldi:explicitMember dimension="drug:ConsolidatedStatementsOfComprehensiveIncomeLossStatementLocationAxis">drug:ConsultingFeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-05-31</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="C_20201001to20210930_drugConsolidatedStatementsOfComprehensiveIncomeLossStatementLocationAxis_drugDirectorsCompensationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001827401</identifier>
            <segment>
                <xbrldi:explicitMember dimension="drug:ConsolidatedStatementsOfComprehensiveIncomeLossStatementLocationAxis">drug:DirectorsCompensationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="C_20191001to20200930_drugConsolidatedStatementsOfComprehensiveIncomeLossStatementLocationAxis_drugDirectorsCompensationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001827401</identifier>
            <segment>
                <xbrldi:explicitMember dimension="drug:ConsolidatedStatementsOfComprehensiveIncomeLossStatementLocationAxis">drug:DirectorsCompensationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="C_20190531to20190930_drugConsolidatedStatementsOfComprehensiveIncomeLossStatementLocationAxis_drugDirectorsCompensationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001827401</identifier>
            <segment>
                <xbrldi:explicitMember dimension="drug:ConsolidatedStatementsOfComprehensiveIncomeLossStatementLocationAxis">drug:DirectorsCompensationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-05-31</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="C_20201001to20210930_drugConsolidatedStatementsOfComprehensiveIncomeLossStatementLocationAxis_drugMarketingAdvertisingAndInvestorRelationsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001827401</identifier>
            <segment>
                <xbrldi:explicitMember dimension="drug:ConsolidatedStatementsOfComprehensiveIncomeLossStatementLocationAxis">drug:MarketingAdvertisingAndInvestorRelationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="C_20191001to20200930_drugConsolidatedStatementsOfComprehensiveIncomeLossStatementLocationAxis_drugMarketingAdvertisingAndInvestorRelationsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001827401</identifier>
            <segment>
                <xbrldi:explicitMember dimension="drug:ConsolidatedStatementsOfComprehensiveIncomeLossStatementLocationAxis">drug:MarketingAdvertisingAndInvestorRelationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="C_20190531to20190930_drugConsolidatedStatementsOfComprehensiveIncomeLossStatementLocationAxis_drugMarketingAdvertisingAndInvestorRelationsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001827401</identifier>
            <segment>
                <xbrldi:explicitMember dimension="drug:ConsolidatedStatementsOfComprehensiveIncomeLossStatementLocationAxis">drug:MarketingAdvertisingAndInvestorRelationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-05-31</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="C_20201001to20210930_drugConsolidatedStatementsOfComprehensiveIncomeLossStatementLocationAxis_drugProfessionalFeesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001827401</identifier>
            <segment>
                <xbrldi:explicitMember dimension="drug:ConsolidatedStatementsOfComprehensiveIncomeLossStatementLocationAxis">drug:ProfessionalFeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="C_20191001to20200930_drugConsolidatedStatementsOfComprehensiveIncomeLossStatementLocationAxis_drugProfessionalFeesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001827401</identifier>
            <segment>
                <xbrldi:explicitMember dimension="drug:ConsolidatedStatementsOfComprehensiveIncomeLossStatementLocationAxis">drug:ProfessionalFeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="C_20190531to20190930_drugConsolidatedStatementsOfComprehensiveIncomeLossStatementLocationAxis_drugProfessionalFeesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001827401</identifier>
            <segment>
                <xbrldi:explicitMember dimension="drug:ConsolidatedStatementsOfComprehensiveIncomeLossStatementLocationAxis">drug:ProfessionalFeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-05-31</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="C_20201001to20210930_drugConsolidatedStatementsOfComprehensiveIncomeLossStatementLocationAxis_drugResearchAndDevelopmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001827401</identifier>
            <segment>
                <xbrldi:explicitMember dimension="drug:ConsolidatedStatementsOfComprehensiveIncomeLossStatementLocationAxis">drug:ResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="C_20191001to20200930_drugConsolidatedStatementsOfComprehensiveIncomeLossStatementLocationAxis_drugResearchAndDevelopmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001827401</identifier>
            <segment>
                <xbrldi:explicitMember dimension="drug:ConsolidatedStatementsOfComprehensiveIncomeLossStatementLocationAxis">drug:ResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="C_20190531to20190930_drugConsolidatedStatementsOfComprehensiveIncomeLossStatementLocationAxis_drugResearchAndDevelopmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001827401</identifier>
            <segment>
                <xbrldi:explicitMember dimension="drug:ConsolidatedStatementsOfComprehensiveIncomeLossStatementLocationAxis">drug:ResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-05-31</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="C_20190930_ifrsfullClassesOfShareCapitalAxis_drugWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001827401</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">drug:WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="C_20191001to20200930_ifrsfullClassesOfShareCapitalAxis_drugWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001827401</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">drug:WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="C_20200930_ifrsfullClassesOfShareCapitalAxis_drugWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001827401</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">drug:WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="C_20201001to20210930_ifrsfullClassesOfShareCapitalAxis_drugWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001827401</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">drug:WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="C_20210930_ifrsfullClassesOfShareCapitalAxis_drugWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001827401</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">drug:WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="C_20210930_drugExpiryDateAxis_drugExpiryDateThirtyJulyTwoThousandAndTwentyFourMember_ifrsfullClassesOfShareCapitalAxis_drugWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001827401</identifier>
            <segment>
                <xbrldi:explicitMember dimension="drug:ExpiryDateAxis">drug:ExpiryDateThirtyJulyTwoThousandAndTwentyFourMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">drug:WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="C_20201001to20210930_drugExpiryDateAxis_drugExpiryDateThirtyJulyTwoThousandAndTwentyFourMember_ifrsfullClassesOfShareCapitalAxis_drugWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001827401</identifier>
            <segment>
                <xbrldi:explicitMember dimension="drug:ExpiryDateAxis">drug:ExpiryDateThirtyJulyTwoThousandAndTwentyFourMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">drug:WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="C_20210930_drugExpiryDateAxis_drugExpiryDateSeventeenMarchTwoThousandAndTwentyFourOneMember_ifrsfullClassesOfShareCapitalAxis_drugWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001827401</identifier>
            <segment>
                <xbrldi:explicitMember dimension="drug:ExpiryDateAxis">drug:ExpiryDateSeventeenMarchTwoThousandAndTwentyFourOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">drug:WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="C_20201001to20210930_drugExpiryDateAxis_drugExpiryDateSeventeenMarchTwoThousandAndTwentyFourOneMember_ifrsfullClassesOfShareCapitalAxis_drugWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001827401</identifier>
            <segment>
                <xbrldi:explicitMember dimension="drug:ExpiryDateAxis">drug:ExpiryDateSeventeenMarchTwoThousandAndTwentyFourOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">drug:WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="C_20210930_drugExpiryDateAxis_drugExpiryDateSeventeenMarchTwoThousandAndTwentyFourTwoMember_ifrsfullClassesOfShareCapitalAxis_drugWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001827401</identifier>
            <segment>
                <xbrldi:explicitMember dimension="drug:ExpiryDateAxis">drug:ExpiryDateSeventeenMarchTwoThousandAndTwentyFourTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">drug:WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="C_20201001to20210930_drugExpiryDateAxis_drugExpiryDateSeventeenMarchTwoThousandAndTwentyFourTwoMember_ifrsfullClassesOfShareCapitalAxis_drugWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001827401</identifier>
            <segment>
                <xbrldi:explicitMember dimension="drug:ExpiryDateAxis">drug:ExpiryDateSeventeenMarchTwoThousandAndTwentyFourTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">drug:WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="C_20201101to20201102_ifrsfullClassesOfShareCapitalAxis_drugSecondTrancheOfNonBrokeredPrivatePlacementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001827401</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">drug:SecondTrancheOfNonBrokeredPrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-11-01</startDate>
            <endDate>2020-11-02</endDate>
        </period>
    </context>
    <context id="C_20201102_ifrsfullClassesOfShareCapitalAxis_drugSecondTrancheOfNonBrokeredPrivatePlacementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001827401</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">drug:SecondTrancheOfNonBrokeredPrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-11-02</instant>
        </period>
    </context>
    <context id="C_20210101to20210106_drugAgreementAxis_drugDebtSettlementAgreementMember_ifrsfullCategoriesOfRelatedPartiesAxis_drugConsultantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001827401</identifier>
            <segment>
                <xbrldi:explicitMember dimension="drug:AgreementAxis">drug:DebtSettlementAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">drug:ConsultantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-01-06</endDate>
        </period>
    </context>
    <context id="C_20210106_drugAgreementAxis_drugDebtSettlementAgreementMember_ifrsfullCategoriesOfRelatedPartiesAxis_drugConsultantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001827401</identifier>
            <segment>
                <xbrldi:explicitMember dimension="drug:AgreementAxis">drug:DebtSettlementAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">drug:ConsultantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-06</instant>
        </period>
    </context>
    <context id="C_20210301to20210317">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001827401</identifier>
        </entity>
        <period>
            <startDate>2021-03-01</startDate>
            <endDate>2021-03-17</endDate>
        </period>
    </context>
    <context id="C_20210317">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001827401</identifier>
        </entity>
        <period>
            <instant>2021-03-17</instant>
        </period>
    </context>
    <context id="C_20210301to20210317_ifrsfullCategoriesOfRelatedPartiesAxis_drugUnderwritersMember_ifrsfullClassesOfShareCapitalAxis_drugWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001827401</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">drug:UnderwritersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">drug:WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-01</startDate>
            <endDate>2021-03-17</endDate>
        </period>
    </context>
    <context id="C_20210401to20210406_ifrsfullClassesOfShareCapitalAxis_drugWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001827401</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">drug:WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-04-06</endDate>
        </period>
    </context>
    <context id="C_20210401to20210406_ifrsfullCategoriesOfRelatedPartiesAxis_drugThreeInvestorsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001827401</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">drug:ThreeInvestorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-04-06</endDate>
        </period>
    </context>
    <context id="C_20210401to20210423_ifrsfullClassesOfShareCapitalAxis_drugEscrowedSharePurchaseWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001827401</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">drug:EscrowedSharePurchaseWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-04-23</endDate>
        </period>
    </context>
    <context id="C_20210401to20210428">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001827401</identifier>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-04-28</endDate>
        </period>
    </context>
    <context id="C_20210428">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001827401</identifier>
        </entity>
        <period>
            <instant>2021-04-28</instant>
        </period>
    </context>
    <context id="C_20200901to20200930_ifrsfullClassesOfShareCapitalAxis_drugFirstTrancheOfNonBrokeredPrivatePlacementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001827401</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">drug:FirstTrancheOfNonBrokeredPrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-09-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="C_20200930_ifrsfullClassesOfShareCapitalAxis_drugFirstTrancheOfNonBrokeredPrivatePlacementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001827401</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">drug:FirstTrancheOfNonBrokeredPrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="C_20190701to20190730_ifrsfullClassesOfShareCapitalAxis_drugNonBrokeredPrivatePlacementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001827401</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">drug:NonBrokeredPrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-07-30</endDate>
        </period>
    </context>
    <context id="C_20190730_ifrsfullClassesOfShareCapitalAxis_drugNonBrokeredPrivatePlacementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001827401</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">drug:NonBrokeredPrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-07-30</instant>
        </period>
    </context>
    <context id="C_20201001to20210930_ifrsfullClassesOfShareCapitalAxis_drugNonBrokeredPrivatePlacementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001827401</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">drug:NonBrokeredPrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="C_20201001to20201031_ifrsfullClassesOfShareCapitalAxis_drugSpecialWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001827401</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">drug:SpecialWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-10-31</endDate>
        </period>
    </context>
    <context id="C_20201101to20201102_ifrsfullClassesOfShareCapitalAxis_drugSpecialWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001827401</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">drug:SpecialWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-11-01</startDate>
            <endDate>2020-11-02</endDate>
        </period>
    </context>
    <context id="C_20210101to20210119_ifrsfullClassesOfShareCapitalAxis_drugSpecialWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001827401</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">drug:SpecialWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-01-19</endDate>
        </period>
    </context>
    <context id="C_20210201to20210203_ifrsfullClassesOfShareCapitalAxis_drugSpecialWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001827401</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">drug:SpecialWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-01</startDate>
            <endDate>2021-02-03</endDate>
        </period>
    </context>
    <context id="C_20190701to20190731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001827401</identifier>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-07-31</endDate>
        </period>
    </context>
    <context id="C_20191007to20200928">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001827401</identifier>
        </entity>
        <period>
            <startDate>2019-10-07</startDate>
            <endDate>2020-09-28</endDate>
        </period>
    </context>
    <context id="C_20210128_drugAgreementAxis_drugEscrowAgreementMember_ifrsfullClassesOfShareCapitalAxis_drugWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001827401</identifier>
            <segment>
                <xbrldi:explicitMember dimension="drug:AgreementAxis">drug:EscrowAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">drug:WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-28</instant>
        </period>
    </context>
    <context id="C_20210201to20210208_drugAgreementAxis_drugEscrowAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001827401</identifier>
            <segment>
                <xbrldi:explicitMember dimension="drug:AgreementAxis">drug:EscrowAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-01</startDate>
            <endDate>2021-02-08</endDate>
        </period>
    </context>
    <context id="C_20201101to20201117_ifrsfullCategoriesOfRelatedPartiesAxis_drugChiefFinancialOfficerTwoDirectorsAndSevenConsultantsMember_ifrsfullClassesOfShareCapitalAxis_drugStockOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001827401</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">drug:ChiefFinancialOfficerTwoDirectorsAndSevenConsultantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">drug:StockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-11-01</startDate>
            <endDate>2020-11-17</endDate>
        </period>
    </context>
    <context id="C_20201101to20201117_drugStockOptionAxis_drugStockOptionsOneMember_ifrsfullCategoriesOfRelatedPartiesAxis_drugChiefFinancialOfficerTwoDirectorsAndSevenConsultantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001827401</identifier>
            <segment>
                <xbrldi:explicitMember dimension="drug:StockOptionAxis">drug:StockOptionsOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">drug:ChiefFinancialOfficerTwoDirectorsAndSevenConsultantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-11-01</startDate>
            <endDate>2020-11-17</endDate>
        </period>
    </context>
    <context id="C_20201101to20201117_drugStockOptionAxis_drugStockOptionsOneMember_drugVestingsAxis_drugFirstTrancheMember_ifrsfullCategoriesOfRelatedPartiesAxis_drugChiefFinancialOfficerTwoDirectorsAndSevenConsultantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001827401</identifier>
            <segment>
                <xbrldi:explicitMember dimension="drug:StockOptionAxis">drug:StockOptionsOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="drug:VestingsAxis">drug:FirstTrancheMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">drug:ChiefFinancialOfficerTwoDirectorsAndSevenConsultantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-11-01</startDate>
            <endDate>2020-11-17</endDate>
        </period>
    </context>
    <context id="C_20201101to20201117_drugStockOptionAxis_drugStockOptionsTwoMember_ifrsfullCategoriesOfRelatedPartiesAxis_drugChiefFinancialOfficerTwoDirectorsAndSevenConsultantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001827401</identifier>
            <segment>
                <xbrldi:explicitMember dimension="drug:StockOptionAxis">drug:StockOptionsTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">drug:ChiefFinancialOfficerTwoDirectorsAndSevenConsultantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-11-01</startDate>
            <endDate>2020-11-17</endDate>
        </period>
    </context>
    <context id="C_20201101to20201117_drugStockOptionAxis_drugStockOptionsTwoMember_drugVestingsAxis_drugSecondTrancheMember_ifrsfullCategoriesOfRelatedPartiesAxis_drugChiefFinancialOfficerTwoDirectorsAndSevenConsultantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001827401</identifier>
            <segment>
                <xbrldi:explicitMember dimension="drug:StockOptionAxis">drug:StockOptionsTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="drug:VestingsAxis">drug:SecondTrancheMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">drug:ChiefFinancialOfficerTwoDirectorsAndSevenConsultantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-11-01</startDate>
            <endDate>2020-11-17</endDate>
        </period>
    </context>
    <context id="C_20210401to20210428_ifrsfullCategoriesOfRelatedPartiesAxis_drugThreeConsultantsMember_ifrsfullClassesOfShareCapitalAxis_drugStockOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001827401</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">drug:ThreeConsultantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">drug:StockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-04-28</endDate>
        </period>
    </context>
    <context id="C_20201101to20201117_drugStockOptionAxis_drugStockOptionsThreeMember_ifrsfullCategoriesOfRelatedPartiesAxis_drugChiefFinancialOfficerTwoDirectorsAndSevenConsultantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001827401</identifier>
            <segment>
                <xbrldi:explicitMember dimension="drug:StockOptionAxis">drug:StockOptionsThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">drug:ChiefFinancialOfficerTwoDirectorsAndSevenConsultantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-11-01</startDate>
            <endDate>2020-11-17</endDate>
        </period>
    </context>
    <context id="C_20201101to20201117_drugStockOptionAxis_drugStockOptionsFourMember_ifrsfullCategoriesOfRelatedPartiesAxis_drugChiefFinancialOfficerTwoDirectorsAndSevenConsultantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001827401</identifier>
            <segment>
                <xbrldi:explicitMember dimension="drug:StockOptionAxis">drug:StockOptionsFourMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">drug:ChiefFinancialOfficerTwoDirectorsAndSevenConsultantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-11-01</startDate>
            <endDate>2020-11-17</endDate>
        </period>
    </context>
    <context id="C_20201117_ifrsfullCategoriesOfRelatedPartiesAxis_drugChiefFinancialOfficerTwoDirectorsAndSevenConsultantsMember_ifrsfullClassesOfShareCapitalAxis_drugStockOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001827401</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">drug:ChiefFinancialOfficerTwoDirectorsAndSevenConsultantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">drug:StockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-11-17</instant>
        </period>
    </context>
    <context id="C_20210401to20210428_drugStockOptionAxis_drugStockOptionsOneMember_ifrsfullCategoriesOfRelatedPartiesAxis_drugThreeConsultantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001827401</identifier>
            <segment>
                <xbrldi:explicitMember dimension="drug:StockOptionAxis">drug:StockOptionsOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">drug:ThreeConsultantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-04-28</endDate>
        </period>
    </context>
    <context id="C_20210401to20210428_drugStockOptionAxis_drugStockOptionsOneMember_drugVestingsAxis_drugSixthTrancheMember_ifrsfullCategoriesOfRelatedPartiesAxis_drugThreeConsultantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001827401</identifier>
            <segment>
                <xbrldi:explicitMember dimension="drug:StockOptionAxis">drug:StockOptionsOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="drug:VestingsAxis">drug:SixthTrancheMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">drug:ThreeConsultantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-04-28</endDate>
        </period>
    </context>
    <context id="C_20210401to20210428_drugStockOptionAxis_drugStockOptionsTwoMember_ifrsfullCategoriesOfRelatedPartiesAxis_drugThreeConsultantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001827401</identifier>
            <segment>
                <xbrldi:explicitMember dimension="drug:StockOptionAxis">drug:StockOptionsTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">drug:ThreeConsultantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-04-28</endDate>
        </period>
    </context>
    <context id="C_20210428_ifrsfullCategoriesOfRelatedPartiesAxis_drugThreeConsultantsMember_ifrsfullClassesOfShareCapitalAxis_drugStockOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001827401</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">drug:ThreeConsultantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">drug:StockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-28</instant>
        </period>
    </context>
    <context id="C_20210601to20210615_ifrsfullCategoriesOfRelatedPartiesAxis_drugDirectorAndConsultantMember_ifrsfullClassesOfShareCapitalAxis_drugStockOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001827401</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">drug:DirectorAndConsultantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">drug:StockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-01</startDate>
            <endDate>2021-06-15</endDate>
        </period>
    </context>
    <context id="C_20210601to20210615_drugVestingsAxis_drugSixthTrancheMember_ifrsfullCategoriesOfRelatedPartiesAxis_drugDirectorAndConsultantMember_ifrsfullClassesOfShareCapitalAxis_drugStockOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001827401</identifier>
            <segment>
                <xbrldi:explicitMember dimension="drug:VestingsAxis">drug:SixthTrancheMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">drug:DirectorAndConsultantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">drug:StockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-01</startDate>
            <endDate>2021-06-15</endDate>
        </period>
    </context>
    <context id="C_20210601to20210615_drugVestingsAxis_drugSeventhTrancheMember_ifrsfullCategoriesOfRelatedPartiesAxis_drugDirectorAndConsultantMember_ifrsfullClassesOfShareCapitalAxis_drugStockOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001827401</identifier>
            <segment>
                <xbrldi:explicitMember dimension="drug:VestingsAxis">drug:SeventhTrancheMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">drug:DirectorAndConsultantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">drug:StockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-01</startDate>
            <endDate>2021-06-15</endDate>
        </period>
    </context>
    <context id="C_20210601to20210615_drugVestingsAxis_drugEighthTrancheMember_ifrsfullCategoriesOfRelatedPartiesAxis_drugDirectorAndConsultantMember_ifrsfullClassesOfShareCapitalAxis_drugStockOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001827401</identifier>
            <segment>
                <xbrldi:explicitMember dimension="drug:VestingsAxis">drug:EighthTrancheMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">drug:DirectorAndConsultantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">drug:StockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-01</startDate>
            <endDate>2021-06-15</endDate>
        </period>
    </context>
    <context id="C_20210601to20210615_drugVestingsAxis_drugNinthTrancheMember_ifrsfullCategoriesOfRelatedPartiesAxis_drugDirectorAndConsultantMember_ifrsfullClassesOfShareCapitalAxis_drugStockOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001827401</identifier>
            <segment>
                <xbrldi:explicitMember dimension="drug:VestingsAxis">drug:NinthTrancheMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">drug:DirectorAndConsultantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">drug:StockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-01</startDate>
            <endDate>2021-06-15</endDate>
        </period>
    </context>
    <context id="C_20210615_ifrsfullCategoriesOfRelatedPartiesAxis_drugDirectorAndConsultantMember_ifrsfullClassesOfShareCapitalAxis_drugStockOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001827401</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">drug:DirectorAndConsultantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">drug:StockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-15</instant>
        </period>
    </context>
    <context id="C_20210901to20210921_ifrsfullCategoriesOfRelatedPartiesAxis_drugConsultantMember_ifrsfullClassesOfShareCapitalAxis_drugStockOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001827401</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">drug:ConsultantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">drug:StockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-09-01</startDate>
            <endDate>2021-09-21</endDate>
        </period>
    </context>
    <context id="C_20210901to20210921_drugVestingsAxis_drugTwelfthTrancheMember_ifrsfullCategoriesOfRelatedPartiesAxis_drugConsultantMember_ifrsfullClassesOfShareCapitalAxis_drugStockOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001827401</identifier>
            <segment>
                <xbrldi:explicitMember dimension="drug:VestingsAxis">drug:TwelfthTrancheMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">drug:ConsultantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">drug:StockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-09-01</startDate>
            <endDate>2021-09-21</endDate>
        </period>
    </context>
    <context id="C_20210901to20210921_drugVestingsAxis_drugThirteenthTrancheMember_ifrsfullCategoriesOfRelatedPartiesAxis_drugConsultantMember_ifrsfullClassesOfShareCapitalAxis_drugStockOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001827401</identifier>
            <segment>
                <xbrldi:explicitMember dimension="drug:VestingsAxis">drug:ThirteenthTrancheMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">drug:ConsultantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">drug:StockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-09-01</startDate>
            <endDate>2021-09-21</endDate>
        </period>
    </context>
    <context id="C_20210901to20210921_drugVestingsAxis_drugFourteenthTrancheMember_ifrsfullCategoriesOfRelatedPartiesAxis_drugConsultantMember_ifrsfullClassesOfShareCapitalAxis_drugStockOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001827401</identifier>
            <segment>
                <xbrldi:explicitMember dimension="drug:VestingsAxis">drug:FourteenthTrancheMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">drug:ConsultantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">drug:StockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-09-01</startDate>
            <endDate>2021-09-21</endDate>
        </period>
    </context>
    <context id="C_20210901to20210921_drugVestingsAxis_drugFifteenthTrancheMember_ifrsfullCategoriesOfRelatedPartiesAxis_drugConsultantMember_ifrsfullClassesOfShareCapitalAxis_drugStockOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001827401</identifier>
            <segment>
                <xbrldi:explicitMember dimension="drug:VestingsAxis">drug:FifteenthTrancheMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">drug:ConsultantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">drug:StockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-09-01</startDate>
            <endDate>2021-09-21</endDate>
        </period>
    </context>
    <context id="C_20210921_ifrsfullCategoriesOfRelatedPartiesAxis_drugConsultantMember_ifrsfullClassesOfShareCapitalAxis_drugStockOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001827401</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">drug:ConsultantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">drug:StockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-21</instant>
        </period>
    </context>
    <context id="C_20200701to20200723_ifrsfullClassesOfShareCapitalAxis_drugStockOptionsMember_srtTitleOfIndividualAxis_drugChiefMedicalOfficerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001827401</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">drug:ChiefMedicalOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">drug:StockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-07-23</endDate>
        </period>
    </context>
    <context id="C_20200723_ifrsfullClassesOfShareCapitalAxis_drugStockOptionsMember_srtTitleOfIndividualAxis_drugChiefMedicalOfficerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001827401</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">drug:ChiefMedicalOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">drug:StockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-07-23</instant>
        </period>
    </context>
    <context id="C_20200723_ifrsfullClassesOfShareCapitalAxis_drugRestrictedShareUnitMember_srtTitleOfIndividualAxis_drugChiefMedicalOfficerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001827401</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">drug:ChiefMedicalOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">drug:RestrictedShareUnitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-07-23</instant>
        </period>
    </context>
    <context id="C_20200918_ifrsfullClassesOfShareCapitalAxis_drugRestrictedShareUnitMember_srtTitleOfIndividualAxis_drugChiefMedicalOfficerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001827401</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">drug:ChiefMedicalOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">drug:RestrictedShareUnitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-18</instant>
        </period>
    </context>
    <context id="C_20210601to20210615_ifrsfullClassesOfShareCapitalAxis_drugWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001827401</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">drug:WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-01</startDate>
            <endDate>2021-06-15</endDate>
        </period>
    </context>
    <context id="C_20201101to20201117_drugStockOptionAxis_drugStockOptionsTwoMember_drugVestingsAxis_drugThirdTrancheMember_ifrsfullCategoriesOfRelatedPartiesAxis_drugChiefFinancialOfficerTwoDirectorsAndSevenConsultantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001827401</identifier>
            <segment>
                <xbrldi:explicitMember dimension="drug:StockOptionAxis">drug:StockOptionsTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="drug:VestingsAxis">drug:ThirdTrancheMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">drug:ChiefFinancialOfficerTwoDirectorsAndSevenConsultantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-11-01</startDate>
            <endDate>2020-11-17</endDate>
        </period>
    </context>
    <context id="C_20201101to20201117_drugStockOptionAxis_drugStockOptionsTwoMember_drugVestingsAxis_drugFourthTrancheMember_ifrsfullCategoriesOfRelatedPartiesAxis_drugChiefFinancialOfficerTwoDirectorsAndSevenConsultantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001827401</identifier>
            <segment>
                <xbrldi:explicitMember dimension="drug:StockOptionAxis">drug:StockOptionsTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="drug:VestingsAxis">drug:FourthTrancheMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">drug:ChiefFinancialOfficerTwoDirectorsAndSevenConsultantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-11-01</startDate>
            <endDate>2020-11-17</endDate>
        </period>
    </context>
    <context id="C_20201101to20201117_drugStockOptionAxis_drugStockOptionsThreeMember_drugVestingsAxis_drugSecondTrancheMember_ifrsfullCategoriesOfRelatedPartiesAxis_drugChiefFinancialOfficerTwoDirectorsAndSevenConsultantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001827401</identifier>
            <segment>
                <xbrldi:explicitMember dimension="drug:StockOptionAxis">drug:StockOptionsThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="drug:VestingsAxis">drug:SecondTrancheMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">drug:ChiefFinancialOfficerTwoDirectorsAndSevenConsultantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-11-01</startDate>
            <endDate>2020-11-17</endDate>
        </period>
    </context>
    <context id="C_20201101to20201117_drugStockOptionAxis_drugStockOptionsThreeMember_drugVestingsAxis_drugFifthTrancheMember_ifrsfullCategoriesOfRelatedPartiesAxis_drugChiefFinancialOfficerTwoDirectorsAndSevenConsultantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001827401</identifier>
            <segment>
                <xbrldi:explicitMember dimension="drug:StockOptionAxis">drug:StockOptionsThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="drug:VestingsAxis">drug:FifthTrancheMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">drug:ChiefFinancialOfficerTwoDirectorsAndSevenConsultantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-11-01</startDate>
            <endDate>2020-11-17</endDate>
        </period>
    </context>
    <context id="C_20201101to20201117_drugStockOptionAxis_drugStockOptionsFourMember_drugVestingsAxis_drugSixthTrancheMember_ifrsfullCategoriesOfRelatedPartiesAxis_drugChiefFinancialOfficerTwoDirectorsAndSevenConsultantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001827401</identifier>
            <segment>
                <xbrldi:explicitMember dimension="drug:StockOptionAxis">drug:StockOptionsFourMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="drug:VestingsAxis">drug:SixthTrancheMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">drug:ChiefFinancialOfficerTwoDirectorsAndSevenConsultantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-11-01</startDate>
            <endDate>2020-11-17</endDate>
        </period>
    </context>
    <context id="C_20201101to20201117_drugStockOptionAxis_drugStockOptionsFourMember_drugVestingsAxis_drugSeventhTrancheMember_ifrsfullCategoriesOfRelatedPartiesAxis_drugChiefFinancialOfficerTwoDirectorsAndSevenConsultantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001827401</identifier>
            <segment>
                <xbrldi:explicitMember dimension="drug:StockOptionAxis">drug:StockOptionsFourMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="drug:VestingsAxis">drug:SeventhTrancheMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">drug:ChiefFinancialOfficerTwoDirectorsAndSevenConsultantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-11-01</startDate>
            <endDate>2020-11-17</endDate>
        </period>
    </context>
    <context id="C_20201101to20201117_drugStockOptionAxis_drugStockOptionsFourMember_drugVestingsAxis_drugEighthTrancheMember_ifrsfullCategoriesOfRelatedPartiesAxis_drugChiefFinancialOfficerTwoDirectorsAndSevenConsultantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001827401</identifier>
            <segment>
                <xbrldi:explicitMember dimension="drug:StockOptionAxis">drug:StockOptionsFourMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="drug:VestingsAxis">drug:EighthTrancheMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">drug:ChiefFinancialOfficerTwoDirectorsAndSevenConsultantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-11-01</startDate>
            <endDate>2020-11-17</endDate>
        </period>
    </context>
    <context id="C_20210401to20210428_drugStockOptionAxis_drugStockOptionsOneMember_drugVestingsAxis_drugSeventhTrancheMember_ifrsfullCategoriesOfRelatedPartiesAxis_drugThreeConsultantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001827401</identifier>
            <segment>
                <xbrldi:explicitMember dimension="drug:StockOptionAxis">drug:StockOptionsOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="drug:VestingsAxis">drug:SeventhTrancheMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">drug:ThreeConsultantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-04-28</endDate>
        </period>
    </context>
    <context id="C_20210401to20210428_drugStockOptionAxis_drugStockOptionsOneMember_drugVestingsAxis_drugEighthTrancheMember_ifrsfullCategoriesOfRelatedPartiesAxis_drugThreeConsultantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001827401</identifier>
            <segment>
                <xbrldi:explicitMember dimension="drug:StockOptionAxis">drug:StockOptionsOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="drug:VestingsAxis">drug:EighthTrancheMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">drug:ThreeConsultantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-04-28</endDate>
        </period>
    </context>
    <context id="C_20210401to20210428_drugStockOptionAxis_drugStockOptionsOneMember_drugVestingsAxis_drugNinthTrancheMember_ifrsfullCategoriesOfRelatedPartiesAxis_drugThreeConsultantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001827401</identifier>
            <segment>
                <xbrldi:explicitMember dimension="drug:StockOptionAxis">drug:StockOptionsOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="drug:VestingsAxis">drug:NinthTrancheMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">drug:ThreeConsultantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-04-28</endDate>
        </period>
    </context>
    <context id="C_20210401to20210428_drugStockOptionAxis_drugStockOptionsTwoMember_drugVestingsAxis_drugTenthTrancheMember_ifrsfullCategoriesOfRelatedPartiesAxis_drugThreeConsultantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001827401</identifier>
            <segment>
                <xbrldi:explicitMember dimension="drug:StockOptionAxis">drug:StockOptionsTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="drug:VestingsAxis">drug:TenthTrancheMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">drug:ThreeConsultantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-04-28</endDate>
        </period>
    </context>
    <context id="C_20210401to20210428_drugStockOptionAxis_drugStockOptionsTwoMember_drugVestingsAxis_drugSixthTrancheMember_ifrsfullCategoriesOfRelatedPartiesAxis_drugThreeConsultantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001827401</identifier>
            <segment>
                <xbrldi:explicitMember dimension="drug:StockOptionAxis">drug:StockOptionsTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="drug:VestingsAxis">drug:SixthTrancheMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">drug:ThreeConsultantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-04-28</endDate>
        </period>
    </context>
    <context id="C_20210401to20210428_drugStockOptionAxis_drugStockOptionsTwoMember_drugVestingsAxis_drugEleventhTrancheMember_ifrsfullCategoriesOfRelatedPartiesAxis_drugThreeConsultantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001827401</identifier>
            <segment>
                <xbrldi:explicitMember dimension="drug:StockOptionAxis">drug:StockOptionsTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="drug:VestingsAxis">drug:EleventhTrancheMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">drug:ThreeConsultantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-04-28</endDate>
        </period>
    </context>
    <context id="C_20210401to20210428_drugStockOptionAxis_drugStockOptionsTwoMember_drugVestingsAxis_drugSeventhTrancheMember_ifrsfullCategoriesOfRelatedPartiesAxis_drugThreeConsultantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001827401</identifier>
            <segment>
                <xbrldi:explicitMember dimension="drug:StockOptionAxis">drug:StockOptionsTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="drug:VestingsAxis">drug:SeventhTrancheMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">drug:ThreeConsultantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-04-28</endDate>
        </period>
    </context>
    <context id="C_20201102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001827401</identifier>
        </entity>
        <period>
            <instant>2020-11-02</instant>
        </period>
    </context>
    <context id="C_20200711">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001827401</identifier>
        </entity>
        <period>
            <instant>2020-07-11</instant>
        </period>
    </context>
    <context id="C_20210101to20210121_ifrsfullClassesOfShareCapitalAxis_drugStockOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001827401</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">drug:StockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-01-21</endDate>
        </period>
    </context>
    <context id="C_20200501to20200526_drugAgreementAxis_drugOptionAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001827401</identifier>
            <segment>
                <xbrldi:explicitMember dimension="drug:AgreementAxis">drug:OptionAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-05-01</startDate>
            <endDate>2020-05-26</endDate>
        </period>
    </context>
    <context id="C_20210401to20210423_drugAgreementAxis_drugLicenseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001827401</identifier>
            <segment>
                <xbrldi:explicitMember dimension="drug:AgreementAxis">drug:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-04-23</endDate>
        </period>
    </context>
    <context id="C_20210401to20210423_drugAgreementAxis_drugPriorToSublicensingAgreementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001827401</identifier>
            <segment>
                <xbrldi:explicitMember dimension="drug:AgreementAxis">drug:PriorToSublicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-04-23</endDate>
        </period>
    </context>
    <context id="C_20210401to20210423_drugAgreementAxis_drugAfterSublicensingAgreementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001827401</identifier>
            <segment>
                <xbrldi:explicitMember dimension="drug:AgreementAxis">drug:AfterSublicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-04-23</endDate>
        </period>
    </context>
    <context id="C_20200601to20200605_drugAgreementAxis_drugIndependentConsultantAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001827401</identifier>
            <segment>
                <xbrldi:explicitMember dimension="drug:AgreementAxis">drug:IndependentConsultantAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-01</startDate>
            <endDate>2020-06-05</endDate>
        </period>
    </context>
    <context id="C_20210301to20210331_drugAgreementAxis_drugIndependentConsultantAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001827401</identifier>
            <segment>
                <xbrldi:explicitMember dimension="drug:AgreementAxis">drug:IndependentConsultantAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="C_20210801to20210831_drugAgreementAxis_drugIndependentConsultantAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001827401</identifier>
            <segment>
                <xbrldi:explicitMember dimension="drug:AgreementAxis">drug:IndependentConsultantAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-08-01</startDate>
            <endDate>2021-08-31</endDate>
        </period>
    </context>
    <context id="C_20200601to20210412_drugAgreementAxis_drugScientificAdvisoryBoardAgreementsMember_ifrsfullRangeAxis_ifrsfullBottomOfRangeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001827401</identifier>
            <segment>
                <xbrldi:explicitMember dimension="drug:AgreementAxis">drug:ScientificAdvisoryBoardAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-01</startDate>
            <endDate>2021-04-12</endDate>
        </period>
    </context>
    <context id="C_20201101to20201117_drugAgreementAxis_drugScientificAdvisoryBoardAgreementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001827401</identifier>
            <segment>
                <xbrldi:explicitMember dimension="drug:AgreementAxis">drug:ScientificAdvisoryBoardAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-11-01</startDate>
            <endDate>2020-11-17</endDate>
        </period>
    </context>
    <context id="C_20200601to20210412_drugAgreementAxis_drugScientificAdvisoryBoardAgreementsMember_ifrsfullRangeAxis_ifrsfullTopOfRangeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001827401</identifier>
            <segment>
                <xbrldi:explicitMember dimension="drug:AgreementAxis">drug:ScientificAdvisoryBoardAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-01</startDate>
            <endDate>2021-04-12</endDate>
        </period>
    </context>
    <context id="C_20210101to20210131_drugAgreementAxis_drugScientificAdvisoryBoardAgreementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001827401</identifier>
            <segment>
                <xbrldi:explicitMember dimension="drug:AgreementAxis">drug:ScientificAdvisoryBoardAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-01-31</endDate>
        </period>
    </context>
    <context id="C_20201118to20210428_drugAgreementAxis_drugConsultingAgreementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001827401</identifier>
            <segment>
                <xbrldi:explicitMember dimension="drug:AgreementAxis">drug:ConsultingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-11-18</startDate>
            <endDate>2021-04-28</endDate>
        </period>
    </context>
    <context id="C_20201001to20210930_drugAgreementAxis_drugConsultingAgreementsMember_ifrsfullRangeAxis_ifrsfullBottomOfRangeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001827401</identifier>
            <segment>
                <xbrldi:explicitMember dimension="drug:AgreementAxis">drug:ConsultingAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="C_20201001to20210930_drugAgreementAxis_drugConsultingAgreementsMember_ifrsfullRangeAxis_ifrsfullTopOfRangeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001827401</identifier>
            <segment>
                <xbrldi:explicitMember dimension="drug:AgreementAxis">drug:ConsultingAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="C_20201001to20201009_drugAgreementAxis_drugConsultingAgreementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001827401</identifier>
            <segment>
                <xbrldi:explicitMember dimension="drug:AgreementAxis">drug:ConsultingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-10-09</endDate>
        </period>
    </context>
    <context id="C_20201101to20201106_drugAgreementAxis_drugConsultingAgreementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001827401</identifier>
            <segment>
                <xbrldi:explicitMember dimension="drug:AgreementAxis">drug:ConsultingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-11-01</startDate>
            <endDate>2020-11-06</endDate>
        </period>
    </context>
    <context id="C_20201101to20201117_drugAgreementAxis_drugConsultingAgreementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001827401</identifier>
            <segment>
                <xbrldi:explicitMember dimension="drug:AgreementAxis">drug:ConsultingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-11-01</startDate>
            <endDate>2020-11-17</endDate>
        </period>
    </context>
    <context id="C_20210301to20210331_drugAgreementAxis_drugIndependentContractorAgreementToServeAsChiefScienceOfficerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001827401</identifier>
            <segment>
                <xbrldi:explicitMember dimension="drug:AgreementAxis">drug:IndependentContractorAgreementToServeAsChiefScienceOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="C_20210801to20210831_drugAgreementAxis_drugIndependentContractorAgreementToServeAsChiefScienceOfficerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001827401</identifier>
            <segment>
                <xbrldi:explicitMember dimension="drug:AgreementAxis">drug:IndependentContractorAgreementToServeAsChiefScienceOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-08-01</startDate>
            <endDate>2021-08-31</endDate>
        </period>
    </context>
    <context id="C_20210930_ifrsfullClassesOfFinancialInstrumentsAxis_drugFinancialInstrumentsAtFairValueThroughProfitOrLossMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001827401</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">drug:FinancialInstrumentsAtFairValueThroughProfitOrLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="C_20200930_ifrsfullClassesOfFinancialInstrumentsAxis_drugFinancialInstrumentsAtFairValueThroughProfitOrLossMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001827401</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">drug:FinancialInstrumentsAtFairValueThroughProfitOrLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="C_20210930_ifrsfullClassesOfFinancialInstrumentsAxis_drugFinancialInstrumentsAtAmortizedCostMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001827401</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">drug:FinancialInstrumentsAtAmortizedCostMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="C_20200930_ifrsfullClassesOfFinancialInstrumentsAxis_drugFinancialInstrumentsAtAmortizedCostMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001827401</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">drug:FinancialInstrumentsAtAmortizedCostMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="C_20210930_ifrsfullTypesOfRisksAxis_ifrsfullCreditRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001827401</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CreditRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="C_20210930_ifrsfullTypesOfRisksAxis_ifrsfullCurrencyRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001827401</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CurrencyRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="C_20210930_ifrsfullTypesOfRisksAxis_ifrsfullLiquidityRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001827401</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:LiquidityRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="C_20191001to20200930_drugCategoriesOfResearchAndDevelopmentExpensesAxis_drugLaboratoryCostsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001827401</identifier>
            <segment>
                <xbrldi:explicitMember dimension="drug:CategoriesOfResearchAndDevelopmentExpensesAxis">drug:LaboratoryCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="C_20190601to20190930_drugCategoriesOfResearchAndDevelopmentExpensesAxis_drugLaboratoryCostsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001827401</identifier>
            <segment>
                <xbrldi:explicitMember dimension="drug:CategoriesOfResearchAndDevelopmentExpensesAxis">drug:LaboratoryCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-06-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="C_20191001to20200930_drugCategoriesOfResearchAndDevelopmentExpensesAxis_drugNovelDrugDevelopmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001827401</identifier>
            <segment>
                <xbrldi:explicitMember dimension="drug:CategoriesOfResearchAndDevelopmentExpensesAxis">drug:NovelDrugDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="C_20190601to20190930_drugCategoriesOfResearchAndDevelopmentExpensesAxis_drugNovelDrugDevelopmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001827401</identifier>
            <segment>
                <xbrldi:explicitMember dimension="drug:CategoriesOfResearchAndDevelopmentExpensesAxis">drug:NovelDrugDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-06-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="C_20191001to20200930_drugCategoriesOfResearchAndDevelopmentExpensesAxis_ifrsfullCopyrightsPatentsAndOtherIndustrialPropertyRightsServiceAndOperatingRightsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001827401</identifier>
            <segment>
                <xbrldi:explicitMember dimension="drug:CategoriesOfResearchAndDevelopmentExpensesAxis">ifrs-full:CopyrightsPatentsAndOtherIndustrialPropertyRightsServiceAndOperatingRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="C_20190601to20190930_drugCategoriesOfResearchAndDevelopmentExpensesAxis_ifrsfullCopyrightsPatentsAndOtherIndustrialPropertyRightsServiceAndOperatingRightsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001827401</identifier>
            <segment>
                <xbrldi:explicitMember dimension="drug:CategoriesOfResearchAndDevelopmentExpensesAxis">ifrs-full:CopyrightsPatentsAndOtherIndustrialPropertyRightsServiceAndOperatingRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-06-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="C_20191001to20200930_drugCategoriesOfResearchAndDevelopmentExpensesAxis_drugSalaryAndSubcontractorsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001827401</identifier>
            <segment>
                <xbrldi:explicitMember dimension="drug:CategoriesOfResearchAndDevelopmentExpensesAxis">drug:SalaryAndSubcontractorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="C_20190601to20190930_drugCategoriesOfResearchAndDevelopmentExpensesAxis_drugSalaryAndSubcontractorsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001827401</identifier>
            <segment>
                <xbrldi:explicitMember dimension="drug:CategoriesOfResearchAndDevelopmentExpensesAxis">drug:SalaryAndSubcontractorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-06-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="C_20191001to20200930_drugCategoriesOfResearchAndDevelopmentExpensesAxis_drugShareBasedCompensationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001827401</identifier>
            <segment>
                <xbrldi:explicitMember dimension="drug:CategoriesOfResearchAndDevelopmentExpensesAxis">drug:ShareBasedCompensationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="C_20190601to20190930_drugCategoriesOfResearchAndDevelopmentExpensesAxis_drugShareBasedCompensationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001827401</identifier>
            <segment>
                <xbrldi:explicitMember dimension="drug:CategoriesOfResearchAndDevelopmentExpensesAxis">drug:ShareBasedCompensationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-06-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="C_20201001to20210930_drugCategoriesOfResearchAndDevelopmentExpensesAxis_drugLaboratoryCostsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001827401</identifier>
            <segment>
                <xbrldi:explicitMember dimension="drug:CategoriesOfResearchAndDevelopmentExpensesAxis">drug:LaboratoryCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="C_20201001to20210930_drugCategoriesOfResearchAndDevelopmentExpensesAxis_drugNovelDrugDevelopmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001827401</identifier>
            <segment>
                <xbrldi:explicitMember dimension="drug:CategoriesOfResearchAndDevelopmentExpensesAxis">drug:NovelDrugDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="C_20201001to20210930_drugCategoriesOfResearchAndDevelopmentExpensesAxis_ifrsfullCopyrightsPatentsAndOtherIndustrialPropertyRightsServiceAndOperatingRightsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001827401</identifier>
            <segment>
                <xbrldi:explicitMember dimension="drug:CategoriesOfResearchAndDevelopmentExpensesAxis">ifrs-full:CopyrightsPatentsAndOtherIndustrialPropertyRightsServiceAndOperatingRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="C_20201001to20210930_drugCategoriesOfResearchAndDevelopmentExpensesAxis_drugSalaryAndSubcontractorsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001827401</identifier>
            <segment>
                <xbrldi:explicitMember dimension="drug:CategoriesOfResearchAndDevelopmentExpensesAxis">drug:SalaryAndSubcontractorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="C_20201001to20210930_drugCategoriesOfResearchAndDevelopmentExpensesAxis_drugShareBasedCompensationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001827401</identifier>
            <segment>
                <xbrldi:explicitMember dimension="drug:CategoriesOfResearchAndDevelopmentExpensesAxis">drug:ShareBasedCompensationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="C_20210601to20210930_ifrsfullClassesOfAssetsAxis_drugCommercialLaboratoryLeaseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001827401</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">drug:CommercialLaboratoryLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="C_20210901to20210930_ifrsfullClassesOfAssetsAxis_ifrsfullBuildingsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001827401</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:BuildingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-09-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="C_20210601to20210930_ifrsfullClassesOfAssetsAxis_ifrsfullBuildingsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001827401</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:BuildingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="C_20181001to20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001827401</identifier>
        </entity>
        <period>
            <startDate>2018-10-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="C_20210930_ifrsfullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_ifrsfullUnusedTaxLossesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001827401</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:UnusedTaxLossesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="C_20200930_ifrsfullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_ifrsfullUnusedTaxLossesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001827401</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:UnusedTaxLossesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="C_20210930_ifrsfullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_drugTemporaryDifferencesShareIssueCostsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001827401</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">drug:TemporaryDifferencesShareIssueCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="C_20200930_ifrsfullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_drugTemporaryDifferencesShareIssueCostsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001827401</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">drug:TemporaryDifferencesShareIssueCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="C_20210930_ifrsfullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_drugTemporaryDifferencesIntangibleAssetsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001827401</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">drug:TemporaryDifferencesIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="C_20200930_ifrsfullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_drugTemporaryDifferencesIntangibleAssetsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001827401</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">drug:TemporaryDifferencesIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="C_20210930_ifrsfullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_drugTemporaryDifferencesValuationAllowanceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001827401</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">drug:TemporaryDifferencesValuationAllowanceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="C_20200930_ifrsfullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_drugTemporaryDifferencesValuationAllowanceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001827401</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">drug:TemporaryDifferencesValuationAllowanceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="C_20201001to20210930_drugIncomeTaxAuthorityNameOfCountryAxis_drugTaxAuthorityOfCanadaMember_drugNonCapitalLossCarryForwardsYearOfOriginAxis_drugTaxYearOfOrigin2019Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001827401</identifier>
            <segment>
                <xbrldi:explicitMember dimension="drug:IncomeTaxAuthorityNameOfCountryAxis">drug:TaxAuthorityOfCanadaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="drug:NonCapitalLossCarryForwardsYearOfOriginAxis">drug:TaxYearOfOrigin2019Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="C_20201001to20210930_drugIncomeTaxAuthorityNameOfCountryAxis_drugTaxAuthorityOfCanadaMember_drugNonCapitalLossCarryForwardsYearOfOriginAxis_drugTaxYearOfOrigin2020Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001827401</identifier>
            <segment>
                <xbrldi:explicitMember dimension="drug:IncomeTaxAuthorityNameOfCountryAxis">drug:TaxAuthorityOfCanadaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="drug:NonCapitalLossCarryForwardsYearOfOriginAxis">drug:TaxYearOfOrigin2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="C_20201001to20210930_drugIncomeTaxAuthorityNameOfCountryAxis_drugTaxAuthorityOfCanadaMember_drugNonCapitalLossCarryForwardsYearOfOriginAxis_drugTaxYearOfOrigin2021Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001827401</identifier>
            <segment>
                <xbrldi:explicitMember dimension="drug:IncomeTaxAuthorityNameOfCountryAxis">drug:TaxAuthorityOfCanadaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="drug:NonCapitalLossCarryForwardsYearOfOriginAxis">drug:TaxYearOfOrigin2021Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="C_20210930_drugIncomeTaxAuthorityNameOfCountryAxis_drugTaxAuthorityOfCanadaMember_drugNonCapitalLossCarryForwardsYearOfOriginAxis_drugTaxYearOfOrigin2019Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001827401</identifier>
            <segment>
                <xbrldi:explicitMember dimension="drug:IncomeTaxAuthorityNameOfCountryAxis">drug:TaxAuthorityOfCanadaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="drug:NonCapitalLossCarryForwardsYearOfOriginAxis">drug:TaxYearOfOrigin2019Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="C_20210930_drugIncomeTaxAuthorityNameOfCountryAxis_drugTaxAuthorityOfCanadaMember_drugNonCapitalLossCarryForwardsYearOfOriginAxis_drugTaxYearOfOrigin2020Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001827401</identifier>
            <segment>
                <xbrldi:explicitMember dimension="drug:IncomeTaxAuthorityNameOfCountryAxis">drug:TaxAuthorityOfCanadaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="drug:NonCapitalLossCarryForwardsYearOfOriginAxis">drug:TaxYearOfOrigin2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="C_20210930_drugIncomeTaxAuthorityNameOfCountryAxis_drugTaxAuthorityOfCanadaMember_drugNonCapitalLossCarryForwardsYearOfOriginAxis_drugTaxYearOfOrigin2021Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001827401</identifier>
            <segment>
                <xbrldi:explicitMember dimension="drug:IncomeTaxAuthorityNameOfCountryAxis">drug:TaxAuthorityOfCanadaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="drug:NonCapitalLossCarryForwardsYearOfOriginAxis">drug:TaxYearOfOrigin2021Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="C_20210930_drugIncomeTaxAuthorityNameOfCountryAxis_drugTaxAuthorityOfCanadaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001827401</identifier>
            <segment>
                <xbrldi:explicitMember dimension="drug:IncomeTaxAuthorityNameOfCountryAxis">drug:TaxAuthorityOfCanadaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="C_20190930_drugIncomeTaxAuthorityNameOfCountryAxis_drugTaxAuthorityOfCanadaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001827401</identifier>
            <segment>
                <xbrldi:explicitMember dimension="drug:IncomeTaxAuthorityNameOfCountryAxis">drug:TaxAuthorityOfCanadaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="C_20210930_drugIncomeTaxAuthorityNameOfCountryAxis_drugTaxAuthorityOfUnitedStatesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001827401</identifier>
            <segment>
                <xbrldi:explicitMember dimension="drug:IncomeTaxAuthorityNameOfCountryAxis">drug:TaxAuthorityOfUnitedStatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="C_20190930_drugIncomeTaxAuthorityNameOfCountryAxis_drugTaxAuthorityOfUnitedStatesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001827401</identifier>
            <segment>
                <xbrldi:explicitMember dimension="drug:IncomeTaxAuthorityNameOfCountryAxis">drug:TaxAuthorityOfUnitedStatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="C_20210930_drugIncomeTaxAuthorityNameOfCountryAxis_drugTaxAuthorityOfAustraliaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001827401</identifier>
            <segment>
                <xbrldi:explicitMember dimension="drug:IncomeTaxAuthorityNameOfCountryAxis">drug:TaxAuthorityOfAustraliaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="C_20190930_drugIncomeTaxAuthorityNameOfCountryAxis_drugTaxAuthorityOfAustraliaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001827401</identifier>
            <segment>
                <xbrldi:explicitMember dimension="drug:IncomeTaxAuthorityNameOfCountryAxis">drug:TaxAuthorityOfAustraliaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="C_20211001to20211101_drugTypeOfArrangementsAxis_drugLetterAgreementMember_ifrsfullNonadjustingEventsAfterReportingPeriodAxis_drugSubsequentEventsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001827401</identifier>
            <segment>
                <xbrldi:explicitMember dimension="drug:TypeOfArrangementsAxis">drug:LetterAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">drug:SubsequentEventsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-11-01</endDate>
        </period>
    </context>
    <context id="C_20211101_drugTypeOfArrangementsAxis_drugLetterAgreementMember_ifrsfullNonadjustingEventsAfterReportingPeriodAxis_drugSubsequentEventsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001827401</identifier>
            <segment>
                <xbrldi:explicitMember dimension="drug:TypeOfArrangementsAxis">drug:LetterAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">drug:SubsequentEventsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-11-01</instant>
        </period>
    </context>
    <context id="C_20211101_drugTranchesAxis_drugFirstTrancheMember_drugTypeOfArrangementsAxis_drugLetterAgreementMember_ifrsfullNonadjustingEventsAfterReportingPeriodAxis_drugSubsequentEventsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001827401</identifier>
            <segment>
                <xbrldi:explicitMember dimension="drug:TranchesAxis">drug:FirstTrancheMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="drug:TypeOfArrangementsAxis">drug:LetterAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">drug:SubsequentEventsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-11-01</instant>
        </period>
    </context>
    <context id="C_20211101_drugTranchesAxis_drugSecondTrancheMember_drugTypeOfArrangementsAxis_drugLetterAgreementMember_ifrsfullNonadjustingEventsAfterReportingPeriodAxis_drugSubsequentEventsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001827401</identifier>
            <segment>
                <xbrldi:explicitMember dimension="drug:TranchesAxis">drug:SecondTrancheMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="drug:TypeOfArrangementsAxis">drug:LetterAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">drug:SubsequentEventsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-11-01</instant>
        </period>
    </context>
    <context id="C_20211101_drugTranchesAxis_drugThirdTrancheMember_drugTypeOfArrangementsAxis_drugLetterAgreementMember_ifrsfullNonadjustingEventsAfterReportingPeriodAxis_drugSubsequentEventsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001827401</identifier>
            <segment>
                <xbrldi:explicitMember dimension="drug:TranchesAxis">drug:ThirdTrancheMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="drug:TypeOfArrangementsAxis">drug:LetterAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">drug:SubsequentEventsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-11-01</instant>
        </period>
    </context>
    <context id="C_20211001to20211109_drugTypeOfArrangementsAxis_drugLetterAgreementMember_ifrsfullNonadjustingEventsAfterReportingPeriodAxis_drugSubsequentEventsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001827401</identifier>
            <segment>
                <xbrldi:explicitMember dimension="drug:TypeOfArrangementsAxis">drug:LetterAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">drug:SubsequentEventsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-11-09</endDate>
        </period>
    </context>
    <unit id="CAD">
        <measure>iso4217:CAD</measure>
    </unit>
    <unit id="CAD_per_share">
        <divide>
            <unitNumerator>
                <measure>iso4217:CAD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Percent">
        <measure>pure</measure>
    </unit>
    <unit id="Share">
        <measure>shares</measure>
    </unit>
    <unit id="Shares">
        <measure>drug:Shares</measure>
    </unit>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Unit_Per_Share">
        <divide>
            <unitNumerator>
                <measure>iso4217:CAD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>drug:Shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Year">
        <measure>drug:Year</measure>
    </unit>
    <drug:TotalAnnualMinimumRoyaltiesCurrentYears
      contextRef="C_20210401to20210423_drugAgreementAxis_drugLicenseAgreementMember"
      id="Fxbrl_20211229013458419"
      unitRef="CAD"
      xsi:nil="true"/>
    <drug:NonCapitalLossCarryForwardsYearOfExpiry
      contextRef="C_20201001to20210930_drugIncomeTaxAuthorityNameOfCountryAxis_drugTaxAuthorityOfCanadaMember_drugNonCapitalLossCarryForwardsYearOfOriginAxis_drugTaxYearOfOrigin2019Member"
      id="Fxbrl_20211228221904526">2039</drug:NonCapitalLossCarryForwardsYearOfExpiry>
    <drug:NonCapitalLossCarryForwardsYearOfExpiry
      contextRef="C_20201001to20210930_drugIncomeTaxAuthorityNameOfCountryAxis_drugTaxAuthorityOfCanadaMember_drugNonCapitalLossCarryForwardsYearOfOriginAxis_drugTaxYearOfOrigin2020Member"
      id="Fxbrl_20211228221912500">2040</drug:NonCapitalLossCarryForwardsYearOfExpiry>
    <drug:NonCapitalLossCarryForwardsYearOfExpiry
      contextRef="C_20201001to20210930_drugIncomeTaxAuthorityNameOfCountryAxis_drugTaxAuthorityOfCanadaMember_drugNonCapitalLossCarryForwardsYearOfOriginAxis_drugTaxYearOfOrigin2021Member"
      id="Fxbrl_20211228221915311">2041</drug:NonCapitalLossCarryForwardsYearOfExpiry>
    <dei:EntityCentralIndexKey
      contextRef="C_20201001to20210930"
      id="Fdei_EntityCentralIndexKey20211227125953579">0001827401</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag
      contextRef="C_20201001to20210930"
      id="Fdei_AmendmentFlag20211227130004095">true</dei:AmendmentFlag>
    <dei:CurrentFiscalYearEndDate
      contextRef="C_20201001to20210930"
      id="Fdei_CurrentFiscalYearEndDate20211227130033503">--09-30</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="C_20201001to20210930"
      id="Fdei_DocumentFiscalYearFocus20211227130053805">2021</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="C_20201001to20210930"
      id="Fdei_DocumentFiscalPeriodFocus20211227130104855">FY</dei:DocumentFiscalPeriodFocus>
    <dei:EntityAddressCountry
      contextRef="C_20201001to20210930"
      id="Fdei_EntityAddressCountry20211228132535640">US</dei:EntityAddressCountry>
    <dei:DocumentType
      contextRef="C_20201001to20210930"
      id="Fxbrl_20211227133624053">20-F/A</dei:DocumentType>
    <dei:DocumentRegistrationStatement
      contextRef="C_20201001to20210930"
      id="Fxbrl_20211227133655465">false</dei:DocumentRegistrationStatement>
    <dei:DocumentAnnualReport
      contextRef="C_20201001to20210930"
      id="Fxbrl_20211227133704248">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate
      contextRef="C_20201001to20210930"
      id="Fxbrl_20211227133718692">2021-09-30</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="C_20201001to20210930"
      id="Fxbrl_20211227133708582">false</dei:DocumentTransitionReport>
    <dei:DocumentShellCompanyReport
      contextRef="C_20201001to20210930"
      id="Fxbrl_20211227133712580">false</dei:DocumentShellCompanyReport>
    <dei:EntityFileNumber
      contextRef="C_20201001to20210930"
      id="Fxbrl_20211227133904872">001-40997</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="C_20201001to20210930"
      id="Fxbrl_20211227133920615">BRIGHT MINDS BIOSCIENCES INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="C_20201001to20210930"
      id="Fxbrl_20211227133951552">Z4</dei:EntityIncorporationStateCountryCode>
    <dei:EntityAddressAddressLine1
      contextRef="C_20201001to20210930"
      id="Fxbrl_20211227134011473">19 Vestry Street</dei:EntityAddressAddressLine1>
    <dei:EntityAddressStateOrProvince
      contextRef="C_20201001to20210930"
      id="Fxbrl_20211227134030405">NY</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressCityOrTown
      contextRef="C_20201001to20210930"
      id="Fxbrl_20211227161511346">NY</dei:EntityAddressCityOrTown>
    <dei:EntityAddressPostalZipCode
      contextRef="C_20201001to20210930"
      id="Fxbrl_20211227134055444">10013</dei:EntityAddressPostalZipCode>
    <dei:ContactPersonnelName
      contextRef="C_20201001to20210930_deiEntityAddressesAddressTypeAxis_deiBusinessContactMember"
      id="Fxbrl_20211227134141232">Ian McDonald</dei:ContactPersonnelName>
    <dei:CityAreaCode
      contextRef="C_20201001to20210930_deiEntityAddressesAddressTypeAxis_deiBusinessContactMember"
      id="Fxbrl_20211227134158579">647</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="C_20201001to20210930_deiEntityAddressesAddressTypeAxis_deiBusinessContactMember"
      id="Fxbrl_20211227134215898">407-2515</dei:LocalPhoneNumber>
    <dei:ContactPersonnelEmailAddress
      contextRef="C_20201001to20210930_deiEntityAddressesAddressTypeAxis_deiBusinessContactMember"
      id="Fxbrl_20211227134230744">ian@brightmindsbio.com</dei:ContactPersonnelEmailAddress>
    <dei:EntityAddressAddressLine1
      contextRef="C_20201001to20210930_deiEntityAddressesAddressTypeAxis_deiBusinessContactMember"
      id="Fxbrl_20211227134108266">19 Vestry Street</dei:EntityAddressAddressLine1>
    <dei:EntityAddressStateOrProvince
      contextRef="C_20201001to20210930_deiEntityAddressesAddressTypeAxis_deiBusinessContactMember"
      id="Fxbrl_20211227134115387">NY</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressCityOrTown
      contextRef="C_20201001to20210930_deiEntityAddressesAddressTypeAxis_deiBusinessContactMember"
      id="Fxbrl_20211227161545234">NY</dei:EntityAddressCityOrTown>
    <dei:EntityAddressPostalZipCode
      contextRef="C_20201001to20210930_deiEntityAddressesAddressTypeAxis_deiBusinessContactMember"
      id="Fxbrl_20211227134122394">10013</dei:EntityAddressPostalZipCode>
    <dei:Security12bTitle
      contextRef="C_20201001to20210930"
      id="Fxbrl_20211227134257248">Common Shares</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="C_20201001to20210930"
      id="Fxbrl_20211227134314472">DRUG</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="C_20201001to20210930"
      id="Fxbrl_20211227134327209">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="C_20210930"
      decimals="INF"
      id="Fxbrl_20211227134413747"
      unitRef="Share">11834361</dei:EntityCommonStockSharesOutstanding>
    <dei:EntityWellKnownSeasonedIssuer
      contextRef="C_20201001to20210930"
      id="Fxbrl_20211227134432190">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers
      contextRef="C_20201001to20210930"
      id="Fxbrl_20211227134439438">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus
      contextRef="C_20201001to20210930"
      id="Fxbrl_20211227134443141">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="C_20201001to20210930"
      id="Fxbrl_20211227134448157">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="C_20201001to20210930"
      id="Fxbrl_20211227134628914">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntityEmergingGrowthCompany
      contextRef="C_20201001to20210930"
      id="Fxbrl_20211227134657226">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod
      contextRef="C_20201001to20210930"
      id="Fxbrl_20211227134709450">false</dei:EntityExTransitionPeriod>
    <dei:DocumentAccountingStandard
      contextRef="C_20201001to20210930"
      id="Fxbrl_20211227134728240">International Financial Reporting Standards</dei:DocumentAccountingStandard>
    <dei:EntityShellCompany
      contextRef="C_20201001to20210930"
      id="Fxbrl_20211227134750504">false</dei:EntityShellCompany>
    <dei:AmendmentDescription
      contextRef="C_20201001to20210930"
      id="Fxbrl_20220115013011986">

                            Bright Minds Biosciences Inc. (the "Company") is filing this Amendment No. 1 to Form 20-F (the "Form 20-F/A") for the year ended September 30, 2021 to furnish Exhibit 101 to the Form 20-F, which provides certain items from our Form 20-F formatted in eXtensible Business Reporting Language ("XBRL"). In accordance with the policy of the Securities and Exchange Commission (the "Commission") stated in Release No. 33-9002, we are filing this Form 20-F/A within the 30-day period available to first-time XBRL filers following the filing of our Form 20-F, as filed with the Commission on December 29, 2021. Accordingly, this Form 20-F/A consists only of the facing page, this explanatory note, Item 18, Item 19, the signature page and Exhibit 101.
                            No other changes have been made to the Form 20-F other than the furnishing of the exhibit described above. This Form 20-F/A does not reflect subsequent events occurring after the original date of the Form 20-F, or modify or update in any way disclosures made in the Form 20-F.

                    </dei:AmendmentDescription>
    <ifrs-full:CashAndCashEquivalents
      contextRef="C_20210930"
      decimals="0"
      id="Fxbrl_20211228161301545_53"
      unitRef="CAD">19760015</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents
      contextRef="C_20200930"
      decimals="0"
      id="Fxbrl_20211228161301545_56"
      unitRef="CAD">799929</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CurrentTaxAssetsCurrent
      contextRef="C_20210930"
      decimals="0"
      id="Fxbrl_20211228161301545_63"
      unitRef="CAD">110146</ifrs-full:CurrentTaxAssetsCurrent>
    <ifrs-full:CurrentTaxAssetsCurrent
      contextRef="C_20200930"
      decimals="0"
      id="Fxbrl_20211228161301545_66"
      unitRef="CAD">0</ifrs-full:CurrentTaxAssetsCurrent>
    <ifrs-full:CurrentPrepaidExpenses
      contextRef="C_20210930"
      decimals="0"
      id="Fxbrl_20211228161301545_73"
      unitRef="CAD">168207</ifrs-full:CurrentPrepaidExpenses>
    <ifrs-full:CurrentPrepaidExpenses
      contextRef="C_20200930"
      decimals="0"
      id="Fxbrl_20211228161301545_76"
      unitRef="CAD">78287</ifrs-full:CurrentPrepaidExpenses>
    <ifrs-full:CurrentAssets
      contextRef="C_20210930"
      decimals="0"
      id="Fxbrl_20211228161301545_83"
      unitRef="CAD">20038368</ifrs-full:CurrentAssets>
    <ifrs-full:CurrentAssets
      contextRef="C_20200930"
      decimals="0"
      id="Fxbrl_20211228161301545_86"
      unitRef="CAD">878216</ifrs-full:CurrentAssets>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="C_20210930"
      decimals="0"
      id="Fxbrl_20211228161301545_103"
      unitRef="CAD">2000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="C_20200930"
      decimals="0"
      id="Fxbrl_20211228161301545_106"
      unitRef="CAD">2000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:Assets
      contextRef="C_20210930"
      decimals="0"
      id="Fxbrl_20211228161301545_113"
      unitRef="CAD">20040368</ifrs-full:Assets>
    <ifrs-full:Assets
      contextRef="C_20200930"
      decimals="0"
      id="Fxbrl_20211228161301545_116"
      unitRef="CAD">880216</ifrs-full:Assets>
    <ifrs-full:TradeAndOtherCurrentPayables
      contextRef="C_20210930"
      decimals="0"
      id="Fxbrl_20211228161301545_153"
      unitRef="CAD">638573</ifrs-full:TradeAndOtherCurrentPayables>
    <ifrs-full:TradeAndOtherCurrentPayables
      contextRef="C_20200930"
      decimals="0"
      id="Fxbrl_20211228161301545_156"
      unitRef="CAD">150923</ifrs-full:TradeAndOtherCurrentPayables>
    <ifrs-full:Liabilities
      contextRef="C_20210930"
      decimals="0"
      id="Fxbrl_20211228161301545_163"
      unitRef="CAD">638573</ifrs-full:Liabilities>
    <ifrs-full:Liabilities
      contextRef="C_20200930"
      decimals="0"
      id="Fxbrl_20211228161301545_166"
      unitRef="CAD">150923</ifrs-full:Liabilities>
    <ifrs-full:IssuedCapital
      contextRef="C_20210930"
      decimals="0"
      id="Fxbrl_20211228161301545_193"
      unitRef="CAD">27080281</ifrs-full:IssuedCapital>
    <ifrs-full:IssuedCapital
      contextRef="C_20200930"
      decimals="0"
      id="Fxbrl_20211228161301545_196"
      unitRef="CAD">980661</ifrs-full:IssuedCapital>
    <drug:SubscriptionsReceivable
      contextRef="C_20210930"
      decimals="0"
      id="Fxbrl_20211228161301545_203"
      unitRef="CAD">33684</drug:SubscriptionsReceivable>
    <drug:SubscriptionsReceivable
      contextRef="C_20200930"
      decimals="0"
      id="Fxbrl_20211228161301545_206"
      unitRef="CAD">1000</drug:SubscriptionsReceivable>
    <drug:SubscriptionsReceived
      contextRef="C_20210930"
      decimals="0"
      id="Fxbrl_20211228161301545_213"
      unitRef="CAD">0</drug:SubscriptionsReceived>
    <drug:SubscriptionsReceived
      contextRef="C_20200930"
      decimals="0"
      id="Fxbrl_20211228161301545_216"
      unitRef="CAD">147426</drug:SubscriptionsReceived>
    <ifrs-full:OtherReserves
      contextRef="C_20210930"
      decimals="0"
      id="Fxbrl_20211228161301545_223"
      unitRef="CAD">1565055</ifrs-full:OtherReserves>
    <ifrs-full:OtherReserves
      contextRef="C_20200930"
      decimals="0"
      id="Fxbrl_20211228161301545_226"
      unitRef="CAD">161300</ifrs-full:OtherReserves>
    <ifrs-full:RetainedEarnings
      contextRef="C_20210930"
      decimals="0"
      id="Fxbrl_20211228161301545_233"
      unitRef="CAD">-9209857</ifrs-full:RetainedEarnings>
    <ifrs-full:RetainedEarnings
      contextRef="C_20200930"
      decimals="0"
      id="Fxbrl_20211228161301545_236"
      unitRef="CAD">-559094</ifrs-full:RetainedEarnings>
    <ifrs-full:Equity
      contextRef="C_20210930"
      decimals="0"
      id="Fxbrl_20211228161301545_243"
      unitRef="CAD">19401795</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="C_20200930"
      decimals="0"
      id="Fxbrl_20211228161301545_246"
      unitRef="CAD">729293</ifrs-full:Equity>
    <ifrs-full:EquityAndLiabilities
      contextRef="C_20210930"
      decimals="0"
      id="Fxbrl_20211228161301545_253"
      unitRef="CAD">20040368</ifrs-full:EquityAndLiabilities>
    <ifrs-full:EquityAndLiabilities
      contextRef="C_20200930"
      decimals="0"
      id="Fxbrl_20211228161301545_256"
      unitRef="CAD">880216</ifrs-full:EquityAndLiabilities>
    <drug:ConsultingFees
      contextRef="C_20201001to20210930"
      decimals="0"
      id="Fxbrl_20211228163809986_43"
      unitRef="CAD">394624</drug:ConsultingFees>
    <drug:ConsultingFees
      contextRef="C_20191001to20200930"
      decimals="0"
      id="Fxbrl_20211228163809986_46"
      unitRef="CAD">0</drug:ConsultingFees>
    <drug:ConsultingFees
      contextRef="C_20190601to20190930"
      decimals="0"
      id="Fxbrl_20211228163809986_49"
      unitRef="CAD">0</drug:ConsultingFees>
    <ifrs-full:DirectorsRemunerationExpense
      contextRef="C_20201001to20210930"
      decimals="0"
      id="Fxbrl_20211228163809986_53"
      unitRef="CAD">136612</ifrs-full:DirectorsRemunerationExpense>
    <ifrs-full:DirectorsRemunerationExpense
      contextRef="C_20191001to20200930"
      decimals="0"
      id="Fxbrl_20211228163809986_56"
      unitRef="CAD">0</ifrs-full:DirectorsRemunerationExpense>
    <ifrs-full:DirectorsRemunerationExpense
      contextRef="C_20190601to20190930"
      decimals="0"
      id="Fxbrl_20211228163809986_59"
      unitRef="CAD">0</ifrs-full:DirectorsRemunerationExpense>
    <ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss
      contextRef="C_20201001to20210930"
      decimals="0"
      id="Fxbrl_20211228163809986_63"
      unitRef="CAD">154099</ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss>
    <ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss
      contextRef="C_20191001to20200930"
      decimals="0"
      id="Fxbrl_20211228163809986_66"
      unitRef="CAD">0</ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss>
    <ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss
      contextRef="C_20190601to20190930"
      decimals="0"
      id="Fxbrl_20211228163809986_69"
      unitRef="CAD">0</ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss>
    <drug:ProcessingFees
      contextRef="C_20201001to20210930"
      decimals="0"
      id="Fxbrl_20211228163809986_73"
      unitRef="CAD">18665</drug:ProcessingFees>
    <drug:ProcessingFees
      contextRef="C_20191001to20200930"
      decimals="0"
      id="Fxbrl_20211228163809986_76"
      unitRef="CAD">5568</drug:ProcessingFees>
    <drug:ProcessingFees
      contextRef="C_20190601to20190930"
      decimals="0"
      id="Fxbrl_20211228163809986_79"
      unitRef="CAD">0</drug:ProcessingFees>
    <ifrs-full:SalesAndMarketingExpense
      contextRef="C_20201001to20210930"
      decimals="0"
      id="Fxbrl_20211228163809986_83"
      unitRef="CAD">852151</ifrs-full:SalesAndMarketingExpense>
    <ifrs-full:SalesAndMarketingExpense
      contextRef="C_20191001to20200930"
      decimals="0"
      id="Fxbrl_20211228163809986_86"
      unitRef="CAD">9618</ifrs-full:SalesAndMarketingExpense>
    <ifrs-full:SalesAndMarketingExpense
      contextRef="C_20190601to20190930"
      decimals="0"
      id="Fxbrl_20211228163809986_89"
      unitRef="CAD">0</ifrs-full:SalesAndMarketingExpense>
    <ifrs-full:GeneralAndAdministrativeExpense
      contextRef="C_20201001to20210930"
      decimals="0"
      id="Fxbrl_20211228163809986_93"
      unitRef="CAD">197125</ifrs-full:GeneralAndAdministrativeExpense>
    <ifrs-full:GeneralAndAdministrativeExpense
      contextRef="C_20191001to20200930"
      decimals="0"
      id="Fxbrl_20211228163809986_96"
      unitRef="CAD">637</ifrs-full:GeneralAndAdministrativeExpense>
    <ifrs-full:GeneralAndAdministrativeExpense
      contextRef="C_20190601to20190930"
      decimals="0"
      id="Fxbrl_20211228163809986_99"
      unitRef="CAD">0</ifrs-full:GeneralAndAdministrativeExpense>
    <ifrs-full:ProfessionalFeesExpense
      contextRef="C_20201001to20210930"
      decimals="0"
      id="Fxbrl_20211228163809986_103"
      unitRef="CAD">709954</ifrs-full:ProfessionalFeesExpense>
    <ifrs-full:ProfessionalFeesExpense
      contextRef="C_20191001to20200930"
      decimals="0"
      id="Fxbrl_20211228163809986_106"
      unitRef="CAD">104251</ifrs-full:ProfessionalFeesExpense>
    <ifrs-full:ProfessionalFeesExpense
      contextRef="C_20190601to20190930"
      decimals="0"
      id="Fxbrl_20211228163809986_109"
      unitRef="CAD">36708</ifrs-full:ProfessionalFeesExpense>
    <drug:RegulatoryAndFilingExpenses
      contextRef="C_20201001to20210930"
      decimals="0"
      id="Fxbrl_20211228163809986_113"
      unitRef="CAD">181743</drug:RegulatoryAndFilingExpenses>
    <drug:RegulatoryAndFilingExpenses
      contextRef="C_20191001to20200930"
      decimals="0"
      id="Fxbrl_20211228163809986_116"
      unitRef="CAD">5451</drug:RegulatoryAndFilingExpenses>
    <drug:RegulatoryAndFilingExpenses
      contextRef="C_20190601to20190930"
      decimals="0"
      id="Fxbrl_20211228163809986_119"
      unitRef="CAD">0</drug:RegulatoryAndFilingExpenses>
    <ifrs-full:ResearchAndDevelopmentExpense
      contextRef="C_20201001to20210930"
      decimals="0"
      id="Fxbrl_20211228163809986_123"
      unitRef="CAD">6313988</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense
      contextRef="C_20191001to20200930"
      decimals="0"
      id="Fxbrl_20211228163809986_126"
      unitRef="CAD">354852</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense
      contextRef="C_20190601to20190930"
      decimals="0"
      id="Fxbrl_20211228163809986_129"
      unitRef="CAD">42009</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ProfitLoss
      contextRef="C_20201001to20210930"
      decimals="0"
      id="Fxbrl_20211228163809986_133"
      unitRef="CAD">-8650763</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss
      contextRef="C_20191001to20200930"
      decimals="0"
      id="Fxbrl_20211228163809986_136"
      unitRef="CAD">-480377</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss
      contextRef="C_20190601to20190930"
      decimals="0"
      id="Fxbrl_20211228163809986_139"
      unitRef="CAD">-78717</ifrs-full:ProfitLoss>
    <ifrs-full:BasicAndDilutedEarningsLossPerShare
      contextRef="C_20201001to20210930"
      decimals="2"
      id="Fxbrl_20211228163809986_153"
      unitRef="CAD_per_share">-0.96</ifrs-full:BasicAndDilutedEarningsLossPerShare>
    <ifrs-full:BasicAndDilutedEarningsLossPerShare
      contextRef="C_20191001to20200930"
      decimals="2"
      id="Fxbrl_20211228163809986_156"
      unitRef="CAD_per_share">-0.13</ifrs-full:BasicAndDilutedEarningsLossPerShare>
    <ifrs-full:BasicAndDilutedEarningsLossPerShare
      contextRef="C_20190601to20190930"
      decimals="2"
      id="Fxbrl_20211228163809986_159"
      unitRef="CAD_per_share">-0.04</ifrs-full:BasicAndDilutedEarningsLossPerShare>
    <ifrs-full:WeightedAverageShares
      contextRef="C_20201001to20210930"
      decimals="0"
      id="Fxbrl_20211228163809986_173"
      unitRef="Share">8974023</ifrs-full:WeightedAverageShares>
    <ifrs-full:WeightedAverageShares
      contextRef="C_20191001to20200930"
      decimals="0"
      id="Fxbrl_20211228163809986_176"
      unitRef="Share">3612436</ifrs-full:WeightedAverageShares>
    <ifrs-full:WeightedAverageShares
      contextRef="C_20190601to20190930"
      decimals="0"
      id="Fxbrl_20211228163809986_179"
      unitRef="Share">2073240</ifrs-full:WeightedAverageShares>
    <ifrs-full:NumberOfSharesOutstanding
      contextRef="C_20190531_ifrsfullComponentsOfEquityAxis_ifrsfullIssuedCapitalMember"
      decimals="INF"
      id="Fxbrl_20211228194258211_32"
      unitRef="Share">0</ifrs-full:NumberOfSharesOutstanding>
    <ifrs-full:Equity
      contextRef="C_20190531_ifrsfullComponentsOfEquityAxis_ifrsfullIssuedCapitalMember"
      decimals="0"
      id="Fxbrl_20211228194258211_35"
      unitRef="CAD">0</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="C_20190531_ifrsfullComponentsOfEquityAxis_drugSubscriptionReceivableMember"
      decimals="0"
      id="Fxbrl_20211228194258211_38"
      unitRef="CAD">0</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="C_20190531_ifrsfullComponentsOfEquityAxis_drugSubscriptionReceivedMember"
      decimals="0"
      id="Fxbrl_20211228194258211_311"
      unitRef="CAD">0</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="C_20190531_ifrsfullComponentsOfEquityAxis_ifrsfullOtherReservesMember"
      decimals="0"
      id="Fxbrl_20211228194258211_314"
      unitRef="CAD">0</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="C_20190531_ifrsfullComponentsOfEquityAxis_ifrsfullRetainedEarningsMember"
      decimals="0"
      id="Fxbrl_20211228194258211_317"
      unitRef="CAD">0</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="C_20190531"
      decimals="0"
      id="Fxbrl_20211228194258211_320"
      unitRef="CAD">0</ifrs-full:Equity>
    <drug:IncreaseDecreaseThroughPrivatePlacementShares
      contextRef="C_20190601to20190930_ifrsfullComponentsOfEquityAxis_ifrsfullIssuedCapitalMember"
      decimals="INF"
      id="Fxbrl_20211228194258211_42"
      unitRef="Share">4079600</drug:IncreaseDecreaseThroughPrivatePlacementShares>
    <drug:IncreaseDecreaseThroughPrivatePlacement
      contextRef="C_20190601to20190930_ifrsfullComponentsOfEquityAxis_ifrsfullIssuedCapitalMember"
      decimals="0"
      id="Fxbrl_20211228194258211_45"
      unitRef="CAD">203980</drug:IncreaseDecreaseThroughPrivatePlacement>
    <drug:IncreaseDecreaseThroughPrivatePlacement
      contextRef="C_20190601to20190930_ifrsfullComponentsOfEquityAxis_drugSubscriptionReceivableMember"
      decimals="0"
      id="Fxbrl_20211228194258211_48"
      unitRef="CAD">-81980</drug:IncreaseDecreaseThroughPrivatePlacement>
    <drug:IncreaseDecreaseThroughPrivatePlacement
      contextRef="C_20190601to20190930_ifrsfullComponentsOfEquityAxis_drugSubscriptionReceivedMember"
      decimals="0"
      id="Fxbrl_20211228194258211_411"
      unitRef="CAD">0</drug:IncreaseDecreaseThroughPrivatePlacement>
    <drug:IncreaseDecreaseThroughPrivatePlacement
      contextRef="C_20190601to20190930_ifrsfullComponentsOfEquityAxis_ifrsfullOtherReservesMember"
      decimals="0"
      id="Fxbrl_20211228194258211_414"
      unitRef="CAD">0</drug:IncreaseDecreaseThroughPrivatePlacement>
    <drug:IncreaseDecreaseThroughPrivatePlacement
      contextRef="C_20190601to20190930_ifrsfullComponentsOfEquityAxis_ifrsfullRetainedEarningsMember"
      decimals="0"
      id="Fxbrl_20211228194258211_417"
      unitRef="CAD">0</drug:IncreaseDecreaseThroughPrivatePlacement>
    <drug:IncreaseDecreaseThroughPrivatePlacement
      contextRef="C_20190601to20190930"
      decimals="0"
      id="Fxbrl_20211228194258211_420"
      unitRef="CAD">122000</drug:IncreaseDecreaseThroughPrivatePlacement>
    <drug:IncreaseDecreaseThroughAcquisitionOfIntangibleAssetsShares
      contextRef="C_20190601to20190930_ifrsfullComponentsOfEquityAxis_ifrsfullIssuedCapitalMember"
      decimals="INF"
      id="Fxbrl_20211228194258211_52"
      unitRef="Share">40000</drug:IncreaseDecreaseThroughAcquisitionOfIntangibleAssetsShares>
    <drug:IncreaseDecreaseThroughAcquisitionOfIntangibleAssets
      contextRef="C_20190601to20190930_ifrsfullComponentsOfEquityAxis_ifrsfullIssuedCapitalMember"
      decimals="0"
      id="Fxbrl_20211228194258211_55"
      unitRef="CAD">2000</drug:IncreaseDecreaseThroughAcquisitionOfIntangibleAssets>
    <drug:IncreaseDecreaseThroughAcquisitionOfIntangibleAssets
      contextRef="C_20190601to20190930_ifrsfullComponentsOfEquityAxis_drugSubscriptionReceivableMember"
      decimals="0"
      id="Fxbrl_20211228194258211_58"
      unitRef="CAD">0</drug:IncreaseDecreaseThroughAcquisitionOfIntangibleAssets>
    <drug:IncreaseDecreaseThroughAcquisitionOfIntangibleAssets
      contextRef="C_20190601to20190930_ifrsfullComponentsOfEquityAxis_drugSubscriptionReceivedMember"
      decimals="0"
      id="Fxbrl_20211228194258211_511"
      unitRef="CAD">0</drug:IncreaseDecreaseThroughAcquisitionOfIntangibleAssets>
    <drug:IncreaseDecreaseThroughAcquisitionOfIntangibleAssets
      contextRef="C_20190601to20190930_ifrsfullComponentsOfEquityAxis_ifrsfullOtherReservesMember"
      decimals="0"
      id="Fxbrl_20211228194258211_514"
      unitRef="CAD">0</drug:IncreaseDecreaseThroughAcquisitionOfIntangibleAssets>
    <drug:IncreaseDecreaseThroughAcquisitionOfIntangibleAssets
      contextRef="C_20190601to20190930_ifrsfullComponentsOfEquityAxis_ifrsfullRetainedEarningsMember"
      decimals="0"
      id="Fxbrl_20211228194258211_517"
      unitRef="CAD">0</drug:IncreaseDecreaseThroughAcquisitionOfIntangibleAssets>
    <drug:IncreaseDecreaseThroughAcquisitionOfIntangibleAssets
      contextRef="C_20190601to20190930"
      decimals="0"
      id="Fxbrl_20211228194258211_520"
      unitRef="CAD">2000</drug:IncreaseDecreaseThroughAcquisitionOfIntangibleAssets>
    <ifrs-full:ProfitLoss
      contextRef="C_20190601to20190930_ifrsfullComponentsOfEquityAxis_ifrsfullIssuedCapitalMember"
      decimals="0"
      id="Fxbrl_20211228194258211_65"
      unitRef="CAD">0</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss
      contextRef="C_20190601to20190930_ifrsfullComponentsOfEquityAxis_drugSubscriptionReceivableMember"
      decimals="0"
      id="Fxbrl_20211228194258211_68"
      unitRef="CAD">0</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss
      contextRef="C_20190601to20190930_ifrsfullComponentsOfEquityAxis_drugSubscriptionReceivedMember"
      decimals="0"
      id="Fxbrl_20211228194258211_611"
      unitRef="CAD">0</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss
      contextRef="C_20190601to20190930_ifrsfullComponentsOfEquityAxis_ifrsfullOtherReservesMember"
      decimals="0"
      id="Fxbrl_20211228194258211_614"
      unitRef="CAD">0</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss
      contextRef="C_20190601to20190930_ifrsfullComponentsOfEquityAxis_ifrsfullRetainedEarningsMember"
      decimals="0"
      id="Fxbrl_20211228194258211_617"
      unitRef="CAD">-78717</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss
      contextRef="C_20190601to20190930"
      decimals="0"
      id="Fxbrl_20211228194258211_620"
      unitRef="CAD">-78717</ifrs-full:ProfitLoss>
    <ifrs-full:NumberOfSharesOutstanding
      contextRef="C_20190930_ifrsfullComponentsOfEquityAxis_ifrsfullIssuedCapitalMember"
      decimals="INF"
      id="Fxbrl_20211228194258211_72"
      unitRef="Share">4119600</ifrs-full:NumberOfSharesOutstanding>
    <ifrs-full:Equity
      contextRef="C_20190930_ifrsfullComponentsOfEquityAxis_ifrsfullIssuedCapitalMember"
      decimals="0"
      id="Fxbrl_20211228194258211_75"
      unitRef="CAD">205980</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="C_20190930_ifrsfullComponentsOfEquityAxis_drugSubscriptionReceivableMember"
      decimals="0"
      id="Fxbrl_20211228194258211_78"
      unitRef="CAD">-81980</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="C_20190930_ifrsfullComponentsOfEquityAxis_drugSubscriptionReceivedMember"
      decimals="0"
      id="Fxbrl_20211228194258211_711"
      unitRef="CAD">0</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="C_20190930_ifrsfullComponentsOfEquityAxis_ifrsfullOtherReservesMember"
      decimals="0"
      id="Fxbrl_20211228194258211_714"
      unitRef="CAD">0</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="C_20190930_ifrsfullComponentsOfEquityAxis_ifrsfullRetainedEarningsMember"
      decimals="0"
      id="Fxbrl_20211228194258211_717"
      unitRef="CAD">-78717</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="C_20190930"
      decimals="0"
      id="Fxbrl_20211228194258211_720"
      unitRef="CAD">45283</ifrs-full:Equity>
    <ifrs-full:NumberOfSharesOutstanding
      contextRef="C_20190930_ifrsfullComponentsOfEquityAxis_ifrsfullIssuedCapitalMember"
      decimals="INF"
      id="Fxbrl_20211228194258211_92"
      unitRef="Share">4119600</ifrs-full:NumberOfSharesOutstanding>
    <ifrs-full:Equity
      contextRef="C_20190930_ifrsfullComponentsOfEquityAxis_ifrsfullIssuedCapitalMember"
      decimals="0"
      id="Fxbrl_20211228194258211_95"
      unitRef="CAD">205980</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="C_20190930_ifrsfullComponentsOfEquityAxis_drugSubscriptionReceivableMember"
      decimals="0"
      id="Fxbrl_20211228194258211_98"
      unitRef="CAD">-81980</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="C_20190930_ifrsfullComponentsOfEquityAxis_drugSubscriptionReceivedMember"
      decimals="0"
      id="Fxbrl_20211228194258211_911"
      unitRef="CAD">0</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="C_20190930_ifrsfullComponentsOfEquityAxis_ifrsfullOtherReservesMember"
      decimals="0"
      id="Fxbrl_20211228194258211_914"
      unitRef="CAD">0</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="C_20190930_ifrsfullComponentsOfEquityAxis_ifrsfullRetainedEarningsMember"
      decimals="0"
      id="Fxbrl_20211228194258211_917"
      unitRef="CAD">-78717</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="C_20190930"
      decimals="0"
      id="Fxbrl_20211228194258211_920"
      unitRef="CAD">45283</ifrs-full:Equity>
    <drug:IncreaseDecreaseThroughPrivatePlacementShares
      contextRef="C_20191001to20200930_ifrsfullComponentsOfEquityAxis_ifrsfullIssuedCapitalMember"
      decimals="INF"
      id="Fxbrl_20211228194258211_102"
      unitRef="Share">623941</drug:IncreaseDecreaseThroughPrivatePlacementShares>
    <drug:IncreaseDecreaseThroughPrivatePlacement
      contextRef="C_20191001to20200930_ifrsfullComponentsOfEquityAxis_ifrsfullIssuedCapitalMember"
      decimals="0"
      id="Fxbrl_20211228194258211_105"
      unitRef="CAD">779924</drug:IncreaseDecreaseThroughPrivatePlacement>
    <drug:IncreaseDecreaseThroughPrivatePlacement
      contextRef="C_20191001to20200930_ifrsfullComponentsOfEquityAxis_drugSubscriptionReceivableMember"
      decimals="0"
      id="Fxbrl_20211228194258211_108"
      unitRef="CAD">80980</drug:IncreaseDecreaseThroughPrivatePlacement>
    <drug:IncreaseDecreaseThroughPrivatePlacement
      contextRef="C_20191001to20200930_ifrsfullComponentsOfEquityAxis_drugSubscriptionReceivedMember"
      decimals="0"
      id="Fxbrl_20211228194258211_1011"
      unitRef="CAD">147426</drug:IncreaseDecreaseThroughPrivatePlacement>
    <drug:IncreaseDecreaseThroughPrivatePlacement
      contextRef="C_20191001to20200930_ifrsfullComponentsOfEquityAxis_ifrsfullOtherReservesMember"
      decimals="0"
      id="Fxbrl_20211228194258211_1014"
      unitRef="CAD">0</drug:IncreaseDecreaseThroughPrivatePlacement>
    <drug:IncreaseDecreaseThroughPrivatePlacement
      contextRef="C_20191001to20200930_ifrsfullComponentsOfEquityAxis_ifrsfullRetainedEarningsMember"
      decimals="0"
      id="Fxbrl_20211228194258211_1017"
      unitRef="CAD">0</drug:IncreaseDecreaseThroughPrivatePlacement>
    <drug:IncreaseDecreaseThroughPrivatePlacement
      contextRef="C_20191001to20200930"
      decimals="0"
      id="Fxbrl_20211228194258211_1020"
      unitRef="CAD">1008330</drug:IncreaseDecreaseThroughPrivatePlacement>
    <ifrs-full:ShareIssueRelatedCost
      contextRef="C_20191001to20200930_ifrsfullComponentsOfEquityAxis_ifrsfullIssuedCapitalMember"
      decimals="0"
      id="Fxbrl_20211228194258211_115"
      unitRef="CAD">5243</ifrs-full:ShareIssueRelatedCost>
    <ifrs-full:ShareIssueRelatedCost
      contextRef="C_20191001to20200930_ifrsfullComponentsOfEquityAxis_drugSubscriptionReceivableMember"
      decimals="0"
      id="Fxbrl_20211228194258211_118"
      unitRef="CAD">0</ifrs-full:ShareIssueRelatedCost>
    <ifrs-full:ShareIssueRelatedCost
      contextRef="C_20191001to20200930_ifrsfullComponentsOfEquityAxis_drugSubscriptionReceivedMember"
      decimals="0"
      id="Fxbrl_20211228194258211_1111"
      unitRef="CAD">0</ifrs-full:ShareIssueRelatedCost>
    <ifrs-full:ShareIssueRelatedCost
      contextRef="C_20191001to20200930_ifrsfullComponentsOfEquityAxis_ifrsfullOtherReservesMember"
      decimals="0"
      id="Fxbrl_20211228194258211_1114"
      unitRef="CAD">0</ifrs-full:ShareIssueRelatedCost>
    <ifrs-full:ShareIssueRelatedCost
      contextRef="C_20191001to20200930_ifrsfullComponentsOfEquityAxis_ifrsfullRetainedEarningsMember"
      decimals="0"
      id="Fxbrl_20211228194258211_1117"
      unitRef="CAD">0</ifrs-full:ShareIssueRelatedCost>
    <ifrs-full:ShareIssueRelatedCost
      contextRef="C_20191001to20200930"
      decimals="0"
      id="Fxbrl_20211228194258211_1120"
      unitRef="CAD">5243</ifrs-full:ShareIssueRelatedCost>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="C_20191001to20200930_ifrsfullComponentsOfEquityAxis_ifrsfullIssuedCapitalMember"
      decimals="0"
      id="Fxbrl_20211228194258211_125"
      unitRef="CAD">0</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="C_20191001to20200930_ifrsfullComponentsOfEquityAxis_drugSubscriptionReceivableMember"
      decimals="0"
      id="Fxbrl_20211228194258211_128"
      unitRef="CAD">0</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="C_20191001to20200930_ifrsfullComponentsOfEquityAxis_drugSubscriptionReceivedMember"
      decimals="0"
      id="Fxbrl_20211228194258211_1211"
      unitRef="CAD">0</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="C_20191001to20200930_ifrsfullComponentsOfEquityAxis_ifrsfullOtherReservesMember"
      decimals="0"
      id="Fxbrl_20211228194258211_1214"
      unitRef="CAD">161300</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="C_20191001to20200930_ifrsfullComponentsOfEquityAxis_ifrsfullRetainedEarningsMember"
      decimals="0"
      id="Fxbrl_20211228194258211_1217"
      unitRef="CAD">0</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="C_20191001to20200930"
      decimals="0"
      id="Fxbrl_20211228194258211_1220"
      unitRef="CAD">161300</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <ifrs-full:ProfitLoss
      contextRef="C_20191001to20200930_ifrsfullComponentsOfEquityAxis_ifrsfullIssuedCapitalMember"
      decimals="0"
      id="Fxbrl_20211228194258211_135"
      unitRef="CAD">0</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss
      contextRef="C_20191001to20200930_ifrsfullComponentsOfEquityAxis_drugSubscriptionReceivableMember"
      decimals="0"
      id="Fxbrl_20211228194258211_138"
      unitRef="CAD">0</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss
      contextRef="C_20191001to20200930_ifrsfullComponentsOfEquityAxis_drugSubscriptionReceivedMember"
      decimals="0"
      id="Fxbrl_20211228194258211_1311"
      unitRef="CAD">0</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss
      contextRef="C_20191001to20200930_ifrsfullComponentsOfEquityAxis_ifrsfullOtherReservesMember"
      decimals="0"
      id="Fxbrl_20211228194258211_1314"
      unitRef="CAD">0</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss
      contextRef="C_20191001to20200930_ifrsfullComponentsOfEquityAxis_ifrsfullRetainedEarningsMember"
      decimals="0"
      id="Fxbrl_20211228194258211_1317"
      unitRef="CAD">-480377</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss
      contextRef="C_20191001to20200930"
      decimals="0"
      id="Fxbrl_20211228194258211_1320"
      unitRef="CAD">-480377</ifrs-full:ProfitLoss>
    <ifrs-full:NumberOfSharesOutstanding
      contextRef="C_20200930_ifrsfullComponentsOfEquityAxis_ifrsfullIssuedCapitalMember"
      decimals="INF"
      id="Fxbrl_20211228194258211_142"
      unitRef="Share">4743541</ifrs-full:NumberOfSharesOutstanding>
    <ifrs-full:Equity
      contextRef="C_20200930_ifrsfullComponentsOfEquityAxis_ifrsfullIssuedCapitalMember"
      decimals="0"
      id="Fxbrl_20211228194258211_145"
      unitRef="CAD">980661</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="C_20200930_ifrsfullComponentsOfEquityAxis_drugSubscriptionReceivableMember"
      decimals="0"
      id="Fxbrl_20211228194258211_148"
      unitRef="CAD">-1000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="C_20200930_ifrsfullComponentsOfEquityAxis_drugSubscriptionReceivedMember"
      decimals="0"
      id="Fxbrl_20211228194258211_1411"
      unitRef="CAD">147426</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="C_20200930_ifrsfullComponentsOfEquityAxis_ifrsfullOtherReservesMember"
      decimals="0"
      id="Fxbrl_20211228194258211_1414"
      unitRef="CAD">161300</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="C_20200930_ifrsfullComponentsOfEquityAxis_ifrsfullRetainedEarningsMember"
      decimals="0"
      id="Fxbrl_20211228194258211_1417"
      unitRef="CAD">-559094</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="C_20200930"
      decimals="0"
      id="Fxbrl_20211228194258211_1420"
      unitRef="CAD">729293</ifrs-full:Equity>
    <ifrs-full:NumberOfSharesOutstanding
      contextRef="C_20200930_ifrsfullComponentsOfEquityAxis_ifrsfullIssuedCapitalMember"
      decimals="INF"
      id="Fxbrl_20211228194258211_162"
      unitRef="Share">4743541</ifrs-full:NumberOfSharesOutstanding>
    <ifrs-full:Equity
      contextRef="C_20200930_ifrsfullComponentsOfEquityAxis_ifrsfullIssuedCapitalMember"
      decimals="0"
      id="Fxbrl_20211228194258211_165"
      unitRef="CAD">980661</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="C_20200930_ifrsfullComponentsOfEquityAxis_drugSubscriptionReceivableMember"
      decimals="0"
      id="Fxbrl_20211228194258211_168"
      unitRef="CAD">-1000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="C_20200930_ifrsfullComponentsOfEquityAxis_drugSubscriptionReceivedMember"
      decimals="0"
      id="Fxbrl_20211228194258211_1611"
      unitRef="CAD">147426</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="C_20200930_ifrsfullComponentsOfEquityAxis_ifrsfullOtherReservesMember"
      decimals="0"
      id="Fxbrl_20211228194258211_1614"
      unitRef="CAD">161300</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="C_20200930_ifrsfullComponentsOfEquityAxis_ifrsfullRetainedEarningsMember"
      decimals="0"
      id="Fxbrl_20211228194258211_1617"
      unitRef="CAD">-559094</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="C_20200930"
      decimals="0"
      id="Fxbrl_20211228194258211_1620"
      unitRef="CAD">729293</ifrs-full:Equity>
    <drug:IncreaseDecreaseThroughPrivatePlacementShares
      contextRef="C_20201001to20210930_ifrsfullComponentsOfEquityAxis_ifrsfullIssuedCapitalMember"
      decimals="INF"
      id="Fxbrl_20211228194258211_172"
      unitRef="Share">5049021</drug:IncreaseDecreaseThroughPrivatePlacementShares>
    <drug:IncreaseDecreaseThroughPrivatePlacement
      contextRef="C_20201001to20210930_ifrsfullComponentsOfEquityAxis_ifrsfullIssuedCapitalMember"
      decimals="0"
      id="Fxbrl_20211228194258211_175"
      unitRef="CAD">27924936</drug:IncreaseDecreaseThroughPrivatePlacement>
    <drug:IncreaseDecreaseThroughPrivatePlacement
      contextRef="C_20201001to20210930_ifrsfullComponentsOfEquityAxis_drugSubscriptionReceivableMember"
      decimals="0"
      id="Fxbrl_20211228194258211_178"
      unitRef="CAD">-32684</drug:IncreaseDecreaseThroughPrivatePlacement>
    <drug:IncreaseDecreaseThroughPrivatePlacement
      contextRef="C_20201001to20210930_ifrsfullComponentsOfEquityAxis_drugSubscriptionReceivedMember"
      decimals="0"
      id="Fxbrl_20211228194258211_1711"
      unitRef="CAD">-147426</drug:IncreaseDecreaseThroughPrivatePlacement>
    <drug:IncreaseDecreaseThroughPrivatePlacement
      contextRef="C_20201001to20210930_ifrsfullComponentsOfEquityAxis_ifrsfullOtherReservesMember"
      decimals="0"
      id="Fxbrl_20211228194258211_1714"
      unitRef="CAD">0</drug:IncreaseDecreaseThroughPrivatePlacement>
    <drug:IncreaseDecreaseThroughPrivatePlacement
      contextRef="C_20201001to20210930_ifrsfullComponentsOfEquityAxis_ifrsfullRetainedEarningsMember"
      decimals="0"
      id="Fxbrl_20211228194258211_1717"
      unitRef="CAD">0</drug:IncreaseDecreaseThroughPrivatePlacement>
    <drug:IncreaseDecreaseThroughPrivatePlacement
      contextRef="C_20201001to20210930"
      decimals="0"
      id="Fxbrl_20211228194258211_1720"
      unitRef="CAD">27744826</drug:IncreaseDecreaseThroughPrivatePlacement>
    <drug:IncreaseDecreaseThroughFindersFeesCash
      contextRef="C_20201001to20210930_ifrsfullComponentsOfEquityAxis_ifrsfullIssuedCapitalMember"
      decimals="0"
      id="Fxbrl_20211228194258211_185"
      unitRef="CAD">-1516317</drug:IncreaseDecreaseThroughFindersFeesCash>
    <drug:IncreaseDecreaseThroughFindersFeesCash
      contextRef="C_20201001to20210930_ifrsfullComponentsOfEquityAxis_drugSubscriptionReceivableMember"
      decimals="0"
      id="Fxbrl_20211228194258211_188"
      unitRef="CAD">0</drug:IncreaseDecreaseThroughFindersFeesCash>
    <drug:IncreaseDecreaseThroughFindersFeesCash
      contextRef="C_20201001to20210930_ifrsfullComponentsOfEquityAxis_drugSubscriptionReceivedMember"
      decimals="0"
      id="Fxbrl_20211228194258211_1811"
      unitRef="CAD">0</drug:IncreaseDecreaseThroughFindersFeesCash>
    <drug:IncreaseDecreaseThroughFindersFeesCash
      contextRef="C_20201001to20210930_ifrsfullComponentsOfEquityAxis_ifrsfullOtherReservesMember"
      decimals="0"
      id="Fxbrl_20211228194258211_1814"
      unitRef="CAD">0</drug:IncreaseDecreaseThroughFindersFeesCash>
    <drug:IncreaseDecreaseThroughFindersFeesCash
      contextRef="C_20201001to20210930_ifrsfullComponentsOfEquityAxis_ifrsfullRetainedEarningsMember"
      decimals="0"
      id="Fxbrl_20211228194258211_1817"
      unitRef="CAD">0</drug:IncreaseDecreaseThroughFindersFeesCash>
    <drug:IncreaseDecreaseThroughFindersFeesCash
      contextRef="C_20201001to20210930"
      decimals="0"
      id="Fxbrl_20211228194258211_1820"
      unitRef="CAD">-1516317</drug:IncreaseDecreaseThroughFindersFeesCash>
    <drug:IncreaseDecreaseThroughFindersFeesBrokerWarrants
      contextRef="C_20201001to20210930_ifrsfullComponentsOfEquityAxis_ifrsfullIssuedCapitalMember"
      decimals="0"
      id="Fxbrl_20211228194258211_195"
      unitRef="CAD">-521000</drug:IncreaseDecreaseThroughFindersFeesBrokerWarrants>
    <drug:IncreaseDecreaseThroughFindersFeesBrokerWarrants
      contextRef="C_20201001to20210930_ifrsfullComponentsOfEquityAxis_drugSubscriptionReceivableMember"
      decimals="0"
      id="Fxbrl_20211228194258211_198"
      unitRef="CAD">0</drug:IncreaseDecreaseThroughFindersFeesBrokerWarrants>
    <drug:IncreaseDecreaseThroughFindersFeesBrokerWarrants
      contextRef="C_20201001to20210930_ifrsfullComponentsOfEquityAxis_drugSubscriptionReceivedMember"
      decimals="0"
      id="Fxbrl_20211228194258211_1911"
      unitRef="CAD">0</drug:IncreaseDecreaseThroughFindersFeesBrokerWarrants>
    <drug:IncreaseDecreaseThroughFindersFeesBrokerWarrants
      contextRef="C_20201001to20210930_ifrsfullComponentsOfEquityAxis_ifrsfullOtherReservesMember"
      decimals="0"
      id="Fxbrl_20211228194258211_1914"
      unitRef="CAD">521000</drug:IncreaseDecreaseThroughFindersFeesBrokerWarrants>
    <drug:IncreaseDecreaseThroughFindersFeesBrokerWarrants
      contextRef="C_20201001to20210930_ifrsfullComponentsOfEquityAxis_ifrsfullRetainedEarningsMember"
      decimals="0"
      id="Fxbrl_20211228194258211_1917"
      unitRef="CAD">0</drug:IncreaseDecreaseThroughFindersFeesBrokerWarrants>
    <drug:IncreaseDecreaseThroughFindersFeesBrokerWarrants
      contextRef="C_20201001to20210930"
      decimals="0"
      id="Fxbrl_20211228194258211_1920"
      unitRef="CAD">0</drug:IncreaseDecreaseThroughFindersFeesBrokerWarrants>
    <drug:IncreaseDecreaseThroughFindersFeesShareOptions
      contextRef="C_20201001to20210930_ifrsfullComponentsOfEquityAxis_ifrsfullIssuedCapitalMember"
      decimals="0"
      id="Fxbrl_20211228194258211_205"
      unitRef="CAD">-2140</drug:IncreaseDecreaseThroughFindersFeesShareOptions>
    <drug:IncreaseDecreaseThroughFindersFeesShareOptions
      contextRef="C_20201001to20210930_ifrsfullComponentsOfEquityAxis_drugSubscriptionReceivableMember"
      decimals="0"
      id="Fxbrl_20211228194258211_208"
      unitRef="CAD">0</drug:IncreaseDecreaseThroughFindersFeesShareOptions>
    <drug:IncreaseDecreaseThroughFindersFeesShareOptions
      contextRef="C_20201001to20210930_ifrsfullComponentsOfEquityAxis_drugSubscriptionReceivedMember"
      decimals="0"
      id="Fxbrl_20211228194258211_2011"
      unitRef="CAD">0</drug:IncreaseDecreaseThroughFindersFeesShareOptions>
    <drug:IncreaseDecreaseThroughFindersFeesShareOptions
      contextRef="C_20201001to20210930_ifrsfullComponentsOfEquityAxis_ifrsfullOtherReservesMember"
      decimals="0"
      id="Fxbrl_20211228194258211_2014"
      unitRef="CAD">2140</drug:IncreaseDecreaseThroughFindersFeesShareOptions>
    <drug:IncreaseDecreaseThroughFindersFeesShareOptions
      contextRef="C_20201001to20210930_ifrsfullComponentsOfEquityAxis_ifrsfullRetainedEarningsMember"
      decimals="0"
      id="Fxbrl_20211228194258211_2017"
      unitRef="CAD">0</drug:IncreaseDecreaseThroughFindersFeesShareOptions>
    <drug:IncreaseDecreaseThroughFindersFeesShareOptions
      contextRef="C_20201001to20210930"
      decimals="0"
      id="Fxbrl_20211228194258211_2020"
      unitRef="CAD">0</drug:IncreaseDecreaseThroughFindersFeesShareOptions>
    <ifrs-full:ShareIssueRelatedCost
      contextRef="C_20201001to20210930_ifrsfullComponentsOfEquityAxis_ifrsfullIssuedCapitalMember"
      decimals="0"
      id="Fxbrl_20211228194258211_215"
      unitRef="CAD">290309</ifrs-full:ShareIssueRelatedCost>
    <ifrs-full:ShareIssueRelatedCost
      contextRef="C_20201001to20210930_ifrsfullComponentsOfEquityAxis_drugSubscriptionReceivableMember"
      decimals="0"
      id="Fxbrl_20211228194258211_218"
      unitRef="CAD">0</ifrs-full:ShareIssueRelatedCost>
    <ifrs-full:ShareIssueRelatedCost
      contextRef="C_20201001to20210930_ifrsfullComponentsOfEquityAxis_drugSubscriptionReceivedMember"
      decimals="0"
      id="Fxbrl_20211228194258211_2111"
      unitRef="CAD">0</ifrs-full:ShareIssueRelatedCost>
    <ifrs-full:ShareIssueRelatedCost
      contextRef="C_20201001to20210930_ifrsfullComponentsOfEquityAxis_ifrsfullOtherReservesMember"
      decimals="0"
      id="Fxbrl_20211228194258211_2114"
      unitRef="CAD">0</ifrs-full:ShareIssueRelatedCost>
    <ifrs-full:ShareIssueRelatedCost
      contextRef="C_20201001to20210930_ifrsfullComponentsOfEquityAxis_ifrsfullRetainedEarningsMember"
      decimals="0"
      id="Fxbrl_20211228194258211_2117"
      unitRef="CAD">0</ifrs-full:ShareIssueRelatedCost>
    <ifrs-full:ShareIssueRelatedCost
      contextRef="C_20201001to20210930"
      decimals="0"
      id="Fxbrl_20211228194258211_2120"
      unitRef="CAD">290309</ifrs-full:ShareIssueRelatedCost>
    <drug:IncreaseDecreaseThroughDebtSettlementWithShareShares
      contextRef="C_20201001to20210930_ifrsfullComponentsOfEquityAxis_ifrsfullIssuedCapitalMember"
      decimals="INF"
      id="Fxbrl_20211228194258211_222"
      unitRef="Share">14799</drug:IncreaseDecreaseThroughDebtSettlementWithShareShares>
    <drug:IncreaseDecreaseThroughDebtSettlementWithShare
      contextRef="C_20201001to20210930_ifrsfullComponentsOfEquityAxis_ifrsfullIssuedCapitalMember"
      decimals="0"
      id="Fxbrl_20211228194258211_225"
      unitRef="CAD">18500</drug:IncreaseDecreaseThroughDebtSettlementWithShare>
    <drug:IncreaseDecreaseThroughDebtSettlementWithShare
      contextRef="C_20201001to20210930_ifrsfullComponentsOfEquityAxis_drugSubscriptionReceivableMember"
      decimals="0"
      id="Fxbrl_20211228194258211_228"
      unitRef="CAD">0</drug:IncreaseDecreaseThroughDebtSettlementWithShare>
    <drug:IncreaseDecreaseThroughDebtSettlementWithShare
      contextRef="C_20201001to20210930_ifrsfullComponentsOfEquityAxis_drugSubscriptionReceivedMember"
      decimals="0"
      id="Fxbrl_20211228194258211_2211"
      unitRef="CAD">0</drug:IncreaseDecreaseThroughDebtSettlementWithShare>
    <drug:IncreaseDecreaseThroughDebtSettlementWithShare
      contextRef="C_20201001to20210930_ifrsfullComponentsOfEquityAxis_ifrsfullOtherReservesMember"
      decimals="0"
      id="Fxbrl_20211228194258211_2214"
      unitRef="CAD">0</drug:IncreaseDecreaseThroughDebtSettlementWithShare>
    <drug:IncreaseDecreaseThroughDebtSettlementWithShare
      contextRef="C_20201001to20210930_ifrsfullComponentsOfEquityAxis_ifrsfullRetainedEarningsMember"
      decimals="0"
      id="Fxbrl_20211228194258211_2217"
      unitRef="CAD">0</drug:IncreaseDecreaseThroughDebtSettlementWithShare>
    <drug:IncreaseDecreaseThroughDebtSettlementWithShare
      contextRef="C_20201001to20210930"
      decimals="0"
      id="Fxbrl_20211228194258211_2220"
      unitRef="CAD">18500</drug:IncreaseDecreaseThroughDebtSettlementWithShare>
    <drug:IncreaseDecreaseThroughSpecialWarrantConversionShares
      contextRef="C_20201001to20210930_ifrsfullComponentsOfEquityAxis_ifrsfullIssuedCapitalMember"
      decimals="INF"
      id="Fxbrl_20211228194258211_232"
      unitRef="Share">16000</drug:IncreaseDecreaseThroughSpecialWarrantConversionShares>
    <drug:IncreaseDecreaseThroughSpecialWarrantConversion
      contextRef="C_20201001to20210930_ifrsfullComponentsOfEquityAxis_ifrsfullIssuedCapitalMember"
      decimals="0"
      id="Fxbrl_20211228194258211_235"
      unitRef="CAD">20000</drug:IncreaseDecreaseThroughSpecialWarrantConversion>
    <drug:IncreaseDecreaseThroughSpecialWarrantConversion
      contextRef="C_20201001to20210930_ifrsfullComponentsOfEquityAxis_drugSubscriptionReceivableMember"
      decimals="0"
      id="Fxbrl_20211228194258211_238"
      unitRef="CAD">0</drug:IncreaseDecreaseThroughSpecialWarrantConversion>
    <drug:IncreaseDecreaseThroughSpecialWarrantConversion
      contextRef="C_20201001to20210930_ifrsfullComponentsOfEquityAxis_drugSubscriptionReceivedMember"
      decimals="0"
      id="Fxbrl_20211228194258211_2311"
      unitRef="CAD">0</drug:IncreaseDecreaseThroughSpecialWarrantConversion>
    <drug:IncreaseDecreaseThroughSpecialWarrantConversion
      contextRef="C_20201001to20210930_ifrsfullComponentsOfEquityAxis_ifrsfullOtherReservesMember"
      decimals="0"
      id="Fxbrl_20211228194258211_2314"
      unitRef="CAD">0</drug:IncreaseDecreaseThroughSpecialWarrantConversion>
    <drug:IncreaseDecreaseThroughSpecialWarrantConversion
      contextRef="C_20201001to20210930_ifrsfullComponentsOfEquityAxis_ifrsfullRetainedEarningsMember"
      decimals="0"
      id="Fxbrl_20211228194258211_2317"
      unitRef="CAD">0</drug:IncreaseDecreaseThroughSpecialWarrantConversion>
    <drug:IncreaseDecreaseThroughSpecialWarrantConversion
      contextRef="C_20201001to20210930"
      decimals="0"
      id="Fxbrl_20211228194258211_2320"
      unitRef="CAD">20000</drug:IncreaseDecreaseThroughSpecialWarrantConversion>
    <drug:IncreaseDecreaseThroughExerciseOfWarrantsShares
      contextRef="C_20201001to20210930_ifrsfullComponentsOfEquityAxis_ifrsfullIssuedCapitalMember"
      decimals="INF"
      id="Fxbrl_20211228194258211_242"
      unitRef="Share">1948000</drug:IncreaseDecreaseThroughExerciseOfWarrantsShares>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity
      contextRef="C_20201001to20210930_ifrsfullComponentsOfEquityAxis_ifrsfullIssuedCapitalMember"
      decimals="0"
      id="Fxbrl_20211228194258211_245"
      unitRef="CAD">97400</ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity
      contextRef="C_20201001to20210930_ifrsfullComponentsOfEquityAxis_drugSubscriptionReceivableMember"
      decimals="0"
      id="Fxbrl_20211228194258211_248"
      unitRef="CAD">0</ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity
      contextRef="C_20201001to20210930_ifrsfullComponentsOfEquityAxis_drugSubscriptionReceivedMember"
      decimals="0"
      id="Fxbrl_20211228194258211_2411"
      unitRef="CAD">0</ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity
      contextRef="C_20201001to20210930_ifrsfullComponentsOfEquityAxis_ifrsfullOtherReservesMember"
      decimals="0"
      id="Fxbrl_20211228194258211_2414"
      unitRef="CAD">0</ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity
      contextRef="C_20201001to20210930_ifrsfullComponentsOfEquityAxis_ifrsfullRetainedEarningsMember"
      decimals="0"
      id="Fxbrl_20211228194258211_2417"
      unitRef="CAD">0</ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity
      contextRef="C_20201001to20210930"
      decimals="0"
      id="Fxbrl_20211228194258211_2420"
      unitRef="CAD">97400</ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity>
    <drug:IncreaseDecreaseThroughSharesIssuedToUniversityShares
      contextRef="C_20201001to20210930_ifrsfullComponentsOfEquityAxis_ifrsfullIssuedCapitalMember"
      decimals="INF"
      id="Fxbrl_20211228194258211_252"
      unitRef="Share">63000</drug:IncreaseDecreaseThroughSharesIssuedToUniversityShares>
    <drug:IncreaseDecreaseThroughSharesIssuedToUniversity
      contextRef="C_20201001to20210930_ifrsfullComponentsOfEquityAxis_ifrsfullIssuedCapitalMember"
      decimals="0"
      id="Fxbrl_20211228194258211_255"
      unitRef="CAD">368550</drug:IncreaseDecreaseThroughSharesIssuedToUniversity>
    <drug:IncreaseDecreaseThroughSharesIssuedToUniversity
      contextRef="C_20201001to20210930_ifrsfullComponentsOfEquityAxis_drugSubscriptionReceivableMember"
      decimals="0"
      id="Fxbrl_20211228194258211_258"
      unitRef="CAD">0</drug:IncreaseDecreaseThroughSharesIssuedToUniversity>
    <drug:IncreaseDecreaseThroughSharesIssuedToUniversity
      contextRef="C_20201001to20210930_ifrsfullComponentsOfEquityAxis_drugSubscriptionReceivedMember"
      decimals="0"
      id="Fxbrl_20211228194258211_2511"
      unitRef="CAD">0</drug:IncreaseDecreaseThroughSharesIssuedToUniversity>
    <drug:IncreaseDecreaseThroughSharesIssuedToUniversity
      contextRef="C_20201001to20210930_ifrsfullComponentsOfEquityAxis_ifrsfullOtherReservesMember"
      decimals="0"
      id="Fxbrl_20211228194258211_2514"
      unitRef="CAD">0</drug:IncreaseDecreaseThroughSharesIssuedToUniversity>
    <drug:IncreaseDecreaseThroughSharesIssuedToUniversity
      contextRef="C_20201001to20210930_ifrsfullComponentsOfEquityAxis_ifrsfullRetainedEarningsMember"
      decimals="0"
      id="Fxbrl_20211228194258211_2517"
      unitRef="CAD">0</drug:IncreaseDecreaseThroughSharesIssuedToUniversity>
    <drug:IncreaseDecreaseThroughSharesIssuedToUniversity
      contextRef="C_20201001to20210930"
      decimals="0"
      id="Fxbrl_20211228194258211_2520"
      unitRef="CAD">368550</drug:IncreaseDecreaseThroughSharesIssuedToUniversity>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="C_20201001to20210930_ifrsfullComponentsOfEquityAxis_ifrsfullIssuedCapitalMember"
      decimals="0"
      id="Fxbrl_20211228194258211_265"
      unitRef="CAD">0</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="C_20201001to20210930_ifrsfullComponentsOfEquityAxis_drugSubscriptionReceivableMember"
      decimals="0"
      id="Fxbrl_20211228194258211_268"
      unitRef="CAD">0</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="C_20201001to20210930_ifrsfullComponentsOfEquityAxis_drugSubscriptionReceivedMember"
      decimals="0"
      id="Fxbrl_20211228194258211_2611"
      unitRef="CAD">0</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="C_20201001to20210930_ifrsfullComponentsOfEquityAxis_ifrsfullOtherReservesMember"
      decimals="0"
      id="Fxbrl_20211228194258211_2614"
      unitRef="CAD">880615</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="C_20201001to20210930_ifrsfullComponentsOfEquityAxis_ifrsfullRetainedEarningsMember"
      decimals="0"
      id="Fxbrl_20211228194258211_2617"
      unitRef="CAD">0</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="C_20201001to20210930"
      decimals="0"
      id="Fxbrl_20211228194258211_2620"
      unitRef="CAD">880615</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <ifrs-full:ProfitLoss
      contextRef="C_20201001to20210930_ifrsfullComponentsOfEquityAxis_ifrsfullIssuedCapitalMember"
      decimals="0"
      id="Fxbrl_20211228194258211_275"
      unitRef="CAD">0</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss
      contextRef="C_20201001to20210930_ifrsfullComponentsOfEquityAxis_drugSubscriptionReceivableMember"
      decimals="0"
      id="Fxbrl_20211228194258211_278"
      unitRef="CAD">0</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss
      contextRef="C_20201001to20210930_ifrsfullComponentsOfEquityAxis_drugSubscriptionReceivedMember"
      decimals="0"
      id="Fxbrl_20211228194258211_2711"
      unitRef="CAD">0</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss
      contextRef="C_20201001to20210930_ifrsfullComponentsOfEquityAxis_ifrsfullOtherReservesMember"
      decimals="0"
      id="Fxbrl_20211228194258211_2714"
      unitRef="CAD">0</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss
      contextRef="C_20201001to20210930_ifrsfullComponentsOfEquityAxis_ifrsfullRetainedEarningsMember"
      decimals="0"
      id="Fxbrl_20211228194258211_2717"
      unitRef="CAD">-8650763</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss
      contextRef="C_20201001to20210930"
      decimals="0"
      id="Fxbrl_20211228194258211_2720"
      unitRef="CAD">-8650763</ifrs-full:ProfitLoss>
    <ifrs-full:NumberOfSharesOutstanding
      contextRef="C_20210930_ifrsfullComponentsOfEquityAxis_ifrsfullIssuedCapitalMember"
      decimals="INF"
      id="Fxbrl_20211228194258211_282"
      unitRef="Share">11834361</ifrs-full:NumberOfSharesOutstanding>
    <ifrs-full:Equity
      contextRef="C_20210930_ifrsfullComponentsOfEquityAxis_ifrsfullIssuedCapitalMember"
      decimals="0"
      id="Fxbrl_20211228194258211_285"
      unitRef="CAD">27080281</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="C_20210930_ifrsfullComponentsOfEquityAxis_drugSubscriptionReceivableMember"
      decimals="0"
      id="Fxbrl_20211228194258211_288"
      unitRef="CAD">-33684</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="C_20210930_ifrsfullComponentsOfEquityAxis_drugSubscriptionReceivedMember"
      decimals="0"
      id="Fxbrl_20211228194258211_2811"
      unitRef="CAD">0</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="C_20210930_ifrsfullComponentsOfEquityAxis_ifrsfullOtherReservesMember"
      decimals="0"
      id="Fxbrl_20211228194258211_2814"
      unitRef="CAD">1565055</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="C_20210930_ifrsfullComponentsOfEquityAxis_ifrsfullRetainedEarningsMember"
      decimals="0"
      id="Fxbrl_20211228194258211_2817"
      unitRef="CAD">-9209857</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="C_20210930"
      decimals="0"
      id="Fxbrl_20211228194258211_2820"
      unitRef="CAD">19401795</ifrs-full:Equity>
    <ifrs-full:ProfitLoss
      contextRef="C_20201001to20210930"
      decimals="0"
      id="Fxbrl_20211228210724323"
      unitRef="CAD">-8650763</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss
      contextRef="C_20191001to20200930"
      decimals="0"
      id="Fxbrl_20211228210737306"
      unitRef="CAD">-480377</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss
      contextRef="C_20190601to20190930"
      decimals="0"
      id="Fxbrl_20211228210742778"
      unitRef="CAD">-78717</ifrs-full:ProfitLoss>
    <ifrs-full:AdjustmentsForUnrealisedForeignExchangeLossesGains
      contextRef="C_20201001to20210930"
      decimals="0"
      id="Fxbrl_20211228210958068_62"
      unitRef="CAD">-223787</ifrs-full:AdjustmentsForUnrealisedForeignExchangeLossesGains>
    <ifrs-full:AdjustmentsForUnrealisedForeignExchangeLossesGains
      contextRef="C_20191001to20200930"
      decimals="0"
      id="Fxbrl_20211228210958068_65"
      unitRef="CAD">0</ifrs-full:AdjustmentsForUnrealisedForeignExchangeLossesGains>
    <ifrs-full:AdjustmentsForUnrealisedForeignExchangeLossesGains
      contextRef="C_20190601to20190930"
      decimals="0"
      id="Fxbrl_20211228210958068_68"
      unitRef="CAD">0</ifrs-full:AdjustmentsForUnrealisedForeignExchangeLossesGains>
    <drug:AdjustmentsForSharesRecordedAsResearchAndDevelopment
      contextRef="C_20201001to20210930"
      decimals="0"
      id="Fxbrl_20211228210958068_72"
      unitRef="CAD">368550</drug:AdjustmentsForSharesRecordedAsResearchAndDevelopment>
    <drug:AdjustmentsForSharesRecordedAsResearchAndDevelopment
      contextRef="C_20191001to20200930"
      decimals="0"
      id="Fxbrl_20211228210958068_75"
      unitRef="CAD">0</drug:AdjustmentsForSharesRecordedAsResearchAndDevelopment>
    <drug:AdjustmentsForSharesRecordedAsResearchAndDevelopment
      contextRef="C_20190601to20190930"
      decimals="0"
      id="Fxbrl_20211228210958068_78"
      unitRef="CAD">0</drug:AdjustmentsForSharesRecordedAsResearchAndDevelopment>
    <ifrs-full:AdjustmentsForSharebasedPayments
      contextRef="C_20201001to20210930"
      decimals="0"
      id="Fxbrl_20211228210958068_82"
      unitRef="CAD">880615</ifrs-full:AdjustmentsForSharebasedPayments>
    <ifrs-full:AdjustmentsForSharebasedPayments
      contextRef="C_20191001to20200930"
      decimals="0"
      id="Fxbrl_20211228210958068_85"
      unitRef="CAD">161300</ifrs-full:AdjustmentsForSharebasedPayments>
    <ifrs-full:AdjustmentsForSharebasedPayments
      contextRef="C_20190601to20190930"
      decimals="0"
      id="Fxbrl_20211228210958068_88"
      unitRef="CAD">0</ifrs-full:AdjustmentsForSharebasedPayments>
    <drug:AdjustmentsForDecreaseIncreaseInSalesTaxReceivable
      contextRef="C_20201001to20210930"
      decimals="0"
      id="Fxbrl_20211228210958068_102"
      unitRef="CAD">-110146</drug:AdjustmentsForDecreaseIncreaseInSalesTaxReceivable>
    <drug:AdjustmentsForDecreaseIncreaseInSalesTaxReceivable
      contextRef="C_20191001to20200930"
      decimals="0"
      id="Fxbrl_20211228210958068_105"
      unitRef="CAD">0</drug:AdjustmentsForDecreaseIncreaseInSalesTaxReceivable>
    <drug:AdjustmentsForDecreaseIncreaseInSalesTaxReceivable
      contextRef="C_20190601to20190930"
      decimals="0"
      id="Fxbrl_20211228210958068_108"
      unitRef="CAD">0</drug:AdjustmentsForDecreaseIncreaseInSalesTaxReceivable>
    <drug:AdjustmentsForDecreaseIncreaseInPrepaidExpenses
      contextRef="C_20201001to20210930"
      decimals="0"
      id="Fxbrl_20211228210958068_112"
      unitRef="CAD">-89920</drug:AdjustmentsForDecreaseIncreaseInPrepaidExpenses>
    <drug:AdjustmentsForDecreaseIncreaseInPrepaidExpenses
      contextRef="C_20191001to20200930"
      decimals="0"
      id="Fxbrl_20211228210958068_115"
      unitRef="CAD">-78287</drug:AdjustmentsForDecreaseIncreaseInPrepaidExpenses>
    <drug:AdjustmentsForDecreaseIncreaseInPrepaidExpenses
      contextRef="C_20190601to20190930"
      decimals="0"
      id="Fxbrl_20211228210958068_118"
      unitRef="CAD">0</drug:AdjustmentsForDecreaseIncreaseInPrepaidExpenses>
    <ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAccountPayable
      contextRef="C_20201001to20210930"
      decimals="0"
      id="Fxbrl_20211228210958068_122"
      unitRef="CAD">506150</ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAccountPayable>
    <ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAccountPayable
      contextRef="C_20191001to20200930"
      decimals="0"
      id="Fxbrl_20211228210958068_125"
      unitRef="CAD">108972</ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAccountPayable>
    <ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAccountPayable
      contextRef="C_20190601to20190930"
      decimals="0"
      id="Fxbrl_20211228210958068_128"
      unitRef="CAD">36708</ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAccountPayable>
    <ifrs-full:CashFlowsFromUsedInOperatingActivities
      contextRef="C_20201001to20210930"
      decimals="0"
      id="Fxbrl_20211228210958068_132"
      unitRef="CAD">-7319301</ifrs-full:CashFlowsFromUsedInOperatingActivities>
    <ifrs-full:CashFlowsFromUsedInOperatingActivities
      contextRef="C_20191001to20200930"
      decimals="0"
      id="Fxbrl_20211228210958068_135"
      unitRef="CAD">-288392</ifrs-full:CashFlowsFromUsedInOperatingActivities>
    <ifrs-full:CashFlowsFromUsedInOperatingActivities
      contextRef="C_20190601to20190930"
      decimals="0"
      id="Fxbrl_20211228210958068_138"
      unitRef="CAD">-42009</ifrs-full:CashFlowsFromUsedInOperatingActivities>
    <ifrs-full:ProceedsFromIssuingShares
      contextRef="C_20201001to20210930"
      decimals="0"
      id="Fxbrl_20211228210958068_162"
      unitRef="CAD">27744826</ifrs-full:ProceedsFromIssuingShares>
    <ifrs-full:ProceedsFromIssuingShares
      contextRef="C_20191001to20200930"
      decimals="0"
      id="Fxbrl_20211228210958068_165"
      unitRef="CAD">1008330</ifrs-full:ProceedsFromIssuingShares>
    <ifrs-full:ProceedsFromIssuingShares
      contextRef="C_20190601to20190930"
      decimals="0"
      id="Fxbrl_20211228210958068_168"
      unitRef="CAD">122000</ifrs-full:ProceedsFromIssuingShares>
    <drug:PaymentsForFindersFees
      contextRef="C_20201001to20210930"
      decimals="0"
      id="Fxbrl_20211228210958068_172"
      unitRef="CAD">1516317</drug:PaymentsForFindersFees>
    <drug:PaymentsForFindersFees
      contextRef="C_20191001to20200930"
      decimals="0"
      id="Fxbrl_20211228210958068_175"
      unitRef="CAD">0</drug:PaymentsForFindersFees>
    <drug:PaymentsForFindersFees
      contextRef="C_20190601to20190930"
      decimals="0"
      id="Fxbrl_20211228210958068_178"
      unitRef="CAD">0</drug:PaymentsForFindersFees>
    <ifrs-full:PaymentsForShareIssueCosts
      contextRef="C_20201001to20210930"
      decimals="0"
      id="Fxbrl_20211228210958068_182"
      unitRef="CAD">290309</ifrs-full:PaymentsForShareIssueCosts>
    <ifrs-full:PaymentsForShareIssueCosts
      contextRef="C_20191001to20200930"
      decimals="0"
      id="Fxbrl_20211228210958068_185"
      unitRef="CAD">0</ifrs-full:PaymentsForShareIssueCosts>
    <ifrs-full:PaymentsForShareIssueCosts
      contextRef="C_20190601to20190930"
      decimals="0"
      id="Fxbrl_20211228210958068_188"
      unitRef="CAD">0</ifrs-full:PaymentsForShareIssueCosts>
    <drug:ProceedsFromIssuingWarrants
      contextRef="C_20201001to20210930"
      decimals="0"
      id="Fxbrl_20211228210958068_192"
      unitRef="CAD">22875</drug:ProceedsFromIssuingWarrants>
    <drug:ProceedsFromIssuingWarrants
      contextRef="C_20191001to20200930"
      decimals="0"
      id="Fxbrl_20211228210958068_195"
      unitRef="CAD">0</drug:ProceedsFromIssuingWarrants>
    <drug:ProceedsFromIssuingWarrants
      contextRef="C_20190601to20190930"
      decimals="0"
      id="Fxbrl_20211228210958068_198"
      unitRef="CAD">0</drug:ProceedsFromIssuingWarrants>
    <drug:RefundOfSpecialWarrantsProceeds
      contextRef="C_20201001to20210930"
      decimals="0"
      id="Fxbrl_20211228210958068_202"
      unitRef="CAD">2875</drug:RefundOfSpecialWarrantsProceeds>
    <drug:RefundOfSpecialWarrantsProceeds
      contextRef="C_20191001to20200930"
      decimals="0"
      id="Fxbrl_20211228210958068_205"
      unitRef="CAD">0</drug:RefundOfSpecialWarrantsProceeds>
    <drug:RefundOfSpecialWarrantsProceeds
      contextRef="C_20190601to20190930"
      decimals="0"
      id="Fxbrl_20211228210958068_208"
      unitRef="CAD">0</drug:RefundOfSpecialWarrantsProceeds>
    <drug:ProceedsFromWarrantsExercise
      contextRef="C_20201001to20210930"
      decimals="0"
      id="Fxbrl_20211228210958068_212"
      unitRef="CAD">97400</drug:ProceedsFromWarrantsExercise>
    <drug:ProceedsFromWarrantsExercise
      contextRef="C_20191001to20200930"
      decimals="0"
      id="Fxbrl_20211228210958068_215"
      unitRef="CAD">0</drug:ProceedsFromWarrantsExercise>
    <drug:ProceedsFromWarrantsExercise
      contextRef="C_20190601to20190930"
      decimals="0"
      id="Fxbrl_20211228210958068_218"
      unitRef="CAD">0</drug:ProceedsFromWarrantsExercise>
    <ifrs-full:CashFlowsFromUsedInFinancingActivities
      contextRef="C_20201001to20210930"
      decimals="0"
      id="Fxbrl_20211228210958068_222"
      unitRef="CAD">26055600</ifrs-full:CashFlowsFromUsedInFinancingActivities>
    <ifrs-full:CashFlowsFromUsedInFinancingActivities
      contextRef="C_20191001to20200930"
      decimals="0"
      id="Fxbrl_20211228210958068_225"
      unitRef="CAD">1008330</ifrs-full:CashFlowsFromUsedInFinancingActivities>
    <ifrs-full:CashFlowsFromUsedInFinancingActivities
      contextRef="C_20190601to20190930"
      decimals="0"
      id="Fxbrl_20211228210958068_228"
      unitRef="CAD">122000</ifrs-full:CashFlowsFromUsedInFinancingActivities>
    <ifrs-full:IncreaseDecreaseInCashAndCashEquivalents
      contextRef="C_20201001to20210930"
      decimals="0"
      id="Fxbrl_20211228210958068_242"
      unitRef="CAD">18736299</ifrs-full:IncreaseDecreaseInCashAndCashEquivalents>
    <ifrs-full:IncreaseDecreaseInCashAndCashEquivalents
      contextRef="C_20191001to20200930"
      decimals="0"
      id="Fxbrl_20211228210958068_245"
      unitRef="CAD">719938</ifrs-full:IncreaseDecreaseInCashAndCashEquivalents>
    <ifrs-full:IncreaseDecreaseInCashAndCashEquivalents
      contextRef="C_20190601to20190930"
      decimals="0"
      id="Fxbrl_20211228210958068_248"
      unitRef="CAD">79991</ifrs-full:IncreaseDecreaseInCashAndCashEquivalents>
    <ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents
      contextRef="C_20201001to20210930"
      decimals="0"
      id="Fxbrl_20211228210958068_252"
      unitRef="CAD">223787</ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents>
    <ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents
      contextRef="C_20191001to20200930"
      decimals="0"
      id="Fxbrl_20211228210958068_255"
      unitRef="CAD">0</ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents>
    <ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents
      contextRef="C_20190601to20190930"
      decimals="0"
      id="Fxbrl_20211228210958068_258"
      unitRef="CAD">0</ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents
      contextRef="C_20200930"
      decimals="0"
      id="Fxbrl_20211228210958068_262"
      unitRef="CAD">799929</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents
      contextRef="C_20190930"
      decimals="0"
      id="Fxbrl_20211228210958068_265"
      unitRef="CAD">79991</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents
      contextRef="C_20180930"
      decimals="0"
      id="Fxbrl_20211228210958068_268"
      unitRef="CAD">0</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents
      contextRef="C_20210930"
      decimals="0"
      id="Fxbrl_20211228210958068_282"
      unitRef="CAD">19760015</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents
      contextRef="C_20200930"
      decimals="0"
      id="Fxbrl_20211228210958068_285"
      unitRef="CAD">799929</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents
      contextRef="C_20190930"
      decimals="0"
      id="Fxbrl_20211228210958068_288"
      unitRef="CAD">79991</ifrs-full:CashAndCashEquivalents>
    <drug:DebtSettledByIssuingShares
      contextRef="C_20201001to20210930"
      decimals="0"
      id="Fxbrl_20211228210958068_312"
      unitRef="CAD">18500</drug:DebtSettledByIssuingShares>
    <drug:DebtSettledByIssuingShares
      contextRef="C_20191001to20200930"
      decimals="0"
      id="Fxbrl_20211228210958068_315"
      unitRef="CAD">0</drug:DebtSettledByIssuingShares>
    <drug:DebtSettledByIssuingShares
      contextRef="C_20190601to20190930"
      decimals="0"
      id="Fxbrl_20211228210958068_318"
      unitRef="CAD">0</drug:DebtSettledByIssuingShares>
    <drug:FairValueAscribedToBrokersWarrantsIssued
      contextRef="C_20201001to20210930"
      decimals="0"
      id="Fxbrl_20211228210958068_322"
      unitRef="CAD">521000</drug:FairValueAscribedToBrokersWarrantsIssued>
    <drug:FairValueAscribedToBrokersWarrantsIssued
      contextRef="C_20191001to20200930"
      decimals="0"
      id="Fxbrl_20211228210958068_325"
      unitRef="CAD">0</drug:FairValueAscribedToBrokersWarrantsIssued>
    <drug:FairValueAscribedToBrokersWarrantsIssued
      contextRef="C_20190601to20190930"
      decimals="0"
      id="Fxbrl_20211228210958068_328"
      unitRef="CAD">0</drug:FairValueAscribedToBrokersWarrantsIssued>
    <drug:FairValueOfOptionsIssuedAsFindersFees
      contextRef="C_20201001to20210930"
      decimals="0"
      id="Fxbrl_20211228210958068_332"
      unitRef="CAD">2140</drug:FairValueOfOptionsIssuedAsFindersFees>
    <drug:FairValueOfOptionsIssuedAsFindersFees
      contextRef="C_20191001to20200930"
      decimals="0"
      id="Fxbrl_20211228210958068_335"
      unitRef="CAD">0</drug:FairValueOfOptionsIssuedAsFindersFees>
    <drug:FairValueOfOptionsIssuedAsFindersFees
      contextRef="C_20190601to20190930"
      decimals="0"
      id="Fxbrl_20211228210958068_338"
      unitRef="CAD">0</drug:FairValueOfOptionsIssuedAsFindersFees>
    <drug:ShareIssueCostsIncludedInAccountsPayable
      contextRef="C_20201001to20210930"
      decimals="0"
      id="Fxbrl_20211228210958068_342"
      unitRef="CAD">0</drug:ShareIssueCostsIncludedInAccountsPayable>
    <drug:ShareIssueCostsIncludedInAccountsPayable
      contextRef="C_20191001to20200930"
      decimals="0"
      id="Fxbrl_20211228210958068_345"
      unitRef="CAD">5243</drug:ShareIssueCostsIncludedInAccountsPayable>
    <drug:ShareIssueCostsIncludedInAccountsPayable
      contextRef="C_20190601to20190930"
      decimals="0"
      id="Fxbrl_20211228210958068_348"
      unitRef="CAD">0</drug:ShareIssueCostsIncludedInAccountsPayable>
    <drug:AcquisitionOfIntangibleAssetsByIssuingCommonShares
      contextRef="C_20201001to20210930"
      decimals="0"
      id="Fxbrl_20211228210958068_352"
      unitRef="CAD">0</drug:AcquisitionOfIntangibleAssetsByIssuingCommonShares>
    <drug:AcquisitionOfIntangibleAssetsByIssuingCommonShares
      contextRef="C_20191001to20200930"
      decimals="0"
      id="Fxbrl_20211228210958068_355"
      unitRef="CAD">0</drug:AcquisitionOfIntangibleAssetsByIssuingCommonShares>
    <drug:AcquisitionOfIntangibleAssetsByIssuingCommonShares
      contextRef="C_20190601to20190930"
      decimals="0"
      id="Fxbrl_20211228210958068_358"
      unitRef="CAD">2000</drug:AcquisitionOfIntangibleAssetsByIssuingCommonShares>
    <drug:DisclosureOfNatureAndContinuanceOfOperationsExplanatory
      contextRef="C_20201001to20210930"
      id="Fxbrl_20211228152627751">
                        &lt;div&gt;
                            &lt;p style="margin-left: 18pt; text-indent: -18pt; text-align: justify;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;1.&lt;/b&gt;&lt;span style="width: 9pt; text-indent: 0pt; display: inline-block;"&gt;&#160;&lt;/span&gt;&lt;b&gt;NATURE AND CONTINUANCE OF OPERATIONS&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                            &lt;p style="text-align: justify;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;Bright Minds Biosciences Inc. (the "Company") was incorporated under the Business Corporations Act of British Columbia on May 31, 2019. The Company's objective is to generate income and achieve long term profitable growth through the development of therapeutics to improve the lives of patients with certain severe and life-altering diseases. On February 8, 2021, the Company started trading on the Canadian Stock Exchange ("CSE") under the symbol DRUG. On May 17, 2021, the Company started trading on the OTCQB under the symbol BMBIF. On November 8, 2021, the Company started trading on NASDAQ under the symbol DRUG. The head office, and principal address of the Company are located at 1500 - 1055 West Georgia Street, Vancouver, British Columbia, V6E 4N7, Canada.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                            &lt;p style="text-align: justify;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;These consolidated financial statements have been prepared on a going concern basis which assumes that the Company will be able to realize its assets and discharge its liabilities in the normal course of business for the foreseeable future. As at September 30, 2021, the Company is not able to finance day to day activities through operations and has incurred a loss of $8,650,763 for the year ended September 30, 2021. The Company has a deficit of $9,209,857 since inception and negative operating cash flows. As at September 30, 2021, the Company has working capital of $19,399,795 (September 30, 2020 - $727,293). The continuing operations of the Company are dependent upon its ability to attain profitable operations and generate funds therefrom. Management intends to finance operating costs with equity financings, loans from directors and companies controlled by directors and/or private placement of common shares.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                            &lt;p style="text-align: justify;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;The coronavirus, also known as "COVID-19", has spread across the globe and is impacting worldwide economic activity. Government authorities have implemented emergency measures to mitigate the spread of the virus. The outbreak and the related mitigation measures may have an adverse impact on global economic conditions as well as on the Company's business activities specifically related to possible disruptions in the operations of the laboratories upon whom the Company relies, including laboratories situated in various parts of the United States and Europe. The extent to which the coronavirus may impact the Company's business activities will depend on future developments, such as the duration of the outbreak, travel restrictions, business disruptions, and the effectiveness of actions taken in Canada and other countries to contain and treat the disease. These events are highly uncertain and as such, the Company cannot determine their financial impact at this time.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                        &lt;/div&gt;
                    </drug:DisclosureOfNatureAndContinuanceOfOperationsExplanatory>
    <ifrs-full:ProfitLoss
      contextRef="C_20210930to20210930"
      decimals="0"
      id="Fxbrl_20211228152648303"
      unitRef="CAD">-8650763</ifrs-full:ProfitLoss>
    <ifrs-full:RetainedEarnings
      contextRef="C_20210930"
      decimals="0"
      id="Fxbrl_20211228152715046"
      unitRef="CAD">-9209857</ifrs-full:RetainedEarnings>
    <drug:WorkingCapital
      contextRef="C_20210930"
      decimals="0"
      id="Fxbrl_20211228152733166"
      unitRef="CAD">19399795</drug:WorkingCapital>
    <drug:WorkingCapital
      contextRef="C_20200930"
      decimals="0"
      id="Fxbrl_20211228152740154"
      unitRef="CAD">727293</drug:WorkingCapital>
    <ifrs-full:DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory
      contextRef="C_20201001to20210930"
      id="Fxbrl_20211228152858359">
                        &lt;div&gt;
                            &lt;p style="text-align: justify;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;2.&lt;/b&gt;&lt;span style="width: 9pt; text-indent: 0pt; display: inline-block;"&gt;&#160;&lt;/span&gt;&lt;b&gt;STATEMENT OF COMPLIANCE AND BASIS OF PREPARATION&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                            &lt;p style="text-align: justify;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;These consolidated financial statements were authorized for issue on December 24, 2021 by the directors of the Company.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                            &lt;p style="margin-bottom: 0pt; text-align: justify;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;Statement of compliance&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                            &lt;p style="margin-top: 0px; text-align: justify; margin-bottom: 0px;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;These consolidated financial statements have been prepared in accordance with the International Financial Reporting Standards ("IFRS") issued by the International Accounting Standards Board ("IASB") and Interpretations of the International Financial Reporting Interpretations Committee ("IFRIC"). The principal accounting policies applied in the preparation of these financial statements are set out below.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                            &lt;p style="margin-bottom: 0px; text-align: justify; margin-top: 13px;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;Basis of preparation&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                            &lt;p style="margin-top: 0px; text-align: justify; margin-bottom: 0px;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;Depending on the applicable IFRS requirements, the measurement basis used in the preparation of these financial statements is cost, net realizable value, fair value or recoverable amount. These financial statements, except for the statement of cash flows, are based on the accrual basis.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                        &lt;/div&gt;
                    </ifrs-full:DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory>
    <ifrs-full:DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory
      contextRef="C_20201001to20210930"
      id="Fxbrl_20211228162019468">
                        &lt;div&gt;
                            &lt;p style="text-align: justify;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;3.&lt;span style="display: inline-block; width: 9pt;"&gt;&#160;&lt;/span&gt;SIGNIFICANT ACCOUNTING POLICIES &lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

                                &lt;div&gt;
                                    &lt;p style="margin-bottom: 0pt; text-align: justify;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;Basis of consolidation &lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;p style="margin-top: 0pt; text-align: justify;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;These consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries Psilocybinlabs Ltd. (see Note 4), Bright Minds Biosciences LLC, a Delaware limited liability company, and Bright Minds Bioscience Pty Ltd., a proprietary company registered under the Corporations Act of Australia on June 24, 2021.&#160; On June 10, 2021, the CEO of the Company transferred, assigned and conveyed all of his membership interests in Bright Minds Biosciences LLC to the Company.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;p style="text-align: justify;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;A subsidiary is an entity that the Company controls, either directly or indirectly, where control is defined as the power to govern the financial and operating policies of an entity so as to obtain benefits from its activities. The financial results of the Company's subsidiaries are included in the financial statements from the date that control commences until the date that control ceases. The accounting policies of the Company's subsidiaries have been aligned with the policies adopted by the Company. When the Company ceases to control a subsidiary, the financial statements of that subsidiary are de-consolidated.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                &lt;/div&gt;

                        &lt;/div&gt;

                        &lt;div&gt;

                                &lt;p style="text-align: justify;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;Inter-company balances and transactions, and any income and expenses arising from inter-company transactions, have been eliminated in these financial statements.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;


                                &lt;div&gt;
                                    &lt;p style="margin-bottom: 0pt; text-align: justify;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;Critical accounting estimates&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;p style="margin-top: 0pt; text-align: justify;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;The preparation of the financial statements in conformity with IFRS requires management to make estimates, judgments and assumptions that affect the application of accounting policies and the reported amounts of assets, liabilities, income and expenses. Actual results may differ from these estimates. Estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognized in the period in which the estimates are revised and in any future periods affected.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;p style="text-align: justify;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;Certain of the Company's accounting policies and disclosures require key assumptions concerning the future and other estimates that have a significant risk of causing a material adjustment to the carrying amounts of assets and liabilities or disclosures within the next fiscal year. Where applicable, further information about the assumptions made is disclosed in the notes specific to that asset or liability. The critical accounting estimates and judgments set out below have been applied consistently to all periods presented in these financial statements.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;p style="margin-bottom: 0pt; text-align: justify;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="text-decoration: underline;"&gt;Ability to continue as a going concern&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;p style="margin-top: 0pt; text-align: justify;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;Evaluation of the ability of the Company to realize its strategy for funding its future needs for working capital involves making judgments.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;p style="margin-bottom: 0pt; text-align: justify;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="text-decoration: underline;"&gt;Share-based compensation&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;p style="margin-top: 0pt; text-align: justify;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;The fair value of stock options is measured using a Black Scholes option pricing model. Measurement inputs include the common share price on the grant date, the exercise price of the instrument, the expected common share price volatility, the weighted average expected life of the instruments, the expected dividends and the risk-free interest rate. Service and non-market performance conditions are not taken into account in determining fair value. The fair value of equity settled RSUs is measured based on management's best estimate of the Company's share price on the grant date.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;p style="text-align: justify;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;The share-based compensation recognized is also determined based on management's grant date estimate of the forfeitures that are expected to occur over the life of the stock options and equity settled RSUs. Cash settled RSUs outstanding are fair valued using a mark-to-market calculation based on the Company's closing common share price at the end of the period. The number of stock options and RSUs that actually vest could differ from the estimated number of awards expected to vest and any differences between the actual and estimated forfeitures are recognized prospectively as they occur.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                &lt;/div&gt;


                                &lt;div&gt;
                                    &lt;p style="margin-bottom: 0pt; text-align: justify;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;Foreign currency translation&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;p style="margin-top: 0pt; text-align: justify;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;The functional currency of the Company, Psilocybinlabs Ltd., Bright Minds Biosciences LLC and Bright Minds Bioscience Pty Ltd. is the Canadian dollar and the presentation currency of the Company is the Canadian dollar. Transactions in currencies other than the functional currency are recorded at the rates of exchange prevailing on the transaction date. Monetary assets and liabilities that are denominated in foreign currencies are translated at the rates prevailing at each reporting date. Non-monetary assets and liabilities denominated in foreign currencies that are measured at fair value are retranslated to the functional currency at the exchange rate at the date the fair value was determined. Non-monetary items that are measured in terms of historical cost in a foreign currency are not retranslated. Foreign currency translation differences are recognized in profit or loss.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                &lt;/div&gt;


                                &lt;div&gt;
                                    &lt;p style="margin-bottom: 0pt; text-align: justify;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;Business combinations&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;p style="margin-top: 0pt; text-align: justify;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;The Company uses the acquisition method to account for business combinations. The Company measures goodwill as the fair value of the consideration transferred, less the net recognized amount (generally fair value) of the identifiable assets acquired and liabilities assumed, all measured as of the acquisition date. When the excess is negative, a gain on acquisition is recognized immediately in net income or loss.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                &lt;/div&gt;

                        &lt;/div&gt;

                        &lt;div&gt;

                                &lt;div&gt;
                                    &lt;p style="margin-top: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;Goodwill is not amortized and is tested for impairment annually. Additionally, goodwill is reviewed at each reporting date to determine if events or changes in circumstances indicate that the asset might be impaired, in which case an impairment test is performed. Goodwill is measured at cost less accumulated impairment losses.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;p style="text-align: justify;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;Transaction costs, other than those associated with the issue of debt or equity securities, that the Company incurs in connection with a business combination are expensed as incurred.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                &lt;/div&gt;


                                &lt;div&gt;
                                    &lt;p style="margin-bottom: 0pt; text-align: justify;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;Internally generated intangible assets - Research and development expenditure&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;p style="margin-top: 0pt; text-align: justify;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;Intangible assets acquired separately are initially recognized at cost. Expenditure on research activities is recognized as an expense in the period in which it is incurred. An internally-generated intangible asset arising from development (or from the development phase of an internal project) is recognized if, and only if, all of the following have been demonstrated:&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;p style="margin-left: 36pt; margin-bottom: 0pt; text-indent: -18pt; text-align: justify;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&#x2022;&lt;span style="display: inline-block; width: 16.7pt;"&gt;&#160;&lt;/span&gt;The technical feasibility of completing the intangible asset so that it will be available for use or sale;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;p style="margin-top: 0pt; margin-left: 36pt; margin-bottom: 0pt; text-indent: -18pt; text-align: justify;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&#x2022;&lt;span style="display: inline-block; width: 16.7pt;"&gt;&#160;&lt;/span&gt;The intention to complete the intangible asset and use or sell it;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;p style="margin-top: 0pt; margin-left: 36pt; margin-bottom: 0pt; text-indent: -18pt; text-align: justify;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&#x2022;&lt;span style="display: inline-block; width: 16.7pt;"&gt;&#160;&lt;/span&gt;The ability to use or sell the intangible asset;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;p style="margin-top: 0pt; margin-left: 36pt; margin-bottom: 0pt; text-indent: -18pt; text-align: justify;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&#x2022;&lt;span style="display: inline-block; width: 16.7pt;"&gt;&#160;&lt;/span&gt;How the intangible asset will generate probable future economic benefits;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;p style="margin-top: 0pt; margin-left: 36pt; margin-bottom: 0pt; text-indent: -18pt; text-align: justify;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&#x2022;&lt;span style="display: inline-block; width: 16.7pt;"&gt;&#160;&lt;/span&gt;The availability of adequate technical, financial and other resources to complete the development and to use or sell the intangible asset; and&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;p style="margin-top: 0pt; margin-left: 36pt; text-indent: -18pt; text-align: justify;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&#x2022;&lt;span style="display: inline-block; width: 16.7pt;"&gt;&#160;&lt;/span&gt;The ability to measure reliably the expenditure attributable to the intangible asset during its development.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;p style="text-align: justify;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;The amount initially recognized for internally-generated intangible assets is the sum of the expenditure incurred from the date when the intangible asset first meets the recognition criteria listed above. Where no internally-generated intangible asset can be recognized, development expenditure is recognized in profit or loss in the period in which it is incurred.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;p style="text-align: justify;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;Subsequent to initial recognition, internally-generated intangible assets are reported at cost less accumulated amortization and accumulated impairment losses, on the same basis as intangible assets that are acquired separately.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;p style="text-align: justify;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;At September 30, 2021 and 2020, the Company has not recognized any internally-generated intangible assets.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                &lt;/div&gt;


                                &lt;div&gt;
                                    &lt;p style="margin-bottom: 0pt; text-align: justify;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;Share-based compensation awards&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;p style="margin-top: 0pt; text-align: justify;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;Share-based compensation expense relates to stock options as well as cash and equity settled restricted share units ("RSUs"). The grant date fair values of stock options and equity settled RSUs granted are recognized as an expense, with a corresponding increase in reserves in equity, over the vesting period. The amount recognized as an expense is based on the estimate of the number of awards expected to vest, which is revised if subsequent information indicates that actual forfeitures are likely to differ from the estimate. Upon exercise of stock options, the consideration paid by the holder is included in share capital and the related reserves associated with the stock options exercised is reclassified into share capital. Upon vesting of equity settled RSUs, the related reserves associated with the RSU is reclassified into share capital.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;p style="text-align: justify;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;For cash settled RSUs, the fair value of the RSUs is recognized as share-based compensation expense, with a corresponding increase in accrued liabilities over the vesting period. The amount recognized as an expense is based on the estimate of the number of RSUs expected to vest. Cash settled RSUs are measured at their fair value at each reporting period on a mark-to-market basis. Upon vesting of the cash settled RSUs, the liability is reduced by the cash payout.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                &lt;/div&gt;


                                &lt;div&gt;
                                    &lt;p style="margin-bottom: 0pt; text-align: justify;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;Provisions&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;p style="margin-top: 0pt; text-align: justify;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;A provision is recognized if, as a result of a past event, the Company has a present legal or constructive obligation that can be estimated reliably, and it is probable that an outflow of economic benefits will be required to settle the obligation. Provisions are determined by discounting the expected future cash flows at a pre-tax rate that reflects current market assessments of the time value of money and the risks specific to the liability. The unwinding of the discount is recognized as a finance cost within net income or loss.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                &lt;/div&gt;

                        &lt;/div&gt;

                        &lt;div&gt;

                                &lt;div&gt;
                                    &lt;p style="margin-bottom: 0pt; text-align: justify;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;Income taxes&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;p style="margin-top: 0pt; margin-bottom: 0pt; text-align: justify;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="text-decoration: underline;"&gt;Current income tax: &lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;p style="margin-top: 0pt; text-align: justify;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;Current income tax assets and liabilities for the current period are measured at the amount expected to be recovered from or paid to the taxation authorities. The tax rates and tax laws used to compute the amount are those that are enacted or substantively enacted, at the reporting date, in the countries where the Company operates and generates taxable income.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;p style="margin-bottom: 0pt; text-align: justify;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="text-decoration: underline;"&gt;Deferred tax: &lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;p style="margin-top: 0pt; text-align: justify;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;Deferred tax is provided on temporary differences at the reporting date between the tax bases of assets and liabilities and their carrying amounts for financial reporting purposes. The carrying amount of deferred tax assets is reviewed at the end of each reporting period and recognized only to the extent that it is probable that sufficient taxable profit will be available to allow all or part of the deferred tax asset to be utilized.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;p style="text-align: justify;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;Deferred tax assets and liabilities are measured at the tax rates that are expected to apply to the year when the asset is realized or the liability is settled, based on tax rates (and tax laws) that have been enacted or substantively enacted by the end of the reporting period. Deferred tax assets and deferred tax liabilities are offset if a legally enforceable right exists to set off current tax assets against current income tax liabilities and the deferred taxes relate to the same taxable entity and the same taxation authority.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                &lt;/div&gt;


                                &lt;div&gt;
                                    &lt;p style="margin-bottom: 0pt; text-align: justify;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;Loss per share&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;p style="margin-top: 0pt; text-align: justify;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;Basic loss per share is calculated by dividing the loss attributable to common shareholders by the weighted average number of common shares outstanding in the period. The loss attributable to common shareholders equals the reported loss attributable to owners of the Company. Diluted loss per share is calculated using the treasury stock method. Under the treasury stock method, the weighted average number of common shares outstanding for the calculation of diluted loss per share assumes that the proceeds to be received on the exercise of dilutive share options and warrants are used to repurchase common shares at the average market price during the period. Because the Company incurred net losses, the effect of dilutive instruments would be anti-dilutive and therefore diluted loss per share equals loss per share.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                &lt;/div&gt;


                                &lt;div&gt;
                                    &lt;p style="margin-bottom: 0pt; text-align: justify;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;Share capital&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;p style="margin-top: 0pt; text-align: justify;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;Financial instruments issued by the Company are classified as equity only to the extent that they do not meet the definition of a financial liability or financial asset. The Company's common shares are classified as equity instruments.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;p style="text-align: justify;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;Incremental costs directly attributable to the issue of new common shares are recognized as a deduction from equity, net of tax.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                &lt;/div&gt;


                                &lt;div&gt;
                                    &lt;p style="margin-bottom: 0pt; text-align: justify;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;Financial instruments&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;p style="margin-top: 0pt; text-align: justify;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;Financial instruments are accounted for in accordance with IFRS 9, "Financial Instruments: Classification and Measurement". A financial instrument is any contract that gives rise to a financial asset of one entity and a financial liability or equity instrument of another entity.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;p style="margin-bottom: 0pt; text-align: justify;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="text-decoration: underline;"&gt;Financial assets&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;p style="margin-top: 0pt; margin-bottom: 0pt; text-align: justify;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;(a) Recognition and measurement of financial assets&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;p style="margin-top: 0pt; margin-left: 13.5pt; text-align: justify;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;The Company recognizes a financial asset when it becomes a party to the contractual provisions of the instrument.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;p style="margin-bottom: 0pt; text-align: justify;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;(b) Classification of financial assets&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;p style="margin-top: 0pt; margin-left: 13.5pt; text-align: justify;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;The Company classifies financial assets at initial recognition as financial assets: measured at amortized cost, measured at fair value through other comprehensive income ("FVTOCI") or measured at fair value through profit or loss ("FVTPL").&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;p style="margin-bottom: 0pt; text-indent: 22.5pt; text-align: justify;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;(i) Financial assets measured at amortized cost&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;p style="margin-top: 0pt; margin-left: 36pt; text-align: justify;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;A financial asset that meets both of the following conditions is classified as a financial asset measured at amortized cost:&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;p style="margin-left: 49.5pt; margin-bottom: 0pt; text-indent: -4.5pt; text-align: justify;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&#x2022;&lt;span style="display: inline-block; width: 1.7pt;"&gt;&#160;&lt;/span&gt;The Company's business model for such financial assets is to hold the assets in order to collect contractual cash flows.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;p style="margin-top: 0pt; margin-left: 49.5pt; text-indent: -4.5pt; text-align: justify;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&#x2022;&lt;span style="display: inline-block; width: 1.7pt;"&gt;&#160;&lt;/span&gt;The contractual terms of the financial asset give rise on specified dates to cash flows that are solely payments of principal and interest on the amount outstanding.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                &lt;/div&gt;

                        &lt;/div&gt;

                        &lt;div&gt;

                                &lt;div&gt;
                                    &lt;p style="margin-left: 36pt; text-align: justify; margin-top: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;A financial asset measured at amortized cost is initially recognized at fair value plus transaction costs directly attributable to the asset. After initial recognition, the carrying amount of the financial asset measured at amortized cost is determined using the effective interest method, net of impairment loss, if necessary.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;p style="margin-bottom: 0pt; text-indent: 22.5pt; text-align: justify;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;(ii) Financial assets measured at FVTOCI&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;p style="margin-top: 0pt; margin-left: 36pt; text-align: justify;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;A financial asset measured at FVOCI is recognized initially at fair value plus transaction costs directly attributable to the asset. After initial recognition, the asset is measured at fair value with changes in fair value included as "financial asset at fair value through other comprehensive income" in other comprehensive income or loss.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;p style="margin-bottom: 0pt; text-indent: 22.5pt; text-align: justify;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;(iii) Financial assets measured at FVTPL&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;p style="margin-top: 0pt; margin-left: 36pt; text-align: justify;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;A financial asset measured at FVTPL is initially recognized at fair value with any associated transaction costs being recognized in profit or loss when incurred. Subsequently, the financial asset is re-measured at fair value and a gain or loss is recognized in profit or loss in the reporting period in which it arises.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;p style="margin-left: 36pt; text-align: justify;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;The Company's cash and cash equivalents are classified as subsequently measured at FVTPL.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;p style="margin-bottom: 0pt; text-align: justify;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;(c) Derecognition of financial assets&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;p style="margin-top: 0pt; margin-left: 13.6pt; text-align: justify;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;The Company derecognizes a financial asset if the contractual rights to the cash flows from the asset expire, or the Company transfers substantially all the risks and rewards of ownership of the financial asset. Any interests in transferred financial assets that are created or retained by the Company are recognized as a separate asset or liability. Gains and losses on derecognition are generally recognized in the statement of comprehensive loss. However, gains and losses on derecognition of financial assets classified as FVTOCI remain within accumulated other comprehensive income or loss.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;p style="margin-bottom: 0pt; text-align: justify;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="text-decoration: underline;"&gt;Financial liabilities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;p style="margin-top: 0pt; margin-bottom: 0pt; text-align: justify;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;(a) Recognition and measurement of financial liabilities&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;p style="margin-top: 0pt; margin-left: 13.5pt; text-align: justify;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;The Company recognizes a financial liability when it becomes a party to the contractual provisions of the instrument.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;p style="margin-bottom: 0pt; text-align: justify;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;(b) Classification of financial liabilities&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;p style="margin-top: 0pt; margin-bottom: 0pt; text-indent: 22.5pt; text-align: justify;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;(i) Financial liabilities measured at amortized cost&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;p style="margin-top: 0pt; margin-left: 36pt; text-align: justify;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;A financial liability measured at amortized cost is initially measured at fair value less transaction costs directly attributable to the issuance of the financial liability. Subsequently, the financial liability is measured at amortized cost using the effective interest method.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;p style="margin-left: 36pt; text-align: justify;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;The Company's accounts payable and accrued liabilities are classified as subsequently measured at amortized cost.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;p style="margin-bottom: 0pt; text-indent: 22.5pt; text-align: justify;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;(ii) Financial liabilities measured at fair value through profit or loss&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;p style="margin-top: 0pt; margin-left: 36pt; text-align: justify;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;A financial liability measured at fair value through profit or loss is initially measured at fair value with any associated transaction costs being recognized in profit or loss when incurred. Subsequently, the financial liability is re-measured at fair value and a gain or loss is recognized in profit or loss in the reporting period in which it arises.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;p style="margin-bottom: 0pt; text-align: justify;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;(c) Derecognition of financial liabilities&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;p style="margin-top: 0pt; margin-left: 13.6pt; text-align: justify;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;The Company derecognizes a financial liability when the financial liability is discharged, cancelled or expired. Generally, the difference between the carrying amount of the financial liability derecognized and the consideration paid and payable, including any non-cash assets transferred or liabilities assumed, is recognized in the statement of comprehensive loss.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;p style="margin-bottom: 0pt; text-align: justify;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="text-decoration: underline;"&gt;Offsetting financial assets and liabilities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;p style="margin-top: 0pt; text-align: justify;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;Financial assets and liabilities are offset and the net amount is presented in the statement of financial position only when the Company has a legally enforceable right to offset the recognized amounts and intends either to settle on a net basis, or to realize the asset and settle the liability simultaneously.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;p style="margin-bottom: 0pt; text-align: justify;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="text-decoration: underline;"&gt;Impairment of financial assets&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;p style="margin-top: 0pt; text-align: justify;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;The Company recognizes a loss allowance for expected credit losses on financial assets that are measured at amortized cost.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                &lt;/div&gt;

                        &lt;/div&gt;

                        &lt;div&gt;

                                &lt;div&gt;
                                    &lt;p style="margin-bottom: 0pt; text-align: justify; margin-top: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;At each reporting date, the Company measures the loss allowance for the financial asset at an amount equal to the lifetime expected credit losses if the credit risk on the financial asset has increased significantly since initial recognition. If at the reporting date, the financial asset has not increased significantly since initial recognition, the Company measures the loss allowance for the financial asset at an amount equal to the twelve-month expected credit&#160;&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;losses. The Company recognizes in the statement of comprehensive income or loss, as an impairment loss (or gain), the amount of expected credit losses (or reversal) that is required to adjust the loss allowance at the reporting date to the amount that is required to be recognized.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                &lt;/div&gt;


                                &lt;div&gt;
                                    &lt;p style="margin-bottom: 0pt; text-align: justify;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;Leases&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;p style="margin-top: 0pt; text-align: justify;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;Leases are accounted for in accordance with IFRS 16, "Leases". At inception of a contract, the Company assesses whether a contract is, or contains, a lease.&#160; A contract is, or contains, a lease if the contract conveys the right to control the use of an identified asset over a period of time in exchange for consideration.&#160; The Company assesses whether the contract involves the use of an identified asset, whether it has the right to obtain substantially all of the economic benefits from the use of the asset during the term of the contract and if it has the right to direct the use of the asset.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;p style="text-align: justify;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;As a lessee, the Company recognizes a right-of-use asset and a lease liability at the commencement date of the lease.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;p style="margin-bottom: 0pt; text-align: justify;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="text-decoration: underline;"&gt;Right-of-use asset&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;p style="margin-top: 0pt; margin-bottom: 0pt; text-align: justify;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;The right-of-use asset is initially measured at cost, which is comprised of the initial amount of the lease liability adjusted for any lease payments made and any initial direct costs incurred at or before the commencement date, less any lease incentives received.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;p style="margin-top: 0pt; text-align: justify;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;The right-of-use asset is subsequently depreciated from the commencement date to the earlier of the end of the lease term, or the end of the useful life of the asset.&#160; In addition, the right-of-use asset may be reduced due to impairment losses, if any, and adjusted for certain re-measurements of the lease liability.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;p style="margin-bottom: 0pt; text-align: justify;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="text-decoration: underline;"&gt;Lease liability&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;p style="margin-top: 0pt; text-align: justify;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;A lease liability is initially measured at the present value of the lease payments that are not paid at the commencement date discounted by the interest rate implicit in the lease or, if that rate cannot be readily determined, the incremental borrowing rate. The lease liability is subsequently measured at amortized cost using the effective interest method.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                &lt;/div&gt;


                                &lt;div&gt;
                                    &lt;p style="margin-bottom: 0pt; text-align: justify;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;New standards and interpretations not yet adopted&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;p style="margin-top: 0pt; text-align: justify;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;A number of new standards, amendments to standards and interpretations are not yet effective for the year ended September 30, 2021 and have not been applied in preparing these financial statements. The following new standards have not been adopted which may impact the Company in future:&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;p style="margin-bottom: 0pt; text-align: justify;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="text-decoration: underline;"&gt;IAS 1 - Presentation of Financial Statements &lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;p style="margin-top: 0pt; text-align: justify;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;An amendment to IAS 1 clarifies the criterion for classifying a liability as non-current relating to the right to defer settlement of a liability for at least 12 months after the reporting period.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;p style="text-align: justify;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;IAS 1 has amended the definition of material to "information is material if omitting, misstating or obscuring it could reasonably be expected to influence decisions that the primary users of general-purpose financial statements make on the basis of those financial statements, which provide financial information about a specific reporting entity." The previous definition of material from IAS1 was "omissions or misstatements of items are material if they could, individually or collectively, influence the economic decisions that users make on the basis of the financial statements. Materiality depends on the size and nature of the omission or misstatement judged in the surrounding circumstances. The size or nature of the item, or a combination of both, could be the determining factor."&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;p style="margin-bottom: 0pt; text-align: justify;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="text-decoration: underline;"&gt;IAS 8 - Accounting Policies, Changes in Accounting Estimates and Errors&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;p style="margin-top: 0pt; text-align: justify;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;IAS 8 amended the definition of material reflect the changes outlined above under IAS 1.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;p style="margin-bottom: 0pt; text-align: justify;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="text-decoration: underline;"&gt;IAS 12 and IFRIC 23 - Income Taxes&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;p style="margin-top: 0pt; text-align: justify;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;IAS 12 currently provides guidance on current and deferred tax assets and liabilities however uncertainty may exist on how tax law applies to certain transactions. IFRIC 23 provides guidance on how to address uncertainty related to tax treatments.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                &lt;/div&gt;

                        &lt;/div&gt;
                    </ifrs-full:DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory>
    <drug:DescriptionOfAccountingPolicyForBasisOfConsolidationExplanatory
      contextRef="C_20201001to20210930"
      id="Fxbrl_20211228162659674">
                                &lt;div&gt;
                                    &lt;p style="margin-bottom: 0pt; text-align: justify;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;Basis of consolidation &lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;p style="margin-top: 0pt; text-align: justify;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;These consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries Psilocybinlabs Ltd. (see Note 4), Bright Minds Biosciences LLC, a Delaware limited liability company, and Bright Minds Bioscience Pty Ltd., a proprietary company registered under the Corporations Act of Australia on June 24, 2021.&#160; On June 10, 2021, the CEO of the Company transferred, assigned and conveyed all of his membership interests in Bright Minds Biosciences LLC to the Company.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;p style="text-align: justify;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;A subsidiary is an entity that the Company controls, either directly or indirectly, where control is defined as the power to govern the financial and operating policies of an entity so as to obtain benefits from its activities. The financial results of the Company's subsidiaries are included in the financial statements from the date that control commences until the date that control ceases. The accounting policies of the Company's subsidiaries have been aligned with the policies adopted by the Company. When the Company ceases to control a subsidiary, the financial statements of that subsidiary are de-consolidated.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                &lt;/div&gt;

                                &lt;p style="text-align: justify;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;Inter-company balances and transactions, and any income and expenses arising from inter-company transactions, have been eliminated in these financial statements.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                            </drug:DescriptionOfAccountingPolicyForBasisOfConsolidationExplanatory>
    <drug:DescriptionOfAccountingPolicyForCriticalAccountingEstimatesExplanatory
      contextRef="C_20201001to20210930"
      id="Fxbrl_20211228162737281">
                                &lt;div&gt;
                                    &lt;p style="margin-bottom: 0pt; text-align: justify;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;Critical accounting estimates&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;p style="margin-top: 0pt; text-align: justify;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;The preparation of the financial statements in conformity with IFRS requires management to make estimates, judgments and assumptions that affect the application of accounting policies and the reported amounts of assets, liabilities, income and expenses. Actual results may differ from these estimates. Estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognized in the period in which the estimates are revised and in any future periods affected.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;p style="text-align: justify;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;Certain of the Company's accounting policies and disclosures require key assumptions concerning the future and other estimates that have a significant risk of causing a material adjustment to the carrying amounts of assets and liabilities or disclosures within the next fiscal year. Where applicable, further information about the assumptions made is disclosed in the notes specific to that asset or liability. The critical accounting estimates and judgments set out below have been applied consistently to all periods presented in these financial statements.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;p style="margin-bottom: 0pt; text-align: justify;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="text-decoration: underline;"&gt;Ability to continue as a going concern&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;p style="margin-top: 0pt; text-align: justify;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;Evaluation of the ability of the Company to realize its strategy for funding its future needs for working capital involves making judgments.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;p style="margin-bottom: 0pt; text-align: justify;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="text-decoration: underline;"&gt;Share-based compensation&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;p style="margin-top: 0pt; text-align: justify;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;The fair value of stock options is measured using a Black Scholes option pricing model. Measurement inputs include the common share price on the grant date, the exercise price of the instrument, the expected common share price volatility, the weighted average expected life of the instruments, the expected dividends and the risk-free interest rate. Service and non-market performance conditions are not taken into account in determining fair value. The fair value of equity settled RSUs is measured based on management's best estimate of the Company's share price on the grant date.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;p style="text-align: justify;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;The share-based compensation recognized is also determined based on management's grant date estimate of the forfeitures that are expected to occur over the life of the stock options and equity settled RSUs. Cash settled RSUs outstanding are fair valued using a mark-to-market calculation based on the Company's closing common share price at the end of the period. The number of stock options and RSUs that actually vest could differ from the estimated number of awards expected to vest and any differences between the actual and estimated forfeitures are recognized prospectively as they occur.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                &lt;/div&gt;
                            </drug:DescriptionOfAccountingPolicyForCriticalAccountingEstimatesExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory
      contextRef="C_20201001to20210930"
      id="Fxbrl_20211228163638218">
                                &lt;div&gt;
                                    &lt;p style="margin-bottom: 0pt; text-align: justify;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;Foreign currency translation&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;p style="margin-top: 0pt; text-align: justify;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;The functional currency of the Company, Psilocybinlabs Ltd., Bright Minds Biosciences LLC and Bright Minds Bioscience Pty Ltd. is the Canadian dollar and the presentation currency of the Company is the Canadian dollar. Transactions in currencies other than the functional currency are recorded at the rates of exchange prevailing on the transaction date. Monetary assets and liabilities that are denominated in foreign currencies are translated at the rates prevailing at each reporting date. Non-monetary assets and liabilities denominated in foreign currencies that are measured at fair value are retranslated to the functional currency at the exchange rate at the date the fair value was determined. Non-monetary items that are measured in terms of historical cost in a foreign currency are not retranslated. Foreign currency translation differences are recognized in profit or loss.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                &lt;/div&gt;
                            </ifrs-full:DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForBusinessCombinationsExplanatory
      contextRef="C_20201001to20210930"
      id="Fxbrl_20211228163652370">
                                &lt;div&gt;
                                    &lt;p style="margin-bottom: 0pt; text-align: justify;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;Business combinations&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;p style="margin-top: 0pt; text-align: justify;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;The Company uses the acquisition method to account for business combinations. The Company measures goodwill as the fair value of the consideration transferred, less the net recognized amount (generally fair value) of the identifiable assets acquired and liabilities assumed, all measured as of the acquisition date. When the excess is negative, a gain on acquisition is recognized immediately in net income or loss.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                &lt;/div&gt;

                                &lt;div&gt;
                                    &lt;p style="margin-top: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;Goodwill is not amortized and is tested for impairment annually. Additionally, goodwill is reviewed at each reporting date to determine if events or changes in circumstances indicate that the asset might be impaired, in which case an impairment test is performed. Goodwill is measured at cost less accumulated impairment losses.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;p style="text-align: justify;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;Transaction costs, other than those associated with the issue of debt or equity securities, that the Company incurs in connection with a business combination are expensed as incurred.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                &lt;/div&gt;
                            </ifrs-full:DescriptionOfAccountingPolicyForBusinessCombinationsExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory
      contextRef="C_20201001to20210930"
      id="Fxbrl_20211228164211145">
                                &lt;div&gt;
                                    &lt;p style="margin-bottom: 0pt; text-align: justify;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;Internally generated intangible assets - Research and development expenditure&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;p style="margin-top: 0pt; text-align: justify;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;Intangible assets acquired separately are initially recognized at cost. Expenditure on research activities is recognized as an expense in the period in which it is incurred. An internally-generated intangible asset arising from development (or from the development phase of an internal project) is recognized if, and only if, all of the following have been demonstrated:&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;p style="margin-left: 36pt; margin-bottom: 0pt; text-indent: -18pt; text-align: justify;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&#x2022;&lt;span style="display: inline-block; width: 16.7pt;"&gt;&#160;&lt;/span&gt;The technical feasibility of completing the intangible asset so that it will be available for use or sale;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;p style="margin-top: 0pt; margin-left: 36pt; margin-bottom: 0pt; text-indent: -18pt; text-align: justify;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&#x2022;&lt;span style="display: inline-block; width: 16.7pt;"&gt;&#160;&lt;/span&gt;The intention to complete the intangible asset and use or sell it;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;p style="margin-top: 0pt; margin-left: 36pt; margin-bottom: 0pt; text-indent: -18pt; text-align: justify;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&#x2022;&lt;span style="display: inline-block; width: 16.7pt;"&gt;&#160;&lt;/span&gt;The ability to use or sell the intangible asset;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;p style="margin-top: 0pt; margin-left: 36pt; margin-bottom: 0pt; text-indent: -18pt; text-align: justify;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&#x2022;&lt;span style="display: inline-block; width: 16.7pt;"&gt;&#160;&lt;/span&gt;How the intangible asset will generate probable future economic benefits;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;p style="margin-top: 0pt; margin-left: 36pt; margin-bottom: 0pt; text-indent: -18pt; text-align: justify;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&#x2022;&lt;span style="display: inline-block; width: 16.7pt;"&gt;&#160;&lt;/span&gt;The availability of adequate technical, financial and other resources to complete the development and to use or sell the intangible asset; and&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;p style="margin-top: 0pt; margin-left: 36pt; text-indent: -18pt; text-align: justify;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&#x2022;&lt;span style="display: inline-block; width: 16.7pt;"&gt;&#160;&lt;/span&gt;The ability to measure reliably the expenditure attributable to the intangible asset during its development.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;p style="text-align: justify;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;The amount initially recognized for internally-generated intangible assets is the sum of the expenditure incurred from the date when the intangible asset first meets the recognition criteria listed above. Where no internally-generated intangible asset can be recognized, development expenditure is recognized in profit or loss in the period in which it is incurred.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;p style="text-align: justify;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;Subsequent to initial recognition, internally-generated intangible assets are reported at cost less accumulated amortization and accumulated impairment losses, on the same basis as intangible assets that are acquired separately.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;p style="text-align: justify;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;At September 30, 2021 and 2020, the Company has not recognized any internally-generated intangible assets.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                &lt;/div&gt;
                            </ifrs-full:DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory
      contextRef="C_20201001to20210930"
      id="Fxbrl_20211228164225417">
                                &lt;div&gt;
                                    &lt;p style="margin-bottom: 0pt; text-align: justify;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;Share-based compensation awards&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;p style="margin-top: 0pt; text-align: justify;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;Share-based compensation expense relates to stock options as well as cash and equity settled restricted share units ("RSUs"). The grant date fair values of stock options and equity settled RSUs granted are recognized as an expense, with a corresponding increase in reserves in equity, over the vesting period. The amount recognized as an expense is based on the estimate of the number of awards expected to vest, which is revised if subsequent information indicates that actual forfeitures are likely to differ from the estimate. Upon exercise of stock options, the consideration paid by the holder is included in share capital and the related reserves associated with the stock options exercised is reclassified into share capital. Upon vesting of equity settled RSUs, the related reserves associated with the RSU is reclassified into share capital.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;p style="text-align: justify;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;For cash settled RSUs, the fair value of the RSUs is recognized as share-based compensation expense, with a corresponding increase in accrued liabilities over the vesting period. The amount recognized as an expense is based on the estimate of the number of RSUs expected to vest. Cash settled RSUs are measured at their fair value at each reporting period on a mark-to-market basis. Upon vesting of the cash settled RSUs, the liability is reduced by the cash payout.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                &lt;/div&gt;
                            </ifrs-full:DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForProvisionsExplanatory
      contextRef="C_20201001to20210930"
      id="Fxbrl_20211228164238401">
                                &lt;div&gt;
                                    &lt;p style="margin-bottom: 0pt; text-align: justify;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;Provisions&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;p style="margin-top: 0pt; text-align: justify;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;A provision is recognized if, as a result of a past event, the Company has a present legal or constructive obligation that can be estimated reliably, and it is probable that an outflow of economic benefits will be required to settle the obligation. Provisions are determined by discounting the expected future cash flows at a pre-tax rate that reflects current market assessments of the time value of money and the risks specific to the liability. The unwinding of the discount is recognized as a finance cost within net income or loss.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                &lt;/div&gt;
                            </ifrs-full:DescriptionOfAccountingPolicyForProvisionsExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForIncomeTaxExplanatory
      contextRef="C_20201001to20210930"
      id="Fxbrl_20211228164256440">
                                &lt;div&gt;
                                    &lt;p style="margin-bottom: 0pt; text-align: justify;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;Income taxes&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;p style="margin-top: 0pt; margin-bottom: 0pt; text-align: justify;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="text-decoration: underline;"&gt;Current income tax: &lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;p style="margin-top: 0pt; text-align: justify;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;Current income tax assets and liabilities for the current period are measured at the amount expected to be recovered from or paid to the taxation authorities. The tax rates and tax laws used to compute the amount are those that are enacted or substantively enacted, at the reporting date, in the countries where the Company operates and generates taxable income.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;p style="margin-bottom: 0pt; text-align: justify;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="text-decoration: underline;"&gt;Deferred tax: &lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;p style="margin-top: 0pt; text-align: justify;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;Deferred tax is provided on temporary differences at the reporting date between the tax bases of assets and liabilities and their carrying amounts for financial reporting purposes. The carrying amount of deferred tax assets is reviewed at the end of each reporting period and recognized only to the extent that it is probable that sufficient taxable profit will be available to allow all or part of the deferred tax asset to be utilized.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;p style="text-align: justify;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;Deferred tax assets and liabilities are measured at the tax rates that are expected to apply to the year when the asset is realized or the liability is settled, based on tax rates (and tax laws) that have been enacted or substantively enacted by the end of the reporting period. Deferred tax assets and deferred tax liabilities are offset if a legally enforceable right exists to set off current tax assets against current income tax liabilities and the deferred taxes relate to the same taxable entity and the same taxation authority.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                &lt;/div&gt;
                            </ifrs-full:DescriptionOfAccountingPolicyForIncomeTaxExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForEarningsPerShareExplanatory
      contextRef="C_20201001to20210930"
      id="Fxbrl_20211228164308737">
                                &lt;div&gt;
                                    &lt;p style="margin-bottom: 0pt; text-align: justify;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;Loss per share&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;p style="margin-top: 0pt; text-align: justify;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;Basic loss per share is calculated by dividing the loss attributable to common shareholders by the weighted average number of common shares outstanding in the period. The loss attributable to common shareholders equals the reported loss attributable to owners of the Company. Diluted loss per share is calculated using the treasury stock method. Under the treasury stock method, the weighted average number of common shares outstanding for the calculation of diluted loss per share assumes that the proceeds to be received on the exercise of dilutive share options and warrants are used to repurchase common shares at the average market price during the period. Because the Company incurred net losses, the effect of dilutive instruments would be anti-dilutive and therefore diluted loss per share equals loss per share.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                &lt;/div&gt;
                            </ifrs-full:DescriptionOfAccountingPolicyForEarningsPerShareExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForIssuedCapitalExplanatory
      contextRef="C_20201001to20210930"
      id="Fxbrl_20211228164323097">
                                &lt;div&gt;
                                    &lt;p style="margin-bottom: 0pt; text-align: justify;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;Share capital&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;p style="margin-top: 0pt; text-align: justify;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;Financial instruments issued by the Company are classified as equity only to the extent that they do not meet the definition of a financial liability or financial asset. The Company's common shares are classified as equity instruments.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;p style="text-align: justify;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;Incremental costs directly attributable to the issue of new common shares are recognized as a deduction from equity, net of tax.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                &lt;/div&gt;
                            </ifrs-full:DescriptionOfAccountingPolicyForIssuedCapitalExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory
      contextRef="C_20201001to20210930"
      id="Fxbrl_20211228164345985">
                                &lt;div&gt;
                                    &lt;p style="margin-bottom: 0pt; text-align: justify;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;Financial instruments&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;p style="margin-top: 0pt; text-align: justify;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;Financial instruments are accounted for in accordance with IFRS 9, "Financial Instruments: Classification and Measurement". A financial instrument is any contract that gives rise to a financial asset of one entity and a financial liability or equity instrument of another entity.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;p style="margin-bottom: 0pt; text-align: justify;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="text-decoration: underline;"&gt;Financial assets&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;p style="margin-top: 0pt; margin-bottom: 0pt; text-align: justify;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;(a) Recognition and measurement of financial assets&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;p style="margin-top: 0pt; margin-left: 13.5pt; text-align: justify;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;The Company recognizes a financial asset when it becomes a party to the contractual provisions of the instrument.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;p style="margin-bottom: 0pt; text-align: justify;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;(b) Classification of financial assets&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;p style="margin-top: 0pt; margin-left: 13.5pt; text-align: justify;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;The Company classifies financial assets at initial recognition as financial assets: measured at amortized cost, measured at fair value through other comprehensive income ("FVTOCI") or measured at fair value through profit or loss ("FVTPL").&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;p style="margin-bottom: 0pt; text-indent: 22.5pt; text-align: justify;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;(i) Financial assets measured at amortized cost&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;p style="margin-top: 0pt; margin-left: 36pt; text-align: justify;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;A financial asset that meets both of the following conditions is classified as a financial asset measured at amortized cost:&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;p style="margin-left: 49.5pt; margin-bottom: 0pt; text-indent: -4.5pt; text-align: justify;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&#x2022;&lt;span style="display: inline-block; width: 1.7pt;"&gt;&#160;&lt;/span&gt;The Company's business model for such financial assets is to hold the assets in order to collect contractual cash flows.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;p style="margin-top: 0pt; margin-left: 49.5pt; text-indent: -4.5pt; text-align: justify;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&#x2022;&lt;span style="display: inline-block; width: 1.7pt;"&gt;&#160;&lt;/span&gt;The contractual terms of the financial asset give rise on specified dates to cash flows that are solely payments of principal and interest on the amount outstanding.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                &lt;/div&gt;

                                &lt;div&gt;
                                    &lt;p style="margin-left: 36pt; text-align: justify; margin-top: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;A financial asset measured at amortized cost is initially recognized at fair value plus transaction costs directly attributable to the asset. After initial recognition, the carrying amount of the financial asset measured at amortized cost is determined using the effective interest method, net of impairment loss, if necessary.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;p style="margin-bottom: 0pt; text-indent: 22.5pt; text-align: justify;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;(ii) Financial assets measured at FVTOCI&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;p style="margin-top: 0pt; margin-left: 36pt; text-align: justify;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;A financial asset measured at FVOCI is recognized initially at fair value plus transaction costs directly attributable to the asset. After initial recognition, the asset is measured at fair value with changes in fair value included as "financial asset at fair value through other comprehensive income" in other comprehensive income or loss.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;p style="margin-bottom: 0pt; text-indent: 22.5pt; text-align: justify;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;(iii) Financial assets measured at FVTPL&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;p style="margin-top: 0pt; margin-left: 36pt; text-align: justify;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;A financial asset measured at FVTPL is initially recognized at fair value with any associated transaction costs being recognized in profit or loss when incurred. Subsequently, the financial asset is re-measured at fair value and a gain or loss is recognized in profit or loss in the reporting period in which it arises.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;p style="margin-left: 36pt; text-align: justify;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;The Company's cash and cash equivalents are classified as subsequently measured at FVTPL.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;p style="margin-bottom: 0pt; text-align: justify;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;(c) Derecognition of financial assets&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;p style="margin-top: 0pt; margin-left: 13.6pt; text-align: justify;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;The Company derecognizes a financial asset if the contractual rights to the cash flows from the asset expire, or the Company transfers substantially all the risks and rewards of ownership of the financial asset. Any interests in transferred financial assets that are created or retained by the Company are recognized as a separate asset or liability. Gains and losses on derecognition are generally recognized in the statement of comprehensive loss. However, gains and losses on derecognition of financial assets classified as FVTOCI remain within accumulated other comprehensive income or loss.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;p style="margin-bottom: 0pt; text-align: justify;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="text-decoration: underline;"&gt;Financial liabilities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;p style="margin-top: 0pt; margin-bottom: 0pt; text-align: justify;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;(a) Recognition and measurement of financial liabilities&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;p style="margin-top: 0pt; margin-left: 13.5pt; text-align: justify;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;The Company recognizes a financial liability when it becomes a party to the contractual provisions of the instrument.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;p style="margin-bottom: 0pt; text-align: justify;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;(b) Classification of financial liabilities&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;p style="margin-top: 0pt; margin-bottom: 0pt; text-indent: 22.5pt; text-align: justify;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;(i) Financial liabilities measured at amortized cost&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;p style="margin-top: 0pt; margin-left: 36pt; text-align: justify;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;A financial liability measured at amortized cost is initially measured at fair value less transaction costs directly attributable to the issuance of the financial liability. Subsequently, the financial liability is measured at amortized cost using the effective interest method.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;p style="margin-left: 36pt; text-align: justify;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;The Company's accounts payable and accrued liabilities are classified as subsequently measured at amortized cost.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;p style="margin-bottom: 0pt; text-indent: 22.5pt; text-align: justify;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;(ii) Financial liabilities measured at fair value through profit or loss&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;p style="margin-top: 0pt; margin-left: 36pt; text-align: justify;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;A financial liability measured at fair value through profit or loss is initially measured at fair value with any associated transaction costs being recognized in profit or loss when incurred. Subsequently, the financial liability is re-measured at fair value and a gain or loss is recognized in profit or loss in the reporting period in which it arises.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;p style="margin-bottom: 0pt; text-align: justify;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;(c) Derecognition of financial liabilities&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;p style="margin-top: 0pt; margin-left: 13.6pt; text-align: justify;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;The Company derecognizes a financial liability when the financial liability is discharged, cancelled or expired. Generally, the difference between the carrying amount of the financial liability derecognized and the consideration paid and payable, including any non-cash assets transferred or liabilities assumed, is recognized in the statement of comprehensive loss.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;p style="margin-bottom: 0pt; text-align: justify;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="text-decoration: underline;"&gt;Offsetting financial assets and liabilities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;p style="margin-top: 0pt; text-align: justify;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;Financial assets and liabilities are offset and the net amount is presented in the statement of financial position only when the Company has a legally enforceable right to offset the recognized amounts and intends either to settle on a net basis, or to realize the asset and settle the liability simultaneously.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;p style="margin-bottom: 0pt; text-align: justify;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="text-decoration: underline;"&gt;Impairment of financial assets&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;p style="margin-top: 0pt; text-align: justify;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;The Company recognizes a loss allowance for expected credit losses on financial assets that are measured at amortized cost.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                &lt;/div&gt;

                                &lt;div&gt;
                                    &lt;p style="margin-bottom: 0pt; text-align: justify; margin-top: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;At each reporting date, the Company measures the loss allowance for the financial asset at an amount equal to the lifetime expected credit losses if the credit risk on the financial asset has increased significantly since initial recognition. If at the reporting date, the financial asset has not increased significantly since initial recognition, the Company measures the loss allowance for the financial asset at an amount equal to the twelve-month expected credit&#160;&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;losses. The Company recognizes in the statement of comprehensive income or loss, as an impairment loss (or gain), the amount of expected credit losses (or reversal) that is required to adjust the loss allowance at the reporting date to the amount that is required to be recognized.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                &lt;/div&gt;
                            </ifrs-full:DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForLeasesExplanatory
      contextRef="C_20201001to20210930"
      id="Fxbrl_20211228164437799">
                                &lt;div&gt;
                                    &lt;p style="margin-bottom: 0pt; text-align: justify;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;Leases&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;p style="margin-top: 0pt; text-align: justify;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;Leases are accounted for in accordance with IFRS 16, "Leases". At inception of a contract, the Company assesses whether a contract is, or contains, a lease.&#160; A contract is, or contains, a lease if the contract conveys the right to control the use of an identified asset over a period of time in exchange for consideration.&#160; The Company assesses whether the contract involves the use of an identified asset, whether it has the right to obtain substantially all of the economic benefits from the use of the asset during the term of the contract and if it has the right to direct the use of the asset.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;p style="text-align: justify;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;As a lessee, the Company recognizes a right-of-use asset and a lease liability at the commencement date of the lease.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;p style="margin-bottom: 0pt; text-align: justify;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="text-decoration: underline;"&gt;Right-of-use asset&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;p style="margin-top: 0pt; margin-bottom: 0pt; text-align: justify;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;The right-of-use asset is initially measured at cost, which is comprised of the initial amount of the lease liability adjusted for any lease payments made and any initial direct costs incurred at or before the commencement date, less any lease incentives received.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;p style="margin-top: 0pt; text-align: justify;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;The right-of-use asset is subsequently depreciated from the commencement date to the earlier of the end of the lease term, or the end of the useful life of the asset.&#160; In addition, the right-of-use asset may be reduced due to impairment losses, if any, and adjusted for certain re-measurements of the lease liability.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;p style="margin-bottom: 0pt; text-align: justify;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="text-decoration: underline;"&gt;Lease liability&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;p style="margin-top: 0pt; text-align: justify;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;A lease liability is initially measured at the present value of the lease payments that are not paid at the commencement date discounted by the interest rate implicit in the lease or, if that rate cannot be readily determined, the incremental borrowing rate. The lease liability is subsequently measured at amortized cost using the effective interest method.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                &lt;/div&gt;
                            </ifrs-full:DescriptionOfAccountingPolicyForLeasesExplanatory>
    <drug:DescriptionOfAccountingPolicyForNewStandardsAndInterpretationsNotYetAdoptedExplanatory
      contextRef="C_20201001to20210930"
      id="Fxbrl_20211228164450736">
                                &lt;div&gt;
                                    &lt;p style="margin-bottom: 0pt; text-align: justify;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;New standards and interpretations not yet adopted&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;p style="margin-top: 0pt; text-align: justify;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;A number of new standards, amendments to standards and interpretations are not yet effective for the year ended September 30, 2021 and have not been applied in preparing these financial statements. The following new standards have not been adopted which may impact the Company in future:&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;p style="margin-bottom: 0pt; text-align: justify;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="text-decoration: underline;"&gt;IAS 1 - Presentation of Financial Statements &lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;p style="margin-top: 0pt; text-align: justify;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;An amendment to IAS 1 clarifies the criterion for classifying a liability as non-current relating to the right to defer settlement of a liability for at least 12 months after the reporting period.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;p style="text-align: justify;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;IAS 1 has amended the definition of material to "information is material if omitting, misstating or obscuring it could reasonably be expected to influence decisions that the primary users of general-purpose financial statements make on the basis of those financial statements, which provide financial information about a specific reporting entity." The previous definition of material from IAS1 was "omissions or misstatements of items are material if they could, individually or collectively, influence the economic decisions that users make on the basis of the financial statements. Materiality depends on the size and nature of the omission or misstatement judged in the surrounding circumstances. The size or nature of the item, or a combination of both, could be the determining factor."&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;p style="margin-bottom: 0pt; text-align: justify;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="text-decoration: underline;"&gt;IAS 8 - Accounting Policies, Changes in Accounting Estimates and Errors&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;p style="margin-top: 0pt; text-align: justify;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;IAS 8 amended the definition of material reflect the changes outlined above under IAS 1.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;p style="margin-bottom: 0pt; text-align: justify;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="text-decoration: underline;"&gt;IAS 12 and IFRIC 23 - Income Taxes&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;p style="margin-top: 0pt; text-align: justify;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;IAS 12 currently provides guidance on current and deferred tax assets and liabilities however uncertainty may exist on how tax law applies to certain transactions. IFRIC 23 provides guidance on how to address uncertainty related to tax treatments.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                &lt;/div&gt;
                            </drug:DescriptionOfAccountingPolicyForNewStandardsAndInterpretationsNotYetAdoptedExplanatory>
    <drug:DisclosureOfShareExchangeAndAssignmentExplanatory
      contextRef="C_20201001to20210930"
      id="Fxbrl_20211228170632122">
                        &lt;div&gt;
                            &lt;p style="text-align: justify;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;4.&lt;span style="display: inline-block; width: 9pt;"&gt;&#160;&lt;/span&gt;SHARE EXCHANGE AND ASSIGNMENT&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                            &lt;p style="text-align: justify; margin-bottom: 0px;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;Psilocybinlabs Ltd. ("PL") was incorporated under the laws of the province of British Columbia on April 25, 2019, with the incorporator share being held by a company controlled by the CEO of the Company. On May 17, 2019, this share was transferred to the Company. On April 25, 2019, PL entered into a confirmatory assignment and waiver (the "CAW") with an individual, which was amended and restated on May 17, 2019. Pursuant to the amended and restated CAW, this individual assigned all of the right, title and interest, including all other intellectual property rights (the Rights, as described) to PL. As compensation for the assignment of the Rights, PL issued 100,000 common shares valued at $2,000 to this individual. On August 7, 2019, the Company then purchased the 100,000 common shares of PL by issuing 100,000 common shares of the Company valued at $2,000, with the reacquisition being recorded as an asset acquisition.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                        &lt;/div&gt;
                    </drug:DisclosureOfShareExchangeAndAssignmentExplanatory>
    <drug:NumberOfSharesIssuedByRelatedParty
      contextRef="C_20190425_ifrsfullCategoriesOfRelatedPartiesAxis_drugPsilocybinlabsLtdMember"
      decimals="INF"
      id="Fxbrl_20211228180500243"
      unitRef="Share">100000</drug:NumberOfSharesIssuedByRelatedParty>
    <drug:ValueOfCommonStockSharesIssuedByRelatedParty
      contextRef="C_20190425_ifrsfullCategoriesOfRelatedPartiesAxis_drugPsilocybinlabsLtdMember"
      decimals="0"
      id="Fxbrl_20211228180513940"
      unitRef="CAD">2000</drug:ValueOfCommonStockSharesIssuedByRelatedParty>
    <drug:CommonStockSharesPurchased
      contextRef="C_20190807_ifrsfullCategoriesOfRelatedPartiesAxis_drugPsilocybinlabsLtdMember"
      decimals="INF"
      id="Fxbrl_20211228180534851"
      unitRef="Share">100000</drug:CommonStockSharesPurchased>
    <ifrs-full:NumberOfInstrumentsOrInterestsIssuedOrIssuable
      contextRef="C_20190807_ifrsfullCategoriesOfRelatedPartiesAxis_drugPsilocybinlabsLtdMember"
      decimals="INF"
      id="Fxbrl_20211228180624725"
      unitRef="Shares">100000</ifrs-full:NumberOfInstrumentsOrInterestsIssuedOrIssuable>
    <ifrs-full:EquityInterestsOfAcquirer
      contextRef="C_20190807_ifrsfullCategoriesOfRelatedPartiesAxis_drugPsilocybinlabsLtdMember"
      decimals="0"
      id="Fxbrl_20211228180638636"
      unitRef="CAD">2000</ifrs-full:EquityInterestsOfAcquirer>
    <ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory
      contextRef="C_20201001to20210930"
      id="Fxbrl_20211228162231396">
                    &lt;div&gt;
                        &lt;p style="text-align: justify;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;5.&lt;span style="display: inline-block; width: 9pt;"&gt;&#160;&lt;/span&gt;ACCOUNTS PAYABLE AND ACCRUED LIABILITIES&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

                            &lt;table cellpadding="0" cellspacing="0" style="width: 100%; border-collapse: collapse; font-size: 10pt; border-color: #000000;"&gt;
                                &lt;tr&gt;
                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1.5pt solid #000000; border-bottom: 0.75pt solid #000000; vertical-align: bottom;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-top: 1.5pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-top: 1.5pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;September 30, &lt;/b&gt;&lt;br/&gt;&lt;b&gt;2021&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-top: 1.5pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-top: 1.5pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-top: 1.5pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;September 30, &lt;/b&gt;&lt;br/&gt;&lt;b&gt;2020&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-top: 1.5pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right;"&gt;&#160;&lt;/td&gt;
                                &lt;/tr&gt;
                                &lt;tr&gt;
                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;$&#160;&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right;"&gt;&#160;&lt;/td&gt;
                                &lt;/tr&gt;
                                &lt;tr&gt;
                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;Accounts payable&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;596,573&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;138,423&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                &lt;/tr&gt;
                                &lt;tr&gt;
                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;Accrued liabilities&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;42,000&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;12,500&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                &lt;/tr&gt;
                                &lt;tr&gt;
                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 2.25pt double #000000; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;Total accounts payable and accrued liabilities&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;638,573&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;150,923&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                &lt;/tr&gt;
                            &lt;/table&gt;

                    &lt;/div&gt;
                </ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory>
    <drug:DisclosureOfDetailedInformationAboutTradePayableAndAccruedExpensesExplanatory
      contextRef="C_20201001to20210930"
      id="Fxbrl_20211228162242620">
                            &lt;table cellpadding="0" cellspacing="0" style="width: 100%; border-collapse: collapse; font-size: 10pt; border-color: #000000;"&gt;
                                &lt;tr&gt;
                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1.5pt solid #000000; border-bottom: 0.75pt solid #000000; vertical-align: bottom;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-top: 1.5pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-top: 1.5pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;September 30, &lt;/b&gt;&lt;br/&gt;&lt;b&gt;2021&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-top: 1.5pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-top: 1.5pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-top: 1.5pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;September 30, &lt;/b&gt;&lt;br/&gt;&lt;b&gt;2020&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-top: 1.5pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right;"&gt;&#160;&lt;/td&gt;
                                &lt;/tr&gt;
                                &lt;tr&gt;
                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;$&#160;&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right;"&gt;&#160;&lt;/td&gt;
                                &lt;/tr&gt;
                                &lt;tr&gt;
                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;Accounts payable&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;596,573&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;138,423&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                &lt;/tr&gt;
                                &lt;tr&gt;
                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;Accrued liabilities&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;42,000&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;12,500&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                &lt;/tr&gt;
                                &lt;tr&gt;
                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 2.25pt double #000000; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;Total accounts payable and accrued liabilities&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;638,573&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;150,923&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                &lt;/tr&gt;
                            &lt;/table&gt;
                        </drug:DisclosureOfDetailedInformationAboutTradePayableAndAccruedExpensesExplanatory>
    <ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers
      contextRef="C_20210930"
      decimals="0"
      id="Fxbrl_20211228162400108_22"
      unitRef="CAD">596573</ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers>
    <ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers
      contextRef="C_20200930"
      decimals="0"
      id="Fxbrl_20211228162400108_25"
      unitRef="CAD">138423</ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers>
    <ifrs-full:AccrualsClassifiedAsCurrent
      contextRef="C_20210930"
      decimals="0"
      id="Fxbrl_20211228162400108_32"
      unitRef="CAD">42000</ifrs-full:AccrualsClassifiedAsCurrent>
    <ifrs-full:AccrualsClassifiedAsCurrent
      contextRef="C_20200930"
      decimals="0"
      id="Fxbrl_20211228162400108_35"
      unitRef="CAD">12500</ifrs-full:AccrualsClassifiedAsCurrent>
    <ifrs-full:TradeAndOtherCurrentPayables
      contextRef="C_20210930"
      decimals="0"
      id="Fxbrl_20211228162400108_42"
      unitRef="CAD">638573</ifrs-full:TradeAndOtherCurrentPayables>
    <ifrs-full:TradeAndOtherCurrentPayables
      contextRef="C_20200930"
      decimals="0"
      id="Fxbrl_20211228162400108_45"
      unitRef="CAD">150923</ifrs-full:TradeAndOtherCurrentPayables>
    <ifrs-full:DisclosureOfIssuedCapitalExplanatory
      contextRef="C_20201001to20210930"
      id="Fxbrl_20211229021204284">
                                    &lt;div&gt;
                                        &lt;p style="text-align: justify; margin-top: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;6.&lt;span style="display: inline-block; width: 9pt;"&gt;&#160;&lt;/span&gt;SHARE CAPITAL&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                        &lt;p style="margin-bottom: 0pt; text-align: justify;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="text-decoration: underline;"&gt;&lt;b&gt;Authorized share capital&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                        &lt;p style="margin-top: 0pt; text-align: justify;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;Unlimited number of common shares without par value.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                        &lt;p style="text-align: justify;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;
                                                    On November 10, 2020, the Directors of the Company approved the consolidation of the Company's issued and outstanding common shares on a 2.5:1 basis. All common shares, stock options and warrant references in these financial statements reflect the effect of the share consolidation.
                                                &lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                        &lt;p style="margin-bottom: 0pt; text-align: justify;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;Issued share capital for the year ended September 30, 2021&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                        &lt;p style="margin-top: 0pt; text-align: justify;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;On November 2, 2020, the Company closed the second tranche of a non-brokered private placement financing through the issuance of 1,629,138 common shares at a price $1.25 per common share for gross proceeds of $2,036,422.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                        &lt;p style="text-align: justify;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;On January 6, 2021, the Company issued 14,799 common shares at a deemed price of $1.25 per share to settle an $18,500 debt owing to a consultant pursuant to a debt settlement agreement entered into by the Company with the consultant.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                        &lt;p style="text-align: justify;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;On February 3, 2021, the 16,000 SWs were deemed to be exercised for SW shares and 16,000 common shares of the Company were issued to the SW holders (see below).&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                        &lt;p style="text-align: justify;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;On March 17, 2021, the Company issued 3,419,883 Units at a price per Unit of $7.57 for aggregate gross proceeds of $25,888,514. Each Unit comprised one common share and one-half of one common share purchase warrant of the Company. Each warrant is exercisable to acquire one common share of the Company at an exercise price of $9.46 per warrant until March 17, 2024, subject to adjustment and acceleration in certain events. If the daily volume weighted average trading price of the common shares on the CSE is equal to or greater than $13.25 per common share for any 10 consecutive trading days, the Company shall have the right to accelerate the expiry date of the warrants to a date that is at least 30 trading days following the date of the Company issuing a press release disclosing such acceleration. The underwriters were paid fees for their services in the amount of $916,317 and received compensation warrants entitling them to purchase an aggregate of 132,666 common shares at a price of $7.57 per common share for a period of thirty-six months following closing. These warrants have an ascribed value of $521,000.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                        &lt;p style="text-align: justify;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;On April 6, 2021, the Company paid a New York-based company a contingent cash fee in the amount of $600,000, being 4.5% of $13,333,333 in net equity proceeds received from three investors introduced to the Company by the company. The company was also entitled to receive compensation warrants allowing it to purchase an aggregate of 8,807 common shares at a price of $7.57 per common share for a period of five years. These warrants, having an ascribed value of $33,100, were never issued. Instead, on September 21,2021, the Company granted compensation options (see below).&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;/div&gt;

                                    &lt;div&gt;
                                        &lt;p style="text-align: justify;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;On April 23, 2021, 1,948,000 escrowed share purchase warrants were exercised for $0.05 per share for gross proceeds of $97,400.&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                        &lt;p style="text-align: justify;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;On April 28, 2021, the Company issued 63,000 common shares to the University at a deemed price of $5.85 per share. The $368,550 value attributed to these shares has been recognized as a research and development expense in the consolidated statements of comprehensive loss during the year ended September 30, 2021. See Note 8.&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                        &lt;p style="margin-bottom: 0pt; text-align: justify;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;Issued share capital for the year ended September 30, 2020&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                        &lt;p style="margin-top: 0pt; text-align: justify;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;On September 30, 2020, the Company closed the first tranche of a non-brokered private placement financing through the issuance of 623,941 common shares at a price $1.25 per common share for gross proceeds of $779,924.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                        &lt;p style="margin-bottom: 0pt; text-align: justify;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;Issued share capital from May 31, 2019 (date of incorporation) to September 30, 2019&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                        &lt;p style="margin-top: 0pt; text-align: justify;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;On July 30, 2019, the Company closed a non-brokered private placement financing through the issuance of 4,079,600 units at a price of $0.05 per unit for gross proceeds of $203,980. Of this amount, $80,980 was received subsequent to year end. Each unit comprises one common share, and one share purchase warrant exercisable at $0.05 per share until July 30, 2024.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                        &lt;p style="margin-bottom: 0pt; text-align: justify;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;Special Warrants and Resulting Share Issuance&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                        &lt;p style="margin-top: 0pt; text-align: justify;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;In October 2020, the Company entered into subscription agreements for special warrants (the "SWs") whereby the subscribers subscribed for a total of 18,300 SWs at $1.25 per SW, with the SWs providing that each SW is deemed to be exercised, without payment of any additional consideration and without any further action by the SW holders, for one SW share, subject to adjustment in accordance with the provisions of the SW certificate on the SW exercise date.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                        &lt;p style="text-align: justify;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;On November 2, 2020, the Company issued 18,300 SWs for gross proceeds of $22,875. On January 19, 2021, as a result of a compliance review of the SW offering by the British Columbia Securities Commission, the Company rescinded the issuance of 2,300 SWs and refunded the $2,875 in proceeds received. On February 3, 2021, the $20,000 in escrowed proceeds was released to the Company, the SWs were deemed to be exercised for SW shares and 16,000 common shares of the Company were issued to the SW holders.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                        &lt;p style="margin-bottom: 0pt; text-align: justify;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;Share subscriptions received/receivable&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                        &lt;p style="margin-top: 0pt; text-align: justify;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;During the fiscal year ended September 30, 2020, the Company received $147,426 in subscriptions for 294,852 common shares relating to the private placement that closed on November 2, 2020.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                        &lt;p style="text-align: justify;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;On July 31, 2019, 4,049,000 common shares were issued for which the gross proceeds of $80,980 were received on October 7, 2019 and September 28, 2020.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                        &lt;p style="margin-bottom: 0pt; text-align: justify;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;Escrowed Securities&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                        &lt;p style="margin-top: 0pt; text-align: justify;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;On January 28, 2021, the Company entered into an escrow agreement under National Policy 46-201 &lt;i&gt;Escrow for Initial Public Offerings&lt;/i&gt; (the "Policy") in connection with the listing of common shares of the Company on the CSE, whereby 2,852,800 common shares of the Company and 1,948,000 share purchase warrants (exercised on April 23, 2021), being an aggregate of 4,800,800 securities, were deposited to be held in escrow. As the Company is defined as an emerging issuer under the Policy, the escrowed securities will be released as follows:&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                        &lt;p style="text-align: justify; padding-left: 8.25pt; margin-bottom: 0pt; margin-top: 0pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&#160; &#160;&#x2022;&#160; &#160; &#160; 480,080 on the date that the Company's shares are listed on the CSE (February 8, 2021); and&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                        &lt;p style="text-align: justify; padding-left: 8.25pt; margin-bottom: 0pt; margin-top: 0pt;"&gt;&lt;span style="font-family: Times New Roman, Times, serif; font-size: 10pt;"&gt;&#160; &#160;&#x2022;&#160; &#160; &#160; &lt;/span&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;720,120 six, 12, 18, 24, 30 and 36 months after the listing date.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                        &lt;p style="margin-bottom: 0pt; text-align: justify;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="text-decoration: underline;"&gt;&lt;b&gt;Stock options&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                        &lt;p style="margin-top: 0pt; text-align: justify;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;The Company's stock option plan provides for stock options to be issued to directors, officers, employees and consultants of the Company, its subsidiaries and any personal holding company of such individuals so that they may participate in the growth and development of the Company. Subject to the specific provisions of the stock option plan, eligibility, vesting period, terms of the options and the number of options granted are to be determined by the Board of Directors at the time of grant. The stock option plan allows the Board of Directors to issue up to 10% of the Company's outstanding common shares as stock options.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;/div&gt;

                                    &lt;div&gt;
                                        &lt;p style="margin-bottom: 0pt; text-align: justify;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;Options granted during the year ended September 30, 2021&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                        &lt;p style="margin-top: 0pt; margin-bottom: 11px; text-align: justify; font-size: 10pt; font-family: Times New Roman, Times, serif;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="line-height: normal;"&gt;On November 17, 2020, the Company granted 467,000 options, to the Chief Financial Officer of the Company, two directors of the Company and seven consultants. These options have an exercise price of $1.25 per share, expire on November 17, 2025 and vest as follows:&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                        &lt;p style="margin-top: 0pt; margin-left: 58px; margin-bottom: 0pt; text-align: justify; text-indent: -21.25pt; font-size: 10pt; font-family: Times New Roman, Times, serif;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="line-height: normal;"&gt;&#x2022;&#160; &#160; &#160; &#160;25,000 options - 100% on the date of grant;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                        &lt;p style="margin-top: 0pt; margin-left: 58px; margin-bottom: 0pt; text-align: justify; text-indent: -21.25pt; font-size: 10pt; font-family: Times New Roman, Times, serif;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="line-height: normal;"&gt;&#x2022;&#160; &#160;&#160; &#160; 14,000 options - 25% on the Company's listing date, 25% on the first anniversary of the listing date and 50% on the second anniversary of the listing date;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                        &lt;p style="margin-top: 0pt; margin-left: 58px; margin-bottom: 0pt; text-align: justify; text-indent: -21.25pt; font-size: 10pt; font-family: Times New Roman, Times, serif;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="line-height: normal;"&gt;&#x2022;&#160; &#160; &#160;&#160; 4,000 options - 50% on the Company's listing date and 50% on the six-month anniversary of the listing date; and&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                        &lt;p style="margin-top: 0pt; margin-left: 58px; margin-bottom: 0pt; text-align: justify; text-indent: -21.25pt; font-size: 10pt; font-family: Times New Roman, Times, serif;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="line-height: normal;"&gt;&#x2022;&#160; &#160; &#160;&#160; 424,000 options - 33% on the first anniversary of the grant date, 33% on the second anniversary of the grant date and 33% on the third anniversary of the grant date.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                        &lt;p style="text-align: justify;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;The fair value of these stock options was measured using the Black Scholes option pricing model using the following inputs: i) exercise price: $1.25; ii) share price: $1.25; iii) term: 5 years; iv) volatility: 100%; v) discount rate: 0.43%; and dividends: nil.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                        &lt;p style="margin-top: 0pt; margin-bottom: 11px; font-size: 10pt; font-family: Times New Roman, Times, serif;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="line-height: 107%;"&gt;On April 28, 2021, the Company granted 240,000 options to three consultants of the Company. These options have an exercise price of $7.60 per share, expire on April 28, 2026 and vest as follows:&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                        &lt;p style="margin-top: 0pt; margin-left: 58px; margin-bottom: 0pt; text-align: justify; text-indent: -21.25pt; font-size: 10pt; font-family: Times New Roman, Times, serif;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="line-height: normal;"&gt;&#x2022;&#160; &#160; &#160; 160,000 options - 25% on the first anniversary of the grant date, 25% on the second anniversary of the grant date, 25% on the third anniversary of the grant date and 25% on the fourth anniversary of the grant date; and&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                        &lt;p style="margin-top: 0pt; margin-left: 58px; margin-bottom: 0pt; text-align: justify; text-indent: -21.25pt; font-size: 10pt; font-family: Times New Roman, Times, serif;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="line-height: normal;"&gt;&#x2022;&#160; &#160; &#160; 80,000 options - 25% on the six-month anniversary of the grant date, 25% on the first anniversary of the grant date, 25% on the eighteen-month anniversary of the grant date and 25% on the second anniversary of the grant date.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                        &lt;p style="text-align: justify;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;The fair value of these stock options was measured using the Black Scholes option pricing model using the following inputs: i) exercise price: $7.60; ii) share price: $5.98; iii) term: 5 years; iv) volatility: 100%; v) discount rate: 0.92%; and dividends: nil.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                        &lt;p style="text-align: justify;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;On June 15, 2021, the Company granted 180,000 options to a director and a consultant of the Company. These options have an exercise price of $7.60 per share, expire on June 15, 2026 and vest as follows: 25% on the first anniversary of the grant date, 25% on the second anniversary of the grant date, 25% on the third anniversary of the grant date and 25% on the fourth anniversary of the grant date. The fair value of these stock options was measured using the Black Scholes option pricing model using the following inputs: i) exercise price: $7.60; ii) share price: $5.55; iii) term: 5 years; iv) volatility: 100%; v) discount rate: 0.84%; and dividends: nil.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                        &lt;p style="text-align: justify;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;On September 21, 2021, the Company granted 8,807 options to a consultant of the Company (see above). These options have an exercise price of $7.64 per share, expire on September 21, 2024 and vest as follows: 25% on December 21, 2021, 25% on March 21, 2022, 25% on June 21, 2022 and 25% on September 21, 2022. The fair value of these stock options was measured using the Black Scholes option pricing model using the following inputs: i) exercise price: $7.64; ii) share price: $7.64; iii) term: 3 years; iv) volatility: 100%; v) discount rate: 0.55%; and dividends: nil.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                        &lt;p style="margin-bottom: 0pt; text-align: justify;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;Options granted during the year ended September 30, 2020&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                        &lt;p style="margin-top: 0pt; text-align: justify;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;On July 23, 2020, the Company granted 150,000 options to the Company's Chief Medical Officer. The fair value of these stock options was measured using the Black Scholes option pricing model using the following inputs: i) exercise price: $1.25; ii) share price: $1.25; iii) term: 5 years; iv) volatility: 100%; v) discount rate: 0.35%; and dividends: nil.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;/div&gt;

                                    &lt;div&gt;
                                        &lt;p style="text-align: justify;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;The following table summarizes the movements in the Company's outstanding stock options for the years ended September 30, 2021 and 2020:&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

                                            &lt;div&gt;
                                                &lt;div style="margin-left: 5.4pt;"&gt;
                                                    &lt;table cellpadding="0" cellspacing="0" style="width: 100%; border-collapse: collapse; font-size: 10pt; border-color: #000000;"&gt;
                                                        &lt;tr&gt;
                                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1.5pt solid #000000; border-bottom: 0.75pt solid #000000; vertical-align: bottom;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-top: 1.5pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-top: 1.5pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&#160;&lt;br/&gt;&lt;b&gt;Number of options&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-top: 1.5pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-top: 1.5pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-top: 1.5pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;&#160; Weighted average&#160; &lt;/b&gt;&lt;br/&gt;&lt;b&gt;exercise price&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-top: 1.5pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right;"&gt;&#160;&lt;/td&gt;
                                                        &lt;/tr&gt;
                                                        &lt;tr&gt;
                                                            &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;Balance at September 30, 2019 and May 31, 2019&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;-&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;-&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                        &lt;/tr&gt;
                                                        &lt;tr&gt;
                                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&#160; Granted&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;150,000&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;1.25&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                                        &lt;/tr&gt;
                                                        &lt;tr&gt;
                                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;Balance at September 30, 2020&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;150,000&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;1.25&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                        &lt;/tr&gt;
                                                        &lt;tr&gt;
                                                            &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&#160; Granted&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; text-align: right; width: 12%;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;895,807&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; text-align: right; width: 12%;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;4.29&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                                        &lt;/tr&gt;
                                                        &lt;tr&gt;
                                                            &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: justify; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&#160; Cancelled*&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;(20,000&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;1.25&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                        &lt;/tr&gt;
                                                        &lt;tr&gt;
                                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 2.25pt double #000000; vertical-align: bottom;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;Balance at September 30, 2021&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 12%;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;1,025,807&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 12%;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;3.90&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                                        &lt;/tr&gt;
                                                    &lt;/table&gt;
                                                &lt;/div&gt;
                                            &lt;/div&gt;

                                        &lt;p style="text-align: justify;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;i&gt;* On January 21, 2021, the Company cancelled 20,000 options granted to a consultant in error on November 17, 2020.&lt;/i&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                        &lt;p style="text-align: justify;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;As at September 30, 2021, the options have a weighted average remaining life of 4.28 years (September 30, 2020 - 4.81).&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                        &lt;p style="text-align: justify;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;The following table summarizes the stock options issued and outstanding:&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

                                            &lt;div&gt;
                                                &lt;table cellpadding="0" cellspacing="0" style="width: 90%; border-collapse: collapse; font-size: 10pt; border-color: #000000; margin-left: auto; margin-right: auto;"&gt;
                                                    &lt;tr&gt;
                                                        &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-top: 1.5pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                        &lt;td colspan="1" style="vertical-align: bottom; border-top: 1.5pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: center;"&gt;&#160;&lt;/td&gt;
                                                        &lt;td colspan="10" style="vertical-align: bottom; border-top: 1.5pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;Options Outstanding and Exercisable&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                        &lt;td colspan="1" style="vertical-align: bottom; border-top: 1.5pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: center;"&gt;&#160;&lt;/td&gt;
                                                    &lt;/tr&gt;
                                                    &lt;tr&gt;
                                                        &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-indent: 2.8pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;br/&gt;&lt;b&gt;Expiry Date&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                        &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right;"&gt;&#160;&lt;/td&gt;
                                                        &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;Number of&lt;br/&gt;options&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                        &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
                                                        &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
                                                        &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;br/&gt;&lt;b&gt;Exercisable&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                        &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
                                                        &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
                                                        &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;br/&gt;&lt;b&gt;Exercise price&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                        &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
                                                        &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
                                                        &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;Remaining life&lt;br/&gt;(Years)&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                        &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right;"&gt;&#160;&lt;/td&gt;
                                                    &lt;/tr&gt;
                                                    &lt;tr&gt;
                                                        &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;September 21, 2024&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                        &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                        &lt;td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;8,807&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                        &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                        &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                        &lt;td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                        &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                        &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                        &lt;td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;7.64&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                        &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                        &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                        &lt;td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;
                                                                    2.98
                                                                &lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                        &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                    &lt;/tr&gt;
                                                    &lt;tr&gt;
                                                        &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;July 23, 2025&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                        &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                                        &lt;td style="vertical-align: bottom; text-align: right; width: 12%;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;150,000&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                        &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                                        &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                                        &lt;td style="vertical-align: bottom; text-align: right; width: 12%;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;150,000&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                        &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                                        &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                        &lt;td style="vertical-align: bottom; text-align: right; width: 12%;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;1.25&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                        &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                                        &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                                        &lt;td style="vertical-align: bottom; text-align: right; width: 12%;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;
                                                                    3.81
                                                                &lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                        &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                                    &lt;/tr&gt;
                                                    &lt;tr&gt;
                                                        &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;November 17, 2025&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                        &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                        &lt;td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;447,000&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                        &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                        &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                        &lt;td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;30,500&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                        &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                        &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                        &lt;td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;1.25&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                        &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                        &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                        &lt;td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;
                                                                    4.13
                                                                &lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                        &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                    &lt;/tr&gt;
                                                    &lt;tr&gt;
                                                        &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;April 28, 2026&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                        &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                                        &lt;td style="vertical-align: bottom; text-align: right; width: 12%;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;240,000&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                        &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                                        &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                                        &lt;td style="vertical-align: bottom; text-align: right; width: 12%;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                        &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                                        &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                        &lt;td style="vertical-align: bottom; text-align: right; width: 12%;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;7.60&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                        &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                                        &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                                        &lt;td style="vertical-align: bottom; text-align: right; width: 12%;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;
                                                                    4.58
                                                                &lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                        &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                                    &lt;/tr&gt;
                                                    &lt;tr&gt;
                                                        &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 2.25pt double #000000; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;June 15, 2026&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                        &lt;td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                        &lt;td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;180,000&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                        &lt;td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                        &lt;td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                        &lt;td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                        &lt;td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                        &lt;td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                        &lt;td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;7.60&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                        &lt;td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                        &lt;td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                        &lt;td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;
                                                                    4.71
                                                                &lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                        &lt;td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                    &lt;/tr&gt;
                                                &lt;/table&gt;
                                            &lt;/div&gt;

                                        &lt;p style="margin-bottom: 0pt; text-align: justify;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="text-decoration: underline;"&gt;&lt;b&gt;Restricted share unit plan&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                        &lt;p style="margin-top: 0pt; text-align: justify;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;The Company's restricted share unit ("RSU") plan provides RSUs to be issued to directors, officers, employees and consultants of the Company, its subsidiaries and any personal holding company of such individuals so that they may participate in the growth and development of the Company. Subject to the specific provisions of the RSU plan, eligibility, vesting period, terms of the RSUs and the number of RSUs granted are to be determined by the Board of Directors at the time of the grant. The RSU plan allows the Board of Directors to issue common shares of the company as equity settled RSUs, provided that, when combined, the maximum number of common shares reserved for issuance under all share-based compensation arrangements of the Company does not exceed 10% of the Company's outstanding common shares.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                        &lt;p style="text-align: justify;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;On July 23, 2020 and September 18, 2020, the Company issued 150,000 RSUs and 230,000 RSUs, respectively, to the Chief Medical Officer of the Company. These RSUs vest on an annual basis over a period of four years commencing on the first anniversary of the grant date.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                        &lt;p style="text-align: justify;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;The following table summarizes the movements in the Company's outstanding RSUs for the years ended September 30, 2021 and 2020:&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                        &lt;div&gt;

                                                &lt;div&gt;
                                                    &lt;table cellpadding="0" cellspacing="0" style="width: 100%; border-collapse: collapse; font-size: 10pt; border-color: #000000;"&gt;
                                                        &lt;tr&gt;
                                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; border-top: 1.5pt solid #000000; vertical-align: bottom;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-top: 1.5pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-top: 1.5pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;Equity settled&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-top: 1.5pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td colspan="1" style="vertical-align: bottom; border-top: 1.5pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td colspan="1" style="vertical-align: bottom; border-top: 1.5pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;Cash settled&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td colspan="1" style="vertical-align: bottom; border-top: 1.5pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-top: 1.5pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-top: 1.5pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-top: 1.5pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
                                                        &lt;/tr&gt;
                                                        &lt;tr&gt;
                                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;Balance at September 30, 2019 and May 31, 2019&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td colspan="1" style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td colspan="1" style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td colspan="1" style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                        &lt;/tr&gt;
                                                        &lt;tr&gt;
                                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;Granted&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;380,000&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td colspan="1" style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td colspan="1" style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td colspan="1" style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;380,000&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                                        &lt;/tr&gt;
                                                        &lt;tr&gt;
                                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;Balance at September 30, 2020&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;380,000&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;380,000&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                        &lt;/tr&gt;
                                                        &lt;tr&gt;
                                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;Vested&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;(95,000&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;(95,000&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                        &lt;/tr&gt;
                                                        &lt;tr&gt;
                                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 2.25pt double #000000; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;Balance at September 30, 2021&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;285,000&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;285,000&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                        &lt;/tr&gt;
                                                    &lt;/table&gt;
                                                &lt;/div&gt;

                                        &lt;/div&gt;
                                        &lt;p style="text-align: justify;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;The estimated fair value of the equity settled RSUs granted during the year ended September 30, 2020 was $475,000 and will be recognized as an expense over the vesting period of the RSUs.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;/div&gt;

                                    &lt;div&gt;
                                        &lt;p style="text-align: justify;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;The accounting fair value of the equity settled RSUs as at the grant date was estimated by management using the following inputs:&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

                                            &lt;div&gt;
                                                &lt;table cellpadding="0" cellspacing="0" style="width: 80%; border-collapse: collapse; font-size: 10pt; border-color: #000000; margin-left: auto; margin-right: auto;"&gt;
                                                    &lt;tr&gt;
                                                        &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; border-top: 1.5pt solid #000000; vertical-align: bottom;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                        &lt;td style="vertical-align: bottom; border-top: 1.5pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right;"&gt;&#160;&lt;/td&gt;
                                                        &lt;td style="vertical-align: bottom; border-top: 1.5pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;Year ended&lt;br/&gt;September 30, 2020&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                        &lt;td style="vertical-align: bottom; border-top: 1.5pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right;"&gt;&#160;&lt;/td&gt;
                                                    &lt;/tr&gt;
                                                    &lt;tr&gt;
                                                        &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;Share price on grant date&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                        &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                        &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 22%; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;1.25&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                        &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                    &lt;/tr&gt;
                                                    &lt;tr&gt;
                                                        &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;Forfeiture rate&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 22%;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;0%&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                                    &lt;/tr&gt;
                                                &lt;/table&gt;
                                            &lt;/div&gt;

                                        &lt;p style="text-align: justify;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;Share-based compensation expense recognized in the consolidated statements of comprehensive loss is comprised of the following:&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                        &lt;div style="margin-left: 5.4pt;"&gt;

                                                &lt;div&gt;
                                                    &lt;table cellpadding="0" cellspacing="0" style="width: 100%; border-collapse: collapse; font-size: 10pt; border-color: #000000;"&gt;
                                                        &lt;tr&gt;
                                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1.5pt solid #000000; border-bottom: 0.75pt solid #000000; vertical-align: bottom;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-top: 1.5pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-top: 1.5pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;Year ended&lt;br/&gt;September 30,&lt;br/&gt;2021&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-top: 1.5pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-top: 1.5pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-top: 1.5pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;Year ended&lt;br/&gt;September 30,&lt;br/&gt;2020&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-top: 1.5pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-top: 1.5pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-top: 1.5pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;Period ended&lt;br/&gt;September 30,&lt;br/&gt;2019&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-top: 1.5pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right;"&gt;&#160;&lt;/td&gt;
                                                        &lt;/tr&gt;
                                                        &lt;tr&gt;
                                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right;"&gt;&#160;&lt;/td&gt;
                                                        &lt;/tr&gt;
                                                        &lt;tr&gt;
                                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;Stock options&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;643,963&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;138,000&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                        &lt;/tr&gt;
                                                        &lt;tr&gt;
                                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;Restricted share units - equity settled grants&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;236,652&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;23,300&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                                        &lt;/tr&gt;
                                                        &lt;tr&gt;
                                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;Total equity settled share-based compensation expense&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;880,615&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;161,300&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                        &lt;/tr&gt;
                                                        &lt;tr&gt;
                                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;Restricted share units - cash settled grants&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;-&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                                        &lt;/tr&gt;
                                                        &lt;tr&gt;
                                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 2.25pt double #000000; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;Total share-based compensation expense&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;880,615&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;161,300&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                        &lt;/tr&gt;
                                                    &lt;/table&gt;
                                                &lt;/div&gt;

                                        &lt;/div&gt;
                                        &lt;p style="text-align: justify;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;Share-based compensation expense is included in the consolidated statements of comprehensive loss as follows:&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                        &lt;div style="margin-left: 5.4pt;"&gt;

                                                &lt;div&gt;
                                                    &lt;table cellpadding="0" cellspacing="0" style="width: 100%; border-collapse: collapse; font-size: 10pt; border-color: #000000;"&gt;
                                                        &lt;tr&gt;
                                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1.5pt solid #000000; border-bottom: 0.75pt solid #000000; vertical-align: bottom;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-top: 1.5pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-top: 1.5pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;Year ended&lt;br/&gt;September 30,&lt;br/&gt;2021&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-top: 1.5pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-top: 1.5pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-top: 1.5pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;Year ended&lt;br/&gt;September 30,&lt;br/&gt;2020&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-top: 1.5pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-top: 1.5pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-top: 1.5pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;Period ended&lt;br/&gt;September 30,&lt;br/&gt;2019&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-top: 1.5pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right;"&gt;&#160;&lt;/td&gt;
                                                        &lt;/tr&gt;
                                                        &lt;tr&gt;
                                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right;"&gt;&#160;&lt;/td&gt;
                                                        &lt;/tr&gt;
                                                        &lt;tr&gt;
                                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;Consulting fees&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;8,045&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                        &lt;/tr&gt;
                                                        &lt;tr&gt;
                                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;Directors' compensation&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; text-align: right; width: 12%;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;136,612&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; text-align: right; width: 12%;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; text-align: right; width: 12%;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                                        &lt;/tr&gt;
                                                        &lt;tr&gt;
                                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;Marketing, advertising and investor relations&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;3,696&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                        &lt;/tr&gt;
                                                        &lt;tr&gt;
                                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;Professional fees&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; text-align: right; width: 12%;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;23,126&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; text-align: right; width: 12%;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; text-align: right; width: 12%;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                                        &lt;/tr&gt;
                                                        &lt;tr&gt;
                                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;Research and development&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;709,136&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;161,300&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                        &lt;/tr&gt;
                                                        &lt;tr&gt;
                                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 2.25pt double #000000; vertical-align: bottom;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;Total share-based compensation expense&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 12%;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;880,615&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 12%;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;161,300&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 12%;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                                        &lt;/tr&gt;
                                                    &lt;/table&gt;
                                                &lt;/div&gt;

                                        &lt;/div&gt;
                                        &lt;p style="margin-bottom: 0pt; text-align: justify;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="text-decoration: underline;"&gt;&lt;b&gt;Warrants&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                        &lt;p style="margin-top: 0pt; text-align: justify;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;The following table summarizes the movements in the Company's outstanding warrants for the years ended September 30, 2021 and 2020:&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                        &lt;div style="margin-left: 5.4pt;"&gt;

                                                &lt;div&gt;
                                                    &lt;table cellpadding="0" cellspacing="0" style="width: 100%; border-collapse: collapse; font-size: 10pt; border-color: #000000;"&gt;
                                                        &lt;tr&gt;
                                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1.5pt solid #000000; border-bottom: 0.75pt solid #000000; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-top: 1.5pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-top: 1.5pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;Number of warrants&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-top: 1.5pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-top: 1.5pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-top: 1.5pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&#160;&lt;b&gt;Weighted average &lt;/b&gt;&lt;br/&gt;&lt;b&gt;exercise price&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-top: 1.5pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right;"&gt;&#160;&lt;/td&gt;
                                                        &lt;/tr&gt;
                                                        &lt;tr&gt;
                                                            &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;Balance at September 30, 2019 and May 31, 2019&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;-&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;-&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                        &lt;/tr&gt;
                                                        &lt;tr&gt;
                                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&#160; Issued&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 15%;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;4,079,600&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 15%;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;0.05&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                                        &lt;/tr&gt;
                                                        &lt;tr&gt;
                                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;Balance at September 30, 2020&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 15%; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;4,079,600&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 15%; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;0.05&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                        &lt;/tr&gt;
                                                        &lt;tr&gt;
                                                            &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&#160; Issued*&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; text-align: right; width: 15%;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;1,709,938&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; text-align: right; width: 15%;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;9.46&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                                        &lt;/tr&gt;
                                                        &lt;tr&gt;
                                                            &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&#160; Issued - broker&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;132,666&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;7.57&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                        &lt;/tr&gt;
                                                        &lt;tr&gt;
                                                            &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: justify;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&#160; Exercised&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; text-align: right; width: 15%;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;(1,948,000&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; text-align: right; width: 15%;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;0.05&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                                        &lt;/tr&gt;
                                                        &lt;tr&gt;
                                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 2.25pt double #000000; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;Balance at September 30, 2021&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 15%; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;3,974,204&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 15%; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;4.35&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                        &lt;/tr&gt;
                                                    &lt;/table&gt;
                                                &lt;/div&gt;

                                        &lt;/div&gt;
                                        &lt;p style="text-align: justify;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;i&gt;*On November 2, 2020, the Directors of the Company reduced the exercise price of the outstanding warrants from $0.125 to $0.05 effective July 11, 2020.&lt;/i&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;/div&gt;

                                    &lt;div&gt;
                                        &lt;p style="text-align: justify;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;On March 17, 2021, the Company issued 132,666 compensation warrants to underwriters. The fair value of these share purchase warrants of $521,000 was measured using the Black Scholes option pricing model using the following inputs: i) exercise price: $7.57; ii) share price: $6.65; iii) term: 3 years; iv) volatility: 100%; v) discount rate: 0.35%; and dividends: nil. The fair value of these broker warrants was recorded as a reduction against share capital.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                        &lt;p style="text-align: justify;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;As at September 30, 2021, the warrants have a weighted average remaining life of 2.66 (September 30, 2020 - 3.83) years.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                        &lt;p style="text-align: justify;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;The following table summarizes the warrants issued and outstanding:&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                        &lt;div style="margin-left: 9pt;"&gt;

                                                &lt;div&gt;
                                                    &lt;table cellpadding="0" cellspacing="0" style="width: 100%; border-collapse: collapse; font-size: 10pt; border-color: #000000;"&gt;
                                                        &lt;tr&gt;
                                                            &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-top: 1.5pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td colspan="1" style="vertical-align: bottom; border-top: 1.5pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: center;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td colspan="7" style="vertical-align: bottom; border-top: 1.5pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;Warrants Outstanding&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td colspan="1" style="vertical-align: bottom; border-top: 1.5pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: center;"&gt;&#160;&lt;/td&gt;
                                                        &lt;/tr&gt;
                                                        &lt;tr&gt;
                                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;Expiry Date&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;Number of&lt;br/&gt;warrants&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;br/&gt;&lt;b&gt;Exercise price&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;Remaining life&lt;br/&gt;(Years)&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right;"&gt;&#160;&lt;/td&gt;
                                                        &lt;/tr&gt;
                                                        &lt;tr&gt;
                                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;July 30, 2024 (1)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;2,131,600&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;0.05&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;
                                                                        2.83
                                                                    &lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                        &lt;/tr&gt;
                                                        &lt;tr&gt;
                                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;March 17, 2024&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; text-align: right; width: 12%;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;1,709,938&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; text-align: right; width: 12%;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;9.46&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; text-align: right; width: 12%;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;
                                                                        2.46
                                                                    &lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                                        &lt;/tr&gt;
                                                        &lt;tr&gt;
                                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 2.25pt double #000000; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;March 17, 2024&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;132,666&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;7.57&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;
                                                                        2.46
                                                                    &lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                        &lt;/tr&gt;
                                                    &lt;/table&gt;
                                                &lt;/div&gt;

                                        &lt;/div&gt;
                                        &lt;p style="text-align: justify; margin-bottom: 0px;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;(1) On June 15, 2021, the Company entered into warrant exercise agreements with the two warrant holders, whereby the warrant holders authorized the Company to issue only such number of common shares (or other class of voting securities of the Company, if applicable) as will result in the warrant holders and any other person (as defined) holding less than the threshold number of 4.99% (as defined) of any class of&#160; voting securities of the Company as of the date of exercise or conversion of the warrants.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;/div&gt;
                                </ifrs-full:DisclosureOfIssuedCapitalExplanatory>
    <drug:DescriptionOfIssuedAndOutstandingCommonShares
      contextRef="C_20201001to20210930"
      id="Fxbrl_20211231151630181">On November 10, 2020, the Directors of the Company approved the consolidation of the Company's issued and outstanding common shares on a 2.5:1 basis.</drug:DescriptionOfIssuedAndOutstandingCommonShares>
    <ifrs-full:IncreaseDecreaseInNumberOfSharesOutstanding
      contextRef="C_20201101to20201102_ifrsfullClassesOfShareCapitalAxis_drugSecondTrancheOfNonBrokeredPrivatePlacementMember"
      decimals="INF"
      id="Fxbrl_20211229044005459"
      unitRef="Share">1629138</ifrs-full:IncreaseDecreaseInNumberOfSharesOutstanding>
    <drug:IssuePricePerShare
      contextRef="C_20201102_ifrsfullClassesOfShareCapitalAxis_drugSecondTrancheOfNonBrokeredPrivatePlacementMember"
      decimals="2"
      id="Fxbrl_20211229044011459"
      unitRef="CAD_per_share">1.25</drug:IssuePricePerShare>
    <ifrs-full:ProceedsFromIssueOfOrdinaryShares
      contextRef="C_20201101to20201102_ifrsfullClassesOfShareCapitalAxis_drugSecondTrancheOfNonBrokeredPrivatePlacementMember"
      decimals="0"
      id="Fxbrl_20211229044018281"
      unitRef="CAD">2036422</ifrs-full:ProceedsFromIssueOfOrdinaryShares>
    <ifrs-full:IncreaseDecreaseInNumberOfSharesOutstanding
      contextRef="C_20210101to20210106_drugAgreementAxis_drugDebtSettlementAgreementMember_ifrsfullCategoriesOfRelatedPartiesAxis_drugConsultantMember"
      decimals="INF"
      id="Fxbrl_20211229044311046"
      unitRef="Share">14799</ifrs-full:IncreaseDecreaseInNumberOfSharesOutstanding>
    <drug:IssuePricePerShare
      contextRef="C_20210106_drugAgreementAxis_drugDebtSettlementAgreementMember_ifrsfullCategoriesOfRelatedPartiesAxis_drugConsultantMember"
      decimals="2"
      id="Fxbrl_20211229044318387"
      unitRef="CAD_per_share">1.25</drug:IssuePricePerShare>
    <drug:DebtSettledThroughIssuanceOfShares
      contextRef="C_20210101to20210106_drugAgreementAxis_drugDebtSettlementAgreementMember_ifrsfullCategoriesOfRelatedPartiesAxis_drugConsultantMember"
      decimals="0"
      id="Fxbrl_20211229044330754"
      unitRef="CAD">18500</drug:DebtSettledThroughIssuanceOfShares>
    <drug:NumberOfWarrantsDeemedToBeExercised
      contextRef="C_20210201to20210203_ifrsfullClassesOfShareCapitalAxis_drugSpecialWarrantsMember"
      decimals="INF"
      id="Fxbrl_20211229180420598"
      unitRef="Share">16000</drug:NumberOfWarrantsDeemedToBeExercised>
    <drug:NumberOfWarrantsDeemedToBeExercised
      contextRef="C_20210201to20210203_ifrsfullClassesOfShareCapitalAxis_drugSpecialWarrantsMember"
      decimals="INF"
      id="Fxbrl_20211230153159642"
      unitRef="Share">16000</drug:NumberOfWarrantsDeemedToBeExercised>
    <drug:NumberOfUnitsIssued
      contextRef="C_20210301to20210317"
      decimals="INF"
      id="Fxbrl_20211229044728226"
      unitRef="Share">3419883</drug:NumberOfUnitsIssued>
    <drug:UnitsIssuedPricePerUnit
      contextRef="C_20210317"
      decimals="2"
      id="Fxbrl_20211229044718715"
      unitRef="Unit_Per_Share">7.57</drug:UnitsIssuedPricePerUnit>
    <drug:GrossProceedsFromUnitsIssued
      contextRef="C_20210301to20210317"
      decimals="0"
      id="Fxbrl_20211229044711793"
      unitRef="CAD">25888514</drug:GrossProceedsFromUnitsIssued>
    <drug:ExercisePriceWarrantsGranted
      contextRef="C_20210301to20210317"
      decimals="2"
      id="Fxbrl_20211229045137635"
      unitRef="CAD_per_share">9.46</drug:ExercisePriceWarrantsGranted>
    <drug:MinimumDailyVolumeWeightedAverageTradingSharePrice
      contextRef="C_20210317"
      decimals="2"
      id="Fxbrl_20211229045242648"
      unitRef="CAD_per_share">13.25</drug:MinimumDailyVolumeWeightedAverageTradingSharePrice>
    <drug:UnderwritersFeesPaid
      contextRef="C_20210301to20210317"
      decimals="0"
      id="Fxbrl_20211229045340407"
      unitRef="CAD">916317</drug:UnderwritersFeesPaid>
    <drug:NumberOfWarrantsIssued
      contextRef="C_20210301to20210317_ifrsfullCategoriesOfRelatedPartiesAxis_drugUnderwritersMember_ifrsfullClassesOfShareCapitalAxis_drugWarrantsMember"
      decimals="INF"
      id="Fxbrl_20211230153735590"
      unitRef="Share">132666</drug:NumberOfWarrantsIssued>
    <drug:ExercisePriceWarrantsGranted
      contextRef="C_20210301to20210317_ifrsfullCategoriesOfRelatedPartiesAxis_drugUnderwritersMember_ifrsfullClassesOfShareCapitalAxis_drugWarrantsMember"
      decimals="2"
      id="Fxbrl_20211230153857735"
      unitRef="CAD_per_share">7.57</drug:ExercisePriceWarrantsGranted>
    <drug:WarrantAscribedValue
      contextRef="C_20210301to20210317_ifrsfullCategoriesOfRelatedPartiesAxis_drugUnderwritersMember_ifrsfullClassesOfShareCapitalAxis_drugWarrantsMember"
      decimals="0"
      id="Fxbrl_20211229045403345"
      unitRef="CAD">521000</drug:WarrantAscribedValue>
    <drug:ContingentCashFee
      contextRef="C_20210401to20210406_ifrsfullCategoriesOfRelatedPartiesAxis_drugThreeInvestorsMember"
      decimals="0"
      id="Fxbrl_20211229060458652"
      unitRef="CAD">600000</drug:ContingentCashFee>
    <drug:PercentageOfNetEquityProceedsReceivedFromThreeInvestors
      contextRef="C_20210401to20210406_ifrsfullCategoriesOfRelatedPartiesAxis_drugThreeInvestorsMember"
      decimals="3"
      id="Fxbrl_20211229060508530"
      unitRef="Percent">0.045</drug:PercentageOfNetEquityProceedsReceivedFromThreeInvestors>
    <ifrs-full:ProceedsFromIssueOfOrdinaryShares
      contextRef="C_20210401to20210406_ifrsfullCategoriesOfRelatedPartiesAxis_drugThreeInvestorsMember"
      decimals="0"
      id="Fxbrl_20211229060513657"
      unitRef="CAD">13333333</ifrs-full:ProceedsFromIssueOfOrdinaryShares>
    <drug:NumberOfWarrantsIssued
      contextRef="C_20210401to20210406_ifrsfullClassesOfShareCapitalAxis_drugWarrantsMember"
      decimals="INF"
      id="Fxbrl_20211230154332217"
      unitRef="Share">8807</drug:NumberOfWarrantsIssued>
    <drug:ExercisePriceWarrantsGranted
      contextRef="C_20210401to20210406_ifrsfullClassesOfShareCapitalAxis_drugWarrantsMember"
      decimals="2"
      id="Fxbrl_20211230154412347"
      unitRef="CAD_per_share">7.57</drug:ExercisePriceWarrantsGranted>
    <drug:TermOfWarrant
      contextRef="C_20210401to20210406_ifrsfullClassesOfShareCapitalAxis_drugWarrantsMember"
      id="Fxbrl_20211229061018091">P5Y</drug:TermOfWarrant>
    <drug:WarrantAscribedValue
      contextRef="C_20210401to20210406_ifrsfullClassesOfShareCapitalAxis_drugWarrantsMember"
      decimals="0"
      id="Fxbrl_20211229060308845"
      unitRef="CAD">33100</drug:WarrantAscribedValue>
    <drug:NumberOfWarrantsExercised
      contextRef="C_20210401to20210423_ifrsfullClassesOfShareCapitalAxis_drugEscrowedSharePurchaseWarrantsMember"
      decimals="INF"
      id="Fxbrl_20211229061501452"
      unitRef="Share">1948000</drug:NumberOfWarrantsExercised>
    <drug:WeightedAverageExercisePriceOfWarrantsExercisedInShareBasedPaymentArrangement
      contextRef="C_20210401to20210423_ifrsfullClassesOfShareCapitalAxis_drugEscrowedSharePurchaseWarrantsMember"
      decimals="2"
      id="Fxbrl_20211229061540621"
      unitRef="CAD_per_share">0.05</drug:WeightedAverageExercisePriceOfWarrantsExercisedInShareBasedPaymentArrangement>
    <drug:GrossProceedsFromWarrantsExercised
      contextRef="C_20210401to20210423_ifrsfullClassesOfShareCapitalAxis_drugEscrowedSharePurchaseWarrantsMember"
      decimals="0"
      id="Fxbrl_20211229061603798"
      unitRef="CAD">97400</drug:GrossProceedsFromWarrantsExercised>
    <drug:IncreaseDecreaseThroughSharesIssuedToUniversityShares
      contextRef="C_20210401to20210428"
      decimals="INF"
      id="Fxbrl_20211229062800233"
      unitRef="Share">63000</drug:IncreaseDecreaseThroughSharesIssuedToUniversityShares>
    <drug:IssuePricePerShare
      contextRef="C_20210428"
      decimals="2"
      id="Fxbrl_20211229062814471"
      unitRef="CAD_per_share">5.85</drug:IssuePricePerShare>
    <drug:IncreaseDecreaseThroughSharesIssuedToUniversity
      contextRef="C_20210401to20210428"
      decimals="0"
      id="Fxbrl_20211229062828331"
      unitRef="CAD">368550</drug:IncreaseDecreaseThroughSharesIssuedToUniversity>
    <ifrs-full:IncreaseDecreaseInNumberOfSharesOutstanding
      contextRef="C_20200901to20200930_ifrsfullClassesOfShareCapitalAxis_drugFirstTrancheOfNonBrokeredPrivatePlacementMember"
      decimals="INF"
      id="Fxbrl_20211229063007514"
      unitRef="Share">623941</ifrs-full:IncreaseDecreaseInNumberOfSharesOutstanding>
    <drug:IssuePricePerShare
      contextRef="C_20200930_ifrsfullClassesOfShareCapitalAxis_drugFirstTrancheOfNonBrokeredPrivatePlacementMember"
      decimals="2"
      id="Fxbrl_20211229063020753"
      unitRef="CAD_per_share">1.25</drug:IssuePricePerShare>
    <ifrs-full:ProceedsFromIssueOfOrdinaryShares
      contextRef="C_20200901to20200930_ifrsfullClassesOfShareCapitalAxis_drugFirstTrancheOfNonBrokeredPrivatePlacementMember"
      decimals="0"
      id="Fxbrl_20211229063031356"
      unitRef="CAD">779924</ifrs-full:ProceedsFromIssueOfOrdinaryShares>
    <drug:NumberOfUnitsIssued
      contextRef="C_20190701to20190730_ifrsfullClassesOfShareCapitalAxis_drugNonBrokeredPrivatePlacementMember"
      decimals="INF"
      id="Fxbrl_20211229063259787"
      unitRef="Share">4079600</drug:NumberOfUnitsIssued>
    <drug:UnitsIssuedPricePerUnit
      contextRef="C_20190730_ifrsfullClassesOfShareCapitalAxis_drugNonBrokeredPrivatePlacementMember"
      decimals="2"
      id="Fxbrl_20211229063249970"
      unitRef="Unit_Per_Share">0.05</drug:UnitsIssuedPricePerUnit>
    <drug:GrossProceedsFromUnitsIssued
      contextRef="C_20190701to20190730_ifrsfullClassesOfShareCapitalAxis_drugNonBrokeredPrivatePlacementMember"
      decimals="0"
      id="Fxbrl_20211229063243227"
      unitRef="CAD">203980</drug:GrossProceedsFromUnitsIssued>
    <drug:GrossProceedsFromUnitsIssued
      contextRef="C_20201001to20210930_ifrsfullClassesOfShareCapitalAxis_drugNonBrokeredPrivatePlacementMember"
      decimals="0"
      id="Fxbrl_20211229063616831"
      unitRef="CAD">80980</drug:GrossProceedsFromUnitsIssued>
    <drug:WeightedAverageExercisePriceOfWarrantsIssuedInShareBasedPaymentArrangement
      contextRef="C_20190701to20190730_ifrsfullClassesOfShareCapitalAxis_drugNonBrokeredPrivatePlacementMember"
      decimals="2"
      id="Fxbrl_20211231152001303"
      unitRef="CAD_per_share">0.05</drug:WeightedAverageExercisePriceOfWarrantsIssuedInShareBasedPaymentArrangement>
    <drug:NumberOfWarrantsIssued
      contextRef="C_20201001to20201031_ifrsfullClassesOfShareCapitalAxis_drugSpecialWarrantsMember"
      decimals="INF"
      id="Fxbrl_20211229063722291"
      unitRef="Share">18300</drug:NumberOfWarrantsIssued>
    <drug:WarrantsIssuedPricePerWarrant
      contextRef="C_20201001to20201031_ifrsfullClassesOfShareCapitalAxis_drugSpecialWarrantsMember"
      decimals="2"
      id="Fxbrl_20211229063747893"
      unitRef="CAD_per_share">1.25</drug:WarrantsIssuedPricePerWarrant>
    <drug:NumberOfWarrantsIssued
      contextRef="C_20201101to20201102_ifrsfullClassesOfShareCapitalAxis_drugSpecialWarrantsMember"
      decimals="INF"
      id="Fxbrl_20211229184210252"
      unitRef="Share">18300</drug:NumberOfWarrantsIssued>
    <drug:ProceedsForWarrantsIssued
      contextRef="C_20201101to20201102_ifrsfullClassesOfShareCapitalAxis_drugSpecialWarrantsMember"
      decimals="0"
      id="Fxbrl_20211229063853028"
      unitRef="CAD">22875</drug:ProceedsForWarrantsIssued>
    <drug:NumberOfIssuedWarrantsRescinded
      contextRef="C_20210101to20210119_ifrsfullClassesOfShareCapitalAxis_drugSpecialWarrantsMember"
      decimals="INF"
      id="Fxbrl_20211229063905590"
      unitRef="Share">2300</drug:NumberOfIssuedWarrantsRescinded>
    <drug:RefundFromIssuedWarrantsRescinded
      contextRef="C_20210101to20210119_ifrsfullClassesOfShareCapitalAxis_drugSpecialWarrantsMember"
      decimals="0"
      id="Fxbrl_20211229063918736"
      unitRef="CAD">2875</drug:RefundFromIssuedWarrantsRescinded>
    <drug:AmountOfEscrowProceedsReleased
      contextRef="C_20210201to20210203_ifrsfullClassesOfShareCapitalAxis_drugSpecialWarrantsMember"
      decimals="0"
      id="Fxbrl_20211229093908558"
      unitRef="CAD">20000</drug:AmountOfEscrowProceedsReleased>
    <drug:NumberOfWarrantsDeemedToBeExercised
      contextRef="C_20210201to20210203_ifrsfullClassesOfShareCapitalAxis_drugSpecialWarrantsMember"
      decimals="INF"
      id="Fxbrl_20211230161024172"
      unitRef="Share">16000</drug:NumberOfWarrantsDeemedToBeExercised>
    <drug:SubscriptionsReceived
      contextRef="C_20200930"
      decimals="0"
      id="Fxbrl_20211229094222980"
      unitRef="CAD">147426</drug:SubscriptionsReceived>
    <drug:NumberOfCommonSharesSubscribed
      contextRef="C_20201001to20210930"
      decimals="INF"
      id="Fxbrl_20211229094303965"
      unitRef="Share">294852</drug:NumberOfCommonSharesSubscribed>
    <ifrs-full:IncreaseDecreaseInNumberOfSharesOutstanding
      contextRef="C_20190701to20190731"
      decimals="INF"
      id="Fxbrl_20211229100341375"
      unitRef="Share">4049000</ifrs-full:IncreaseDecreaseInNumberOfSharesOutstanding>
    <ifrs-full:ProceedsFromIssueOfOrdinaryShares
      contextRef="C_20191007to20200928"
      decimals="0"
      id="Fxbrl_20211229100349500"
      unitRef="CAD">80980</ifrs-full:ProceedsFromIssueOfOrdinaryShares>
    <drug:NumberOfCommonSharesDepositedToBeHeldInEscrow
      contextRef="C_20210128_drugAgreementAxis_drugEscrowAgreementMember_ifrsfullClassesOfShareCapitalAxis_drugWarrantsMember"
      decimals="INF"
      id="Fxbrl_20211229100757388"
      unitRef="Share">2852800</drug:NumberOfCommonSharesDepositedToBeHeldInEscrow>
    <drug:NumberOfWarrantsDepositedToBeHeldInEscrow
      contextRef="C_20210128_drugAgreementAxis_drugEscrowAgreementMember_ifrsfullClassesOfShareCapitalAxis_drugWarrantsMember"
      decimals="INF"
      id="Fxbrl_20211229100624840"
      unitRef="Share">1948000</drug:NumberOfWarrantsDepositedToBeHeldInEscrow>
    <drug:AggregateSecuritiesDepositedToBeHeldInEscrow
      contextRef="C_20210128_drugAgreementAxis_drugEscrowAgreementMember_ifrsfullClassesOfShareCapitalAxis_drugWarrantsMember"
      decimals="INF"
      id="Fxbrl_20211229101530164"
      unitRef="Share">4800800</drug:AggregateSecuritiesDepositedToBeHeldInEscrow>
    <drug:EscrowedSecuritiesToBeReleasedOnceSharesAreListedOnCanadianStockExchange
      contextRef="C_20210201to20210208_drugAgreementAxis_drugEscrowAgreementMember"
      decimals="INF"
      id="Fxbrl_20211229101936429"
      unitRef="Share">480080</drug:EscrowedSecuritiesToBeReleasedOnceSharesAreListedOnCanadianStockExchange>
    <drug:EscrowedSecuritiesToBeReleasedAfterListingDate
      contextRef="C_20210201to20210208_drugAgreementAxis_drugEscrowAgreementMember"
      decimals="INF"
      id="Fxbrl_20211231113144057"
      unitRef="Share">720120</drug:EscrowedSecuritiesToBeReleasedAfterListingDate>
    <drug:PercentageOfOutstandingSharesAuthorizedUnderStockOptionPlan
      contextRef="C_20201001to20210930_ifrsfullClassesOfShareCapitalAxis_drugStockOptionsMember"
      decimals="2"
      id="Fxbrl_20211229061358559"
      unitRef="Percent">0.10</drug:PercentageOfOutstandingSharesAuthorizedUnderStockOptionPlan>
    <ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement
      contextRef="C_20201101to20201117_ifrsfullCategoriesOfRelatedPartiesAxis_drugChiefFinancialOfficerTwoDirectorsAndSevenConsultantsMember_ifrsfullClassesOfShareCapitalAxis_drugStockOptionsMember"
      decimals="INF"
      id="Fxbrl_20211229103146955"
      unitRef="Share">467000</ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019
      contextRef="C_20201101to20201117_ifrsfullCategoriesOfRelatedPartiesAxis_drugChiefFinancialOfficerTwoDirectorsAndSevenConsultantsMember_ifrsfullClassesOfShareCapitalAxis_drugStockOptionsMember"
      decimals="2"
      id="Fxbrl_20211229103227400"
      unitRef="CAD_per_share">1.25</ifrs-full:WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement
      contextRef="C_20201101to20201117_drugStockOptionAxis_drugStockOptionsOneMember_ifrsfullCategoriesOfRelatedPartiesAxis_drugChiefFinancialOfficerTwoDirectorsAndSevenConsultantsMember"
      decimals="INF"
      id="Fxbrl_20211229103720163"
      unitRef="Share">25000</ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement>
    <drug:VestingPercentage
      contextRef="C_20201101to20201117_drugStockOptionAxis_drugStockOptionsOneMember_drugVestingsAxis_drugFirstTrancheMember_ifrsfullCategoriesOfRelatedPartiesAxis_drugChiefFinancialOfficerTwoDirectorsAndSevenConsultantsMember"
      decimals="2"
      id="Fxbrl_20211229103729535"
      unitRef="Percent">1</drug:VestingPercentage>
    <ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement
      contextRef="C_20201101to20201117_drugStockOptionAxis_drugStockOptionsTwoMember_ifrsfullCategoriesOfRelatedPartiesAxis_drugChiefFinancialOfficerTwoDirectorsAndSevenConsultantsMember"
      decimals="INF"
      id="Fxbrl_20211229103802654"
      unitRef="Share">14000</ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement>
    <drug:VestingPercentage
      contextRef="C_20201101to20201117_drugStockOptionAxis_drugStockOptionsTwoMember_drugVestingsAxis_drugSecondTrancheMember_ifrsfullCategoriesOfRelatedPartiesAxis_drugChiefFinancialOfficerTwoDirectorsAndSevenConsultantsMember"
      decimals="2"
      id="Fxbrl_20211229103817151"
      unitRef="Percent">0.25</drug:VestingPercentage>
    <drug:VestingPercentage
      contextRef="C_20201101to20201117_drugStockOptionAxis_drugStockOptionsTwoMember_drugVestingsAxis_drugThirdTrancheMember_ifrsfullCategoriesOfRelatedPartiesAxis_drugChiefFinancialOfficerTwoDirectorsAndSevenConsultantsMember"
      decimals="2"
      id="Fxbrl_20211229194554073"
      unitRef="Percent">0.25</drug:VestingPercentage>
    <drug:VestingPercentage
      contextRef="C_20201101to20201117_drugStockOptionAxis_drugStockOptionsTwoMember_drugVestingsAxis_drugFourthTrancheMember_ifrsfullCategoriesOfRelatedPartiesAxis_drugChiefFinancialOfficerTwoDirectorsAndSevenConsultantsMember"
      decimals="2"
      id="Fxbrl_20211229194602674"
      unitRef="Percent">0.50</drug:VestingPercentage>
    <ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement
      contextRef="C_20201101to20201117_drugStockOptionAxis_drugStockOptionsThreeMember_ifrsfullCategoriesOfRelatedPartiesAxis_drugChiefFinancialOfficerTwoDirectorsAndSevenConsultantsMember"
      decimals="INF"
      id="Fxbrl_20211229122855966"
      unitRef="Share">4000</ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement>
    <drug:VestingPercentage
      contextRef="C_20201101to20201117_drugStockOptionAxis_drugStockOptionsThreeMember_drugVestingsAxis_drugSecondTrancheMember_ifrsfullCategoriesOfRelatedPartiesAxis_drugChiefFinancialOfficerTwoDirectorsAndSevenConsultantsMember"
      decimals="2"
      id="Fxbrl_20211229194616248"
      unitRef="Percent">0.50</drug:VestingPercentage>
    <drug:VestingPercentage
      contextRef="C_20201101to20201117_drugStockOptionAxis_drugStockOptionsThreeMember_drugVestingsAxis_drugFifthTrancheMember_ifrsfullCategoriesOfRelatedPartiesAxis_drugChiefFinancialOfficerTwoDirectorsAndSevenConsultantsMember"
      decimals="2"
      id="Fxbrl_20211229194622792"
      unitRef="Percent">0.50</drug:VestingPercentage>
    <ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement
      contextRef="C_20201101to20201117_drugStockOptionAxis_drugStockOptionsFourMember_ifrsfullCategoriesOfRelatedPartiesAxis_drugChiefFinancialOfficerTwoDirectorsAndSevenConsultantsMember"
      decimals="INF"
      id="Fxbrl_20211229123350466"
      unitRef="Share">424000</ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement>
    <drug:VestingPercentage
      contextRef="C_20201101to20201117_drugStockOptionAxis_drugStockOptionsFourMember_drugVestingsAxis_drugSixthTrancheMember_ifrsfullCategoriesOfRelatedPartiesAxis_drugChiefFinancialOfficerTwoDirectorsAndSevenConsultantsMember"
      decimals="2"
      id="Fxbrl_20211229194631710"
      unitRef="Percent">0.33</drug:VestingPercentage>
    <drug:VestingPercentage
      contextRef="C_20201101to20201117_drugStockOptionAxis_drugStockOptionsFourMember_drugVestingsAxis_drugSeventhTrancheMember_ifrsfullCategoriesOfRelatedPartiesAxis_drugChiefFinancialOfficerTwoDirectorsAndSevenConsultantsMember"
      decimals="2"
      id="Fxbrl_20211229194755111"
      unitRef="Percent">0.33</drug:VestingPercentage>
    <drug:VestingPercentage
      contextRef="C_20201101to20201117_drugStockOptionAxis_drugStockOptionsFourMember_drugVestingsAxis_drugEighthTrancheMember_ifrsfullCategoriesOfRelatedPartiesAxis_drugChiefFinancialOfficerTwoDirectorsAndSevenConsultantsMember"
      decimals="2"
      id="Fxbrl_20211229194805655"
      unitRef="Percent">0.33</drug:VestingPercentage>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="C_20201101to20201117_ifrsfullCategoriesOfRelatedPartiesAxis_drugChiefFinancialOfficerTwoDirectorsAndSevenConsultantsMember_ifrsfullClassesOfShareCapitalAxis_drugStockOptionsMember"
      decimals="2"
      id="Fxbrl_20211229123752113"
      unitRef="CAD_per_share">1.25</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019
      contextRef="C_20201101to20201117_ifrsfullCategoriesOfRelatedPartiesAxis_drugChiefFinancialOfficerTwoDirectorsAndSevenConsultantsMember_ifrsfullClassesOfShareCapitalAxis_drugStockOptionsMember"
      decimals="2"
      id="Fxbrl_20211229123825908"
      unitRef="CAD_per_share">1.25</ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019>
    <ifrs-full:DescriptionOfOptionLifeShareOptionsGranted
      contextRef="C_20201101to20201117_ifrsfullCategoriesOfRelatedPartiesAxis_drugChiefFinancialOfficerTwoDirectorsAndSevenConsultantsMember_ifrsfullClassesOfShareCapitalAxis_drugStockOptionsMember"
      decimals="0"
      id="Fxbrl_20211229123850395"
      unitRef="Year">5</ifrs-full:DescriptionOfOptionLifeShareOptionsGranted>
    <ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted
      contextRef="C_20201101to20201117_ifrsfullCategoriesOfRelatedPartiesAxis_drugChiefFinancialOfficerTwoDirectorsAndSevenConsultantsMember_ifrsfullClassesOfShareCapitalAxis_drugStockOptionsMember"
      decimals="2"
      id="Fxbrl_20211229123854660"
      unitRef="Percent">1</ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted>
    <drug:DiscountRateStockOptionGranted
      contextRef="C_20201117_ifrsfullCategoriesOfRelatedPartiesAxis_drugChiefFinancialOfficerTwoDirectorsAndSevenConsultantsMember_ifrsfullClassesOfShareCapitalAxis_drugStockOptionsMember"
      decimals="4"
      id="Fxbrl_20211229124453622"
      unitRef="Percent">0.0043</drug:DiscountRateStockOptionGranted>
    <ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement
      contextRef="C_20210401to20210428_ifrsfullCategoriesOfRelatedPartiesAxis_drugThreeConsultantsMember_ifrsfullClassesOfShareCapitalAxis_drugStockOptionsMember"
      decimals="INF"
      id="Fxbrl_20211229104501879"
      unitRef="Share">240000</ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019
      contextRef="C_20210401to20210428_ifrsfullCategoriesOfRelatedPartiesAxis_drugThreeConsultantsMember_ifrsfullClassesOfShareCapitalAxis_drugStockOptionsMember"
      decimals="2"
      id="Fxbrl_20211229104542222"
      unitRef="CAD_per_share">7.60</ifrs-full:WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement
      contextRef="C_20210401to20210428_drugStockOptionAxis_drugStockOptionsOneMember_ifrsfullCategoriesOfRelatedPartiesAxis_drugThreeConsultantsMember"
      decimals="INF"
      id="Fxbrl_20211229125643692"
      unitRef="Share">160000</ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement>
    <drug:VestingPercentage
      contextRef="C_20210401to20210428_drugStockOptionAxis_drugStockOptionsOneMember_drugVestingsAxis_drugSixthTrancheMember_ifrsfullCategoriesOfRelatedPartiesAxis_drugThreeConsultantsMember"
      decimals="2"
      id="Fxbrl_20211229125701908"
      unitRef="Percent">0.25</drug:VestingPercentage>
    <drug:VestingPercentage
      contextRef="C_20210401to20210428_drugStockOptionAxis_drugStockOptionsOneMember_drugVestingsAxis_drugSeventhTrancheMember_ifrsfullCategoriesOfRelatedPartiesAxis_drugThreeConsultantsMember"
      decimals="2"
      id="Fxbrl_20211229204615710"
      unitRef="Percent">0.25</drug:VestingPercentage>
    <drug:VestingPercentage
      contextRef="C_20210401to20210428_drugStockOptionAxis_drugStockOptionsOneMember_drugVestingsAxis_drugEighthTrancheMember_ifrsfullCategoriesOfRelatedPartiesAxis_drugThreeConsultantsMember"
      decimals="2"
      id="Fxbrl_20211229204629096"
      unitRef="Percent">0.25</drug:VestingPercentage>
    <drug:VestingPercentage
      contextRef="C_20210401to20210428_drugStockOptionAxis_drugStockOptionsOneMember_drugVestingsAxis_drugNinthTrancheMember_ifrsfullCategoriesOfRelatedPartiesAxis_drugThreeConsultantsMember"
      decimals="2"
      id="Fxbrl_20211229204638134"
      unitRef="Percent">0.25</drug:VestingPercentage>
    <ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement
      contextRef="C_20210401to20210428_drugStockOptionAxis_drugStockOptionsTwoMember_ifrsfullCategoriesOfRelatedPartiesAxis_drugThreeConsultantsMember"
      decimals="INF"
      id="Fxbrl_20211229130137460"
      unitRef="Share">80000</ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement>
    <drug:VestingPercentage
      contextRef="C_20210401to20210428_drugStockOptionAxis_drugStockOptionsTwoMember_drugVestingsAxis_drugTenthTrancheMember_ifrsfullCategoriesOfRelatedPartiesAxis_drugThreeConsultantsMember"
      decimals="2"
      id="Fxbrl_20211229204648133"
      unitRef="Percent">0.25</drug:VestingPercentage>
    <drug:VestingPercentage
      contextRef="C_20210401to20210428_drugStockOptionAxis_drugStockOptionsTwoMember_drugVestingsAxis_drugSixthTrancheMember_ifrsfullCategoriesOfRelatedPartiesAxis_drugThreeConsultantsMember"
      decimals="2"
      id="Fxbrl_20211229204700917"
      unitRef="Percent">0.25</drug:VestingPercentage>
    <drug:VestingPercentage
      contextRef="C_20210401to20210428_drugStockOptionAxis_drugStockOptionsTwoMember_drugVestingsAxis_drugEleventhTrancheMember_ifrsfullCategoriesOfRelatedPartiesAxis_drugThreeConsultantsMember"
      decimals="2"
      id="Fxbrl_20211229204708773"
      unitRef="Percent">0.25</drug:VestingPercentage>
    <drug:VestingPercentage
      contextRef="C_20210401to20210428_drugStockOptionAxis_drugStockOptionsTwoMember_drugVestingsAxis_drugSeventhTrancheMember_ifrsfullCategoriesOfRelatedPartiesAxis_drugThreeConsultantsMember"
      decimals="2"
      id="Fxbrl_20211229204718669"
      unitRef="Percent">0.25</drug:VestingPercentage>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="C_20210401to20210428_ifrsfullCategoriesOfRelatedPartiesAxis_drugThreeConsultantsMember_ifrsfullClassesOfShareCapitalAxis_drugStockOptionsMember"
      decimals="2"
      id="Fxbrl_20211229130827756"
      unitRef="CAD_per_share">7.60</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019
      contextRef="C_20210401to20210428_ifrsfullCategoriesOfRelatedPartiesAxis_drugThreeConsultantsMember_ifrsfullClassesOfShareCapitalAxis_drugStockOptionsMember"
      decimals="2"
      id="Fxbrl_20211229130835242"
      unitRef="CAD_per_share">5.98</ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019>
    <ifrs-full:DescriptionOfOptionLifeShareOptionsGranted
      contextRef="C_20210401to20210428_ifrsfullCategoriesOfRelatedPartiesAxis_drugThreeConsultantsMember_ifrsfullClassesOfShareCapitalAxis_drugStockOptionsMember"
      decimals="0"
      id="Fxbrl_20211229130841315"
      unitRef="Year">5</ifrs-full:DescriptionOfOptionLifeShareOptionsGranted>
    <ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted
      contextRef="C_20210401to20210428_ifrsfullCategoriesOfRelatedPartiesAxis_drugThreeConsultantsMember_ifrsfullClassesOfShareCapitalAxis_drugStockOptionsMember"
      decimals="2"
      id="Fxbrl_20211229130848489"
      unitRef="Percent">1</ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted>
    <drug:DiscountRateStockOptionGranted
      contextRef="C_20210428_ifrsfullCategoriesOfRelatedPartiesAxis_drugThreeConsultantsMember_ifrsfullClassesOfShareCapitalAxis_drugStockOptionsMember"
      decimals="4"
      id="Fxbrl_20211229130854019"
      unitRef="Percent">0.0092</drug:DiscountRateStockOptionGranted>
    <ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement
      contextRef="C_20210601to20210615_ifrsfullCategoriesOfRelatedPartiesAxis_drugDirectorAndConsultantMember_ifrsfullClassesOfShareCapitalAxis_drugStockOptionsMember"
      decimals="INF"
      id="Fxbrl_20211229131041170"
      unitRef="Share">180000</ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019
      contextRef="C_20210601to20210615_ifrsfullCategoriesOfRelatedPartiesAxis_drugDirectorAndConsultantMember_ifrsfullClassesOfShareCapitalAxis_drugStockOptionsMember"
      decimals="2"
      id="Fxbrl_20211229131236954"
      unitRef="CAD_per_share">7.60</ifrs-full:WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019>
    <drug:VestingPercentage
      contextRef="C_20210601to20210615_drugVestingsAxis_drugSixthTrancheMember_ifrsfullCategoriesOfRelatedPartiesAxis_drugDirectorAndConsultantMember_ifrsfullClassesOfShareCapitalAxis_drugStockOptionsMember"
      decimals="2"
      id="Fxbrl_20211229131502857"
      unitRef="Percent">0.25</drug:VestingPercentage>
    <drug:VestingPercentage
      contextRef="C_20210601to20210615_drugVestingsAxis_drugSeventhTrancheMember_ifrsfullCategoriesOfRelatedPartiesAxis_drugDirectorAndConsultantMember_ifrsfullClassesOfShareCapitalAxis_drugStockOptionsMember"
      decimals="2"
      id="Fxbrl_20211229131505665"
      unitRef="Percent">0.25</drug:VestingPercentage>
    <drug:VestingPercentage
      contextRef="C_20210601to20210615_drugVestingsAxis_drugEighthTrancheMember_ifrsfullCategoriesOfRelatedPartiesAxis_drugDirectorAndConsultantMember_ifrsfullClassesOfShareCapitalAxis_drugStockOptionsMember"
      decimals="2"
      id="Fxbrl_20211229131700044"
      unitRef="Percent">0.25</drug:VestingPercentage>
    <drug:VestingPercentage
      contextRef="C_20210601to20210615_drugVestingsAxis_drugNinthTrancheMember_ifrsfullCategoriesOfRelatedPartiesAxis_drugDirectorAndConsultantMember_ifrsfullClassesOfShareCapitalAxis_drugStockOptionsMember"
      decimals="2"
      id="Fxbrl_20211229131719794"
      unitRef="Percent">0.25</drug:VestingPercentage>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="C_20210601to20210615_ifrsfullCategoriesOfRelatedPartiesAxis_drugDirectorAndConsultantMember_ifrsfullClassesOfShareCapitalAxis_drugStockOptionsMember"
      decimals="2"
      id="Fxbrl_20211229131744083"
      unitRef="CAD_per_share">7.60</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019
      contextRef="C_20210601to20210615_ifrsfullCategoriesOfRelatedPartiesAxis_drugDirectorAndConsultantMember_ifrsfullClassesOfShareCapitalAxis_drugStockOptionsMember"
      decimals="2"
      id="Fxbrl_20211229131751066"
      unitRef="CAD_per_share">5.55</ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019>
    <ifrs-full:DescriptionOfOptionLifeShareOptionsGranted
      contextRef="C_20210601to20210615_ifrsfullCategoriesOfRelatedPartiesAxis_drugDirectorAndConsultantMember_ifrsfullClassesOfShareCapitalAxis_drugStockOptionsMember"
      decimals="0"
      id="Fxbrl_20211229131757129"
      unitRef="Year">5</ifrs-full:DescriptionOfOptionLifeShareOptionsGranted>
    <ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted
      contextRef="C_20210601to20210615_ifrsfullCategoriesOfRelatedPartiesAxis_drugDirectorAndConsultantMember_ifrsfullClassesOfShareCapitalAxis_drugStockOptionsMember"
      decimals="2"
      id="Fxbrl_20211229131804512"
      unitRef="Percent">1</ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted>
    <drug:DiscountRateStockOptionGranted
      contextRef="C_20210615_ifrsfullCategoriesOfRelatedPartiesAxis_drugDirectorAndConsultantMember_ifrsfullClassesOfShareCapitalAxis_drugStockOptionsMember"
      decimals="4"
      id="Fxbrl_20211229131811631"
      unitRef="Percent">0.0084</drug:DiscountRateStockOptionGranted>
    <ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement
      contextRef="C_20210901to20210921_ifrsfullCategoriesOfRelatedPartiesAxis_drugConsultantMember_ifrsfullClassesOfShareCapitalAxis_drugStockOptionsMember"
      decimals="INF"
      id="Fxbrl_20211229132037072"
      unitRef="Share">8807</ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019
      contextRef="C_20210901to20210921_ifrsfullCategoriesOfRelatedPartiesAxis_drugConsultantMember_ifrsfullClassesOfShareCapitalAxis_drugStockOptionsMember"
      decimals="2"
      id="Fxbrl_20211229132123850"
      unitRef="CAD_per_share">7.64</ifrs-full:WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019>
    <drug:VestingPercentage
      contextRef="C_20210901to20210921_drugVestingsAxis_drugTwelfthTrancheMember_ifrsfullCategoriesOfRelatedPartiesAxis_drugConsultantMember_ifrsfullClassesOfShareCapitalAxis_drugStockOptionsMember"
      decimals="2"
      id="Fxbrl_20211229132143659"
      unitRef="Percent">0.25</drug:VestingPercentage>
    <drug:VestingPercentage
      contextRef="C_20210901to20210921_drugVestingsAxis_drugThirteenthTrancheMember_ifrsfullCategoriesOfRelatedPartiesAxis_drugConsultantMember_ifrsfullClassesOfShareCapitalAxis_drugStockOptionsMember"
      decimals="2"
      id="Fxbrl_20211229132229122"
      unitRef="Percent">0.25</drug:VestingPercentage>
    <drug:VestingPercentage
      contextRef="C_20210901to20210921_drugVestingsAxis_drugFourteenthTrancheMember_ifrsfullCategoriesOfRelatedPartiesAxis_drugConsultantMember_ifrsfullClassesOfShareCapitalAxis_drugStockOptionsMember"
      decimals="2"
      id="Fxbrl_20211229132232345"
      unitRef="Percent">0.25</drug:VestingPercentage>
    <drug:VestingPercentage
      contextRef="C_20210901to20210921_drugVestingsAxis_drugFifteenthTrancheMember_ifrsfullCategoriesOfRelatedPartiesAxis_drugConsultantMember_ifrsfullClassesOfShareCapitalAxis_drugStockOptionsMember"
      decimals="2"
      id="Fxbrl_20211229132234634"
      unitRef="Percent">0.25</drug:VestingPercentage>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="C_20210901to20210921_ifrsfullCategoriesOfRelatedPartiesAxis_drugConsultantMember_ifrsfullClassesOfShareCapitalAxis_drugStockOptionsMember"
      decimals="2"
      id="Fxbrl_20211229135004512"
      unitRef="CAD_per_share">7.64</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019
      contextRef="C_20210901to20210921_ifrsfullCategoriesOfRelatedPartiesAxis_drugConsultantMember_ifrsfullClassesOfShareCapitalAxis_drugStockOptionsMember"
      decimals="2"
      id="Fxbrl_20211229135030515"
      unitRef="CAD_per_share">7.64</ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019>
    <ifrs-full:DescriptionOfOptionLifeShareOptionsGranted
      contextRef="C_20210901to20210921_ifrsfullCategoriesOfRelatedPartiesAxis_drugConsultantMember_ifrsfullClassesOfShareCapitalAxis_drugStockOptionsMember"
      decimals="0"
      id="Fxbrl_20211229135042831"
      unitRef="Year">3</ifrs-full:DescriptionOfOptionLifeShareOptionsGranted>
    <ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted
      contextRef="C_20210901to20210921_ifrsfullCategoriesOfRelatedPartiesAxis_drugConsultantMember_ifrsfullClassesOfShareCapitalAxis_drugStockOptionsMember"
      decimals="2"
      id="Fxbrl_20211229135052991"
      unitRef="Percent">1</ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted>
    <drug:DiscountRateStockOptionGranted
      contextRef="C_20210921_ifrsfullCategoriesOfRelatedPartiesAxis_drugConsultantMember_ifrsfullClassesOfShareCapitalAxis_drugStockOptionsMember"
      decimals="4"
      id="Fxbrl_20211229135258239"
      unitRef="Percent">0.0055</drug:DiscountRateStockOptionGranted>
    <ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement
      contextRef="C_20200701to20200723_ifrsfullClassesOfShareCapitalAxis_drugStockOptionsMember_srtTitleOfIndividualAxis_drugChiefMedicalOfficerMember"
      decimals="INF"
      id="Fxbrl_20211229135605852"
      unitRef="Share">150000</ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="C_20200701to20200723_ifrsfullClassesOfShareCapitalAxis_drugStockOptionsMember_srtTitleOfIndividualAxis_drugChiefMedicalOfficerMember"
      decimals="2"
      id="Fxbrl_20211229135703966"
      unitRef="CAD_per_share">1.25</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019
      contextRef="C_20200701to20200723_ifrsfullClassesOfShareCapitalAxis_drugStockOptionsMember_srtTitleOfIndividualAxis_drugChiefMedicalOfficerMember"
      decimals="2"
      id="Fxbrl_20211229135716197"
      unitRef="CAD_per_share">1.25</ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019>
    <ifrs-full:DescriptionOfOptionLifeShareOptionsGranted
      contextRef="C_20200701to20200723_ifrsfullClassesOfShareCapitalAxis_drugStockOptionsMember_srtTitleOfIndividualAxis_drugChiefMedicalOfficerMember"
      decimals="0"
      id="Fxbrl_20211229135724959"
      unitRef="Year">5</ifrs-full:DescriptionOfOptionLifeShareOptionsGranted>
    <ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted
      contextRef="C_20200701to20200723_ifrsfullClassesOfShareCapitalAxis_drugStockOptionsMember_srtTitleOfIndividualAxis_drugChiefMedicalOfficerMember"
      decimals="2"
      id="Fxbrl_20211229135731606"
      unitRef="Percent">1</ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted>
    <drug:DiscountRateStockOptionGranted
      contextRef="C_20200723_ifrsfullClassesOfShareCapitalAxis_drugStockOptionsMember_srtTitleOfIndividualAxis_drugChiefMedicalOfficerMember"
      decimals="4"
      id="Fxbrl_20211229135739458"
      unitRef="Percent">0.0035</drug:DiscountRateStockOptionGranted>
    <ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory
      contextRef="C_20201001to20210930"
      id="Fxbrl_20211228202438632">
                                            &lt;div&gt;
                                                &lt;div style="margin-left: 5.4pt;"&gt;
                                                    &lt;table cellpadding="0" cellspacing="0" style="width: 100%; border-collapse: collapse; font-size: 10pt; border-color: #000000;"&gt;
                                                        &lt;tr&gt;
                                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1.5pt solid #000000; border-bottom: 0.75pt solid #000000; vertical-align: bottom;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-top: 1.5pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-top: 1.5pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&#160;&lt;br/&gt;&lt;b&gt;Number of options&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-top: 1.5pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-top: 1.5pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-top: 1.5pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;&#160; Weighted average&#160; &lt;/b&gt;&lt;br/&gt;&lt;b&gt;exercise price&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-top: 1.5pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right;"&gt;&#160;&lt;/td&gt;
                                                        &lt;/tr&gt;
                                                        &lt;tr&gt;
                                                            &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;Balance at September 30, 2019 and May 31, 2019&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;-&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;-&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                        &lt;/tr&gt;
                                                        &lt;tr&gt;
                                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&#160; Granted&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;150,000&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;1.25&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                                        &lt;/tr&gt;
                                                        &lt;tr&gt;
                                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;Balance at September 30, 2020&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;150,000&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;1.25&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                        &lt;/tr&gt;
                                                        &lt;tr&gt;
                                                            &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&#160; Granted&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; text-align: right; width: 12%;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;895,807&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; text-align: right; width: 12%;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;4.29&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                                        &lt;/tr&gt;
                                                        &lt;tr&gt;
                                                            &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: justify; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&#160; Cancelled*&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;(20,000&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;1.25&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                        &lt;/tr&gt;
                                                        &lt;tr&gt;
                                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 2.25pt double #000000; vertical-align: bottom;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;Balance at September 30, 2021&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 12%;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;1,025,807&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 12%;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;3.90&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                                        &lt;/tr&gt;
                                                    &lt;/table&gt;
                                                &lt;/div&gt;
                                            &lt;/div&gt;
                                        </ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="C_20190930_ifrsfullClassesOfShareCapitalAxis_drugStockOptionsMember"
      decimals="INF"
      id="Fxbrl_20211228203008645"
      unitRef="Share">0</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019
      contextRef="C_20190930_ifrsfullClassesOfShareCapitalAxis_drugStockOptionsMember"
      decimals="0"
      id="Fxbrl_20211228204812693"
      unitRef="CAD_per_share">0</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement
      contextRef="C_20191001to20200930_ifrsfullClassesOfShareCapitalAxis_drugStockOptionsMember"
      decimals="INF"
      id="Fxbrl_20211228203131501"
      unitRef="Share">150000</ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019
      contextRef="C_20191001to20200930_ifrsfullClassesOfShareCapitalAxis_drugStockOptionsMember"
      decimals="2"
      id="Fxbrl_20211228204432005"
      unitRef="CAD_per_share">1.25</ifrs-full:WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="C_20200930_ifrsfullClassesOfShareCapitalAxis_drugStockOptionsMember"
      decimals="INF"
      id="Fxbrl_20211228203439827"
      unitRef="Share">150000</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019
      contextRef="C_20200930_ifrsfullClassesOfShareCapitalAxis_drugStockOptionsMember"
      decimals="2"
      id="Fxbrl_20211228204846412"
      unitRef="CAD_per_share">1.25</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement
      contextRef="C_20201001to20210930_ifrsfullClassesOfShareCapitalAxis_drugStockOptionsMember"
      decimals="INF"
      id="Fxbrl_20211228203513495"
      unitRef="Share">895807</ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019
      contextRef="C_20201001to20210930_ifrsfullClassesOfShareCapitalAxis_drugStockOptionsMember"
      decimals="2"
      id="Fxbrl_20211228205026138"
      unitRef="CAD_per_share">4.29</ifrs-full:WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement
      contextRef="C_20201001to20210930_ifrsfullClassesOfShareCapitalAxis_drugStockOptionsMember"
      decimals="INF"
      id="Fxbrl_20211228203711789"
      unitRef="Share">20000</ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019
      contextRef="C_20201001to20210930_ifrsfullClassesOfShareCapitalAxis_drugStockOptionsMember"
      decimals="2"
      id="Fxbrl_20211228205114791"
      unitRef="CAD_per_share">1.25</ifrs-full:WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="C_20210930_ifrsfullClassesOfShareCapitalAxis_drugStockOptionsMember"
      decimals="INF"
      id="Fxbrl_20211228203529839"
      unitRef="Share">1025807</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019
      contextRef="C_20210930_ifrsfullClassesOfShareCapitalAxis_drugStockOptionsMember"
      decimals="2"
      id="Fxbrl_20211228204858020"
      unitRef="CAD_per_share">3.90</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement
      contextRef="C_20210101to20210121_ifrsfullClassesOfShareCapitalAxis_drugStockOptionsMember"
      decimals="INF"
      id="Fxbrl_20211230145723310"
      unitRef="Shares">20000</ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019
      contextRef="C_20201001to20210930_ifrsfullClassesOfShareCapitalAxis_drugStockOptionsMember"
      id="Fxbrl_20211229135844309">P4Y3M10D</ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019>
    <ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019
      contextRef="C_20191001to20200930_ifrsfullClassesOfShareCapitalAxis_drugStockOptionsMember"
      id="Fxbrl_20211229135906182">P4Y9M21D</ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019>
    <drug:DisclosureOfNumberOfIssuedAndOutstandingStockOptionsExplanatory
      contextRef="C_20201001to20210930"
      id="Fxbrl_20211228202513216">
                                            &lt;div&gt;
                                                &lt;table cellpadding="0" cellspacing="0" style="width: 90%; border-collapse: collapse; font-size: 10pt; border-color: #000000; margin-left: auto; margin-right: auto;"&gt;
                                                    &lt;tr&gt;
                                                        &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-top: 1.5pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                        &lt;td colspan="1" style="vertical-align: bottom; border-top: 1.5pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: center;"&gt;&#160;&lt;/td&gt;
                                                        &lt;td colspan="10" style="vertical-align: bottom; border-top: 1.5pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;Options Outstanding and Exercisable&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                        &lt;td colspan="1" style="vertical-align: bottom; border-top: 1.5pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: center;"&gt;&#160;&lt;/td&gt;
                                                    &lt;/tr&gt;
                                                    &lt;tr&gt;
                                                        &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-indent: 2.8pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;br/&gt;&lt;b&gt;Expiry Date&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                        &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right;"&gt;&#160;&lt;/td&gt;
                                                        &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;Number of&lt;br/&gt;options&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                        &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
                                                        &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
                                                        &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;br/&gt;&lt;b&gt;Exercisable&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                        &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
                                                        &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
                                                        &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;br/&gt;&lt;b&gt;Exercise price&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                        &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
                                                        &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
                                                        &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;Remaining life&lt;br/&gt;(Years)&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                        &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right;"&gt;&#160;&lt;/td&gt;
                                                    &lt;/tr&gt;
                                                    &lt;tr&gt;
                                                        &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;September 21, 2024&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                        &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                        &lt;td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;8,807&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                        &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                        &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                        &lt;td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                        &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                        &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                        &lt;td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;7.64&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                        &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                        &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                        &lt;td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;
                                                                    2.98
                                                                &lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                        &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                    &lt;/tr&gt;
                                                    &lt;tr&gt;
                                                        &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;July 23, 2025&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                        &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                                        &lt;td style="vertical-align: bottom; text-align: right; width: 12%;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;150,000&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                        &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                                        &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                                        &lt;td style="vertical-align: bottom; text-align: right; width: 12%;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;150,000&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                        &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                                        &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                        &lt;td style="vertical-align: bottom; text-align: right; width: 12%;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;1.25&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                        &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                                        &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                                        &lt;td style="vertical-align: bottom; text-align: right; width: 12%;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;
                                                                    3.81
                                                                &lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                        &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                                    &lt;/tr&gt;
                                                    &lt;tr&gt;
                                                        &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;November 17, 2025&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                        &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                        &lt;td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;447,000&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                        &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                        &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                        &lt;td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;30,500&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                        &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                        &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                        &lt;td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;1.25&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                        &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                        &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                        &lt;td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;
                                                                    4.13
                                                                &lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                        &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                    &lt;/tr&gt;
                                                    &lt;tr&gt;
                                                        &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;April 28, 2026&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                        &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                                        &lt;td style="vertical-align: bottom; text-align: right; width: 12%;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;240,000&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                        &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                                        &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                                        &lt;td style="vertical-align: bottom; text-align: right; width: 12%;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                        &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                                        &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                        &lt;td style="vertical-align: bottom; text-align: right; width: 12%;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;7.60&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                        &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                                        &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                                        &lt;td style="vertical-align: bottom; text-align: right; width: 12%;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;
                                                                    4.58
                                                                &lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                        &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                                    &lt;/tr&gt;
                                                    &lt;tr&gt;
                                                        &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 2.25pt double #000000; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;June 15, 2026&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                        &lt;td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                        &lt;td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;180,000&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                        &lt;td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                        &lt;td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                        &lt;td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                        &lt;td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                        &lt;td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                        &lt;td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;7.60&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                        &lt;td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                        &lt;td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                        &lt;td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;
                                                                    4.71
                                                                &lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                        &lt;td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                    &lt;/tr&gt;
                                                &lt;/table&gt;
                                            &lt;/div&gt;
                                        </drug:DisclosureOfNumberOfIssuedAndOutstandingStockOptionsExplanatory>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="C_20210930_drugExpiryDateAxis_drugExpiryDateTwentyOneSeptemberTwoThousandAndTwentyFourMember_ifrsfullClassesOfShareCapitalAxis_drugStockOptionsMember"
      decimals="INF"
      id="Fxbrl_20211228205652752"
      unitRef="Share">8807</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement
      contextRef="C_20210930_drugExpiryDateAxis_drugExpiryDateTwentyOneSeptemberTwoThousandAndTwentyFourMember_ifrsfullClassesOfShareCapitalAxis_drugStockOptionsMember"
      decimals="INF"
      id="Fxbrl_20211228210227203"
      unitRef="Share">0</ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement>
    <ifrs-full:ExercisePriceOfOutstandingShareOptions2019
      contextRef="C_20210930_drugExpiryDateAxis_drugExpiryDateTwentyOneSeptemberTwoThousandAndTwentyFourMember_ifrsfullClassesOfShareCapitalAxis_drugStockOptionsMember"
      decimals="2"
      id="Fxbrl_20211228210641762"
      unitRef="CAD_per_share">7.64</ifrs-full:ExercisePriceOfOutstandingShareOptions2019>
    <ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019
      contextRef="C_20201001to20210930_drugExpiryDateAxis_drugExpiryDateTwentyOneSeptemberTwoThousandAndTwentyFourMember_ifrsfullClassesOfShareCapitalAxis_drugStockOptionsMember"
      id="Fxbrl_20211228210855274">P2Y11M23D</ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="C_20210930_drugExpiryDateAxis_drugExpiryDateTwentyThreeJulyTwoThousandAndTwentyFiveMember_ifrsfullClassesOfShareCapitalAxis_drugStockOptionsMember"
      decimals="INF"
      id="Fxbrl_20211228210116540"
      unitRef="Share">150000</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement
      contextRef="C_20210930_drugExpiryDateAxis_drugExpiryDateTwentyThreeJulyTwoThousandAndTwentyFiveMember_ifrsfullClassesOfShareCapitalAxis_drugStockOptionsMember"
      decimals="INF"
      id="Fxbrl_20211228210236234"
      unitRef="Share">150000</ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement>
    <ifrs-full:ExercisePriceOfOutstandingShareOptions2019
      contextRef="C_20210930_drugExpiryDateAxis_drugExpiryDateTwentyThreeJulyTwoThousandAndTwentyFiveMember_ifrsfullClassesOfShareCapitalAxis_drugStockOptionsMember"
      decimals="2"
      id="Fxbrl_20211228210701378"
      unitRef="CAD_per_share">1.25</ifrs-full:ExercisePriceOfOutstandingShareOptions2019>
    <ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019
      contextRef="C_20201001to20210930_drugExpiryDateAxis_drugExpiryDateTwentyThreeJulyTwoThousandAndTwentyFiveMember_ifrsfullClassesOfShareCapitalAxis_drugStockOptionsMember"
      id="Fxbrl_20211228210936779">P3Y9M21D</ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="C_20210930_drugExpiryDateAxis_drugExpiryDateSeventeenNovemberTwoThousandAndTwentyFiveMember_ifrsfullClassesOfShareCapitalAxis_drugStockOptionsMember"
      decimals="INF"
      id="Fxbrl_20211228210120581"
      unitRef="Share">447000</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement
      contextRef="C_20210930_drugExpiryDateAxis_drugExpiryDateSeventeenNovemberTwoThousandAndTwentyFiveMember_ifrsfullClassesOfShareCapitalAxis_drugStockOptionsMember"
      decimals="INF"
      id="Fxbrl_20211228210324245"
      unitRef="Share">30500</ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement>
    <ifrs-full:ExercisePriceOfOutstandingShareOptions2019
      contextRef="C_20210930_drugExpiryDateAxis_drugExpiryDateSeventeenNovemberTwoThousandAndTwentyFiveMember_ifrsfullClassesOfShareCapitalAxis_drugStockOptionsMember"
      decimals="2"
      id="Fxbrl_20211228210707076"
      unitRef="CAD_per_share">1.25</ifrs-full:ExercisePriceOfOutstandingShareOptions2019>
    <ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019
      contextRef="C_20201001to20210930_drugExpiryDateAxis_drugExpiryDateSeventeenNovemberTwoThousandAndTwentyFiveMember_ifrsfullClassesOfShareCapitalAxis_drugStockOptionsMember"
      id="Fxbrl_20211228210940644">P4Y1M17D</ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="C_20210930_drugExpiryDateAxis_drugExpiryDateTwentyEightAprilTwoThousandAndTwentySixMember_ifrsfullClassesOfShareCapitalAxis_drugStockOptionsMember"
      decimals="INF"
      id="Fxbrl_20211228210126203"
      unitRef="Share">240000</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement
      contextRef="C_20210930_drugExpiryDateAxis_drugExpiryDateTwentyEightAprilTwoThousandAndTwentySixMember_ifrsfullClassesOfShareCapitalAxis_drugStockOptionsMember"
      decimals="INF"
      id="Fxbrl_20211228210553560"
      unitRef="Share">0</ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement>
    <ifrs-full:ExercisePriceOfOutstandingShareOptions2019
      contextRef="C_20210930_drugExpiryDateAxis_drugExpiryDateTwentyEightAprilTwoThousandAndTwentySixMember_ifrsfullClassesOfShareCapitalAxis_drugStockOptionsMember"
      decimals="2"
      id="Fxbrl_20211228210716106"
      unitRef="CAD_per_share">7.60</ifrs-full:ExercisePriceOfOutstandingShareOptions2019>
    <ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019
      contextRef="C_20201001to20210930_drugExpiryDateAxis_drugExpiryDateTwentyEightAprilTwoThousandAndTwentySixMember_ifrsfullClassesOfShareCapitalAxis_drugStockOptionsMember"
      id="Fxbrl_20211228210945411">P4Y6M29D</ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="C_20210930_drugExpiryDateAxis_drugExpiryDateFifteenJuneTwoThousandAndTwentySixMember_ifrsfullClassesOfShareCapitalAxis_drugStockOptionsMember"
      decimals="INF"
      id="Fxbrl_20211228210138961"
      unitRef="Share">180000</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement
      contextRef="C_20210930_drugExpiryDateAxis_drugExpiryDateFifteenJuneTwoThousandAndTwentySixMember_ifrsfullClassesOfShareCapitalAxis_drugStockOptionsMember"
      decimals="INF"
      id="Fxbrl_20211228210530706"
      unitRef="Share">0</ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement>
    <ifrs-full:ExercisePriceOfOutstandingShareOptions2019
      contextRef="C_20210930_drugExpiryDateAxis_drugExpiryDateFifteenJuneTwoThousandAndTwentySixMember_ifrsfullClassesOfShareCapitalAxis_drugStockOptionsMember"
      decimals="2"
      id="Fxbrl_20211228210722410"
      unitRef="CAD_per_share">7.60</ifrs-full:ExercisePriceOfOutstandingShareOptions2019>
    <ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019
      contextRef="C_20201001to20210930_drugExpiryDateAxis_drugExpiryDateFifteenJuneTwoThousandAndTwentySixMember_ifrsfullClassesOfShareCapitalAxis_drugStockOptionsMember"
      id="Fxbrl_20211228210950124">P4Y8M15D</ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019>
    <drug:IssuanceOfRestrictedStockUnits
      contextRef="C_20200723_ifrsfullClassesOfShareCapitalAxis_drugRestrictedShareUnitMember_srtTitleOfIndividualAxis_drugChiefMedicalOfficerMember"
      decimals="0"
      id="Fxbrl_20211229140025888"
      unitRef="CAD">150000</drug:IssuanceOfRestrictedStockUnits>
    <drug:IssuanceOfRestrictedStockUnits
      contextRef="C_20200918_ifrsfullClassesOfShareCapitalAxis_drugRestrictedShareUnitMember_srtTitleOfIndividualAxis_drugChiefMedicalOfficerMember"
      decimals="0"
      id="Fxbrl_20211229140042790"
      unitRef="CAD">230000</drug:IssuanceOfRestrictedStockUnits>
    <ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory
      contextRef="C_20201001to20210930"
      id="Fxbrl_20211228202543657">
                                                &lt;div&gt;
                                                    &lt;table cellpadding="0" cellspacing="0" style="width: 100%; border-collapse: collapse; font-size: 10pt; border-color: #000000;"&gt;
                                                        &lt;tr&gt;
                                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; border-top: 1.5pt solid #000000; vertical-align: bottom;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-top: 1.5pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-top: 1.5pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;Equity settled&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-top: 1.5pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td colspan="1" style="vertical-align: bottom; border-top: 1.5pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td colspan="1" style="vertical-align: bottom; border-top: 1.5pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;Cash settled&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td colspan="1" style="vertical-align: bottom; border-top: 1.5pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-top: 1.5pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-top: 1.5pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-top: 1.5pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
                                                        &lt;/tr&gt;
                                                        &lt;tr&gt;
                                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;Balance at September 30, 2019 and May 31, 2019&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td colspan="1" style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td colspan="1" style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td colspan="1" style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                        &lt;/tr&gt;
                                                        &lt;tr&gt;
                                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;Granted&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;380,000&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td colspan="1" style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td colspan="1" style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td colspan="1" style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;380,000&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                                        &lt;/tr&gt;
                                                        &lt;tr&gt;
                                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;Balance at September 30, 2020&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;380,000&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;380,000&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                        &lt;/tr&gt;
                                                        &lt;tr&gt;
                                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;Vested&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;(95,000&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;(95,000&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                        &lt;/tr&gt;
                                                        &lt;tr&gt;
                                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 2.25pt double #000000; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;Balance at September 30, 2021&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;285,000&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;285,000&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                        &lt;/tr&gt;
                                                    &lt;/table&gt;
                                                &lt;/div&gt;
                                            </ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="C_20190930_ifrsfullClassesOfShareCapitalAxis_drugRestrictedShareUnitMember_ifrsfullTypesOfSharebasedPaymentArrangementsAxis_drugEquitySettledShareBasedPaymentArrangementsMember"
      decimals="0"
      id="Fxbrl_20211228211150289_12"
      unitRef="Share">0</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="C_20190930_ifrsfullClassesOfShareCapitalAxis_drugRestrictedShareUnitMember_ifrsfullTypesOfSharebasedPaymentArrangementsAxis_drugCashSettledShareBasedPaymentArrangementsMember"
      decimals="0"
      id="Fxbrl_20211228211150289_15"
      unitRef="Share">0</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="C_20190930_ifrsfullClassesOfShareCapitalAxis_drugRestrictedShareUnitMember"
      decimals="0"
      id="Fxbrl_20211228211150289_18"
      unitRef="Share">0</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted
      contextRef="C_20191001to20200930_ifrsfullClassesOfShareCapitalAxis_drugRestrictedShareUnitMember_ifrsfullTypesOfSharebasedPaymentArrangementsAxis_drugEquitySettledShareBasedPaymentArrangementsMember"
      decimals="0"
      id="Fxbrl_20211228211150289_22"
      unitRef="Share">380000</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
    <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted
      contextRef="C_20191001to20200930_ifrsfullClassesOfShareCapitalAxis_drugRestrictedShareUnitMember_ifrsfullTypesOfSharebasedPaymentArrangementsAxis_drugCashSettledShareBasedPaymentArrangementsMember"
      decimals="0"
      id="Fxbrl_20211228211150289_25"
      unitRef="Share">0</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
    <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted
      contextRef="C_20191001to20200930_ifrsfullClassesOfShareCapitalAxis_drugRestrictedShareUnitMember"
      decimals="0"
      id="Fxbrl_20211228211150289_28"
      unitRef="Share">380000</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="C_20200930_ifrsfullClassesOfShareCapitalAxis_drugRestrictedShareUnitMember_ifrsfullTypesOfSharebasedPaymentArrangementsAxis_drugEquitySettledShareBasedPaymentArrangementsMember"
      decimals="0"
      id="Fxbrl_20211228211150289_32"
      unitRef="Share">380000</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="C_20200930_ifrsfullClassesOfShareCapitalAxis_drugRestrictedShareUnitMember_ifrsfullTypesOfSharebasedPaymentArrangementsAxis_drugCashSettledShareBasedPaymentArrangementsMember"
      decimals="0"
      id="Fxbrl_20211228211150289_35"
      unitRef="Share">0</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="C_20200930_ifrsfullClassesOfShareCapitalAxis_drugRestrictedShareUnitMember"
      decimals="0"
      id="Fxbrl_20211228211150289_38"
      unitRef="Share">380000</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement
      contextRef="C_20201001to20210930_ifrsfullClassesOfShareCapitalAxis_drugRestrictedShareUnitMember_ifrsfullTypesOfSharebasedPaymentArrangementsAxis_drugEquitySettledShareBasedPaymentArrangementsMember"
      decimals="0"
      id="Fxbrl_20211228211150289_42"
      unitRef="Share">95000</ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement
      contextRef="C_20201001to20210930_ifrsfullClassesOfShareCapitalAxis_drugRestrictedShareUnitMember_ifrsfullTypesOfSharebasedPaymentArrangementsAxis_drugCashSettledShareBasedPaymentArrangementsMember"
      decimals="0"
      id="Fxbrl_20211228211150289_45"
      unitRef="Share">0</ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement
      contextRef="C_20201001to20210930_ifrsfullClassesOfShareCapitalAxis_drugRestrictedShareUnitMember"
      decimals="0"
      id="Fxbrl_20211228211150289_48"
      unitRef="Share">95000</ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="C_20210930_ifrsfullClassesOfShareCapitalAxis_drugRestrictedShareUnitMember_ifrsfullTypesOfSharebasedPaymentArrangementsAxis_drugEquitySettledShareBasedPaymentArrangementsMember"
      decimals="0"
      id="Fxbrl_20211228211150289_52"
      unitRef="Share">285000</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="C_20210930_ifrsfullClassesOfShareCapitalAxis_drugRestrictedShareUnitMember_ifrsfullTypesOfSharebasedPaymentArrangementsAxis_drugCashSettledShareBasedPaymentArrangementsMember"
      decimals="0"
      id="Fxbrl_20211228211150289_55"
      unitRef="Share">0</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="C_20210930_ifrsfullClassesOfShareCapitalAxis_drugRestrictedShareUnitMember"
      decimals="0"
      id="Fxbrl_20211228211150289_58"
      unitRef="Share">285000</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <drug:EstimatedFairValueOfEquitySettledRsusGranted
      contextRef="C_20191001to20200930_ifrsfullClassesOfShareCapitalAxis_drugRestrictedShareUnitMember"
      decimals="0"
      id="Fxbrl_20211229142113090"
      unitRef="CAD">475000</drug:EstimatedFairValueOfEquitySettledRsusGranted>
    <drug:DisclosureOfDetailedInformationAboutEquitySettledRestrictedShareUnitsFairValueInputsExplanatory
      contextRef="C_20201001to20210930"
      id="Fxbrl_20211228202617266">
                                            &lt;div&gt;
                                                &lt;table cellpadding="0" cellspacing="0" style="width: 80%; border-collapse: collapse; font-size: 10pt; border-color: #000000; margin-left: auto; margin-right: auto;"&gt;
                                                    &lt;tr&gt;
                                                        &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; border-top: 1.5pt solid #000000; vertical-align: bottom;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                        &lt;td style="vertical-align: bottom; border-top: 1.5pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right;"&gt;&#160;&lt;/td&gt;
                                                        &lt;td style="vertical-align: bottom; border-top: 1.5pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;Year ended&lt;br/&gt;September 30, 2020&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                        &lt;td style="vertical-align: bottom; border-top: 1.5pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right;"&gt;&#160;&lt;/td&gt;
                                                    &lt;/tr&gt;
                                                    &lt;tr&gt;
                                                        &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;Share price on grant date&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                        &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                        &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 22%; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;1.25&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                        &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                    &lt;/tr&gt;
                                                    &lt;tr&gt;
                                                        &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;Forfeiture rate&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 22%;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;0%&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                                    &lt;/tr&gt;
                                                &lt;/table&gt;
                                            &lt;/div&gt;
                                        </drug:DisclosureOfDetailedInformationAboutEquitySettledRestrictedShareUnitsFairValueInputsExplanatory>
    <drug:SharePriceOnGrantDateOfOtherEquityInstruments
      contextRef="C_20191001to20200930_ifrsfullClassesOfShareCapitalAxis_drugRestrictedShareUnitMember_ifrsfullTypesOfSharebasedPaymentArrangementsAxis_drugEquitySettledShareBasedPaymentArrangementsMember"
      decimals="2"
      id="Fxbrl_20211228212157350"
      unitRef="CAD_per_share">1.25</drug:SharePriceOnGrantDateOfOtherEquityInstruments>
    <drug:ForfeitureRateOfOtherEquityInstruments
      contextRef="C_20191001to20200930_ifrsfullClassesOfShareCapitalAxis_drugRestrictedShareUnitMember_ifrsfullTypesOfSharebasedPaymentArrangementsAxis_drugEquitySettledShareBasedPaymentArrangementsMember"
      decimals="2"
      id="Fxbrl_20211228212218505"
      unitRef="Percent">0</drug:ForfeitureRateOfOtherEquityInstruments>
    <drug:DisclosureOfDetailedInformationAboutShareBasedPaymentsRecognizedInConsolidatedStatementsOfComprehensiveLossExplanatory
      contextRef="C_20201001to20210930"
      id="Fxbrl_20211228202640434">
                                                &lt;div&gt;
                                                    &lt;table cellpadding="0" cellspacing="0" style="width: 100%; border-collapse: collapse; font-size: 10pt; border-color: #000000;"&gt;
                                                        &lt;tr&gt;
                                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1.5pt solid #000000; border-bottom: 0.75pt solid #000000; vertical-align: bottom;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-top: 1.5pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-top: 1.5pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;Year ended&lt;br/&gt;September 30,&lt;br/&gt;2021&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-top: 1.5pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-top: 1.5pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-top: 1.5pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;Year ended&lt;br/&gt;September 30,&lt;br/&gt;2020&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-top: 1.5pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-top: 1.5pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-top: 1.5pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;Period ended&lt;br/&gt;September 30,&lt;br/&gt;2019&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-top: 1.5pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right;"&gt;&#160;&lt;/td&gt;
                                                        &lt;/tr&gt;
                                                        &lt;tr&gt;
                                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right;"&gt;&#160;&lt;/td&gt;
                                                        &lt;/tr&gt;
                                                        &lt;tr&gt;
                                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;Stock options&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;643,963&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;138,000&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                        &lt;/tr&gt;
                                                        &lt;tr&gt;
                                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;Restricted share units - equity settled grants&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;236,652&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;23,300&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                                        &lt;/tr&gt;
                                                        &lt;tr&gt;
                                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;Total equity settled share-based compensation expense&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;880,615&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;161,300&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                        &lt;/tr&gt;
                                                        &lt;tr&gt;
                                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;Restricted share units - cash settled grants&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;-&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                                        &lt;/tr&gt;
                                                        &lt;tr&gt;
                                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 2.25pt double #000000; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;Total share-based compensation expense&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;880,615&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;161,300&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                        &lt;/tr&gt;
                                                    &lt;/table&gt;
                                                &lt;/div&gt;
                                            </drug:DisclosureOfDetailedInformationAboutShareBasedPaymentsRecognizedInConsolidatedStatementsOfComprehensiveLossExplanatory>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees
      contextRef="C_20201001to20210930_ifrsfullClassesOfShareCapitalAxis_drugStockOptionsMember_ifrsfullTypesOfSharebasedPaymentArrangementsAxis_drugEquitySettledShareBasedPaymentArrangementsMember"
      decimals="0"
      id="Fxbrl_20211228212406390_22"
      unitRef="CAD">643963</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees
      contextRef="C_20191001to20200930_ifrsfullClassesOfShareCapitalAxis_drugStockOptionsMember_ifrsfullTypesOfSharebasedPaymentArrangementsAxis_drugEquitySettledShareBasedPaymentArrangementsMember"
      decimals="0"
      id="Fxbrl_20211228212406390_25"
      unitRef="CAD">138000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees
      contextRef="C_20190531to20190930_ifrsfullClassesOfShareCapitalAxis_drugStockOptionsMember_ifrsfullTypesOfSharebasedPaymentArrangementsAxis_drugEquitySettledShareBasedPaymentArrangementsMember"
      decimals="0"
      id="Fxbrl_20211228212406390_28"
      unitRef="CAD">0</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees
      contextRef="C_20201001to20210930_ifrsfullClassesOfShareCapitalAxis_drugRestrictedShareUnitMember_ifrsfullTypesOfSharebasedPaymentArrangementsAxis_drugEquitySettledShareBasedPaymentArrangementsMember"
      decimals="0"
      id="Fxbrl_20211228212406390_32"
      unitRef="CAD">236652</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees
      contextRef="C_20191001to20200930_ifrsfullClassesOfShareCapitalAxis_drugRestrictedShareUnitMember_ifrsfullTypesOfSharebasedPaymentArrangementsAxis_drugEquitySettledShareBasedPaymentArrangementsMember"
      decimals="0"
      id="Fxbrl_20211228212406390_35"
      unitRef="CAD">23300</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees
      contextRef="C_20190531to20190930_ifrsfullClassesOfShareCapitalAxis_drugRestrictedShareUnitMember_ifrsfullTypesOfSharebasedPaymentArrangementsAxis_drugEquitySettledShareBasedPaymentArrangementsMember"
      decimals="0"
      id="Fxbrl_20211228212406390_38"
      unitRef="CAD">0</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees
      contextRef="C_20201001to20210930_ifrsfullTypesOfSharebasedPaymentArrangementsAxis_drugEquitySettledShareBasedPaymentArrangementsMember"
      decimals="0"
      id="Fxbrl_20211228212406390_42"
      unitRef="CAD">880615</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees
      contextRef="C_20191001to20200930_ifrsfullTypesOfSharebasedPaymentArrangementsAxis_drugEquitySettledShareBasedPaymentArrangementsMember"
      decimals="0"
      id="Fxbrl_20211228212406390_45"
      unitRef="CAD">161300</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees
      contextRef="C_20190531to20190930_ifrsfullTypesOfSharebasedPaymentArrangementsAxis_drugEquitySettledShareBasedPaymentArrangementsMember"
      decimals="0"
      id="Fxbrl_20211228212406390_48"
      unitRef="CAD">0</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees
      contextRef="C_20201001to20210930_ifrsfullClassesOfShareCapitalAxis_drugRestrictedShareUnitMember_ifrsfullTypesOfSharebasedPaymentArrangementsAxis_drugCashSettledShareBasedPaymentArrangementsMember"
      decimals="0"
      id="Fxbrl_20211228212406390_52"
      unitRef="CAD">0</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees
      contextRef="C_20191001to20200930_ifrsfullClassesOfShareCapitalAxis_drugRestrictedShareUnitMember_ifrsfullTypesOfSharebasedPaymentArrangementsAxis_drugCashSettledShareBasedPaymentArrangementsMember"
      decimals="0"
      id="Fxbrl_20211228212406390_55"
      unitRef="CAD">0</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees
      contextRef="C_20190531to20190930_ifrsfullClassesOfShareCapitalAxis_drugRestrictedShareUnitMember_ifrsfullTypesOfSharebasedPaymentArrangementsAxis_drugCashSettledShareBasedPaymentArrangementsMember"
      decimals="0"
      id="Fxbrl_20211228212406390_58"
      unitRef="CAD">0</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees
      contextRef="C_20201001to20210930"
      decimals="0"
      id="Fxbrl_20211228212406390_62"
      unitRef="CAD">880615</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees
      contextRef="C_20191001to20200930"
      decimals="0"
      id="Fxbrl_20211228212406390_65"
      unitRef="CAD">161300</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees
      contextRef="C_20190531to20190930"
      decimals="0"
      id="Fxbrl_20211228212406390_68"
      unitRef="CAD">0</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
    <drug:DisclosureOfDetailedInformationAboutShareBasedPaymentsIncludedInConsolidatedStatementsOfComprehensiveLossExplanatory
      contextRef="C_20201001to20210930"
      id="Fxbrl_20211228202706210">
                                                &lt;div&gt;
                                                    &lt;table cellpadding="0" cellspacing="0" style="width: 100%; border-collapse: collapse; font-size: 10pt; border-color: #000000;"&gt;
                                                        &lt;tr&gt;
                                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1.5pt solid #000000; border-bottom: 0.75pt solid #000000; vertical-align: bottom;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-top: 1.5pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-top: 1.5pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;Year ended&lt;br/&gt;September 30,&lt;br/&gt;2021&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-top: 1.5pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-top: 1.5pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-top: 1.5pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;Year ended&lt;br/&gt;September 30,&lt;br/&gt;2020&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-top: 1.5pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-top: 1.5pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-top: 1.5pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;Period ended&lt;br/&gt;September 30,&lt;br/&gt;2019&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-top: 1.5pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right;"&gt;&#160;&lt;/td&gt;
                                                        &lt;/tr&gt;
                                                        &lt;tr&gt;
                                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right;"&gt;&#160;&lt;/td&gt;
                                                        &lt;/tr&gt;
                                                        &lt;tr&gt;
                                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;Consulting fees&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;8,045&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                        &lt;/tr&gt;
                                                        &lt;tr&gt;
                                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;Directors' compensation&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; text-align: right; width: 12%;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;136,612&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; text-align: right; width: 12%;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; text-align: right; width: 12%;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                                        &lt;/tr&gt;
                                                        &lt;tr&gt;
                                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;Marketing, advertising and investor relations&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;3,696&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                        &lt;/tr&gt;
                                                        &lt;tr&gt;
                                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;Professional fees&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; text-align: right; width: 12%;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;23,126&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; text-align: right; width: 12%;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; text-align: right; width: 12%;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                                        &lt;/tr&gt;
                                                        &lt;tr&gt;
                                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;Research and development&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;709,136&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;161,300&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                        &lt;/tr&gt;
                                                        &lt;tr&gt;
                                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 2.25pt double #000000; vertical-align: bottom;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;Total share-based compensation expense&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 12%;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;880,615&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 12%;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;161,300&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 12%;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                                        &lt;/tr&gt;
                                                    &lt;/table&gt;
                                                &lt;/div&gt;
                                            </drug:DisclosureOfDetailedInformationAboutShareBasedPaymentsIncludedInConsolidatedStatementsOfComprehensiveLossExplanatory>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees
      contextRef="C_20201001to20210930_drugConsolidatedStatementsOfComprehensiveIncomeLossStatementLocationAxis_drugConsultingFeesMember"
      decimals="0"
      id="Fxbrl_20211228213355534_22"
      unitRef="CAD">8045</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees
      contextRef="C_20191001to20200930_drugConsolidatedStatementsOfComprehensiveIncomeLossStatementLocationAxis_drugConsultingFeesMember"
      decimals="0"
      id="Fxbrl_20211228213355534_25"
      unitRef="CAD">0</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees
      contextRef="C_20190531to20190930_drugConsolidatedStatementsOfComprehensiveIncomeLossStatementLocationAxis_drugConsultingFeesMember"
      decimals="0"
      id="Fxbrl_20211228213355534_28"
      unitRef="CAD">0</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees
      contextRef="C_20201001to20210930_drugConsolidatedStatementsOfComprehensiveIncomeLossStatementLocationAxis_drugDirectorsCompensationMember"
      decimals="0"
      id="Fxbrl_20211228213355534_32"
      unitRef="CAD">136612</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees
      contextRef="C_20191001to20200930_drugConsolidatedStatementsOfComprehensiveIncomeLossStatementLocationAxis_drugDirectorsCompensationMember"
      decimals="0"
      id="Fxbrl_20211228213355534_35"
      unitRef="CAD">0</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees
      contextRef="C_20190531to20190930_drugConsolidatedStatementsOfComprehensiveIncomeLossStatementLocationAxis_drugDirectorsCompensationMember"
      decimals="0"
      id="Fxbrl_20211228213355534_38"
      unitRef="CAD">0</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees
      contextRef="C_20201001to20210930_drugConsolidatedStatementsOfComprehensiveIncomeLossStatementLocationAxis_drugMarketingAdvertisingAndInvestorRelationsMember"
      decimals="0"
      id="Fxbrl_20211228213355534_42"
      unitRef="CAD">3696</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees
      contextRef="C_20191001to20200930_drugConsolidatedStatementsOfComprehensiveIncomeLossStatementLocationAxis_drugMarketingAdvertisingAndInvestorRelationsMember"
      decimals="0"
      id="Fxbrl_20211228213355534_45"
      unitRef="CAD">0</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees
      contextRef="C_20190531to20190930_drugConsolidatedStatementsOfComprehensiveIncomeLossStatementLocationAxis_drugMarketingAdvertisingAndInvestorRelationsMember"
      decimals="0"
      id="Fxbrl_20211228213355534_48"
      unitRef="CAD">0</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees
      contextRef="C_20201001to20210930_drugConsolidatedStatementsOfComprehensiveIncomeLossStatementLocationAxis_drugProfessionalFeesMember"
      decimals="0"
      id="Fxbrl_20211228213355534_52"
      unitRef="CAD">23126</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees
      contextRef="C_20191001to20200930_drugConsolidatedStatementsOfComprehensiveIncomeLossStatementLocationAxis_drugProfessionalFeesMember"
      decimals="0"
      id="Fxbrl_20211228213355534_55"
      unitRef="CAD">0</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees
      contextRef="C_20190531to20190930_drugConsolidatedStatementsOfComprehensiveIncomeLossStatementLocationAxis_drugProfessionalFeesMember"
      decimals="0"
      id="Fxbrl_20211228213355534_58"
      unitRef="CAD">0</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees
      contextRef="C_20201001to20210930_drugConsolidatedStatementsOfComprehensiveIncomeLossStatementLocationAxis_drugResearchAndDevelopmentMember"
      decimals="0"
      id="Fxbrl_20211228213355534_62"
      unitRef="CAD">709136</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees
      contextRef="C_20191001to20200930_drugConsolidatedStatementsOfComprehensiveIncomeLossStatementLocationAxis_drugResearchAndDevelopmentMember"
      decimals="0"
      id="Fxbrl_20211228213355534_65"
      unitRef="CAD">161300</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees
      contextRef="C_20190531to20190930_drugConsolidatedStatementsOfComprehensiveIncomeLossStatementLocationAxis_drugResearchAndDevelopmentMember"
      decimals="0"
      id="Fxbrl_20211228213355534_68"
      unitRef="CAD">0</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees
      contextRef="C_20201001to20210930"
      decimals="0"
      id="Fxbrl_20211228213355534_72"
      unitRef="CAD">880615</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees
      contextRef="C_20191001to20200930"
      decimals="0"
      id="Fxbrl_20211228213355534_75"
      unitRef="CAD">161300</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees
      contextRef="C_20190531to20190930"
      decimals="0"
      id="Fxbrl_20211228213355534_78"
      unitRef="CAD">0</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
    <drug:DisclosureOfNumberAndWeightedAverageExercisePricesOfWarrantsExplanatory
      contextRef="C_20201001to20210930"
      id="Fxbrl_20211228202726585">
                                                &lt;div&gt;
                                                    &lt;table cellpadding="0" cellspacing="0" style="width: 100%; border-collapse: collapse; font-size: 10pt; border-color: #000000;"&gt;
                                                        &lt;tr&gt;
                                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1.5pt solid #000000; border-bottom: 0.75pt solid #000000; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-top: 1.5pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-top: 1.5pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;Number of warrants&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-top: 1.5pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-top: 1.5pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-top: 1.5pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&#160;&lt;b&gt;Weighted average &lt;/b&gt;&lt;br/&gt;&lt;b&gt;exercise price&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-top: 1.5pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right;"&gt;&#160;&lt;/td&gt;
                                                        &lt;/tr&gt;
                                                        &lt;tr&gt;
                                                            &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;Balance at September 30, 2019 and May 31, 2019&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;-&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;-&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                        &lt;/tr&gt;
                                                        &lt;tr&gt;
                                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&#160; Issued&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 15%;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;4,079,600&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 15%;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;0.05&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                                        &lt;/tr&gt;
                                                        &lt;tr&gt;
                                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;Balance at September 30, 2020&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 15%; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;4,079,600&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 15%; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;0.05&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                        &lt;/tr&gt;
                                                        &lt;tr&gt;
                                                            &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&#160; Issued*&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; text-align: right; width: 15%;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;1,709,938&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; text-align: right; width: 15%;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;9.46&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                                        &lt;/tr&gt;
                                                        &lt;tr&gt;
                                                            &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&#160; Issued - broker&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;132,666&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;7.57&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                        &lt;/tr&gt;
                                                        &lt;tr&gt;
                                                            &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: justify;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&#160; Exercised&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; text-align: right; width: 15%;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;(1,948,000&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; text-align: right; width: 15%;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;0.05&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                                        &lt;/tr&gt;
                                                        &lt;tr&gt;
                                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 2.25pt double #000000; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;Balance at September 30, 2021&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 15%; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;3,974,204&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 15%; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;4.35&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                        &lt;/tr&gt;
                                                    &lt;/table&gt;
                                                &lt;/div&gt;
                                            </drug:DisclosureOfNumberAndWeightedAverageExercisePricesOfWarrantsExplanatory>
    <drug:NumberOfWarrantsOutstanding
      contextRef="C_20190930_ifrsfullClassesOfShareCapitalAxis_drugWarrantsMember"
      decimals="INF"
      id="Fxbrl_20211228213841279_12"
      unitRef="Share">0</drug:NumberOfWarrantsOutstanding>
    <drug:WeightedAverageExercisePriceOfWarrantsOutstandingInShareBasedPaymentArrangement
      contextRef="C_20190930_ifrsfullClassesOfShareCapitalAxis_drugWarrantsMember"
      decimals="0"
      id="Fxbrl_20211228213841279_15"
      unitRef="CAD_per_share">0</drug:WeightedAverageExercisePriceOfWarrantsOutstandingInShareBasedPaymentArrangement>
    <drug:NumberOfWarrantsIssued
      contextRef="C_20191001to20200930_ifrsfullClassesOfShareCapitalAxis_drugWarrantsMember"
      decimals="INF"
      id="Fxbrl_20211228213841279_22"
      unitRef="Share">4079600</drug:NumberOfWarrantsIssued>
    <drug:WeightedAverageExercisePriceOfWarrantsIssuedInShareBasedPaymentArrangement
      contextRef="C_20191001to20200930_ifrsfullClassesOfShareCapitalAxis_drugWarrantsMember"
      decimals="2"
      id="Fxbrl_20211228213841279_25"
      unitRef="CAD_per_share">0.05</drug:WeightedAverageExercisePriceOfWarrantsIssuedInShareBasedPaymentArrangement>
    <drug:NumberOfWarrantsOutstanding
      contextRef="C_20200930_ifrsfullClassesOfShareCapitalAxis_drugWarrantsMember"
      decimals="INF"
      id="Fxbrl_20211228213841279_32"
      unitRef="Share">4079600</drug:NumberOfWarrantsOutstanding>
    <drug:WeightedAverageExercisePriceOfWarrantsOutstandingInShareBasedPaymentArrangement
      contextRef="C_20200930_ifrsfullClassesOfShareCapitalAxis_drugWarrantsMember"
      decimals="2"
      id="Fxbrl_20211228213841279_35"
      unitRef="CAD_per_share">0.05</drug:WeightedAverageExercisePriceOfWarrantsOutstandingInShareBasedPaymentArrangement>
    <drug:NumberOfWarrantsIssued
      contextRef="C_20201001to20210930_ifrsfullClassesOfShareCapitalAxis_drugWarrantsMember"
      decimals="INF"
      id="Fxbrl_20211228213841279_42"
      unitRef="Share">1709938</drug:NumberOfWarrantsIssued>
    <drug:WeightedAverageExercisePriceOfWarrantsIssuedInShareBasedPaymentArrangement
      contextRef="C_20201001to20210930_ifrsfullClassesOfShareCapitalAxis_drugWarrantsMember"
      decimals="2"
      id="Fxbrl_20211228213841279_45"
      unitRef="CAD_per_share">9.46</drug:WeightedAverageExercisePriceOfWarrantsIssuedInShareBasedPaymentArrangement>
    <drug:NumberOfWarrantsIssuedToBroker
      contextRef="C_20201001to20210930_ifrsfullClassesOfShareCapitalAxis_drugWarrantsMember"
      decimals="INF"
      id="Fxbrl_20211228213841279_52"
      unitRef="Share">132666</drug:NumberOfWarrantsIssuedToBroker>
    <drug:WeightedAverageExercisePriceOfWarrantsIssuedToBrokerInShareBasedPaymentArrangement
      contextRef="C_20201001to20210930_ifrsfullClassesOfShareCapitalAxis_drugWarrantsMember"
      decimals="2"
      id="Fxbrl_20211228213841279_55"
      unitRef="CAD_per_share">7.57</drug:WeightedAverageExercisePriceOfWarrantsIssuedToBrokerInShareBasedPaymentArrangement>
    <drug:NumberOfWarrantsExercised
      contextRef="C_20201001to20210930_ifrsfullClassesOfShareCapitalAxis_drugWarrantsMember"
      decimals="INF"
      id="Fxbrl_20211228213841279_62"
      unitRef="Share">1948000</drug:NumberOfWarrantsExercised>
    <drug:WeightedAverageExercisePriceOfWarrantsExercisedInShareBasedPaymentArrangement
      contextRef="C_20201001to20210930_ifrsfullClassesOfShareCapitalAxis_drugWarrantsMember"
      decimals="2"
      id="Fxbrl_20211228213841279_65"
      unitRef="CAD_per_share">0.05</drug:WeightedAverageExercisePriceOfWarrantsExercisedInShareBasedPaymentArrangement>
    <drug:NumberOfWarrantsOutstanding
      contextRef="C_20210930_ifrsfullClassesOfShareCapitalAxis_drugWarrantsMember"
      decimals="INF"
      id="Fxbrl_20211228213841279_72"
      unitRef="Share">3974204</drug:NumberOfWarrantsOutstanding>
    <drug:WeightedAverageExercisePriceOfWarrantsOutstandingInShareBasedPaymentArrangement
      contextRef="C_20210930_ifrsfullClassesOfShareCapitalAxis_drugWarrantsMember"
      decimals="2"
      id="Fxbrl_20211228213841279_75"
      unitRef="CAD_per_share">4.35</drug:WeightedAverageExercisePriceOfWarrantsOutstandingInShareBasedPaymentArrangement>
    <drug:WeightedAverageExercisePriceOfWarrantsOutstandingInShareBasedPaymentArrangement
      contextRef="C_20201102"
      decimals="3"
      id="Fxbrl_20211229223356551"
      unitRef="CAD_per_share">0.125</drug:WeightedAverageExercisePriceOfWarrantsOutstandingInShareBasedPaymentArrangement>
    <drug:WeightedAverageExercisePriceOfWarrantsOutstandingInShareBasedPaymentArrangement
      contextRef="C_20200711"
      decimals="2"
      id="Fxbrl_20211229223410282"
      unitRef="CAD_per_share">0.05</drug:WeightedAverageExercisePriceOfWarrantsOutstandingInShareBasedPaymentArrangement>
    <drug:NumberOfWarrantsIssued
      contextRef="C_20210301to20210317_ifrsfullCategoriesOfRelatedPartiesAxis_drugUnderwritersMember_ifrsfullClassesOfShareCapitalAxis_drugWarrantsMember"
      decimals="INF"
      id="Fxbrl_20211229140749550"
      unitRef="Share">132666</drug:NumberOfWarrantsIssued>
    <drug:FairValueOfWarrants
      contextRef="C_20210301to20210317_ifrsfullCategoriesOfRelatedPartiesAxis_drugUnderwritersMember_ifrsfullClassesOfShareCapitalAxis_drugWarrantsMember"
      decimals="INF"
      id="Fxbrl_20211229141147506"
      unitRef="Share">521000</drug:FairValueOfWarrants>
    <drug:ExercisePriceWarrantsGranted
      contextRef="C_20210301to20210317_ifrsfullCategoriesOfRelatedPartiesAxis_drugUnderwritersMember_ifrsfullClassesOfShareCapitalAxis_drugWarrantsMember"
      decimals="2"
      id="Fxbrl_20211229141220766"
      unitRef="CAD_per_share">7.57</drug:ExercisePriceWarrantsGranted>
    <drug:WeightedAverageSharePriceWarrantsGranted
      contextRef="C_20210301to20210317_ifrsfullCategoriesOfRelatedPartiesAxis_drugUnderwritersMember_ifrsfullClassesOfShareCapitalAxis_drugWarrantsMember"
      decimals="2"
      id="Fxbrl_20211229141235476"
      unitRef="CAD_per_share">6.65</drug:WeightedAverageSharePriceWarrantsGranted>
    <drug:EstimatedLifeOfWarrantsGranted
      contextRef="C_20210301to20210317_ifrsfullCategoriesOfRelatedPartiesAxis_drugUnderwritersMember_ifrsfullClassesOfShareCapitalAxis_drugWarrantsMember"
      decimals="0"
      id="Fxbrl_20211229141247923"
      unitRef="Year">3</drug:EstimatedLifeOfWarrantsGranted>
    <drug:ExpectedVolatilityWarrantsGranted
      contextRef="C_20210301to20210317_ifrsfullCategoriesOfRelatedPartiesAxis_drugUnderwritersMember_ifrsfullClassesOfShareCapitalAxis_drugWarrantsMember"
      decimals="2"
      id="Fxbrl_20211229141258839"
      unitRef="Percent">1</drug:ExpectedVolatilityWarrantsGranted>
    <drug:DiscountRateOfWarrantsGranted
      contextRef="C_20210301to20210317_ifrsfullCategoriesOfRelatedPartiesAxis_drugUnderwritersMember_ifrsfullClassesOfShareCapitalAxis_drugWarrantsMember"
      decimals="4"
      id="Fxbrl_20211229141308615"
      unitRef="Percent">0.0035</drug:DiscountRateOfWarrantsGranted>
    <drug:WeightedAverageRemainingContractualLifeOfOtherEquityInstruments
      contextRef="C_20201001to20210930_ifrsfullClassesOfShareCapitalAxis_drugWarrantsMember"
      id="Fxbrl_20211229141448500">P2Y7M28D</drug:WeightedAverageRemainingContractualLifeOfOtherEquityInstruments>
    <drug:WeightedAverageRemainingContractualLifeOfOtherEquityInstruments
      contextRef="C_20191001to20200930_ifrsfullClassesOfShareCapitalAxis_drugWarrantsMember"
      id="Fxbrl_20211229141506061">P3Y9M29D</drug:WeightedAverageRemainingContractualLifeOfOtherEquityInstruments>
    <drug:DisclosureOfNumberOfIssuedAndOutstandingWarrantsExplanatory
      contextRef="C_20201001to20210930"
      id="Fxbrl_20211228202748130">
                                                &lt;div&gt;
                                                    &lt;table cellpadding="0" cellspacing="0" style="width: 100%; border-collapse: collapse; font-size: 10pt; border-color: #000000;"&gt;
                                                        &lt;tr&gt;
                                                            &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-top: 1.5pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td colspan="1" style="vertical-align: bottom; border-top: 1.5pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: center;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td colspan="7" style="vertical-align: bottom; border-top: 1.5pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;Warrants Outstanding&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td colspan="1" style="vertical-align: bottom; border-top: 1.5pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: center;"&gt;&#160;&lt;/td&gt;
                                                        &lt;/tr&gt;
                                                        &lt;tr&gt;
                                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;Expiry Date&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;Number of&lt;br/&gt;warrants&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;br/&gt;&lt;b&gt;Exercise price&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;Remaining life&lt;br/&gt;(Years)&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right;"&gt;&#160;&lt;/td&gt;
                                                        &lt;/tr&gt;
                                                        &lt;tr&gt;
                                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;July 30, 2024 (1)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;2,131,600&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;0.05&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;
                                                                        2.83
                                                                    &lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                        &lt;/tr&gt;
                                                        &lt;tr&gt;
                                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;March 17, 2024&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; text-align: right; width: 12%;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;1,709,938&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; text-align: right; width: 12%;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;9.46&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; text-align: right; width: 12%;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;
                                                                        2.46
                                                                    &lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                                        &lt;/tr&gt;
                                                        &lt;tr&gt;
                                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 2.25pt double #000000; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;March 17, 2024&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;132,666&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;7.57&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;
                                                                        2.46
                                                                    &lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                        &lt;/tr&gt;
                                                    &lt;/table&gt;
                                                &lt;/div&gt;
                                            </drug:DisclosureOfNumberOfIssuedAndOutstandingWarrantsExplanatory>
    <drug:NumberOfWarrantsOutstanding
      contextRef="C_20210930_drugExpiryDateAxis_drugExpiryDateThirtyJulyTwoThousandAndTwentyFourMember_ifrsfullClassesOfShareCapitalAxis_drugWarrantsMember"
      decimals="INF"
      id="Fxbrl_20211228215910095_22"
      unitRef="Share">2131600</drug:NumberOfWarrantsOutstanding>
    <drug:WeightedAverageExercisePriceOfWarrantsOutstandingInShareBasedPaymentArrangement
      contextRef="C_20210930_drugExpiryDateAxis_drugExpiryDateThirtyJulyTwoThousandAndTwentyFourMember_ifrsfullClassesOfShareCapitalAxis_drugWarrantsMember"
      decimals="2"
      id="Fxbrl_20211228215910095_25"
      unitRef="CAD_per_share">0.05</drug:WeightedAverageExercisePriceOfWarrantsOutstandingInShareBasedPaymentArrangement>
    <drug:WeightedAverageRemainingContractualLifeOfWarrants
      contextRef="C_20201001to20210930_drugExpiryDateAxis_drugExpiryDateThirtyJulyTwoThousandAndTwentyFourMember_ifrsfullClassesOfShareCapitalAxis_drugWarrantsMember"
      id="Fxbrl_20211228215910095_28">P2Y9M29D</drug:WeightedAverageRemainingContractualLifeOfWarrants>
    <drug:NumberOfWarrantsOutstanding
      contextRef="C_20210930_drugExpiryDateAxis_drugExpiryDateSeventeenMarchTwoThousandAndTwentyFourOneMember_ifrsfullClassesOfShareCapitalAxis_drugWarrantsMember"
      decimals="INF"
      id="Fxbrl_20211228215910095_32"
      unitRef="Share">1709938</drug:NumberOfWarrantsOutstanding>
    <drug:WeightedAverageExercisePriceOfWarrantsOutstandingInShareBasedPaymentArrangement
      contextRef="C_20210930_drugExpiryDateAxis_drugExpiryDateSeventeenMarchTwoThousandAndTwentyFourOneMember_ifrsfullClassesOfShareCapitalAxis_drugWarrantsMember"
      decimals="2"
      id="Fxbrl_20211228215910095_35"
      unitRef="CAD_per_share">9.46</drug:WeightedAverageExercisePriceOfWarrantsOutstandingInShareBasedPaymentArrangement>
    <drug:WeightedAverageRemainingContractualLifeOfWarrants
      contextRef="C_20201001to20210930_drugExpiryDateAxis_drugExpiryDateSeventeenMarchTwoThousandAndTwentyFourOneMember_ifrsfullClassesOfShareCapitalAxis_drugWarrantsMember"
      id="Fxbrl_20211228215910095_38">P2Y5M15D</drug:WeightedAverageRemainingContractualLifeOfWarrants>
    <drug:NumberOfWarrantsOutstanding
      contextRef="C_20210930_drugExpiryDateAxis_drugExpiryDateSeventeenMarchTwoThousandAndTwentyFourTwoMember_ifrsfullClassesOfShareCapitalAxis_drugWarrantsMember"
      decimals="INF"
      id="Fxbrl_20211228215910095_42"
      unitRef="Share">132666</drug:NumberOfWarrantsOutstanding>
    <drug:WeightedAverageExercisePriceOfWarrantsOutstandingInShareBasedPaymentArrangement
      contextRef="C_20210930_drugExpiryDateAxis_drugExpiryDateSeventeenMarchTwoThousandAndTwentyFourTwoMember_ifrsfullClassesOfShareCapitalAxis_drugWarrantsMember"
      decimals="2"
      id="Fxbrl_20211228215910095_45"
      unitRef="CAD_per_share">7.57</drug:WeightedAverageExercisePriceOfWarrantsOutstandingInShareBasedPaymentArrangement>
    <drug:WeightedAverageRemainingContractualLifeOfWarrants
      contextRef="C_20201001to20210930_drugExpiryDateAxis_drugExpiryDateSeventeenMarchTwoThousandAndTwentyFourTwoMember_ifrsfullClassesOfShareCapitalAxis_drugWarrantsMember"
      id="Fxbrl_20211228215910095_48">P2Y5M15D</drug:WeightedAverageRemainingContractualLifeOfWarrants>
    <drug:ThresholdPercentageOfWarrants
      contextRef="C_20210601to20210615_ifrsfullClassesOfShareCapitalAxis_drugWarrantsMember"
      decimals="4"
      id="Fxbrl_20211229141952369"
      unitRef="Percent">0.0499</drug:ThresholdPercentageOfWarrants>
    <ifrs-full:DisclosureOfRelatedPartyExplanatory
      contextRef="C_20201001to20210930"
      id="Fxbrl_20211228171822090">
                        &lt;div&gt;
                            &lt;p style="margin-left: 18pt; text-indent: -18pt; text-align: justify; margin-top: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;7.&lt;/b&gt;&lt;span style="width: 9pt; text-indent: 0pt; display: inline-block;"&gt;&#160;&lt;/span&gt;&lt;b&gt;RELATED PARTY TRANSACTIONS&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                            &lt;p style="text-align: justify;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;Related party transactions were recorded at the exchange value, which is the consideration determined and agreed to by the related parties. The Company's related parties include directors, key management and companies controlled by directors and key management.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                            &lt;p style="margin-bottom: 0pt; text-align: justify;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="text-decoration: underline;"&gt;Compensation of Key Management Personnel&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                            &lt;p style="margin-top: 0pt; text-align: justify;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;Key management personnel are those persons that have authority and responsibility for planning, directing and controlling the activities of the Company, directly and indirectly, and by definition include the directors of the Company.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                            &lt;p style="text-align: justify;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;The following table summarizes expenses related to key management personnel:&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

                                &lt;div&gt;
                                    &lt;table cellpadding="0" cellspacing="0" style="width: 100%; border-collapse: collapse; font-size: 10pt; border-color: #000000;"&gt;
                                        &lt;tr&gt;
                                            &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-top: 1.5pt solid #000000; text-align: justify;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 1.5pt solid #000000; text-align: right;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 1.5pt solid #000000; text-align: right; white-space: nowrap;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;Year ended&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 1.5pt solid #000000; text-align: right; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 1.5pt solid #000000; text-align: right; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 1.5pt solid #000000; text-align: right; white-space: nowrap;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;Year ended&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 1.5pt solid #000000; text-align: right; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 1.5pt solid #000000; text-align: right; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 1.5pt solid #000000; text-align: right; white-space: nowrap;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;Period ended &lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 1.5pt solid #000000; text-align: right;"&gt;&#160;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; white-space: nowrap;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;September 30, &lt;/b&gt;&lt;br/&gt;&lt;b&gt;2021&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; white-space: nowrap;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;September 30, &lt;/b&gt;&lt;br/&gt;&lt;b&gt;2020&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; white-space: nowrap;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;September 30,&lt;br/&gt;2019&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right;"&gt;&#160;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: justify;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right;"&gt;&#160;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;Professional fees&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;87,074&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;22,575&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;Research and development&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 12%;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;772,596&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 12%;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;26,777&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 12%;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;Share-based compensation included in directors' compensation&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;136,612&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;Share-based compensation included in professional fees&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 12%;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;23,126&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 12%;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 12%;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: justify; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;Share-based compensation included in research and development&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;236,652&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;161,300&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: justify;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 12%;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;1,256,060&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 12%;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;210,652&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 12%;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                        &lt;/tr&gt;
                                    &lt;/table&gt;
                                &lt;/div&gt;

                            &lt;p style="text-align: justify; margin-top: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;See Note 8 for related party contractual obligations.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                        &lt;/div&gt;
                    </ifrs-full:DisclosureOfRelatedPartyExplanatory>
    <ifrs-full:DisclosureOfInformationAboutKeyManagementPersonnelExplanatory
      contextRef="C_20201001to20210930"
      id="Fxbrl_20211228171839263">
                                &lt;div&gt;
                                    &lt;table cellpadding="0" cellspacing="0" style="width: 100%; border-collapse: collapse; font-size: 10pt; border-color: #000000;"&gt;
                                        &lt;tr&gt;
                                            &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-top: 1.5pt solid #000000; text-align: justify;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 1.5pt solid #000000; text-align: right;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 1.5pt solid #000000; text-align: right; white-space: nowrap;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;Year ended&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 1.5pt solid #000000; text-align: right; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 1.5pt solid #000000; text-align: right; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 1.5pt solid #000000; text-align: right; white-space: nowrap;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;Year ended&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 1.5pt solid #000000; text-align: right; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 1.5pt solid #000000; text-align: right; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 1.5pt solid #000000; text-align: right; white-space: nowrap;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;Period ended &lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 1.5pt solid #000000; text-align: right;"&gt;&#160;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; white-space: nowrap;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;September 30, &lt;/b&gt;&lt;br/&gt;&lt;b&gt;2021&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; white-space: nowrap;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;September 30, &lt;/b&gt;&lt;br/&gt;&lt;b&gt;2020&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; white-space: nowrap;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;September 30,&lt;br/&gt;2019&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right;"&gt;&#160;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: justify;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right;"&gt;&#160;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;Professional fees&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;87,074&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;22,575&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;Research and development&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 12%;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;772,596&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 12%;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;26,777&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 12%;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;Share-based compensation included in directors' compensation&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;136,612&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;Share-based compensation included in professional fees&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 12%;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;23,126&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 12%;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 12%;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: justify; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;Share-based compensation included in research and development&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;236,652&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;161,300&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: justify;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 12%;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;1,256,060&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 12%;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;210,652&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 12%;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                        &lt;/tr&gt;
                                    &lt;/table&gt;
                                &lt;/div&gt;
                            </ifrs-full:DisclosureOfInformationAboutKeyManagementPersonnelExplanatory>
    <drug:KeyManagementPersonnelProfessionalFees
      contextRef="C_20201001to20210930"
      decimals="0"
      id="Fxbrl_20211228171901012_32"
      unitRef="CAD">87074</drug:KeyManagementPersonnelProfessionalFees>
    <drug:KeyManagementPersonnelProfessionalFees
      contextRef="C_20191001to20200930"
      decimals="0"
      id="Fxbrl_20211228171901012_35"
      unitRef="CAD">22575</drug:KeyManagementPersonnelProfessionalFees>
    <drug:KeyManagementPersonnelProfessionalFees
      contextRef="C_20190601to20190930"
      decimals="0"
      id="Fxbrl_20211228171901012_38"
      unitRef="CAD">0</drug:KeyManagementPersonnelProfessionalFees>
    <drug:KeyManagementPersonnelResearchAndDevelopment
      contextRef="C_20201001to20210930"
      decimals="0"
      id="Fxbrl_20211228171901012_42"
      unitRef="CAD">772596</drug:KeyManagementPersonnelResearchAndDevelopment>
    <drug:KeyManagementPersonnelResearchAndDevelopment
      contextRef="C_20191001to20200930"
      decimals="0"
      id="Fxbrl_20211228171901012_45"
      unitRef="CAD">26777</drug:KeyManagementPersonnelResearchAndDevelopment>
    <drug:KeyManagementPersonnelResearchAndDevelopment
      contextRef="C_20190601to20190930"
      decimals="0"
      id="Fxbrl_20211228171901012_48"
      unitRef="CAD">0</drug:KeyManagementPersonnelResearchAndDevelopment>
    <ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment
      contextRef="C_20201001to20210930"
      decimals="0"
      id="Fxbrl_20211228171901012_52"
      unitRef="CAD">136612</ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment>
    <ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment
      contextRef="C_20191001to20200930"
      decimals="0"
      id="Fxbrl_20211228171901012_55"
      unitRef="CAD">0</ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment>
    <ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment
      contextRef="C_20190601to20190930"
      decimals="0"
      id="Fxbrl_20211228171901012_58"
      unitRef="CAD">0</ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment>
    <drug:KeyManagementPersonnelCompensationShareBasedPaymentIncludedInProfessionalFees
      contextRef="C_20201001to20210930"
      decimals="0"
      id="Fxbrl_20211228171901012_62"
      unitRef="CAD">23126</drug:KeyManagementPersonnelCompensationShareBasedPaymentIncludedInProfessionalFees>
    <drug:KeyManagementPersonnelCompensationShareBasedPaymentIncludedInProfessionalFees
      contextRef="C_20191001to20200930"
      decimals="0"
      id="Fxbrl_20211228171901012_65"
      unitRef="CAD">0</drug:KeyManagementPersonnelCompensationShareBasedPaymentIncludedInProfessionalFees>
    <drug:KeyManagementPersonnelCompensationShareBasedPaymentIncludedInProfessionalFees
      contextRef="C_20190601to20190930"
      decimals="0"
      id="Fxbrl_20211228171901012_68"
      unitRef="CAD">0</drug:KeyManagementPersonnelCompensationShareBasedPaymentIncludedInProfessionalFees>
    <drug:KeyManagementPersonnelCompensationShareBasedPaymentIncludedInResearchAndDevelopment
      contextRef="C_20201001to20210930"
      decimals="0"
      id="Fxbrl_20211228171901012_72"
      unitRef="CAD">236652</drug:KeyManagementPersonnelCompensationShareBasedPaymentIncludedInResearchAndDevelopment>
    <drug:KeyManagementPersonnelCompensationShareBasedPaymentIncludedInResearchAndDevelopment
      contextRef="C_20191001to20200930"
      decimals="0"
      id="Fxbrl_20211228171901012_75"
      unitRef="CAD">161300</drug:KeyManagementPersonnelCompensationShareBasedPaymentIncludedInResearchAndDevelopment>
    <drug:KeyManagementPersonnelCompensationShareBasedPaymentIncludedInResearchAndDevelopment
      contextRef="C_20190601to20190930"
      decimals="0"
      id="Fxbrl_20211228171901012_78"
      unitRef="CAD">0</drug:KeyManagementPersonnelCompensationShareBasedPaymentIncludedInResearchAndDevelopment>
    <ifrs-full:KeyManagementPersonnelCompensation
      contextRef="C_20201001to20210930"
      decimals="0"
      id="Fxbrl_20211228171901012_82"
      unitRef="CAD">1256060</ifrs-full:KeyManagementPersonnelCompensation>
    <ifrs-full:KeyManagementPersonnelCompensation
      contextRef="C_20191001to20200930"
      decimals="0"
      id="Fxbrl_20211228171901012_85"
      unitRef="CAD">210652</ifrs-full:KeyManagementPersonnelCompensation>
    <ifrs-full:KeyManagementPersonnelCompensation
      contextRef="C_20190601to20190930"
      decimals="0"
      id="Fxbrl_20211228171901012_88"
      unitRef="CAD">0</ifrs-full:KeyManagementPersonnelCompensation>
    <ifrs-full:DisclosureOfCommitmentsExplanatory
      contextRef="C_20201001to20210930"
      id="Fxbrl_20211228212847030">
                        &lt;div&gt;
                            &lt;p style="margin-left: 18pt; text-indent: -18pt; text-align: justify; margin-top: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;8.&lt;/b&gt;&lt;span style="display: inline-block; width: 9pt;"&gt;&#160;&lt;/span&gt;&lt;b&gt;CONTRACTUAL OBLIGATIONS&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                            &lt;p style="margin-bottom: 0pt; text-align: justify;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="text-decoration: underline;"&gt;Option agreement&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                            &lt;p style="margin-top: 0pt; text-align: justify;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;On May 26, 2020, the Company entered into an option agreement (the "OA") with the University of Illinois at Chicago (the "UIC"), whereby the Company obtained the right to evaluate certain of the UIC's technology (as defined) for the purpose of making a decision as to whether to exclusively license the rights to the technology. Pursuant to the OA, the Company was granted an exclusive option to evaluate the technology and obtain an exclusive license to the patents and patent applications (as listed) and a non-exclusive right to use the technology for non-commercial research purposes. The Company paid US$15,000 ($20,313) in non-refundable option fees prior to exercising its option.&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                        &lt;/div&gt;

                        &lt;div&gt;
                            &lt;p style="margin-bottom: 0pt; text-align: justify;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="text-decoration: underline;"&gt;License agreement&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                            &lt;p style="margin-top: 0pt; text-align: justify;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;On April 23, 2021, the Company entered into an exclusive license agreement with equity (the "LA") with the Board of Trustees of the UIC (the "University") whereby the University granted to the Company, in all fields of use and worldwide, an exclusive, non-transferable license with the right to sublicense under the University's rights in and to the Patent Rights (as defined) and a non-exclusive, non-transferable license with the right to sublicense under the University's rights in and to the Technical Information (as defined) to make, have made, construct, have constructed, use, import, sell, and offer for sale royalty-bearing Product (as defined). As consideration for the grant of license, the Company will pay the following amounts (in US$) to the University:&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                            &lt;table border="0" cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; font-family: Times New Roman, Times, serif;"&gt;
                                &lt;tr&gt;
                                    &lt;td style="width: 10px;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="text-align: center; vertical-align: top; width: 3%;"&gt;&#x2022;&lt;/td&gt;
                                    &lt;td&gt;
                                        &lt;p style="font-size: 10pt; font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;i&gt;Signing Fee&lt;/i&gt; - a signing fee of $100,000 less $15,000 in option fees was paid (CDN$105,502) and 63,000 common shares of the Company were issued to the University (see Note 6);&lt;/p&gt;
                                    &lt;/td&gt;
                                &lt;/tr&gt;
                                &lt;tr&gt;
                                    &lt;td style="width: 10px;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="text-align: center; vertical-align: top; width: 3%;"&gt;&#160;&lt;/td&gt;
                                    &lt;td&gt;&#160;&lt;/td&gt;
                                &lt;/tr&gt;
                                &lt;tr&gt;
                                    &lt;td style="width: 10px;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="text-align: center; vertical-align: top; width: 3%;"&gt;&#x2022;&lt;/td&gt;
                                    &lt;td&gt;
                                        &lt;p style="font-size: 10pt; font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;i&gt;Net Sales&lt;/i&gt; - royalties on Net Sales (as defined) ranging from 3% (under $1 billion) to 4.5% (over $2 billion), with such royalty payments being credited toward the annual minimum for the license year in which the royalty payment accrues;&lt;/p&gt;
                                    &lt;/td&gt;
                                &lt;/tr&gt;
                                &lt;tr&gt;
                                    &lt;td style="width: 10px;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="text-align: center; vertical-align: top; width: 3%;"&gt;&#160;&lt;/td&gt;
                                    &lt;td&gt;&#160;&lt;/td&gt;
                                &lt;/tr&gt;
                                &lt;tr&gt;
                                    &lt;td style="width: 10px;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="text-align: center; vertical-align: top; width: 3%;"&gt;&#x2022;&lt;/td&gt;
                                    &lt;td&gt;
                                        &lt;p style="font-size: 10pt; font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;i&gt;Sublicensee Revenues&lt;/i&gt; - royalties (as for net sales above) on Sublicensee Revenue (as defined), with such royalty payments being credited toward the annual minimum for the license year in which the royalty payment accrues and 12% on all non-royalty revenue until the Company has raised $7.5 million and then 10% thereafter;&lt;/p&gt;
                                    &lt;/td&gt;
                                &lt;/tr&gt;
                                &lt;tr&gt;
                                    &lt;td style="width: 10px;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="text-align: center; vertical-align: top; width: 3%;"&gt;&#160;&lt;/td&gt;
                                    &lt;td&gt;&#160;&lt;/td&gt;
                                &lt;/tr&gt;
                                &lt;tr&gt;
                                    &lt;td style="width: 10px;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="text-align: center; vertical-align: top; width: 3%;"&gt;&#x2022;&lt;/td&gt;
                                    &lt;td&gt;
                                        &lt;p style="font-size: 10pt; font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;i&gt;Annual Minimums&lt;/i&gt; - if the total royalties paid to the University for any license year are less than the following annual minimums, the Company must pay the University the amount equal to the shortfall:&lt;/p&gt;
                                    &lt;/td&gt;
                                &lt;/tr&gt;
                                &lt;tr&gt;
                                    &lt;td style="width: 10px;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="text-align: center; width: 3%;"&gt;&#160;&lt;/td&gt;
                                    &lt;td&gt;&#160;&lt;/td&gt;
                                &lt;/tr&gt;
                            &lt;/table&gt;
                            &lt;table border="0" cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; font-family: Times New Roman, Times, serif;"&gt;
                                &lt;tr&gt;
                                    &lt;td style="width: 3%;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="width: 3%;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="width: 3%;"&gt;&lt;span style="font-size: 8pt;"&gt;o&lt;/span&gt;&lt;/td&gt;
                                    &lt;td&gt;
                                        &lt;p style="font-size: 10pt; font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;"&gt;Years 1 and 2 - $&lt;span style="-sec-ix-hidden: Fxbrl_20211229013458419;"&gt;nil&lt;/span&gt;;&lt;/p&gt;
                                    &lt;/td&gt;
                                &lt;/tr&gt;
                                &lt;tr&gt;
                                    &lt;td style="width: 3%;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="width: 3%;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="width: 3%;"&gt;
                                        &lt;p style="font-size: 10pt; font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="font-size: 8pt;"&gt;o&lt;/span&gt;&lt;/p&gt;
                                    &lt;/td&gt;
                                    &lt;td&gt;
                                        &lt;p style="font-size: 10pt; font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;"&gt;Year 3 - $5,000;&lt;/p&gt;
                                    &lt;/td&gt;
                                &lt;/tr&gt;
                                &lt;tr&gt;
                                    &lt;td style="width: 3%;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="width: 3%;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="width: 3%;"&gt;&lt;span style="font-size: 8pt;"&gt;o&lt;/span&gt;&lt;/td&gt;
                                    &lt;td&gt;
                                        &lt;p style="font-size: 10pt; font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;"&gt;Year 4 - $15,000;&lt;/p&gt;
                                    &lt;/td&gt;
                                &lt;/tr&gt;
                                &lt;tr&gt;
                                    &lt;td style="width: 3%;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="width: 3%;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="width: 3%;"&gt;
                                        &lt;p style="font-size: 10pt; font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="font-size: 8pt;"&gt;o&lt;/span&gt;&lt;/p&gt;
                                    &lt;/td&gt;
                                    &lt;td&gt;
                                        &lt;p style="font-size: 10pt; font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;"&gt;Year 5 - $35,000;&lt;/p&gt;
                                    &lt;/td&gt;
                                &lt;/tr&gt;
                                &lt;tr&gt;
                                    &lt;td style="width: 3%;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="width: 3%;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="width: 3%;"&gt;&lt;span style="font-size: 8pt;"&gt;o&lt;/span&gt;&lt;/td&gt;
                                    &lt;td&gt;
                                        &lt;p style="font-size: 10pt; font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;"&gt;Year 6 and thereafter - $50,000; and&lt;/p&gt;
                                    &lt;/td&gt;
                                &lt;/tr&gt;
                                &lt;tr&gt;
                                    &lt;td style="width: 3%;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="width: 3%;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="width: 3%;"&gt;
                                        &lt;p style="font-size: 10pt; font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="font-size: 8pt;"&gt;o&lt;/span&gt;&lt;/p&gt;
                                    &lt;/td&gt;
                                    &lt;td&gt;
                                        &lt;p style="font-size: 10pt; font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;"&gt;After first commercial sale - $250,000 or net sales royalty, whichever is higher.&lt;/p&gt;
                                    &lt;/td&gt;
                                &lt;/tr&gt;
                                &lt;tr&gt;
                                    &lt;td style="width: 3%;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="width: 3%;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="width: 3%;"&gt;&#160;&lt;/td&gt;
                                    &lt;td&gt;&#160;&lt;/td&gt;
                                &lt;/tr&gt;
                            &lt;/table&gt;
                            &lt;table border="0" cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; font-family: Times New Roman, Times, serif;"&gt;
                                &lt;tr&gt;
                                    &lt;td style="width: 10px;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="text-align: center; vertical-align: top; width: 3%;"&gt;&#x2022;&lt;/td&gt;
                                    &lt;td&gt;
                                        &lt;p style="font-size: 10pt; font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;i&gt;Milestone Payments&lt;/i&gt; - milestone payments after the occurrence of the following milestone events:&lt;/p&gt;
                                    &lt;/td&gt;
                                &lt;/tr&gt;
                                &lt;tr&gt;
                                    &lt;td style="width: 10px;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="width: 3%;"&gt;&#160;&lt;/td&gt;
                                    &lt;td&gt;&#160;&lt;/td&gt;
                                &lt;/tr&gt;
                                &lt;tr&gt;
                                    &lt;td style="width: 10px;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="width: 3%;"&gt;&#160;&lt;/td&gt;
                                    &lt;td&gt;
                                        &lt;p style="font-size: 10pt; font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;"&gt;Prior to any sublicensing agreements, joint ventures or change of control:&lt;/p&gt;
                                    &lt;/td&gt;
                                &lt;/tr&gt;
                            &lt;/table&gt;
                            &lt;table border="0" cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; font-family: Times New Roman, Times, serif;"&gt;
                                &lt;tr&gt;
                                    &lt;td style="width: 3%;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="width: 3%;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="width: 3%;"&gt;&#160;&lt;/td&gt;
                                    &lt;td&gt;&#160;&lt;/td&gt;
                                &lt;/tr&gt;
                                &lt;tr&gt;
                                    &lt;td style="width: 3%;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="width: 3%;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="width: 3%;"&gt;
                                        &lt;p style="font-size: 10pt; font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="font-size: 8pt;"&gt;o&lt;/span&gt;&lt;/p&gt;
                                    &lt;/td&gt;
                                    &lt;td&gt;
                                        &lt;p style="font-size: 10pt; font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;"&gt;$10,000 upon dosing the first patient in a Phase I trial;&lt;/p&gt;
                                    &lt;/td&gt;
                                &lt;/tr&gt;
                                &lt;tr&gt;
                                    &lt;td style="width: 3%;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="width: 3%;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="width: 3%;"&gt;
                                        &lt;p style="font-size: 10pt; font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="font-size: 8pt;"&gt;o&lt;/span&gt;&lt;/p&gt;
                                    &lt;/td&gt;
                                    &lt;td&gt;
                                        &lt;p style="font-size: 10pt; font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;"&gt;$50,000 upon dosing the first patient in the first Phase II trial;&lt;/p&gt;
                                    &lt;/td&gt;
                                &lt;/tr&gt;
                                &lt;tr&gt;
                                    &lt;td style="width: 3%;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="width: 3%;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="width: 3%;"&gt;
                                        &lt;p style="font-size: 10pt; font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="font-size: 8pt;"&gt;o&lt;/span&gt;&lt;/p&gt;
                                    &lt;/td&gt;
                                    &lt;td&gt;
                                        &lt;p style="font-size: 10pt; font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;"&gt;$250,000 upon dosing the first patient in a Phase III trial in the first clinical indication; and&lt;/p&gt;
                                    &lt;/td&gt;
                                &lt;/tr&gt;
                                &lt;tr&gt;
                                    &lt;td style="width: 3%;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="width: 3%;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="width: 3%;"&gt;
                                        &lt;p style="font-size: 10pt; font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="font-size: 8pt;"&gt;o&lt;/span&gt;&lt;/p&gt;
                                    &lt;/td&gt;
                                    &lt;td&gt;
                                        &lt;p style="font-size: 10pt; font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;"&gt;$2 million upon the first commercial sale of each clinical indication.&lt;/p&gt;
                                    &lt;/td&gt;
                                &lt;/tr&gt;
                            &lt;/table&gt;
                            &lt;table style="width: 100%; font-size: 10pt; font-family: Times New Roman, Times, serif; margin-top: 5px;"&gt;
                                &lt;tr&gt;
                                    &lt;td style="width: 10px;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="width: 3%;"&gt;&#160;&lt;/td&gt;
                                    &lt;td&gt;
                                        &lt;p style="font-size: 10pt; font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;"&gt;&#160;After any sublicensing agreements, joint ventures or change of control:&lt;/p&gt;
                                    &lt;/td&gt;
                                &lt;/tr&gt;
                            &lt;/table&gt;
                            &lt;table border="0" cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; font-family: Times New Roman, Times, serif;"&gt;
                                &lt;tr&gt;
                                    &lt;td style="width: 3%;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="width: 3%;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="width: 3%;"&gt;&#160;&lt;/td&gt;
                                    &lt;td&gt;&#160;&lt;/td&gt;
                                &lt;/tr&gt;
                                &lt;tr&gt;
                                    &lt;td style="width: 3%;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="width: 3%;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="width: 3%;"&gt;
                                        &lt;p style="font-size: 10pt; font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="font-size: 8pt;"&gt;o&lt;/span&gt;&lt;/p&gt;
                                    &lt;/td&gt;
                                    &lt;td&gt;
                                        &lt;p style="font-size: 10pt; font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;"&gt;As above;&lt;/p&gt;
                                    &lt;/td&gt;
                                &lt;/tr&gt;
                                &lt;tr&gt;
                                    &lt;td style="width: 3%;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="width: 3%;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="width: 3%;"&gt;
                                        &lt;p style="font-size: 10pt; font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="font-size: 8pt;"&gt;o&lt;/span&gt;&lt;/p&gt;
                                    &lt;/td&gt;
                                    &lt;td&gt;
                                        &lt;p style="font-size: 10pt; font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;"&gt;$250,000 upon dosing the first patient in each Phase II trial;&lt;/p&gt;
                                    &lt;/td&gt;
                                &lt;/tr&gt;
                                &lt;tr&gt;
                                    &lt;td style="width: 3%;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="width: 3%;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="width: 3%;"&gt;
                                        &lt;p style="font-size: 10pt; font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="font-size: 8pt;"&gt;o&lt;/span&gt;&lt;/p&gt;
                                    &lt;/td&gt;
                                    &lt;td&gt;
                                        &lt;p style="font-size: 10pt; font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;"&gt;$500,000 upon dosing the first patient in each Phase III trial; and&lt;/p&gt;
                                    &lt;/td&gt;
                                &lt;/tr&gt;
                                &lt;tr&gt;
                                    &lt;td style="width: 3%;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="width: 3%;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="width: 3%;"&gt;
                                        &lt;p style="font-size: 10pt; font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="font-size: 8pt;"&gt;o&lt;/span&gt;&lt;/p&gt;
                                    &lt;/td&gt;
                                    &lt;td&gt;
                                        &lt;p style="font-size: 10pt; font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;"&gt;$2 million upon the first commercial sale of each clinical indication.&lt;/p&gt;
                                    &lt;/td&gt;
                                &lt;/tr&gt;
                            &lt;/table&gt;
                            &lt;p style="text-align: justify;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;Unless otherwise agreed to in writing by the University, the Company will reimburse the University for all documented costs and expenses in connection with the Patent Rights, including the preparation, filing, prosecution, maintenance and defense thereof. From time to time, the anticipated costs and expenses may be significant and, upon request, the Company will pay the estimated costs and expenses in advance of such costs and expenses being incurred by the University.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                        &lt;/div&gt;

                        &lt;div&gt;
                            &lt;p style="text-align: justify;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;The term of the LA ends on the later of the last to expire of the Patent Rights, expiration of regulatory exclusivity for Product or when the Company provides notice that use of Technical Information has ceased. The University has the right to terminate the LA if the Company fails to make any required payments or is in breach of any provision of the LA.&#160; The Company may terminate the LA at any time upon providing at least 90 days written notice to the University.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                            &lt;p style="margin-bottom: 0pt; text-align: justify;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="text-decoration: underline;"&gt;Related party contracts&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                            &lt;p style="margin-top: 0pt; text-align: justify;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;On June 5, 2020, the Company entered into an independent consultant agreement (the "ICA") whereby the consultant, a private corporation incorporated in the State of California, USA, was engaged and the consultant's representative will serve as the Company's Chief Medical Officer, with the services being provided in California. As compensation for performing these services, the consultant or the consultant's representative will participate in the Company's equity incentive plans and will be eligible for cash payments in respect of fees at such time as the Company begins to compensate other C-level personnel in cash and in similar proportion to total compensation (the "fees"). The non-cash portion of the consultant's fees for the first year of the term was in the form of a grant of 150,000 vested stock options and 150,000 RSUs (see Note 6). The services will continue for an initial term of one year unless sooner terminated. The ICA can be terminated by either party giving the other 30 days written notice or by mutual written agreement. At the end of the initial term, the ICA will automatically be extended for additional one-year period(s) unless either party gives the other 30 days written notice. In March 2021, the Board of Directors authorized a monthly fee of US$15,000 and was further amended to US$25,000 in August 2021.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                            &lt;p style="text-align: justify;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;On October 29, 2020, the Company entered into an independent contractor agreement (the "ICA") whereby the contractor was engaged to serve as the Company's Chief Science Officer on an as-needed basis. The contractor will be compensated for these services as determined by the Board of Directors of the Company. The services will continue for an initial term of one year unless sooner terminated. The ICA can be terminated by the Company providing five working days written notice, the contractor providing three months' written notice or by mutual written agreement. At the end of the initial term, the ICA will automatically be extended for additional one-year period(s) unless the Company provides the contractor with 30 days written notice. In March 2021, the Board of Directors authorized a monthly fee of US$15,000 and was further amended to US$25,000 in August 2021.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                            &lt;p style="margin-bottom: 0pt; text-align: justify;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="text-decoration: underline;"&gt;Scientific advisory board agreements&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                            &lt;p style="margin-top: 0pt; text-align: justify;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;On June 1, 2020, July 14, 2020 and April 12, 2021, the Company entered into scientific advisory board agreements (the "SABAs") whereby the advisors were retained to serve as members of the Company's scientific advisory board and as consultants to the Company and senior management in the areas of scientific, technical and business advice. As compensation for performing these services, the Company will pay the advisors hourly rates of $150 and $160 per hour. The Company also granted 130,000 share purchase options to the advisors as part of the Company's November 17, 2020 and April 28, 2021 grant of options of which 20,000 options were cancelled on January 21, 2021 (see Note 6). The advisors have the same hour requirements and restrictions as noted below. The services will continue for initial terms of one year unless sooner terminated. At the end of the initial terms, the SABAs will automatically be extended for an additional one-year period(s) unless either party gives the other 30 days written notice.&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                            &lt;p style="margin-bottom: 0pt; text-align: justify;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="text-decoration: underline;"&gt;Consulting agreements&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                            &lt;p style="margin-top: 0pt; text-align: justify;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;The Company has entered into numerous consulting agreements (the "CAs") whereby the consultants were retained to serve as advisors to the Company and senior management in the areas of public relations and content creation and scientific, technical and business advice. As compensation for performing these services, the Company will pay the advisors hourly rates between US$30 to US$600. The Company also granted 302,000 share purchase options to six advisors as part of the Company's November 17, 2020 and April 28, 2021 grant of options (see Note 6). The advisors being paid $400 and $600 per hour will reserve at least six full days of services to the Company and such additional days as requested by the Company each annual period, but not to exceed 36 full days of service per year unless otherwise agreed and up to a maximum of 288 hours total per year, unless otherwise agreed. The services will continue for initial terms of one year unless sooner terminated. At the end of the initial terms, the CAs will automatically be extended for an additional one-year period(s) unless either party gives the other 30 days written notice.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                            &lt;p style="text-align: justify;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;On October 9, 2020, the Company entered into a consulting agreement whereby the consultant was retained to serve as an advisor to the Company in the areas of scientific, technical and business advice. As compensation for performing these services, the Company will pay the advisor an hourly rate of US$130. The Company granted 90,000 stock options to the consultant on November 17, 2020 (see Note 6).&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                        &lt;/div&gt;

                        &lt;div&gt;
                            &lt;p style="text-align: justify;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;On November 6, 2020, the Company entered into a sponsored research agreement (the "SRA") with the University of Texas Medical Branch (the "UTMB") whereby the UTMB conducted a research program on behalf of the Company. Pursuant to the SRA, the agreement is effective as of October 15, 2020 and the research program was carried out through to its conclusion on February 15, 2021. As consideration for UTMB's performance, the Company paid US$66,764 which was recorded in research and development costs.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                            &lt;p style="text-align: justify; margin-bottom: 0px;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;On November 17, 2020, the Company entered into an ICA whereby the contractor was engaged to serve as the Company's Vice President (Discovery). The contractor will be compensated for these services as determined by the Board of Directors of the Company. The services will continue for an initial term of one year unless sooner terminated. The ICA can be terminated by the Company providing five working days written notice, the contractor providing three months' written notice or by mutual written agreement. At the end of the initial term, the ICA will automatically be extended for additional one-year period(s) unless the Company provides the contractor with 30 days written notice. In March 2021, the Board of Directors authorized a monthly fee of US$15,000.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                        &lt;/div&gt;
                    </ifrs-full:DisclosureOfCommitmentsExplanatory>
    <drug:NonRefundableOptionFeesPaid
      contextRef="C_20200501to20200526_drugAgreementAxis_drugOptionAgreementMember"
      decimals="0"
      id="Fxbrl_20211228213108475"
      unitRef="USD">15000</drug:NonRefundableOptionFeesPaid>
    <drug:NonRefundableOptionFeesPaid
      contextRef="C_20200501to20200526_drugAgreementAxis_drugOptionAgreementMember"
      decimals="0"
      id="Fxbrl_20211228213120424"
      unitRef="CAD">20313</drug:NonRefundableOptionFeesPaid>
    <drug:SigningFee
      contextRef="C_20210401to20210423_drugAgreementAxis_drugLicenseAgreementMember"
      decimals="0"
      id="Fxbrl_20211228213348198"
      unitRef="USD">100000</drug:SigningFee>
    <drug:OptionFeesPaid
      contextRef="C_20210401to20210423_drugAgreementAxis_drugLicenseAgreementMember"
      decimals="0"
      id="Fxbrl_20211228213606762"
      unitRef="USD">15000</drug:OptionFeesPaid>
    <drug:SigningFeeNetOfOptionFeesPaid
      contextRef="C_20210401to20210423_drugAgreementAxis_drugLicenseAgreementMember"
      decimals="0"
      id="Fxbrl_20211228213625115"
      unitRef="CAD">105502</drug:SigningFeeNetOfOptionFeesPaid>
    <drug:SigningFeeSharesIssued
      contextRef="C_20210401to20210423_drugAgreementAxis_drugLicenseAgreementMember"
      decimals="INF"
      id="Fxbrl_20211228213938887"
      unitRef="Share">63000</drug:SigningFeeSharesIssued>
    <drug:PercentageOfRoyaltiesOnNetSalesUnder1Billion
      contextRef="C_20210401to20210423_drugAgreementAxis_drugLicenseAgreementMember"
      decimals="2"
      id="Fxbrl_20211228214027918"
      unitRef="Percent">0.03</drug:PercentageOfRoyaltiesOnNetSalesUnder1Billion>
    <drug:PercentageOfRoyaltiesOnNetSalesOver2Billion
      contextRef="C_20210401to20210423_drugAgreementAxis_drugLicenseAgreementMember"
      decimals="3"
      id="Fxbrl_20211228221237258"
      unitRef="Percent">0.045</drug:PercentageOfRoyaltiesOnNetSalesOver2Billion>
    <drug:DescriptionOfSublicenseeRevenueOfRoyaltyPaymentAccrues
      contextRef="C_20210401to20210423_drugAgreementAxis_drugLicenseAgreementMember"
      id="Fxbrl_20211228221219591">royalty payments being credited toward the annual minimum for the license year in which the royalty payment accrues and 12% on all non-royalty revenue until the Company has raised $7.5 million and then 10% thereafter</drug:DescriptionOfSublicenseeRevenueOfRoyaltyPaymentAccrues>
    <drug:TotalAnnualMinimumRoyaltiesYear3
      contextRef="C_20210401to20210423_drugAgreementAxis_drugLicenseAgreementMember"
      decimals="0"
      id="Fxbrl_20211229013617200"
      unitRef="CAD">5000</drug:TotalAnnualMinimumRoyaltiesYear3>
    <drug:TotalAnnualMinimumRoyaltiesYear4
      contextRef="C_20210401to20210423_drugAgreementAxis_drugLicenseAgreementMember"
      decimals="0"
      id="Fxbrl_20211229013643424"
      unitRef="CAD">15000</drug:TotalAnnualMinimumRoyaltiesYear4>
    <drug:TotalAnnualMinimumRoyaltiesYear5
      contextRef="C_20210401to20210423_drugAgreementAxis_drugLicenseAgreementMember"
      decimals="0"
      id="Fxbrl_20211229013651135"
      unitRef="CAD">35000</drug:TotalAnnualMinimumRoyaltiesYear5>
    <drug:TotalAnnualMinimumRoyaltiesYear6AndThereafter
      contextRef="C_20210401to20210423_drugAgreementAxis_drugLicenseAgreementMember"
      decimals="0"
      id="Fxbrl_20211229013657727"
      unitRef="CAD">50000</drug:TotalAnnualMinimumRoyaltiesYear6AndThereafter>
    <drug:TotalAnnualMinimumRoyaltiesAfterFirstCommercialSale
      contextRef="C_20210401to20210423_drugAgreementAxis_drugLicenseAgreementMember"
      decimals="0"
      id="Fxbrl_20211229013734288"
      unitRef="CAD">250000</drug:TotalAnnualMinimumRoyaltiesAfterFirstCommercialSale>
    <drug:MilestonePaymentsUponDosingFirstPatientInPhaseITrial
      contextRef="C_20210401to20210423_drugAgreementAxis_drugPriorToSublicensingAgreementsMember"
      decimals="0"
      id="Fxbrl_20211229013833832"
      unitRef="CAD">10000</drug:MilestonePaymentsUponDosingFirstPatientInPhaseITrial>
    <drug:MilestonePaymentsUponDosingFirstPatientInFirstPhaseIiTrial
      contextRef="C_20210401to20210423_drugAgreementAxis_drugPriorToSublicensingAgreementsMember"
      decimals="0"
      id="Fxbrl_20211229013857264"
      unitRef="CAD">50000</drug:MilestonePaymentsUponDosingFirstPatientInFirstPhaseIiTrial>
    <drug:MilestonePaymentsUponDosingFirstPatientInFirstPhaseIiiTrial
      contextRef="C_20210401to20210423_drugAgreementAxis_drugPriorToSublicensingAgreementsMember"
      decimals="0"
      id="Fxbrl_20211229013904320"
      unitRef="CAD">250000</drug:MilestonePaymentsUponDosingFirstPatientInFirstPhaseIiiTrial>
    <drug:MilestonePaymentsUponFirstCommercialSaleOfClinical
      contextRef="C_20210401to20210423_drugAgreementAxis_drugPriorToSublicensingAgreementsMember"
      decimals="-6"
      id="Fxbrl_20211229013907766"
      unitRef="CAD">2000000</drug:MilestonePaymentsUponFirstCommercialSaleOfClinical>
    <drug:MilestonePaymentsUponDosingFirstPatientInFirstPhaseIiTrial
      contextRef="C_20210401to20210423_drugAgreementAxis_drugAfterSublicensingAgreementsMember"
      decimals="0"
      id="Fxbrl_20211229014106424"
      unitRef="CAD">250000</drug:MilestonePaymentsUponDosingFirstPatientInFirstPhaseIiTrial>
    <drug:MilestonePaymentsUponDosingFirstPatientInFirstPhaseIiiTrial
      contextRef="C_20210401to20210423_drugAgreementAxis_drugAfterSublicensingAgreementsMember"
      decimals="0"
      id="Fxbrl_20211229014056661"
      unitRef="CAD">500000</drug:MilestonePaymentsUponDosingFirstPatientInFirstPhaseIiiTrial>
    <drug:MilestonePaymentsUponFirstCommercialSaleOfClinical
      contextRef="C_20210401to20210423_drugAgreementAxis_drugAfterSublicensingAgreementsMember"
      decimals="-6"
      id="Fxbrl_20211229014049344"
      unitRef="CAD">2000000</drug:MilestonePaymentsUponFirstCommercialSaleOfClinical>
    <ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement
      contextRef="C_20200601to20200605_drugAgreementAxis_drugIndependentConsultantAgreementMember"
      decimals="0"
      id="Fxbrl_20211229014204254"
      unitRef="Shares">150000</ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted
      contextRef="C_20200601to20200605_drugAgreementAxis_drugIndependentConsultantAgreementMember"
      decimals="0"
      id="Fxbrl_20211229014505682"
      unitRef="Shares">150000</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
    <drug:MonthlyFeeAuthorizedByBoardOfDirectors
      contextRef="C_20210301to20210331_drugAgreementAxis_drugIndependentConsultantAgreementMember"
      decimals="0"
      id="Fxbrl_20211229014932071"
      unitRef="USD">15000</drug:MonthlyFeeAuthorizedByBoardOfDirectors>
    <drug:MonthlyFeeAuthorizedByBoardOfDirectors
      contextRef="C_20210801to20210831_drugAgreementAxis_drugIndependentConsultantAgreementMember"
      decimals="0"
      id="Fxbrl_20211229015041976"
      unitRef="USD">25000</drug:MonthlyFeeAuthorizedByBoardOfDirectors>
    <drug:MonthlyFeeAuthorizedByBoardOfDirectors
      contextRef="C_20210301to20210331_drugAgreementAxis_drugIndependentContractorAgreementToServeAsChiefScienceOfficerMember"
      decimals="0"
      id="Fxbrl_20211229163355300"
      unitRef="USD">15000</drug:MonthlyFeeAuthorizedByBoardOfDirectors>
    <drug:MonthlyFeeAuthorizedByBoardOfDirectors
      contextRef="C_20210801to20210831_drugAgreementAxis_drugIndependentContractorAgreementToServeAsChiefScienceOfficerMember"
      decimals="0"
      id="Fxbrl_20211229163428205"
      unitRef="USD">25000</drug:MonthlyFeeAuthorizedByBoardOfDirectors>
    <drug:AdvisorHourlyRate
      contextRef="C_20200601to20210412_drugAgreementAxis_drugScientificAdvisoryBoardAgreementsMember_ifrsfullRangeAxis_ifrsfullBottomOfRangeMember"
      decimals="0"
      id="Fxbrl_20211229015327669"
      unitRef="USD">150</drug:AdvisorHourlyRate>
    <drug:AdvisorHourlyRate
      contextRef="C_20200601to20210412_drugAgreementAxis_drugScientificAdvisoryBoardAgreementsMember_ifrsfullRangeAxis_ifrsfullTopOfRangeMember"
      decimals="0"
      id="Fxbrl_20211229015544000"
      unitRef="USD">160</drug:AdvisorHourlyRate>
    <ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement
      contextRef="C_20201101to20201117_drugAgreementAxis_drugScientificAdvisoryBoardAgreementsMember"
      decimals="0"
      id="Fxbrl_20211229015347160"
      unitRef="Shares">130000</ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement
      contextRef="C_20210101to20210131_drugAgreementAxis_drugScientificAdvisoryBoardAgreementsMember"
      decimals="0"
      id="Fxbrl_20211229015752960"
      unitRef="Shares">20000</ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement>
    <drug:AdvisorHourlyRate
      contextRef="C_20201001to20210930_drugAgreementAxis_drugConsultingAgreementsMember_ifrsfullRangeAxis_ifrsfullBottomOfRangeMember"
      decimals="0"
      id="Fxbrl_20211229015915101"
      unitRef="USD">30</drug:AdvisorHourlyRate>
    <drug:AdvisorHourlyRate
      contextRef="C_20201001to20210930_drugAgreementAxis_drugConsultingAgreementsMember_ifrsfullRangeAxis_ifrsfullTopOfRangeMember"
      decimals="0"
      id="Fxbrl_20211229015922917"
      unitRef="USD">600</drug:AdvisorHourlyRate>
    <ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement
      contextRef="C_20201118to20210428_drugAgreementAxis_drugConsultingAgreementsMember"
      decimals="0"
      id="Fxbrl_20211229015907037"
      unitRef="Shares">302000</ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement>
    <drug:AdvisorHourlyRate
      contextRef="C_20201001to20201009_drugAgreementAxis_drugConsultingAgreementsMember"
      decimals="0"
      id="Fxbrl_20211229020336758"
      unitRef="USD">130</drug:AdvisorHourlyRate>
    <ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement
      contextRef="C_20201001to20201009_drugAgreementAxis_drugConsultingAgreementsMember"
      decimals="0"
      id="Fxbrl_20211229020428020"
      unitRef="Shares">90000</ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement>
    <ifrs-full:ResearchAndDevelopmentExpense
      contextRef="C_20201101to20201106_drugAgreementAxis_drugConsultingAgreementsMember"
      decimals="0"
      id="Fxbrl_20211229020511763"
      unitRef="USD">66764</ifrs-full:ResearchAndDevelopmentExpense>
    <drug:MonthlyFeeAuthorizedByBoardOfDirectors
      contextRef="C_20201101to20201117_drugAgreementAxis_drugConsultingAgreementsMember"
      decimals="0"
      id="Fxbrl_20211229020602092"
      unitRef="USD">15000</drug:MonthlyFeeAuthorizedByBoardOfDirectors>
    <ifrs-full:DisclosureOfFinancialInstrumentsExplanatory
      contextRef="C_20201001to20210930"
      id="Fxbrl_20211228154218915">
                        &lt;div&gt;
                            &lt;p style="text-align: justify; margin-top: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;9.&lt;span style="display: inline-block; width: 9pt;"&gt;&#160;&lt;/span&gt;FINANCIAL INSTRUMENTS AND CAPITAL MANAGEMENT&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                            &lt;p style="text-align: justify;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;The following table summarizes the carrying value of financial assets and liabilities:&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

                                &lt;div&gt;
                                    &lt;div style="margin-left: 5.4pt;"&gt;
                                        &lt;table cellpadding="0" cellspacing="0" style="width: 100%; border-collapse: collapse; font-size: 10pt; border-color: #000000;"&gt;
                                            &lt;tr&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1.5pt solid #000000; border-bottom: 0.75pt solid #000000; vertical-align: bottom;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-top: 1.5pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-top: 1.5pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;September 30, &lt;/b&gt;&lt;br/&gt;&lt;b&gt;2021&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-top: 1.5pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-top: 1.5pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-top: 1.5pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;September 30, &lt;/b&gt;&lt;br/&gt;&lt;b&gt;2020&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-top: 1.5pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right;"&gt;&#160;&lt;/td&gt;
                                            &lt;/tr&gt;
                                            &lt;tr&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;FVTPL&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right;"&gt;&#160;&lt;/td&gt;
                                            &lt;/tr&gt;
                                            &lt;tr&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&#160; Cash&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;19,673,765&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;799,929&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;/tr&gt;
                                            &lt;tr&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&#160; Guaranteed investment certificate&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;86,250&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                            &lt;/tr&gt;
                                            &lt;tr&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&#160; Cash and cash equivalents&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;19,760,015&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;799,929&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;/tr&gt;
                                            &lt;tr&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;Amortized cost&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                            &lt;/tr&gt;
                                            &lt;tr&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 2.25pt double #000000; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&#160; Accounts payable and accrued liabilities&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;638,573&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;150,923&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;/tr&gt;
                                        &lt;/table&gt;
                                    &lt;/div&gt;
                                &lt;/div&gt;

                            &lt;p style="margin-bottom: 0pt; text-align: justify; margin-top: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;Fair value measurement&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                            &lt;p style="margin-top: 0pt; text-align: justify;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;Financial assets and liabilities that are recognized on the statement of financial position at fair value can be classified in a hierarchy that is based on the significance of the inputs used in making the measurements.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                            &lt;p style="margin-bottom: 0pt; text-align: justify;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="text-decoration: underline;"&gt;The levels in the hierarchy are:&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                            &lt;p style="margin-top: 0pt; margin-bottom: 0pt; text-align: justify;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;Level 1 - quoted prices (unadjusted) in active markets for identical assets or liabilities;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                            &lt;p style="margin-top: 0pt; margin-left: 39.6pt; margin-bottom: 0pt; text-indent: -39.6pt; text-align: justify;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;Level 2 - inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly (that is, as prices) or indirectly (that is, derived from prices); and&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                            &lt;p style="margin-top: 0pt; text-align: justify;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;Level 3 - inputs for the asset or liability that are not based on observable market data (that is, unobservable inputs).&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                            &lt;p style="text-align: justify;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;The Company's cash and cash equivalents is classified as Level 1, whereas accounts payable and accrued liabilities are classified as Level 2. As at September 30, 2021, the Company believes that the carrying values of cash and cash equivalents and accounts payable and accrued liabilities approximate their fair values because of their nature and relatively short maturity dates or durations.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                            &lt;p style="margin-bottom: 0pt; text-align: justify;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;Financial risk management&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                            &lt;p style="margin-top: 0pt; text-align: justify;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;The Company is exposed in varying degrees to a variety of financial instrument related risks. The Board of Directors approves and monitors the risk management processes. The type of risk exposure and the way in which such exposure is managed is provided as follows:&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                            &lt;p style="margin-bottom: 0pt; text-align: justify;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="text-decoration: underline;"&gt;Credit risk &lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                            &lt;p style="margin-top: 0pt; text-align: justify;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;Credit risk is the risk that one party to a financial instrument will fail to discharge an obligation and cause the other party to incur a financial loss. The Company's primary exposure to credit risk is on its cash and cash equivalents balance. As at September 30, 2021, the Company had cash and cash equivalents of $19,760,015 which was held with a major bank in Canada and a major bank in the United States. Because deposits are with two banks, there is a concentration of credit risk. This risk is managed by using major banks that are high credit quality financial institutions as determined by rating agencies. The maximum exposure to credit risk is the carrying amount of the Company's financial instruments. The credit risk is assessed as low.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                        &lt;/div&gt;

                        &lt;div&gt;
                            &lt;p style="margin-bottom: 0pt; text-align: justify; margin-top: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="text-decoration: underline;"&gt;Foreign exchange risk &lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                            &lt;p style="margin-top: 0pt; text-align: justify;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;Foreign currency risk is the risk that the fair values of future cash flows of a financial instrument will fluctuate because they are denominated in currencies that differ from the respective functional currency. As at September 30, 2021, the Company had the following foreign currency balances - cash (US$2,789,264) and accounts payable and accrued liabilities (US$420,481). A 10% fluctuation in the US$ against the Canadian dollar would have an impact of approximately $301,807 on the net comprehensive loss.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                            &lt;p style="margin-bottom: 0pt; text-align: justify;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="text-decoration: underline;"&gt;Liquidity risk &lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                            &lt;p style="margin-top: 0pt; text-align: justify;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;Liquidity risk arises through the excess of financial obligations over available financial assets due at any point in time. The Company's objective in managing liquidity risk is to maintain sufficient readily available reserves in order to meet its liquidity requirements at any point in time. The Company's main source of funding has been the issuance of equity securities for cash, primarily through private placements. The Company's access to financing is always uncertain. There can be no assurance of continued access to significant equity funding. As at September 30, 2021, the Company had cash and cash equivalents of $19,760,015 to cover current liabilities of $638,573.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                            &lt;p style="margin-bottom: 0pt; text-align: justify;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="text-decoration: underline;"&gt;Capital management&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                            &lt;p style="margin-top: 0pt; text-align: justify;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;Management's objective is to manage its capital to ensure that there are adequate capital resources to safeguard the Company's ability to continue as a going concern through the optimization of its capital structure. The capital structure consists of share capital and working capital. In order to achieve this objective, management makes adjustments to it in light of changes in economic conditions and risk characteristics of the underlying assets. To maintain or adjust the capital structure, management may invest its excess cash in interest bearing accounts of Canadian chartered banks and/or raise additional funds externally as needed. The Company is not subject to externally imposed capital requirements. The Company's management of capital did not change during the year ended September 30, 2021.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                        &lt;/div&gt;
                    </ifrs-full:DisclosureOfFinancialInstrumentsExplanatory>
    <ifrs-full:DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory
      contextRef="C_20201001to20210930"
      id="Fxbrl_20211228162450382">
                                &lt;div&gt;
                                    &lt;div style="margin-left: 5.4pt;"&gt;
                                        &lt;table cellpadding="0" cellspacing="0" style="width: 100%; border-collapse: collapse; font-size: 10pt; border-color: #000000;"&gt;
                                            &lt;tr&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1.5pt solid #000000; border-bottom: 0.75pt solid #000000; vertical-align: bottom;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-top: 1.5pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-top: 1.5pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;September 30, &lt;/b&gt;&lt;br/&gt;&lt;b&gt;2021&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-top: 1.5pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-top: 1.5pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-top: 1.5pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;September 30, &lt;/b&gt;&lt;br/&gt;&lt;b&gt;2020&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-top: 1.5pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right;"&gt;&#160;&lt;/td&gt;
                                            &lt;/tr&gt;
                                            &lt;tr&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;FVTPL&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right;"&gt;&#160;&lt;/td&gt;
                                            &lt;/tr&gt;
                                            &lt;tr&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&#160; Cash&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;19,673,765&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;799,929&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;/tr&gt;
                                            &lt;tr&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&#160; Guaranteed investment certificate&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;86,250&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                            &lt;/tr&gt;
                                            &lt;tr&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&#160; Cash and cash equivalents&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;19,760,015&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;799,929&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;/tr&gt;
                                            &lt;tr&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;Amortized cost&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                            &lt;/tr&gt;
                                            &lt;tr&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 2.25pt double #000000; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&#160; Accounts payable and accrued liabilities&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;638,573&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;150,923&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;/tr&gt;
                                        &lt;/table&gt;
                                    &lt;/div&gt;
                                &lt;/div&gt;
                            </ifrs-full:DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory>
    <ifrs-full:Cash
      contextRef="C_20210930_ifrsfullClassesOfFinancialInstrumentsAxis_drugFinancialInstrumentsAtFairValueThroughProfitOrLossMember"
      decimals="0"
      id="Fxbrl_20211228162620010_22"
      unitRef="CAD">19673765</ifrs-full:Cash>
    <ifrs-full:Cash
      contextRef="C_20200930_ifrsfullClassesOfFinancialInstrumentsAxis_drugFinancialInstrumentsAtFairValueThroughProfitOrLossMember"
      decimals="0"
      id="Fxbrl_20211228162620010_25"
      unitRef="CAD">799929</ifrs-full:Cash>
    <ifrs-full:ShorttermInvestmentsClassifiedAsCashEquivalents
      contextRef="C_20210930_ifrsfullClassesOfFinancialInstrumentsAxis_drugFinancialInstrumentsAtFairValueThroughProfitOrLossMember"
      decimals="0"
      id="Fxbrl_20211228162620010_32"
      unitRef="CAD">86250</ifrs-full:ShorttermInvestmentsClassifiedAsCashEquivalents>
    <ifrs-full:ShorttermInvestmentsClassifiedAsCashEquivalents
      contextRef="C_20200930_ifrsfullClassesOfFinancialInstrumentsAxis_drugFinancialInstrumentsAtFairValueThroughProfitOrLossMember"
      decimals="0"
      id="Fxbrl_20211228162620010_35"
      unitRef="CAD">0</ifrs-full:ShorttermInvestmentsClassifiedAsCashEquivalents>
    <ifrs-full:CashAndCashEquivalents
      contextRef="C_20210930_ifrsfullClassesOfFinancialInstrumentsAxis_drugFinancialInstrumentsAtFairValueThroughProfitOrLossMember"
      decimals="0"
      id="Fxbrl_20211228162620010_42"
      unitRef="CAD">19760015</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents
      contextRef="C_20200930_ifrsfullClassesOfFinancialInstrumentsAxis_drugFinancialInstrumentsAtFairValueThroughProfitOrLossMember"
      decimals="0"
      id="Fxbrl_20211228162620010_45"
      unitRef="CAD">799929</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:TradeAndOtherCurrentPayables
      contextRef="C_20210930_ifrsfullClassesOfFinancialInstrumentsAxis_drugFinancialInstrumentsAtAmortizedCostMember"
      decimals="0"
      id="Fxbrl_20211228162620010_62"
      unitRef="CAD">638573</ifrs-full:TradeAndOtherCurrentPayables>
    <ifrs-full:TradeAndOtherCurrentPayables
      contextRef="C_20200930_ifrsfullClassesOfFinancialInstrumentsAxis_drugFinancialInstrumentsAtAmortizedCostMember"
      decimals="0"
      id="Fxbrl_20211228162620010_65"
      unitRef="CAD">150923</ifrs-full:TradeAndOtherCurrentPayables>
    <ifrs-full:CashAndCashEquivalents
      contextRef="C_20210930_ifrsfullTypesOfRisksAxis_ifrsfullCreditRiskMember"
      decimals="0"
      id="Fxbrl_20211228163150482"
      unitRef="CAD">19760015</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:Cash
      contextRef="C_20210930_ifrsfullTypesOfRisksAxis_ifrsfullCurrencyRiskMember"
      decimals="0"
      id="Fxbrl_20211228163206276"
      unitRef="USD">2789264</ifrs-full:Cash>
    <ifrs-full:TradeAndOtherCurrentPayables
      contextRef="C_20210930_ifrsfullTypesOfRisksAxis_ifrsfullCurrencyRiskMember"
      decimals="0"
      id="Fxbrl_20211228163214525"
      unitRef="USD">420481</ifrs-full:TradeAndOtherCurrentPayables>
    <drug:PercentageOfForeignCurrencyFluctuationInUsDollarAgainstCanadianDollar
      contextRef="C_20210930_ifrsfullTypesOfRisksAxis_ifrsfullCurrencyRiskMember"
      decimals="2"
      id="Fxbrl_20211228163343560"
      unitRef="Percent">0.10</drug:PercentageOfForeignCurrencyFluctuationInUsDollarAgainstCanadianDollar>
    <ifrs-full:ValueAtRisk
      contextRef="C_20210930_ifrsfullTypesOfRisksAxis_ifrsfullCurrencyRiskMember"
      decimals="0"
      id="Fxbrl_20211228163347871"
      unitRef="CAD">301807</ifrs-full:ValueAtRisk>
    <ifrs-full:CashAndCashEquivalents
      contextRef="C_20210930_ifrsfullTypesOfRisksAxis_ifrsfullLiquidityRiskMember"
      decimals="0"
      id="Fxbrl_20211228163654068"
      unitRef="CAD">19760015</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:TradeAndOtherCurrentPayables
      contextRef="C_20210930_ifrsfullTypesOfRisksAxis_ifrsfullLiquidityRiskMember"
      decimals="0"
      id="Fxbrl_20211228163732773"
      unitRef="CAD">638573</ifrs-full:TradeAndOtherCurrentPayables>
    <ifrs-full:DisclosureOfResearchAndDevelopmentExpenseExplanatory
      contextRef="C_20201001to20210930"
      id="Fxbrl_20211228165204922">
                    &lt;div&gt;
                        &lt;p style="text-align: justify; margin-top: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;10.&lt;span style="display: inline-block; width: 9pt;"&gt;&#160;&lt;/span&gt;RESEARCH AND DEVELOPMENT&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                        &lt;p style="text-align: justify;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;Research and development expense recognized in the consolidated statements of comprehensive loss is comprised of the following:&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

                            &lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-size: 10pt; width: 100%;"&gt;
                                &lt;tr&gt;
                                    &lt;td style="width: 36%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top; border-top: 1.5pt solid #000000;"&gt;
                                        &lt;p style="text-align: justify; margin-top: 0pt; margin-bottom: 0pt;"&gt;&#160;&lt;/p&gt;
                                    &lt;/td&gt;
                                    &lt;td style="width: 20%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-top: 1.5pt solid #000000; white-space: nowrap;"&gt;
                                        &lt;p style="text-align: right; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;Year ended&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;/td&gt;
                                    &lt;td style="width: 17%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-top: 1.5pt solid #000000; white-space: nowrap;"&gt;
                                        &lt;p style="text-align: right; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;Year ended&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;/td&gt;
                                    &lt;td style="width: 16%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top; border-top: 1.5pt solid #000000; white-space: nowrap;"&gt;
                                        &lt;p style="text-align: right; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;Period ended&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;/td&gt;
                                &lt;/tr&gt;
                                &lt;tr&gt;
                                    &lt;td style="width: 36%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top;"&gt;
                                        &lt;p style="text-align: justify; margin-top: 0pt; margin-bottom: 0pt;"&gt;&#160;&lt;/p&gt;
                                    &lt;/td&gt;
                                    &lt;td style="width: 20%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; white-space: nowrap;"&gt;
                                        &lt;p style="margin-bottom: 0pt; text-align: right; margin-top: 0pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;September 30, &lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                        &lt;p style="margin-top: 0pt; text-align: right; margin-bottom: 0pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;2021&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;/td&gt;
                                    &lt;td style="width: 17%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; white-space: nowrap;"&gt;
                                        &lt;p style="margin-bottom: 0pt; text-align: right; margin-top: 0pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;September 30, &lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                        &lt;p style="margin-top: 0pt; text-align: right; margin-bottom: 0pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;2020&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;/td&gt;
                                    &lt;td style="width: 16%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top; white-space: nowrap;"&gt;
                                        &lt;p style="text-align: right; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;September 30,&lt;br/&gt;2019&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;/td&gt;
                                &lt;/tr&gt;
                                &lt;tr&gt;
                                    &lt;td style="width: 36%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top; border-top: 0.75pt solid #000000;"&gt;
                                        &lt;p style="text-align: justify; margin-top: 0pt; margin-bottom: 0pt;"&gt;&#160;&lt;/p&gt;
                                    &lt;/td&gt;
                                    &lt;td style="width: 20%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-top: 0.75pt solid #000000;"&gt;
                                        &lt;p style="text-align: right; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;/td&gt;
                                    &lt;td style="width: 17%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-top: 0.75pt solid #000000;"&gt;
                                        &lt;p style="text-align: right; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;/td&gt;
                                    &lt;td style="width: 16%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top; border-top: 0.75pt solid #000000;"&gt;
                                        &lt;p style="text-align: right; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;/td&gt;
                                &lt;/tr&gt;
                                &lt;tr&gt;
                                    &lt;td style="width: 36%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top; background-color: #e6efff;"&gt;
                                        &lt;p style="text-align: justify; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;Laboratory costs (see Note 11)&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;/td&gt;
                                    &lt;td style="width: 20%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top; background-color: #e6efff;"&gt;
                                        &lt;p style="text-align: right; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;82,871&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;/td&gt;
                                    &lt;td style="width: 17%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top; background-color: #e6efff;"&gt;
                                        &lt;p style="text-align: right; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;25,874&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;/td&gt;
                                    &lt;td style="width: 16%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top; background-color: #e6efff;"&gt;
                                        &lt;p style="text-align: right; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;27,164&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;/td&gt;
                                &lt;/tr&gt;
                                &lt;tr&gt;
                                    &lt;td style="width: 36%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top;"&gt;
                                        &lt;p style="text-align: justify; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;Novel drug development&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;/td&gt;
                                    &lt;td style="width: 20%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top;"&gt;
                                        &lt;p style="text-align: right; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;3,638,910&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;/td&gt;
                                    &lt;td style="width: 17%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top;"&gt;
                                        &lt;p style="text-align: right; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;110,029&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;/td&gt;
                                    &lt;td style="width: 16%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top;"&gt;
                                        &lt;p style="text-align: right; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;/td&gt;
                                &lt;/tr&gt;
                                &lt;tr&gt;
                                    &lt;td style="width: 36%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top; background-color: #e6efff;"&gt;
                                        &lt;p style="text-align: justify; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;Patents and related payments&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;/td&gt;
                                    &lt;td style="width: 20%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top; background-color: #e6efff;"&gt;
                                        &lt;p style="text-align: right; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;513,302&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;/td&gt;
                                    &lt;td style="width: 17%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top; background-color: #e6efff;"&gt;
                                        &lt;p style="text-align: right; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;13,895&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;/td&gt;
                                    &lt;td style="width: 16%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top; background-color: #e6efff;"&gt;
                                        &lt;p style="text-align: right; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;/td&gt;
                                &lt;/tr&gt;
                                &lt;tr&gt;
                                    &lt;td style="width: 36%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top;"&gt;
                                        &lt;p style="text-align: justify; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;Salary and subcontractors&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;/td&gt;
                                    &lt;td style="width: 20%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top;"&gt;
                                        &lt;p style="text-align: right; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;1,369,769&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;/td&gt;
                                    &lt;td style="width: 17%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top;"&gt;
                                        &lt;p style="text-align: right; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;43,754&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;/td&gt;
                                    &lt;td style="width: 16%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top;"&gt;
                                        &lt;p style="text-align: right; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;14,845&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;/td&gt;
                                &lt;/tr&gt;
                                &lt;tr&gt;
                                    &lt;td style="width: 36%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top; border-bottom: 0.75pt solid #000000; background-color: #e6efff;"&gt;
                                        &lt;p style="text-align: justify; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;Share-based compensation (see Note 6)&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;/td&gt;
                                    &lt;td style="width: 20%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top; border-bottom: 0.75pt solid #000000; background-color: #e6efff;"&gt;
                                        &lt;p style="text-align: right; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;709,136&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;/td&gt;
                                    &lt;td style="width: 17%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top; border-bottom: 0.75pt solid #000000; background-color: #e6efff;"&gt;
                                        &lt;p style="text-align: right; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;161,300&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;/td&gt;
                                    &lt;td style="width: 16%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top; border-bottom: 0.75pt solid #000000; background-color: #e6efff;"&gt;
                                        &lt;p style="text-align: right; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;/td&gt;
                                &lt;/tr&gt;
                                &lt;tr&gt;
                                    &lt;td style="width: 36%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000;"&gt;
                                        &lt;p style="text-align: justify; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;/td&gt;
                                    &lt;td style="width: 20%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000;"&gt;
                                        &lt;p style="text-align: right; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;6,313,988&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;/td&gt;
                                    &lt;td style="width: 17%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000;"&gt;
                                        &lt;p style="text-align: right; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;354,852&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;/td&gt;
                                    &lt;td style="width: 16%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000;"&gt;
                                        &lt;p style="text-align: right; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;42,009&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;/td&gt;
                                &lt;/tr&gt;
                            &lt;/table&gt;

                    &lt;/div&gt;
                </ifrs-full:DisclosureOfResearchAndDevelopmentExpenseExplanatory>
    <drug:DisclosureOfDetailedInformationAboutResearchAndDevelopmentExplanatory
      contextRef="C_20201001to20210930"
      id="Fxbrl_20211228172608751">
                            &lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-size: 10pt; width: 100%;"&gt;
                                &lt;tr&gt;
                                    &lt;td style="width: 36%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top; border-top: 1.5pt solid #000000;"&gt;
                                        &lt;p style="text-align: justify; margin-top: 0pt; margin-bottom: 0pt;"&gt;&#160;&lt;/p&gt;
                                    &lt;/td&gt;
                                    &lt;td style="width: 20%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-top: 1.5pt solid #000000; white-space: nowrap;"&gt;
                                        &lt;p style="text-align: right; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;Year ended&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;/td&gt;
                                    &lt;td style="width: 17%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-top: 1.5pt solid #000000; white-space: nowrap;"&gt;
                                        &lt;p style="text-align: right; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;Year ended&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;/td&gt;
                                    &lt;td style="width: 16%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top; border-top: 1.5pt solid #000000; white-space: nowrap;"&gt;
                                        &lt;p style="text-align: right; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;Period ended&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;/td&gt;
                                &lt;/tr&gt;
                                &lt;tr&gt;
                                    &lt;td style="width: 36%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top;"&gt;
                                        &lt;p style="text-align: justify; margin-top: 0pt; margin-bottom: 0pt;"&gt;&#160;&lt;/p&gt;
                                    &lt;/td&gt;
                                    &lt;td style="width: 20%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; white-space: nowrap;"&gt;
                                        &lt;p style="margin-bottom: 0pt; text-align: right; margin-top: 0pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;September 30, &lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                        &lt;p style="margin-top: 0pt; text-align: right; margin-bottom: 0pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;2021&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;/td&gt;
                                    &lt;td style="width: 17%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; white-space: nowrap;"&gt;
                                        &lt;p style="margin-bottom: 0pt; text-align: right; margin-top: 0pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;September 30, &lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                        &lt;p style="margin-top: 0pt; text-align: right; margin-bottom: 0pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;2020&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;/td&gt;
                                    &lt;td style="width: 16%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top; white-space: nowrap;"&gt;
                                        &lt;p style="text-align: right; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;September 30,&lt;br/&gt;2019&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;/td&gt;
                                &lt;/tr&gt;
                                &lt;tr&gt;
                                    &lt;td style="width: 36%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top; border-top: 0.75pt solid #000000;"&gt;
                                        &lt;p style="text-align: justify; margin-top: 0pt; margin-bottom: 0pt;"&gt;&#160;&lt;/p&gt;
                                    &lt;/td&gt;
                                    &lt;td style="width: 20%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-top: 0.75pt solid #000000;"&gt;
                                        &lt;p style="text-align: right; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;/td&gt;
                                    &lt;td style="width: 17%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-top: 0.75pt solid #000000;"&gt;
                                        &lt;p style="text-align: right; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;/td&gt;
                                    &lt;td style="width: 16%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top; border-top: 0.75pt solid #000000;"&gt;
                                        &lt;p style="text-align: right; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;/td&gt;
                                &lt;/tr&gt;
                                &lt;tr&gt;
                                    &lt;td style="width: 36%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top; background-color: #e6efff;"&gt;
                                        &lt;p style="text-align: justify; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;Laboratory costs (see Note 11)&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;/td&gt;
                                    &lt;td style="width: 20%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top; background-color: #e6efff;"&gt;
                                        &lt;p style="text-align: right; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;82,871&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;/td&gt;
                                    &lt;td style="width: 17%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top; background-color: #e6efff;"&gt;
                                        &lt;p style="text-align: right; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;25,874&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;/td&gt;
                                    &lt;td style="width: 16%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top; background-color: #e6efff;"&gt;
                                        &lt;p style="text-align: right; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;27,164&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;/td&gt;
                                &lt;/tr&gt;
                                &lt;tr&gt;
                                    &lt;td style="width: 36%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top;"&gt;
                                        &lt;p style="text-align: justify; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;Novel drug development&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;/td&gt;
                                    &lt;td style="width: 20%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top;"&gt;
                                        &lt;p style="text-align: right; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;3,638,910&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;/td&gt;
                                    &lt;td style="width: 17%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top;"&gt;
                                        &lt;p style="text-align: right; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;110,029&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;/td&gt;
                                    &lt;td style="width: 16%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top;"&gt;
                                        &lt;p style="text-align: right; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;/td&gt;
                                &lt;/tr&gt;
                                &lt;tr&gt;
                                    &lt;td style="width: 36%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top; background-color: #e6efff;"&gt;
                                        &lt;p style="text-align: justify; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;Patents and related payments&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;/td&gt;
                                    &lt;td style="width: 20%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top; background-color: #e6efff;"&gt;
                                        &lt;p style="text-align: right; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;513,302&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;/td&gt;
                                    &lt;td style="width: 17%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top; background-color: #e6efff;"&gt;
                                        &lt;p style="text-align: right; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;13,895&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;/td&gt;
                                    &lt;td style="width: 16%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top; background-color: #e6efff;"&gt;
                                        &lt;p style="text-align: right; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;/td&gt;
                                &lt;/tr&gt;
                                &lt;tr&gt;
                                    &lt;td style="width: 36%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top;"&gt;
                                        &lt;p style="text-align: justify; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;Salary and subcontractors&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;/td&gt;
                                    &lt;td style="width: 20%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top;"&gt;
                                        &lt;p style="text-align: right; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;1,369,769&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;/td&gt;
                                    &lt;td style="width: 17%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top;"&gt;
                                        &lt;p style="text-align: right; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;43,754&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;/td&gt;
                                    &lt;td style="width: 16%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top;"&gt;
                                        &lt;p style="text-align: right; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;14,845&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;/td&gt;
                                &lt;/tr&gt;
                                &lt;tr&gt;
                                    &lt;td style="width: 36%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top; border-bottom: 0.75pt solid #000000; background-color: #e6efff;"&gt;
                                        &lt;p style="text-align: justify; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;Share-based compensation (see Note 6)&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;/td&gt;
                                    &lt;td style="width: 20%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top; border-bottom: 0.75pt solid #000000; background-color: #e6efff;"&gt;
                                        &lt;p style="text-align: right; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;709,136&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;/td&gt;
                                    &lt;td style="width: 17%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top; border-bottom: 0.75pt solid #000000; background-color: #e6efff;"&gt;
                                        &lt;p style="text-align: right; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;161,300&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;/td&gt;
                                    &lt;td style="width: 16%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top; border-bottom: 0.75pt solid #000000; background-color: #e6efff;"&gt;
                                        &lt;p style="text-align: right; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;/td&gt;
                                &lt;/tr&gt;
                                &lt;tr&gt;
                                    &lt;td style="width: 36%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000;"&gt;
                                        &lt;p style="text-align: justify; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;/td&gt;
                                    &lt;td style="width: 20%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000;"&gt;
                                        &lt;p style="text-align: right; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;6,313,988&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;/td&gt;
                                    &lt;td style="width: 17%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000;"&gt;
                                        &lt;p style="text-align: right; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;354,852&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;/td&gt;
                                    &lt;td style="width: 16%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000;"&gt;
                                        &lt;p style="text-align: right; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;42,009&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;/td&gt;
                                &lt;/tr&gt;
                            &lt;/table&gt;
                        </drug:DisclosureOfDetailedInformationAboutResearchAndDevelopmentExplanatory>
    <ifrs-full:ResearchAndDevelopmentExpense
      contextRef="C_20201001to20210930_drugCategoriesOfResearchAndDevelopmentExpensesAxis_drugLaboratoryCostsMember"
      decimals="0"
      id="Fxbrl_20211228165647777"
      unitRef="CAD">82871</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense
      contextRef="C_20191001to20200930_drugCategoriesOfResearchAndDevelopmentExpensesAxis_drugLaboratoryCostsMember"
      decimals="0"
      id="Fxbrl_20211228165636946_32"
      unitRef="CAD">25874</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense
      contextRef="C_20190601to20190930_drugCategoriesOfResearchAndDevelopmentExpensesAxis_drugLaboratoryCostsMember"
      decimals="0"
      id="Fxbrl_20211228165636946_33"
      unitRef="CAD">27164</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense
      contextRef="C_20201001to20210930_drugCategoriesOfResearchAndDevelopmentExpensesAxis_drugNovelDrugDevelopmentMember"
      decimals="0"
      id="Fxbrl_20211228165650860"
      unitRef="CAD">3638910</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense
      contextRef="C_20191001to20200930_drugCategoriesOfResearchAndDevelopmentExpensesAxis_drugNovelDrugDevelopmentMember"
      decimals="0"
      id="Fxbrl_20211228165636946_42"
      unitRef="CAD">110029</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense
      contextRef="C_20190601to20190930_drugCategoriesOfResearchAndDevelopmentExpensesAxis_drugNovelDrugDevelopmentMember"
      decimals="0"
      id="Fxbrl_20211228165636946_43"
      unitRef="CAD">0</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense
      contextRef="C_20201001to20210930_drugCategoriesOfResearchAndDevelopmentExpensesAxis_ifrsfullCopyrightsPatentsAndOtherIndustrialPropertyRightsServiceAndOperatingRightsMember"
      decimals="0"
      id="Fxbrl_20211228165653868"
      unitRef="CAD">513302</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense
      contextRef="C_20191001to20200930_drugCategoriesOfResearchAndDevelopmentExpensesAxis_ifrsfullCopyrightsPatentsAndOtherIndustrialPropertyRightsServiceAndOperatingRightsMember"
      decimals="0"
      id="Fxbrl_20211228165636946_52"
      unitRef="CAD">13895</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense
      contextRef="C_20190601to20190930_drugCategoriesOfResearchAndDevelopmentExpensesAxis_ifrsfullCopyrightsPatentsAndOtherIndustrialPropertyRightsServiceAndOperatingRightsMember"
      decimals="0"
      id="Fxbrl_20211228165636946_53"
      unitRef="CAD">0</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense
      contextRef="C_20201001to20210930_drugCategoriesOfResearchAndDevelopmentExpensesAxis_drugSalaryAndSubcontractorsMember"
      decimals="0"
      id="Fxbrl_20211228165658244"
      unitRef="CAD">1369769</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense
      contextRef="C_20191001to20200930_drugCategoriesOfResearchAndDevelopmentExpensesAxis_drugSalaryAndSubcontractorsMember"
      decimals="0"
      id="Fxbrl_20211228165636946_62"
      unitRef="CAD">43754</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense
      contextRef="C_20190601to20190930_drugCategoriesOfResearchAndDevelopmentExpensesAxis_drugSalaryAndSubcontractorsMember"
      decimals="0"
      id="Fxbrl_20211228165636946_63"
      unitRef="CAD">14845</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense
      contextRef="C_20201001to20210930_drugCategoriesOfResearchAndDevelopmentExpensesAxis_drugShareBasedCompensationMember"
      decimals="0"
      id="Fxbrl_20211228165701075"
      unitRef="CAD">709136</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense
      contextRef="C_20191001to20200930_drugCategoriesOfResearchAndDevelopmentExpensesAxis_drugShareBasedCompensationMember"
      decimals="0"
      id="Fxbrl_20211228165636946_72"
      unitRef="CAD">161300</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense
      contextRef="C_20190601to20190930_drugCategoriesOfResearchAndDevelopmentExpensesAxis_drugShareBasedCompensationMember"
      decimals="0"
      id="Fxbrl_20211228165636946_73"
      unitRef="CAD">0</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense
      contextRef="C_20201001to20210930"
      decimals="0"
      id="Fxbrl_20211228165705419"
      unitRef="CAD">6313988</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense
      contextRef="C_20191001to20200930"
      decimals="0"
      id="Fxbrl_20211228165636946_82"
      unitRef="CAD">354852</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense
      contextRef="C_20190601to20190930"
      decimals="0"
      id="Fxbrl_20211228165636946_83"
      unitRef="CAD">42009</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:DisclosureOfLeasesExplanatory
      contextRef="C_20201001to20210930"
      id="Fxbrl_20211228205315972">
                        &lt;div&gt;
                            &lt;p style="text-align: justify; margin-top: 10pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;11.&lt;span style="display: inline-block; width: 8pt;"&gt;&#160;&lt;/span&gt;PREMISES LEASES&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                            &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Commencing June 1, 2021, the Company entered into a commercial laboratory lease in Wauwatosa, Wisconsin USA for a term of one year at a monthly base rent of US$1,709. For the year ended September 30, 2021, $7,003 is included in laboratory costs (see Note 10).&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                            &lt;p style="text-align: justify; margin-bottom: 0px;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Commencing September 1, 2021, the Company entered into an apartment lease in New York, New York USA for a term of one year at a monthly base rent of US$5,300. For the year ended September 30, 2021, $6,700 is included in office and administrative expense.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                        &lt;/div&gt;
                    </ifrs-full:DisclosureOfLeasesExplanatory>
    <drug:TermOfLease
      contextRef="C_20210601to20210930_ifrsfullClassesOfAssetsAxis_drugCommercialLaboratoryLeaseMember"
      id="Fxbrl_20211228210132379">P1Y</drug:TermOfLease>
    <drug:MonthlyBaseRent
      contextRef="C_20210601to20210930_ifrsfullClassesOfAssetsAxis_drugCommercialLaboratoryLeaseMember"
      decimals="0"
      id="Fxbrl_20211228210145977"
      unitRef="USD">1709</drug:MonthlyBaseRent>
    <drug:LeaseCost
      contextRef="C_20210601to20210930_ifrsfullClassesOfAssetsAxis_drugCommercialLaboratoryLeaseMember"
      decimals="0"
      id="Fxbrl_20211228210400355"
      unitRef="CAD">7003</drug:LeaseCost>
    <drug:TermOfLease
      contextRef="C_20210901to20210930_ifrsfullClassesOfAssetsAxis_ifrsfullBuildingsMember"
      id="Fxbrl_20211228210438410">P1Y</drug:TermOfLease>
    <drug:MonthlyBaseRent
      contextRef="C_20210901to20210930_ifrsfullClassesOfAssetsAxis_ifrsfullBuildingsMember"
      decimals="0"
      id="Fxbrl_20211228210520727"
      unitRef="USD">5300</drug:MonthlyBaseRent>
    <drug:LeaseCost
      contextRef="C_20210601to20210930_ifrsfullClassesOfAssetsAxis_ifrsfullBuildingsMember"
      decimals="0"
      id="Fxbrl_20211228210600034"
      unitRef="CAD">6700</drug:LeaseCost>
    <ifrs-full:DisclosureOfIncomeTaxExplanatory
      contextRef="C_20201001to20210930"
      id="Fxbrl_20211228212858237">
                    &lt;div&gt;
                        &lt;p style="text-align: justify; margin-top: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;12.&lt;span style="display: inline-block; width: 8pt;"&gt;&#160;&lt;/span&gt;INCOME TAXES&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                        &lt;p style="text-align: justify;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;A reconciliation of the expected income tax recovery to the actual income tax recovery is as follows:&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                    &lt;/div&gt;

                    &lt;div&gt;&#160;
                            &lt;div&gt;
                                &lt;div style="margin-left: 36pt;"&gt;
                                    &lt;table cellpadding="0" cellspacing="0" style="width: 100%; border-collapse: collapse; font-size: 10pt; border-color: #000000;"&gt;
                                        &lt;tr&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; vertical-align: bottom;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;September 30, &lt;/b&gt;&lt;br/&gt;&lt;b&gt;2021&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;September 30, &lt;/b&gt;&lt;br/&gt;&lt;b&gt;2020&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;September 30,&lt;br/&gt;2019&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right;"&gt;&#160;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right;"&gt;&#160;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;Net loss&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;(8,650,763&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;)&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;(480,377&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;(78,717&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;Statutory tax rate&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;27.75%&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;27%&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;27%&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;Expected income tax recovery&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;(2,400,311&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;)&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;(129,702&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;(21,254&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;Deductible and non-deductible items&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 12%;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;(256,939&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;)&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 12%;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;42,136&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 12%;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;Change in deferred tax assets not recognized&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;2,657,250&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;87,566&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;21,254&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 2.25pt double #000000; vertical-align: bottom;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;Total income tax recovery&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 12%;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;-&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 12%;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 12%;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                        &lt;/tr&gt;
                                    &lt;/table&gt;
                                &lt;/div&gt;
                            &lt;/div&gt;

                        &lt;p style="text-align: justify; margin-top: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;The Company has the following deductible temporary differences for which no deferred tax has been recognized:&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

                            &lt;div&gt;
                                &lt;div style="margin-left: 36pt;"&gt;
                                    &lt;table cellpadding="0" cellspacing="0" style="width: 100%; border-collapse: collapse; font-size: 10pt; border-color: #000000;"&gt;
                                        &lt;tr&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; vertical-align: bottom;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;September 30, &lt;/b&gt;&lt;br/&gt;&lt;b&gt;2021&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;September 30, &lt;/b&gt;&lt;br/&gt;&lt;b&gt;2020&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right;"&gt;&#160;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right;"&gt;&#160;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;Non-capital losses&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;9,976,000&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;403,000&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;Share issue costs&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 15%;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;1,448,000&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 15%;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;4,000&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;Intangible assets&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;(1,000&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;)&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;(2,000&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; border-bottom: 0.75pt solid #000000;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;Valuation allowance&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 15%;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;(11,423,000&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;)&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 15%;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;(405,000&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; border-bottom: 2.25pt double #000000; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;Net deferred income tax assets&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 15%; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;-&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 15%; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;/tr&gt;
                                    &lt;/table&gt;
                                &lt;/div&gt;
                            &lt;/div&gt;

                        &lt;p style="text-align: justify; margin-top: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;The Company has Canadian non-capital losses of approximately $9,940,000 (2019 - $403,000), US non-capital losses of $ 30,000 (2019 - $Nil) and Australian non-capital losses of $6,000 (2019- $Nil), which may be carried forward and applied against taxable income in future years. Future tax benefits which may arise as a result of these losses have not been recognized in these financial statements and have been offset by a valuation allowance.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                        &lt;p style="text-align: justify;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;The Company's Canadian non-capital loss carry-forwards expire as follows:&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

                            &lt;div&gt;
                                &lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-size: 10pt; width: 70%; border-color: #000000; margin-left: auto; margin-right: auto;"&gt;
                                    &lt;tr&gt;
                                        &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;Year of Origin&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;Year of Expiry&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;Non-Capital Losses&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: center;"&gt;&#160;&lt;/td&gt;
                                    &lt;/tr&gt;
                                    &lt;tr&gt;
                                        &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: center;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: center;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: right;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: right;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: right;"&gt;&#160;&lt;/td&gt;
                                    &lt;/tr&gt;
                                    &lt;tr&gt;
                                        &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: center; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;2019&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: center; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="-sec-ix-hidden: Fxbrl_20211228221904526;"&gt;2039&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; width: 22%; text-align: right; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;79,000&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;/tr&gt;
                                    &lt;tr&gt;
                                        &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: center;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;2020&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: center;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="-sec-ix-hidden: Fxbrl_20211228221912500;"&gt;2040&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; width: 22%; text-align: right;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;324,000&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; width: 2%; text-align: left;"&gt;&#160;&lt;/td&gt;
                                    &lt;/tr&gt;
                                    &lt;tr&gt;
                                        &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;2021&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="-sec-ix-hidden: Fxbrl_20211228221915311;"&gt;2041&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 22%; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;9,537,000&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;/tr&gt;
                                    &lt;tr&gt;
                                        &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: center;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: center;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 22%;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;9,940,000&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                    &lt;/tr&gt;
                                &lt;/table&gt;
                            &lt;/div&gt;

                    &lt;/div&gt;
                </ifrs-full:DisclosureOfIncomeTaxExplanatory>
    <drug:DisclosureOfReconciliationOfExpectedIncomeTaxRecoveryToActualIncomeTaxRecoveryExplanatory
      contextRef="C_20201001to20210930"
      id="Fxbrl_20211228224836084">
                            &lt;div&gt;
                                &lt;div style="margin-left: 36pt;"&gt;
                                    &lt;table cellpadding="0" cellspacing="0" style="width: 100%; border-collapse: collapse; font-size: 10pt; border-color: #000000;"&gt;
                                        &lt;tr&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; vertical-align: bottom;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;September 30, &lt;/b&gt;&lt;br/&gt;&lt;b&gt;2021&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;September 30, &lt;/b&gt;&lt;br/&gt;&lt;b&gt;2020&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;September 30,&lt;br/&gt;2019&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right;"&gt;&#160;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right;"&gt;&#160;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;Net loss&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;(8,650,763&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;)&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;(480,377&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;(78,717&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;Statutory tax rate&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;27.75%&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;27%&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;27%&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;Expected income tax recovery&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;(2,400,311&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;)&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;(129,702&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;(21,254&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;Deductible and non-deductible items&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 12%;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;(256,939&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;)&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 12%;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;42,136&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 12%;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;Change in deferred tax assets not recognized&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;2,657,250&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;87,566&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;21,254&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 2.25pt double #000000; vertical-align: bottom;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;Total income tax recovery&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 12%;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;-&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 12%;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 12%;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                        &lt;/tr&gt;
                                    &lt;/table&gt;
                                &lt;/div&gt;
                            &lt;/div&gt;
                        </drug:DisclosureOfReconciliationOfExpectedIncomeTaxRecoveryToActualIncomeTaxRecoveryExplanatory>
    <ifrs-full:AccountingProfit
      contextRef="C_20201001to20210930"
      decimals="0"
      id="Fxbrl_20211228190802176_22"
      unitRef="CAD">-8650763</ifrs-full:AccountingProfit>
    <ifrs-full:AccountingProfit
      contextRef="C_20191001to20200930"
      decimals="0"
      id="Fxbrl_20211228190802176_25"
      unitRef="CAD">-480377</ifrs-full:AccountingProfit>
    <ifrs-full:AccountingProfit
      contextRef="C_20181001to20190930"
      decimals="0"
      id="Fxbrl_20211228190802176_28"
      unitRef="CAD">-78717</ifrs-full:AccountingProfit>
    <ifrs-full:ApplicableTaxRate
      contextRef="C_20201001to20210930"
      decimals="4"
      id="Fxbrl_20211228190802176_32"
      unitRef="Percent">0.2775</ifrs-full:ApplicableTaxRate>
    <ifrs-full:ApplicableTaxRate
      contextRef="C_20191001to20200930"
      decimals="2"
      id="Fxbrl_20211228190802176_35"
      unitRef="Percent">0.27</ifrs-full:ApplicableTaxRate>
    <ifrs-full:ApplicableTaxRate
      contextRef="C_20181001to20190930"
      decimals="2"
      id="Fxbrl_20211228190802176_38"
      unitRef="Percent">0.27</ifrs-full:ApplicableTaxRate>
    <ifrs-full:TaxExpenseIncomeAtApplicableTaxRate
      contextRef="C_20201001to20210930"
      decimals="0"
      id="Fxbrl_20211228190802176_42"
      unitRef="CAD">-2400311</ifrs-full:TaxExpenseIncomeAtApplicableTaxRate>
    <ifrs-full:TaxExpenseIncomeAtApplicableTaxRate
      contextRef="C_20191001to20200930"
      decimals="0"
      id="Fxbrl_20211228190802176_45"
      unitRef="CAD">-129702</ifrs-full:TaxExpenseIncomeAtApplicableTaxRate>
    <ifrs-full:TaxExpenseIncomeAtApplicableTaxRate
      contextRef="C_20181001to20190930"
      decimals="0"
      id="Fxbrl_20211228190802176_48"
      unitRef="CAD">-21254</ifrs-full:TaxExpenseIncomeAtApplicableTaxRate>
    <drug:TaxEffectOfDeductibleAndNotDeductibleItems
      contextRef="C_20201001to20210930"
      decimals="0"
      id="Fxbrl_20211228190802176_52"
      unitRef="CAD">-256939</drug:TaxEffectOfDeductibleAndNotDeductibleItems>
    <drug:TaxEffectOfDeductibleAndNotDeductibleItems
      contextRef="C_20191001to20200930"
      decimals="0"
      id="Fxbrl_20211228190802176_55"
      unitRef="CAD">42136</drug:TaxEffectOfDeductibleAndNotDeductibleItems>
    <drug:TaxEffectOfDeductibleAndNotDeductibleItems
      contextRef="C_20181001to20190930"
      decimals="0"
      id="Fxbrl_20211228190802176_58"
      unitRef="CAD">0</drug:TaxEffectOfDeductibleAndNotDeductibleItems>
    <drug:TaxEffectOfChangeInDeferredTaxAssetsNotRecognized
      contextRef="C_20201001to20210930"
      decimals="0"
      id="Fxbrl_20211228190802176_62"
      unitRef="CAD">2657250</drug:TaxEffectOfChangeInDeferredTaxAssetsNotRecognized>
    <drug:TaxEffectOfChangeInDeferredTaxAssetsNotRecognized
      contextRef="C_20191001to20200930"
      decimals="0"
      id="Fxbrl_20211228190802176_65"
      unitRef="CAD">87566</drug:TaxEffectOfChangeInDeferredTaxAssetsNotRecognized>
    <drug:TaxEffectOfChangeInDeferredTaxAssetsNotRecognized
      contextRef="C_20181001to20190930"
      decimals="0"
      id="Fxbrl_20211228190802176_68"
      unitRef="CAD">21254</drug:TaxEffectOfChangeInDeferredTaxAssetsNotRecognized>
    <ifrs-full:IncomeTaxExpenseContinuingOperations
      contextRef="C_20201001to20210930"
      decimals="0"
      id="Fxbrl_20211228190802176_72"
      unitRef="CAD">0</ifrs-full:IncomeTaxExpenseContinuingOperations>
    <ifrs-full:IncomeTaxExpenseContinuingOperations
      contextRef="C_20191001to20200930"
      decimals="0"
      id="Fxbrl_20211228190802176_75"
      unitRef="CAD">0</ifrs-full:IncomeTaxExpenseContinuingOperations>
    <ifrs-full:IncomeTaxExpenseContinuingOperations
      contextRef="C_20181001to20190930"
      decimals="0"
      id="Fxbrl_20211228190802176_78"
      unitRef="CAD">0</ifrs-full:IncomeTaxExpenseContinuingOperations>
    <ifrs-full:DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory
      contextRef="C_20201001to20210930"
      id="Fxbrl_20211228224849623">
                            &lt;div&gt;
                                &lt;div style="margin-left: 36pt;"&gt;
                                    &lt;table cellpadding="0" cellspacing="0" style="width: 100%; border-collapse: collapse; font-size: 10pt; border-color: #000000;"&gt;
                                        &lt;tr&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; vertical-align: bottom;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;September 30, &lt;/b&gt;&lt;br/&gt;&lt;b&gt;2021&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;September 30, &lt;/b&gt;&lt;br/&gt;&lt;b&gt;2020&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right;"&gt;&#160;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right;"&gt;&#160;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;Non-capital losses&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;9,976,000&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;403,000&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;Share issue costs&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 15%;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;1,448,000&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 15%;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;4,000&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;Intangible assets&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;(1,000&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;)&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;(2,000&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; border-bottom: 0.75pt solid #000000;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;Valuation allowance&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 15%;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;(11,423,000&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;)&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 15%;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;(405,000&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; border-bottom: 2.25pt double #000000; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;Net deferred income tax assets&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 15%; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;-&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 15%; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;/tr&gt;
                                    &lt;/table&gt;
                                &lt;/div&gt;
                            &lt;/div&gt;
                        </ifrs-full:DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory>
    <ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised
      contextRef="C_20210930_ifrsfullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_ifrsfullUnusedTaxLossesMember"
      decimals="0"
      id="Fxbrl_20211228191625472_22"
      unitRef="CAD">9976000</ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised>
    <ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised
      contextRef="C_20200930_ifrsfullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_ifrsfullUnusedTaxLossesMember"
      decimals="0"
      id="Fxbrl_20211228191625472_25"
      unitRef="CAD">403000</ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised>
    <ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised
      contextRef="C_20210930_ifrsfullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_drugTemporaryDifferencesShareIssueCostsMember"
      decimals="0"
      id="Fxbrl_20211228191625472_32"
      unitRef="CAD">1448000</ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised>
    <ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised
      contextRef="C_20200930_ifrsfullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_drugTemporaryDifferencesShareIssueCostsMember"
      decimals="0"
      id="Fxbrl_20211228191625472_35"
      unitRef="CAD">4000</ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised>
    <ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised
      contextRef="C_20210930_ifrsfullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_drugTemporaryDifferencesIntangibleAssetsMember"
      decimals="0"
      id="Fxbrl_20211228191625472_42"
      unitRef="CAD">-1000</ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised>
    <ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised
      contextRef="C_20200930_ifrsfullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_drugTemporaryDifferencesIntangibleAssetsMember"
      decimals="0"
      id="Fxbrl_20211228191625472_45"
      unitRef="CAD">-2000</ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised>
    <ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised
      contextRef="C_20210930_ifrsfullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_drugTemporaryDifferencesValuationAllowanceMember"
      decimals="0"
      id="Fxbrl_20211228191625472_52"
      unitRef="CAD">-11423000</ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised>
    <ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised
      contextRef="C_20200930_ifrsfullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_drugTemporaryDifferencesValuationAllowanceMember"
      decimals="0"
      id="Fxbrl_20211228191625472_55"
      unitRef="CAD">-405000</ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised>
    <ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised
      contextRef="C_20210930"
      decimals="0"
      id="Fxbrl_20211228191625472_62"
      unitRef="CAD">0</ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised>
    <ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised
      contextRef="C_20200930"
      decimals="0"
      id="Fxbrl_20211228191625472_65"
      unitRef="CAD">0</ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised>
    <drug:NonCapitalLossCarryForwards
      contextRef="C_20210930_drugIncomeTaxAuthorityNameOfCountryAxis_drugTaxAuthorityOfCanadaMember"
      decimals="0"
      id="Fxbrl_20211228222104778"
      unitRef="CAD">9940000</drug:NonCapitalLossCarryForwards>
    <drug:NonCapitalLossCarryForwards
      contextRef="C_20190930_drugIncomeTaxAuthorityNameOfCountryAxis_drugTaxAuthorityOfCanadaMember"
      decimals="0"
      id="Fxbrl_20211228222111085"
      unitRef="CAD">403000</drug:NonCapitalLossCarryForwards>
    <drug:NonCapitalLossCarryForwards
      contextRef="C_20210930_drugIncomeTaxAuthorityNameOfCountryAxis_drugTaxAuthorityOfUnitedStatesMember"
      decimals="0"
      id="Fxbrl_20211228222200554"
      unitRef="CAD">30000</drug:NonCapitalLossCarryForwards>
    <drug:NonCapitalLossCarryForwards
      contextRef="C_20190930_drugIncomeTaxAuthorityNameOfCountryAxis_drugTaxAuthorityOfUnitedStatesMember"
      decimals="0"
      id="Fxbrl_20211228222207542"
      unitRef="CAD">0</drug:NonCapitalLossCarryForwards>
    <drug:NonCapitalLossCarryForwards
      contextRef="C_20210930_drugIncomeTaxAuthorityNameOfCountryAxis_drugTaxAuthorityOfAustraliaMember"
      decimals="0"
      id="Fxbrl_20211228222230089"
      unitRef="CAD">6000</drug:NonCapitalLossCarryForwards>
    <drug:NonCapitalLossCarryForwards
      contextRef="C_20190930_drugIncomeTaxAuthorityNameOfCountryAxis_drugTaxAuthorityOfAustraliaMember"
      decimals="0"
      id="Fxbrl_20211228222237537"
      unitRef="CAD">0</drug:NonCapitalLossCarryForwards>
    <drug:DisclosureOfNonCapitalLossCarryForwardsExpiryExplanatory
      contextRef="C_20201001to20210930"
      id="Fxbrl_20211228224903863">
                            &lt;div&gt;
                                &lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-size: 10pt; width: 70%; border-color: #000000; margin-left: auto; margin-right: auto;"&gt;
                                    &lt;tr&gt;
                                        &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;Year of Origin&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;Year of Expiry&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;Non-Capital Losses&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: center;"&gt;&#160;&lt;/td&gt;
                                    &lt;/tr&gt;
                                    &lt;tr&gt;
                                        &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: center;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: center;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: right;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: right;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: right;"&gt;&#160;&lt;/td&gt;
                                    &lt;/tr&gt;
                                    &lt;tr&gt;
                                        &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: center; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;2019&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: center; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="-sec-ix-hidden: Fxbrl_20211228221904526;"&gt;2039&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; width: 22%; text-align: right; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;79,000&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;/tr&gt;
                                    &lt;tr&gt;
                                        &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: center;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;2020&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: center;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="-sec-ix-hidden: Fxbrl_20211228221912500;"&gt;2040&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; width: 22%; text-align: right;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;324,000&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; width: 2%; text-align: left;"&gt;&#160;&lt;/td&gt;
                                    &lt;/tr&gt;
                                    &lt;tr&gt;
                                        &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;2021&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="-sec-ix-hidden: Fxbrl_20211228221915311;"&gt;2041&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 22%; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;9,537,000&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;/tr&gt;
                                    &lt;tr&gt;
                                        &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: center;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: center;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 22%;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;9,940,000&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                    &lt;/tr&gt;
                                &lt;/table&gt;
                            &lt;/div&gt;
                        </drug:DisclosureOfNonCapitalLossCarryForwardsExpiryExplanatory>
    <drug:NonCapitalLossCarryForwards
      contextRef="C_20210930_drugIncomeTaxAuthorityNameOfCountryAxis_drugTaxAuthorityOfCanadaMember_drugNonCapitalLossCarryForwardsYearOfOriginAxis_drugTaxYearOfOrigin2019Member"
      decimals="0"
      id="Fxbrl_20211228222021893"
      unitRef="CAD">79000</drug:NonCapitalLossCarryForwards>
    <drug:NonCapitalLossCarryForwards
      contextRef="C_20210930_drugIncomeTaxAuthorityNameOfCountryAxis_drugTaxAuthorityOfCanadaMember_drugNonCapitalLossCarryForwardsYearOfOriginAxis_drugTaxYearOfOrigin2020Member"
      decimals="0"
      id="Fxbrl_20211228222028848"
      unitRef="CAD">324000</drug:NonCapitalLossCarryForwards>
    <drug:NonCapitalLossCarryForwards
      contextRef="C_20210930_drugIncomeTaxAuthorityNameOfCountryAxis_drugTaxAuthorityOfCanadaMember_drugNonCapitalLossCarryForwardsYearOfOriginAxis_drugTaxYearOfOrigin2021Member"
      decimals="0"
      id="Fxbrl_20211228222032143"
      unitRef="CAD">9537000</drug:NonCapitalLossCarryForwards>
    <drug:NonCapitalLossCarryForwards
      contextRef="C_20210930_drugIncomeTaxAuthorityNameOfCountryAxis_drugTaxAuthorityOfCanadaMember"
      decimals="0"
      id="Fxbrl_20211228222035291"
      unitRef="CAD">9940000</drug:NonCapitalLossCarryForwards>
    <drug:DisclosureOfComparativeAmountsExplanatory
      contextRef="C_20201001to20210930"
      id="Fxbrl_20211228162510889">
                        &lt;div&gt;
                            &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;13.&lt;span style="display: inline-block; width: 8pt;"&gt;&#160;&lt;/span&gt;COMPARATIVE AMOUNTS&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                            &lt;p style="text-align: justify; margin-bottom: 0px;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Certain of the prior year's amounts have been reclassified to conform with the current year's presentation (see Note 10).&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                        &lt;/div&gt;
                    </drug:DisclosureOfComparativeAmountsExplanatory>
    <ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory
      contextRef="C_20201001to20210930"
      id="Fxbrl_20211228155240606">
                        &lt;div&gt;
                            &lt;p style="text-align: justify; margin-top: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;14.&lt;span style="display: inline-block; width: 8pt;"&gt;&#160;&lt;/span&gt;SUBSEQUENT EVENTS&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                            &lt;p style="text-align: justify;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;Events not disclosed elsewhere in these consolidated financial statements are as follows:&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                            &lt;p style="text-align: justify;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;On November 1, 2021, the Company entered into a letter agreement (the "LA") with a New York-based company, whereby the company will provide investor relations services to the Company. As compensation for performing these services, the Company will pay a non-refundable monthly retainer of US$5,000 and issue 11,200 shares of restricted stock in three tranches: 3,800 on January 1, 2022; 3,700 on April 1, 2022 and 3,700 on July 1, 2022. If the contract is terminated prior to the issuance date, the outstanding balance is not owed. The services will continue for an initial term of one year unless sooner terminated by either party giving the other 15 days written notice. &lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                        &lt;/div&gt;

                        &lt;div&gt;
                            &lt;div style="text-align: justify; margin-top: 10pt;"&gt;&lt;span style="font-family: Times New Roman, Times, serif; font-size: 10pt;"&gt;On November 9, 2021, 12,500 warrants were exercised for gross proceeds of $118,250.&lt;/span&gt;&lt;br/&gt;&#160;&lt;/div&gt;
                            &lt;div style="margin-top: 0pt; margin-bottom: 11px; text-align: justify; font-size: 10pt; font-family: Times New Roman, Times, serif;"&gt;&lt;span style="font-family: Times New Roman, Times, serif; font-size: 10pt; line-height: normal;"&gt;In November 2021, the Company entered into director indemnity agreements (the "DIAs") with five directors of the Company. Pursuant to the DIAs and subject to all applicable laws, including the applicable limitations and restrictions set forth in the Business Corporations Act (British Columbia), the Company will:&#160;&lt;/span&gt;&lt;/div&gt;
                            &lt;div style="margin-top: 0pt; margin-bottom: 11px; text-align: justify; font-size: 10pt; font-family: Times New Roman, Times, serif;"&gt;
                                &lt;table style="width: 100%; border: 0px;"&gt;
                                    &lt;tr&gt;
                                        &lt;td style="width: 42px; padding: 0.1px;"&gt;
                                            &lt;p style="margin-top: 6px; margin-bottom: 0pt; font-size: 10pt; font-family: Times New Roman, Times, serif;"&gt;&lt;span style="line-height: normal; font-size: 10pt; font-family: Times New Roman, serif;"&gt;&#160; &#160; &#160; &#160;&#x2022;&lt;/span&gt;&lt;/p&gt;
                                        &lt;/td&gt;
                                        &lt;td colspan="2" style="width: 1087px; padding: 0.1px; vertical-align: top;"&gt;
                                            &lt;p style="margin-top: 6px; margin-bottom: 0pt; text-align: justify; font-size: 10pt; font-family: Times New Roman, Times, serif;"&gt;&lt;span style="font-size: 11pt; line-height: normal; font-family: Calibri, sans-serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman, serif;"&gt;&lt;span style="color: black;"&gt;Indemnify and save harmless the Directors against and from:&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                        &lt;/td&gt;
                                    &lt;/tr&gt;
                                    &lt;tr&gt;
                                        &lt;td style="width: 42px; padding: 0.1px;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="width: 22px; padding: 0.1px; vertical-align: top;"&gt;
                                            &lt;p style="margin-top: 10pt; margin-bottom: 0pt; font-size: 10pt; font-family: Times New Roman, Times, serif;"&gt;&lt;span style="font-size: 11pt; line-height: normal; font-family: Calibri, sans-serif;"&gt;&lt;span style="font-size: 8pt;"&gt;&lt;span style="font-family: Times New Roman, serif;"&gt;o&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                        &lt;/td&gt;
                                        &lt;td style="width: 1065px; padding: 0.1px; vertical-align: top;"&gt;
                                            &lt;p style="margin-top: 10pt; margin-bottom: 0pt; text-align: justify; font-size: 10pt; font-family: Times New Roman, Times, serif;"&gt;&lt;span style="line-height: normal; font-size: 10pt; font-family: Times New Roman, serif;"&gt;any and all charges or claims by reason of them being or having been a director of the Company or another corporation, at a time when the other corporation is or was an affiliate of the Company, or at the request of the Company;&lt;/span&gt;&lt;/p&gt;
                                        &lt;/td&gt;
                                    &lt;/tr&gt;
                                    &lt;tr&gt;
                                        &lt;td style="width: 42px; padding: 0.1px;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="width: 22px; padding: 0.1px; vertical-align: top;"&gt;
                                            &lt;p style="margin-top: 0px; margin-bottom: 0pt; font-size: 10pt; font-family: Times New Roman, Times, serif;"&gt;&lt;span style="font-size: 11pt; line-height: normal; font-family: Calibri, sans-serif;"&gt;&lt;span style="font-size: 8pt;"&gt;&lt;span style="font-family: Times New Roman, serif;"&gt;o&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                        &lt;/td&gt;
                                        &lt;td style="width: 1065px; padding: 0.1px; vertical-align: top;"&gt;
                                            &lt;p style="margin-top: 0px; margin-bottom: 0pt; text-align: justify; font-size: 10pt; font-family: Times New Roman, Times, serif;"&gt;&lt;span style="line-height: normal; font-size: 10pt; font-family: Times New Roman, serif;"&gt;any and all costs, damages, expenses, fines, liabilities, losses and penalties (the "Consequences") which they may sustain, incur or be liable for in consequence of their acting as a director of the Company, whether sustained or incurred by reason of their negligence, default, breach of duty or trust, failure to exercise due diligence or otherwise in relation to the Company or any of its affairs; and&lt;/span&gt;&lt;/p&gt;
                                        &lt;/td&gt;
                                    &lt;/tr&gt;
                                    &lt;tr&gt;
                                        &lt;td style="width: 42px; padding: 0.1px;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="width: 22px; padding: 0.1px; vertical-align: top;"&gt;
                                            &lt;p style="margin-top: 0px; margin-bottom: 0pt; font-size: 10pt; font-family: Times New Roman, Times, serif;"&gt;&lt;span style="font-size: 11pt; line-height: normal; font-family: Calibri, sans-serif;"&gt;&lt;span style="font-size: 8pt;"&gt;&lt;span style="font-family: Times New Roman, serif;"&gt;o&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                        &lt;/td&gt;
                                        &lt;td style="width: 1065px; padding: 0.1px; vertical-align: top;"&gt;
                                            &lt;p style="margin-top: 0px; margin-bottom: 0pt; text-align: justify; font-size: 10pt; font-family: Times New Roman, Times, serif;"&gt;&lt;span style="line-height: normal; font-size: 10pt; font-family: Times New Roman, serif;"&gt;in particular, and without in any way limiting the generality of the foregoing, any and all Consequences which they may sustain, incur or be liable for as a result of or in connection with the release or presence in the environment of substances, contaminants, litter, waste, effluent, refuse, pollutants or deleterious materials and that arise out of or are in any way connected with the management, operation, activities or existence of the Company or by virtue of them holding any other directorship with any other entity at the Company's request.&lt;/span&gt;&lt;/p&gt;
                                        &lt;/td&gt;
                                    &lt;/tr&gt;
                                    &lt;tr&gt;
                                        &lt;td style="width: 42px; padding: 0.1px;"&gt;
                                            &lt;p style="margin-top: 10pt; margin-bottom: 0pt; font-size: 10pt; font-family: Times New Roman, Times, serif;"&gt;&lt;span style="line-height: normal; font-size: 10pt; font-family: Times New Roman, serif;"&gt;&#160; &#160; &#160; &#x2022;&lt;/span&gt;&lt;/p&gt;
                                        &lt;/td&gt;
                                        &lt;td colspan="2" style="width: 1087px; padding: 0.1px; vertical-align: top;"&gt;
                                            &lt;p style="margin-top: 10pt; margin-bottom: 0pt; text-align: justify; font-size: 10pt; font-family: Times New Roman, Times, serif;"&gt;&lt;span style="line-height: normal; font-size: 10pt; font-family: Times New Roman, serif;"&gt;gross up any indemnity payment made pursuant to the DIAs by the amount of any income tax payable by the Directors in respect of that payment; and&lt;/span&gt;&lt;/p&gt;
                                        &lt;/td&gt;
                                    &lt;/tr&gt;
                                    &lt;tr&gt;
                                        &lt;td style="width: 42px; padding: 0.1px;"&gt;
                                            &lt;p style="margin-top: 10pt; margin-bottom: 0pt; font-size: 10pt; font-family: Times New Roman, Times, serif;"&gt;&lt;span style="line-height: normal; font-size: 10pt; font-family: Times New Roman, serif;"&gt;&#160; &#160; &#160; &#x2022;&lt;/span&gt;&lt;/p&gt;
                                        &lt;/td&gt;
                                        &lt;td colspan="2" style="width: 1087px; padding: 0.1px; vertical-align: top;"&gt;
                                            &lt;p style="margin-top: 10pt; margin-bottom: 0pt; text-align: justify; font-size: 10pt; font-family: Times New Roman, Times, serif;"&gt;&lt;span style="line-height: normal; font-size: 10pt; font-family: Times New Roman, serif;"&gt;indemnify the Directors for the amount of all costs they incur in obtaining any Court approval required to enable or require the Company to make a payment to them under the DIAs, or enforce the DIAs against the Company, including without limitation legal fees and disbursements on a full indemnity basis.&lt;/span&gt;&lt;/p&gt;
                                        &lt;/td&gt;
                                    &lt;/tr&gt;
                                &lt;/table&gt;
                            &lt;/div&gt;
                            &lt;div style="text-align: justify; margin-top: 10pt;"&gt;&lt;span style="font-family: Times New Roman, Times, serif; font-size: 10pt;"&gt;Notwithstanding the above-noted, the Company will have no obligation to indemnify or save harmless the Directors in respect of any liability for which they are entitled to indemnity pursuant to any valid and collectible policy of insurance obtained and maintained by the Company, to the extent of the amounts actually collected by the Directors under the insurance policy.&lt;/span&gt;&lt;/div&gt;
                        &lt;/div&gt;
                    </ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory>
    <drug:AmountOfNonRefundableMonthlyRetainerAsServiceCompensation
      contextRef="C_20211001to20211101_drugTypeOfArrangementsAxis_drugLetterAgreementMember_ifrsfullNonadjustingEventsAfterReportingPeriodAxis_drugSubsequentEventsMember"
      decimals="0"
      id="Fxbrl_20211228163430937"
      unitRef="CAD">5000</drug:AmountOfNonRefundableMonthlyRetainerAsServiceCompensation>
    <drug:NumberOfRestrictedStockIssuedForCompensation
      contextRef="C_20211101_drugTypeOfArrangementsAxis_drugLetterAgreementMember_ifrsfullNonadjustingEventsAfterReportingPeriodAxis_drugSubsequentEventsMember"
      decimals="INF"
      id="Fxbrl_20211228163501137"
      unitRef="Share">11200</drug:NumberOfRestrictedStockIssuedForCompensation>
    <drug:NumberOfRestrictedStockIssuedForCompensation
      contextRef="C_20211101_drugTranchesAxis_drugFirstTrancheMember_drugTypeOfArrangementsAxis_drugLetterAgreementMember_ifrsfullNonadjustingEventsAfterReportingPeriodAxis_drugSubsequentEventsMember"
      decimals="INF"
      id="Fxbrl_20211228163517849"
      unitRef="Share">3800</drug:NumberOfRestrictedStockIssuedForCompensation>
    <drug:NumberOfRestrictedStockIssuedForCompensation
      contextRef="C_20211101_drugTranchesAxis_drugSecondTrancheMember_drugTypeOfArrangementsAxis_drugLetterAgreementMember_ifrsfullNonadjustingEventsAfterReportingPeriodAxis_drugSubsequentEventsMember"
      decimals="INF"
      id="Fxbrl_20211228163522517"
      unitRef="Share">3700</drug:NumberOfRestrictedStockIssuedForCompensation>
    <drug:NumberOfRestrictedStockIssuedForCompensation
      contextRef="C_20211101_drugTranchesAxis_drugThirdTrancheMember_drugTypeOfArrangementsAxis_drugLetterAgreementMember_ifrsfullNonadjustingEventsAfterReportingPeriodAxis_drugSubsequentEventsMember"
      decimals="INF"
      id="Fxbrl_20211228163527244"
      unitRef="Share">3700</drug:NumberOfRestrictedStockIssuedForCompensation>
    <drug:NumberOfWarrantsExercised
      contextRef="C_20211001to20211109_drugTypeOfArrangementsAxis_drugLetterAgreementMember_ifrsfullNonadjustingEventsAfterReportingPeriodAxis_drugSubsequentEventsMember"
      decimals="INF"
      id="Fxbrl_20211228163913666"
      unitRef="Share">12500</drug:NumberOfWarrantsExercised>
    <drug:GrossProceedsFromWarrantsExercised
      contextRef="C_20211001to20211109_drugTypeOfArrangementsAxis_drugLetterAgreementMember_ifrsfullNonadjustingEventsAfterReportingPeriodAxis_drugSubsequentEventsMember"
      decimals="0"
      id="Fxbrl_20211228163928849"
      unitRef="CAD">118250</drug:GrossProceedsFromWarrantsExercised>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>58
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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MKUE<C6)P7HWB@(QLL  NW1S]3#H6$'RE%31.F^@M:6P>;TH!=1/V4J0TIUK
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M.06.<,W\62EN,LK3[3BVTL,1.<W_M;#%K<S4MA9<#&*1M9$=[KPX-S;#?CU
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M2)O''<GS*2NR<L50)M#G[/D]HOAW1!P<F:; *9/?9FI6Q*<[YV;V=-E<D%B
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MZ9=2IQ>BVK<_U%E60E2[]NF69?(VKP'D_S=5)5Y>-+_].?]>[>Y_4$L#!!0
M   ( *:%,E0&=JH<6 8  $0:   8    >&PO=V]R:W-H965T<R]S:&5E=#4N
M>&ULE5E=;Z,X%/TK5K32[$J3"3;?55NI35KM2-M.U<[L:!\=XC36 &:QT[3_
M?J^!0@+&=%\:H.<>?.SK>VQS?A#E+[EC3*'7+,WEQ6RG5'&V6,ADQS(JOXB"
MY?"?K2@SJN"V?%[(HF1T4P5EZ8(X3K#(*,]GE^?5LX?R\ESL5<IS]E BN<\R
M6KY=LU0<+F9X]O[@D3_OE'ZPN#POZ#-[8NI'\5#"W:)EV?",Y9*+')5L>S&[
MPF<KMPJH$']S=I!'UTA+60OQ2]]\W5S,'-TBEK)$:0H*/R]LR=)4,T$[_FU(
M9^T[=>#Q]3O[;24>Q*RI9$N1_N0;M;N813.T85NZ3]6C./S)&D&^YDM$*JN_
MZ%!C?0 G>ZE$U@1#"S*>U[_TM>F(HP#@,0>0)H#T X*1 +<)</L!WDB UP1X
M5<_44JI^6%%%+\]+<4"E1@.;OJ@ZLXH&^3S7X_ZD2O@OASAUN12Y%"G?4,4V
MZ$G!#PRJDDALT9+*';J%Q)!HCI97*_3[;W^<+Q2\5(<NDN8%U_4+R,@+/'0G
M<K63Z";?L(TA?FF/Q\1"L "UK63R+OF:6!F?6/$%N<YG1!P<FQKTX7""#>&K
MCX<[%C5N.X!NQ>>.\'TK6$D5SY_K*<059])"Z[6T7D7KC=#>0\E)A90(2@M2
M.X;>&"U-HU_3!!6-+C(OE_,P"G%XOG@Y[E,#+ I\)PS<4^#* /0BQPT[PA,]
M?JO'MW;3O<CGB4YH#ADNSRP]%+2,@;6'H.Q 4<D1>TUV-']FILZI&?PC,4ZO
M7X:(.2$N]&"O6VQ,)\T/V^:'UN8_[6C)))3N1)0PKQ#5UQ(&.=DAFF^@=KZ
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M'\UQ.D<G_X>IY</EK_,O%<YOYS?OHL8%TE&ML/JC 2QF]U>S7[_E(U>XQ*Q
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M[_X*E+9J)ZZBY<3)]/9FTZERW$F/IW)QQ>F9AZEYH$A00H<B- !I1?WU>RX
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M('&P,.(/''F0!_Q1U_C6!IBWE=N5-':C=L .Q-$28X[23+0Z7G$IKGN.' 0
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MR-R0'3%!#%>US& CAO!741254Q1% AM18)M#%($N@A?KN==HW+;=R0*WRCM
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MF@S>749=@0\;;YHP^'/CZ1D)RXK>;;2L0/*-,?ZP80?'?P*S?P%02P,$%
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M+L P"$M@4AOGUQD%]FB \+L4= (AY"2@J33?J3CF#F5N_:@)6U&03;BKPG\
MR@UFS6 N*0HIJ0N#L =CV#'<$Q#%@MTNP#2^-A:>H +V[PY&PVM9P,GP;8/A
M&9C>,O*_52@\GR^]91 -"05QZ#V'@-%'5OTE.S$GF<SBO-CEZE@Z14/H"@9&
M8W1=0Y1@;O1*ZAL()?(FP < +QR-G: 0F;1.AD\'DX()"':!3D;'3ZDAW6/'
MBPD^("2U" WA4PGP+52@;HQ&1W>U&T26>Z&<9Z+(H9#1#0F!E2Y(J(#.$2SJ
M[VHG*$7\;%$<]O@H,/Q'R5W1S'=&9N\R]A/DPP2)>Q;<2BV04<#=G2HTF?1#
MQ1FEWM,BW DN<P29Q-$IN]W (OIDTHNL,%ZQUXD^!ZH<30WCAX47ZD0$N;9V
M?/79:U(:?(HINTR40<!(@3*'K )TUI^[>$ZQX)Y,"GT1C_0DD<@83PEX9&+"
M7DK)]1P<N*X+V+R@2AL\UFPUF8Q'O*!*38HT%&%++->!ZR2D!\L6L532B:/#
M1%@((V^YEC&Y7&;NVI@?77'\<'IN4MA&ND,>$'B+^;25$Z/+JG/&H#C8DT(R
MM.]4$A>%N,$B94-XOEX+0F8MJ-<0JTH(F-Y@MK"2'+ BKO$>> >0N042@?4V
MV; 7^'RBH=3U]J Q$XI?U[4==DPLH)#W@JH#&3#X/IV8F.280]S.5VY/H7DW
M\/*L1?Z;$^>Q]F?7.1M.S]4%P<?;YH1<0UX!AG[P@.NJ0*/=L1]!!!+,4$+M
M/9&Y8!EYBVG0X0=DQBM=X5 6WL5U<EY]".3[5CQNC@_?'!\ ]-&R1WBNM)"D
MVXV,E6/UV+G!<YQC6<P;1)SKTPM5Y82."T/6I;$1QXH=G^F/S5J@RHVA.04=
M2NK8CUSCT0>(@N)[%LW.@!:]);'V#@X7!-T/]0I&P&FE7*UDO_N_11#,GK$(
M^)L ?QHQFG2U7<TT]@A"2&59*1&8A/S$.HIFYO09B</L,0=3\2$>@@0-0F!0
MF(_C(@_38!P7SDS>QM<JDU>[J/088>NJ50+]U";->8;VDFG$U^EMNWJJW*WQ
ME,24>CV$(0@!\$H 5N7W0OM?4Q;KNIW','Q $X?SA1=23Z#D$!8BS: /ZKHO
M:18+[IBG UA)(+*&;(N5N17Y/=MR3"T!RF.Y0V7H4!<L\[;:#XB[]:*KYABA
MHQ3/7&"KY\38$QOPG<IKN9(IQ/L>PT22:C*4>(%YBF)K)[O%:/S=E-W-$Y,F
MZ:KF"@$/EY 9W#1 G_."4KJFX*X-KY); F]:1:45^VJFS+,<6@DV)36S>H?7
M_N2[_1K]<&&>M^VJA&RNP]ACLXG6D:LK:I/^E#*:S0FM])Z>/4 V4JS9#[:P
M_Y.RU#UKK&X=@]XK 8*J2JS*N09M,FBC-5,5Z:D4MBO5GJI\B184:^ZFM!?:
M#XI1E6+*"XL&P=1EDIV!:E W#OX8Q3^S<_RH,R>8VBF-.EW,\-PA*K7BF4IG
M$:BT<-P91/6T(46_G7A@5D-CET1GJ7X2]S:4=V>$@P_OZ:)K%'1W#L.'.2<!
M:TDYXX>9;B8HS&[F8/GM@2G*A==<%DT]1I<"6O",X=,6@J<:#[^Z- [V&J*
M+^PJ!C#%V$=C )@F#MCFB4B=P4WM3V8[</ +)D\[!GVAS/D9D_!(IU6=^_
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M&\%!QC@ GJ_SO#(_< /[WR*\_"=02P,$%     @ IH4R5!#X6HC; P  T0@
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M,!L$+_\65D?BR;FY5;_. "S9#@L>#S^'0<7A-[41DAWQ"L4I6^YT5;(8$2'
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M@4X+K)CNRQH%K>125<S05"T'NE;(,F=4E8,H",:#BG'A79X[V8.Z/)>-*;G
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MH;(*M)Y+:;83&V#W^KO\'U!+ P04    " "FA3)4)NH<"$$"  #0!   &0
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MJXM&;M6]BI^:#QYORT%*H6ME@W96>%5>SJ[7YS<GM)\W_*+5+DR>!7F2.?=
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M= U?BS,7<<GFQTHA9SUMP/?2(?3="RD8?B>Y^A-02P,$%     @ IH4R5+(
MDX^,&0   5P  !D   !X;"]W;W)K<VAE971S+W-H965T,C N>&ULQ3S;<MM&
MEN_YBBYNU8Y5!=&6[#B)UW&5K-@93?E6EC/S,#4/(- @.P;1'#0@FOGZ/9>^
MXD+1R6[FQ19)X/3I<[]U/]_K]K/92-F)+]NZ,3\N-EVW>_;PH2DV<IN;I=[)
M!GZI=+O-._C8KA^:72OSDE[:U@\O'SUZ^G";JV;QXCE]]Z%]\5SW7:T:^:$5
MIM]N\_;P4M9Z_^/B8N&^^*C6FPZ_>/CB^2Y?RUO9_;+[T,*GAQY*J;:R,4HW
MHI75CXNKBV<O+Y[B"_3$WY7<F^AO@5M9:?T9/]R4/RX>(4:RED6'('+X[TY>
MR[I&2(#'ORW0A5\37XS_=M!?T^9A,ZO<R&M=_T.5W>;'Q?<+4<HJ[^ONH][_
M5=H-?8OP"ET;^E?L[;./%J+H3:>W]F7 8*L:_C__8@EQR@N7]H5+PIL7(BQ_
MRKO\Q?-6[T6+3P,T_(.V2F\#<JI!KMQV+?RJX+WNQ>W-S^]N7M]<7[W[)*ZN
MK]__\N[3S;N?Q8?W;VZN;U[=B@<?=*T*)<W9\X<=K(=O/2PL[)<,^W(&]L6E
M>*N;;F/$JZ:490K@(2#JL;UTV+Z\/ KQ5NZ6XO&C3%P^NKPX N^QW_UC@O=X
M!MY/RA2U-GTKQ?M*_"2[7-6R%#<-BSN*S=4*9%G<JG6C*E7D32>NBD+W3:>:
MM7#$$?^\6IFN!1'[UQ&LGGBLGA!63V:P>ID;982N1*$; RN4C,D_:;6#^"2_
M=.)EK8O/_YKBR>^"_6DCC8R^ R)4JLF;0N6U,!U\ 9K8&:&:HNY+*;J-!(4B
M.A T_'RMM[N\.8B\*86"K_<;7=>'<[UO )KI5T:5*F^16A^, O0/*T O7QGQ
MIBN7XH&14KS3G11/SC+QLD5M$F]54QKQ4FD#5&X*>/7-F^M,Y,"J.M_GP+9:
M;15B6ZM\I6K5'6 3A$9&>,S $1_@05P68>U:O0.T.C!*[F6P-VME.MD"Y!YD
MM[4;;'>Z)8(9D((.-W[5(]]A=0%4_%O?2''YA,5S*=[;;RZLP&8,Y=7[(<4
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M2S"H(*?G3KE6>9T3>9#E)/LYN6C#.HN/  OT5M)'^04B$$.L408IQ+Q.(*9
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M<H21HTHFN$?\.LD+O:=F /%OG)@.&BRCL'*J V.["V[?F#2X&<CQH<\4OX#
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MDK.+O@>RF>O&T*)RLY0(;2;3+7/S%**T 69_)83>&9:@?5Q';U!+ P04
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M\!0E%WD=U3V*WE[G_)LM.H["7AJ'X(>)2[C.V=V)T*\3IBDQ2XJB_3#NQ:/
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M8P'7]11=# A]3(RCCU#[NZF?HK>N0J"F%!&5'E[^NR$=RE&5<U ZJN;F0RJ
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MG+$DOX#_^T,<9_5?3KG]YSCY5CSC]?\#4$L#!!0    ( *>%,E0LVY3X30,
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MT&8*<I<;,]FBM 'F_DH(_;BP!U2S\O0W4$L#!!0    ( *>%,E1ETR'VF 0
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MM<T.#UZJ]L'QJOM,JL#"C4$Q![ET\[-"B2BYKN:B9K>9T2=N,GVR/[6SNQM
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M;:HINWPZ$D*C.*;AGE6=5+N2MCY4M%/2 U,O8-^D3X2E:U"&:_M:L<)^B-:
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M/ILL*^JNC@AV<5=OVUF1-BMR%CU5M/T\"+=FC=U7I','YE^F>7BG; [HW=]
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M[#6J88KM(T@#P.=[(?3+Q&S0-J3S_P!02P,$%     @ IX4R5%TB:UR!"
M "\  !D   !X;"]W;W)K<VAE971S+W-H965T-# N>&UL[5I;;]LX%OXKA-$"
M':"-1=UL%TF Q)FTZ>0V23N+1;$/M$S;G)%$#44ES6)__!S*LFE;(B6WJ)_V
MQ5>>C^?ZG2-*Q\]<_)4O*)7H6Q*G^4EO(67VOM_/HP5-2'[$,YK"/S,N$B+A
MJYCW\TQ0,BV%DKCO.D[83PA+>Z?'Y6_WXO28%S)F*;T7*"^2A(B7<QKSYY,>
M[JU^>&#SA50_]$^/,S*GCU1^R>X%?.NO4:8LH6G.>(H$G9WTSO#[A]!5 N6*
M/QA]SC<^(V7*A/._U)>KZ4G/41K1F$9201!X>Z)C&L<*"?3XNP+MK?=4@IN?
M5^B7I?%@S(3D=,SC?[&I7)STACTTI3-2Q/*!/W^DE4&!PHMXG)>OZ+E:Z_10
M5.22)Y4P:)"P=/E.OE6.V!!PL4' K03<78&!0<"K!+Q= 9-*?B7@=U4IJ 2"
M'0&CT6$E$'85&%0"@ZXJ#2N!85>C1Y7 J*M;L;.*G--U#[P.=BW:1I%5N'$M
MWB;3\2K@N'/$\2KDN'/,\2KH>#?J9I%5V/%NW,TBJ\#CSI''J]#C,O;]92F6
M=7Q!)#D]%OP9";4>\-2'D@Q*>2A?EBK>>I0"_F4@)T_'=[>?'\[&G[^<7:.[
M\^NK#V>?K^YN']&;6R($49SR"WIS025A<?[+<5_"EDJP'U7PYTMXUP!_RY^.
MD!.^1:[C.E\>+]";5TTH8SO*720!9;2%\K@@@N8-6!=VK$]%"EC!$LL(\JL=
MY*R8'R$/ER#8;-9E"THFCI#K+5'&9R5*;M+HPQY8E49&K(]VK!LBNEAWU>)H
MDFH4HZ,_=<@?/.@6^=_:S'I!;I6*E;<;0*Z[@YA=<V,'>:09N,91*'AD5N6V
M2\B'+0Z^ZP""W;98WW<V:)W)#2B_[X%BUN6A.TISG/O D6NB=-=$Z9:PG@'V
M@N51S/-"4'0W0V.>2@$S5T%B=#>)V9R44]C7:Y!"5Y(F^7\L>WKK/;UR3]^P
MYP/-*1'1 I%T"L/8$TR9&<R,$M%O,+?FM"GSEHAAB:B&UJ=3'V;8T7'_:3.<
M]56AA[W1<+B][J&^S@O\8>"NEVW9Y:_M\JUVW67+F74N*"WM^7I#DPD5-I\%
M:^S@8'$*UWN&5GMN>?H.QNTBG9))3!%?FC>C-$<98=,FJ@IKCG4=B,"V^Z_K
MJW#@.$ZS]P=K;0=6;:]9I))G/_</U^##@[E_M-YS9#7HD<U3ELZ5PYL:YZCN
M1,<Q>A$[>G)RNF2Q+<P?*HB.$<0;4QON:O);E,+E+9]U2;O+"G;;&4'@& H:
M:W;$;G>%EH,'8GE>T"GZ'S(.(I<5:K!%1)O^J=S8MFQ;:\VOV$ZP]U1 +4BX
M0%<.%/R%Q)*!YN!&Y=2<Q/ %RIH*] JC"8MC\'"C'?9]O"/'>=V8'WO+;5NJ
M&1?;*;>3I?Q)&>I:#;5OXQ\%!D/WEMLV5-,_#JQ(%S2/!%N6 EB:%T [)=]1
M)*"#IL6& UZ@3EY*!B11) I#BMKWVT'*T82J.H@$G3()V2_Y,Q'PM@#"35-%
MA' =QY(B03,NRI\K_= +]'K$4O2\8-#RU3\&+<MQ +NO5?!('*-4M9]JZ<K&
M(I4L+D'&/,E(^H(6)$>"L!QT>C4X"D"-,L@E&*Q+$79>JP^"DIFDHC&(_W?%
M;E[J$0';9X2S;8MU!;Y#_P9K<X3+[=W&%+1"JZ/-]WE&(GK2RX!GJ7BBO5-D
MTUJ/"M@^*[1HC;Q&=0<UMK;T/#U9X.$/Z>(WZC*LZ6)KP'KDP/:9HTV9H%&9
M44T9SZR,JR<1USZ)M"D3KC+;7-N7U1:[03/IIB<5USZI&'4K-4$S)G*)(IXD
MT* 8+%2=J%$_7-//M2FX<5UGGUR6X[ B*CT0OT.98(J3.%)\L6XB6ZORM^A/
MSF UT(PLU, #$M&"I,L>&ZG9E\==AFM7#RRN=[#QVM7#@VOOSC<,I@/) 71-
M[44&&TUYZ9%E##/87/D.:/L>"!840%) 1!N#Z=>KTA)+W?Q=>P?:5U'5%)8_
M5BK;= [V*A#=&%Q[8_AQG6U*A_M5C6X,KKTQF+1NK&=5#I1 )X\ AD7P*TNG
M\"X-0Z9;;R"N8[EF<W4/<>T]I+G8EU1TD$K7#<8='>Z\27<2S]Y)?F8!>?4.
M8\M%3[<8S]YB?FH%>?6^$UA2T=-]Q[/WG9]:0=7>8=<*\C:.).V7I%=P-9Q1
M> %?0E;F12P)?#S;YS#)TYW'\P]7!;J->/8V<ELH"_292H[F HPLSS+,]YV\
M>H/ MOS6'<)K.5Y<J_/P^*6C+G7>M^JB>=]KX7T(P2)^4><\B!1RP07[+^@R
M>4$3KB[N0,DI$S227#3>5ZO@PUT2V#[P^=BPS#*V>YK_/3O_[V1OF4W Y?ME
MK^9P[W <[FL.]ULX_ =#Y-?/+)M"U+#,$B)?L[G?<K09*9YF,Q8A,GUB.1<K
MQ74_[A(F7S.Q?[A;.[XF4M].I-]%,I\JT*W"]LR%[6_<DK'/^'5U(I)&-([M
M"EWY]5'>M>BC.=BW<_!>:0 :GG,I>5*>[95SV=>D/4,T _OAX3)$<ZW?<OBR
MM!LM>"&@G@6135?&=WXC5QK\KYG2MS/EOO[_S+/]G*]9U#\<BP::18.6,Y5N
MS@\:6# T.#_0'!C8.; :K+8O0CK=)=6D%QR.] )->L%/(+UQ4">]D5/K2+<-
MRSS'-7)1H+DQ:#G_^+&.^JF"[]@J@XU;W7:.[):CXPHEW.X9ALTU)P;VJ?0[
M'DXX#^HWM,-P$/H&7313!G:FM-?+]W6'0%-E<+A[WH&FQ:#E!+I3\'\/ZK>_
M3;$/-3F&=G)L]?>^W2#4U!CBPSW?H=DRM%^L=W1V6+_L#FMEWM]X6E,]&WY#
MQ)P!$\9T!E+.T0#*52P?MUY^D3PK'^"<E$E<?EQ0,J5"+8#_9YS+U1?U3.CZ
MH??3?P!02P,$%     @ IX4R5+D IZW, P  -PX  !D   !X;"]W;W)K<VAE
M971S+W-H965T-#$N>&ULS5=1;^(X$/XK5G0G=:538R<D(2M 8J'<(6T1*NW=
MP^H>3&+ JF.SC@/MOU\[20,L23:KVY/Z HXSW^=O9NP99W 4\CG=$:+ 2\)X
M.K1V2NT_VG8:[4B"TUNQ)UR_V0B98*4?Y=9.]Y+@. <ES'8@].T$4VZ-!OG<
M4HX&(E.,<K*4(,V2!,O73X2)X]!"UMO$ ]WNE)FP1X,]WI(544_[I=1/=L42
MTX3PE H.)-D,K3'Z.$.! >06?U-R3,_&P+BR%N+9/,SCH06-(L)(I P%UG\'
M,B&,&2:MXVM):E5K&N#Y^(U]ECNOG5GCE$P$^X?&:C>T^A:(R09G3#V(XU^D
M=,@S?)%@:?X+CJ4MM$"4I4HD)5@K2"@O_O%+&8@S@(,: $X)<+H"W!+@=@7T
M2D"O*\ K 5Y7@%\"_#SV1;#R2$^QPJ.!%$<@C;5F,X,\73E:!YARL[-62NJW
M5./4:#9?C!>3^?@SF"]6CP]/]W>+QQ48+Z9@,E[.'_7\_7@Q_O/.S(.;!982
MFZWP =Q,B<*4I1\&MM(Z#)L=E6M^*M9T&M9<D?TM<.$?P($.FHRGX.:W.I;)
M3[ \K9I8IMU98+.6N\XL*&QFF75GZ=>RV#J[58J=*L5.3NLVT$YI&C&19I(
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MJ38CIU74DLA(!UA?XDQ:-N4NB#(I"8]>P89ED<J*]% .GE8@%HQA"? 6F_2
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M4V>)@WC;O[0#R7;F1E\SJ?H#\UBJE@^X!JCW&\;D\T OT#>1B_\ 4$L#!!0
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MRQ1G;- N .^G2MGWC9OBZJE]^ ]02P,$%     @ IX4R5 NYXJXB P  50L
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MIJ\<^4W>I*W?$?G6R\AW]T9^DTOIX61Z4XIC#CS=Y#S:?N7 ;W(</3;)_:_
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ML@X U%I69I S4DI!.@T;CWY@:!>4\UMH[._%'O>JV*GK"*HJAJ$1U \MC9T
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MU)V#!^=1L#FG@NUO)+-?4$L#!!0    ( *>%,E27BKL<P    !,"   +
M7W)E;',O+G)E;'.=DKENPS ,0'_%T)XP!] AB#-E\18$^0%6H@_8$@6*19V_
MK]JE<9 +&7D]/!+<'FE [3BDMHNI&/T04FE:U;@!2+8ECVG.D4*NU"P>-8?2
M0$3;8T.P6BP^0"X99K>]9!:G<Z17B%S7G:4]VR]/06^ KSI,<4)I2$LS#O#-
MTG\R]_,,-47E2B.56QIXT^7^=N!)T:$B6!::1<G3HAVE?QW']I#3Z:]C(K1Z
M6^CY<6A4"H[<8R6,<6*T_C6"R0_L?@!02P,$%     @ IX4R5#/%2O%/!
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ML^Y_Z_034$L! A0#%     @ IH4R5 =!36*!    L0   !
M ( !     &1O8U!R;W!S+V%P<"YX;6Q02P$"% ,4    " "FA3)4Z=:EW.\
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M=V]R:W-H965T<R]S:&5E=#(N>&UL4$L! A0#%     @ IH4R5-$NAL]=!
M^@X  !@              ("!W!0  'AL+W=O<FMS:&5E=',O<VAE970S+GAM
M;%!+ 0(4 Q0    ( *:%,E08#S +!P<  +LF   8              " @6\9
M  !X;"]W;W)K<VAE971S+W-H965T-"YX;6Q02P$"% ,4    " "FA3)4!G:J
M'%@&  !$&@  &               @(&L(   >&PO=V]R:W-H965T<R]S:&5E
M=#4N>&UL4$L! A0#%     @ IH4R5&2A@PC=!@  %@\  !@
M ("!.B<  'AL+W=O<FMS:&5E=',O<VAE970V+GAM;%!+ 0(4 Q0    ( *:%
M,E1(T_.0A@,  #D(   8              " @4TN  !X;"]W;W)K<VAE971S
M+W-H965T-RYX;6Q02P$"% ,4    " "FA3)4F2O5,\$8  !.5   &
M        @($),@  >&PO=V]R:W-H965T<R]S:&5E=#@N>&UL4$L! A0#%
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M+GAM;%!+ 0(4 Q0    ( *:%,E1^U'W:I0P  ,XI   9              "
M@?YG  !X;"]W;W)K<VAE971S+W-H965T,3,N>&UL4$L! A0#%     @ IH4R
M5 \V\O_K"   4!8  !D              ("!VG0  'AL+W=O<FMS:&5E=',O
M<VAE970Q-"YX;6Q02P$"% ,4    " "FA3)45?\\MQT#  !2!@  &0
M        @('\?0  >&PO=V]R:W-H965T<R]S:&5E=#$U+GAM;%!+ 0(4 Q0
M   ( *:%,E1D]+T%U0(  %\&   9              " @5"!  !X;"]W;W)K
M<VAE971S+W-H965T,38N>&UL4$L! A0#%     @ IH4R5*!W3@69!   "0H
M !D              ("!7(0  'AL+W=O<FMS:&5E=',O<VAE970Q-RYX;6Q0
M2P$"% ,4    " "FA3)4)NH<"$$"  #0!   &0              @($LB0
M>&PO=V]R:W-H965T<R]S:&5E=#$X+GAM;%!+ 0(4 Q0    ( *:%,E2@51!!
MD <  #,1   9              " @:2+  !X;"]W;W)K<VAE971S+W-H965T
M,3DN>&UL4$L! A0#%     @ IH4R5+( DX^,&0   5P  !D
M ("!:Y,  'AL+W=O<FMS:&5E=',O<VAE970R,"YX;6Q02P$"% ,4    " "F
MA3)4WH,&D(@"  !H!0  &0              @($NK0  >&PO=V]R:W-H965T
M<R]S:&5E=#(Q+GAM;%!+ 0(4 Q0    ( *:%,E3*?,4+N@4  (L2   9
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M970R-BYX;6Q02P$"% ,4    " "FA3)4\K769I@"   ^!P  &0
M    @(%HPP  >&PO=V]R:W-H965T<R]S:&5E=#(W+GAM;%!+ 0(4 Q0    (
M *:%,E3/WKE/IP(  .@&   9              " @3?&  !X;"]W;W)K<VAE
M971S+W-H965T,C@N>&UL4$L! A0#%     @ IH4R5+FKFDAV @  $@8  !D
M             ("!%<D  'AL+W=O<FMS:&5E=',O<VAE970R.2YX;6Q02P$"
M% ,4    " "GA3)4L^$"KI@4  "&F@  &0              @('"RP  >&PO
M=V]R:W-H965T<R]S:&5E=#,P+GAM;%!+ 0(4 Q0    ( *>%,E0LVY3X30,
M #<+   9              " @9'@  !X;"]W;W)K<VAE971S+W-H965T,S$N
M>&UL4$L! A0#%     @ IX4R5&73(?:8!   V1@  !D              ("!
M%>0  'AL+W=O<FMS:&5E=',O<VAE970S,BYX;6Q02P$"% ,4    " "GA3)4
MIS@D15H#  #=#   &0              @('DZ   >&PO=V]R:W-H965T<R]S
M:&5E=#,S+GAM;%!+ 0(4 Q0    ( *>%,E0=B/RB;@(  &\%   9
M      " @77L  !X;"]W;W)K<VAE971S+W-H965T,S0N>&UL4$L! A0#%
M  @ IX4R5/P1\5YG P  10T  !D              ("!&N\  'AL+W=O<FMS
M:&5E=',O<VAE970S-2YX;6Q02P$"% ,4    " "GA3)4T^F2$*T#  "\#@
M&0              @(&X\@  >&PO=V]R:W-H965T<R]S:&5E=#,V+GAM;%!+
M 0(4 Q0    ( *>%,E3HC?@!? ,  !L-   9              " @9SV  !X
M;"]W;W)K<VAE971S+W-H965T,S<N>&UL4$L! A0#%     @ IX4R5(M_.]7C
M P  9!$  !D              ("!3_H  'AL+W=O<FMS:&5E=',O<VAE970S
M."YX;6Q02P$"% ,4    " "GA3)4.WJK?58#  "<"@  &0
M@(%I_@  >&PO=V]R:W-H965T<R]S:&5E=#,Y+GAM;%!+ 0(4 Q0    ( *>%
M,E1=(FM<@0@    O   9              " @?8! 0!X;"]W;W)K<VAE971S
M+W-H965T-# N>&UL4$L! A0#%     @ IX4R5+D IZW, P  -PX  !D
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M=#0U+GAM;%!+ 0(4 Q0    ( *>%,E2Y!T-L9@,  % *   9
M  " @1X< 0!X;"]W;W)K<VAE971S+W-H965T-#8N>&UL4$L! A0#%     @
MIX4R5.?$_ZH- P  P0L  !D              ("!NQ\! 'AL+W=O<FMS:&5E
M=',O<VAE970T-RYX;6Q02P$"% ,4    " "GA3)4"[GBKB(#  !5"P  &0
M            @('_(@$ >&PO=V]R:W-H965T<R]S:&5E=#0X+GAM;%!+ 0(4
M Q0    ( *>%,E3YXBV/8@,  (D+   9              " @5@F 0!X;"]W
M;W)K<VAE971S+W-H965T-#DN>&UL4$L! A0#%     @ IX4R5$F?H(<0 P
M,!$   T              ( !\2D! 'AL+W-T>6QE<RYX;6Q02P$"% ,4
M" "GA3)4EXJ[',     3 @  "P              @ $L+0$ 7W)E;',O+G)E
M;'-02P$"% ,4    " "GA3)4,\5*\4\$   $(0  #P              @ $5
M+@$ >&PO=V]R:V)O;VLN>&UL4$L! A0#%     @ IX4R5(YA./J] 0  >AT
M !H              ( !D3(! 'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QS
M4$L! A0#%     @ IX4R5)PKTP^] 0  =QT  !,              ( !AC0!
J %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&     #D .0"&#P  =#8!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.21.4</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>255</ContextCount>
  <ElementCount>347</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>95</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>8</UnitCount>
  <MyReports>
    <Report instance="form20fa.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://brightmindsbio.com/role/DocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="form20fa.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>0002 - Statement - Consolidated Statements of Financial Position</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://brightmindsbio.com/role/ConsolidatedStatementsOfFinancialPosition</Role>
      <ShortName>Consolidated Statements of Financial Position</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="form20fa.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>0003 - Statement - Consolidated Statements of Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://brightmindsbio.com/role/ConsolidatedStatementsOfComprehensiveLoss</Role>
      <ShortName>Consolidated Statements of Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="form20fa.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>0004 - Statement - Consolidated Statements of Changes in Shareholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://brightmindsbio.com/role/ConsolidatedStatementsOfChangesInShareholdersEquity</Role>
      <ShortName>Consolidated Statements of Changes in Shareholders' Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="form20fa.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>0005 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://brightmindsbio.com/role/ConsolidatedStatementsOfCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="form20fa.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>0006 - Disclosure - NATURE AND CONTINUANCE OF OPERATIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://brightmindsbio.com/role/NATUREANDCONTINUANCEOFOPERATIONS</Role>
      <ShortName>NATURE AND CONTINUANCE OF OPERATIONS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="form20fa.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>0007 - Disclosure - STATEMENT OF COMPLIANCE AND BASIS OF PREPARATION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://brightmindsbio.com/role/STATEMENTOFCOMPLIANCEANDBASISOFPREPARATION</Role>
      <ShortName>STATEMENT OF COMPLIANCE AND BASIS OF PREPARATION</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="form20fa.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>0008 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://brightmindsbio.com/role/SIGNIFICANTACCOUNTINGPOLICIES</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="form20fa.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>0009 - Disclosure - SHARE EXCHANGE AND ASSIGNMENT</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://brightmindsbio.com/role/SHAREEXCHANGEANDASSIGNMENT</Role>
      <ShortName>SHARE EXCHANGE AND ASSIGNMENT</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="form20fa.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>0010 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED LIABILITIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://brightmindsbio.com/role/ACCOUNTSPAYABLEANDACCRUEDLIABILITIES</Role>
      <ShortName>ACCOUNTS PAYABLE AND ACCRUED LIABILITIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="form20fa.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>0011 - Disclosure - SHARE CAPITAL</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://brightmindsbio.com/role/SHARECAPITAL</Role>
      <ShortName>SHARE CAPITAL</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="form20fa.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>0012 - Disclosure - RELATED PARTY TRANSACTIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://brightmindsbio.com/role/RELATEDPARTYTRANSACTIONS</Role>
      <ShortName>RELATED PARTY TRANSACTIONS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="form20fa.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>0013 - Disclosure - CONTRACTUAL OBLIGATIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://brightmindsbio.com/role/CONTRACTUALOBLIGATIONS</Role>
      <ShortName>CONTRACTUAL OBLIGATIONS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="form20fa.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>0014 - Disclosure - FINANCIAL INSTRUMENTS AND CAPITAL MANAGEMENT</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://brightmindsbio.com/role/FINANCIALINSTRUMENTSANDCAPITALMANAGEMENT</Role>
      <ShortName>FINANCIAL INSTRUMENTS AND CAPITAL MANAGEMENT</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="form20fa.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>0015 - Disclosure - RESEARCH AND DEVELOPMENT</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://brightmindsbio.com/role/RESEARCHANDDEVELOPMENT</Role>
      <ShortName>RESEARCH AND DEVELOPMENT</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="form20fa.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>0016 - Disclosure - PREMISES LEASES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://brightmindsbio.com/role/PREMISESLEASES</Role>
      <ShortName>PREMISES LEASES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="form20fa.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>0017 - Disclosure - INCOME TAXES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://brightmindsbio.com/role/INCOMETAXES</Role>
      <ShortName>INCOME TAXES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="form20fa.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>0018 - Disclosure - COMPARATIVE AMOUNTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://brightmindsbio.com/role/ComparativeAmounts</Role>
      <ShortName>COMPARATIVE AMOUNTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="form20fa.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>0019 - Disclosure - SUBSEQUENT EVENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://brightmindsbio.com/role/SUBSEQUENTEVENTS</Role>
      <ShortName>SUBSEQUENT EVENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="form20fa.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>0020 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://brightmindsbio.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="form20fa.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>0021 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED LIABILITIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://brightmindsbio.com/role/ACCOUNTSPAYABLEANDACCRUEDLIABILITIESTables</Role>
      <ShortName>ACCOUNTS PAYABLE AND ACCRUED LIABILITIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://brightmindsbio.com/role/ACCOUNTSPAYABLEANDACCRUEDLIABILITIES</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="form20fa.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>0022 - Disclosure - SHARE CAPITAL (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://brightmindsbio.com/role/SHARECAPITALTables</Role>
      <ShortName>SHARE CAPITAL (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://brightmindsbio.com/role/SHARECAPITAL</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="form20fa.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>0023 - Disclosure - RELATED PARTY TRANSACTIONS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://brightmindsbio.com/role/RELATEDPARTYTRANSACTIONSTables</Role>
      <ShortName>RELATED PARTY TRANSACTIONS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://brightmindsbio.com/role/RELATEDPARTYTRANSACTIONS</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="form20fa.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>0024 - Disclosure - FINANCIAL INSTRUMENTS AND CAPITAL MANAGEMENT (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://brightmindsbio.com/role/FINANCIALINSTRUMENTSANDCAPITALMANAGEMENTTables</Role>
      <ShortName>FINANCIAL INSTRUMENTS AND CAPITAL MANAGEMENT (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://brightmindsbio.com/role/FINANCIALINSTRUMENTSANDCAPITALMANAGEMENT</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="form20fa.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>0025 - Disclosure - RESEARCH AND DEVELOPMENT (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://brightmindsbio.com/role/RESEARCHANDDEVELOPMENTTables</Role>
      <ShortName>RESEARCH AND DEVELOPMENT (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://brightmindsbio.com/role/RESEARCHANDDEVELOPMENT</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="form20fa.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>0026 - Disclosure - INCOME TAXES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://brightmindsbio.com/role/INCOMETAXESTables</Role>
      <ShortName>INCOME TAXES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://brightmindsbio.com/role/INCOMETAXES</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="form20fa.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>0027 - Disclosure - NATURE AND CONTINUANCE OF OPERATIONS (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://brightmindsbio.com/role/NATUREANDCONTINUANCEOFOPERATIONSDetailTextuals</Role>
      <ShortName>NATURE AND CONTINUANCE OF OPERATIONS (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://brightmindsbio.com/role/NATUREANDCONTINUANCEOFOPERATIONS</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="form20fa.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>0029 - Disclosure - SHARE EXCHANGE AND ASSIGNMENT (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://brightmindsbio.com/role/SHAREEXCHANGEANDASSIGNMENTDetailTextuals</Role>
      <ShortName>SHARE EXCHANGE AND ASSIGNMENT (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://brightmindsbio.com/role/SHAREEXCHANGEANDASSIGNMENT</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="form20fa.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>0030 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED LIABILITIES - Disclosure of accounts payable and accrued liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://brightmindsbio.com/role/ACCOUNTSPAYABLEANDACCRUEDLIABILITIESDetails</Role>
      <ShortName>ACCOUNTS PAYABLE AND ACCRUED LIABILITIES - Disclosure of accounts payable and accrued liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="form20fa.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>0031 - Disclosure - SHARE CAPITAL (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://brightmindsbio.com/role/SHARECAPITALDetailTextuals</Role>
      <ShortName>SHARE CAPITAL (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://brightmindsbio.com/role/SHARECAPITALTables</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="form20fa.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>0032 - Disclosure - SHARE CAPITAL - Disclosure of number and weighted average exercise prices of share options (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://brightmindsbio.com/role/SHARECAPITALDetails</Role>
      <ShortName>SHARE CAPITAL - Disclosure of number and weighted average exercise prices of share options (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="form20fa.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>0033 - Disclosure - SHARE CAPITAL - Disclosure of number of issued and outstanding stock options (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://brightmindsbio.com/role/SHARECAPITALDetails1</Role>
      <ShortName>SHARE CAPITAL - Disclosure of number of issued and outstanding stock options (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="form20fa.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>0034 - Disclosure - SHARE CAPITAL - Disclosure of number and weighted average exercise prices of restricted share units (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://brightmindsbio.com/role/SHARECAPITALDetails2</Role>
      <ShortName>SHARE CAPITAL - Disclosure of number and weighted average exercise prices of restricted share units (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="form20fa.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>0035 - Disclosure - SHARE CAPITAL - Disclosure of equity-settled restricted share units fair value inputs (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://brightmindsbio.com/role/SHARECAPITALDetails3</Role>
      <ShortName>SHARE CAPITAL - Disclosure of equity-settled restricted share units fair value inputs (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="form20fa.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>0036 - Disclosure - SHARE CAPITAL - Disclosure of share based payments recognized in the consolidated statements of comprehensive loss (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://brightmindsbio.com/role/SHARECAPITALDetails4</Role>
      <ShortName>SHARE CAPITAL - Disclosure of share based payments recognized in the consolidated statements of comprehensive loss (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="form20fa.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>0037 - Disclosure - SHARE CAPITAL - Disclosure of share based payments included in the consolidated statements of comprehensive loss (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://brightmindsbio.com/role/SHARECAPITALDetails5</Role>
      <ShortName>SHARE CAPITAL - Disclosure of share based payments included in the consolidated statements of comprehensive loss (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="form20fa.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>0038 - Disclosure - SHARE CAPITAL -  Disclosure of number and weighted average exercise prices of warrants (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://brightmindsbio.com/role/SHARECAPITALDetails6</Role>
      <ShortName>SHARE CAPITAL -  Disclosure of number and weighted average exercise prices of warrants (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="form20fa.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>0039 - Disclosure - SHARE CAPITAL - Disclosure of number of outstanding warrants (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://brightmindsbio.com/role/SHARECAPITALDetails7</Role>
      <ShortName>SHARE CAPITAL - Disclosure of number of outstanding warrants (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="form20fa.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>0040 - Disclosure - RELATED PARTY TRANSACTIONS - Disclosure of expenses related to key management personnel (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://brightmindsbio.com/role/RELATEDPARTYTRANSACTIONSDetails</Role>
      <ShortName>RELATED PARTY TRANSACTIONS - Disclosure of expenses related to key management personnel (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="form20fa.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>0041 - Disclosure - CONTRACTUAL OBLIGATIONS (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://brightmindsbio.com/role/CONTRACTUALOBLIGATIONSDetailTextuals</Role>
      <ShortName>CONTRACTUAL OBLIGATIONS (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://brightmindsbio.com/role/CONTRACTUALOBLIGATIONS</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="form20fa.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>0042 - Disclosure - FINANCIAL INSTRUMENTS AND CAPITAL MANAGEMENT (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://brightmindsbio.com/role/FINANCIALINSTRUMENTSANDCAPITALMANAGEMENTDetailTextuals</Role>
      <ShortName>FINANCIAL INSTRUMENTS AND CAPITAL MANAGEMENT (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://brightmindsbio.com/role/FINANCIALINSTRUMENTSANDCAPITALMANAGEMENTTables</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="form20fa.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>0043 - Disclosure - FINANCIAL INSTRUMENTS AND CAPITAL MANAGEMENT - Disclosure of carrying value of financial assets and liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://brightmindsbio.com/role/FINANCIALINSTRUMENTSANDCAPITALMANAGEMENTDetails</Role>
      <ShortName>FINANCIAL INSTRUMENTS AND CAPITAL MANAGEMENT - Disclosure of carrying value of financial assets and liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="form20fa.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>0044 - Disclosure - RESEARCH AND DEVELOPMENT - Disclosure of research and development expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://brightmindsbio.com/role/RESEARCHANDDEVELOPMENTDetails</Role>
      <ShortName>RESEARCH AND DEVELOPMENT - Disclosure of research and development expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="form20fa.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>0045 - Disclosure - PREMISES LEASES (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://brightmindsbio.com/role/PREMISESLEASESDetailTextuals</Role>
      <ShortName>PREMISES LEASES (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://brightmindsbio.com/role/PREMISESLEASES</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="form20fa.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>0046 - Disclosure - INCOME TAXES (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://brightmindsbio.com/role/INCOMETAXESDetailTextuals</Role>
      <ShortName>INCOME TAXES (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://brightmindsbio.com/role/INCOMETAXESTables</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="form20fa.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>0047 - Disclosure - INCOME TAXES  - Disclosure of reconciliation of the expected income tax recovery to the actual income tax recovery (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://brightmindsbio.com/role/INCOMETAXESDetails</Role>
      <ShortName>INCOME TAXES  - Disclosure of reconciliation of the expected income tax recovery to the actual income tax recovery (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="form20fa.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>0048 - Disclosure - INCOME TAXES - Disclosure of deductible temporary differences for which no deferred tax has been recognized (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://brightmindsbio.com/role/INCOMETAXESDetails1</Role>
      <ShortName>INCOME TAXES - Disclosure of deductible temporary differences for which no deferred tax has been recognized (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="form20fa.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>0049 - Disclosure - INCOME TAXES  - Disclosure of non-capital loss carry-forwards expiry (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://brightmindsbio.com/role/INCOMETAXESDetails2</Role>
      <ShortName>INCOME TAXES  - Disclosure of non-capital loss carry-forwards expiry (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="form20fa.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>0050 - Disclosure - SUBSEQUENT EVENTS (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://brightmindsbio.com/role/SUBSEQUENTEVENTSDetailTextuals</Role>
      <ShortName>SUBSEQUENT EVENTS (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://brightmindsbio.com/role/SUBSEQUENTEVENTS</ParentRole>
      <Position>49</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="20-F/A" original="form20fa.htm">form20fa.htm</File>
    <File>drug-20210930.xsd</File>
    <File>drug-20210930_cal.xml</File>
    <File>drug-20210930_def.xml</File>
    <File>drug-20210930_lab.xml</File>
    <File>drug-20210930_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>form20faxz004.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/srt/2020-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>64
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "form20fa.htm": {
   "axisCustom": 10,
   "axisStandard": 12,
   "contextCount": 255,
   "dts": {
    "calculationLink": {
     "local": [
      "drug-20210930_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "drug-20210930_def.xml"
     ]
    },
    "inline": {
     "local": [
      "form20fa.htm"
     ]
    },
    "labelLink": {
     "local": [
      "drug-20210930_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "drug-20210930_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "drug-20210930.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd",
      "https://xbrl.sec.gov/exch/2020/exch-2020-01-31.xsd",
      "https://xbrl.sec.gov/sic/2020/sic-2020-01-31.xsd",
      "https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd",
      "https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd",
      "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd",
      "http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd"
     ]
    }
   },
   "elementCount": 477,
   "entityCount": 1,
   "hidden": {
    "http://brightmindsbio.com/20210930": 4,
    "http://xbrl.sec.gov/dei/2020-01-31": 6,
    "total": 10
   },
   "keyCustom": 134,
   "keyStandard": 213,
   "memberCustom": 80,
   "memberStandard": 12,
   "nsprefix": "drug",
   "nsuri": "http://brightmindsbio.com/20210930",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "b",
       "span",
       "span",
       "p",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "form20fa.htm",
      "contextRef": "C_20201001to20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:EntityRegistrantName",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001 - Document - Document and Entity Information",
     "role": "http://brightmindsbio.com/role/DocumentAndEntityInformation",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "b",
       "span",
       "span",
       "p",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "form20fa.htm",
      "contextRef": "C_20201001to20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:EntityRegistrantName",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "form20fa.htm",
      "contextRef": "C_20201001to20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0010 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED LIABILITIES",
     "role": "http://brightmindsbio.com/role/ACCOUNTSPAYABLEANDACCRUEDLIABILITIES",
     "shortName": "ACCOUNTS PAYABLE AND ACCRUED LIABILITIES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "form20fa.htm",
      "contextRef": "C_20201001to20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "form20fa.htm",
      "contextRef": "C_20201001to20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfIssuedCapitalExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0011 - Disclosure - SHARE CAPITAL",
     "role": "http://brightmindsbio.com/role/SHARECAPITAL",
     "shortName": "SHARE CAPITAL",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "form20fa.htm",
      "contextRef": "C_20201001to20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfIssuedCapitalExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "form20fa.htm",
      "contextRef": "C_20201001to20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfRelatedPartyExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0012 - Disclosure - RELATED PARTY TRANSACTIONS",
     "role": "http://brightmindsbio.com/role/RELATEDPARTYTRANSACTIONS",
     "shortName": "RELATED PARTY TRANSACTIONS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "form20fa.htm",
      "contextRef": "C_20201001to20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfRelatedPartyExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "form20fa.htm",
      "contextRef": "C_20201001to20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfCommitmentsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0013 - Disclosure - CONTRACTUAL OBLIGATIONS",
     "role": "http://brightmindsbio.com/role/CONTRACTUALOBLIGATIONS",
     "shortName": "CONTRACTUAL OBLIGATIONS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "form20fa.htm",
      "contextRef": "C_20201001to20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfCommitmentsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "form20fa.htm",
      "contextRef": "C_20201001to20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfFinancialInstrumentsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0014 - Disclosure - FINANCIAL INSTRUMENTS AND CAPITAL MANAGEMENT",
     "role": "http://brightmindsbio.com/role/FINANCIALINSTRUMENTSANDCAPITALMANAGEMENT",
     "shortName": "FINANCIAL INSTRUMENTS AND CAPITAL MANAGEMENT",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "form20fa.htm",
      "contextRef": "C_20201001to20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfFinancialInstrumentsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "form20fa.htm",
      "contextRef": "C_20201001to20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfResearchAndDevelopmentExpenseExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0015 - Disclosure - RESEARCH AND DEVELOPMENT",
     "role": "http://brightmindsbio.com/role/RESEARCHANDDEVELOPMENT",
     "shortName": "RESEARCH AND DEVELOPMENT",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "form20fa.htm",
      "contextRef": "C_20201001to20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfResearchAndDevelopmentExpenseExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "form20fa.htm",
      "contextRef": "C_20201001to20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfLeasesExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0016 - Disclosure - PREMISES LEASES",
     "role": "http://brightmindsbio.com/role/PREMISESLEASES",
     "shortName": "PREMISES LEASES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "form20fa.htm",
      "contextRef": "C_20201001to20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfLeasesExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "form20fa.htm",
      "contextRef": "C_20201001to20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfIncomeTaxExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0017 - Disclosure - INCOME TAXES",
     "role": "http://brightmindsbio.com/role/INCOMETAXES",
     "shortName": "INCOME TAXES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "form20fa.htm",
      "contextRef": "C_20201001to20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfIncomeTaxExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "form20fa.htm",
      "contextRef": "C_20201001to20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "drug:DisclosureOfComparativeAmountsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0018 - Disclosure - COMPARATIVE AMOUNTS",
     "role": "http://brightmindsbio.com/role/ComparativeAmounts",
     "shortName": "COMPARATIVE AMOUNTS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "form20fa.htm",
      "contextRef": "C_20201001to20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "drug:DisclosureOfComparativeAmountsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "form20fa.htm",
      "contextRef": "C_20201001to20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0019 - Disclosure - SUBSEQUENT EVENTS",
     "role": "http://brightmindsbio.com/role/SUBSEQUENTEVENTS",
     "shortName": "SUBSEQUENT EVENTS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "form20fa.htm",
      "contextRef": "C_20201001to20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "b",
       "span",
       "span",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "form20fa.htm",
      "contextRef": "C_20210930",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "ifrs-full:CashAndCashEquivalents",
      "reportCount": 1,
      "unitRef": "CAD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0002 - Statement - Consolidated Statements of Financial Position",
     "role": "http://brightmindsbio.com/role/ConsolidatedStatementsOfFinancialPosition",
     "shortName": "Consolidated Statements of Financial Position",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "b",
       "span",
       "span",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "form20fa.htm",
      "contextRef": "C_20210930",
      "decimals": "0",
      "lang": null,
      "name": "ifrs-full:CurrentTaxAssetsCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "CAD",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ifrs-full:DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "form20fa.htm",
      "contextRef": "C_20201001to20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "drug:DescriptionOfAccountingPolicyForBasisOfConsolidationExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0020 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "role": "http://brightmindsbio.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies",
     "shortName": "SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ifrs-full:DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "form20fa.htm",
      "contextRef": "C_20201001to20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "drug:DescriptionOfAccountingPolicyForBasisOfConsolidationExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "form20fa.htm",
      "contextRef": "C_20201001to20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "drug:DisclosureOfDetailedInformationAboutTradePayableAndAccruedExpensesExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0021 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED LIABILITIES (Tables)",
     "role": "http://brightmindsbio.com/role/ACCOUNTSPAYABLEANDACCRUEDLIABILITIESTables",
     "shortName": "ACCOUNTS PAYABLE AND ACCRUED LIABILITIES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "form20fa.htm",
      "contextRef": "C_20201001to20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "drug:DisclosureOfDetailedInformationAboutTradePayableAndAccruedExpensesExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "form20fa.htm",
      "contextRef": "C_20201001to20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0022 - Disclosure - SHARE CAPITAL (Tables)",
     "role": "http://brightmindsbio.com/role/SHARECAPITALTables",
     "shortName": "SHARE CAPITAL (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "form20fa.htm",
      "contextRef": "C_20201001to20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ifrs-full:DisclosureOfRelatedPartyExplanatory",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "form20fa.htm",
      "contextRef": "C_20201001to20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfInformationAboutKeyManagementPersonnelExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0023 - Disclosure - RELATED PARTY TRANSACTIONS (Tables)",
     "role": "http://brightmindsbio.com/role/RELATEDPARTYTRANSACTIONSTables",
     "shortName": "RELATED PARTY TRANSACTIONS (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ifrs-full:DisclosureOfRelatedPartyExplanatory",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "form20fa.htm",
      "contextRef": "C_20201001to20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfInformationAboutKeyManagementPersonnelExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ifrs-full:DisclosureOfFinancialInstrumentsExplanatory",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "form20fa.htm",
      "contextRef": "C_20201001to20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0024 - Disclosure - FINANCIAL INSTRUMENTS AND CAPITAL MANAGEMENT (Tables)",
     "role": "http://brightmindsbio.com/role/FINANCIALINSTRUMENTSANDCAPITALMANAGEMENTTables",
     "shortName": "FINANCIAL INSTRUMENTS AND CAPITAL MANAGEMENT (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ifrs-full:DisclosureOfFinancialInstrumentsExplanatory",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "form20fa.htm",
      "contextRef": "C_20201001to20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ifrs-full:DisclosureOfResearchAndDevelopmentExpenseExplanatory",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "form20fa.htm",
      "contextRef": "C_20201001to20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "drug:DisclosureOfDetailedInformationAboutResearchAndDevelopmentExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0025 - Disclosure - RESEARCH AND DEVELOPMENT (Tables)",
     "role": "http://brightmindsbio.com/role/RESEARCHANDDEVELOPMENTTables",
     "shortName": "RESEARCH AND DEVELOPMENT (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ifrs-full:DisclosureOfResearchAndDevelopmentExpenseExplanatory",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "form20fa.htm",
      "contextRef": "C_20201001to20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "drug:DisclosureOfDetailedInformationAboutResearchAndDevelopmentExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "form20fa.htm",
      "contextRef": "C_20201001to20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "drug:DisclosureOfReconciliationOfExpectedIncomeTaxRecoveryToActualIncomeTaxRecoveryExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0026 - Disclosure - INCOME TAXES (Tables)",
     "role": "http://brightmindsbio.com/role/INCOMETAXESTables",
     "shortName": "INCOME TAXES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "form20fa.htm",
      "contextRef": "C_20201001to20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "drug:DisclosureOfReconciliationOfExpectedIncomeTaxRecoveryToActualIncomeTaxRecoveryExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "div",
       "drug:DisclosureOfNatureAndContinuanceOfOperationsExplanatory",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "form20fa.htm",
      "contextRef": "C_20210930to20210930",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "ifrs-full:ProfitLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "CAD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0027 - Disclosure - NATURE AND CONTINUANCE OF OPERATIONS (Narrative) (Details)",
     "role": "http://brightmindsbio.com/role/NATUREANDCONTINUANCEOFOPERATIONSDetailTextuals",
     "shortName": "NATURE AND CONTINUANCE OF OPERATIONS (Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "div",
       "drug:DisclosureOfNatureAndContinuanceOfOperationsExplanatory",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "form20fa.htm",
      "contextRef": "C_20210930to20210930",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "ifrs-full:ProfitLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "CAD",
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "div",
       "drug:DisclosureOfShareExchangeAndAssignmentExplanatory",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "form20fa.htm",
      "contextRef": "C_20190425_ifrsfullCategoriesOfRelatedPartiesAxis_drugPsilocybinlabsLtdMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "drug:NumberOfSharesIssuedByRelatedParty",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Share",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0029 - Disclosure - SHARE EXCHANGE AND ASSIGNMENT (Narrative) (Details)",
     "role": "http://brightmindsbio.com/role/SHAREEXCHANGEANDASSIGNMENTDetailTextuals",
     "shortName": "SHARE EXCHANGE AND ASSIGNMENT (Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "div",
       "drug:DisclosureOfShareExchangeAndAssignmentExplanatory",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "form20fa.htm",
      "contextRef": "C_20190425_ifrsfullCategoriesOfRelatedPartiesAxis_drugPsilocybinlabsLtdMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "drug:NumberOfSharesIssuedByRelatedParty",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Share",
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "b",
       "span",
       "span",
       "td",
       "tr",
       "table",
       "drug:DisclosureOfDetailedInformationAboutTradePayableAndAccruedExpensesExplanatory",
       "div",
       "ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "form20fa.htm",
      "contextRef": "C_20210930",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers",
      "reportCount": 1,
      "unique": true,
      "unitRef": "CAD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0030 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED LIABILITIES - Disclosure of accounts payable and accrued liabilities (Details)",
     "role": "http://brightmindsbio.com/role/ACCOUNTSPAYABLEANDACCRUEDLIABILITIESDetails",
     "shortName": "ACCOUNTS PAYABLE AND ACCRUED LIABILITIES - Disclosure of accounts payable and accrued liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "b",
       "span",
       "span",
       "td",
       "tr",
       "table",
       "drug:DisclosureOfDetailedInformationAboutTradePayableAndAccruedExpensesExplanatory",
       "div",
       "ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "form20fa.htm",
      "contextRef": "C_20210930",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers",
      "reportCount": 1,
      "unique": true,
      "unitRef": "CAD",
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "form20fa.htm",
      "contextRef": "C_20190601to20190930",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "drug:ConsultingFees",
      "reportCount": 1,
      "unique": true,
      "unitRef": "CAD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0003 - Statement - Consolidated Statements of Comprehensive Loss",
     "role": "http://brightmindsbio.com/role/ConsolidatedStatementsOfComprehensiveLoss",
     "shortName": "Consolidated Statements of Comprehensive Loss",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "form20fa.htm",
      "contextRef": "C_20190601to20190930",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "drug:ConsultingFees",
      "reportCount": 1,
      "unique": true,
      "unitRef": "CAD",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "div",
       "ifrs-full:DisclosureOfIssuedCapitalExplanatory",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "form20fa.htm",
      "contextRef": "C_20201001to20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "drug:DescriptionOfIssuedAndOutstandingCommonShares",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0031 - Disclosure - SHARE CAPITAL (Narrative) (Details)",
     "role": "http://brightmindsbio.com/role/SHARECAPITALDetailTextuals",
     "shortName": "SHARE CAPITAL (Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "div",
       "ifrs-full:DisclosureOfIssuedCapitalExplanatory",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "form20fa.htm",
      "contextRef": "C_20201001to20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "drug:DescriptionOfIssuedAndOutstandingCommonShares",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "b",
       "span",
       "span",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory",
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "form20fa.htm",
      "contextRef": "C_20200930_ifrsfullClassesOfShareCapitalAxis_drugStockOptionsMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "ifrs-full:NumberOfOutstandingShareOptions",
      "reportCount": 1,
      "unitRef": "Share",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0032 - Disclosure - SHARE CAPITAL - Disclosure of number and weighted average exercise prices of share options (Details)",
     "role": "http://brightmindsbio.com/role/SHARECAPITALDetails",
     "shortName": "SHARE CAPITAL - Disclosure of number and weighted average exercise prices of share options (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "b",
       "span",
       "span",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory",
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "form20fa.htm",
      "contextRef": "C_20190930_ifrsfullClassesOfShareCapitalAxis_drugStockOptionsMember",
      "decimals": "0",
      "lang": null,
      "name": "ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019",
      "reportCount": 1,
      "unique": true,
      "unitRef": "CAD_per_share",
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "b",
       "span",
       "span",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory",
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "form20fa.htm",
      "contextRef": "C_20210930_ifrsfullClassesOfShareCapitalAxis_drugStockOptionsMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "ifrs-full:NumberOfOutstandingShareOptions",
      "reportCount": 1,
      "unitRef": "Share",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0033 - Disclosure - SHARE CAPITAL - Disclosure of number of issued and outstanding stock options (Details)",
     "role": "http://brightmindsbio.com/role/SHARECAPITALDetails1",
     "shortName": "SHARE CAPITAL - Disclosure of number of issued and outstanding stock options (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "div",
       "drug:DisclosureOfNumberOfIssuedAndOutstandingStockOptionsExplanatory",
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "form20fa.htm",
      "contextRef": "C_20210930_drugExpiryDateAxis_drugExpiryDateTwentyOneSeptemberTwoThousandAndTwentyFourMember_ifrsfullClassesOfShareCapitalAxis_drugStockOptionsMember",
      "decimals": "INF",
      "lang": null,
      "name": "ifrs-full:NumberOfOutstandingShareOptions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Share",
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "b",
       "span",
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory",
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "form20fa.htm",
      "contextRef": "C_20200930_ifrsfullClassesOfShareCapitalAxis_drugRestrictedShareUnitMember",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement",
      "reportCount": 1,
      "unitRef": "Share",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0034 - Disclosure - SHARE CAPITAL - Disclosure of number and weighted average exercise prices of restricted share units (Details)",
     "role": "http://brightmindsbio.com/role/SHARECAPITALDetails2",
     "shortName": "SHARE CAPITAL - Disclosure of number and weighted average exercise prices of restricted share units (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory",
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "form20fa.htm",
      "contextRef": "C_20190930_ifrsfullClassesOfShareCapitalAxis_drugRestrictedShareUnitMember",
      "decimals": "0",
      "lang": null,
      "name": "ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Share",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "div",
       "drug:DisclosureOfDetailedInformationAboutEquitySettledRestrictedShareUnitsFairValueInputsExplanatory",
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "form20fa.htm",
      "contextRef": "C_20191001to20200930_ifrsfullClassesOfShareCapitalAxis_drugRestrictedShareUnitMember_ifrsfullTypesOfSharebasedPaymentArrangementsAxis_drugEquitySettledShareBasedPaymentArrangementsMember",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "drug:SharePriceOnGrantDateOfOtherEquityInstruments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "CAD_per_share",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0035 - Disclosure - SHARE CAPITAL - Disclosure of equity-settled restricted share units fair value inputs (Details)",
     "role": "http://brightmindsbio.com/role/SHARECAPITALDetails3",
     "shortName": "SHARE CAPITAL - Disclosure of equity-settled restricted share units fair value inputs (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "div",
       "drug:DisclosureOfDetailedInformationAboutEquitySettledRestrictedShareUnitsFairValueInputsExplanatory",
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "form20fa.htm",
      "contextRef": "C_20191001to20200930_ifrsfullClassesOfShareCapitalAxis_drugRestrictedShareUnitMember_ifrsfullTypesOfSharebasedPaymentArrangementsAxis_drugEquitySettledShareBasedPaymentArrangementsMember",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "drug:SharePriceOnGrantDateOfOtherEquityInstruments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "CAD_per_share",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "div",
       "drug:DisclosureOfDetailedInformationAboutShareBasedPaymentsRecognizedInConsolidatedStatementsOfComprehensiveLossExplanatory",
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "form20fa.htm",
      "contextRef": "C_20190531to20190930",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees",
      "reportCount": 1,
      "unitRef": "CAD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0036 - Disclosure - SHARE CAPITAL - Disclosure of share based payments recognized in the consolidated statements of comprehensive loss (Details)",
     "role": "http://brightmindsbio.com/role/SHARECAPITALDetails4",
     "shortName": "SHARE CAPITAL - Disclosure of share based payments recognized in the consolidated statements of comprehensive loss (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "div",
       "drug:DisclosureOfDetailedInformationAboutShareBasedPaymentsRecognizedInConsolidatedStatementsOfComprehensiveLossExplanatory",
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "form20fa.htm",
      "contextRef": "C_20190531to20190930_ifrsfullTypesOfSharebasedPaymentArrangementsAxis_drugEquitySettledShareBasedPaymentArrangementsMember",
      "decimals": "0",
      "lang": null,
      "name": "ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees",
      "reportCount": 1,
      "unique": true,
      "unitRef": "CAD",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "div",
       "drug:DisclosureOfDetailedInformationAboutShareBasedPaymentsRecognizedInConsolidatedStatementsOfComprehensiveLossExplanatory",
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "form20fa.htm",
      "contextRef": "C_20190531to20190930",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees",
      "reportCount": 1,
      "unitRef": "CAD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0037 - Disclosure - SHARE CAPITAL - Disclosure of share based payments included in the consolidated statements of comprehensive loss (Details)",
     "role": "http://brightmindsbio.com/role/SHARECAPITALDetails5",
     "shortName": "SHARE CAPITAL - Disclosure of share based payments included in the consolidated statements of comprehensive loss (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "div",
       "drug:DisclosureOfDetailedInformationAboutShareBasedPaymentsIncludedInConsolidatedStatementsOfComprehensiveLossExplanatory",
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "form20fa.htm",
      "contextRef": "C_20190531to20190930_drugConsolidatedStatementsOfComprehensiveIncomeLossStatementLocationAxis_drugConsultingFeesMember",
      "decimals": "0",
      "lang": null,
      "name": "ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees",
      "reportCount": 1,
      "unique": true,
      "unitRef": "CAD",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "i",
       "span",
       "span",
       "p",
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "form20fa.htm",
      "contextRef": "C_20201102",
      "decimals": "3",
      "first": true,
      "lang": null,
      "name": "drug:WeightedAverageExercisePriceOfWarrantsOutstandingInShareBasedPaymentArrangement",
      "reportCount": 1,
      "unitRef": "CAD_per_share",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0038 - Disclosure - SHARE CAPITAL -  Disclosure of number and weighted average exercise prices of warrants (Details)",
     "role": "http://brightmindsbio.com/role/SHARECAPITALDetails6",
     "shortName": "SHARE CAPITAL -  Disclosure of number and weighted average exercise prices of warrants (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "div",
       "drug:DisclosureOfNumberAndWeightedAverageExercisePricesOfWarrantsExplanatory",
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "form20fa.htm",
      "contextRef": "C_20201001to20210930_ifrsfullClassesOfShareCapitalAxis_drugWarrantsMember",
      "decimals": "INF",
      "lang": null,
      "name": "drug:NumberOfWarrantsIssuedToBroker",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Share",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "i",
       "span",
       "span",
       "p",
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "form20fa.htm",
      "contextRef": "C_20201102",
      "decimals": "3",
      "first": true,
      "lang": null,
      "name": "drug:WeightedAverageExercisePriceOfWarrantsOutstandingInShareBasedPaymentArrangement",
      "reportCount": 1,
      "unitRef": "CAD_per_share",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0039 - Disclosure - SHARE CAPITAL - Disclosure of number of outstanding warrants (Details)",
     "role": "http://brightmindsbio.com/role/SHARECAPITALDetails7",
     "shortName": "SHARE CAPITAL - Disclosure of number of outstanding warrants (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "div",
       "drug:DisclosureOfNumberOfIssuedAndOutstandingWarrantsExplanatory",
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "form20fa.htm",
      "contextRef": "C_20210930_drugExpiryDateAxis_drugExpiryDateThirtyJulyTwoThousandAndTwentyFourMember_ifrsfullClassesOfShareCapitalAxis_drugWarrantsMember",
      "decimals": "INF",
      "lang": null,
      "name": "drug:NumberOfWarrantsOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Share",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ifrs-full:DisclosureOfInformationAboutKeyManagementPersonnelExplanatory",
       "div",
       "ifrs-full:DisclosureOfRelatedPartyExplanatory",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "form20fa.htm",
      "contextRef": "C_20190601to20190930",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "drug:KeyManagementPersonnelProfessionalFees",
      "reportCount": 1,
      "unique": true,
      "unitRef": "CAD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0040 - Disclosure - RELATED PARTY TRANSACTIONS - Disclosure of expenses related to key management personnel (Details)",
     "role": "http://brightmindsbio.com/role/RELATEDPARTYTRANSACTIONSDetails",
     "shortName": "RELATED PARTY TRANSACTIONS - Disclosure of expenses related to key management personnel (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ifrs-full:DisclosureOfInformationAboutKeyManagementPersonnelExplanatory",
       "div",
       "ifrs-full:DisclosureOfRelatedPartyExplanatory",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "form20fa.htm",
      "contextRef": "C_20190601to20190930",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "drug:KeyManagementPersonnelProfessionalFees",
      "reportCount": 1,
      "unique": true,
      "unitRef": "CAD",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "b",
       "span",
       "span",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "form20fa.htm",
      "contextRef": "C_20190531_ifrsfullComponentsOfEquityAxis_ifrsfullIssuedCapitalMember",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "ifrs-full:Equity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "CAD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0004 - Statement - Consolidated Statements of Changes in Shareholders' Equity",
     "role": "http://brightmindsbio.com/role/ConsolidatedStatementsOfChangesInShareholdersEquity",
     "shortName": "Consolidated Statements of Changes in Shareholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "b",
       "span",
       "span",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "form20fa.htm",
      "contextRef": "C_20190531_ifrsfullComponentsOfEquityAxis_ifrsfullIssuedCapitalMember",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "ifrs-full:Equity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "CAD",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "form20fa.htm",
      "contextRef": "C_20190601to20190930",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "ifrs-full:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unitRef": "CAD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0041 - Disclosure - CONTRACTUAL OBLIGATIONS (Narrative) (Details)",
     "role": "http://brightmindsbio.com/role/CONTRACTUALOBLIGATIONSDetailTextuals",
     "shortName": "CONTRACTUAL OBLIGATIONS (Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "div",
       "ifrs-full:DisclosureOfCommitmentsExplanatory",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "form20fa.htm",
      "contextRef": "C_20200501to20200526_drugAgreementAxis_drugOptionAgreementMember",
      "decimals": "0",
      "lang": null,
      "name": "drug:NonRefundableOptionFeesPaid",
      "reportCount": 1,
      "unique": true,
      "unitRef": "CAD",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "b",
       "span",
       "span",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "form20fa.htm",
      "contextRef": "C_20210930",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "ifrs-full:CashAndCashEquivalents",
      "reportCount": 1,
      "unitRef": "CAD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0042 - Disclosure - FINANCIAL INSTRUMENTS AND CAPITAL MANAGEMENT (Narrative) (Details)",
     "role": "http://brightmindsbio.com/role/FINANCIALINSTRUMENTSANDCAPITALMANAGEMENTDetailTextuals",
     "shortName": "FINANCIAL INSTRUMENTS AND CAPITAL MANAGEMENT (Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "div",
       "ifrs-full:DisclosureOfFinancialInstrumentsExplanatory",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "form20fa.htm",
      "contextRef": "C_20210930_ifrsfullTypesOfRisksAxis_ifrsfullCreditRiskMember",
      "decimals": "0",
      "lang": null,
      "name": "ifrs-full:CashAndCashEquivalents",
      "reportCount": 1,
      "unique": true,
      "unitRef": "CAD",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "b",
       "span",
       "span",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "form20fa.htm",
      "contextRef": "C_20210930",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "ifrs-full:CashAndCashEquivalents",
      "reportCount": 1,
      "unitRef": "CAD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0043 - Disclosure - FINANCIAL INSTRUMENTS AND CAPITAL MANAGEMENT - Disclosure of carrying value of financial assets and liabilities (Details)",
     "role": "http://brightmindsbio.com/role/FINANCIALINSTRUMENTSANDCAPITALMANAGEMENTDetails",
     "shortName": "FINANCIAL INSTRUMENTS AND CAPITAL MANAGEMENT - Disclosure of carrying value of financial assets and liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "b",
       "span",
       "span",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ifrs-full:DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory",
       "div",
       "ifrs-full:DisclosureOfFinancialInstrumentsExplanatory",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "form20fa.htm",
      "contextRef": "C_20210930_ifrsfullClassesOfFinancialInstrumentsAxis_drugFinancialInstrumentsAtFairValueThroughProfitOrLossMember",
      "decimals": "0",
      "lang": null,
      "name": "ifrs-full:Cash",
      "reportCount": 1,
      "unique": true,
      "unitRef": "CAD",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "form20fa.htm",
      "contextRef": "C_20190601to20190930",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "ifrs-full:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unitRef": "CAD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0044 - Disclosure - RESEARCH AND DEVELOPMENT - Disclosure of research and development expense (Details)",
     "role": "http://brightmindsbio.com/role/RESEARCHANDDEVELOPMENTDetails",
     "shortName": "RESEARCH AND DEVELOPMENT - Disclosure of research and development expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "td",
       "tr",
       "table",
       "drug:DisclosureOfDetailedInformationAboutResearchAndDevelopmentExplanatory",
       "div",
       "ifrs-full:DisclosureOfResearchAndDevelopmentExpenseExplanatory",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "form20fa.htm",
      "contextRef": "C_20190601to20190930_drugCategoriesOfResearchAndDevelopmentExpensesAxis_drugLaboratoryCostsMember",
      "decimals": "0",
      "lang": null,
      "name": "ifrs-full:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "CAD",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "div",
       "ifrs-full:DisclosureOfLeasesExplanatory",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "form20fa.htm",
      "contextRef": "C_20210601to20210930_ifrsfullClassesOfAssetsAxis_drugCommercialLaboratoryLeaseMember",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "drug:TermOfLease",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0045 - Disclosure - PREMISES LEASES (Narrative) (Details)",
     "role": "http://brightmindsbio.com/role/PREMISESLEASESDetailTextuals",
     "shortName": "PREMISES LEASES (Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "div",
       "ifrs-full:DisclosureOfLeasesExplanatory",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "form20fa.htm",
      "contextRef": "C_20210601to20210930_ifrsfullClassesOfAssetsAxis_drugCommercialLaboratoryLeaseMember",
      "decimals": "0",
      "lang": null,
      "name": "drug:MonthlyBaseRent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "form20fa.htm",
      "contextRef": "C_20210930_drugIncomeTaxAuthorityNameOfCountryAxis_drugTaxAuthorityOfCanadaMember",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "drug:NonCapitalLossCarryForwards",
      "reportCount": 1,
      "unitRef": "CAD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0046 - Disclosure - INCOME TAXES (Narrative) (Details)",
     "role": "http://brightmindsbio.com/role/INCOMETAXESDetailTextuals",
     "shortName": "INCOME TAXES (Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "form20fa.htm",
      "contextRef": "C_20210930_drugIncomeTaxAuthorityNameOfCountryAxis_drugTaxAuthorityOfUnitedStatesMember",
      "decimals": "0",
      "lang": null,
      "name": "drug:NonCapitalLossCarryForwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "CAD",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "b",
       "span",
       "span",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "drug:DisclosureOfReconciliationOfExpectedIncomeTaxRecoveryToActualIncomeTaxRecoveryExplanatory",
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "form20fa.htm",
      "contextRef": "C_20201001to20210930",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "ifrs-full:AccountingProfit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "CAD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0047 - Disclosure - INCOME TAXES  - Disclosure of reconciliation of the expected income tax recovery to the actual income tax recovery (Details)",
     "role": "http://brightmindsbio.com/role/INCOMETAXESDetails",
     "shortName": "INCOME TAXES  - Disclosure of reconciliation of the expected income tax recovery to the actual income tax recovery (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "b",
       "span",
       "span",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "drug:DisclosureOfReconciliationOfExpectedIncomeTaxRecoveryToActualIncomeTaxRecoveryExplanatory",
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "form20fa.htm",
      "contextRef": "C_20201001to20210930",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "ifrs-full:AccountingProfit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "CAD",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "b",
       "span",
       "span",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ifrs-full:DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory",
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "form20fa.htm",
      "contextRef": "C_20210930",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised",
      "reportCount": 1,
      "unique": true,
      "unitRef": "CAD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0048 - Disclosure - INCOME TAXES - Disclosure of deductible temporary differences for which no deferred tax has been recognized (Details)",
     "role": "http://brightmindsbio.com/role/INCOMETAXESDetails1",
     "shortName": "INCOME TAXES - Disclosure of deductible temporary differences for which no deferred tax has been recognized (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "b",
       "span",
       "span",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ifrs-full:DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory",
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "form20fa.htm",
      "contextRef": "C_20210930",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised",
      "reportCount": 1,
      "unique": true,
      "unitRef": "CAD",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "form20fa.htm",
      "contextRef": "C_20210930_drugIncomeTaxAuthorityNameOfCountryAxis_drugTaxAuthorityOfCanadaMember",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "drug:NonCapitalLossCarryForwards",
      "reportCount": 1,
      "unitRef": "CAD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0049 - Disclosure - INCOME TAXES  - Disclosure of non-capital loss carry-forwards expiry (Details)",
     "role": "http://brightmindsbio.com/role/INCOMETAXESDetails2",
     "shortName": "INCOME TAXES  - Disclosure of non-capital loss carry-forwards expiry (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "div",
       "drug:DisclosureOfNonCapitalLossCarryForwardsExpiryExplanatory",
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "form20fa.htm",
      "contextRef": "C_20210930_drugIncomeTaxAuthorityNameOfCountryAxis_drugTaxAuthorityOfCanadaMember_drugNonCapitalLossCarryForwardsYearOfOriginAxis_drugTaxYearOfOrigin2019Member",
      "decimals": "0",
      "lang": null,
      "name": "drug:NonCapitalLossCarryForwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "CAD",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "div",
       "ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "form20fa.htm",
      "contextRef": "C_20211001to20211101_drugTypeOfArrangementsAxis_drugLetterAgreementMember_ifrsfullNonadjustingEventsAfterReportingPeriodAxis_drugSubsequentEventsMember",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "drug:AmountOfNonRefundableMonthlyRetainerAsServiceCompensation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "CAD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0050 - Disclosure - SUBSEQUENT EVENTS (Narrative) (Details)",
     "role": "http://brightmindsbio.com/role/SUBSEQUENTEVENTSDetailTextuals",
     "shortName": "SUBSEQUENT EVENTS (Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "div",
       "ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "form20fa.htm",
      "contextRef": "C_20211001to20211101_drugTypeOfArrangementsAxis_drugLetterAgreementMember_ifrsfullNonadjustingEventsAfterReportingPeriodAxis_drugSubsequentEventsMember",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "drug:AmountOfNonRefundableMonthlyRetainerAsServiceCompensation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "CAD",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "form20fa.htm",
      "contextRef": "C_20190601to20190930",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "ifrs-full:ProfitLoss",
      "reportCount": 1,
      "unitRef": "CAD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0005 - Statement - Consolidated Statements of Cash Flows",
     "role": "http://brightmindsbio.com/role/ConsolidatedStatementsOfCashFlows",
     "shortName": "Consolidated Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "form20fa.htm",
      "contextRef": "C_20190601to20190930",
      "decimals": "0",
      "lang": null,
      "name": "ifrs-full:AdjustmentsForUnrealisedForeignExchangeLossesGains",
      "reportCount": 1,
      "unique": true,
      "unitRef": "CAD",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "form20fa.htm",
      "contextRef": "C_20201001to20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "drug:DisclosureOfNatureAndContinuanceOfOperationsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0006 - Disclosure - NATURE AND CONTINUANCE OF OPERATIONS",
     "role": "http://brightmindsbio.com/role/NATUREANDCONTINUANCEOFOPERATIONS",
     "shortName": "NATURE AND CONTINUANCE OF OPERATIONS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "form20fa.htm",
      "contextRef": "C_20201001to20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "drug:DisclosureOfNatureAndContinuanceOfOperationsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "form20fa.htm",
      "contextRef": "C_20201001to20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0007 - Disclosure - STATEMENT OF COMPLIANCE AND BASIS OF PREPARATION",
     "role": "http://brightmindsbio.com/role/STATEMENTOFCOMPLIANCEANDBASISOFPREPARATION",
     "shortName": "STATEMENT OF COMPLIANCE AND BASIS OF PREPARATION",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "form20fa.htm",
      "contextRef": "C_20201001to20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "form20fa.htm",
      "contextRef": "C_20201001to20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0008 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES",
     "role": "http://brightmindsbio.com/role/SIGNIFICANTACCOUNTINGPOLICIES",
     "shortName": "SIGNIFICANT ACCOUNTING POLICIES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "form20fa.htm",
      "contextRef": "C_20201001to20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "form20fa.htm",
      "contextRef": "C_20201001to20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "drug:DisclosureOfShareExchangeAndAssignmentExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0009 - Disclosure - SHARE EXCHANGE AND ASSIGNMENT",
     "role": "http://brightmindsbio.com/role/SHAREEXCHANGEANDASSIGNMENT",
     "shortName": "SHARE EXCHANGE AND ASSIGNMENT",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "form20fa.htm",
      "contextRef": "C_20201001to20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "drug:DisclosureOfShareExchangeAndAssignmentExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 95,
   "tag": {
    "dei_AddressTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An entity may have several addresses for different purposes and this domain represents all such types.",
        "label": "Address Type [Domain]"
       }
      }
     },
     "localname": "AddressTypeDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://brightmindsbio.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of changes contained within amended document.",
        "label": "Amendment Description"
       }
      }
     },
     "localname": "AmendmentDescription",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://brightmindsbio.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://brightmindsbio.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AnnualInformationForm": {
     "auth_ref": [
      "r114"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.",
        "label": "Annual Information Form"
       }
      }
     },
     "localname": "AnnualInformationForm",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://brightmindsbio.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditedAnnualFinancialStatements": {
     "auth_ref": [
      "r114"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.",
        "label": "Audited Annual Financial Statements"
       }
      }
     },
     "localname": "AuditedAnnualFinancialStatements",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://brightmindsbio.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_BusinessContactMember": {
     "auth_ref": [
      "r113",
      "r114"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business contact for the entity",
        "label": "Business Contact [Member]"
       }
      }
     },
     "localname": "BusinessContactMember",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://brightmindsbio.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://brightmindsbio.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_ContactPersonnelEmailAddress": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Email address of contact personnel.",
        "label": "Contact Personnel Email Address"
       }
      }
     },
     "localname": "ContactPersonnelEmailAddress",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://brightmindsbio.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_ContactPersonnelFaxNumber": {
     "auth_ref": [
      "r113"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fax Number of contact personnel.",
        "label": "Contact Personnel Fax Number"
       }
      }
     },
     "localname": "ContactPersonnelFaxNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://brightmindsbio.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_ContactPersonnelName": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of contact personnel",
        "label": "Contact Personnel Name"
       }
      }
     },
     "localname": "ContactPersonnelName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://brightmindsbio.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://brightmindsbio.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAccountingStandard": {
     "auth_ref": [
      "r113"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.",
        "label": "Document Accounting Standard"
       }
      }
     },
     "localname": "DocumentAccountingStandard",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://brightmindsbio.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "accountingStandardItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r112",
      "r113",
      "r114"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://brightmindsbio.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://brightmindsbio.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://brightmindsbio.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://brightmindsbio.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentRegistrationStatement": {
     "auth_ref": [
      "r119"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a registration statement.",
        "label": "Document Registration Statement"
       }
      }
     },
     "localname": "DocumentRegistrationStatement",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://brightmindsbio.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentShellCompanyReport": {
     "auth_ref": [
      "r113"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.",
        "label": "Document Shell Company Report"
       }
      }
     },
     "localname": "DocumentShellCompanyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://brightmindsbio.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r115"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://brightmindsbio.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://brightmindsbio.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://brightmindsbio.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://brightmindsbio.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://brightmindsbio.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCountry": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ISO 3166-1 alpha-2 country code.",
        "label": "Entity Address, Country"
       }
      }
     },
     "localname": "EntityAddressCountry",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://brightmindsbio.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "countryCodeItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://brightmindsbio.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://brightmindsbio.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityAddressesAddressTypeAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table.",
        "label": "Entity Addresses, Address Type [Axis]"
       }
      }
     },
     "localname": "EntityAddressesAddressTypeAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://brightmindsbio.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_EntityAddressesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Entity Addresses [Line Items]"
       }
      }
     },
     "localname": "EntityAddressesLineItems",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://brightmindsbio.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_EntityAddressesTable": {
     "auth_ref": [
      "r116"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Container of address information for the entity",
        "label": "Entity Addresses [Table]"
       }
      }
     },
     "localname": "EntityAddressesTable",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://brightmindsbio.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r116"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://brightmindsbio.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://brightmindsbio.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://brightmindsbio.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.",
        "label": "Entity [Domain]"
       }
      }
     },
     "localname": "EntityDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://brightmindsbio.com/role/SHARECAPITALDetailTextuals"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r116"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://brightmindsbio.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r118"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Entity Ex Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://brightmindsbio.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://brightmindsbio.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r116"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://brightmindsbio.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://brightmindsbio.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r117"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://brightmindsbio.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r116"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://brightmindsbio.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r116"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://brightmindsbio.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://brightmindsbio.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://brightmindsbio.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_IcfrAuditorAttestationFlag": {
     "auth_ref": [
      "r112",
      "r113",
      "r114"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "localname": "IcfrAuditorAttestationFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://brightmindsbio.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_LegalEntityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The set of legal entities associated with a report.",
        "label": "Legal Entity [Axis]"
       }
      }
     },
     "localname": "LegalEntityAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://brightmindsbio.com/role/SHARECAPITALDetailTextuals"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://brightmindsbio.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r110"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://brightmindsbio.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r111"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://brightmindsbio.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://brightmindsbio.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "drug_AcquisitionOfIntangibleAssetsByIssuingCommonShares": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents amount of acquisition of intangible assets by issuing common shares.",
        "label": "Acquisition Of Intangible Assets By Issuing Common Shares",
        "terseLabel": "Acquisition of intangible assets by issuing common shares"
       }
      }
     },
     "localname": "AcquisitionOfIntangibleAssetsByIssuingCommonShares",
     "nsuri": "http://brightmindsbio.com/20210930",
     "presentation": [
      "http://brightmindsbio.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "drug_AdjustmentsForDecreaseIncreaseInPrepaidExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://brightmindsbio.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 10.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents adjustments for decrease increase in prepaid expenses.",
        "label": "Adjustments For Decrease Increase In Prepaid Expenses",
        "terseLabel": "Prepaids"
       }
      }
     },
     "localname": "AdjustmentsForDecreaseIncreaseInPrepaidExpenses",
     "nsuri": "http://brightmindsbio.com/20210930",
     "presentation": [
      "http://brightmindsbio.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "drug_AdjustmentsForDecreaseIncreaseInSalesTaxReceivable": {
     "auth_ref": [],
     "calculation": {
      "http://brightmindsbio.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 20.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents adjustments for decrease increase in sales tax receivable.",
        "label": "Adjustments For Decrease Increase In Sales Tax Receivable",
        "terseLabel": "Sales tax receivable"
       }
      }
     },
     "localname": "AdjustmentsForDecreaseIncreaseInSalesTaxReceivable",
     "nsuri": "http://brightmindsbio.com/20210930",
     "presentation": [
      "http://brightmindsbio.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "drug_AdjustmentsForSharesRecordedAsResearchAndDevelopment": {
     "auth_ref": [],
     "calculation": {
      "http://brightmindsbio.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 40.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Adjustments For Shares recorded as research and development",
        "label": "Adjustments For Shares Recorded As Research And Development",
        "negatedLabel": "Shares recorded as research and development",
        "terseLabel": "Research and development",
        "verboseLabel": "Shares recorded as research and development"
       }
      }
     },
     "localname": "AdjustmentsForSharesRecordedAsResearchAndDevelopment",
     "nsuri": "http://brightmindsbio.com/20210930",
     "presentation": [
      "http://brightmindsbio.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "drug_AdvisorHourlyRate": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Advisor hourly rate.",
        "label": "Advisor Hourly Rate",
        "verboseLabel": "Advisor hourly rate"
       }
      }
     },
     "localname": "AdvisorHourlyRate",
     "nsuri": "http://brightmindsbio.com/20210930",
     "presentation": [
      "http://brightmindsbio.com/role/CONTRACTUALOBLIGATIONSDetailTextuals"
     ],
     "xbrltype": "monetaryItemType"
    },
    "drug_AfterSublicensingAgreementsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information about after any sublicensing agreements.",
        "label": "After Sublicensing agreements [Member]",
        "verboseLabel": "Licensing agreement - after any sublicensing agreements, joint ventures or change of control [Member]"
       }
      }
     },
     "localname": "AfterSublicensingAgreementsMember",
     "nsuri": "http://brightmindsbio.com/20210930",
     "presentation": [
      "http://brightmindsbio.com/role/CONTRACTUALOBLIGATIONSDetailTextuals"
     ],
     "xbrltype": "domainItemType"
    },
    "drug_AggregatePurchaseWarrantsDeposited": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the amount of aggregate purchase warrants deposited.",
        "label": "Aggregate Purchase Warrants Deposited",
        "verboseLabel": "Aggregate purchase warrants deposited"
       }
      }
     },
     "localname": "AggregatePurchaseWarrantsDeposited",
     "nsuri": "http://brightmindsbio.com/20210930",
     "presentation": [
      "http://brightmindsbio.com/role/SHARECAPITALDetailTextuals"
     ],
     "xbrltype": "monetaryItemType"
    },
    "drug_AggregateSecuritiesDepositedToBeHeldInEscrow": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate securities deposited to be held in escrow.",
        "label": "Aggregate Securities Deposited To Be Held In Escrow",
        "verboseLabel": "Aggregate securities deposited to be held in escrow"
       }
      }
     },
     "localname": "AggregateSecuritiesDepositedToBeHeldInEscrow",
     "nsuri": "http://brightmindsbio.com/20210930",
     "presentation": [
      "http://brightmindsbio.com/role/SHARECAPITALDetailTextuals"
     ],
     "xbrltype": "sharesItemType"
    },
    "drug_AgreementAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the types of agreement.",
        "label": "Agreement [Axis]"
       }
      }
     },
     "localname": "AgreementAxis",
     "nsuri": "http://brightmindsbio.com/20210930",
     "presentation": [
      "http://brightmindsbio.com/role/CONTRACTUALOBLIGATIONSDetailTextuals",
      "http://brightmindsbio.com/role/SHARECAPITALDetailTextuals"
     ],
     "xbrltype": "stringItemType"
    },
    "drug_AgreementDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the types of agreement.",
        "label": "Agreement [Domain]"
       }
      }
     },
     "localname": "AgreementDomain",
     "nsuri": "http://brightmindsbio.com/20210930",
     "presentation": [
      "http://brightmindsbio.com/role/CONTRACTUALOBLIGATIONSDetailTextuals",
      "http://brightmindsbio.com/role/SHARECAPITALDetailTextuals"
     ],
     "xbrltype": "domainItemType"
    },
    "drug_AmountOfEscrowProceedsReleased": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of escrow proceeds released.",
        "label": "Amount Of Escrow Proceeds Released",
        "verboseLabel": "Amount of escrow proceeds released"
       }
      }
     },
     "localname": "AmountOfEscrowProceedsReleased",
     "nsuri": "http://brightmindsbio.com/20210930",
     "presentation": [
      "http://brightmindsbio.com/role/SHARECAPITALDetailTextuals"
     ],
     "xbrltype": "monetaryItemType"
    },
    "drug_AmountOfNonRefundableMonthlyRetainerAsServiceCompensation": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of non-refundable monthly retainer as service compensation.",
        "label": "Amount Of Non Refundable Monthly Retainer As Service Compensation",
        "terseLabel": "Amount of non-refundable monthly retainer as service compensation"
       }
      }
     },
     "localname": "AmountOfNonRefundableMonthlyRetainerAsServiceCompensation",
     "nsuri": "http://brightmindsbio.com/20210930",
     "presentation": [
      "http://brightmindsbio.com/role/SUBSEQUENTEVENTSDetailTextuals"
     ],
     "xbrltype": "monetaryItemType"
    },
    "drug_ArrangementsAndNonarrangementTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for arrangements and nonarrangement transaction.",
        "label": "Arrangements And Nonarrangement Transaction [Domain]"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionDomain",
     "nsuri": "http://brightmindsbio.com/20210930",
     "presentation": [
      "http://brightmindsbio.com/role/SUBSEQUENTEVENTSDetailTextuals"
     ],
     "xbrltype": "domainItemType"
    },
    "drug_BritishColumbiaSecuritiesCommissionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "British Columbia Securities Commission [Member]",
        "label": "British Columbia Securities Commission [Member]"
       }
      }
     },
     "localname": "BritishColumbiaSecuritiesCommissionMember",
     "nsuri": "http://brightmindsbio.com/20210930",
     "presentation": [
      "http://brightmindsbio.com/role/SHARECAPITALDetailTextuals"
     ],
     "xbrltype": "domainItemType"
    },
    "drug_CashSettledShareBasedPaymentArrangementsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for an agreement for cash settled transactions.",
        "label": "Cash Settled Share Based Payment Arrangements [Member]",
        "verboseLabel": "Cash settled [Member]"
       }
      }
     },
     "localname": "CashSettledShareBasedPaymentArrangementsMember",
     "nsuri": "http://brightmindsbio.com/20210930",
     "presentation": [
      "http://brightmindsbio.com/role/SHARECAPITALDetails2",
      "http://brightmindsbio.com/role/SHARECAPITALDetails4"
     ],
     "xbrltype": "domainItemType"
    },
    "drug_CategoriesOfResearchAndDevelopmentExpensesAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents categories of Research and Development expenses.",
        "label": "Categories Of Research And Development Expenses [Axis]"
       }
      }
     },
     "localname": "CategoriesOfResearchAndDevelopmentExpensesAxis",
     "nsuri": "http://brightmindsbio.com/20210930",
     "presentation": [
      "http://brightmindsbio.com/role/RESEARCHANDDEVELOPMENTDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "drug_CategoriesOfResearchAndDevelopmentExpensesDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents categories of Research and Development expenses",
        "label": "Categories Of Research And Development Expenses [Domain]"
       }
      }
     },
     "localname": "CategoriesOfResearchAndDevelopmentExpensesDomain",
     "nsuri": "http://brightmindsbio.com/20210930",
     "presentation": [
      "http://brightmindsbio.com/role/RESEARCHANDDEVELOPMENTDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "drug_ChangesInNonCashWorkingOperatingCapitalBalancesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Changes In Non Cash Working Operating Capital Balances [Abstract]",
        "label": "Changes In Non Cash Working Operating Capital Balances [Abstract]",
        "verboseLabel": "Changes in non-cash operating working capital items:"
       }
      }
     },
     "localname": "ChangesInNonCashWorkingOperatingCapitalBalancesAbstract",
     "nsuri": "http://brightmindsbio.com/20210930",
     "presentation": [
      "http://brightmindsbio.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "drug_ChiefFinancialOfficerTwoDirectorsAndSevenConsultantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Chief Financial Officer, two directors and seven consultants.",
        "label": "Chief Financial Officer, Two Directors And Seven Consultants [Member]",
        "verboseLabel": "Chief Financial Officer, two directors and seven consultants [Member]"
       }
      }
     },
     "localname": "ChiefFinancialOfficerTwoDirectorsAndSevenConsultantsMember",
     "nsuri": "http://brightmindsbio.com/20210930",
     "presentation": [
      "http://brightmindsbio.com/role/SHARECAPITALDetailTextuals"
     ],
     "xbrltype": "domainItemType"
    },
    "drug_ChiefMedicalOfficerMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Chief Medical Officer.",
        "label": "Chief Medical Officer [Member]"
       }
      }
     },
     "localname": "ChiefMedicalOfficerMember",
     "nsuri": "http://brightmindsbio.com/20210930",
     "presentation": [
      "http://brightmindsbio.com/role/SHARECAPITALDetailTextuals"
     ],
     "xbrltype": "domainItemType"
    },
    "drug_CommercialLaboratoryLeaseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commercial laboratory lease.",
        "label": "Commercial Laboratory Lease [Member]",
        "terseLabel": "Commercial laboratory [Member]"
       }
      }
     },
     "localname": "CommercialLaboratoryLeaseMember",
     "nsuri": "http://brightmindsbio.com/20210930",
     "presentation": [
      "http://brightmindsbio.com/role/PREMISESLEASESDetailTextuals"
     ],
     "xbrltype": "domainItemType"
    },
    "drug_CommonStockSharesPurchased": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the number of common stock shares purchased.",
        "label": "Common Stock Shares Purchased",
        "verboseLabel": "Common shares purchased"
       }
      }
     },
     "localname": "CommonStockSharesPurchased",
     "nsuri": "http://brightmindsbio.com/20210930",
     "presentation": [
      "http://brightmindsbio.com/role/SHAREEXCHANGEANDASSIGNMENTDetailTextuals"
     ],
     "xbrltype": "sharesItemType"
    },
    "drug_ComparativeAmountsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Comparative Amounts [Abstract]",
        "label": "Comparative Amounts [Abstract]"
       }
      }
     },
     "localname": "ComparativeAmountsAbstract",
     "nsuri": "http://brightmindsbio.com/20210930",
     "xbrltype": "stringItemType"
    },
    "drug_ConsolidatedStatementsOfComprehensiveIncomeLossStatementLocationAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the consolidated statements of comprehensive Income (loss) statement.",
        "label": "Consolidated Statements Of Comprehensive Income (Loss) Statement Location [Axis]"
       }
      }
     },
     "localname": "ConsolidatedStatementsOfComprehensiveIncomeLossStatementLocationAxis",
     "nsuri": "http://brightmindsbio.com/20210930",
     "presentation": [
      "http://brightmindsbio.com/role/SHARECAPITALDetails5"
     ],
     "xbrltype": "stringItemType"
    },
    "drug_ConsolidatedStatementsOfComprehensiveIncomeLossStatementLocationDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the consolidated statements of comprehensive Income (loss) statement.",
        "label": "Consolidated Statements Of Comprehensive Income (Loss) Statement Location [Domain]"
       }
      }
     },
     "localname": "ConsolidatedStatementsOfComprehensiveIncomeLossStatementLocationDomain",
     "nsuri": "http://brightmindsbio.com/20210930",
     "presentation": [
      "http://brightmindsbio.com/role/SHARECAPITALDetails5"
     ],
     "xbrltype": "domainItemType"
    },
    "drug_ConsultantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "consultant [Member]",
        "label": "Consultant [Member]"
       }
      }
     },
     "localname": "ConsultantMember",
     "nsuri": "http://brightmindsbio.com/20210930",
     "presentation": [
      "http://brightmindsbio.com/role/SHARECAPITALDetailTextuals"
     ],
     "xbrltype": "domainItemType"
    },
    "drug_ConsultingAgreementsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information about consulting agreements.",
        "label": "Consulting agreements [Member]"
       }
      }
     },
     "localname": "ConsultingAgreementsMember",
     "nsuri": "http://brightmindsbio.com/20210930",
     "presentation": [
      "http://brightmindsbio.com/role/CONTRACTUALOBLIGATIONSDetailTextuals"
     ],
     "xbrltype": "domainItemType"
    },
    "drug_ConsultingFees": {
     "auth_ref": [],
     "calculation": {
      "http://brightmindsbio.com/role/ConsolidatedStatementsOfComprehensiveLoss": {
       "order": 80.0,
       "parentTag": "ifrs-full_ProfitLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of consulting fees.",
        "label": "Consulting Fees",
        "negatedTotalLabel": "Total fee and commission expense",
        "terseLabel": "Consulting fees"
       }
      }
     },
     "localname": "ConsultingFees",
     "nsuri": "http://brightmindsbio.com/20210930",
     "presentation": [
      "http://brightmindsbio.com/role/ConsolidatedStatementsOfComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "drug_ConsultingFeesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the primary financial statement caption encompassing consulting fees.",
        "label": "Consulting Fees [Member]",
        "verboseLabel": "Consulting fees [Member]"
       }
      }
     },
     "localname": "ConsultingFeesMember",
     "nsuri": "http://brightmindsbio.com/20210930",
     "presentation": [
      "http://brightmindsbio.com/role/SHARECAPITALDetails5"
     ],
     "xbrltype": "domainItemType"
    },
    "drug_ContingentCashFee": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information about contingent cash fee.",
        "label": "Contingent Cash Fee",
        "terseLabel": "Contingent cash fee"
       }
      }
     },
     "localname": "ContingentCashFee",
     "nsuri": "http://brightmindsbio.com/20210930",
     "presentation": [
      "http://brightmindsbio.com/role/SHARECAPITALDetailTextuals"
     ],
     "xbrltype": "monetaryItemType"
    },
    "drug_DebtSettledByIssuingShares": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents debt settled by issuing shares",
        "label": "Debt Settled By Issuing Shares",
        "terseLabel": "Debt settled by issuing shares"
       }
      }
     },
     "localname": "DebtSettledByIssuingShares",
     "nsuri": "http://brightmindsbio.com/20210930",
     "presentation": [
      "http://brightmindsbio.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "drug_DebtSettledThroughIssuanceOfShares": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents amount of debt settled through issuance of shares.",
        "label": "Debt Settled Through Issuance Of Shares",
        "verboseLabel": "Debt settled through issuance of shares"
       }
      }
     },
     "localname": "DebtSettledThroughIssuanceOfShares",
     "nsuri": "http://brightmindsbio.com/20210930",
     "presentation": [
      "http://brightmindsbio.com/role/SHARECAPITALDetailTextuals"
     ],
     "xbrltype": "monetaryItemType"
    },
    "drug_DebtSettlementAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Settlement Agreement [Member]",
        "label": "Debt Settlement Agreement [Member]"
       }
      }
     },
     "localname": "DebtSettlementAgreementMember",
     "nsuri": "http://brightmindsbio.com/20210930",
     "presentation": [
      "http://brightmindsbio.com/role/SHARECAPITALDetailTextuals"
     ],
     "xbrltype": "domainItemType"
    },
    "drug_DescriptionOfAccountingPolicyForBasisOfConsolidationExplanatory": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The description of the entity's accounting policy for basis of consolidation.",
        "label": "Description Of Accounting Policy For Basis Of Consolidation Explanatory",
        "verboseLabel": "Basis of consolidation [Policy Text Block]"
       }
      }
     },
     "localname": "DescriptionOfAccountingPolicyForBasisOfConsolidationExplanatory",
     "nsuri": "http://brightmindsbio.com/20210930",
     "presentation": [
      "http://brightmindsbio.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "drug_DescriptionOfAccountingPolicyForCriticalAccountingEstimatesExplanatory": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The description of the entity's accounting policy for critical accounting estimates.",
        "label": "Description Of Accounting Policy For Critical Accounting Estimates Explanatory",
        "verboseLabel": "Critical accounting estimates [Policy Text Block]"
       }
      }
     },
     "localname": "DescriptionOfAccountingPolicyForCriticalAccountingEstimatesExplanatory",
     "nsuri": "http://brightmindsbio.com/20210930",
     "presentation": [
      "http://brightmindsbio.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "drug_DescriptionOfAccountingPolicyForNewStandardsAndInterpretationsNotYetAdoptedExplanatory": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The description of the entity's accounting policy for New standards and interpretations not yet adopted.",
        "label": "Description Of Accounting Policy For New Standards And Interpretations Not Yet Adopted Explanatory",
        "verboseLabel": "New standards and interpretations not yet adopted [Policy Text Block]"
       }
      }
     },
     "localname": "DescriptionOfAccountingPolicyForNewStandardsAndInterpretationsNotYetAdoptedExplanatory",
     "nsuri": "http://brightmindsbio.com/20210930",
     "presentation": [
      "http://brightmindsbio.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "drug_DescriptionOfIssuedAndOutstandingCommonShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of issued and outstanding common shares.",
        "label": "Description Of Issued And Outstanding Common Shares",
        "terseLabel": "Description of issued and outstanding common shares"
       }
      }
     },
     "localname": "DescriptionOfIssuedAndOutstandingCommonShares",
     "nsuri": "http://brightmindsbio.com/20210930",
     "presentation": [
      "http://brightmindsbio.com/role/SHARECAPITALDetailTextuals"
     ],
     "xbrltype": "stringItemType"
    },
    "drug_DescriptionOfSublicenseeRevenueOfRoyaltyPaymentAccrues": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information about description of sublicensee revenue of royalty payment accrues.",
        "label": "Description Of Sublicensee Revenue Of Royalty Payment Accrues",
        "terseLabel": "Description of sublicensee revenue of royalty payment accrues"
       }
      }
     },
     "localname": "DescriptionOfSublicenseeRevenueOfRoyaltyPaymentAccrues",
     "nsuri": "http://brightmindsbio.com/20210930",
     "presentation": [
      "http://brightmindsbio.com/role/CONTRACTUALOBLIGATIONSDetailTextuals"
     ],
     "xbrltype": "stringItemType"
    },
    "drug_DirectorAndConsultantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Director and consultant",
        "label": "Director And Consultant [Member]",
        "verboseLabel": "Director and Consultant [Member]"
       }
      }
     },
     "localname": "DirectorAndConsultantMember",
     "nsuri": "http://brightmindsbio.com/20210930",
     "presentation": [
      "http://brightmindsbio.com/role/SHARECAPITALDetailTextuals"
     ],
     "xbrltype": "domainItemType"
    },
    "drug_DirectorsCompensationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the primary financial statement caption encompassing directors compensation.",
        "label": "Directors Compensation [Member]",
        "verboseLabel": "Directors' compensation [Member]"
       }
      }
     },
     "localname": "DirectorsCompensationMember",
     "nsuri": "http://brightmindsbio.com/20210930",
     "presentation": [
      "http://brightmindsbio.com/role/SHARECAPITALDetails5"
     ],
     "xbrltype": "domainItemType"
    },
    "drug_DisclosureOfComparativeAmountsExplanatory": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of comparative amounts.",
        "label": "Disclosure Of Comparative Amounts Explanatory",
        "terseLabel": "COMPARATIVE AMOUNTS [Text Block]"
       }
      }
     },
     "localname": "DisclosureOfComparativeAmountsExplanatory",
     "nsuri": "http://brightmindsbio.com/20210930",
     "presentation": [
      "http://brightmindsbio.com/role/ComparativeAmounts"
     ],
     "xbrltype": "textBlockItemType"
    },
    "drug_DisclosureOfContractualObligationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure Of Contractual Obligation [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfContractualObligationAbstract",
     "nsuri": "http://brightmindsbio.com/20210930",
     "xbrltype": "stringItemType"
    },
    "drug_DisclosureOfContractualObligationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure Of Contractual Obligation [Line Items]"
       }
      }
     },
     "localname": "DisclosureOfContractualObligationLineItems",
     "nsuri": "http://brightmindsbio.com/20210930",
     "presentation": [
      "http://brightmindsbio.com/role/CONTRACTUALOBLIGATIONSDetailTextuals"
     ],
     "xbrltype": "stringItemType"
    },
    "drug_DisclosureOfContractualObligationTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of contractual obligation.",
        "label": "Disclosure Of Contractual Obligation [Table]"
       }
      }
     },
     "localname": "DisclosureOfContractualObligationTable",
     "nsuri": "http://brightmindsbio.com/20210930",
     "presentation": [
      "http://brightmindsbio.com/role/CONTRACTUALOBLIGATIONSDetailTextuals"
     ],
     "xbrltype": "stringItemType"
    },
    "drug_DisclosureOfDetailedInformationAboutEquitySettledRestrictedShareUnitsFairValueInputsExplanatory": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure about equity settled restricted share units fair value inputs.",
        "label": "Disclosure Of Detailed Information About Equity Settled Restricted Share Units Fair Value Inputs Explanatory",
        "verboseLabel": "Disclosure of equity-settled restricted share units fair value inputs [Table Text Block]"
       }
      }
     },
     "localname": "DisclosureOfDetailedInformationAboutEquitySettledRestrictedShareUnitsFairValueInputsExplanatory",
     "nsuri": "http://brightmindsbio.com/20210930",
     "presentation": [
      "http://brightmindsbio.com/role/SHARECAPITALTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "drug_DisclosureOfDetailedInformationAboutResearchAndDevelopmentExplanatory": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of detailed information about research and development.",
        "label": "Disclosure Of Detailed Information About Research And Development Explanatory",
        "terseLabel": "Disclosure of research and development expenses [Table Text Block]"
       }
      }
     },
     "localname": "DisclosureOfDetailedInformationAboutResearchAndDevelopmentExplanatory",
     "nsuri": "http://brightmindsbio.com/20210930",
     "presentation": [
      "http://brightmindsbio.com/role/RESEARCHANDDEVELOPMENTTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "drug_DisclosureOfDetailedInformationAboutShareBasedPaymentsIncludedInConsolidatedStatementsOfComprehensiveLossExplanatory": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of detailed information about share based payments included in consolidated statements of comprehensive loss statement.",
        "label": "Disclosure Of Detailed Information About Share Based Payments Included In Consolidated Statements Of Comprehensive Loss Explanatory",
        "verboseLabel": "Disclosure of share based payments included in the consolidated statements of comprehensive loss [Table Text Block]"
       }
      }
     },
     "localname": "DisclosureOfDetailedInformationAboutShareBasedPaymentsIncludedInConsolidatedStatementsOfComprehensiveLossExplanatory",
     "nsuri": "http://brightmindsbio.com/20210930",
     "presentation": [
      "http://brightmindsbio.com/role/SHARECAPITALTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "drug_DisclosureOfDetailedInformationAboutShareBasedPaymentsRecognizedInConsolidatedStatementsOfComprehensiveLossExplanatory": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of detailed information about share based payments recognized in the consolidated statements of comprehensive loss statement.",
        "label": "Disclosure Of Detailed Information About Share Based Payments Recognized In Consolidated Statements Of Comprehensive Loss Explanatory",
        "verboseLabel": "Disclosure of share based payments recognized in the consolidated statements of comprehensive loss [Table Text Block]"
       }
      }
     },
     "localname": "DisclosureOfDetailedInformationAboutShareBasedPaymentsRecognizedInConsolidatedStatementsOfComprehensiveLossExplanatory",
     "nsuri": "http://brightmindsbio.com/20210930",
     "presentation": [
      "http://brightmindsbio.com/role/SHARECAPITALTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "drug_DisclosureOfDetailedInformationAboutSignificantAccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure Of Detailed Information About Significant Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfDetailedInformationAboutSignificantAccountingPoliciesAbstract",
     "nsuri": "http://brightmindsbio.com/20210930",
     "xbrltype": "stringItemType"
    },
    "drug_DisclosureOfDetailedInformationAboutTradePayableAndAccruedExpensesExplanatory": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The disclosure of detailed information about trade payables and accrued expenses.",
        "label": "Disclosure Of Detailed Information About Trade Payable And Accrued Expenses Explanatory",
        "terseLabel": "Disclosure of accounts payable and accrued liabilities [Table Text Block]"
       }
      }
     },
     "localname": "DisclosureOfDetailedInformationAboutTradePayableAndAccruedExpensesExplanatory",
     "nsuri": "http://brightmindsbio.com/20210930",
     "presentation": [
      "http://brightmindsbio.com/role/ACCOUNTSPAYABLEANDACCRUEDLIABILITIESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "drug_DisclosureOfNatureAndContinuanceOfOperationsExplanatory": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The disclosure of nature and continuation of operation.",
        "label": "Disclosure Of Nature And Continuance Of Operations Explanatory",
        "verboseLabel": "NATURE AND CONTINUANCE OF OPERATIONS [Text Block]"
       }
      }
     },
     "localname": "DisclosureOfNatureAndContinuanceOfOperationsExplanatory",
     "nsuri": "http://brightmindsbio.com/20210930",
     "presentation": [
      "http://brightmindsbio.com/role/NATUREANDCONTINUANCEOFOPERATIONS"
     ],
     "xbrltype": "textBlockItemType"
    },
    "drug_DisclosureOfNonCapitalLossCarryForwardsExpiryExplanatory": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The disclosure of non-capital loss carry-forwards expiry.",
        "label": "Disclosure Of Non Capital Loss Carry Forwards Expiry Explanatory",
        "terseLabel": "Disclosure of non-capital loss carry-forwards expiry [Table Text Block]"
       }
      }
     },
     "localname": "DisclosureOfNonCapitalLossCarryForwardsExpiryExplanatory",
     "nsuri": "http://brightmindsbio.com/20210930",
     "presentation": [
      "http://brightmindsbio.com/role/INCOMETAXESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "drug_DisclosureOfNumberAndWeightedAverageExercisePricesOfWarrantsExplanatory": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of number and weighted average exercise prices of warrants explanatory.",
        "label": "Disclosure Of Number And Weighted Average Exercise Prices Of Warrants Explanatory",
        "verboseLabel": "Disclosure of number and weighted average exercise prices of warrants [Table Text Block]"
       }
      }
     },
     "localname": "DisclosureOfNumberAndWeightedAverageExercisePricesOfWarrantsExplanatory",
     "nsuri": "http://brightmindsbio.com/20210930",
     "presentation": [
      "http://brightmindsbio.com/role/SHARECAPITALTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "drug_DisclosureOfNumberOfIssuedAndOutstandingStockOptionsExplanatory": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of number of issued and outstanding stock options explanatory.",
        "label": "Disclosure Of Number Of Issued And Outstanding Stock Options Explanatory",
        "verboseLabel": "Disclosure of number of issued and outstanding stock options [Table Text Block]"
       }
      }
     },
     "localname": "DisclosureOfNumberOfIssuedAndOutstandingStockOptionsExplanatory",
     "nsuri": "http://brightmindsbio.com/20210930",
     "presentation": [
      "http://brightmindsbio.com/role/SHARECAPITALTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "drug_DisclosureOfNumberOfIssuedAndOutstandingWarrantsExplanatory": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of number of issued and outstanding warrants explanatory.",
        "label": "Disclosure Of Number Of Issued And Outstanding Warrants Explanatory",
        "verboseLabel": "Disclosure of number of outstanding warrants [Table Text Block]"
       }
      }
     },
     "localname": "DisclosureOfNumberOfIssuedAndOutstandingWarrantsExplanatory",
     "nsuri": "http://brightmindsbio.com/20210930",
     "presentation": [
      "http://brightmindsbio.com/role/SHARECAPITALTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "drug_DisclosureOfReconciliationOfExpectedIncomeTaxRecoveryToActualIncomeTaxRecoveryExplanatory": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The disclosure of reconciliation of the expected income tax recovery to the actual income tax recovery.",
        "label": "Disclosure Of Reconciliation Of Expected Income Tax Recovery To Actual Income Tax Recovery Explanatory",
        "terseLabel": "Disclosure of reconciliation of the expected income tax recovery to the actual income tax recovery [Table Text Block]"
       }
      }
     },
     "localname": "DisclosureOfReconciliationOfExpectedIncomeTaxRecoveryToActualIncomeTaxRecoveryExplanatory",
     "nsuri": "http://brightmindsbio.com/20210930",
     "presentation": [
      "http://brightmindsbio.com/role/INCOMETAXESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "drug_DisclosureOfShareExchangeAndAssignmentExplanatory": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The disclosure of share exchange and assignment.",
        "label": "Disclosure Of Share Exchange And Assignment Explanatory",
        "verboseLabel": "SHARE EXCHANGE AND ASSIGNMENT [Text Block]"
       }
      }
     },
     "localname": "DisclosureOfShareExchangeAndAssignmentExplanatory",
     "nsuri": "http://brightmindsbio.com/20210930",
     "presentation": [
      "http://brightmindsbio.com/role/SHAREEXCHANGEANDASSIGNMENT"
     ],
     "xbrltype": "textBlockItemType"
    },
    "drug_DisclosureOfShareExchangeAndAssignmentTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule disclosing information related to share exchange and assignment.",
        "label": "Disclosure Of Share Exchange And Assignment [Table]"
       }
      }
     },
     "localname": "DisclosureOfShareExchangeAndAssignmentTable",
     "nsuri": "http://brightmindsbio.com/20210930",
     "presentation": [
      "http://brightmindsbio.com/role/SHAREEXCHANGEANDASSIGNMENTDetailTextuals"
     ],
     "xbrltype": "stringItemType"
    },
    "drug_DiscountRateOfWarrantsGranted": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discount rate of warrants granted.",
        "label": "Discount Rate Of Warrants Granted",
        "verboseLabel": "Discount rate, warrants granted"
       }
      }
     },
     "localname": "DiscountRateOfWarrantsGranted",
     "nsuri": "http://brightmindsbio.com/20210930",
     "presentation": [
      "http://brightmindsbio.com/role/SHARECAPITALDetailTextuals"
     ],
     "xbrltype": "percentItemType"
    },
    "drug_DiscountRateStockOptionGranted": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of discount rate of stock option granted.",
        "label": "Discount Rate, Stock Option Granted",
        "verboseLabel": "Discount rate, stock options granted"
       }
      }
     },
     "localname": "DiscountRateStockOptionGranted",
     "nsuri": "http://brightmindsbio.com/20210930",
     "presentation": [
      "http://brightmindsbio.com/role/SHARECAPITALDetailTextuals"
     ],
     "xbrltype": "percentItemType"
    },
    "drug_EighthTrancheMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Eighth tranche",
        "label": "Eighth Tranche [Member]",
        "verboseLabel": "On the third anniversary of the grant date [Member]"
       }
      }
     },
     "localname": "EighthTrancheMember",
     "nsuri": "http://brightmindsbio.com/20210930",
     "presentation": [
      "http://brightmindsbio.com/role/SHARECAPITALDetailTextuals"
     ],
     "xbrltype": "domainItemType"
    },
    "drug_EleventhTrancheMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Eleventh tranche.",
        "label": "Eleventh Tranche [Member]",
        "verboseLabel": "On the eighteen-month anniversary of the grant date [Member]"
       }
      }
     },
     "localname": "EleventhTrancheMember",
     "nsuri": "http://brightmindsbio.com/20210930",
     "presentation": [
      "http://brightmindsbio.com/role/SHARECAPITALDetailTextuals"
     ],
     "xbrltype": "domainItemType"
    },
    "drug_EquitySettledShareBasedPaymentArrangementsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for an agreement for equity settled transactions.",
        "label": "Equity Settled Share Based Payment Arrangements [Member]",
        "verboseLabel": "Equity settled [Member]"
       }
      }
     },
     "localname": "EquitySettledShareBasedPaymentArrangementsMember",
     "nsuri": "http://brightmindsbio.com/20210930",
     "presentation": [
      "http://brightmindsbio.com/role/SHARECAPITALDetails2",
      "http://brightmindsbio.com/role/SHARECAPITALDetails3",
      "http://brightmindsbio.com/role/SHARECAPITALDetails4"
     ],
     "xbrltype": "domainItemType"
    },
    "drug_EscrowAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "escrow agreement [Member]",
        "label": "Escrow Agreement [Member]"
       }
      }
     },
     "localname": "EscrowAgreementMember",
     "nsuri": "http://brightmindsbio.com/20210930",
     "presentation": [
      "http://brightmindsbio.com/role/SHARECAPITALDetailTextuals"
     ],
     "xbrltype": "domainItemType"
    },
    "drug_EscrowedSecuritiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Escrowed Securities [Member]",
        "label": "Escrowed securities [Member]"
       }
      }
     },
     "localname": "EscrowedSecuritiesMember",
     "nsuri": "http://brightmindsbio.com/20210930",
     "presentation": [
      "http://brightmindsbio.com/role/SHARECAPITALDetailTextuals"
     ],
     "xbrltype": "domainItemType"
    },
    "drug_EscrowedSecuritiesToBeReleasedAfterListingDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents number of escrowed securities to be released after listing date.",
        "label": "Escrowed Securities To Be Released After Listing Date",
        "verboseLabel": "Escrowed securities to be released after listing date"
       }
      }
     },
     "localname": "EscrowedSecuritiesToBeReleasedAfterListingDate",
     "nsuri": "http://brightmindsbio.com/20210930",
     "presentation": [
      "http://brightmindsbio.com/role/SHARECAPITALDetailTextuals"
     ],
     "xbrltype": "sharesItemType"
    },
    "drug_EscrowedSecuritiesToBeReleasedOnceSharesAreListedOnCanadianStockExchange": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents escrowed securities to be released once shares are listed on Canadian Stock Exchange.",
        "label": "Escrowed Securities To Be Released Once Shares Are Listed On Canadian Stock Exchange",
        "verboseLabel": "Escrowed securities to be released once shares are listed on Canadian Stock Exchange"
       }
      }
     },
     "localname": "EscrowedSecuritiesToBeReleasedOnceSharesAreListedOnCanadianStockExchange",
     "nsuri": "http://brightmindsbio.com/20210930",
     "presentation": [
      "http://brightmindsbio.com/role/SHARECAPITALDetailTextuals"
     ],
     "xbrltype": "sharesItemType"
    },
    "drug_EscrowedSharePurchaseWarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Escrowed share purchase warrants.",
        "label": "Escrowed Share Purchase Warrants [Member]",
        "verboseLabel": "Escrowed share purchase warrants [Member]"
       }
      }
     },
     "localname": "EscrowedSharePurchaseWarrantsMember",
     "nsuri": "http://brightmindsbio.com/20210930",
     "presentation": [
      "http://brightmindsbio.com/role/SHARECAPITALDetailTextuals"
     ],
     "xbrltype": "domainItemType"
    },
    "drug_EstimatedFairValueOfEquitySettledRsusGranted": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Estimated fair value of equity settled RSUs granted.",
        "label": "Estimated Fair Value Of Equity Settled Rsus Granted",
        "verboseLabel": "Estimated fair value of equity settled RSUs granted"
       }
      }
     },
     "localname": "EstimatedFairValueOfEquitySettledRsusGranted",
     "nsuri": "http://brightmindsbio.com/20210930",
     "presentation": [
      "http://brightmindsbio.com/role/SHARECAPITALDetailTextuals"
     ],
     "xbrltype": "monetaryItemType"
    },
    "drug_EstimatedLifeOfWarrantsGranted": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Estimated life of warrants granted.",
        "label": "Estimated Life Of Warrants Granted",
        "verboseLabel": "Estimated life, warrants granted"
       }
      }
     },
     "localname": "EstimatedLifeOfWarrantsGranted",
     "nsuri": "http://brightmindsbio.com/20210930",
     "presentation": [
      "http://brightmindsbio.com/role/SHARECAPITALDetailTextuals"
     ],
     "xbrltype": "decimalItemType"
    },
    "drug_ExercisePriceWarrantsGranted": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise price, warrants granted.",
        "label": "Exercise Price, Warrants Granted",
        "verboseLabel": "Exercise price, warrants granted"
       }
      }
     },
     "localname": "ExercisePriceWarrantsGranted",
     "nsuri": "http://brightmindsbio.com/20210930",
     "presentation": [
      "http://brightmindsbio.com/role/SHARECAPITALDetailTextuals"
     ],
     "xbrltype": "perShareItemType"
    },
    "drug_ExpectedVolatilityWarrantsGranted": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected volatility of warrants granted.",
        "label": "Expected Volatility, Warrants Granted",
        "verboseLabel": "Expected volatility, warrants granted"
       }
      }
     },
     "localname": "ExpectedVolatilityWarrantsGranted",
     "nsuri": "http://brightmindsbio.com/20210930",
     "presentation": [
      "http://brightmindsbio.com/role/SHARECAPITALDetailTextuals"
     ],
     "xbrltype": "percentItemType"
    },
    "drug_ExpiryDateAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table.",
        "label": "Expiry Date [Axis]"
       }
      }
     },
     "localname": "ExpiryDateAxis",
     "nsuri": "http://brightmindsbio.com/20210930",
     "presentation": [
      "http://brightmindsbio.com/role/SHARECAPITALDetails1",
      "http://brightmindsbio.com/role/SHARECAPITALDetails7"
     ],
     "xbrltype": "stringItemType"
    },
    "drug_ExpiryDateDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for the expiry date.",
        "label": "Expiry Date [Domain]"
       }
      }
     },
     "localname": "ExpiryDateDomain",
     "nsuri": "http://brightmindsbio.com/20210930",
     "presentation": [
      "http://brightmindsbio.com/role/SHARECAPITALDetails1",
      "http://brightmindsbio.com/role/SHARECAPITALDetails7"
     ],
     "xbrltype": "domainItemType"
    },
    "drug_ExpiryDateFifteenJuneTwoThousandAndTwentySixMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expiry Date Fifteen June Two Thousand And Twenty Six",
        "label": "Expiry Date Fifteen June Two Thousand And Twenty Six [Member]",
        "verboseLabel": "June 15, 2026 [Member]"
       }
      }
     },
     "localname": "ExpiryDateFifteenJuneTwoThousandAndTwentySixMember",
     "nsuri": "http://brightmindsbio.com/20210930",
     "presentation": [
      "http://brightmindsbio.com/role/SHARECAPITALDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "drug_ExpiryDateSeventeenMarchTwoThousandAndTwentyFourOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for the expiry date of March 17, 2024.",
        "label": "Expiry Date Seventeen March Two Thousand And Twenty Four One [Member]",
        "verboseLabel": "March 17, 2024 [Member]"
       }
      }
     },
     "localname": "ExpiryDateSeventeenMarchTwoThousandAndTwentyFourOneMember",
     "nsuri": "http://brightmindsbio.com/20210930",
     "presentation": [
      "http://brightmindsbio.com/role/SHARECAPITALDetails7"
     ],
     "xbrltype": "domainItemType"
    },
    "drug_ExpiryDateSeventeenMarchTwoThousandAndTwentyFourTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for the expiry date of March 17, 2024.",
        "label": "Expiry Date Seventeen March Two Thousand And Twenty Four Two [Member]",
        "verboseLabel": "March 17, 2024 [Member]"
       }
      }
     },
     "localname": "ExpiryDateSeventeenMarchTwoThousandAndTwentyFourTwoMember",
     "nsuri": "http://brightmindsbio.com/20210930",
     "presentation": [
      "http://brightmindsbio.com/role/SHARECAPITALDetails7"
     ],
     "xbrltype": "domainItemType"
    },
    "drug_ExpiryDateSeventeenNovemberTwoThousandAndTwentyFiveMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for the expiry date of November 17, 2025.",
        "label": "Expiry Date Seventeen November Two Thousand And Twenty Five [Member]",
        "verboseLabel": "November 17, 2025 [Member]"
       }
      }
     },
     "localname": "ExpiryDateSeventeenNovemberTwoThousandAndTwentyFiveMember",
     "nsuri": "http://brightmindsbio.com/20210930",
     "presentation": [
      "http://brightmindsbio.com/role/SHARECAPITALDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "drug_ExpiryDateThirtyJulyTwoThousandAndTwentyFourMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for the expiry date of July 30, 2024.",
        "label": "Expiry Date Thirty July Two Thousand And Twenty Four [Member]",
        "verboseLabel": "July 30, 2024 [Member]"
       }
      }
     },
     "localname": "ExpiryDateThirtyJulyTwoThousandAndTwentyFourMember",
     "nsuri": "http://brightmindsbio.com/20210930",
     "presentation": [
      "http://brightmindsbio.com/role/SHARECAPITALDetails7"
     ],
     "xbrltype": "domainItemType"
    },
    "drug_ExpiryDateTwentyEightAprilTwoThousandAndTwentySixMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for the expiry date of April 28, 2026.",
        "label": "Expiry Date Twenty Eight April Two Thousand And Twenty Six [Member]",
        "verboseLabel": "April 28, 2026 [Member]"
       }
      }
     },
     "localname": "ExpiryDateTwentyEightAprilTwoThousandAndTwentySixMember",
     "nsuri": "http://brightmindsbio.com/20210930",
     "presentation": [
      "http://brightmindsbio.com/role/SHARECAPITALDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "drug_ExpiryDateTwentyOneSeptemberTwoThousandAndTwentyFourMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for the expiry date of September 21, 2024.",
        "label": "Expiry Date Twenty One September Two Thousand And Twenty Four [Member]",
        "verboseLabel": "September 21, 2024 [Member]"
       }
      }
     },
     "localname": "ExpiryDateTwentyOneSeptemberTwoThousandAndTwentyFourMember",
     "nsuri": "http://brightmindsbio.com/20210930",
     "presentation": [
      "http://brightmindsbio.com/role/SHARECAPITALDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "drug_ExpiryDateTwentyThreeJulyTwoThousandAndTwentyFiveMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for the expiry date of July 23, 2025.",
        "label": "Expiry Date Twenty Three July Two Thousand And Twenty Five [Member]",
        "verboseLabel": "July 23, 2025 [Member]"
       }
      }
     },
     "localname": "ExpiryDateTwentyThreeJulyTwoThousandAndTwentyFiveMember",
     "nsuri": "http://brightmindsbio.com/20210930",
     "presentation": [
      "http://brightmindsbio.com/role/SHARECAPITALDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "drug_FairValueAscribedToBrokersWarrantsIssued": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value ascribed to brokers' warrants issued",
        "label": "Fair Value Ascribed To Brokers Warrants Issued",
        "terseLabel": "Fair value ascribed to brokers' warrants issued"
       }
      }
     },
     "localname": "FairValueAscribedToBrokersWarrantsIssued",
     "nsuri": "http://brightmindsbio.com/20210930",
     "presentation": [
      "http://brightmindsbio.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "drug_FairValueOfOptionsIssuedAsFindersFees": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of options issued as finder's fees",
        "label": "Fair Value Of Options Issued As Finders Fees",
        "terseLabel": "Fair value of options issued as finder's fees"
       }
      }
     },
     "localname": "FairValueOfOptionsIssuedAsFindersFees",
     "nsuri": "http://brightmindsbio.com/20210930",
     "presentation": [
      "http://brightmindsbio.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "drug_FairValueOfWarrants": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents fair value of warrants.",
        "label": "Fair Value Of Warrants",
        "verboseLabel": "Fair value of share purchase warrants"
       }
      }
     },
     "localname": "FairValueOfWarrants",
     "nsuri": "http://brightmindsbio.com/20210930",
     "presentation": [
      "http://brightmindsbio.com/role/SHARECAPITALDetailTextuals"
     ],
     "xbrltype": "sharesItemType"
    },
    "drug_FifteenthTrancheMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fifteenth tranche",
        "label": "Fifteenth Tranche [Member]",
        "verboseLabel": "On September 21, 2022 [Member]"
       }
      }
     },
     "localname": "FifteenthTrancheMember",
     "nsuri": "http://brightmindsbio.com/20210930",
     "presentation": [
      "http://brightmindsbio.com/role/SHARECAPITALDetailTextuals"
     ],
     "xbrltype": "domainItemType"
    },
    "drug_FifthTrancheMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fifth tranche",
        "label": "Fifth Tranche [Member]",
        "verboseLabel": "On the six-month anniversary of the listing date [Member]"
       }
      }
     },
     "localname": "FifthTrancheMember",
     "nsuri": "http://brightmindsbio.com/20210930",
     "presentation": [
      "http://brightmindsbio.com/role/SHARECAPITALDetailTextuals"
     ],
     "xbrltype": "domainItemType"
    },
    "drug_FinancialInstrumentsAtAmortizedCostMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financial Instruments At Amortized Cost.",
        "label": "Financial Instruments At Amortized Cost [Member]",
        "terseLabel": "Amortized cost [Member]"
       }
      }
     },
     "localname": "FinancialInstrumentsAtAmortizedCostMember",
     "nsuri": "http://brightmindsbio.com/20210930",
     "presentation": [
      "http://brightmindsbio.com/role/FINANCIALINSTRUMENTSANDCAPITALMANAGEMENTDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "drug_FinancialInstrumentsAtFairValueThroughProfitOrLossMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financial Instruments At Fair Value Through Profit Or Loss.",
        "label": "Financial Instruments At Fair Value Through Profit Or Loss [Member]",
        "terseLabel": "FVTPL [Member]"
       }
      }
     },
     "localname": "FinancialInstrumentsAtFairValueThroughProfitOrLossMember",
     "nsuri": "http://brightmindsbio.com/20210930",
     "presentation": [
      "http://brightmindsbio.com/role/FINANCIALINSTRUMENTSANDCAPITALMANAGEMENTDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "drug_FirstTrancheMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "First tranche [Member]",
        "label": "First Tranche [Member]",
        "terseLabel": "January 1, 2022",
        "verboseLabel": "On the date of grant [Member]"
       }
      }
     },
     "localname": "FirstTrancheMember",
     "nsuri": "http://brightmindsbio.com/20210930",
     "presentation": [
      "http://brightmindsbio.com/role/SHARECAPITALDetailTextuals",
      "http://brightmindsbio.com/role/SUBSEQUENTEVENTSDetailTextuals"
     ],
     "xbrltype": "domainItemType"
    },
    "drug_FirstTrancheOfNonBrokeredPrivatePlacementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "First tranche of non brokered private placement.",
        "label": "First Tranche Of Non Brokered Private Placement [Member]",
        "verboseLabel": "First tranche of a non-brokered private placement [Member]"
       }
      }
     },
     "localname": "FirstTrancheOfNonBrokeredPrivatePlacementMember",
     "nsuri": "http://brightmindsbio.com/20210930",
     "presentation": [
      "http://brightmindsbio.com/role/SHARECAPITALDetailTextuals"
     ],
     "xbrltype": "domainItemType"
    },
    "drug_ForfeitureRateOfOtherEquityInstruments": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the percentage of forfeiture of other equity instruments.",
        "label": "Forfeiture Rate Of Other Equity Instruments",
        "verboseLabel": "Forfeiture rate"
       }
      }
     },
     "localname": "ForfeitureRateOfOtherEquityInstruments",
     "nsuri": "http://brightmindsbio.com/20210930",
     "presentation": [
      "http://brightmindsbio.com/role/SHARECAPITALDetails3"
     ],
     "xbrltype": "percentItemType"
    },
    "drug_FourteenthTrancheMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fourteenth tranche",
        "label": "Fourteenth Tranche [Member]",
        "verboseLabel": "On June 21, 2022 [Member]"
       }
      }
     },
     "localname": "FourteenthTrancheMember",
     "nsuri": "http://brightmindsbio.com/20210930",
     "presentation": [
      "http://brightmindsbio.com/role/SHARECAPITALDetailTextuals"
     ],
     "xbrltype": "domainItemType"
    },
    "drug_FourthTrancheMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fourth tranche",
        "label": "Fourth Tranche [Member]",
        "verboseLabel": "On the second anniversary of the listing date [Member]"
       }
      }
     },
     "localname": "FourthTrancheMember",
     "nsuri": "http://brightmindsbio.com/20210930",
     "presentation": [
      "http://brightmindsbio.com/role/SHARECAPITALDetailTextuals"
     ],
     "xbrltype": "domainItemType"
    },
    "drug_GrossProceedsFromUnitsIssued": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of gross proceeds from units issued.",
        "label": "Gross Proceeds From Units Issued",
        "verboseLabel": "Gross proceeds from units issued"
       }
      }
     },
     "localname": "GrossProceedsFromUnitsIssued",
     "nsuri": "http://brightmindsbio.com/20210930",
     "presentation": [
      "http://brightmindsbio.com/role/SHARECAPITALDetailTextuals"
     ],
     "xbrltype": "monetaryItemType"
    },
    "drug_GrossProceedsFromWarrantsExercised": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represent the gross proceeds from warrants exercised.",
        "label": "Gross Proceeds From Warrants Exercised",
        "terseLabel": "Gross proceeds from warrants exercised"
       }
      }
     },
     "localname": "GrossProceedsFromWarrantsExercised",
     "nsuri": "http://brightmindsbio.com/20210930",
     "presentation": [
      "http://brightmindsbio.com/role/SHARECAPITALDetailTextuals",
      "http://brightmindsbio.com/role/SUBSEQUENTEVENTSDetailTextuals"
     ],
     "xbrltype": "monetaryItemType"
    },
    "drug_GrossProceedsFromWarrantsIssued": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of gross proceeds from warrants issued.",
        "label": "Gross Proceeds From Warrants Issued",
        "verboseLabel": "Gross proceeds from warrants issued"
       }
      }
     },
     "localname": "GrossProceedsFromWarrantsIssued",
     "nsuri": "http://brightmindsbio.com/20210930",
     "presentation": [
      "http://brightmindsbio.com/role/SHARECAPITALDetailTextuals"
     ],
     "xbrltype": "monetaryItemType"
    },
    "drug_IncomeTaxAuthorityNameOfCountryAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income tax authority name of country.",
        "label": "Income Tax Authority Name Of Country [Axis]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityNameOfCountryAxis",
     "nsuri": "http://brightmindsbio.com/20210930",
     "presentation": [
      "http://brightmindsbio.com/role/INCOMETAXESDetailTextuals",
      "http://brightmindsbio.com/role/INCOMETAXESDetails2"
     ],
     "xbrltype": "stringItemType"
    },
    "drug_IncomeTaxAuthorityNameOfCountryDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income tax authority name of country.",
        "label": "Income Tax Authority Name Of Country [Domain]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityNameOfCountryDomain",
     "nsuri": "http://brightmindsbio.com/20210930",
     "presentation": [
      "http://brightmindsbio.com/role/INCOMETAXESDetailTextuals",
      "http://brightmindsbio.com/role/INCOMETAXESDetails2"
     ],
     "xbrltype": "domainItemType"
    },
    "drug_IncreaseDecreaseThroughAcquisitionOfIntangibleAssets": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) in equity resulting from the acquisition of of intangible assets.",
        "label": "Increase Decrease Through Acquisition Of Intangible Assets",
        "terseLabel": "Acquisition of intangible assets"
       }
      }
     },
     "localname": "IncreaseDecreaseThroughAcquisitionOfIntangibleAssets",
     "nsuri": "http://brightmindsbio.com/20210930",
     "presentation": [
      "http://brightmindsbio.com/role/ConsolidatedStatementsOfChangesInShareholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "drug_IncreaseDecreaseThroughAcquisitionOfIntangibleAssetsShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase and decrease in equity resulting from acquisition of intangible assets shares.",
        "label": "Increase Decrease Through Acquisition Of Intangible Assets Shares",
        "terseLabel": "Acquisition of intangible asset (shares)"
       }
      }
     },
     "localname": "IncreaseDecreaseThroughAcquisitionOfIntangibleAssetsShares",
     "nsuri": "http://brightmindsbio.com/20210930",
     "presentation": [
      "http://brightmindsbio.com/role/ConsolidatedStatementsOfChangesInShareholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "drug_IncreaseDecreaseThroughDebtSettlementWithShare": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase decrease in equity through settlement of debt with shares.",
        "label": "Increase Decrease Through Debt Settlement With Share",
        "terseLabel": "Debt settlement with shares"
       }
      }
     },
     "localname": "IncreaseDecreaseThroughDebtSettlementWithShare",
     "nsuri": "http://brightmindsbio.com/20210930",
     "presentation": [
      "http://brightmindsbio.com/role/ConsolidatedStatementsOfChangesInShareholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "drug_IncreaseDecreaseThroughDebtSettlementWithShareShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) through debt settlement with share shares.",
        "label": "Increase Decrease Through Debt Settlement With Share Shares",
        "terseLabel": "Debt settlement with shares (shares)"
       }
      }
     },
     "localname": "IncreaseDecreaseThroughDebtSettlementWithShareShares",
     "nsuri": "http://brightmindsbio.com/20210930",
     "presentation": [
      "http://brightmindsbio.com/role/ConsolidatedStatementsOfChangesInShareholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "drug_IncreaseDecreaseThroughExerciseOfWarrantsShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) through exercise of warrants shares.",
        "label": "Increase Decrease Through Exercise Of Warrants Shares",
        "terseLabel": "Warrants exercised (shares)"
       }
      }
     },
     "localname": "IncreaseDecreaseThroughExerciseOfWarrantsShares",
     "nsuri": "http://brightmindsbio.com/20210930",
     "presentation": [
      "http://brightmindsbio.com/role/ConsolidatedStatementsOfChangesInShareholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "drug_IncreaseDecreaseThroughFindersFeesBrokerWarrants": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Increase decrease through distribution of broker warrants for finders fees.",
        "label": "Increase Decrease Through Finders Fees Broker Warrants",
        "terseLabel": "Finder's fees - broker warrants"
       }
      }
     },
     "localname": "IncreaseDecreaseThroughFindersFeesBrokerWarrants",
     "nsuri": "http://brightmindsbio.com/20210930",
     "presentation": [
      "http://brightmindsbio.com/role/ConsolidatedStatementsOfChangesInShareholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "drug_IncreaseDecreaseThroughFindersFeesCash": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the increase (decrease) through cash distribution for finder's fee.",
        "label": "Increase Decrease Through Finders Fees Cash",
        "terseLabel": "Finder's fees - cash"
       }
      }
     },
     "localname": "IncreaseDecreaseThroughFindersFeesCash",
     "nsuri": "http://brightmindsbio.com/20210930",
     "presentation": [
      "http://brightmindsbio.com/role/ConsolidatedStatementsOfChangesInShareholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "drug_IncreaseDecreaseThroughFindersFeesShareOptions": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents increase (decrease) through exercise of options for finders fee.",
        "label": "Increase Decrease Through Finders Fees Share Options",
        "terseLabel": "Finder's fees - share options"
       }
      }
     },
     "localname": "IncreaseDecreaseThroughFindersFeesShareOptions",
     "nsuri": "http://brightmindsbio.com/20210930",
     "presentation": [
      "http://brightmindsbio.com/role/ConsolidatedStatementsOfChangesInShareholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "drug_IncreaseDecreaseThroughPrivatePlacement": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the amount of shares issued under private placement.",
        "label": "Increase Decrease Through Private Placement",
        "terseLabel": "Private placement"
       }
      }
     },
     "localname": "IncreaseDecreaseThroughPrivatePlacement",
     "nsuri": "http://brightmindsbio.com/20210930",
     "presentation": [
      "http://brightmindsbio.com/role/ConsolidatedStatementsOfChangesInShareholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "drug_IncreaseDecreaseThroughPrivatePlacementShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the number of shares issued under private placement.",
        "label": "Increase Decrease Through Private Placement Shares",
        "terseLabel": "Private placement (shares)"
       }
      }
     },
     "localname": "IncreaseDecreaseThroughPrivatePlacementShares",
     "nsuri": "http://brightmindsbio.com/20210930",
     "presentation": [
      "http://brightmindsbio.com/role/ConsolidatedStatementsOfChangesInShareholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "drug_IncreaseDecreaseThroughSharesIssuedToUniversity": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) through shares issued to university.",
        "label": "Increase Decrease Through Shares Issued To University",
        "terseLabel": "Shares issued to the University"
       }
      }
     },
     "localname": "IncreaseDecreaseThroughSharesIssuedToUniversity",
     "nsuri": "http://brightmindsbio.com/20210930",
     "presentation": [
      "http://brightmindsbio.com/role/ConsolidatedStatementsOfChangesInShareholdersEquity",
      "http://brightmindsbio.com/role/SHARECAPITALDetailTextuals"
     ],
     "xbrltype": "monetaryItemType"
    },
    "drug_IncreaseDecreaseThroughSharesIssuedToUniversityShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) through shares issued to university shares.",
        "label": "Increase Decrease Through Shares Issued To University Shares",
        "terseLabel": "Shares issued to the University (shares)"
       }
      }
     },
     "localname": "IncreaseDecreaseThroughSharesIssuedToUniversityShares",
     "nsuri": "http://brightmindsbio.com/20210930",
     "presentation": [
      "http://brightmindsbio.com/role/ConsolidatedStatementsOfChangesInShareholdersEquity",
      "http://brightmindsbio.com/role/SHARECAPITALDetailTextuals"
     ],
     "xbrltype": "sharesItemType"
    },
    "drug_IncreaseDecreaseThroughSpecialWarrantConversion": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) through special warrant conversion.",
        "label": "Increase Decrease Through Special Warrant Conversion",
        "terseLabel": "Special warrant conversion"
       }
      }
     },
     "localname": "IncreaseDecreaseThroughSpecialWarrantConversion",
     "nsuri": "http://brightmindsbio.com/20210930",
     "presentation": [
      "http://brightmindsbio.com/role/ConsolidatedStatementsOfChangesInShareholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "drug_IncreaseDecreaseThroughSpecialWarrantConversionShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) through special warrant conversion shares.",
        "label": "Increase Decrease Through Special Warrant Conversion Shares",
        "terseLabel": "Special warrant conversion (shares)"
       }
      }
     },
     "localname": "IncreaseDecreaseThroughSpecialWarrantConversionShares",
     "nsuri": "http://brightmindsbio.com/20210930",
     "presentation": [
      "http://brightmindsbio.com/role/ConsolidatedStatementsOfChangesInShareholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "drug_IndependentConsultantAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information about independent consultant agreement.",
        "label": "Independent Consultant Agreement [Member]"
       }
      }
     },
     "localname": "IndependentConsultantAgreementMember",
     "nsuri": "http://brightmindsbio.com/20210930",
     "presentation": [
      "http://brightmindsbio.com/role/CONTRACTUALOBLIGATIONSDetailTextuals"
     ],
     "xbrltype": "domainItemType"
    },
    "drug_IndependentContractorAgreementToServeAsChiefScienceOfficerMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Independent Contractor Agreement To Serve as Chief Science Officer.",
        "label": "Independent contractor agreement to serve as Chief Science Officer [Member]",
        "terseLabel": "Independent Contractor Agreement [Member]"
       }
      }
     },
     "localname": "IndependentContractorAgreementToServeAsChiefScienceOfficerMember",
     "nsuri": "http://brightmindsbio.com/20210930",
     "presentation": [
      "http://brightmindsbio.com/role/CONTRACTUALOBLIGATIONSDetailTextuals"
     ],
     "xbrltype": "domainItemType"
    },
    "drug_IssuanceOfRestrictedStockUnits": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the amount of issuance of restricted stock units.",
        "label": "Issuance Of Restricted Stock Units",
        "verboseLabel": "Issuance of RSU"
       }
      }
     },
     "localname": "IssuanceOfRestrictedStockUnits",
     "nsuri": "http://brightmindsbio.com/20210930",
     "presentation": [
      "http://brightmindsbio.com/role/SHARECAPITALDetailTextuals"
     ],
     "xbrltype": "monetaryItemType"
    },
    "drug_IssuePricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issue price per share.",
        "label": "Issue Price Per Share",
        "terseLabel": "Shares issued price per share"
       }
      }
     },
     "localname": "IssuePricePerShare",
     "nsuri": "http://brightmindsbio.com/20210930",
     "presentation": [
      "http://brightmindsbio.com/role/SHARECAPITALDetailTextuals"
     ],
     "xbrltype": "perShareItemType"
    },
    "drug_KeyManagementPersonnelCompensationShareBasedPaymentIncludedInProfessionalFees": {
     "auth_ref": [],
     "calculation": {
      "http://brightmindsbio.com/role/RELATEDPARTYTRANSACTIONSDetails": {
       "order": 10.0,
       "parentTag": "ifrs-full_KeyManagementPersonnelCompensation",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of compensation to key management personnel in the form of share-based payments included in Professional Fees.",
        "label": "Key Management Personnel Compensation Share Based Payment Included In Professional Fees",
        "terseLabel": "Share-based compensation included in professional fees"
       }
      }
     },
     "localname": "KeyManagementPersonnelCompensationShareBasedPaymentIncludedInProfessionalFees",
     "nsuri": "http://brightmindsbio.com/20210930",
     "presentation": [
      "http://brightmindsbio.com/role/RELATEDPARTYTRANSACTIONSDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "drug_KeyManagementPersonnelCompensationShareBasedPaymentIncludedInResearchAndDevelopment": {
     "auth_ref": [],
     "calculation": {
      "http://brightmindsbio.com/role/RELATEDPARTYTRANSACTIONSDetails": {
       "order": 0.0,
       "parentTag": "ifrs-full_KeyManagementPersonnelCompensation",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of compensation to key management personnel in the form of share-based payments included in Research And Development.",
        "label": "Key Management Personnel Compensation Share Based Payment Included In Research And Development",
        "terseLabel": "Share-based compensation included in research and development"
       }
      }
     },
     "localname": "KeyManagementPersonnelCompensationShareBasedPaymentIncludedInResearchAndDevelopment",
     "nsuri": "http://brightmindsbio.com/20210930",
     "presentation": [
      "http://brightmindsbio.com/role/RELATEDPARTYTRANSACTIONSDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "drug_KeyManagementPersonnelProfessionalFees": {
     "auth_ref": [],
     "calculation": {
      "http://brightmindsbio.com/role/RELATEDPARTYTRANSACTIONSDetails": {
       "order": 20.0,
       "parentTag": "ifrs-full_KeyManagementPersonnelCompensation",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of compensation to key management personnel in the form of professional fees.",
        "label": "Key Management Personnel Professional Fees",
        "terseLabel": "Professional fees"
       }
      }
     },
     "localname": "KeyManagementPersonnelProfessionalFees",
     "nsuri": "http://brightmindsbio.com/20210930",
     "presentation": [
      "http://brightmindsbio.com/role/RELATEDPARTYTRANSACTIONSDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "drug_KeyManagementPersonnelResearchAndDevelopment": {
     "auth_ref": [],
     "calculation": {
      "http://brightmindsbio.com/role/RELATEDPARTYTRANSACTIONSDetails": {
       "order": 30.0,
       "parentTag": "ifrs-full_KeyManagementPersonnelCompensation",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of compensation to key management personnel in the form of Research And Development.",
        "label": "Key Management Personnel Research And Development",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "KeyManagementPersonnelResearchAndDevelopment",
     "nsuri": "http://brightmindsbio.com/20210930",
     "presentation": [
      "http://brightmindsbio.com/role/RELATEDPARTYTRANSACTIONSDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "drug_LaboratoryCostsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents laboratory costs.",
        "label": "Laboratory Costs [Member]",
        "terseLabel": "Laboratory costs [Member]"
       }
      }
     },
     "localname": "LaboratoryCostsMember",
     "nsuri": "http://brightmindsbio.com/20210930",
     "presentation": [
      "http://brightmindsbio.com/role/RESEARCHANDDEVELOPMENTDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "drug_LeaseCost": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lease cost.",
        "label": "Lease Cost",
        "terseLabel": "Lease cost"
       }
      }
     },
     "localname": "LeaseCost",
     "nsuri": "http://brightmindsbio.com/20210930",
     "presentation": [
      "http://brightmindsbio.com/role/PREMISESLEASESDetailTextuals"
     ],
     "xbrltype": "monetaryItemType"
    },
    "drug_LetterAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for letter agreement.",
        "label": "Letter agreement [Member]"
       }
      }
     },
     "localname": "LetterAgreementMember",
     "nsuri": "http://brightmindsbio.com/20210930",
     "presentation": [
      "http://brightmindsbio.com/role/SUBSEQUENTEVENTSDetailTextuals"
     ],
     "xbrltype": "domainItemType"
    },
    "drug_LicenseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License agreement.",
        "label": "License agreement [Member]"
       }
      }
     },
     "localname": "LicenseAgreementMember",
     "nsuri": "http://brightmindsbio.com/20210930",
     "presentation": [
      "http://brightmindsbio.com/role/CONTRACTUALOBLIGATIONSDetailTextuals"
     ],
     "xbrltype": "domainItemType"
    },
    "drug_MarketingAdvertisingAndInvestorRelationsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the primary financial statement caption encompassing marketing, advertising and investor relations.",
        "label": "Marketing, Advertising And Investor Relations [Member]",
        "verboseLabel": "Marketing, advertising and investor relations [Member]"
       }
      }
     },
     "localname": "MarketingAdvertisingAndInvestorRelationsMember",
     "nsuri": "http://brightmindsbio.com/20210930",
     "presentation": [
      "http://brightmindsbio.com/role/SHARECAPITALDetails5"
     ],
     "xbrltype": "domainItemType"
    },
    "drug_MilestonePaymentsUponDosingFirstPatientInFirstPhaseIiTrial": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "milestone payments upon dosing first patient in the first Phase II trial.",
        "label": "Milestone Payments Upon Dosing First Patient In First Phase Ii Trial",
        "terseLabel": "Milestone payments upon dosing first patient in the first Phase II trial"
       }
      }
     },
     "localname": "MilestonePaymentsUponDosingFirstPatientInFirstPhaseIiTrial",
     "nsuri": "http://brightmindsbio.com/20210930",
     "presentation": [
      "http://brightmindsbio.com/role/CONTRACTUALOBLIGATIONSDetailTextuals"
     ],
     "xbrltype": "monetaryItemType"
    },
    "drug_MilestonePaymentsUponDosingFirstPatientInFirstPhaseIiiTrial": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "milestone payments upon dosing first patient in the first Phase III trial.",
        "label": "Milestone Payments Upon Dosing First Patient In First Phase Iii Trial",
        "terseLabel": "Milestone payments upon dosing first patient in the first Phase III trial"
       }
      }
     },
     "localname": "MilestonePaymentsUponDosingFirstPatientInFirstPhaseIiiTrial",
     "nsuri": "http://brightmindsbio.com/20210930",
     "presentation": [
      "http://brightmindsbio.com/role/CONTRACTUALOBLIGATIONSDetailTextuals"
     ],
     "xbrltype": "monetaryItemType"
    },
    "drug_MilestonePaymentsUponDosingFirstPatientInPhaseITrial": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information about milestone payments upon dosing first patient in Phase I trial.",
        "label": "Milestone Payments Upon Dosing First Patient In Phase I Trial",
        "terseLabel": "Milestone payments upon dosing first patient in Phase I trial"
       }
      }
     },
     "localname": "MilestonePaymentsUponDosingFirstPatientInPhaseITrial",
     "nsuri": "http://brightmindsbio.com/20210930",
     "presentation": [
      "http://brightmindsbio.com/role/CONTRACTUALOBLIGATIONSDetailTextuals"
     ],
     "xbrltype": "monetaryItemType"
    },
    "drug_MilestonePaymentsUponFirstCommercialSaleOfClinical": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "milestone payments upon first commercial sale of clinical.",
        "label": "Milestone Payments Upon First Commercial Sale Of Clinical",
        "terseLabel": "Milestone payments upon first commercial sale of each clinical indication"
       }
      }
     },
     "localname": "MilestonePaymentsUponFirstCommercialSaleOfClinical",
     "nsuri": "http://brightmindsbio.com/20210930",
     "presentation": [
      "http://brightmindsbio.com/role/CONTRACTUALOBLIGATIONSDetailTextuals"
     ],
     "xbrltype": "monetaryItemType"
    },
    "drug_MinimumDailyVolumeWeightedAverageTradingSharePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The minimum daily volume weighted average trading share price.",
        "label": "Minimum Daily Volume Weighted Average Trading Share Price",
        "verboseLabel": "Minimum daily volume weighted average trading share price on the CSE"
       }
      }
     },
     "localname": "MinimumDailyVolumeWeightedAverageTradingSharePrice",
     "nsuri": "http://brightmindsbio.com/20210930",
     "presentation": [
      "http://brightmindsbio.com/role/SHARECAPITALDetailTextuals"
     ],
     "xbrltype": "perShareItemType"
    },
    "drug_MonthlyBaseRent": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of monthly base rent.",
        "label": "Monthly Base Rent",
        "terseLabel": "Monthly base rent"
       }
      }
     },
     "localname": "MonthlyBaseRent",
     "nsuri": "http://brightmindsbio.com/20210930",
     "presentation": [
      "http://brightmindsbio.com/role/PREMISESLEASESDetailTextuals"
     ],
     "xbrltype": "monetaryItemType"
    },
    "drug_MonthlyFeeAuthorizedByBoardOfDirectors": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Monthly Fee Authorized By Board of Directors.",
        "label": "Monthly Fee Authorized By Board Of Directors",
        "terseLabel": "Monthly fee authorized by board of directors"
       }
      }
     },
     "localname": "MonthlyFeeAuthorizedByBoardOfDirectors",
     "nsuri": "http://brightmindsbio.com/20210930",
     "presentation": [
      "http://brightmindsbio.com/role/CONTRACTUALOBLIGATIONSDetailTextuals"
     ],
     "xbrltype": "monetaryItemType"
    },
    "drug_NatureAndContinuanceOfOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nature And Continuance Of Operations [Abstract]"
       }
      }
     },
     "localname": "NatureAndContinuanceOfOperationsAbstract",
     "nsuri": "http://brightmindsbio.com/20210930",
     "xbrltype": "stringItemType"
    },
    "drug_NinthTrancheMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ninth tranche",
        "label": "Ninth Tranche [Member]",
        "verboseLabel": "On the fourth anniversary of the grant date [Member]"
       }
      }
     },
     "localname": "NinthTrancheMember",
     "nsuri": "http://brightmindsbio.com/20210930",
     "presentation": [
      "http://brightmindsbio.com/role/SHARECAPITALDetailTextuals"
     ],
     "xbrltype": "domainItemType"
    },
    "drug_NonBrokeredPrivatePlacementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non brokered private placement [Member]",
        "label": "Non Brokered Private Placement [Member]",
        "verboseLabel": "Non-brokered private placement [Member]"
       }
      }
     },
     "localname": "NonBrokeredPrivatePlacementMember",
     "nsuri": "http://brightmindsbio.com/20210930",
     "presentation": [
      "http://brightmindsbio.com/role/SHARECAPITALDetailTextuals"
     ],
     "xbrltype": "domainItemType"
    },
    "drug_NonCapitalLossCarryForwards": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amont of non-capital loss carry forwards.",
        "label": "Non Capital Loss Carry Forwards",
        "terseLabel": "Non-capital loss carry-forwards",
        "verboseLabel": "Non-Capital Losses"
       }
      }
     },
     "localname": "NonCapitalLossCarryForwards",
     "nsuri": "http://brightmindsbio.com/20210930",
     "presentation": [
      "http://brightmindsbio.com/role/INCOMETAXESDetailTextuals",
      "http://brightmindsbio.com/role/INCOMETAXESDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "drug_NonCapitalLossCarryForwardsYearOfExpiry": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Year of expiry for Non-capital loss carry forwards.",
        "label": "Non Capital Loss Carry Forwards Year Of Expiry",
        "terseLabel": "Year of Expiry"
       }
      }
     },
     "localname": "NonCapitalLossCarryForwardsYearOfExpiry",
     "nsuri": "http://brightmindsbio.com/20210930",
     "presentation": [
      "http://brightmindsbio.com/role/INCOMETAXESDetails2"
     ],
     "xbrltype": "gYearItemType"
    },
    "drug_NonCapitalLossCarryForwardsYearOfOriginAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information of non-capital loss carry forwards year of origin.",
        "label": "Non Capital Loss Carry Forwards Year Of Origin [Axis]"
       }
      }
     },
     "localname": "NonCapitalLossCarryForwardsYearOfOriginAxis",
     "nsuri": "http://brightmindsbio.com/20210930",
     "presentation": [
      "http://brightmindsbio.com/role/INCOMETAXESDetails2"
     ],
     "xbrltype": "stringItemType"
    },
    "drug_NonCapitalLossCarryForwardsYearOfOriginDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information of non-capital loss carry forwards year of origin.",
        "label": "Non Capital Loss Carry Forwards Year Of Origin [Domain]"
       }
      }
     },
     "localname": "NonCapitalLossCarryForwardsYearOfOriginDomain",
     "nsuri": "http://brightmindsbio.com/20210930",
     "presentation": [
      "http://brightmindsbio.com/role/INCOMETAXESDetails2"
     ],
     "xbrltype": "domainItemType"
    },
    "drug_NonRefundableOptionFeesPaid": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the amount of non-refundable option fees paid.",
        "label": "Non Refundable Option Fees Paid",
        "verboseLabel": "Non-refundable option fees paid"
       }
      }
     },
     "localname": "NonRefundableOptionFeesPaid",
     "nsuri": "http://brightmindsbio.com/20210930",
     "presentation": [
      "http://brightmindsbio.com/role/CONTRACTUALOBLIGATIONSDetailTextuals"
     ],
     "xbrltype": "monetaryItemType"
    },
    "drug_NovelDrugDevelopmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents development for novel drug.",
        "label": "Novel Drug Development [Member]",
        "terseLabel": "Novel drug development [Member]"
       }
      }
     },
     "localname": "NovelDrugDevelopmentMember",
     "nsuri": "http://brightmindsbio.com/20210930",
     "presentation": [
      "http://brightmindsbio.com/role/RESEARCHANDDEVELOPMENTDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "drug_NumberOfCommonSharesCalledByWarrants": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of common shares called by warrants.",
        "label": "Number Of Common Shares Called By Warrants",
        "verboseLabel": "Number of common shares called by warrants"
       }
      }
     },
     "localname": "NumberOfCommonSharesCalledByWarrants",
     "nsuri": "http://brightmindsbio.com/20210930",
     "presentation": [
      "http://brightmindsbio.com/role/SHARECAPITALDetailTextuals"
     ],
     "xbrltype": "sharesItemType"
    },
    "drug_NumberOfCommonSharesDepositedToBeHeldInEscrow": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of common shares deposited to be held in escrow.",
        "label": "Number Of Common Shares Deposited To Be Held In Escrow",
        "verboseLabel": "Number of common shares deposited to be held in escrow"
       }
      }
     },
     "localname": "NumberOfCommonSharesDepositedToBeHeldInEscrow",
     "nsuri": "http://brightmindsbio.com/20210930",
     "presentation": [
      "http://brightmindsbio.com/role/SHARECAPITALDetailTextuals"
     ],
     "xbrltype": "sharesItemType"
    },
    "drug_NumberOfCommonSharesSubscribed": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of common shares subscribed.",
        "label": "Number Of Common Shares Subscribed",
        "terseLabel": "Number of common shares subscribed"
       }
      }
     },
     "localname": "NumberOfCommonSharesSubscribed",
     "nsuri": "http://brightmindsbio.com/20210930",
     "presentation": [
      "http://brightmindsbio.com/role/SHARECAPITALDetailTextuals"
     ],
     "xbrltype": "sharesItemType"
    },
    "drug_NumberOfIssuedWarrantsRescinded": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of issued warrants rescinded.",
        "label": "Number Of Issued Warrants Rescinded",
        "verboseLabel": "Number of issued warrants rescinded"
       }
      }
     },
     "localname": "NumberOfIssuedWarrantsRescinded",
     "nsuri": "http://brightmindsbio.com/20210930",
     "presentation": [
      "http://brightmindsbio.com/role/SHARECAPITALDetailTextuals"
     ],
     "xbrltype": "sharesItemType"
    },
    "drug_NumberOfRestrictedStockIssuedForCompensation": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of restricted stock issued for compensation.",
        "label": "Number Of Restricted Stock Issued For Compensation",
        "terseLabel": "Number of restricted stock issued for compensation"
       }
      }
     },
     "localname": "NumberOfRestrictedStockIssuedForCompensation",
     "nsuri": "http://brightmindsbio.com/20210930",
     "presentation": [
      "http://brightmindsbio.com/role/SHARECAPITALDetailTextuals",
      "http://brightmindsbio.com/role/SUBSEQUENTEVENTSDetailTextuals"
     ],
     "xbrltype": "sharesItemType"
    },
    "drug_NumberOfShareListed": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the number of share listed.",
        "label": "Number Of Share Listed",
        "verboseLabel": "Number of shares listed"
       }
      }
     },
     "localname": "NumberOfShareListed",
     "nsuri": "http://brightmindsbio.com/20210930",
     "presentation": [
      "http://brightmindsbio.com/role/SHARECAPITALDetailTextuals"
     ],
     "xbrltype": "sharesItemType"
    },
    "drug_NumberOfSharesIssuedByRelatedParty": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the number of shares issued by related party.",
        "label": "Number Of Shares Issued By Related Party",
        "terseLabel": "Number of shares issued by PL to individual"
       }
      }
     },
     "localname": "NumberOfSharesIssuedByRelatedParty",
     "nsuri": "http://brightmindsbio.com/20210930",
     "presentation": [
      "http://brightmindsbio.com/role/SHAREEXCHANGEANDASSIGNMENTDetailTextuals"
     ],
     "xbrltype": "sharesItemType"
    },
    "drug_NumberOfUnitsIssued": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of units issued.",
        "label": "Number Of Units Issued",
        "verboseLabel": "Number of units issued"
       }
      }
     },
     "localname": "NumberOfUnitsIssued",
     "nsuri": "http://brightmindsbio.com/20210930",
     "presentation": [
      "http://brightmindsbio.com/role/SHARECAPITALDetailTextuals"
     ],
     "xbrltype": "sharesItemType"
    },
    "drug_NumberOfWarrantsDeemedToBeExercised": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of warrants deemed to be exercised.",
        "label": "Number Of Warrants Deemed To Be Exercised",
        "verboseLabel": "Number of warrants deemed to be exercised"
       }
      }
     },
     "localname": "NumberOfWarrantsDeemedToBeExercised",
     "nsuri": "http://brightmindsbio.com/20210930",
     "presentation": [
      "http://brightmindsbio.com/role/SHARECAPITALDetailTextuals"
     ],
     "xbrltype": "sharesItemType"
    },
    "drug_NumberOfWarrantsDepositedToBeHeldInEscrow": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of warrants deposited to be held in escrow.",
        "label": "Number Of Warrants Deposited To Be Held In Escrow",
        "verboseLabel": "Number of warrants deposited to be held in escrow"
       }
      }
     },
     "localname": "NumberOfWarrantsDepositedToBeHeldInEscrow",
     "nsuri": "http://brightmindsbio.com/20210930",
     "presentation": [
      "http://brightmindsbio.com/role/SHARECAPITALDetailTextuals"
     ],
     "xbrltype": "sharesItemType"
    },
    "drug_NumberOfWarrantsExercised": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represent the number of warrants exercised.",
        "label": "Number Of Warrants Exercised",
        "negatedLabel": "Number of warrants, Exercised",
        "terseLabel": "Number of warrants exercised",
        "verboseLabel": "Number of warrants, Exercised"
       }
      }
     },
     "localname": "NumberOfWarrantsExercised",
     "nsuri": "http://brightmindsbio.com/20210930",
     "presentation": [
      "http://brightmindsbio.com/role/SHARECAPITALDetailTextuals",
      "http://brightmindsbio.com/role/SHARECAPITALDetails6",
      "http://brightmindsbio.com/role/SUBSEQUENTEVENTSDetailTextuals"
     ],
     "xbrltype": "sharesItemType"
    },
    "drug_NumberOfWarrantsIssued": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the number of warrants Issued.",
        "label": "Number Of Warrants Issued",
        "verboseLabel": "Number of warrants, Issued"
       }
      }
     },
     "localname": "NumberOfWarrantsIssued",
     "nsuri": "http://brightmindsbio.com/20210930",
     "presentation": [
      "http://brightmindsbio.com/role/SHARECAPITALDetailTextuals",
      "http://brightmindsbio.com/role/SHARECAPITALDetails6"
     ],
     "xbrltype": "sharesItemType"
    },
    "drug_NumberOfWarrantsIssuedToBroker": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the number of warrants issued to broker.",
        "label": "Number Of Warrants Issued To Broker",
        "verboseLabel": "Number of warrants, Issued - broker"
       }
      }
     },
     "localname": "NumberOfWarrantsIssuedToBroker",
     "nsuri": "http://brightmindsbio.com/20210930",
     "presentation": [
      "http://brightmindsbio.com/role/SHARECAPITALDetails6"
     ],
     "xbrltype": "sharesItemType"
    },
    "drug_NumberOfWarrantsOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of warrants outstanding.",
        "label": "Number Of Warrants Outstanding",
        "periodEndLabel": "Number of warrants, Ending Balance",
        "periodStartLabel": "Number of warrants, Beginning Balance",
        "terseLabel": "Number of outstanding warrants",
        "verboseLabel": "Warrants Outstanding, Number of warrants"
       }
      }
     },
     "localname": "NumberOfWarrantsOutstanding",
     "nsuri": "http://brightmindsbio.com/20210930",
     "presentation": [
      "http://brightmindsbio.com/role/SHARECAPITALDetails6",
      "http://brightmindsbio.com/role/SHARECAPITALDetails7"
     ],
     "xbrltype": "sharesItemType"
    },
    "drug_NumberOfWarrantsOutstandingInShareBasedPaymentArrangement": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of warrants outstanding in a share-based payment arrangement.",
        "label": "Number Of Warrants Outstanding In Share Based Payment Arrangement",
        "periodEndLabel": "Number of warrants, Ending Balance",
        "periodStartLabel": "Number of warrants, Beginning Balance",
        "terseLabel": "Number of outstanding warrants",
        "verboseLabel": "Warrants Outstanding, Number of warrants"
       }
      }
     },
     "localname": "NumberOfWarrantsOutstandingInShareBasedPaymentArrangement",
     "nsuri": "http://brightmindsbio.com/20210930",
     "presentation": [
      "http://brightmindsbio.com/role/SHARECAPITALDetailTextuals"
     ],
     "xbrltype": "sharesItemType"
    },
    "drug_OptionAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Option agreement",
        "label": "Option agreement [Member]"
       }
      }
     },
     "localname": "OptionAgreementMember",
     "nsuri": "http://brightmindsbio.com/20210930",
     "presentation": [
      "http://brightmindsbio.com/role/CONTRACTUALOBLIGATIONSDetailTextuals"
     ],
     "xbrltype": "domainItemType"
    },
    "drug_OptionFeesPaid": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of option fees paid.",
        "label": "Option Fees Paid",
        "terseLabel": "Option fees paid"
       }
      }
     },
     "localname": "OptionFeesPaid",
     "nsuri": "http://brightmindsbio.com/20210930",
     "presentation": [
      "http://brightmindsbio.com/role/CONTRACTUALOBLIGATIONSDetailTextuals"
     ],
     "xbrltype": "monetaryItemType"
    },
    "drug_PaymentsForFindersFees": {
     "auth_ref": [],
     "calculation": {
      "http://brightmindsbio.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 20.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the payments for finders fees",
        "label": "Payments For Finders Fees",
        "negatedLabel": "Finder's fees"
       }
      }
     },
     "localname": "PaymentsForFindersFees",
     "nsuri": "http://brightmindsbio.com/20210930",
     "presentation": [
      "http://brightmindsbio.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "drug_PercentageOfForeignCurrencyFluctuationInUsDollarAgainstCanadianDollar": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of foreign currency fluctuation.",
        "label": "Percentage Of Foreign Currency Fluctuation In Us Dollar Against Canadian Dollar",
        "terseLabel": "Percentage of foreign currency fluctuation in US dollar against Canadian dollar"
       }
      }
     },
     "localname": "PercentageOfForeignCurrencyFluctuationInUsDollarAgainstCanadianDollar",
     "nsuri": "http://brightmindsbio.com/20210930",
     "presentation": [
      "http://brightmindsbio.com/role/FINANCIALINSTRUMENTSANDCAPITALMANAGEMENTDetailTextuals"
     ],
     "xbrltype": "percentItemType"
    },
    "drug_PercentageOfNetEquityProceedsReceivedFromThreeInvestors": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of equity proceeds received from three investors.",
        "label": "Percentage Of Net Equity Proceeds Received From Three Investors",
        "terseLabel": "Percentage of equity proceeds received from three investors"
       }
      }
     },
     "localname": "PercentageOfNetEquityProceedsReceivedFromThreeInvestors",
     "nsuri": "http://brightmindsbio.com/20210930",
     "presentation": [
      "http://brightmindsbio.com/role/SHARECAPITALDetailTextuals"
     ],
     "xbrltype": "percentItemType"
    },
    "drug_PercentageOfOutstandingSharesAuthorizedUnderStockOptionPlan": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents percentage of outstanding shares authorized under stock option plan.",
        "label": "Percentage Of Outstanding Shares Authorized Under Stock Option Plan",
        "verboseLabel": "Percentage of outstanding shares authorized under stock option plan"
       }
      }
     },
     "localname": "PercentageOfOutstandingSharesAuthorizedUnderStockOptionPlan",
     "nsuri": "http://brightmindsbio.com/20210930",
     "presentation": [
      "http://brightmindsbio.com/role/SHARECAPITALDetailTextuals"
     ],
     "xbrltype": "percentItemType"
    },
    "drug_PercentageOfRoyaltiesOnNetSales": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The percentage of royalties on net sales.",
        "label": "Percentage Of Royalties On Net Sales",
        "verboseLabel": "Percentage of royalties on net sales"
       }
      }
     },
     "localname": "PercentageOfRoyaltiesOnNetSales",
     "nsuri": "http://brightmindsbio.com/20210930",
     "presentation": [
      "http://brightmindsbio.com/role/CONTRACTUALOBLIGATIONSDetailTextuals"
     ],
     "xbrltype": "percentItemType"
    },
    "drug_PercentageOfRoyaltiesOnNetSalesOver2Billion": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information about percentage of royalties on net sales over 2 billion.",
        "label": "Percentage Of Royalties On Net Sales Over 2 Billion",
        "terseLabel": "Percentage of royalties on net sales over $2 billion"
       }
      }
     },
     "localname": "PercentageOfRoyaltiesOnNetSalesOver2Billion",
     "nsuri": "http://brightmindsbio.com/20210930",
     "presentation": [
      "http://brightmindsbio.com/role/CONTRACTUALOBLIGATIONSDetailTextuals"
     ],
     "xbrltype": "percentItemType"
    },
    "drug_PercentageOfRoyaltiesOnNetSalesUnder1Billion": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information about percentage of royalties on net sales under $1 billion.",
        "label": "Percentage Of Royalties On Net Sales Under 1 Billion",
        "terseLabel": "Percentage of royalties on net sales under $1 billion"
       }
      }
     },
     "localname": "PercentageOfRoyaltiesOnNetSalesUnder1Billion",
     "nsuri": "http://brightmindsbio.com/20210930",
     "presentation": [
      "http://brightmindsbio.com/role/CONTRACTUALOBLIGATIONSDetailTextuals"
     ],
     "xbrltype": "percentItemType"
    },
    "drug_PercentageOfStockOptionPlanAllowsBoardOfDirectorsToIssue": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of stock option plan allows Board of Directors to issue.",
        "label": "Percentage Of Stock Option Plan Allows Board Of Directors To Issue",
        "terseLabel": "Percentage of stock option plan allows Board of Directors to issue"
       }
      }
     },
     "localname": "PercentageOfStockOptionPlanAllowsBoardOfDirectorsToIssue",
     "nsuri": "http://brightmindsbio.com/20210930",
     "presentation": [
      "http://brightmindsbio.com/role/SHARECAPITALDetailTextuals"
     ],
     "xbrltype": "percentItemType"
    },
    "drug_PercentageOfStockOptionShareGranted": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the percentage of stock option share granted.",
        "label": "Percentage Of Stock Option Share Granted",
        "verboseLabel": "Percentage of stock option share granted"
       }
      }
     },
     "localname": "PercentageOfStockOptionShareGranted",
     "nsuri": "http://brightmindsbio.com/20210930",
     "presentation": [
      "http://brightmindsbio.com/role/SHARECAPITALDetailTextuals"
     ],
     "xbrltype": "percentItemType"
    },
    "drug_PriorToSublicensingAgreementsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information about prior to any sublicensing agreements.",
        "label": "Prior to Sublicensing agreements [Member]",
        "verboseLabel": "Licensing agreement - prior to any sublicensing agreements, joint ventures or change of control [Member]"
       }
      }
     },
     "localname": "PriorToSublicensingAgreementsMember",
     "nsuri": "http://brightmindsbio.com/20210930",
     "presentation": [
      "http://brightmindsbio.com/role/CONTRACTUALOBLIGATIONSDetailTextuals"
     ],
     "xbrltype": "domainItemType"
    },
    "drug_ProceedsForWarrantsIssued": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents amount of proceeds for warrants issued.",
        "label": "Proceeds For Warrants Issued",
        "verboseLabel": "Proceeds for warrants issued"
       }
      }
     },
     "localname": "ProceedsForWarrantsIssued",
     "nsuri": "http://brightmindsbio.com/20210930",
     "presentation": [
      "http://brightmindsbio.com/role/SHARECAPITALDetailTextuals"
     ],
     "xbrltype": "monetaryItemType"
    },
    "drug_ProceedsFromIssuingWarrants": {
     "auth_ref": [],
     "calculation": {
      "http://brightmindsbio.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 30.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents amount of proceeds from issuing warrants.",
        "label": "Proceeds From Issuing Warrants",
        "terseLabel": "Special warrant proceeds"
       }
      }
     },
     "localname": "ProceedsFromIssuingWarrants",
     "nsuri": "http://brightmindsbio.com/20210930",
     "presentation": [
      "http://brightmindsbio.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "drug_ProceedsFromWarrantsExercise": {
     "auth_ref": [],
     "calculation": {
      "http://brightmindsbio.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 0.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents Proceeds From Warrants Exercise",
        "label": "Proceeds From Warrants Exercise",
        "terseLabel": "Warrant exercise proceeds"
       }
      }
     },
     "localname": "ProceedsFromWarrantsExercise",
     "nsuri": "http://brightmindsbio.com/20210930",
     "presentation": [
      "http://brightmindsbio.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "drug_ProcessingFees": {
     "auth_ref": [],
     "calculation": {
      "http://brightmindsbio.com/role/ConsolidatedStatementsOfComprehensiveLoss": {
       "order": 70.0,
       "parentTag": "ifrs-full_ProfitLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expenses related to initial listing of the company.",
        "label": "Processing Fees",
        "terseLabel": "Funds processing fees - private placements"
       }
      }
     },
     "localname": "ProcessingFees",
     "nsuri": "http://brightmindsbio.com/20210930",
     "presentation": [
      "http://brightmindsbio.com/role/ConsolidatedStatementsOfComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "drug_ProfessionalFeesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the primary financial statement caption encompassing professional fees.",
        "label": "Professional Fees [Member]",
        "verboseLabel": "Professional fees [Member]"
       }
      }
     },
     "localname": "ProfessionalFeesMember",
     "nsuri": "http://brightmindsbio.com/20210930",
     "presentation": [
      "http://brightmindsbio.com/role/SHARECAPITALDetails5"
     ],
     "xbrltype": "domainItemType"
    },
    "drug_PsilocybinlabsLtdMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Psilocybinlabs Ltd.",
        "label": "PsilocybinLabs Ltd [Member]"
       }
      }
     },
     "localname": "PsilocybinlabsLtdMember",
     "nsuri": "http://brightmindsbio.com/20210930",
     "presentation": [
      "http://brightmindsbio.com/role/SHAREEXCHANGEANDASSIGNMENTDetailTextuals"
     ],
     "xbrltype": "domainItemType"
    },
    "drug_RefundFromIssuedWarrantsRescinded": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Refund from issued warrants rescinded.",
        "label": "Refund From Issued Warrants Rescinded",
        "verboseLabel": "Refund from issued warrants rescinded"
       }
      }
     },
     "localname": "RefundFromIssuedWarrantsRescinded",
     "nsuri": "http://brightmindsbio.com/20210930",
     "presentation": [
      "http://brightmindsbio.com/role/SHARECAPITALDetailTextuals"
     ],
     "xbrltype": "monetaryItemType"
    },
    "drug_RefundOfSpecialWarrantsProceeds": {
     "auth_ref": [],
     "calculation": {
      "http://brightmindsbio.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 10.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents refund of special warrants proceeds.",
        "label": "Refund Of Special Warrants Proceeds",
        "negatedLabel": "Refund of special warrant proceeds",
        "terseLabel": "Refund of special warrant proceeds"
       }
      }
     },
     "localname": "RefundOfSpecialWarrantsProceeds",
     "nsuri": "http://brightmindsbio.com/20210930",
     "presentation": [
      "http://brightmindsbio.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "drug_RegulatoryAndFilingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://brightmindsbio.com/role/ConsolidatedStatementsOfComprehensiveLoss": {
       "order": 10.0,
       "parentTag": "ifrs-full_ProfitLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expenses related to regulatory and filing.",
        "label": "Regulatory And Filing Expenses",
        "terseLabel": "Regulatory and filing"
       }
      }
     },
     "localname": "RegulatoryAndFilingExpenses",
     "nsuri": "http://brightmindsbio.com/20210930",
     "presentation": [
      "http://brightmindsbio.com/role/ConsolidatedStatementsOfComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "drug_ResearchAndDevelopmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research And Development [Abstract]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentAbstract",
     "nsuri": "http://brightmindsbio.com/20210930",
     "xbrltype": "stringItemType"
    },
    "drug_ResearchAndDevelopmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research And Development [Line Items]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentLineItems",
     "nsuri": "http://brightmindsbio.com/20210930",
     "presentation": [
      "http://brightmindsbio.com/role/RESEARCHANDDEVELOPMENTDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "drug_ResearchAndDevelopmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the primary financial statement caption encompassing research and development.",
        "label": "Research And Development [Member]",
        "verboseLabel": "Research and development [Member]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentMember",
     "nsuri": "http://brightmindsbio.com/20210930",
     "presentation": [
      "http://brightmindsbio.com/role/SHARECAPITALDetails5"
     ],
     "xbrltype": "domainItemType"
    },
    "drug_ResearchDevelopmentTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research Development [Table]"
       }
      }
     },
     "localname": "ResearchDevelopmentTable",
     "nsuri": "http://brightmindsbio.com/20210930",
     "presentation": [
      "http://brightmindsbio.com/role/RESEARCHANDDEVELOPMENTDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "drug_RestrictedShareUnitMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for restricted share unit.",
        "label": "Restricted Share Unit [Member]",
        "verboseLabel": "Restricted Share Units [Member]"
       }
      }
     },
     "localname": "RestrictedShareUnitMember",
     "nsuri": "http://brightmindsbio.com/20210930",
     "presentation": [
      "http://brightmindsbio.com/role/SHARECAPITALDetailTextuals",
      "http://brightmindsbio.com/role/SHARECAPITALDetails2",
      "http://brightmindsbio.com/role/SHARECAPITALDetails3",
      "http://brightmindsbio.com/role/SHARECAPITALDetails4"
     ],
     "xbrltype": "domainItemType"
    },
    "drug_RoyaltiesOnNetSales": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of royalties on net sales.",
        "label": "Royalties On Net Sales",
        "verboseLabel": "Royalties on net sales"
       }
      }
     },
     "localname": "RoyaltiesOnNetSales",
     "nsuri": "http://brightmindsbio.com/20210930",
     "presentation": [
      "http://brightmindsbio.com/role/CONTRACTUALOBLIGATIONSDetailTextuals"
     ],
     "xbrltype": "monetaryItemType"
    },
    "drug_SalaryAndSubcontractorsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents salary and subcontractors.",
        "label": "Salary And Subcontractors [Member]",
        "terseLabel": "Salary and subcontractors [Member]"
       }
      }
     },
     "localname": "SalaryAndSubcontractorsMember",
     "nsuri": "http://brightmindsbio.com/20210930",
     "presentation": [
      "http://brightmindsbio.com/role/RESEARCHANDDEVELOPMENTDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "drug_ScientificAdvisoryBoardAgreementsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information about scientific advisory board agreements.",
        "label": "Scientific advisory board agreements [Member]"
       }
      }
     },
     "localname": "ScientificAdvisoryBoardAgreementsMember",
     "nsuri": "http://brightmindsbio.com/20210930",
     "presentation": [
      "http://brightmindsbio.com/role/CONTRACTUALOBLIGATIONSDetailTextuals"
     ],
     "xbrltype": "domainItemType"
    },
    "drug_SecondTrancheMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Second Tranche [Member]",
        "label": "Second Tranche [Member]",
        "terseLabel": "April 1, 2022",
        "verboseLabel": "On the Company's listing date [Member]"
       }
      }
     },
     "localname": "SecondTrancheMember",
     "nsuri": "http://brightmindsbio.com/20210930",
     "presentation": [
      "http://brightmindsbio.com/role/SHARECAPITALDetailTextuals",
      "http://brightmindsbio.com/role/SUBSEQUENTEVENTSDetailTextuals"
     ],
     "xbrltype": "domainItemType"
    },
    "drug_SecondTrancheOfNonBrokeredPrivatePlacementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Second tranche of non brokered private placement",
        "label": "Second Tranche Of Non Brokered Private Placement [Member]",
        "verboseLabel": "Second tranche of a non-brokered private placement [Member]"
       }
      }
     },
     "localname": "SecondTrancheOfNonBrokeredPrivatePlacementMember",
     "nsuri": "http://brightmindsbio.com/20210930",
     "presentation": [
      "http://brightmindsbio.com/role/SHARECAPITALDetailTextuals"
     ],
     "xbrltype": "domainItemType"
    },
    "drug_SeventhTrancheMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Seventh tranche",
        "label": "Seventh Tranche [Member]",
        "verboseLabel": "On the second anniversary of the grant date [Member]"
       }
      }
     },
     "localname": "SeventhTrancheMember",
     "nsuri": "http://brightmindsbio.com/20210930",
     "presentation": [
      "http://brightmindsbio.com/role/SHARECAPITALDetailTextuals"
     ],
     "xbrltype": "domainItemType"
    },
    "drug_ShareBasedCompensationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents share based compensation.",
        "label": "Share Based Compensation [Member]",
        "terseLabel": "Share-based compensation [Member]"
       }
      }
     },
     "localname": "ShareBasedCompensationMember",
     "nsuri": "http://brightmindsbio.com/20210930",
     "presentation": [
      "http://brightmindsbio.com/role/RESEARCHANDDEVELOPMENTDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "drug_ShareExchangeAndAssignmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Exchange And Assignment [Abstract]"
       }
      }
     },
     "localname": "ShareExchangeAndAssignmentAbstract",
     "nsuri": "http://brightmindsbio.com/20210930",
     "xbrltype": "stringItemType"
    },
    "drug_ShareExchangeAndAssignmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table.",
        "label": "Share Exchange And Assignment [Line Items]"
       }
      }
     },
     "localname": "ShareExchangeAndAssignmentLineItems",
     "nsuri": "http://brightmindsbio.com/20210930",
     "presentation": [
      "http://brightmindsbio.com/role/SHAREEXCHANGEANDASSIGNMENTDetailTextuals"
     ],
     "xbrltype": "stringItemType"
    },
    "drug_ShareIssueCostsIncludedInAccountsPayable": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share issue costs included in accounts payable",
        "label": "Share Issue Costs Included In Accounts Payable",
        "terseLabel": "Share issue costs included in accounts payable"
       }
      }
     },
     "localname": "ShareIssueCostsIncludedInAccountsPayable",
     "nsuri": "http://brightmindsbio.com/20210930",
     "presentation": [
      "http://brightmindsbio.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "drug_SharePriceOnGrantDateOfOtherEquityInstruments": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share price on grant date of Other Equity Instruments",
        "label": "Share Price On Grant Date Of Other Equity Instruments",
        "verboseLabel": "Share price on grant date"
       }
      }
     },
     "localname": "SharePriceOnGrantDateOfOtherEquityInstruments",
     "nsuri": "http://brightmindsbio.com/20210930",
     "presentation": [
      "http://brightmindsbio.com/role/SHARECAPITALDetails3"
     ],
     "xbrltype": "perShareItemType"
    },
    "drug_SigningFee": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of signing fee.",
        "label": "Signing Fee",
        "terseLabel": "Signing fee"
       }
      }
     },
     "localname": "SigningFee",
     "nsuri": "http://brightmindsbio.com/20210930",
     "presentation": [
      "http://brightmindsbio.com/role/CONTRACTUALOBLIGATIONSDetailTextuals"
     ],
     "xbrltype": "monetaryItemType"
    },
    "drug_SigningFeeNetOfOptionFeesPaid": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents amount paid towards signing fee net of option fees.",
        "label": "Signing Fee Net Of Option Fees Paid",
        "terseLabel": "Signing fee, net of option fees paid"
       }
      }
     },
     "localname": "SigningFeeNetOfOptionFeesPaid",
     "nsuri": "http://brightmindsbio.com/20210930",
     "presentation": [
      "http://brightmindsbio.com/role/CONTRACTUALOBLIGATIONSDetailTextuals"
     ],
     "xbrltype": "monetaryItemType"
    },
    "drug_SigningFeeSharesIssued": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents signing fee, shares issued.",
        "label": "Signing Fee, Shares Issued",
        "verboseLabel": "Signing fee, shares issued"
       }
      }
     },
     "localname": "SigningFeeSharesIssued",
     "nsuri": "http://brightmindsbio.com/20210930",
     "presentation": [
      "http://brightmindsbio.com/role/CONTRACTUALOBLIGATIONSDetailTextuals"
     ],
     "xbrltype": "sharesItemType"
    },
    "drug_SixthTrancheMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sixth tranche",
        "label": "Sixth Tranche [Member]",
        "verboseLabel": "On the first anniversary of the grant date [Member]"
       }
      }
     },
     "localname": "SixthTrancheMember",
     "nsuri": "http://brightmindsbio.com/20210930",
     "presentation": [
      "http://brightmindsbio.com/role/SHARECAPITALDetailTextuals"
     ],
     "xbrltype": "domainItemType"
    },
    "drug_SpecialWarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Special Warrants [Member]",
        "label": "Special Warrants [Member]"
       }
      }
     },
     "localname": "SpecialWarrantsMember",
     "nsuri": "http://brightmindsbio.com/20210930",
     "presentation": [
      "http://brightmindsbio.com/role/SHARECAPITALDetailTextuals"
     ],
     "xbrltype": "domainItemType"
    },
    "drug_StatementOfComplianceAndBasisOfPreparationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement Of Compliance And Basis Of Preparation [Abstract]"
       }
      }
     },
     "localname": "StatementOfComplianceAndBasisOfPreparationAbstract",
     "nsuri": "http://brightmindsbio.com/20210930",
     "xbrltype": "stringItemType"
    },
    "drug_StockOptionAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table.",
        "label": "Stock Option [Axis]"
       }
      }
     },
     "localname": "StockOptionAxis",
     "nsuri": "http://brightmindsbio.com/20210930",
     "presentation": [
      "http://brightmindsbio.com/role/SHARECAPITALDetailTextuals"
     ],
     "xbrltype": "stringItemType"
    },
    "drug_StockOptionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Option [Domain].",
        "label": "Stock Option [Domain]"
       }
      }
     },
     "localname": "StockOptionDomain",
     "nsuri": "http://brightmindsbio.com/20210930",
     "presentation": [
      "http://brightmindsbio.com/role/SHARECAPITALDetailTextuals"
     ],
     "xbrltype": "domainItemType"
    },
    "drug_StockOptionsFourMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock options four",
        "label": "Stock Options Four [Member]"
       }
      }
     },
     "localname": "StockOptionsFourMember",
     "nsuri": "http://brightmindsbio.com/20210930",
     "presentation": [
      "http://brightmindsbio.com/role/SHARECAPITALDetailTextuals"
     ],
     "xbrltype": "domainItemType"
    },
    "drug_StockOptionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for stock options.",
        "label": "Stock Options [Member]",
        "verboseLabel": "Stock Options [Member]"
       }
      }
     },
     "localname": "StockOptionsMember",
     "nsuri": "http://brightmindsbio.com/20210930",
     "presentation": [
      "http://brightmindsbio.com/role/SHARECAPITALDetailTextuals",
      "http://brightmindsbio.com/role/SHARECAPITALDetails",
      "http://brightmindsbio.com/role/SHARECAPITALDetails1",
      "http://brightmindsbio.com/role/SHARECAPITALDetails4"
     ],
     "xbrltype": "domainItemType"
    },
    "drug_StockOptionsOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents member information related to stock options one.",
        "label": "Stock Options One [Member]"
       }
      }
     },
     "localname": "StockOptionsOneMember",
     "nsuri": "http://brightmindsbio.com/20210930",
     "presentation": [
      "http://brightmindsbio.com/role/SHARECAPITALDetailTextuals"
     ],
     "xbrltype": "domainItemType"
    },
    "drug_StockOptionsThreeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents member information related to stock options three.",
        "label": "Stock Options Three [Member]"
       }
      }
     },
     "localname": "StockOptionsThreeMember",
     "nsuri": "http://brightmindsbio.com/20210930",
     "presentation": [
      "http://brightmindsbio.com/role/SHARECAPITALDetailTextuals"
     ],
     "xbrltype": "domainItemType"
    },
    "drug_StockOptionsTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents member information related to stock options two.",
        "label": "Stock Options Two [Member]"
       }
      }
     },
     "localname": "StockOptionsTwoMember",
     "nsuri": "http://brightmindsbio.com/20210930",
     "presentation": [
      "http://brightmindsbio.com/role/SHARECAPITALDetailTextuals"
     ],
     "xbrltype": "domainItemType"
    },
    "drug_SubscriptionReceivableMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Subscription Receivable [Member]",
        "label": "Subscription Receivable [Member]",
        "verboseLabel": "Subscriptions receivable [Member]"
       }
      }
     },
     "localname": "SubscriptionReceivableMember",
     "nsuri": "http://brightmindsbio.com/20210930",
     "presentation": [
      "http://brightmindsbio.com/role/ConsolidatedStatementsOfChangesInShareholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "drug_SubscriptionReceivedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Subscription Received [Member]",
        "label": "Subscription Received [Member]",
        "verboseLabel": "Subscriptions received [Member]"
       }
      }
     },
     "localname": "SubscriptionReceivedMember",
     "nsuri": "http://brightmindsbio.com/20210930",
     "presentation": [
      "http://brightmindsbio.com/role/ConsolidatedStatementsOfChangesInShareholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "drug_SubscriptionsReceivable": {
     "auth_ref": [],
     "calculation": {
      "http://brightmindsbio.com/role/ConsolidatedStatementsOfFinancialPosition": {
       "order": 30.0,
       "parentTag": "ifrs-full_Equity",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the amount of subscriptions receivable.",
        "label": "Subscriptions Receivable",
        "negatedLabel": "Subscription receivable",
        "terseLabel": "Subscription receivable"
       }
      }
     },
     "localname": "SubscriptionsReceivable",
     "nsuri": "http://brightmindsbio.com/20210930",
     "presentation": [
      "http://brightmindsbio.com/role/ConsolidatedStatementsOfFinancialPosition"
     ],
     "xbrltype": "monetaryItemType"
    },
    "drug_SubscriptionsReceived": {
     "auth_ref": [],
     "calculation": {
      "http://brightmindsbio.com/role/ConsolidatedStatementsOfFinancialPosition": {
       "order": 40.0,
       "parentTag": "ifrs-full_Equity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the amount of subscriptions received.",
        "label": "Subscriptions Received",
        "terseLabel": "Subscription received"
       }
      }
     },
     "localname": "SubscriptionsReceived",
     "nsuri": "http://brightmindsbio.com/20210930",
     "presentation": [
      "http://brightmindsbio.com/role/ConsolidatedStatementsOfFinancialPosition",
      "http://brightmindsbio.com/role/SHARECAPITALDetailTextuals"
     ],
     "xbrltype": "monetaryItemType"
    },
    "drug_SubsequentEventsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent events [Member]"
       }
      }
     },
     "localname": "SubsequentEventsMember",
     "nsuri": "http://brightmindsbio.com/20210930",
     "presentation": [
      "http://brightmindsbio.com/role/SUBSEQUENTEVENTSDetailTextuals"
     ],
     "xbrltype": "domainItemType"
    },
    "drug_SupplementaryInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Supplementary Information Abstract",
        "label": "Supplementary Information [Abstract]",
        "verboseLabel": "SUPPLEMENTARY INFORMATION"
       }
      }
     },
     "localname": "SupplementaryInformationAbstract",
     "nsuri": "http://brightmindsbio.com/20210930",
     "presentation": [
      "http://brightmindsbio.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "drug_TaxAuthorityOfAustraliaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax authority of Australia.",
        "label": "Tax Authority Of Australia [Member]",
        "terseLabel": "Tax authority of Australia [Member]"
       }
      }
     },
     "localname": "TaxAuthorityOfAustraliaMember",
     "nsuri": "http://brightmindsbio.com/20210930",
     "presentation": [
      "http://brightmindsbio.com/role/INCOMETAXESDetailTextuals"
     ],
     "xbrltype": "domainItemType"
    },
    "drug_TaxAuthorityOfCanadaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax authority of canada.",
        "label": "Tax authority of Canada [Member]"
       }
      }
     },
     "localname": "TaxAuthorityOfCanadaMember",
     "nsuri": "http://brightmindsbio.com/20210930",
     "presentation": [
      "http://brightmindsbio.com/role/INCOMETAXESDetailTextuals",
      "http://brightmindsbio.com/role/INCOMETAXESDetails2"
     ],
     "xbrltype": "domainItemType"
    },
    "drug_TaxAuthorityOfUnitedStatesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax authority of United States.",
        "label": "Tax Authority Of United States [Member]",
        "terseLabel": "Tax authority of United States [Member]"
       }
      }
     },
     "localname": "TaxAuthorityOfUnitedStatesMember",
     "nsuri": "http://brightmindsbio.com/20210930",
     "presentation": [
      "http://brightmindsbio.com/role/INCOMETAXESDetailTextuals"
     ],
     "xbrltype": "domainItemType"
    },
    "drug_TaxEffectOfChangeInDeferredTaxAssetsNotRecognized": {
     "auth_ref": [],
     "calculation": {
      "http://brightmindsbio.com/role/INCOMETAXESDetails": {
       "order": 20.0,
       "parentTag": "ifrs-full_IncomeTaxExpenseContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount that represents the difference between the tax expense (income) and the product of the accounting profit multiplied by the applicable tax rate(s) that relates to deferred tax assets not recognized.",
        "label": "Tax Effect Of Change In Deferred Tax Assets Not Recognized",
        "verboseLabel": "Change in deferred tax assets not recognized"
       }
      }
     },
     "localname": "TaxEffectOfChangeInDeferredTaxAssetsNotRecognized",
     "nsuri": "http://brightmindsbio.com/20210930",
     "presentation": [
      "http://brightmindsbio.com/role/INCOMETAXESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "drug_TaxEffectOfDeductibleAndNotDeductibleItems": {
     "auth_ref": [],
     "calculation": {
      "http://brightmindsbio.com/role/INCOMETAXESDetails": {
       "order": 10.0,
       "parentTag": "ifrs-full_IncomeTaxExpenseContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount that represents the difference between the tax expense (income) and the product of the accounting profit multiplied by the applicable tax rate(s) that relates to expenses deductible and not deductible items in determining taxable profit (tax loss).",
        "label": "Tax Effect Of Deductible And Not Deductible Items",
        "negatedLabel": "Deductible and non-deductible items",
        "verboseLabel": "Deductible and non-deductible items"
       }
      }
     },
     "localname": "TaxEffectOfDeductibleAndNotDeductibleItems",
     "nsuri": "http://brightmindsbio.com/20210930",
     "presentation": [
      "http://brightmindsbio.com/role/INCOMETAXESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "drug_TaxYearOfOrigin2019Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax Year of origin 2019.",
        "label": "Tax Year Of Origin 2019 [Member]",
        "terseLabel": "2019 [Member]"
       }
      }
     },
     "localname": "TaxYearOfOrigin2019Member",
     "nsuri": "http://brightmindsbio.com/20210930",
     "presentation": [
      "http://brightmindsbio.com/role/INCOMETAXESDetails2"
     ],
     "xbrltype": "domainItemType"
    },
    "drug_TaxYearOfOrigin2020Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax Year Of Origin 2020.",
        "label": "Tax Year Of Origin 2020 [Member]",
        "terseLabel": "2020 [Member]"
       }
      }
     },
     "localname": "TaxYearOfOrigin2020Member",
     "nsuri": "http://brightmindsbio.com/20210930",
     "presentation": [
      "http://brightmindsbio.com/role/INCOMETAXESDetails2"
     ],
     "xbrltype": "domainItemType"
    },
    "drug_TaxYearOfOrigin2021Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax Year Of Origin 2021.",
        "label": "Tax Year Of Origin 2021 [Member]",
        "terseLabel": "2021 [Member]"
       }
      }
     },
     "localname": "TaxYearOfOrigin2021Member",
     "nsuri": "http://brightmindsbio.com/20210930",
     "presentation": [
      "http://brightmindsbio.com/role/INCOMETAXESDetails2"
     ],
     "xbrltype": "domainItemType"
    },
    "drug_TemporaryDifferencesIntangibleAssetsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for temporary differences intangible assets member.",
        "label": "Temporary Differences Intangible Assets [Member]",
        "terseLabel": "Intangible assets [Member]"
       }
      }
     },
     "localname": "TemporaryDifferencesIntangibleAssetsMember",
     "nsuri": "http://brightmindsbio.com/20210930",
     "presentation": [
      "http://brightmindsbio.com/role/INCOMETAXESDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "drug_TemporaryDifferencesShareIssueCostsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents temporary differences share issue costs member.",
        "label": "Temporary Differences Share Issue Costs [Member]",
        "verboseLabel": "Share issue costs [Member]"
       }
      }
     },
     "localname": "TemporaryDifferencesShareIssueCostsMember",
     "nsuri": "http://brightmindsbio.com/20210930",
     "presentation": [
      "http://brightmindsbio.com/role/INCOMETAXESDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "drug_TemporaryDifferencesValuationAllowanceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for an temporary differences valuation allowance member.",
        "label": "Temporary Differences Valuation Allowance [Member]",
        "verboseLabel": "Valuation allowance [Member]"
       }
      }
     },
     "localname": "TemporaryDifferencesValuationAllowanceMember",
     "nsuri": "http://brightmindsbio.com/20210930",
     "presentation": [
      "http://brightmindsbio.com/role/INCOMETAXESDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "drug_TenthTrancheMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tenth tranche",
        "label": "Tenth Tranche [Member]",
        "verboseLabel": "On the six-month anniversary of the grant date [Member]"
       }
      }
     },
     "localname": "TenthTrancheMember",
     "nsuri": "http://brightmindsbio.com/20210930",
     "presentation": [
      "http://brightmindsbio.com/role/SHARECAPITALDetailTextuals"
     ],
     "xbrltype": "domainItemType"
    },
    "drug_TermOfLease": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lease.",
        "label": "Term Of Lease",
        "terseLabel": "Term of lease"
       }
      }
     },
     "localname": "TermOfLease",
     "nsuri": "http://brightmindsbio.com/20210930",
     "presentation": [
      "http://brightmindsbio.com/role/PREMISESLEASESDetailTextuals"
     ],
     "xbrltype": "durationItemType"
    },
    "drug_TermOfWarrant": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information about term of warrant.",
        "label": "Term Of Warrant",
        "terseLabel": "Term of warrant"
       }
      }
     },
     "localname": "TermOfWarrant",
     "nsuri": "http://brightmindsbio.com/20210930",
     "presentation": [
      "http://brightmindsbio.com/role/SHARECAPITALDetailTextuals"
     ],
     "xbrltype": "durationItemType"
    },
    "drug_TermsOfContract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represent the term of contract.",
        "label": "Terms Of Contract",
        "terseLabel": "Terms of contract"
       }
      }
     },
     "localname": "TermsOfContract",
     "nsuri": "http://brightmindsbio.com/20210930",
     "presentation": [
      "http://brightmindsbio.com/role/SUBSEQUENTEVENTSDetailTextuals"
     ],
     "xbrltype": "stringItemType"
    },
    "drug_ThirdTrancheMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Third tranche",
        "label": "Third Tranche [Member]",
        "terseLabel": "July 1, 2022",
        "verboseLabel": "On the first anniversary of the listing date [Member]"
       }
      }
     },
     "localname": "ThirdTrancheMember",
     "nsuri": "http://brightmindsbio.com/20210930",
     "presentation": [
      "http://brightmindsbio.com/role/SHARECAPITALDetailTextuals",
      "http://brightmindsbio.com/role/SUBSEQUENTEVENTSDetailTextuals"
     ],
     "xbrltype": "domainItemType"
    },
    "drug_ThirteenthTrancheMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Thirteenth tranche",
        "label": "Thirteenth Tranche [Member]",
        "verboseLabel": "On March 21, 2022 [Member]"
       }
      }
     },
     "localname": "ThirteenthTrancheMember",
     "nsuri": "http://brightmindsbio.com/20210930",
     "presentation": [
      "http://brightmindsbio.com/role/SHARECAPITALDetailTextuals"
     ],
     "xbrltype": "domainItemType"
    },
    "drug_ThreeConsultantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Three consultants",
        "label": "Three Consultants [Member]"
       }
      }
     },
     "localname": "ThreeConsultantsMember",
     "nsuri": "http://brightmindsbio.com/20210930",
     "presentation": [
      "http://brightmindsbio.com/role/SHARECAPITALDetailTextuals"
     ],
     "xbrltype": "domainItemType"
    },
    "drug_ThreeInvestorsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Three investors [Member]",
        "label": "Three Investors [Member]"
       }
      }
     },
     "localname": "ThreeInvestorsMember",
     "nsuri": "http://brightmindsbio.com/20210930",
     "presentation": [
      "http://brightmindsbio.com/role/SHARECAPITALDetailTextuals"
     ],
     "xbrltype": "domainItemType"
    },
    "drug_ThresholdPercentageOfWarrants": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Threshold percentage of warrants.",
        "label": "Threshold Percentage Of Warrants",
        "verboseLabel": "Threshold percentage of warrants"
       }
      }
     },
     "localname": "ThresholdPercentageOfWarrants",
     "nsuri": "http://brightmindsbio.com/20210930",
     "presentation": [
      "http://brightmindsbio.com/role/SHARECAPITALDetailTextuals"
     ],
     "xbrltype": "percentItemType"
    },
    "drug_TotalAnnualMinimumRoyaltiesAfterFirstCommercialSale": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information about total annual minimum royalties after first commercial sale.",
        "label": "Total Annual Minimum Royalties After First Commercial Sale",
        "terseLabel": "Annual minimum royalties after first commercial sale"
       }
      }
     },
     "localname": "TotalAnnualMinimumRoyaltiesAfterFirstCommercialSale",
     "nsuri": "http://brightmindsbio.com/20210930",
     "presentation": [
      "http://brightmindsbio.com/role/CONTRACTUALOBLIGATIONSDetailTextuals"
     ],
     "xbrltype": "monetaryItemType"
    },
    "drug_TotalAnnualMinimumRoyaltiesCurrentYears": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information about total annual minimum royalties current years.",
        "label": "Total Annual Minimum Royalties Current Years",
        "terseLabel": "Annual minimum royalties - Years 1 and 2"
       }
      }
     },
     "localname": "TotalAnnualMinimumRoyaltiesCurrentYears",
     "nsuri": "http://brightmindsbio.com/20210930",
     "presentation": [
      "http://brightmindsbio.com/role/CONTRACTUALOBLIGATIONSDetailTextuals"
     ],
     "xbrltype": "monetaryItemType"
    },
    "drug_TotalAnnualMinimumRoyaltiesNextYears": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information about total annual minimum royalties next years.",
        "label": "Total Annual Minimum Royalties Next Years",
        "terseLabel": "Total annual minimum royalties next years"
       }
      }
     },
     "localname": "TotalAnnualMinimumRoyaltiesNextYears",
     "nsuri": "http://brightmindsbio.com/20210930",
     "presentation": [
      "http://brightmindsbio.com/role/CONTRACTUALOBLIGATIONSDetailTextuals"
     ],
     "xbrltype": "monetaryItemType"
    },
    "drug_TotalAnnualMinimumRoyaltiesYear3": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information about total annual minimum royalties current years 3.",
        "label": "Total Annual Minimum Royalties Year 3",
        "terseLabel": "Annual minimum royalties - Year 3"
       }
      }
     },
     "localname": "TotalAnnualMinimumRoyaltiesYear3",
     "nsuri": "http://brightmindsbio.com/20210930",
     "presentation": [
      "http://brightmindsbio.com/role/CONTRACTUALOBLIGATIONSDetailTextuals"
     ],
     "xbrltype": "monetaryItemType"
    },
    "drug_TotalAnnualMinimumRoyaltiesYear4": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information about total annual minimum royalties years 4.",
        "label": "Total Annual Minimum Royalties Year 4",
        "terseLabel": "Annual minimum royalties - Year 4"
       }
      }
     },
     "localname": "TotalAnnualMinimumRoyaltiesYear4",
     "nsuri": "http://brightmindsbio.com/20210930",
     "presentation": [
      "http://brightmindsbio.com/role/CONTRACTUALOBLIGATIONSDetailTextuals"
     ],
     "xbrltype": "monetaryItemType"
    },
    "drug_TotalAnnualMinimumRoyaltiesYear5": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information about total annual minimum royalties years 5.",
        "label": "Total Annual Minimum Royalties Year 5",
        "terseLabel": "Annual minimum royalties - Year 5"
       }
      }
     },
     "localname": "TotalAnnualMinimumRoyaltiesYear5",
     "nsuri": "http://brightmindsbio.com/20210930",
     "presentation": [
      "http://brightmindsbio.com/role/CONTRACTUALOBLIGATIONSDetailTextuals"
     ],
     "xbrltype": "monetaryItemType"
    },
    "drug_TotalAnnualMinimumRoyaltiesYear6AndThereafter": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information about total annual minimum royalties year 6 and thereafter",
        "label": "Total Annual Minimum Royalties Year 6 And Thereafter",
        "terseLabel": "Annual minimum royalties - Year 6 and thereafter"
       }
      }
     },
     "localname": "TotalAnnualMinimumRoyaltiesYear6AndThereafter",
     "nsuri": "http://brightmindsbio.com/20210930",
     "presentation": [
      "http://brightmindsbio.com/role/CONTRACTUALOBLIGATIONSDetailTextuals"
     ],
     "xbrltype": "monetaryItemType"
    },
    "drug_TranchesAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tranches [Axis]"
       }
      }
     },
     "localname": "TranchesAxis",
     "nsuri": "http://brightmindsbio.com/20210930",
     "presentation": [
      "http://brightmindsbio.com/role/SUBSEQUENTEVENTSDetailTextuals"
     ],
     "xbrltype": "stringItemType"
    },
    "drug_TranchesDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tranches [Domain]"
       }
      }
     },
     "localname": "TranchesDomain",
     "nsuri": "http://brightmindsbio.com/20210930",
     "presentation": [
      "http://brightmindsbio.com/role/SUBSEQUENTEVENTSDetailTextuals"
     ],
     "xbrltype": "domainItemType"
    },
    "drug_TwelfthTrancheMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Twelfth tranche",
        "label": "Twelfth Tranche [Member]",
        "verboseLabel": "On December 21, 2021 [Member]"
       }
      }
     },
     "localname": "TwelfthTrancheMember",
     "nsuri": "http://brightmindsbio.com/20210930",
     "presentation": [
      "http://brightmindsbio.com/role/SHARECAPITALDetailTextuals"
     ],
     "xbrltype": "domainItemType"
    },
    "drug_TypeOfArrangementsAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table.",
        "label": "Type Of Arrangements [Axis]"
       }
      }
     },
     "localname": "TypeOfArrangementsAxis",
     "nsuri": "http://brightmindsbio.com/20210930",
     "presentation": [
      "http://brightmindsbio.com/role/SUBSEQUENTEVENTSDetailTextuals"
     ],
     "xbrltype": "stringItemType"
    },
    "drug_UnderwritersFeesPaid": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Underwriters fees paid.",
        "label": "Underwriters fees paid"
       }
      }
     },
     "localname": "UnderwritersFeesPaid",
     "nsuri": "http://brightmindsbio.com/20210930",
     "presentation": [
      "http://brightmindsbio.com/role/SHARECAPITALDetailTextuals"
     ],
     "xbrltype": "monetaryItemType"
    },
    "drug_UnderwritersMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Underwriters.",
        "label": "Underwriters [Member]"
       }
      }
     },
     "localname": "UnderwritersMember",
     "nsuri": "http://brightmindsbio.com/20210930",
     "presentation": [
      "http://brightmindsbio.com/role/SHARECAPITALDetailTextuals"
     ],
     "xbrltype": "domainItemType"
    },
    "drug_UnitsIssuedPricePerUnit": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents unit issued price per unit.",
        "label": "Units Issued, Price Per Unit",
        "verboseLabel": "Units issued, price per unit"
       }
      }
     },
     "localname": "UnitsIssuedPricePerUnit",
     "nsuri": "http://brightmindsbio.com/20210930",
     "presentation": [
      "http://brightmindsbio.com/role/SHARECAPITALDetailTextuals"
     ],
     "xbrltype": "perUnitItemType"
    },
    "drug_ValueOfCommonStockSharesIssuedByRelatedParty": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the value of common stock shares issued by related party.",
        "label": "Value Of Common Stock Shares Issued By Related Party",
        "terseLabel": "Value of common stock issued by PL to individual"
       }
      }
     },
     "localname": "ValueOfCommonStockSharesIssuedByRelatedParty",
     "nsuri": "http://brightmindsbio.com/20210930",
     "presentation": [
      "http://brightmindsbio.com/role/SHAREEXCHANGEANDASSIGNMENTDetailTextuals"
     ],
     "xbrltype": "monetaryItemType"
    },
    "drug_VestingDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vesting [Domain]"
       }
      }
     },
     "localname": "VestingDomain",
     "nsuri": "http://brightmindsbio.com/20210930",
     "presentation": [
      "http://brightmindsbio.com/role/SHARECAPITALDetailTextuals"
     ],
     "xbrltype": "domainItemType"
    },
    "drug_VestingPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vesting percentage of share-based payment award.",
        "label": "Vesting Percentage",
        "verboseLabel": "Vesting percentage"
       }
      }
     },
     "localname": "VestingPercentage",
     "nsuri": "http://brightmindsbio.com/20210930",
     "presentation": [
      "http://brightmindsbio.com/role/SHARECAPITALDetailTextuals"
     ],
     "xbrltype": "percentItemType"
    },
    "drug_VestingsAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table.",
        "label": "Vestings [Axis]"
       }
      }
     },
     "localname": "VestingsAxis",
     "nsuri": "http://brightmindsbio.com/20210930",
     "presentation": [
      "http://brightmindsbio.com/role/SHARECAPITALDetailTextuals"
     ],
     "xbrltype": "stringItemType"
    },
    "drug_WarrantAscribedValue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrant ascribed value.",
        "label": "Warrant Ascribed Value",
        "terseLabel": "Warrant ascribed value"
       }
      }
     },
     "localname": "WarrantAscribedValue",
     "nsuri": "http://brightmindsbio.com/20210930",
     "presentation": [
      "http://brightmindsbio.com/role/SHARECAPITALDetailTextuals"
     ],
     "xbrltype": "monetaryItemType"
    },
    "drug_WarrantsIssuedPricePerWarrant": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents per share price of warrants issued.",
        "label": "Warrants Issued, Price Per Warrant",
        "verboseLabel": "Warrants issued, price per warrant"
       }
      }
     },
     "localname": "WarrantsIssuedPricePerWarrant",
     "nsuri": "http://brightmindsbio.com/20210930",
     "presentation": [
      "http://brightmindsbio.com/role/SHARECAPITALDetailTextuals"
     ],
     "xbrltype": "perShareItemType"
    },
    "drug_WarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for warrants.",
        "label": "Warrants [Member]",
        "verboseLabel": "Warrants [Member]"
       }
      }
     },
     "localname": "WarrantsMember",
     "nsuri": "http://brightmindsbio.com/20210930",
     "presentation": [
      "http://brightmindsbio.com/role/SHARECAPITALDetailTextuals",
      "http://brightmindsbio.com/role/SHARECAPITALDetails6",
      "http://brightmindsbio.com/role/SHARECAPITALDetails7"
     ],
     "xbrltype": "domainItemType"
    },
    "drug_WeightedAverageExercisePriceOfWarrantsExercisedInShareBasedPaymentArrangement": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the weighted average exercise price of warrants exercised In share based payment arrangement.",
        "label": "Weighted Average Exercise Price Of Warrants Exercised In Share Based Payment Arrangement",
        "negatedLabel": "Weighted average exercise price, Exercised",
        "verboseLabel": "Weighted average exercise price, Exercised"
       }
      }
     },
     "localname": "WeightedAverageExercisePriceOfWarrantsExercisedInShareBasedPaymentArrangement",
     "nsuri": "http://brightmindsbio.com/20210930",
     "presentation": [
      "http://brightmindsbio.com/role/SHARECAPITALDetailTextuals",
      "http://brightmindsbio.com/role/SHARECAPITALDetails6"
     ],
     "xbrltype": "perShareItemType"
    },
    "drug_WeightedAverageExercisePriceOfWarrantsIssuedInShareBasedPaymentArrangement": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the weighted average exercise price of warrants issued In share based payment arrangement.",
        "label": "Weighted Average Exercise Price Of Warrants Issued In Share Based Payment Arrangement",
        "terseLabel": "Weighted average exercise price of warrants issued",
        "verboseLabel": "Weighted average exercise price, Issued"
       }
      }
     },
     "localname": "WeightedAverageExercisePriceOfWarrantsIssuedInShareBasedPaymentArrangement",
     "nsuri": "http://brightmindsbio.com/20210930",
     "presentation": [
      "http://brightmindsbio.com/role/SHARECAPITALDetailTextuals",
      "http://brightmindsbio.com/role/SHARECAPITALDetails6"
     ],
     "xbrltype": "perShareItemType"
    },
    "drug_WeightedAverageExercisePriceOfWarrantsIssuedToBrokerInShareBasedPaymentArrangement": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the weighted average exercise price of warrants issued to broker in share based payment arrangement.",
        "label": "Weighted Average Exercise Price Of Warrants Issued To Broker In Share Based Payment Arrangement",
        "verboseLabel": "Weighted average exercise price, Issued - broker"
       }
      }
     },
     "localname": "WeightedAverageExercisePriceOfWarrantsIssuedToBrokerInShareBasedPaymentArrangement",
     "nsuri": "http://brightmindsbio.com/20210930",
     "presentation": [
      "http://brightmindsbio.com/role/SHARECAPITALDetails6"
     ],
     "xbrltype": "perShareItemType"
    },
    "drug_WeightedAverageExercisePriceOfWarrantsOutstandingInShareBasedPaymentArrangement": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the weighted average exercise price of warrants outstanding in share based payment arrangement.",
        "label": "Weighted Average Exercise Price Of Warrants Outstanding In Share Based Payment Arrangement",
        "periodEndLabel": "Weighted average exercise price, Ending Balance",
        "periodStartLabel": "Weighted average exercise price, Beginning Balance",
        "terseLabel": "Warrants exercise price",
        "verboseLabel": "Warrants Outstanding, Exercise price"
       }
      }
     },
     "localname": "WeightedAverageExercisePriceOfWarrantsOutstandingInShareBasedPaymentArrangement",
     "nsuri": "http://brightmindsbio.com/20210930",
     "presentation": [
      "http://brightmindsbio.com/role/SHARECAPITALDetailTextuals",
      "http://brightmindsbio.com/role/SHARECAPITALDetails6",
      "http://brightmindsbio.com/role/SHARECAPITALDetails7"
     ],
     "xbrltype": "perShareItemType"
    },
    "drug_WeightedAverageRemainingContractualLifeOfOtherEquityInstruments": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average remaining contractual life of other equity instruments.",
        "label": "Weighted Average Remaining Contractual Life Of Other Equity Instruments",
        "terseLabel": "Weighted average remaining contractual life of outstanding warrants",
        "verboseLabel": "Warrants Outstanding, Remaining life (Years)"
       }
      }
     },
     "localname": "WeightedAverageRemainingContractualLifeOfOtherEquityInstruments",
     "nsuri": "http://brightmindsbio.com/20210930",
     "presentation": [
      "http://brightmindsbio.com/role/SHARECAPITALDetailTextuals"
     ],
     "xbrltype": "durationItemType"
    },
    "drug_WeightedAverageRemainingContractualLifeOfWarrants": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average remaining contractual life of warrants.",
        "label": "Weighted Average Remaining Contractual Life Of Warrants",
        "terseLabel": "Weighted average remaining contractual life of outstanding warrants",
        "verboseLabel": "Warrants Outstanding, Remaining life (Years)"
       }
      }
     },
     "localname": "WeightedAverageRemainingContractualLifeOfWarrants",
     "nsuri": "http://brightmindsbio.com/20210930",
     "presentation": [
      "http://brightmindsbio.com/role/SHARECAPITALDetails7"
     ],
     "xbrltype": "durationItemType"
    },
    "drug_WeightedAverageSharePriceWarrantsGranted": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average share price, warrants granted.",
        "label": "Weighted Average Share Price, Warrants Granted",
        "verboseLabel": "Share price, warrants granted"
       }
      }
     },
     "localname": "WeightedAverageSharePriceWarrantsGranted",
     "nsuri": "http://brightmindsbio.com/20210930",
     "presentation": [
      "http://brightmindsbio.com/role/SHARECAPITALDetailTextuals"
     ],
     "xbrltype": "perShareItemType"
    },
    "drug_WeightedAverageTradingPriceOfCommonSharesOnCanadianStockExchange": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average trading price of common shares on canadian stock exchange.",
        "label": "Weighted Average Trading Price Of Common Shares On Canadian Stock Exchange",
        "terseLabel": "Weighted average trading price of common shares on canadian stock exchange"
       }
      }
     },
     "localname": "WeightedAverageTradingPriceOfCommonSharesOnCanadianStockExchange",
     "nsuri": "http://brightmindsbio.com/20210930",
     "presentation": [
      "http://brightmindsbio.com/role/SHARECAPITALDetailTextuals"
     ],
     "xbrltype": "perShareItemType"
    },
    "drug_WorkingCapital": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the amount working capital",
        "label": "Working capital"
       }
      }
     },
     "localname": "WorkingCapital",
     "nsuri": "http://brightmindsbio.com/20210930",
     "presentation": [
      "http://brightmindsbio.com/role/NATUREANDCONTINUANCEOFOPERATIONSDetailTextuals"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_AccountingProfit": {
     "auth_ref": [
      "r27",
      "r28"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of profit (loss) for a period before deducting tax expense. [Refer: Profit (loss)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Accounting profit",
        "terseLabel": "Net loss"
       }
      }
     },
     "localname": "AccountingProfit",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://brightmindsbio.com/role/INCOMETAXESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_AccrualsClassifiedAsCurrent": {
     "auth_ref": [
      "r16"
     ],
     "calculation": {
      "http://brightmindsbio.com/role/ACCOUNTSPAYABLEANDACCRUEDLIABILITIESDetails": {
       "order": 10.0,
       "parentTag": "ifrs-full_TradeAndOtherCurrentPayables",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of accruals classified as current. [Refer: Accruals]"
       }
      },
      "en-us": {
       "role": {
        "label": "Accruals classified as current",
        "terseLabel": "Accrued liabilities"
       }
      }
     },
     "localname": "AccrualsClassifiedAsCurrent",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://brightmindsbio.com/role/ACCOUNTSPAYABLEANDACCRUEDLIABILITIESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable": {
     "auth_ref": [
      "r48"
     ],
     "calculation": {
      "http://brightmindsbio.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 30.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "Adjustments for increase (decrease) in trade accounts payable to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Adjustments for increase (decrease) in trade accounts payable",
        "verboseLabel": "Accounts payable and accrued liabilities"
       }
      }
     },
     "localname": "AdjustmentsForIncreaseDecreaseInTradeAccountPayable",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://brightmindsbio.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_AdjustmentsForReconcileProfitLossAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to reconcile profit (loss) [abstract]",
        "terseLabel": "Non-cash items:"
       }
      }
     },
     "localname": "AdjustmentsForReconcileProfitLossAbstract",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://brightmindsbio.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_AdjustmentsForSharebasedPayments": {
     "auth_ref": [
      "r49"
     ],
     "calculation": {
      "http://brightmindsbio.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 50.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "Adjustments for share-based payments to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Adjustments for share-based payments",
        "terseLabel": "Share-based compensation"
       }
      }
     },
     "localname": "AdjustmentsForSharebasedPayments",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://brightmindsbio.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains": {
     "auth_ref": [
      "r49"
     ],
     "calculation": {
      "http://brightmindsbio.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 60.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "Adjustments for unrealised foreign exchange losses (gains) to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Adjustments for unrealised foreign exchange losses (gains)",
        "terseLabel": "Foreign exchange"
       }
      }
     },
     "localname": "AdjustmentsForUnrealisedForeignExchangeLossesGains",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://brightmindsbio.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ApplicableTaxRate": {
     "auth_ref": [
      "r28"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The applicable income tax rate."
       }
      },
      "en-us": {
       "role": {
        "label": "Applicable tax rate",
        "verboseLabel": "Statutory tax rate"
       }
      }
     },
     "localname": "ApplicableTaxRate",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://brightmindsbio.com/role/INCOMETAXESDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ifrs-full_Assets": {
     "auth_ref": [
      "r12",
      "r63",
      "r64",
      "r65",
      "r98",
      "r100"
     ],
     "calculation": {
      "http://brightmindsbio.com/role/ConsolidatedStatementsOfFinancialPosition": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of a present economic resource controlled by the entity as a result of past events. Economic resource is a right that has the potential to produce economic benefits."
       }
      },
      "en-us": {
       "role": {
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://brightmindsbio.com/role/ConsolidatedStatementsOfFinancialPosition"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [abstract]",
        "verboseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://brightmindsbio.com/role/ConsolidatedStatementsOfFinancialPosition"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_BasicAndDilutedEarningsLossPerShare": {
     "auth_ref": [
      "r22"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of earnings per share when the basic and diluted measurements are equal. [Refer: Basic earnings (loss) per share; Diluted earnings (loss) per share]"
       }
      },
      "en-us": {
       "role": {
        "label": "Basic and diluted earnings (loss) per share",
        "terseLabel": "Basic and diluted loss per share"
       }
      }
     },
     "localname": "BasicAndDilutedEarningsLossPerShare",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://brightmindsbio.com/role/ConsolidatedStatementsOfComprehensiveLoss"
     ],
     "xbrltype": "perShareItemType"
    },
    "ifrs-full_BottomOfRangeMember": {
     "auth_ref": [
      "r67",
      "r68",
      "r69",
      "r79",
      "r94",
      "r103"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for the bottom of a range."
       }
      },
      "en-us": {
       "role": {
        "label": "Bottom of range [member]"
       }
      }
     },
     "localname": "BottomOfRangeMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://brightmindsbio.com/role/CONTRACTUALOBLIGATIONSDetailTextuals"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_BuildingsMember": {
     "auth_ref": [
      "r32"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for a class of plant, property and equipment representing depreciable buildings and similar structures for use in operations. [Refer: Property, plant and equipment]"
       }
      },
      "en-us": {
       "role": {
        "label": "Buildings [member]",
        "terseLabel": "Apartment [Member]"
       }
      }
     },
     "localname": "BuildingsMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://brightmindsbio.com/role/PREMISESLEASESDetailTextuals"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_Cash": {
     "auth_ref": [
      "r52"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of cash on hand and demand deposits. [Refer: Cash on hand]"
       }
      },
      "en-us": {
       "role": {
        "label": "Cash"
       }
      }
     },
     "localname": "Cash",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://brightmindsbio.com/role/FINANCIALINSTRUMENTSANDCAPITALMANAGEMENTDetailTextuals",
      "http://brightmindsbio.com/role/FINANCIALINSTRUMENTSANDCAPITALMANAGEMENTDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CashAndCashEquivalents": {
     "auth_ref": [
      "r9",
      "r52",
      "r61"
     ],
     "calculation": {
      "http://brightmindsbio.com/role/ConsolidatedStatementsOfFinancialPosition": {
       "order": 0.0,
       "parentTag": "ifrs-full_CurrentAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]"
       }
      },
      "en-us": {
       "role": {
        "label": "Cash and cash equivalents",
        "periodEndLabel": "Cash and cash equivalents, end of year",
        "periodStartLabel": "Cash, beginning of year",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalents",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://brightmindsbio.com/role/ConsolidatedStatementsOfCashFlows",
      "http://brightmindsbio.com/role/ConsolidatedStatementsOfFinancialPosition",
      "http://brightmindsbio.com/role/FINANCIALINSTRUMENTSANDCAPITALMANAGEMENTDetailTextuals",
      "http://brightmindsbio.com/role/FINANCIALINSTRUMENTSANDCAPITALMANAGEMENTDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CashFlowsFromUsedInFinancingActivities": {
     "auth_ref": [
      "r44",
      "r53"
     ],
     "calculation": {
      "http://brightmindsbio.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 10.0,
       "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The cash flows from (used in) financing activities, which are activities that result in changes in the size and composition of the contributed equity and borrowings of the entity."
       }
      },
      "en-us": {
       "role": {
        "label": "Cash flows from (used in) financing activities",
        "totalLabel": "Net cash from financing activities"
       }
      }
     },
     "localname": "CashFlowsFromUsedInFinancingActivities",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://brightmindsbio.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows from (used in) financing activities [abstract]",
        "verboseLabel": "Financing activities"
       }
      }
     },
     "localname": "CashFlowsFromUsedInFinancingActivitiesAbstract",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://brightmindsbio.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_CashFlowsFromUsedInOperatingActivities": {
     "auth_ref": [
      "r44",
      "r53"
     ],
     "calculation": {
      "http://brightmindsbio.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 0.0,
       "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalents",
       "weight": 1.0
      }
     },
     "lang": {
      "en": {
       "role": {
        "documentation": "The cash flows from (used in) operating activities, which are the principal revenue-producing activities of the entity and other activities that are not investing or financing activities. [Refer: Revenue]"
       }
      },
      "en-us": {
       "role": {
        "label": "Cash flows from (used in) operating activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "CashFlowsFromUsedInOperatingActivities",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://brightmindsbio.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows from (used in) operating activities [abstract]",
        "verboseLabel": "Operating activities"
       }
      }
     },
     "localname": "CashFlowsFromUsedInOperatingActivitiesAbstract",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://brightmindsbio.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_CategoriesOfFinancialLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Categories of financial liabilities [abstract]",
        "terseLabel": "Amortized cost"
       }
      }
     },
     "localname": "CategoriesOfFinancialLiabilitiesAbstract",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://brightmindsbio.com/role/FINANCIALINSTRUMENTSANDCAPITALMANAGEMENTDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_CategoriesOfRelatedPartiesAxis": {
     "auth_ref": [
      "r36"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Categories of related parties [axis]"
       }
      }
     },
     "localname": "CategoriesOfRelatedPartiesAxis",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://brightmindsbio.com/role/SHARECAPITALDetailTextuals",
      "http://brightmindsbio.com/role/SHAREEXCHANGEANDASSIGNMENTDetailTextuals"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_ClassesOfAssetsAxis": {
     "auth_ref": [
      "r40",
      "r41",
      "r66",
      "r70"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Classes of assets [axis]"
       }
      }
     },
     "localname": "ClassesOfAssetsAxis",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://brightmindsbio.com/role/PREMISESLEASESDetailTextuals"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_ClassesOfAssetsMember": {
     "auth_ref": [
      "r40",
      "r66",
      "r70"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for a present economic resource controlled by the entity as a result of past events. Economic resource is a right that has the potential to produce economic benefits. It also represents the standard value for the 'Classes of assets' axis if no other member is used."
       }
      },
      "en-us": {
       "role": {
        "label": "Assets [member]"
       }
      }
     },
     "localname": "ClassesOfAssetsMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://brightmindsbio.com/role/PREMISESLEASESDetailTextuals"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_ClassesOfFinancialInstrumentsAxis": {
     "auth_ref": [
      "r89",
      "r90",
      "r91",
      "r92"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Classes of financial instruments [axis]"
       }
      }
     },
     "localname": "ClassesOfFinancialInstrumentsAxis",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://brightmindsbio.com/role/FINANCIALINSTRUMENTSANDCAPITALMANAGEMENTDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_ClassesOfFinancialInstrumentsMember": {
     "auth_ref": [
      "r89",
      "r90",
      "r91",
      "r92"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for aggregated classes of financial instruments. Financial instruments are contracts that give rise to a financial asset of one entity and a financial liability or equity instrument of another entity. It also represents the standard value for the 'Classes of financial instruments' axis if no other member is used. [Refer: Financial assets; Financial liabilities]"
       }
      },
      "en-us": {
       "role": {
        "label": "Financial instruments, class [member]"
       }
      }
     },
     "localname": "ClassesOfFinancialInstrumentsMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://brightmindsbio.com/role/FINANCIALINSTRUMENTSANDCAPITALMANAGEMENTDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_ClassesOfShareCapitalAxis": {
     "auth_ref": [
      "r18"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Classes of share capital [axis]"
       }
      }
     },
     "localname": "ClassesOfShareCapitalAxis",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://brightmindsbio.com/role/SHARECAPITALDetailTextuals",
      "http://brightmindsbio.com/role/SHARECAPITALDetails",
      "http://brightmindsbio.com/role/SHARECAPITALDetails1",
      "http://brightmindsbio.com/role/SHARECAPITALDetails2",
      "http://brightmindsbio.com/role/SHARECAPITALDetails3",
      "http://brightmindsbio.com/role/SHARECAPITALDetails4",
      "http://brightmindsbio.com/role/SHARECAPITALDetails6",
      "http://brightmindsbio.com/role/SHARECAPITALDetails7"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_ClassesOfShareCapitalMember": {
     "auth_ref": [
      "r18"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for share capital of the entity. It also represents the standard value for the 'Classes of share capital' axis if no other member is used."
       }
      },
      "en-us": {
       "role": {
        "label": "Share capital [member]"
       }
      }
     },
     "localname": "ClassesOfShareCapitalMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://brightmindsbio.com/role/SHARECAPITALDetailTextuals",
      "http://brightmindsbio.com/role/SHARECAPITALDetails",
      "http://brightmindsbio.com/role/SHARECAPITALDetails1",
      "http://brightmindsbio.com/role/SHARECAPITALDetails2",
      "http://brightmindsbio.com/role/SHARECAPITALDetails3",
      "http://brightmindsbio.com/role/SHARECAPITALDetails4",
      "http://brightmindsbio.com/role/SHARECAPITALDetails6",
      "http://brightmindsbio.com/role/SHARECAPITALDetails7"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_ComponentsOfEquityAxis": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Components of equity [axis]"
       }
      }
     },
     "localname": "ComponentsOfEquityAxis",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://brightmindsbio.com/role/ConsolidatedStatementsOfChangesInShareholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_CopyrightsPatentsAndOtherIndustrialPropertyRightsServiceAndOperatingRightsMember": {
     "auth_ref": [
      "r42"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for a class of intangible assets representing copyrights, patents and other industrial property rights, service and operating rights. [Refer: Intangible assets other than goodwill]"
       }
      },
      "en-us": {
       "role": {
        "label": "Copyrights, patents and other industrial property rights, service and operating rights [member]",
        "terseLabel": "Patents and related payments [Member]"
       }
      }
     },
     "localname": "CopyrightsPatentsAndOtherIndustrialPropertyRightsServiceAndOperatingRightsMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://brightmindsbio.com/role/RESEARCHANDDEVELOPMENTDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_CreditRiskMember": {
     "auth_ref": [
      "r86",
      "r104",
      "r105",
      "r106"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for the risk that one party to a financial instrument will cause a financial loss for the other party by failing to discharge an obligation. [Refer: Financial instruments, class [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Credit risk [member]",
        "terseLabel": "Credit risk [Member]"
       }
      }
     },
     "localname": "CreditRiskMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://brightmindsbio.com/role/FINANCIALINSTRUMENTSANDCAPITALMANAGEMENTDetailTextuals"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_CurrencyRiskMember": {
     "auth_ref": [
      "r95",
      "r104",
      "r105",
      "r106",
      "r107"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for a type of market risk representing the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in foreign exchange rates. [Refer: Financial instruments, class [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Currency risk [member]",
        "terseLabel": "Foreign exchange risk [Member]"
       }
      }
     },
     "localname": "CurrencyRiskMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://brightmindsbio.com/role/FINANCIALINSTRUMENTSANDCAPITALMANAGEMENTDetailTextuals"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_CurrentAssets": {
     "auth_ref": [
      "r13",
      "r59",
      "r60"
     ],
     "calculation": {
      "http://brightmindsbio.com/role/ConsolidatedStatementsOfFinancialPosition": {
       "order": 0.0,
       "parentTag": "ifrs-full_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of assets that the entity (a) expects to realise or intends to sell or consume in its normal operating cycle; (b) holds primarily for the purpose of trading; (c) expects to realise within twelve months after the reporting period; or (d) classifies as cash or cash equivalents (as defined in IAS 7) unless the asset is restricted from being exchanged or used to settle a liability for at least twelve months after the reporting period. [Refer: Assets]"
       }
      },
      "en-us": {
       "role": {
        "label": "Current assets",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "CurrentAssets",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://brightmindsbio.com/role/ConsolidatedStatementsOfFinancialPosition"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CurrentAssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current assets [abstract]",
        "verboseLabel": "Current assets"
       }
      }
     },
     "localname": "CurrentAssetsAbstract",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://brightmindsbio.com/role/ConsolidatedStatementsOfFinancialPosition"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_CurrentFinancialAssetsAtFairValueThroughProfitOrLossAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current financial assets at fair value through profit or loss [abstract]",
        "terseLabel": "FVTPL"
       }
      }
     },
     "localname": "CurrentFinancialAssetsAtFairValueThroughProfitOrLossAbstract",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://brightmindsbio.com/role/FINANCIALINSTRUMENTSANDCAPITALMANAGEMENTDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_CurrentLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current liabilities [abstract]",
        "verboseLabel": "Current liabilities"
       }
      }
     },
     "localname": "CurrentLiabilitiesAbstract",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://brightmindsbio.com/role/ConsolidatedStatementsOfFinancialPosition"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_CurrentPrepaidExpenses": {
     "auth_ref": [
      "r6"
     ],
     "calculation": {
      "http://brightmindsbio.com/role/ConsolidatedStatementsOfFinancialPosition": {
       "order": 20.0,
       "parentTag": "ifrs-full_CurrentAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount recognised as a current asset for expenditures made prior to the period when the economic benefit will be realised."
       }
      },
      "en-us": {
       "role": {
        "label": "Current prepaid expenses",
        "terseLabel": "Prepaids"
       }
      }
     },
     "localname": "CurrentPrepaidExpenses",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://brightmindsbio.com/role/ConsolidatedStatementsOfFinancialPosition"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CurrentTaxAssetsCurrent": {
     "auth_ref": [
      "r11"
     ],
     "calculation": {
      "http://brightmindsbio.com/role/ConsolidatedStatementsOfFinancialPosition": {
       "order": 10.0,
       "parentTag": "ifrs-full_CurrentAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The current amount of current tax assets. [Refer: Current tax assets]"
       }
      },
      "en-us": {
       "role": {
        "label": "Current tax assets, current",
        "terseLabel": "Sales tax receivable"
       }
      }
     },
     "localname": "CurrentTaxAssetsCurrent",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://brightmindsbio.com/role/ConsolidatedStatementsOfFinancialPosition"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised": {
     "auth_ref": [
      "r29"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of deductible temporary differences for which no deferred tax asset is recognised in the statement of financial position. [Refer: Temporary differences [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Deductible temporary differences for which no deferred tax asset is recognised",
        "verboseLabel": "Temporary differences not recognized"
       }
      }
     },
     "localname": "DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://brightmindsbio.com/role/INCOMETAXESDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_DescriptionOfAccountingPolicyForBusinessCombinationsExplanatory": {
     "auth_ref": [
      "r7"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The description of the entity's accounting policy for business combinations. [Refer: Business combinations [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Description of accounting policy for business combinations [text block]",
        "verboseLabel": "Business combinations [Policy Text Block]"
       }
      }
     },
     "localname": "DescriptionOfAccountingPolicyForBusinessCombinationsExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://brightmindsbio.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory": {
     "auth_ref": [
      "r7"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The description of the entity's accounting policy for earnings per share."
       }
      },
      "en-us": {
       "role": {
        "label": "Description of accounting policy for earnings per share [text block]",
        "verboseLabel": "Loss per share [Policy Text Block]"
       }
      }
     },
     "localname": "DescriptionOfAccountingPolicyForEarningsPerShareExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://brightmindsbio.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory": {
     "auth_ref": [
      "r7"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The description of the entity's accounting policy for financial instruments. [Refer: Financial instruments, class [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Description of accounting policy for financial instruments [text block]",
        "verboseLabel": "Financial instruments [Policy Text Block]"
       }
      }
     },
     "localname": "DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://brightmindsbio.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory": {
     "auth_ref": [
      "r7"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The description of the entity's accounting policy for foreign currency translation."
       }
      },
      "en-us": {
       "role": {
        "label": "Description of accounting policy for foreign currency translation [text block]",
        "verboseLabel": "Foreign currency translation [Policy Text Block]"
       }
      }
     },
     "localname": "DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://brightmindsbio.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory": {
     "auth_ref": [
      "r7"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The description of the entity's accounting policy for income tax."
       }
      },
      "en-us": {
       "role": {
        "label": "Description of accounting policy for income tax [text block]",
        "verboseLabel": "Income taxes [Policy Text Block]"
       }
      }
     },
     "localname": "DescriptionOfAccountingPolicyForIncomeTaxExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://brightmindsbio.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DescriptionOfAccountingPolicyForIssuedCapitalExplanatory": {
     "auth_ref": [
      "r7"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The description of the entity's accounting policy for issued capital. [Refer: Issued capital]"
       }
      },
      "en-us": {
       "role": {
        "label": "Description of accounting policy for issued capital [text block]",
        "verboseLabel": "Share capital [Policy Text Block]"
       }
      }
     },
     "localname": "DescriptionOfAccountingPolicyForIssuedCapitalExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://brightmindsbio.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory": {
     "auth_ref": [
      "r7"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The description of the entity's accounting policy for leases. A lease is an agreement whereby the lessor conveys to the lessee in return for a payment or series of payments the right to use an asset for an agreed period of time."
       }
      },
      "en-us": {
       "role": {
        "label": "Description of accounting policy for leases [text block]",
        "verboseLabel": "Leases [Policy Text Block]"
       }
      }
     },
     "localname": "DescriptionOfAccountingPolicyForLeasesExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://brightmindsbio.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory": {
     "auth_ref": [
      "r7"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The description of the entity's accounting policy for provisions. [Refer: Provisions]"
       }
      },
      "en-us": {
       "role": {
        "label": "Description of accounting policy for provisions [text block]",
        "terseLabel": "Provisions [Policy Text Block]"
       }
      }
     },
     "localname": "DescriptionOfAccountingPolicyForProvisionsExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://brightmindsbio.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory": {
     "auth_ref": [
      "r7"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The description of the entity's accounting policy for research and development expense. [Refer: Research and development expense]"
       }
      },
      "en-us": {
       "role": {
        "label": "Description of accounting policy for research and development expense [text block]",
        "verboseLabel": "Internally generated intangible assets - Research and development expenditure [Policy Text Block]"
       }
      }
     },
     "localname": "DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://brightmindsbio.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory": {
     "auth_ref": [
      "r7"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The description of the entity's accounting policy for transactions in which the entity: (a) receives goods or services from the supplier of those goods or services (including an employee) in a share-based payment arrangement; or (b) incurs an obligation to settle the transaction with the supplier in a share-based payment arrangement when another group entity receives those goods or services. [Refer: Share-based payment arrangements [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Description of accounting policy for share-based payment transactions [text block]",
        "verboseLabel": "Share-based compensation awards [Policy Text Block]"
       }
      }
     },
     "localname": "DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://brightmindsbio.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted": {
     "auth_ref": [
      "r81"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The expected volatility of the share price used to calculate the fair value of the share options granted. Expected volatility is a measure of the amount by which a price is expected to fluctuate during a period. The measure of volatility used in option pricing models is the annualised standard deviation of the continuously compounded rates of return on the share over a period of time."
       }
      },
      "en-us": {
       "role": {
        "label": "Expected volatility, share options granted",
        "verboseLabel": "Volatility rate, stock options granted"
       }
      }
     },
     "localname": "DescriptionOfExpectedVolatilityShareOptionsGranted",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://brightmindsbio.com/role/SHARECAPITALDetailTextuals"
     ],
     "xbrltype": "percentItemType"
    },
    "ifrs-full_DescriptionOfOptionLifeShareOptionsGranted": {
     "auth_ref": [
      "r81"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The option life of share options granted."
       }
      },
      "en-us": {
       "role": {
        "label": "Option life, share options granted",
        "terseLabel": "Option life, stock options granted"
       }
      }
     },
     "localname": "DescriptionOfOptionLifeShareOptionsGranted",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://brightmindsbio.com/role/SHARECAPITALDetailTextuals"
     ],
     "xbrltype": "decimalItemType"
    },
    "ifrs-full_DirectorsRemunerationExpense": {
     "auth_ref": [
      "r6"
     ],
     "calculation": {
      "http://brightmindsbio.com/role/ConsolidatedStatementsOfComprehensiveLoss": {
       "order": 30.0,
       "parentTag": "ifrs-full_ProfitLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of remuneration paid or payable to the entity's directors."
       }
      },
      "en-us": {
       "role": {
        "label": "Directors' remuneration expense",
        "terseLabel": "Directors' compensation"
       }
      }
     },
     "localname": "DirectorsRemunerationExpense",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://brightmindsbio.com/role/ConsolidatedStatementsOfComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of the basis used for the preparation of the financial statements."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of basis of preparation of financial statements [text block]",
        "verboseLabel": "STATEMENT OF COMPLIANCE AND BASIS OF PREPARATION [Text Block]"
       }
      }
     },
     "localname": "DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://brightmindsbio.com/role/STATEMENTOFCOMPLIANCEANDBASISOFPREPARATION"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfClassesOfShareCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of classes of share capital [abstract]"
       }
      }
     },
     "localname": "DisclosureOfClassesOfShareCapitalAbstract",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfClassesOfShareCapitalLineItems": {
     "auth_ref": [],
     "lang": {
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of classes of share capital [line items]"
       }
      }
     },
     "localname": "DisclosureOfClassesOfShareCapitalLineItems",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://brightmindsbio.com/role/SHARECAPITALDetailTextuals",
      "http://brightmindsbio.com/role/SHARECAPITALDetails",
      "http://brightmindsbio.com/role/SHARECAPITALDetails1",
      "http://brightmindsbio.com/role/SHARECAPITALDetails2",
      "http://brightmindsbio.com/role/SHARECAPITALDetails3",
      "http://brightmindsbio.com/role/SHARECAPITALDetails4",
      "http://brightmindsbio.com/role/SHARECAPITALDetails5",
      "http://brightmindsbio.com/role/SHARECAPITALDetails6",
      "http://brightmindsbio.com/role/SHARECAPITALDetails7"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfClassesOfShareCapitalTable": {
     "auth_ref": [
      "r18"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to classes of share capital."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of classes of share capital [table]"
       }
      }
     },
     "localname": "DisclosureOfClassesOfShareCapitalTable",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://brightmindsbio.com/role/SHARECAPITALDetailTextuals",
      "http://brightmindsbio.com/role/SHARECAPITALDetails",
      "http://brightmindsbio.com/role/SHARECAPITALDetails1",
      "http://brightmindsbio.com/role/SHARECAPITALDetails2",
      "http://brightmindsbio.com/role/SHARECAPITALDetails3",
      "http://brightmindsbio.com/role/SHARECAPITALDetails4",
      "http://brightmindsbio.com/role/SHARECAPITALDetails5",
      "http://brightmindsbio.com/role/SHARECAPITALDetails6",
      "http://brightmindsbio.com/role/SHARECAPITALDetails7"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfCommitmentsExplanatory": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of commitments."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of commitments [text block]",
        "verboseLabel": "CONTRACTUAL OBLIGATIONS [Text Block]"
       }
      }
     },
     "localname": "DisclosureOfCommitmentsExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://brightmindsbio.com/role/CONTRACTUALOBLIGATIONS"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory": {
     "auth_ref": [
      "r85",
      "r90",
      "r94"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of detailed information about financial instruments. [Refer: Financial instruments, class [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of detailed information about financial instruments [text block]",
        "terseLabel": "Disclosure of carrying value of financial assets and liabilities [Table Text Block]"
       }
      }
     },
     "localname": "DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://brightmindsbio.com/role/FINANCIALINSTRUMENTSANDCAPITALMANAGEMENTTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory": {
     "auth_ref": [
      "r25"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The entire disclosure for events after the reporting period."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of events after reporting period [text block]",
        "terseLabel": "SUBSEQUENT EVENTS [Text Block]"
       }
      }
     },
     "localname": "DisclosureOfEventsAfterReportingPeriodExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://brightmindsbio.com/role/SUBSEQUENTEVENTS"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfFinancialInstrumentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of detailed information about financial instruments [abstract]"
       }
      }
     },
     "localname": "DisclosureOfFinancialInstrumentsAbstract",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfFinancialInstrumentsExplanatory": {
     "auth_ref": [
      "r96"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The entire disclosure for financial instruments."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of financial instruments [text block]",
        "terseLabel": "FINANCIAL INSTRUMENTS AND CAPITAL MANAGEMENT [Text Block]"
       }
      }
     },
     "localname": "DisclosureOfFinancialInstrumentsExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://brightmindsbio.com/role/FINANCIALINSTRUMENTSANDCAPITALMANAGEMENT"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfFinancialInstrumentsLineItems": {
     "auth_ref": [],
     "lang": {
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of detailed information about financial instruments [line items]"
       }
      }
     },
     "localname": "DisclosureOfFinancialInstrumentsLineItems",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://brightmindsbio.com/role/FINANCIALINSTRUMENTSANDCAPITALMANAGEMENTDetailTextuals",
      "http://brightmindsbio.com/role/FINANCIALINSTRUMENTSANDCAPITALMANAGEMENTDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfFinancialInstrumentsTable": {
     "auth_ref": [
      "r85",
      "r90",
      "r94"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to details of financial instruments."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of detailed information about financial instruments [table]"
       }
      }
     },
     "localname": "DisclosureOfFinancialInstrumentsTable",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://brightmindsbio.com/role/FINANCIALINSTRUMENTSANDCAPITALMANAGEMENTDetailTextuals",
      "http://brightmindsbio.com/role/FINANCIALINSTRUMENTSANDCAPITALMANAGEMENTDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfIncomeTaxExplanatory": {
     "auth_ref": [
      "r31"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The entire disclosure for income taxes."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of income tax [text block]",
        "terseLabel": "INCOME TAXES [Text Block]"
       }
      }
     },
     "localname": "DisclosureOfIncomeTaxExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://brightmindsbio.com/role/INCOMETAXES"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfInformationAboutKeyManagementPersonnelExplanatory": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of information about key management personnel. [Refer: Key management personnel of entity or parent [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of information about key management personnel [text block]",
        "terseLabel": "Disclosure of expenses related to key management personnel [Table Text Block]"
       }
      }
     },
     "localname": "DisclosureOfInformationAboutKeyManagementPersonnelExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://brightmindsbio.com/role/RELATEDPARTYTRANSACTIONSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfIssuedCapitalExplanatory": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of issued capital. [Refer: Issued capital]"
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of issued capital [text block]",
        "verboseLabel": "SHARE CAPITAL [Text Block]"
       }
      }
     },
     "localname": "DisclosureOfIssuedCapitalExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://brightmindsbio.com/role/SHARECAPITAL"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfLeasesExplanatory": {
     "auth_ref": [
      "r71",
      "r72"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The entire disclosure for leases."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of leases [text block]",
        "terseLabel": "PREMISES LEASES [Text Block]"
       }
      }
     },
     "localname": "DisclosureOfLeasesExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://brightmindsbio.com/role/PREMISESLEASES"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of non-adjusting events after reporting period [abstract]"
       }
      }
     },
     "localname": "DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems": {
     "auth_ref": [],
     "lang": {
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of non-adjusting events after reporting period [line items]"
       }
      }
     },
     "localname": "DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://brightmindsbio.com/role/SUBSEQUENTEVENTSDetailTextuals"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable": {
     "auth_ref": [
      "r24"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to non-adjusting events after the reporting period."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of non-adjusting events after reporting period [table]"
       }
      }
     },
     "localname": "DisclosureOfNonadjustingEventsAfterReportingPeriodTable",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://brightmindsbio.com/role/SUBSEQUENTEVENTSDetailTextuals"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory": {
     "auth_ref": [
      "r80"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of the number and weighted average exercise prices of other equity instruments (ie other than share options)."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of number and weighted average exercise prices of other equity instruments [text block]",
        "verboseLabel": "Disclosure of number and weighted average exercise prices of restricted share units [Table Text Block]"
       }
      }
     },
     "localname": "DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://brightmindsbio.com/role/SHARECAPITALTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory": {
     "auth_ref": [
      "r78"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of the number and weighted average exercise prices of share options. [Refer: Weighted average [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of number and weighted average exercise prices of share options [text block]",
        "verboseLabel": "Disclosure of number and weighted average exercise prices of share options [Table Text Block]"
       }
      }
     },
     "localname": "DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://brightmindsbio.com/role/SHARECAPITALTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of quantitative information about right-of-use assets [line items]"
       }
      }
     },
     "localname": "DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://brightmindsbio.com/role/PREMISESLEASESDetailTextuals"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable": {
     "auth_ref": [
      "r70"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to right-of-use assets."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of quantitative information about right-of-use assets [table]"
       }
      }
     },
     "localname": "DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://brightmindsbio.com/role/PREMISESLEASESDetailTextuals"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfRelatedPartyExplanatory": {
     "auth_ref": [
      "r37"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The entire disclosure for related parties."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of related party [text block]",
        "terseLabel": "RELATED PARTY TRANSACTIONS [Text Block]"
       }
      }
     },
     "localname": "DisclosureOfRelatedPartyExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://brightmindsbio.com/role/RELATEDPARTYTRANSACTIONS"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfResearchAndDevelopmentExpenseExplanatory": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of research and development expense. [Refer: Research and development expense]"
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of research and development expense [text block]",
        "terseLabel": "RESEARCH AND DEVELOPMENT [Text Block]"
       }
      }
     },
     "localname": "DisclosureOfResearchAndDevelopmentExpenseExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://brightmindsbio.com/role/RESEARCHANDDEVELOPMENT"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory": {
     "auth_ref": [
      "r8"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The entire disclosure for significant accounting policies applied by the entity."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of significant accounting policies [text block]",
        "verboseLabel": "SIGNIFICANT ACCOUNTING POLICIES [Text Block]"
       }
      }
     },
     "localname": "DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://brightmindsbio.com/role/SIGNIFICANTACCOUNTINGPOLICIES"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory": {
     "auth_ref": [
      "r30"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of types of temporary differences, unused tax losses and unused tax credits. [Refer: Unused tax credits [member]; Unused tax losses [member]; Temporary differences [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of temporary difference, unused tax losses and unused tax credits [text block]",
        "terseLabel": "Disclosure of deductible temporary differences for which no deferred tax has been recognized [Table Text Block]"
       }
      }
     },
     "localname": "DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://brightmindsbio.com/role/INCOMETAXESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems": {
     "auth_ref": [],
     "lang": {
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of temporary difference, unused tax losses and unused tax credits [line items]"
       }
      }
     },
     "localname": "DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://brightmindsbio.com/role/INCOMETAXESDetailTextuals",
      "http://brightmindsbio.com/role/INCOMETAXESDetails1",
      "http://brightmindsbio.com/role/INCOMETAXESDetails2"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable": {
     "auth_ref": [
      "r30"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to temporary differences, unused tax losses and unused tax credits."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of temporary difference, unused tax losses and unused tax credits [table]"
       }
      }
     },
     "localname": "DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://brightmindsbio.com/role/INCOMETAXESDetailTextuals",
      "http://brightmindsbio.com/role/INCOMETAXESDetails1",
      "http://brightmindsbio.com/role/INCOMETAXESDetails2"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of trade and other payables. [Refer: Trade and other payables]"
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of trade and other payables [text block]",
        "terseLabel": "ACCOUNTS PAYABLE AND ACCRUED LIABILITIES [Text Block]"
       }
      }
     },
     "localname": "DisclosureOfTradeAndOtherPayablesExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://brightmindsbio.com/role/ACCOUNTSPAYABLEANDACCRUEDLIABILITIES"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of transactions between related parties [abstract]"
       }
      }
     },
     "localname": "DisclosureOfTransactionsBetweenRelatedPartiesAbstract",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "xbrltype": "stringItemType"
    },
    "ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents": {
     "auth_ref": [
      "r50",
      "r51"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The effect of exchange rate changes on cash and cash equivalents held or due in a foreign currency. [Refer: Cash and cash equivalents]"
       }
      },
      "en-us": {
       "role": {
        "label": "Effect of exchange rate changes on cash and cash equivalents",
        "terseLabel": "Effect of foreign exchange on cash"
       }
      }
     },
     "localname": "EffectOfExchangeRateChangesOnCashAndCashEquivalents",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://brightmindsbio.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_EntitysTotalForRelatedPartiesMember": {
     "auth_ref": [
      "r36"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for the standard value for the 'Categories of related parties' axis if no other member is used."
       }
      },
      "en-us": {
       "role": {
        "label": "Entity's total for related parties [member]"
       }
      }
     },
     "localname": "EntitysTotalForRelatedPartiesMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://brightmindsbio.com/role/SHARECAPITALDetailTextuals",
      "http://brightmindsbio.com/role/SHAREEXCHANGEANDASSIGNMENTDetailTextuals"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_Equity": {
     "auth_ref": [
      "r12",
      "r15",
      "r55",
      "r57",
      "r63",
      "r64",
      "r65"
     ],
     "calculation": {
      "http://brightmindsbio.com/role/ConsolidatedStatementsOfFinancialPosition": {
       "order": 10.0,
       "parentTag": "ifrs-full_EquityAndLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of residual interest in the assets of the entity after deducting all its liabilities."
       }
      },
      "en-us": {
       "role": {
        "label": "Equity",
        "periodEndLabel": "Balance",
        "periodStartLabel": "Balance",
        "totalLabel": "TOTAL SHAREHOLDERS' EQUITY"
       }
      }
     },
     "localname": "Equity",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://brightmindsbio.com/role/ConsolidatedStatementsOfChangesInShareholdersEquity",
      "http://brightmindsbio.com/role/ConsolidatedStatementsOfFinancialPosition"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [abstract]",
        "verboseLabel": "Shareholders' equity"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://brightmindsbio.com/role/ConsolidatedStatementsOfFinancialPosition"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_EquityAndLiabilities": {
     "auth_ref": [
      "r12"
     ],
     "calculation": {
      "http://brightmindsbio.com/role/ConsolidatedStatementsOfFinancialPosition": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of the entity's equity and liabilities. [Refer: Equity; Liabilities]"
       }
      },
      "en-us": {
       "role": {
        "label": "Equity and liabilities",
        "totalLabel": "TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY"
       }
      }
     },
     "localname": "EquityAndLiabilities",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://brightmindsbio.com/role/ConsolidatedStatementsOfFinancialPosition"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_EquityAndLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity and liabilities [abstract]",
        "verboseLabel": "LIABILITIES AND SHAREHOLDERS' EQUITY"
       }
      }
     },
     "localname": "EquityAndLiabilitiesAbstract",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://brightmindsbio.com/role/ConsolidatedStatementsOfFinancialPosition"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_EquityInterestsOfAcquirer": {
     "auth_ref": [
      "r83"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The fair value, at the acquisition date, of equity interests of the acquirer transferred as consideration in a business combination. [Refer: Business combinations [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Equity interests of acquirer",
        "verboseLabel": "Value of common stock shares issued"
       }
      }
     },
     "localname": "EquityInterestsOfAcquirer",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://brightmindsbio.com/role/SHAREEXCHANGEANDASSIGNMENTDetailTextuals"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_EquityMember": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for the residual interest in the assets of the entity after deducting all its liabilities. It also represents the standard value for the 'Components of equity' axis if no other member is used."
       }
      },
      "en-us": {
       "role": {
        "label": "Equity [member]",
        "verboseLabel": "Equity [Domain]"
       }
      }
     },
     "localname": "EquityMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://brightmindsbio.com/role/ConsolidatedStatementsOfChangesInShareholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_ExercisePriceOfOutstandingShareOptions2019": {
     "auth_ref": [
      "r79"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The exercise price of outstanding share options."
       }
      },
      "en-us": {
       "role": {
        "label": "Exercise price of outstanding share options",
        "verboseLabel": "Options Outstanding and Exercisable, Exercise price"
       }
      }
     },
     "localname": "ExercisePriceOfOutstandingShareOptions2019",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://brightmindsbio.com/role/SHARECAPITALDetailTextuals",
      "http://brightmindsbio.com/role/SHARECAPITALDetails1"
     ],
     "xbrltype": "perShareItemType"
    },
    "ifrs-full_ExercisePriceShareOptionsGranted2019": {
     "auth_ref": [
      "r81"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The exercise price of share options granted."
       }
      },
      "en-us": {
       "role": {
        "label": "Exercise price, share options granted",
        "terseLabel": "Exercise price, stock options granted"
       }
      }
     },
     "localname": "ExercisePriceShareOptionsGranted2019",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://brightmindsbio.com/role/SHARECAPITALDetailTextuals"
     ],
     "xbrltype": "perShareItemType"
    },
    "ifrs-full_ExpenseByNatureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expenses by nature [abstract]",
        "verboseLabel": "EXPENSES"
       }
      }
     },
     "localname": "ExpenseByNatureAbstract",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://brightmindsbio.com/role/ConsolidatedStatementsOfComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees": {
     "auth_ref": [
      "r6"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of expense from share-based payment transactions with employees."
       }
      },
      "en-us": {
       "role": {
        "label": "Expense from share-based payment transactions with employees",
        "verboseLabel": "Share-based compensation expense"
       }
      }
     },
     "localname": "ExpenseFromSharebasedPaymentTransactionsWithEmployees",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://brightmindsbio.com/role/SHARECAPITALDetails4",
      "http://brightmindsbio.com/role/SHARECAPITALDetails5"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss": {
     "auth_ref": [
      "r33",
      "r54"
     ],
     "calculation": {
      "http://brightmindsbio.com/role/ConsolidatedStatementsOfComprehensiveLoss": {
       "order": 40.0,
       "parentTag": "ifrs-full_ProfitLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of exchange differences recognised in profit or loss that arise from foreign currency transactions, excluding those arising on financial instruments measured at fair value through profit or loss in accordance with IFRS 9. [Refer: At fair value [member]; Financial instruments, class [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Foreign exchange gain (loss)",
        "negatedLabel": "Foreign exchange",
        "terseLabel": "Foreign exchange"
       }
      }
     },
     "localname": "GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://brightmindsbio.com/role/ConsolidatedStatementsOfComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r6"
     ],
     "calculation": {
      "http://brightmindsbio.com/role/ConsolidatedStatementsOfComprehensiveLoss": {
       "order": 20.0,
       "parentTag": "ifrs-full_ProfitLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of expense relating to general and administrative activities of the entity."
       }
      },
      "en-us": {
       "role": {
        "label": "General and administrative expense",
        "terseLabel": "Office and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://brightmindsbio.com/role/ConsolidatedStatementsOfComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Profit or loss [abstract]",
        "terseLabel": "Income Statement"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "xbrltype": "stringItemType"
    },
    "ifrs-full_IncomeTaxExpenseContinuingOperations": {
     "auth_ref": [
      "r21",
      "r26",
      "r27",
      "r28",
      "r38",
      "r62",
      "r97"
     ],
     "calculation": {
      "http://brightmindsbio.com/role/INCOMETAXESDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The aggregate amount included in the determination of profit (loss) for the period in respect of current tax and deferred tax. [Refer: Current tax expense (income); Deferred tax expense (income)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Tax expense (income)",
        "totalLabel": "Total income tax recovery",
        "verboseLabel": "Total income tax recovery"
       }
      }
     },
     "localname": "IncomeTaxExpenseContinuingOperations",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://brightmindsbio.com/role/INCOMETAXESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_IncreaseDecreaseInCashAndCashEquivalents": {
     "auth_ref": [
      "r52"
     ],
     "calculation": {
      "http://brightmindsbio.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The increase (decrease) in cash and cash equivalents. [Refer: Cash and cash equivalents]"
       }
      },
      "en-us": {
       "role": {
        "label": "Increase (decrease) in cash and cash equivalents",
        "terseLabel": "Change in cash",
        "totalLabel": "Change in cash"
       }
      }
     },
     "localname": "IncreaseDecreaseInCashAndCashEquivalents",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://brightmindsbio.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_IncreaseDecreaseInNumberOfSharesOutstanding": {
     "auth_ref": [
      "r17"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The increase (decrease) in the number of shares outstanding. [Refer: Number of shares outstanding]"
       }
      },
      "en-us": {
       "role": {
        "label": "Increase (decrease) in number of shares outstanding",
        "verboseLabel": "Number of shares issued during period"
       }
      }
     },
     "localname": "IncreaseDecreaseInNumberOfSharesOutstanding",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://brightmindsbio.com/role/SHARECAPITALDetailTextuals"
     ],
     "xbrltype": "sharesItemType"
    },
    "ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity": {
     "auth_ref": [
      "r3"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The increase (decrease) in equity resulting from the exercise of warrants."
       }
      },
      "en-us": {
       "role": {
        "label": "Increase (decrease) through exercise of warrants, equity",
        "terseLabel": "Warrants exercised"
       }
      }
     },
     "localname": "IncreaseDecreaseThroughExerciseOfWarrantsEquity",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://brightmindsbio.com/role/ConsolidatedStatementsOfChangesInShareholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions": {
     "auth_ref": [
      "r2"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The increase (decrease) in equity resulting from share-based payment transactions. [Refer: Equity]"
       }
      },
      "en-us": {
       "role": {
        "label": "Increase (decrease) through share-based payment transactions, equity",
        "terseLabel": "Share-based compensation"
       }
      }
     },
     "localname": "IncreaseDecreaseThroughSharebasedPaymentTransactions",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://brightmindsbio.com/role/ConsolidatedStatementsOfChangesInShareholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_IntangibleAssetsAndGoodwill": {
     "auth_ref": [
      "r12"
     ],
     "calculation": {
      "http://brightmindsbio.com/role/ConsolidatedStatementsOfFinancialPosition": {
       "order": 10.0,
       "parentTag": "ifrs-full_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of intangible assets and goodwill held by the entity. [Refer: Goodwill; Intangible assets other than goodwill]"
       }
      },
      "en-us": {
       "role": {
        "label": "Intangible assets and goodwill",
        "terseLabel": "Intangible assets"
       }
      }
     },
     "localname": "IntangibleAssetsAndGoodwill",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://brightmindsbio.com/role/ConsolidatedStatementsOfFinancialPosition"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_IssuedCapital": {
     "auth_ref": [
      "r15"
     ],
     "calculation": {
      "http://brightmindsbio.com/role/ConsolidatedStatementsOfFinancialPosition": {
       "order": 10.0,
       "parentTag": "ifrs-full_Equity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The nominal value of capital issued."
       }
      },
      "en-us": {
       "role": {
        "label": "Issued capital",
        "terseLabel": "Share capital"
       }
      }
     },
     "localname": "IssuedCapital",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://brightmindsbio.com/role/ConsolidatedStatementsOfFinancialPosition"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_IssuedCapitalMember": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for a component of equity representing issued capital."
       }
      },
      "en-us": {
       "role": {
        "label": "Issued capital [member]",
        "verboseLabel": "Share capital [Member]"
       }
      }
     },
     "localname": "IssuedCapitalMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://brightmindsbio.com/role/ConsolidatedStatementsOfChangesInShareholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_KeyManagementPersonnelCompensation": {
     "auth_ref": [
      "r35"
     ],
     "calculation": {
      "http://brightmindsbio.com/role/RELATEDPARTYTRANSACTIONSDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of compensation to key management personnel. [Refer: Key management personnel of entity or parent [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Key management personnel compensation",
        "totalLabel": "Total expenses related to key management personnel"
       }
      }
     },
     "localname": "KeyManagementPersonnelCompensation",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://brightmindsbio.com/role/RELATEDPARTYTRANSACTIONSDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment": {
     "auth_ref": [
      "r34"
     ],
     "calculation": {
      "http://brightmindsbio.com/role/RELATEDPARTYTRANSACTIONSDetails": {
       "order": 40.0,
       "parentTag": "ifrs-full_KeyManagementPersonnelCompensation",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of compensation to key management personnel in the form of share-based payments. [Refer: Key management personnel of entity or parent [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Key management personnel compensation, share-based payment",
        "terseLabel": "Share-based compensation included in directors' compensation"
       }
      }
     },
     "localname": "KeyManagementPersonnelCompensationSharebasedPayment",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://brightmindsbio.com/role/RELATEDPARTYTRANSACTIONSDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_Liabilities": {
     "auth_ref": [
      "r12",
      "r63",
      "r64",
      "r65",
      "r98",
      "r101"
     ],
     "calculation": {
      "http://brightmindsbio.com/role/ConsolidatedStatementsOfFinancialPosition": {
       "order": 0.0,
       "parentTag": "ifrs-full_EquityAndLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of a present obligation of the entity to transfer an economic resource as a result of past events. Economic resource is a right that has the potential to produce economic benefits."
       }
      },
      "en-us": {
       "role": {
        "label": "Liabilities",
        "totalLabel": "TOTAL LIABILITIES"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://brightmindsbio.com/role/ConsolidatedStatementsOfFinancialPosition"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_LiquidityRiskMember": {
     "auth_ref": [
      "r86",
      "r104",
      "r105",
      "r106"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for the risk that an entity will encounter difficulty in meeting obligations associated with financial liabilities that are settled by delivering cash or another financial asset. [Refer: Financial assets; Financial liabilities]"
       }
      },
      "en-us": {
       "role": {
        "label": "Liquidity risk [member]",
        "terseLabel": "Liquidity risk [Member]"
       }
      }
     },
     "localname": "LiquidityRiskMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://brightmindsbio.com/role/FINANCIALINSTRUMENTSANDCAPITALMANAGEMENTDetailTextuals"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Major components of tax expense (income) [abstract]"
       }
      }
     },
     "localname": "MajorComponentsOfTaxExpenseIncomeAbstract",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "xbrltype": "stringItemType"
    },
    "ifrs-full_NonadjustingEventsAfterReportingPeriodAxis": {
     "auth_ref": [
      "r24"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Non-adjusting events after reporting period [axis]"
       }
      }
     },
     "localname": "NonadjustingEventsAfterReportingPeriodAxis",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://brightmindsbio.com/role/SUBSEQUENTEVENTSDetailTextuals"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_NonadjustingEventsMember": {
     "auth_ref": [
      "r24"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for events that occur between the end of the reporting period and the date when the financial statements are authorised for issue and are indicative of conditions that arose after the reporting period. It also represents the standard value for the 'Non-adjusting events after reporting period' axis if no other member is used."
       }
      },
      "en-us": {
       "role": {
        "label": "Non-adjusting events after reporting period [member]"
       }
      }
     },
     "localname": "NonadjustingEventsMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://brightmindsbio.com/role/SUBSEQUENTEVENTSDetailTextuals"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_NoncurrentAssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-current assets [abstract]",
        "verboseLabel": "Non-current assets"
       }
      }
     },
     "localname": "NoncurrentAssetsAbstract",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://brightmindsbio.com/role/ConsolidatedStatementsOfFinancialPosition"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_NumberOfInstrumentsOrInterestsIssuedOrIssuable": {
     "auth_ref": [
      "r83"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The number of instruments or interests issued or issuable at acquisition date for equity interests of the acquirer transferred as consideration in a business combination."
       }
      },
      "en-us": {
       "role": {
        "label": "Number of instruments or interests issued or issuable",
        "verboseLabel": "Number of shares issued"
       }
      }
     },
     "localname": "NumberOfInstrumentsOrInterestsIssuedOrIssuable",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://brightmindsbio.com/role/SHAREEXCHANGEANDASSIGNMENTDetailTextuals"
     ],
     "xbrltype": "decimalItemType"
    },
    "ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted": {
     "auth_ref": [
      "r80",
      "r82"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The number of other equity instruments (ie other than share options) granted in a share-based payment arrangement."
       }
      },
      "en-us": {
       "role": {
        "label": "Number of other equity instruments granted in share-based payment arrangement",
        "terseLabel": "Number of RSUs granted",
        "verboseLabel": "Granted"
       }
      }
     },
     "localname": "NumberOfInstrumentsOtherEquityInstrumentsGranted",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://brightmindsbio.com/role/CONTRACTUALOBLIGATIONSDetailTextuals",
      "http://brightmindsbio.com/role/SHARECAPITALDetails2"
     ],
     "xbrltype": "decimalItemType"
    },
    "ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement": {
     "auth_ref": [
      "r80"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The number of other equity instruments (ie other than share options) exercised or vested in a share-based payment arrangement."
       }
      },
      "en-us": {
       "role": {
        "label": "Number of other equity instruments exercised or vested in share-based payment arrangement",
        "negatedLabel": "Vested",
        "verboseLabel": "Vested"
       }
      }
     },
     "localname": "NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://brightmindsbio.com/role/SHARECAPITALDetails2"
     ],
     "xbrltype": "decimalItemType"
    },
    "ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement": {
     "auth_ref": [
      "r80"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The number of other equity instruments (ie other than share options) outstanding in a share-based payment arrangement."
       }
      },
      "en-us": {
       "role": {
        "label": "Number of other equity instruments outstanding in share-based payment arrangement",
        "periodEndLabel": "Ending Balance",
        "periodStartLabel": "Beginning Balance",
        "verboseLabel": "Number of warrants, Beginning Balance"
       }
      }
     },
     "localname": "NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://brightmindsbio.com/role/SHARECAPITALDetails2"
     ],
     "xbrltype": "decimalItemType"
    },
    "ifrs-full_NumberOfOutstandingShareOptions": {
     "auth_ref": [
      "r73",
      "r76",
      "r79"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The number of share options outstanding in a share-based payment arrangement."
       }
      },
      "en-us": {
       "role": {
        "label": "Number of share options outstanding in share-based payment arrangement",
        "periodEndLabel": "Number of options, Ending Balance",
        "periodStartLabel": "Number of options, Beginning Balance",
        "verboseLabel": "Options Outstanding and Exercisable, Number of options"
       }
      }
     },
     "localname": "NumberOfOutstandingShareOptions",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://brightmindsbio.com/role/SHARECAPITALDetails",
      "http://brightmindsbio.com/role/SHARECAPITALDetails1"
     ],
     "xbrltype": "decimalItemType"
    },
    "ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement": {
     "auth_ref": [
      "r77"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The number of share options exercisable in a share-based payment arrangement."
       }
      },
      "en-us": {
       "role": {
        "label": "Number of share options exercisable in share-based payment arrangement",
        "verboseLabel": "Options Outstanding and Exercisable, Exercisable"
       }
      }
     },
     "localname": "NumberOfShareOptionsExercisableInSharebasedPaymentArrangement",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://brightmindsbio.com/role/SHARECAPITALDetails1"
     ],
     "xbrltype": "decimalItemType"
    },
    "ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement": {
     "auth_ref": [
      "r75"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The number of share options forfeited in a share-based payment arrangement."
       }
      },
      "en-us": {
       "role": {
        "label": "Number of share options forfeited in share-based payment arrangement",
        "negatedLabel": "Number of options, Cancelled",
        "terseLabel": "Number of options cancelled",
        "verboseLabel": "Number of options, Cancelled"
       }
      }
     },
     "localname": "NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://brightmindsbio.com/role/CONTRACTUALOBLIGATIONSDetailTextuals",
      "http://brightmindsbio.com/role/SHARECAPITALDetailTextuals",
      "http://brightmindsbio.com/role/SHARECAPITALDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement": {
     "auth_ref": [
      "r74"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The number of share options granted in a share-based payment arrangement."
       }
      },
      "en-us": {
       "role": {
        "label": "Number of share options granted in share-based payment arrangement",
        "terseLabel": "Number of options granted",
        "verboseLabel": "Number of options, Granted"
       }
      }
     },
     "localname": "NumberOfShareOptionsGrantedInSharebasedPaymentArrangement",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://brightmindsbio.com/role/CONTRACTUALOBLIGATIONSDetailTextuals",
      "http://brightmindsbio.com/role/SHARECAPITALDetailTextuals",
      "http://brightmindsbio.com/role/SHARECAPITALDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "ifrs-full_NumberOfSharesIssued": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The number of shares issued by the entity."
       }
      },
      "en-us": {
       "role": {
        "label": "Number of shares issued"
       }
      }
     },
     "localname": "NumberOfSharesIssued",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://brightmindsbio.com/role/SHARECAPITALDetailTextuals"
     ],
     "xbrltype": "sharesItemType"
    },
    "ifrs-full_NumberOfSharesOutstanding": {
     "auth_ref": [
      "r17"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The number of shares that have been authorised and issued, reduced by treasury shares held. [Refer: Treasury shares]"
       }
      },
      "en-us": {
       "role": {
        "label": "Number of shares outstanding",
        "periodEndLabel": "Balance (shares)",
        "periodStartLabel": "Balance (shares)"
       }
      }
     },
     "localname": "NumberOfSharesOutstanding",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://brightmindsbio.com/role/ConsolidatedStatementsOfChangesInShareholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "ifrs-full_OtherReserves": {
     "auth_ref": [
      "r15"
     ],
     "calculation": {
      "http://brightmindsbio.com/role/ConsolidatedStatementsOfFinancialPosition": {
       "order": 20.0,
       "parentTag": "ifrs-full_Equity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "A component of equity representing reserves within equity, not including retained earnings. [Refer: Retained earnings]"
       }
      },
      "en-us": {
       "role": {
        "label": "Other reserves",
        "terseLabel": "Reserves"
       }
      }
     },
     "localname": "OtherReserves",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://brightmindsbio.com/role/ConsolidatedStatementsOfFinancialPosition"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_OtherReservesMember": {
     "auth_ref": [
      "r4",
      "r19"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for a component of equity representing reserves within equity, not including retained earnings. It also represents the standard value for the 'Reserves within equity' axis if no other member is used. [Refer: Retained earnings]"
       }
      },
      "en-us": {
       "role": {
        "label": "Other reserves [member]",
        "verboseLabel": "Reserves [Member]"
       }
      }
     },
     "localname": "OtherReservesMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://brightmindsbio.com/role/ConsolidatedStatementsOfChangesInShareholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_PaymentsForShareIssueCosts": {
     "auth_ref": [
      "r46"
     ],
     "calculation": {
      "http://brightmindsbio.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 40.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The cash outflow for share issue costs."
       }
      },
      "en-us": {
       "role": {
        "label": "Payments for share issue costs",
        "terseLabel": "Share issuance costs"
       }
      }
     },
     "localname": "PaymentsForShareIssueCosts",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://brightmindsbio.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_PresentationOfLeasesForLesseeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Presentation of leases for lessee [abstract]"
       }
      }
     },
     "localname": "PresentationOfLeasesForLesseeAbstract",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "xbrltype": "stringItemType"
    },
    "ifrs-full_ProceedsFromIssueOfOrdinaryShares": {
     "auth_ref": [
      "r46"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The cash inflow from the issuing of ordinary shares. [Refer: Ordinary shares [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Proceeds from issue of ordinary shares"
       }
      }
     },
     "localname": "ProceedsFromIssueOfOrdinaryShares",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://brightmindsbio.com/role/SHARECAPITALDetailTextuals"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ProceedsFromIssuingShares": {
     "auth_ref": [
      "r45"
     ],
     "calculation": {
      "http://brightmindsbio.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 50.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The cash inflow from issuing shares."
       }
      },
      "en-us": {
       "role": {
        "label": "Proceeds from issuing shares",
        "terseLabel": "Private placement proceeds"
       }
      }
     },
     "localname": "ProceedsFromIssuingShares",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://brightmindsbio.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ProfessionalFeesExpense": {
     "auth_ref": [
      "r6"
     ],
     "calculation": {
      "http://brightmindsbio.com/role/ConsolidatedStatementsOfComprehensiveLoss": {
       "order": 50.0,
       "parentTag": "ifrs-full_ProfitLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of fees paid or payable for professional services."
       }
      },
      "en-us": {
       "role": {
        "label": "Professional fees expense",
        "terseLabel": "Professional fees"
       }
      }
     },
     "localname": "ProfessionalFeesExpense",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://brightmindsbio.com/role/ConsolidatedStatementsOfComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ProfitLoss": {
     "auth_ref": [
      "r1",
      "r20",
      "r47",
      "r56",
      "r58",
      "r59",
      "r98",
      "r99",
      "r102",
      "r109"
     ],
     "calculation": {
      "http://brightmindsbio.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 0.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://brightmindsbio.com/role/ConsolidatedStatementsOfComprehensiveLoss": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]"
       }
      },
      "en-us": {
       "role": {
        "label": "Profit (loss)",
        "terseLabel": "Net loss for the year",
        "totalLabel": "Net loss and comprehensive loss",
        "verboseLabel": "Net loss"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://brightmindsbio.com/role/ConsolidatedStatementsOfCashFlows",
      "http://brightmindsbio.com/role/ConsolidatedStatementsOfChangesInShareholdersEquity",
      "http://brightmindsbio.com/role/ConsolidatedStatementsOfComprehensiveLoss",
      "http://brightmindsbio.com/role/NATUREANDCONTINUANCEOFOPERATIONSDetailTextuals"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_RangeAxis": {
     "auth_ref": [
      "r67",
      "r68",
      "r69",
      "r79",
      "r94",
      "r103"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Range [axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://brightmindsbio.com/role/CONTRACTUALOBLIGATIONSDetailTextuals"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_RangesMember": {
     "auth_ref": [
      "r67",
      "r68",
      "r69",
      "r79",
      "r94",
      "r103"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for aggregate ranges. It also represents the standard value for the 'Range' axis if no other member is used."
       }
      },
      "en-us": {
       "role": {
        "label": "Ranges [member]"
       }
      }
     },
     "localname": "RangesMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://brightmindsbio.com/role/CONTRACTUALOBLIGATIONSDetailTextuals"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r43"
     ],
     "calculation": {
      "http://brightmindsbio.com/role/ConsolidatedStatementsOfComprehensiveLoss": {
       "order": 0.0,
       "parentTag": "ifrs-full_ProfitLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of expenditure directly attributable to research or development activities, recognised in profit or loss."
       }
      },
      "en-us": {
       "role": {
        "label": "Research and development expense",
        "terseLabel": "Research and development",
        "verboseLabel": "Research and development expense"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://brightmindsbio.com/role/CONTRACTUALOBLIGATIONSDetailTextuals",
      "http://brightmindsbio.com/role/ConsolidatedStatementsOfComprehensiveLoss",
      "http://brightmindsbio.com/role/RESEARCHANDDEVELOPMENTDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_RetainedEarnings": {
     "auth_ref": [
      "r15",
      "r23"
     ],
     "calculation": {
      "http://brightmindsbio.com/role/ConsolidatedStatementsOfFinancialPosition": {
       "order": 0.0,
       "parentTag": "ifrs-full_Equity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "A component of equity representing the entity's cumulative undistributed earnings or deficit."
       }
      },
      "en-us": {
       "role": {
        "label": "Retained earnings",
        "verboseLabel": "Deficit"
       }
      }
     },
     "localname": "RetainedEarnings",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://brightmindsbio.com/role/ConsolidatedStatementsOfFinancialPosition",
      "http://brightmindsbio.com/role/NATUREANDCONTINUANCEOFOPERATIONSDetailTextuals"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_RetainedEarningsMember": {
     "auth_ref": [
      "r4",
      "r5"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for a component of equity representing an entity's cumulative undistributed earnings or deficit."
       }
      },
      "en-us": {
       "role": {
        "label": "Retained earnings [member]",
        "verboseLabel": "Deficit [Member]"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://brightmindsbio.com/role/ConsolidatedStatementsOfChangesInShareholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_SalesAndMarketingExpense": {
     "auth_ref": [
      "r22"
     ],
     "calculation": {
      "http://brightmindsbio.com/role/ConsolidatedStatementsOfComprehensiveLoss": {
       "order": 60.0,
       "parentTag": "ifrs-full_ProfitLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of expense relating to the marketing and selling of goods or services."
       }
      },
      "en-us": {
       "role": {
        "label": "Sales and marketing expense",
        "terseLabel": "Marketing, advertising, and investor relations"
       }
      }
     },
     "localname": "SalesAndMarketingExpense",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://brightmindsbio.com/role/ConsolidatedStatementsOfComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ShareIssueRelatedCost": {
     "auth_ref": [
      "r3"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of cost related to the issuance of shares."
       }
      },
      "en-us": {
       "role": {
        "label": "Share issue related cost",
        "negatedLabel": "Share issue costs",
        "terseLabel": "Share issue costs"
       }
      }
     },
     "localname": "ShareIssueRelatedCost",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://brightmindsbio.com/role/ConsolidatedStatementsOfChangesInShareholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_SharebasedPaymentArrangementsMember": {
     "auth_ref": [
      "r80"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for an agreement between the entity or another group entity or any shareholder of the group entity and another party (including an employee) that entitles the other party to receive (a) cash or other assets of the entity for amounts that are based on the price (or value) of equity instruments (including shares or share options) of the entity or another group entity; or (b) equity instruments (including shares or share options) of the entity or another group entity, provided that the specified vesting conditions, if any, are met. It also represents the standard value for the 'Types of share-based payment arrangements' axis if no other member is used."
       }
      },
      "en-us": {
       "role": {
        "label": "Share-based payment arrangements [member]"
       }
      }
     },
     "localname": "SharebasedPaymentArrangementsMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://brightmindsbio.com/role/SHARECAPITALDetails2",
      "http://brightmindsbio.com/role/SHARECAPITALDetails3",
      "http://brightmindsbio.com/role/SHARECAPITALDetails4"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_ShorttermInvestmentsClassifiedAsCashEquivalents": {
     "auth_ref": [
      "r52"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "A classification of cash equivalents representing short-term investments. [Refer: Cash equivalents]"
       }
      },
      "en-us": {
       "role": {
        "label": "Short-term investments, classified as cash equivalents",
        "terseLabel": "Guaranteed investment certificate"
       }
      }
     },
     "localname": "ShorttermInvestmentsClassifiedAsCashEquivalents",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://brightmindsbio.com/role/FINANCIALINSTRUMENTSANDCAPITALMANAGEMENTDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of cash flows [abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "xbrltype": "stringItemType"
    },
    "ifrs-full_StatementOfChangesInEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of changes in equity [abstract]"
       }
      }
     },
     "localname": "StatementOfChangesInEquityAbstract",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "xbrltype": "stringItemType"
    },
    "ifrs-full_StatementOfChangesInEquityLineItems": {
     "auth_ref": [],
     "lang": {
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Statement of changes in equity [line items]"
       }
      }
     },
     "localname": "StatementOfChangesInEquityLineItems",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://brightmindsbio.com/role/ConsolidatedStatementsOfChangesInShareholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_StatementOfChangesInEquityTable": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to changes in equity."
       }
      },
      "en-us": {
       "role": {
        "label": "Statement of changes in equity [table]"
       }
      }
     },
     "localname": "StatementOfChangesInEquityTable",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://brightmindsbio.com/role/ConsolidatedStatementsOfChangesInShareholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of financial position [abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "xbrltype": "stringItemType"
    },
    "ifrs-full_TaxExpenseIncomeAtApplicableTaxRate": {
     "auth_ref": [
      "r27"
     ],
     "calculation": {
      "http://brightmindsbio.com/role/INCOMETAXESDetails": {
       "order": 0.0,
       "parentTag": "ifrs-full_IncomeTaxExpenseContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The product of the accounting profit multiplied by the applicable tax rate(s). [Refer: Accounting profit; Applicable tax rate]"
       }
      },
      "en-us": {
       "role": {
        "label": "Tax expense (income) at applicable tax rate",
        "verboseLabel": "Expected income tax recovery"
       }
      }
     },
     "localname": "TaxExpenseIncomeAtApplicableTaxRate",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://brightmindsbio.com/role/INCOMETAXESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis": {
     "auth_ref": [
      "r30"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Temporary difference, unused tax losses and unused tax credits [axis]"
       }
      }
     },
     "localname": "TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://brightmindsbio.com/role/INCOMETAXESDetails1"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember": {
     "auth_ref": [
      "r30"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for temporary differences, unused tax losses and unused tax credits. It also represents the standard value for the 'Temporary difference, unused tax losses and unused tax credits' axis if no other member is used. [Refer: Temporary differences [member]; Unused tax credits [member]; Unused tax losses [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Temporary difference, unused tax losses and unused tax credits [member]"
       }
      }
     },
     "localname": "TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://brightmindsbio.com/role/INCOMETAXESDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_TopOfRangeMember": {
     "auth_ref": [
      "r67",
      "r68",
      "r69",
      "r79",
      "r94",
      "r103"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for top of a range."
       }
      },
      "en-us": {
       "role": {
        "label": "Top of range [member]"
       }
      }
     },
     "localname": "TopOfRangeMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://brightmindsbio.com/role/CONTRACTUALOBLIGATIONSDetailTextuals"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_TradeAndOtherCurrentPayables": {
     "auth_ref": [
      "r10"
     ],
     "calculation": {
      "http://brightmindsbio.com/role/ACCOUNTSPAYABLEANDACCRUEDLIABILITIESDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://brightmindsbio.com/role/ConsolidatedStatementsOfFinancialPosition": {
       "order": 0.0,
       "parentTag": "ifrs-full_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of current trade payables and current other payables. [Refer: Current trade payables; Other current payables]"
       }
      },
      "en-us": {
       "role": {
        "label": "Trade and other current payables",
        "terseLabel": "Accounts payable and accrued liabilities",
        "totalLabel": "Total accounts payable and accrued liabilities"
       }
      }
     },
     "localname": "TradeAndOtherCurrentPayables",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://brightmindsbio.com/role/ACCOUNTSPAYABLEANDACCRUEDLIABILITIESDetails",
      "http://brightmindsbio.com/role/ConsolidatedStatementsOfFinancialPosition",
      "http://brightmindsbio.com/role/FINANCIALINSTRUMENTSANDCAPITALMANAGEMENTDetailTextuals",
      "http://brightmindsbio.com/role/FINANCIALINSTRUMENTSANDCAPITALMANAGEMENTDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_TradeAndOtherCurrentPayablesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trade and other current payables [abstract]"
       }
      }
     },
     "localname": "TradeAndOtherCurrentPayablesAbstract",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "xbrltype": "stringItemType"
    },
    "ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers": {
     "auth_ref": [
      "r14",
      "r16"
     ],
     "calculation": {
      "http://brightmindsbio.com/role/ACCOUNTSPAYABLEANDACCRUEDLIABILITIESDetails": {
       "order": 0.0,
       "parentTag": "ifrs-full_TradeAndOtherCurrentPayables",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The current amount of payment due to suppliers for goods and services used in entity's business. [Refer: Current liabilities; Trade payables]"
       }
      },
      "en-us": {
       "role": {
        "label": "Current trade payables",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "TradeAndOtherCurrentPayablesToTradeSuppliers",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://brightmindsbio.com/role/ACCOUNTSPAYABLEANDACCRUEDLIABILITIESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_TypesOfRisksAxis": {
     "auth_ref": [
      "r84",
      "r87",
      "r88",
      "r104",
      "r105",
      "r106",
      "r108"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Types of risks [axis]"
       }
      }
     },
     "localname": "TypesOfRisksAxis",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://brightmindsbio.com/role/FINANCIALINSTRUMENTSANDCAPITALMANAGEMENTDetailTextuals"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_TypesOfRisksMember": {
     "auth_ref": [
      "r84",
      "r87",
      "r88",
      "r104",
      "r105",
      "r106",
      "r108"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for all types of risks. It also represents the standard value for the 'Types of risks' axis if no other member is used."
       }
      },
      "en-us": {
       "role": {
        "label": "Risks [member]"
       }
      }
     },
     "localname": "TypesOfRisksMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://brightmindsbio.com/role/FINANCIALINSTRUMENTSANDCAPITALMANAGEMENTDetailTextuals"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_TypesOfSharebasedPaymentArrangementsAxis": {
     "auth_ref": [
      "r80"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Types of share-based payment arrangements [axis]"
       }
      }
     },
     "localname": "TypesOfSharebasedPaymentArrangementsAxis",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://brightmindsbio.com/role/SHARECAPITALDetails2",
      "http://brightmindsbio.com/role/SHARECAPITALDetails3",
      "http://brightmindsbio.com/role/SHARECAPITALDetails4"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_UnusedTaxLossesMember": {
     "auth_ref": [
      "r30"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for tax losses that have been incurred and are carried forward for use against future taxable profit."
       }
      },
      "en-us": {
       "role": {
        "label": "Unused tax losses [member]",
        "verboseLabel": "Non-capital losses [Member]"
       }
      }
     },
     "localname": "UnusedTaxLossesMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://brightmindsbio.com/role/INCOMETAXESDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_ValueAtRisk": {
     "auth_ref": [
      "r93"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The measure of a potential loss exposure as a result of future market movements, based on a specified confidence interval and measurement horizon."
       }
      },
      "en-us": {
       "role": {
        "label": "Value at risk",
        "verboseLabel": "Foreign currency fluctuation impact on net comprehensive loss"
       }
      }
     },
     "localname": "ValueAtRisk",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://brightmindsbio.com/role/FINANCIALINSTRUMENTSANDCAPITALMANAGEMENTDetailTextuals"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019": {
     "auth_ref": [
      "r75"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The weighted average exercise price of share options forfeited in a share-based payment arrangement. [Refer: Weighted average [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Weighted average exercise price of share options forfeited in share-based payment arrangement",
        "verboseLabel": "Weighted average exercise price, Cancelled"
       }
      }
     },
     "localname": "WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://brightmindsbio.com/role/SHARECAPITALDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019": {
     "auth_ref": [
      "r74"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The weighted average exercise price of share options granted in a share-based payment arrangement. [Refer: Weighted average [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Weighted average exercise price of share options granted in share-based payment arrangement",
        "terseLabel": "Weighted average exercise price of options granted",
        "verboseLabel": "Weighted average exercise price, Granted"
       }
      }
     },
     "localname": "WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://brightmindsbio.com/role/SHARECAPITALDetailTextuals",
      "http://brightmindsbio.com/role/SHARECAPITALDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019": {
     "auth_ref": [
      "r73",
      "r76"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The weighted average exercise price of share options outstanding in a share-based payment arrangement. [Refer: Weighted average [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Weighted average exercise price of share options outstanding in share-based payment arrangement",
        "periodEndLabel": "Weighted average exercise price, Ending Balance",
        "periodStartLabel": "Weighted average exercise price, Beginning Balance"
       }
      }
     },
     "localname": "WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://brightmindsbio.com/role/SHARECAPITALDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019": {
     "auth_ref": [
      "r79"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The weighted average remaining contractual life of outstanding share options. [Refer: Weighted average [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Weighted average remaining contractual life of outstanding share options",
        "verboseLabel": "Options Outstanding and Exercisable, Remaining life (Years)"
       }
      }
     },
     "localname": "WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://brightmindsbio.com/role/SHARECAPITALDetailTextuals",
      "http://brightmindsbio.com/role/SHARECAPITALDetails1"
     ],
     "xbrltype": "durationItemType"
    },
    "ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019": {
     "auth_ref": [
      "r81"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The weighted average share price used as input to the option pricing model to calculate the fair value of share options granted. [Refer: Option pricing model [member]; Weighted average [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Weighted average share price, share options granted",
        "terseLabel": "Share price, stock options granted"
       }
      }
     },
     "localname": "WeightedAverageSharePriceShareOptionsGranted2019",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://brightmindsbio.com/role/SHARECAPITALDetailTextuals"
     ],
     "xbrltype": "perShareItemType"
    },
    "ifrs-full_WeightedAverageShares": {
     "auth_ref": [
      "r39"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The number of ordinary shares outstanding at the beginning of the period, adjusted by the number of ordinary shares bought back or issued during the period multiplied by a time-weighting factor."
       }
      },
      "en-us": {
       "role": {
        "label": "Weighted average number of ordinary shares outstanding",
        "terseLabel": "Weighted average number of common shares outstanding\u00a0-basic and diluted"
       }
      }
     },
     "localname": "WeightedAverageShares",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://brightmindsbio.com/role/ConsolidatedStatementsOfComprehensiveLoss"
     ],
     "xbrltype": "sharesItemType"
    },
    "srt_ChiefExecutiveOfficerMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Chief Executive Officer [Member]"
       }
      }
     },
     "localname": "ChiefExecutiveOfficerMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://brightmindsbio.com/role/SHARECAPITALDetailTextuals"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_TitleOfIndividualAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Axis]"
       }
      }
     },
     "localname": "TitleOfIndividualAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://brightmindsbio.com/role/SHARECAPITALDetailTextuals"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Domain]"
       }
      }
     },
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://brightmindsbio.com/role/SHARECAPITALDetailTextuals"
     ],
     "xbrltype": "domainItemType"
    }
   },
   "unitCount": 8
  }
 },
 "std_ref": {
  "r0": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "10",
   "Subparagraph": "e",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2020-en-r&anchor=para_10_e&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r1": {
   "Clause": "i",
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "106",
   "Subparagraph": "d",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2020-en-r&anchor=para_106_d_i&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r10": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "54",
   "Subparagraph": "k",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2020-en-r&anchor=para_54_k&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r100": {
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Number": "8",
   "Paragraph": "28",
   "Subparagraph": "c",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2020-en-r&anchor=para_28_c&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r101": {
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Number": "8",
   "Paragraph": "28",
   "Subparagraph": "d",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2020-en-r&anchor=para_28_d&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r102": {
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Note": "Effective 2021-01-01",
   "Number": "17",
   "Paragraph": "113",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2020-en-r&anchor=para_113_b&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r103": {
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Note": "Effective 2021-01-01",
   "Number": "17",
   "Paragraph": "120",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2020-en-r&anchor=para_120&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r104": {
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Note": "Effective 2021-01-01",
   "Number": "17",
   "Paragraph": "124",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2020-en-r&anchor=para_124&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r105": {
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Note": "Effective 2021-01-01",
   "Number": "17",
   "Paragraph": "125",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2020-en-r&anchor=para_125&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r106": {
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Note": "Effective 2021-01-01",
   "Number": "17",
   "Paragraph": "127",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2020-en-r&anchor=para_127&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r107": {
   "Clause": "ii",
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Note": "Effective 2021-01-01",
   "Number": "17",
   "Paragraph": "128",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2020-en-r&anchor=para_128_a_ii&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r108": {
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Note": "Effective 2021-01-01",
   "Number": "17",
   "Paragraph": "128",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2020-en-r&anchor=para_128_a&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r109": {
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Note": "Effective on first application of IFRS 9",
   "Number": "4",
   "Paragraph": "39L",
   "Subparagraph": "e",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=4&code=ifrs-tx-2020-en-b&anchor=para_39L_e&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r11": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "54",
   "Subparagraph": "n",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2020-en-r&anchor=para_54_n&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r110": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r111": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r112": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310"
  },
  "r113": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f"
  },
  "r114": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f"
  },
  "r115": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r116": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r117": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r118": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2"
  },
  "r119": {
   "Name": "Securities Act",
   "Number": "Section",
   "Publisher": "SEC",
   "Section": "12"
  },
  "r12": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "55",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2020-en-r&anchor=para_55&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r13": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "66",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2020-en-r&anchor=para_66&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r14": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "70",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2020-en-r&anchor=para_70&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r15": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "78",
   "Subparagraph": "e",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2020-en-r&anchor=para_78_e&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r16": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "78",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2020-en-r&anchor=para_78&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r17": {
   "Clause": "iv",
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "79",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2020-en-r&anchor=para_79_a_iv&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r18": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "79",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2020-en-r&anchor=para_79_a&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r19": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "79",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2020-en-r&anchor=para_79_b&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r2": {
   "Clause": "iii",
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "106",
   "Subparagraph": "d",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2020-en-r&anchor=para_106_d_iii&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r20": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "81A",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2020-en-r&anchor=para_81A_a&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r21": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "82",
   "Subparagraph": "d",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2020-en-r&anchor=para_82_d&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r22": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "85",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2020-en-r&anchor=para_85&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r23": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "IG6",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2020-en-r&anchor=para_IG6&doctype=Implementation%20Guidance",
   "URIDate": "2020-01-01"
  },
  "r24": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "10",
   "Paragraph": "21",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=10&code=ifrs-tx-2020-en-r&anchor=para_21&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r25": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "10",
   "Section": "Disclosure",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=10&code=ifrs-tx-2020-en-r&doctype=Standard&dita_xref=IAS10_g17-22_TI",
   "URIDate": "2020-01-01"
  },
  "r26": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "12",
   "Paragraph": "79",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=12&code=ifrs-tx-2020-en-r&anchor=para_79&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r27": {
   "Clause": "i",
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "12",
   "Paragraph": "81",
   "Subparagraph": "c",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=12&code=ifrs-tx-2020-en-r&anchor=para_81_c_i&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r28": {
   "Clause": "ii",
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "12",
   "Paragraph": "81",
   "Subparagraph": "c",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=12&code=ifrs-tx-2020-en-r&anchor=para_81_c_ii&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r29": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "12",
   "Paragraph": "81",
   "Subparagraph": "e",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=12&code=ifrs-tx-2020-en-r&anchor=para_81_e&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r3": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "106",
   "Subparagraph": "d",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2020-en-r&anchor=para_106_d&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r30": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "12",
   "Paragraph": "81",
   "Subparagraph": "g",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=12&code=ifrs-tx-2020-en-r&anchor=para_81_g&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r31": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "12",
   "Section": "Disclosure",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=12&code=ifrs-tx-2020-en-r&doctype=Standard&dita_xref=IAS12_g79-88_TI",
   "URIDate": "2020-01-01"
  },
  "r32": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "16",
   "Paragraph": "37",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=16&code=ifrs-tx-2020-en-r&anchor=para_37&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r33": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "21",
   "Paragraph": "52",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=21&code=ifrs-tx-2020-en-r&anchor=para_52_a&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r34": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "24",
   "Paragraph": "17",
   "Subparagraph": "e",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=24&code=ifrs-tx-2020-en-r&anchor=para_17_e&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r35": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "24",
   "Paragraph": "17",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=24&code=ifrs-tx-2020-en-r&anchor=para_17&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r36": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "24",
   "Paragraph": "19",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=24&code=ifrs-tx-2020-en-r&anchor=para_19&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r37": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "24",
   "Section": "Disclosures",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=24&code=ifrs-tx-2020-en-r&doctype=Standard&dita_xref=IAS24_g13-24_TI",
   "URIDate": "2020-01-01"
  },
  "r38": {
   "Clause": "viii",
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "26",
   "Paragraph": "35",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=26&code=ifrs-tx-2020-en-r&anchor=para_35_b_viii&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r39": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "33",
   "Paragraph": "70",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=33&code=ifrs-tx-2020-en-r&anchor=para_70_b&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r4": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "106",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2020-en-r&anchor=para_106&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r40": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "36",
   "Paragraph": "126",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=36&code=ifrs-tx-2020-en-r&anchor=para_126&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r41": {
   "Clause": "ii",
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "36",
   "Paragraph": "130",
   "Subparagraph": "d",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=36&code=ifrs-tx-2020-en-r&anchor=para_130_d_ii&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r42": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "38",
   "Paragraph": "119",
   "Subparagraph": "e",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=38&code=ifrs-tx-2020-en-r&anchor=para_119_e&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r43": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "38",
   "Paragraph": "126",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=38&code=ifrs-tx-2020-en-r&anchor=para_126&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r44": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "10",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2020-en-r&anchor=para_10&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r45": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "17",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2020-en-r&anchor=para_17_a&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r46": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "17",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2020-en-r&anchor=para_17&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r47": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "18",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2020-en-r&anchor=para_18_b&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r48": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "20",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2020-en-r&anchor=para_20_a&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r49": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "20",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2020-en-r&anchor=para_20_b&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r5": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "108",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2020-en-r&anchor=para_108&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r50": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "25",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2020-en-r&anchor=para_25&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r51": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "28",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2020-en-r&anchor=para_28&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r52": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "45",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2020-en-r&anchor=para_45&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r53": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "50",
   "Subparagraph": "d",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2020-en-r&anchor=para_50_d&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r54": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "7",
   "Section": "A Statement of cash flows for an entity other than a financial institution",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2020-en-r&doctype=Illustrative%20Examples&dita_xref=IAS07_IE_A_TI",
   "URIDate": "2020-01-01"
  },
  "r55": {
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Number": "1",
   "Paragraph": "24",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2020-en-r&anchor=para_24_a&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r56": {
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Number": "1",
   "Paragraph": "24",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2020-en-r&anchor=para_24_b&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r57": {
   "Clause": "i",
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Number": "1",
   "Paragraph": "32",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2020-en-r&anchor=para_32_a_i&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r58": {
   "Clause": "ii",
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Number": "1",
   "Paragraph": "32",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2020-en-r&anchor=para_32_a_ii&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r59": {
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Number": "12",
   "Paragraph": "B10",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2020-en-r&anchor=para_B10_b&doctype=Appendix&subtype=B",
   "URIDate": "2020-01-01"
  },
  "r6": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "112",
   "Subparagraph": "c",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2020-en-r&anchor=para_112_c&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r60": {
   "Clause": "i",
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Number": "12",
   "Paragraph": "B12",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2020-en-r&anchor=para_B12_b_i&doctype=Appendix&subtype=B",
   "URIDate": "2020-01-01"
  },
  "r61": {
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Number": "12",
   "Paragraph": "B13",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2020-en-r&anchor=para_B13_a&doctype=Appendix&subtype=B",
   "URIDate": "2020-01-01"
  },
  "r62": {
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Number": "12",
   "Paragraph": "B13",
   "Subparagraph": "g",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2020-en-r&anchor=para_B13_g&doctype=Appendix&subtype=B",
   "URIDate": "2020-01-01"
  },
  "r63": {
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Number": "13",
   "Paragraph": "93",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2020-en-r&anchor=para_93_a&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r64": {
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Number": "13",
   "Paragraph": "93",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2020-en-r&anchor=para_93_b&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r65": {
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Number": "13",
   "Paragraph": "93",
   "Subparagraph": "e",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2020-en-r&anchor=para_93_e&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r66": {
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Number": "13",
   "Paragraph": "93",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2020-en-r&anchor=para_93&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r67": {
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Number": "13",
   "Paragraph": "B6",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2020-en-r&anchor=para_B6&doctype=Appendix&subtype=B",
   "URIDate": "2020-01-01"
  },
  "r68": {
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Number": "13",
   "Paragraph": "IE63",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2020-en-r&anchor=para_IE63&doctype=Illustrative%20Examples",
   "URIDate": "2020-01-01"
  },
  "r69": {
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Number": "14",
   "Paragraph": "33",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=14&code=ifrs-tx-2020-en-r&anchor=para_33_b&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r7": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "117",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2020-en-r&anchor=para_117_b&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r70": {
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Number": "16",
   "Paragraph": "53",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2020-en-r&anchor=para_53&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r71": {
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Number": "16",
   "Section": "Disclosure",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2020-en-r&doctype=Standard&dita_xref=IFRS16_g51-60_TI",
   "URIDate": "2020-01-01"
  },
  "r72": {
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Number": "16",
   "Section": "Presentation",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2020-en-r&doctype=Standard&dita_xref=IFRS16_g47-50_TI",
   "URIDate": "2020-01-01"
  },
  "r73": {
   "Clause": "i",
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Number": "2",
   "Paragraph": "45",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2020-en-r&anchor=para_45_b_i&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r74": {
   "Clause": "ii",
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Number": "2",
   "Paragraph": "45",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2020-en-r&anchor=para_45_b_ii&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r75": {
   "Clause": "iii",
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Number": "2",
   "Paragraph": "45",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2020-en-r&anchor=para_45_b_iii&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r76": {
   "Clause": "vi",
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Number": "2",
   "Paragraph": "45",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2020-en-r&anchor=para_45_b_vi&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r77": {
   "Clause": "vii",
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Number": "2",
   "Paragraph": "45",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2020-en-r&anchor=para_45_b_vii&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r78": {
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Number": "2",
   "Paragraph": "45",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2020-en-r&anchor=para_45_b&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r79": {
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Number": "2",
   "Paragraph": "45",
   "Subparagraph": "d",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2020-en-r&anchor=para_45_d&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r8": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "117",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2020-en-r&anchor=para_117&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r80": {
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Number": "2",
   "Paragraph": "45",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2020-en-r&anchor=para_45&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r81": {
   "Clause": "i",
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Number": "2",
   "Paragraph": "47",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2020-en-r&anchor=para_47_a_i&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r82": {
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Number": "2",
   "Paragraph": "47",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2020-en-r&anchor=para_47_b&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r83": {
   "Clause": "iv",
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Number": "3",
   "Paragraph": "B64",
   "Subparagraph": "f",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2020-en-r&anchor=para_B64_f_iv&doctype=Appendix&subtype=B",
   "URIDate": "2020-01-01"
  },
  "r84": {
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "21C",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2020-en-r&anchor=para_21C&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r85": {
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "31",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2020-en-r&anchor=para_31&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r86": {
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "32",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2020-en-r&anchor=para_32&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r87": {
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "33",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2020-en-r&anchor=para_33&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r88": {
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "34",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2020-en-r&anchor=para_34&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r89": {
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "35H",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2020-en-r&anchor=para_35H&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r9": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "54",
   "Subparagraph": "i",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2020-en-r&anchor=para_54_i&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r90": {
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "35K",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2020-en-r&anchor=para_35K&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r91": {
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "35M",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2020-en-r&anchor=para_35M&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r92": {
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "36",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2020-en-r&anchor=para_36&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r93": {
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "41",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2020-en-r&anchor=para_41&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r94": {
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "7",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2020-en-r&anchor=para_7&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r95": {
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Number": "7",
   "Section": "Defined terms",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2020-en-r&doctype=Appendix&subtype=A&dita_xref=IFRS07_APPA_TI",
   "URIDate": "2020-01-01"
  },
  "r96": {
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Number": "7",
   "Section": "Scope",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2020-en-r&doctype=Standard&dita_xref=IFRS07_g3-5A_TI",
   "URIDate": "2020-01-01"
  },
  "r97": {
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Number": "8",
   "Paragraph": "23",
   "Subparagraph": "h",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2020-en-r&anchor=para_23_h&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r98": {
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Number": "8",
   "Paragraph": "23",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2020-en-r&anchor=para_23&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r99": {
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Number": "8",
   "Paragraph": "28",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2020-en-r&anchor=para_28_b&doctype=Standard",
   "URIDate": "2020-01-01"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>65
<FILENAME>0001062993-22-001182-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001062993-22-001182-xbrl.zip
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M#:.4L,@+P_5G$F'JB@3UY5.:Y![T-1DCNQGTX&_NF>5'Y&F*.^=Q 30 Y.:
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M<;6M2 I0CCBTUX)^02K%_=VN_U^&+_\'4$L#!!0    ( *>%,E16/Z6GU"\
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M]<<?#\-=JGZ8G'K^XG35YM0- LP(8?'7Y.T9?OT8^XOG .:_S1&<<260LT>
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M&CG,%9N +PWRE$\:.4.HSB!ADMD'7#;(M1.&^)Q]@,\1DC%;; HZS1T^-WX
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M=UN!GN9.68HUB8%MNXDV4YPE>D7663SO1\%R\>B[ZY77CQ8+/R9A6.(UJTS
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MGPQYRAF;$1V%&&)_AP'6(K+UK+.C<8E@U@W%J>X8CTNR+26 63;UY'PUL>O
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M[7[@89*ZH5?60C&J>F>?/GWZ6OP6BB;\7Q-1_R[RW%00:,7EU); ?WW(BWW
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M21Z4J\55E(!&B7Q5MT:)?$^W1HD\22'RGJ7XGKI.DIW&2@"-R'L, 8W(3PP
MC>A&>-E*]7V =DS5T@"&R-K3@"&RWS1@B"PR?_L<P;*ILCFMNZG=6A- 4MG>
M04%2V>HWW97J44D 066[3P)!9<M/ D%DM?>/[K7@4!4&*$16F@ *T2WBIQ04
M'P,C\=3@)N#X;@^LOF#1S9/IXB%F&S<6J^[6Q7!G24""R)J7MVZ;7A<_* ;-
M$]GOOLT36>Q2;O-+WT<% 0*1/3X% I&U+24G&MOCRM( ALCJTH ALKX5\?I
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MW^-"FI.@.)D/P("R-_-3JG).8[IPRDJ.J"7S,YBZHMQ"1JF!E3%Y?/IB5,\
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M>5&\AR! 8WD;)D4-AYH9<<S!@AVD+K<=RKC8EIL.NK<;[+K/H'N'X=&N6PL
MU!61^M/V.8]5HUAS<SL1E84_2/:JCZ\TS3Q4ZB-K"+>\7\?PDZ'-3)2?<.N&
MP;PE>O(X%.$+[DW\%Y[ (D^<A>UYKB\II#EN)LYY%F=K39[KT^6H5$(-1A:,
M(@.E\B=AR,$2)J!KTX4X:7H%0;M^U)\%+KPRK)4=F$2T 4I<-((^29Q)=7PH
M9&!<VUDKAU02J=3##4%1T\&JM@SG#!!YJZ;QRYAD!<V%^2J\#3T_!EX-,ZX
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M@RS'7SMQ\6H46 8/_$KB\- +MC[S93+S%+\V_=&9K:!4649\LDGD-HC/$R\
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M+B^I5!CKZD9S]S<Q4(Y"E<'$ILLG%6#R<3=<>C3%>54F90T[QN*(0>M8C,1
M*QII(J*,2RH5\M?T!F?24ZM84YXUQ8BP85.7==0HUI1U;7ST_;2I(*&K2P.S
MZ*Q)23DK.GX!J)DHQK)XU;%J5:\2N]%94<7<KDV/@X+6^+A:@UQU!VO$WNZK
M_WI/QS1KOXGDB6HJ;2I?OI%KC?+4?4H]5AV37U$!#?OG%HI=O[1=!??E+6F6
M..*0OMR0CCSQ:K7ON OH):%3SVX@MOR3%6/95Z3G;>H\,WSG6I5O2)Z^S1)$
M1K'COK@\$"$*+*.>V9#?R5M54=$Y=;HHB\K.L2)FWVP"T;]NO*O<XV_^?%.M
MY%1O_^?5#(Q""P_U>-3Q&/9[DU[,U4)(:3:^/#S<77^^OI]-'O_JW-[?3!\_
M3V:WTWMC^C5SW[+'C-/==#'9(OB NTU[TNY;_E9Q*KXU%Y7&G]O-Z%4JA>B+
M*O@5LZAD^#Y+,Q65,M4/A+GEU#Z+2S=T_4ZZ)&N8-[L-/.JT:H^')VH,,B%Z
MX,=D6LP7'_4;OS8=LI#U'%G1].Q6D-":X'LDK)KD"D9:\WP\1FW#<[U8, _/
MFH@K1;?A%5LPC".19Y*P-+F/4HBCHV6([]K7*IT4(\Z:R+M)MZ&3BW+$@ IA
M#DAS2G$F)U='XDI%+1=N(@:/]]=T/H<F8H8A>/4@2@J]D:5==G[/,;,G^T-Q
MYF031_[62_,#8-FMF?P=#)XZZVV0\DW H5N?=[(,1#'<DV$ZB(Y!I7Z?_"%'
M% @-P\MT^6A@(5>.1AAAD9RCL0.PW4=#-<DRQ>.A!E4;%.^*X4AS&+=)Z .]
M\M_U]RO?E<85N<7]@IEH%8>B\B-YPDH,&YC?-1<'G$&ND)]A^#VV$T1)\@=C
MFX =1DYE*ZX.^R#\<-@')LU_&Z4ZKU;:_0I!/&.(AK[RH]NA"':T+VT\59N,
MAH9.UYX\@NJ6]+I[[_=D4@PYL;99U&$(Z@)>%+$WFTS$3IJ3J0/=]^RH_\K<
M>+J8QGS)P_-OSCZUK+NPN+C6)2HX6,.(,M; KE,\ 1MOUI6PS2^Q:CBHM&EP
MP/W4Y?P;'76I]OOY-Q:H2P%;6UW.O[%-70H.:G49&'!/=3GKK"YG-JC+66=U
M.;-.7<Z:U658P'KJPM:;*';CW541C26W4"=<BDA6.,[N9]#37&HER,.%6"XW
M]\BRI@%MTV>M5+^"7J6^4PK(PRK#ZJA/4J6?MT>C9:6RWD?AI;OAJ1O<P2)>
M^[U8I8)B!EI/"A-; LPN#:VAJJ^AF'LVD^!($<9/IW7@J5)2*/KA8,2LU-*#
M]$>G*&ERE S))AU5$]57T>-<5C9JJ)JE7NHJ*_7S)S?8RA,*01"]XMF>[D[?
M#6LT]B47[KBY=*MTMI:\OMH6(IQ"QO]M[UV7&\>5=-'_YRD4YT2<Z171'5.N
M6U?M?6)'R+=>FN6R/+:J>Z]9/QPT!<F8HD@ODK*M>?J#"TGQ@@0!2G*F>G9$
M1U>5C4SFET@@/X) @F3@@E!-L?N[H=\(1*]3>=X9:G%>@Y'F6*)4F-=@M*TL
M+W_]I5M,A6!UB1E+5]/%%0LRH-:9^+VT.Y(M,":DK7GF&!'FB==<U0+K16)K
MHO%K3=V#R/U<5-EPO.DH+RPOKES&ZOW2:%O_%VTP(Z TTQ8#+X<STSD*,EG?
M)+;=7EO6#U;?FPK+RPN]<(*@;C,4!IDNN!(?;).N6R#4385"(:M[%"\8'GEZ
MX/NT<OD(2M=I]6,V[S>2, A?IJ4,=*!]"@<:[>L:"3N;QOU9!I--8_K?UM$&
M^_8L@ZF6R[/ RF>T[M*2H'+F^$Y3M46-<).Y4)@7YI)YQ0',!]YSOJF+K,O;
M=B@$2\J8R+W9.LI[*N7IHAOAMBU"J!B--4>*-+;6EHBK)_$SRWKNZ=6V\[(E
MXHYKD\6PMR=O8K&SK[/'))K?,*%>-%ZRZF4#VJQ:2(R>*I':VP?&<00K!J@;
M-(:M2.U%#V]+HQ6)D?#W] 9>8"5Y$ E2NPZB;SSFJ_6JNA9\+,^R7DJ.<):L
M5L)L'D3R-G'7A0.I6;(+H7JTTKIK-[OKD[*:@H25?G4'.4)H#O"",6 59JUH
M5&@:;>]95[I&2MEHJTW=%H]$;0?@-EX=.Z"7*8;\F3S%'>=RBXIY5O4.\U!K
M'&VD2E*!W< Z()@+>;7)Z"#SUT[AVT#G%;*_:$2C$[6C^B"O<KN&Z35[W6>,
MQD(=P0#=HAP0G5*8:&AN<1F9@FM?40Q,">O# 2;.T0=2D:EA#HA*M2'S [F(
MU'@&S)*'P;*/*/RXGRC4T?>17/1]'!Q]![G6>>?H^S@H^O"NJ.Z!\VF?T?>)
M7/1]&AQ]GTA&WZ=!T7<0+/N(OL_C>#Y[9"E3;U_["\71Y_*08:&:6ERV@ \-
MTL_J#.WLH#!WCMD6UB$!C-^=^@N#]?1-\5GDL.= 7*S,X%M1B@8'O.+#R4#+
MO1Y;$[&OR9B]L&CA]"E/-\3[CF<RU#BE%(:2^8)G,ASX?'?.0KUWH_B"1^&X
ME5 _78SENOA2%T;\/]<1.42KV6O&>!5-5>6V6F/LVXF^QW.6OJ1<ID7KM:OU
MAMO+.]_>WT:#3=XV&TS"T9;)M]X,U[F6B;?A6O1Y2U85*VX/53=AW[!4_JAO
M_]Q:M"FKONKKKY_$="Q_BN%W,P2S\T7;XA;:GXM[RD5[55P-*_-!]IN2G[:?
M%_8W/8\90W(KEJIN-XE$DX1GX_SLD8?!TG8=RU9.IL)2<B1R4R&+$4J]2("P
M,B$95TA(#/0*VHR]!F**F@O3HE-%N)Q[28F."MF1%L9[R7$"U=]A;P[*J<?D
M*2VF;O1<);&ZY*?WRFVP0KP\J<?TUFVIK;C@Z/!W65M[KP>@J=^42'$]J<2A
M[SXZ^.7B+M-X#QKH'%Y/KQ"-OM/-K=XJ?Q.D^<8E%ATB4!;V*G?@/TF]U$*R
MA7I@@(Y.-Z-"ST@IPEFI\X+J'KW;KKRYDN<H>#SGSWR^#J*W[TRF-H1;%IB*
M%OCK2X4AVYUY5G.;N_'4&/KE(<C4L-FH"YR#ER#%F-$[,(QCI("Q;88V9W?L
M-09ZQ^W8<?)_%I?<@Q%>4BH;8"\C%7MPQ_)NF0<V5_.JL7.+AJ.@:*F3ZMM[
MUFBPR<.EP65+54X!:=>HT6C3<#=[&<O)K94!VS'H4L*POG' 0\8^(0Z ,85.
MC3[*!0Y='$<O>-1VH!_RW<4E@=AQ6:++M(B#?<2Z-,V_0@S>\8R6S99)"+_@
M4,M6:W2@KS[\P?CR4?#_L4 F&,_%J]P$GS$5XMMC(^6/YY-8O3V<2A9ZHTEH
M[4N-RPOB2_' 4:"?.&*%;L.H+W\UEW=&Z*FAQ7^WST:K_KY?#QHCV^ZRGT>5
M\K<?EWL%;QPJ)?CB$178(NW53EQM_2#C15?N4H\:%<^J?U5$FQWVZC'3 6K<
M<-GCK*.S[=M..<6ZQEO/-_L;:TY.L\XR#@-M4GGIJ$>9DZ^LDQ(TQ ZW1NWP
M!K0_[ .F%\-H.HII9I:<ILD/EJ),-_(25?5TN01SU!./HQOW- '-DI%^W)]D
M*G+TW@Y3TNB7(M*(#\KI.E<OGCQ>ONV(3+8/QAJ,3RSER?PBWL=[A[L?A[UY
M:$>=ZOND#^>,NSQ(\S=UQZ Q=LJ6/(X/[)$]S-7N;K R (>)NO8DI#EZ7X3)
MW6<?;2L^S9"AG93<(7^R0:ZIV;Y\'@[_D"QTR^1G,6%@61EQ'417?"%\,95'
M4"[^N>;Y9A)G>:I4PQ_E.JDF+357Y13EL9=(Z%8W0DGM(Z;4BW13Z4<G>=X.
M<6)TE=913>U(ZE4WP2AG:-6CFFX2LX*W0YP22$]TU";/0Q;C&3!C>+O#F$B,
M,\0V2)0??E+E"/Y"=T!8*UUY#H%#%H_:[[S84QO+>R8\Z+>E/8YV:R6M_P[C
MNW( Q1$]),85L5',I[1>%<X%]MYVNKCVR?KG[6OD4JM S^,P.*>$K?GZC097
M=6ZA@DBHPA#A"UV [J(2DK,TD".GH./%WDVU;7,:GP6Q^&6@]W)>O(;JRE2W
M4,VUVNVJ1[FE4^];5;=G:>7%+D]6J$</8W^'.(5WH7;[WEINY]4.F<KKM@J'
MZ!V^I7H22<K?*4XY:W"4X(V>)/TA4Y6^2,SCR,2+%BPOC7O[*&\:;HQ9/!/Y
M(LU^6:RCZ'Y<W=-]HZ[I-KIXW+[,^\T'B<5@DVNO6:XNG4/S:2I(5786!5G&
M%UP,Z[(P(.1>U7X45@*CH"I%ANMK$(C)[:J],#[BP0./N"SZ@=0#\_]<9[EZ
M/;U,TDD<IO("G'.F_YS$<GYE123=!!NYO=G<,UL]:IL<+S2-?IH7NOZBME9+
M=>65]_*DM=*(0*)V\P#0I0U0:O-X0+.?Y17T<<@CIF<&>47E^"&#;YNI]VZ>
MJ OHE7@QR8U^DE/(7T;_" HE;W\1Q!"DQOE07<:9/>K=_O^#0F<I.O-06W0V
MK[*T1Z#AK,S;KR)Z8#+UQET-@SQGP>),D2 *W?(]%A-$)+>0B7\(_AB7#%-?
M^/J;>-MWZZAUI4C^4VJJV&1Y'^Q/2ZGM(*L%@[K/";NI0R]; +$Z4I;<DK-
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M#)/:F9S(H@C[/60(0H<%CRKF%Z7.XU@5&.*.'G96."(\9'_O-*Y=<=JY%>7
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M\05@$HU&>.%36%'L7/L"<(16,W3/EN8"^;_5#,V[*[FO:+K00Z>\W/F6J?O
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M*U_P<#Q_YIEX@U.[2#M[ICX#13-=Y='BSAF?.8N[RJ/%(A.MYN,XYL\LS42
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M&M'50F%.[A81&G$E"T&QN?K<765+H#I<KR"-?C$B,N?_7D'"?61F KV"B#/
MQ6+!0KFA0IV]F<3G;,'2E,VES5G&\NPZR07_39:QO*]<0#13 W]-B''IC=E,
M'OPU(4:N-V:087AJ(A#;YVR^#G,NWOK'\5Q8M_VW/EKV*U#@SD,%@6CN1PF2
M$U<5!.*W%R50/,]#Q3%$+%!@ST,%UOJ7,/%6I+ZMF?9Y"*B^YZ<%<71Z804)
MD8<6Q#'JA16D2AY:$$?JWUF03A?3E"]Y_/[=R=>2 @*U^F )Q-@$,8!\!Y!
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M4Z"D7:L9=A15UIJ3:*L9=IQ4UIIS:*L96B0POGP4['G\S%+!.RY>Y=[OC*E
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MN ZB*[X0D*;Y(TLO_KGF^6829WFZ5CNEA7^<R+VW7B+Y;X _G.B[MUXB^6V
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MC[F<07+^S"Y>GUB<L?NOW1K&?2+(O6A&86-*1A'<OGAZBG@H\_0L>+T-<HG
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M(]A6)-M!GCX^&ZOJER<S"YVS/."1/)"^2-*5FD+'#\DZ[_W^:*N,O8\'D(F
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MM4F"CN>W$"Q,PRB!":'(6I+_J=&H)OVS)).'V4YL%:0M@JA]8@=D2?,V051
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M0[252G;2@ JQ>_M\]?)E*XT,R^'V6->L[_%:O"(60T:]"%<_.4O9G.=9\4W
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MHP;$KBLA=EV?(&D%JP?'^P$A0*9#526V/^R.OO=FQN\RJFJ^$R !LG?N85=
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MA<!2*9SL5;4+!TU(JF*BTN=HJQ5C60N:1N=DK;A2S'_MP2JW)*D62RWS.-4
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M%S2W+2<9/IF9[<;F=C,[,/<F+_^P"&C[?<R.,E>BV#$&<!*:'65NOL.+FK"
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MJ*"RBG--08L?O:&/;EH)))D $MT,GI4Q*XICT4@7K0283"R-1C)$)<S*1?&
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MTTC]R\/UK_]X4KY>WUX\*E^N[Q[/KR]OST$=7]^>GVV!A$CN5=]Q^7#Y3HR
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MM7"H?4IA^L;]?\% 6'O>%'[$>A$]A]=:YYW@G21^H'0UQ203'Q?WM>#;M0I
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M?NWU[C,$8YF?QKTSX#V+RH(',_8I;P7S%A8-%I2:#+=)1_:$#8"_G'7=@?F
M;SSZ:OG<W(K[S7HZ=GBV M]M(YZY*L[[@?PHM+E24:FM=1M-P0;"Y?NT9&I8
M<KB0XH(RV(4RXWZ52\%26_K$M_B6^@Q6!%@=^Z&;'1$D*G,MY(=AC\UP*X\'
M ,+@WR<99%0%VST^DJ.M.)51W4S51$T6:>I'T]<ZO.G+U=1MUSJUAK >;"]1
M X_1BI%&,?.8C\.C@: .KA+%D(24E?AIRQ$>T"X\$<#<FXE[N)R[XT$CN1S*
M/<TP'B%8!9(H<VZ>PU,],*6N\L6%/S+L%%=E8G?"1B$>V%QUI>5*2CM;HAN>
M7YP'=L)5TLETLYA;I*&]"([7R'68&^3&^T2OECOVE;_&U&>X7.E@A;:LP" %
M1XZ^K'.^V)XVV'KNVZ=HBT'XQS5[BMY>2-H(/^UDT*]'[89$.X)S.4T;LIC6
M;7O,UR;_(,@BU&M]1;B3\*,4[HB\>X/+^4FW;CJ[LJDU-4$(=?:6@1Q" %O%
MTN3.(1"E9.=99_#^_N;ZO/?EYE*YN[WY@UVX</WX^.WR@17P_NWNYK?+"_B+
M\J5W^S\/W^Z?SO]0[A_NSB\O+ZYO?WU4+KX]P)_\+H;[WN.3<G7]VZ7RQV4\
MVQLV.!X>)3N M&05;#B1)!*H)!O \^EE9N3$^7RK-66RF0]Z4MT^TY-E7OCP
M!AI&%-D/3=8[JS^.]XG]Z5/XH0)0WB,;Y@#8/K"\E[ W!/XY3GED0W@E\QYE
MQ@J1DZ00>9HA\,[R G<"RW'Y#FK!1^)KJ>%3T<9-*RJ4R2OJ+3]LG_S3A01,
M/^+46CVSA@T_4)40!,N!0'8JYO*?]S>]V][3W<,?RNW=T^7<Z9%LT%VSO,(R
MJ#<UO0Y_=#MS6U;)I;L7U#<\:\0HEV897>WGK.S@\HPOSHB293K3>&;*KBS>
M*,(OO%2E\I75JE2^6*YO6-0QX!G7CG&F?&#:["2V6WY4DG!V:,DNW'C,U-\5
MF#8*N^4Y^BV[7CK^B%W\W/\,CXES7V<NB%R^/Y%[)F//807I+]^'5M\*H--Z
MK&.3IZJ1\\.J,UHF]-P 'YKP.R?HBQ_>3@:*=:9GH?D5A(8R_6= '=]B@?&X
MPM],U.X&-/X8M('R@8WDGU\>;L(AG,'\+.V#<9?-!24X$9S=80M2LH3,W(J3
M3-/TLVB6N \7&O/@K!%P"]DLU^NG74V#!>N-*FPC8E8>,S/->\2W("C,Z*E)
M)O$>&GDEELTW G@ZL^<'IP& 1&&#"S.5_,@CC+="HE?P,X[>[,0G:V\R_)F!
MP?]?4".4::T;RO2,AU4\ME-@3]3E3@-O?5@[??BQG4SB@.\T*$PI1S^A[VSY
M)('K3=CF(7P<>:+Q7[HJ_Z4/O"'!V*/\QY$($B2=I8G<2$+XY5*PN]$>W!F7
MFU,A('VPHUYI&(]X(29=(EG4.H#6H4Q"8D:P"'=MPXDUN1[N,X.L[[[2,^5I
M4<BF2^.3. ,6A)@UH/@E7"!^ WC#TV7Y^LM?X(*FLEADSHPN[%K0 J!37EP3
MYHO];3SBK=AF-?C&L'8SFXR=I!VSS6T^Q(@<R1-2P6&%[1!^M:$"S2J[HSQT
MK?3?,ME7R4,VF6F+_TQC8,W93[.EI#5MP=):-JZ2FFRSQM3R.#9;CBM(2+A1
M<OUT^57OP#\_DE+.)2>#TZ."<[!6L#Z NCN;JR,+*^WU;>_V_+IW,[V'_E%T
MG#>#(5FXZW '2XIP(_V-E9R(MMM-4=K)]=7#HSK=/8L/P%_W'K^$9W)(^ "?
MV<+\"?RR& MZ8[+=;2^'\S:%3<N5:$JB]9[I5A^6-"](3AF$EZU'ADNVX%[F
M92GV+7915^LC2=*48DGK4EDOSXKO&4R0WDM-&Y#W?VM:X^Q?H^<3Z'#PRXER
MLK#7VM%JK)-QC_5&@\77N'>:-717Y+T2T3VE=U?*]>W%Y?TE_,_MD_)P^>OU
MX]/EP^6%<O_MR\WUN=([/[_[=OO$@F17UP]?,]]K5RJW6+VPT+X)]_. 1!>6
M!Y:(ZX5V.B^-,'1MD]G"\.U:)VG;._QR]?.RCO]N9#F1D1Z:[0XO:QJEX<:J
MYW&J>G:\J;#L(?Y.0XN6C$V+[W(-^8F,T)%E=J4Q.^(9%0O2GJY&(]=/SGIL
M<)1/(N\G<I3#\BT"IY;!B\4CPA6*_<BC-N_$FAZQ?@,@F9\*8P(K%O1H;+C#
MLN;/P/4'A04[@PE_O$' =QZ )^?/N=S^:I\[[E[2N]D[OK^"&5W764N]JWR(
MS?"Y&\E^#),JYY_+W+'%T3*WS5<^L#0SRH]*V>QZW0'UHC@M3."J%+L?S^+M
M1X<[I&Z(975U3EYD!( G:7G,[V3&A&V#)@?U:?%-.'999> O/F)6_C/RS29=
M?VR'4F0IM>Z(AA,5*AI^+:8\0K+"D#2L80Q!H9&5/K%)8(JES*C(MS18&?KS
MG$5U##8HIF!@T@,8J5\Q)9D,@FM)Y24<!+<RIW^W?"8P#BU>C2H\S9@$D_@O
MXTI5LQI,2$2>8\X->U;L:NSPC1XSS-V>VZ.9^SH*1H3O8M^P@[DT0C\!ZXG5
M&0@5"U<=(<Y\]MA9KY^_/!I<R/OHP<*NQH?Z+>?5M5]9)T'5<#UA\;/$H']!
M=3DLDUZ-#_R#&E.5.$6=OH,$S6?^M#/E=W9V$%[[PC?HXP.]7AC#<US%$,JB
M>L3XPM.IF2*+3(R*<>)I"$O%"D1$:=]1EH[5MVRF)N?7AA]8=,D!KX7]YDQA
MWNU">Y@>P!U]'_$[4* O[J(M%C](V(L^89GH;KCT<;"$Z&*](\IHW+<M8S:7
MG6TPSI8T34*U]V'3>$V;T<YWKP ];NV$]O&';PXWHK@YZ/\(QL[]>>_N"S-S
M(B][@;U@(]$16[[8.77VOFB!C0D7OW/569(!!5.&#7L:/K?)FY^L=].M1L4;
MVS3>[8W/X_L9PN_Q(_F()(X'_,[5JSGF.5M3T8NFD$>^DP4VFHIP?,K3D!43
MG'X;"2Y6S.&V-)L3T._,#IA1O" [M\\W5CQ>#8M//X'UW@M?/;,_OY(^ X]R
M<R31P$P,<1,U>88Y#C<G/'@STZ=@%;H>Z_P,=):+.3&#7X5/O7"%@=& >@8F
MAN<VPO&$9\+C1<L*[1.;[Q=ZKJVP4HHSO4]JG9XIO6G 93K[R2;,;#>B28+W
M\+W^I"9DEO>I2G\<\ $F96+&8+Z%=2 CU<&CXTO:@PX&X4(T6RERJE*RC'AV
MIX9-9J2QG*BH3?1BB3ES-TN3Z%1.A .^H>2Y!C5#TX Y'#X;'5?PEO_=7PG3
M9%M* /(E"'/D,@AS+*NSU%KL F-@N%1$%@\3-^_*F?(X#C<XX\;)<.@[3)3#
M$<.4&:R5?A >:5(5RK9#&35!,Q(NR9#-+Z%UQ+HR:QY%^R&B887K6#25Q/;=
MF0Z\$GM,DE-3,PM/=)TK4\_\\!1[']N0LP:@NME6#TB?37"T'0,NPW3AY&%=
M5C&1_;GP"H98YKU%3AV9==#$G?^=[6S9%GV-]-R,^HPVC7E=XT2I]1,;9L:]
ME!CG8'9]]#\J%_3T-\ I@.]7#YS FYM[Z<-PY__H/41QQ(>[J\O'Q^N[V]Y-
M'$WLK=B^D&<(<9@)FK^&4?EY=<M1QHKZL%LEN<]>,8O^-Z"3.WYEU5'XY@FI
MD"D_S3YHA($3N9(PQ5L/.1W1#!LGIS.+/JW)>YCZG,I>#_LP'S6'<'XRJCR.
MQ63;?E\A,#F $_9E#7C"!ML B/]2#A#-[9<\SL7JIR'2^RAZG %-D@WSPV5H
M\XMWS],DM<\-:OTAN-7G*E>=)&/_A5L!!5)BINU\CDDI]$BU.1_U,&PDNJ1P
MZ5!O^/,"E:PH@:4]8/\WL_4_CY[HCW4869B<:+9/O6CI/6NPV8@_9=>D)!^N
MF( 44R=:[-^&5D!/F?!AR([[YI%1U><RGPGBDE@U/W%7Y>I5<6;&W Z;R*R0
M:R+D%(^<O2KL[J4YQ$B!EG0B6+UZAUTK9L5;>S/O2ITO6B *$VG/5TBP@RA3
M3<>JD>Y_[6)W8P54N#&>'Y[7PV"/JB:GCA4GG# J@K(YP(X5!!H6PY0'+5(N
M3MG6G2T M"^_9^_6F 0=*$X7_TTB%T&"B=Y[!PJ2]-\J)6))5*?@K!=MT<%@
M4+(U#S3M/3Y>BK<ER]7@(MM^]33ERB>!#2+GFXM#03RF0C1V9>87W[SBK7)H
MS;)58W33C=+S?1KLZO,7HR(+1D[ACS\8C59U04CP>$FT3&K;3&\6NB7/CE$E
MA]Y8/NXKL=FFO'0Z:!\F2[=@4K.YF.8]";.>REJ\XT[4-O2B.%6Z\:;XCMYB
MM:R:C>:?S7I<S<H:>/[I8&S;GQB4>X[)_KB<XOA$\6$"*,\UF%X8K^UV7?QY
M[^+DL]Y5VRU-A0XM719?PGHP!YU-0BL(.@C?:2F##-AME8I=383==K>K=FM=
M 7"K!5I)%O,R5^Q'PLX&!.1=8=>A E3Z-I5NL2Y-Y92H5V19^UJBM2_T(9_(
M>^A%)K>G%K;XZ9JJ-UHRK'S'CK7%$D&9L"1:BW; TK^IYYJPB*5=ATY7KT!2
MH*9*"3J2>)3WK/:895;,@40+62X'K[UZD8L =OD^HHY/BW3P6AVUIK5E6.,0
MNU7Q[MJK5]0B@"OV[@"W'1%NJX79"BV^TF\QE)+\E#D=K812C(5NT!0P)84Z
M'07T5UX_N;/:A @=F^(LAYJF:O6.6F]URC(>BD9BWGXV,J=4YF2AS6H#)D?:
M".V6#C-<=%%0Z7#Y(DD$6Z)4P5O7.:U 3@RZ9'L.)Y26>H/.^%:2+V,FCLS-
M+#60>^T$Q'FVHGJ%5,*4H,*&WB@Y[T?2G:4BO3-=$[AG4\B%"W_/,7]U7?/-
MLNT"G345*"=#D/?8-S(+<VET3>#3%(TUH8>S"FL2XFR_RV+MK,:61=,=L_4G
MO[W/XMV7I[LG5HM1DO-.F?W<%1._1P>HB"'LRYPN8BS2.&295+(N6/[+",LV
M-*G#LEFQ6Z(3ACRL! \SD5!@%Q4>Y.UHT@9Y]\$^20+ 99M)LNQJ8_*R'*)$
MASD65$EQTTII)XG\NYOKWI?KF^NGZ\M'I7=[H3S^H_=P^8^[FXO+A\<?E,O_
M^^WZZ0\IU=K>@_75V+8X0#V)DL<-*V'W*V4QQCD!-Q;A=\)9.Q?(1/,1S<>#
M$]0QFX_EG)\J6-5%US1'?_3B:UE'9!+>'<@NCS0,CUT8;,^JPJVY4Y1E7N:.
M?1,K=4@:Z!>5ZGCRB$E[CGG'+OV+3\>$^"XP_-^J=]1FNR[#5O_>[=#CAG F
M_ IBY(7C5Q@YUYN:VJV)\%LM[%;)*-A/]L!,C&G_+DZ1Y[[D/J&!)TIRLP)$
M14MF'/F#6?2E.5<B27^1-5L;'J+:+'E39M]VAC1TD22FFCD&4:%[,.3)[9'!
M*]KN6K6]N_Y[/DXO@T^-^))D-BOHB\KB9CX.B4>'K@U3[__ RSX'D_U[FKB9
M)K=^QLVTO4Z>)+I*SGTRKM$4@XRL@-C2J;%]6&LMW!*3=$NL*SKZZOMC:IZ'
M^"WP"$Q;U5@"?D?';;"CAVTFS(J.T.:.66$\J@N ;;5$@*T66"59O_>Y2(_[
MON%9(R8^7^[Z]0>R*!^(6_,ABZZJ34M+F-[X^=,<ZAX2T!6WR-;K:JO3D&&!
M+5(F/Y8]G@.!<T8LMTK#LG@S2(Z*%07)XL<L Y%D_9;4_Q8L[=24;F%'1[QB
M'LW2[2;9?.V:OM$6H.:N5YL(C0#1U2;]ZC@KB,.2/.N:OG&%3XG0[=;W1EMM
MU$HIQX#.=:$K\ .%G[WN=!($G>F#]SZRKI\U0:R:I[W'<"OP_AVUV6JJ6E.*
M^U4/<W]3AO6O)H@LYX\P\>+7TM6Z#.ZMA"O< 9ZEO* #R[ "*8Y39#XL47)"
MUO;YWM)V5!+?(&LTNRY8@1]H0"R'FI?$<P!Y6ZE('R;EEY/3M*MQ5ZUI7;73
M+.T^O)TSO_<DW:+BXDC,8D67D94"JZ585@HMF&:SJVI=T5Z39/C;DU!E#O!7
M\&"JJ-B9LO_$83RBBH?M=HYT- 1VUB7/C"\PQ-%5&YJNMKNEQ3BD.7$G27^1
M,UL';AH"$RA'PHBO-JZ!']+%LZFS(\&;.%+6TI"X7BO>TR&C"WN(]P-DM(I$
MY;M")=]SS%(J>."M'5*/!5E9MMTEJDA6&"7Q#H^=+#3XAN7GKOARM&"8S=EA
MLSW^U]@/K,&D. #>DF#LA<5%&00L9TP<@RKN0'%'U"-A5N>'6S>@BKX44QNE
M'-[4[BQU;"RCBOXU9K6CZ2MEM52C@312CX0+,7Y#K"LT[>\)^@ V-AGY\-+X
M;S\I2ST!B\RVX4T&F(6<B.S?D9G(_EV>D<^(SGKB_')27_/:J20+-$=ZHY'G
MOE)3 ;W7IT-B#QCL@B%5OKC$,]D_+BR/&H'K^9]$*_X*H26=E\BY2C?7L<K9
M:6 +O8M V_C[U#'9WEU)-8SXS2*7)-U<%3@/-6V_$Q&9'27.0WY CZ'4RF4*
M4T512@)<8=;=YY-K:/#5N' =8ILG8#CEJ\562 C)'LY#K42D3E=6O?JH[=G0
MXG_<?UO?W3?_NY4_<&772JO]CFH+-[:H4 M550NM0>;!J*!"4+JSLU[F$0=0
MPD_@"1'#<%^@X010HCC@O/H*X>ZZ8L'[GSUB X:\('*<?,J<> X*$H!C-; <
M\.8M:.0'\,$+\X'/,JCRGTWK=9V2SL<Y#ALG?O%6?G+8GPV+1MAHD9YS/<Y4
M-K'(6'UM6M#M?Y5[\IR]5,;Z!78MXC^NE/O/0V^Z^?5,3_L>)=]/R0"X\$DA
M]AN9^.*]J"&-%-_H?1IT#6=^*0;7M^$C ,;'Y3X(NB;Z2-C_U6B6"<E;F#Z\
MI_N.YGSAG%"^6H[I*U\LUS<LZACPR&O'.!-$;_H>R+>@[IS/*L''1/4Q+7D.
MZM2C0^KXUBM5;ES?#WORX?(=/O=]^('E*.?$(:8%KS"9M#U_,5Y89.=#XL?T
MEV#]6TV.)1LA UMFVO*X^]2&D256FF)-6&FSYE&>F[UPV40,/\VW0/?;T KH
M*9MTD([COGED5/8&GFAKKD*]*DZO7KD>CXE/*/%"O4,=DQ78V-,.>,4%)6>O
M"H+/2NP@;@ZC5P7C9@3-75,^Y)2=/IGGTIPU_7<KZ*4R;T26P*K.E[WJL7WZ
M76]YSOV86DF*(:>.%7B) !V!1]6GGE+7U/ 44.@0]3^SK"44VT%VK*@DG5DP
MA3ABV6<(H(/K6)D TKOR $C*PQZ'$;G8NUTN00>*6^?_)E&008*)WGL'"I+T
MWU#$TG0 1:S(LA3*=*+Q\I_WE[>/^5\*OLU"O<>3A@)34\XW'\ ];U+/+[X9
MW[S_-\NQ3I540S'Z@Z56C.V I:,-:+XUAW-:C+#JL$P%8=.=.J]WM&ZWT_JS
M,5^T?PJV*YK7L59=T_3 77F#3[>AMFJ27.&#A8=S/4>=@*RU*\A67PFA=Q-\
M"0]0BRZ'0%0=!*JZ1:)*:X6H@K]5%U5RV$O[<-R$IE1RN/D'A27Y4\?GQ^TE
M-*GV<GF2VL;KD^2J#12K.E%IH 3,#_1E[$25(R[?&:ISNJ1NO>&FUUMJ2Z_)
M8+CA%4RR5]1)@"PHJ+,SD"ML'")R*X/<;LG(E=P Q5C>%@;HE>M1>+M"WXTA
M<;8X8EA&, _=U=QO&(F52$M@Q_U*+,=GQ^*H?P?*(P3&A3484(\?Y[MSGCSB
M^#97+@_4<)\=RZ?FM7/ON0,KN//8;TLQ^)H-%88A@\%7I$#QLNWB%].6P PL
MCP<5MA=1.Q>%2(%Y)P<B);<#JV3L21.(O!JS,_LCSP44^?'.KG(*GUBO)*#*
MR"9&>()>0@L1?=8*10[;\_N[]PGDRMK?U3MJJR7%O;*(VZK$6MJM@D&[R<YK
MJDUA#7S$*^)5A-?NKGBML &(@< M#,"OQ/M.6:Z"JA"3]\@/_^&P:DBOU ]<
M3_%HZ%K(: 1BSI],CFXVF[ CB$(^@HKR>XZ9 +/$G>1.LZ;J35T&&Q'C*P4M
MD1U!Q*](S&VR\+IJ2]^[A8=H*PIM@FC>3FBKL'U6)2-,F@#=W6!@&>$E/<1\
ML1S+#]CN_JN,.[;[F#1=QU1!.0-^7=$6,V7)*38HO]X<F,O,%NRV5;V&<4"$
M<Q8LB[:)B\?R)MNQ56_O>U%'#%<&PZ*-Y1PP7&&+%".&6UBD+*> !979M5;'
M=Q"X]*,I!^$Q9[,<=4U@.L["CNUFE&@RMK6NVFWBR>#*P2X3Y@0F7H&8VV3:
MZ5I#K0E#T8BWP\";P!PK%&_K;;$ZK&Q:1>+0<EA=TH0('^CSV":!ZTUXF'!@
MV6 [26B4H:M8H>B=KL_GZTU!!L[B%8=8I)U*2M[3U7:C+H,)AC"N2L1#UUME
M8GAS+E]C_P8=HK<ZZ.WFBEZ,TZWN73&WQZVO%B]%,.^!^I1XQI!;CB9]I;8[
M8L<])#0?BXSIJ7H1MTX<O+^;T:2L"<)Z,0!!IUU,X5=B<*^EUO6ZVNV(?%\,
M[TD-OTS8$X3W"L?>)HNPWFRHG::H<A&B[C!0)PCRE8"Z]>9<HZ8"&JL!NOT:
M;K6S&C/<3'?,KD'>9+G)=&O +0T4V_5];M<9<Q=?LX]EN$Q@N_N*#[#T?K:)
MV)<SO=W5I7N/>6:JBJ/75VP\6\&VM6U\F(Y?3DZW.(NBMIJ:VFZ5%O/< 8;[
M$V]1-7*0DT4)+2,A5^S*%T#(3<9ZHZ.I]78I"9?5H^*/<LT"<C!/#J[(5"B$
M@^M=EW9';>M(P=TI*$D*A=@MDN$>TA6N7]%U*C-VH=  2\:^E!MX+LTCRRJ%
MO.-I!X8(269&IKZ@E#!,N*<PX1?B6T:X]VO9XX":8=!P1#W%'Q*/*A(%"C?,
M]AX3#K-W<,_.2H:>RN&P9 [DB>XIX6!GNRXAU"^)YP (>5W5>^H],KR+G9E:
M$1&^/X%D?W*2G7S6SKJMDL-\VX+U8$-]R%Y)P@VBFUG*IN[Z6. \=751A%XV
ME%8A)H%\K29?!>'!\OFZ+FXXSU=-=)!3-I16@:]2QQ ECSQAO%+*N(?DJ,%(
M6.F(D&1F9.H+2@GCE7N*5_Y.F?"IJ1#H+'FF"AB(?>HI[H E.;Z J<K-/%]Q
MQX$?$,?D)Z'[GQ7XK7+:7XQV2K2(8W3S>/VMK.=HVH+@9LR,7D@,[F(5?3([
M].,^=]1NNZ%JM;(S%8ORK9 [5>).)N((0HN%$6=-##$B3IU=6ZXVZJ+8/Y(&
M22,):03QO0))LS*0%Y&FIFKMNEIK:$="FM6N GQ#H!\KOAS%8ROS*/7/UN>G
M(56(P8X<$6?";A1TW  >R)()X)<6O/_9(S88R5[ S/9@2'W*8,"S*PFS[0>6
M0QS#@D9@P@?A[8-G(.TE 8]6#-VT7M<Y5VS2XB'$1-2TOR?2!C'99.3#J.*_
M_:0L#35JS/%M4-N&+ADPVN3?D1/ _KT)A1N<O;"1N:['F9*/BS1CZ],PU_\J
M]V2+>\77.\9K$?]QI=Q_'GI3G^V9GO8]2KZ?D@%PX9-"[#<R\<4NUI!&KMWH
M?:JTPYE?HG7?AH\ &!^7^R#HFN@C8?]7HUDF)&<)6<SV= ,Y^"]'129 <4XH
M7RUV#>H7R_4-B]^HJUP[QIG ?>E[(-^"NG,^JP0?$]7'M.0YO_'7!_6I\&5P
MZ-H@,O^__K-3T]L_*9=_C:U@$G;NP^7["!9CG[+[NY1SXA#3@K=>, !X_M(&
MSPH=FDQ^$6M3J"2*P71G)MX5K[>1+BP)WDM1H88H*-3([VCLO\9^8 TF:P#6
MR2\L%\]I>\#^;]/>1IGG,5(5W1$90PQ(K*._G.@EGPS:MLO*V] *Z"F#,DC7
M<=\\,IH=1V.SZML6"_W/7 &!8AE9 ;'W=ORRJ*FK-@0JW??B(+OGX_LHXX/H
M.^+S\&5<Y;XC/@]?QE7N.^+S\&5<Y;XC/K?*%)4D#3C-(%'&RYL!<C,VWB\M
MF;"W<5I9&%,-D\JJ)MM*JNA#[7K!\;@0IT;5@G*'*NT*=[U H([[ON%9(Y:L
MX8> ]:A!K5>VY8.8Q:Y7";,[)X_+,G<5%GN%NUX<8EEY<>\5K57LNI3PO* #
MR[ "1.<V\8L#Z%AQR'IR"W=]BHFNR!% VWM17.P =J P_?"WO9<(EF:&]]X!
M%/'!=Z @$0NO,$S]!P)$G@Z@#CCX#J"(#[X#*&)%%O<MCRHM>7GB7XA-'(,J
M)%"^DHE2UU6%G>=5/K"C3>PXD^48KC=R/<+"ZD75=97A@/CJH]_MS">_\Y).
MBL/?W4:MV8&__UFO+9_]#G,C[@;AH>^[::&=V5/?U[=7&6X?;];U/]D+V///
MW9>1Z["#;W>#\%Q;[]WRDZ^O?7],S>CTR5?*NK)\1EQT87FY&"NQ7 +B/ ><
M-Y=Q'H(O55&#<L#-;T!":".TLT&[LU=HF][X>783_2')^$!\([[SP+>N2PAP
M:B*\$=ZYP+LAA6ER%PRI%^>6(+81V[E@NRT%MA]H0"QG>DT!PAOAG4OP1"L4
MWH<)4$G"J:7&3.\]<(D"JHQL8O"B3R6'0\NC;7'<S$#,1A+59,;[IVO'\"CQ
MZ04-_WP: GR?AY%0[F.9Q$4NUP0Y,Q:WS#7FV5"U=E=M::74Q2SMG@)$[12U
MS6U06T11UAS#F36MKG8[B-D*83;-[6!3T';* FWJN\'RCEAV=#D07)"XB[C"
M[\ 9DHD@T_!E[@Q9ZT#DP(DL04Y4YP<!UD8%P+ICR!*1>A!(;5<(J=L'(!&L
MAP#6::!PWZ[=(N:@HZI6E9B")*%#63(Q>P9H&M_B\.-)EP%QGBU67IWX/@U\
MS+DL:=L@@RIHI@I-SDCV;G"=R+7'Q2I[G%*30:'@/EI5")$JZKF6$+*'0)$/
MR(?T?$@54-V=#T7'CK)E@"(7D L"+J2+G<I/!FD#J4B%RE A5616)BI4*4R+
M/*@,#U+%?67D046"P$B%JE A752Y=-?Y,/W?DF//J0K229';>DL#Q7;](J+-
MF:OR%;K/M'6=Q.(WHTZEF_R\=Q,1"@6L("W!J?A[SQU8P0T0>D]FTI9GY!'_
MB/_,^!<<G=\;_J4,HR()#I\$HO/UDK%@K_%3Y, 1<$!P"'_OEI L@5,D0"4)
MD.D<3TMT5#\C XHZL),M@-KNJ&V]71%>5.A,#_*N$-Z):@B4Q#MDSH[,J5),
M6):DY=GRL3ZK(/M(1P%7Y$I="^O(5N?NH'WM6Q5X#5*5"K"T<ZM>NWF+*_]R
M#KJ^JIQ#)>%?XM8Q,OG@F+Q;?=X2Z1M5M6BNJ F U$7J5I^ZF5R8]FX%B#-X
M+V46]SA((A>'F*(N>4!]405]D4E=%%G/N90=IDH"'==X28923<X66*2Z^!TQ
M)"P2MOJ$S6:4[UAZ.U^K/*<=O(/D,=KDJ"[VOK[O6,D\5?QMD>:-IEKKU(^%
MYA*>,<EV?&1OEY&6D4>0Z=K0N20".::EH"0KE!!*""6$$I)D6E!"*"&4$$H(
M)11V0PYW 3,+98AD5#T$T<5<OAP A_5;J@5Z3'M#E%<2Y9DVH[J8(58XYJNW
MC834RF$!P60J7#D.&=Z8=X38K@ZVLUE%F*)3-.31*#H49F4+)1U\-LOQIJ$4
M!+'H[C5E%%^^AK?B%EEP2==2W8.U>"->'E=?Z5I8 Z.FY1X';M7J:K>A[[O6
M,5[C6!1H4]U55<PUCD7 -C3EVEVU6VL@: \5M*DNE)(!M)DCL]J*R"P"]R"
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MM:4MYX9U1O-/5)V]2 M/[/^! U@K+0HF93X'0CO?-5)4_+W0",=>XQH(Z6.
M](KTHOPMN\[>[#G,"\*\H(/<PS\^R54CJ^%0\"7';%:CERASV62^WTA+[:S&
M!FRZX[Y-Y0RU*,0QP^0A.C7S5(6&Q9_*B[RLF*I]&?,INB-Q[$54KKS V(LX
M":FKMEN:JNFEE8O:$5$%.ZL(\+S<55&Y<GDBBPAKA/5VL,XW"E.MP&)AJ,:
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M';,4#:ZYOHQ]F#7?!\V>J"=?Z87WM<%; LL?PG?V^*5O$79?VZQZ.U.>^)K
MW_.#K[C]?U'PTU[9]CY3<<_488"G_.4OE*M+8@PM"BUL%_P&L+M>E)'G#JS0
M@ $CZRT80L? V'H>\@Z:T-AV1VQQB7P)#\@R!E>.O\)Z@9_#XUA3&][LLT8C
M& 9;C,"*@Z<9X/@14$D^/,D+.V%; PJR@M<S[P4@Q&XX! ?DSE&N:-\;$V^B
M=$)EKT;K'A\C\U8\-H&!1TQ^JXD3?AUKN\< T*?$=^PH'T[.'R]! -/Y]B<O
M?==6+AZ^_<I?QZ93;V=XU=W3^?_]LOS +U^_7%_Q)]["=/!E)>T ;GN/%[W_
MNZJ/3,)#2E@9T8%E4)7/WPCFS;!&L/*#1<B4?B2:Y#7,%00B<K"10-&;FJ:<
M GB;3>5WZ@?*K]0%]4-@OCQ* U7Y#12D.P;YJ$N@@R];ETKC%B:)3S,YJP9%
MG])YO<J0 'S[E#HPJQ1<9F@'0B'*LQMN"P&M/0=<$!\X]3:TC"';/!JSC@5#
MF-K967^S;!L>I7 N 3G \[&A2XH%KXEVG)CT .^ 3^\Y_,*V2-^R8<XI4Q+\
M>0X+X]CP[K'G<^NE'VN)060@L9L<?4KYBP9CMM:=*3V?B7K97)H'((S"<8.D
MB^&4 ,V!!_!/]@<+];R&_8D5@9LLG'P PU"?C3TV602 %@+P;YNC8&SE;G3J
M6GVY1M\]5T,W\*QMPEL^@.J7D]-55557;[1TU%934]NMY<2#9+*9-;K2&)W3
MP7QF"'0:J&H%Z>>D#01MM);GY($RS4G-2^*Q2YR*F)G%^>BJ-:VK=IK+MSC"
MDQA2V/_PC$,.!8<^$[[B1!!AE&%5D >V^^:GQ22;M3?7^Q[^>@2+D9UA[NIU
MO=6:LP1_#Y]U'CZJT-J\]6Y7;7>7:_,J'Y8&S31PRB$U-+W9*'I(XH*LM;9:
MZRZ3X<<0YT9H3O.5:ZH3!(N/24>4FXG*>,2&R50?5W-<S9" 6P0SEL>"ADDL
ME\&865C,ZJ#,NSN#!=LASUQU\T G_W:JQF90R%,;N0'"*G+#>R/M#S120641
M>!/W%TW+ Z/)]<(7AT%5IOO84#UPGL(B)W.M/H)B@"7XE740C%^#QM;17!)!
M==9)Z+?G.N35\L8P-X E5_GNN&\..Z%S<G[WV_7%J=X]43E/?5@E"3,C/:;U
MF=B?;;<?FG6PMH ]R! # @!"VR;X#E2A,)7N"WART<HR.5-^!2/)<_BTD7$P
M=+UPO>%K,3S"YC,*,P]_PCKI&!/E!4Q$6.:XM%^@]3.;?&XMA1V*,,C'$&+5
M'0<\]IA$"3QJ<S,@^CFC7_+4%S()WPY314SHG$^CL3!K@ T1=%(R$/C3M"*T
M L@H+/OP9VR,)O9XLFS/+*G^" @Y8!LA]B3I$8QI!-/)4U/ .O#&\4&I\(G+
M5+-)GSD+,&_P2,ZPMR%@>9:%\&SX4HVR>YE$YG[D6\&8OQO>\4H\RQW[?,,@
M><4WT MLQ6.64LB-R[$'/0DG%Q#*A <=#VVB8!Y%?#ZC^=L\)]QN"C4&F\30
MH)GU/& 8_IA;7J%/,@ZG(^YJ+&F5F=7P(QB['W@6UUSPT^25,U.K)JB@_&).
M6,*<R(X.-1Z\B7RG3A)+(?P'+M-$"L]/X[,(XV=Z@BDS_CSH13C@R*?ADP50
M@J$P6Y-IQB%XCB#ZL1/[1=PK\_D YY=%@SC,5#,I<]-@!.Q+RYNQ8J,)YJ]D
M'A_0/HO261>"^3@7@RDMRIXB\M-I=NK-[K*M-!O^^<*L];O!/3?H2;BSFD1+
MI\'2_4>!R@[OU(H*[SP^]9YX.486T3F_^WI_<\WC.RS>\Z7W>/W(/K]_N+SO
M/:PLTRCM^IC*CWSCP8UP,?LW:P1&0GC* A35!35"6[#6B&+88%.$>B*V*^:-
MJ.V-!U$Z9]DP2R@6&44C<')!W^TD]/G@^KMX4,L1]_?](T,088A.VG@FMUJY
ME<J$?\UV0AVNL. 1T_V=!SIR/6Y5P<PZ)O' ZOUP<GWU\'CR8WR:.@+4_".B
M7.KY7WYQX0_V^][C%_@]6W_XKZ!WP;R9L;D_BS]D:2I6$% :]N_Z_"3R'&9"
M5M,^C6#B#+:.DA% ))P7OI\S5=S3! ;AW+(5U:<!,P%@BL'IS)$X&S#&D:C7
MBT08V]WD@2<65)W.R8'QZ();?C,Q5HX&@_N%#.-@SH$'Y]'($F0M(KN=JY@P
M-#?VMX&/Y7-'454<P% 8KN.OY24+5&4P4[[ @^\-YK;P!N2%83@V[T3/5L%&
M9I&2)(SDSRG%)$BB<@S#(,+ 8Q#F]GAC>!@?V:%;="VVD]$0W9TZ:]$]CE\
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MGYX82O(>*\ZR E'QM<[W6"( [\2CFF$LNA?FF<-+[JFJ('*@(ILWX5>1%9B
M@_M+D%8RZ]XLMJB6^2)76+^%+\Y!+8-HWFYN)XD +W#A<5GBI L!)EC@1'M
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M,)$NTB>7-)K/D[_IP7: FI&\!8?FHZ8MW[<(EHS/>A4C)=9!6,7!9AB>GU@
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M\_V*T79BX5RA)\3>@OTCS% ,I#[!+Q]L#"]1(#4DM9AWE(BJTA[=?J*=%?.
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M .L\@J5"?YLERD0^ (YR%G]%6W/ND,3Y]I,#?!L)F3>=VA3CYT+]P0>5$,R
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MA:ML%0V):-WOI'6UFA-Q!2KC3]$O:YM0OHJ\7'-7T1#5LHM>:6S^K7/LZA/
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M!A1*?^#U8(@XWH39GG% )>D-4@WM5<<=>_Z"([F^1=)F\9A.AXYO/OU<^':
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MQ@%8Z_!BX8L'?/'L[GR0<V(R.+H2F;>PEG0+\DO(IV!4H/*&I32WD?I#69J
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M8\1!'>YA39(UC3)>Q)H4%\<-01S;O,G$NV6!,V'BT8@;^)_@W+5M9$@XE)V
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M)]+KWET_PO7/W=ONKY=X?0LK]XAU#69=E .WB3^&E8&[ L #+6^*WSY3TQ?
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M6/&P3'TFVUJSAJW6DZH#'2QFZA&$W?TRO$<HF>M[(Q<?KV\<_A2K[SABIE1
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MPI8!^VRLL4J9SK6MAJ[I[48;%(G5VO"U!7H->Z2ONRC$L]Y?72_6>Q>&T-$
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M-GF'-W]WT_WNO40O*D;R3]OY=M:G2,N!?! &7<.#^E.);\'37[AI KK9S]Q
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M&6I_<,>(BF,/$19'9PKJO*I)Q"&+/!:)N5HJA +&$0\&A=$E5NSP)'87'N7
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MH'AZH#BG<M1S4#GJ2J/+D[R7@(GV"XE**1!95">L\*BW9>4.I=@I#-MF(N7
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MY)ZYC,(T2 P=;VYZ%?)WBNW5N,4 &#_9_M,,&S_#0UH*%A4L[C"14L)B'I'
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MJSEQ]1?Y[4+0;VYN-XL=(LW8S,X)?F\DL>Q9^CRW4$6#03C)=P1WWZZ"3.E
M+ )M_G]4YBJR:;D+!87$"U]_?5:B^>Q+7\1[!XWM!6FS*H@B),4P3R)#TE@=
M+>O]=](@4B"+%K(M]D:%JY@Y%^R<EY07[ K5T?FR*SE:R('_?+#_>OE'"']<
MNP?UY@]FEH;9GSY(6'XW)5=Q34BGY@6!NI,FD0?ZP,0C1E_?_@MPFL>G7B1-
MS/%G$%</?>^<. FF^<JA-TJ!4\S"I.7R3=VZ&_F'\@!8AY*#W(9FSL?T=/53
M3Y8 $]3UP)^46,\ZTX!4K8Z9X_51R5*B7[H>%.AH1FF2"_(I>"=\P7JT/XS_
M""XV NN<KV1UJ_P*_S"T!#S"E5+<QR%H\?(*8 +N*E&MHX2'-GF0H<6P4_*#
M.T94"&=;K.#)Q8;P<YU:M"K58/$?'&B@XKB>J53VW9<^UK<X=3=8\RS#G21)
MOW2Z)O0H4%Y+!IEZ34O'KG!(JE%$W8YHMF9X\@I'()NH.GKK5!2E=/F\OX(^
MZ%6IQ&:.DT0PNV_-T-RRRN6[+7_ZFF9YG85Y?EY.+\";X/E5AZY*H);<LM7:
M9AG%&)#?;)Q10\#1-;V1B4X/TT^>&0B;Q+I@(AGT1IV^A'1E[&QGFJ("M6O%
MIHF@3?5E,ZGP+2!GQQ<<+F$7!W!U0#/L).J3TU+>(<I&!L0%4LZ1DOVUJE=4
MN[&N*S''FX)']+U1;$AQ*EA:SBQLPKS0IN.JDO%,NJIGB21C]G?C;VT\1Z(^
M#!F9&Y)=*PY+U+7%[!V_TT1]0,7#/&:8O:/6FJDZZROCZGYLZ61+$3U7GFB_
MT=4UQJZ-F_&8UHZVT>+TYZ2C;06(8$E  &)6H VT,#.-.9%;&RDT,XF>W^J4
MV<733='P?N0!K_9LTU^_8"$"62*4DB#2OXX)AO]P-8:QT9$O3KQ(,&'",7IE
MH(710;7D;N6"6AJTQ$">U%Y+H#"&&BT/I,@#5 <'S1%WN17.HH*_EA)M#C"]
MOLPVL'K\3B?U>(.#$95<%K S(E5(CJ1PMI1R/N:8$\_./GVVM+?H".G*?Q$I
MQIJAXZ/C%_"UOZZ?U8V%+>G[VYZO0B'#W2'*-:WTD.P:=\710*RME4J@,S07
MX[=7O12[;2EA4M0T6X\!4A(2]K#$I0/V4,Z#W.!$<GW?4$4Z">>O.^?MI*BS
MSYV;QFVEDL_5&'-$!LJ;)'\G?:IREPYFH7&1?06!%.; >5GZ\V(3Y%4$I[IK
M B(M:([U6-($#71^Q:^]=\[5F-C[K>TOI2XC/^Q]2G2T''7"7X1T'/(@0%'\
MW!D*99_]Q>[9-4:?_/UM8+YGESM<+"GICT-/*(H_#'Y*!WJ">!?*@;2L]*3*
M>5>Z0,] 5Q:Y^>=EB">EP5=Z<6<QW&?)573AKK;N$HK"5LYY)"-:OM(@9^=M
M)5(6$@VWWF$CLG6GU;H/V<8B0R-/[=.94BZ,Z8SULF+YWOM"^OX0+]ZMHIY<
M7NF;:PC8!*SR8N DA:NBRT9]C)3>JUL:#0,(_KI K6T3[+6V(][G]*!G"?C@
MGG)?,WPV_ERFPMAN$XW_M6:]RH>#T'CYO=;K,DI]->6!!)Z__13I_]0 (/@9
MA@N%9N4I2ENKZRT)B*1U*$GD:D5K==B&<E>)T?SU,_NFM#"X6H$?45';$WIQ
M/3A+4+&J>H$+(*_K!C(C_WWXT4DEH0(NY9"./]R-?FN8.I0A[U"LSD5RSF+8
M@5U@FE"-6L,&&X#]U.I#4G;?)/"W#CF'9EQ#."77XT]!MHQAZ59,D-AD>:UM
M8?* KN%0BGF[Q1.EIAN.RTPU[TX"'6>5[FZ1-;ASW?>",F]&.SIVM7U,. D@
M@/QZR'C5(\:7B=W8 W]TI[H^N<9Y*<\WWSG#:;J93//GF/L2?IC?5*@7'H;?
M:H_:>N;/,W7BQ?[1WQ*4;X?Q;*H9@\?\>40R#_6\[X*-QW(*25N^5<ZT@.D"
M@H?HP8,6LGJD9BL'V:U+.:$6HVOW@&]7'&8?JULW&SI^J^OQ:><-(_5B)+2.
MH;I,4Q$[O""_RR#S4 QHNTYB_.<79D\ &7NB-BF&[>>KWNSH$V-"[91>]=LA
MN4S0)QBX\=1LQ#:& P5#^TG^^T=Y/B_*1.)*5>AY!MX! (#19S8])B8W*B3Q
M.#%367#N'A:*J5KQDEEOUSS;1ON<Z=%L&[DL/VP.QEUE'-J\MDA%]MY8Z$O8
M-8.%&TW?HA2]7VH O2I7'=/"N"+*+"C7DA]@S2*IV@50]6(1_!-QB9NLG=E&
M]WTW0&;T'F!:%9#X<@ZD4&+I\@>:WE_IW-#]\XJ<"T;H6>W@&:Z'3_(<^-U-
M&#8Y!;97B,ER^]SV3OA&HU@@.R@T/;AD]:=QVL88O8[<%%7:4%/C<BP&G5Q>
M3Q*J&W;6BP:U+_[1BOTLP.ML:F1@5E2'I%E4@Y[G^ST %Q",'\N@T*='<&.'
MT$L&J;E5+F_J,(,]7<Y7AZL.<JCUY/DCC\D*.<X!ZV71W&A-;V5J\J2.T;:)
M;,T@<Y\A,NB'4NJSTP8AB@&?A4^491+X2R)Y679',)B6^\; >,T((PA\FA3E
M/JV^! 763_D0Z>AU0)&6&8O9JR)Y7T8R^A^UO<N%PLC?!,9:AQ;H?4))C1PK
M18#PMN,4F5U$40FCUXKCU]H++1VVC;/#'2J<HZMT\MEDOX-+1!J%UD22,EKA
M:<S3X(!:#431I;9+CK/M;64P<X%C-VWMNK0<143TU"R:-%W?H;H79#J>F021
M==)L6WW8FN>Z:I\ I(\<CS:BY?![FKY&.]'Y&$/N QBPH)=<B%<$)QE4\-!J
M2-/XS,>YE\-[1/63F*OM;7#HI?AT*[#/UP,WH'DTC!"BQ[)^8+H4>U$0/"QK
M61=<K@KL-6B9==U-)N>,?K^G1L#99TZ1(TWX%E]+L=2Q2WCD'H!F@=)X@<1;
ML@[A6OWA?,5W>19_-[OFMY;OIR?^I7_)Q74"&Q/],5"U7XD,)(9D=:'."]:Y
MG&"GZYZ%Z."YN7\BNJLKQ,MZS8\E9X;)R$BN0G6^660/YY'H5AJ.G!@JY$<H
MQ=R\SO%SJUZ16;!OS7F>@><H(LHQ)T Q<>9N<$VP\]80[(F02E2"22-':JM>
M!]@ %:A7!QB<;E2KE\<<?8-Y_1UBI'?5,L>2WIRPHI\QE49JSFIJF'G"D^GG
MABZ#"',NC^HW^P7GJ4/L,VC'8T-E 7;ZF4<C+L(DJ%@UY&*!PF*1O&Q!.>3G
MI?L(&Q5WI%'"JT'BFL-!!62:9CV."<+N83?:4O1.7L.Z^+.>9&*-6K7+XF4Q
M:+#GVY-,;6P]_&M5BF\[X<!XE$6U5L6-+!(<6=&PV+)%[F*Z%&<T/35SRAXE
M1>-/A!D#LSE;T/1QVVU 8YS5-XLXLB1%]6X7L03$6/ _6:J#*#S?E,K5M_4]
M9S<^^YY!8T_ AS.0G=2 0R>?<%*[.[W2.6$Y>[&%Y=R@!<\]%K\'$.5;D:VA
M"H>+8Y]#U2+8$F;R)# X[;%L!.F>JG._Q;S5>)KQ[+_$[/%78%-Q>(ZRF*K0
M853?W .F7+1YYI]:XS>,JFA3I@R"#_1*DI53)Z2/HI;$"TT8=RX.[L+J=/37
M(]UVUT@__)2.2Y-"SA7*5."(;1?%_<$9HEF<4Y['0LWXTHG7CKYZ4^M):W"(
MQ_*8(7Q=^@M;H[PU<F(P%!>)N:I[Z.+O;5(F>BCFW EJ>WPP,SYL"XQ1]L.(
M4?CRXG62MSGW3V/$K$>,%?;BEA'B R(VOO[TI%Y"D\Z:B%?LRPSI3+,#I\8K
M93V +<!W-Y0')(!4NA'P8#F458\'6QR9GK\V#P":SD*4V.:>%4J3TTCA[?$P
M:&.[EL:J+\LEE)5.5G,WLJ1L4EG1%9%X]&S=EMZFWE9?RB@UWVTUAZV$SB3W
M..H?=.U.G?"["\<S,[6CTKG#2[HH K*9Q ^;34HRV-K.J6B"?0QT(FED1J5'
MB (^6^(A@WIO6"=A$YDT-]S<0W5PBQD"=L?+Z=:8Z^N;8U3BQ,II 70V@!TF
ME=K##')J7 17SD%5WW1BE_@J&,SI.57V=F3#\;1)KS #ZVT9 I;CF?LH;4FR
M_#$6H)[(KL%-M(6*.;#M@O")H)O1W>VO;D6S\KECDURCX,CPGR^;G@#&V"1=
M2<OF:8J8;P3MX8W%'?-,Y'^8A-PL^7D9]"(O7QDE;.S3O?+;HOV%_10S4AE,
MA\I'/.P&MY+DS> $PH2H/%V=H4[!*%20F]A+LY>E+OJC;"R0XP\\=L)T@O$T
M+ITI91(*+V$TB4**C[8L=4J!!J@2*^K7AXNKY>7KSK!%2-P3L,#BR#/Q$O$/
MY#.YA)&2+\/Q>UZOO56HV=H9R;@3FH'*><.V* ^65NO65E;&@DO'&$4[^>4:
M0M]&&+:>A)-]^5*G1 <RGP/1@?M+PVR!?S9+!<%KIH(DNL&]7(+#:%Z5!!F?
M ?< N\6P:*A2K=6-";(H4:*6EYQ NF3&!W>"WV&>3==3-'P4V^3#HREBP4Q(
M8-'P/8#0/&#V<M_<*B:4+W\H*#66K6WF@H#)VCKS>2<1OX#W2'/- '*,32F/
M,")& P&KF E".[;D1^7"[@&8ASVT#0NG]%L&2,'#@S]N)2.F6IQ\KW<U-EYA
M9,OSLOJR4@-[*:%RL&D&YU"2PCTMD%;5RKJ5F?-BHWB*=;374,3 ?DG451RK
MCP2<61@E@A1 )0[*GA_^T8CS%:ES%O:4;S6@$ZBKVWDTT/:QQN;<5(O!A5\D
MS3'ZA? *B 5Y&8ML&Y"]Z8S)JC=3+*VV/,PK6=9B_)+QI)KR&>%W0&/-,*U^
M].KK2(NF>8-#G+( JYWL++@5W3+*_ <SY\R%69>S.\S"3#. 8CS1R4_ N\5^
MGO"".VFI?"D7Q(M8K+T'X DG/UC/P-6R  G1?=@C9D6)T]LWTQZGO4DKGLX7
MP8"N7XY6S+<FJ*A1&B;QE"0 _JL$+U-D*34K#QW'K_*J^L1$DR3/^#)<OY%1
MM"EIS.LYLETKG%XG0>$=JT1YQPJ4UXSCC+R43[;56F(P87RP"(Y_#CGY@$A4
MJSH,X?F1O@T.3FY !0]=K2JDQDB R0MXS H,W/BDRZX?Y;]74_<-_*AQ/:*9
ME5"-\S'<^QY@?QH=E#J0&A5DF5Z_:KJ&RMX#%J@:49>;*,Z(GVD;/J9]I!I-
MNY,B78\#+^HC\K=";J6<^CQ,*,Z=G^_XJ84K _* _42CL?8QXO$%Q@QG\HU\
M'U),>HSZ  NF4C2JLSBCW1)0(P&E1M^7)?< M[ !:7FU5N$F)M7B.*%[@)1'
M[G4IUV2/XT1A1:MKJ-"/H)SAB=Y8O\*0$8AC!=/S0QAI2*& %GT@9_-=&WFI
M&]TJG=:AV)[G#2^R<Y,%5R*Y&-%[P[D_= ] I#/T[]&&SEWVXZ0GCU@IX;47
MY&,'W4!PHI0<3VEO9%#@\J/L3:Z<(5.)E-@J5;Z-M355B>.O5V23NYHP[UPF
MG99NKW!;S 2_N%1E9-%(%4@$KC-)H8>8:H;G)TO.\F_H73^RL0521D,AN&?\
MNOP"7H\3'G]]LE\KY&)U$S;G"M63++J-KYDN73V2W&3I6C(>(^T/$QVQ31HR
MUS:^FN%]^P&K.Y[9#2FW[1AW8PLGH709[,]SJ Z#WY*/KQ+4=FN]NA$.HQ>%
MUJQY+0LSQ#\:S(ZE[<<N65!R[*78 *EUS%L];>E9*D,2%=8Z(M$NB#),30;8
MC<+7?(5WRQK"T0RXUE^3.I>%7\2@>JM-44=/$%.EVVZFXSNO\PPCK5I-OE+S
M] O+U6B;V%BE48]NIN,8#>ON3">)H.2&A(L/[N@7H*]JS):)GI\P<3PAZNYP
MT!P]90*-,9;EL^E^76-(R<T<""5<J+OC1.T/=T+)Z(1"IRM^-)85)S@CU1GO
M >VSYEIBS*C7Y]^,,VZ>HX3A>O3 /^!X;@1U5KU50,[@BP.'\>N7SU!!OPG;
M<^W68LR?]4+C\- 2(\[M.($1!Z%BJ+FP[:VF=9UM-YLK76A[:TM31\S>K(Q0
MV8<JM=?,K])8\M,,J7"'$'AE+$PS\EI :ZEWD DWR7N 0?O,KUM+F+6F^PG,
MA+9FQ.Z<BF'LO4!2A);Y=UY"76[85"_W4"KNYE$.^\N9&T'8%MOFB59\]M&K
M'++)MQ,?OZO2H<5/_WE:9+HC%,H0<#K,0B'_J 8HRU4$K$5Y&^6I(R'E/ZP@
M!W;C:C6KX*^?#]C8L7^K/.E/4:ZH:YBZ'KP'T'A<*,5)6I+-@RAJ?K1=41NX
MD'"T&66.>N"GU=B?E=MTK?%!0<-631^#+ *W!HJP75:%2G>8PH9$ACHW>S]/
M/%YAS9QH3+PR\K3S''*Q8[^>4_*VC#<9W\".3. I>_Q/?S7ZOR4P[E?^&U!+
M 0(4 Q0    ( *>%,E1V ?&/[1X  $]\ 0 1              "  0    !D
M<G5G+3(P,C$P.3,P+GAS9%!+ 0(4 Q0    ( *>%,E0Z.Q"V@P@  (IB   5
M              "  1P?  !D<G5G+3(P,C$P.3,P7V-A;"YX;6Q02P$"% ,4
M    " "GA3)45C^EI]0O  #P.0, %0              @ '2)P  9')U9RTR
M,#(Q,#DS,%]D968N>&UL4$L! A0#%     @ IX4R5&^5S"@6T@  (L(+ !4
M             ( !V5<  &1R=6<M,C R,3 Y,S!?;&%B+GAM;%!+ 0(4 Q0
M   ( *>%,E3L#( Q_T,  ++7!  5              "  2(J 0!D<G5G+3(P
M,C$P.3,P7W!R92YX;6Q02P$"% ,4    " "GA3)4%A%$ J@1 0#\(A( #
M            @ %4;@$ 9F]R;3(P9F$N:'1M4$L! A0#%     @ IX4R5 >L
M AA?,    CD  !$              ( !)H " &9O<FTR,&9A>'HP,#0N:G!G
64$L%!@     '  < Q $  +2P @    $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
